<SEC-DOCUMENT>0001193125-24-078991.txt : 20240327
<SEC-HEADER>0001193125-24-078991.hdr.sgml : 20240327
<ACCEPTANCE-DATETIME>20240327173029
ACCESSION NUMBER:		0001193125-24-078991
CONFORMED SUBMISSION TYPE:	POS AM
PUBLIC DOCUMENT COUNT:		95
FILED AS OF DATE:		20240327
DATE AS OF CHANGE:		20240327

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Scilex Holding Co
		CENTRAL INDEX KEY:			0001820190
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		POS AM
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-275117
		FILM NUMBER:		24792202

	BUSINESS ADDRESS:	
		STREET 1:		960 SAN ANTONIO ROAD
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94303
		BUSINESS PHONE:		(650) 516-4310

	MAIL ADDRESS:	
		STREET 1:		960 SAN ANTONIO ROAD
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94303

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Scilex Holding Company/DE
		DATE OF NAME CHANGE:	20221117

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Vickers Vantage Corp. I
		DATE OF NAME CHANGE:	20200804
</SEC-HEADER>
<DOCUMENT>
<TYPE>POS AM
<SEQUENCE>1
<FILENAME>d759370dposam.htm
<DESCRIPTION>POS AM
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:sclx="http://www.vickersvantagecorp.com/20231231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>POS AM</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style="line-height:normal;background-color:white;">
<h5><a href="#toc">Table of Contents</a></h5>
<div style="display: none"><ix:header><ix:hidden><ix:nonNumeric name="dei:DocumentType" id="hidden107552269" contextRef="P01_01_2023To12_31_2023">POS AM</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2023To12_31_2023" id="ixv-23974">true</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="hidden107552536" contextRef="P01_01_2023To12_31_2023">CA</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="hidden107552537" contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">CA</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2023To12_31_2023" id="ixv-23977">0001820190</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="sclx-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="PAsOn12_31_2022"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_25_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-25</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_30_2023To04_30_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-30</xbrli:startDate> <xbrli:endDate>2023-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_02_2022To06_02_2022"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-06-02</xbrli:startDate> <xbrli:endDate>2022-06-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P06_27_2023To06_27_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-27</xbrli:startDate> <xbrli:endDate>2023-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P02_13_2023To02_13_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-02-13</xbrli:startDate> <xbrli:endDate>2023-02-13</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_30_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-04-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:PatentRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AcquiredTechnologyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AssembledWorkforceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AcquiredLicensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_MaximumMembersrtRangeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_WarrantsMemberusgaapAwardTypeAxis_WarrantTransferAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:WarrantTransferAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RomegLicenseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AssembledWorkforceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AcquiredLicensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AcquiredTechnologyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:PatentRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_BRileyPurchaseAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:BRileyPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_WarrantsMemberusgaapAwardTypeAxis_WarrantTransferAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:WarrantTransferAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_MaximumMembersrtRangeAxis_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ResearchMemberusgaapTaxCreditCarryforwardAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_PreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RomegLicenseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_EquityUnitPurchaseAgreementsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_GloperbaMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:GloperbaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_MaximumMembersrtRangeAxis_NonCancelableLeaseAgreementsMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentFacilitiesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sclx:ResearchAndDevelopmentFacilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:NonCancelableLeaseAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_MinimumMembersrtRangeAxis_NonCancelableLeaseAgreementsMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentFacilitiesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sclx:ResearchAndDevelopmentFacilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:NonCancelableLeaseAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants2MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrants2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants4MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrants4Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants3MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrants3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants1MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrants1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:ARYorkvillePurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:AtmSalesAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_NonEmployeeDirectorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:NonEmployeeDirectorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CoveLaneMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:CoveLaneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_HudsonBayMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:HudsonBayMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_SorrentoMemberusgaapBusinessAcquisitionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_StockOptionsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:StockOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_PublicWarrantsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ConvertibleDebenturesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ConvertibleDebenturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_SharesIssuablePursuantToEsppMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SharesIssuablePursuantToEsppMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_PrivateWarrantsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PrivateWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RetainerSharesMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:RetainerSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_WarrantsMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_StockOptionsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:StockOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PublicWarrantsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ConvertibleDebenturesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ConvertibleDebenturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PrivateWarrantsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PrivateWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_RetainerSharesMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:RetainerSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_SharesIssuablePursuantToEsppMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SharesIssuablePursuantToEsppMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberusgaapStatementBusinessSegmentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PreferredStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ThreeCustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_WarrantsMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_StockOptionsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:StockOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ConvertibleDebenturesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ConvertibleDebenturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_PrivateWarrantsMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PrivateWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_RetainerSharesMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:RetainerSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_SharesIssuablePursuantToEsppMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SharesIssuablePursuantToEsppMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_FormerEmployeeOneMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:FormerEmployeeOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_FormerEmployeeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:FormerEmployeeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_EmployeeStockPurchasePlanMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sclx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sclx:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_StockOptionMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sclx:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ConvertibleDebtSecuritiesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_MaximumMembersrtRangeAxis_StockOptionMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sclx:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_MinimumMembersrtRangeAxis_StockOptionMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sclx:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_EpoladermMemberusgaapStatementBusinessSegmentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sclx:EpoladermMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_EnveltaMemberusgaapStatementBusinessSegmentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sclx:EnveltaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ProbudurMemberusgaapStatementBusinessSegmentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sclx:ProbudurMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberusgaapStatementBusinessSegmentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ThreeCustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_WarrantsMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:ARYorkvillePurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis_CommonStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:ARYorkvillePurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_EquityUnitPurchaseAgreementsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_BRileyPurchaseAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:BRileyPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_NonEmployeeDirectorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:NonEmployeeDirectorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_MaximumMembersrtRangeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_MinimumMembersrtRangeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PennyWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_SubsequentPennyWarrants3MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrants3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_SubsequentPennyWarrants2MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrants2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_SubsequentPennyWarrants1MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrants1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_SubsequentPennyWarrants4MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrants4Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:AtTheMarketSalesAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockPreferredMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_30_2022_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-04-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P11_17_2022To11_17_2022_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:ARYorkvillePurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-11-17</xbrli:startDate> <xbrli:endDate>2022-11-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_17_2022To11_17_2022_BRileyPurchaseAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:BRileyPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-11-17</xbrli:startDate> <xbrli:endDate>2022-11-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_17_2022_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:ARYorkvillePurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-03-21</xbrli:startDate> <xbrli:endDate>2023-03-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-03-21</xbrli:startDate> <xbrli:endDate>2023-03-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-03-21</xbrli:startDate> <xbrli:endDate>2023-03-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ShareBasedCompensationAwardTrancheThreeMemberusgaapVestingAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-03-21</xbrli:startDate> <xbrli:endDate>2023-03-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_21_2023To03_21_2023_EquityUnitPurchaseAgreementsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-03-21</xbrli:startDate> <xbrli:endDate>2023-03-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_27_2023To06_27_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-27</xbrli:startDate> <xbrli:endDate>2023-06-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_22_2023_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis_CommonStockMemberusgaapStatementClassOfStockAxis_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:AtmSalesAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P05_31_2022To05_31_2022_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_SorrentoMemberusgaapRelatedPartyTransactionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-31</xbrli:startDate> <xbrli:endDate>2022-05-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_14_2022To06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RomegLicenseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-06-14</xbrli:startDate> <xbrli:endDate>2022-06-14</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RomegLicenseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P09_30_2023To09_30_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-30</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_30_2023To04_30_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:ARYorkvillePurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-30</xbrli:startDate> <xbrli:endDate>2023-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_30_2022To11_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-11-30</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_11_2023_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-10-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_11_2023_MinimumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-10-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_27_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-27</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To07_01_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-07-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_21_2023_WarrantMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:StockPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_21_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:StockPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_21_2023_PublicWarrantsMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:PublicWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:StockPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_21_2023_PrivateWarrantsMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:PrivateWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:StockPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_21_2023_ClosingPennyWarrantMemberusgaapClassOfWarrantOrRightAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:ClosingPennyWarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_21_2023_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PennyWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PennyWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_21_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_21_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-21</xbrli:startDate> <xbrli:endDate>2023-09-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_21_2023To09_21_2023_FristInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:FristInstallmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-21</xbrli:startDate> <xbrli:endDate>2023-09-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_21_2023To09_21_2023_SecondInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:SecondInstallmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-21</xbrli:startDate> <xbrli:endDate>2023-09-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ThirdInstallmentMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ThirdInstallmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-21</xbrli:startDate> <xbrli:endDate>2023-09-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_21_2023To09_21_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-21</xbrli:startDate> <xbrli:endDate>2023-09-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_21_2023To09_21_2023_MonthlyBasisMemberSCLXDebtPayableAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:DebtPayableAxis">sclx:MonthlyBasisMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-21</xbrli:startDate> <xbrli:endDate>2023-09-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_21_2023To09_21_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:StockPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-21</xbrli:startDate> <xbrli:endDate>2023-09-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_21_2023To09_21_2023_FristInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:FristInstallmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-21</xbrli:startDate> <xbrli:endDate>2023-09-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_21_2023To09_21_2023_SecondInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:SecondInstallmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-21</xbrli:startDate> <xbrli:endDate>2023-09-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_ThirdInstallmentMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ThirdInstallmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-21</xbrli:startDate> <xbrli:endDate>2023-09-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_21_2023To09_21_2023_FourthInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:FourthInstallmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-21</xbrli:startDate> <xbrli:endDate>2023-09-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_21_2023To09_21_2023_FiveInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:FiveInstallmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-21</xbrli:startDate> <xbrli:endDate>2023-09-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SixInstallmentMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:SixInstallmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-21</xbrli:startDate> <xbrli:endDate>2023-09-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_05_2023To07_05_2023_JuniorDipFacilityMemberusgaapLongtermDebtTypeAxis_SorrentoMemberusgaapBusinessAcquisitionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:JuniorDipFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-05</xbrli:startDate> <xbrli:endDate>2023-07-05</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_05_2023_JuniorDipFacilityMemberusgaapLongtermDebtTypeAxis_SorrentoMemberusgaapBusinessAcquisitionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:JuniorDipFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-07-05</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P08_31_2023To08_31_2023_HudsonBayMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:HudsonBayMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-31</xbrli:startDate> <xbrli:endDate>2023-08-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_22_2023To12_22_2023_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:AtTheMarketSalesAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-12-22</xbrli:startDate> <xbrli:endDate>2023-12-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_22_2023To12_22_2023_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:AtTheMarketSalesAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-12-22</xbrli:startDate> <xbrli:endDate>2023-12-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_04_2023_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-05-04</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_04_2023_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-05-04</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_04_2023_MaximumMembersrtRangeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-05-04</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_04_2023_MinimumMembersrtRangeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-05-04</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_17_2023_TwoThousandTwentyThreeInducementPlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-01-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2022To10_31_2022_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-01</xbrli:startDate> <xbrli:endDate>2022-10-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2013To02_28_2013_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MaximumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2013-02-01</xbrli:startDate> <xbrli:endDate>2013-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2013To02_28_2013_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MinimumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2013-02-01</xbrli:startDate> <xbrli:endDate>2013-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2013To02_28_2013_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2013-02-01</xbrli:startDate> <xbrli:endDate>2013-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_29_2024To02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RodmanRenshawLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-02-29</xbrli:startDate> <xbrli:endDate>2024-02-29</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_29_2024To02_29_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-02-29</xbrli:startDate> <xbrli:endDate>2024-02-29</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RodmanRenshawLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-02-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_29_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis_WarrantMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-02-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_29_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-02-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P02_16_2024To02_16_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-02-16</xbrli:startDate> <xbrli:endDate>2024-02-16</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ConvertibleDebtSecuritiesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ConvertibleDebtSecuritiesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PreferredStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SeniorNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockPreferredMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD"> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares"> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure"> <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year"> <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share"> <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit></ix:resources></ix:header></div><div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As filed with the U.S.&#160;Securities and Exchange Commission on </div></div> <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 11.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; orphans: 2; text-align: center; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">March 27, 2024</div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: right;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Registration <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-275117</div> </div></div><div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div><div style="line-height: 1pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0);;text-indent: 0px;">&#160;</div><div style="line-height: 3pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0);;text-indent: 0px;">&#160;</div><div style="margin-top: 4pt; margin-bottom: 0pt; font-size: 14pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">UNITED STATES </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 14pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Washington, D.C. 20549 </div></div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div><div style="text-align:center;text-indent: 0px;"><div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 14pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:AmendmentDescription" contextRef="P01_01_2023To12_31_2023" id="ixv-25970">Post-Effective Amendment No.&#160;1</ix:nonNumeric> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 14pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">to </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 14pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;<div style="-sec-ix-hidden:hidden107552269;display:inline;">S-1</div></div> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 14pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">REGISTRATION STATEMENT </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">UNDER </div></div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">THE SECURITIES ACT OF&#160;1933 </div></div></div></div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div><div style="text-align:center;text-indent: 0px;"><div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 20pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P01_01_2023To12_31_2023" id="ixv-25971">Scilex Holding Company</ix:nonNumeric> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">(Exact name of Registrant as specified in its charter) </div></div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div><div style="text-align:center;text-indent: 0px;"><div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div></div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt;width:100%;border:0;margin:0 auto;text-indent: 0px;">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:stateprovnameen" id="ixv-25972">Delaware</ix:nonNumeric></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityPrimarySicNumber" contextRef="P01_01_2023To12_31_2023" id="ixv-25973">2836</ix:nonNumeric></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="P01_01_2023To12_31_2023" id="ixv-25974">92-1062542</ix:nonNumeric></div></div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">(State or other jurisdiction of</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">incorporation or organization)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">(Primary Standard Industrial</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Classification Code Number)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">(I.R.S. Employer</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Identification Number)</div></div></td></tr></table><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Scilex Holding Company</div> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2023To12_31_2023" id="ixv-25975">960 San Antonio Road</ix:nonNumeric> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2023To12_31_2023" id="ixv-25976">Palo Alto</ix:nonNumeric>, <div style="-sec-ix-hidden:hidden107552536;display:inline;">CA</div>&#160;<ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2023To12_31_2023" id="ixv-25977">94303</ix:nonNumeric> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2023To12_31_2023" id="ixv-25978">650</ix:nonNumeric>) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2023To12_31_2023" id="ixv-25979">516-4310</ix:nonNumeric></div> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">(Address, including zip code, and telephone number, including area code, of Registrant&#8217;s principal executive offices) </div></div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div><div style="text-align:center;text-indent: 0px;"><div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:ContactPersonnelName" contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-25980">Jaisim Shah</ix:nonNumeric> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Chief Executive Officer&#160;&amp; President </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-25981">960 San Antonio Road</ix:nonNumeric> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-25982">Palo Alto</ix:nonNumeric>, <div style="-sec-ix-hidden:hidden107552537;display:inline;">CA</div>&#160;<ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-25983">94303</ix:nonNumeric> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-25984">650</ix:nonNumeric>) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-25985">516-4310</ix:nonNumeric></div> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">(Name, address, including zip code, and telephone number, including area code, of agent for service) </div></div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div><div style="text-align:center;text-indent: 0px;"><div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Copies to: </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Jeffrey T. Hartlin, Esq. </div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Elizabeth A. Razzano, Esq. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Paul Hastings LLP </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">1117 S. California Avenue </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Palo Alto, CA&#160;94304 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; text-align: center;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">(650) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">320-1800</div> </div></div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div><div style="text-align:center;text-indent: 0px;"><div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Approximate date of commencement of proposed sale to the public</div></div>: As soon as practicable after this registration statement becomes effective. If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&#160;415 under the Securities Act of&#160;1933, check the following box.&#8194;&#9746; </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering pursuant to Rule&#160;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8.5pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accelerated</div> filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Rule&#160;12b-2</div> of the Exchange Act. </div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt;width:100%;border:0;margin:0 auto;text-indent: 0px;">
<tr>
<td style="width:17%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:58%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:20%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:2%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:bottom">Large&#160;accelerated&#160;filer</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#9744;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Accelerated filer</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#9744;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td colspan="2" style="height:6pt"/>
<td colspan="2" style="height:6pt"/>
<td colspan="2" style="height:6pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:entityfilercategoryen" id="ixv-25986">Non-accelerated filer</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#9746;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Smaller&#160;reporting&#160;company</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P01_01_2023To12_31_2023" format="ixt:fixed-false" id="ixv-25987">&#9744;</ix:nonNumeric></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td colspan="2" style="height:6pt"/>
<td colspan="2" style="height:6pt"/>
<td colspan="2" style="height:6pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Emerging&#160;growth&#160;company</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P01_01_2023To12_31_2023" format="ixt:fixed-true" id="ixv-25988">&#9746;</ix:nonNumeric></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman;text-indent: 0px;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act.&#8194;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="P01_01_2023To12_31_2023" format="ixt:fixed-false" id="ixv-25989">&#9744;</ix:nonNumeric> </div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of&#160;1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&#160;8(a), may determine. </div></div><div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div><div style="line-height: 1pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0);;text-indent: 0px;">&#160;</div><div style="line-height: 3pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0);;text-indent: 0px;">&#160;</div></div></div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">EXPLANATORY NOTE </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Post-Effective Amendment No.&#160;1 (&#8220;Post-Effective Amendment No.&#160;1&#8221;) to the Registration Statement on Form <span style="white-space:nowrap">S-1</span> (File <span style="white-space:nowrap">No.&#160;333-275117)</span> (the &#8220;Registration Statement&#8221;), as originally declared effective by the Securities and Exchange Commission (the &#8220;SEC&#8221;) on November&#160;22, 2023, is being filed to include information contained in the Registrant&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> for the fiscal year ended December&#160;31, 2023 filed with the SEC on March&#160;12, 2024 and to update certain other information in the Registration Statement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information included in this filing amends the Registration Statement and the prospectus contained therein. No additional securities are being registered under this Post-Effective Amendment No.&#160;1. All applicable registration fees were paid at the time of the original filing of the Registration Statement on October&#160;20, 2023. </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><span style="color:#ff4338"><span style="font-weight:bold">The information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the U.S. Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. </span></span></p> <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:center"><span style="color:#ff4338"><span style="font-weight:bold">PRELIMINARY &#8212; SUBJECT TO COMPLETION, DATED MARCH 27, 2024 </span></span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">PRELIMINARY PROSPECTUS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman;font-weight:bold;text-align:center">SCILEX HOLDING COMPANY </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Up to 13,324,683 Shares of Common Stock </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">This prospectus relates to the resale from time to time by the selling stockholders named in this prospectus (including their permitted transferees, donees, pledgees and other <span style="white-space:nowrap"><span style="white-space:nowrap">successors-in-interest)</span></span> (collectively, the &#8220;Selling Stockholders&#8221;) of up to an aggregate of 13,324,683 shares (the &#8220;Resale Shares&#8221;) of our common stock, par value $0.0001 per share (&#8220;Common Stock&#8221;), consisting of: </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">(i) up to 324,683 shares of Common Stock (the &#8220;HB Shares&#8221;), of which 110,392 shares of Common Stock are held by Cove Lane Onshore Fund, LLC (&#8220;Cove Lane&#8221;) and 214,291 shares of Common Stock are held by HBC Investments LLC (&#8220;HBC&#8221;), in each case issued on September 25, 2023, pursuant to the Settlement Agreement (as defined and described below); and </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">(ii) up to 13,000,000 shares of Common Stock issuable upon exercise of warrants to purchase Common Stock, having an exercise price of $0.01 per share (such shares issuable upon exercise, the &#8220;Penny Warrant Shares&#8221; and such warrants, the &#8220;Penny Warrants&#8221;), issued to Oramed Pharmaceuticals Inc. (&#8220;Oramed&#8221;) pursuant to the Scilex Oramed SPA (as defined and described below). </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">On September 21, 2023, we entered into, and consummated the transactions contemplated by that certain Securities Purchase Agreement, dated as of such date, between us and Oramed (the &#8220;Scilex-Oramed SPA&#8221;). Pursuant to the Scilex-Oramed SPA, among other things, on September 21, 2023, we (i)&#160;issued to Oramed (A)&#160;a senior secured promissory note due 18 months from the date of issuance in the principal amount of $101,875,000 (the &#8220;Oramed Note&#8221;), (B) a warrant to purchase up to an aggregate of 4,500,000 shares of Common Stock (the &#8220;Closing Penny Warrant&#8221;), with an exercise price of $0.01 per share and restrictions on exercisability (as more fully described elsewhere in this prospectus), and (C)&#160;warrants to purchase up to an aggregate of 8,500,000 shares of Common Stock (the &#8220;Subsequent Penny Warrants&#8221; and together with the Closing Penny Warrant, the &#8220;Penny Warrants&#8221;), each with an exercise price of $0.01 per share and each with restrictions on exercisability (as more fully described elsewhere in this prospectus), and (ii)&#160;caused certain outstanding warrants to purchase up to an aggregate of 4,000,000 shares of Common Stock, with an exercise price of $11.50 per share, that we acquired from Sorrento pursuant to the Sorrento SPA (as defined and described elsewhere in this prospectus) to be transferred to Oramed (the &#8220;Transferred Warrants&#8221;). See the section titled &#8220;<span style="font-style:italic">Certain Relationships and Related Party Transactions</span>&#8221; for additional information regarding the Scilex-Oramed SPA and transactions related thereto. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">On September 15, 2023, we entered into that certain Settlement Agreement (the &#8220;Settlement Agreement&#8221;) with Cove Lane, HBC and Hudson Bay Capital Management LP (&#8220;Hudson Bay&#8221; and collectively with Cove Lane and HBC, the &#8220;Hudson Bay Parties&#8221; and each a &#8220;Hudson Bay Party&#8221;) in connection with a previously contemplated financing with the Hudson Bay Parties. The HB Shares were issued to Cove Lane and HBC pursuant to the Settlement Agreement. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">We are registering the resale of the Penny Warrant Shares as required by that certain Registration Rights Agreement between us and Oramed, dated September 21, 2023 (the &#8220;Oramed RRA&#8221;). We are registering the resale of the HB Shares as required by the terms of the Settlement Agreement. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Our registration of the Resale Shares covered by this prospectus does not mean that the Selling Stockholders will offer or sell any of the Resale Shares. The Selling Stockholders may sell the Resale Shares covered by this prospectus in a number of different ways and at varying prices. For additional information on the possible methods of sale that may be used by the Selling Stockholders, you should refer to the section of this prospectus titled &#8220;<span style="font-style:italic">Plan of Distribution</span>&#8221; beginning on page 234 of this prospectus. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">We will not receive any of the proceeds from the resale of the Resale Shares sold by the Selling Stockholders. We will receive up to $130,000 from the exercise of the Penny Warrants, assuming the exercise in full of all of the Penny Warrants for cash, but not from the sale of the shares of Common Stock issuable upon such exercise. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">The sale of all the Resale Shares being offered in this prospectus could result in a significant decline in the public trading price of our securities. Despite such decline in the public trading price, the Selling Stockholders may still experience a positive rate of return on the securities they acquired due to the difference in the purchase prices. Based on the closing price of our Common Stock of $1.51 on March&#160;26, 2024, (i) Cove Lane and HBC may experience a potential profit of $1.51 per share of our Common Stock given that they acquired the HB Shares at no cost in connection with the Settlement Agreement, and (ii)&#160;Oramed may experience a potential profit of up to $1.50 per Penny Warrant Share given that the exercise price of the Penny Warrants is $0.01 per share. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">No underwriter or other person has been engaged to facilitate the sale of the shares of our Common Stock in these offerings. The Selling Stockholders may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), of the Resale Shares that they are offering pursuant to this prospectus. We will bear all costs, expenses and fees in connection with the registration of the shares of our Common Stock hereunder. The Selling Stockholders will bear all commissions and discounts, if any, attributable to their respective sales of the Resale Shares. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Our Common Stock is listed on the Nasdaq Capital Market under the symbol &#8220;SCLX&#8221;. On March 26, 2024, the last reported sales price per share of our Common Stock was $1.51. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">We are an &#8220;emerging growth company&#8221; as that term is used in the Jumpstart Our Business Startups Act of&#160;2012 (the &#8220;JOBS Act&#8221;) and, as such, we have elected to comply with certain reduced public company reporting requirements for this prospectus and future filings with the Securities and Exchange Commission. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">We may amend or supplement this prospectus from time to time by filing amendments or supplements as required. You should read this prospectus, together with additional information described under the heading &#8220;Where You Can Find More Information&#8221;, and any amendments or supplements carefully before you invest in any of our securities. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">INVESTING IN OUR COMMON STOCK INVOLVES SUBSTANTIAL RISKS. YOU SHOULD REVIEW CAREFULLY THE RISKS AND UNCERTAINTIES DESCRIBED UNDER THE HEADING &#8220;</span><span style="font-weight:bold"><span style="font-style:italic"><a href="#tx759370_6">RISK FACTORS</a></span></span><span style="font-weight:bold">&#8221; BEGINNING ON PAGE 18 OF THIS PROSPECTUS. </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman;font-weight:bold">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">The date of this prospectus is&#8195;&#8195;&#8195;&#8195;, 2024 </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc">TABLE OF CONTENTS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:95%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Page</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx759370_1">ABOUT THIS PROSPECTUS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx759370_2">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx759370_3">CERTAIN DEFINED TERMS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx759370_4">PROSPECTUS SUMMARY</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx759370_5">THE OFFERING</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx759370_6">RISK FACTORS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx759370_7">MARKET AND INDUSTRY DATA</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">95</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx759370_8">USE OF PROCEEDS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">96</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx759370_9">DETERMINATION OF OFFERING PRICE</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">97</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx759370_10">MARKET INFORMATION FOR SECURITIES AND DIVIDEND POLICY</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">98</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx759370_11">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">101</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx759370_12">BUSINESS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">118</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx759370_13">MANAGEMENT</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">181</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx759370_14">EXECUTIVE AND DIRECTOR COMPENSATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">194</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx759370_15">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx759370_16">PRINCIPAL SECURITYHOLDERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">230</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx759370_17">SELLING STOCKHOLDERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx759370_18">PLAN OF DISTRIBUTION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">234</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx759370_19">MATERIAL U.S.&#160;FEDERAL INCOME TAX CONSEQUENCES</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">236</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx759370_20">DESCRIPTION OF OUR SECURITIES</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">243</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx759370_21">LEGAL MATTERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">256</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx759370_22">EXPERTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">256</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx759370_23">WHERE YOU CAN FIND MORE INFORMATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">256</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx759370_24">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">F-1</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should rely only on the information we have provided in this prospectus, any applicable prospectus supplement and any related free writing prospectus. Neither we nor the Selling Stockholders have authorized anyone to provide you with information different from that contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus. You must not rely on any unauthorized information or representation. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate only as of the date on the front of the applicable document, regardless of the time of delivery of this prospectus or any sale of a security. Since the date of this prospectus and the documents incorporated by reference into this prospectus, our business, financial condition, results of operations and prospects may have changed. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">For Investors Outside the United States</span>: The Selling Stockholders are offering to sell, and seeking offers to buy, the securities offered by this prospectus only in jurisdictions where offers and sales are permitted. Neither we nor the Selling Stockholders have done anything that would permit this offering or the possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities offered by this prospectus and the distribution of this prospectus outside the United States. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">-i- </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx759370_1">ABOUT THIS PROSPECTUS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <span style="white-space:nowrap">S-1</span> that we filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) using the &#8220;shelf&#8221; registration process. Under this shelf registration process, the Selling Stockholders may, from time to time, sell the securities offered by them described in this prospectus. We will not receive any proceeds from the sale by such Selling Stockholders of the securities offered by them described in this prospectus. We will not receive any proceeds from the sale of shares of Common Stock underlying the Penny Warrants pursuant to this prospectus, except with respect to amounts received by us upon the exercise of the Penny Warrants for cash, which will be minimal as the exercise price is $0.01 per share. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the Selling Stockholders have authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus or any applicable prospectus supplement, any post-effective amendment or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. Neither we nor the Selling Stockholders take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is not an offer to sell securities, and it is not soliciting an offer to buy securities, in any jurisdiction where the offer or sale is not permitted. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also provide a prospectus supplement or post-effective amendment to the registration statement to add information to, or update or change information contained in, this prospectus. You should read both this prospectus and any applicable prospectus supplement or post-effective amendment to the registration statement together with the additional information to which we refer you in the section of this prospectus entitled &#8220;<span style="font-style:italic">Where You Can Find More Information</span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;10, 2022, we consummated the previously-announced business combination (the &#8220;Business Combination&#8221;) pursuant to that certain Agreement and Plan of Merger, dated as of March&#160;17, 2022 (as amended, restated or supplemented from time to time, including by Amendment No.&#160;1 to Agreement and Plan of Merger, dated as of September&#160;12, 2022) (the &#8220;Merger Agreement&#8221;), by and among us, Vantage Merger Sub Inc., our then-wholly owned subsidiary (the &#8220;Merger Sub&#8221;), and the <span style="white-space:nowrap">pre-Business</span> Combination Scilex Holding Company (&#8220;Legacy Scilex&#8221;). Pursuant to the terms of the Merger Agreement, we effected a deregistration under the Cayman Islands Companies Act (as revised) and a domestication under Section&#160;388 of the Delaware General Corporation Law, as amended (the &#8220;DGCL&#8221;), pursuant to which our jurisdiction of incorporation was changed from the Cayman Islands to the State of Delaware (the &#8220;Domestication&#8221;), and, on the terms and subject to the conditions set forth in the Merger Agreement and in accordance with the DGCL, Merger Sub merged with and into Legacy Scilex (the &#8220;Merger&#8221; or the &#8220;Business Combination&#8221;), with Legacy Scilex surviving as our wholly owned subsidiary. In connection with the Business Combination, we changed our name from Vickers Vantage Corp. I to Scilex Holding Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;21, 2023, we entered into, and consummated the transactions contemplated by that certain Securities Purchase Agreement, dated as of such date, between us and Oramed (the &#8220;Scilex-Oramed SPA&#8221;). Pursuant to the Scilex-Oramed SPA, among other things, on September&#160;21, 2023, we (i)&#160;issued to Oramed (A)&#160;a senior secured promissory note due 18 months from the date of issuance in the principal amount of $101,875,000 (the &#8220;Oramed Note&#8221;), (B) a warrant to purchase up to an aggregate of 4,500,000 shares of Common Stock (the &#8220;Closing Penny Warrant&#8221;), with an exercise price of $0.01 per share and restrictions on exercisability (as more fully described elsewhere in this prospectus), and (C)&#160;warrants to purchase up to an aggregate of 8,500,000 shares of Common Stock (the &#8220;Subsequent Penny Warrants&#8221; and together with the Closing Penny Warrant, the &#8220;Penny Warrants&#8221;), each with an exercise price of $0.01 per share and each with restrictions on exercisability (as more fully described elsewhere in this prospectus), and (ii)&#160;caused certain outstanding SPAC Warrants to purchase up to an aggregate of 4,000,000 shares of Common Stock, with an exercise price of $11.50 per share, that we acquired from Sorrento pursuant to the Sorrento SPA (as defined and described elsewhere in this prospectus) to be transferred to Oramed (the &#8220;Transferred Warrants&#8221;). See the section titled &#8220;<span style="font-style:italic">Certain Relationships and Related Party Transactions</span>&#8221; for additional information regarding the Scilex-Oramed SPA and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the transactions related thereto. In connection with the Scilex-Oramed SPA, on September&#160;21, 2023, we and Oramed also entered into a registration rights agreement (the &#8220;Oramed RRA&#8221;), pursuant to which we agreed to, among other things, file with the SEC on or before October&#160;21, 2023, and keep effective, a registration statement covering the resale of the shares underlying the Penny Warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;15, 2023, we entered into that certain Settlement Agreement (the &#8220;Settlement Agreement&#8221;) with Cove Lane, HBC and Hudson Bay Capital Management LP (&#8220;Hudson Bay&#8221; and collectively with Cove Lane and HBC, the &#8220;Hudson Bay Parties&#8221; and each a &#8220;Hudson Bay Party&#8221;) in connection with a previously contemplated financing with the Hudson Bay Parties. The HB Shares were issued to Cove Lane and HBC pursuant to the Settlement Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context indicates otherwise, references in this prospectus to the &#8220;Company,&#8221; &#8220;Scilex,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and similar terms refer to Scilex Holding Company, a Delaware corporation formerly known as Vickers Vantage Corp. I, and its consolidated subsidiaries. References to &#8220;Legacy Scilex&#8221; refer to the private Delaware corporation that is now our wholly owned subsidiary, named Scilex, Inc. (formerly known as Scilex Holding Company). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under &#8220;<span style="font-style:italic">Where You Can Find More Information</span>.&#8221; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx759370_2">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain statements contained in this prospectus may constitute &#8220;forward-looking statements&#8221; for purposes of federal securities laws. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. Forward-looking statements appear in a number of places in this prospectus including, without limitation, in the sections of this prospectus titled &#8220;<span style="font-style:italic">Business</span>&#8221; and &#8220;<span style="font-style:italic">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span>.&#8221; In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Forward-looking statements are typically identified by words such as &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;contemplate,&#8221; &#8220;intend,&#8221; &#8220;outlook,&#8221; &#8220;estimate,&#8221; &#8220;forecast,&#8221; &#8220;project,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other similar words and expressions (including the negative of any of the foregoing), but the absence of these words does not mean that a statement is not forward-looking. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements are based on information available as of the date of this prospectus and our management&#8217;s current expectations, forecasts and assumptions, and involve a number of judgments, known and unknown risks and uncertainties and other factors, many of which are outside the control of the Company and our directors, officers and affiliates, that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading &#8220;Risk Factors&#8221; in this prospectus. There can be no assurance that future developments will be those that have been anticipated. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Forward-looking statements in this prospectus may include, but are not limited to, statements about: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to maintain the listing of our Common Stock on the Nasdaq Capital Market; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our public securities&#8217; liquidity and trading; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to raise financing in the future; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our future use of equity or debt financings to execute our business strategy; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to use cash on hand to meet current and future financial obligations, including funding or operations, debt service requirements and capital expenditures; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the outcome of any legal proceedings that may be instituted against us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to attract and retain qualified directors, officers, employees and key personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to compete effectively in a highly competitive market; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the competition from larger biotechnology companies that have greater resources, technology, relationships and/or expertise; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ability to protect and enhance our corporate reputation and brand; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the impact from future regulatory, judicial and legislative changes in our industry; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to obtain and maintain regulatory approval of any of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to research, discover and develop additional product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to grow and manage growth profitably; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to obtain and maintain intellectual property protection and not infringe on the rights of others; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to execute our business plans and strategy; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to prevent, respond to, and recover from a cybersecurity incident; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effect of global economic and political developments, including the conflicts in Ukraine and Israel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the impact of <span style="white-space:nowrap">COVID-19</span> and other similar disruptions in the future; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other factors detailed under the section of this prospectus titled &#8220;<span style="font-style:italic">Risk Factors</span>.&#8221; </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should one or more of these risks or uncertainties materialize or should any of the assumptions made by our management prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Some of these risks and uncertainties may in the future be amplified by <span style="white-space:nowrap">COVID-19</span> (or other similar disruptions), and there may be additional risks that we consider immaterial or which are unknown. It is not possible to predict or identify all such risks. We do not undertake any obligation to update, add or to otherwise correct any forward-looking statements contained herein to reflect events or circumstances after the date they were made, whether as a result of new information, future events, inaccuracies that become apparent after the date hereof or otherwise, except as may be required under applicable securities laws. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx759370_3">CERTAIN DEFINED TERMS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">A&amp;R Yorkville Purchase Agreement</span>&#8221; means the Amended and Restated Standby Equity Purchase Agreement, dated February&#160;8, 2023, between the Company and Yorkville, amending, restating and superseding the Standby Equity Purchase Agreement dated November&#160;17, 2022 between the Company and Yorkville. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">ATM Sales Agreement</span>&#8221; means the Sales Agreement, dated December&#160;22, 2023, by and among the Company, B. Riley Securities, Inc., Cantor Fitzgerald&#160;&amp; Co. and H.C. Wainwright&#160;&amp; Co., LLC. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">B.</span> <span style="font-style:italic">Riley</span>&#8221; means B. Riley Principal Capital II, LLC. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">B.</span> <span style="font-style:italic">Riley Purchase Agreement</span>&#8221; means the Standby Equity Purchase Agreement, dated January&#160;8, 2023, between the Company and B. Riley. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Board</span>&#8221; means the board of directors of the Company. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Business Combination</span>&#8221; means the merger contemplated by the Merger Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Bylaws</span>&#8221; means the Bylaws of Scilex Holding Company, effective as of November&#160;10, 2022. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Certificate of Designations</span>&#8221; means the Certificate of Designations of the Company, designating the series of preferred stock, par value $0.0001&#160;per share, of the Company as &#8220;Series A Preferred Stock&#8221;. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Certificate of Incorporation</span>&#8221; means the Restated Certificate of Incorporation of Scilex Holding Company, filed with Secretary of State of the State of Delaware on November&#160;10, 2022. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Closing</span>&#8221; means the closing of the Business Combination. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Closing Date</span>&#8221; means date of the Closing. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Closing Penny Warrant</span>&#8221; means the warrant to purchase up to an aggregate of 4,500,000 shares of our Common Stock, with an exercise price of $0.01 per share, issued to Oramed pursuant to the Scilex-Oramed SPA. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Code</span>&#8221; means the Internal Revenue Code of&#160;1986, as amended. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Common Stock</span>&#8221; means the common stock, par value $0.0001&#160;per share, of Scilex. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Continental</span>&#8221; means Continental Stock Transfer&#160;&amp; Trust Company, our transfer agent. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Convertible Debentures</span>&#8221; means certain convertible debentures in an aggregate amount of $20,000,000 issued to Yorkville pursuant to a securities purchase agreement dated March&#160;21, 2023 between the Company and Yorkville. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Debt Exchange Agreement</span>&#8221; means the Contribution and Satisfaction of Indebtedness Agreement, dated as of September&#160;12, 2022, by and among Sorrento, Legacy Scilex and Scilex Pharmaceuticals, Inc. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">DGCL</span>&#8221; means the General Corporation Law of the State of Delaware, as amended. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Domestication</span>&#8221; means the change of our domicile pursuant to a transfer by way of continuation of an exempted company out of the Cayman Islands and a domestication into the State of Delaware as a corporation, and our <span style="white-space:nowrap">de-registration</span> in the Cayman Islands. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Effective Time</span>&#8221; means the time at which the Business Combination became effective. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Equity Incentive Plan</span>&#8221; means the Scilex Holding Company&#160;2022 Equity Incentive Plan, as amended. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">ESPP</span>&#8221; means the Scilex Holding Company&#160;2022 Employee Stock Purchase Plan. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Exchange Act</span>&#8221; means the Securities Exchange Act of&#160;1934, as amended. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">founder shares</span>&#8221; means the&#160;3,450,000 outstanding Vickers Ordinary Shares held by the Sponsors and the following directors of Vickers: Pei Wei Woo, Suneel Kaji and Steve Myint, which were converted into&#160;3,450,000 shares of Common Stock in connection with the Domestication. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Funding Commitment Letter</span>&#8221; means that certain letter agreement, dated as of October&#160;17, 2022, between Sorrento and Legacy Scilex. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">GAAP</span>&#8221; means accounting principles generally accepted in the United States of America. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Initial Shareholders</span>&#8221; means the Sponsors, Pei Wei Woo, Suneel Kaji and Steve Myint, each as the holders of founder shares. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">IPO</span>&#8221; refers to the initial public offering of&#160;13,800,000 Units of Vickers consummated on January&#160;11, 2021. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">IRS</span>&#8221; means the United States Internal Revenue Service. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Legacy Scilex Board</span>&#8221; means the board of directors of Legacy Scilex. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Legacy Scilex Common Stock</span>&#8221; means the common stock of Legacy Scilex, par value $0.0001&#160;per share, prior to the Effective Time. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Legacy Scilex Preferred Stock</span>&#8221; means the Series A Preferred Stock, par value $0.0001&#160;per share, of Legacy Scilex issued to Sorrento prior to the Effective Time pursuant to the Debt Exchange Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Maxim</span>&#8221; means Maxim Group LLC, the representative of the underwriters in the IPO. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Merger Agreement</span>&#8221; means that certain Agreement and Plan of Merger, dated as of March&#160;17, 2022, by and among us, Merger Sub and Legacy Scilex, as it may be amended or restated from time to time, including by the Merger Agreement Amendment. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Merger Agreement Amendment</span>&#8221; means that Amendment No.&#160;1 to Agreement and Plan of Merger, dated as of September&#160;12, 2022, by and among us, Merger Sub and Legacy Scilex. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Merger Sub</span>&#8221; means Vantage Merger Sub Inc., a Delaware corporation that was a wholly owned subsidiary of Vickers prior to the Closing and that, pursuant to the Business Combination, was merged with and into Legacy Scilex, with Legacy Scilex continuing as our wholly owned subsidiary. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Nasdaq</span>&#8221; means The Nasdaq Stock Market LLC. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Nasdaq Listing Rules</span>&#8221; means the rules and listing standards of Nasdaq. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Oramed</span>&#8221; means Oramed Pharmaceuticals Inc., a Delaware corporation. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Oramed RRA&#8221; </span>means that certain Registration Rights Agreement, dated as of September&#160;21, 2023, entered into between us and Oramed. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Penny Warrants</span>&#8221; means warrants to purchase Common Stock, having an exercise price of $0.01&#160;per share, subject to adjustment as provided therein. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Private Warrants</span>&#8221; means the&#160;6,840,000 warrants sold in a private placement to Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan)&#160;Pte Ltd consummated on January&#160;11, 2021 (of which&#160;2,736,000 were forfeited pursuant to the Sponsor Support Agreement and&#160;3,104,000 were transferred to Sorrento pursuant to the Warrant Transfer Agreement, in each case in connection with the Business Combination). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">public shareholders</span>&#8221; means the holders of the public shares. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">public shares</span>&#8221; means the Vickers Ordinary Shares which were sold as part of the IPO, whether they were purchased in the IPO or in the aftermarket, including any of our Initial Shareholders to the extent that they purchase such public shares (except that our Initial Shareholders will not have conversion or tender rights with respect to any public shares they own). </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Public Warrants</span>&#8221; means the redeemable warrants that were included in the Units that entitle the holder of each whole warrant to purchase one Vickers Ordinary Share at a price of $11.50&#160;per share. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Scilex-Oramed SPA</span>&#8221; means the Securities Purchase Agreement, dated as of September&#160;21, 2023, by and among us, Oramed and Acquiom Agency Services LLC, as the collateral agent. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">SEC</span>&#8221; means the U.S.&#160;Securities and Exchange Commission. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Securities Act</span>&#8221; means the Securities Act of&#160;1933, as amended. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Series A Preferred Stock</span>&#8221; means the preferred stock, par value $0.0001&#160;per share, of the Company, designated as Series A Preferred Stock pursuant to the Certificate of Designations. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Sorrento</span>&#8221; means Sorrento Therapeutics, Inc. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Sorrento Group</span>&#8221; means Sorrento together with its affiliates, subsidiaries, successors and assigns (other than us and our subsidiaries). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Sorrento Trigger Event</span>&#8221; means the time that the Sorrento Group first ceases to beneficially own more than&#160;50% in voting power of the then-outstanding shares of our capital stock entitled to vote generally in the election of directors. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Sponsors</span>&#8221; means Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan)&#160;Pte Ltd. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Sponsor Support Agreement</span>&#8221; means that certain Sponsor Support Agreement, dated March&#160;17, 2022, by and among the Initial Shareholders and with Scilex, Inc. (f/k/a Scilex Holding Company). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Stockholder Agreement</span>&#8221; means the Stockholder Agreement, dated as of September&#160;12, 2022, between Vickers and Sorrento. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Subsequent Penny Warrant</span>&#8221; means the warrants to purchase up to an aggregate of 8,500,000 shares of our Common Stock, each with an exercise price of $0.01 per share, issued to Oramed pursuant to the Scilex-Oramed SPA. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Trust Account</span>&#8221; means the Trust Account of Vickers that held the proceeds from Vickers&#8217;s IPO and the private placement of the Private Warrants. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Units</span>&#8221; means the units of Vickers, each of which consisted of one Vickers Ordinary Share and <span style="white-space:nowrap">one-half</span> of one redeemable warrant upon the consummation of an initial business combination, which units, if not separated into its component securities as of immediately prior to the Effective Time were, without any action on the part of the holder, separated automatically into its component securities, comprised of one share of Common Stock and <span style="white-space:nowrap">one-half</span> of one warrant to purchase one share of Common Stock. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Vickers</span>&#8221; means Vickers Vantage Corp. I, our predecessor company. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Vickers Debt Agreement</span>&#8221; means that certain Debt Contribution Agreement, dated as of October&#160;17, 2022, by and among Vickers and the Sponsors. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Vickers Ordinary Shares</span>&#8221; means (i)&#160;the ordinary shares, par value $0.0001&#160;per share, of Vickers prior to the Domestication and (ii)&#160;the Common Stock following the Domestication. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Warrant Transfer Agreement</span>&#8221; means that certain Warrant Transfer Agreement, dated as of October&#160;17, 2022, by and among Sorrento, the Sponsors, Vickers and Maxim. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Yorkville</span>&#8221; means YA II PN, Ltd., a Cayman Islands exempt limited partnership. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx759370_4">PROSPECTUS SUMMARY </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">This summary highlights selected information that is presented in greater detail elsewhere in this prospectus. Because it is only a summary, it does not contain all of the information you should consider before investing in our securities and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information included elsewhere in this prospectus. Before you decide whether to purchase our securities, you should read this entire prospectus carefully, including the sections of this prospectus titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;. You should also carefully read the information in this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">The Company </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an innovative revenue-generating company focused on acquiring, developing and commercializing <span style="white-space:nowrap">non-opioid</span> pain management products for the treatment of acute and chronic pain. We target indications with high unmet needs and large market opportunities with <span style="white-space:nowrap">non-opioid</span> therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our commercial products are: (i)&#160;ZTlido<sup style="font-size:75%; vertical-align:top">&#174;</sup> (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) for the relief of neuropathic pain associated with postherpetic neuralgia (&#8220;PHN&#8221;), which is a form of post-shingles nerve pain; (ii)&#160;ELYXYB<sup style="font-size:75%; vertical-align:top">&#174;</sup>, a potential first-line treatment and the only <span style="white-space:nowrap">FDA-approved,</span> <span style="white-space:nowrap"><span style="white-space:nowrap">ready-to-use</span></span> oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii)&#160;GLOPERBA<sup style="font-size:75%; vertical-align:top">&#174;</sup>, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults, expected to launch in the first half of 2024. In addition, we have three product candidates: <span style="white-space:nowrap">(i)&#160;SP-102</span> (10 mg, dexamethasone sodium phosphate viscous gel) (&#8220;SEMDEXA<sup style="font-size:75%; vertical-align:top">&#8482;</sup>&#8221;), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica for which we have completed a Phase 3 study; <span style="white-space:nowrap">(ii)&#160;SP-103</span> (lidocaine topical system) 5.4% <span style="white-space:nowrap">(&#8220;SP-103&#8221;),</span> a next-generation, triple-strength formulation of ZTlido, for the treatment of chronic neck pain and for which we have completed a Phase 2 trial in low back pain (&#8220;LBP&#8221;) in the third quarter of 2023; and <span style="white-space:nowrap">(iii)&#160;SP-104</span> (4.5 mg, <span style="white-space:nowrap">low-dose</span> naltrexone hydrochloride delayed-release capsules) <span style="white-space:nowrap">(&#8220;SP-104&#8221;),</span> a novel <span style="white-space:nowrap">low-dose</span> delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia, for which Phase 1 trials were completed in the second quarter of 2022 and a Phase 2 clinical trial is expected to commence in 2024. We believe our currently approved products and future product candidates, if approved by the FDA, could uniquely address what we believe are the significant unmet needs of the targeted populations and become the preferred treatment option for their respective indications. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our guiding principle has always been and remains a patient-first approach, which drives our mission to meet the increasing global demand for more effective and safer <span style="white-space:nowrap">non-opioid</span> pain management solutions. Through rigorous research and development, we believe we are on the cusp of establishing Scilex as the preeminent name in commercial <span style="white-space:nowrap">non-opioid</span> pain management, specifically targeting the unmet needs in both acute and chronic pain sectors with our innovative and leading therapies. We believe that we have not only responded to the global demand for safer, more effective pain relief solutions, but also made substantial progress in demonstrating the rapid onset and enhanced safety of our products. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our Products </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We launched our first commercial product, ZTlido<sup style="font-size:75%; vertical-align:top">&#174;</sup> (lidocaine topical system) 1.8% in October 2018. ZTlido possesses novel delivery and adhesion technology designed to address many of the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the <span style="white-space:nowrap">12-hour</span> administration period. ZTlido is a single-layer, <span style="white-space:nowrap"><span style="white-space:nowrap">drug-in-adhesive</span></span> topical delivery system </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
comprised of an adhesive material containing 36 mg lidocaine, which is applied to a pliable nonwoven cloth backing and covered with a polyethylene terephthalate film release liner. ZTlido is commercially manufactured for us by Oishi Koseido Co., Ltd. (&#8220;Oishi&#8221;) in Japan. We license the rights to ZTlido from and rely exclusively on Oishi and Itochu Chemical Frontier Corporation (&#8220;Itochu&#8221;) pursuant to the Product Development Agreement (the &#8220;Product Development Agreement&#8221;) dated as of May&#160;11, 2011, by and among Scilex Pharmaceuticals Inc., our wholly owned subsidiary (&#8220;Scilex Pharma&#8221;), Oishi and Itochu, and the Commercial Supply Agreement (the &#8220;Commercial Supply Agreement&#8221;), dated as of February&#160;16, 2017, by and among Scilex Pharma, Oishi and Itochu. We have exclusive worldwide rights to Oishi&#8217;s proprietary formulation and manufacturing technologies except with respect to Japan. In 2023, there were more than 182&#160;million prescription lidocaine patches sold in the United States, according to Symphony Healthcare. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We launched our second commercial product, ELYXYB<sup style="font-size:75%; vertical-align:top">&#174;</sup> in April 2023.&#160;We acquired the rights to certain patents, trademarks, regulatory approvals, data, contracts, and other rights related to ELYXYB<sup style="font-size:75%; vertical-align:top">&#174;</sup> (celecoxib oral solution) and the commercialization thereof in the United States and Canada from BioDelivery Sciences International, Inc. and Collegium Pharmaceutical, Inc. in February 2023.&#160;ELYXYB<sup style="font-size:75%; vertical-align:top">&#174;</sup><sup style="font-size:75%; vertical-align:top"> </sup>is a potential first-line treatment and the only <span style="white-space:nowrap">FDA-approved,</span> <span style="white-space:nowrap"><span style="white-space:nowrap">ready-to-use</span></span> oral solution for the acute treatment of migraine, with or without aura, in adults. We filed a New Drug Submission to Health Canada&#8217;s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the approval of ELYXYB<sup style="font-size:75%; vertical-align:top">&#174;</sup> for acute treatment of migraine with or without aura in Canada. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to launch our third commercial product, GLOPERBA, in the first half of 2024. We acquired certain rights to GLOPERBA on June&#160;14, 2022, when we entered into a License and Commercialization Agreement (the &#8220;Romeg Agreement&#8221;) with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.) (&#8220;Romeg&#8221;). Pursuant to the Romeg Agreement, among other things, Romeg granted us (1)&#160;the right to manufacture, promote, market, distribute and sell pharmaceutical products comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans in the United States, and (2)&#160;an exclusive, transferable license to use the trademark &#8220;GLOPERBA<sup style="font-size:75%; vertical-align:top">&#174;</sup>&#8221;. GLOPERBA is an <span style="white-space:nowrap">FDA-approved,</span> oral medication for the treatment of gout in adults. Gout is a painful arthritic disorder affecting an estimated 9.2&#160;million people in the United States. Gout pain can be excruciating and is a form of inflammatory arthritis that develops in some people who have high levels of uric acid in their blood. It can cause sudden severe episodes of pain and can be disabling with tenderness, warmth and swelling. <span style="white-space:nowrap">Non-steroidal</span> anti-inflammatory drugs, colchicine and corticosteroids are used a majority of time as the first line to treat acute gout. The U.S. is observed to have a high prevalence of gout, owing to lifestyle issues such as high alcohol intake, obesity, and smoking. We expect to commercialize GLOPERBA in the first half of 2024 and believe we are well positioned to market and distribute the product. We have a direct distribution network to national and regional wholesalers and pharmacies throughout the U.S. For more information on Scilex, please see the section titled &#8220;<span style="font-style:italic">Business &#8212; Material Agreements &#8212; Romeg License and Commercialization Agreement.</span>&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our Product Candidates </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We acquired <span style="white-space:nowrap">SP-102</span> from Semnur Pharmaceuticals, Inc. (&#8220;Semnur&#8221;) in March 2019 and are developing <span style="white-space:nowrap">SP-102</span> to be an injectable viscous gel formulation of a widely used corticosteroid designed to address the serious risks posed by <span style="white-space:nowrap">off-label</span> epidural steroid injections (&#8220;ESI&#8221;), which are administered over 12&#160;million times annually in the United States. SEMDEXA<sup style="font-size:75%; vertical-align:top">&#8482;</sup> has been granted fast track designation by the FDA and, if approved, could become the only <span style="white-space:nowrap">FDA-approved</span> ESI for the treatment of sciatica. According to a report by Decision Resources Group, it was estimated that over 4.8&#160;million patients would suffer from sciatica in the United States in 2022. We received our <span style="white-space:nowrap">SP-103</span> Phase 2 <span style="white-space:nowrap">top-line</span> results in August 2023 and the trial achieved its objectives characterizing safety, tolerability and preliminary efficacy of <span style="white-space:nowrap">SP-103</span> in acute LBP associated with muscle spasms. <span style="white-space:nowrap">SP-103</span> was safe and well tolerated. Increase of lidocaine load in topical system by three times, compared with approved ZTlido, 5.4% vs. 1.8%, did not result in signs of systemic toxicity or increased application site reactions with </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
daily applications over one month treatment. <span style="white-space:nowrap">SP-103</span> received FDA Fast Track status in LBP. We will continue to analyze the <span style="white-space:nowrap">SP-103</span> Phase 2 trial data along with an investigator study of ZTlido in patients with chronic neck pain completed in the second half of 2023, which also has shown promising <span style="white-space:nowrap">top-line</span> efficacy and safety results. Scilex is planning to initiate Phase 2/3 trial in chronic neck pain in 2024. <span style="white-space:nowrap">SP-103,</span> if approved, could become the first <span style="white-space:nowrap">FDA-approved</span> lidocaine topical product for the treatment of chronic neck pain. We are developing <span style="white-space:nowrap">SP-104</span> as a novel delayed-release formulation of <span style="white-space:nowrap">low-dose</span> naltrexone hydrochloride for the treatment of fibromyalgia, which remains a largely unmet medical need given the low response rates of commercially available therapies. Naltrexone is routinely used <span style="white-space:nowrap">off-label</span> to treat fibromyalgia. There are no <span style="white-space:nowrap">low-dose</span> formulations commercially available in the United States. Our patented formulation is designed to overcome undesirable effects of immediate release naltrexone, such as hyperalgesia, dysphoria, nausea, anxiety and insomnia. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are focused on identifying treatment options for pain management with established mechanisms that have deficiencies in safety, efficacy or patient experience. We believe this approach allows us to potentially leverage the regulatory approval pathway available under Section&#160;505(b)(2) of the Federal Food, Drug, and Cosmetic Act for each of our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following chart illustrates completed and anticipated milestones for our current commercial products and novel product candidates. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g759370g00a01.jpg" alt="LOGO"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at&#160;960 San Antonio Road, Palo Alto, California&#160;94303, and our telephone number is (650) <span style="white-space:nowrap">516-4310.</span> For additional information about us, please see the sections of this prospectus titled &#8220;<span style="font-style:italic">Business</span>&#8221; and &#8220;<span style="font-style:italic">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See the section of this prospectus titled &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; in this prospectus for a discussion of some of the risks related to the execution of our business strategy. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Business Combination </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;10, 2022 (the &#8220;Closing Date&#8221;), Vickers consummated the previously announced Business Combination pursuant to the terms of the Merger Agreement, by and among Vickers, Merger Sub and Legacy Scilex. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger Agreement, (i)&#160;prior to the Closing, Vickers changed its jurisdiction of incorporation by deregistering as a Cayman Islands exempted company and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware (the &#8220;Domestication&#8221;) and (ii)&#160;at the Closing, and following the Domestication, Merger Sub merged with and into Legacy Scilex (the &#8220;Merger&#8221;), with Legacy Scilex as the surviving company in the Merger, and, after giving effect to such Merger, Legacy Scilex became a wholly owned subsidiary of Vickers. The Merger was approved by Vickers&#8217;s shareholders at a meeting held on November&#160;9, 2022. In connection with the Business Combination, Vickers changed its name to &#8220;Scilex Holding Company.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the terms and subject to the conditions of the Merger Agreement, at the Effective Time, (i)&#160;each outstanding share of Legacy Scilex Common Stock outstanding immediately prior to the Effective Time was automatically cancelled in exchange for the right to receive&#160;0.673498 shares of our Common Stock, (ii)&#160;each share of Legacy Scilex Preferred Stock outstanding immediately prior to the Effective Time was cancelled in exchange for the right to receive (a)&#160;one share of Series A Preferred Stock and <span style="white-space:nowrap">(b)&#160;one-tenth</span> of one share of our Common Stock, and (iii)&#160;each option to purchase shares of Legacy Scilex Common Stock outstanding as of immediately prior to the Effective Time was converted into the right to receive a comparable option to purchase shares of our Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock and Public Warrants are currently listed on the Nasdaq Capital Market under the symbols &#8220;SCLX&#8221; and &#8220;SCLXW,&#8221; respectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights of holders of our Common Stock and Warrants are governed by the Certificate of Incorporation, the Bylaws and the DGCL, and, in the case of the Warrants, the Warrant Agreement, dated January&#160;6, 2021, between Vickers and Continental (the &#8220;Warrant Agreement&#8221;). See sections of this prospectus titled &#8220;<span style="font-style:italic">Description of Our Securities</span>&#8221; and &#8220;<span style="font-style:italic">Certain Relationships and Related Party Transactions</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recent Development </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;29, 2024, we entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Rodman&#160;&amp; Renshaw LLC and StockBlock Securities LLC, as the representatives (the &#8220;Representatives&#8221;) of the underwriters named in Schedule A (the &#8220;Underwriters&#8221;). Pursuant to the Underwriting Agreement, we agreed to sell, in an underwritten offering (the &#8220;Bought Deal Offering&#8221;), 5,882,353 shares (the &#8220;Firm Shares&#8221;) of the Common Stock, and accompanying common warrants to purchase up to an aggregate of 5,882,353 shares of Common Stock (the &#8220;Firm Warrants&#8221;). Pursuant to the Underwriting Agreement, we also granted the Underwriters an option for a period of 30 days from the date of the Underwriting Agreement to purchase up to 882,352 additional shares of Common Stock (the &#8220;Optional Shares&#8221;, and together with the Firm Shares, the &#8220;Shares&#8221;) and/or common warrants to purchase up to 882,352 shares of Common Stock (the &#8220;Optional Warrants&#8221;, and together with the Firm Warrants, the &#8220;Common Warrants&#8221;) that may be purchased by the Underwriters, at a price per Optional Share of $1.5548 and a price per Optional Warrant of $0.0092, which amounts reflect the public offering price of $1.69 per Optional Share and $0.01 per Optional Warrant, less underwriting discounts and commissions, as applicable (the &#8220;Underwriters&#8217; Option&#8221;).&#160;Each Firm Share was sold together with a Firm Warrant at a combined public offering price of $1.70. The combined price per Firm Share and accompanying Firm Warrant paid by the Underwriters was $1.564, which amount reflects the combined public offering price of $1.70, less underwriting discounts and commissions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to certain ownership limitations, the Common Warrants are exercisable immediately from the date of issuance, will expire on the five-year anniversary of the date of issuance and have an exercise price of $1.70 per share. The exercise price of the Common Warrants is subject to certain adjustments, including (but not limited to) for stock dividends, stock splits, combinations and reclassifications of the Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Bought Deal Offering, we agreed, pursuant to the Underwriting Agreement, to issue the Representatives warrants (the &#8220;Representative Warrants&#8221;, and together with the Common Warrants, the </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#8220;Warrants&#8221;) to purchase up to an aggregate of 470,588 shares of Common Stock (which represents 8.0% of the aggregate number of Firm Shares sold in the Bought Deal Offering), or up to an aggregate of 541,176 shares of Common Stock if the Underwriters exercise the Underwriters&#8217; Option in full. The Representative Warrants are immediately exercisable and have the same terms as the Common Warrants described above, except that the exercise price of the Representative Warrants is $2.125 per share, which represents 125% of the combined public offering price per Firm Share and accompanying Firm Warrant. We also agreed to pay certain expenses of the Representatives in connection with the Bought Deal Offering, including their legal fees and <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses up to $200,000 and up to $15,950 for clearing expenses. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Shares, the Warrants and the shares of Common Stock issuable upon exercise of the Warrants were offered and sold by us pursuant to an effective shelf registration statement on Form <span style="white-space:nowrap">S-3,</span> which was originally filed with the SEC on December&#160;22, 2023, as amended, and was declared effective on January&#160;11, 2024 (File <span style="white-space:nowrap">No.&#160;333-276245),</span> a base prospectus dated January&#160;11, 2024, and a final prospectus supplement dated February&#160;29, 2024. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Emerging Growth Company </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of&#160;2012 (the &#8220;JOBS Act&#8221;). As an emerging growth company, we are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of&#160;2002, as amended (the &#8220;Sarbanes-Oxley Act&#8221;), reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <span style="white-space:nowrap">non-emerging</span> growth companies but any such election to opt out is irrevocable. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, changes in rules of U.S.&#160;generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance to changes in our business could significantly affect our business, financial condition and results of operations. In addition, we are in the process of evaluating the benefits of relying on the other exemptions and reduced reporting requirements provided by the JOBS Act, as more fully described in the section of this prospectus titled &#8220;<span style="font-style:italic">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Emerging Growth Company</span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the earlier of: (i)&#160;the last day of the fiscal year (a)&#160;following the fifth anniversary of the closing of the IPO, (b)&#160;in which we have total annual gross revenue of at least $1.235&#160;billion, or (c)&#160;in which we are deemed to be a large accelerated filer, which means the market value of our common equity that is held by <span style="white-space:nowrap">non-affiliates</span> equals or exceeds $700&#160;million as of the last business day of our most recently completed second fiscal quarter; and (ii)&#160;the date on which we have issued more than $1.0&#160;billion in <span style="white-space:nowrap">non-convertible</span> debt securities during the prior three-year period. References herein to &#8220;emerging growth company&#8221; have the meaning associated with it in the JOBS Act. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Summary Risk Factors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to our Limited Operating History, Financial Condition and Capital Requirements </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We currently have two commercial products (with our third, GLOPERBA, expected to launch in the first half of 2024), ZTlido and ELYXYB; but we are currently heavily dependent on the commercial success of ZTlido, as ELYXYB is in the initial stages of commercialization and we have not yet launched GLOPERBA, and we may be unable to generate sufficient revenue to support our operations. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We have a limited operating history and have incurred significant losses since our inception. We anticipate that we will incur continued losses for the foreseeable future. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The terms of the Oramed Note (as defined below) place restrictions on our operating and financial flexibility. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We will require substantial additional funding, which may not be available to us on acceptable terms, or at all. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our recurring losses from operations, negative cash flows and substantial cumulative net losses raise substantial doubt about our ability to continue as a going concern. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to our Commercial Operations and Product Development </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We obtain our commercial supply of certain of our products, the clinical supply of our product candidates and certain of the raw materials used in our product candidates from sole or single source suppliers and manufacturers. In the event of a loss of one of these suppliers or manufacturers, or a failure by any such supplier or manufacturer to comply with FDA regulations, we may not be able to find an alternative source on commercially reasonable terms, or at all. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We rely on third parties to conduct our clinical trials and intend to rely on third parties to conduct all of our future clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Interim <span style="white-space:nowrap">&#8220;top-line&#8221;</span> and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ZTlido, GLOPERBA and ELYXYB may have undesirable properties that could result in significant negative consequences, and our product candidates may cause undesirable side effects that could delay or prevent their regulatory approval. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to our Business and Operations </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If we are unable to retain our key executives, it may delay our development efforts and harm our business, financial condition and results of operations. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Any disruption in our research and development facilities could adversely affect our business, financial condition and results of operations. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to our Intellectual Property </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We are substantially dependent on the intellectual property we <span style="white-space:nowrap">in-license</span> from Oishi and Itochu, and if we lose the right to license such intellectual property or if the Product Development Agreement is terminated for any reason, our ability to commercialize ZTlido and develop and commercialize <span style="white-space:nowrap">SP-103</span> would be harmed. </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We are party to the Romeg Agreement for the <span style="white-space:nowrap">in-licensing</span> of certain intellectual property rights from Romeg with respect to the commercialization of GLOPERBA, and if we lose the right to license such intellectual property or if the Romeg Agreement is terminated for any reason, our ability to commercialize GLOPERBA would be harmed. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If we are unable to maintain patent protection for ZTlido, GLOPERBA, ELYXYB and our product candidates, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to Government Regulations </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The regulatory approval processes of the FDA and comparable <span style="white-space:nowrap">non-U.S.&#160;regulatory</span> authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business, financial condition and results of operations will be substantially harmed. Moreover, gaining approval for a product candidate in one country or jurisdiction does not guarantee that we will be able to obtain approval for or commercialize it in any other jurisdiction, which would limit our ability to realize our full market potential. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Any approved product candidate will be subject to ongoing and continued regulatory review, which may result in significant expense and limit our ability to commercialize such products. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to our Relationship with Sorrento </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Certain of our directors and officers may have actual or potential conflicts of interest because of their positions with Sorrento. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our Executive Chairperson holds an executive officer position at Sorrento and devotes time to both companies. In addition, our Executive Chairperson is the chairperson of Sorrento&#8217;s board of directors. The ongoing Chapter&#160;11 Cases (as defined below) could require that such executive devotes time to such proceedings, which could cause a diversion of his time and attention from our business and operations, and as a result could have a material adverse effect on our business and operations. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to Ownership of our Common Stock </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If our operations and performance do not meet the expectations of investors or securities analysts, the market price of our securities may decline. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The securities being offered in this prospectus represent a significant percentage of our outstanding Common Stock. The Selling Stockholders acquired or may acquire the securities covered by this prospectus at different prices, some substantially below the current trading price of such securities and may therefore make substantial profits upon resales. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We are an emerging growth company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our Common Stock less attractive to investors. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We are no longer a &#8220;controlled company&#8221; under the corporate governance rules of Nasdaq. However, during the applicable <span style="white-space:nowrap">phase-in</span> periods, we may rely on exemptions from certain corporate governance requirements, which may limit the presence of independent directors on our Board or committees of our Board. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Corporate Information </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated under the name &#8220;Vickers Vantage Corp. I&#8221; on February&#160;21, 2020 as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reorganization or similar business combination with one or more businesses or entities. On November&#160;9, 2022, we changed our jurisdiction of incorporation by deregistering as a Cayman Islands exempted company and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware. On November&#160;9, 2022, we changed our name to &#8220;Scilex Holding Company&#8221;. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at&#160;960 San Antonio Road, Palo Alto, California&#160;94303, and our telephone number is (650) <span style="white-space:nowrap">516-4310.</span> Our website address is <span style="font-style:italic">www.scilexholding.com</span>. Any information contained on, or that can be accessed through, our website is not incorporated by reference into, nor is it in any way part of this prospectus and should not be relied upon in connection with making any decision with respect to an investment in our securities. We are required to file annual, quarterly and current reports, proxy statements and other information with the SEC. You may obtain any of the documents filed by us with the SEC at no cost from the SEC&#8217;s website at <span style="font-style:italic">http://www.sec.gov.</span> </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">15 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx759370_5">THE OFFERING </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Resale of Common Stock </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of Common Stock offered by the Selling Stockholders </p></td>
<td>Up to 13,324,683 shares of our Common Stock, consisting of: </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:40%">&#160;</td>
<td style="width:2%;vertical-align:top" align="right">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">13,000,000 Penny Warrant Shares; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:40%">&#160;</td>
<td style="width:2%;vertical-align:top" align="right">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">324,683 HB Shares. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; padding-bottom:3pt; margin-top:-2pt; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of Common Stock outstanding before this Offering<sup style="font-size:75%; vertical-align:top">(1)</sup> </p></td>
<td>166,189,835 shares of Common Stock (as of March&#160;15, 2024). </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of Common Stock outstanding after the Offering and giving effect to the issuance of 13,000,000 shares of Common Stock </p></td>
<td>179,189,835 shares of Common Stock (based on total shares outstanding as of March&#160;15, 2024). </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Terms of the Offering </p></td>
<td>The Selling Stockholders will determine when and how they will dispose of any shares of Common Stock registered under this prospectus for resale. </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </p></td>
<td>We will not receive any proceeds from the sale of shares of Common Stock by the Selling Stockholders. However, to the extent the Penny Warrants are exercised for cash, if at all, we will receive the exercise price of the Penny Warrants in an amount of up to an aggregate of $130,000, assuming the exercise in full of all of the Penny Warrants. Each Penny Warrant entitles the holder thereof to purchase one share of Common Stock at a price of $0.01 per share. We expect to use the net proceeds from the exercise of the Penny Warrants for cash for working capital and general corporate purposes, which may include capital expenditures, commercialization expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital stock. See &#8220;<span style="font-style:italic">Use of Proceeds</span>&#8221; elsewhere in this prospectus. </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Market for our Common Stock </p></td>
<td>Our Common Stock is listed on the Nasdaq Capital Market under the symbol &#8220;SCLX&#8221;. </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </p></td>
<td>See &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; beginning on page 18 and other information included in this prospectus for a discussion of factors you should carefully consider before deciding to invest in the securities being offered by this prospectus. </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The number of shares of Common Stock outstanding assumes that an aggregate of 166,189,835 shares are outstanding immediately prior to the completion of this offering, which number is based on an aggregate of 160,084,250 shares outstanding as of December&#160;31, 2023 plus an aggregate of 6,105,585 shares of Common Stock issued after December&#160;31, 2023 and on or prior to March&#160;15, 2024 (comprised of (i)&#160;an aggregate of 96,982 shares of Common Stock issued pursuant to advances made under the Company&#8217;s then-existing standby equity lines of credit, (ii) 92,295 shares of Common Stock issued pursuant to the ATM Sales Agreement, (iii) 33,955 shares of Common Stock issued upon exercise of outstanding stock options, and </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">16 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
(iv)&#160;an aggregate of 5,882,353 shares of Common Stock issued in connection with the closing of an underwritten offering of shares of our Common Stock on March&#160;5, 2024), and assumes that following March&#160;15, 2024 we have not issued any additional shares of Common Stock to Yorkville pursuant to the A&amp;R Yorkville Purchase Agreement (which was terminated on March&#160;25, 2024) or the Convertible Debentures (which are no longer outstanding as of March&#160;18, 2024), and excludes: </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">653,282 shares of Common Stock issuable upon the exercise of stock options outstanding under the&#160;2017 Scilex Pharmaceuticals Inc. Equity Incentive Plan (the &#8220;Scilex Pharma&#160;2017 Plan&#8221;) with a weighted average exercise price of $0.77 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">15,599,900 shares of Common Stock issuable upon the exercise of stock options outstanding under the&#160;2019 Stock Option Plan of Legacy Scilex (the &#8220;2019 Stock Option Plan&#8221;) with a weighted average exercise price of $1.73 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">16,798,718 shares of Common Stock issuable upon the exercise of stock options outstanding under the Scilex Holding Company 2022 Equity Incentive Plan (the &#8220;Equity Incentive Plan&#8221;), with a weighted average exercise price of $6.98 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">up to 13,764,217 shares of Common Stock available for future issuance under the Equity Incentive Plan; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">up to 2,875,759 shares of Common Stock available for future issuance under the Scilex Holding Company 2022 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">up to&#160;1,400,000 shares of Common Stock available for future issuance under the Scilex Holding Company&#160;2023 Inducement Plan (the &#8220;Inducement Plan&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">10,958,309 shares of Common Stock issuable upon the exercise of the Warrants, with an exercise price of $11.50&#160;per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">13,000,000 shares of Common Stock issuable upon the exercise of the Penny Warrants, with an exercise price of $0.01&#160;per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">5,882,353 shares of Common Stock issuable upon the exercise of the warrants to purchase shares of Common Stock, with an exercise price of $1.70&#160;per share; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">470,588 shares of Common Stock issuable upon the exercise of the warrants to purchase shares of Common Stock, with an exercise price of $2.125&#160;per share. </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">17 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx759370_6">RISK FACTORS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Investing in our securities involves a high degree of risk. Before making an investment decision, you should consider carefully the following risk factors, as well as the other information set forth in this prospectus, including matters addressed in the section of this prospectus titled &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221;. If any of these risks actually occur, it may materially harm our business, financial condition, liquidity and results of operations. As a result, the market price of our securities could decline, and you could lose all or part of your investment. Additionally, the risks and uncertainties described in this prospectus, any prospectus supplement, any post-effective amendment or in any document incorporated by reference herein or therein are not the only risks and uncertainties that we face. We may face additional risks and uncertainties that are not presently known to us, or that we currently deem immaterial. The following discussions should be read in conjunction with our financial statements and the notes to the financial statements included therein. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to our Limited Operating History, Financial Condition and Capital Requirements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We currently have two commercial products (with our third, GLOPERBA, expected to launch in the first half of 2024), ZTlido and ELYXYB; but we are currently heavily dependent on the commercial success of ZTlido, as ELYXYB is in the initial stages of commercialization and we have not yet launched GLOPERBA, and we may be unable to generate sufficient revenue to support our operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently have two commercial products (with our third, GLOPERBA, expected to launch in the first half of 2024), ZTlido and ELYXYB; but we are currently heavily dependent upon ZTlido sales to generate revenue, as ELYXYB is in the initial stages of commercialization and we have not yet launched GLOPERBA. In February 2018, we obtained regulatory approval for ZTlido for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve pain, and we began commercializing ZTlido in the United States in October 2018. In late February 2023, we acquired ELYXYB, a potential first-line treatment and the only <span style="white-space:nowrap">FDA-approved,</span> <span style="white-space:nowrap"><span style="white-space:nowrap">ready-to-use</span></span> oral solution for the acute treatment of migraine, with or without aura, in adults, in the U.S. We launched ELYXYB in April of 2023. As a result, it is difficult to evaluate our current business and predict our future prospects. We cannot assure that ZTlido or ELYXYB will gain market acceptance among physicians, health care payors, patients and the medical community, which is critical to our commercial success. We have limited experience engaging in commercial activities and limited relationships with physicians, hospitals and payors. Market acceptance of ZTlido and ELYXYB and following its launch, GLOPERBA, depends on a number of factors, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">acceptance by physicians, major operators of clinics and patients of ZTlido and ELYXYB, and following its launch, GLOPERBA, as a safe and effective treatment for the relief of neuropathic pain associated with PHN; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the availability, cost and potential advantages of alternative treatments, including less expensive generic products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effectiveness of our sales and marketing efforts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the availability of coverage, adequacy of reimbursement and favorability of pricing policies by third-party payors and government authorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing of market introduction of other competitive products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the product labeling or any product inserts required by the FDA; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the prevalence and severity of adverse side effects. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to successfully commercialize ZTlido, ELYXYB and GLOPERBA (which we expect to launch in the first half of 2024), we will need to expand our marketing efforts to develop new relationships and expand existing relationships. Physicians may decide not to prescribe ZTlido, ELYXYB or GLOPERBA for a variety of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">18 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reasons, including changes in available offerings, adverse publicity, perceived safety issues, inadequate coverage or reimbursement for ZTlido, ELYXYB or GLOPERBA or the utilization of products developed by other parties, all of which are circumstances outside of our control. Demand for ZTlido may not increase, or may not develop for ELYXYB or GLOPERBA, as quickly as we predict, and we may be unable to increase our revenue to the level that we currently expect. Even if we succeed in increasing market acceptance of ZTlido or developing market acceptance of ELYXYB and GLOPERBA, and maintaining and creating relationships with physicians, we may be unable to reach or sustain a level of profitability. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to effectively promote ZTlido, ELYXYB and GLOPERBA will also depend on pricing and cost-effectiveness, including our ability to produce at a competitive price. In addition, our efforts to educate the medical community and third-party payors on the benefits of ZTlido, ELYXYB and GLOPERBA may require significant resources, may be constrained by FDA rules and policies on product promotion and may never be successful. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have a limited operating history and have incurred significant losses since our inception. We anticipate that we will incur continued losses for the foreseeable future. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have a limited operating history. Prior to March 2019, our operations were conducted through Scilex Pharma, which was formed in September 2012 and is now our wholly owned subsidiary. In March 2019, we effected a corporate reorganization and acquired Semnur, which was formed in June 2013. Since our inception, we have focused on organizing and staffing our company, business planning, raising capital, identifying potential <span style="white-space:nowrap">non-opioid</span> pain therapy candidates, undertaking preclinical studies and clinical trials of our product candidates and establishing research and development and manufacturing collaborations. Most of our revenue to date is attributable to sales of ZTlido, and we expect that sales of ZTlido will account for most of our revenue for at least the near term. Our relatively short operating history as a company makes any assessment of our future success and viability subject to significant uncertainty. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval and become commercially viable. We will encounter risks and difficulties frequently experienced by early-stage biopharmaceutical companies in rapidly evolving fields, and we have not yet demonstrated an ability to overcome such risks and difficulties successfully. Our ability to execute on our business model and generate revenues depends on a number of factors including our ability to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">successfully complete ongoing <span style="white-space:nowrap">pre-clinical</span> studies and clinical trials and obtain regulatory approvals for our current and future product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">identify new acquisition or <span style="white-space:nowrap">in-licensing</span> opportunities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">successfully identify new product candidates and advance those product candidates into <span style="white-space:nowrap">pre-clinical</span> studies and clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">raise additional funds when needed and on terms acceptable to us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">attract and retain experienced management and advisory teams; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">add operational, financial and management information systems and personnel, including personnel to support clinical, <span style="white-space:nowrap">pre-clinical</span> manufacturing and planned future commercialization efforts and operations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">launch commercial sales of our product candidates, whether alone or in collaboration with others; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">initiate and continue relationships with third-party suppliers and manufacturers and have commercial quantities of product candidates manufactured at acceptable cost and quality levels and in compliance with the FDA, and other regulatory requirements; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">19 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">set acceptable prices for product candidates and obtain coverage and adequate reimbursement from third-party payors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">achieve market acceptance of product candidates in the medical community and with third-party payors and consumers; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">maintain, expand and protect our intellectual property portfolio. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we cannot successfully execute any one of the foregoing, our business may not succeed or become profitable. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since our inception, we have incurred significant net losses, with net losses of $114.3&#160;million, $23.4&#160;million and $88.4&#160;million for the years ended December&#160;31, 2023, 2022 and 2021, respectively. As of December&#160;31, 2023 and December&#160;31, 2022, we had an accumulated deficit of approximately $490.2&#160;million and $375.9&#160;million, respectively. For the foreseeable future, we expect to continue to incur significant expenses related to the commercialization of ZTlido, GLOPERBA and ELYXYB and the research and development of our product candidates, <span style="white-space:nowrap">SP-102</span> (10 mg dexamethasone sodium phosphate viscous gel) (&#8220;SEMDEXA&#8221;), <span style="white-space:nowrap">SP-103</span> (lidocaine topical system) 5.4% <span style="white-space:nowrap">(&#8220;SP-103&#8221;),</span> and <span style="white-space:nowrap">SP-104</span> (4.5mg, <span style="white-space:nowrap">low-dose</span> naltrexone hydrochloride delayed-release capsules) <span style="white-space:nowrap">(&#8220;SP-104&#8221;).</span> We anticipate that our expenses will increase substantially due to any future trials related to SEMDEXA and <span style="white-space:nowrap">SP-103</span> and initiation of the Phase 2 clinical trial for <span style="white-space:nowrap">SP-104.</span> Consequently, we expect to incur substantial losses for the foreseeable future and may never become profitable. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to risks incidental to the development of new biopharmaceutical products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are unable to raise capital through a registered offering, we would be required to conduct our equity financing transactions on a private placement basis, which may be subject to pricing, size and other limitations imposed under the Nasdaq Listing Rules, or seek other sources of capital. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The terms of the eCapital Credit Agreement may restrict the operation of our business and limit the cash available for investment in our business operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The eCapital Credit Agreement (the &#8220;eCapital Credit Agreement&#8221;), dated as of June&#160;27, 2023, between Scilex Pharma and eCapital Healthcare Corp. (the &#8220;ABL Lender&#8221;), provides that Scilex Pharma will be made available loans (the &#8220;Revolving Facility&#8221;) in an aggregate principal amount of up to $30,000,000, subject to certain terms and conditions, which facility cap may be increased at the request of Scilex Pharma and with the consent of the ABL Lender. Under the eCapital Credit Agreement, Scilex Pharma shall make interest payments monthly in arrears. We agreed to unconditionally guarantee the prompt, complete and full payment of Scilex Pharma&#8217;s obligations under the eCapital Credit Agreement. The payment and performance obligations under the eCapital Credit Agreement are also secured by a continuing security interest in Scilex Pharma&#8217;s accounts receivable, related deposit accounts and in the other &#8220;Collateral&#8221; as defined in the eCapital Credit Agreement. In addition, the eCapital Credit Agreement includes customary affirmative and negative covenants that will limit or restrict the ability of Scilex Pharma, subject to negotiated exceptions, to incur additional indebtedness and additional liens on its assets, engage in mergers or acquisitions or dispose of assets, pay dividends or make other distributions, enter into transactions with affiliated persons, or make investments. Pursuant to that certain Subordination Agreement (the &#8220;Subordination Agreement&#8221;), dated as of September&#160;21, 2023, entered into by Scilex Pharma with the ABL Lender and Acquiom Agency Services LLC (the &#8220;Agent&#8221;), the parties agreed that the ABL Lender&#8217;s rights and interests under the eCapital Credit Agreement and the Agent&#8217;s rights and interests under that certain Subsidiary Guarantee (the &#8220;Subsidiary Guarantee&#8221;), dated as of September&#160;21, 2023, entered into by us and each of our subsidiaries with Oramed and the Agent, shall be secured by first priority liens on certain other collateral and second priority liens on the ABL Priority Collateral (as defined in the Subordination Agreement). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">20 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms of the eCapital Credit Agreement and borrowings we may make in the future could have significant adverse consequences for our business, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">requiring us, Scilex Pharma or our other subsidiaries to dedicate a substantial portion of cash and cash equivalents and marketable securities to the payment of interest on, and principal of, our debt, which would reduce the amounts available to fund operating expenditures, including working capital, capital expenditures and other general corporate purposes; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obligating us, Scilex Pharma or our other subsidiaries to additional negative covenants further restricting our activities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">requiring compliance with affirmative covenants, including payment and reporting covenants; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">making it more difficult for us to successfully execute our business strategy, invest in our growth strategy and compete against companies who are not subject to such restrictions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">limiting our flexibility in planning for, or reacting to, changes in our business and our industry; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">placing us at a competitive disadvantage compared to our competitors that have less debt, better debt servicing options or stronger debt servicing capacity. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scilex Pharma intends to satisfy the payment obligation under the eCapital Credit Agreement with its existing cash and cash equivalents, anticipated product revenue from ZTlido, GLOPERBA and ELYXYB, and funds from external sources. However, Scilex Pharma may not have sufficient funds or may be unable to arrange for additional financing to pay the amounts due under the eCapital Credit Agreement or future debt. Funds from external sources may not be available on acceptable terms, if at all. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, failure to comply with the covenants under the eCapital Credit Agreement, including those outside of Scilex Pharma&#8217;s control, could result in an event of default. The events of default include, among others, a change of control of Scilex Pharma. Upon an event of default, subject to notice requirements in the case of certain events of default, the commitments and other obligations of the ABL Lender under the eCapital Credit Agreement may be terminated and all amounts outstanding under the eCapital Credit Agreement may become immediately due and payable. Scilex Pharma may not have sufficient funds or may be unable to arrange for additional financing to repay its indebtedness or to make any accelerated payments, and the ABL Lender could seek to enforce its security interests in the collateral securing such indebtedness or other remedies available to it under the eCapital Credit Agreement or as provided by applicable law. The ABL Lender could also seek to enforce the guaranty provided by us to carry out Scilex Pharma&#8217;s payment obligations. Any failure by Scilex Pharma or us to comply with the obligations under the eCapital Credit Agreement could have a negative effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The terms of the Oramed Note place restrictions on our operating and financial flexibility. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;21, 2023 (the &#8220;Oramed Closing Date&#8221;), we issued and sold to Oramed a senior secured promissory note due 18 months from the date of issuance in the principal amount of $101,875,000 (the &#8220;Oramed Note&#8221;) pursuant to that certain securities purchase agreement we entered into with Oramed, dated as of September&#160;21, 2023 (the &#8220;Scilex-Oramed SPA&#8221;). The Oramed Note matures on March&#160;21, 2025 and is payable in six principal installments, with the first installment in the principal amount of $5,000,000 paid on December&#160;21, 2023, the second installment in the principal amount of $15,000,000 payable on March&#160;21, 2024 and the next three installments each in the principal amount of $20,000,000 payable on each of June&#160;21, 2024, September&#160;21, 2024 and December&#160;21, 2024 and the last installment in the entire remaining principal balance of the Oramed Note payable on March&#160;21, 2025. Interest under the Oramed Note accrues at a fluctuating per annum interest rate equal to the sum of (1)&#160;greater of (x)&#160;four percent (4%) and (y)&#160;Term SOFR (as defined in the Oramed Note) and (2)&#160;eight and one half percent (8.5%), payable <span style="white-space:nowrap">in-kind</span> on a monthly basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Oramed Note, if the outstanding principal of the Oramed Note has not been repaid in full on or prior to March&#160;21, 2024, an exit fee of $3,056,250 shall become fully earned with respect to the Oramed Note, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">21 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which shall be due and payable on the date on which the outstanding principal amount of the Oramed Note is paid in full. Such exit fee has been fully earned. Upon the occurrence and during the continuance of an event of default under the Oramed Note, holders of more than 50% of the aggregate unpaid principal amount of the Oramed Notes may elect to cause all outstanding amounts under the Oramed Note to accrue interest at a default rate equal to the lesser of (i)&#160;Term SOFR plus fifteen percent (15%) or (ii)&#160;the maximum rate permitted under applicable law. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any voluntary prepayments of the Oramed Note occurring prior to the <span style="white-space:nowrap">one-year</span> anniversary of the Oramed Closing Date are required to be paid together with a make-whole amount equal to 50% of the amount of additional interest that would accrue on the principal amount so prepaid under the Oramed Note from the date of such prepayment through and including the maturity date. If the Oramed Note is accelerated upon an event of default, the Company is required to repay the principal amount of the Oramed Note at a mandatory default rate of 125% of such principal amount (together with 100% of accrued and unpaid interest thereon and all other amounts due in respect of the Oramed Note). The Oramed Note contains mandatory prepayment provisions requiring us and our subsidiaries to, following the earlier of (x)&#160;April&#160;1, 2024, and (y)&#160;the date on which the Acceptable Indebtedness (as defined in the Oramed Note) is repaid in full, use 70% of the net cash proceeds of any Cash Sweep Financing (as defined in the Oramed Note) or advance under the ELOCs (as defined in the Oramed Note) to prepay the outstanding principal amount of the Oramed Note (the &#8220;Mandatory Prepayment Sweep&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Oramed Note contains affirmative and negative covenants binding on us and our subsidiaries which restrict, among other things, us and our subsidiaries from incurring indebtedness or liens, amending charter and organizational documents, repaying or repurchasing stock, repaying, repurchasing, or acquiring indebtedness, paying or declaring cash dividends, assigning, selling, transferring or otherwise disposing of assets, making or holding investments, entering into transactions with affiliates, and entering into settlement agreements, in each case as more fully set forth in, and subject to certain qualifications, exceptions, and &#8220;baskets&#8221; set forth in the Oramed Note. The Oramed Note also contains covenants requiring the Company to maintain a segregated bank account under specific terms and conditions, for purposes of receiving the Mandatory Prepayment Sweep, requiring SCLX JV to comply with the separateness representations and covenants in its organizational documents, and requiring our subsidiary, SCLX DRE Holdings LLC, to maintain its status as a passive holding company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Oramed Note contains certain customary events of default, including, without limitation, a cross-default to other specified indebtedness or any other indebtedness involving an obligation of greater than $1,000,000, as well as an event of default upon a Change of Control Transaction or Fundamental Transaction (in each case, as defined in the Oramed Note). See the risk factor titled &#8220;<span style="font-style:italic">We may not have the ability to raise the funds necessary to settle the Oramed Note in cash upon a change of control or other event of default</span>&#8221; for additional information regarding such event of default provisions. The Oramed Note also contains additional events of default with respect to certain events relating to our obligations under that certain registration rights agreement, dated as of September&#160;21, 2023, between us and Oramed and relating to (i)&#160;the warrants to purchase up to an aggregate of 13,000,000 shares of Common Stock, with an exercise price of $0.01 per share (the &#8220;Penny Warrants&#8221;), that we issued to Oramed pursuant to the Scilex-Oramed SPA, (ii)&#160;the warrants to purchase up to 4,000,000 shares of Common Stock, with an exercise price of $11.50 per share (the &#8220;Transferred Warrants&#8221;), that we transferred to Oramed pursuant to the Scilex-Oramed SPA and/or (iii)&#160;the shares of Common Stock underlying the Penny Warrants or Transferred Warrants, in each case as more fully set forth in the Oramed Note. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, failure to comply with the covenants under the Oramed Note could result in an event of default. The events of default include, among others, a change of control of the Company. Upon an event of default, subject to notice requirements in the case of certain events of default, all amounts outstanding under the Oramed Note may become immediately due and payable. We may not have sufficient funds or may be unable to arrange for additional financing to repay such indebtedness or to make any accelerated payments, and Oramed could seek to enforce its security interests in the collateral securing such indebtedness or other remedies available to it under the Oramed Note or as provided by applicable law. Oramed could also seek to enforce the guaranty under the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">22 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Subsidiary Guarantee entered into by us and each of our subsidiaries (collectively, the &#8220;Guarantors&#8221;), dated as of September&#160;21, 2023, to carry out our payment obligations under the Oramed Note. Any failure by us to comply with the obligations under the Oramed Note could have a negative effect on our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our outstanding indebtedness and any future indebtedness we may incur, combined with our other financial obligations, could increase our vulnerability to adverse changes in general economic, industry and market conditions, limit our flexibility in planning for, or reacting to, changes in our business and the industry and impose a competitive disadvantage compared to our competitors that have less debt or better debt servicing options. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not have the ability to raise the funds necessary to settle the Oramed Note in cash upon a change of control or other event of default. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A change of control transaction triggers an event of default under the Oramed Note, which will result in the full unpaid principal amount of the Oramed Note, together with interest and other amounts owing in respect thereof, to the date of acceleration becoming, at the election of the holder of the Oramed Note, immediately due and payable in cash at the Mandatory Default Amount (as defined in the Oramed Note). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In such event or in the event of any other event of default under the Oramed Note, we may not have enough available cash or be able to obtain financing at the time we are required to pay cash with respect to the Oramed Note. In addition, our ability to pay cash upon default of the Oramed Note may be limited by law, regulatory authority, or any agreements governing our future indebtedness<span style="font-weight:bold"><span style="font-style:italic">.</span></span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be required to make milestone payments to the former stockholders of Semnur in connection with our development and commercialization of SEMDEXA, which could adversely affect the overall profitability of SEMDEXA, if approved. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the Agreement and Plan of Merger we entered into with Semnur, Sigma Merger Sub, Inc., our prior wholly owned subsidiary, Fortis Advisors LLC, solely as representative of the holders of Semnur equity (the &#8220;Semnur Equityholders&#8221;), and Sorrento, for limited purposes, we are obligated to pay the Semnur Equityholders up to an aggregate of $280.0&#160;million in contingent cash consideration based on the achievement of certain milestones. A $40.0&#160;million payment will be due upon obtaining the first approval of a new drug application by the FDA (&#8220;NDA&#8221;) of any Semnur product, which includes SEMDEXA. Additional payments will be due upon the achievement of certain cumulative net sales of Semnur products, as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a $20.0&#160;million payment upon the achievement of $100.0&#160;million in cumulative net sales of a Semnur product; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a $20.0&#160;million payment upon the achievement of $250.0&#160;million in cumulative net sales of a Semnur product; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a $50.0&#160;million payment upon the achievement of $500.0&#160;million in cumulative net sales of a Semnur product; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a $150.0&#160;million payment upon the achievement of $750.0&#160;million in cumulative net sales of a Semnur product. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These milestone obligations could impose substantial additional costs on us, divert resources from other aspects of our business, and adversely affect the overall profitability of SEMDEXA, if approved. We may need to obtain additional financing to satisfy these milestone payments, and cannot be sure that any additional funding, if needed, will be available on terms favorable to us, or at all. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">23 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We will require substantial additional funding, which may not be available to us on acceptable terms, or at all. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our operations have consumed substantial amounts of cash since inception. We expect to significantly increase our spending to continue our commercialization efforts for ZTlido, GLOPERBA and ELYXYB, advance development of our current product candidates and launch and commercialize any product candidates for which we receive regulatory approval. Furthermore, we expect to incur additional costs associated with operating as a public company. We will also require additional capital to fund our other operating expenses and capital expenditures. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, our cash and cash equivalents were approximately $3.9&#160;million and we had an accumulated deficit of approximately $490.2&#160;million. The amount and timing of our future funding requirements will depend on many factors, some of which are outside of our control, including but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs and expenses associated with our ongoing commercialization efforts for ZTlido, GLOPERBA and ELYXYB; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the degree of success we experience in commercializing ZTlido, GLOPERBA and ELYXYB; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the revenue generated by sales of ZTlido, GLOPERBA, ELYXYB and other products that may be approved, if any; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the scope, progress, results and costs of conducting studies and clinical trials for our product candidates, SEMDEXA, <span style="white-space:nowrap">SP-103</span> and <span style="white-space:nowrap">SP-104;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of manufacturing ZTlido, GLOPERBA, ELYXYB and our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing and amount of any milestone, royalty or other payments we are required to make pursuant to any current or future collaboration or license agreements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the extent to which ZTlido, GLOPERBA, ELYXYB or any of our product candidates, if approved for commercialization, is adopted by the physician community; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our need to expand our research and development activities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of acquiring, licensing or investing in businesses, product candidates and technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effect of competing products and product candidates and other market developments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number and types of future products we develop and commercialize; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any product liability or other lawsuits related to our products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the expenses needed to attract, hire and retain skilled personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs associated with being a public company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our need to implement additional internal systems and infrastructure, including financial and reporting systems; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the extent and scope of our general and administrative expenses. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until we are able to generate significant revenue, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">24 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transactions. We cannot be sure that any additional funding, if needed, will be available on terms favorable to us, or at all. Any additional fundraising efforts may divert our management from their <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> activities, which may adversely affect our ability to develop and commercialize our product candidates. Furthermore, any additional equity or equity-related financing may be dilutive to our stockholders, and debt or equity financing, if available, may subject us to restrictive covenants and significant interest costs. If we raise additional funds through collaborations or strategic alliances with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams, research programs or technologies, or grant licenses on terms that may not be favorable to us. If we are unsuccessful in our efforts to raise additional financing on acceptable terms, we may be required to significantly reduce or cease our operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our recurring losses from operations, negative cash flows and substantial cumulative net losses raise substantial doubt about our ability to continue as a going concern. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In Note 2 titled &#8220;<span style="font-style:italic">Liquidity and Going Concern</span>&#8221; of our consolidated financial statements included elsewhere in this prospectus, we disclose that there is substantial doubt about our ability to continue as a going concern. In addition, our independent registered public accounting firm included an explanatory paragraph in its report on our consolidated financial statements as of and for the year ended December&#160;31, 2023, which stated that management has concluded that substantial doubt exists about our ability to continue as a going concern for one year after the date our consolidated financial statements are issued. We have negative working capital and have incurred significant operating losses and negative cash flows from operations and expect to continue incurring losses for the foreseeable future. Further, we had an accumulated deficit of approximately $490.2&#160;million as of December&#160;31, 2023 and approximately $375.9&#160;million as of December&#160;31, 2022. These conditions raise substantial doubt about our ability to continue as a going concern. Our consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to become a profitable operating company is dependent upon our ability to generate revenue and obtain financing adequate to fulfill our development and commercialization activities, and achieving a level of revenue adequate to support our cost structure. We have plans to obtain additional resources to fund our currently planned operations and expenditures through additional debt and equity financing. We will need to seek additional financing to fund our current operations, including the commercialization of ZTlido, GLOPERBA and ELYXYB, as well as the development of our other material product candidates for the next 12 months. Our plans are substantially dependent upon the success of future sales of ZTlido and ELYXYB, among which ELYXYB is still in the early stages of commercialization, and are dependent upon, among other things, the success of our marketing of ZTlido and ELYXYB and our ability to secure additional payor contracts with terms that are consistent with our business plan. If we are unable to obtain sufficient funding, our financial condition and results of operations will be materially and adversely affected and we may be unable to continue as a going concern. Future financial statements may disclose substantial doubt about our ability to continue as a going concern. If we seek additional financing to fund our business activities in the future and there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding to us on commercially reasonable terms, or at all. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have previously identified a material weakness in our internal control over financial reporting. If we experience additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to timely and accurately report our financial results and such material weaknesses may result in a material misstatement of our financial statements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the audit of our consolidated financial statements for the years ended December&#160;31, 2022 and 2021, we identified control deficiencies in the design and operation of our internal control over financial reporting that constituted a material weakness. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">25 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As more fully disclosed our Annual Report on Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2023, for the years ended December&#160;31, 2022 and 2021, the material weakness identified in our internal control over financial reporting related to ineffective control activities in the areas of revenue, business combination, debt and derivative liabilities caused by a lack of sufficient accounting resources with appropriate experience and technical expertise to effectively execute controls over certain judgmental and technical accounting areas. As a result of the material weakness, we hired additional accounting personnel and are implementing remediation measures including, but not limited to, performing a comprehensive assessment of accounting and finance resource requirements and hiring other personnel with sufficient accounting expertise at our company to improve the operating effectiveness of our review controls and monitoring activities, and utilizing external accounting experts as appropriate. Any potential material misstatements were identified and corrected as audit adjustments in the applicable periods and are properly reflected in our financial statements included in this prospectus. We hired a new Chief Financial Officer in May 2022 at Legacy Scilex and she served as Chief Financial Officer of the Company through September 2023. In May 2023, we appointed a Chief Accounting Officer, who became our Chief Financial Officer in September 2023. In addition, we expect to hire additional personnel with accounting expertise and utilize external accounting experts. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, we have remediated the previously identified material weaknesses in our internal control over financial reporting. If we identify additional material weaknesses or deficiencies in internal controls in the future and we are unable to correct them in a timely manner, our ability to record, process, summarize and report financial information accurately and within the time periods specified in the rules and forms of the SEC, will be adversely affected. Any such failure could negatively affect the market price and trading liquidity of our Common Stock, lead to delisting, cause investors to lose confidence in our reported financial information, subject us to civil and criminal investigations and penalties, and generally materially and adversely impact our business and financial condition. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If, in the future, we identify material weaknesses in our internal controls over financial reporting or fail to meet the demands that will be placed upon us as a public company, including the requirements of the Sarbanes-Oxley Act, we may be unable to accurately report our financial results or report them within the timeframes required by law or stock exchange regulations. Failure to comply with Section&#160;404 of the Sarbanes-Oxley Act could also potentially subject us to sanctions or investigations by the SEC or other regulatory authorities. If additional material weaknesses exist or are discovered in the future, and we are unable to remediate any such material weakness, our business, financial condition and results of operations could suffer. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to our Commercial Operations and Product Development </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We obtain our commercial supply of certain of our products, the clinical supply of our product candidates and certain of the raw materials used in our product candidates from sole or single source suppliers and manufacturers. In the event of a loss of one of these suppliers or manufacturers, or a failure by any such supplier or manufacturer to comply with FDA regulations, we may not be able to find an alternative source on commercially reasonable terms, or at all. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely on a number of sole or single source suppliers and manufacturers, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the manufacturer and supplier for the commercial supply of ZTlido, ELYXYB and GLOPERBA; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the manufacturer and supplier for the clinical supply of <span style="white-space:nowrap">SP-103;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the manufacturer and supplier for the clinical supply of <span style="white-space:nowrap">SP-104;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the supplier of sodium hyaluronate, one of the excipients for SEMDEXA; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the manufacturer for the clinical supply of SEMDEXA. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Product Development Agreement and the Commercial Supply Agreement, we license the rights to ZTlido from, and rely exclusively on, Oishi and Itochu for the manufacturing and supply of ZTlido and <span style="white-space:nowrap">SP-103.</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">26 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Oishi and Itochu have the right to terminate the Product Development Agreement and the Commercial Supply Agreement under certain circumstances, including, among other things: (1)&#160;if we are in material breach of the agreement and the breach is not curable or if the breach is curable and we fail to cure such material breach within 180 days after notice requesting to cure; (2)&#160;if, at any time during the term of the Product Development Agreement and the Commercial Supply Agreement, the market conditions are such that (a)&#160;our total net profits for ZTlido and <span style="white-space:nowrap">SP-103</span> are equal to or less than five percent of our net sales of ZTlido and <span style="white-space:nowrap">SP-103</span> for a period of four or more consecutive quarters, or (b)&#160;the economic viability of ZTlido and <span style="white-space:nowrap">SP-103</span> is affected significantly as evidenced by documentation and substantial information by any external circumstances deemed detrimental to all parties as agreed to by us, on the one hand, and Oishi and Itochu, on the other hand, and the parties are unable to resolve the concerns under the foregoing clauses (a)&#160;and (b) after 30 days of good-faith discussion; and (3)&#160;in the event of our bankruptcy or assignment for the benefit of creditors. As of December&#160;31, 2023, our net profits for ZTlido and <span style="white-space:nowrap">SP-103</span> have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of December&#160;31, 2023, neither Oishi nor Itochu has exercised its right of termination. If the Product Development Agreement and the Commercial Supply Agreement are terminated, we would lose access to the intellectual property and proprietary manufacturing process upon which ZTlido and <span style="white-space:nowrap">SP-103</span> depend. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect our third-party manufacturers and suppliers of both GLOPERBA (which product we expect to launch in the first half of 2024) and ELYXYB are capable of providing sufficient quantities of these products to meet anticipated commercial demands; however, if third parties with whom we currently work are unable to meet our manufacturing and supply requirements, we will need to secure alternate manufacturers and suppliers or face potential delays or shortages. While we believe that there are other contract manufacturers and suppliers with the technical capabilities to manufacture and supply these products, we cannot be certain that identifying and establishing relationships with such sources would not result in significant delay or material additional costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our exclusive Supply Agreement, dated December&#160;17, 2015 (the &#8220;Genzyme Supply Agreement&#8221;), with Genzyme Corporation (&#8220;Genzyme&#8221;), we depend on Genzyme to fulfill our clinical and commercial supply requirements for sodium hyaluronate, one of the excipients for SEMDEXA, and we are aware of only a limited number of suppliers of the excipient. Genzyme has the right to terminate the Genzyme Supply Agreement under certain circumstances, including, but not limited to, if Genzyme decides to discontinue manufacturing the product at its facility for economic or strategic reasons and provides us with 24 months&#8217; notice. Genzyme has notified us of its intention to terminate the Genzyme Supply Agreement as it has determined to discontinue manufacturing the product at its facility, effective as of May&#160;31, 2024. Although we are currently in the process of identifying and certifying new suppliers to fulfill our clinical and commercial supply requirements for sodium hyaluronate, we may not be able to find an alternative supplier of sodium hyaluronate on commercially reasonable terms. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our Master Services Agreement, dated January&#160;27, 2017 (as amended, the &#8220;Lifecore Master Services Agreement&#8221;), with Lifecore Biomedical, LLC (&#8220;Lifecore&#8221;), we depend on Lifecore to manufacture clinical supplies of SEMDEXA. Lifecore has the right to terminate the Lifecore Master Services Agreement under certain circumstances, including, but not limited to: (1)&#160;if we are in material breach of the agreement and fail to cure such breach within 30 days of written notice; (2)&#160;if we (a)&#160;become insolvent, (b)&#160;cease to function as a going concern, (c)&#160;become convicted of or plead guilty to a charge of violating any law relating to either party&#8217;s business, or (d)&#160;engage in any act which materially impairs goodwill associated with SEMDEXA or materially impairs the terminating party&#8217;s trademark or trade name; (3)&#160;if we fail to pay past due invoices upon 30 days&#8217; written notice, or (4)&#160;if we reject or fail to respond to a major change proposed by Lifecore that does not change Semnur&#8217;s written and approved acceptance criteria in its product specifications. In the event that Lifecore decides to terminate the Lifecore Master Services Agreement, finding an alternative manufacturer on commercially reasonable terms, or at all, may be difficult. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Master Services Agreement (the &#8220;Tulex Master Services Agreement&#8221;) and the statement of work with Tulex Pharmaceuticals Inc. (&#8220;Tulex&#8221;), we depend on Tulex to develop, test and manufacture clinical supplies of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">27 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<span style="white-space:nowrap">SP-104.</span> Tulex has the right to terminate the Tulex Master Services Agreement under certain circumstances, including, but not limited to: (1)&#160;if we are in material breach of the agreement or a statement of work and fail to cure such breach within 15 days after receipt of notice of such breach (or such other time period expressly stated in the applicable statement of work) or (2)&#160;in the event of our insolvency, bankruptcy, reorganization, liquidation or receivership, or a failure to remove any insolvency, bankruptcy, reorganization, liquidation or receivership proceedings within ten days from the date of institution of such proceedings. In addition, we may terminate the agreement or any statement of work (a)&#160;without cause upon 30 days prior written notice to Tulex or (b)&#160;immediately upon written notice in the event Tulex is dissolved or undergoes a change in control. In the event that the Tulex Master Services Agreement or a statement of work is terminated, we may not be able to find an alternative manufacturer and supplier on commercially reasonable terms. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, the manufacturing facilities used by our third-party suppliers and manufacturers must continue to comply with FDA regulations and are subject to periodic announced or unannounced inspections. We have limited control over the ability of our third-party suppliers and manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If our third-party suppliers and manufacturers fail to comply with FDA regulations, the FDA may not authorize the manufacture of our products and product candidates at these facilities, and we may be unable to find alternative manufacturing facilities in a timely manner or at all. The failure by such third parties to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, import detention, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls of our product, operating restrictions and criminal prosecutions. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, our product candidates may compete with other product candidates and products for access to manufacturing facilities and other supplies. There are a limited number of manufacturers that operate under current Good Manufacturing Practices (&#8220;cGMP&#8221;) regulations and that might be capable of manufacturing for us. Also, prior to the approval of our product candidates, we would need to identify a contract manufacturer that could produce our products at a commercial scale and that could successfully complete FDA <span style="white-space:nowrap">pre-approval</span> inspection and inspections by other health authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need to have that capability and capacity. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the commercial supply of our commercial products, clinical supply of our product candidates and certain of the raw materials used in our product candidates are disrupted or delayed, there can be no assurance that alternative sources can serve as adequate replacements or that supplies will be available on terms that are favorable to us, if at all. Any disruption in supply could affect the profitability of ZTlido, the commercialization of GLOPERBA and ELYXYB, and the development of SEMDEXA, <span style="white-space:nowrap">SP-103</span> and <span style="white-space:nowrap">SP-104.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We rely on a single third-party logistics distribution provider, Cardinal Health 105, which until recently had also been our only customer. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently rely on Cardinal Health 105, LLC (&#8220;Cardinal Health 105&#8221;) as our third-party logistics distribution provider for ZTlido and ELYXYB in the United States. Cardinal Health 105 also performs the following services on our behalf: customer service, credit checks, invoicing, chargebacks, distributor fee for service, government reporting, customer returns, accounts receivable, inventory control, product security (DSCSA serialization) inquiries and recall assistance. If we are unable to maintain a favorable relationship with Cardinal Health 105, we expect that our revenue would decline and our business would be harmed as a result. We may be unable to control the timing of the delivery of ZTlido and ELYXYB to distributors, and any financial uncertainty or loss of key logistic employees of Cardinal Health 105, as our only third-party logistics provider, may negatively impact our sales. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the years ended December&#160;31, 2020 and 2021 and the first quarter of 2022, Cardinal Health 105 was also our only customer for ZTlido and sales to Cardinal Health 105 represented all of our net revenue for such periods. As we continue to expand the commercialization of ZTlido, we discontinued our use of &#8220;title model&#8221; services provided by Cardinal Health 105 in the second quarter of 2022 and expanded our direct distribution network to national and regional distributors and pharmacies. Beginning on April&#160;1, 2022, we began selling ZTlido directly </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">28 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to three large distributors, McKesson, Cardinal Health 110 and AmerisourceBergen, as well as to numerous pharmacies. We expect that Cardinal Health 105 will continue to perform other third-party logistics services for us. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any disruption in the above-mentioned distribution channel would adversely affect our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we fail to achieve certain milestones in our Product Development Agreement with Itochu and Oishi, we could lose rights that are important to our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of our existing license and supply agreements impose various milestone and other obligations on us. For example, under our Product Development Agreement with Itochu and Oishi, if our total net profits for ZTlido and <span style="white-space:nowrap">SP-103</span> are equal to or less than five percent of our net sales of ZTlido and <span style="white-space:nowrap">SP-103</span> for a period of four or more consecutive quarters, Itochu and Oishi have the right to terminate the Product Development Agreement if the parties are unable to resolve the concerns after 30 days of good-faith negotiation. As of December&#160;31, 2023, our net profits for ZTlido and <span style="white-space:nowrap">SP-103</span> have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of December&#160;31, 2023, neither Oishi nor Itochu has exercised its right of termination. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we fail to achieve the milestones under the Product Development Agreement, we may lose our exclusivity rights or the counterparty may have the right to terminate the agreement, any of which could adversely affect our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We rely on third parties to conduct our clinical trials and intend to rely on third parties to conduct all of our future clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently do not have the ability to independently conduct any clinical trials. The FDA and regulatory authorities in other jurisdictions require us to comply with regulations and standards, commonly referred to as good clinical practice (&#8220;GCP&#8221;) requirements for conducting, monitoring, recording and reporting the results of clinical trials, in order to ensure that the data and results are scientifically credible and accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. We rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as contract research organizations (&#8220;CROs&#8221;), to conduct <span style="white-space:nowrap">GCP-compliant</span> clinical trials of our product candidates properly and on time. While we have agreements governing their activities, we control only certain aspects of their activities and have limited influence over their actual performance. The third parties with whom we contract for execution of our <span style="white-space:nowrap">GCP-compliant</span> clinical trials play a significant role in the conduct of these studies and trials and the subsequent collection and analysis of data. These third parties are not our employees and, except for restrictions imposed by our contracts with such third parties, we have limited ability to control the amount and timing of resources that they devote to our programs. Although we rely on these third parties to conduct our <span style="white-space:nowrap">GCP-compliant</span> clinical trials, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with our investigational plan and protocol and applicable laws and regulations, and our reliance on the CROs does not relieve us of our regulatory responsibilities. For any violations of laws and regulations in the conduct of our preclinical studies and clinical trials, we could be subject to warning letters or enforcement actions that may include civil penalties up to and including criminal prosecution. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. We face the risk of potential unauthorized disclosure or infringement, misappropriation or other violation of our intellectual property by CROs, which may reduce our trade secret and intellectual property protection and allow our potential competitors to access and exploit our proprietary technology. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">29 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, any of these third parties may terminate their engagements with us or be unable to fulfill their contractual obligations. If the third parties conducting our clinical trials do not adequately perform their contractual duties or obligations, experience significant business challenges, disruptions or failures, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to our protocols or to GCPs, or for any other reason, we may need to enter into new arrangements with alternative third parties. This could be difficult, costly or impossible, and our clinical trials may need to be extended, delayed, terminated or repeated. As a result, we may not be able to obtain regulatory approval or successful commercialization in a timely fashion, or at all, for the applicable product candidate. Our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to generate revenue could be delayed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may in the future enter into collaborations, <span style="white-space:nowrap">in-licensing</span> arrangements, joint ventures, or strategic alliances with third parties that may not result in the development of commercially viable products or the generation of significant future revenues. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business is substantially dependent upon the intellectual property licensed from Oishi and Itochu. In the ordinary course of our business, we may enter into collaborations, additional <span style="white-space:nowrap">in-licensing</span> arrangements (such as, for example, the Romeg Agreement), joint ventures, or strategic alliances to develop proposed products and to pursue new markets. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proposing, negotiating and implementing collaborations, <span style="white-space:nowrap">in-licensing</span> arrangements, joint ventures, strategic alliances or partnerships may be a lengthy and complex process. Other companies, including those with substantially greater financial, marketing, sales, technology or other business resources, may compete with us for these opportunities or arrangements. We may not identify, secure or complete any such transactions or arrangements in a timely manner, on a cost-effective basis, on acceptable terms, or at all, and may not realize the anticipated benefits of any such transactions or arrangements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, with respect to current and future collaborations, we may not be in a position to exercise sole decision-making authority regarding the transaction or arrangement, which could create the potential risk of creating impasses on decisions, and our collaborators may have economic or business interests or goals that are, or that may become, inconsistent with our business interests or goals. It is possible that conflicts may arise with our collaborators, such as conflicts concerning the achievement of performance milestones, or the interpretation of significant terms under any agreement, such as those related to financial obligations or the ownership or control of intellectual property developed during the collaboration. If any conflicts arise with our current or future collaborators, they may act in their self-interest, which may be adverse to our best interest, and they may breach their obligations to us. In addition, we have limited control over the amount and timing of resources that our current collaborators or any future collaborators devote to our collaborators&#8217; or our future products. Disputes between us and our collaborators may result in litigation or arbitration which would increase our expenses and divert the attention of our management. Further, these transactions and arrangements are contractual in nature and may be terminated or dissolved under the terms of the applicable agreements and, in such event, we may not continue to have rights to the products relating to such transaction or arrangement or may need to purchase such rights at a premium. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Delays in clinical trials could result in increased costs to us and delay our ability to obtain commercial approval and generate additional revenue. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before obtaining marketing approval for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates for their intended indications. Clinical testing is expensive, time-consuming and uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of testing. Events that may prevent successful or timely completion of clinical development include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in obtaining regulatory authorizations to commence a clinical trial or reaching a consensus with regulatory authorities on trial design; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">30 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in identifying prospective clinical investigators or clinical trial sites that have necessary qualifications, interest and capacity to perform a requested protocol; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in obtaining approval from one or more institutional review boards (&#8220;IRBs&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">IRBs refusing to approve, suspending or terminating the trial at the investigational site, precluding enrollment of additional subjects, or withdrawing their approval of the trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes to the clinical trial protocol; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in recruiting suitable subjects to participate in our clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure by us, any CROs we engage or any other third parties to adhere to clinical trial requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to perform in accordance with GCPs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in the testing, validation, manufacturing and delivery of our product candidates to the clinical sites, including delays by third parties with whom we have contracted to perform certain of those functions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in subjects completing participation in a trial or returning for post-treatment <span style="white-space:nowrap">follow-up,</span> including, for example, as a result of reluctance to visit medical facilities as a result of <span style="white-space:nowrap">COVID-19;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">clinical trial sites or subjects dropping out of a trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">key investigators departing their clinical sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">lack of adequate funding to continue the trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">subjects experiencing severe or unexpected drug-related adverse effects; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">imposition of a clinical hold by regulatory authorities as a result of a serious adverse event, after an inspection of our clinical trial operations, trial sites or manufacturing facilities, or for other reasons; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">occurrence of serious adverse events in our trials or in trials of the same class of agents conducted by other sponsors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in regulatory requirements or guidance that require amending or submitting new clinical protocols; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a facility manufacturing our product candidates or any of their components being ordered by the FDA to temporarily or permanently shut down due to violations of cGMP regulations or other applicable requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any changes to our manufacturing process that may be necessary or desired; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials and/or not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, GCP, or other regulatory requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">third-party contractors not performing data collection or analysis in a timely or accurate manner; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by subcontractors in support of our marketing applications. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">31 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, participants being exposed to unacceptable health risks, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing or successful completion of a clinical trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our product development costs will increase if we experience delays in testing or marketing approvals. The FDA and other regulatory agencies may impose new or refined testing expectations based on experience and increased knowledge over time. In addition, if we make manufacturing or other changes to our product candidates, we may need to conduct additional studies to bridge our modified product candidates to earlier versions. We do not know whether any of our clinical trials, including our planned clinical trials of <span style="white-space:nowrap">SP-103,</span> <span style="white-space:nowrap">SP-104</span> and SEMDEXA, will begin or continue as planned, will need to be restructured or will be completed on schedule, or at all. We may not have the necessary capabilities, including adequate staffing, to successfully manage the execution and completion of any clinical trials we initiate in a way that leads to our obtaining marketing approval for our product candidates in a timely manner, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We face potential business disruptions and related risks resulting from the <span style="white-space:nowrap">COVID-19</span> pandemic, which could have a material adverse effect on our business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2019, a novel strain of coronavirus, or <span style="white-space:nowrap"><span style="white-space:nowrap">SARS-CoV-2,</span></span> was reported to have surfaced in Wuhan, China. <span style="white-space:nowrap"><span style="white-space:nowrap">SARS-CoV-2</span></span> is the virus that causes <span style="white-space:nowrap">COVID-19.</span> The <span style="white-space:nowrap">COVID-19</span> outbreak has grown into a global pandemic that has impacted countries throughout the world. Financial markets have been experiencing extreme fluctuations that may cause a contraction in available liquidity globally as important segments of the credit markets react to the development. The pandemic may lead to a decline in business and consumer confidence. The global outbreak of <span style="white-space:nowrap">COVID-19</span> continues to rapidly evolve. As a result, businesses have closed or limited operations and limits have been placed on travel. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We continue to monitor the potential impact of the <span style="white-space:nowrap">COVID-19</span> outbreak, and if <span style="white-space:nowrap">COVID-19</span> or variants of concern continue to spread globally, including in the United States, we may experience disruptions that could severely impact the development of our product candidates, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays or difficulties in enrolling patients in our clinical trials as patients may be reluctant, or unable, to visit clinical sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators, clinical site staff and potential closure of clinical facilities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">decreases in patients seeking treatment for chronic pain; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials, including interruption in global shipping that may affect the transport of clinical trial materials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in local regulations as part of a response to the <span style="white-space:nowrap">COVID-19</span> outbreak, which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or cause us to discontinue the clinical trials altogether; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">32 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">risk that participants enrolled in our clinical trials will acquire <span style="white-space:nowrap">COVID-19</span> while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The spread of <span style="white-space:nowrap">COVID-19,</span> which has caused a broad impact globally, may materially affect the Company economically. While the potential economic impact brought by, and the duration of, <span style="white-space:nowrap">COVID-19</span> may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of <span style="white-space:nowrap">COVID-19</span> could materially affect our business and the value of our Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the continued spread of <span style="white-space:nowrap">COVID-19</span> globally could materially and adversely impact our operations, including without limitation, our manufacturing and supply chain, sales and marketing efforts, sales of ZTlido, GLOPERBA and ELYXYB, travel and employee health and availability, which may have a material and adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval for our product candidates and the approval may be for a more narrow indication than we seek. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot commercialize our product candidates until the appropriate regulatory authorities have reviewed and approved the product candidates. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state and local statutes and regulations require the expenditure of substantial time and financial resources and we may not be able to obtain the required regulatory approvals. Even if our product candidates meet the safety and efficacy endpoints in clinical trials, the regulatory authorities may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA advisory committee, if convened, recommends <span style="white-space:nowrap">non-approval</span> or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action or changes in regulatory authority policy or data requirements during the period of product development, clinical trials and the regulatory review process. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we receive regulatory approval, the FDA may approve a product candidate for more limited indications than requested or they may impose significant limitations in the form of narrow indications, warnings or a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;). The FDA may require labeling that includes precautions or contra-indications with respect to conditions of use, or may grant approval subject to the performance of costly post-marketing clinical trials. In addition, the FDA may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, if the results of any clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with our product candidates, we may: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">be delayed or fail in obtaining marketing approval for our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtain approval for indications or patient populations that are not as broad as we intended or desired; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">33 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">be subject to changes in the way the products are administered; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">have regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions on its distribution in the form of a modified REMS; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">be sued and held liable for harm caused to patients; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">experience damage to our reputation. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may find it difficult to enroll or maintain patients in our clinical trials, which could delay or prevent us from proceeding with clinical trials of our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Identifying and qualifying patients to participate in any clinical trials of our product candidates is critical to our success. The timing of any clinical trials depends on our ability to recruit patients and to complete required <span style="white-space:nowrap">follow-up</span> periods. If patients are unwilling to participate in our clinical trials due to negative publicity from adverse events, competitive clinical trials for similar patient populations, or for other reasons, the timeline for recruiting patients, conducting trials and potentially obtaining regulatory approval may be delayed. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also experience delays if patients withdraw from a clinical trial or do not complete the required monitoring period. These delays could result in increased costs, delays in advancing our product candidates, delays in testing the effectiveness of our product candidates or termination of clinical trials altogether. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patient enrollment is affected by many factors, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the size and nature of the patient population; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the proximity of patients to clinical sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the eligibility and exclusion criteria for the trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the design of the clinical trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">competing clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the risk that enrolled patients will not complete a clinical trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ability to monitor patients adequately during and after treatment; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">potential disruptions caused by <span style="white-space:nowrap">COVID-19</span> (or other similar disruptions), including difficulties in initiating clinical sites, enrolling and retaining participants, diversion of healthcare resources away from clinical trials, travel or quarantine policies that may be implemented and other factors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to recruit clinical trial investigators with the appropriate competencies and experience; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate in relation to other available products. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The conditions for which we currently plan to evaluate our product candidates are common, but the eligibility criteria of our clinical trials limit the pool of available trial participants. For example, we experienced a delay in the enrollment of our now completed SEMDEXA Phase 3 clinical trial in sciatica due to the selective eligibility criteria in place to reduce the placebo effect and the impacts of <span style="white-space:nowrap">COVID-19,</span> and may experience similar issues with enrollment of our other planned clinical trials. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to it, because some patients who have opted to enroll in our trials may instead opt to enroll in a trial </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">34 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
being conducted by a competitor. We may conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The incidence and prevalence for target patient populations of our product candidates are based on estimates and third-party sources. If the market opportunities for our product candidates are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability might be materially and adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Periodically, we make estimates regarding the incidence and prevalence of target patient populations of our product candidates based on various third-party sources and internally generated analyses and use such estimates in making decisions regarding our product development strategy, including acquiring or <span style="white-space:nowrap">in-licensing</span> product candidates and determining indications on which to focus in preclinical studies or clinical trials. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These estimates may be inaccurate or based on imprecise data. For example, the total addressable market opportunities will depend on, among other things, acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients in the addressable markets may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our product candidates, or new patients may become increasingly difficult to identify or gain access to, all of which may significantly harm our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We face significant competition and our competitors may discover, develop or commercialize products faster or more successfully than us. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The biotechnology and pharmaceutical industries are characterized by intense competition and rapid technological advances. In addition, the competition in the pain management market, and other relevant markets, is intense. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ZTlido and our product candidate, <span style="white-space:nowrap">SP-103,</span> face and will likely face competition from other prescription patches, generic topical lidocaine patches, and OTC lidocaine patches, including Lidoderm<sup style="font-size:75%; vertical-align:top">&#174;</sup>, generic lidocaine patches manufactured by Mylan N.V., Teva Pharmaceutical Industries Limited and Par Pharmaceutical, Inc., and various OTC patches. Additionally, <span style="white-space:nowrap">SP-103,</span> if approved, will likely compete with various opioid pain medications, nonsteroidal anti-inflammatory drugs (&#8220;NSAIDs&#8221;), muscle relaxants, antidepressants and anticonvulsants particularly as we seek approval for the treatment of chronic neck pain. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SEMDEXA, if approved, has the potential to become the first <span style="white-space:nowrap">FDA-approved</span> epidural steroid product for the treatment of sciatica. While there are currently no FDA approved epidural steroid injections indicated for the treatment of sciatica, we are aware of certain <span style="white-space:nowrap">non-steroid</span> product candidates in development. SEMDEXA, if approved, also will compete with various opioid pain medications, NSAIDs, muscle relaxants, antidepressants, anticonvulsants and surgical procedures. Procedures may include nerve blocks and transcutaneous electrical nerve stimulations. We may also face indirect competition from the <span style="white-space:nowrap">off-label</span> and unapproved use of branded and generic injectable steroids. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While there are currently no formulations containing naltrexone in clinical development for the treatment of fibromyalgia, we are aware of certain <span style="white-space:nowrap">non-opioid</span> therapeutics currently in a late-stage phase 3 pipeline containing two 505(b)(2) development programs. Our product candidate, <span style="white-space:nowrap">SP-104,</span> will likely face direct competition from these candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that the market will become increasingly competitive in the future. Many of our competitors, either alone or together with their collaborative partners, operate larger research and development programs and have substantially greater financial resources than we do, as well as significantly greater experience in developing product candidates and technologies, undertaking preclinical studies and clinical trials, obtaining FDA and other regulatory approvals of product candidates, formulating and manufacturing product candidates, and launching, marketing and selling product candidates. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">35 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval more rapidly than we are able to and may be more effective in selling and marketing their products as well. Smaller or early-stage companies or generic or biosimilar pharmaceutical manufacturers may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our commercial opportunity could be reduced or eliminated if our competitors succeed in developing, acquiring or licensing on an exclusive basis, products that are more effective or less costly than any product candidate that we are currently developing or that we may develop. If approved, our product candidates will face competition from commercially available drugs as well as drugs that are in the development pipelines of our competitors and later enter the market. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Established pharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to <span style="white-space:nowrap">in-license</span> novel compounds that could make our product candidates less competitive. Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA approval or discovering, developing and commercializing medicines before we do, which would have a material adverse impact on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The third-party payor coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain coverage and adequate reimbursement for ZTlido, GLOPERBA, ELYXYB or our product candidates, if approved, could decrease our ability to generate product revenue. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is significant uncertainty related to the third-party coverage and reimbursement of existing and newly approved products. Market acceptance and sales of ZTlido, GLOPERBA, ELYXYB and our product candidates, if approved, in domestic markets will depend significantly on the availability of coverage and adequacy of reimbursement from third-party payors, including government programs (such as Medicare and Medicaid) and private payor healthcare and insurance programs. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Coverage and reimbursement for ZTlido can differ significantly from payor to payor, and we may not be able to maintain adequate coverage and reimbursement in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our products to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be obtained or applied consistently. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. Additionally, coverage may be more limited than the purposes for which the product is approved by the FDA or similar regulatory authorities outside of the United States. Assuming that coverage is obtained for a given product, the resulting reimbursement rates might not be adequate or may require <span style="white-space:nowrap">co-payments</span> or <span style="white-space:nowrap">co-insurance</span> that patients find unacceptably high. Patients, physicians, and other healthcare providers may be less likely to prescribe, dispense or use, as applicable, any approved product unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The market for our products will depend significantly on access to third-party payors&#8217; drug formularies for which third-party payors provide coverage and reimbursement. The industry competition to be included in such formularies often leads to downward pricing pressures on pharmaceutical companies. Also, third-party payors may refuse to include a particular branded product in their formularies or otherwise restrict patient access to a branded product when a less costly generic equivalent or other alternative is available. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">36 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, even if we obtain adequate levels of reimbursement, third-party payors carefully review and increasingly question the coverage of, and challenge the prices charged for, products. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Increasingly, third-party payors are requiring that pharmaceutical companies provide them with predetermined discounts from list prices and are challenging the prices for products. We cannot be sure that coverage and reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, what the level of reimbursement will be. If coverage and reimbursement of our product candidates are unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability. Furthermore, the requirements governing medical product pricing vary widely from country to country. In some foreign countries, the proposed pricing for a prescription device must be approved before it may be lawfully marketed. Historically, products launched in the European Union do not follow price structures of the United States and generally prices tend to be significantly lower. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our product candidate SEMDEXA is expected to be a physician-administered injectable viscous gel and as such, separate reimbursement for the product itself may not be available. Instead, if SEMDEXA receives regulatory approval, the administering physician may be reimbursed only for providing the treatment or procedure in which SEMDEXA is used. To the extent separate coverage and reimbursement should become available for SEMDEXA, we anticipate that it will be sold to physicians on a &#8220;buy and bill&#8221; basis. Buy and bill products must be purchased by healthcare providers before they can be administered to patients. Healthcare providers subsequently must seek reimbursement for the product from the applicable third-party payor, such as Medicare or a health insurance company. Healthcare providers may be reluctant to administer our product candidates, if approved, because they would have to fund the purchase of the product and then seek reimbursement, which may be lower than their purchase price, or because they do not want the additional administrative burden required to obtain reimbursement for the product. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, the codes used by providers to bill for SEMDEXA, if approved, could also affect reimbursement. <span style="white-space:nowrap">J-Codes</span> are codes maintained by the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;), which are a component of the Healthcare Common Procedure Coding System and are typically used to report injectable drugs that ordinarily cannot be self-administered. We do not have a specific <span style="white-space:nowrap">J-Code</span> for any of our product candidates. If our product candidates are approved, we may apply for one but cannot guarantee that a <span style="white-space:nowrap">J-Code</span> will be granted. To the extent separate coverage or reimbursement is available for any product candidate, if approved, and a specific <span style="white-space:nowrap">J-Code</span> is not available, physicians would need to use a <span style="white-space:nowrap">non-specific</span> miscellaneous <span style="white-space:nowrap">J-Code</span> to bill third-party payors for these physician-administered drugs. Because miscellaneous <span style="white-space:nowrap">J-Codes</span> may be used for a wide variety of products, health plans may have more difficulties determining the actual product used and billed for the patient. These claims must often be submitted with additional information and manually processed, which can create delays in claims processing times as well as increasing the likelihood for claim denials and claim errors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Because we have multiple programs and product candidates in our development pipeline and are pursuing a variety of target indications and treatment approaches, we may expend our limited resources to pursue a particular product candidate and fail to capitalize on development opportunities or product candidates that may be more profitable or for which there is a greater likelihood of success. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Apart from our <span style="white-space:nowrap">FDA-approved</span> products, ZTlido, GLOPERBA and ELYXYB, we currently have several product candidates that are at various stages of development. We have limited financial and management resources. As a result, we may forego or delay pursuit of opportunities with potential target indications or product candidates that later prove to have greater commercial potential than our current and planned development programs and product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We strive to progress product candidates that can address unmet or underserved medical needs and favor those candidates with large market opportunities. However, our resource allocation decisions may cause us to fail to capitalize on viable commercial product candidates or profitable market opportunities. Our spending on current </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">37 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and future research and development programs and other future product candidates for specific indications may not yield any commercially viable future product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may be required to relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such future product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, we may pursue additional <span style="white-space:nowrap">in-licenses</span> or acquisitions of product candidates or programs, which entails additional risk to us. Identifying, selecting and acquiring promising product candidates requires substantial technical, financial and human resources expertise. Efforts to do so may not result in the actual acquisition or license of a successful product candidate, potentially resulting in a diversion of our management&#8217;s time and the expenditure of our resources with no resulting benefit. For example, if we are unable to identify programs that ultimately result in approved products, we may spend material amounts of our capital and other resources evaluating, acquiring and developing products that ultimately do not provide a return on our investment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive, difficult to design and implement, and can take many years to complete, in part because it is subject to rigorous regulatory requirements. The FDA or other regulatory authorities may not agree with the proposed analysis plans or trial design for the clinical trials of our product candidates. They may also not agree with the scope of our proposed investigational plan. In addition, the outcome of our clinical trials is risky and uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. It is not uncommon for companies in the pharmaceutical industry to suffer significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Our future clinical trial results may not be successful. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This product candidate development risk is heightened by any changes in the planned clinical trials compared to the completed clinical trials. As product candidates are developed through preclinical to early and late stage clinical trials towards approval and commercialization, it is customary that various aspects of the development program, such as manufacturing and methods of administration, are altered along the way in an effort to optimize processes and results. While these types of changes are common and are intended to optimize the product candidates for late stage clinical trials, approval and commercialization, such changes carry the risk that they will not achieve their intended objectives. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Phase 3 trial was completed for SEMDEXA for the treatment of sciatica, a Phase 2 trial completed for <span style="white-space:nowrap">SP-103,</span> and multiple Phase 1 trials were completed in the first half of 2022 for <span style="white-space:nowrap">SP-104.</span> We may not have the necessary capabilities, including adequate staffing, to successfully manage the execution and completion of such clinical trials in a way that leads to our obtaining marketing approval for our product candidates in a timely manner, or at all. Our clinical trials may produce negative or inconclusive results, and, in the future, we may decide, or regulators may require us, to conduct additional clinical trials and preclinical studies in addition to those we have planned. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2022, we announced final results from our Phase 3 trial for SEMDEXA, which results reflect achievement of primary and secondary endpoints, and we intend to use the results to support an NDA submission seeking approval for the treatment of sciatica. However, the FDA may disagree with our assumptions and require us to conduct an additional Phase 3 trial before submitting an NDA. Our failure to adequately demonstrate the safety and effectiveness of our product candidates would prevent receipt of regulatory clearance or approval and, ultimately, the commercialization of that product or indication for use. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">38 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interim <span style="white-space:nowrap">&#8220;top-line&#8221;</span> and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, we may publish interim <span style="white-space:nowrap">&#8220;top-line&#8221;</span> or preliminary data from our clinical trials, which are based on a preliminary analysis of then-available data. Preliminary or interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or interim data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. In some instances, there can be significant variability in safety or efficacy results between different clinical trials or clinical trial sites for the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial procedures and the rate of dropout among clinical trial participants. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. Data disclosures must be carefully managed to conform to limitations on preapproval promotion and laws related to clinical trial registration and posting of results. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and stockholders may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, product, product candidate or our business. If the <span style="white-space:nowrap">&#8220;top-line&#8221;</span> data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of product candidates that we may identify and pursue for their intended uses, which would prevent, delay or limit the scope of regulatory approval and commercialization. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive <span style="white-space:nowrap">non-clinical</span> studies, <span style="white-space:nowrap">pre-clinical</span> studies and clinical trials that the applicable product candidate is both safe and effective for use in each target indication. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical development process. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot be certain that our current clinical trials or any other future clinical trials will be successful. Additionally, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business, financial condition and results of operations. In addition, even if such clinical trials are successfully completed, we cannot guarantee that the FDA or comparable <span style="white-space:nowrap">non-U.S.</span> regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or comparable </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">39 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<span style="white-space:nowrap">non-U.S.</span> regulatory authorities for support of a marketing approval, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Even if regulatory approval is secured for a product candidate, the terms of such approval may limit the scope and use of the specific product candidate, which may also limit its commercial potential. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if we obtain FDA approval for any of our product candidates in the United States, we may never obtain approval for or commercialize any of them in any other jurisdiction, which would limit our ability to realize their full market potential. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a <span style="white-space:nowrap"><span style="white-space:nowrap">country-by-country</span></span> basis regarding safety and efficacy. Approval by the FDA in the United States does not ensure approval by regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. In cases where data from United States clinical trials are intended to serve as the basis for marketing approval in the foreign countries, the standards for clinical trials and approval may be different. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials, which could be costly and time-consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be impeded. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our business may suffer reputational harm due to failures of our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The failure of any of our product candidates could have a lasting negative impact on our reputation, which could, in turn, impact our ability to successfully enter into future licensing arrangements or other transactions with potential counterparties, raise future capital or attract key personnel to join us. As a result, our business and prospects would be materially harmed and our results of operations and financial condition would likely suffer materially. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ZTlido, GLOPERBA and ELYXYB may have undesirable properties that could result in significant negative consequences, and our product candidates may cause undesirable side effects that could delay or prevent their regulatory approval. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As is the case with pharmaceuticals generally, it is likely that there may be side effects and adverse events associated with ZTlido, GLOPERBA, ELYXYB and our product candidates. In the event that ZTlido, GLOPERBA or ELYXYB is identified to have undesirable side effects, a number of potentially significant negative consequences could occur. Regulatory authorities may withdraw their approval of the product or seize the product. Restrictions may be imposed on the manufacturing or marketing of ZTlido, GLOPERBA or ELYXYB or any component thereof, including the imposition of a REMS plan that may require creation of a Medication Guide outlining the risks of such side effects for distribution to patients, as well as elements to assure safe use of the product, such as a patient registry and training and certification of prescribers. Any of these events could damage our reputation and prevent us from achieving or maintaining market acceptance of ZTlido, GLOPERBA or ELYXYB. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the clinical trials we conduct with our product candidates, patients may experience changes in their health, including illnesses, injuries, discomforts or a fatal outcome. Often, it is not possible to determine whether the product candidate being studied caused or was associated with these conditions. In addition, it is possible that as </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">40 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
we test our clinical products in larger, longer and more extensive clinical programs, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier clinical trials, as well as conditions that did not occur or went undetected in previous clinical trials, will be reported by subjects. Many times, side effects are only detectable after investigational products are tested in large-scale, Phase 3 clinical trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that our product candidates reveal an unacceptable severity and prevalence of these or other side effects, the clinical trials could be suspended or terminated and the FDA could order us to cease further development of or deny approval of our product candidates, for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and results of operations significantly. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ZTlido, GLOPERBA, ELYXYB and our product candidates are complex and difficult to manufacture. We could experience delays in satisfying regulatory authorities or manufacturing problems that result in delays in our development or commercialization programs, limit the supply of our product candidates, or otherwise harm our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently depend on contract manufacturers to conduct the manufacturing and supply activities for ZTlido, GLOPERBA, ELYXYB and our product candidates. Manufacturing these product candidates require facilities specifically designed for and validated for this purpose and sophisticated quality assurance and quality control procedures are necessary. Several factors could cause production interruptions, including equipment malfunctions, facility contamination, raw material shortages or contamination, natural disasters, disruption in utility services, human error or disruptions in the operations of our suppliers. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If contaminations are discovered in our supply of ZTlido, GLOPERBA, ELYXYB or our product candidates or in the manufacturing facilities, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We may not be successful in securing additional sources at all or on a timely basis, which could materially harm our development timelines. Any delay or interruption in the supply of clinical trial supplies could delay the completion of clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to begin new clinical trials at additional expense or terminate clinical trials completely. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, there are risks associated with large scale manufacturing for clinical trials or commercial scale including, among others, cost overruns, potential problems with process <span style="white-space:nowrap">scale-up,</span> process reproducibility, stability issues, compliance with cGMP, lot consistency and timely availability of raw materials. Slight deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. Lot failures or product recalls could cause us to delay clinical trials or product launches, which could be costly to us and otherwise harm our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, our manufacturers may encounter problems hiring and retaining the experienced scientific, quality assurance, quality-control and manufacturing personnel needed to operate our complex manufacturing processes, which could result in delays in production or difficulties in maintaining compliance with applicable regulatory requirements. Any problems in our manufacturing process or facilities could make us a less attractive collaborator for potential partners, including larger biotechnology companies and academic research institutions, which could limit our access to additional attractive development programs. Problems in our manufacturing process could restrict our ability to meet potential future market demand for products, which could harm our business, financial condition and results of operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">41 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to our Business and Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to retain our key executives, it may delay our development efforts and harm our business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our industry has experienced a high rate of turnover of management personnel in recent years. If we are not able to attract, retain and motivate key executives to accomplish our business objectives, we may experience constraints that will significantly impede our ability to raise additional capital and our ability to implement our overall business strategy. In particular, we are highly dependent upon our executive officers, including Jaisim Shah, our President and Chief Executive Officer, Henry Ji, Ph.D., our Executive Chairperson, and Stephen Ma, our Chief Financial Officer. The loss of services of these executive officers could delay or prevent the successful development of our product pipeline, completion of our planned clinical trials and the successful commercialization of ZTlido, GLOPERBA and ELYXYB. We do not carry &#8220;key person&#8221; insurance on any of our executive officers or other employees. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Competition for key executives in the biotechnology and pharmaceuticals field is intense, due to the limited number of individuals who possess the skills and experience required by our industry. Many of the pharmaceutical companies against which we compete for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They may also provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to qualified candidates than what we have to offer. In addition, regulation or legislation impacting the workforce, such as the proposed rule published by the Federal Trade Commission which would, if issued, generally prevent employers from entering into <span style="white-space:nowrap">non-compete</span> agreements with employees and require employers to rescind existing <span style="white-space:nowrap">non-compete</span> agreements, may lead to increased uncertainty in hiring and competition for talent. Further, we may experience employee turnover as a result of the ongoing &#8220;great resignation&#8221; occurring throughout the U.S. economy, which has impacted job market dynamics. New hires require training and take time before they achieve full productivity. New employees may not become as productive as we expect, and we may be unable to hire or retain sufficient numbers of qualified individuals. Moreover, we conduct our operations in the San Francisco Bay Area, a region that is home to many other biopharmaceutical companies as well as many academic and research institutions, resulting in fierce competition for qualified personnel. As such, we could have difficulty attracting and retaining experienced executives and may be required to expend significant financial resources in our recruitment and retention efforts. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may need to increase the size of our company and may not effectively manage our growth. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, we had approximately 105 full-time employees. We may need to continue to expand our managerial, operational, sales and marketing, finance and other resources in order to manage our operations, clinical trials, research and development activities, regulatory filings, manufacturing and supply activities, and any marketing and commercialization activities, including <span style="white-space:nowrap">co-promotion</span> activities. Future growth would impose significant added responsibilities on members of management, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">identifying, recruiting, integrating, maintaining and motivating additional employees; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">managing our internal development efforts effectively, including the clinical, FDA and internal regulatory review process for our product candidates, while complying with our contractual obligations to contractors and other third parties; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">improving our operational, financial and management controls, reporting systems and procedures. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth, if any, which may cause a significant strain on our management, and our operational, financial and other resources. Our ability to manage our growth effectively will require us to implement and improve our operational, financial and management systems and to expand, train, manage and motivate our employees. These demands may require the hiring of additional management </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">42 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
personnel and the development of additional expertise by management. Any increase in resources devoted to research and product development without a corresponding increase in our operational, financial and management systems could have a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we endeavor to obtain appropriate insurance coverage for insurable risks that we identify, we do not carry insurance for all categories of risk that our business may encounter. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Insurance coverage is becoming increasingly expensive. We have observed rapidly changing conditions in the insurance markets relating to nearly all areas of traditional corporate insurance. Such conditions have resulted in higher premium costs, higher policy deductibles and lower coverage limits. We may not be able to maintain insurance coverage at a reasonable cost, or in sufficient amounts to protect us against losses due to liability. While we maintain property, casualty and general liability coverage, we do not carry specific biological or hazardous waste insurance coverage and our insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not know if we will be able to maintain existing insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Manufacturing and marketing of ZTlido, GLOPERBA and ELYXYB and clinical testing of our product candidates may expose us to individual product liability claims, class action lawsuits or actions, and other individual or mass tort claims. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. In addition, physicians may misuse our products with their patients if they are not adequately trained, potentially leading to injury and increased risk of product liability. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of risks inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates, if approved. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">loss of revenue from product sales; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">decreased demand for our product candidates or products that we develop; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">injury to our reputation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">withdrawal of clinical trial participants; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">initiation of investigations by regulators; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on labeling, the marketing or manufacturing of the product, withdrawal of the product from the market or voluntary or mandatory product recalls; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs to defend the related litigation; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">43 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a diversion of management&#8217;s time and our resources; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">substantial monetary awards to trial participants or patients; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the inability to commercialize our product candidates. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of any products we develop. We currently carry product liability insurance covering use in our clinical trials in the amount of $10.0&#160;million in the aggregate. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Any disruption in our research and development facilities could adversely affect our business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our principal executive offices are in the San Francisco Bay Area, California. Our facilities may be affected by natural or <span style="white-space:nowrap">man-made</span> disasters. Earthquakes are of particular significance since our facilities are located in an earthquake-prone area. We are also vulnerable to damage from other types of disasters, including power loss, attacks from extremist organizations, fires, floods and similar events. If our facilities are affected by a natural or <span style="white-space:nowrap">man-made</span> disaster, we may be forced to curtail our operations and/or rely on third parties to perform some or all of our research and development activities. Although we believe we possess adequate insurance for damage to our property and the disruption of our business from casualties, such insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, or at all. In the future, we may choose to expand our operations in either our existing facilities or in new facilities. If we expand our worldwide manufacturing locations, there can be no assurance that this expansion will occur without implementation difficulties, or at all. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may seek to grow our business through acquisitions and may fail to realize the anticipated benefits of any acquisition, and acquisitions can be costly and dilutive. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our success depends on our ability to continually enhance and broaden our product offerings in response to changing customer demands, competitive pressures, technologies and market pressures. Accordingly, from time to time we may expand our business and intellectual property portfolio through the acquisition of new businesses and technologies. We cannot assure that we will achieve anticipated benefits from any acquisition to justify the transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Competition within our industry for acquisitions of businesses, technologies and assets may become intense. Even if we are able to identify an acquisition that we would like to consummate, we may not be able to complete the acquisition on commercially reasonable terms or the target may be acquired by another company. We may enter into negotiations for acquisitions that are not ultimately consummated. Those negotiations could result in diversion of management time and significant <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The success of any acquisition depends on, among other things, our ability to combine our business with an acquired business in a manner that does not materially disrupt existing relationships and that allows us to achieve development and operational synergies. If we are unable to achieve these objectives, the anticipated benefits of an acquisition may not be realized fully, or at all, or may take longer to realize than expected. If we are obligated to make any milestone payments in connection with an acquisition or licensing agreement, such obligations could </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">44 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
impose substantial additional costs on us and divert resources from other aspects of our business. In addition, if we undertake such a transaction, we may issue dilutive securities, assume or incur debt obligations, incur large <span style="white-space:nowrap">one-time</span> expenses or acquire intangible assets that could result in significant future amortization expenses. As a result, an acquisition may not be accretive to our stock value or development pipeline in the near or long term. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to incur higher development and regulatory costs, and additional costs integrating the operations and personnel of any companies we acquire, which cannot be estimated accurately at this time. If the total costs of the integration of our companies and advancement of acquired product candidates and technologies exceed the anticipated benefits of the acquisition, our business, financial condition and results of operations could be adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">International components of our business expose us to business, legal, regulatory, political, operational, financial and economic risks associated with conducting business outside of the United States. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently collaborate with international manufacturing partners and may potentially expand our business internationally in the future. The purchase and shipment of components from international sources subjects us to U.S. and foreign governmental trade, import and export, and customs regulations and laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Compliance with these regulations and laws is costly and exposes us to penalties for <span style="white-space:nowrap">non-compliance.</span> Other laws and regulations that can significantly impact us include various anti-bribery laws, including the U.S. Foreign Corrupt Practices Act (the &#8220;FCPA&#8221;), as well as export controls laws. Any failure to comply with applicable legal and regulatory obligations could impact us in a variety of ways that include, but are not limited to, significant criminal, civil and administrative penalties, including imprisonment of individuals, fines and penalties, denial of export privileges, seizure of shipments, restrictions on certain business activities and exclusion or debarment from government contracting. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Conducting business internationally involves a number of risks, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">multiple, sometimes conflicting and changing laws and regulations such as tax laws, export and import restrictions, employment laws, anti-bribery and anti-corruption laws, regulatory requirements and other governmental approvals, permits and licenses; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">difficulties in enforcing our intellectual property rights and in defending against third-party threats and intellectual property enforcement actions against us, our distributors or any of our third-party suppliers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure by us or our distributors to obtain appropriate licenses or regulatory approvals for the sale or use of our product candidates, if approved, in various countries; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">difficulties in managing foreign operations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">cost and availability of shipping and other means of product transportation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">foreign currency exchange rate fluctuations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in duties and tariffs, license obligations and other <span style="white-space:nowrap">non-tariff</span> barriers to trade; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the imposition of new trade restrictions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">difficulties in enforcing agreements and collecting receivables through certain foreign legal systems; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">complexities associated with managing multiple payor-reimbursement regimes or <span style="white-space:nowrap">self-pay</span> systems; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to comply with the FCPA, including its books and records provisions and its anti-bribery provisions, and similar anti-bribery and anti-corruption laws in other jurisdictions, for example, by failing to maintain accurate information and control over sales or distributors&#8217; activities. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">45 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of these risks, if encountered, could significantly harm our future international expansion and operations and, consequently, negatively impact our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The increasing use of social media platforms presents new risks and challenges. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Social media is increasingly being used to communicate about our research, product candidates, investigational medicines and the diseases our product candidates and investigational medicines are being developed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of <span style="white-space:nowrap">non-compliance</span> with regulations applicable to our business, resulting in potential regulatory actions against us. For example, patients may use social media channels to comment on their experience in an ongoing blinded clinical study or to report an alleged adverse event. When such disclosures occur, there is a risk that we may fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend our business or the public&#8217;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our product candidates. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. Furthermore, our employees, affiliates and/or business partners may use social media for their personal use, and their activities on social media or in other forums could result in adverse publicity for us. Any negative publicity as a result of social media posts, whether or not such claims are accurate, could adversely impact us. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions, or incur other harm to our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our business and operations would suffer in the event of a system failure. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While we have implemented and maintain security measures, our computer systems and those of our CROs and other contractors and consultants are vulnerable to computer viruses, unauthorized access, cybersecurity attacks, and other security incidents, including as perpetrated by hackers, or as the result of natural disasters, terrorism, war, or telecommunications or electrical failures. While we have not experienced any material system failure or a security breach to date, if such an event were to occur, it could result in a material disruption of our product development programs or a loss of our trade secrets or other proprietary information. For example, the loss of clinical trial data from completed, ongoing, or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce such data. To the extent that any disruption or security breach were to result in the loss of or damage to our data or applications, or the unauthorized disclosure of confidential or proprietary information, including personal data, we could incur material legal liability or be the subject of legal claims, suffer damage to our reputation, lose or harm our intellectual property rights, and delay the continued research, development and commercial efforts of ZTlido, GLOPERBA, ELYXYB and our product candidates, if approved. If we are held liable for a claim against which we are not insured or for damages exceeding the limits of our insurance coverage, whether arising out of cybersecurity matters or some other matter, that claim could have a material adverse effect on our business, financial condition, and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, a security incident or privacy violation that leads to the unauthorized acquisition, interruption, modification, loss, theft, corruption, interference, or other unauthorized disclosure of, or prevents access to, personal data, including patient data or other protected health information, could harm our reputation, compel us to comply with federal or state breach notification laws and foreign equivalents, subject us to mandatory corrective action, require us to verify the correctness of database contents, and otherwise subject us to liability under laws and regulations that protect personal data, resulting in increased costs or loss of revenue. Our ability to effectively manage and maintain our internal business information, and to ship products to customers and invoice them on a timely basis, depends significantly on our enterprise resource planning system and other information systems. Portions of our information technology systems may experience interruptions, delays, or cessations of service or produce errors in connection with ongoing systems implementation work. Cybersecurity attacks in particular are continually evolving and include, but are not limited to, malicious software, ransomware, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">46 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
attempts to gain unauthorized access to data under our custody or control, and other electronic security breaches that could lead to disruptions in systems, misappropriation of confidential or otherwise protected information, and corruption of data. If we are unable to prevent such cybersecurity attacks or privacy violations or implement satisfactory remedial measures, our operations could be disrupted, we may suffer loss of reputation, we may be the subject of governmental investigations, legal claims, or litigation, or we may incur financial loss or other regulatory penalties, each of which may not be covered by our insurance. In addition, these breaches and other unauthorized access to our systems can be difficult to detect, and any delay in identifying any such event may lead to increased harm of the type described above. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As widely reported, global credit and financial markets have experienced volatility and disruptions in the past several years and especially in 2021, 2022 and 2023 due to the impacts of the <span style="white-space:nowrap">COVID-19</span> pandemic, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability, as well as the continued hostilities between Russia and Ukraine and, more recently, Hamas&#8217; attack against Israel and the ensuing conflict. For example, an overall decrease in or loss of insurance coverage among individuals in the United States as a result of unemployment, underemployment or the repeal of certain provisions of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2020 (the &#8220;ACA&#8221;), may decrease the demand for healthcare services and pharmaceuticals. If fewer patients seek medical care because they do not have insurance coverage, we may experience difficulties in any eventual commercialization of our product candidates and our business, results of operations, financial condition and cash flows could be adversely affected. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, Russia&#8217;s invasion of Ukraine and sanctions against Russia are causing disruptions to global economic conditions. The escalation in October 2023 of the conflict between Israel and Hamas also could cause disruptions to global economic conditions and affect the stability of the Middle East region. It is not possible to predict the broader consequences of these ongoing conflicts. It is also not possible to predict with certainty these ongoing conflicts and additional adverse effects on existing U.S. macroeconomic conditions and financial markets, all of which could impact the business, financial condition, and results of operations of the Company as well as our ability to raise capital. There can be no assurances that further deterioration in credit and financial markets and confidence in economic conditions will not occur. In addition, the closure of any additional national or regional commercial banks could lead to further economic instability. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and price of our Common Stock, and could require us to delay or abandon clinical development plans. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our ability to effectively monitor and respond to the rapid and ongoing developments and expectations relating to the environmental, social and governance matters, including related social expectations and concerns, may impose unexpected costs or results in reputational or other harm that could have a material adverse effect on our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is an increasing focus from certain investors, employees, regulators, listing exchanges and other stakeholders concerning corporate responsibility and sustainability matters, specifically related to environmental, social and governance (&#8220;ESG&#8221;) factors. Some investors and investor advocacy groups may use these factors to guide investment strategies and, in some cases, investors may choose not to invest in us if they believe our policies relating to corporate responsibility are inadequate. Third-party providers of corporate responsibility </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">47 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ratings and reports on companies have increased to meet growing investor demand for measurement of corporate responsibility performance, and a variety of organizations currently measure the performance of companies on such ESG topics, and the results of these assessments are widely publicized. Investors, particularly institutional investors, use these ratings to benchmark companies against their peers, and major institutional investors have publicly emphasized the importance of ESG measures to their investment decisions. Topics taken into account in such assessments include, among others, companies&#8217; efforts and impacts on climate change and human rights, ethics and compliance with law, diversity and the role of companies&#8217; board of directors in supervising various sustainability issues. In light of investors&#8217; increased focus on ESG matters, if we are perceived as lagging with respect to ESG initiatives, these investors may engage with us to improve ESG disclosures or performance and may also make voting decisions, or take other actions, to hold us and our Board accountable. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, there are rapid and ongoing developments and changing expectations relating to ESG matters, and the criteria by which our corporate responsibility practices are assessed may change, which could result in greater expectations of us and cause us to undertake costly initiatives to satisfy such new criteria. If we elect not to or are unable to adequately recognize and respond to such developments and governmental, societal, investor and consumer expectations relating to such ESG matters, we may miss corporate opportunities, become subject to additional scrutiny or incur unexpected costs. We may face risk of litigation or reputational damage in the event that our corporate responsibility procedures or standards do not meet the standards set by various constituencies. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also face reputational damage if we are unable to achieve an acceptable ESG or sustainability rating from third-party rating services. A low ESG or sustainability rating by a third-party rating service could also result in the exclusion of our Common Stock from consideration by certain investors who may elect to invest with our competitors instead. Ongoing focus on corporate responsibility matters by investors and other parties as described above may impose additional costs or expose us to new risks. Any failure or perceived failure by us in this regard could have a material adverse effect on our reputation and on our business, financial condition or results of operations, including the sustainability of our business over time, and could cause the market value of our Common Stock to decline. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, our emphasis on ESG issues may not maximize short-term financial results and may yield financial results that conflict with the market&#8217;s expectations. We may in the future make business decisions that may reduce our short-term financial results if we believe that the decisions are consistent with our ESG goals, which we believe will improve our financial results over the long-term. These decisions may not be consistent with the short-term expectations of our stockholders and may not produce the long-term benefits that we expect, in which case our business, financial condition and results of operations could be harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to our Intellectual Property </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are substantially dependent on the intellectual property we <span style="white-space:nowrap">in-license</span> from Oishi and Itochu, and if we lose the right to license such intellectual property or if the Product Development Agreement is terminated for any reason, our ability to commercialize ZTlido and develop and commercialize <span style="white-space:nowrap">SP-103</span> would be harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business is substantially dependent upon the intellectual property licensed from Oishi and Itochu. Pursuant to the Product Development Agreement, we have been granted an exclusive, worldwide license (except with respect to Japan) under current and future intellectual property rights relating to ZTlido and <span style="white-space:nowrap">SP-103</span> lidocaine tape products and the lidocaine in such products, including, among other things: (1)&#160;any patent applications, continuation applications, any issued or issuing patents, as well as any foreign patent applications; (2)&#160;all <span style="white-space:nowrap">know-how,</span> work product, trade secrets, inventions, data, processes, techniques, procedures, compositions, devices, methods, formulas, protocols and information, whether patentable or not; (3)&#160;copyrightable works, copyrights and applications, registrations and renewals; (4)&#160;logos, trademarks, service marks, and all applications and registrations relating thereto; (5)&#160;other proprietary rights; (6)&#160;abbreviated new drug applications or other applications to market; and (7)&#160;any regulatory exclusivities or supplemental protection certificates. Our ability to commercialize ZTlido and develop <span style="white-space:nowrap">SP-103</span> depends on the effectiveness and continuation of the Product </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">48 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Development Agreement. If we lose the right to license the intellectual property rights granted by the Product Development Agreement, our ability to develop ZTlido and <span style="white-space:nowrap">SP-103</span> as well as new product candidates based on the licensed intellectual property would be harmed. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Product Development Agreement imposes various development, regulatory and/or commercial diligence obligations, payments and other obligations. Oishi and Itochu have the right to terminate the Product Development Agreement under certain circumstances, including, among other things: (1)&#160;if we are in material breach of the agreement and the breach is not curable or if the breach is curable and we fail to cure such material breach within 180 days after notice requesting to cure; (2)&#160;if, at any time during the term of the Product Development Agreement, the market conditions are such that (a)&#160;our total net profits for ZTlido and <span style="white-space:nowrap">SP-103</span> are equal to or less than five percent of our net sales of ZTlido and <span style="white-space:nowrap">SP-103</span> for a period of four or more consecutive quarters, or (b)&#160;the economic viability of ZTlido and <span style="white-space:nowrap">SP-103</span> is affected significantly as evidenced by documentation and substantial information by any external circumstances deemed detrimental to all parties as agreed to by us, on the one hand, and Oishi and Itochu, on the other hand, and the parties are unable to resolve the concerns under the foregoing clauses (a)&#160;and (b) after 30 days of good-faith discussion; and (3)&#160;in the event of our bankruptcy or assignment for the benefit of creditors. As of December&#160;31, 2023, Scilex&#8217;s net profits for ZTlido and <span style="white-space:nowrap">SP-103</span> have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of December&#160;31, 2023, neither Oishi nor Itochu has exercised its right of termination. If the Product Development Agreement is terminated for certain reasons, such as our material breach of the agreement, our bankruptcy, or lack of economic viability, we will be required to transfer all licensed intellectual property rights, including those relating to ZTlido and <span style="white-space:nowrap">SP-103,</span> to Oishi and Itochu or their designee, at our own cost and expense. The loss of such licenses could materially harm our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are party to the Romeg Agreement for the <span style="white-space:nowrap">in-licensing</span> of certain intellectual property rights from Romeg with respect to the commercialization of GLOPERBA, and if we lose the right to license such intellectual property or if the Romeg Agreement is terminated for any reason, our ability to commercialize GLOPERBA would be harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;14, 2022, we entered into the Romeg Agreement for the <span style="white-space:nowrap">in-licensing</span> of certain intellectual property rights from Romeg with respect to the commercialization of GLOPERBA. Pursuant to the Romeg Agreement, we have been granted (1)&#160;the right to manufacture, promote, market, distribute and sell pharmaceutical products comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans in the United States and (2)&#160;an exclusive, transferable license to use the trademark &#8220;GLOPERBA.&#8221; Under the Romeg Agreement, among other things, Romeg granted us (1)&#160;a transferable license, with the right to sublicense, under the patents and <span style="white-space:nowrap">know-how</span> specified therein to (a)&#160;commercialize the pharmaceutical product comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans (the &#8220;Initial Licensed Product&#8221;) in the United States (including its territories) (the &#8220;Romeg Territory&#8221;), (b) develop other products comprising the Initial Licensed Product as an active pharmaceutical ingredient (together with the Initial Licensed Product, the &#8220;Licensed Products&#8221;) and commercialize any such products and (c)&#160;manufacture Licensed Products anywhere in the world, solely for commercialization in the Romeg Territory; and (2)&#160;an exclusive, transferable license, with right to sublicense, to use the trademark &#8220;GLOPERBA&#8221; and logos, designs, translations, and modifications thereof in connection with the commercialization of the Initial Licensed Product solely in the Romeg Territory. The license to <span style="white-space:nowrap">know-how</span> is exclusive for purposes of developing and commercializing Licensed Products in the Romeg Territory during the royalty term, but is otherwise <span style="white-space:nowrap">non-exclusive.</span> The license to patents is exclusive for purposes of developing and commercializing Licensed Products in the Romeg Territory until July&#160;1, 2027 and, thereafter, is <span style="white-space:nowrap">co-exclusive</span> with Granules Pharmaceuticals, Inc. for the royalty term for such purposes. The royalty term begins on the date of the agreement and ends on the later of (i)&#160;expiration of the <span style="white-space:nowrap"><span style="white-space:nowrap">last-to-expire</span></span> of the patents that covers the manufacture or commercialization of the Licensed Products in the Romeg Territory or (ii)&#160;the tenth anniversary of the date of the Romeg Agreement. Our ability to commercialize GLOPERBA and develop Licensed Products depends on the effectiveness and continuation of the Romeg Agreement. If we lose </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">49 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the right to license the intellectual property rights granted by the Romeg Agreement, our ability to develop GLOPERBA as well as new product candidates based on the licensed intellectual property would be harmed. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Romeg Agreement imposes various development, regulatory and/or commercial diligence obligations, payments and other obligations. Romeg has the right to terminate the Romeg Agreement under certain circumstances, including, among other things: (a)&#160;in the event we are in material breach of the Romeg Agreement, unless we have cured any such breach within 60 days after any notice thereof was provided; (b)&#160;upon notice to us, if we fail to timely pay any milestone payment, percentage royalties or minimum quarterly royalties or fail to timely deliver the requisite quarterly report, which termination will be effective 30 days after the date of such notice, unless we have made such payment in full or delivered such quarterly report within such 30 day period; (c)&#160;immediately, if we challenge the licensed patents under any court action or proceeding or before any patent office or assist any third party to conduct any of these activities; (d)&#160;by written notice to us if sales of Licensed Products do not commence or continue within specified periods agreed to by the parties; or (e)&#160;in the event of our bankruptcy or assignment for the benefit of creditors. If the Romeg Agreement is terminated for certain reasons, such as our material breach of the agreement, our bankruptcy, or our failure to timely pay milestone payments, we will be required upon Romeg&#8217;s request to transfer all licensed intellectual property rights, including those relating to GLOPERBA and the Licensed Products, to Romeg or its designee, within thirty days after the termination of the Romeg Agreement at a price to be agreed upon by the parties. The loss of such licenses could materially harm our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Potential disputes over intellectual property rights that we have licensed may prevent or impair our ability to maintain our current licensing arrangements on acceptable terms. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Licensing of intellectual property rights is of high importance to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property rights subject to a license agreement, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the scope of rights granted under the license agreement and other interpretation-related issues; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our financial or other obligations under the license agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">whether and the extent to which our technology and processes infringe on intellectual property rights of the licensor that are not subject to the licensing agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our right to sublicense intellectual property rights to third parties under collaborative development relationships; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ownership of inventions and <span style="white-space:nowrap">know-how</span> resulting from the joint creation or use of intellectual property by our licensors and us and our partners. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If disputes over intellectual property rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, our business, financial condition and results of operations may be adversely affected. We may enter into additional licenses in the future and if we fail to comply with obligations under those agreements, we could suffer adverse consequences. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, if our licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products identical or competitive to ours and we may be required to cease our development and commercialization of certain of our product candidates, if approved. Moreover, if disputes over intellectual property that we license prevent or impair our ability to maintain other licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. Any of the foregoing could have a material adverse effect on our business, financial condition and results of operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">50 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to maintain patent protection for ZTlido, GLOPERBA, ELYXYB and our product candidates, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely upon a combination of patents, trademarks, trade secret protection, and confidentiality agreements to protect the intellectual property related to ZTlido, GLOPERBA, ELYXYB and our product candidates. Our success depends in part on our ability to obtain and maintain patent protection in the United States for GLOPERBA, in the United States and Canada for ELYXYB, and in the United States and other countries with respect to ZTlido and our product candidates. We seek to protect our proprietary position by filing and/or <span style="white-space:nowrap">in-licensing</span> patent applications in the United States and abroad related to our development programs and product candidates. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patents and patent applications that we own or <span style="white-space:nowrap">in-license</span> may fail to result in issued patents with claims that protect ZTlido, GLOPERBA, ELYXYB and our product candidates in the United States or in other foreign countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can prevent a patent from issuing from a pending patent application, or be used to invalidate a patent. Even if patents do successfully issue and even if such patents cover ZTlido, GLOPERBA, ELYXYB and our product candidates, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated or held unenforceable. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the U.S. Patent and Trademark Office (&#8220;PTO&#8221;) and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the <span style="white-space:nowrap">non-compliance</span> with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">patent applications may not result in any patents being issued; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or block our ability to make, use and sell our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other parties may have designed around our claims or developed technologies that may be related or competitive to our platform, may have filed or may file patent applications and may have received or may receive patents that overlap or conflict with our patent applications, either by claiming the same methods or devices or by claiming subject matter that could dominate our patent position; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">51 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any successful intellectual property challenge to any patents owned by or licensed to us could deprive us of rights necessary for the practice of our technologies or the successful commercialization of any products or product candidates that we may develop; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">because patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we or our licensors were the first to file any patent application related to our product candidates, proprietary technologies and their uses; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an interference proceeding can be provoked by a third party or instituted by the PTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications for any application with an effective filing date before March&#160;16, 2013. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patent prosecution process is also expensive and time-consuming, and we and our licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. It is also possible that we and our licensors will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the patent applications we hold or <span style="white-space:nowrap">in-license</span> with respect to our development programs and product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for ZTlido, GLOPERBA, ELYXYB and our product candidates, it could dissuade other companies from collaborating with us to develop product candidates, and threaten our ability to commercialize ZTlido, GLOPERBA, ELYXYB and our product candidates. Any such outcome could have a materially adverse effect on our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be successful in obtaining or maintaining necessary rights to product components and processes and brands for our development pipeline through acquisitions and <span style="white-space:nowrap">in-licenses.</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Presently we have intellectual property rights, through acquisitions and licenses from third parties, related to ZTlido, <span style="white-space:nowrap">SP-103</span> and GLOPERBA. Because our programs for ZTlido, GLOPERBA, ELYXYB, <span style="white-space:nowrap">SP-103</span> and <span style="white-space:nowrap">SP-104</span> may require the use of additional proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, <span style="white-space:nowrap">in-license</span> or use these proprietary rights. In addition, our product candidates may require specific formulations to work effectively and efficiently and these rights may be held by others. It may also be commercially advantageous to use trademarks held by others. We may be unable to acquire or <span style="white-space:nowrap">in-license</span> proprietary rights related to any compositions, formulations, methods of use, processes or other intellectual property rights from third parties that we identify as being necessary for our product candidates. Even if we are able to obtain a license to such proprietary rights, it may be <span style="white-space:nowrap">non-exclusive,</span> thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where we obtain licenses from or collaborate with third parties, we may not have the right to control the preparation, filing and prosecution of patent and trademark applications, or to maintain the patents covering technology that we license from third parties and associated trademark registrations, or such activities, if controlled by us, may require the input of such third parties. We may also require the cooperation of our licensors and collaborators to enforce any licensed patent rights, and such cooperation may not be provided. Therefore, these patents, trademarks and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business, in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents and trademarks, or any patents and trademark registrations that may issue from such applications. Moreover, if we do obtain necessary licenses, we will likely have obligations under those licenses, including making royalty and milestone payments, and any failure to satisfy those obligations could give our licensor the right to terminate the license. Termination of a necessary license, or expiration of licensed patents or patent applications, or loss of trademark rights, could have a material adverse impact on our business. Our business would suffer if any such licenses terminate, if the licensors fail to abide by the terms of the license, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">52 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
if the licensors fail to enforce licensed patents or trademarks against infringing third parties, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms. Furthermore, if any licenses terminate, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties may gain the freedom to seek regulatory approval of, and to market, products identical to ours. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#8217;s rights. In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The licensing and acquisition of third-party proprietary rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party proprietary rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. We may be unable to negotiate a license within the specified time frame or under terms that are acceptable to us. If we are unable to do so, the third-party may offer, on an exclusive basis, their proprietary rights to other parties, potentially blocking our ability to pursue our program. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us, either on reasonable terms, or at all. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment, or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights on commercially reasonable terms, our ability to commercialize our products, and our business, financial condition and results of operations could suffer. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may be subject to claims that former employees (including former employees of our licensors), collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or <span style="white-space:nowrap">co-inventor.</span> The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding <span style="white-space:nowrap">co-ownership</span> of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Claims that we infringe, misappropriate, or violate the intellectual property rights of third parties may give rise to costly and lengthy litigation, and we could be prevented from selling products, forced to pay damages, and defend against litigation. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third parties may assert patent or other intellectual property infringement or misappropriation claims against us or our strategic partners, licensors or licensees with respect to ZTlido, GLOPERBA, ELYXYB and our product candidates. If ZTlido, GLOPERBA, ELYXYB or any of our product candidates, methods, processes and other </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">53 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
technologies are alleged to infringe on or be improperly based on the proprietary rights of other parties, we could face adverse consequences. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The pharmaceutical and biotechnology industries have produced a proliferation of patents, and it is not always clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. We cannot assure that any of our current or future product candidates will not infringe existing or future patents. We may not be aware of patents that have already issued that a third party might assert are infringed by one of our current or future product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There may be third-party patents of which we are currently unaware with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue and may be confidential for 18 months or more after filing, there may be currently pending third-party patent applications which may later result in issued patents that our product candidates or our technologies may infringe, or which such third parties claim are infringed by the use of our technologies. Parties making claims against us for infringement or misappropriation of their intellectual property rights may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, could involve substantial expenses and could be a substantial diversion of our valuable management and employee resources from our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we collaborate with third parties in the development of technology in the future, our collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to litigation or potential liability. Further, collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability. In the future, we may agree to indemnify our commercial collaborators against certain intellectual property infringement claims brought by third parties. Any claims of patent infringement asserted by third parties would be time-consuming and could: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">result in costly litigation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">divert the time and attention of our technical personnel and management; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">cause development delays; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">prevent us from commercializing our product candidates until the asserted patent expires or is held finally invalid or not infringed in a court of law; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">require us to develop <span style="white-space:nowrap">non-infringing</span> technology, which may not be possible on a cost-effective basis; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">require us to pay damages to the party whose intellectual property rights we may be found to be infringing, which may include treble damages if we are found to have been willfully infringing such intellectual property; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">require us to pay the attorney&#8217;s fees and costs of litigation to the party whose intellectual property rights we may be found to be infringing; and/or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are sued for patent infringement, we would need to demonstrate that our products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do either. Proving invalidity is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and divert management&#8217;s time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">54 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
infringing the patent rights of others, we may be required to seek a license, which may not be available, defend an infringement action or challenge the validity of the patents in court. Patent litigation is costly and time-consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a license, develop or obtain <span style="white-space:nowrap">non-infringing</span> technology, fail to defend an infringement action successfully or have infringed patents declared invalid, we may incur substantial monetary damages, encounter significant delays in bringing our product candidates to market and be precluded from manufacturing or selling our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot be certain that others have not filed patent applications for technology covered by our pending applications, or that we were the first to invent the technology, because: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">some patent applications in the United States may be maintained in secrecy until the patents are issued; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">patent applications in the United States and elsewhere can be pending for many years before issuance, or unintentionally abandoned patents or applications can be revived; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, our product candidates or the use of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">patent applications in the United States are typically not published until 18 months after the priority date; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">publications in the scientific literature often lag behind actual discoveries. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, the scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history and can involve other factors such as expert opinion. Our interpretation of the relevance or the scope of claims in a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. Further, we may incorrectly determine that our technologies, products, or product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending patent application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or internationally that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our products or product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our competitors may have filed, and may in the future file, patent applications covering technology similar to ours, and others may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our product candidates and future approved products or impair our competitive position. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Any such patent application may have priority over our patent applications, which could further require us to obtain rights to issued patents covering such technologies. If another party has filed a U.S. patent application on inventions similar to ours, we may have to participate in an interference proceeding declared by the PTO to determine priority of invention in the United States. The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful if, unbeknownst to us, the other party had independently arrived at the same or similar invention prior to our own invention, resulting in a loss of our U.S. patent position with respect to such inventions. Other countries have similar laws that permit secrecy of patent applications, and may be entitled to priority over our applications in such jurisdictions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">55 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we were to prevail, any litigation or administrative proceeding could be costly and time-consuming and would divert the attention of our management and key personnel from our business operations. Furthermore, as a result of a patent infringement suit brought against us or our strategic partners or licensees, we or our strategic partners or licensees may be forced to stop or delay developing, manufacturing or selling technologies, product candidates or potential products that are claimed to infringe a third party&#8217;s intellectual property unless that party grants us or our strategic partners&#8217; or licensees&#8217; rights to use its intellectual property. Ultimately, we may be unable to develop some of our product candidates or may have to discontinue development of a product candidate or cease some of our business operations as a result of patent infringement claims, which could severely harm our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Competitors may infringe our patents, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming and divert the time and attention of our management and key personnel. For example, on June&#160;22, 2022, we filed a complaint against Aveva Drug Delivery Systems, Inc. and Apotex Corp. and Apotex, Inc. (together, &#8220;Apotex&#8221;) in the U.S. District Court for the Southern District of Florida alleging infringement of certain Orange Book patents covering ZTlido. See the section of this prospectus titled &#8220;<span style="font-style:italic">Business &#8212; Legal Proceedings</span>&#8221; for additional information regarding such proceedings. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors, and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our business, financial condition and results of operations. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing our issued patent, any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">56 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
high or not in the best interest of our company or our stockholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other <span style="white-space:nowrap">non-litigious</span> action or solution. Any of the foregoing may have a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If our intellectual property rights are invalidated or circumvented, our business, financial condition and results of operations will be adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our long-term success depends on our ability to continually discover, develop and commercialize innovative new pharmaceutical products. Without strong intellectual property protection, we would be unable to generate the returns necessary to support the enormous investments in research and development and capital as well as other expenditures required to bring new product candidates to the market and for commercialization. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intellectual property protection varies throughout the world and is subject to change over time. In the United States, for small molecule drug products, such as ZTlido, GLOPERBA and ELYXYB, the Hatch-Waxman Act provides generic companies powerful incentives to seek to invalidate our pharmaceutical patents. As a result, we expect that our U.S. patents on major pharmaceutical products will be routinely challenged, and there can be no assurance that our patents will be upheld. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a distraction to management and other employees. We face generic manufacturer challenges to our patents outside the United States as well. In addition, competitors or other third parties may claim that our activities infringe patents or other intellectual property rights held by them. If successful, such claims could result in our being unable to market a product in a particular territory or being required to pay damages for past infringement or royalties on future sales. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition and our business, financial condition and results of operations may be adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have registered trademarks with the PTO for the mark &#8220;ZTlido,&#8221; &#8220;SCILEX,&#8221; &#8220;ELYXYB,&#8221; and &#8220;RESPONSIBLE BY DESIGN,&#8221; and we have filed trademark applications for the marks &#8220;SEMNUR PHARMACEUTICALS&#8221; and &#8220;SEMDEXA&#8221; in the United States. We also have trademark registrations for ZTlido in the UK and Greece and we have a pending trademark application for ZTlido in China. In China, we are involved in an ongoing dispute regarding third-party trademarks for ZTlido filed in the name of <span style="font-family:pmingliu; font-size:9pt">&#31206;&#30343;&#23798;&#24646;&#39423;&#21830;&#36031;&#26377;&#38480;&#20844;&#21496;</span><span style="font-family:Times New Roman; font-size:10pt"> (Qinhuangdao Hengjun Trading Co., Ltd.). Our trademarks or trade names may be challenged, infringed, diluted, tarnished, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement, dilution or tarnishment claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business, financial condition and results of operations may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As is the case with other biotechnology and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology and pharmaceutical industries involve both technological and legal complexity. Therefore, obtaining and enforcing biotechnology and pharmaceutical patents is costly, time-consuming and inherently uncertain. In addition, the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">57 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
America Invents Act (the &#8220;AIA&#8221;), which was passed in September 2011, resulted in significant changes to the U.S. patent system. An important change introduced by the AIA is that, as of March&#160;16, 2013, the United States transitioned from a <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;first-to-invent&#8221;</span></span> to a <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;first-to-file&#8221;</span></span> system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. Under a <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;first-to-file&#8221;</span></span> system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. A third party that files a patent application in the PTO after that date but before us could therefore be awarded a patent covering an invention of ours even if we made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application and diligent in filing patent applications, but circumstances could prevent us from promptly filing patent applications on our inventions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and providing opportunities for third parties to challenge any issued patent in the PTO. This applies to all of our U.S. patents, even those issued before March&#160;16, 2013. Because of a lower evidentiary standard in PTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a PTO proceeding sufficient for the PTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accordingly, a third party may attempt to use the PTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. It is not clear what, if any, impact the AIA will have on the operation of our business. However, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensors&#8217; patent applications and the enforcement or defense of our or our licensors&#8217; issued patents. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may become involved in opposition, interference, derivation, <span style="font-style:italic">inter partes </span>review, post-grant review, or other proceedings challenging our or our licensors&#8217; patent rights, and the outcome of any proceedings are highly uncertain. An adverse determination in any such proceeding could reduce the scope of, or invalidate, our owned or <span style="white-space:nowrap">in-licensed</span> patent rights, allow third parties to commercialize ZTlido, GLOPERBA, ELYXYB and our product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, the U.S. Supreme Court has ruled on several patent cases in recent years either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations, and there are other open questions under patent law that courts have yet to decisively address. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts and the PTO, the laws and regulations governing patents could change in unpredictable ways and could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, the Biden administration recently indicated its support for a proposal at the World Trade Organization to waive patent rights with respect to <span style="white-space:nowrap">COVID-19</span> vaccines. Any waiver of our patent or other intellectual property protection by the U.S. and other foreign governments could have a material adverse effect on our competitive position, business, financial condition and results of operations. For example, recent decisions raise questions regarding the award of patent term adjustment (&#8220;PTA&#8221;) for patents in families where related patents have issued without PTA. Thus, it cannot be said with certainty how PTA will or will not be viewed in the future and whether patent expiration dates may be impacted. In addition, the European patent system is relatively stringent in the type of amendments that are allowed during prosecution, but, the complexity and uncertainty of European patent laws has also increased in recent years. For example, in Europe, a new unitary patent system took effect June&#160;1, 2023, which will significantly impact European patents, including those granted before the introduction of such a system. Under the unitary patent system, European applications have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">58 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
jurisdiction of the Unitary Patent Court (&#8220;UPC&#8221;). As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single <span style="white-space:nowrap">UPC-based</span> revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes. Complying with these laws and regulations could limit our ability to obtain new patents in the future that may be important for our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <span style="white-space:nowrap">non-compliance</span> with these requirements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The PTO and various foreign patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions to maintain patent applications and issued patents. For example, periodic maintenance fees on any issued patent are due to be paid to the PTO and other foreign patent agencies in several stages over the lifetime of the patent. The PTO and various foreign national or international patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which <span style="white-space:nowrap">non-compliance</span> can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. <span style="white-space:nowrap">Non-compliance</span> events that could result in abandonment or lapse of patent rights include, but are not limited to, failure to timely file national and regional stage patent applications based on our international patent application, failure to respond to official actions within prescribed time limits, <span style="white-space:nowrap">non-payment</span> of fees, and failure to properly legalize and submit formal documents. If we or any of our licensors fail to maintain the patents or patent applications covering ZTlido, GLOPERBA, ELYXYB and our product candidates, our competitors may be able to enter the market, which would have an adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Confidentiality agreements with employees may not adequately prevent disclosure of our trade secrets and other proprietary information and may not adequately protect our intellectual property, which could limit our ability to compete. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To help protect our proprietary <span style="white-space:nowrap">know-how</span> and our inventions for which patents may be unobtainable or difficult to obtain, or prior to seeking patent protection, we rely on trade secret protection and confidentiality agreements. To this end, we require all our employees to enter into agreements that prohibit the disclosure of confidential information and, where applicable, require disclosure and assignment to us of the ideas, developments, discoveries and inventions important to our business. These agreements typically limit the rights of the third parties to use or disclose our confidential information. We also typically obtain agreements from these parties that provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, current or former employees may unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. For example, on March&#160;12, 2021, we filed the Former Employee Action, as described under the section titled &#8220;<span style="font-style:italic">Legal Proceedings</span>&#8221; of this prospectus. The need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our competitive position is based, in part, on our <span style="white-space:nowrap">know-how</span> and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business, financial condition and results of operations. Enforcing a claim that a third party obtained illegally, and is using, trade secrets and/or confidential <span style="white-space:nowrap">know-how</span> is </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">59 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expensive, time-consuming and unpredictable, and the enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of our trade secrets, <span style="white-space:nowrap">know-how</span> or other proprietary information is disclosed, the value of our trade secrets, <span style="white-space:nowrap">know-how</span> and other proprietary rights would be significantly impaired and our business and competitive position would suffer. Moreover, our third-party licensing partners may retain rights in some of our proprietary or joint trade secrets, <span style="white-space:nowrap">know-how,</span> patented inventions or other proprietary information, including rights to sublicense and rights of publication, which may adversely impact our ability to obtain patents and protect trade secrets, <span style="white-space:nowrap">know-how</span> or other proprietary information. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors, as well as our academic partners. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or <span style="white-space:nowrap">know-how</span> of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. We may also be subject to claims that patents and applications that we may file to protect inventions of our employees or consultants are rightfully owned by their former employers or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. An inability to incorporate such technologies or features would have a material adverse effect on our business, financial condition and results of operations and may prevent us from successfully commercializing ZTlido, GLOPERBA, ELYXYB and our product candidates, if approved. Moreover, any such litigation or the threat of such litigation may adversely affect our ability to hire employees or contract with independent contractors. A loss of key personnel or their work product could hamper or prevent our ability to commercialize ZTlido, GLOPERBA, ELYXYB and our product candidates, if approved. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. Moreover, even when we obtain agreements assigning intellectual property to us, the assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. In addition, individuals executing agreements with us may have preexisting or competing obligations to a third party. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our position as a relatively small company may cause us to be at a significant disadvantage in defending our intellectual property rights and in defending against infringement claims by third parties. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Litigation relating to the ownership and use of intellectual property is expensive, and our position as a relatively small company in an industry dominated by very large companies may cause us to be at a significant disadvantage in defending our intellectual property rights and in defending against claims that ZTlido, GLOPERBA, ELYXYB or any of our product candidates infringes or misappropriates third-party intellectual property rights. However, we may seek to use various post-grant administrative proceedings, including procedures created under the AIA, to invalidate potentially overly-broad third-party rights. Even if we can defend our position, the cost of doing so may adversely affect our ability to grow, generate revenue or become profitable. In the course of the ongoing litigation or any future additional litigation to which we may be subject, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">60 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
we may not be able to protect our intellectual property at a reasonable cost, or at all. The outcome of litigation is always uncertain, and in some cases could include judgments against us that require us to pay damages, enjoin us from certain activities or otherwise affect our legal, contractual or intellectual property rights, which could have a significant adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Third-party claims of intellectual property infringement may prevent or delay our drug discovery and development efforts. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including PTO administrative proceedings, such as <span style="font-style:italic">inter partes </span>reviews, post-grant reviews, and reexamination proceedings before the PTO or oppositions and revocations and other comparable proceedings in foreign jurisdictions. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that the development and/or commercialization of ZTlido, GLOPERBA, ELYXYB or our product candidates may give rise to claims of infringement of the patent rights of others. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Despite safe harbor provisions for products prior to commercial launch, third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents, of which we are currently unaware, with claims to materials, formulations, methods of doing research, methods of manufacture or methods for treatment related to the use or manufacture of ZTlido, GLOPERBA, ELYXYB or our product candidates. Because patent applications can take many years to issue, there may be currently pending unpublished patent applications which may later result in issued patents that ZTlido, GLOPERBA, ELYXYB or our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that the use of our technologies infringes these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of ZTlido, GLOPERBA, ELYXYB or any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtain a license under the applicable patents, or until such patents expire or they are finally determined to be held invalid or unenforceable. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy or patient selection methods, the holders of any such patent may be able to block our ability to develop and commercialize the applicable product candidate unless we obtain a license, limit our uses, or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms, or at all. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further commercialize ZTlido, GLOPERBA and ELYXYB, or develop and commercialize one or more of our product candidates. For example, Takeda filed the GLOPERBA Patent Litigation against us on November&#160;6, 2023, alleging that our filing with the FDA of an application for approval of a proposed revision to the product label for our GLOPERBA product infringed the Colcrys Patents. Takeda is seeking an order that the effective date of any FDA approval of our labeling revision be no earlier than the expiration date of the Colcrys Patents, and such further and other relief as the court may deem appropriate. The filing of the complaint subjects us to a <span style="white-space:nowrap">30-month</span> stay, preventing us from selling GLOPERBA under a revised label (but not from selling GLOPERBA under its current label) during that time. The stay could last as long as until May&#160;6, 2026, unless the litigation is resolved before that time. See the section of this prospectus titled &#8220;<span style="font-style:italic">Business &#8211; Legal Proceedings</span>&#8221; for additional information regarding such proceedings. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, cease marketing ZTlido, GLOPERBA or ELYXYB, or developing our product candidates, limit our uses, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">61 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pay royalties or redesign our infringing product candidates, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of ZTlido, GLOPERBA or ELYXYB or our product candidates, if approved. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further commercialize ZTlido, GLOPERBA or ELYXYB, or develop and commercialize one or more of our product candidates, which could harm our business, financial condition and results of operations significantly. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As is common in the biotechnology and pharmaceutical industries, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other pharmaceutical companies including our competitors or potential competitors. We may become subject to claims that we, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team and other employees. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be able to protect our intellectual property rights throughout the world. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The requirements for patentability and the patent enforcement differ in many countries. Filing, prosecuting and defending patents on ZTlido, GLOPERBA, ELYXYB and all of our product candidates throughout the world would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement in some countries is not as strong as that in the United States. These products may compete with ZTlido, GLOPERBA, ELYXYB or our product candidates, if approved, in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ongoing conflict in Ukraine and related sanctions could significantly devalue our Ukrainian and Russian patent applications. Russian decrees may significantly limit our ability to enforce Russian patents. We cannot predict when or how this situation will change. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals and methods of treatment of the human body, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">62 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, many countries have compulsory licensing laws under which a patent owner may be compelled under specified circumstances to grant licenses to third parties. Furthermore, many countries limit the enforceability of patents against government agencies or government contractors. In those countries, we may have limited remedies if patents are infringed or if we are compelled to grant a license to a third party, which could materially diminish the value of those patents and limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license, which could adversely affect our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely on trade secrets to protect our proprietary technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors, and inventions agreements with employees, consultants and advisors, to protect our trade secrets and other proprietary information. In addition to contractual measures, we try to protect the confidential nature of our proprietary information using commonly accepted physical and technological security measures. Despite these efforts, we cannot provide any assurances that all such agreements have been duly executed, and these agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information. For example, in 2010, the FDA, as part of its Transparency Initiative, recommended steps that the FDA could take to increase transparency, including with respect to making additional information publicly available on a routine basis, which may include information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA&#8217;s disclosure policies may change in the future, if at all. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, such security measures may not provide adequate protection for our proprietary information, for example, in the case of misappropriation of a trade secret by an employee, consultant, customer or third party with authorized access. Our security measures may not prevent an employee, consultant or customer from misappropriating our trade secrets and providing them to a competitor, and any recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. Unauthorized parties may also attempt to copy or reverse engineer certain aspects of our products that we consider proprietary. Competitors and other third parties could attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual property rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive and time-consuming, and the outcome is unpredictable. Even though we use commonly accepted security measures, the criteria for protection of trade secrets can vary among different jurisdictions. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Moreover, trade secrets will over time be disseminated within the industry through independent development, the publication of journal articles and the movement of personnel skilled in the art from company to company or academic to industry scientific positions. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced and our competitive position would be harmed. If we do not apply for patent protection prior to such publication or if we cannot </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">63 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our reliance on third parties may require us to share our trade secrets, which increases the possibility that our trade secrets will be misappropriated or disclosed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because we rely on third parties to help manufacture and supply our products and product candidates, and we expect to collaborate with third parties on the continuing development of future product candidates, we must, at times, share trade secrets with them. We also expect to conduct research and development programs that may require us to share trade secrets under the terms of our partnerships or agreements with CROs, research institutions and/or investigators. We seek to protect our proprietary technology in part by entering into agreements containing confidentiality and use restrictions and obligations, including, material transfer agreements, consulting agreements, confidentiality agreements or other similar agreements with our advisors, contractors, service providers and consultants prior to disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our <span style="white-space:nowrap">know-how</span> and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, these agreements typically restrict the ability of our advisors, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#8217;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Intellectual property rights and regulatory exclusivity rights do not necessarily address all potential threats to our competitive advantage. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. If we do not adequately protect our intellectual property and proprietary technology, competitors may be able to use our product candidates and proprietary technologies and erode or negate any competitive advantage we may have, which could have a material adverse effect on our financial condition and results of operations. For example: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Others may be able to make products that are similar to ZTlido, GLOPERBA, ELYXYB or our product candidates but that are not covered by the claims of the patents that we own or have exclusively licensed; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We or our licensors or strategic partners might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We or our licensors or strategic partners might not have been the first to file patent applications covering certain of our inventions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our pending patent applications may not lead to issued patents; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">64 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Issued patents that we own or have exclusively licensed may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may not develop additional proprietary technologies that are patentable; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The patents of others may have an adverse effect on our business. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Should any of these events occur, they could significantly harm our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope or requests for PTA. If we or our partners, collaborators, licensees or licensors, whether current or future, fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our partners, collaborators, licensees or licensors, are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution or enforcement of our patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been and will continue to be the subject of litigation and new legislation. Publications in scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our own patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result of these and other factors, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued that protect ZTlido, GLOPERBA, ELYXYB and our product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. If these changes were to occur, they could have a material adverse effect on our ability to generate revenue. For example, recent decisions raise questions regarding the award of PTA for patents in families where related patents have issued without PTA. Thus, it cannot be said with certainty how PTA will/will not be viewed in the future and whether patent expiration dates may be impacted. Similarly, the complexity and uncertainty of European patent laws have also increased in recent years. In Europe, a new unitary patent system took effect on June&#160;1, 2023, which will significantly impact European patents, including those granted before the introduction of such a system. Under the unitary patent system, European applications have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the UPC. As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single <span style="white-space:nowrap">UPC-based</span> revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, we may be subject to a third-party <span style="white-space:nowrap">pre-issuance</span> submission of prior art to the PTO or become involved in opposition, derivation, reexamination, <span style="font-style:italic">inter partes </span>review, post-grant review or interference proceedings </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">65 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
challenging our patent rights or the patent rights of others. The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings and litigation can be substantial and the outcome can be uncertain. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize ZTlido, GLOPERBA, ELYXYB and our product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and potentially licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of ZTlido, GLOPERBA, ELYXYB or our product candidates. Generally, patents are granted a term of 20 years from the earliest claimed <span style="white-space:nowrap">non-provisional</span> filing date. In certain instances, patent term can be adjusted and increased to recapture a portion of delay incurred by the PTO in examining the patent application. The scope of patent protection may also be limited. Without patent protection for our current or future product candidates, we may be open to competition from generic versions of such products. Given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Government Regulations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The regulatory approval processes of the FDA and comparable <span style="white-space:nowrap">non-U.S.</span> regulatory authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business, financial condition and results of operations will be substantially harmed. Moreover, gaining approval for a product candidate in one country or jurisdiction does not guarantee that we will be able to obtain approval for or commercialize it in any other jurisdiction, which would limit our ability to realize our full market potential. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The time required to obtain marketing approval from the FDA or comparable <span style="white-space:nowrap">non-U.S.</span> regulatory authorities for a product candidate is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities, and its outcome is inherently uncertain. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. For example, we believe that the data from our Phase 3 CLEAR trial will be sufficient to support a 505(b)(2) NDA submission for SEMDEXA. However, the FDA has disagreed and has issued guidance requiring us to conduct an additional clinical study for the purpose of collecting additional safety data before we are able to submit the NDA, even though we believe the data from the CLEAR trial are adequate (see the section titled &#8220;<span style="font-style:italic">Business</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;&#8212; The Company &#8212; Our Product Candidates</span>&#8221; for additional information). Our future success depends on our ability to develop, receive regulatory approval for, and introduce new products or product enhancements that will be accepted by the market in a timely manner. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA or comparable <span style="white-space:nowrap">non-U.S.</span> regulatory authorities can delay, limit or deny approval of a product candidate for many reasons, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it may disagree with the design or implementation of our clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may be unable to demonstrate to such authorities&#8217; satisfaction that a product candidate is safe and effective for its proposed indication; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">negative or ambiguous results from our clinical trials may not meet the level of statistical significance required for approval by the FDA; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">66 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it may disagree with our interpretation of data from preclinical studies or clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it may not agree that the data collected from clinical trials of our product candidates are acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States, and such authorities may impose requirements for additional preclinical studies or clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it may disagree regarding the formulation, labeling and/or the specifications of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">such authorities may decline to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the approval policies or regulations of the FDA or comparable <span style="white-space:nowrap">non-U.S.</span> regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Of the large number of drugs in development, only a small percentage successfully complete the regulatory approval processes and are commercialized. This lengthy approval process, as well as the unpredictability of future clinical trial results, may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, financial condition and results of operations. In addition, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our product candidates, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than an NDA submitted for ZTlido in the United States, which was approved by the FDA in February 2018, we have not previously submitted an NDA to the FDA for any product candidate, and we cannot be certain that any of our product candidates will be successful in clinical trials or receive regulatory approval. Further, our product candidates may not receive regulatory approval even if our clinical trials are successful. In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a <span style="white-space:nowrap"><span style="white-space:nowrap">country-by-country</span></span> basis regarding safety and efficacy. Approval of a product candidate by the FDA does not ensure approval by regulatory authorities in any other country or jurisdiction outside the United States. In addition, the clinical trials conducted in one country, and the data generated therefrom, may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. Approval processes vary among countries and can involve additional product testing and validation, as well as additional administrative review periods. If we do not receive regulatory approvals for our product candidates, our business, financial condition and results of operations will be substantially harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If the FDA does not conclude that certain of our product candidates satisfy the requirements for the Section&#160;505(b)(2) regulatory approval pathway, or if the requirements for such product candidates under Section&#160;505(b)(2) are not as we expect, the approval pathway for those product candidates will likely take significantly longer, cost significantly more and entail significantly greater complications and risks than anticipated, and in either case may not be successful. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For our product candidates SEMDEXA, <span style="white-space:nowrap">SP-103</span> and <span style="white-space:nowrap">SP-104,</span> we may seek FDA approval through the Section&#160;505(b)(2) regulatory pathway. The Hatch-Waxman Act added Section&#160;505(b)(2) to the Federal Food, Drug and Cosmetic Act (the &#8220;FDCA&#8221;). Section&#160;505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from trials that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference. Section&#160;505(b)(2) allows an NDA we submit to the FDA to rely in part on data in the public domain or the FDA&#8217;s prior conclusions regarding the safety and effectiveness of approved compounds, which could expedite the development program for our product candidates by potentially decreasing the amount of data that we would need to generate in order to obtain FDA approval. If the FDA does </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">67 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
not agree that the Section&#160;505(b)(2) regulatory pathway is acceptable as we anticipated, we may need to conduct additional clinical trials, provide additional data and information and meet additional standards for regulatory approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if FDA accepts our plan to pursue the Section&#160;505(b)(2) regulatory pathway, we cannot assure that our product candidates will receive the requisite approvals for commercialization. In addition, the pharmaceutical industry is highly competitive, and Section&#160;505(b)(2) NDAs are subject to special requirements designed to protect the patent and market exclusivity rights of sponsors of previously approved drugs that are referenced in a Section&#160;505(b)(2) NDA. These requirements may give rise to patent litigation against us and mandatory delays in approval of our NDAs for up to 30 months or longer depending on the outcome of any litigation. Further, a manufacturer of an approved product may file a citizen petition with the FDA seeking to delay approval of, or impose additional approval requirements for, pending competing products. FDA imposes strict requirements on such petitions in part to dissuade companies from improperly using these petitions to delay approval of competing drug products. Nonetheless, if successful, such petitions can significantly delay, or even prevent, the approval of the new product. However, even if the FDA ultimately denies such a petition, the FDA may delay approval while it considers and responds to the petition. In addition, even if we are able to utilize the Section&#160;505(b)(2) regulatory pathway, there is no guarantee this would ultimately lead to accelerated product development or earlier approval. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Any approved product candidate will be subject to ongoing and continued regulatory review, which may result in significant expense and limit our ability to commercialize such products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even after a product is approved, we will remain subject to ongoing FDA and other regulatory requirements governing the manufacturing, testing, labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, import, export, record-keeping and reporting of safety and other post-market information. The holder of an approved NDA is obligated to monitor and report adverse events and, among other things, any failure of a distributed product to meet the specifications in the NDA. The holder of an approved NDA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws. In addition, the FDA may impose significant restrictions on the approved indicated uses for which the product may be marketed. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These requirements include submissions of safety and other post-marketing information and reports, registration and listing, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. The future discovery of previously unknown problems with a product, including adverse events of unanticipated type, severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">investigation or additional study obligations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">communications to prescribers or patients about specific information or issues; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">fines, warning or untitled letters or holds on clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">refusal by the FDA to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product license approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">product seizure or detention, or refusal to permit the import or export of products; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">injunctions or the imposition of civil or criminal penalties. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The occurrence of any event or penalty described above may inhibit our ability to successfully commercialize our product candidates and generate revenue and could require us to expend significant time and resources in </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">68 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
response and could generate negative publicity. We may not be able to regain compliance, or we may only be able to regain compliance after a lengthy delay, significant expense, lost revenues and damage to our reputation. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional laws or government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our ability to generate revenue and achieve or sustain profitability. Changes in law or government regulations may also alter the competitive landscape, potentially to our disadvantage. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain manufacturers in the market in which we compete distribute certain products without completing the FDA approval process. For example, we believe certain lidocaine topical patches, plaster or poultice products marketed OTC and without FDA approval, require approval and compete inappropriately with ZTlido. In December 2018, we filed a citizen&#8217;s petition asking the FDA to clarify its requirements and take enforcement action against such products. Furthermore, we believe the labeling and marketing of certain OTC lidocaine patches products are false and deceptive, which could cause significant damages to our business and a diminution of goodwill in our intellectual property. In addition, on March&#160;7, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) was signed into law, which included statutory provisions reforming FDA&#8217;s mechanisms for regulating OTC drugs. Under the CARES Act, the FDA considers a drug to be generally recognized as safe and effective (&#8220;GRASE&#8221;) if it meets certain requirements, including items such as the active ingredient, indication for use, dosage, route of administration, and labeling set forth in the OTC monograph and related rulemakings. Historically, the FDA was required to establish, revise, and amend an OTC monograph by <span style="white-space:nowrap"><span style="white-space:nowrap">notice-and-comment</span></span> rulemaking, which was lengthy and resource-intensive. The CARES Act replaces the rulemaking process with a final administrative order process. Administrative orders may be initiated by the FDA or at the request of a drug manufacturer or any other person. After a period for public comment on the administrative order, the FDA is able to issue a final administrative order, rather than a regulation, permitting the drug to be marketed over the counter. As this process is much more streamlined and less burdensome, this may benefit the manufacturers of lidocaine topical patches to obtain GRASE status from the FDA and thereby legally market these products <span style="white-space:nowrap"><span style="white-space:nowrap">over-the-counter</span></span> and compete with ZTlido. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA ultimately denied our citizen&#8217;s petition in light of the new administrative order process under the CARES Act for considering OTC drug products. In February 2021, we filed a complaint against Sanofi and Hisamitsu, certain manufacturers of OTC lidocaine patches, to seek an award of damages and the entry of injunctive relief enjoining further dissemination of false and deceptive advertisement concerning claims about their lidocaine patches. On January&#160;26 and February&#160;2, 2024, Scilex Pharma entered into two separate settlement agreements and mutual releases with the two manufacturers that resolve the Action. The terms of those agreements are confidential. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the current U.S. administration may impact our business and industry. Namely, recent U.S. administrations have taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict how these executive actions, including the Executive Orders, will be implemented, and the extent to which they will impact the FDA&#8217;s ability to exercise its regulatory authority. If these executive actions impose constraints on FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business, financial condition and results of operations may be negatively affected. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">69 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">A fast track product designation, breakthrough therapy designation or other designation to facilitate product candidate development may not lead to faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A product sponsor may apply for fast track designation from the FDA if a product is intended for the treatment of a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address an unmet medical need for this condition. The FDA has broad discretion whether or not to grant this designation. We have received fast track designation for SEMDEXA for the treatment of sciatica and <span style="white-space:nowrap">SP-103</span> for the treatment of chronic neck pain. Even though SEMDEXA and <span style="white-space:nowrap">SP-103</span> have received fast track designation, we may not experience a faster process, review or approval compared to conventional FDA procedures. A fast track designation does not expedite clinical trials, or mean that regulatory requirements are less stringent or provide assurance of ultimate marketing approval by the FDA. Instead, fast track designation provides opportunities for frequent interactions with FDA review staff, as well as eligibility for priority review, if relevant criteria are met, and rolling review of individual sections of an NDA submitted to the FDA as they become finalized. The FDA may rescind the fast track designation if it believes that the designation is no longer supported by data from our clinical development program. The FDA may also withdraw any fast track designation at any time. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes in funding for the FDA could hinder its ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disruptions at the FDA and other regulatory authorities may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business, financial condition and results of operations. For example, over the last several years, including for 35 days beginning on December&#160;22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities. Separately, in response to the <span style="white-space:nowrap">COVID-19</span> pandemic, the FDA temporarily postponed routine surveillance inspections of manufacturing facilities in 2020. If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Failure to comply with health and data protection laws and regulations could lead to government enforcement actions and civil or criminal penalties, private litigation or adverse publicity and could negatively affect our operating results and business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and our collaborators are subject to federal, state and foreign data protection laws and regulations. In the United States, such laws may include, but are not limited to, U.S. state personal data breach notification laws, state health information privacy laws, and federal and state consumer protection laws, including Section&#160;5 of the FTC Act, each of which govern the collection, use, disclosure and protection of health-related and other personal information. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we are not subject to HIPAA, as we are neither a Covered Entity nor Business Associate (as such terms are defined in HIPAA), we may have access to very sensitive data regarding patients who participate in, or whose tissue samples or other biospecimens are used in, our clinical trials. The maintenance of this data imposes upon </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">70 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
us administrative and financial burdens and litigation risks. In addition, we may obtain health information from third parties, including research institutions from which we obtain clinical trial data that are subject to HIPAA and other privacy, data security and consumer protection laws. Depending on the facts and circumstances, we could be subject to criminal penalties if we knowingly receive individually identifiable health information maintained by a Covered Entity in a manner that is not authorized by HIPAA, and we may be subject to other civil and/or criminal penalties if we obtain, use, or disclose information in a manner not permitted by other privacy and data security and consumer protection laws. Our ability to use or disclose information may be limited by the scope of an authorization signed by clinical trial subjects or the terms of the contract that we enter into with providers or other data sources. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, U.S. state laws and regulations relating to data privacy and security and consumer protection are constantly evolving. For example, the CCPA, which went into effect on January&#160;1, 2020, created new individual privacy rights for California consumers and placed increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA has been amended by the CPRA, which largely took effect on January&#160;1, 2023. The CPRA also created a new state agency, the CPPA, vested with authority to implement and, along with the California Attorney General, enforce the CCPA. Several other states have enacted or are considering similar state consumer privacy laws. The state privacy laws vary from each other in many ways, which may complicate compliance efforts. The effects on our business of the state privacy laws and general consumer protection authorities are potentially significant, and may require us to modify our data processing practices and policies and to incur substantial costs and expenses in an effort to so comply. Privacy laws and regulations are constantly evolving and there are a number of legislative proposals at both the state and federal levels that could impose new obligations or limitations in areas affecting our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FTC also sets expectations for failing to take appropriate steps to keep consumers&#8217; personal information secure, or failing to provide a level of security commensurate to promises made to individuals about the security of their personal information (such as in a privacy notice) may constitute unfair or deceptive acts or practices in violation of Section&#160;5(a) of the FTC Act. While we do not intend to engage in unfair or deceptive acts or practices, the FTC has the power to enforce promises as it interprets them, and events that we cannot fully control, such as data breaches, may be result in FTC enforcement. Enforcement by the FTC under the FTC Act can result in civil penalties or enforcement actions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">International data protection laws, including the EU&#8217;s and UK&#8217;s GDPR, may also apply to health-related and other personal information obtained outside of the United States. The GDPR imposes several data protection requirements in the EU, as well as fines for violations that can reach up to the greater of &#8364;20&#160;million or 4% of annual global revenue. The regulation imposes numerous requirements for the collection, use, storage and disclosure of personal information, including more stringent requirements relating to consent and the information that must be shared with data subjects about how their personal information is used, the obligation to notify regulators and affected individuals of personal data breaches, extensive new internal privacy governance obligations and obligations to honor expanded rights of individuals in relation to their personal information, including the right to access, correct and delete their data. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Compliance with international data protection laws and regulations could require us to take on more onerous obligations in our contracts, increase our compliance costs, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. We cannot guarantee that we are or will be in compliance with all applicable international regulations as they are enforced now or as they evolve. Claims that we have violated individual privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend against and could result in adverse publicity that could harm our business, financial condition, and results of operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">71 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our business involves the use of hazardous materials and we and third parties with whom we contract must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our research and development activities involve the controlled storage, use and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and manufacturers and suppliers with whom we may contract are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at our manufacturers&#8217; facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly <span style="white-space:nowrap">clean-up</span> and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. We cannot guarantee that the safety procedures utilized by third-party manufacturers and suppliers with whom we may contract will comply with the standards prescribed by laws and regulations or will eliminate the risk of accidental contamination or injury from these materials. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. We may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our employees, independent contractors, consultants, commercial partners, and vendors may engage in misconduct or other improper activities, including <span style="white-space:nowrap">non-compliance</span> with regulatory standards and requirements, which could have a material adverse effect on our business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of fraud, illegal activity or other misconduct by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by employees could include intentional, reckless and/or negligent conduct that fails to comply with the laws and regulations of the FDA, EU Member States, EMA and other similar foreign regulatory bodies, provide true, complete and accurate information to the FDA, EMA and other similar foreign regulatory bodies, comply with manufacturing standards we have established, comply with federal and state health-care fraud and abuse laws and regulations, comply with laws and regulations, including, but not limited to the FCPA and internal policies restricting payments to government agencies and representatives, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by employees, independent contractors, consultants, commercial partners and vendors could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by our employees, independent contractors, consultants, commercial partners and vendors, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or FDA debarment or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition and results of operations, including the imposition of significant fines or other sanctions and serious harm to our reputation. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">72 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, transparency and disclosure, or sunshine, laws, government price reporting, and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our current and future arrangements with healthcare professionals, clinical sites and clinical investigators, consultants, customers, patient organizations and third-party payors may subject us to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act. These laws may impact, among other things, our current activities with clinical study investigators and research subjects, as well as our current and future sales, marketing, patient assistance and education programs. In addition, we may be subject to physician payment transparency laws and patient privacy regulation by both the federal government and the states and foreign jurisdictions in which we conduct our business. The laws that may affect our ability to operate include, but are not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, either the referral of an individual, or the furnishing, recommending, or arranging for an item or service for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs &#8212; a person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or special intent to violate the law in order to have committed a violation; in addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">federal civil and criminal false claims laws, including the False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds, or knowingly making, using, or causing to be made or used a false statement material to a false or fraudulent claim, or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government. The False Claims Act has been used to assert liability on the basis of kickbacks and other improper referrals, improperly reported government pricing metrics such as Best Price or Average Manufacturer Price, and improper promotion of <span style="white-space:nowrap">off-label</span> uses (i.e., uses not expressly approved by the FDA in a drug&#8217;s label); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the federal Physician Payment Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to CMS information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), teaching hospitals and, beginning in 2022, certain other healthcare professionals, as well as ownership and investment interests held by the physicians described above and their immediate family members; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">federal government price reporting laws, which require drug manufacturers to calculate and report complex pricing metrics to government agencies, including CMS and Department of Veterans Affairs (&#8220;VA&#8221;), where such reported prices may be used in the calculation of reimbursement and/or discounts on marketed products paid by government healthcare programs. Participation in these programs and compliance with the applicable requirements may result in potentially significant discounts on products subject to reimbursement under federal healthcare programs and increased infrastructure costs, and may potentially limit a drug manufacturer&#8217;s ability to offer certain marketplace discounts; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">73 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Prescription Drug Marketing Act, which restricts the manner in which manufacturers may disseminate complimentary drug samples to healthcare practitioners, requires physical and accounting controls, and establishes penalties for improper sample distribution; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">state law equivalents of each of the above federal laws, such as licensing, anti-kickback, false claims, consumer protection and unfair competition laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with states regarding pricing information and marketing expenditures, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, our current and future research and development of our product candidates outside the United States, and any future sales of our product or product candidates once commercialized outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Efforts to ensure that our business practices and arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to, without limitation, civil, criminal, and administrative penalties, damages, monetary fines, disgorgement, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of <span style="white-space:nowrap">non-compliance,</span> imprisonment, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our business, financial condition and results of operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from participation in government healthcare programs, which could also materially affect our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of <span style="white-space:nowrap">off-label</span> uses. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are found to have improperly promoted <span style="white-space:nowrap">off-label</span> uses of ZTlido, GLOPERBA, ELYXYB, or our product candidates, if approved, or if we are found to have improperly engaged in <span style="white-space:nowrap">pre-approval</span> promotion prior to the approval of such product candidates, we may become subject to significant liability. Such enforcement has become more common in the industry. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, such as ZTlido, GLOPERBA, ELYXYB, and our product candidates, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#8217;s approved labeling. Physicians may use our products, and our product candidates if they receive marketing approval, for their patients in a manner that is </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">74 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
inconsistent with the approved labels, if the physicians believe in their professional medical judgment they could be used in such manner. However, if we are found to have promoted any of our products for any <span style="white-space:nowrap">off-label</span> uses, the federal government could levy civil, criminal and/or administrative penalties, and seek fines against us. The FDA, Department of Justice or other regulatory authorities could also request that we enter into a consent decree or a corporate integrity agreement, or seek a permanent injunction against us under which specified promotional conduct is monitored, changed or curtailed. If we cannot successfully manage the promotion of ZTlido, GLOPERBA, ELYXYB, or our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Healthcare reform measures could hinder or prevent our product candidates&#8217; commercial success. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There have been, and we expect there will continue to be, a number of legislative and regulatory changes to health care systems in the United States and abroad that could impact our ability to sell our products profitably. The United States government and other governments have shown significant interest in pursuing healthcare reform. For example, in 2010, the ACA was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States. Healthcare reform measures like the ACA may adversely impact the pricing of healthcare products and services in the United States or internationally and the amount of reimbursement available from governmental agencies or other third-party payors. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been ongoing efforts to modify the ACA and its implementing regulations. For example, tax legislation enacted at the end of 2017 included provisions that, effective January&#160;1, 2019, eliminated the tax penalty for individuals who do not maintain sufficient health insurance coverage, or the <span style="white-space:nowrap">so-called</span> &#8220;individual mandate.&#8221; It is unclear how healthcare reform measures enacted by Congress or implemented by the Biden administration or efforts, if any, to modify the ACA or its implementing regulations, or portions thereof, will impact our business. Litigation and legislation over the ACA and other healthcare reform measures are likely to continue, with unpredictable and uncertain results. Further, additional legislative changes to and regulatory changes under or related to the ACA remain possible. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, led to aggregate reductions of Medicare payments to providers of, on average, 2% per fiscal year. These reductions went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May&#160;1, 2020, through May&#160;31, 2022, due to the <span style="white-space:nowrap">COVID-19</span> pandemic. The law provides for 1% Medicare sequestration in the second quarter of 2022 and allows the full 2% sequestration thereafter until 2030. To offset the temporary suspension during the <span style="white-space:nowrap">COVID-19</span> pandemic, in 2030, the sequestration will be 2.25% for the first half of the year, and 3% in the second half of the year. The American Taxpayer Relief Act of 2012 further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under government payor programs, and review the relationship between pricing and manufacturer patient programs, as addressed further in the risk factor below titled &#8220;<span style="font-style:italic">If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs applicable to our product or product candidates, if approved, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations and future prospects</span>.&#8221; While any proposed measures may require authorization through additional legislation to become effective, Congress and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">75 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Biden administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal health care programs and commercial payers will pay for healthcare products and services, which could result in reduced demand for ZTlido, GLOPERBA, ELYXYB and our product candidates, if approved, or additional pricing pressures. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally-mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial condition and results of operations. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. Furthermore, there has been increased interest by third-party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. These or other reforms could reduce the ultimate demand for ZTlido, GLOPERBA, ELYXYB and our product candidates, if approved, or put pressure on our product pricing. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, ZTlido, GLOPERBA and/or ELYXYB may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs applicable to our product or product candidates, if approved, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations and future prospects. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pricing and rebate calculations vary across products and programs, are complex, and are often subject to interpretation by manufacturers, governmental or regulatory agencies and the courts. Such interpretation can change and evolve over time. In the case of Medicaid pricing data, if a manufacturer becomes aware that its reporting for a prior quarter was incorrect, or has changed as a result of recalculation of the pricing data, the manufacturer is obligated to resubmit the corrected data for up to three years after those data originally were due. Such restatements and recalculations increase costs for complying with the laws and regulations governing the Medicaid Drug Rebate Program and could result in an overage or underage in rebate liability for past quarters. Price recalculations also may affect the ceiling price at which a manufacturer is required to offer its products under the 340B program. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A failure to comply with reporting and payment obligations under the Medicaid Drug Rebate program and other governmental programs could negatively affect financial results. CMS issued a final regulation, which became effective on April&#160;1, 2016, to implement the changes under the ACA to the Medicaid Drug Rebate Program. The final regulation has increased and will continue to increase costs and the complexity of compliance, has been and will continue to be time-consuming to implement, and could have a material adverse effect on the results of operations, particularly if CMS challenges the approach a manufacturer has taken in the implementation of the final regulation. Other regulations and coverage expansion by various governmental agencies relating to the Medicaid Drug Rebate Program may have a similar impact. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Manufacturers have obligations to report the average sales price for certain of drugs to the Medicare program as a part of the agreement to participate in the Medicaid Drug Rebate program. For calendar quarters beginning January&#160;1, 2022, manufacturers are required to report the average sales price for certain drugs under the Medicare program regardless of whether they participate in the Medicaid Drug Rebate program. Statutory or regulatory </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">76 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
changes or CMS guidance could affect the average sales price calculations for products and the resulting Medicare payment rate, and could negatively affect results of operations. Starting in 2023, manufacturers must pay refunds to Medicare for single source drugs or biologics, or biosimilar biological products, reimbursed under Medicare Part B and packaged in single-dose containers or <span style="white-space:nowrap">single-use</span> packages, for units of discarded drug reimbursed by Medicare Part B in excess of 10% of total allowed charges under Medicare Part B for that drug. Manufacturers that fail to pay refunds could be subject to civil monetary penalties of 125&#160;percent of the refund amount. Congress further could enact a Medicare Part B inflation rebate, under which manufacturers would owe additional rebates if the average sales price of a drug were to increase faster than the pace of inflation. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Health Resources and Services Administration (&#8220;HRSA&#8221;) issued a final regulation regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities, which became effective on January&#160;1, 2019. Implementation of this regulation has affected manufacturer obligations and potential liability under the 340B program. Manufacturers are also required to report the 340B ceiling prices for covered outpatient drugs to HRSA, which then publishes them to 340B covered entities. Any charge by HRSA that a manufacturer has violated the requirements of the program or the regulation could negatively affect financial results. Moreover, under a final regulation effective January&#160;13, 2021, HRSA newly established an administrative dispute resolution (&#8220;ADR&#8221;) process for claims by covered entities that a manufacturer has engaged in overcharging, and by manufacturers that a covered entity violated the prohibitions against diversion or duplicate discounts. Such claims are to be resolved through an ADR panel of government officials rendering a decision that can be appealed to a federal court. An ADR proceeding could subject a manufacturer to onerous procedural requirements and could result in additional liability. Further, any additional future changes to the definition of average manufacturer price and the Medicaid rebate amount under the ACA or otherwise could affect our 340B ceiling price calculations and negatively affect results of operations. The U.S. Court of Appeals for the Third Circuit (the &#8220;Third Circuit&#8221;) ruled in January 2023 that, under Section&#160;340B, manufacturers are not required to provide the discounted drugs to an unlimited number of contract pharmacies, but can impose limitations on the availability to the hospital&#8217;s own pharmacy, and one contract pharmacy. The Third Circuit also upheld the ADR rules. Two other cases are pending, one in the U.S. Court of Appeals for the Seventh Circuit and one in the U.S. Court of Appeals for the District of Columbia Circuit. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Civil monetary penalties can be applied if a manufacturer (i)&#160;is found to have knowingly submitted any false price or product information to the government, (ii)&#160;is found to have made a misrepresentation in the reporting of its average sales price, (iii)&#160;fails to submit the required price data on a timely basis, or (iv)&#160;is found to have knowingly and intentionally charged 340B covered entities more than the statutorily mandated ceiling price. CMS could also decide to terminate the Medicaid Drug Rebate Agreement, or HRSA, or to terminate the 340B program participation agreement, in which case federal payments may not be available under Medicaid or Medicare Part B for the manufacturer&#8217;s covered outpatient drugs. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, manufacturers are required to provide to CMS a 70% discount on brand name prescription drugs utilized by Medicare Part D beneficiaries when those beneficiaries are in the coverage gap phase of the Part D benefit design. Congress could enact legislation that sunsets this discount program and replaces it with a new manufacturer discount program. Under either program, civil monetary penalties could be applied if a manufacturer fails to provide these discounts in the amount of 125&#160;percent of the discount that was due. Furthermore, the Inflation Reduction Act of 2022 (the &#8220;IRA&#8221;), PL <span style="white-space:nowrap">117-169,</span> seeks to limit manufacturers&#8217; price increases for drugs reimbursed by Medicare, to not more than the rate of inflation, at least where those increases would otherwise affect payments under Medicare. Under the provisions, beginning in October 2022, if a manufacturer increases the price of a drug reimbursed under Medicare by more than the rate of inflation (as measured by the consumer price index), the manufacturer must pay rebates to the federal government, equal to the amount by which the increase exceeds the rate of inflation in the relevant period. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Congress could also enact additional changes that affect our overall rebate liability and the information we report to the government as part of price reporting calculations. The IRA also requires the U.S. Department of Health </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">77 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and Human Services (&#8220;HHS&#8221;) to negotiate prices for a limited number of single-source brand-name drugs or biologics without generic or biosimilar competitors that are covered under Medicare Part D (starting in 2026) and Part B (starting in 2028). The number of drugs affected is limited to ten Part D drugs for 2026, another fifteen Part D drugs for 2027, another fifteen Part D and Part B drugs for 2028, and another twenty Part D and Part B drugs for 2029 and later years. On August&#160;29, 2023, HHS announced the list of the ten drugs for which negotiations will occur. Drugs that are less than 9 years (for small-molecule drugs) or 13 years (for biological products) from their FDA approval or licensure date are excluded from the negotiation process. Small biotech drugs, defined as those which account for 1% or less of Part D or Part B spending and account for 80% or more of spending under each part on that manufacturer&#8217;s drugs, are also excluded until 2029. CMS has issued initial guidance on the implementation of the provisions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to applicable law, knowing provision of false information in connection with price reporting or contract-based requirements under the VA Federal Supply Schedule and/or Tricare programs can subject a manufacturer to civil monetary penalties. These programs and contract-based obligations also contain extensive disclosure and certification requirements. If a manufacturer overcharges the government in connection with its arrangements with Federal Supply Schedule or Tricare, the manufacturer may be required to refund the difference to the government. Failure to make necessary disclosures or to identify contract overcharges can result in allegations against us under the False Claims Act and other laws and regulations. Unexpected refunds to the government, and/or response to a government investigation or enforcement action, would be expensive and time-consuming, and could have a material adverse effect on our business, financial condition, results of operations and future prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We will need to obtain prior FDA authorization for any proposed product brand names, and any failure or delay associated with such approval may adversely impact our business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any brand names we intend to use for our product candidates will require authorization from the FDA regardless of whether we have secured a formal trademark registration from the PTO. The FDA typically conducts a review of proposed product brand names, including an evaluation of potential for confusion with other product names. The FDA may also object to a product brand name if it believes the name inappropriately implies medical claims. If the FDA objects to any of our proposed product brand names, we may be required to adopt an alternative brand name for our product candidates. If we adopt an alternative brand name, we would lose the benefit of our existing trademark applications for such product candidate and may be required to expend significant additional resources in an effort to identify a suitable product brand name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. We may be unable to build a successful brand identity for a new trademark in a timely manner, or at all, which would limit our ability to successfully commercialize our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures, and legal expenses, which could adversely affect our business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our operations are subject to certain anti-corruption laws, including the FCPA, and other anti-corruption laws that apply in countries where we conduct business, including performing clinical trials. The FCPA and other anti-corruption laws generally prohibit us and our employees and intermediaries from bribing, being bribed or making other prohibited payments to foreign government officials or other persons to obtain or retain business or gain some other business advantage. We, our commercial partners and our affiliates operate in a number of jurisdictions that pose a risk of potential FCPA violations and we participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the FCPA or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">78 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the FCPA or other legal requirements, such as trade control laws. Any investigation of potential violations of the FCPA, other anti-corruption laws or trade control laws by U.S., European Union or other authorities could have an adverse impact on our reputation, our business, financial condition and results of operations. Furthermore, should we be found not to be in compliance with the FCPA, other anti-corruption laws or trade control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, as well as the accompanying legal expenses, any of which could have a material adverse effect on our reputation and liquidity, as well as on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are subject to recently enacted state laws in California that require gender and diversity quotas for boards of directors of public companies headquartered in California. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2018, California enacted Senator Bill 826 (&#8220;SB 826&#8221;), which generally requires public companies with principal executive offices in California to have at least two female directors on its board of directors if the company has at least five directors, and at least three female directors on its board of directors if the company has at least six directors. SB 826 has been challenged in legal proceedings and on May&#160;13, 2022, the Superior Court of California for the County of Los Angeles entered an order striking down SB 826, holding that the statute violates the Equal Protection Clause of the California Constitution. The California Secretary of State has appealed the order and such appeal is currently pending. On September&#160;16, 2022, the appellate court ruled to temporarily stay enforcement of the trial court&#8217;s order, which prevented the California Secretary of State from collecting diversity data on corporate disclosure forms pursuant to SB 826, pending a further order of the appellate court. On December&#160;1, 2022, the appellate court vacated the temporary stay order and on February&#160;3, 2023, a record on appeal was filed and such appeal is currently pending. To the extent that this ruling of the appellate court permits the Secretary of State of California to collect and report diversity data, we may be required to comply with additional disclosure requirements. However, ultimate enforceability of SB 826 remains uncertain. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, on September&#160;30, 2020, California enacted Assembly Bill 979 (&#8220;AB 979&#8221;), which generally requires public companies with principal executive offices in California to include specified numbers of directors from &#8220;underrepresented communities&#8221;. A director from an &#8220;underrepresented community&#8221; means a director who self-identifies as Black, African American, Hispanic, Latino, Asian, Pacific Islander, Native American, Native Hawaiian, Alaska Native, gay, lesbian, bisexual or transgender. By December&#160;31, 2021, each public company with principal executive offices in California was required to have at least one director from an underrepresented community. By December&#160;31, 2022, a public company with more than four but fewer than nine directors will be required to have a minimum of two directors from underrepresented communities, and a public company with nine or more directors will need to have a minimum of three directors from underrepresented communities. On April&#160;1, 2022, the Superior Court of California for the County of Los Angeles entered an order striking down AB 979, holding that the statute violates the Equal Protection Clause of the California Constitution. On June&#160;6, 2022, a notice of appeal was filed. On September&#160;16, 2022, the appellate court ruled to temporarily stay enforcement of the trial court&#8217;s order, which prevented the California Secretary of State from collecting diversity data on corporate disclosure forms pursuant to AB 979, pending a further order of the appellate court. On December&#160;1, 2022, the appellate court vacated the temporary stay order and on February&#160;3, 2023, a record on appeal was filed and such appeal is currently pending. To the extent that this ruling of the appellate court permits the Secretary of State of California to collect and report diversity data, we may be required to comply with additional disclosure requirements. In June 2023, the federal district court for the Eastern District of California granted the plaintiffs a summary judgment and determined that AB 979 was unconstitutional on its face. The Eastern District of California&#8217;s decision is currently on appeal. Litigation regarding AB 979 will continue. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot assure that we can recruit, attract and/or retain qualified members of our Board and meet gender and diversity quotas under Nasdaq Listing Rules or any California law that may become applicable to the Company, which may expose us to financial penalties and adversely affect our reputation. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">79 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to our Relationship with Sorrento </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Certain of our directors and officers may have actual or potential conflicts of interest because of their positions with Sorrento. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&#160;Jaisim Shah, Dr.&#160;Henry Ji, Mr.&#160;Dorman Followwill, Mr.&#160;David Lemus and Dr.&#160;Alexander Wu serve on our Board. Mr.&#160;Jaisim Shah and Dr.&#160;Henry Ji, who are our executive officers, are also members of the board of directors of Sorrento (and in the case of Dr.&#160;Henry Ji, the positions of President, Chief Executive Officer and Chairman of the board of directors of Sorrento). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While our Board has determined that Mr.&#160;Dorman Followwill, Mr.&#160;David Lemus and Dr.&#160;Alexander Wu are &#8220;independent directors&#8221; within the meaning of applicable regulatory and stock exchange requirements in the United States, each of Mr.&#160;David Lemus, Mr.&#160;Dorman Followwill and Dr.&#160;Alexander Wu have served, and continue to serve, as directors of Sorrento (and in the case of Mr.&#160;Dorman Followwill, the Lead Independent Director of Sorrento). In May 2022, pursuant to a bill of sale and assignment and assumption agreement (the &#8220;Bill of Sale&#8221;), Sorrento sold, conveyed, assigned and transferred to us all of its rights, title and interest in and to the delayed burst release low dose naltrexone formulation asset and intellectual property rights that it had previously acquired from Aardvark. When Sorrento had previously purchased such assets from Aardvark, it also purchased shares of Aardvark&#8217;s Series B Preferred Stock, resulting in Sorrento holding approximately 9.4% of Aardvark&#8217;s ownership interest as of December&#160;31, 2023. Also as part of such investment, Dr.&#160;Henry Ji joined the board of directors of Aardvark in May 2021.We may enter into commercial arrangements with Aardvark in the future and Sorrento and Aardvark may also enter into more commercial arrangements in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to the interrelated nature of Sorrento and Aardvark with us as a result of the foregoing overlapping relationships, conflicts of interest may arise with respect to transactions involving business dealings between us and Aardvark and between us and Sorrento. Service as an overlapping director or officer of Sorrento and/or Aardvark and us could create, or appear to create, conflicts of interest with respect to matters involving or affecting more than one of the companies to which such directors or officers owe fiduciary duties. For example, these matters could relate to potential acquisitions of businesses or products, the development and ownership of technologies and product candidates, the sale of products, markets and other matters in which our best interest and the best interests of our stockholders may conflict with the best interests of Sorrento or Aardvark and their respective stockholders. In particular, it is possible that we may be precluded from participating in certain business opportunities that we might otherwise have participated in as those opportunities may be presented to Aardvark or Sorrento because such directors may deem such opportunities to have a greater benefit to Aardvark or Sorrento than to us. In addition, we, Sorrento and Aardvark may disagree regarding the interpretation of certain terms in the Aardvark Asset Purchase Agreement or the Bill of Sale. Conflicts could also arise in any renegotiation or extension of these agreements. From time to time, Aardvark, Sorrento or their respective affiliates may enter into additional transactions with us or our subsidiaries or affiliates. In an effort to balance their conflicting interests, our directors or officers may approve terms equally favorable to Aardvark, Sorrento and us as opposed to negotiating terms more favorable to us but adverse to Sorrento or Aardvark. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, such directors and officers may own shares of Sorrento or Aardvark common stock, options to purchase shares of Sorrento or Aardvark common stock or other Sorrento or Aardvark equity awards. These individuals&#8217; holdings of such common stock, options or other equity awards of Sorrento or Aardvark may be significant for some of these persons compared to these persons&#8217; total assets. Their ownership of any Sorrento or Aardvark equity or equity awards creates, or may create the appearance of, conflicts of interest when these directors and officers are faced with decisions that could have different implications for Sorrento or Aardvark than the decisions have for us. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any potential conflict that qualifies as a &#8220;related party transaction&#8221; (as defined in Item 404 of Regulation <span style="white-space:nowrap">S-K</span> under the Securities Act) is subject to review by our audit committee in accordance with our related person transaction policy. There can be no assurance that the terms of any such transactions will be as favorable to us or our stockholders as would be the case where there are no overlapping officers or directors. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">80 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sorrento previously supported many of our important corporate functions. Accordingly, our historical financial statements may not necessarily be indicative of the conditions that would have existed or our results of operations if we had been operated as an unaffiliated company of Sorrento, and we have and will continue to incur incremental costs as a stand-alone public company. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have completed the process of replicating and replacing certain functions, systems and infrastructure previously provided by Sorrento prior to and subsequent to the Business Combination. We currently have no shared services or other intercompany arrangements other than as it relates to our continued access to and usage of Sorrento&#8217;s software consolidation system for financial reporting purposes. We have made and continue to make investments and hire additional employees to operate without access to Sorrento&#8217;s operational and administrative infrastructure. These functions, systems and infrastructure are costly to implement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Historically, Sorrento performed or supported many important corporate functions for us. Our financial statements for the fiscal years ended December&#160;31, 2023, 2022 and 2021 reflect charges for these services on an allocation basis. As a result, such financial statements may not be reflective of conditions that would have existed or what our results of operations would have been had we been a stand-alone public company and no longer a majority-owned subsidiary of Sorrento during such periods. We have incurred significant costs to replace the services and resources that are no longer provided by Sorrento. We are also incurring additional costs as a stand-alone public company. As a stand-alone public company, our total costs related to certain support functions may differ from the costs that were historically allocated to us from Sorrento. As we now operate separately from Sorrento, if we are not able to maintain adequate systems and business functions, we may not be able to operate our business effectively or at comparable costs, and our profitability may decline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our Executive Chairperson holds an executive officer position at Sorrento and devotes time to both companies. In addition, our Executive Chairperson is the chairperson of Sorrento&#8217;s board of directors. The ongoing Chapter 11 Cases could require that such executive devotes time to such proceedings, which could cause a diversion of his time and attention from our business and operations, and as a result could have a material adverse effect on our business and operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&#160;Henry Ji is our Executive Chairperson and also serves as President, Chief Executive Officer and Chairman of the board of directors of Sorrento. The amount of time that Dr.&#160;Ji devotes to us varies <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> and <span style="white-space:nowrap"><span style="white-space:nowrap">week-to-week</span></span> depending on the then current needs and demands of each company&#8217;s business, transactions each company may be evaluating, and other corporate matters. On February&#160;13, 2023, Sorrento and Sorrento&#8217;s wholly owned direct subsidiary, Scintilla Pharmaceuticals, Inc. (&#8220;Scintilla&#8221; and together with Sorrento, the &#8220;Debtors&#8221;), commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code (the &#8220;Bankruptcy Code&#8221;) in the United States Bankruptcy Court for the Southern District of Texas (the &#8220;Bankruptcy Court&#8221;). The Debtors&#8217; Chapter 11 proceedings are jointly administered under the caption In re Sorrento Therapeutics, Inc., et al., Case Number <span style="white-space:nowrap">23-90085</span> (DRJ) (the &#8220;Chapter 11 Cases&#8221;). So long as the proceedings related to the Chapter 11 Cases continue, Dr.&#160;Ji may be required to devote additional time and effort dealing with the reorganization of Sorrento instead of focusing on our business operations. Such diversion of management attention could have a material adverse effect on our business and operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Ownership of our Common Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The market price of our Common Stock may fluctuate significantly, and investors in our Common Stock may lose all or a part of their investment. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The market prices for securities of biotechnology and pharmaceutical companies have historically been highly volatile, and the market has from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. For example, from November&#160;11, 2022 (the first trading day following the closing of the Business Combination) to March&#160;15, 2024, our closing stock price ranged from $0.95 to $14.80. The market price of our Common Stock may fluctuate significantly in response to numerous factors, some of which are beyond our control, such as: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to commercialize ZTlido, GLOPERBA, ELYXYB or our product candidates, if approved; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">81 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">legal disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for ZTlido, GLOPERBA, ELYXYB or our product candidates, government investigations and the results of any proceedings or lawsuits, including, but not limited to, patent or stockholder litigation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our relationship with Sorrento; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Sorrento&#8217;s voluntary proceedings under Chapter 11 of the United States Bankruptcy Code; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">extension of the <span style="white-space:nowrap">lock-up</span> restriction by court order in the Chapter 11 Cases on the 76,000,000 shares of our Common Stock that were previously distributed by Sorrento to Sorrento equityholders as a dividend; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements of the introduction of new products by our company and our competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">issuances of debt or equity securities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">market conditions and trends in the pharmaceutical and biotechnology sectors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">overall performance of the equity markets and other factors that may be unrelated to our operating performance or the operating performance of our competitors, including changes in market valuations of similar companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">trading volume of our Common Stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ineffectiveness of our internal controls; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other events or factors, many of which are beyond our control. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See the risk factor below titled &#8220;<span style="font-style:italic">If our operations and performance do not meet the expectations of investors or securities analysts, the market price of our securities may decline</span>&#8221; for more factors affecting the trading price of our securities. The realization of any of the above risks or any of a broad range of other risks, including those described in these &#8220;Risk Factors,&#8221; could have a dramatic and material adverse impact on the market price of our Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The equity markets in general have recently experienced extreme price and volume fluctuations. Continued market fluctuations could result in extreme volatility in the price of our Common Stock. Further, price volatility of our Common Stock might worsen if the trading volume of our Common Stock is low. If an active trading market for our Common Stock does not continue, the price of our Common Stock may be more volatile and it may be more difficult and time consuming to complete a transaction in our Common Stock, which could have an adverse effect on the realized price of our Common Stock. In addition, an adverse development in the market price for our Common Stock could negatively affect our ability to issue new equity to fund our activities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If our operations and performance do not meet the expectations of investors or securities analysts, the market price of our securities may decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of the factors listed below could have a negative impact on your investment in our securities, and our securities may trade at prices significantly below the price you paid for them. In such circumstances, the trading price of our securities may not recover and may experience a further decline. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Factors affecting the trading price of our securities may include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to commercialize ZTlido, GLOPERBA, ELYXYB or our product candidates, if approved; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the status and cost of our marketing commitments for ZTlido, GLOPERBA, ELYXYB and our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements regarding results of any clinical trials relating to our product candidates; </p></td></tr></table> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">82 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">unanticipated serious safety concerns related to the use of ZTlido, GLOPERBA, ELYXYB or any of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adverse regulatory decisions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in laws or regulations applicable to ZTlido, GLOPERBA, ELYXYB or our product candidates, including but not limited to clinical trial requirements for approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">legal disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for ZTlido, GLOPERBA, ELYXYB or our product candidates, government investigations and the results of any proceedings or lawsuits, including, but not limited to, patent or stockholder litigation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our decision to initiate a clinical trial, not initiate a clinical trial or to terminate an existing clinical trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our dependence on third parties; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements of the introduction of new products by our competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">market conditions and trends in the pharmaceutical and biotechnology sectors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements concerning product development results or intellectual property rights of others; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">future issuances of common stock or other securities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the recruitment or departure of key personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to meet or exceed any financial guidance or expectations regarding product development milestones that we may provide to the public; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">actual or anticipated variations in quarterly operating results; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our failure to meet or exceed the estimates and projections of the investment community; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">overall performance of the equity markets and other factors that may be unrelated to our operating performance or the operating performance of our competitors, including changes in market valuations of similar companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in financial estimates by the Company or by any securities analysts who might cover our stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">fluctuation of the market values of any of our potential strategic investments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">issuances of debt or equity securities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">compliance with our contractual obligations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sales of our Common Stock by us or our stockholders in the future; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">trading volume of our Common Stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ineffectiveness of our internal controls; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">publication of research reports about the Company or its industry or positive or negative recommendations or withdrawal of research coverage by securities analysts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to effectively integrate the operations of Semnur; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our relationship with Sorrento; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">general political and economic conditions, including the wars in Ukraine and Israel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">effects of natural or <span style="white-space:nowrap">man-made</span> catastrophic events; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">83 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">effects of public health crises, pandemics and epidemics, such as the <span style="white-space:nowrap">COVID-19</span> pandemic; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other events or factors, many of which are beyond our control, such as the government closure of Silicon Valley Bank and Signature Bank, and liquidity concerns at other financial institutions. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, the global equity markets in general have recently experienced extreme price and volume fluctuations, including as a result of the <span style="white-space:nowrap">COVID-19</span> pandemic, economic uncertainty and increased interest rates, inflation, the government closure of Silicon Valley Bank and Signature Bank, and liquidity concerns at other financial institutions that may be unrelated to our operating performance. Continued market fluctuations could result in extreme volatility in the price of our Common Stock, which could cause a decline in the value of our Common Stock. Price volatility of our Common Stock might worsen if the trading volume of our Common Stock is low. In the past, stockholders have initiated class action lawsuits against pharmaceutical and biotechnology companies following periods of volatility in the market prices of these companies&#8217; stock. Such litigation, if instituted against the Company, could cause us to incur substantial costs and divert management&#8217;s attention and resources from our business. The realization of any of the above risks or any of a broad range of other risks, including those described in these &#8220;<span style="font-style:italic">Risk Factors</span>&#8221;, could have a dramatic and material adverse impact on the market price of our Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have not paid cash dividends in the past and we do not expect to pay cash dividends in the foreseeable future. Any return on investment may be limited to the capital appreciation, if any, of our Common Stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not paid cash dividends on our Common Stock and we do not anticipate paying cash dividends on our Common Stock in the foreseeable future. Should we decide in the future to do so, as a holding company, our ability to pay dividends on our capital stock and meet other obligations depends upon the receipt of dividends or other payments from our operating subsidiaries, including Legacy Scilex. In addition, our ability to pay dividends may be limited by covenants in future outstanding indebtedness that we or our subsidiaries may incur. Since we do not intend to pay dividends, a stockholder&#8217;s ability to receive a return on such stockholder&#8217;s investment will depend on any future appreciation in the market value of our Common Stock. There is no guarantee that our Common Stock will appreciate or even maintain the price at which our stockholders have purchased it. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Future sales, or the perception of future sales, of a substantial number of shares of our Common Stock may cause the price of our Common Stock to decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our Common Stock, the trading price of our Common Stock could decline and it could impair our ability to raise capital through the sale of additional equity securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;30, 2022, Sorrento announced that its board of directors authorized Sorrento to dividend to Sorrento equityholders of record as of January&#160;9, 2023 an aggregate of 76,000,000 shares of our Common Stock that were held by Sorrento (the &#8220;Dividend Shares&#8221;). Such shares were initially subject to a <span style="white-space:nowrap">lock-up</span> restriction prohibiting the sale, pledge or other transfer until May&#160;11, 2023. Such <span style="white-space:nowrap">lock-up</span> restriction was extended to March&#160;31, 2024 by court order in the Chapter 11 Cases, and on March 26, 2024, the Bankruptcy Court approved a motion to extend the lock-up period of the Dividend Shares to the earlier of (i) September 30, 2024 or (ii) the date on which Sorrento and its Official Committee of Unsecured Creditors agree in writing or on the record in the Chapter 11 Cases that certain claims that may be asserted in potential litigation to avoid Sorrento&#8217;s distribution of Dividend Shares and to recover such Dividend Shares (the &#8220;Stock Clawback Claims&#8221;) should not be pursued, or on such date that the Bankruptcy Court deems just and proper. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the restrictions on resale end, the market price of shares of our Common Stock could drop significantly if the holders of these shares of Common Stock sell them or are perceived by the market as intending to sell them. These factors could also make it more difficult for us to raise additional funds through future offerings of our shares of Common Stock or other securities. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">84 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The securities being offered in this prospectus represent a significant percentage of our outstanding Common Stock. The Selling Stockholders acquired or may acquire the securities covered by this prospectus at different prices, some substantially below the current trading price of such securities and may therefore make substantial profits upon resales. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Stockholders can sell, under this prospectus, up to 13,324,683 shares of Common Stock representing approximately 7.44% of the shares of our Common Stock outstanding as of March&#160;15, 2024, assuming the exercise of all outstanding Penny Warrants for which underlying shares are registered for resale hereunder, which consists of: (i) 324,683 shares of Common Stock held by Cove Lane and HBC that were issued on September 25, 2023 in connection with the Settlement Agreement and (ii)&#160;up to 13,000,000 shares of Common Stock issuable upon the exercise of the Penny Warrants held by Oramed at an exercise price of $0.01 per share. The Selling Stockholders will be able to sell such shares registered for resale hereunder for so long as the registration statement of which this prospectus forms a part is available for use and if applicable, upon exercise of the Penny Warrants, if and when such Penny Warrants become exercisable. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The sale of all the securities being offered in this prospectus could result in a significant decline in the public trading price of our securities. Even if the current trading price of our Common Stock is at or significantly below the price at which the Resale Shares were issued, the Selling Stockholders may have an incentive to sell because they will still profit on sales due to the lower price at which they acquired their shares compared to the other securityholders. Other securityholders may not experience a similar rate of return on the securities they purchased due to differences in the purchase prices and the current trading price. For example, based on the closing price of our Common Stock of $1.37 on March&#160;15, 2024, (i) Cove Lane and HBC may experience a potential profit of $1.37 per share of our Common Stock given that they acquired the HB Shares at no cost in connection with the Settlement Agreement, and (ii)&#160;Oramed may experience a potential profit of up to $1.36 per Penny Warrant Share given that the exercise price of the Penny Warrants is $0.01 per share. Depending on the price, the public securityholders may have paid significantly more than the Selling Stockholders for any shares they may have purchased in the open market based on variable market prices and therefore may not be able to experience the same positive rates of return on securities they purchase. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our operating results may fluctuate significantly. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect our operating results to be subject to quarterly, and possibly annual, fluctuations. Our net loss and other operating results will be affected by numerous factors, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">variations in the level of expenses related to our development programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the addition or termination of clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any intellectual property infringement lawsuit in which we may become involved; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory developments affecting ZTlido, GLOPERBA, ELYXYB or our product candidates, regulatory approvals of our product candidates, and the level of underlying demand for such products and purchasing patterns; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our execution of any collaborative, licensing or similar arrangements, and the timing of payments we may make or receive under these arrangements; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effect on pharmaceutical purchases and prices of the timing during which patients who purchase our product satisfy their deductibles under the reimbursement requirements of their health providers&#8217; plans. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If our quarterly or annual operating results fall below the expectations of investors or securities analysts, the price of our Common Stock could decline substantially. Furthermore, any quarterly or annual fluctuations in our operating results may, in turn, cause the price of our Common Stock to fluctuate substantially. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">85 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our cash and cash equivalents could be adversely affected if the financial institutions in which we hold our cash and cash equivalents fail. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;10, 2023, the Federal Deposit Insurance Corporation (the &#8220;FDIC&#8221;) announced that Silicon Valley Bank had been closed by the California Department of Financial Protection and Innovation and on March&#160;12, 2023, Signature Bank was closed by the New York State Department of Financial Services and the FDIC was named receiver. Although we do not maintain any bank accounts with Silicon Valley Bank or Signature Bank, we regularly maintain cash balances at third-party financial institutions in excess of the FDIC insurance limit. Any failure of a depository institution to return any of our deposits, or any other adverse conditions in the financial or credit markets affecting depository institutions, could impact access to our invested cash or cash equivalents and could adversely impact our operating liquidity and financial performance. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse opinion regarding our stock, our stock price and trading volume could decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trading market for our Common Stock will be influenced by the research and reports that industry or securities analysts publish about the Company or our business. We may never obtain research coverage by securities and industry analysts. Since we became public through a merger, securities analysts of major brokerage firms may not provide coverage of the Company since there is no incentive to brokerage firms to recommend the purchase of our Common Stock. If no or few securities or industry analysts commence coverage of the Company, the trading price for our Common Stock would be negatively impacted. In the event we obtain securities or industry analyst coverage, if any of the analysts who cover it issues an adverse opinion regarding the Company, our business model, our intellectual property or our stock performance, or if our clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of the Company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to ZTlido or our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue additional equity securities to fund future expansion and pursuant to equity incentive or employee benefit plans. We may also issue additional equity for other purposes. These securities may have the same rights as our Common Stock or, alternatively, may have dividend, liquidation or other preferences to our Common Stock. The issuance of additional equity securities pursuant to the ATM Sales Agreement or otherwise will dilute the holdings of existing stockholders and may reduce the share price of our Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Scilex Holding Company 2022 Equity Incentive Plan (the &#8220;Equity Incentive Plan&#8221;), which became effective on November&#160;9, 2022, we are authorized to grant equity awards to our employees, directors and consultants. In addition, pursuant to the Scilex Holding Company 2022 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), which became effective on November&#160;9, 2022, we are authorized to sell shares to our employees. Further, pursuant to the Scilex Holding Company 2023 Inducement Plan (the &#8220;Inducement Plan&#8221;), which was adopted on January&#160;17, 2023, we are authorized to grant equity awards to individuals as a material inducement to join the Company. A total of 20,167,587 (which number of shares accounts for the annual increase on January&#160;1, 2024 and the increase of 10,000,000 shares authorized for issuance thereunder that was approved by our stockholders on May&#160;4, 2023), 4,476,601 (which number of shares accounts for the annual increase on January&#160;1, 2024) and 1,400,000 shares of our Common Stock have been reserved for future issuance under the Equity Incentive Plan, the ESPP and the Inducement Plan, respectively. In addition, the Equity Incentive Plan and ESPP provide for annual automatic increases in the number of shares reserved thereunder, in each case, beginning on January&#160;1, 2023. As a result of such annual increases, our stockholders may experience additional dilution, which could cause the price of our Common Stock to fall. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Amended and Restated Registration Rights Agreement, dated as of November&#160;10, 2022, by and among us, Vickers Venture Fund VI Pte Ltd, Vickers Venture Fund VI (Plan) Pte Ltd, Sorrento Therapeutics, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">86 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Inc. and certain security holders set forth on the signature pages thereto (the &#8220;Registration Rights Agreement&#8221;), which was entered into in connection with the Business Combination, certain stockholders of Vickers and Legacy Scilex can each demand that we register their registrable securities under certain circumstances and will each also have piggyback registration rights for these securities. In addition, we are required to file and maintain an effective registration statement under the Securities Act covering such securities and certain of our other securities. We have filed a registration statement on Form <span style="white-space:nowrap">S-1</span> (File <span style="white-space:nowrap">No.&#160;333-268603)</span> which was initially declared effective by the SEC on December&#160;27, 2022, in order to satisfy these obligations. The registration of these securities will permit the public sale of such securities, subject to certain contractual restrictions imposed by the Registration Rights Agreement and the Merger Agreement. The presence of these additional shares of our Common Stock trading in the public market may have an adverse effect on the market price of our securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we raise additional funds through collaboration, licensing or other similar arrangements, we may have to relinquish valuable rights to ZTlido, GLOPERBA, ELYXYB or our product candidates, or grant licenses on terms unfavorable to the Company. If adequate funds are not available, our ability to achieve profitability or to respond to competitive pressures would be significantly limited and we may be required to delay, significantly curtail or eliminate the development of our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have in the past and may in the future be subject to short selling strategies that may drive down the market price of our Common Stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Short sellers have in the past and may attempt in the future to drive down the market price of our Common Stock. Short selling is the practice of selling securities that the seller does not own but may have borrowed with the intention of buying identical securities back at a later date. The short seller hopes to profit from a decline in the value of the securities between the time the securities are borrowed and the time they are replaced. As it is in the short seller&#8217;s best interests for the price of the stock to decline, many short sellers (sometimes known as &#8220;disclosed shorts&#8221;) publish, or arrange for the publication of, negative opinions regarding the relevant issuer and its business prospects to create negative market momentum. Although traditionally these disclosed shorts were limited in their ability to access mainstream business media or to otherwise create negative market rumors, the rise of the Internet and technological advancements regarding document creation, videotaping and publication by weblog (&#8220;blogging&#8221;) have allowed many disclosed shorts to publicly attack a company&#8217;s credibility, strategy and veracity by means of <span style="white-space:nowrap">so-called</span> &#8220;research reports&#8221; that mimic the type of investment analysis performed by large Wall Street firms and independent research analysts. These short attacks have, in the past, led to selling of shares in the market. Further, these short seller publications are not regulated by any governmental, self-regulatory organization or other official authority in the U.S. and they are not subject to certification requirements imposed by the SEC. Accordingly, the opinions they express may be based on distortions, omissions or fabrications. Companies that are subject to unfavorable allegations, even if untrue, may have to expend a significant amount of resources to investigate such allegations and/or defend themselves, including stockholder suits against the company that may be prompted by such allegations. We may in the future be the subject of stockholder suits that we believe were prompted by allegations made by short sellers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our ability to use our net operating loss and tax credit carryforwards may be subject to limitation. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, a change of more than 50% in the ownership of a company&#8217;s stock, by value, over a three-year period constitutes an ownership change for U.S. federal income tax purposes. An ownership change may limit our ability to use our net operating loss carryforwards attributable to the period prior to the change. We have experienced a corporate reorganization in the past, some ownership changes as a result of the Business Combination and may experience some subsequent changes in the future in our stock ownership (some of which shifts are outside our control). As a result, if we earn net taxable income, our ability to use our <span style="white-space:nowrap">pre-change</span> net operating loss carryforwards to offset U.S. federal taxable income may become subject to limitations, which could potentially result in increased future tax liability for the Company. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">87 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Tax Cuts and JOBS Act of 2017 (the &#8220;TCJA&#8221;), as amended by the CARES Act, includes changes to U.S. federal tax rates and the rules governing net operating loss (&#8220;NOL&#8221;) carryforwards. The TCJA, as modified by the CARES Act, limits a taxpayer&#8217;s ability to utilize NOL carryforwards to 80% of taxable income (as calculated before taking the NOLs, and certain other tax attributes, into account) for taxable years beginning after December&#160;31, 2020. In addition, NOLs arising in tax years ending after December&#160;31, 2017 and before January&#160;1, 2021 may be carried back to each of the five taxable years preceding the tax year of such loss, but NOLs arising in taxable years beginning after December&#160;31, 2020 may not be carried back. NOLs arising in tax years beginning after December&#160;31, 2017 can be carried forward indefinitely. NOLs generated in tax years beginning before January&#160;1, 2021 will not be subject to the taxable income limitation, and NOLs generated in tax years ending before January&#160;1, 2018 will continue to have a <span style="white-space:nowrap">two-year</span> carryback and <span style="white-space:nowrap">20-year</span> carryforward period. Deferred tax assets for NOLs will need to be measured at the applicable tax rate in effect when the NOL is expected to be utilized. The changes in the carryforward/carryback periods, as well as the new limitation on use of NOLs may significantly impact our ability to utilize our NOLs to offset taxable income in the future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If our estimates or judgments relating to our critical accounting policies are based on assumptions that change or prove to be incorrect, our operating results could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our Common Stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in our combined consolidated financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue and expenses that are not readily apparent from other sources. If our assumptions change or if actual circumstances differ from our assumptions, our operating results may be adversely affected and could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Anti-takeover provisions in the Certificate of Incorporation and the Bylaws and under Delaware law could make an acquisition of our Company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation, the Bylaws and the DGCL, contain provisions that could make it more difficult for a third party to acquire the Company, even if doing so might be beneficial to our stockholders. Among other things, these provisions include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">allow our Board to authorize the issuance of undesignated preferred stock, the terms of which may be established and the shares of which may be issued without stockholder approval, and which may include supermajority voting, special approval, dividend, or other rights or preferences superior to the rights of other stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">provide for a classified board of directors with staggered three-year terms; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">provide that directors may only be removed for cause, and only by the affirmative vote of holders of at least 66 2/3% in voting power of all the then-outstanding shares of our capital stock entitled to vote thereon, voting together as a single class; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">prohibit stockholder action by written consent; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">provide that special meetings may only be called by or at the direction of the Chairperson of the Board, the Board or the Chief Executive Officer; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">provide that any alteration, amendment or repeal, in whole or in part, of any provision of the Bylaws by our stockholders will require the affirmative vote of the holders of at least 66 2/3% in voting power of </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">88 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
all the then-outstanding shares of our capital stock entitled to vote thereon, voting together as a single class; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establish advance notice requirements for nominations for elections to the Board and for proposing matters that can be acted upon by stockholders at stockholder meetings. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&#160;203 of the DGCL generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with any interested stockholder for a period of three years following the date on which the stockholder became an interested stockholder. We are governed by Section&#160;203 of the DGCL, except that the restrictions on business combinations of Section&#160;203 of the DGCL will not apply to Sorrento or its current or future Affiliates (as defined in the Certificate of Incorporation) regardless of its percentage ownership of our Common Stock. These provisions could discourage, delay or prevent a transaction involving a change in control of the Company. These provisions could also discourage proxy contests and make it more difficult for our stockholders to elect directors of their choosing and cause us to take other corporate actions they desire, including actions that our stockholders may deem advantageous. In addition, because our Board is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These anti-takeover provisions and other provisions in the Certificate of Incorporation, the Bylaws and Delaware law could make it more difficult for stockholders or potential acquirors to obtain control of the Board or initiate actions that are opposed by our then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving the Company. The existence of these provisions could negatively affect the price of our Common Stock and limit opportunities for a stockholder to realize value in a corporate transaction. For additional information regarding these and other provisions, see the section of this prospectus titled &#8220;<span style="font-style:italic">Description of Our Securities</span>&#8221;. In addition, if prospective takeovers are not consummated for any reason, we may experience negative reactions from the financial markets, including negative impacts on the price of our Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Certificate of Incorporation designates the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation that may be initiated by our stockholders and the federal district courts of the United States as the exclusive forum for litigation arising under the Securities Act, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with the Company. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Certificate of Incorporation, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom, will, to the fullest extent permitted by law, be the sole and exclusive forum for (i)&#160;any derivative action or proceeding brought on our behalf; (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers, employees or stockholders to us or our stockholders; (iii)&#160;any action asserting a claim against us or any of our current or former directors, officers, employees or stockholders arising pursuant to any provision of the DGCL, the Certificate of Incorporation or the Bylaws; (iv)&#160;any claim or cause of action seeking to interpret, apply, enforce or determine the validity of the Certificate of Incorporation or the Bylaws; (v)&#160;any action or proceeding asserting a claim against us or any of our current or former directors, officers, employees or stockholders as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware and (vi)&#160;any action asserting an &#8220;internal corporate claim,&#8221; as that term is defined in Section&#160;115 of the DGCL; <span style="font-style:italic">provided that</span>, for the avoidance of doubt, the foregoing forum selection provision will not apply to claims arising under the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation also provides that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. The Certificate of Incorporation further provides that any person or entity purchasing or otherwise acquiring any </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">89 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
interest in shares of our Common Stock is deemed to have notice of and consented to the provisions of the Certificate of Incorporation described above. See the section of this prospectus titled &#8220;<span style="font-style:italic">Description of Our Securities &#8211; Anti-Takeover Measures in our Governing Documents and Under Delaware Law &#8211; Exclusive Forum.</span>&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The forum selection provisions in the Certificate of Incorporation may have the effect of discouraging lawsuits against our directors and officers. The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings and there is uncertainty as to whether a court would enforce such provisions. In addition, investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. If the enforceability of our forum selection provisions were to be challenged, it may incur additional costs associated with resolving such challenge. While we currently have no basis to expect any such challenge would be successful, if a court were to find its forum selection provisions to be inapplicable or unenforceable with respect to one or more of these specified types of actions or proceedings, we may incur additional costs associated with having to litigate in other jurisdictions, which could result in a diversion of the time and resources of our employees, management and board of directors, and could have an adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are an emerging growth company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our Common Stock less attractive to investors. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an emerging growth company, as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements and exemptions from the requirements of holding nonbinding advisory stockholder votes on executive compensation and stockholder approval of any golden parachute payments not previously approved. We cannot predict if investors will find our Common Stock less attractive because we may rely on these exemptions. If some investors find our Common Stock less attractive as a result, there may be a less active trading market for our Common Stock and our stock price may be more volatile. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the earlier of (1)&#160;the last day of the fiscal year (a)&#160;following the fifth anniversary of the closing of the IPO, (b)&#160;in which we have total annual gross revenue of at least $1.235&#160;billion, or (c)&#160;in which we are deemed to be a large accelerated filer, which requires the market value of our Common Stock that is held by <span style="white-space:nowrap">non-affiliates</span> to equal or exceed $700&#160;million as of the last business day of the second fiscal quarter of such year, and (2)&#160;the date on which we have issued more than $1&#160;billion in <span style="white-space:nowrap">non-convertible</span> debt during the prior three-year period. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance to changes in our business could significantly affect our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are no longer a &#8220;controlled company&#8221; under the corporate governance rules of Nasdaq. However, during the applicable <span style="white-space:nowrap">phase-in</span> periods, we may rely on exemptions from certain corporate governance requirements, which may limit the presence of independent directors on our Board or committees of our Board. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Previously, Sorrento beneficially owned, in the aggregate, more than 50% of the combined voting power for the election of our Board. However, on September&#160;21, 2023, in connection with the Scilex-Oramed SPA, we and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">90 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Sorrento entered into and consummated the transactions contemplated by that certain Stock Purchase Agreement (the &#8220;Sorrento SPA&#8221;), dated as of such date, pursuant to which, among other things, we purchased from Sorrento (i) 60,068,585 shares of Common Stock, (ii) 29,057,097 shares of Series A Preferred Stock, and (iii)&#160;warrants exercisable for 4,490,617 shares of Common Stock, each with an exercise price of $11.50 (which constitutes the entirety of the holdings of our capital stock that was held by Sorrento, other than the 1,917,210 additional shares of Common Stock held by Sorrento in abeyance for the benefit of certain holders of warrants to purchase shares of common stock of Sorrento) ((i) through (iii)&#160;collectively, the &#8220;Purchased Securities&#8221;, and such transactions, the &#8220;Equity Repurchase Transaction&#8221;). As a result of the consummation of the Equity Repurchase Transaction, Sorrento no longer controls a majority of the voting power of our outstanding capital stock and at such time we ceased to be a &#8220;controlled company&#8221; within the meaning of Nasdaq&#8217;s corporate governance standards. As a result, we are subject to additional corporate governance requirements, including the requirements that (i)&#160;a majority of our Board consists of independent directors, (ii)&#160;our Board has a compensation committee that is composed entirely of independent directors with a written charter addressing the committee&#8217;s purpose and responsibilities and (iii)&#160;director nominees must be selected or recommended for the board&#8217;s selection, either by independent directors constituting a majority of the board&#8217;s independent directors in a vote in which only independent directors participate, or a nominating and corporate governance committee comprised solely of independent directors with a written charter addressing the committee&#8217;s purpose and responsibilities. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nasdaq Listing Rules provide for <span style="white-space:nowrap">phase-in</span> periods for these requirements (including that each such committee consist of a majority of independent directors within 90 days of no longer being a &#8220;controlled company&#8221;), but we must be fully compliant with the requirements within one year of the date on which we cease to be a &#8220;controlled company.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, a majority of the directors on our Board are independent, and each of the directors serving on our audit, nominating and corporate governance and compensation committees are independent. We also adopted formal written charters for each of our audit, nominating and corporate governance, and our compensation committees at the closing of the Business Combination. While as of December&#160;31, 2023, we are in compliance with the additional Nasdaq corporate governance requirements listed above, we may be unable to retain the number of independent directors needed to comply with such rules during the transition period. Moreover, until we are fully subject to these requirements, our stockholders will not have the same protections afforded to stockholders of companies that are subject to all of the corporate governance requirements of Nasdaq. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We will incur increased costs as a result of operating as a public company, and our management will devote substantial time to related compliance initiatives. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We incur significant legal, accounting and other expenses that Legacy Scilex did not incur as a private company, and these expenses may increase even more after we are no longer an &#8220;emerging growth company.&#8221; We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act (the &#8220;Dodd-Frank Act&#8221;), as well as rules and regulations adopted, and to be adopted, by the SEC and Nasdaq. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, we expect these rules and regulations to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly, which will increase our operating expenses. For example, we expect these rules and regulations to make it more difficult and more expensive for the Company to obtain directors&#8217; and officers&#8217; liability insurance and we may be required to incur substantial costs to maintain sufficient coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on the Board, our board committees or as executive officers. Advocacy efforts by stockholders and third parties may also prompt additional changes in governance and reporting requirements, which could further increase costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we have implemented an enterprise resource planning (&#8220;ERP&#8221;) system and will continue to invest in the system. An ERP system is intended to combine and streamline the management of our financial, accounting, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">91 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
human resources, sales and marketing and other functions, enabling it to manage operations and track performance more effectively. However, an ERP system would likely require us to complete many processes and procedures for the effective use of the system or to run our business using the system, which may result in substantial costs. Any disruptions or difficulties in implementing or using an ERP system could adversely affect our controls and harm our business, financial condition and results of operations, including our ability to forecast or make sales and collect our receivables. Moreover, such disruption or difficulties could result in unanticipated costs and diversion of management attention. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a public company, we are required to incur additional costs and obligations in order to comply with SEC rules that implement Section&#160;404 of the Sarbanes-Oxley Act. Under these rules, we are required to make a formal assessment of the effectiveness of our internal control over financial reporting, and once we cease to be an emerging growth company, we will be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section&#160;404 within the prescribed period, we will be engaging in a process to document and evaluate its internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of our internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are designed and operating effectively, and implement a continuous reporting and improvement process for internal control over financial reporting. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation to meet the detailed standards under the rules. During the course of our testing, our management may identify material weaknesses or deficiencies which may not be remedied in time to meet the deadline imposed by the Sarbanes-Oxley Act. See &#8220;<span style="font-style:italic">Risk Factors &#8212; We have identified a material weakness in our internal control over financial reporting. Any material weakness may cause us to fail to timely and accurately report our financial results or result in a material misstatement of our financial statements.</span>&#8221; above for additional information regarding a previously identified material weakness. These reporting and other obligations place significant demands on our management and administrative and operational resources, including accounting resources. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of our management&#8217;s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and there could be a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our failure to meet Nasdaq&#8217;s continued listing requirements could result in a delisting of our Common Stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we fail to satisfy Nasdaq&#8217;s continued listing requirements, such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our Common Stock. Such a delisting would likely have a negative effect on the price of our Common Stock and would impair a stockholder&#8217;s ability to sell or purchase our Common Stock when a stockholder wishes to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our Common Stock to become listed again, stabilize the market price or improve the liquidity of our Common Stock, prevent our Common Stock from dropping below the Nasdaq minimum bid price requirement or prevent future <span style="white-space:nowrap">non-compliance</span> with Nasdaq&#8217;s listing requirements. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">92 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Comprehensive U.S. federal income tax reform could adversely affect the Company. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes to tax laws, which changes may have retroactive application, could adversely affect the Company or holders of our Common Stock. In recent years, many changes have been made to applicable tax laws and changes are likely to continue to occur in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The TCJA, which was enacted in 2017, included changes to U.S. federal tax rates, imposed significant additional limitations on the deductibility of interest, allowed for the expensing of capital expenditures, and put into effect the migration from a &#8220;worldwide&#8221; system of taxation to a modified territorial system. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;27, 2020, then-President Trump signed into law the CARES Act, which included certain changes in tax law (including to the TCJA) intended to stimulate the U.S. economy in light of the <span style="white-space:nowrap">COVID-19</span> pandemic, including temporary beneficial changes to the treatment of net operating losses, interest deductibility limitations and payroll tax matters. On August&#160;16, 2022, President Biden signed the IRA into law, which contained certain tax measures, including a corporate alternative minimum tax of 15% on some large corporations, an excise tax of 1% on certain corporate stock <span style="white-space:nowrap">buy-backs,</span> and an excise tax with respect to certain drug sales for failing to offer a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law or for taking price increases that exceed inflation. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. The impact of these tax reforms on holders of our Common Stock is uncertain and could be adverse. We urge our stockholders to consult with their legal and tax advisors with respect to such legislation and the potential tax consequences of investing in our Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our Warrants are exercisable for our Common Stock, which would increase the number of shares eligible for future resale in the public market and result in dilution to our stockholders. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, outstanding SPAC Warrants (as defined below) to purchase an aggregate of 10,958,309 shares of our Common Stock are exercisable in accordance with the terms of the Warrant Agreement governing those securities. The exercise price of these SPAC Warrants is $11.50 per share. As of December&#160;31, 2023, none of the outstanding Penny Warrants to purchase an aggregate of 13,000,000 shares of our Common Stock are exercisable under the terms thereof, the exercise price of which is $0.01 per share. &#8220;SPAC Warrants&#8221; means (i)&#160;the redeemable warrants that were included in the Units (each of which consisted of one Vickers ordinary share and <span style="white-space:nowrap">one-half</span> of one redeemable warrant) that entitle the holder of each whole warrant to purchase one Vickers ordinary share at a price of $11.50 per share (the &#8220;Public Warrants&#8221;), and (ii)&#160;the 6,840,000 warrants sold in a private placement to Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd consummated on January&#160;11, 2021 (of which 2,736,000 were subsequently forfeited and 3,104,000 were transferred to Sorrento, in each case in connection with the Business Combination) (the &#8220;Private Warrants&#8221;). &#8220;Warrants&#8221; means the SPAC Warrants and the Penny Warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent the Penny Warrants become exercisable and such Penny Warrants and/or the SPAC Warrants are exercised, additional shares of our Common Stock will be issued, which will result in dilution to the holders of our Common Stock and increase the number of shares eligible for resale in the public market. Sales of substantial numbers of such shares in the public market, or the fact that such Warrants may be exercised, could adversely affect the prevailing market prices of our Common Stock. With respect to the SPAC Warrants, there is no guarantee that the SPAC Warrants will ever be in the money prior to their expiration, and as such, the SPAC Warrants may expire worthless. See below risk factor, &#8220;<span style="font-style:italic">The SPAC Warrants may never be in the money, they</span> <span style="font-style:italic">may expire worthless and the terms of the SPAC Warrants may be amended in a manner adverse to a holder if holders of a majority of the then-outstanding SPAC Warrants approve of such amendment</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The SPAC Warrants may never be in the money, they may expire worthless and the terms of the SPAC Warrants may be amended in a manner adverse to a holder if holders of a majority of the then-outstanding SPAC Warrants approve of such amendment. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, the exercise price for our SPAC Warrants is $11.50 per share of Common Stock. On March&#160;15, 2024, the closing price of our Common Stock on the Nasdaq Capital Market was $1.37. If the price of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">93 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our shares of Common Stock remains below $11.50 per share, which is the exercise price of our SPAC Warrants, we believe our warrant holders will be unlikely to cash exercise their SPAC Warrants, resulting in little or no cash proceeds to us. There is no guarantee that our SPAC Warrants will be in the money prior to their expiration and, as such, our SPAC Warrants may expire worthless. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the SPAC Warrants were issued in registered form under the Warrant Agreement between Continental, as warrant agent, and Vickers. The Warrant Agreement provides that the terms of the SPAC Warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision or correct any mistake, but requires the approval by the holders of a majority of the then-outstanding SPAC Warrants to make any change that adversely affects the interests of the registered holders of SPAC Warrants. Accordingly, we may amend the terms of the SPAC Warrants in a manner adverse to a holder if holders of a majority of the then-outstanding SPAC Warrants approve of such amendment. Although our ability to amend the terms of the SPAC Warrants with the consent of majority of the then-outstanding SPAC Warrants is unlimited, examples of such amendments could be amendments to, among other things, increase the exercise price of the SPAC Warrants, convert the SPAC Warrants into cash, shorten the exercise period, or decrease the number of shares of our Common Stock purchasable upon exercise of a SPAC Warrant. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may redeem any unexpired SPAC Warrants prior to their exercise at a time that is disadvantageous to you, thereby making the SPAC Warrants worthless. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have the ability to redeem outstanding SPAC Warrants (other than Private Warrants still held by the initial purchasers thereof) at any time after they become exercisable and prior to their expiration, at a price of $0.01 per SPAC Warrant, provided that the closing price of our Common Stock equals or exceeds $18.00 per share (as adjusted for share subdivisions, share dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like) on each of the 20 trading days within any <span style="white-space:nowrap"><span style="white-space:nowrap">30-trading-day</span></span> period commencing after the SPAC Warrants become exercisable and ending on the third trading day prior to the date on which notice of redemption is given. If and when the SPAC Warrants become redeemable by us, we may exercise our redemption right even if we are unable to register or qualify the underlying securities for sale under all applicable state securities laws. Redemption of the outstanding SPAC Warrants could force the holders thereof to: (i)&#160;exercise such SPAC Warrants and pay the exercise price therefor at a time when it may be disadvantageous for a holder to do so; (ii)&#160;sell such SPAC Warrants at the then-current market price when a holder might otherwise wish to hold such SPAC Warrants; or (iii)&#160;accept the nominal redemption price that, at the time the outstanding SPAC Warrants are called for redemption, is likely to be substantially less than the market value of such Warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we may redeem the SPAC Warrants (other than Private Warrants still held by the initial purchasers thereof) at any time after they become exercisable and prior to their expiration for a number of shares of our Common Stock determined based on the fair market value of our Common Stock. The value received upon exercise of the SPAC Warrants (1)&#160;may be less than the value the holders would have received if they had exercised their SPAC Warrants at a later time where the underlying share price is higher and (2)&#160;may not compensate the holders for the value of the SPAC Warrants. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">94 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx759370_7">MARKET AND INDUSTRY DATA </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain information contained in this prospectus relates to or is based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this prospectus, we have not independently verified the market and industry data contained in this prospectus or the underlying assumptions relied on therein. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source. Notwithstanding the foregoing, we are liable for the information provided in this prospectus. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section of this prospectus titled &#8220;<span style="font-style:italic">Risk Factors</span>&#8221;. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">95 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx759370_8">USE OF PROCEEDS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will receive no proceeds from the sale of the Resale Shares by the Selling Stockholders. The Selling Stockholders will pay any underwriting discounts, selling commissions or transfer taxes incurred in disposing of the Resale Shares and the expenses of any attorney or other advisor they decide to employ. We will bear all other costs, fees and expenses incurred in effecting the registration of the Resale Shares covered by this prospectus. These may include, without limitation, all registration, filing, stock exchange fees, printing expenses, all fees and expenses of complying with applicable securities laws and the fees and disbursements of our counsel and of our independent accountants and reasonable fees. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent the Penny Warrants are exercised for cash, if at all, we will receive the exercise price of any such exercise of the Penny Warrants, but will not receive any proceeds from the sale of the shares of our Common Stock issuable upon such exercise. If all of the Penny Warrants were exercised, we would receive gross proceeds of $130,000. However, the holders of the Penny Warrants are not obligated to exercise the Penny Warrants and we cannot predict whether or when, if ever, the holders of the Penny Warrants will choose to exercise the Penny Warrants, in whole or in part. Each Penny Warrant entitles the holder thereof to purchase one share of Common Stock at a price of $0.01 per share. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to use the proceeds from the exercise of the Penny Warrants for cash for working capital and general corporate purposes, which may include capital expenditures, commercialization expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital stock, although we believe we can fund our operations with cash on hand including cash proceeds received under the ATM Sales Agreement and from additional sources of financing that we may seek from time to time.<span style="font-weight:bold"><span style="font-style:italic"> </span></span>However, we have not designated any specific uses and have no current agreement with respect to any acquisition or strategic transaction. As of the date of this prospectus, we cannot specify with certainty all of the particular uses, and the respective amounts we may allocate to those uses, for any proceeds we receive from the exercise of the Penny Warrants. Accordingly, we will retain broad discretion over the use of these proceeds. Pending our use of the proceeds as described above, we intend to invest such proceeds in interest-bearing instruments. There is no assurance that the holders of the Penny Warrants will elect to exercise any or all of such Penny Warrants. To the extent that the Penny Warrants are exercised on a &#8220;cashless basis,&#8221; the amount of cash we would receive from the exercise of the Penny Warrants will decrease. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">96 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx759370_9">DETERMINATION OF OFFERING PRICE </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot currently determine the price or prices at which shares of our Common Stock may be sold by the Selling Stockholders under this prospectus. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">97 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx759370_10">MARKET INFORMATION FOR SECURITIES AND DIVIDEND POLICY </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Market Information </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock and Public Warrants are currently listed on Nasdaq under the symbols &#8220;SCLX&#8221; and &#8220;SCLXW,&#8221; respectively. Prior to the consummation of the Business Combination, Vickers&#8217;s Ordinary Shares, units and warrants were each listed on Nasdaq under the symbols &#8220;VCKA,&#8221; &#8220;VCKAU&#8221; and &#8220;VCKAW,&#8221; respectively. At the Effective Time, without any action on the part of the holder, each Unit then outstanding separated automatically into its component securities, comprised of one share of Common Stock and <span style="white-space:nowrap">one-half</span> of one warrant to purchase one share of Common Stock. As of March&#160;15, 2024, there were 315 holders of record of our Common Stock and 3 holders of record of our Warrants, which amount does not include participants of The Depository Trust Company or beneficial owners holding shares through nominee names. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Dividend Policy </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any dividend on shares of our Common Stock. We anticipate that we will retain all of our future earnings, if any, to fund the development and growth of our business. Any future determination to pay dividends on our capital stock will be at the discretion of our Board. It is the present intention of our Board to retain all earnings, if any, for use in our business operations and, accordingly, our Board does not anticipate declaring any dividend in the foreseeable future, except as disclosed in the section titled &#8220;<span style="font-style:italic">Use of Proceeds</span>&#8221;. Should we decide in the future to do so, as a holding company, our ability to pay dividends on our capital stock and meet other obligations depends upon the receipt of dividends or other payments from our operating subsidiaries, including Legacy Scilex. Further, our ability to pay dividends may be limited by covenants of any existing and future outstanding indebtedness we or our subsidiaries incur. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Securities Authorized for Issuance under Equity Compensation Plans </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, the Equity Incentive Plan and the ESPP were the only compensation plans under which securities of the Company were authorized for future grant. Each of the&#160;Equity Incentive Plan and the ESPP were approved by our stockholders. In March 2019, the Scilex Pharma 2017 Plan, which was adopted by the board of directors and stockholders of Scilex Pharma on June&#160;26, 2017, and amended and restated on July&#160;5, 2018, terminated in connection with a corporate reorganization that was effected in March 2019. However, the Scilex Pharma 2017 Plan continues to govern awards outstanding thereunder. Additionally, the 2019 Stock Option Plan, which was adopted by the board of directors and stockholders of Legacy Scilex on May&#160;28, 2019 and June&#160;24, 2019, respectively, and amended on December&#160;21, 2020, terminated at the closing of the Business Combination. However, the 2019 Stock Option Plan continues to govern awards outstanding thereunder. On January&#160;17, 2023, the Compensation Committee adopted the Company&#8217;s 2023 Inducement Plan (the &#8220;Inducement Plan&#8221;). The Inducement Plan has not been approved by our stockholders. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">98 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides information as of December&#160;31, 2023 with respect to the Company&#8217;s existing and predecessor plans. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:47%"/>

<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Plan Category</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">(a)</span><br/><span style="font-weight:bold">Number&#160;of&#160;Securities<br/>to be Issued Upon<br/>Exercise of<br/>Outstanding&#160;Options,<br/>Warrants and Rights</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">(b)<br/>Weighted-<br/>Average<br/>Exercise<br/>Price of<br/>Outstanding<br/>Options,<br/>Warrants<br/>and Rights</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">(c)</span><br/><span style="font-weight:bold">Number of<br/>Securities<br/>Remaining<br/>Available for<br/>Future&#160;Issuance<br/>Under Equity<br/>Compensation<br/>Plans&#160;(Excluding<br/>Securities<br/>Reflected in<br/>Column (a))</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans approved by stockholders<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">33,123,798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">4.38</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">16,602,033</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(4)(5)</sup>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans not approved by stockholders<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,400,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">33,123,798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">4.38</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">18,002,033</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(4)(5)</sup>&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes the following plans: the Equity Incentive Plan, the ESPP, the Scilex Pharma 2017 Plan and the 2019 Stock Option Plan. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents the Inducement Plan. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amount is based on the weighted-average exercise price of vested and unvested stock options outstanding under the Equity Incentive Plan, the Scilex Pharma 2017 Plan and the 2019 Stock Option Plan. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">As of December&#160;31, 2023, a total of 13,726,274 shares of our Common Stock were reserved for future issuance pursuant to the Equity Incentive Plan, the Scilex Pharma 2017 Plan and the 2019 Stock Option Plan, which number excludes the 6,403,370 shares that were added to the Equity Incentive Plan as a result of the automatic annual increase on January&#160;1, 2024. The Equity Incentive Plan provides that the number of shares of our Common Stock reserved and available for issuance under the Equity Incentive Plan will automatically increase on January&#160;1 of each year for a period of ten years, beginning on January&#160;1, 2023 and ending on (and including) January&#160;1, 2032, in an amount equal to the lesser of (A) 4% of the total number of shares of our Common Stock outstanding on December&#160;31 of the immediately preceding year, (B) 7,311,356 shares of our Common Stock (subject to the adjustment for recapitalizations, stock splits, stock dividends and similar transactions), and (C)&#160;such number of shares of our Common Stock determined by our Board or our Compensation Committee prior to January&#160;1 of a given year. All of the foregoing share numbers are subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. Shares subject to awards granted under the Equity Incentive Plan that expire or terminate without being exercised in full will not reduce the number of shares available for issuance under the Equity Incentive Plan. The settlement of any portion of an award in cash will not reduce the number of shares available for issuance under the Equity Incentive Plan. Shares of our Common Stock withheld under an award to satisfy. The exercise, strike or purchase price of an award or to satisfy a tax withholding obligation will not reduce the number of shares available for issuance under the Equity Incentive Plan. With respect to a stock appreciation right, only shares of our Common Stock that are issued upon settlement of the stock appreciation right will count towards reducing the number of shares available for issuance under the Equity Incentive Plan. If any shares of our Common Stock issued pursuant to an award are forfeited back to or repurchased or reacquired by us (i)&#160;because of a failure to meet a contingency or condition required for the vesting of such shares; (ii)&#160;to satisfy the exercise, strike or purchase price of an award; or (iii)&#160;to satisfy a tax withholding obligation in connection with an award, the shares that are forfeited or repurchased or reacquired will revert to and again become available for issuance under the Equity Incentive Plan. The Company no longer makes grants under the Scilex Pharma 2017 Plan or the 2019 Stock Option Plan. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">As of December&#160;31, 2023, a total of 2,875,759 shares of our Common Stock have been reserved for future issuance pursuant to the ESPP, which number excludes the 1,600,842 shares that were added to the ESPP as a result of the automatic annual increase on January&#160;1, 2024. The ESPP provides that the number of shares </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">99 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
of our Common Stock reserved and available for issuance under the ESPP will automatically increase on January&#160;1 of each year for a period of up to ten years, commencing on January&#160;1, 2023 and ending on (and including) January&#160;1, 2032, in an amount equal to the lesser of (A) 1% of the total number of shares of our Common Stock outstanding on December&#160;31 of the immediately preceding calendar year, (B) 1,827,839 shares of our Common Stock (subject to the adjustment for recapitalizations, stock splits, stock dividends and similar transactions), and (C)&#160;such number of shares of our Common Stock determined by our Board or our Compensation Committee prior to January&#160;1 of a given year, provided however, that our Board may act prior to January&#160;1 of a given calendar year to provide that there will be no increase for such calendar year or the increase for such year will be a lesser number of shares than the amount set forth in clauses (A)&#160;to (C)&#160;above. </td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">100 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx759370_11">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following discussion and analysis of our financial condition and results of operations should be read together with the consolidated financial statements and related notes thereto included elsewhere in this prospectus. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from these forward-looking statements as a result of certain factors. We discuss factors that we believe could cause or contribute to these differences below and elsewhere in this prospectus, including those set forth in the sections of this prospectus titled &#8220;Risk Factors&#8221; and &#8220;Cautionary Note Regarding Forward-Looking Statements.&#8221; </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an innovative revenue-generating company focused on acquiring, developing and commercializing <span style="white-space:nowrap">non-opioid</span> management products for the treatment of acute and chronic pain. We believe that our innovative <span style="white-space:nowrap">non-opioid</span> product portfolio has the potential to provide effective pain management therapies that can have a transformative impact on patients&#8217; lives. We target indications with high unmet needs and large market opportunities with <span style="white-space:nowrap">non-opioid</span> therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. We launched our first commercial product in October 2018 and are developing our late-stage pipeline. Our commercial product, ZTlido, is a prescription lidocaine topical product approved by the federal Food and Drug Administration (&#8220;FDA&#8221;) for the relief of neuropathic pain associated with post-herpetic neuralgia (&#8220;PHN&#8221;), which is a form of post-shingles nerve pain. ZTlido possesses novel delivery and adhesion technology designed to address many of the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the <span style="white-space:nowrap">12-hour</span> administration period. We market ZTlido through a dedicated sales force of approximately 65 people, targeting 10,000 primary care physicians, pain specialists, neurologists and palliative care physicians who we believe treat the majority of PHN patients. We <span style="white-space:nowrap">in-licensed</span> the exclusive right to commercialize GLOPERBA (colchicine USP) oral solution, an <span style="white-space:nowrap">FDA-approved</span> prophylactic treatment for painful gout flares in adults, in the United States of America (&#8220;U.S.&#8221; or the &#8220;United States&#8221;). We expect to commercialize GLOPERBA in the first half of 2024 and believe we are well positioned to market and distribute the product. In February 2023, we acquired the rights to patents, trademarks, regulatory approvals and other rights related to ELYXYB (celecoxib oral solution) and its commercialization in the U.S. and Canada. In April 2023, we launched ELYXYB in the U.S. for the treatment of acute migraine, with or without aura, in adults. We filed a New Drug Submission (&#8220;NDS&#8221;) to Health Canada&#8217;s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the approval of ELYXYB<sup style="font-size:75%; vertical-align:top">&#174;</sup> for acute treatment of migraine with or without aura in Canada. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our development pipeline consists of three product candidates, <span style="white-space:nowrap">(i)&#160;SP-102</span> (&#8220;SEMDEXA&#8221;) (10 mg, dexamethasone sodium phosphate viscous gel), novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain or sciatica with completed Phase 3 study, <span style="white-space:nowrap">(ii)&#160;SP-103</span> (lidocaine topical system) 5.4%, a Phase 2, next-generation, triple-strength formulation of ZTlido, for the treatment of chronic neck pain and for which we have completed a Phase 2 trial in LBP in the third quarter of 2023, and <span style="white-space:nowrap">(iii)&#160;SP-104</span> (4.5 mg, <span style="white-space:nowrap">low-dose</span> naltrexone hydrochloride delayed-release capsules), a novel <span style="white-space:nowrap">low-dose</span> delayed-release naltrexone hydrochloride formulation for treatment of fibromyalgia, for which Phase 1 trials were completed in the second quarter of 2022 and a Phase 2 clinical trial is expected to commence in 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SEMDEXA has been granted fast track designation by the FDA and, if approved, could become the first <span style="white-space:nowrap">FDA-approved</span> alternative to <span style="white-space:nowrap">off-label</span> epidural steroid injections, which are administered over 12&#160;million times annually in the United States. We have completed a pivotal Phase 3 study with final results received in March 2022, which results reflected achievement of primary and secondary endpoints. <span style="white-space:nowrap">SP-103</span> has also been granted fast track designation by the FDA for LBP. We received our <span style="white-space:nowrap">SP-103</span> Phase 2 <span style="white-space:nowrap">top-line</span> results in August 2023 and the trial achieved its objectives characterizing safety, tolerability and preliminary efficacy of <span style="white-space:nowrap">SP-103</span> in acute LBP associated with muscle spasms. <span style="white-space:nowrap">SP-103</span> was safe and well tolerated. Increase of lidocaine load in topical system </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">101 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by three times, compared with approved ZTlido, 5.4% vs. 1.8%, did not result in signs of systemic toxicity or increased application site reactions with daily applications over one month treatment. We will continue to analyze the <span style="white-space:nowrap">SP-103</span> Phase 2 trial data along with an investigator study of ZTlido in patients with neck pain completed in the second half of 2023, which also has shown promising <span style="white-space:nowrap">top-line</span> efficacy and safety results. <span style="white-space:nowrap">SP-103,</span> if approved, could become the first <span style="white-space:nowrap">FDA-approved</span> lidocaine topical product for the treatment of chronic neck pain. <span style="white-space:nowrap">SP-103</span> is a triple-strength lidocaine topical system designed to deliver a dose of lidocaine three times higher than any lidocaine topical product that we are aware of, either approved or in development. We are examining <span style="white-space:nowrap">SP-103</span> as a treatment for chronic neck pain, a condition with high unmet need which we expect could affect over 20&#160;million patients in the United States as of 2023. Once the data analysis has been completed from both studies, we will request end of Phase 2 meeting with the FDA to discuss next steps to Phase 3. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently contract with third parties for the manufacture, assembly, testing, packaging, storage and distribution of our products. We obtain our commercial supply of certain of our products, the clinical supply of our product candidates and certain of the raw materials used in our product candidates from sole or single source suppliers and manufacturers. Prior to April 2022, we relied on a single third-party logistics distribution provider, Cardinal Health 105, for ZTlido distribution in the United States. Cardinal Health 105 purchased and shipped ZTlido to customer wholesale distribution centers. Cardinal Health 105 also performed order management services on our behalf. On April&#160;2, 2022, we announced the expansion of our direct distribution network to national and regional wholesalers and pharmacies. Cardinal Health 105 will continue to provide traditional third-party logistics functions for us. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since our inception, we have invested substantial efforts and financial resources on acquiring product and technology rights while building our intellectual property portfolio and infrastructure. In June 2022, we <span style="white-space:nowrap">in-licensed</span> the exclusive right to commercialize GLOPERBA (colchicine USP) oral solution, an <span style="white-space:nowrap">FDA-approved</span> prophylactic treatment for painful gout flares in adults, in the U.S. In February 2023, we acquired rights to <span style="white-space:nowrap">FDA-approved</span> ELYXYB (celecoxib oral solution) in the U.S. and Canada for the acute treatment of migraine. We intend to continue to explore and evaluate additional opportunities such as these to grow our business. We have incurred significant operating losses as a result of such investment efforts, including the development of SEMDEXA, conducting of Phase 3 trials for SEMDEXA, and the development of <span style="white-space:nowrap">SP-103</span> and <span style="white-space:nowrap">SP-104.</span> Our ability to generate revenue sufficient to achieve profitability will depend on the successful commercialization of our products, ZTlido, GLOPERBA and ELYXYB, and the development of our product candidates. We had a net loss of $114.3&#160;million, $23.4&#160;million and $88.4&#160;million for the years ended December&#160;31, 2023, 2022 and 2021 respectively. As of December&#160;31, 2023, we had an accumulated deficit of approximately $490.2&#160;million. As of December&#160;31, 2023, we had cash and cash equivalents of approximately $3.9&#160;million. Our management has concluded that there is substantial doubt about our ability to continue as a going concern for one year after the date that the consolidated financial statements are issued. See Note 2 titled &#8220;Liquidity and Going Concern&#8221; to our consolidated financial statements and our independent registered public accounting firm report included elsewhere in this prospectus for additional information. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to continue to make investments in our sales and marketing organization and expand digital marketing efforts to broaden awareness of ZTlido, GLOPERBA and ELYXYB and in research and development, clinical trials and regulatory affairs to develop our product candidates, SEMDEXA, <span style="white-space:nowrap">SP-103</span> and <span style="white-space:nowrap">SP-104.</span> As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until we can generate significant revenue, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions. We may be unable to raise additional funds or enter into such agreements or arrangements when needed on favorable terms, or at all. If adequate funds on acceptable terms are not available when needed, we may be required to reduce the scope of the commercialization of ZTlido, GLOPERBA and ELYXYB or delay, scale back or discontinue the development of one or more of our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recent Development </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;29, 2024, we entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">102 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Rodman&#160;&amp; Renshaw LLC and StockBlock Securities LLC, as the representatives (the &#8220;Representatives&#8221;) of the underwriters named in Schedule A (the &#8220;Underwriters&#8221;). Pursuant to the Underwriting Agreement, we agreed to sell, in an underwritten offering (the &#8220;Bought Deal Offering&#8221;), 5,882,353 shares (the &#8220;Firm Shares&#8221;) of the Common Stock, and accompanying common warrants to purchase up to an aggregate of 5,882,353 shares of Common Stock (the &#8220;Firm Warrants&#8221;). Pursuant to the Underwriting Agreement, we also granted the Underwriters an option for a period of 30 days from the date of the Underwriting Agreement to purchase up to 882,352 additional shares of Common Stock (the &#8220;Optional Shares&#8221;, and together with the Firm Shares, the &#8220;Shares&#8221;) and/or common warrants to purchase up to 882,352 shares of Common Stock (the &#8220;Optional Warrants&#8221;, and together with the Firm Warrants, the &#8220;Common Warrants&#8221;) that may be purchased by the Underwriters, at a price per Optional Share of $1.5548 and a price per Optional Warrant of $0.0092, which amounts reflect the public offering price of $1.69 per Optional Share and $0.01 per Optional Warrant, less underwriting discounts and commissions, as applicable (the &#8220;Underwriters&#8217; Option&#8221;).&#160;Each Firm Share was sold together with a Firm Warrant at a combined public offering price of $1.70. The combined price per Firm Share and accompanying Firm Warrant paid by the Underwriters was $1.564, which amount reflects the combined public offering price of $1.70, less underwriting discounts and commissions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to certain ownership limitations, the Common Warrants are exercisable immediately from the date of issuance, will expire on the five-year anniversary of the date of issuance and have an exercise price of $1.70 per share. The exercise price of the Common Warrants is subject to certain adjustments, including (but not limited to) for stock dividends, stock splits, combinations and reclassifications of the Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Bought Deal Offering, we agreed, pursuant to the Underwriting Agreement, to issue the Representatives warrants (the &#8220;Representative Warrants&#8221;, and together with the Common Warrants, the &#8220;Warrants&#8221;) to purchase up to an aggregate of 470,588 shares of Common Stock (which represents 8.0% of the aggregate number of Firm Shares sold in the Bought Deal Offering), or up to an aggregate of 541,176 shares of Common Stock if the Underwriters exercise the Underwriters&#8217; Option in full. The Representative Warrants are immediately exercisable and have the same terms as the Common Warrants described above, except that the exercise price of the Representative Warrants is $2.125 per share, which represents 125% of the combined public offering price per Firm Share and accompanying Firm Warrant. We also agreed to pay certain expenses of the Representatives in connection with the Bought Deal Offering, including their legal fees and <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses up to $200,000 and up to $15,950 for clearing expenses. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Shares, the Warrants and the shares of Common Stock issuable upon exercise of the Warrants were offered and sold by us pursuant to an effective shelf registration statement on Form <span style="white-space:nowrap">S-3,</span> which was originally filed with the SEC on December&#160;22, 2023, as amended, and was declared effective on January&#160;11, 2024 (File <span style="white-space:nowrap">No.&#160;333-276245),</span> a base prospectus dated January&#160;11, 2024, and a final prospectus supplement dated February&#160;29, 2024. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Sorrento Chapter 11 Filing </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;13, 2023, Sorrento, together with its wholly owned direct subsidiary, Scintilla Pharmaceuticals, Inc., commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas. The Chapter 11 proceedings are jointly administered under the caption In re Sorrento Therapeutics, Inc., et al. While we were previously majority-owned by Sorrento, we were not a debtor in Sorrento&#8217;s voluntary Chapter 11 filing. As of December&#160;31, 2023, Sorrento no longer holds a majority of the voting power of our outstanding capital stock entitled to vote. As of December&#160;31, 2023, we had a $3.2&#160;million receivable from Sorrento, which was fully reserved. We evaluate the collectability of this receivable on a quarterly basis. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">103 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Components of Our Results of Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Net Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net revenue consists of product sales of ZTlido and ELYXYB in the United States. For product sales of ZTlido and ELYXYB, we record <span style="white-space:nowrap"><span style="white-space:nowrap">gross-to-net</span></span> sales adjustments for government and commercial rebates, chargebacks, wholesaler and distributor fees, sales returns, special marketing programs, and prompt payment discounts. We expect that any net revenue we generate will fluctuate from year to year as a result of the unpredictability of the demand for our product. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Operating Costs and Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cost of Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cost of revenue consists of the cost of purchasing ZTlido and ELYXYB from our manufacturing partners, inventory write-downs related to expiration dates for <span style="white-space:nowrap">on-hand</span> inventory, cost of shipments, and royalty payments to our manufacturers. We expect the cost of revenue to fluctuate with related sales revenue. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Research and Development </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses are expensed when incurred and consist primarily of costs incurred for our research activities, including the development of our product candidates, and include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs related to clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">salaries, benefits and other related costs, including stock-based compensation expense for personnel engaged in research and development functions; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs related to outside consultants. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect our research and development expenses to increase, as we will incur incremental expenses associated with our product candidates that are currently under development and in clinical trials. Product candidates in later stages of clinical development generally have higher development costs, primarily due to the increased size and duration of later-stage clinical trials. Accordingly, we expect to incur significant research and development expenses in connection with our clinical trials for SEMDEXA, <span style="white-space:nowrap">SP-103</span> and <span style="white-space:nowrap">SP-104.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Selling, General and Administrative </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses consist primarily of costs related to our contract sales force, salaries and other related costs, including stock-based compensation, for personnel in our executive, marketing, finance, corporate and business development and administrative functions. Selling, general and administrative expenses also include professional fees for legal, patent, accounting, auditing, tax and consulting services, travel expenses and facility-related expenses, which include direct depreciation costs, and allocated expenses from Sorrento for director and officer insurance as well as employee health benefits through the consummation of the transactions pursuant to the Sorrento SPA on September&#160;21, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that our selling, general and administrative expenses will vary year over year in the future as we adapt our commercial strategies to changes in the business environment. We also expect to incur increased expenses as a result of operating as a public company, including expenses related to compliance with the rules and regulations of the SEC, listing standards applicable to companies listed on a national securities exchange, additional insurance expenses, investor relations activities and other administrative and professional services. We also expect to adjust the size of our administrative, finance and legal functions to adapt to the changes above and the anticipated growth of our business. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">104 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Intangible Amortization </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intangible amortization expense consists of the amortization expense of intangible assets recognized on a straight-line basis over the estimated useful lives of the assets. Our intangible assets, excluding goodwill, are composed of patent rights, acquired technology, acquired licenses and assembled workforce. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other (Income) Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Loss (Gain) on Derivative Liability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Loss (Gain) on derivative liability includes the remeasurement of the derivative warrant liability. See Note 4 titled <span style="font-style:italic">&#8220;Fair Value Measurements&#8221;</span> to our consolidated financial statements appearing elsewhere in this prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Change in Fair Value of Debt and Liability Instruments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Change in fair value of debt and liability instruments includes the remeasurement of the convertible debentures (the &#8220;Convertible Debentures&#8221;) issued to YA II, Ltd. (&#8220;Yorkville&#8221;) pursuant to that certain securities purchase agreement dated as of March&#160;21, 2023 and amended on October&#160;11, 2023, between Yorkville and us (the &#8220;Yorkville SPA&#8221;) and a senior secured promissory note to Oramed Pharmaceuticals Inc. (&#8220;Oramed&#8221;) issued in September 2023 in the principal amount of $101.9&#160;million (the &#8220;Oramed Note&#8221;). See Note 4 titled <span style="font-style:italic">&#8220;Fair Value Measurements&#8221;</span> to our consolidated financial statements appearing elsewhere in this prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Interest Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interest expense for the year ended December&#160;31, 2023 consists of interest related to the Revolving Facility. Interest expense for the year ended December&#160;31, 2022 consists of interest related to the senior secured notes issued by Scilex Pharma in September 2018 (the &#8220;Scilex Pharma Notes&#8221;) and related party note payables to Sorrento. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Loss on Foreign Currency Exchange </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Loss on foreign currency exchange relates to foreign exchange losses on payments made to our foreign supplier, Itochu, a manufacturer and supplier of lidocaine tape products, including ZTlido and <span style="white-space:nowrap">SP-103.</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">105 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Results of Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables summarize our results of operations for the years ended December&#160;31, 2023 and 2022 (in thousands):<span style="font-weight:bold"> </span> </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:63%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year&#160;Ended&#160;December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Changes</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Statements of Operations Data:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Net revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">46,743</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">38,034</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">8,709</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Operating costs and expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">15,681</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10,797</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,884</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">12,746</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">9,054</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,692</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">119,641</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">64,895</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">54,746</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible amortization</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,106</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,922</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">184</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total operating costs and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">152,174</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">88,668</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">63,506</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(105,431</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(50,634</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(54,797</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Other (income) expense:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss (gain) on derivative liability</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">512</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(8,310</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">8,822</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of debt and liability instruments</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">7,189</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">7,189</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on debt extinguishment, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(28,634</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">28,634</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,068</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">9,604</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(8,536</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on foreign currency exchange</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">118</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">66</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total other expense (income)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">8,887</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(27,274</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">36,161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Loss before income taxes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(114,318</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(23,360</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(90,958</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Net loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">(114,331</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">(23,364</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">(90,967</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For financial information and discussions pertaining to the year ended December&#160;31, 2021, refer to the Annual Report on Form <span style="white-space:nowrap">10-K</span> filed with the SEC on March&#160;7, 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Comparison of the Years Ended December&#160;31, 2023 and 2022 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Net Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net revenue for the years ended December&#160;31, 2023 and 2022 was $46.7&#160;million and $38.0&#160;million, respectively. The increase of $8.7&#160;million was driven by the increase in gross product sales of ZTlido by approximately 55% and launch of ELYXYB with sales commencing in April 2023, offset by an increase in rebates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cost of Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cost of revenue for the years ended December&#160;31, 2023 and 2022 was $15.7&#160;million and $10.8&#160;million, respectively. The increase of $4.9&#160;million was primarily due to an increase in gross product sales of approximately 61% for the year ended December&#160;31, 2023 compared to the year ended December&#160;31, 2022, and royalty expense of $8.6&#160;million and $4.5&#160;million in the years ended December&#160;31, 2023 and 2022, respectively, that started to accrue in the second quarter of 2022. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">106 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Research and Development Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes research and development expenses by project for the years ended December&#160;31, 2023 and 2022 (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:66%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="10" align="center"><span style="font-weight:bold">Year Ended December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Increase<br/>(Decrease)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">SP-102</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">1,229</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">1,488</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">(259</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">254</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">82</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(18</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total <span style="white-space:nowrap">SP-102</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,547</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,820</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(273</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">SP-103</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,270</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,739</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(469</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,107</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">596</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">511</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">474</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,147</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(673</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total <span style="white-space:nowrap">SP-103</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5,851</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6,482</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(631</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">SP-104</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">925</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">388</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">537</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">605</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">605</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">149</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">163</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(14</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total <span style="white-space:nowrap">SP-104</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,679</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">551</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,128</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">GLOPERBA</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">345</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">103</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">242</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">658</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">658</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">115</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">98</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total GLOPERBA</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,118</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">201</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">ELYXYB</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,252</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,252</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">908</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">908</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">391</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">391</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total ELYXYB</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2,551</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2,551</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Total Research and Development Expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">12,746</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">9,054</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">3,692</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses for the years ended December&#160;31, 2023 and 2022 were $12.7&#160;million and $9.0&#160;million, respectively. The $3.7&#160;million increase was primarily attributed to the costs associated with planning for Phase 2 clinical trials of <span style="white-space:nowrap">SP-104</span> and development costs of our new products GLOPERBA and ELYXYB for the year ended December&#160;31, 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Selling, General and Administrative Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses for the years ended December&#160;31, 2023 and 2022 were $119.6&#160;million and $64.9&#160;million, respectively. The increase of approximately $54.7&#160;million was primarily due to a $16.8&#160;million increase in advisory expenses, which primarily includes an aggregate of $9.4&#160;million fees paid to Hudson Bay Capital Management LP (&#8220;Hudson Bay&#8221;), Cove Lane Onshore Fund, LLC (&#8220;Cove Lane&#8221;) and HBC Investments LLC (&#8220;HBC&#8221; and collectively, the &#8220;Hudson Bay Parties&#8221;) (which amount includes shares of Common Stock worth approximately $0.8&#160;million at the date of issuance), a $16.6&#160;million increase in personnel expense due to increase in headcount, a 7% merit increase starting January 2023 and new stock-based </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">107 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
compensation from January 2023 and October 2023 equity grants, a $10.1&#160;million increase in legal expenses primarily related to an assumption of third-party legal fees and expenses in connection with recent financing transactions, a $4.4&#160;million increase in contracted services, a $3.5&#160;million increase in marketing expense, a $1.4&#160;million increase in travel and business development expenses, and a $1.9&#160;million increase in other expenses. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Intangible Amortization Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intangible amortization expense for the years ended December&#160;31, 2023 and 2022 was $4.1&#160;million and $3.9&#160;million, respectively. The increase of $0.2&#160;million is related to the amortization of the acquired exclusive license of GLOPERBA. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Loss (Gain) on Derivative Liability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Loss (gain) on derivative liability for the years ended December&#160;31, 2023 and 2022 was $0.5&#160;million and $(8.3) million, respectively. The loss recognized during the year ended December&#160;31, 2023 was attributed to the change in the fair value of the derivative warrant liability associated with the Private Warrants. The gain recognized during the year ended December&#160;31, 2022 was attributed to the change in the fair value of the derivative liability pertaining to the Scilex Pharma Notes, as described in Note 4 of the Notes to Consolidated Financial Statements in the Annual Report on Form <span style="white-space:nowrap">10-K</span> filed with the SEC on March&#160;7, 2023, taking into account a risk adjusted sales forecast and the derivative warrant liability associated with the Private Warrants assumed in the Business Combination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Change in Fair Value of Debt and Liability Instruments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Change in fair value of debt and liability instruments for the years ended December&#160;31, 2023 and 2022 was $7.2&#160;million and nil, respectively. The change in fair value of $7.2&#160;million during the year ended December&#160;31, 2023 was attributed to the Convertible Debentures and the Oramed Note. The Convertible Debentures were issued in March and April 2023 in an aggregate principal amount of $25.0&#160;million, of which the principal amount of $4.4&#160;million remained outstanding as of December&#160;31, 2023. The Oramed Note was issued in September 2023 in the principal amount of $101.9&#160;million, of which the principal amount of $96.9&#160;million remained outstanding as of December&#160;31, 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Gain on Debt Extinguishment, Net </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gain on debt extinguishment, net for the years ended December&#160;31, 2023 and 2022 was nil and $28.6&#160;million, respectively. The gain recognized during the year ended December&#160;31, 2022 was attributed to Scilex Pharma&#8217;s repurchase of the Scilex Pharma Notes of $20.0&#160;million and $41.4&#160;million in February 2022 and June 2022, respectively, as well as the early paydown provision of such Scilex Pharma Notes of $39.7&#160;million in September 2022 (see Note 7 titled &#8220;<span style="font-style:italic">Debt</span>&#8221; included in the Annual Report on Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2022 filed with the SEC on March&#160;7, 2023 for additional information). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interest Expense, Net </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interest expense for the years ended December&#160;31, 2023 and 2022 was $1.1&#160;million and $9.6&#160;million, respectively. The decrease was attributed to the repayment of Scilex Pharma Notes in September 2022 and the conversion of related party notes payable to Sorrento that were outstanding as of the closing of the Business Combination into shares of Preferred Stock and Common Stock in November 2022 in connection with the closing of the Business Combination. Interest expense for the year ended December&#160;31, 2023 consists of interest related to the Revolving Facility. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Liquidity and Capital Resources </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, we had cash and cash equivalents of approximately $3.9&#160;million. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">108 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have funded our operations primarily through the Yorkville financing pursuant to the A&amp;R Yorkville Purchase Agreement (as defined below), the B. Riley financing pursuant to the B. Riley Purchase Agreement, the Revolving Facility, the issuance of the Convertible Debentures and the issuance of the Oramed Note in 2023. We also have deferred consideration related to the GLOPERBA license acquired in 2022. The following table summarizes the aggregate indebtedness of these issuances as of December&#160;31, 2023 and December&#160;31, 2022 (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:55%"/>

<td style="vertical-align:bottom;width:15%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:15%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31,&#160;2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31,&#160;2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oramed Note (Outstanding Principal Balance: $96.9 million)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">104,089</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible Debentures (Outstanding Principal Balance: $4.4 million)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revolving Facility</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">17,038</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred Consideration with Romeg</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,386</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3,651</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total indebtedness</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">128,853</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">3,651</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The Oramed Note </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, we have $104.1&#160;million outstanding under the Oramed Note pursuant to the Scilex-Oramed SPA (see Note 7 titled &#8220;<span style="font-style:italic">Debt</span>&#8221;<span style="font-style:italic"> </span>to our consolidated financial statements included elsewhere in this prospectus for additional information). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Convertible Debentures </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, we have $4.3&#160;million in Convertible Debentures outstanding pursuant to the Yorkville SPA (see Note 7 titled &#8220;<span style="font-style:italic">Debt</span>&#8221;<span style="font-style:italic"> </span>to our consolidated financial statements included elsewhere in this prospectus for additional information). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Revolving Facility </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, we have $17.0&#160;million outstanding under the Revolving Facility (see Note 7 titled &#8220;<span style="font-style:italic">Debt</span>&#8221;<span style="font-style:italic"> </span>to our consolidated financial statements included elsewhere in this prospectus for additional information). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Deferred Consideration </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, we have $3.4&#160;million of deferred consideration related to minimum royalty payments that were included in the initial measurement of consideration transferred for the GLOPERBA license. Deferred consideration minimum royalty payments began in July 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">ZTlido and ELYXYB Royalties </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2013, Scilex Pharma became a party to a product development agreement (as amended, the &#8220;Product Development Agreement&#8221;) with Itochu and Oishi Koseido Co., Ltd. (&#8220;Oishi&#8221;, and together with Itochu, the &#8220;Developers&#8221;), pursuant to which the Developers will manufacture and supply lidocaine tape products, including ZTlido and <span style="white-space:nowrap">SP-103,</span> for Scilex Pharma. Pursuant to the Product Development Agreement, Scilex Pharma is required to make aggregate royalty payments between 25% and 35% to the Developers based on net profits. During the year ended December&#160;31, 2023, Scilex Pharma made royalty payments in the amount of $8.3&#160;million. As of December&#160;31, 2023 and 2022, Scilex Pharma had ending balances of accrued royalty payables of $2.4&#160;million and $2.2&#160;million, respectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2023, we entered into an asset purchase agreement to acquire the rights to certain patents, trademarks, regulatory approvals, data, contracts, and other rights related to ELYXYB and its commercialization </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">109 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in the United States and Canada (the &#8220;ELYXYB Territory&#8221;). We are obligated to make quarterly royalty payments on net sales of ELYXYB in the ELYXYB Territory that range from high single digits to the low double digits on net sales based on the volume of sales. In April 2023, we launched ELYXYB in the U.S. During the year ended December&#160;31, 2023, we made royalty payments in the amount of $26.0&#160;thousand As of December&#160;31, 2023, we had ending balances of accrued royalty payables of $5.0&#160;thousand. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Contingent Consideration </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have $280.0&#160;million, $13.0&#160;million and $23.0&#160;million in aggregate contingent consideration obligations in connection with the SEMDEXA, GLOPERBA and <span style="white-space:nowrap">SP-104</span> acquisitions, respectively, that are contingent upon achieving certain specified milestones or the occurrence of certain events. Contingent consideration obligations are comprised of regulatory milestones and additional payments that will be due upon the achievement of certain amounts of net sales (see Note 3 titled &#8220;<span style="font-style:italic">Acquisitions</span>&#8221; to our consolidated financial statements included elsewhere in this prospectus for additional information). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Standby Equity Purchase Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;17, 2022, we entered into a standby equity purchase agreement (the &#8220;Original Purchase Agreement&#8221;) with Yorkville. On February&#160;8, 2023, we entered into an amended and restated standby equity purchase agreement with Yorkville (the &#8220;A&amp;R Yorkville Purchase Agreement&#8221;), amending, restating and superseding the Original Purchase Agreement. Pursuant to the A&amp;R Yorkville Purchase Agreement, we have the right, but not the obligation, to sell to Yorkville up to $500.0&#160;million of shares of Common Stock at our request during the 36 months following the date on which the initial registration statement filed with respect to the shares of Common Stock issuable pursuant thereto was declared effective by the SEC, subject to the terms therein. The registration statement filed with the SEC in connection with the Original Purchase Agreement was initially declared effective by the SEC on December&#160;9, 2022 and we were able to offer and sell shares of our Common Stock under that agreement, subject to the limitations set forth therein. As of December&#160;31, 2023, we have sold 11,552,074 shares of Common Stock under the A&amp;R Yorkville Purchase Agreement for aggregate net proceeds of approximately $32.3&#160;million. On, and effective as of, March&#160;25, 2024, we and Yorkville mutually agreed to terminate the A&amp;R Yorkville Purchase Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;8, 2023, we entered into the B. Riley Purchase Agreement (together with the A&amp;R Yorkville Purchase Agreement, the &#8220;Standby Equity Purchase Agreements&#8221;) with B. Riley, pursuant to which we had the right, but not the obligation, to sell to B. Riley up to $500.0&#160;million of shares of Common Stock at our request during the 36 months following the date on which the initial registration statement filed with respect to the shares of Common Stock issuable pursuant thereto was declared effective by the SEC, subject to the terms therein. The registration statement filed with the SEC in connection with the B. Riley Purchase Agreement was initially declared effective by the SEC on January&#160;20, 2023 and we were able to offer and sell shares of our Common Stock under that agreement, subject to the limitations set forth therein and the limitations set forth in the Convertible Debentures. As of December&#160;31, 2023, we had sold 1,414,554 shares of Common Stock pursuant to advances under the B. Riley Purchase Agreement for aggregate net proceeds of approximately $3.2&#160;million. On, and effective as of, February&#160;16, 2024, we and B. Riley mutually agreed to terminate the B. Riley Purchase Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap"><span style="white-space:nowrap">At-the-Market</span></span> Sales Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;22, 2023, we entered into a Sales Agreement (the &#8220;ATM Sales Agreement&#8221;) with B. Riley Securities, Inc., Cantor Fitzgerald&#160;&amp; Co. and H.C. Wainwright&#160;&amp; Co., LLC (the &#8220;Sales Agents&#8221;). Pursuant to the ATM Sales Agreement, we may offer and sell (the &#8220;Offering&#8221;) shares of Common Stock up to $170,000,000 (the &#8220;ATM Shares&#8221;), through or to the Sales Agents as part of the Offering. We have no obligation to sell any shares of Common Stock under the ATM Sales Agreement and may suspend offers at any time. The Offering will be terminated upon (i)&#160;the election of the Sales Agents upon the occurrence of certain adverse events, (ii)&#160;three </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">110 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
business days&#8217; advance notice from us to the Sales Agents or a Sales Agent to us, or (iii)&#160;the sale of all $170,000,000 of shares of Common Stock thereunder. The ATM Shares offered and sold in the Offering will be issued pursuant to our Shelf <span style="white-space:nowrap">S-3</span> Registration Statement. The ATM Shares may be offered only by means of a prospectus forming a part of the Shelf <span style="white-space:nowrap">S-3</span> Registration Statement. The Sales Agents are entitled to a commission equal to 3.0% of the gross proceeds from each sale of shares of Common Stock. We will also reimburse the Sales Agents for certain expenses and have agreed to provide indemnification and contribution to the Sales Agents against certain civil liabilities, including liabilities under the&#160;Securities Act&#160;of&#160;1933, as amended. As of December&#160;31, 2023, no sales of Common Stock had been made under the ATM Sales Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Future Liquidity Needs </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have based our anticipated operating capital requirements on assumptions that may prove to be incorrect and we may use all our available capital resources sooner than we expect. The amount and timing of our future funding requirements will depend on many factors, some of which are outside of our control, including but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs and expenses associated with our ongoing commercialization efforts for ZTlido, GLOPERBA and ELYXYB; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the degree of success we experience in commercializing ZTlido, GLOPERBA and ELYXYB; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the revenue generated by sales of ZTlido, GLOPERBA, ELYXYB and other products that may be approved, if any; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the scope, progress, results and costs of conducting studies and clinical trials for our product candidates, SEMDEXA, <span style="white-space:nowrap">SP-103</span> and <span style="white-space:nowrap">SP-104;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of manufacturing ZTlido, GLOPERBA, ELYXYB and our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing and amount of any milestone, royalty or other payments we are required to make pursuant to any current or future collaboration or license agreements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the extent to which ZTlido, GLOPERBA, ELYXYB or any of our product candidates, if approved for commercialization, is adopted by the physician community; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our need to expand our research and development activities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of acquiring, licensing or investing in businesses, product candidates and technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effect of competing products and product candidates and other market developments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number and types of future products we develop and commercialize; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any product liability or other lawsuits related to our products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the expenses needed to attract, hire and retain skilled personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs associated with being a public company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our need to implement additional internal systems and infrastructure, including financial and reporting systems; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the extent and scope of our general and administrative expenses. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">111 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Should our sales of ZTlido, GLOPERBA, ELYXYB and other product candidates not materialize at the anticipated rate contemplated in our business plan, we will need to raise additional capital in order to continue to fund our research and development, including our plans for clinical and preclinical trials and new product development, as well as to fund operations generally. We will seek to raise additional funds through various potential sources, such as equity and debt financings and license agreements. As discussed above, following the completion of the Business Combination, we entered into the A&amp;R Yorkville Purchase Agreement (which was terminated in March 2024), the B. Riley Purchase Agreement (which was terminated in February 2024), the Yorkville SPA (which provided for the issuance of the Convertible Debentures which are no longer outstanding as of March&#160;18, 2024), the eCapital Credit Agreement and the ATM Sales Agreement. The Shelf <span style="white-space:nowrap">S-3</span> Registration Statement was initially declared effective by the SEC on January&#160;11, 2024 and we are now able to offer and sell shares of our Common Stock under the ATM Sales Agreement, subject to any limitations set forth therein, which will provide us with an additional source of liquidity. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the liquidity provided by revenue generating products, advances under the A&amp;R Yorkville Purchase Agreement and the issuance of the Common Stock under the ATM Sales Agreement, as of December&#160;31, 2023, we will receive up to an aggregate of approximately $120.4&#160;million from the exercise of the Private Warrants and public warrants to purchase Common Stock (the &#8220;Public Warrants&#8221;, and together with the Private Warrants, the &#8220; SPAC Warrants&#8221;) (at an exercise price of $11.50 per share of Common Stock), assuming the exercise in full of all of the SPAC Warrants for cash, but will not receive any proceeds from the sale of the shares of our Common Stock issuable upon such exercise. However, our ability to generate proceeds will depend on the market price of our Common Stock. If the price of our Common Stock remains below $11.50 per share, we believe warrant holders will be unlikely to cash exercise their SPAC Warrants, resulting in little or no cash proceeds to us. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We can give no assurances that we will be able to secure additional sources of funds to support our operations on acceptable terms, or at all, or, if such funds are available to us, that such additional financing will be sufficient to meet our needs. These conditions, among others, raise substantial doubt about our ability to continue as a going concern. If we raise additional funds by issuing equity or convertible debt securities, including pursuant to the ATM Sales Agreement, or as we have done pursuant to the Convertible Debentures and the Oramed Note, it could result in dilution to our existing stockholders or increased fixed payment obligations. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. If we incur additional indebtedness, we could become subject to covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Additionally, any future collaborations we enter into with third parties may provide capital in the near term but we may have to relinquish valuable rights to ZTlido, GLOPERBA, ELYXYB, or our product candidates or grant licenses on terms that are not favorable to us. Any of the foregoing could significantly harm our business, financial condition and results of operations. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may be required to reduce the scope of the commercialization of ZTlido, GLOPERBA or ELYXYB or delay, scale back or discontinue the development of one or more of our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also need to take certain other actions to allow us to maintain our projected cash and projected financial position including but not limited to, additional reductions in general and administrative costs, sales and marketing costs, suspension or winding down of clinical development programs for <span style="white-space:nowrap">SP-102,</span> <span style="white-space:nowrap">SP-103</span> and <span style="white-space:nowrap">SP-104</span> and other discretionary costs. Although we believe such plans, if executed and coupled with the above described sources of liquidity, should provide us with financing to meet our needs, successful completion of such plans is dependent on factors outside of our control. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We anticipate that we will continue to incur net losses into the foreseeable future as we support our clinical development to expand approved indications, continue our development of, and seek regulatory approvals for, our product candidates, and expand our corporate infrastructure. As a result, we have concluded that there is </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">112 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
substantial doubt about our ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. See Note 2 titled &#8220;<span style="font-style:italic">Liquidity and Going Concern</span>&#8221; to our consolidated financial statements included elsewhere in this prospectus for additional information. Our existing cash and cash equivalents, proceeds from the Revolving Facility, proceeds from the issuance of the Convertible Debentures, proceeds from the issuance of the Oramed Note and the issuance of the Common Stock pursuant to the ATM Sales Agreement may be insufficient to enable us to fund our operating expenses, capital expenditure requirements, and to service our debt obligations (whether under the Oramed Note or otherwise) for at least the next 12 months. If these sources are insufficient to satisfy our liquidity requirements, we may seek to raise additional funds through equity offerings, debt financings, collaborations, government contracts or other strategic transactions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cash Flows </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our cash flows for each of the periods presented (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:72%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year&#160;Ended&#160;December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Cash Flow Data:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used for operating activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">(20,707</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">(21,258</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used for investing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(330</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(2,067</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash proceeds from financing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">23,582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">21,171</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net change in cash, cash equivalents and restricted cash</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">2,545</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">(2,154</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cash Flows from Operating Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2023, net cash used for operating activities was approximately $20.7&#160;million, attributable to our net loss of $114.3&#160;million, partially offset by other <span style="white-space:nowrap">non-cash</span> reconciling items of $27.9&#160;million related to loss on derivative liabilities, stock-based compensation, change in fair value of debt and liability instruments, depreciation and amortization and <span style="white-space:nowrap">non-cash</span> operating lease cost, and changes in operating assets and liabilities that provided $65.7&#160;million of cash. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2022, net cash used for operating activities was approximately $21.3&#160;million, primarily from our net loss of $23.4&#160;million, other <span style="white-space:nowrap">non-cash</span> reconciling items of $43.6&#160;million related to depreciation and amortization, stock-based compensation, <span style="white-space:nowrap">non-cash</span> operating lease cost, <span style="white-space:nowrap">non-cash</span> interest for debt issuance costs and debt discount, interest payments related to the debt discount on the Scilex Pharma Notes, net gain on debt extinguishment, and a gain on derivative liabilities and offset by changes in operating assets and liabilities that provided $45.7&#160;million of cash. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cash Flows from Investing Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2023, net cash used for investing activities was approximately $0.3&#160;million, related to payments of deferred consideration for Romeg intangible asset acquisition and $30.0&#160;thousand attributed to cash paid for property and equipment purchases. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2022, net cash used for investing activities was approximately $2.1&#160;million attributed to cash paid for the acquisition of GLOPERBA licenses from Romeg and $7.0&#160;thousand attributed to cash paid for property and equipment purchases. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cash Flows from Financing Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2023, net cash provided by financing activities was approximately $23.6&#160;million and is primarily related to $86.4&#160;million in gross proceeds from the Revolving Facility between </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">113 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Scilex Pharma and eCapital Healthcare Corp., $35.5&#160;million in proceeds from the Standby Equity Purchase Agreements, $24.0&#160;million in proceeds from the Convertible Debentures and $1.1&#160;million in proceeds from the exercise of stock options and warrants, partially offset by $89.6&#160;million repayment of the borrowings under the Revolving Facility, Convertible Debentures, and Oramed Note, $20.0&#160;million capital distribution to Sorrento, $10.0&#160;million cash consideration paid for the Purchased Securities, $2.0&#160;million payment of the transaction costs related to the Scilex-Oramed SPA and the Sorrento SPA and $1.8&#160;million payment of the transaction costs related to the Business Combination and debt issuance costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2022, net cash provided by financing activities was approximately $21.2&#160;million and is primarily related to $62.5&#160;million in proceeds from related party note payables, $51.9&#160;million in proceeds from related party payables, $9.8&#160;million in proceeds from the revolving loan we previously had with CNH Finance Fund I., L.P. (the &#8220;CNH Revolving Loan&#8221;), $3.4&#160;million in proceeds from the Business Combination, and $0.1&#160;million in proceeds from the exercise of stock options offset by $84.8&#160;million repayment of the Scilex Pharma Notes, $18.8&#160;million repayment on the CNH Revolving Loan, and $2.9&#160;million on transaction costs payment related to the Business Combination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Critical Accounting Estimates </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This management&#8217;s discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements which are prepared in accordance with the accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities and the reported amounts of revenue and expenses during the reporting period. We continually evaluate our estimates and judgments and base them on historical experience and other factors that we believe to be reasonable under the circumstances. Materially different results can occur as circumstances change and additional information becomes known. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe the following accounting policies and estimates are most critical to aid in understanding and evaluating our reported financial results. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Revenue Recognition </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our revenue to date has been generated from product sales of ZTlido and ELYXYB in the United States. We do not have significant costs associated with obtaining contracts with our customers. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We recognize revenue when control of the products is transferred to the customers in an amount that reflects the consideration we expect to receive from the customers in exchange for those products. In accordance with FASB ASC Topic 606 &#8220;<span style="font-style:italic">Revenue from Contracts with Customers</span>&#8221;<span style="font-style:italic">, </span>this process involves identifying the contract with a customer, determining the performance obligations in the contract and the contract price, allocating the contract price to the distinct performance obligations in the contract and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. We consider a performance obligation satisfied once we have transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. We recognize revenue for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of control. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our performance obligations with respect to sales of ZTlido and ELYXYB are satisfied at a certain point in time, and we consider control to have transferred upon delivery to the customer, because, upon delivery, the customer has legal title to the asset, physical possession of the asset has been transferred to the customer, the customer has significant risks and rewards in connection with ownership of the asset, and we have a present right to payment from the customer at that time.&#160;Invoicing typically occurs upon shipment and the length of time between invoicing and the date on which payment is due is not significant. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">114 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenues from product sales are recorded net of reserves established for commercial and government rebates, fees, and chargebacks, wholesaler and distributor fees, sales returns and prompt payment discounts. Such variable consideration is estimated in the period of the sale and is estimated using a most likely amount approach based primarily upon provisions included in our customer contracts, customary industry practices and current government regulations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Rebates and Chargebacks </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rebates are discounts that we pay under either government or private health care programs. Government rebate programs include state Medicaid drug rebate programs, the Medicare coverage gap discount programs and the Tricare programs. Commercial rebate and fee programs relate to contractual agreements with commercial healthcare providers, under which we pay rebates and fees for access to and position on that provider&#8217;s patient drug formulary. Rebates and chargebacks paid under government programs are generally mandated under law, whereas private rebates and fees are generally contractually negotiated with commercial healthcare providers. Both types of rebates vary over time.&#160;We record a reduction to gross product sales at the time the customer takes title to the product based on estimates of expected rebate claims. We monitor the sales trends and adjust for these rebates on a regular basis to reflect the most recent rebate experience and contractual obligations. Reserves for rebates and chargebacks are recorded as accrued rebates and fees under current liabilities within the Company&#8217;s consolidated balance sheet. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Prompt Payment Discounts </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We provide our customers with prompt payment discounts which may result in adjustments to the price that is invoiced for the product transferred, in the case that payments are made within a defined period. The prompt payment discount reserve is based on actual gross sales and contractual discount rates. Reserves for prompt payment discounts are included in accounts receivable, net on the consolidated balance sheets. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Service Fees </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We compensate our customers and others in the distribution chain for wholesaler and distribution services. The Company has determined such services received are not distinct from our sale of products to the customers, and therefore, these payments have been recorded as a reduction of revenue. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Product Returns </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are obligated to accept the return of products sold that are damaged or do not meet certain specifications. We currently estimate our product returns using historical trends and product return rates typically experienced in the industry and record this estimate as a reduction of revenue in the period the related product revenue is recognized. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap">Co-payment</span> Assistance </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients who have commercial insurance or pay cash and meet certain eligibility requirements may receive <span style="white-space:nowrap">co-</span> payment assistance. We accrue for <span style="white-space:nowrap">co-payment</span> assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Derivative Liability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Derivative liabilities are recorded on our consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the closing of the Business Combination, the Company assumed a derivative warrant liability of $2.5&#160;million related to Private Warrants (See Note 8 titled &#8220;Stockholders&#8217; Equity&#8221;<span style="font-style:italic"> </span>to our Consolidated Financial </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">115 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Statements in the Annual Report on Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2022 filed with the SEC on March&#160;7, 2023 for additional information). The warrant liability associated with the Private Warrants was valued using the Black-Scholes option pricing model, which is considered to be Level&#160;3 fair value measurement. The primary unobservable input utilized in determining the fair value of the warrant is the expected volatility of the Common Stock. The expected volatility assumption is based on historical volatilities of comparable companies whose share prices are publicly available as well as the implied volatility of the Public Warrants. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stock-Based Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We account for stock-based compensation in accordance with FASB ASC Topic 718 &#8220;<span style="font-style:italic">Compensation &#8211; Stock Compensation</span>&#8221;, which establishes accounting for equity instruments exchanged for employee and consulting services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line-method, over the employee&#8217;s requisite service period (generally the vesting period of the equity grant) or <span style="white-space:nowrap">non-employee&#8217;s</span> vesting period. We account for forfeitures as incurred. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of determining the inputs used in the calculation of stock-based compensation, the Company determines the expected life assumption for options issued using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period since the Company does not have historic exercise behavior. Then the Company determines an estimate of option volatility based on an assessment of historical volatilities of comparable companies whose share prices are publicly available. We use these estimates as variables in the Black-Scholes option pricing model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in our consolidated statement of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Convertible Debentures and the Oramed Note </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We elected the fair value option to account for the Convertible Debentures in an aggregate principal amount of up to $25.0&#160;million that were issued in March and April 2023 and for the Oramed Note in the principal amount of $101.9&#160;million that was issued in September 2023. The Convertible Debentures and the Oramed Note are discussed in Note 7 titled &#8220;<span style="font-style:italic">Debt&#8221;</span> of the Notes to our consolidated financial statements included elsewhere in this prospectus. These instruments are measured at fair value on a recurring basis using Level&#160;3 inputs. We employ the Binomial Lattice Model valuation technique and a discounted cash flow model to measure the fair value of the Convertible Debentures and the Oramed Note, respectively, with any changes in fair value recorded as change in fair value of debt and liability instruments in the consolidated statements of operations, except for changes due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. Interest expense related to these financial instruments is included in the changes in fair value. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recent Accounting Pronouncements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See Note 1 titled &#8220;<span style="font-style:italic">Nature of Operations and Basis of Presentation</span>&#8221; of the Notes to our consolidated financial statements included elsewhere in this prospectus for a discussion of recent accounting pronouncements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Emerging Growth Company </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An &#8220;emerging growth company&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the JOBS Act, is eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">116 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transition period and comply with the requirements that apply to <span style="white-space:nowrap">non-emerging</span> growth companies but any such election to opt out is irrevocable. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance to changes in Scilex&#8217;s business could significantly affect our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we are in the process of evaluating the benefits of relying on the other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, as an emerging growth company we may take advantage of certain exemptions from various reporting requirements and other burdens that are otherwise applicable generally to public companies. These provisions include, but are not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an exemption from compliance with the requirement to obtain an attestation and report from our auditors on the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002, as amended (the &#8220;Sarbanes-Oxley Act&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an exemption from compliance with any new requirements adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reduced disclosure about our executive compensation arrangements in our periodic reports, proxy statements and registration statements; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">exemptions from the requirements of holding <span style="white-space:nowrap">non-binding</span> advisory votes on executive compensation or golden parachute arrangements. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scilex qualifies and will remain as an emerging growth company until the earlier of (i)&#160;the last day of the fiscal year (a)&#160;following the fifth anniversary of the closing of the IPO, (b)&#160;in which Scilex has total annual gross revenue of at least $1.235&#160;billion, or (c)&#160;in which Scilex is deemed to be a large accelerated filer, which means the market value of the common equity of Scilex that is held by <span style="white-space:nowrap">non-affiliates</span> equals or exceeds $700&#160;million as of the last business day of its most recently completed second fiscal quarter; and (ii)&#160;the date on which Scilex has issued more than $1.00&#160;billion in <span style="white-space:nowrap">non-convertible</span> debt securities during the prior three-year period. References herein to &#8220;emerging growth company&#8221; have the meaning associated with it in the JOBS Act. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Smaller Reporting Company </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We are not currently a smaller reporting company, as at the time such status was determined in accordance with SEC rules we were a majority-owned subsidiary of Sorrento. The next date for determining whether we are a smaller reporting company is June&#160;30, 2024. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">117 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx759370_12">BUSINESS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">The Company </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an innovative revenue-generating company focused on acquiring, developing and commercializing <span style="white-space:nowrap">non-opioid</span> pain management products for the treatment of acute and chronic pain. We target indications with high unmet needs and large market opportunities with <span style="white-space:nowrap">non-opioid</span> therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our commercial products are: (i)&#160;ZTlido<sup style="font-size:75%; vertical-align:top">&#174;</sup> (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) for the relief of neuropathic pain associated with postherpetic neuralgia (&#8220;PHN&#8221;), which is a form of post-shingles nerve pain; (ii)&#160;ELYXYB<sup style="font-size:75%; vertical-align:top">&#174;</sup>, a potential first-line treatment and the only <span style="white-space:nowrap">FDA-approved,</span> <span style="white-space:nowrap"><span style="white-space:nowrap">ready-to-use</span></span> oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii)&#160;GLOPERBA<sup style="font-size:75%; vertical-align:top">&#174;</sup>, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults, expected to launch in the first half of 2024. In addition, we have three product candidates: <span style="white-space:nowrap">(i)&#160;SP-102</span> (10 mg, dexamethasone sodium phosphate viscous gel) (&#8220;SEMDEXA<sup style="font-size:75%; vertical-align:top">&#8482;</sup>&#8221;), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica for which we have completed a Phase 3 study; <span style="white-space:nowrap">(ii)&#160;SP-103</span> (lidocaine topical system) 5.4% <span style="white-space:nowrap">(&#8220;SP-103&#8221;),</span> a next-generation, triple-strength formulation of ZTlido, for the treatment of chronic neck pain and for which we have completed a Phase 2 trial in low back pain (&#8220;LBP&#8221;) in the third quarter of 2023; and <span style="white-space:nowrap">(iii)&#160;SP-104</span> (4.5 mg, <span style="white-space:nowrap">low-dose</span> naltrexone hydrochloride delayed-release capsules) <span style="white-space:nowrap">(&#8220;SP-104&#8221;),</span> a novel <span style="white-space:nowrap">low-dose</span> delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia, for which Phase 1 trials were completed in the second quarter of 2022 and a Phase 2 clinical trial is expected to commence in 2024. We believe our currently approved products and future product candidates, if approved by the FDA, could uniquely address what we believe are the significant unmet needs of the targeted populations and become the preferred treatment option for their respective indications. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our guiding principle has always been and remains a patient-first approach, which drives our mission to meet the increasing global demand for more effective and safer <span style="white-space:nowrap">non-opioid</span> pain management solutions. Through rigorous research and development, we believe we are on the cusp of establishing Scilex as the preeminent name in commercial <span style="white-space:nowrap">non-opioid</span> pain management, specifically targeting the unmet needs in both acute and chronic pain sectors with our innovative and leading therapies. We believe that we have not only responded to the global demand for safer, more effective pain relief solutions, but also made substantial progress in demonstrating the rapid onset and enhanced safety of our products. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our Products </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We launched our first commercial product, ZTlido<sup style="font-size:75%; vertical-align:top">&#174;</sup> (lidocaine topical system) 1.8% in October 2018. ZTlido possesses novel delivery and adhesion technology designed to address many of the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the <span style="white-space:nowrap">12-hour</span> administration period. ZTlido is a single-layer, <span style="white-space:nowrap"><span style="white-space:nowrap">drug-in-adhesive</span></span> topical delivery system comprised of an adhesive material containing 36 mg lidocaine, which is applied to a pliable nonwoven cloth backing and covered with a polyethylene terephthalate film release liner. ZTlido is commercially manufactured for us by Oishi Koseido Co., Ltd. (&#8220;Oishi&#8221;) in Japan. We license the rights to ZTlido from and rely exclusively on Oishi and Itochu Chemical Frontier Corporation (&#8220;Itochu&#8221;) pursuant to the Product Development Agreement (the &#8220;Product Development Agreement&#8221;) dated as of May&#160;11, 2011, by and among Scilex Pharmaceuticals Inc., our wholly owned subsidiary (&#8220;Scilex Pharma&#8221;), Oishi and Itochu, and the Commercial Supply Agreement (the &#8220;Commercial Supply Agreement&#8221;), dated as of February&#160;16, 2017, by and among Scilex Pharma, Oishi and Itochu. We have exclusive worldwide rights to Oishi&#8217;s proprietary formulation and manufacturing technologies except with respect to Japan. In 2023, there were more than 182&#160;million prescription lidocaine patches sold in the United States, according to Symphony Healthcare. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We launched our second commercial product, ELYXYB<sup style="font-size:75%; vertical-align:top">&#174;</sup> in April 2023.&#160;We acquired the rights to certain patents, trademarks, regulatory approvals, data, contracts, and other rights related to ELYXYB<sup style="font-size:75%; vertical-align:top">&#174;</sup> (celecoxib oral </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">118 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
solution) and the commercialization thereof in the United States and Canada from BioDelivery Sciences International, Inc. and Collegium Pharmaceutical, Inc. in February 2023.&#160;ELYXYB<sup style="font-size:75%; vertical-align:top">&#174;</sup><sup style="font-size:75%; vertical-align:top"> </sup>is a potential first-line treatment and the only FDA-approved, <span style="white-space:nowrap"><span style="white-space:nowrap">ready-to-use</span></span> oral solution for the acute treatment of migraine, with or without aura, in adults. We filed a New Drug Submission to Health Canada&#8217;s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the approval of ELYXYB<sup style="font-size:75%; vertical-align:top">&#174;</sup> for acute treatment of migraine with or without aura in Canada. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to launch our third commercial product, GLOPERBA, in the first half of 2024. We acquired certain rights to GLOPERBA on June&#160;14, 2022, when we entered into a License and Commercialization Agreement (the &#8220;Romeg Agreement&#8221;) with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.) (&#8220;Romeg&#8221;). Pursuant to the Romeg Agreement, among other things, Romeg granted us (1)&#160;the right to manufacture, promote, market, distribute and sell pharmaceutical products comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans in the United States, and (2)&#160;an exclusive, transferable license to use the trademark &#8220;GLOPERBA<sup style="font-size:75%; vertical-align:top">&#174;</sup>&#8221;. GLOPERBA is an <span style="white-space:nowrap">FDA-approved,</span> oral medication for the treatment of gout in adults. Gout is a painful arthritic disorder affecting an estimated 9.2&#160;million people in the United States. Gout pain can be excruciating and is a form of inflammatory arthritis that develops in some people who have high levels of uric acid in their blood. It can cause sudden severe episodes of pain and can be disabling with tenderness, warmth and swelling. <span style="white-space:nowrap">Non-steroidal</span> anti-inflammatory drugs, colchicine and corticosteroids are used a majority of time as the first line to treat acute gout. The U.S. is observed to have a high prevalence of gout, owing to lifestyle issues such as high alcohol intake, obesity, and smoking. We expect to commercialize GLOPERBA in the first half of 2024 and believe we are well positioned to market and distribute the product. We have a direct distribution network to national and regional wholesalers and pharmacies throughout the U.S. For more information on Scilex, please see the section titled &#8220;<span style="font-style:italic">Business &#8212; Material Agreements &#8212; Romeg License and Commercialization Agreement.</span>&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our Product Candidates </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We acquired <span style="white-space:nowrap">SP-102</span> from Semnur Pharmaceuticals, Inc. (&#8220;Semnur&#8221;) in March 2019 and are developing <span style="white-space:nowrap">SP-102</span> to be an injectable viscous gel formulation of a widely used corticosteroid designed to address the serious risks posed by <span style="white-space:nowrap">off-label</span> epidural steroid injections (&#8220;ESI&#8221;), which are administered over 12&#160;million times annually in the United States. SEMDEXA<sup style="font-size:75%; vertical-align:top">&#8482;</sup> has been granted fast track designation by the FDA and, if approved, could become the only <span style="white-space:nowrap">FDA-approved</span> ESI for the treatment of sciatica. According to a report by Decision Resources Group, it was estimated that over 4.8&#160;million patients would suffer from sciatica in the United States in 2022. We received our <span style="white-space:nowrap">SP-103</span> Phase 2 <span style="white-space:nowrap">top-line</span> results in August 2023 and the trial achieved its objectives characterizing safety, tolerability and preliminary efficacy of <span style="white-space:nowrap">SP-103</span> in acute LBP associated with muscle spasms. <span style="white-space:nowrap">SP-103</span> was safe and well tolerated. Increase of lidocaine load in topical system by three times, compared with approved ZTlido, 5.4% vs. 1.8%, did not result in signs of systemic toxicity or increased application site reactions with daily applications over one month treatment. <span style="white-space:nowrap">SP-103</span> received FDA Fast Track status in LBP. We will continue to analyze the <span style="white-space:nowrap">SP-103</span> Phase 2 trial data along with an investigator study of ZTlido in patients with chronic neck pain completed in the second half of 2023, which also has shown promising <span style="white-space:nowrap">top-line</span> efficacy and safety results. Scilex is planning to initiate Phase 2/3 trial in chronic neck pain in 2024. <span style="white-space:nowrap">SP-103,</span> if approved, could become the first <span style="white-space:nowrap">FDA-approved</span> lidocaine topical product for the treatment of chronic neck pain. We are developing <span style="white-space:nowrap">SP-104</span> as a novel delayed-release formulation of <span style="white-space:nowrap">low-dose</span> naltrexone hydrochloride for the treatment of fibromyalgia, which remains a largely unmet medical need given the low response rates of commercially available therapies. Naltrexone is routinely used <span style="white-space:nowrap">off-label</span> to treat fibromyalgia. There are no <span style="white-space:nowrap">low-dose</span> formulations commercially available in the United States. Our patented formulation is designed to overcome undesirable effects of immediate release naltrexone, such as hyperalgesia, dysphoria, nausea, anxiety and insomnia. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are focused on identifying treatment options for pain management with established mechanisms that have deficiencies in safety, efficacy or patient experience. We believe this approach allows us to potentially leverage the regulatory approval pathway available under Section&#160;505(b)(2) of the Federal Food, Drug, and Cosmetic Act for each of our product candidates. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">119 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following chart illustrates completed and anticipated milestones for our current commercial products and novel product candidates. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g759370g00a01.jpg" alt="LOGO"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Strategy </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our vision is to become the leading pain management company delivering novel <span style="white-space:nowrap">non-opioid</span> and <span style="white-space:nowrap">non-addictive</span> treatments to provide safe, effective and durable relief of multiple pain conditions. To accomplish this, the principal elements of our strategy are the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Maximize the commercial potential of ZTlido</span><sup style="font-size:75%; vertical-align:top">&#174;</sup><span style="font-weight:bold">.</span> We have assembled an integrated commercial organization using a dedicated sales force and sales management team, marketing and managed care capabilities to support continued uptake of ZTlido. We leverage a sales force of approximately <span style="white-space:nowrap">60-70</span> people, targeting over 10,000 primary care physicians, pain specialists, neurologists, rheumatologist, and palliative care physicians who we believe treat the majority of PHN patients. Additionally, we are utilizing <span style="white-space:nowrap"><span style="white-space:nowrap">direct-to-patient</span></span> marketing strategies to expand awareness and utilization of ZTlido. Our managed healthcare account executives have extensive experience in negotiating contracts and have already achieved significant uptake by adding ZTlido to key formularies such as CVS Caremark/Aetna Commercial, Cigna HealthCare (commercial and Medicare plans), Express Scripts (commercial), United Healthcare Commercial, Optum Rx Select Commercial, Anthem Blue Cross Blue Shield (&#8220;BCBS&#8221;), BCBS Louisiana and Kansas, Lifetime/Excellus BCBS, MedImpact, CareFirst, Elixir Commercial and Medicaid in California, Florida, Idaho, and North Dakota. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Commercialize and successfully continue launch of ELYXYB</span><sup style="font-size:75%; vertical-align:top">&#174;</sup><span style="font-weight:bold"> for migraine in the U.S. </span>We will utilize our current commercial infrastructure comprised of our sales, marketing and managed health care functions to promote ELYXYB for acute migraine to healthcare providers (&#8220;HCPs&#8221;) in the U.S. market. There is a good degree of overlap between the current Scilex sales force HCP targets and HCPs who prescribe medications for acute migraine, allowing for efficient dual promotion of ELYXYB and ZTlido. The principal elements of the ELYXYB strategy are the following: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Educate the market on the need for and value of a novel and differentiated option for the treatment of acute migraine, where a high degree of unmet medical need already exists. We will leverage our <span style="white-space:nowrap">in-person</span> sales field forces, medical affairs teams, and omni-channel HCP engagement campaigns to drive awareness of ELYXYB features and benefits. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Broaden access to ELYXYB. Our managed healthcare account executives will negotiate contracts with key payer and pharmacy stakeholders to achieve uptake to key formularies. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">120 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Commercialize and successfully <span style="white-space:nowrap">re-launch</span> GLOPERBA</span><sup style="font-size:75%; vertical-align:top">&#174;</sup><span style="font-weight:bold"> for gout in the U.S.</span> We will utilize our current commercial infrastructure comprised of our sales, marketing, and managed health care functions to promote GLOPERBA<sup style="font-size:75%; vertical-align:top">&#174;</sup> for gout to approximately 3,000 HCPs in the U.S. market. We anticipate a good degree of overlap between the current HCPs that we target and HCPs who prescribe colchicine for gout, allowing for efficient dual promotion of GLOPERBA and ZTlido. The principal elements of the GLOPERBA strategy are as follows: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Educate the market on the need for and value of simplified and precise colchicine dose adjustments to allow individualized, <span style="white-space:nowrap"><span style="white-space:nowrap">patient-by-patient</span></span> therapy. Scilex will leverage its <span style="white-space:nowrap">in-person</span> sales forces, medical affairs teams, and omni-channel HCP engagement campaigns to drive awareness of GLOPERBA&#8217;s features and benefits. In addition, target providers, rheumatologists and primary care physicians treating various comorbidities, will be provided with tools to help them identify and prescribe GLOPERBA to appropriate patients. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Increase access to GLOPERBA for subsets of patients in prophylactic treatment of gout, specifically those with comorbidities and GI intolerance. Our managed healthcare account executives will negotiate contracts with key payer and pharmacy customers to achieve uptake of key formularies. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Develop and commercialize SEMDEXA</span><span style="font-weight:bold"><sup style="font-size:75%; vertical-align:top">TM</sup></span><span style="font-weight:bold"> as a novel epidural injection for the first approved treatment of sciatica.</span> We are developing SEMDEXA to address the limitations associated with the available corticosteroid epidural injectable products that are used <span style="white-space:nowrap">off-label.</span> Many of these products contain potentially neurotoxic preservatives and particulates, and are administered over 12&#160;million times annually despite a warning on the label of serious neurologic complications, including loss of vision, stroke, paralysis and death. These products carry warnings required by the FDA that the safety and efficacy of epidural administration has not been established. SEMDEXA has received fast track designation from the FDA and, if approved, could become the first <span style="white-space:nowrap">FDA-approved</span> epidural steroid product with long-term patent protection, which we also believe would create significant barriers to entry. Due to the novelty of our formulation as well as the associated patents and trade secrets, future potential competitors could be required to conduct extensive preclinical studies and costly comparative clinical trials. A full <span style="white-space:nowrap">6-month</span> data analysis was completed in February 2022 and we have completed a pivotal Phase 3 study with final results received in March 2022, which results reflect achievement of primary and secondary endpoints. We have extensive clinical and <span style="white-space:nowrap">pre-clinical</span> data (including those obtained from multiple Phase 2 clinical trials) with the novel viscous gel formulation of <span style="white-space:nowrap">SP-102.</span> We expect to present the robust data collected over the course of our multi-year clinical development program to the FDA as part of a New Drug Application (&#8220;NDA&#8221;). We also presented the pivotal Phase 3 trial results at the American Society of Interventional Pain Physicians annual meeting in Las Vegas, Nevada in May 2022. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Pursue clinical development of <span style="white-space:nowrap">SP-103</span> for the first approved topical treatment in patients with chronic neck pain.</span> We are developing <span style="white-space:nowrap">SP-103</span> as a triple-strength lidocaine topical system for the treatment of chronic neck pain, to be used where we believe a high-dose strength and superior adhesive qualities of a topical system may provide a greater therapeutic benefit than currently available therapies. <span style="white-space:nowrap">SP-103</span> is designed to use ZTlido&#8217;s delivery and adhesion technology to deliver a dose of lidocaine that is three times higher than any other approved lidocaine topical products. We received our <span style="white-space:nowrap">SP-103</span> Phase 2 <span style="white-space:nowrap">top-line</span> results in August 2023 and the trial achieved its objectives characterizing safety, tolerability and preliminary efficacy of <span style="white-space:nowrap">SP-103</span> in acute LBP associated with muscle spasms. <span style="white-space:nowrap">SP-103</span> was safe and well tolerated. The increase of lidocaine load in topical system by three times, compared with approved ZTlido, 5.4% vs. 1.8%, did not result in signs of systemic toxicity or increased application site reactions with daily applications over one month treatment. <span style="white-space:nowrap">SP-103</span> received FDA Fast Track status in LBP. We will continue to analyze the <span style="white-space:nowrap">SP-103</span> Phase 2 trial data along with an investigator study of ZTlido in patients with chronic neck pain completed in the second half of 2023, which also has shown </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">121 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
promising <span style="white-space:nowrap">top-line</span> efficacy and safety results. Scilex is planning to initiate Phase 2/3 trial in chronic neck pain in 2024. <span style="white-space:nowrap">SP-103,</span> if approved, could become the first <span style="white-space:nowrap">FDA-approved</span> lidocaine topical product for the treatment of chronic neck pain. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Pursue clinical development of <span style="white-space:nowrap">SP-104</span> for the treatment of fibromyalgia, which has very few approved therapies that are marginally effective and have unpleasant side-effects.</span> We are developing <span style="white-space:nowrap">SP-104</span> for fibromyalgia. <span style="white-space:nowrap">Low-dose</span> naltrexone hydrochloride delayed-release capsules are routinely used <span style="white-space:nowrap">off-label</span> to treat fibromyalgia and other chronic pain conditions such as complex regional pain. <span style="white-space:nowrap">SP-104</span> addresses the shortcomings of using the high-dose commercial products and pharmacy-compounded products by delivering a <span style="white-space:nowrap">low-dose</span> of naltrexone hydrochloride (approximately 11 times less than the commercial product) in a delayed-release formulation that bypasses the stomach and releases the drug in the gut (upper intestine). These product characteristics mitigate against the known safety issues associated with the high-dose commercial products and immediate release pharmacy-compounded products, and the overall reliability issues associated with pharmacy-compounded products. <span style="white-space:nowrap">SP-104</span> has completed two Phase 1 studies to characterize the pharmacokinetics (&#8220;PK&#8221;) and safety of the product, and we expect to commence Phase 2 studies in 2024. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Expand our product portfolio by developing or acquiring <span style="white-space:nowrap">non-opioid</span> assets that leverage our novel delivery and adhesion technologies and our existing commercial infrastructure.</span> We are continuously evaluating opportunities to leverage our research and development experience to develop <span style="white-space:nowrap">non-opioid</span> therapeutics for pain management indications that are not adequately served with existing treatment options. We also seek to <span style="white-space:nowrap">in-license</span> or acquire <span style="white-space:nowrap">non-opioid</span> therapeutics that can both complement our existing product portfolio and benefit from our existing commercial infrastructure. In evaluating marketed and clinical-stage expansion opportunities, we intend to pursue therapeutics that address markets served by our established target physician audience and that can be commercialized by our existing sales force. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Leverage our management team&#8217;s experience to further develop and commercialize its current and future product portfolio.</span> Our management team has held senior positions at leading biopharmaceutical companies, including Allergan, Inc., Bristol-Myers Squibb Company, Teva Pharmaceuticals Industries Ltd. (&#8220;Teva&#8221;), Novartis Pharmaceuticals, Cephalon, Inc., Roche AG, PDL BioPharma, Inc., Xenoport, Inc. and Chiron Corp. Our team has substantial experience in rapidly progressing new drugs to clinical proof of concept, completing successful pivotal registration programs and successfully commercializing products. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that our innovative <span style="white-space:nowrap">non-opioid</span> product portfolio has the potential to provide effective pain management therapies that can have a transformative impact on patients&#8217; lives. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Management Team </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have assembled a management team of experienced biopharma industry veterans, who have deep scientific, business and leadership expertise in the pharmaceutical industry, as well as strong transactional and business development track records. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management team is led by our Chief Executive Officer and President, Jaisim Shah, with strategic guidance from our Executive Chairperson, Henry Ji, Ph.D. They collectively have over 60 years of global biopharmaceutical and biotechnology experience. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jaisim Shah has over 30 years of industry success in leading product development and commercializing innovative therapies and creating companies, with documented success in development and commercialization of some of today&#8217;s most recognized pharmaceutical brands. He is a seasoned life science executive and board director with extensive accomplishments at Bristol-Myers Squibb, Roche, PDL Biopharma, Sorrento </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">122 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Therapeutics, Inc. (&#8220;Sorrento&#8221;), Pfizer/Upjohn, Scilex, and <span style="white-space:nowrap">start-ups</span> such as Elevation and Semnur Pharmaceuticals. Mr.&#160;Shah has been Chief Executive Officer and President of Semnur Pharmaceuticals (acquired by Scilex Pharma) since its inception in 2013. He has served as Chief Executive Officer and President of Legacy Scilex and Scilex Pharma since March 2019 and of Scilex since November 2022. Mr.&#160;Shah also serves on the board of directors of Sorrento and Scilex. Most recently, Mr.&#160;Shah served as Chief Business Officer of Elevation Pharmaceuticals where he focused on financing, business strategy, mergers and acquisitions, and business development. He led the sale of Elevation to Sunovion Pharmaceuticals in 2012. At Facet Biotech and PDL BioPharma, he served from 2000 to 2009 as Chief Business Officer and also held the position of senior vice president of marketing and medical affairs. During this time, he completed numerous licensing/partnering and strategic transactions including with Roche, Bristol-Myers Squibb, Otsuka, and Biogen Idec. His leadership in marketing and portfolio management, including leading the commercial enterprise, helped the company make large improvements to meet its profitability potential. At Bristol-Myers Squibb, as vice president of global marketing from 1997 to 2000, Mr.&#160;Shah received the &#8220;Presidents Award&#8221; for completing one of the most significant collaborations in the company&#8217;s history. Prior to working with Bristol-Myers Squibb, Mr.&#160;Shah led international marketing for oncology and virology and was a global business leader for corporate alliances at Roche from 1991 to 1997 with Genentech and IDEC, and prepared products for worldwide launch and <span style="white-space:nowrap">pre-launch</span> at F. <span style="white-space:nowrap">Hoffman-La</span> Roche AG in Switzerland. He has played a key role in the formulation of long-range plans and <span style="white-space:nowrap">pre-launch</span> and launch strategies for brands such as Abilify<sup style="font-size:75%; vertical-align:top">&#174;</sup>, Pegasys<sup style="font-size:75%; vertical-align:top">&#174;</sup>, and Rituxan/MabThera<sup style="font-size:75%; vertical-align:top">&#174;</sup>, each of which have generated well over $1&#160;billion in sales. Dr.&#160;Henry Ji is the holder of several issued and pending patents in the life science research field and is the sole inventor of Sorrento&#8217;s intellectual property. Our Chief Financial Officer, Stephen Ma, has more than 15 years of finance and operational expertise across pharmaceuticals and venture-backed biotechnology companies. Our research efforts are guided by highly experienced scientists and experts. Our management team contributes a diverse range of experiences from leading biopharmaceutical companies, including Allergan, Inc., Bristol-Myers Squibb Company, Teva Pharmaceuticals Industries Ltd., Novartis Pharmaceuticals, Cephalon, Inc., Roche AG, PDL BioPharma, Inc., Xenoport, Inc. and Chiron Corp. With this leadership, we believe we are well positioned to achieve our vision of becoming the leading pain management company delivering novel <span style="white-space:nowrap">non-opioid</span> and <span style="white-space:nowrap">non-addictive</span> treatments to provide safe, effective and durable relief of multiple pain conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we are supported by impressive teams across all levels of the organization. We hire and develop world-class talent from diverse backgrounds in biopharma, academia, technology and finance to ensure we have all of the capabilities to design and deliver effective first-class pain management therapies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Product Portfolio </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ZTlido </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our marketed product, ZTlido, is a lidocaine topical system approved for the relief of neuropathic pain associated with PHN. ZTlido was strategically designed to address the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the <span style="white-space:nowrap">12-hour</span> administration period. We launched ZTlido in October 2018 with an integrated commercial organization and we believe its differentiated therapeutic profile, combined with our competitive pricing strategy and our active direct marketing efforts have driven, and will continue to drive, accelerated sales growth and increased market uptake. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Prescription Lidocaine Patch Market Overview </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prescription lidocaine patches are approved by the FDA as a local anesthetic and are generally used as a first-line treatment for the relief of neuropathic pain associated with PHN. PHN is a chronic neuropathic pain syndrome that results as a complication following an infection of herpes zoster, also known as shingles. Herpes zoster symptoms resolve after a few weeks, but the pain caused by the nerve injury and surrounding the affected area can persist for months and sometimes years. According to Evaluate Ltd., there were over 3.5&#160;million people living with PHN conditions in the United States in 2021. Lidocaine patches have also been used in patients with </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">123 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other types of pain, such as diabetic neuropathy, osteoarthritis and pain associated with surgery, cancer or trauma, and often in patients with LBP. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2023, there were more than 182&#160;million prescription lidocaine patches sold in the United States, according to Symphony Healthcare. Of this number of prescriptions, there are only six main lidocaine patch manufacturers, which accounted for approximately 90% of the total prescriptions, according to Symphony Healthcare. We believe that the PHN market will continue to expand with the introduction of our lidocaine topical system, ZTlido, which is supported by our commercial organization, by prescribing trends away from opioid use, and by continued growth in the population of patients aged 45 years and older who are at greater risk of suffering from PHN. Unlike Lidoderm, the FDA has not determined that any other products are therapeutically equivalent to ZTlido, and accordingly, a prescription for ZTlido may not be able to be substituted by a generic product. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Current Treatment Landscape and Limitations of Existing Treatments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The recommended first-line treatment for the relief of neuropathic pain associated with PHN includes topical lidocaine, gabapentinoids (which have been associated with the potential for abuse as well as numerous adverse events), antidepressants and a multi-modal approach. Topical lidocaine and gabapentinoids are preferred for combination therapies due to their low propensity for <span style="white-space:nowrap"><span style="white-space:nowrap">drug-to-drug</span></span> interactions. For example, an eight-week combination use with pregabalin (Lyrica) has been proven to reduce pain in half for patients who had inadequate relief on monotherapy, despite titration of pregabalin to effect. This efficacy boost was achieved without tolerability issues or adding to side effects. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A survey analyzing treatment patterns for neuropathic pain associated with PHN found that recommended first-line therapeutics were used in only 29% of patients examined from 2010 to 2014, while the remaining patients were started on various <span style="white-space:nowrap">off-label</span> treatments, including nonsteroidal anti-inflammatory drugs (&#8220;NSAIDS&#8221;) and opioids. These drugs can have adverse effects, especially on elderly patients, which represent the majority of PHN patients. For example, opioids carry a well-characterized risk of abuse and misuse and the potential for serious side effects, such as respiratory depression, constipation and others, including death. According to the Centers for Disease Control and Prevention, over 75% of the 100,306 drug overdose deaths during the <span style="white-space:nowrap">12-month</span> period ending in April 2021 involved opioids. Similarly, tricyclic antidepressants, which can be effective in managing the neuropathic pain associated with PHN, can result in significant systemic side effects and cardiotoxicity, posing risks to the elderly and patients with heart disease, epilepsy or glaucoma. These side effects make topical lidocaine products an attractive first-line treatment option from a safety perspective. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The safety of lidocaine patches is well supported in medical literature. Unlike transdermal medications that are designed to achieve systemic drug levels via absorption through the skin or mucosal membrane, leading to effects away from the application site, topical lidocaine has a local effect at the site of application. Because drug application is localized to the immediate area surrounding the patch, systemic absorption from a topical patch is low, reducing the risk of systemic side effects and lowering the potential for drug interactions relative to other systemic pharmacologic therapies. Due to the low systemic exposure and minimal systemic side effects reported in clinical trials, we believe a topical lidocaine patch is well suited for patients being treated with multiple medications or at a higher risk of side effects, including the elderly or those with chronic conditions. As a localized treatment, lidocaine patches have been used concomitantly with other medications in patients for whom monotherapy is inadequate. Furthermore, we believe medication administered topically rather than orally can improve patient compliance. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While lidocaine patches have certain advantages over the treatment alternatives discussed above, certain patches have limitations that may impact efficacy. For example, poor adhesion of the patch is a leading problem for topical lidocaine patches cited in the FDA Adverse Event Reporting System (&#8220;FAERS&#8221;). Because the drug is incorporated in the adhesive for these products, patches must maintain adhesion or risk compromising the ability to deliver their full drug dose. As a result, establishing strong adhesion is a key factor for patient compliance and satisfaction. In draft guidance issued in July 2021, the FDA recommended that developers of topical and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">124 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transdermal delivery systems (&#8220;TDSs&#8221;) conduct studies to characterize the adhesion performance of the product with suggested data requirements. Likewise, the FDA issued a draft guidance in October 2018 outlining the adhesion data requirements for generic TDSs. This guidance, along with Scilex&#8217;s past experience with regulatory agencies, shows the FDA&#8217;s interest and the importance of adhesion performance of these products. There are also dermal safety requirements that force developers to carefully balance adhesion performance against dermal safety. ZTlido is the first TDS product approved by the FDA that was able to demonstrate the targeted adhesion performance with an overall benign dermal safety profile. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following figure depicts data derived from FAERS as of December&#160;31, 2023: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g759370g00a02.jpg" alt="LOGO"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For many of the competing lidocaine patches, a common drawback is the usage of hydrogel technology that limits the overall pharmaceutical efficiency of the product, requiring more total drug to be loaded into the patch to deliver a sufficient amount of drug to achieve a therapeutic effect. For example, Lidoderm has a drug load of 700 mg drug but only delivers 3&#177; 2% of that drug load. Consequently, adhesive thickness must be increased in order to have a drug load sufficient to deliver a therapeutic dose of drug to the skin. As adhesive thickness increases, the product&#8217;s pliability can be compromised to the extent that the patch loses adhesion as the skin moves and wrinkles through normal patient activity. The weight of the hydrogel patches (largely due to high water content) further contributes to the challenge in maintaining adhesion. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The greater drug load also poses a risk of accidental exposure. For example, with a bioavailability of 3 &#177; 2% of the 700 mg drug load for Lidoderm, there is over 650 mg of drug remaining on the patch at the end of the <span style="white-space:nowrap">12-hour</span> administration period, as captured in a bolded warning on the product label. If improperly disposed of, the residual drug poses the potential risk to children, pets and others of accidental exposure to a toxic amount of lidocaine, although we believe the risk with this formulation has not been evaluated. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to prescription lidocaine patches, there are commercially-available OTC topical lidocaine products in the market, but none of these OTC products have been reviewed or approved by the FDA. Notably in 2003, the FDA proposed amending the tentative final monograph for OTC external analgesic drug products to clarify the status of patches (and poultices and plasters), noting that the dosage forms had not been determined to be generally recognized as safe and effective for any analgesia at that time. Therefore, the FDA would likely not consider these OTC products to be compliant with the monograph and do not have legal marketing status. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Our Solution </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our novel adhesion and delivery technology provides significantly improved adhesion compared to Lidoderm, manufactured by Endo Pharmaceuticals, and generic alternatives marketed by Mylan N.V. (&#8220;Mylan&#8221;), while </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">125 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
providing bioequivalent delivery of lidocaine via an efficient drug delivery system. Our product is lighter, thinner and provides for a better patient experience without compromise to dermal safety and with no presentation of dermal sensitization. Below is a comparison of the key advantages of ZTlido to Lidoderm and generic lidocaine patches manufactured by Teva and by Mylan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Key Advantages of ZTlido vs. Lidoderm and Associated Generics </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g759370g00a03.jpg" alt="LOGO"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note: DIA = <span style="white-space:nowrap"><span style="white-space:nowrap">Drug-in-adhesive</span></span> </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Source: A Scilex-sponsored <span style="white-space:nowrap"><span style="white-space:nowrap">head-to-head</span></span> comparative adhesion study <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">(SCI-LIDO-ADH-003)</span></span></span> </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ZTlido has been strategically designed to address poor adhesion, a leading complaint associated with other currently marketed topical lidocaine products. ZTlido uses an advanced <span style="white-space:nowrap">hot-melt</span> technology, which uses premixing and <span style="white-space:nowrap">hot-melt</span> mixing of various excipients and lidocaine, followed by current Good Manufacturing Practices (&#8220;cGMP&#8221;) compliant coating, lining, cutting and filling processes. In clinical studies, the technology provided significantly improved adhesion over Lidoderm<sup style="font-size:75%; vertical-align:top">&#174;</sup> (a branded, prescription 5% lidocaine patch product) (&#8220;Lidoderm&#8221;) and Mylan&#8217;s generic lidocaine patch at 12 hours after application. In a <span style="white-space:nowrap"><span style="white-space:nowrap">head-to-head</span></span> study of 44 subjects, ZTlido showed statistically significant adhesion at <span style="white-space:nowrap">all-time</span> points compared to Lidoderm. Further, ZTlido maintained greater than 90% mean adhesion over the labeled <span style="white-space:nowrap">12-hour</span> administration period while Lidoderm fell below this benchmark within 3 hours. ZTlido also showed superior adhesion when compared to Mylan&#8217;s generic lidocaine patch. In this <span style="white-space:nowrap"><span style="white-space:nowrap">head-to-head</span></span> study, ZTlido maintained greater than 90% mean adhesion throughout the labeled <span style="white-space:nowrap">12-hour</span> administration period, while Mylan&#8217;s generic product had a mean adhesion score of only 80% immediately after application, which progressively worsened over time. The formulation components are also carefully selected to achieve the target adhesion profile without creating dermal sensitization and maintaining a benign irritation profile. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">126 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In two separate studies, adhesion performance of ZTlido was compared to Lidoderm (with 44 subjects) and to Mylan&#8217;s generic lidocaine patch (with 24 subjects), as depicted in the diagrams below. Both studies were performed with healthy volunteers using a standard clinical adhesion protocol where adhesion could not be enhanced (i.e., no reinforcement, pressing or reattaching). The level of adhesion was measured immediately after application (Time 0), and at 3, 6, 9 and 12 hours after application. ZTlido was the only lidocaine product to achieve over 90% adhesion over 12 hours after application in these studies. Maintaining 90% adhesion was a requirement for ZTlido&#8217;s NDA approval. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g759370g00a04.jpg" alt="LOGO"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The proprietary adhesive system utilized for ZTlido allows for a more efficient delivery of the drug from the patch to the skin. This was supported by a clinical study in which ZTlido achieved a bioequivalent dose of lidocaine while using a reduced drug load (36 mg for ZTlido versus 700 mg for Lidoderm). The drug delivery efficiency of ZTlido lessens the danger of accidental exposure. After 12 hours after application, ZTlido contains approximately 18 mg of residual lidocaine. In comparison, each Lidoderm patch leaves over 650 mg in the patch at the end of the <span style="white-space:nowrap">12-hour</span> administration period. If improperly disposed of, the residual drug poses a risk of accidental exposure to a toxic amount of lidocaine to children, pets and others, although the risk with this formulation has not been evaluated. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The drug delivery efficiency of ZTlido also enables it to be manufactured as a thinner product relative to Lidoderm and Teva&#8217;s generic lidocaine patch. We strategically leveraged this property of ZTlido by utilizing a thin patch design with a nonwoven backing cloth that allows for better adhesion of the product. The improved adhesion performance, thinner profile and incorporation of a flexible backing material allows for a product that maintains contact with the skin in contoured areas of the body when encountering torsional strains arising from normal body movements and during contact with clothing and bedding. While Mylan&#8217;s generic lidocaine patch is also thinner than Lidoderm, it incorporates a film backing material that makes the product inflexible with body movements, contributing to its rapid loss in adhesion. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The adhesion profile of ZTlido allows the product to be used under moderate exercise conditions (tested in 4 sessions of <span style="white-space:nowrap">30-minutes</span> of stationary bike exercise, cumulatively 2 hours) as captured in the ZTlido label. No ZTlido patches fell off during the entire <span style="white-space:nowrap">12-hour</span> administration period. Lidoderm and the associated generics have not produced any public data on the use of their products by active pain patients under such conditions. ZTlido is also labeled to allow patients to shower and bathe while wearing the patch, which is supported by an adhesion or PK study showing that, while some degree of lifting is observed in these environments, the patches were able to be pressed back down or reattached in the cases where the product completely detached, with no clinically meaningful change in PK. In contrast, Lidoderm and the associated generics are labeled with the effects of water exposure being unknown. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">127 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although ZTlido, Lidoderm and the associated generics are all labeled to not be used with heat (e.g., heating pad or blanket), the <span style="white-space:nowrap">FDA-approved</span> ZTlido label states that users may apply ZTlido to a treatment site after moderate heat exposure, such as after 15 minutes of heating pad use on a medium setting. This authorized use of ZTlido is of value as heat therapy is widely used in treating pain. In contrast, Lidoderm and the associated generics are not labeled for use with heat. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe ZTlido has other favorable features compared to Lidoderm and associated generic lidocaine patches such as the inclusion of a perforated release liner and the absence of cold flow. The perforated release liner allows for easier removal of the liner before application, which we believe provides convenience to patients who have dexterity challenges. In contrast, Lidoderm and generic lidocaine patches incorporate a single-sheet release liner, requiring patients to pick at the corners and edges to breach and remove before application. Cold flow is the propensity of the adhesive to migrate from the edges of the product under normal conditions, either in the product envelope or while on the skin. This can lead to difficulties in removing the product from the envelope and/or movement of the product, while on the skin, away from the intended administration site. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We launched ZTlido in October 2018 with support from an integrated commercial organization using a dedicated sales force and sales management, marketing and managed care capabilities. We market ZTlido through a dedicated sales force of approximately 65 people, targeting over 10,000 primary care physicians, pain specialists, neurologists and palliative care physicians who we believe treat the majority of PHN patients. We are utilizing a multi-channel marketing strategy to expand awareness and utilization of ZTlido. Our managed healthcare account executives have achieved success in adding ZTlido to key formularies, including CVS Caremark/Aetna Commercial, Cigna HealthCare (commercial and Medicare plans), Express Scripts (commercial and most Medicare plans), United Healthcare Commercial, Optum Rx Select Commercial, Anthem BCBS, BCBS Louisiana and Kansas, Lifetime/Excellus BCBS, MedImpact, CareFirst, Elixir Commercial and Medicaid in California, Florida, Idaho, and North Dakota. We believe the benefits of ZTlido, combined with our competitive pricing strategy and our active direct marketing efforts, have driven, and will continue to drive, accelerated sales growth and increased market uptake. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to support several investigator-initiated research studies to explore the clinical benefits of using ZTlido in patients with carpal tunnel syndrome, neck pain, intercostal neuralgia and other possible indications. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">SP-102</span> (SEMDEXA) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-102</span> (SEMDEXA) is a Phase 3, novel, injectable viscous gel formulation of a widely used corticosteroid for epidural injections to treat sciatica. No ESIs are currently approved by the FDA. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Sciatica Market Overview </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A particularly debilitating complication of back pathology is sciatica, which is a condition caused by mechanical compression of the nerve root, or by the effects of inflammatory mediators arising from a degenerative disc that results in inflammation and damage to the nerve roots. This nerve root compression in the lumbar segment of the spine causes shock-like or burning LBP combined with pain radiating down along the sciatic nerve through the buttocks and down one leg, sometimes reaching the foot. This often severe and debilitating leg pain is usually associated with symptoms of neuropathy-like numbness and tingling. The estimated lifetime incidence of sciatica ranges from 10% to 40% of the U.S. population, and about <span style="white-space:nowrap">one-third</span> of these cases will develop symptoms lasting over a year. According to a report by Decision Resources Group, it was estimated that over 4.8&#160;million patients would suffer from sciatica in the United States in 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Current Treatment Landscape and Limitations of Existing Treatments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the U.S. population ages, the incidence of sciatica and the need for interventions are expected to continue to increase. For example, from 2000 to 2018, ESIs in Medicare beneficiaries increased by more than 125%. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">128 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although there are numerous etiologies of sciatica, and therapies may differ based on the etiology, pain management interventions for sciatica are usually multi-modal. Among the pain management interventions, ESI is considered to be efficacious and has been widely used by physicians across multiple specialties, including anesthesiology, physical medicine and rehabilitation and pain medicine. However, there is no ESI therapy approved by the FDA for sciatica to date, and particulate formulations of glucocorticoids have been associated with severe adverse events. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients with sciatica have a wide range of invasive and <span style="white-space:nowrap">non-invasive</span> treatment options. Surgical intervention options include vertebroplasy, spinal laminectomy, discectomy, microdiscectomy, foraminotomy, intradiscal electrothermal therapy, nucleoplasty, radiofrequency denervation, spinal fusion and artificial disc replacement. These options are generally the last line of treatment because they can result in prolonged recovery time, may not be successful in reducing pain or addressing the underlying cause, and may result in permanent loss of flexibility. For these reasons, less invasive interventions are usually implemented first. Less invasive interventions may include (i)&#160;nonpharmacological therapies such as physical therapy, stretching exercises, spinal manipulations or chiropractic therapy, traction, acupuncture, transcutaneous electrical nerve stimulation, and biofeedback; (ii)&#160;oral pharmaceutical therapies such as NSAIDs, muscle relaxants, opiates, antidepressants, and anticonvulsants; and (iii)&#160;injectable pharmaceutical therapies such as <span style="white-space:nowrap">off-label</span> use of ESIs or nerve blocks. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ESIs for various back pain syndromes are one of the most common procedures performed in the United States and lumbosacral radicular ESI procedures represent 88% of total ESI procedures. ESIs are used when a patient&#8217;s pain is inadequately controlled with oral pain medications, topical systems or interventions such as physical therapy. ESIs have demonstrated efficacy in reducing pain, restoring function, reducing the need for other health care and avoiding back surgery. However, in addition to not being <span style="white-space:nowrap">FDA-approved</span> for the treatment of lumbosacral radicular pain, currently-used ESIs also present various risks and challenges. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When administering an ESI, many physicians use a particulate steroid (including methylprednisolone acetate, triamcinolone acetonide, or betamethasone sodium phosphate or betamethasone sodium acetate) instead of a <span style="white-space:nowrap">non-particulate</span> steroid (dexamethasone sodium phosphate) because early studies suggested that the duration of pain relief was longer with the particulates and fewer repeat injections were required, even though dexamethasone is considered an otherwise potent and therapeutically beneficial therapy. Particulate in injectable products is defined as extraneous undissolved particles present in injectable solution products. An example of such particulate is precipitate of insoluble drug form, or suspended drug particle. These steroid particles or their aggregates have at least two mechanisms for neurological damage: (1)&#160;they can act as emboli if injected into an artery and are of sufficient size to block small terminal arterioles supplying the brain or spinal cord; and (2)&#160;several particulate steroids have an immediate and massive effect on microvascular perfusion because of formation of red blood cell aggregates. These emboli can cause rare but catastrophic neurologic injuries including stroke and spinal cord injury that can result in increased pain, severe permanent disability or death. In addition, fungal meningitis has occurred from the injection of steroids manufactured in a compounding pharmacy that did not adhere to sterility standards. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA has been evaluating serious neurologic events with ESIs since 2009, and in 2014, the FDA required a class warning on the currently <span style="white-space:nowrap">off-label</span> use of injectable corticosteroids to include information about the risk of serious neurologic events with ESIs. The warning on product labels for all injectable glucocorticoids states that the product is to be used for intramuscular or intravenous purposes only, and specifically includes a warning for serious neurologic adverse reactions with epidural administration. These serious neurologic events have been reported with and without use of fluoroscopy. The class warning also includes a statement that safety and effectiveness of epidural administration of these corticosteroids have not been established. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain third-party payors have also provided limited coverage of ESIs to date. Based on coverage criteria established by different health care plans and certain Medicare Administrative Contractors, an ESI is considered medically necessary and therefore reimbursable only when certain specific criteria are met. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">129 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Our Solution </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are developing <span style="white-space:nowrap">SP-102</span> to address problems associated with currently available corticosteroid products that are used in practice but not approved for epidural injection or the treatment of lumbosacral radicular pain. <span style="white-space:nowrap">SP-102</span> is a Phase 3 sterile dexamethasone sodium phosphate viscous gel formulation of 10 mg dexamethasone at a 5 mg/mL concentration in a <span style="white-space:nowrap">pre-filled</span> glass syringe for delivery via an epidural injection. <span style="white-space:nowrap">SP-102</span> allows for the use of the potent dexamethasone and provides for longer residency time at the site of injection through the use of a viscous excipient in lieu of particulates. The product is also formulated without the use of preservatives and packaged in a <span style="white-space:nowrap">pre-filled</span> syringe, so as to confer greater physician convenience. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Currently-used steroids carry a class warning and are not approved to be administered epidurally for the treatment of sciatica. In fact, there are further warnings that the safety and efficacy of the use of these products following epidural administration has not been established. Their formulations include neurotoxic preservatives, surfactants, suspensions or particulates that carry risks of serious neurologic complications. Unlike currently-used steroids, <span style="white-space:nowrap">SP-102</span> does not contain neurotoxic preservatives, surfactants, suspensions or particulates that carry risk of serious neurologic complications, which we believe may improve safety and the extent of pain relief. By using dexamethasone sodium phosphate, the soluble form of the potent dexamethasone, we believe <span style="white-space:nowrap">SP-102</span> may substantially reduce the risk of embolic events in case of inadvertent intra-arterial administration and enable repeat injections. We expect the injectable viscous gel product, <span style="white-space:nowrap">SP-102,</span> which uses a biocompatible, biodegradable, novel excipient and is protected by multiple patents and patent applications and trade secrets, to prolong the residence time at the injection site and result in extended local activity. We believe <span style="white-space:nowrap">SP-102,</span> if successfully developed and approved, has the potential to reduce the disability related to lumbosacral radicular pain and help delay or avoid spine surgery. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If approved, <span style="white-space:nowrap">SP-102</span> could become the first <span style="white-space:nowrap">FDA-approved</span> ESI product. We believe an <span style="white-space:nowrap">FDA-approved</span> therapy for the treatment of sciatica could potentially benefit from <span style="white-space:nowrap"><span style="white-space:nowrap">first-to-market</span></span> advantage if it can be shown to reduce or delay the need for expensive and potentially risky interventions such as spinal surgery and decrease the use of opioids. <span style="white-space:nowrap">SP-102</span> benefits from our substantial intellectual property portfolio and other technical barriers to entry for potential competitors. Further, we are a party to an exclusive supply agreement for a proprietary biocompatible viscosity-enhancing excipient sodium hyaluronate in <span style="white-space:nowrap">SP-102.</span> Our complex manufacturing process, specialized equipment and <span style="white-space:nowrap">know-how</span> for sterile viscous product candidates are also key to our competitive edge. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have completed a pivotal Phase 3 Corticosteroid Lumbar Epidural Analgesia (&#8220;CLEAR&#8221;) trial, which was designed to evaluate the safety and efficacy in the proposed indication. The CLEAR clinical trial is a randomized, double-blind, placebo-controlled Phase 3 trial that enrolled 401 patients with sciatica at over 40 sites across the United States, with a primary objective to evaluate the analgesic effect on average leg pain (as measured by the Numeric Pain Rating Scale in the affected leg) following a single epidural injection of <span style="white-space:nowrap">SP-102,</span> compared to an intramuscular injection of placebo over four weeks. A full <span style="white-space:nowrap">6-month</span> data analysis was completed in February 2022 and we announced final results from the study in March 2022, which results reflect achievement of primary and secondary endpoints. We also presented the pivotal Phase 3 trial results at the American Society of Interventional Pain Physicians annual meeting in Las Vegas, Nevada in May 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Phase 3 CLEAR trial summary results, which results reflect achievement of primary and majority of secondary endpoints, are as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">SP-102</span> (SEMDEXA<sup style="font-size:75%; vertical-align:top">&#8482;</sup>), with 401 patients enrolled in the C.L.E.A.R. trial (Corticosteroid Lumbosacral Epidural Analgesia in Radiculopathy), demonstrated a rapid onset of pain relief, measured by Numeric Pain Rating Scale of average daily pain in the affected leg, with improvement against placebo over the first 4 weeks, following a single transforaminal injection, LS Mean (SEM) difference <span style="white-space:nowrap">-1.08</span> (0.17), with a <span style="white-space:nowrap">p-value</span> &lt; 0.001. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">SP-102</span> (SEMDEXA<sup style="font-size:75%; vertical-align:top">&#8482;</sup>) showed continued reduction of pain beyond one month, and the median time to open-label repeat injection was 99 days (95% CI: 78, 129 days) according to a Kaplan-</p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">130 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Meier estimation. By contrast, <span style="white-space:nowrap">off-label</span> injectable steroids typically provide pain relief for periods ranging from less than a week and up to one month, and then a repeat injection may be required. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The key secondary endpoint of Oswestry Disability Index, the gold standard for measuring degree of disability and estimating quality of life, showed a 28% improvement at 4 weeks on <span style="white-space:nowrap">SP-102</span> (SEMDEXA<sup style="font-size:75%; vertical-align:top">&#8482;</sup>) compared to baseline (minimal clinically meaningful improvement <span style="white-space:nowrap">8%-12%)15.</span> The LS Mean (SEM) difference as compared to placebo was <span style="white-space:nowrap">-6.28</span> (1.49), with a <span style="white-space:nowrap">p-value</span> &lt; 0.001. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">There were no adverse events (&#8220;AEs&#8221;) of special interest reported, such as paraplegia, hematoma, or infection at the injection site, which are associated with the <span style="white-space:nowrap">off-label</span> use of <span style="white-space:nowrap">non-approved</span> injectable steroid preparations. Of the 354 patients receiving at least a single injection of <span style="white-space:nowrap">SP-102,</span> there were 125 (35.3%) patients experiencing treatment emergent adverse events (&#8220;TEAEs&#8221;), with 32 (9.0%) patients experiencing treatment-related AEs, 16 (4.5%) patients experiencing medication-related AEs, 23 (6.5%) patients experiencing procedure-related AEs, four (1.1%) patients experiencing serious AEs, and one (0.3%) patient experiencing AEs related to early withdrawal. Of the 47 patients only receiving a single placebo injection (and no repeat injection of <span style="white-space:nowrap">SP-102),</span> there were 14 (29.8%) patients experiencing TEAEs with (i)&#160;two (4.3%) patients experiencing treatment-related AEs, (ii)&#160;two (4.3%) patients experiencing medication-related AEs, (iii)&#160;one (2.1%) patient experiencing procedure-related AEs, (iv)&#160;one (2.1%) patient experiencing serious AEs, (v)&#160;one (2.1%) patient experiencing AEs related to early withdrawal, and (vi)&#160;one (2.1%) patient death. TEAEs occurring in &#8805; two percent of patients were headache <span style="white-space:nowrap">(SP-102:</span> 13 (6.4%), 17 events; placebo: 11 (5.5%), 11 events), injection site pain <span style="white-space:nowrap">(SP-102:</span> 4 (2.0%), four events; placebo: zero (0.0%), 0 events), upper respiratory tract infection <span style="white-space:nowrap">(SP-102:</span> two (1.0%), 2 events; placebo: four (2.0%) events), sinusitis <span style="white-space:nowrap">(SP-102:</span> 4 (2.0%), four events; placebo zero (0.0%), 0 events) and hypertension <span style="white-space:nowrap">(SP-102:</span> four (2.0%), four events; placebo: one (0.5%), two events). The C.L.E.A.R trial also established the safety of repeat injections, as patients who experienced <span style="white-space:nowrap"><span style="white-space:nowrap">moderate-to-severe</span></span> radicular pain between 4 and 23 weeks were allowed to receive open-label additional <span style="white-space:nowrap">SP-102</span> (SEMDEXA<sup style="font-size:75%; vertical-align:top">&#8482;</sup>) injection. The safety analysis was comparable between treatment groups through 4, 12 and 24 weeks of study period. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Phase 3 <span style="white-space:nowrap">SP-102</span> C.L.E.A.R Trial&#8212;Primary Endpoint </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g759370g00a05.jpg" alt="LOGO"/>
 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">131 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g759370g00a06.jpg" alt="LOGO"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">SP-103</span> (lidocaine topical system) 5.4% </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are developing <span style="white-space:nowrap">SP-103</span> to be a triple-strength, <span style="white-space:nowrap">non-aqueous</span> lidocaine topical system for the treatment of chronic neck pain. <span style="white-space:nowrap">SP-103</span> leverages the same adhesive drug delivery formulation and manufacturing as ZTlido along with comparable backing material, perforated release liner and container-closure system. The increase in drug load is offset by a corresponding decrease in the adhesive diluent. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to our Phase 2 trial in acute LBP using <span style="white-space:nowrap">SP-103,</span> we recently completed an investigator-initiated research study at Johns Hopkins University in the second half of 2023, investigating ZTlido in patients with chronic <span style="white-space:nowrap">non-radicular</span> neck pain. Both studies were the same size, enrolling 76 subjects and provided important insight for potential Phase 3 planning for <span style="white-space:nowrap">SP-103.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While the Phase 2 trial in acute LBP had demonstrated an effect in a subpopulation of patients who had acute LBP associated with more severe muscle spasms, the investigator-initiated randomized, crossover, placebo-controlled trial showed substantial reduction of average daily pain in general population of patients with chronic <span style="white-space:nowrap">non-radicular</span> neck pain following the application of ZTlido. We believe that the application of one <span style="white-space:nowrap">SP-103</span> patch (which is three times stronger than ZTlido) in the area of neck pain has the potential for better and more reliable pain relief due to greater drug load and skin penetration. We therefore plan to prioritize further potential development of <span style="white-space:nowrap">SP-103</span> for the treatment of chronic <span style="white-space:nowrap">non-radicular</span> neck pain as an initial indication for product registration. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given that lidocaine patches are frequently used for other types of neuropathic and musculoskeletal nociceptive pain, we anticipate frequent use of <span style="white-space:nowrap">SP-103</span> for these conditions. We may pursue other indications for <span style="white-space:nowrap">SP-103</span> beyond chronic <span style="white-space:nowrap">non-radicular</span> neck pain in the future, including the neuropathic pain market and acute and chronic LBP market, summaries of which are further discussed below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Chronic Neck Pain Market Overview </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neck pain, or cervicalgia, is one of the most common pain presentations in U.S. and the fourth leading cause of disability. Approximately 52.9&#160;million adults suffer from chronic neck pain in the United States. The prevalence rate of neck pain is estimated at more than 20% of the U.S. adult population. Neck pain was responsible for job absences among 25.5&#160;million Americans, who missed an average of 11.4 days of work per year. According to a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">132 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
2020 Journal of the American Medical Association article, the low back and neck pain market is estimated to be approximately a $134.5&#160;billion market. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Chronic Neck Pain: Current Treatment Landscape and Limitations of Existing Treatments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no one definitive treatment or standard of care for the treatment of chronic neck pain. The majority of patients with neck pain are treated <span style="white-space:nowrap">non-operatively,</span> often with alternative treatments, including such treatments as acupuncture, homeopathy, and massage. Nonsteroidal anti-inflammatory drugs (&#8220;NSAIDs&#8221;) alleviate pain by reducing inflammation and are the standard of care for pharmacological therapy for neck pain. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are currently no competitors on the market or in development that would compete directly with <span style="white-space:nowrap">SP-103</span> in the chronic neck pain treatment market. We believe that <span style="white-space:nowrap">SP-103</span> has the potential to be the first and only product indicated for the treatment of neck pain. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Our Solution </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our triple-strength <span style="white-space:nowrap">SP-103</span> is an investigational, <span style="white-space:nowrap">non-aqueous</span> lidocaine topical system undergoing clinical development in chronic neck pain. If approved, we believe that <span style="white-space:nowrap">SP-103</span> could become the lidocaine topical product for chronic neck pain indications. All current uses of topical lidocaine products for chronic neck pain are <span style="white-space:nowrap">off-label.</span> This program builds on the learning from ZTlido because both products share the same superior adhesion and superior drug delivery formulation and manufacturing technology. We are developing <span style="white-space:nowrap">SP-103</span> to deliver a dose of lidocaine that is at least three times higher than any approved lidocaine topical products (including the approved ZTlido, which has a drug load of 36 mg lidocaine). We manufacture <span style="white-space:nowrap">SP-103</span> to have a drug load of 108 mg lidocaine in a similar superior adhesion as ZTlido, along with comparable backing material, perforated release liner and container-closure system. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-103</span> has demonstrated delivery of three times the level of drug of ZTlido, and consequently delivers three times the level of drug of Lidoderm and associated generics by extrapolation. <span style="white-space:nowrap">SP-103</span> has been granted fast track designation by the FDA in LBP. We believe <span style="white-space:nowrap">SP-103,</span> if successfully developed and approved, may be able to address the limitations of prescription lidocaine patches in treating chronic neck pain by delivering a higher dose of lidocaine to the application site, but with systemic exposure of the drug remaining well below established safety thresholds. <span style="white-space:nowrap">SP-103</span> has three times the drug load of ZTlido (108 mg versus 36 mg) in the adhesive system and can potentially deliver three times the level of the drug within a targeted area, with the convenience of a single topical system. This level of dosage for <span style="white-space:nowrap">SP-103</span> is comparable to the maximum approved daily dosage of ZTlido, or three topical systems for up to 12 hours during a <span style="white-space:nowrap">24-hour</span> period. By contrast, delivering higher levels of drug with other lidocaine patches is encumbered by the underlying hydrogel technology that constrains the level of drug that can be loaded into the adhesive of those products. The level of drug product in such patches can be increased only with a thicker adhesive layer, which can result in a loss of adhesion performance and flexibility. Further, increasing product dimensions can allow delivery of the drug over a larger area, but does not increase drug delivery to a localized area under the topical system. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe the chronic neck pain market presents an attractive commercial opportunity due to the large patient population, lack of any approved drugs and high level of unmet medical need. We believe developing and commercializing a topical <span style="white-space:nowrap">non-opioid</span> product targeting this segment of the pain population represents a commercially attractive strategy. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Potential Additional Markets </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Neuropathic Pain Market Overview </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neuropathic pain is triggered as a consequence of a disease or lesion to the somatosensory nervous system, altering its structure and function. It is maladaptive, meaning that the pain can be felt in the absence of a stimulus, and responses to innocuous and noxious stimuli are pathologically amplified. Neuropathic pain affects around <span style="white-space:nowrap">7-10%</span> of the general population. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">133 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Common causes of the condition include postsurgical and post-traumatic nerve damage or nerve pressure, vascular malformations, alcoholism, metabolic diseases such as diabetes, cancer, viral infections, and neurological diseases such as multiple sclerosis. Chronic neuropathic pain may also be associated with an underlying condition such as diabetic neuropathy or cancer, and with treatments such as chemotherapy. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neuropathic pain often manifests as a burning sensation, with the affected regions becoming sensitive to even a slight touch. The symptoms of neuropathic pain include burning and sensations of electric shock, sleep disturbance, depression and anxiety, numbness, pins and needles, and difficulty in sensing temperatures. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Neuropathic Pain: Current Treatment Landscape and Limitations of Existing Treatments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Recommended first-line treatment for the relief of neuropathic pain associated with PHN includes topical lidocaine, gabapentinoids (which have been associated with the potential for abuse as well as numerous adverse events), antidepressants and a multi-modal approach. Topical lidocaine and gabapentinoids are preferred for combination therapies due to their low propensity for <span style="white-space:nowrap"><span style="white-space:nowrap">drug-to-drug</span></span> interactions. For example, an eight-week combination use with pregabalin (Lyrica) has been proven to reduce pain in half for patients who had inadequate relief on monotherapy, despite titration of pregabalin to effect. This efficacy boost was achieved without tolerability issues or adding to side effects. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">According to the Centers for Disease Control and Prevention, over 75% of the 100,306 drug overdose deaths during the <span style="white-space:nowrap">12-month</span> period ending in April 2021 involved opioids. Similarly, tricyclic antidepressants, which can be effective in managing the neuropathic pain associated with PHN, can result in significant systemic side effects and cardiotoxicity, posing risks to the elderly and patients with heart disease, epilepsy or glaucoma. These side effects make topical lidocaine products an attractive first-line treatment option from a safety perspective. The safety of lidocaine patches is well supported in medical literature. Unlike transdermal medications that are designed to achieve systemic drug levels via absorption through the skin or mucosal membrane, leading to effects away from the application site, topical lidocaine has a local effect at the site of application. Because drug application is localized to the immediate area surrounding the patch, systemic absorption from a topical patch is low, reducing the risk of systemic side effects and lowering the potential for drug interactions relative to other systemic pharmacologic therapies. Due to the low systemic exposure and minimal systemic side effects reported in clinical trials, we believe a topical lidocaine patch is well suited for patients being treated with multiple medications or at a higher risk of side effects, including the elderly or those with chronic conditions. As a localized treatment, lidocaine patches have been used concomitantly with other medications in patients for whom monotherapy is inadequate. Furthermore, we believe medication administered topically rather than orally can improve patient compliance. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While lidocaine patches have certain advantages over the treatment alternatives discussed above, certain patches have limitations that may impact efficacy. For example, poor adhesion of the patch is a leading problem for topical lidocaine patches cited in the FDA Adverse Event Reporting System (&#8220;FAERS&#8221;). Because the drug is incorporated in the adhesive for these products, patches must maintain adhesion or risk compromising the ability to deliver their full drug dose. As a result, establishing strong adhesion is a key factor for patient compliance and satisfaction. In draft guidance issued in July 2021, the FDA recommended that developers of topical and transdermal delivery systems (&#8220;TDSs&#8221;) conduct studies to characterize the adhesion performance of the product with suggested data requirements. Likewise, the FDA issued draft guidance in October 2018 outlining the adhesion data requirements for generic TDSs. This guidance, along with Scilex&#8217;s past experience with regulatory agencies, shows the FDA&#8217;s interest and the importance of adhesion performance of these products. Since <span style="white-space:nowrap">SP-103</span> uses the same technology as ZTlido, we anticipate that <span style="white-space:nowrap">SP-103</span> will have similar superior adhesive properties. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Acute&#160;&amp; Chronic LBP Market Overview </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The safe and effective treatment of acute and chronic LBP addresses a high unmet need and creates large market opportunities. LBP affects about 70% of people in resource-rich countries at some point in their lives. Acute and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">134 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
chronic LBP can be self-limiting, however. One year after an initial episode, as many as 33% of people still have moderate intensity pain and 15% have severe pain. Acute LBP has a high recurrence rate with 75% of those with a first episode having a recurrence. Although acute episodes may resolve completely, they may increase in severity and duration over time. Americans spent approximately $134.5&#160;billion in 2016 on treating LBP and neck pain, which was the highest expenditure among 154 conditions studied by the Department of Institute for Health Metrics and Evaluation at the University of Washington. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Acute&#160;&amp; Chronic LBP: Current Treatment Landscape and Limitations of Existing Treatments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">According to the Centers for Disease Control and Prevention, in 2018, 28.0% of men and 31.6% of women aged 18 years old and older had lower back pain in the past three months. The percentage of women who had lower back pain increased as age increased. Among men, the percentage increased with age through age 74 years and then decreased. Women in the age groups 18&#8212;44, 45&#8212;64, and 75 years and older were more likely to have lower back pain in the past three months than were men in the same age groups, but percentages were similar between men and women in the age group <span style="white-space:nowrap">65-74</span> years. Although most patients recover quickly with minimal treatment, proper evaluation is imperative to identify rare cases of serious underlying pathology. Certain red flags should prompt aggressive treatment or referral to a spine specialist, whereas others are less concerning. Serious red flags include significant trauma related to age (i.e., injury related to a fall from a height or motor vehicle crash in a young patient, or from a minor fall or heavy lifting in a patient with osteoporosis or possible osteoporosis), major or progressive motor or sensory deficit, <span style="white-space:nowrap">new-onset</span> bowel or bladder incontinence or urinary retention, loss of anal sphincter tone, saddle anesthesia, history of cancer metastatic to bone and suspected spinal infection. Without clinical signs of serious pathology, diagnostic imaging and laboratory testing often are not required. Although there are numerous treatments for nonspecific acute LBP, most have little evidence of benefit. Patient education and medications such as nonsteroidal anti-inflammatory drugs, acetaminophen and muscle relaxants are beneficial. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">SP-104</span> (4.5mg, <span style="white-space:nowrap">low-dose</span> naltrexone hydrochloride delayed-release capsules) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are developing <span style="white-space:nowrap">SP-104</span> for the treatment of fibromyalgia. <span style="white-space:nowrap">Low-dose</span> naltrexone hydrochloride delayed-release capsules are routinely used <span style="white-space:nowrap">off-label</span> to treat fibromyalgia and other chronic pain conditions such as complex regional pain. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Fibromyalgia Market Overview </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fibromyalgia affects an estimated 10&#160;million people in the United States and an estimated 3% to 6% of the world population. While it is most prevalent in women, it also occurs in men and children of all ethnic groups. Fibromyalgia is the second most common disorder that rheumatologists encounter, seen in 15% of evaluated patients. Approximately 8% of patients cared for in primary care clinics have fibromyalgia. Prominent fibromyalgia researchers and specialists estimate the economic burden of fibromyalgia in the United States to be between $12&#160;billion to $14&#160;billion each year and the condition accounts for a loss of 1% to 2% of the national overall productivity. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Potential Complications of Fibromyalgia </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a <span style="white-space:nowrap">non-exhaustive</span> list of complications of fibromyalgia: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">extreme allodynia with high levels of distress; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">opioid or alcohol dependence; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">marked functional impairment; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">severe depression and anxiety; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">135 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obesity and physical deconditioning; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">metabolic syndrome. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although fibromyalgia is frequently grouped with arthritis-related conditions, there is no apparent inflammation or damage to the joints, muscles or other tissues. The diagnostic criteria for fibromyalgia are detailed in the chart below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g759370g00a07.jpg" alt="LOGO"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Currently approved products for pain in fibromyalgia, including duloxetine, pregabalin and milnacipran, have limited efficacy. Responders applying such products can only demonstrate a 27% to 40% reduction of symptoms, which is far below the commonly accepted threshold of 50% to prove efficacy in treating fibromyalgia. In light of this, we believe new treatments with higher efficacy are needed to improve management of fibromyalgia. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Our Solution </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-104</span> has key clinical data supporting its use in fibromyalgia. There are investigational trials that support use and development of <span style="white-space:nowrap">SP-104</span> for fibromyalgia. Currently there are no <span style="white-space:nowrap">low-dose</span> formulations (i.e., less than 5 mg) available. Physicians currently use the commercially available high-dose tablets (50 mg) and have compounding pharmacies aliquot lower doses for patients. Pharmacy-compounding is inherently inaccurate and does not involve analyses to confirm that the aliquoted product has the target level of drug, and there is no assurance as to content uniformity within a batch as well as other quality attributes critical for pharmaceutical product performance. This approach can lead to errors in dosing and challenges with titration. The commercial products and pharmacy-compounded products also allow for the immediate release of the drug in the stomach, which can lead to compliance challenges due to severe side effects. Common side effects for naltrexone include hyperalgesia, dysphoria, insomnia and anxiety. All these issues culminate into patient compliance issues and result in the eventual abandonment of an otherwise viable therapy to treat this debilitating disease. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">136 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our <span style="white-space:nowrap">SP-104</span> uses delayed burst release technology that bypasses the stomach and releases the drug in the gut (upper intestine). When taking <span style="white-space:nowrap">SP-104</span> at night before bed, peak drug levels are achieved at night during sleep, allowing the patient to avoid conscious perception of hyperalgesia and other side effects. The combination of the delayed-release and administration at night may also maximize efficacy as most endorphin/ enkephalin release is during sleep, which maximizes the product&#8217;s potential to elicit compensatory response. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are committed to developing <span style="white-space:nowrap">SP-104</span> for fibromyalgia. Phase 1 studies are designed to characterize the PK and safety profile of <span style="white-space:nowrap">SP-104,</span> and Scilex intends to initiate a Phase 2 study in 2024. If successful, we believe <span style="white-space:nowrap">SP-104</span> can become a pivotal treatment for management of fibromyalgia, which represents a large commercial opportunity with high unmet demands. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Commercialization and Market Access </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sales&#160;&amp; Marketing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have built a robust and integrated commercial infrastructure using a dedicated sales force and sales management, marketing and managed care capabilities, to maximize the potential of our two current marketed products, ZTlido and ELYXYB, and our <span style="white-space:nowrap">FDA-approved</span> product (which we expect to launch in the first half of 2024), GLOPERBA, and to commercialize our product candidates, if approved. We are focused on achieving accelerated sales growth and increased market uptake for ZTlido in the topical lidocaine product market, where we believe we have the only actively promoted product, and ELYXYB in the migraine market. Our dedicated sales force of approximately 65 people has broad experience in pain management and is exclusively focused on promoting ZTlido and ELYXYB. Our sales representatives leverage their established relationships to call on over 10,000 target pain specialists, neurologists, select primary care providers and palliative care physicians who Scilex believes treat the majority of PHN patients and migraine patients. We believe these same call points provide treatment for the sciatica, acute LBP, and chronic neck pain patients that could benefit from SEMDEXA and <span style="white-space:nowrap">SP-103,</span> if approved. Our sales representatives typically have over 10 years of experience in promoting a broad scope of pain management products that Scilex intends to leverage as our product candidates are commercialized. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, ZTlido had gained approximately 13.5% market share of the lidocaine patch prescription market across the territories we cover in the United States. The total prescriptions of ZTlido for the year ended December&#160;31, 2023 grew by more than 25.3% over the year ended December&#160;31, 2022, according to Symphony Healthcare&#8217;s national prescription data. Our experienced sales representatives and managers are supported by our marketing team, whose members have successfully launched over 20 products with large pharmaceutical, biotechnology and specialty pharmaceutical companies. Our marketing team has developed a multi-channel marketing strategy to promote the continued uptake of ZTlido by highlighting its significantly improved adhesion and continuous pain relief throughout the <span style="white-space:nowrap">12-hour</span> administration period. We are also promoting ZTlido with a marketing campaign that engages patients seeking relief for neuropathic pain associated with PHN through social media and medical and consumer journals. Further, our marketing function is supported by an experienced analytics team that leverages its experience in forecasting and analytics to draw insights from healthcare databases to inform our marketing strategy. As part of our broader commercial strategy, our marketing analytics team is conducting market research to support the launch of <span style="white-space:nowrap">SP-102,</span> <span style="white-space:nowrap">SP-103</span> and <span style="white-space:nowrap">SP-104,</span> if any of these candidates is approved. We believe that our sales force, supporting commercial infrastructure and established relationships with our targeted physician audience will provide a strategic advantage in pursuing potential partnerships to commercialize other <span style="white-space:nowrap">non-opioid</span> pain management therapeutics. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Market Access </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have established a patient-centric market access function with robust capabilities across the market access continuum, including payor sales, contracting and marketing strategies, supplemental patient assistance programs and responsible drug pricing to support patients&#8217; access to ZTlido. Our team of managed healthcare account </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">137 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
executives has demonstrated experience in establishing products on formularies and have currently prioritized and targeted select payor accounts representing approximately 275&#160;million of the over 300&#160;million lives, with the remaining 25&#160;million to be considered in the future. Currently, ZTlido is covered for over 200&#160;million lives in the United States and coverage continues to improve. As of January 2023, we have secured coverage for ZTlido on CVS Caremark/Aetna Commercial, Cigna HealthCare (commercial and Medicare plans), Express Scripts (commercial and most Medicare plans), United Healthcare Commercial, Optum Rx Select Commercial, Anthem BCBS, BCBS Louisiana and Kansas, Lifetime/Excellus BCBS, MedImpact, CareFirst, Elixir Commercial and Medicaid in California, Florida, Idaho, and North Dakota. We continue to negotiate coverage with large payors and pharmacy benefit managers in all books of business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">ZTlido Formulary Coverage&#8212;Over 90% of Lives Covered or In Negotiation </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g759370g00a08.jpg" alt="LOGO"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We utilize an outside vendor to administer a patient assistance program directed at patients with commercial insurance or those paying <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket.</span></span> With the <span style="white-space:nowrap">co-pay</span> assistance program, qualifying patients do not have to pay any <span style="white-space:nowrap">co-payment</span> for their ZTlido prescription. We utilize an external vendor and train the sales force to work proactively with clinician office managers in completing required forms for prior authorization for ZTlido. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Clinical Development Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ZTlido </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Clinical Trial Highlights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have evaluated ZTlido in over 600 subjects in clinical trials to support marketing approval and promotional campaigns for the relief of neuropathic pain associated with PHN in the United States. Our studies sought to investigate the bioequivalence of ZTlido compared to Lidoderm, adhesion performance and the dermal safety and tolerability of ZTlido under a range of application times and settings. Based on these studies, we concluded that ZTlido: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">demonstrated bioequivalence to Lidoderm in study <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-PK-002A;</span></span></span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">showed greater than or equal to 90% adhesion in over 90% of the subjects at the end of the <span style="white-space:nowrap">12-hour</span> administration period in study <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-ADH-001;</span></span></span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">showed superior adhesion to Lidoderm and Mylan&#8217;s generic lidocaine patch in studies <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-AHD-002</span></span></span> and <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-ADH-003;</span></span></span> </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">138 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">was not meaningfully impacted by heat or exercise in study <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-HEX-001;</span></span></span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">was able to be used under showering and bathing conditions in study <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-ADH-004;</span></span></span> and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">did not show clinically meaningful dermal irritation in study <span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-DERM-001.</span></span> </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">ZTlido Study Details </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Pivotal Bioequivalence Study </span>- <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-PK-002A</span></span></span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted a comparative single-dose PK study between ZTlido and Lidoderm designed as a <span style="white-space:nowrap">two-way</span> cross-over in 54 healthy subjects. In this trial design, each subject received a single dose of three ZTlido or three Lidoderm patches followed by a washout period and the administration of the other product. The purpose of this study was to establish bioequivalence between the products, which was determined by the statistical comparability of Cmax and AUC as shown in the figure below. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This was considered the pivotal clinical trial for ZTlido, as it provided the pharmaceutical bridge between the two products and showed that ZTlido had comparable safety and efficacy to Lidoderm. As a result of successfully establishing the pharmaceutical bridge, no stand-alone clinical efficacy studies were required by the FDA to determine ZTlido&#8217;s analgesic effects for ZTlido&#8217;s approval. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Mean Lidocaine Plasma Concentration Time Profiles&#8212;Semilog Scale </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g759370g00a09.jpg" alt="LOGO"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Pivotal Adhesion Study</span><span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">&#8212;SCI-LIDO-ADH-001</span></span></span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted an open-label, single-treatment, single-period, single-application adhesion performance study in 54 healthy, human subjects to assess the adhesion performance of ZTlido over the <span style="white-space:nowrap">12-hour</span> administration period of the product. The study also investigated whether ZTlido met an FDA established adhesion performance benchmark of greater than or equal to 90% adhesion in greater than or equal to 90% of subjects in the study at the end of the administration period. At the end of the <span style="white-space:nowrap">12-hour</span> administration period, over 90% of the subjects (49 out of the 54 subjects) maintained greater than or equal to 90% adhesion, with no adverse events reported during the study. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">139 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">ZTlido Maintained Greater Than 90% Adhesion Over the <span style="white-space:nowrap">12-Hour</span> Time Period </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g759370g00a10.jpg" alt="LOGO"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This study was considered the pivotal adhesion study for marketing approval and is summarized in the product label. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap"><span style="white-space:nowrap">Head-to-Head</span></span> Adhesion Study versus Lidoderm</span><span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">&#8212;SCI-LIDO-ADH-002</span></span></span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted an open label, single-treatment, three-period, single-application adhesion performance study in 44 healthy, human subjects to evaluate the adhesion performance of ZTlido compared to the adhesion performance of Lidoderm over a <span style="white-space:nowrap">12-hour</span> administration period. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this study, ZTlido demonstrated significantly superior mean adhesion scores compared to Lidoderm at 3, 5, 9 and 12 hours after application. ZTlido maintained a mean percent adhesion performance greater than 90% over the <span style="white-space:nowrap">12-hour</span> administration period, while Lidoderm fell below 90% mean adhesion within three hours. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">140 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">ZTlido Demonstrated Superior Adhesion Compared to Lidoderm </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g759370g00a11.jpg" alt="LOGO"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap"><span style="white-space:nowrap">Head-to-Head</span></span> Adhesion Study versus Mylan&#8217;s Generic</span><span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">&#8212;SCI-LIDO-ADH-003</span></span></span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted an open-label, single-treatment, <span style="white-space:nowrap">two-period,</span> single-application adhesion performance study in 24 healthy, human subjects to evaluate the adhesion performance of ZTlido compared to the adhesion performance of a generic lidocaine patch 5% manufactured by Mylan over a <span style="white-space:nowrap">12-hour</span> administration period. The purpose of this study was to compare the adhesion performance of ZTlido against a topical lidocaine product involving a <span style="white-space:nowrap">non-aqueous</span> formulation. We selected Mylan&#8217;s generic lidocaine patch as a comparator because it has similar product characteristics, including a <span style="white-space:nowrap">non-aqueous</span> polymer <span style="white-space:nowrap"><span style="white-space:nowrap">drug-in-adhesive</span></span> system allowing for a thinner patch and a lower drug load as compared to Lidoderm. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this study, ZTlido demonstrated significantly superior adhesion performance compared to Mylan&#8217;s generic lidocaine patch. ZTlido maintained a mean adhesion greater than 90% over the <span style="white-space:nowrap">12-hour</span> administration period, while the generic product had a mean adhesion score of only 80% immediately after application, which declined to a mean adhesion score of 27% at 12 hours after application. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">141 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">ZTlido Demonstrated Superior Adhesion Compared to Mylan&#8217;s Generic Lidocaine Patch </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g759370g00a12.jpg" alt="LOGO"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">PK and Adhesion Study under Exercise and Heat Conditions</span><span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">&#8212;SCI-LIDO-HEX-001</span></span></span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted an open-label, randomized, three-treatment, three-sequence, three-period, cross-over, PK and adhesion performance study of three ZTlido topical systems applied to separate areas in 12 healthy, human subjects during physical exercise, exposure to heat and under normal conditions, respectively. The three treatment periods were as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Treatment A sought to assess the PK and adhesion performance of ZTlido under physical exercise conditions. In this treatment period, subjects were instructed to perform exercise for 30 minutes on a stationary bike achieving a heart rate of 108 beats per minute, with continuous heart monitoring during exercise. Subjects were instructed to perform exercise immediately after the application of the topical system and at 2.5, 5.5 and 8.5 hours following the application of the topical system. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Treatment B sought to assess the PK and adhesion performance of ZTlido under heat conditions. In this treatment period, a heating pad adjusted to the medium setting was applied for 20 minutes immediately after application of the topical system and at 8.5 hours following the application of the topical system. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Treatment C sought to assess the PK and adhesion performance of ZTlido under normal conditions. In this treatment period, topical systems were applied to the <span style="white-space:nowrap">mid-lower</span> back and worn for 12 hours. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In treatment A, adhesion and PK performance were not compromised by exercise, as reflected in the product label. In treatment B, heat had an effect on PK but had no effect on adhesion. In Treatment C, normal PKs were observed and greater than 90% of subjects showed greater than 90% adhesion. No meaningful irritation was observed across all treatments across all time points in any of the subjects. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">142 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The impact of heat and exercise on PK is presented in the figure below. It was observed that heat had an effect on Cmax, but the drug returned to normal levels after removal of heat and there was no clinically meaningful observed effect on AUC. Heat did not appear to have a deleterious or catastrophic effect on topical system performance, either as a dose-dump (i.e., immediate and complete release of all drug from the product), or as reduced drug delivery (i.e., much lower systemic exposure). There was no significant effect on PK observed with exercise when compared to subjects under normal conditions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">ZTlido Demonstrated Consistent* PK Performance under Exercise and Heat Conditions </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g759370g00a13.jpg" alt="LOGO"/>
 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Defined as no clinically meaningful changes by meeting bioequivalence criteria </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Dermal Sensitization and Irritation Study</span><span style="white-space:nowrap"><span style="white-space:nowrap">&#8212;SCI-LIDO-DERM-001</span></span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted a provocative dermal sensitization and irritation human clinical trial, also referred to as a repeat insult topical system test, intended to elicit the worst-case dermal safety of ZTlido by extended wearing of the product over multiple days. In this trial, we compared the sensitization potential, and the overall irritation profiles of ZTlido and Lidoderm in 218 normal and healthy subjects. We used a <span style="white-space:nowrap">7-point</span> scale where a score of 0 indicated no irritation and a score of 7 was considered a strong reaction spreading beyond the application site. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this study, results showed that the adhesion quality of ZTlido did not compromise dermal safety. The study reported that ZTlido did not show potential for dermal sensitization and showed an overall benign irritation profile. Both ZTlido and Lidoderm had a mean irritation score well below 1, which is defined as barely perceptible erythema. This study allowed for the ZTlido label to adopt the same local tolerance language as labeled for Lidoderm. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Photoallergy and Phototoxicity Studies</span><span style="white-space:nowrap"><span style="white-space:nowrap">&#8212;SCI-LIDO-PHOT0-001</span></span> and <span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-PHOTO-002</span></span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted a <span style="white-space:nowrap">6-week</span> randomized study, <span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-PHOTO-001,</span></span> to evaluate the potential of ZTlido and its comparator, Lidoderm, to induce a photoallergic skin reaction in 54 healthy volunteers. In this study, we observed that ZTlido was not photoallergic. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">143 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted a <span style="white-space:nowrap">4-day,</span> randomized study, <span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-PHOTO-002,</span></span> to evaluate the irritation potential of ZTlido and its comparator, Lidoderm, when application to skin is followed by light exposure in 32 healthy volunteers, using a phototoxicity patch test. In this study, we observed that ZTlido was not phototoxic. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Post-Approval Studies for ZTlido </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Water Stress Study (Shower and Swimming)</span><span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">&#8212;SCI-LIDO-ADH-004</span></span></span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted a single-dose study in 24 subjects to examine the adhesion and lidocaine delivery (PK) of ZTlido when it is exposed to two separate water stress conditions of (1)&#160;showering (10 minutes) and (2)&#160;swimming (15&#160;minutes). The study showed that while some degree of product lifting was observed, the product could be pressed back down or reattached with no further diminished adhesion performance or drug delivery. This study led to a change in the product label indicating that patients may use the product while showering or bathing. This provides significant patient convenience as Lidoderm and the associated generics are labeled to avoid contact with water such as bathing, swimming or showering, as these products may not stick if they get wet. With ZTlido, patients can engage in these activities within the <span style="white-space:nowrap">12-hour</span> administration period. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Investigator-Sponsored Studies </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to support several investigator-initiated research studies to evaluate the clinical benefits of using ZTlido in patients with carpal tunnel syndrome, neck pain, intercostal neuralgia and other possible indications. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">SP-102</span> (SEMDEXA) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have completed a Phase 3 pivotal study of <span style="white-space:nowrap">SP-102.</span> The Corticosteroid Lumbar Epidural Analgesia for Radiculopathy (&#8220;CLEAR&#8221;) study is a randomized, double-blind, placebo-controlled Phase 3 trial that enrolled 401 patients with sciatica to compare the epidural administration of <span style="white-space:nowrap">SP-102</span> to placebo. We announced final results from this study in March 2022. We also presented the pivotal Phase 3 trial results at the American Society of Interventional Pain Physicians annual meeting in Las Vegas, Nevada in May 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Clinical Trial Highlights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-102</span> has been evaluated in a number of preclinical studies and clinical trials as a potential treatment for sciatica. Key findings from the preclinical studies and clinical trials include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Repeat injections of <span style="white-space:nowrap">SP-102</span> showed continued pain reduction with no unexpected adverse events based on preliminary results from the <span style="white-space:nowrap"><span style="white-space:nowrap">SP-102-03</span></span> study; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">SP-102</span> showed an extended local activity with epidural administration in the <span style="white-space:nowrap">ES-1504</span> study; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">SP-102</span> showed an extended residence time and tolerability in the 1014-1512 and the 1014-2847, preclinical studies; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The introduction of <span style="white-space:nowrap">SP-102</span> into blood vessels did not result in neurological complications in the UPD003-IS21 preclinical toxicology study. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap">SP-102</span> (SEMDEXA) Study Details Phase 3 Pivotal Clinical Trial&#8212;CLEAR </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have completed a pivotal, randomized, double-blind, placebo-controlled Phase 3 trial, CLEAR, that enrolled 401 patients with sciatica at over 40 sites across the United States. The study included an open-label extension where subjects were followed for up to 24 weeks after treatment to evaluate the safety of administering <span style="white-space:nowrap">SP-102</span> in a larger patient population. After week 4, subjects who met certain pain criteria received open-label <span style="white-space:nowrap">SP-102</span> to investigate the safety of repeat injections and the duration of pain relief following injection. This well-controlled, randomized trial was designed to demonstrate evidence of the analgesic effect and safety of <span style="white-space:nowrap">SP-102.</span> The schematic of this Phase 3 trial is demonstrated in the flowchart below. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">144 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary objective of this study was to evaluate the analgesic effect of <span style="white-space:nowrap">SP-102</span> on average leg pain, measured using the Numeric Pain Rating Scale (&#8220;NPRS&#8221;) following a single transforaminal injection. These results were compared to an intra-muscular injection of placebo over a four-week period. The secondary objectives of this study include (i)&#160;evaluation of the degree of disability over time as measured by the Oswestry Disability Index; (ii)&#160;characterization of the change of the subject&#8217;s radiculopathy symptoms and overall condition, using a combination of PainDETECT, modified Brief Pain Inventory, Clinical Global Impression of Change, and Patient Global Impression of Change and (iii)&#160;evaluation of the safety of a single and repeat <span style="white-space:nowrap">SP-</span> 102 injections. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Schematic of <span style="white-space:nowrap">CLEAR&#8212;SP-102</span> (SEMDEXA) Phase 3 Pivotal Trial </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g759370g00a14.jpg" alt="LOGO"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Enrollment was completed in the second half of 2021. We announced final data from this study in March 2022. The Pivot Phase 3 trial has met the primary efficacy and key secondary efficacy endpoints: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">For the primary endpoint of change in average daily pain (as measured by the Numeric Pain Rating Scale) in the affected leg over four weeks following the initial injection, the LS Mean (SE) group difference of <span style="white-space:nowrap">-1.08</span> (0.17) compared to placebo with a <span style="white-space:nowrap">p-value</span> less than 0.001. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The two key secondary endpoints assessing Oswestry Disability Index (&#8220;ODI&#8221;) and Time to open label repeat injection have been demonstrated for <span style="white-space:nowrap">SP-102.</span> The LS Mean (SE) group difference in ODI compared to placebo at week 4 was <span style="white-space:nowrap">-6.28</span> (1.49) with a <span style="white-space:nowrap">p-value</span> less than 0.001. A Cox proportional hazard model showed significantly longer duration of initial <span style="white-space:nowrap">SP-102</span> (SEMDEXA) treatment compared to placebo Hazard Ratio (95% CI) 0.49 (0.36, 0.65), with a <span style="white-space:nowrap">p-value</span> less than 0.001. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Phase 2 Repeat Dose Study</span><span style="white-space:nowrap"><span style="white-space:nowrap">&#8212;SP-102-03</span></span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted an open-label, <span style="white-space:nowrap">single-arm,</span> pharmacodynamics (&#8220;PD&#8221;) and safety study of repeat epidural injections of <span style="white-space:nowrap">SP-102</span> in patients with sciatica. We conducted this study to characterize repeat dose PD with respect to hypothalamic-pituitary-adrenal suppression using plasma cortisol levels, white blood cell count and blood glucose levels. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The study enrolled 19 subjects, of which 15 received repeat <span style="white-space:nowrap">SP-102</span> epidural injections 4 to 8 weeks after the initial injection. Four of the subjects did not experience recurrent pain and thus did not require a repeat injection. The daily average, current and worst pain in the affected leg and back showed continuous reduction throughout the <span style="white-space:nowrap">28-day</span> observation period for both treatments. Based on a preliminary review of the results, <span style="white-space:nowrap">SP-102</span> injections were generally well tolerated and there were no new unexpected adverse events observed. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">145 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Mean Percentage Change in Sciatica-Related Leg Pain as Measured by NPRS </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g759370g00a15.jpg" alt="LOGO"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Phase 1 Trial of <span style="white-space:nowrap">SP-102</span> (SEMDEXA) Compared to Reference Listed Drug</span><span style="white-space:nowrap">&#8212;ES-1504</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted an open-label, <span style="white-space:nowrap">single-arm,</span> <span style="white-space:nowrap">two-period,</span> fixed sequential-dose study to evaluate the PK, PD and safety of <span style="white-space:nowrap">SP-102</span> when administered by epidural injection. <span style="white-space:nowrap">SP-102</span> was compared to intravenous dexamethasone sodium phosphate injection in subjects with lumbosacral radiculopathy. There were 12 subjects enrolled in this study, all of whom received <span style="white-space:nowrap">SP-102</span> followed by the intravenous dexamethasone sodium phosphate injection (Reference Listed Drug (&#8220;RLD&#8221;)) administered one month later. A RLD is an approved drug product to which new versions are compared to show that they are bioequivalent. The purpose of this study was to establish the pharmaceutical bridge between <span style="white-space:nowrap">SP-102</span> and the RLD. The Tmax observed with the administration of <span style="white-space:nowrap">SP-102</span> was four hours, compared to 15 minutes observed with intravenous dexamethasone. The PD parameters and safety results of both products were similar, and <span style="white-space:nowrap">SP-102</span> did not prolong cortisol suppression time. <span style="white-space:nowrap">SP-102</span> also maintained analgesic effects throughout a <span style="white-space:nowrap">one-month</span> observation period. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The overall systemic exposure of dexamethasone was similar, whether administered as <span style="white-space:nowrap">SP-102</span> or injected intravenously, with a mean AUCinf of 0.916 <span style="FONT-FAMILY:SYMBOL">m</span>g*h/mL (observed with <span style="white-space:nowrap">SP-102)</span> compared to 0.943 <span style="FONT-FAMILY:SYMBOL">m</span>g*h/mL (observed with intravenously-administered dexamethasone). Notably, there was a <span style="white-space:nowrap">16-</span> fold increase in the time to maximum serum concentration (&#8220;Tmax&#8221;) following epidural injection of <span style="white-space:nowrap">SP-102.</span> The median Tmax was 4.00 hours for <span style="white-space:nowrap">SP-102</span> compared to 0.25 hours for the comparison group. All 12 subjects with sciatica showed continuous reduction in back and leg pain during the <span style="white-space:nowrap">one-month</span> observation period following a single epidural injection of <span style="white-space:nowrap">SP-102.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This study demonstrated that at an equivalent initial dose of dexamethasone, the systemic exposure to dexamethasone following epidural injection of <span style="white-space:nowrap">SP-102</span> did not exceed the exposure following intravenous injection of the RLD. The PD effects, measured as white blood cell count, cortisol levels and glucose levels, as well as the safety profile, were similar between the two treatments. <span style="white-space:nowrap">SP-102</span> injections were generally well tolerated and did not result in new unexpected side effects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Toxicology Studies</span>&#8212;Study Nos. 1014-1512 and 1014-2847 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted PK and toxicology studies in two <span style="white-space:nowrap">non-rodent</span> animal species to assess <span style="white-space:nowrap">SP-102</span> administered via epidural and intrathecal routes with single and multiple dose regimens. Pharmacokinetically, a prolonged increase in the active dexamethasone metabolite was consistent with the extended residence time of the viscous gel formulation of <span style="white-space:nowrap">SP-102</span> at the site of injection. There were no new unexpected toxicology findings apart from well-characterized toxicity findings commonly observed with administration of dexamethasone sodium phosphate. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">146 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Preclinical Toxicology Study</span>&#8212;UPD003-IS21 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted a preclinical toxicology study designed to simulate the accidental introduction of epidural steroids into arterial blood vessels providing blood supply to the spinal cord, which is a major cause of neurological complications associated with current administration of suspension steroids containing particulates. A 2 mL (10 mg of dexamethasone) injection of <span style="white-space:nowrap">SP-102</span> was injected over <span style="white-space:nowrap">1-2</span> minutes into the vertebral artery of large animal species. <span style="white-space:nowrap">Pre-and</span> post-dose angiography showed no remarkable changes and all animals survived for approximately 24 hours until euthanasia. The veterinary animal health report and the pathology report concluded there were no vascular, spinal cord or brain injuries associated with injection into the vertebral artery of the animals. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Hydrodynamic Study</span><span style="white-space:nowrap">&#8212;SP-PC002</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted a hydrodynamic study of <span style="white-space:nowrap">SP-102</span> in <span style="white-space:nowrap">non-rodent</span> animal species, which showed that epidural administration of <span style="white-space:nowrap">SP-102</span> demonstrated an increased local residence half-life and a decreased flow from the injection site. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Intravascular Injection Study</span><span style="white-space:nowrap">&#8212;SEM-005</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted a study to evaluate the accidental intravascular injection of <span style="white-space:nowrap">SP-102</span> into the vertebral artery of <span style="white-space:nowrap">non-rodent</span> animals. There were no adverse clinical signs associated with the accidental intra-arterial injection of <span style="white-space:nowrap">SP-102</span> following a <span style="white-space:nowrap">24-hour</span> survival period. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">SP-103</span> (lidocaine topical system) 5.4% </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-103</span> is an investigational, <span style="white-space:nowrap">non-aqueous</span> lidocaine topical system undergoing clinical development in acute LBP. As a higher strength topical lidocaine system, <span style="white-space:nowrap">SP-103</span> will build on the learnings from ZTlido because both products share the same adhesive drug delivery formulation and manufacturing technology. The clinical program involves evaluating the safety and efficacy of <span style="white-space:nowrap">SP-103</span> for the treatment of acute LBP. A Phase 1 study was completed that demonstrated bioequivalent PK between the administration of a single <span style="white-space:nowrap">SP-103</span> and the administration of three commercial ZTlido. The study also showed linear kinetics among multiple applications of <span style="white-space:nowrap">SP-103</span> (i.e., 1, 2 or 3 patches) over a <span style="white-space:nowrap">12-hour</span> administration period. Adhesion performance was assessed and found to be comparable between <span style="white-space:nowrap">SP-103</span> and ZTlido. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We received our <span style="white-space:nowrap">SP-103</span> Phase 2 <span style="white-space:nowrap">top-line</span> results in August 2023 and the trial achieved its objectives characterizing safety, tolerability and preliminary efficacy of <span style="white-space:nowrap">SP-103</span> in acute LBP associated with muscle spasms. <span style="white-space:nowrap">SP-103</span> was safe and well tolerated. Increase of lidocaine load in topical system by three times, compared with approved ZTlido, 5.4% vs. 1.8%, did not result in signs of systemic toxicity or increased application site reactions with daily applications over one month treatment. <span style="white-space:nowrap">SP-103</span> received FDA Fast Track status in LBP. We will continue to analyze the <span style="white-space:nowrap">SP-103</span> Phase 2 trial data along with an investigator study at Johns Hopkins University completed in the second half of 2023, investigating ZTlido in patients with chronic <span style="white-space:nowrap">non-radicular</span> neck pain, which also has shown promising <span style="white-space:nowrap">top-line</span> efficacy and safety results. While the phase 2 trial in acute LBP had demonstrated an effect in a subpopulation of patients who had acute LBP associated with more severe muscle spasms, the investigator-initiated randomized, crossover, placebo-controlled trial showed substantial reduction of average daily pain in general population of patients with chronic <span style="white-space:nowrap">non-radicular</span> neck pain following the application of ZTlido. We believe that the application of one <span style="white-space:nowrap">SP-103</span> patch (which is three times stronger than ZTlido) in the area of neck pain has the potential for better and more reliable pain relief due to greater drug load and skin penetration. We therefore plan to prioritize further potential development of <span style="white-space:nowrap">SP-103</span> for the treatment of chronic <span style="white-space:nowrap">non-radicular</span> neck pain as an initial indication for product registration. We are planning to initiate Phase 2/3 trials in chronic neck pain in 2024. <span style="white-space:nowrap">SP-103,</span> if approved, could become the first <span style="white-space:nowrap">FDA-approved</span> lidocaine topical product for the treatment of chronic neck pain. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">147 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">SP-104</span> (4.5mg, <span style="white-space:nowrap">low-dose</span> naltrexone hydrochloride delayed-release capsules) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Two Phase 1 trials have been completed for <span style="white-space:nowrap">SP-104</span> at investigative sites in New Zealand: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap"><span style="white-space:nowrap">SP-104-01</span></span> is a food effect and bridging PK study comparing <span style="white-space:nowrap">SP-104</span> to Naltrexone HCL Tablets conducted on approximately 18 healthy adult subjects. The study is designed to be an open-label, three-period, three-treatment, randomized study to characterize the PK and safety and tolerability of <span style="white-space:nowrap">SP-104</span> under fasting and fed conditions. Subjects are randomly administered a single dose of one of three treatments and followed for PK and safety for a period of time followed by a washout period before receiving one of the other treatments. All subjects receive all three treatments. The study characterize the single-dose clinical studies and ultimately the commercial label. The study also serves as a &#8220;pharmaceutical bridge&#8221; between <span style="white-space:nowrap">SP-104</span> and the commercial RLD (Naltrexone HCI tablets, USP 50 mg) to support the eventual Section&#160;505(b)(2) NDA. Assuming that the rate and extent of drug exposure for <span style="white-space:nowrap">SP-104</span> will be lower than that observed for the RLD, this study allows us to rely upon the FDA&#8217;s findings of safety for the RLD instead of having to perform extensive nonclinical animal safety toxicology studies and establish an extensive clinical safety database. Our development program can focus on establishing efficacy of <span style="white-space:nowrap">SP-104</span> in the treatment of fibromyalgia. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap"><span style="white-space:nowrap">SP-104-02</span></span> is a Phase 1 study of <span style="white-space:nowrap">SP-104</span> conducted on approximately 52 healthy human subjects. The study is designed to be a double-blind, randomized, <span style="white-space:nowrap">two-period,</span> <span style="white-space:nowrap">two-treatment</span> crossover study to evaluate the safety of <span style="white-space:nowrap">SP-104,</span> compared to immediate release naltrexone capsules. The primary purpose of the study is to test the hypothesis that, when taken at night, the delayed release of 4.5 mg Naltrexone mitigates against adverse events known for the drug and could affect patient compliance in maintaining treatment for their fibromyalgia. In a small (n=52) cross-over trial in healthy volunteers comparing <span style="white-space:nowrap">SP-104</span> (naltrexone hydrochloride delayed-release 4.5 mg) to naltrexone hydrochloride immediate release 4.5 mg (the &#8220;compared drug&#8221;), there were no serious adverse effects, no AEs leading to discontinuation, no meaningful differences in physical examinations, vital signs, or laboratory parameters between treatments, no severe AEs for either treatment. Of the 52 patients receiving at least a single injection of <span style="white-space:nowrap">SP-104,</span> there were 21 (40%) patients experiencing at least one TEAE, 14 (27%) patients experiencing at least one treatment-related TEAE, 12 (23%) patients experiencing at least one treatment-related TEAE within 72 hours after first administration of <span style="white-space:nowrap">SP-104.</span> Notable AEs of special interest were nausea and headache within 72 hours after first administration of <span style="white-space:nowrap">SP-104.</span> <span style="white-space:nowrap">SP-104</span> administered at night before bed resulted in a lower number of subjects with at least one AE (p = 0.0414), and an even lower number of subjects with at least one AE within 72 hours after the first administration of <span style="white-space:nowrap">SP-140</span> when compared to the compared drug. There was a lower number of subjects with AEs of special interest within 72 hours after administration of <span style="white-space:nowrap">SP-104</span> (n=9; 12 events) versus the compared drug (n=15; 20 events). Notable AEs of special interest observed within 72 hours after administration of the applicable drug are nausea <span style="white-space:nowrap">(SP-104:</span> n=0; the compared drug: n=3) and headache <span style="white-space:nowrap">(SP-104:</span> n=6; the compared drug: n=12). The study randomized subjects to one of two treatments followed by a washout period and then receipt of the other treatment, which allows all subjects to act as their own control. The study will support intellectual property, inform on clinical study design and contribute to safety characterization to support market applications. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We completed both studies in the second quarter of 2022. We plan to use data collected from these studies to support an Investigational New Drug application with the FDA, which is expected to enable further clinical development and initiation of a planned multi-center placebo-controlled registration trial in the field of fibromyalgia. The registration trial is designed to be a Phase 3, randomized double-blind, placebo-controlled, parallel group, multicenter study that meets the regulatory requirements of an &#8220;adequate and well-controlled&#8221; study to establish the efficacy of <span style="white-space:nowrap">SP-104</span> in the treatment of fibromyalgia. Depending on the outcomes, this registration trial alone may be efficient in supporting market approval of <span style="white-space:nowrap">SP-104</span> or an additional Phase 3 study may be required. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">148 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Medical Affairs </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Medical Affairs team includes <span style="white-space:nowrap">in-house</span> medical expertise, health economics and third-party payor support. The Medical Affairs team works with our clinical team to identify sites for clinical trials, support the investigator teams and develop publication plans for clinical and real-world ZTlido data and our product candidates. Our Medical Affairs team also works with Key Opinion Leaders, professional societies and patient advocacy groups to educate on and support the appropriate use of pain therapeutics, including topical pain products. Further, our Medical Affairs team provides our sales organization with therapeutic knowledge and product training. The Medical Affairs team and Promotional Review Committee review all promotional materials for scientific accuracy. The Medical Affairs team also develops lifecycle planning and works with our clinical team to determine registration or supportive studies, oversee post-approval studies and support investigator-sponsored trials. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Manufacturing and Supply Chain </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently contract with third parties for the manufacture, assembly, testing, packaging, storage and distribution of our product. Our technical team has extensive pharmaceutical development, manufacturing, analytical, quality and distribution experience and is qualified and capable of managing manufacturing and supply chain operations. Our Quality System, Standard Operating Procedures and contract manufacturing organizations (&#8220;CMOs&#8221;) comply with cGMP and regulatory requirements. We selected our CMOs for specific competencies having met our development, manufacturing, quality and the FDA regulatory requirements. These CMOs manufacture our clinical supplies and commercial batches. We currently have no plans to build our own manufacturing or distribution infrastructure. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ZTlido </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ZTlido is a single-layer, <span style="white-space:nowrap"><span style="white-space:nowrap">drug-in-adhesive</span></span> topical delivery system comprised of an adhesive material containing 36 mg lidocaine, which is applied to a pliable nonwoven cloth backing and covered with a polyethylene terephthalate film release liner. ZTlido is commercially manufactured for us by Oishi Koseido Co., Ltd. (&#8220;Oishi&#8221;) in Japan. We have exclusive worldwide rights to Oishi&#8217;s proprietary formulation and manufacturing technologies except with respect to Japan. ZTlido is manufactured using premixing and <span style="white-space:nowrap">hot-melt</span> mixing of various excipients and lidocaine, followed by cGMP compliant coating, lining, cutting and filling processes. ZTlido is packaged as a carton of 30 topical systems, into individual child-resistant envelopes. See the section of this prospectus titled &#8220;<span style="font-style:italic">Business&#8212;Material Agreements&#8212;Itochu and Oishi Product Development Agreement</span>&#8221; and &#8220;<span style="font-style:italic">Business&#8212;Material Agreements&#8212;Itochu and Oishi Commercial Supply Agreement</span>&#8221; for additional information regarding the manufacturing and supply chain of ZTlido. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once production is complete, commercial product shipments are sent to the United States, where our exclusive third-party logistics distribution provider, Cardinal Health 105, LLC (&#8220;Cardinal Health 105&#8221;), ships them to temperature-controlled customer distribution centers, which are generally able to deliver finished product to retail pharmacies on the same day, or within 24 hours. We currently contract with multiple pharmaceutical distributors throughout the United States, including McKesson Corporation (&#8220;McKesson&#8221;), Cardinal Health 110, LLC (&#8220;Cardinal Health 110&#8221;) and AmerisourceBergen Corporation (&#8220;AmerisourceBergen&#8221;). Distributors have agreements in place that provide us with access to large retail chains, including CVS, Walgreens, Rite Aid and Walmart, as well as independent pharmacies. In addition to all order fulfillment, Cardinal Health 105 performs the following services on our behalf: customer service, credit checks, invoicing, chargebacks, distributor fee for service, government reporting, customer returns, accounts receivable, inventory control, product security (DSCSA serialization) inquiries and recall assistance. In the years ended December&#160;31, 2020 and 2021 and in the first quarter of 2022, Cardinal Health 105 was our only customer and sales to Cardinal Health 105 represented all of our net revenue for such periods. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As we continue to expand the commercialization of ZTlido, we expanded our direct distribution network to national and regional distributors and pharmacies in the second quarter of 2022. We currently hold wholesaler </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">149 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
licenses and commenced selling directly to our main distributor customers as well as pharmacies from the second quarter of 2022. In April 2022, we discontinued our use of &#8220;title model&#8221; services provided by Cardinal Health 105, but expect that Cardinal Health 105 will continue to perform other third-party logistics services for us. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">SP-102</span> (SEMDEXA) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-102</span> is a Phase 3 sterile dexamethasone sodium phosphate injectable viscous gel drug product containing dexamethasone sodium phosphate equivalent to 10 mg dexamethasone in a <span style="white-space:nowrap">pre-filled</span> glass syringe with a 2 mL deliverable volume. <span style="white-space:nowrap">SP-102</span> also contains sodium hyaluronate, which is a novel, biocompatible, viscosity-enhancing excipient and is listed in the European Pharmacopeia. We have an exclusive supply agreement for sodium hyaluronate for <span style="white-space:nowrap">SP-102</span> from the manufacturer and supplier. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-102</span> is manufactured by a single-source manufacturer, which supports the clinical development, including the completed Phase 3 clinical trial of <span style="white-space:nowrap">SP-102.</span> In March 2022, we announced final results of the Phase 3 clinical trial, satisfying the primary efficacy and key secondary efficacy endpoints. The manufacturing process is proprietary and includes trade secrets. We plan to engage our existing contract manufacturer, Lifecore, for the commercial production of <span style="white-space:nowrap">SP-102,</span> if approved. We plan to use the biocompatible proprietary excipient supplied by Sanofi-Aventis U.S. LLC (&#8220;Sanofi&#8221;) sodium hyaluronate, pursuant to the Genzyme Supply Agreement, and engage Sanofi for commercial supply of dexamethasone sodium phosphate for <span style="white-space:nowrap">SP-102,</span> if approved. See the section of this prospectus titled &#8220;<span style="font-style:italic">Business - Material Agreements&#8212;Genzyme Supply Agreement</span>&#8221; and &#8220;<span style="font-style:italic">Business&#8212;Material Agreements&#8212;Lifecore Master Services Agreement</span>&#8221; for additional information regarding the manufacturing and supply of the proprietary excipient and contact manufacturing of <span style="white-space:nowrap">SP-102</span> product, respectively. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">SP-103</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-103</span> contains 5.4% lidocaine (108 mg lidocaine) and is manufactured for clinical supply by Oishi, using the same manufacturing processes as used for ZTlido. If our Phase 2 and Phase 3 trials are successful, we plan to submit the <span style="white-space:nowrap">SP-103</span> manufacturing protocols in a supplemental new drug application. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">SP-104</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are developing <span style="white-space:nowrap">SP-104,</span> a novel <span style="white-space:nowrap">low-dose,</span> naltrexone hydrochloride delayed release formulation for treating fibromyalgia. <span style="white-space:nowrap">SP-104</span> is 4.5 mg, <span style="white-space:nowrap">low-dose</span> naltrexone hydrochloride delayed release capsule product in clinical development, for which Phase 1 studies were completed in the second quarter of 2022. It is manufactured by a contract manufacturer, Tulex Pharmaceuticals Inc. (&#8220;Tulex&#8221;), located in Cranbury, NJ. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Competition </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our industry is highly competitive and subject to rapid and significant technological change. The large size and expanding scope of the pain management market makes it an attractive therapeutic area for biopharmaceutical businesses. Our potential competitors include pharmaceutical, biotechnology and specialty pharmaceutical companies. Many of these companies have drug pipelines, readily available capital, and established research and development organizations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ZTlido and our product candidate, <span style="white-space:nowrap">SP-103,</span> if approved, face and will likely face competition from prescription, generic, and OTC topical lidocaine patches, including Lidoderm, generic lidocaine patches manufactured by Teva, Mylan and Par Pharmaceutical, Inc., and <span style="white-space:nowrap"><span style="white-space:nowrap">over-the-counter</span></span> lidocaine patches. Additionally, <span style="white-space:nowrap">SP-103,</span> if approved, will likely compete with various opioid pain medications, NSAIDs, muscle relaxants, antidepressants and anticonvulsants, particularly as we seek approval for the treatment of chronic neck pain. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We launched ELYXYB for treatment of acute migraine pain. ELYXYB faces competition from other NSAID products, triptans and newly launched CGRP inhibitors. NSAIDs and triptans are well established for the treatment of migraine. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">150 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to launch GLOPERBA, our liquid colchicine formulation, in the first half of 2024. GLOPERBA will face competition from generic colchicine formulations, uric acid lowering products like alopurinol, and other products that are used for the prophylaxis treatment of gout. GLOPERBA is the only liquid colchicine product approved by the FDA. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-102,</span> if approved, has the potential to become the first <span style="white-space:nowrap">FDA-approved</span> epidural steroid product for the treatment of sciatica. While there are currently no <span style="white-space:nowrap">FDA-approved</span> ESIs indicated for the treatment of sciatica, we are aware of certain <span style="white-space:nowrap">non-steroid</span> product candidates in development. <span style="white-space:nowrap">SP-102,</span> if approved, will compete with various opioid pain medications, NSAIDs, muscle relaxants, antidepressants, anticonvulsants and surgical procedures. Procedures may include nerve blocks and transcutaneous electrical nerve stimulations. We may also face indirect competition from the <span style="white-space:nowrap">off-label</span> and unapproved use of branded and generic injectable steroids. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to our product candidate <span style="white-space:nowrap">SP-104,</span> while there are currently no formulations containing naltrexone in clinical development for the treatment of fibromyalgia, we are aware of certain <span style="white-space:nowrap">non-opioid</span> therapeutics currently in a late-stage phase 3 pipeline containing two 505(b)(2) development programs. Therefore, we believe that <span style="white-space:nowrap">SP-104</span> will likely face direct competition from these candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that the market will become increasingly competitive in the future. Many of our competitors, either alone or together with their collaborative partners, operate larger research and development programs and have substantially greater financial resources than we do, as well as significantly greater experience in: developing product candidates and technologies, undertaking preclinical studies and clinical trials, obtaining the FDA and other regulatory approvals of product candidates, formulating and manufacturing product candidates and launching, marketing and selling product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval more rapidly than we are able to and may be more effective in selling and marketing their products as well. Smaller or early-stage companies or generic or biosimilar pharmaceutical manufacturers may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our commercial opportunity could be reduced or eliminated if our competitors succeed in developing, acquiring or licensing on an exclusive basis, products that are more effective or less costly than any product candidate that we are currently developing or that we may develop. If approved, our product candidates will face competition from commercially available drugs as well as drugs that are in the development pipelines of our competitors and later enter the market. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Established pharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to <span style="white-space:nowrap">in-license</span> novel compounds that could make our product candidates less competitive. Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA approval or discovering, developing and commercializing medicines before we do. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The key competitive factors affecting the success of ZTlido, GLOPERBA, ELYXYB, <span style="white-space:nowrap">SP-102,</span> <span style="white-space:nowrap">SP-103</span> and <span style="white-space:nowrap">SP-104</span> are likely to be their efficacy, durability, safety, price, intellectual property protection, and the availability of reimbursement from government and other third-party payors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Material Agreements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Itochu and Oishi Product Development Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are party to the Product Development Agreement with Oishi and Itochu (the &#8220;Developers&#8221;). Pursuant to the Product Development Agreement, the Developers agreed to develop, exclusively for us, lidocaine tape products, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">151 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including ZTlido and <span style="white-space:nowrap">SP-103</span> (the &#8220;Products&#8221;). Pursuant to the Product Development Agreement, we obtained the rights to market, sell and distribute the Products in global markets outside of Japan. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In carrying out the development responsibilities, the Developers agreed to, among other things, (1)&#160;source and provide the active pharmaceutical ingredient for the Products for manufacturing, (2)&#160;develop a stable final dosage form of the Products suitable for regulatory approvals, (3)&#160;conduct product development activities necessary to support the filing of applications for regulatory approvals for the Products and (4)&#160;conduct manufacturing <span style="white-space:nowrap">scale-up</span> activities and preclinical studies for the Products. We are responsible for, among other things, (a)&#160;conducting all pivotal human clinical trials for the Products, (b)&#160;completing all regulatory filings, correspondence and meetings with the FDA or other applicable governmental authorities with respect to the Products and (c)&#160;commercially launching the Products. We maintain the ultimate responsibility and decision-making control with regard to the marketing and pricing of the Products. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties agreed to cooperate in good faith to determine whether to seek or maintain patent protection with respect to the Products, the active pharmaceutical ingredient, any associated method of use, method of manufacturing, or any other invention that could reasonably be expected to affect the commercialization or value of the Products. The Developers have the first right to pursue patent protection for any invention by them. All parties will jointly agree on the appointment of the patent representatives in each country outside of Japan. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until the expiration or termination of the Product Development Agreement, the Developers granted us an exclusive, royalty-free, sublicensable, worldwide license (except with respect to Japan) under its current and future intellectual property rights relating to the Products and the lidocaine in such Products. As consideration for the Developers&#8217; development obligations under the Product Development Agreement, we agreed to pay a contingent quarterly royalty between 25% and 35% to the Developers based on the net quarterly profits of the Products. In the event that the net profits of any of the first four calendar quarters after the commercial launch equals a negative amount (a &#8220;Net Loss&#8221;), we are allowed to carry over such Net Loss to apply against all future calendar quarters until such Net Loss is covered, all calculated in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Under the Product Development Agreement, if our total net profits for ZTlido and <span style="white-space:nowrap">SP-103</span> are equal to or less than five percent of our net sales of ZTlido and <span style="white-space:nowrap">SP-103</span> for a period of four or more consecutive quarters, the Developers have the right to terminate the Product Development Agreement and the Commercial Supply Agreement. As of the date of this prospectus, our net profits for ZTlido and <span style="white-space:nowrap">SP-103</span> have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. Additionally, if we receive any licensing fees from any third-party sublicensees, we are obligated to pay the same proportions of such licensing fee to the Developers. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The current term of the Product Development Agreement will continue until October&#160;2, 2028, which is the 10th anniversary of the first commercial sale of ZTlido. Afterwards, the agreement will renew automatically for subsequent successive <span style="white-space:nowrap">one-year</span> renewal periods unless we or the Developers terminate it upon <span style="white-space:nowrap">six-month</span> written notice. In addition, we or the Developers may terminate the Product Development Agreement if (1)&#160;the other party is in material breach of the agreement and the breach is not curable, or if the breach is curable and the breaching party has not cured such material breach within 180 days after notice requesting to cure; (2)&#160;the FDA determines that the formulation of the Products would not be eligible for FDA approval in the absence of efficacy studies, and the Developers are unable to address the efficacy study requirements despite good faith efforts; (3)&#160;the market conditions are such that (a)&#160;our total net profits of the Products are equal to or less than five percent of our net sales of the Products for a period of four or more consecutive quarters, or (b)&#160;the Products&#8217; economic viability is affected significantly as evidenced by documentation and substantial information by any external circumstances deemed detrimental to all parties as agreed to by us and the Developers, and the parties are unable to resolve the concerns under the foregoing clauses (a)&#160;and (b) after 30 days of good-faith discussion; (4)&#160;the parties fail to reach mutual agreement as to who will conduct the clinical studies and how the costs will be allocated; or (5)&#160;we or either one of the Developers are bankrupt or make assignment for the benefit of creditors. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">152 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Additionally, we may terminate the Product Development Agreement if (i)&#160;any of the pivotal human clinical trials for any of the Products fail, or (ii)&#160;the FDA issues a &#8220;Refusal to File&#8221; for any of the Products&#8217; regulatory approval application and, after reasonable consultation with the Developers, we believe that it is commercially unreasonable to <span style="white-space:nowrap">re-file.</span> The Developers may terminate the Product Development Agreement if we fail to file for regulatory approval for any of the Products within three months of the date on which all required components of the regulatory approval application are received by us. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Product Development Agreement, we and the Developers have agreed, subject to certain exceptions, to indemnify each other against any third-party liabilities arising out of (1)&#160;any breach of our respective representations, warranties or obligations under the Product Development Agreement, (2)&#160;any failure by either of us to comply with all applicable laws, or (3)&#160;our respective negligence or willful misconduct. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Product Development Agreement and its amendments in the forms filed as exhibits to the registration statement of which this prospectus forms a part. You should read the form of the agreement and its amendments for a complete understanding of all of their respective terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Itochu and Oishi Commercial Supply Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective February&#160;16, 2017, Scilex Pharma entered into the Commercial Supply Agreement with Itochu and Oishi (the &#8220;Commercial Supply Agreement&#8221;). Pursuant to the Commercial Supply Agreement, Oishi agreed to manufacture, store, handle and perform quality control testing of the Products (as defined in the Product Development Agreement) at its facility in Japan. Itochu agreed to purchase Products from Oishi and handle the shipping of the Products. Both Oishi and Itochu agreed to provide us with certain technical support regarding the Products as reasonably requested by us, including but not limited to analytical test methods, method development, physical and chemical properties, and use of the Products. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Itochu and Oishi Commercial Supply Agreement, we pay per item transfer prices for ZTlido, ZTlido professional samples and ZTlido placebo samples, in each case subject to certain minimum order quantities. We are required to provide a <span style="white-space:nowrap">12-month</span> rolling purchase forecast of the estimated quantities of the Products in writing on a monthly basis. Oishi is required to promptly notify us and Itochu if it lacks the capacity to meet the forecast. All Products ordered by us will be in the form of a firm written purchase order. During the years ended December&#160;31, 2022, 2021 and 2020, we purchased inventory in the amount of $6.7&#160;million, $5.7&#160;million, and $0.8&#160;million, respectively, under the Itochu and Oishi Commercial Supply Agreement. The significant increase in inventory purchased in fiscal year 2021 was largely due to an excess of in stock inventory in fiscal year 2020 that was sold throughout fiscal year 2020 and the early part of fiscal year 2021. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Itochu and Oishi Commercial Supply Agreement will remain in effect until the termination of the Product Development Agreement. Additionally, either we or the Developers may terminate the Itochu and Oishi Commercial Supply Agreement (1)&#160;if the other party is in material breach of the agreement and the breach is not substantially cured within 60 days after receiving written notice specifying the nature of the breach, or (2)&#160;in the event of any of the parties&#8217; insolvency, bankruptcy or assignment for the benefit of creditors. Any third-party claim arising out of a breach by a party of any representation, warranty or obligation under the Itochu and Oishi Commercial Supply Agreement, or a failure by a party to comply with applicable laws, or the negligence or willful misconduct of a party, will be subject to and governed by the Product Development Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Itochu and Oishi Commercial Supply Agreement and its amendments in the forms filed as exhibits to the registration statement of which this prospectus forms a part. You should read the form of the agreement and its amendments for a complete understanding of all of their respective terms. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">153 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">ELYXYB</span></span><sup style="font-size:75%; vertical-align:top">&#174;</sup> <span style="font-weight:bold"><span style="font-style:italic">License and Commercialization Agreement</span></span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;12, 2023, we acquired from BioDelivery Sciences International, Inc. (&#8220;BDSI&#8221;) and Collegium Pharmaceutical, Inc. (&#8220;Collegium&#8221;, and together with BDSI, the &#8220;ELYXYB Sellers&#8221;) the rights to certain patents, trademarks, regulatory approvals, data, contracts and other rights related to ELYXYB<sup style="font-size:75%; vertical-align:top">&#174;</sup> (celecoxib oral solution) and its commercialization in the United States and Canada (the &#8220;ELYXYB Territory&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for the acquisition, we assumed various rights and obligations under that certain asset purchase agreement, dated August&#160;3, 2021 (the &#8220;DRL APA&#8221;), between BDSI and Dr.&#160;Reddy&#8217;s Laboratories Limited (&#8220;DRL&#8221;), a company incorporated under the laws of India, including a license from DRL including an irrevocable, royalty-free, exclusive license to <span style="white-space:nowrap">know-how</span> and patents of DRL related to ELYXYB and necessary or used to exploit ELYXYB in the ELYXYB Territory. Additionally, under the DRL APA, the ELYXYB Sellers granted us an irrevocable, royalty-free, exclusive license to <span style="white-space:nowrap">know-how</span> related to ELYXYB and necessary or used to exploit ELYXYB in the ELYXYB Territory. No cash consideration was or will be payable to the ELYXYB Sellers for such acquisition; however, the obligations under the DRL APA that were assumed by us include obligations to pay royalties for sales of ELYXYB in the ELYXYB Territory for all indications and additional amounts if certain milestones are achieved. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Romeg License and Commercialization Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective June&#160;14, 2022, we entered into a License and Commercialization Agreement (the &#8220;Romeg Agreement&#8221;) with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.). Pursuant to the Romeg Agreement, Romeg granted to us (1)&#160;the right to manufacture, promote, market, distribute and sell the Licensed Products (as defined below) in the United States and (2)&#160;an exclusive, transferable license to use the trademark &#8220;GLOPERBA&#8221;. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Romeg Agreement, among other things, Romeg granted us (1)&#160;a transferable license, with the right to sublicense, under the patents and <span style="white-space:nowrap">know-how</span> specified therein to (a)&#160;commercialize the pharmaceutical product comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans (the &#8220;Initial Licensed Product&#8221;) in the United States (including its territories) (the &#8220;Romeg Territory&#8221;), (b) develop other products comprising the Initial Licensed Product as an active pharmaceutical ingredient (together with the Initial Licensed Product, the &#8220;Licensed Products&#8221;) and commercialize any such products and (c)&#160;manufacture Licensed Products anywhere in the world, solely for commercialization in the Romeg Territory; and (2)&#160;an exclusive, transferable license, with right to sublicense, to use the trademark &#8220;GLOPERBA&#8221; and logos, designs, translations, and modifications thereof in connection with the commercialization of the Initial Licensed Product solely in the Romeg Territory. The license to <span style="white-space:nowrap">know-how</span> is exclusive for purposes of developing and commercializing Licensed Products in the Romeg Territory during the royalty term, but is otherwise <span style="white-space:nowrap">non-exclusive.</span> The license to patents is exclusive for purposes of developing and commercializing Licensed Products in the Romeg Territory until July&#160;1, 2027 and, thereafter, is <span style="white-space:nowrap">co-exclusive</span> with Granules Pharmaceuticals, Inc. for the royalty term for such purposes. The royalty term begins on the date of the agreement and ends on the later of (i)&#160;expiration of the last to expire of the patents that covers the manufacture or commercialization of the Licensed Products in the Romeg Territory or (ii)&#160;the tenth anniversary of the date of the Romeg Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for the license under the Romeg Agreement, we agreed to pay Romeg (1)&#160;an <span style="white-space:nowrap">up-front</span> payment of $2.0&#160;million, (2)&#160;upon our achievement of certain net sales milestones, certain milestone payments in the aggregate amount of up to $13.0&#160;million and (3)&#160;certain royalties at rates that do not exceed ten percent, based on annual net sales of the Licensed Products by us during the royalty term. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Romeg Agreement will remain in effect until it is terminated in accordance with the terms thereof. We may terminate the Romeg Agreement (1)&#160;upon written notice to Romeg, if we elect (or are required) to withdraw the Initial Licensed Product from the market as a result of serious adverse reactions from use of such product, which termination will be effective 30 days following the date of such notice or (2)&#160;at any time, without cause, upon written notice to Romeg, which termination will be effective 120 days following the date of such notice, provided that a termination fee of up to $2.0&#160;million shall be paid to Romeg depending on when during the <span style="white-space:nowrap">10-year</span> period </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">154 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
following the date of the agreement any such termination notice set forth in the immediately preceding clause (2)&#160;has been provided. Romeg may terminate the Romeg Agreement (a)&#160;upon notice to us, if we fail to timely pay any milestone payment, percentage royalties or minimum quarterly royalties or fail to timely deliver the requisite quarterly report, which termination will be effective 30 days after the date of such notice, unless we have made such payment in full or delivered such quarterly report within such 30 day period; (b)&#160;immediately, if we challenge the licensed patents under any court action or proceeding or before any patent office or assist any third party to conduct any of these activities; or (c)&#160;by written notice to us if sales of Licensed Products do not commence or continue within specified periods agreed to by the parties. In addition, either party may terminate the Romeg Agreement (1)&#160;in the event the other party materially breaches the agreement, unless the breaching party has cured any such breach within 60 days after any notice thereof was provided or (2)&#160;in the event the other party (a)&#160;files in any court or agency a petition in bankruptcy or insolvency, (b)&#160;is served with an involuntary petition against it in any insolvency proceeding and such involuntary petition has not been stayed or dismissed within 90 days after its filing, or (c)&#160;makes an assignment of substantially all of its assets for the benefit of its creditors. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Romeg Agreement contains customary reciprocal indemnification obligations for Romeg and us. Additionally, we agreed, subject to certain exceptions, to indemnify Romeg against any loss arising out of the manufacture or commercialization of any Licensed Product by or on behalf of us or our affiliates, marketing partners, sublicensees or subcontractors on or after the date of the license. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Romeg Agreement, which is in the form filed as an exhibit to the registration statement of which this prospectus forms a part. You should read the form of the agreement for a complete understanding of all of its terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Genzyme Supply Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;17, 2015, through our wholly owned subsidiary, Semnur, we entered into that certain exclusive Supply Agreement (the &#8220;Genzyme Supply Agreement&#8221;) with Genzyme Corporation (&#8220;Genzyme&#8221;), an affiliate of Sanofi-Aventis U.S. LLC. Pursuant to the Genzyme Supply Agreement, Genzyme agreed to produce and provide sodium hyaluronate, one of the excipients for SEMDEXA, and we agreed to purchase 100% of our clinical and commercial requirements for sodium hyaluronate in specified territories, including the United States and all countries of the European Union (&#8220;EU&#8221;), exclusively from Genzyme. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Genzyme Supply Agreement, we agreed to pay a per gram price for clinical supply of sodium hyaluronate. For commercial supply, the price will depend on the quantity of order. The pricing for both the clinical supply and the commercial supply of sodium hyaluronate is subject to readjustments each year on January&#160;1, provided that in no case will the price be increased by more than 5% each year. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Genzyme Supply Agreement provides for a five-year exclusivity period in favor of us and will remain in effect until 10 years after the effective date unless earlier terminated in accordance with the terms thereof, with automatic renewal for additional five year periods (on an exclusive basis), if the respective requirements for exclusivity are met by us as set forth therein, and for additional <span style="white-space:nowrap">two-year</span> periods thereafter unless either party gives notice of a termination not less than 18 months prior to the expiration of the then-current term. Either party may terminate the Genzyme Supply Agreement if (1)&#160;the other party is in material breach of the agreement and fails to cure within 30 days, or (2)&#160;if the development of SEMDEXA is ceased or we do not file for regulatory approval for SEMDEXA by January&#160;1, 2020. Additionally, Genzyme may terminate the Genzyme Supply Agreement if it decides to discontinue manufacturing the product at its facility for economic or strategic reasons and provides us with 24 months&#8217; notice. We did not file for regulatory approval for SEMDEXA by January&#160;1, 2020 and we are only aware of a limited number of suppliers of the excipient. In accordance with Genzyme&#8217;s right to terminate the Genzyme Supply Agreement if it decides to discontinue manufacturing the product at its facility for economic or strategic reasons, Genzyme has notified us of its intention to terminate the Genzyme Supply Agreement, effective as of May&#160;31, 2024. Although we are currently in the process of identifying and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">155 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certifying new suppliers to fulfill our clinical and commercial supply requirements for sodium hyaluronate, we may not be able to find an alternative supplier of sodium hyaluronate on commercially reasonable terms. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Genzyme Supply Agreement, we and Genzyme have agreed, subject to certain exceptions, to indemnify each other against any third-party liabilities arising out of (1)&#160;any material breach of our respective representations, warranties and obligations thereunder, or (2)&#160;our respective gross negligence or willful misconduct. In addition, we have agreed to indemnify Genzyme against any third-party liabilities arising out of the development, manufacture, storage, handling, use, marketing, distribution, offer for sale, sale, promotion or other commercialization of sodium hyaluronate by us. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Genzyme Supply Agreement in the form filed as an exhibit to the registration statement of which this prospectus forms a part. You should read the form of the agreement for a complete understanding of all of its terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Lifecore Master Services Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;27, 2017, through our wholly owned subsidiary, Semnur, we entered into that certain Master Services Agreement (as amended, the &#8220;Lifecore Master Services Agreement&#8221;), with Lifecore Biomedical, LLC (&#8220;Lifecore&#8221;). Pursuant to the Lifecore Master Services Agreement, Lifecore is responsible for clinical trial material manufacturing and development services for SEMDEXA as set forth in each separate statement of work (each a &#8220;Lifecore Statement of Work&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties entered into a Lifecore Statement of Work on January&#160;27, 2017, pursuant to which Lifecore agreed to provide, among other things, (1)&#160;project management support, (2)&#160;development services, (3)&#160;clinical trial materials, and (4)&#160;stability studies. We paid Lifecore for the development and clinical trial material manufacturing services, which was invoiced at the completion of each service. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of Lifecore&#8217;s development and clinical trial material manufacturing obligations, we granted Lifecore a nonexclusive, worldwide and royalty-free license under our owned or controlled intellectual property rights necessary to manufacture SEMDEXA, without additional right, title or interest in our intellectual property. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Lifecore Master Services Agreement contains customary reciprocal indemnification obligations for Lifecore and Semnur. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Lifecore Master Services Agreement expired on December&#160;31, 2022, and we are currently negotiating a new agreement with Lifecore. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Lifecore Master Services Agreement and the amendment thereto in the forms filed as exhibits to the registration statement of which this prospectus forms a part. You should read the form of the agreement and its amendment for a complete understanding of all of their respective terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Semnur Merger Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;18, 2019, Legacy Scilex acquired Semnur pursuant to an Agreement and Plan of Merger with Semnur (as amended, the &#8220;Semnur Merger Agreement&#8221;), Sigma Merger Sub, Inc., a wholly owned subsidiary of Legacy Scilex (&#8220;Sigma Merger Sub&#8221;), Fortis Advisors LLC, solely as representative of the holders of Semnur equity (the &#8220;Semnur Equityholders&#8217; Representative&#8221;), and for limited purposes, Sorrento. Pursuant to the Semnur Merger Agreement, Sigma Merger Sub merged with and into Semnur (the &#8220;Semnur Merger&#8221;), with Semnur surviving as Legacy Scilex&#8217;s wholly owned subsidiary. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with transactions contemplated by the Semnur Merger Agreement, Sorrento and each of the other holders of outstanding shares of capital stock of Scilex Pharma, contributed each share of Scilex Pharma capital </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">156 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stock it owned to Legacy Scilex in exchange for one share of common stock of Legacy Scilex (&#8220;Legacy Scilex Common Stock&#8221;), par value $0.0001 per share (the &#8220;Contribution&#8221;). As a result of the Contribution, and prior to the consummation of the Semnur Merger, Scilex Pharma became a wholly owned subsidiary of Legacy Scilex and Sorrento became the owner of approximately 77% of Legacy Scilex&#8217;s issued and outstanding capital stock. As a result of the Semnur Merger, Scilex Pharma and Semnur became wholly owned subsidiaries of Legacy Scilex. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the closing of the Semnur Merger, Legacy Scilex issued to the holders of Semnur&#8217;s capital stock (the &#8220;Semnur Equityholders&#8221;) and options to purchase Semnur&#8217;s common stock, upfront consideration with a value of $70.0&#160;million. The upfront consideration was comprised of the following: (i)&#160;a cash payment of approximately $15.0&#160;million, and (ii) $55.0&#160;million in shares of Legacy Scilex Common Stock (47,039,315 shares issued and 352,972 shares issuable, valued at $1.16 per share) (the &#8220;Stock Consideration&#8221;). A portion of the cash consideration otherwise payable to the Semnur Equityholders was set aside for expenses incurred by the Semnur Equityholders&#8217; Representative, and 4,749,095 shares of Legacy Scilex Common Stock otherwise issuable to Semnur Equityholders were placed in escrow with a third party as security for the indemnification obligations of the Semnur Equityholders under the Semnur Merger Agreement. The expense fund and escrow have since been released per the terms of the escrow agreement. The Semnur Equityholders that received the Stock Consideration were required to sign an exchange and registration rights agreement with Legacy Scilex, which is further described below. Following the issuance of the Stock Consideration, Sorrento ownership in Legacy Scilex was diluted to approximately 58% of Legacy Scilex&#8217;s issued and outstanding capital stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Semnur Merger Agreement, and upon the terms and subject to the conditions contained therein, Legacy Scilex also agreed to pay the Semnur Equityholders up to $280.0&#160;million in aggregate contingent cash consideration based on the achievement of certain milestones, comprised of a $40.0&#160;million payment that will be due upon obtaining the first approval of a NDA of a Semnur product by the FDA and additional payments that will be due upon the achievement of certain amounts of net sales of Semnur products, as follows: (i)&#160;a $20.0&#160;million payment upon the achievement of $100.0&#160;million in cumulative net sales of a Semnur product, (ii)&#160;a $20.0&#160;million payment upon the achievement of $250.0&#160;million in cumulative net sales of a Semnur product, (iii)&#160;a $50.0&#160;million payment upon the achievement of $500.0&#160;million in cumulative net sales of a Semnur product, and (iv)&#160;a $150.0&#160;million payment upon the achievement of $750.0&#160;million in cumulative net sales of a Semnur product. As of the date of this prospectus, none of the foregoing payments have been triggered. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Semnur Merger Agreement also provided that following the consummation of Legacy Scilex&#8217;s first bona fide equity financing with one or more third-party financing sources on an arms&#8217; length basis with gross proceeds to Legacy Scilex of at least $40.0&#160;million, certain of the former Semnur optionholders will be paid cash in lieu of: (i)&#160;the 352,972 shares of Legacy Scilex Common Stock otherwise issuable to such former Semnur optionholders pursuant to the Semnur Merger Agreement, and (ii)&#160;any shares that would otherwise be issued to such former Semnur optionholders upon release of shares held in escrow pursuant to the Semnur Merger Agreement, with such shares in each case valued at $1.16 per share. The Semnur optionholders subsequently agreed, under the terms of the Exchange Agreement (as defined and described below) to forego the foregoing right to any such payment in exchange for the right to participate in the Share Exchange (as defined below). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2019, the Semnur Equityholders that received the Stock Consideration were required to sign an Exchange and Registration Rights Agreement with Legacy Scilex (as amended, the &#8220;Exchange Agreement&#8221;). Pursuant to the Exchange Agreement, and upon the terms and subject to the conditions contained therein, if within 18 months following the closing of the Semnur Merger, 100% of the outstanding equity of Legacy Scilex had not been acquired by a third party or Legacy Scilex had not entered into a definitive agreement with respect to, or otherwise consummated, a firmly underwritten offering of Legacy Scilex capital stock on a major stock exchange that met certain requirements, then holders of the Stock Consideration could collectively elect to exchange, during the <span style="white-space:nowrap">60-day</span> period commencing the date that was the <span style="white-space:nowrap">18-month</span> anniversary of the closing of the Semnur Merger (the &#8220;Share Exchange&#8221;), the Stock Consideration for shares of Sorrento&#8217;s common stock with a value of $55.0&#160;million based on a price per share of Sorrento&#8217;s common stock equal to the greater of (a)&#160;the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">157 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<span style="white-space:nowrap">30-day</span> trailing volume weighted average price of one share of Sorrento&#8217;s common stock as reported on The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) as of the consummation of the Share Exchange and (b) $5.55 (subject to adjustment for any stock dividend, stock split, stock combination, reclassification or similar transaction) (the &#8220;Exchange Price&#8221;). Pursuant to an amendment to the Exchange Agreement entered into by Sorrento and the Semnur Equityholders&#8217; Representative on September&#160;28, 2020, on October&#160;9, 2020, Sorrento paid $55.0&#160;million in cash to the Semnur Equityholders in lieu of issuing $55.0&#160;million of shares of Sorrento&#8217;s common stock at the Exchange Price. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Semnur Merger Agreement (including the amendment thereto) in the forms filed as exhibits to the registration statement of which this prospectus forms a part. You should read the Semnur Merger Agreement (including the amendment thereto) for a complete understanding of all of their respective terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Aardvark Asset Purchase Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2021, Sorrento entered into an asset purchase agreement (the &#8220;Aardvark Asset Purchase Agreement&#8221;) with Aardvark Therapeutics, Inc. (&#8220;Aardvark&#8221;), pursuant to which, among other things, Sorrento acquired Aardvark&#8217;s Delayed Burst Release Low Dose Naltrexone <span style="white-space:nowrap">(DBR-LDN)</span> asset and intellectual property rights, for the treatment of chronic pain, fibromyalgia and chronic post-COVID syndrome (collectively, the <span style="white-space:nowrap">&#8220;SP-104</span> Assets&#8221;), which includes a Statement of Work dated November&#160;18, 2020 (the &#8220;Tulex Statement of Work&#8221;), pursuant to which Tulex agreed to, among other things, develop, test and manufacture clinical supplies of <span style="white-space:nowrap">SP-104</span> for Sorrento. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to the acquisition, Sorrento designated Legacy Scilex to lead all development efforts related to <span style="white-space:nowrap">SP-104</span> and on May&#160;12, 2022, Legacy Scilex and Sorrento entered into a bill of sale and assignment and assumption agreement (the &#8220;Bill of Sale&#8221;), pursuant to which Sorrento sold, conveyed, assigned and transferred to Legacy Scilex all of its rights, title and interest in and to the <span style="white-space:nowrap">SP-104</span> Assets (including PCT/US2021/053645 and all patents and patent applications that claim priority rights thereto) and Legacy Scilex assumed all of Sorrento&#8217;s rights, liabilities and obligations under the Aardvark Asset Purchase Agreement (the <span style="white-space:nowrap">&#8220;SP-104</span> Acquisition&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for the <span style="white-space:nowrap">SP-104</span> Acquisition, Legacy Scilex issued a promissory note in the aggregate principal amount of $5,000,000 to Sorrento (the &#8220;Promissory Note&#8221;). The Promissory Note matures seven years from the date of issuance and bears interest at the rate equal to the lesser of (a) 2.66% simple interest per annum and (b)&#160;the maximum interest rate permitted under law. The Promissory Note is payable in cash, shares of Common Stock (any shares so issued, the &#8220;Consideration Shares&#8221;) or any combination thereof, at Legacy Scilex&#8217;s sole discretion, and may be prepaid in whole or in part at any time without penalty. Legacy Scilex also agreed to file with the SEC a resale registration statement, relating to the resale by Sorrento of any Consideration Shares that may be issued to Sorrento, within 60 days of the issuance of such Consideration Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the successor to the Aardvark Asset Purchase Agreement, Legacy Scilex is obligated to pay Aardvark (i) $3,000,000, upon initial approval by the FDA of a new drug application for the LDN Formulation (as defined in the Aardvark Asset Purchase Agreement) (which amount may be paid in shares of Common Stock or cash, in Legacy Scilex&#8217;s sole discretion) (the &#8220;Development Milestone Payment&#8221;) and (ii) $20,000,000, in cash, upon achievement of certain net sales by Legacy Scilex of a commercial product that uses the LDN Formulation (the &#8220;Commercial Product&#8221;). Legacy Scilex will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by Legacy Scilex of a commercial product that uses the LDN Formulation. The royalty percentage is subject to reduction in certain circumstances. Royalties are due for so long as Commercial Product is covered by a valid patent in the country of sale or for ten years following the first commercial sale of the Commercial Product, whichever is longer. As of the date of this prospectus, none of the foregoing payments have been triggered. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">158 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with its acquisition of the <span style="white-space:nowrap">SP-104</span> Assets, Legacy Scilex has agreed that if it issues any shares of Common Stock in respect of the Development Milestone Payment, Legacy Scilex will prepare and file one or more registration statements with the SEC for the purpose of registering for resale such shares and is required to file such registration statement with the SEC within 60 days following the date on which any such shares are issued. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Tien-Li</span> Lee, M.D., a former member of our board of directors (the &#8220;Board&#8221;), is the founder, chief executive officer and a member of the board of directors of Aardvark. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Aardvark Asset Purchase Agreement, Bill of Sale and Promissory Note in the forms filed as exhibits to the registration statement of which this prospectus forms a part. You should read the forms of these agreements for a complete understanding of all of their respective terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Tulex Master Services Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described above, in connection with the <span style="white-space:nowrap">SP-104</span> Acquisition, Legacy Scilex acquired the Tulex Statement of Work, pursuant to which Tulex, among other things, develops, tests and manufactures clinical supplies of <span style="white-space:nowrap">SP-104</span> for Legacy Scilex. The Tulex Statement of Work is governed by the terms of a master services agreement (the &#8220;Tulex Master Services Agreement&#8221;). The Tulex Master Services Agreement was novated to Legacy Scilex on June&#160;15, 2022 and will remain in effect until five years after the effective date, unless terminated early by either party. Either party may terminate the Tulex Master Services Agreement or a Tulex Statement of Work by written notice (1)&#160;if the other party is in material breach of the agreement or a Tulex Statement of Work and fails to cure such breach within 15 days after receipt of notice of such breach (or such other time period expressly stated in the applicable Tulex Statement of Work) or (2)&#160;in the event of the other party&#8217;s insolvency, bankruptcy, reorganization, liquidation or receivership, or a failure to remove any insolvency, bankruptcy, reorganization, liquidation or receivership proceedings within ten days from the date of institution of such proceedings. In addition, we may terminate the agreement or any Tulex Statement of Work (1)&#160;without cause upon 30 days prior written notice to Tulex or (2)&#160;immediately upon written notice in the event Tulex is dissolved or undergoes a change in control. A termination or expiration of a single Tulex Statement of Work will not cause the automatic termination of the agreement or of any other Tulex Statement of Work. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each party under the Tulex Master Services Agreement agreed to indemnify the other party, its affiliates and each of their respective officers, directors, employees, contractors and agents against any third-party liabilities arising out of (1)&#160;such party&#8217;s breach of the Tulex Master Services Agreement or a Tulex Statement of Work or (2)&#160;the negligence or willful misconduct on the part of such party, its officers, directors, employees, agents or other representatives in connection with the Tulex Master Services Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Tulex Master Services Agreement in the form filed as an exhibit to the registration statement of which this prospectus forms a part. You should read the form of the agreement for a complete understanding of all of its terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Intellectual Property </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our success depends in part on our ability to obtain and maintain proprietary protection for our product candidates, technology and <span style="white-space:nowrap">know-how,</span> to operate without infringing the proprietary rights of others and to prevent others from infringing our proprietary rights. Our policy is to seek to protect our proprietary position by, among other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States related to our novel adhesion and delivery technology, inventions, improvements and product candidates that are important to the development and implementation of our business. Our patent portfolio is intended to cover our product candidates, their methods of use and processes for their manufacture, and any other inventions that are commercially important to our business. We also rely on trade secret protection </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">159 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of our confidential information and <span style="white-space:nowrap">know-how</span> relating to our novel adhesion and delivery technology, platforms and product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, patents are granted a term of 20 years from the earliest claimed <span style="white-space:nowrap">non-provisional</span> filing date. In certain instances, patent term can be adjusted to recapture a portion of delay by the PTO in examining the patent application or extended to account for term effectively lost as a result of the FDA regulatory review period, or both. We cannot provide any assurance that any patents will be issued from our pending or future applications or that any patents will adequately protect our product or product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our patent portfolio, consisting of owned and/or licensed IP as of December&#160;31, 2023 contains approximately twenty-five issued and unexpired U.S. patents and ten pending U.S. patent applications. Our portfolio also includes certain foreign counterparts of these patents and patent applications including Australia, Brazil, Canada, China, Hong Kong, India, Israel, Japan, Korea, Mexico, New Zealand, Peru, South Africa, Taiwan and certain countries within the European Patent Convention. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to ZTlido and <span style="white-space:nowrap">SP-103,</span> our patents and patent applications cover compositions and methods of treatment. With respect to our product candidate SEMDEXA, our patents and patent applications include formulations and methods of treatment. The patents are U.S. Pat. Nos. 10,500,284, 10,117,938, and 11,020,485, all of which expire in 2036. With respect to <span style="white-space:nowrap">SP-104,</span> our pending U.S. patent application covers oral delayed burst formulations of <span style="white-space:nowrap">low-dose</span> naloxone or naltrexone and related methods of treatment. We continue to seek to maximize the scope of our patent protection for all our programs. We license eight issued U.S. patents and two pending U.S. patent applications relating to lidocaine topical system compositions and methods of treating pain with lidocaine topical system compositions. The patents are U.S. Pat. Nos. 9,283,174, 9,925,264, 9,931,403, 10,765,749, 10,765,640, 11,278,623, 11,786,455, and 11,793,766, all of which expire in 2031. Related to GLOPERBA, our licensed patents include U.S. Pat. Nos. 9,907,751, 10,226,423, 10,383,820, and 10,383,821, which relate to liquid colchicine formulations for oral administration and associated methods of use. U.S. Pat. No.&#160;10,226,423 expires in 2037. The remaining patents related to GLOPERBA expire in 2036. Related to ELYXYB, our patents and patent applications relate to liquid oral celecoxib formulations and associated methods of use. The issued patents include U.S. Pat. Nos. 9,572,819, 9,795,620, 9,949,990, 10,376,527, 10,799,517, and 10,722,456, which expire in 2036. All statements regarding the expiration of our owned and licensed patents are calculated as 20 years after the earliest nonprovisional priority date and do not account for any patent term adjustment (&#8220;PTA&#8221;), regulatory extension, or terminal disclaimers not already in force as of September&#160;30, 2023; these calculations also assume that all annuity and/or maintenance fees are paid timely. We believe that we have certain <span style="white-space:nowrap">know-how</span> and trade secrets relating to our technology and product candidates. We rely on trade secrets to protect certain aspects of our technology related to our current and future product candidates. However, trade secrets can be difficult to protect. We seek to protect our trade secrets, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors, service providers, and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Trademarks, Trade Secrets and Other Proprietary Information </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file trademark applications and pursue registrations in the United States and abroad when appropriate. We own registered U.S. trademarks for the marks &#8220;SCILEX,&#8221; &#8220;ZTlido,&#8221; &#8220;ELYXYB,&#8221; and &#8220;RESPONSIBLE BY DESIGN.&#8221; We also own pending trademark applications for &#8220;SEMNUR PHARMACEUTICALS&#8221; and &#8220;SEMDEXA&#8221; in the United States. We also license the GLOPERBA trademark as discussed in relation to the Romeg Agreement described above. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also depend upon the skills, knowledge and experience of our scientific and technical personnel, as well as that of our advisors, consultants and other contractors. To help protect our proprietary <span style="white-space:nowrap">know-how,</span> we rely on trade secret protection and confidentiality agreements to protect our interests. Our policy is to require each of our employees, consultants and advisors to execute a confidentiality and inventions assignment agreement before </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">160 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
beginning their employment, consulting or advisory relationship with us. The agreements generally provide that the individual must keep confidential and not disclose to other parties any confidential information developed or learned by the individual during the course of the individual&#8217;s relationship with us except in limited circumstances. These agreements generally also provide that we will own all inventions conceived by the individual in the course of rendering services to us. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SEMDEXA benefits from our substantial intellectual property portfolio and other technical barriers to entry for potential competitors. Further, we are a party to an exclusive supply agreement for a proprietary biocompatible excipient with no generic equivalent. Our complex manufacturing process, specialized equipment and <span style="white-space:nowrap">know-how</span> for sterile viscous product candidates are also key to our competitive edge. We believe that our competitors will be required to conduct lengthy and costly preclinical and clinical trials to establish products with comparable safety and efficacy to SEMDEXA. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Government Regulation and Product Approval </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Government authorities in the United States at the federal, state and local levels, and in other countries and jurisdictions, extensively regulate, among other things, the research, development, testing, manufacture, pricing, reimbursement, sales, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of products such as those we are marketing and developing. <span style="white-space:nowrap">SP-102,</span> <span style="white-space:nowrap">SP-103,</span> <span style="white-space:nowrap">SP-104</span> and any other product candidate that we develop must be approved by the FDA or otherwise authorized for marketing before they may be legally marketed in the United States and by the corresponding foreign regulatory agencies before they may be legally marketed in foreign countries. The processes for obtaining marketing approvals, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">U.S. Drug Development Process </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, the FDA regulates drugs under the FDCA and implementing regulations. Drugs are also subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable requirements at any time during the product development process, approval process or after approval, may subject an applicant or its products to a variety of administrative or judicial sanctions, such as inspection scrutiny, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, or reimbursements, restitution, disgorgement of profits or civil or criminal penalties. The process required by the FDA before a drug may be marketed in the United States generally involves the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">completion of preclinical laboratory tests, animal studies and formulation studies according to Good Laboratory Practices (&#8220;GLPs&#8221;) or other applicable regulations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">submission to the FDA of an Investigational New Drug Application (&#8220;IND&#8221;), which must become effective before human clinical trials may begin; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">approval by an institutional review board (&#8220;IRB&#8221;) covering each clinical site before each trial may be initiated; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">performance of adequate and well-controlled human clinical trials according to the laws and regulations pertaining to the conduct of human clinical trials, collectively referred to as Good Clinical Practice (&#8220;GCP&#8221;) requirements to establish the safety and efficacy of the proposed drug for its intended use; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">161 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">submission to the FDA of an NDA or other marketing application (collectively, an &#8220;NDA&#8221;), for a proposed new drug, including its specific formulation and labeling; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">satisfactory completion of an FDA advisory committee review, if applicable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the drug is produced to assess compliance with the FDA&#8217;s cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">potential FDA audit of the preclinical study and clinical trial sites that generated the data in support of the NDA; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">FDA review and approval of the NDA prior to any commercial marketing, sale or shipment of the drug. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before testing novel compounds with potential therapeutic value in humans, the drug candidate enters the preclinical testing stage, also referred to as preclinical studies. Preclinical studies include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the drug candidate. The conduct of the preclinical studies must comply with federal laws and requirements including GLPs. The IND sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data, and any available clinical data or literature, to the FDA as part of the IND. The sponsor will also include a protocol detailing, among other things, the objectives of the first phase of the clinical trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated, if the first phase lends itself to an efficacy evaluation. Some preclinical studies may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on a clinical hold within that <span style="white-space:nowrap">30-day</span> time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a drug candidate at any time before or during clinical trials due to safety concerns, <span style="white-space:nowrap">non-compliance,</span> or for additional reasons. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the drug candidate to healthy subjects or patients with the target disease under the supervision of qualified investigators, generally physicians not employed by the trial sponsor. Clinical trials are conducted under written study protocols detailing, among other things, the objectives of the clinical trial, subject selection and exclusion criteria, dosing procedures, and the parameters to be used to collect data and to monitor subject safety. Each protocol must be submitted to the FDA as part of the IND, and timely safety reports must be submitted to the FDA and investigators for suspected adverse reactions that are serious and unexpected. Clinical trials must be conducted in accordance with applicable statutes, the FDA&#8217;s regulations and GCP requirements. Further, each clinical trial must be reviewed and approved by an IRB at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to and signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until it is completed. In some instances, additional oversight boards, such as a data safety monitoring board, are required to evaluate interim data and determine whether a study should continue or be modified or terminated. Information about many clinical trials is required to be publicly reported on www.ClinicalTrials.gov or similar databases. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Phase 1</span></span>. The drug is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion and, if possible, to gain an early indication of its effectiveness. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing may be conducted only in patients having the specific disease. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">162 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Phase 2</span></span>. The drug is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule for patients having the specific disease. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Phase 3</span></span>. The drug is administered to an expanded patient population in adequate and well-controlled clinical trials to generate sufficient data to statistically confirm the safety and efficacy of the product for potential approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product. Generally, at least two adequate and well-controlled Phase 3 clinical trials are required by the FDA for approval of an NDA. In some cases, the FDA may approve a drug based on the results of a single adequate and well-controlled Phase 3 trial for excellent design and which provided highly reliable and statistically strong evidence of important clinical benefit. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Post-approval studies, also referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication and may be required by the FDA as part of the approval process. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Progress reports detailing the status of drug development and results of the clinical trials must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and the investigators for suspected adverse reactions that are serious and unexpected (including increased rate of occurrence of such adverse reactions), findings from other studies that suggest a significant risk in humans exposed to the drug, or any findings from tests in laboratory animals that suggests a significant risk for human subjects or patients. Phase 1, Phase 2 and Phase 3 clinical trials may not yield positive results, or may not be completed successfully within any specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to study subjects. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the end of Phase 2 meeting to discuss their Phase 2 clinical results and present their plans for the Phase 3 clinical trials that they believe will support approval of the new drug. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">FDA Review and Approval Processes </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The results of product development, preclinical studies and clinical trials for the claimed indications are incorporated into an NDA. The FDA may grant deferrals for the development and submission of pediatric data or full or partial waivers after the initial submission of a pediatric study plan following an end of Phase 2 meeting. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">163 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
In addition, descriptions of the manufacturing process and controls, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are also submitted to the FDA as part of an NDA requesting approval to market the product. The submission of an NDA is subject to the payment of substantial user fees and a waiver of such fees may be obtained under certain limited circumstances. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA reviews the NDA to determine, among other things, whether the proposed product is safe and effective for its intended use, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#8217;s identity, strength, quality and purity. Under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#8220;filing&#8221; of a standard, original NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to the FDA because the FDA has approximately two months to make a &#8220;filing&#8221; decision after the application is submitted. The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accepting an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA may refer applications for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the drug approval process, the FDA also will determine whether a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) is necessary to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS. The FDA will not approve the NDA without a REMS, if required. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before approving an NDA, the FDA will generally inspect the facilities at which the product is to be manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A Complete Response Letter usually describes the specific deficiencies in the NDA identified by the FDA and may require additional clinical data, such as an additional pivotal Phase 3 trial or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a Complete Response Letter is issued, the sponsor must resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. In addition, the FDA may require post-approval studies, referred to as Phase 4 testing, which involves clinical trials designed to further assess a product&#8217;s safety and effectiveness and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">164 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Expedited Development and Review Programs </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA administers a number of different programs that enable the agency and sponsors in various ways to expedite the development or agency review of a new drug product. Among these, the FDA has a fast track designation that is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria. New drugs are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. As an example of the modified processes available to a fast track product, the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any product submitted to the FDA for approval, including a product with a fast track designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug designated for priority review in an effort to facilitate the review. The FDA endeavors to review applications with priority review designations within six months of the filing date as compared to ten months for review of other NDAs under its current PDUFA review goals. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, a product may be eligible for accelerated approval. Drug products intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform additional adequate and well-controlled post-marketing clinical trials. In addition, the FDA currently requires as a condition for accelerated approval <span style="white-space:nowrap">pre-use</span> submission of promotional materials, which could adversely impact the timing of the commercial launch of the product. Fast track designation, priority review and accelerated approval do not change the standards for approval but may expedite the development or approval process. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Food and Drug Administration Safety and Innovation Act established a category of drugs referred to as &#8220;breakthrough therapies&#8221; that may be eligible to receive breakthrough therapy designation. A sponsor may seek the FDA designation of a product candidate as a &#8220;breakthrough therapy&#8221; if the product is intended, alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance. The breakthrough therapy designation is a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria are met. If a product is designated as breakthrough therapy, the FDA will work with the sponsor to expedite the development and review of such drug. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With passage of the 21st Century Cures Act in December 2016, Congress authorized the FDA to accelerate review and approval of products designated as regenerative advanced therapies. A product is eligible for this designation if it is a regenerative medicine therapy that is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product candidate has the potential to address unmet medical needs for such disease or condition. The benefits of a regenerative advanced therapy designation include early interactions with the FDA to expedite development and review, benefits </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">165 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
available to breakthrough therapies, potential eligibility for priority review and accelerated approval based on surrogate or intermediate endpoints. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Post-Approval Requirements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown risks or problems with a product may result in labeling changes, restrictions on the product or even complete withdrawal of the product from the market. After approval, most changes to the approved product, such as adding new indications, certain manufacturing changes and additional labeling claims, are subject to further FDA review and approval. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP regulations and other laws and regulations. In addition, the FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any drug products for which we receive FDA approvals are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences or quality issues with the product, providing the FDA with updated safety and efficacy information, satisfaction of post-approval requirements or commitments, product sampling and distribution requirements, and complying with FDA promotion and advertising requirements. These promotion and advertising requirements include, among other things, standards for <span style="white-space:nowrap"><span style="white-space:nowrap">direct-to-consumer</span></span> advertising, prohibitions against promoting drugs for uses, or in patient populations, that are not described in the drug&#8217;s approved labeling, which is known as <span style="white-space:nowrap">&#8220;off-label</span> use,&#8221; rules for conducting industry-sponsored scientific and educational activities, and promotional activities involving the internet. Failure to comply with post-approval requirements can have negative consequences, including adverse publicity, enforcement letters from the FDA, mandated corrective advertising or communications with doctors, and civil or criminal penalties. Although physicians may prescribe legally available drugs for <span style="white-space:nowrap">off-label</span> uses, manufacturers may not market or promote such <span style="white-space:nowrap">off-label</span> uses. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant, manufacturer or product to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical holds on post-approval clinical trials, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Hatch-Waxman Amendments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&#160;505 of the FDCA describes three types of NDAs that may be submitted to request marketing authorization for a new drug, the first being a 505(b)(1) NDA. A 505(b)(1) NDA is an application that contains full reports of investigations of safety and effectiveness. A 505(b)(2) NDA likewise contains full reports of investigations of safety and effectiveness relevant to a product, but some of the data are not owned by or licensed to the applicant. Section&#160;505(j) establishes an abbreviated approval process for generic versions of approved drug products through the submission of an abbreviated new drug application (&#8220;ANDA&#8221;). An ANDA generally provides for marketing of a drug product that has the same active ingredients in the same strengths and dosage form, and with the same labeling and route of administration as the listed drug and has been shown to be bioequivalent to the listed drug. ANDA applicants are required to conduct bioequivalence testing to confirm chemical and therapeutic equivalence to the branded reference drug. Generic versions of drugs can often, and sometimes must, be substituted by pharmacists under prescriptions written for the branded reference drug. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">166 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A 505(b)(2) NDA is an application that contains full reports of investigations of safety and effectiveness but where at least some of the information required for approval comes from studies not conducted by or for the applicant, and for which the applicant has not obtained a right of reference. This regulatory pathway enables the applicant to rely, in part, on the FDA&#8217;s findings of safety and efficacy for an existing product, or published literature, in support of its application. Additional preclinical and clinical data may also be submitted. The FDA may then approve the new product candidate for all or some of the labeled indications for which the referenced product has been approved, or for any new indication sought by the 505(b)(2) applicant. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon submission of an ANDA or a 505(b)(2) NDA, an applicant must certify to the FDA at least one of the following (1)&#160;no patent information on the drug product that is relied upon by the ANDA or 505(b)(2) NDA (known as the reference drug) has been submitted to the FDA; (2)&#160;such patent has expired; (3)&#160;the date on which such patent expires; or (4)&#160;such patent is invalid, unenforceable, or will not be infringed by the manufacture, use or sale of the drug product for which the ANDA or 505(b)(2) NDA is submitted. This last certification is known as a Paragraph IV Certification. If the NDA holder for the reference drug or patent owner(s) asserts a patent challenge to the Paragraph IV Certification, the FDA may not approve that application until the earlier of 30 months from the receipt of the notice of the Paragraph IV Certification, the expiration of the patent, when the infringement case concerning each such patent was favorably decided in the applicant&#8217;s favor or such shorter or longer period as may be ordered by a court. This prohibition is generally referred to as the <span style="white-space:nowrap">30-month</span> stay. Thus, approval of an ANDA or 505(b)(2) NDA could be delayed for a significant period of time depending on the patent certification the applicant makes and the reference drug sponsor&#8217;s or patent owner&#8217;s decision to initiate patent litigation. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to, and distinct from the patent protection provisions, the Hatch-Waxman Amendments establish periods of regulatory exclusivity for certain approved drug products, during which the FDA cannot approve (or in some cases accept) an ANDA or 505(b)(2) application that relies on the branded reference drug. For example, the holder of an NDA may obtain five years of exclusivity upon approval of a new drug containing a new chemical entity that has not been previously approved by the FDA. The Hatch-Waxman Amendments also provide three years of marketing exclusivity to the holder of an NDA (including a 505(b)(2) NDA) for a particular condition of approval, or change to a marketed product, such as a new formulation for a previously approved product, if one or more new clinical trials (other than bioavailability or bioequivalence studies) was essential to the approval of the application and was conducted/sponsored by the applicant. This three-year exclusivity period protects against FDA approval of ANDAs and 505(b)(2) NDAs for drugs that include the innovation that required the new clinical data, but generally allows the approval for <span style="white-space:nowrap">non-protected</span> characteristics and labeling. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Third-Party Payor Coverage, Pricing and Reimbursement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Thus, sales of a product will depend, in part, on the extent to which third-party payors provide coverage and establish adequate reimbursement levels for the product. Third-party payors include government payor programs at the federal and state levels, including Medicare and Medicaid, managed care providers, private health insurers and other organizations. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the <span style="white-space:nowrap">FDA-approved</span> products for a particular indication, and which can change over time. Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Additionally, companies may also need to provide discounts to purchasers, private health plans or government healthcare programs, in order for the company&#8217;s products to be considered as </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">167 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a formulary option. Nonetheless, product candidates may not be considered by individual payors to be medically necessary or cost-effective. A payor&#8217;s decision to provide coverage for a product does not imply that a preferred formulary position or an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The cost of pharmaceuticals continues to generate substantial governmental and third-party payor interest. We expect that the pharmaceutical industry will experience pricing pressures due to the trend toward managed healthcare, the increasing influence of managed care organizations and additional legislative proposals. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. Adoption of such controls and measures, and tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for pharmaceuticals such as our products and the product candidates that we are developing and could adversely affect our net revenue and results. See the discussion below under &#8220;<span style="font-style:italic">U.S. Healthcare Reform&#8221;</span>, and regarding the Inflation Reduction Act for further information. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Different pricing and reimbursement schemes exist in other countries. In the European Economic Area (&#8220;EEA&#8221;) (which is currently comprised of the 27 Member States of the EU plus Norway, Iceland and Liechtenstein), governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national healthcare systems that fund a large part of the cost of those products to consumers. Some countries in the EEA operate positive and negative list systems under which some medicinal products are selected for coverage (positive list) and others are explicitly listed as excluded from reimbursement (negative list). To obtain reimbursement or pricing approval, some of these EEA countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product to currently available therapies. Other EEA countries allow companies to fix their own prices for medicinal products, but monitor and control company profits. The downward pressure on healthcare costs in general, particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from <span style="white-space:nowrap">low-priced</span> markets exert a commercial pressure on pricing within a country. There can be no assurance that any country that has price controls or reimbursement limitations for products will allow favorable reimbursement and pricing arrangements for any of our products. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">U.S. Healthcare Reform </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States there have been, and continue to be, proposals by the federal government, state governments, regulators and third-party payors to control or manage the increased costs of healthcare and, more generally, to reform the U.S. healthcare system. The pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2020 (the &#8220;ACA&#8221;) was enacted, which is intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms, and which substantially changes the way healthcare is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry. The ACA, among other things, (1)&#160;subjected therapeutic biologics to potential competition by lower-cost biosimilars by creating a licensure framework for <span style="white-space:nowrap">follow-on</span> biologic products, (2)&#160;prescribed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, (3)&#160;increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, (4)&#160;established annual nondeductible fees and taxes on manufacturers of certain branded </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">168 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prescription drugs, apportioned among these entities according to their market share in certain government healthcare programs, (5)&#160;established a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer <span style="white-space:nowrap"><span style="white-space:nowrap">point-of-sale</span></span> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D, (6)&#160;expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability, (7)&#160;expanded the entities eligible for discounts under the 340B Public Health Service Act program, (8)&#160;created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research, and (9)&#160;established a Center for Medicare Innovation at the CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been judicial, Congressional and Administrative challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, legislation affecting the implementation of certain taxes under the ACA has been signed into law. The Tax Cuts and JOBS Act of 2017 (the &#8220;TCJA&#8221;) included a provision that repealed, effective January&#160;1, 2019, the <span style="white-space:nowrap">tax-based</span> shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. Further, the Bipartisan Budget Act of 2018 (the &#8220;BBA&#8221;), among other things, amended the ACA, effective January&#160;1, 2019, to increase from 50% to 70% the <span style="white-space:nowrap"><span style="white-space:nowrap">point-of-sale</span></span> discount that is owned by pharmaceutical manufacturers who participate in Medicare Part D and to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole&#8221;. On June&#160;17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January&#160;28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. In addition, on August&#160;16, 2022, President Biden signed the Inflation Reduction Act of 2022 into law, which, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The Inflation Reduction Act also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> cost through a newly established manufacturer discount program. It is unclear how additional healthcare reform measures of the Biden administration or other efforts, if any, to modify or invalidate the ACA or its implementing regulations, or portions thereof, will impact our business. Any health care reform measures will likely take time to unfold, and could have an impact on coverage and reimbursement for healthcare items and services. We cannot predict the ultimate content, timing or effect of any healthcare reform legislation or other policy or the impact of potential legislation or other policy on us. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other legislative and administrative changes have been proposed and adopted in the United States since the ACA was enacted to reduce healthcare expenditures. For example, the Budget Control Act of 2011, among other things, in connection with subsequent legislation, reduced Medicare payments to providers, on average, by 2% per fiscal year. These reductions went into effect on April&#160;1, 2013 and, due to subsequent legislative amendments to the statute, including the BBA, will remain in effect through 2030, with the exception of a temporary suspension from May&#160;1, 2020, through May&#160;31, 2022, due to the <span style="white-space:nowrap">COVID-19</span> pandemic. The law provides for 1% Medicare sequestration in the second quarter of 2022 and allows the full 2% sequestration thereafter until 2030. To offset the temporary suspension during the <span style="white-space:nowrap">COVID-19</span> pandemic, in 2030, the sequestration will be 2.25% for the first half of the year, and 3% in the second half of the year. Moreover, on January&#160;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">169 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. If federal spending is further reduced, anticipated budgetary shortfalls may impact the ability of relevant agencies to continue to function at current levels. Amounts allocated to federal grants and contracts may be reduced or eliminated. These reductions may also impact the ability of relevant agencies to timely review and approve research and development, manufacturing, and marketing activities, which may delay our ability to develop, market and sell any products we may develop. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. On May&#160;16, 2019, CMS adopted a final rule that, among other things, will require Part D plans to adopt Real Time Benefit Tools that are capable of integrating with electronic prescribing or electronic health record systems and have the capability to inform prescribers when lower-cost alternative therapies are available under a beneficiary&#8217;s prescription drug benefit. Similarly, since 2021, Part D Explanation of Benefits transmittals to members are required to inform Part D beneficiaries about drug prices and lower cost therapeutic alternatives. On August&#160;16, 2022, President Biden signed into law the Inflation Reduction Act of 2022, which among other things, contains two specific provisions affecting pricing for drugs and biologics. The first provision allows for CMS to negotiate prices for certain single-source drugs and biologics reimbursed under Medicare Part B and Part D, beginning with ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Part D drugs in 2027, 15 Part B or Part D drugs in 2028, and 20 Part B or Part D drugs in 2029 and beyond. The legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law or for taking price increases that exceed inflation. The legislation also caps Medicare beneficiaries&#8217; annual <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> drug expenses at $2,000. The second provision imposes a requirement that pharma manufacturers provide a rebate to Medicare, if the manufacturer increases price at a rate higher than the measured inflation rate. Medicaid has had a rebate program for several years, but Medicare did not. The intent is to limit price increases. The new rebate applies to drugs covered by Medicare under Part B or Part D. The rebate obligation applies if the average sales price (for Part B) or average manufacturers price (for Part D) of a single source drug or biologic increases more than the rate of inflation (as measured by the index for urban consumers). The rebate amount is the total number of units sold in Medicare coverage multiplied by the amount by which the price exceeds the inflation adjusted price. The base year against which the inflation adjustment is measured is 2021. If the price exceeds the inflation adjusted price, the difference is multiplied by the units sold in Medicare and that amount is to be rebated. A failure to pay the rebate is subject to a penalty of 125% of the original rebate amount. The provision for Part D takes effect in 2022, with rebates to be paid beginning in 2023. The provision for Part B takes effect in 2023. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures. In some cases, states appear interested in public policy designed to encourage drug importation from other countries and bulk purchasing. Furthermore, there has been increased interest by third-party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that other healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product, and could seriously harm our future revenue. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">170 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other U.S. Healthcare Laws and Compliance Requirements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, our activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare and Medicaid Services, other divisions of the United States Department of Health and Human Services (e.g., the Office of Inspector General), the United States Department of Justice and individual United States Attorney offices within the Department of Justice, and state and local governments. For example, various activities, including but not limited to sales, marketing and scientific/educational grant programs, must comply with the anti-fraud and abuse provisions of the Social Security Act, the federal Anti-Kickback Statute, the federal False Claims Act and similar state laws, each as amended. Failure to comply with such requirements could potentially result in substantial penalties to us. Even if we structure our programs with the intent of compliance with such laws, there can be no certainty that we would not need to defend against enforcement or litigation, in light of the fact that there is significant enforcement interest in pharmaceutical companies in the United States, and some of the applicable laws are quite broad in scope. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The federal Anti-Kickback Statute prohibits any person, including a pharmaceutical manufacturer (or a party acting on its behalf), from knowingly and willfully soliciting, receiving, offering or providing remuneration, directly or indirectly, to induce or reward either the referral of an individual, or the furnishing, recommending, or arranging for a good or service, for which payment may be made under a federal healthcare program such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. The term &#8220;remuneration&#8221; is not defined in the federal Anti-Kickback Statute and has been broadly interpreted to include anything of value, including for example, gifts, discounts, the furnishing of supplies or equipment, credit arrangements, payments of cash, waivers of payments, ownership interests and providing anything at less than its fair market value. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain business arrangements from prosecution, the exemptions and safe harbors are drawn narrowly and practices that involve remuneration intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Our practices may not in all cases meet all of the criteria for safe harbor protection from federal Anti-Kickback Statute liability. The government can establish a violation of the Anti-Kickback Statute without proving that a person or entity had actual knowledge of this statute or specific intent to violate it. In addition, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act (discussed below) or the civil monetary penalties statute, which imposes fines against any person who is determined to have presented or caused to be presented claims to a federal healthcare program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. Additionally, many states have adopted laws similar to the federal Anti-Kickback Statute, and some of these state prohibitions apply to referral of patients for healthcare items or services reimbursed by any third-party payor, not only the Medicare and Medicaid programs in at least some cases, and do not contain safe harbors. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The federal False Claims Act imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment of government funds, or knowingly makes, uses, or causes to be made or used a false statement material to a false or fraudulent claim, or knowingly conceals or knowingly and improperly avoids, or decreases an obligation to pay money to the government. The qui tam provisions of the False Claims Act allow a private individual to bring civil actions on behalf of the federal government alleging that the defendant has submitted a false claim to the federal government and to share in any monetary recovery. In recent years, the number of suits brought by private individuals has increased dramatically. In addition, various states have enacted false claims laws analogous to the False Claims Act. Many of these state laws apply where a claim is submitted to any third-party payor and not merely a federal healthcare program. There are many potential bases for liability under the False Claims Act. Liability arises, primarily, when an entity knowingly submits, or causes another to submit, a false claim for reimbursement to the federal government. The False Claims Act has been used to assert liability on the basis of inadequate care, kickbacks and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">171 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other improper referrals, improperly reported government pricing metrics such as Best Price or Average Manufacturer Price, improper promotion of <span style="white-space:nowrap">off-label</span> uses (i.e., uses not expressly approved by the FDA in a drug&#8217;s label), and allegations as to misrepresentations with respect to the services rendered. Our activities relating to the reporting of discount and rebate information and other information affecting federal, state and third-party reimbursement of our products, and the sale and marketing of our products and our service arrangements or data purchases, among other activities, may be subject to scrutiny under these laws. We are unable to predict whether we would be subject to actions under the False Claims Act or a similar state law, or the impact of such actions. However, the cost of defending such claims, as well as any sanctions imposed, could adversely affect our financial performance. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The healthcare fraud provisions under the U.S. federal Health Insurance Portability and Accountability Act of 1996 and its implementing regulations (&#8220;HIPAA&#8221;) impose criminal liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any health care benefit program, including private third-party payors, or falsifying or covering up a material fact or making any materially false or fraudulent statement in connection with the delivery of or payment for health care benefits, items or services. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may be subject to, or our marketing activities may be limited by, data privacy and security regulation promulgated by both the U.S. federal government and the U.S. states in which we conduct our business. For example, under HIPAA, the U.S. Department of Health and Human Services imposes upon &#8220;covered entities&#8221; (broadly, healthcare providers, health plans and healthcare clearinghouses) and their respective &#8220;business associates&#8221; (individuals or entities that create, receive, maintain or transmit protected health information on behalf of a covered entity) privacy obligations; requirements to implement appropriate administrative, physical and technical safeguards to ensure the confidentiality, integrity, and security of electronic protected health information; and breach response notification obligations. We are not subject to HIPAA, as we are neither a covered entity nor business associate. The Federal Trade Commission (the &#8220;FTC&#8221;) also requires companies to take appropriate steps to keep consumers&#8217; personal information secure and to make accurate statements regarding how they secure personal information under their custody or control, such as in a privacy notice. The FTC also expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of personal information it holds, the size and complexity of its business, and the cost of available tools to improve data security and reduce vulnerabilities. Individually identifiable health information, which we process, is considered sensitive data that merits stronger safeguards. Violations of the foregoing FTC requirements may constitute unfair or deceptive acts or practices under Section&#160;5(a) of the Federal Trade Commission Act (the &#8220;FTC Act&#8221;). While we do not intend to engage in unfair or deceptive acts or practices, the FTC has the power to enforce public privacy statements as it interprets them. Further, events that we cannot fully control, such as data breaches, may also result in civil penalties, FTC enforcement or enforcement by U.S. state attorneys general or other regulators. Various U.S. states have implemented privacy laws and regulations that regulate the use and disclosure of health information and other personal information. For example, the California Consumer Privacy Act and its implementing regulations (the &#8220;CCPA&#8221;), established a privacy framework for covered businesses by, among other items, expanding the definition of personal information, establishing new data privacy rights for consumers that are resident in the State of California, imposing rules on the collection of personal information from minors, and creating a statutory damages framework for violations of the CCPA, including for failure to implement reasonable security procedures and practices to prevent data breaches. Penalties for violations of the CCPA include civil penalties and may result in related legal claims. The California Privacy Rights Act (&#8220;CPRA&#8221;), most provisions of which became operative on January&#160;1, 2023, introduced significant amendments to the CCPA and established and funded a dedicated California privacy regulator, the California Privacy Protection Agency (the &#8220;CPPA&#8221;). Similarly, the Virginia Consumer Data Protection Act took effect on January&#160;1, 2023; the Colorado Privacy Act took effect on July&#160;1, 2023; the Utah Consumer Privacy Act took effect on December&#160;31, 2023; and the Connecticut Data Privacy Act took effect on July&#160;1, 2023. The foregoing U.S. state privacy laws impose many similar obligations as the CCPA on our processing of personal information. Other U.S. states are considering similar privacy legislation, and industry organizations regularly adopt and advocate for new standards in these areas. The uncertainty, ambiguity, complexity, and potential inconsistency surrounding the implementation and interpretation of the CCPA and other enacted or forthcoming U.S. state privacy laws </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">172 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exemplify the vulnerability of our business to the evolving regulatory environment related to the privacy, security and confidentiality of personal information and protected health information. We may be subject to fines, penalties, or private actions in the event of <span style="white-space:nowrap">non-compliance</span> with such laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our activities outside of the U.S. implicate local, state, provincial, and national data protection standards, impose additional compliance requirements and generate additional risks of enforcement for <span style="white-space:nowrap">non-compliance.</span> Such laws may also restrict the access, use and disclosure of patient health information abroad. We may be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws, to protect against security breaches and hackers, or to remediate issues caused by such breaches. Compliance with these laws is challenging, constantly evolving, time consuming, and requires a flexible privacy framework and substantial resources. Compliance efforts will likely be an increasing and substantial cost in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The U.S. federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to CMS information related to payments or other transfers of value made to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. In addition to this federal requirement, a number of individual states and foreign jurisdictions require detailed reporting and often public disclosures concerning transfers of value to physicians, other health care providers and family members. Effective January&#160;1, 2022, these reporting obligations are extended to include transfers of value made to certain <span style="white-space:nowrap">non-physician</span> providers such as physician assistants and nurse practitioners. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Compliance with such requirements may require investment in infrastructure to ensure that tracking is performed properly, and some of these laws result in the public disclosure of various types of payments and relationships. Several states have enacted legislation requiring pharmaceutical companies to, among other things, establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, or register their sales representatives, as well as prohibiting pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical companies for use in sales and marketing, and prohibiting certain other sales and marketing practices. These laws may affect our sales, marketing and other promotional activities by imposing administrative and compliance burdens on us. If we fail to track and report as required by these laws or otherwise comply with these laws, we could be subject to the penalty provisions of the pertinent state and federal authorities. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where our activities involve foreign government officials, they may also potentially be subject to the Foreign Corrupt Practices Act (&#8220;FCPA&#8221;). If we seek to have a product paid for with federal funds under the Medicaid programs or Medicare Part B, various obligations, including government price reporting, are required under the Medicaid rebate provisions of the Omnibus Budget Reconciliation Act of 1990 and the Veterans Health Care Act of 1992, each as amended, which generally require products to be offered at substantial rebates/discounts to such programs and certain purchasers. Government price reporting may also be required with respect to average sales price, which serves as the basis of reimbursement under Medicare Part B. In order to distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of pharmaceutical products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain. Many of our current as well as possible future activities are potentially subject to federal and state consumer protection and unfair competition laws. We must also comply with laws that require clinical trial registration and reporting of clinical trial results on the publicly available clinical trial databank maintained by the National Institutes of Health at www.ClinicalTrials.gov. We are subject to various environmental, health and safety regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous substances. From time to time, and in the future, our operations may involve the use of hazardous materials. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">173 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the narrowness of available statutory and regulatory exemptions, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the federal and state laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including criminal and significant civil monetary penalties, damages, fines, imprisonment, exclusion from participation in government healthcare programs, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of <span style="white-space:nowrap">pre-marketing</span> product approvals, private &#8220;qui tam&#8221; actions brought by individual whistleblowers in the name of the government or refusal to allow us to enter into supply contracts, including government contracts, integrity oversight and reporting obligations to resolve allegations of <span style="white-space:nowrap">non-compliance,</span> and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. To the extent that any of our products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">U.S. Marketing Exclusivity </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Hatch-Waxman Exclusivity</span>. Market exclusivity provisions under the FDCA can also delay the submission or the approval of certain applications of other companies seeking to reference another company&#8217;s NDA. If the new drug is a new chemical entity subject to an NDA, the FDCA provides a five-year period of <span style="white-space:nowrap">non-patent</span> marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. This definition is currently under FDA review. During the exclusivity period, the FDA may not accept for review an ANDA or a Section&#160;505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, such an application may be submitted after four years if it contains a certification of patent invalidity or <span style="white-space:nowrap">non-infringement</span> to one of the patents listed with the FDA by the innovator NDA holder. The FDCA also provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA, if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, such as new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Pediatric Exclusivity</span>. Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to any existing exclusivity period or patent term. This <span style="white-space:nowrap">six-month</span> exclusivity may be granted by the FDA based on the completion of a pediatric clinical trial in accordance with provisions of the FDCA. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Europe/Rest of World Government Regulation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to regulations in the United States, we are subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials, pricing and reimbursement, anti-bribery, advertising and promotion, data privacy and security and any commercial sales and distribution of our future products. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">174 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the EEA, for example, a clinical trial application (&#8220;CTA&#8221;) must be submitted to each country&#8217;s national health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the CTA is approved in accordance with the EU Clinical Trials Directive 2001/20/EC (the &#8220;Clinical Trials Directive&#8221;) and the related national implementing provisions of the relevant individual EEA country&#8217;s requirements, the clinical trial described in that CTA may proceed. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2014, the new Clinical Trials Regulation, (EU) No 536/2014 (the &#8220;Clinical Trials Regulation&#8221;) was adopted. The Clinical Trials Regulation entered into force on January&#160;31, 2022. The Clinical Trials Regulation is directly applicable in all the EEA countries, repealing the prior Clinical Trials Directive. The new Clinical Trials Regulation allows a sponsor to start and conduct a clinical trial in accordance with the Clinical Trials Directive during a transitional period of one year after the application date, i.e. January&#160;31, 2022. The transition period for the trials ongoing at the moment of applicability will be a maximum of 3 years after the date of application of the Clinical Trials Regulation. Clinical trials authorized under the current Clinical Trials Directive before January&#160;31, 2023 can continue to be conducted under the Clinical Trials Directive until January&#160;31, 2025. An application to transition ongoing trials from the current Clinical Trials Directive to the new Clinical Trials Regulation will need to be submitted and authorized in time before the end of the transitional period. The new Clinical Trials Regulation is intended to simplify and streamline the approval of clinical trials in the EEA. The main characteristics of the regulation include: a streamlined application procedure through a single entry point, the &#8220;EU portal&#8221;; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided into two parts. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For other countries outside of the EEA, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials vary from country to country. Internationally, clinical trials are generally required to be conducted in accordance with GCP, applicable regulatory requirements of each jurisdiction and the medical ethics principles that have their origins in the Declaration of Helsinki. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the EEA, medicinal products can be commercialized only after obtaining a Marketing Authorization (&#8220;MA&#8221;). There are several procedures for requesting marketing authorization which can be more efficient than applying for authorization on a <span style="white-space:nowrap"><span style="white-space:nowrap">country-by-country</span></span> basis. There is a &#8220;centralized&#8221; procedure allowing submission of a single marketing authorization application to the European Medicines Agency (the &#8220;EMA&#8221;). If the EMA issues a positive opinion, the European Commission will grant a centralized marketing authorization that is valid in all EEA countries. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The &#8220;centralized&#8221; procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, and medicinal products containing a new active substance indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases. The &#8220;centralized&#8221; procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EEA. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is also a &#8220;decentralized&#8221; procedure allowing companies to file identical applications to several EEA countries simultaneously for product candidates that have not yet been authorized in any EEA country and a &#8220;mutual recognition&#8221; procedure allowing companies that have a product already authorized in one EEA country to apply for that authorization to be recognized by the competent authorities in other EEA countries. Under the &#8220;decentralized&#8221; procedure, an identical dossier is submitted to the competent authorities of each of the EEA countries in which the MA is sought, one of which is selected by the applicant as the Reference Member State (&#8220;RMS&#8221;). If the RMS proposes to authorize the product, and the other EEA countries do not raise objections, the product is authorized in all the EEA countries where the authorization was sought. Before granting the MA, the EMA or the competent authorities of the EEA countries make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">175 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In many countries outside the United States, procedures to obtain price approvals, coverage and reimbursement can take considerable time after the receipt of a MA. Many EEA countries periodically review their reimbursement of medicinal products, which could have an adverse impact on reimbursement status. In addition, we expect that legislators, policymakers and healthcare insurance funds in the EEA countries will continue to propose and implement cost-containing measures, such as lower maximum prices, lower or lack of reimbursement coverage and incentives to use cheaper, usually generic, products as an alternative to branded products, and/or branded products available through parallel import to keep healthcare costs down. Moreover, in order to obtain reimbursement for our products in some EEA countries, including some EU Member States, we may be required to compile additional data comparing the cost-effectiveness of our products to other available therapies. Health Technology Assessment (&#8220;HTA&#8221;) of medicinal products is becoming an increasingly common part of the pricing and reimbursement procedures in some EEA countries, including those representing the larger markets. The HTA process, which is currently governed by national laws in each EEA country, is the procedure to assess therapeutic, economic and societal impact of a given medicinal product in the national healthcare systems of the individual country. The outcome of an HTA will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EEA countries. The extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product currently varies between EEA countries, although the HTA Regulation, which aims to harmonize the clinical benefit assessment of HTA across the EEA, will apply from January&#160;12, 2025. If we are unable to maintain favorable pricing and reimbursement status in EEA countries that represent significant markets, our anticipated revenue from and growth prospects for our products in the EEA could be negatively affected. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Outside the United States, interactions between pharmaceutical companies and physicians are also governed by strict laws, such as national anti-bribery laws of EEA countries, national sunshine rules, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the EEA, the advertising and promotion of our products are subject to laws governing promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. For example, applicable laws require that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s Summary of Product Characteristics (&#8220;SmPC&#8221;), as approved by the competent authorities in connection with a marketing authorization approval. The SmPC is the document that provides information to physicians concerning the safe and effective use of the product. Promotional activity that does not comply with the SmPC is considered <span style="white-space:nowrap">off-label</span> and is prohibited in the EEA. Other applicable laws at the EEA level and in the individual EU Member States also apply to the advertising and promotion of medicinal products, including laws that prohibit the <span style="white-space:nowrap"><span style="white-space:nowrap">direct-to-consumer</span></span> advertising of prescription-only medicinal products and further limit or restrict the advertising and promotion of our products to the general public and to health care professionals. Violations of the rules governing the promotion of medicinal products in the EEA could be penalized by administrative measures, fines and imprisonment. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to data privacy and security regulations in the United States, we may be subject to, or our marketing activities may be limited by, data privacy and security regulations in the EEA, Switzerland, or the United Kingdom (&#8220;UK&#8221;), where the legislative and regulatory landscape continues to evolve. There has been increased regulator attention to privacy and data security issues that could potentially affect our business, including through legislation such as the EEA General Data Protection Regulation (&#8220;EEA GDPR&#8221;) and UK General Data Protection Regulation (&#8220;UK GDPR,&#8221; and together, the &#8220;GDPR&#8221;), which each imposes strict obligations on the processing of personal data, including the transfer of personal data from the EEA, Switzerland, or UK to third countries that the European Commission has determined does not ensure an adequate level of protection, such as the United States. If we violate the GDPR, we may face significant penalties of up to EUR 10,000,000 or 2% of our total worldwide annual turnover, or for more serious violations, up to EUR 20,000,000 or 4% of our total worldwide annual turnover. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">176 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The GDPR and other EEA and UK data privacy and security regulations generally restrict the transfer of personal data from the EEA, United Kingdom and Switzerland, to the United States and certain other third countries unless the parties to the transfer have implemented specific safeguards to protect the transferred personal data. One of the primary safeguards on which companies may rely to import or export personal data from had been the <span style="white-space:nowrap">EU-U.S.</span> Privacy Shield and <span style="white-space:nowrap">Swiss-U.S.</span> Privacy Shield frameworks administered by the U.S. Department of Commerce. However, the <span style="white-space:nowrap">EU-U.S.</span> Privacy Shield was invalidated in July 2020 by the Court of Justice of the European Union (the &#8220;CJEU&#8221;) in a case known as &#8220;<span style="font-style:italic">Schrems II</span>.&#8221; Following this decision, the Swiss Federal Data Protection and Information Commissioner (the &#8220;FDPIC&#8221;) announced that the <span style="white-space:nowrap">Swiss-U.S.</span> Privacy Shield does not provide adequate safeguards for the purposes of personal data transfers from Switzerland to third countries that are deemed as not providing adequate protection, including the United States. While the FDPIC does not have authority to invalidate the <span style="white-space:nowrap">Swiss-U.S.</span> Privacy Shield regime, the FDPIC&#8217;s announcement casts doubt on the viability of the <span style="white-space:nowrap">Swiss-U.S.</span> Privacy Shield as a compliance mechanism for <span style="white-space:nowrap">Swiss-U.S.</span> data transfers. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The CJEU&#8217;s decision in <span style="font-style:italic">Schrems II</span> also raised questions about whether one of the primary alternatives to the <span style="white-space:nowrap">EU-U.S.</span> Privacy Shield, namely the European Commission&#8217;s Standard Contractual Clauses, can lawfully be used for personal data transfers from Europe to the United States or other third countries that are not the subject of an adequacy decision of the European Commission. While the CJEU upheld the adequacy of the Standard Contractual Clauses in principle in <span style="font-style:italic">Schrems II</span>, it made clear that reliance on the Standard Contractual Clauses alone may not necessarily be sufficient in all circumstances. Use of the Standard Contractual Clauses must now be assessed on a <span style="white-space:nowrap"><span style="white-space:nowrap">case-by-case</span></span> basis taking into account the legal regime applicable in the destination country, in particular regarding applicable surveillance laws and relevant rights of individuals with respect to the transferred data. In the context of any given transfer, where the legal regime applicable in the destination country may or does conflict with the intended operation of the Standard Contractual Clauses and/or applicable European law, the decision in <span style="font-style:italic">Schrems II</span> and subsequent draft guidance from the European Data Protection Board (the &#8220;EDPB&#8221;) would require the parties to that transfer to implement certain supplementary technical, organizational and/or contractual measures to rely on the Standard Contractual Clauses as a lawful &#8220;transfer mechanism.&#8221; However, the draft guidance from the EDPB on such supplementary technical, organizational and/or contractual measures appears to conclude that any combination of such measures may not be sufficient to allow effective reliance on the Standard Contractual Clauses in the context of transfers of personal data &#8220;in the clear&#8221; to recipients in countries where the power granted to public authorities to access the transferred data goes beyond that which is &#8220;necessary and proportionate in a democratic society&#8221;&#8212;which may, following the CJEU&#8217;s conclusions in <span style="font-style:italic">Schrems II</span> on relevant powers of United States public authorities and commentary in draft EDPB guidance, include the United States in certain circumstances (<span style="font-style:italic">e.g</span>., where Section&#160;702 of the U.S. Foreign Intelligence Surveillance Act applies). Further, the UK Information Commissioner&#8217;s Office (&#8220;ICO&#8221;) has provided for separate international data transfer mechanisms for restricted transfers of data from the UK: an international data transfer agreement (the UK equivalent of the EU Standard Contractual Clauses) (&#8220;IDTA&#8221;) and an international data transfer addendum (which amends the EU Standard Contractual Clauses for purposes of international data transfers from the UK to countries without an essentially equivalent data protection framework) (the &#8220;Addendum&#8221;). Both the IDTA and the Addendum came into force in March 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are unable to implement a valid solution to transfer personal data from the EEA to the United States or other countries that have not been deemed to provide an essentially equivalent level of data protection, we may face increased exposure to regulatory action, substantial fines, or injunction orders to stop processing personal data from EEA, Swiss, or UK residents. Any inability to import personal data to the United States may also restrict our clinical trials activities in the EU; limit our ability to collaborate with contract research organizations as well as other service providers, contractors and other companies subject to EU data privacy and security laws; and require us to increase our data processing capabilities in the EU and the UK at a significant expense. Additionally, other countries outside of the EU have enacted or are considering enacting similar cross-border data transfer restrictions and laws requiring local data residency, which could increase the cost and complexity of delivering our services and operating our business. The types of challenges we face in the EEA, Switzerland, and the UK will likely also arise in other jurisdictions that adopt laws similar to the GDPR or regulatory frameworks of equivalent complexity. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">177 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions or criminal prosecution. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Employees and Human Capital Resources </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, we had approximately 105 full-time employees, including five employees who have M.D.s or Ph.D.s. Within our workforce, seven employees were primarily engaged in research and development, 81 were primarily engaged in sales and marketing and 17 were primarily engaged in general management and administration. None of our employees are represented by labor unions or covered by collective bargaining agreements. We believe that we maintain good relationships with our employees. We focus on identifying, attracting, incentivizing, developing and retaining an exceptional team of highly talented and motivated employees to support our current product pipeline and future business goals. In order to drive innovation, we continuously improve our human capital management strategies and find ways to foster engagement and growth within our company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We regularly benchmark total rewards we provide against our industry peers to ensure we offer competitive compensation and benefits packages to our employees and potential new hires. The principal purposes of our equity and cash incentive plans are to attract, retain and reward selected personnel through the granting of stock-based and cash-based compensation awards, as well as provide our employees with the opportunity to participate in our employee stock purchase plan, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. We strive to build a diverse environment where our employees can thrive and one that inspires exceptional contributions and professional and personal development in order to achieve our vision to become the leading pain management company that can have a transformative impact on patients&#8217; lives. The success of our business is fundamentally connected to the well-being, health and safety of our employees. In an effort to protect the health and safety of our employees, we took proactive action from the earliest signs of the <span style="white-space:nowrap">COVID-19</span> outbreak, which included implementing social distancing policies at our facilities, facilitating remote working arrangements, requiring proof of vaccination or acceptable exemption, and imposing employee travel restrictions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to continue to develop our efforts related to attracting, retaining and motivating our workforce as we grow and develop. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Properties </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our principal executive office is currently located in Palo Alto, California, and consists of approximately 12,500 square feet of leased office space. The lease term expires in September 2027. We also sublease office space in San Diego, California. We believe our facilities are adequate to meet our current needs, although we may seek to negotiate new leases or evaluate additional or alternate space for our operations. We believe appropriate additional or alternative space will be available on commercially reasonable terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Legal Proceedings </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time we may become involved in various legal proceedings, including those that may arise in the ordinary course of business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc. Litigation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;23, 2021, we filed an action (the &#8220;Action&#8221;) in the U.S. District Court for the Northern District of California against Sanofi-Aventis U.S. LLC (&#8220;Sanofi&#8221;) and Hisamitsu America, Inc. (&#8220;Hisamitsu&#8221;), two manufacturers of OTC lidocaine patch products, alleging, among other things, false and deceptive advertising and unfair competition under the Lanham Act and California state laws by those companies regarding their </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">178 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
respective OTC patch products. This lawsuit sought, among other relief, damages and an injunction enjoining the defendants from continuing to make false or misleading statements of fact about their respective OTC lidocaine patch products. The defendants filed motions to dismiss, which narrowed slightly the Company&#8217;s claims, but which motions the court largely rejected. Discovery was proceeding. On January&#160;26 and February&#160;2, 2024, Scilex Pharma entered into two separate settlement agreements and mutual releases with the two manufacturers that resolve the Action. The terms of those agreements are confidential. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Former Employee Action </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;12, 2021, Scilex Pharma and Sorrento (the &#8220;Plaintiffs&#8221;) filed an action (the &#8220;Former Employee Action&#8221;) in the Delaware Court of Chancery against the former President of Scilex Pharma, Anthony Mack, and Virpax Pharmaceuticals, Inc. (&#8220;Virpax&#8221;, together with Mr.&#160;Mack, the &#8220;Defendants&#8221;), a company founded and then headed by Mr.&#160;Mack, alleging, among other things, breach by Mr.&#160;Mack of a restrictive covenant agreement with Sorrento related to his sale of his Scilex Pharma stock to Sorrento, tortious interference with that agreement by Virpax, breach of Mr.&#160;Mack&#8217;s fiduciary duties to Scilex Pharma, aiding and abetting of that breach by Virpax, and misappropriation of Scilex Pharma&#8217;s trade secrets by Mr.&#160;Mack and Virpax. Such lawsuit sought, among other relief, damages and various forms of injunctive relief. The case was tried from September&#160;12, 2022 to September&#160;14, 2022. On September&#160;1, 2023, the court found in favor of the Plaintiffs on all but three counts deemed to have been waived. In its <span style="white-space:nowrap">95-page</span> opinion, the court instructed the parties to submit supplemental briefing on the appropriate remedy to implement its rulings. On October&#160;18, 2023, the Plaintiffs submitted a supplemental brief on remedies. On November&#160;29, 2023, Defendants submitted a supplemental brief on remedies. On December&#160;21, 2023, the Plaintiffs submitted a supplemental reply brief on remedies. On February&#160;26, 2024, we and Virpax entered into a term sheet regarding a mutual release and settlement agreement, pursuant to which the parties have agreed to resolve the ongoing disputes. On February&#160;29, 2024, we and Virpax entered into a definitive settlement agreement, which provides for, among other things, that Virpax will be obligated to make the following payments to us to settle the Former Employee Action: (i) $3.5&#160;million (the &#8220;Initial Payment&#8221;) by two business days after the Effective Date (as defined therein); (ii) $2.5&#160;million by July&#160;1, 2024 and (iii)&#160;to the extent any of the following drug candidates are ever sold, royalty payments of (a) 6% of annual Net Sales (as defined therein) of Epoladerm; (b) 6% of annual Net Sales of Probudur and (c) 6% of annual Net Sales of Envelta during the Royalty Term (as defined therein). We and Virpax provide mutual releases of all claims that exist as of the Effective Date, whether known or unknown, arising from any allegations set forth in the Former Employee Action. Plaintiffs&#8217; release relates to claims against Virpax only, which does not affect our claims against Mr.&#160;Mack. Plaintiffs have not released Mr.&#160;Mack, and litigation against him remains ongoing. Plaintiffs&#8217; release as to Virpax is conditioned upon Virpax&#8217;s Initial Payment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ZTlido Patent Litigation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2022, we filed a complaint against Aveva Drug Delivery Systems, Inc. (&#8220;Aveva&#8221;), Apotex Corp., and Apotex, Inc. (together, &#8220;Apotex&#8221;) in the U.S. District Court for the Southern District of Florida (the &#8220;ZTlido Patent Litigation&#8221;) alleging infringement of certain Orange Book listed patents covering ZTlido (the &#8220;ZTlido Patents&#8221;). The ZTlido Patent Litigation was initiated following the submission by Apotex, in accordance with the procedures set out in the Hatch-Waxman Act, of an abbreviated new drug application (&#8220;ANDA&#8221;). Apotex&#8217;s ANDA seeks approval to market a generic version of ZTlido prior to the expiration of the ZTlido Patents and alleges that the ZTlido Patents are invalid, unenforceable, and/or not infringed. We are seeking, among other relief, an order that the effective date of any FDA approval of Apotex&#8217;s ANDA be no earlier than the expiration of the asserted patents listed in the Orange Book, the latest of which expires on May&#160;10, 2031, and such further and other relief as the court may deem appropriate. Apotex is subject to a <span style="white-space:nowrap">30-month</span> stay preventing it from selling a generic version of ZTlido during that time. The stay should expire no earlier than November&#160;11, 2024. The two Apotex entities were recently dismissed from the litigation without prejudice, as they no longer have an interest in the generic product that Aveva seeks to market. Trial in the ZTlido Patent Litigation has been scheduled for July&#160;8, 2024. We cannot make any predictions about the final outcome of this matter or the timing thereof. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">179 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">GLOPERBA Patent Litigation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;6, 2023, Takeda Pharmaceuticals U.S.A., Inc. (&#8220;Takeda&#8221;) filed a complaint against the Company in the U.S. District Court for the District of Delaware (the &#8220;GLOPERBA Patent Litigation&#8221;) alleging that our filing with the FDA of an application for approval of a proposed revision to the product label for our GLOPERBA product infringed certain Orange Book listed patents covering Takeda&#8217;s colchicine product, Colcrys<sup style="font-size:75%; vertical-align:top">&#174;</sup> (the &#8220;Colcrys Patents&#8221;). Takeda is seeking an order that the effective date of any FDA approval of the Company&#8217;s labeling revision be no earlier than the expiration date of the asserted patents listed in the Orange Book, and such further and other relief as the court may deem appropriate. The filing of the complaint subjects us to a <span style="white-space:nowrap">30-month</span> stay, preventing us from selling GLOPERBA under a revised label (but not from selling GLOPERBA under its current label) during that time. The stay could last as long as until May&#160;6, 2026, unless the litigation is resolved before that time. We cannot make any predictions about the final outcome of this matter or the timing thereof. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Corporate History </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Legacy Scilex was incorporated in Delaware in February 2019 for the purpose of effecting a corporate reorganization. On March&#160;18, 2019, Legacy Scilex entered into a Contribution and Loan Agreement with Sorrento and the holders of the outstanding shares of capital stock of Scilex Pharma pursuant to which Legacy Scilex acquired 100% of the outstanding shares of capital stock of Scilex Pharma in exchange for shares of Legacy Scilex Common Stock (such transaction, the &#8220;Contribution&#8221;). Pursuant to the Contribution and Loan Agreement, Sorrento provided Legacy Scilex with a loan with an initial principal amount of $16.5&#160;million in the form of a note payable, which loan was used to fund the acquisition of Semnur. Concurrently therewith, Legacy Scilex entered into an Agreement and Plan of Merger with Semnur, Sigma Merger Sub, Inc., Legacy Scilex&#8217;s prior wholly owned subsidiary, Fortis Advisors LLC, solely as representative of the holders of Semnur equity, and Sorrento, for limited purposes (as amended, the &#8220;Semnur Merger Agreement&#8221;). Pursuant to the Semnur Merger Agreement, Sigma Merger Sub, Inc. merged with and into Semnur (such transaction, the &#8220;Semnur Merger&#8221;), with Semnur surviving the Semnur Merger as Legacy Scilex&#8217;s wholly owned subsidiary. As a result of the Contribution and the Semnur Merger, Scilex Pharma and Semnur became Legacy Scilex&#8217;s wholly owned subsidiaries. Prior to the Contribution and the Semnur Merger, operations of Legacy Scilex were conducted through Scilex Pharma, which was formed in September 2012. Semnur was formed in June 2013. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;10, 2022, we consummated the Business Combination with Vickers and Legacy Scilex. In connection with the Business Combination, Vickers changed its name from Vickers Vantage Corp. I to Scilex Holding Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). As an emerging growth company, we are eligible for exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Website Access to SEC Filings </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and special reports, proxy statements and other information with the SEC. The SEC maintains an Internet website at http://www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, including Scilex. We maintain an Internet website at www.scilexholding.com. Any information contained on, or that can be accessed through, our website is not incorporated by reference into, nor is it in any way part of this prospectus and should not be relied upon in connection with many any decision with respect to any investment in our securities. We make available, free of charge through our Internet website, our Annual Reports on Form <span style="white-space:nowrap">10-K,</span> Quarterly Reports on Form <span style="white-space:nowrap">10-Q,</span> Current Reports on Form <span style="white-space:nowrap">8-K</span> and amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after we electronically file or furnish this information to the SEC. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">180 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx759370_13">MANAGEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following sets forth certain information, as of the date of this prospectus, concerning the persons who are serving as our directors and executive officers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive Officers and Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the name, age and position of each of our directors and executive officers, as of March&#160;1, 2024. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:33%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:61%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Age</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Position(s)</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-style:italic">Executive Officers</span>:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Jaisim Shah<sup style="font-size:75%; vertical-align:top">(4)</sup></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">63</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Executive Officer, President and Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Henry Ji, Ph.D.<sup style="font-size:75%; vertical-align:top">(4)</sup></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">59</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Executive Chairperson of the Board</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Stephen Ma</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">61</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Financial Officer, Senior Vice President and Secretary</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-style:italic"><span style="white-space:nowrap">Non-employee</span></span><span style="font-style:italic"></span><span style="font-style:italic">&#160;Directors</span>:</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Dorman Followwill<sup style="font-size:75%; vertical-align:top">(1)(2)(3)</sup></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">60</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">David Lemus<sup style="font-size:75%; vertical-align:top">(1)</sup></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">61</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Jay Chun, M.D., Ph.D.<sup style="font-size:75%; vertical-align:top">(4)</sup></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">60</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Yue Alexander Wu, Ph.D.<sup style="font-size:75%; vertical-align:top">(1)(2)(3)</sup></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">60</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the Audit Committee. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the Compensation Committee. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the Nominating and Corporate Governance Committee. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the Commercialization and Transaction Committee. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Executive Officers </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Jaisim Shah</span></span><span style="font-style:italic">.</span> Mr.&#160;Shah has served as our Chief Executive Officer and President and a member of our Board since November&#160;10, 2022. Prior to that, he served as Legacy Scilex&#8217;s President, Chief Executive Officer and a board member from March 2019 to November 2022. He has more than 25 years of global biopharma experience, including over 15 years in senior management leading business development, commercial operations, investor relations, marketing and medical affairs. He also served as the Chief Executive Officer and a board member of Semnur Pharmaceuticals, Inc., our wholly owned subsidiary (&#8220;Semnur&#8221;), from its inception in 2013 until its acquisition by Legacy Scilex in March 2019. Mr.&#160;Shah has served on the board of directors of Scilex Pharma since November 2016. Prior to his time at Semnur, Mr.&#160;Shah was a consultant to several businesses, including Sorrento, and was the Chief Business Officer of Elevation Pharmaceuticals, Inc., where Mr.&#160;Shah led a successful sale of Elevation Pharmaceuticals, Inc. to Sunovion Pharmaceuticals Inc. in September 2012. Prior to his time at Elevation Pharmaceuticals, Inc., Mr.&#160;Shah was president of Zelos Therapeutics, Inc., where he focused on financing and business development. Prior to his time at Zelos Therapeutics, Inc., Mr.&#160;Shah was the Senior Vice President and Chief Business Officer at CytRx Corporation, a biopharmaceutical company. Previously, Mr.&#160;Shah was Chief Business Officer at Facet Biotech Corporation and PDL BioPharma, Inc., where he completed numerous licensing/ partnering and strategic transactions with pharmaceutical and biotech companies. Prior to his time at PDL BioPharma, Inc., Mr.&#160;Shah was at Bristol-Myers Squibb Company, most recently as Vice President of Global Marketing where he received the &#8220;President&#8217;s Award&#8221; for completing one of the most significant collaborations in the company&#8217;s history. Previously, Mr.&#160;Shah was at <span style="white-space:nowrap">F.&#160;Hoffman-La&#160;Roche</span> AG in international marketing and was global business leader for corporate alliances with Genentech, Inc. and IDEC Corporation. Mr.&#160;Shah previously served as a director of Celularity Inc. from June 2017 to July 2021. He has served as a director of Sorrento since September 2013. Mr.&#160;Shah holds a M.A. in Economics from the University of Akron and a M.B.A. from Oklahoma University. We believe that Mr.&#160;Shah&#8217;s extensive operational, executive and business development experience qualifies him to serve on our Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Henry Ji, Ph.D</span></span>. Dr.&#160;Ji has served as the Executive Chairperson and a member of our Board since September&#160;22, 2023 and previously served as our Executive Chairperson and a member of our Board from November 2022 to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">181 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
August 2023. Prior to that, he served as Legacy Scilex&#8217;s Executive Chairperson and a board member from March 2019 to November 2022. Dr.&#160;Ji has served on the board of directors of Scilex Pharmaceuticals Inc., our wholly owned subsidiary (&#8220;Scilex Pharma&#8221;), since November 2016 and he served as the Chief Executive Officer of Scilex Pharma from November 2016 to March 2019. <span style="white-space:nowrap">He&#160;co-founded&#160;and</span> has served as a director of Sorrento since January 2006, served as its Chief Scientific Officer from November 2008 to September 2012, as its Interim Chief Executive Officer from April 2011 to September 2012, as its Secretary from September 2009 to June 2011, as its Chief Executive Officer and President since September 2012 and as Chairman of its board of directors since August 2017. In 2002, Dr.&#160;Ji founded BioVintage, Inc., a research and development company focusing on innovative life sciences technology and product development, and has served as its President since 2002. From 2001 to 2002, Dr.&#160;Ji served as Vice President of CombiMatrix Corporation, a publicly-traded biotechnology company that develops proprietary technologies, including products and services in the areas of drug development, genetic analysis, molecular diagnostics and nanotechnology. During his tenure at CombiMatrix Corporation, Dr.&#160;Ji was responsible for strategic technology alliances with biopharmaceutical companies. From 1999 to 2001, Dr.&#160;Ji served as Director of Business Development, and in 2001 as Vice President of Stratagene Corporation (later acquired by Agilent Technologies, Inc.) where he was responsible for novel technology and product licensing and development. In 1997, <span style="white-space:nowrap">Dr.&#160;Ji&#160;co-founded&#160;Stratagene</span> Genomics, Inc., a wholly owned subsidiary of Stratagene Corporation, and served as its President and Chief Executive Officer from its founding until 1999. Dr.&#160;Ji previously served as a director of Celularity Inc. from June 2017 to July 2021. Dr.&#160;Ji is the holder of several issued and pending patents in the life science research field and is the sole inventor of Sorrento&#8217;s intellectual property. Dr.&#160;Ji has a Ph.D. in Animal Physiology from the University of Minnesota and a B.S. in Biochemistry from Fudan University. Dr.&#160;Ji has demonstrated significant leadership skills as President and Chief Executive Officer of Stratagene Genomics, Inc. and Vice President of CombiMatrix Corporation and Stratagene Corporation and brings more than 20 years of biotechnology and biopharmaceutical experience to his position on our Board. We believe that Dr.&#160;Ji&#8217;s extensive knowledge of the industry in which we operate allows him to bring to our Board a broad understanding of the operational and strategic issues we face. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Stephen Ma.</span></span> Mr.&#160;Ma has served as our Chief Financial Officer and Senior Vice President since September&#160;22, 2023 and as our Corporate Secretary since March&#160;6, 2024.<span style="font-weight:bold"><span style="font-style:italic"> </span></span>Mr.&#160;Ma previously served as our Chief Accounting Officer from May 2023 until his appointment as our Chief Financial Officer, Senior Vice President and Secretary and as our Vice President of Finance from January 2022 to April 2023. Mr.&#160;Ma has more than 15 years of finance and operational expertise across pharmaceuticals and venture backed biotechnology companies. He most recently served as Director of Finance and Operations for Anwita Biosciences, Inc., a clinical stage company, from August 2019 to January 2022. Prior to that, from May 2016 to August 2019, he served as Sr. Director of Finance and Controller for Semnur Pharmaceuticals, a specialty pharmaceutical company focused on the clinical and commercial development of innovative products that meet the needs of pain management practitioners and their patients, which was acquired by the Company in March 2019. Prior to that, he served as Controller for Globavir and part of the management team that worked on its IPO process. He also served as the Controller for Ardelyx, which went public in 2014. Prior to that, Mr.&#160;Ma served in various finance positions at PDL BioPharma and Hyperion Therapeutics. Mr.&#160;Ma began his career with more than 10 years in high technology companies and has a wealth of experience in finance, strategic planning, commercial launching, debt financing, public offerings and M&amp;A transactions. Mr.&#160;Ma holds a B.S. in Finance and M.A. in Economics from San Jose State University. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Non-employee</span> Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Dorman Followwill</span></span>. Mr.&#160;Followwill has served as a member of our Board since November&#160;10, 2022. Prior to that, he served as a director of Legacy Scilex from April 2022 to November 2022, as a director of Sorrento since October 2017 and as its lead independent director since August 2020. Mr.&#160;Followwill was Senior Partner of Transformational Health at Frost&#160;&amp; Sullivan, a business consulting firm involved in market research and analysis, growth strategy consulting and corporate training across multiple industries, from 2016 to September 2020. Prior to that time, he served in various roles at Frost&#160;&amp; Sullivan, including Partner on the Executive Committee managing the P&amp;L of the business in Europe, Israel and Africa, and Partner overseeing the Healthcare and Life Sciences business in North America, since initially joining Frost&#160;&amp; Sullivan to help found </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">182 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Consulting practice in January 1988. Mr.&#160;Followwill has more than 30 years of organizational leadership and management consulting experience, having worked on hundreds of consulting projects across all major regions and across multiple industry sectors, each project focused around the strategic imperative of growth. He holds a B.A. from Stanford University in The Management of Organizations. We believe that Mr.&#160;Followwill&#8217;s extensive knowledge and understanding of the healthcare and life sciences industries qualify him to serve on our Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">David Lemus</span></span><span style="font-style:italic">.</span> Mr.&#160;Lemus has served as a member of our Board since November&#160;10, 2022. Prior to that, he served as a director of Legacy Scilex from April 2022 to November 2022 and as a director of Sorrento since October 2017. Additionally, he presently serves as a <span style="white-space:nowrap">non-executive</span> board member of Silence Therapeutics plc and BioHealth Innovation, Inc., and previously served on multiple other boards of public and private companies. Mr.&#160;Lemus also has served as an executive board member, Chief Operating Officer and Chief Financial Officer of miRecule Inc. since August 2023. Prior to that, he served as the Chief Executive Officer of IronShore Pharmaceuticals, Inc. from January 2020 until April 2022, and served as founder and Chief Executive Officer of LEMAX LLC since 2017. Previous positions include serving as the Chief Financial Officer and Chief Operating Officer of Medigene AG, Chief Executive Officer of Sigma Tau Pharmaceuticals, Inc., Chief Financial Officer and executive vice president of MorphoSys AG, Treasurer of Lindt&#160;&amp; Spruengli AG, and various management positions at F. <span style="white-space:nowrap">Hoffmann-La</span> Roche AG. Mr.&#160;Lemus received a M.S. from the Massachusetts Institute of Technology Sloan School of Management and a B.S. in Accounting from the University of Maryland, and is currently an active certified public accountant licensed in the State of Maryland. We believe that Mr.&#160;Lemus&#8217; extensive accounting and financial background and business experience in the life sciences industry qualify him to serve on our Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Jay Chun, M.D., Ph.D.</span></span> Dr.&#160;Chun has served as a member of our Board since September&#160;22, 2023. Dr.&#160;Chun has served as the Chief of Neurosurgery and Director of the Atlantic Health Spine Center at Overlook Medical Center at Atlantic Health System since September 2015. Dr.&#160;Chun has served as a member of the Company&#8217;s Scientific Advisory Board since August 2021 and previously served as a member of Celularity, Inc.&#8217;s (Nasdaq: CELU) Scientific Advisory Board from September 2020 to January 2023. Dr.&#160;Chun completed his M.D. and Ph.D. at Columbia University College of Physicians and Surgeons. His neurosurgical residency was completed at the University of California at San Francisco, followed by specialization in the discipline of complex and minimally invasive spine surgery at Emory in Atlanta, Georgia. Dr.&#160;Chun is board certified and specializes in complex and minimally invasive spine surgery as well as artificial discs. While a member of the Columbia University faculty from June 1995 to June 1997, Dr.&#160;Chun worked in the field of biotechnology. He has received many honors including Medical Research Fellowships from the National Institutes of Health (NIH), working with the late Nobel Laureate Marshall Nirenberg. He received his Ph.D. with Richard Axel, a recipient of the 2004 Nobel Prize. In honor of his stem cell research, he received the NIH Individual National Research Service Award. We believe that Mr.&#160;Chun&#8217;s experience as a member of our Scientific Advisory Board, scientific background and business experience qualify him to serve on our Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Yue Alexander Wu, Ph.D.</span></span> Dr.&#160;Wu has served as a member of our Board since September&#160;22, 2023. Dr.&#160;Wu <span style="white-space:nowrap">is&#160;co-founder&#160;and</span> CEO of Cothera Bioscience, Inc., a translation medicine and precision therapeutics company developing cancer therapeutics for previously undruggable targets. He was previously President, Chief Executive Officer and Chief Strategy Officer of Crown Bioscience International, a leading global drug discovery and development solutions company, which <span style="white-space:nowrap">he&#160;co-founded&#160;in</span> 2006, until 2017. From 2004 to 2006, Dr.&#160;Wu was Chief Business Officer of Starvax International Inc. in Beijing, China, a biotechnology company focusing on oncology and infectious diseases. From 2001 to 2004, Dr.&#160;Wu was a venture capitalist with Burrill&#160;&amp; Company where he was head of Asian Activities. Dr.&#160;Wu has served as a director of CASI Pharmaceuticals, Inc. (Nasdaq: CASI) since June 2013 and Sorrento Therapeutics, Inc., a publicly traded company (&#8220;Sorrento&#8221;), since August 2016. Dr.&#160;Wu received his Ph.D. in Molecular Cell Biology and his MBA from University of California at Berkeley. He earned an M.S. in Biochemistry from University of Illinois, Urbana-Champaign and his B.S. in Biochemistry from Fudan University in Shanghai, China. We believe that Dr.&#160;Wu&#8217;s scientific background and business experience in various roles in the life sciences industry qualify him to serve on our Board. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">183 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Family Relationships </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of the individuals who serve as our directors or executive officers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Involvement in Certain Legal Proceedings </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described elsewhere in this prospectus, Sorrento has commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code in the Bankruptcy Court. At the time of such filing and as of the date of this prospectus, Dr.&#160;Ji was and has been serving as Chairman of the board of directors, President and Chief Executive Officer of Sorrento; and Mr.&#160;Shah, Mr.&#160;Followwill, Dr.&#160;Wu and Mr.&#160;Lemus were and have been serving as directors of Sorrento and Ms.&#160;Czerepak (our former Chief Financial Officer) was serving as Executive Vice President and Chief Financial Officer of Sorrento. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board Composition </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business and affairs are managed under the direction of our Board, which currently consists of six members. Dr.&#160;Ji serves as Executive Chairperson of our Board. The primary responsibilities of our Board are to provide oversight, strategic guidance, counseling and direction to our management. Our Board meets on a regular basis and on an <span style="font-style:italic">ad hoc </span>basis as required. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the terms of our Certificate of Incorporation and our Bylaws, our Board is divided into three classes with staggered three-year terms, as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Class&#160;I directors are Dorman Followwill and David Lemus, and their term will expire at our annual meeting of stockholders to be held in&#160;2026; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Class&#160;II directors are Jay Chun, M.D., Ph.D. and Yue Alexander Wu, Ph.D., and their term will expire at our annual meeting of stockholders to be held in&#160;2024; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Class&#160;III directors are Henry Ji, Ph.D. and Jaisim Shah, and their term will expire at our annual meeting of stockholders to be held in&#160;2025. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At each annual meeting of stockholders, the successors to directors whose terms will then expire will be elected to serve from the time of election and qualification until the third annual meeting following their election. The authorized number of directors that shall constitute our Board will be determined exclusively by our Board. Any increase or decrease in the number of directors will be apportioned among the three classes so that, as nearly equal as practicable, each class will consist of <span style="white-space:nowrap">one-third</span> of the directors. No decrease in the number of directors constituting our Board will shorten the term of any incumbent director. Our directors may be removed only for cause and only by the affirmative vote of the holders of at least 66 2/3% in voting power of all the then-outstanding shares of our capital stock entitled to vote thereon, voting together as a single class. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to applicable law and our Certificate of Incorporation, and subject to the rights of the holders of any series of our preferred stock, any vacancy on our Board shall be filled only by our Board and not by our stockholders. Any director elected in accordance with the preceding sentence shall hold office until the annual meeting of stockholders for the election of directors of the class to which he or she has been appointed and until his or her successor has been duly elected and qualified, subject, however, to such director&#8217;s earlier death, resignation, retirement, removal or disqualification. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Controlled Company Status </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&#160;21, 2023, Sorrento no longer controls a majority of the voting power for the election of directors. As a result, we are no longer a &#8220;controlled company&#8221; within the meaning of the Nasdaq Listing Rules and are subject to additional corporate governance requirements, including the requirements that (i)&#160;a majority of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">184 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our Board consist of independent directors, (ii)&#160;our Board have a compensation committee that is composed entirely of independent directors with a written charter addressing the committee&#8217;s purpose and responsibilities and (iii)&#160;director nominees must be selected or recommended for the Board&#8217;s selection, either by independent directors constituting a majority of the Board&#8217;s independent directors in a vote in which only independent directors participate, or a nominating and corporate governance committee comprised solely of independent directors with a written charter addressing the committee&#8217;s purpose and responsibilities. Nasdaq Listing Rules provide <span style="white-space:nowrap">for&#160;phase-in&#160;periods</span> for these requirements (including that each such committee consist of a majority of independent directors within 90 days of no longer being a &#8220;controlled company&#8221;), but we must be fully compliant with the requirements within one year of the date on which we cease to be a &#8220;controlled company.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Director Independence </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Nasdaq Listing Rules, a majority of the members of our Board must satisfy Nasdaq&#8217;s criteria for &#8220;independence.&#8221; Our Board has determined that each of the directors on our Board, other than Dr.&#160;Ji and Mr.&#160;Shah (as a result of their positions as our Executive Chairperson and our Chief Executive Officer, respectively), qualifies as an independent director, as defined by Rule 5605(a)(2) of the Nasdaq Listing Rules, and our Board consists of a majority of &#8220;independent directors&#8221; as defined under the rules of the SEC and Nasdaq relating to director independence requirements. In addition, we are subject to the rules of the SEC and Nasdaq relating to the membership, qualifications and operations of our Audit Committee, as discussed below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Role of Board in Risk Oversight Process </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Risk assessment and oversight are an integral part of our governance and management processes. Our Board encourages management to promote a culture that incorporates risk management into its corporate strategy and <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> business operations. Management discusses strategic and operational (including cybersecurity) risks at regular management meetings, and conducts specific strategic planning and review sessions during the year that include a focused discussion and analysis of the risks we face. Throughout the year, senior management reviews these risks with our Board at regular board meetings as part of management presentations that focus on particular business functions, operations or strategies, and presents the steps taken by management to mitigate or eliminate such risks. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board is responsible for overseeing our overall risk management process. The responsibility for managing risk rests with executive management while the committees of our Board and our Board as a whole participate in the oversight process. Our Board&#8217;s risk oversight process builds upon management&#8217;s risk assessment and mitigation processes, which include reviews of long-term strategic and operational planning, executive development and evaluation, regulatory and legal compliance and financial reporting and internal controls with respect to areas of potential material risk, including operations, finance, legal, regulatory, cybersecurity, strategic and reputational risk. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board Leadership Structure </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Bylaws provide our Board with the discretion to combine or separate the positions of Chief Executive Officer and Executive Chairperson of our Board. Our Board is chaired by Dr.&#160;Ji. Our Board believes that separation of the positions of Chief Executive Officer and Executive Chairperson of our Board creates an environment that encourages objective oversight of management&#8217;s performance and enhances the effectiveness of our Board as a whole. We believe that this separation of responsibilities provides a balanced approach to managing our Board and overseeing the Company. However, our Board will continue to periodically review its leadership structure and may make such changes in the future as it deems appropriate. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board Diversity </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In evaluating a director candidate&#8217;s qualifications, our Board assesses whether a candidate possesses the integrity, judgment, knowledge, experience, skills and expertise that are likely to enhance our ability, as well as </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">185 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the ability of the committees of our Board, to manage and direct our affairs and business. Our Board may consider many factors, such as: personal and professional integrity, ethics and values, experience in corporate management, such as serving as an officer or former officer of a publicly held company, and experience as a board member or executive officer of another publicly held company. In addition, our Board may consider diversity in identifying potential director nominees, including diversity of expertise and experience in substantive matters pertaining to our business relative to other board members and diversity of background and perspective, including, but not limited to, with respect to age, gender, race, place of residence and specialized experience. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Committees of our Board </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The standing committees of our Board are as follows: an audit committee (the &#8220;Audit Committee&#8221;), a compensation committee (the &#8220;Compensation Committee&#8221;) and a nominating and corporate governance committee (the &#8220;Nominating and Corporate Governance Committee&#8221;). Our Board has adopted a charter for each of these committees, which complies with the applicable requirements of current Nasdaq Listing Rules. In addition, our Board has established a commercialization and transaction committee (the &#8220;C&amp;T Committee&#8221;). Copies of the charters for the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee are available on the investor relations portion of our website. The composition and responsibilities of each of the committees of our Board are as set forth below. The reference to our website address does not constitute incorporation by reference of the information contained at or available or accessible through our website, and you should not consider it to be a part of this prospectus. Members will serve on these committees until their resignation or removal or until otherwise determined by our Board. Our Board may establish other committees as it deems necessary or appropriate from time to time. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Audit Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Audit Committee consists of David Lemus, Dorman Followwill and Yue Alexander Wu, Ph.D., with David Lemus serving as the chairperson of the committee. Each of the members of the Audit Committee satisfies the independence requirements under the applicable Nasdaq Listing Rules and SEC rules. Each member of the Audit Committee can read and understand fundamental financial statements under the applicable rules and regulations of the SEC and Nasdaq Listing Rules. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The responsibilities of the Audit Committee are included in a written charter. The Audit Committee assists our Board in fulfilling our Board&#8217;s oversight responsibilities with respect to our accounting and financial reporting processes, the systems of internal control over financial reporting and audits of financial statements and reports, the performance of our internal audit function, the quality and integrity of our financial statements and reports, the qualifications, independence and performance of our independent registered public accounting firm, and our compliance with legal and regulatory requirements. For this purpose, the Audit Committee performs several functions. The Audit Committee&#8217;s responsibilities include, among others: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">appointing, determining the compensation of, retaining, overseeing and evaluating our independent registered public accounting firm and any other registered public accounting firm engaged for the purpose of performing other review or attest services for us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">prior to commencement of the audit engagement, reviewing and discussing with the independent registered public accounting firm a written disclosure by the prospective independent registered public accounting firm of all relationships between us, or persons in financial oversight roles with us, and such independent registered public accounting firm or their affiliates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">determining and approving engagements of the independent registered public accounting firm, prior to commencement of the engagement, and the scope of and plans for the audit; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">monitoring the rotation of partners of the independent registered public accounting firm on our audit engagement; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">186 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing with management and the independent registered public accounting firm any fraud that includes management or other employees who have a significant role in our internal control over financial reporting and any significant changes in internal controls; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishing and overseeing procedures for the receipt, retention and treatment of complaints regarding accounting, internal accounting controls or auditing matters and the confidential and anonymous submission by employees of concerns regarding questionable accounting or auditing matters; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing the results of management&#8217;s efforts to monitor compliance with our programs and policies designed to ensure compliance with laws and rules; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">overseeing our programs, policies, and procedures related to our information technology systems, including information asset security and data protection; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and discussing with management and the independent registered public accounting firm the results of the annual audit and the independent registered public accounting firm&#8217;s assessment of the quality and acceptability of our accounting principles and practices and all other matters required to be communicated to the Audit Committee by the independent registered public accounting firm under generally accepted accounting standards, the results of the independent registered public accounting firm&#8217;s review of our quarterly financial information prior to public disclosure and our disclosures in our periodic reports filed with the SEC. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">David Lemus qualifies as an audit committee financial expert within the meaning of SEC regulations and each of David Lemus, Dorman Followwill and Yue Alexander Wu, Ph.D. meets the financial sophistication requirements under the Nasdaq Listing Rules. Our independent registered public accounting firm and our management periodically meet separately with the Audit Committee. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee reviews, discusses and assesses its own performance and composition at least annually. The Audit Committee also periodically reviews and assesses the adequacy of its charter, including its role and responsibilities as outlined in its charter, and recommends any proposed changes to our Board for its consideration and approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The composition and functioning of the Audit Committee complies with all applicable requirements of the Sarbanes-Oxley Act and all applicable SEC rules and Nasdaq Listing Rules. We intend to comply with future requirements to the extent they become applicable to us. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Compensation Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Compensation Committee consists of Dorman Followwill and Yue Alexander Wu, Ph.D., with Dorman Followwill serving as the chairperson of the committee. Dorman Followwill and Yue Alexander Wu, Ph.D. each satisfy the independence requirements under the Nasdaq Listing Rules. Each of the members of the Compensation Committee is a <span style="white-space:nowrap">non-employee</span> director as defined in Rule <span style="white-space:nowrap">16b-3</span> promulgated under the Exchange Act and satisfies Nasdaq independence requirements. The Compensation Committee acts on behalf of our Board to fulfill our Board&#8217;s responsibilities in overseeing our compensation policies, plans and programs, and in reviewing and determining the compensation to be paid to our executive officers and <span style="white-space:nowrap">non-employee</span> directors. The responsibilities of the Compensation Committee are included in its written charter. The Compensation Committee&#8217;s responsibilities include, among others: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing, modifying and approving (or, if it deems appropriate, making recommendations to our Board regarding) our overall compensation strategy and policies, and reviewing, modifying and approving corporate performance goals and objectives relevant to the compensation of our executive officers and other senior management; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">determining and approving (or, if it deems appropriate, recommending to our Board for determination and approval) the compensation and terms of employment of our Chief Executive Officer, including </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">187 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
seeking to achieve an appropriate level of risk and reward in determining the long-term incentive component of the compensation of the Chief Executive Officer; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">determining and approving (or, if it deems appropriate, recommending to our Board for determination and approval) the compensation and terms of employment of our executive officers and other members of senior management; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and approving (or, if it deems appropriate, making recommendations to our Board regarding) the terms of employment agreements, severance agreements, <span style="white-space:nowrap"><span style="white-space:nowrap">change-of-control</span></span> protections and other compensatory arrangements for our executive officers and other members of senior management; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">conducting periodic reviews of the base compensation levels of all of our employees generally; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and approving the type and amount of compensation to be paid or awarded to <span style="white-space:nowrap">non-employee</span> directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and approving the adoption, amendment and termination of our equity incentive plans, stock appreciation rights plans, pension and profit sharing plans, incentive plans, stock bonus plans, stock purchase plans, bonus plans, deferred compensation plans, 401(k) plans, supplemental retirement plans and similar programs, if any; and administering all such plans, establishing guidelines, interpreting plan documents, selecting participants, approving grants and awards and exercising such other power and authority as may be permitted or required under such plans; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing our incentive compensation arrangements to determine whether such arrangements encourage excessive risk-taking, reviewing and discussing at least annually the relationship between our risk management policies and practices and compensation and evaluating compensation policies and practices that could mitigate any such risk. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, once we cease to be an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of&#160;2012, as amended (the &#8220;JOBS Act&#8221;), the responsibilities of the Compensation Committee will also include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and recommending to our Board for approval the frequency with which we conduct a vote on executive compensation, taking into account the results of the most recent stockholder advisory vote on the frequency of the vote on executive compensation, and reviewing and approving the proposals regarding the frequency of the vote on executive compensation to be included in our annual meeting proxy statements; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and discussing with management our Compensation Discussion and Analysis, and recommending to our Board that the Compensation Discussion and Analysis be approved for inclusion in our annual reports on <span style="white-space:nowrap">Form&#160;10-K,</span> registration statements and our annual meeting proxy statements. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under its charter, the Compensation Committee may form, and delegate authority to, subcommittees as appropriate. The Compensation Committee reviews, discusses and assesses its own performance and composition at least annually. The Compensation Committee also periodically reviews and assesses the adequacy of its charter, including its role and responsibilities as outlined in its charter, and recommends any proposed changes to our Board for its consideration and approval. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Compensation Committee Processes and Procedures </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agenda for each meeting is usually developed by the chairperson of our Compensation Committee, in consultation with the Chief Executive Officer. Our Compensation Committee meets regularly in executive session. However, from time to time, various members of management and other employees as well as outside advisors or consultants may be invited by our Compensation Committee to make presentations, to provide financial or other background information or advice or to otherwise participate in Compensation Committee meetings. The Chief Executive Officer and the Executive Chairperson may not participate in, or be present </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">188 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
during, any deliberations or determinations of our Compensation Committee regarding their compensation or individual performance objectives. The charter of our Compensation Committee grants our Compensation Committee full access to all books, records, facilities and personnel of the Company. In addition, under the charter, our Compensation Committee has the authority to obtain, at the expense of the Company, advice and assistance from compensation consultants and internal and external legal, accounting or other advisors and other external resources that our Compensation Committee considers necessary or appropriate in the performance of its duties. Our Compensation Committee has direct responsibility for the oversight of the work of any consultants or advisers engaged for the purpose of advising our Compensation Committee. In particular, our Compensation Committee has the sole authority to retain, in its sole discretion, compensation consultants to assist in its evaluation of executive and director compensation, including the authority to approve the consultant&#8217;s reasonable fees and other retention terms. Under the charter, our Compensation Committee may select, or receive advice from, a compensation consultant, legal counsel or other adviser to our Compensation Committee, other than <span style="white-space:nowrap">in-house</span> legal counsel and certain other types of advisers, only after taking into consideration six factors, prescribed by the SEC and Nasdaq, that bear upon the adviser&#8217;s independence; however, there is no requirement that any adviser be independent. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The composition and functioning of the Compensation Committee comply with all applicable requirements of the Sarbanes-Oxley Act and all applicable SEC rules and Nasdaq Listing Rules. We intend to comply with future requirements to the extent they become applicable to us. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Nominating and Corporate Governance Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Nominating and Corporate Governance Committee consists of Dorman Followwill and Yue Alexander Wu, Ph.D., with Dorman Followwill serving as the chairperson of the committee. Dorman Followwill and Yue Alexander Wu, Ph.D. each satisfy the independence requirements under the Nasdaq Listing Rules. The responsibilities of the Nominating and Corporate Governance Committee are included in its written charter. The Nominating and Corporate Governance Committee acts on behalf of our Board to fulfill our Board&#8217;s responsibilities in overseeing all aspects of our nominating and corporate governance functions. The responsibilities of the Nominating and Corporate Governance Committee include, among others: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">making recommendations to our Board regarding corporate governance issues; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">identifying, reviewing and evaluating qualified candidates to serve as directors (consistent with criteria approved by our Board); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">determining the minimum qualifications for service on our Board; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and evaluating incumbent directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">instituting and overseeing director orientation and director continuing education programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">serving as a focal point for communication between candidates, <span style="white-space:nowrap">non-committee</span> directors and our management; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">recommending to our Board for selection candidates to serve as nominees for director for the annual meeting of stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">making other recommendations to our Board regarding matters relating to the directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing succession plans for our Chief Executive Officer and our other executive officers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and overseeing matters of corporate responsibility and sustainability, including potential long- and short-term trends and impacts to our business of environmental, social, and governance issues, and our public reporting on these topics; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">considering any recommendations for nominees and proposals submitted by stockholders. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Nominating and Corporate Governance Committee periodically reviews, discusses and assesses the performance of our Board and the committees of our Board. In fulfilling this responsibility, the Nominating and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">189 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Corporate Governance Committee seeks input from senior management, our Board and others. In assessing our Board, the Nominating and Corporate Governance Committee evaluates the overall composition of our Board, our Board&#8217;s contribution as a whole and its effectiveness in serving our best interests and the best interests of our stockholders. The Nominating and Corporate Governance Committee reviews, discusses and assesses its own performance and composition at least annually. The Nominating and Corporate Governance Committee also periodically reviews and assesses the adequacy of its charter, including its role and responsibilities as outlined in its charter, and recommends any proposed changes to our Board for its consideration and approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The composition and functioning of the Nominating and Corporate Governance Committee comply with all applicable requirements of the Sarbanes-Oxley Act and all applicable SEC rules and Nasdaq Listing Rules. We intend to comply with future requirements to the extent they become applicable to us. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Commercialization and Transaction Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our C&amp;T Committee consists of Jaisim Shah, Jay Chun, M.D., Ph.D. and Henry Ji, Ph.D., with Jaisim Shah serving as the chairperson of the committee. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The responsibilities of the C&amp;T Committee are included in a written charter. The C&amp;T Committee (a)&#160;assists the Board in its oversight of the Company&#8217;s (i)&#160;commercial strategy and operations, including product launch preparation and execution, (ii)&#160;medical affairs activities, and (iii)&#160;research and development (&#8220;R&amp;D&#8221;) portfolio management and (b)&#160;evaluates certain potential strategic transactions, chooses strategic transactions which it believes are in the best interest of the stockholders and takes action to oversee the Company&#8217;s negotiation of the terms and conditions of any such transaction and recommend any such transaction to the Board, and in each case performs such other functions as may be deemed necessary or convenient in carrying out the foregoing. The C&amp;T Committee&#8217;s responsibilities include, among others, the following commercialization matters: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">providing strategic, directional and operational oversight and guidance to the Company regarding its commercial activities and operations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">evaluating the alignment of the Company&#8217;s commercial and R&amp;D programs and progress with the Company&#8217;s strategic goals and objectives, taking into account the results of the Company&#8217;s <span style="white-space:nowrap">pre-clinical</span> studies and clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">overseeing periodic reviews of the Company&#8217;s product development pipeline, intellectual property portfolio and commercial strategies, including a review and analysis of the progress and results of the Company&#8217;s <span style="white-space:nowrap">pre-clinical</span> studies and clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">overseeing key commercial and medical launch strategies prior to regulatory approval of new products or indications as well as the R&amp;D elements of the Company&#8217;s long-range plan and lifecycle management plans; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">overseeing management on the scientific and R&amp;D aspects of business development opportunities, including licensing opportunities (both <span style="white-space:nowrap">in-licensing</span> and <span style="white-space:nowrap">out-licensing),</span> and M&amp;A opportunities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishing, approving, modify, monitoring and directing the process and procedures related to the review and evaluation of certain potential strategic transactions and determining whether to proceed with any such process, procedures, review or evaluation; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">determining on behalf of the Board and the Company whether a possible strategic transaction is advisable and is fair to, and in the best interests of, the Company and its stockholders (or any subset of the stockholders of the Company that the C&amp;T Committee determines to be appropriate), (ii) rejecting or approving a possible strategic transaction, or recommending such rejection or approval to the Board, (iii)&#160;approving or recommending to the Board the consummation of a possible strategic transaction, and (iv)&#160;reviewing, evaluating and monitoring proceedings and activities of the Company related to certain potential strategic transactions. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under its charter, the C&amp;T Committee may form, and delegate authority to, subcommittees as appropriate. The </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">190 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
C&amp;T Committee reviews, discusses and assesses its own performance at least annually. The C&amp;T Committee also periodically reviews the charter of the C&amp;T Committee and the compliance procedures in place to implement such charter and recommend necessary clarifications or changes to such charter to the Board for approval. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Code of Business Conduct and Ethics </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;10, 2022, our Board approved and adopted a written code of business conduct and ethics, applicable to directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A current copy of our code of business conduct and ethics is posted on our website at <span style="font-style:italic">www.scilexholding.com</span>. Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of the website address in this prospectus is an inactive textual reference only. We intend to disclose any amendments to our code of business conduct and ethics, or any waivers of its requirements, on our website to the extent required by the applicable rules and exchange requirements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Compensation Committee Interlocks and Insider Participation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of the members of our Compensation Committee is currently, or has been at any time in the past year, one of our officers or employees. Other than Dr.&#160;Ji and Mr.&#160;Shah, none of our executive officers currently serves, or has served during the last completed fiscal year, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving as a member of our Board or Compensation Committee. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Clawback Policy </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2023, our Board adopted a clawback policy that complies with recently enacted SEC rules and Nasdaq Listing Rules. Our clawback policy provides for our recovery of erroneously awarded incentive-based compensation from our current and former executive officers (as defined in Rule <span style="white-space:nowrap">10D-1</span> promulgated under the Exchange Act and Nasdaq Listing Rule 5608) who were employed by the Company during the applicable recovery period. Under the policy, if the Company is required to prepare an accounting restatement of its financial statements due to its material noncompliance with any financial reporting requirement under the securities laws, the Company shall promptly demand in writing and recoup the amount of any incentive-based compensation received by the applicable executive during the three completed fiscal years immediately preceding the date on which the Company is required to prepare such accounting restatement. The amount to be recouped is that which exceeds the amount of incentive-based compensation that otherwise would have been received by the applicable executive had such compensation been determined based on the restated amounts in the accounting restatement. Incentive-based compensation includes any compensation that is granted, earned or vested based wholly or in part upon the attainment of one or more measures derived from our financial statements. Our Compensation Committee administers our clawback policy and has the authority to determine the amount of recoverable compensation and manner of recovery. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Limitation of Liability and Indemnification of Directors and Officers </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation and the Bylaws contain provisions that limit the liability of our directors for monetary damages to the fullest extent permitted by the DGCL. Consequently, our directors and officers will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors or officers, except liability for the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any breach of their duty of loyalty to us or our stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">191 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in the case of our directors, unlawful payments of dividends or unlawful stock repurchases or redemptions in violation of the DGCL; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any transaction from which the director or officer derived an improper personal benefit. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation also provides that if the DGCL is amended to permit further elimination or limitation of the personal liability of directors or officers, then the liability of our directors and officers will be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bylaws provide that we shall indemnify any person who is or was a director or officer of the Company or who is or was serving at our request as a director, officer or trustee of another corporation, limited liability company, partnership, joint venture, employee benefit plan, trust, nonprofit entity or other enterprise (a &#8220;Covered Person&#8221;), and who is or was a party to, is threatened to be made a party to, or is otherwise involved (including as a witness) in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative, or investigative based on such person&#8217;s actions in his or her official capacity as a director or officer of the Company or as a director, officer or trustee of another corporation, limited liability company, partnership, joint venture, employee benefit plan, trust, nonprofit entity or other enterprise (to the extent serving in such position at our request), in each case against all liability and loss suffered (including, without limitation, any judgments, fines, excise taxes or penalties arising under the Employee Retirement Income Security Act of 1974 and amounts paid in settlement consented to in writing by us) and expenses (including attorneys&#8217; fees), actually and reasonably incurred by such person in connection therewith, subject to certain conditions. In addition, the Bylaws provide that we may, to the fullest extent permitted by law, (i)&#160;advance costs, fees or expenses (including attorneys&#8217; fees) incurred by a Covered Person defending or participating in any proceeding in advance of the final disposition of such proceeding, subject to certain exceptions, and (ii)&#160;purchase and maintain insurance, at our expense, to protect us and any person who is or was our director, officer, employee or agent or is or was our director, officer, employee or agent serving at our request as a director, officer, employee or agent of another corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise against any liability, expense or loss, whether or not we would have the power or obligation to indemnify such person against such liability, expense or loss under the DGCL or the provisions of the Bylaws. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors and executive officers as determined by our Board. These agreements, among other things, require us to indemnify our directors and executive officers against liabilities that may arise by reason of their status or service. These indemnification agreements also require us to advance all expenses actually and reasonably incurred by the directors and executive officers in connection with any proceeding. We believe that these agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers. We also maintain directors&#8217; and officers&#8217; liability insurance. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The above description of the indemnification provisions of the Certificate of Incorporation, the Bylaws and the indemnification agreements is not complete and is qualified in its entirety by reference to these documents, each of which is filed as an exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of our <span style="white-space:nowrap">non-employee</span> directors may, through their relationships with their employers, be insured or indemnified against certain liabilities incurred in their capacity as members of our Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The limitation of liability and indemnification provisions in the Certificate of Incorporation and the Bylaws may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and our stockholders. In addition, a stockholder&#8217;s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. Insofar as indemnification for liabilities arising under the Securities Act of 1933, as amended, may be permitted to directors or executive officers, we have been informed that in the opinion of the SEC, such indemnification is against public policy and is therefore unenforceable. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">192 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At present, there is no pending litigation or proceeding involving any of our directors or executive officers as to which indemnification is required or permitted, and we are not aware of any threatened litigation or proceeding that may result in a claim for indemnification. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">193 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx759370_14">EXECUTIVE AND DIRECTOR COMPENSATION </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To achieve our goals, we have designed, and intend to modify as necessary, our compensation and benefits programs to attract, retain, incentivize and reward deeply talented and qualified executives who share our philosophy and desire to work towards achieving our goals. We believe our compensation programs should promote the success of the Company and align executive incentives with the long-term interests of our stockholders. This section provides an overview of the material components of our executive compensation programs, including a narrative description of the material factors necessary to understand the information disclosed in the summary compensation table below. The following is a discussion and analysis of the material components of the compensation arrangements of Scilex&#8217;s named executive officers in 2023. As an &#8220;emerging growth company&#8221; as defined in the JOBS Act, we are not required to include a Compensation Discussion and Analysis section and have elected to comply with the scaled disclosure requirements applicable to emerging growth companies. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board or the Compensation Committee, with input from our Executive Chairperson and Chief Executive Officer, historically determined the compensation for Scilex&#8217;s named executive officers. Our named executive officers for the year ended December&#160;31, 2023, were Jaisim Shah, our Chief Executive Officer and President, Henry Ji, our Executive Chairperson, Elizabeth Czerepak, our former Executive Vice President, Chief Business Officer, Chief Financial Officer and Secretary, who resigned from her positions effective as of September&#160;20, 2023, and Stephen Ma, our current Chief Financial Officer and Senior Vice President, who was appointed to such position on September&#160;22, 2023 and appointed as our Corporate Secretary on March&#160;6, 2024. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">194 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Summary Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information with respect to the compensation paid or accrued to our named executive officers for the fiscal years ended December&#160;31, 2023 and December&#160;31, 2022: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:36%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name and Principal<br/>Position</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Salary<br/>($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Bonus&#160;($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Stock<br/>Awards<br/>($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br/>Awards&#160;($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap">Non-Equity</span><br/>Incentive Plan<br/>Compensation<br/>($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap">Non-Qualified</span><br/>Deferred<br/>Compensation<br/>Earnings&#160;($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">All Other<br/>Compensation<br/>($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total&#160;($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman;font-weight:bold">Jaisim Shah</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">917,494</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6,402,460</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom" align="right">54,023<span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"><sup style="font-size:75%; vertical-align:top">(1)</sup></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">7,373,977</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><span style="font-style:italic">Chief Executive Officer, President and Director</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">773,298</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">12,435</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(2)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">785,733</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman;font-weight:bold">Henry Ji, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">821,465</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">33,034,320</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">63,965</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">33,919,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><span style="font-style:italic">Executive Chairperson</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">626,548</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">626,548</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman;font-weight:bold">Stephen Ma</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><span style="font-style:italic">Chief Financial Officer, Senior Vice President and Secretary</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">470,676</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,427,260</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2,769</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom" align="right">1,900,705<span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"><sup style="font-size:75%; vertical-align:top">(4)</sup></span>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman;font-weight:bold">Elizabeth Czerepak<sup style="font-size:75%; vertical-align:top">(5)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">202,827</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,276,870</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">23,581</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(7)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,503,278</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><span style="font-style:italic">Former Executive Vice President, Chief</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">172,917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom" align="right">50,000<span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"><sup style="font-size:75%; vertical-align:top">(6)</sup></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">222,917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><span style="font-style:italic">Business Officer, Chief Financial Officer and Secretary</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents (i)&#160;matching contributions made to Mr.&#160;Shah under the Company&#8217;s 401(k) plan, (ii)&#160;accrued unused paid time off and (iii)&#160;life insurance premiums paid by the Company for his benefit. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents matching contributions made to Mr.&#160;Shah under the Company&#8217;s 401(k) plan. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents compensation expense allocated by Sorrento to (and paid by) the Company for services provided by Dr.&#160;Ji (on behalf of Sorrento) to the Company in January 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Mr.&#160;Ma was appointed as our Chief Financial Officer, Senior Vice President and Secretary on September&#160;22, 2023. Represents compensation paid or accrued as our Chief Accounting Officer (from May 2023 until his appointment as our Chief Financial Officer, Senior Vice President and Secretary in September 2023) and as our Chief Financial Officer. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Ms.&#160;Czerepak resigned as our Executive Vice President, Chief Business Officer, Chief Financial Officer and Secretary effective as of September&#160;20, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents a signing bonus awarded to Ms.&#160;Czerepak in connection with her becoming our Executive Vice President, Chief Business Officer, Chief Financial Officer and Secretary. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents compensation expense allocated by Sorrento to (and paid by) the Company for services provided by Ms.&#160;Czerepak (on behalf of Sorrento) to the Company in January 2023. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Narrative Disclosure to Summary Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Arrangements with Executive Officers </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scilex has entered into an offer letter with each of Mr.&#160;Shah and Ms.&#160;Czerepak. The material terms of the offer letters are described below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Shah Offer Letter and Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scilex entered into an offer letter with Mr.&#160;Shah (the &#8220;Shah Offer Letter&#8221;), dated April&#160;19, 2019, pursuant to which Mr.&#160;Shah serves as the Chief Executive Officer of Scilex Pharma. Under the Shah Offer Letter, Mr.&#160;Shah&#8217;s annual base salary was initially set at $407,925, which was increased to $579,280 in 2020 and to $792,000 on </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">195 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
November&#160;11, 2022 (but became effective as of March&#160;17, 2022). On September&#160;22, 2023, our Compensation Committee approved an increase in Mr.&#160;Shah&#8217;s annual base salary to $1,250,000 and a bonus target of 150% of his base salary, effective as of October&#160;16, 2023. Mr.&#160;Shah&#8217;s employment with Scilex is <span style="white-space:nowrap">at-will,</span> and either Scilex or Mr.&#160;Shah may terminate the terms and conditions of the employment relationship at any time, with or without cause and with or without notice. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;6, 2019, Scilex issued to Mr.&#160;Shah an option to purchase 8,126,836 shares of Common Stock, with an exercise price equal to $1.73 per share. The shares subject to such option are now fully vested. On December&#160;21, 2020, Scilex issued to Mr.&#160;Shah an option to purchase 1,626,497 shares of Common Stock, with an exercise price equal to $1.73 per share, whereby 25% of the shares vested on December&#160;21, 2021, and 1/48th of the total amount of the shares vested and shall vest each month thereafter, subject to Mr.&#160;Shah providing continuous service (as defined in the Company&#8217;s 2019 Stock Option Plan (the &#8220;2019 Stock Option Plan&#8221;)) on each such vesting date, inclusive. The foregoing number of shares and exercise prices for Mr.&#160;Shah&#8217;s options reflect the application of the Exchange Ratio (as defined below) in the Business Combination. On January&#160;17, 2023, Scilex issued to Mr.&#160;Shah an option to purchase 1,700,000 shares of Common Stock, with an exercise price of $8.08 per share, and on October&#160;4, 2023, Scilex issued to Mr.&#160;Shah an option to purchase 200,000 shares of Common Stock, with an exercise price of $1.41 per share. The shares subject to such options vest in 48 equal monthly installments following the respective grant date, subject to Mr.&#160;Shah providing continuous service (as defined in the Equity Incentive Plan) on each such vesting date, inclusive. To the extent such options are unvested, the foregoing options will vest in full if there is a Change in Control (as defined in the Severance Agreement (as defined below) to which Mr.&#160;Shah is a party). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Ji Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scilex has not entered into an offer letter or employment agreement in connection with Dr.&#160;Ji&#8217;s service as our Executive Chairperson. On November&#160;11, 2022, our Compensation Committee approved Dr.&#160;Ji&#8217;s annual base salary of $792,000 and bonus of $554,400, effective as of March&#160;17, 2022. On September&#160;22, 2023, our Compensation Committee approved an increase in Dr.&#160;Ji&#8217;s annual base salary to $1,250,000 and a bonus target of 150% of his base salary, effective as of October&#160;16, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;20, 2019, Scilex issued to Dr.&#160;Ji, in connection with his service as a director, an option to purchase 2,031,708 shares of Common Stock, with an exercise price equal to $1.73 per share. The shares subject to such option are now fully vested. The foregoing number of shares and exercise price for Dr.&#160;Ji&#8217;s option reflects the application of the Exchange Ratio in the Business Combination. On January&#160;17, 2023, Scilex issued to Dr.&#160;Ji an option to purchase 9,000,000 shares of Common Stock, with an exercise price of $8.08 per share, and on October&#160;4, 2023, Scilex issued to Dr.&#160;Ji an option to purchase 200,000 shares of Common Stock, with an exercise price of $1.41 per share. The shares subject to such options vest in 48 equal monthly installments following the respective grant date, subject to Dr.&#160;Ji providing continuous service (as defined in the Equity Incentive Plan) on each such vesting date, inclusive. To the extent such options are unvested, the foregoing options will vest in full if there is a Change in Control (as defined in the Severance Agreement (as defined below) to which Dr.&#160;Ji is a party). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Ma Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scilex has not entered into an offer letter or employment agreement in connection with Mr.&#160;Ma&#8217;s service as our Chief Financial Officer, Senior Vice President and Secretary. On September&#160;22, 2023, our Compensation Committee approved Mr.&#160;Ma&#8217;s annual base salary of $600,000 and a bonus target of 60% of his base salary, effective as of October&#160;16, 2023. On January&#160;17, 2023, Scilex issued to Mr.&#160;Ma an option to purchase 350,000 shares of Common Stock, with an exercise price of $8.08 per share, and on October&#160;4, 2023, Scilex issued to Mr.&#160;Ma an option to purchase 150,000 shares of Common Stock, with an exercise price of $1.41 per share. The shares subject to such options vest in 48 equal monthly installments following the respective grant date, subject to Mr.&#160;Ma providing continuous service (as defined in the Equity Incentive Plan) on each such vesting date, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">196 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
inclusive. To the extent such options are unvested, the foregoing options will vest in full if there is a Change in Control (as defined in the Severance Agreement (as defined below) to which Mr.&#160;Ma is a party). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Agreements with Elizabeth Czerepak </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scilex entered into an offer letter with Ms.&#160;Czerepak (the &#8220;Czerepak Offer Letter&#8221;), dated April&#160;27, 2022, pursuant to which Ms.&#160;Czerepak previously served as our then Executive Vice President, Chief Business Officer, and Chief Financial Officer. Under the Czerepak Offer Letter, Ms.&#160;Czerepak&#8217;s annual base salary was $300,000 and she was awarded a $50,000 signing bonus. Following the closing of the Business Combination and Scilex&#8217;s filing of a Registration Statement on <span style="white-space:nowrap">Form&#160;S-8,&#160;upon</span> the Board&#8217;s approval, Scilex granted Ms.&#160;Czerepak an incentive stock option to purchase 350,000 shares of Common Stock, which shall vest over a four year period, whereby 1/4th of the shares subject to the option shall vest on the date that is one year after the vesting commencement date and an additional 1/48th of the shares subject to the option shall vest on the same date of each month thereafter, subject to Ms.&#160;Czerepak providing continuous service (as defined in the equity incentive plan pursuant to which the option will be granted) on each such vesting date, inclusive. In addition, all of the shares subject to the option will vest upon the occurrence of a change in control (as defined in the Equity Incentive Plan) that occurs prior to the termination of her continuous service. Ms.&#160;Czerepak&#8217;s employment with Scilex <span style="white-space:nowrap">was&#160;at-will.</span> Ms.&#160;Czerepak resigned as our Executive Vice President, Chief Business Officer, Chief Financial Officer and Secretary effective as of September&#160;20, 2023 and the Czerepak Offer Letter is no longer in effect. In connection with Ms.&#160;Czerepak&#8217;s resignation, on September&#160;20, 2023, the Company entered into a consulting agreement with Ms.&#160;Czerepak (the &#8220;Czerepak Consulting Agreement&#8221;) pursuant to which she is providing certain consulting and advisory services related to the Company&#8217;s business, business operations and products. Pursuant to the Czerepak Consulting Agreement, Ms.&#160;Czerepak will provide such services for a period of 12 months following her resignation. As consideration for such services, the Company will pay Ms.&#160;Czerepak $26,093.15 per month. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;14, 2019, Scilex issued to Ms.&#160;Czerepak, in connection with her service as a director of Legacy Scilex, an option to purchase 404,098 shares of Common Stock, with an exercise price equal to $1.73 per share. The shares subject to such option are now fully vested. The foregoing number of shares and exercise price for Ms.&#160;Czerepak&#8217;s option reflects the application of the Exchange Ratio in the Business Combination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Additional Arrangements with Executive Officers </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon the information provided by Compensia, a national compensation consulting firm engaged by our Compensation Committee to review and advise on our compensation practices, on September&#160;22, 2023, our Compensation Committee approved the following base salaries, effective as of October&#160;16, 2023, and target bonuses for fiscal year 2023 (on terms and conditions determined by our Board) of our executive officers: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:66%"/>

<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Salary</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Target&#160;Bonus</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Henry Ji, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">1,250,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">150</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jaisim Shah</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">1,250,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">150</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen Ma</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">600,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">60</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;22, 2023, our Compensation Committee also approved the following stock option grants under the Equity Incentive Plan, with a grant date of October&#160;4, 2023 and subject to the terms and conditions of the Equity Incentive Plan and the applicable form of option agreement previously approved for use thereunder: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:80%"/>

<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Stock&#160;Options</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Henry Ji, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">200,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jaisim Shah</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">200,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen Ma</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">150,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">197 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Potential Payments upon Termination or Change in Control </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Severance and Change in Control Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;22, 2023, our Compensation Committee approved the material terms of, and authorized us to enter into, severance and change in control arrangements with our Executive Chairperson, Chief Executive Officer, Chief Financial Officer and each other executive of the Company holding a senior vice president position or above (each, a &#8220;Participating Executive&#8221;), with such arrangements to be set forth in severance and change in control agreements (each a &#8220;Severance Agreement&#8221;). Each named executive officer executed their respective Severance Agreements on November&#160;8, 2023. </p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Severance Agreements generally provide for, among other things, the following benefits in the event of (i)&#160;the executive&#8217;s termination without cause or resignation for good reason and (ii)&#160;a change in control of the Company. </p> <p style="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Termination without a change in control </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any Participating Executive (including each of our named executive officers) is terminated without cause or resigns for good reason, in either case, prior to a change in control, and subject to an irrevocably effective general release of claims in our favor, such executive shall be entitled to receive (i)&#160;one year&#8217;s base salary, paid on a monthly basis, (ii) 12 months of benefits and (iii)&#160;with respect to any Company stock options held by such executive that have vested as of the date of such termination or resignation, such stock options shall be exercisable for a period of 24 months following such date of termination or resignation (or, if earlier, until the expiration of the maximum term of the option). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Payments upon a change in control </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon a change in control of the Company, Dr.&#160;Ji, our Executive Chairperson, and Mr.&#160;Shah, our Chief Executive Officer, each shall be entitled to received (i)&#160;a lump sum payment equal to three times such executive&#8217;s annual base salary, (ii)&#160;a lump sum payment equal to three times such executive&#8217;s target bonus amount, (iii)&#160;a lump sum payment equal to $3,000 multiplied by 36 in respect of payments for benefits, and (iv)&#160;accelerated vesting of all time-based vesting equity awards, with stock options remaining exercisable for a period of not less than 24 months following the change in control (or, if earlier, until the expiration of the maximum term of the option). </p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon a change in control of the Company, Mr.&#160;Ma, our Chief Financial Officer, Senior Vice President and Secretary, shall be entitled to receive (i)&#160;a lump sum payment equal to two times such executive&#8217;s annual base salary, (ii)&#160;a lump sum payment equal to two times such executive&#8217;s target bonus amount, (iii)&#160;a lump sum payment equal to $3,000 multiplied by 24 in respect of payments for benefits, and (iv)&#160;accelerated vesting of all time-based vesting equity awards, with stock options remaining exercisable for a period of not less than 24 months following the change in control (or, if earlier, until the expiration of the maximum term of the option). </p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For any other Participating Executive, upon a change in control, such executive shall be entitled to receive (i)&#160;a lump sum payment equal to such executive&#8217;s annual base salary, (ii)&#160;a lump sum payment equal to such executive&#8217;s target bonus amount, (iii)&#160;a lump sum payment equal to $3,000 multiplied by 12 in respect of payments for benefits, and (iv)&#160;accelerated vesting of all time-based vesting equity awards, with stock options remaining exercisable for a period of not less than 24 months following the change in control (or, if earlier, until the expiration of the maximum term of the option). </p> <p style="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Perquisites, Health, Welfare and Retirement Benefits </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our executive officers, during their employment with us, are eligible to participate in our employee benefit plans, including our medical, vision and dental insurance plans, in each case on the same basis as all of our other employees. We generally do not provide perquisites or personal benefits to our named executive officers, except in limited circumstances. We do, however, pay the premiums for medical, vision and dental insurance for all of our employees, including our named executive officers. Our Board may elect to adopt qualified or nonqualified benefit plans in the future if it determines that doing so is in our best interests. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">198 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Pension Benefits and Nonqualified Deferred Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain a defined contribution 401(k) plan available to eligible employees. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. We made matching contributions to the 401(k) plan totaling $0.5&#160;million and $0.3&#160;million for each of the years ended December&#160;31, 2023 and 2022, respectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&#160;Shah, Dr.&#160;Ji and Mr.&#160;Ma participate in our <span style="white-space:nowrap">tax-qualified</span> Section&#160;401(k) plan and we provide a 4% matching contribution up to an annual compensation limit ($330,000 in 2023). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not provide any other pension plan for our employees, and none of Scilex&#8217;s named executive officers participated in a nonqualified deferred compensation plan during the year ended December&#160;31, 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Outstanding Equity Awards at Fiscal <span style="white-space:nowrap">Year-End</span> 2023 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents certain information concerning outstanding equity awards held by each of our named executive officers as of December&#160;31, 2023. Following the Business Combination, each outstanding equity award with respect to our Common Stock reflected in the table below was equitably adjusted in accordance with the terms of the Merger Agreement and the 2019 Stock Option Plan. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:19%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="4" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center"><span style="font-weight:bold">Option Awards<sup style="font-size:75%; vertical-align:top">(1)(2)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Name</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">Option&#160;Grant&#160;Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">Vesting&#160;Commencement<br/>Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options<br/>(#)&#160;Exercisable</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options<br/>(#)&#160;Unexercisable</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">Option&#160;Exercise<br/>Price&#160;Per&#160;Share&#160;($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">Option<br/>Expiration&#160;Date</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jaisim Shah</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6/6/2019</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3/18/2019</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">8,126,836</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">1.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6/6/2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">12/21/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">12/21/2020</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(4)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,219,866</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">406,631</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">1.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">12/21/2030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1/17/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1/17/2023</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">389,583</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,310,417</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">8.08</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1/17/2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10/4/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10/4/2023</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">8,333</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">191,667</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">1.41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10/4/2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Henry Ji, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">9/20/2019</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3/18/2019</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2,031,708</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">1.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">9/20/2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1/17/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1/17/2023</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2,062,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6,937,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">8.08</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1/17/2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10/4/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10/4/2023</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">8,333</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">191,667</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">1.41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10/4/2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen Ma</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6/13/2019</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">3/18/2019</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">67,349</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">1.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6/13/2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">12/21/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">12/21/2020</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(4)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">37,882</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">12,630</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">1.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">12/21/2030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1/17/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1/17/2023</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">80,208</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">269,792</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">8.08</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1/17/2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10/4/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10/4/2023</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">6,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">143,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">1.41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10/4/2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elizabeth Czerepak<span style="font-weight:bold"><sup style="font-size:75%; vertical-align:top">(6)</sup></span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10/14/2019</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10/23/2019</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">404,098</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">1.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">10/14/2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1/17/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1/17/2023</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">269,792</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">80,208</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">8.08</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1/17/2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pursuant to the terms of the Merger Agreement, effective as of the closing of the Business Combination on November&#160;10, 2022, outstanding equity awards under the 2017 Scilex Pharmaceuticals Inc. Equity Incentive Plan (the &#8220;Scilex Pharma 2017 Plan&#8221;) and 2019 Stock Option Plan were adjusted as follows: (i)&#160;each option to purchase Legacy Scilex common stock that was outstanding as of immediately prior to the Effective Time was converted into the right to receive an option relating to our Common Stock upon substantially the same terms and conditions as were in effect with respect to such option immediately prior to the Effective Time (the &#8220;Option&#8221;) except that (x)&#160;such Option relates to that whole number of shares of our Common Stock (rounded down to the nearest whole share) equal to the number of Legacy Scilex common stock subject to such Option, multiplied by the Exchange Ratio of 0.673498:1 (the &#8220;Exchange Ratio&#8221;), and (y)&#160;the exercise price per share for each such share of our Common Stock equals the exercise price per share of such Option in effect immediately prior to the Effective Time, divided by the Exchange Ratio (rounded up to the nearest whole cent). The numbers in the table reflect the share numbers outstanding and exercise prices as of December&#160;31, 2023, in each case after giving effect to the Exchange Ratio. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">199 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Options granted in 2019 and 2020 were granted under the 2019 Stock Option Plan, and options granted in 2023 were granted under the Equity Incentive Plan. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Options have fully vested. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Each option vested as to 1/4th of the shares subject to the option on the <span style="white-space:nowrap">one-year</span> anniversary of the vesting commencement date and 1/48th of the shares subject to the option vested and shall vest on each monthly anniversary thereafter, subject to full acceleration in the event of an involuntary termination of employment without &#8220;cause&#8221; or due to a voluntary termination of employment with &#8220;good reason&#8221; (each, as defined in the applicable option agreement) within 13 months following a Change in Control (as defined in the 2019 Stock Option Plan). </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Each option vested and shall vest as to 1/48th of the shares subject to the option on each monthly anniversary commencing on the vesting commencement date, subject to full acceleration in the event of a Corporate Transaction (as defined in the Equity Incentive Plan) in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding awards or substitute similar awards for such outstanding awards. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Ms.&#160;Czerepak, our former Executive Vice President, Chief Business Officer, Chief Financial Officer and Secretary, resigned from her positions effective as of September&#160;20, 2023. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Equity-Based Incentive Plans </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">2017 Scilex Pharmaceuticals Inc. Equity Incentive Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2017, our Board adopted the Scilex Pharmaceuticals Inc. Equity Incentive Plan (the &#8220;Scilex Pharma 2017 Plan&#8221;). In connection with the corporate reorganization in March 2019, the Scilex Pharma 2017 Plan was terminated. Accordingly, after such time, no additional awards were granted under the Scilex Pharma 2017 Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Scilex Holding Company&#160;2019 Stock Option Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2019, our Board adopted the Scilex Holding Company 2019 Stock Option Plan (the &#8220;2019 Stock Option Plan&#8221;), which subsequently was amended in December 2020. The 2019 Stock Option Plan was terminated at the closing of the Business Combination, and no further awards have been granted under the 2019 Stock Option Plan thereafter. However, the 2019 Stock Option Plan will continue to govern outstanding awards granted thereunder. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Scilex Holding Company&#160;2022 Equity Incentive Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2022, our Board adopted the Equity Incentive Plan. The total number of shares of Common Stock for which incentive stock options (&#8220;ISOs&#8221;) may be granted under the Equity Incentive Plan is not to exceed 20,276,666 shares, which was increased from 14,622,712 as a result of the automatic annual increase on January&#160;1, 2023 pursuant to the Equity Incentive Plan provisions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;4, 2023, our stockholders approved the amendment to the Equity Incentive Plan to (i)&#160;increase the number of shares authorized for issuance thereunder by 10,000,000 shares from 20,276,666 shares to 30,276,666 shares, (ii)&#160;increase the number of shares authorized for issuance thereunder pursuant to the exercise of ISOs to 30,276,666 shares, and (iii)&#160;modify the commencement date of the automatic increase in the number of shares authorized for issuance thereunder pursuant to the exercise of ISOs to January&#160;1, 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, options to purchase 33,123,798 shares of Common Stock were outstanding under all equity incentive plans. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We<span style="font-weight:bold"> </span>recently determined that the aggregate value of all compensation granted or paid to each <span style="white-space:nowrap">non-employee</span> director for the fiscal year ending December&#160;31, 2023 (when aggregated with any remaining compensation payable for the remainder of such fiscal year) would inadvertently exceed the $750,000 annual compensation </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">200 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
limit for <span style="white-space:nowrap">non-employee</span> directors (the &#8220;Compensation Limit&#8221;) under the Equity Incentive Plan, as a result of the previously disclosed equity grants made thereunder to such <span style="white-space:nowrap">non-employee</span> directors in January 2023 (the &#8220;Awards&#8221;). As a result, our current <span style="white-space:nowrap">non-employee</span> directors, David Lemus and Dorman Followwill, and our former <span style="white-space:nowrap">non-employee</span> directors, <span style="white-space:nowrap">Tien-Li</span> Lee and Laura Hamill, each voluntarily agreed to forfeit (i)&#160;a number of shares of Common Stock subject to their Awards or (ii)&#160;a combination of shares of Common Stock subject to their Awards and cash compensation payable by us for such person&#8217;s service as a director for the remainder of 2023, in each case in an amount that would bring each such <span style="white-space:nowrap">non-employee</span> director&#8217;s aggregate compensation for the fiscal year ending December&#160;31, 2023 below the Compensation Limit. The <span style="white-space:nowrap">non-employee</span> directors forfeited an aggregate of 311,735 shares of Common Stock and an aggregate of approximately $107,424 in cash compensation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material terms of the Equity Incentive Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Purpose of the Equity Incentive Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the Equity Incentive Plan is to secure and retain the services of employees, directors and consultants, to provide incentives for such persons to exert maximum efforts for our success and to provide a means by which such persons may be given an opportunity to benefit from increases in value of our Common Stock through the granting of awards under the Equity Incentive Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Equity Incentive Plan provides for the grant of incentive stock options (&#8220;ISOs&#8221;) within the meaning of Section&#160;422 of the Code, to our employees and our parent and subsidiary corporations&#8217; employees, and for the grant of nonstatutory stock options (&#8220;NSOs&#8221;), stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to our employees, directors and consultants and any of our affiliates&#8217; employees and consultants. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Authorized Shares </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Initially, the maximum number of shares of our Common Stock that may be issued under the Equity Incentive Plan after it becomes effective will not exceed (i) 14,622,712 shares of our Common Stock, plus (ii)&#160;an additional number of shares of Common Stock equal to the number of shares subject to outstanding awards granted under the&#160;2019 Stock Option Plan, that, following the effective date of the Equity Incentive Plan, (a)&#160;are not issued because the award or any portion of the award expires or otherwise terminates without all of the shares covered by the award having been issued, (b)&#160;are not issued because the award or any portion thereof is settled in cash, (c)&#160;are forfeited back to or repurchased by us because of the failure to meet a contingency or condition required for the vesting of such shares, (d)&#160;are withheld or reacquired to satisfy the exercise, strike or purchase price or (e)&#160;are withheld or reacquired to satisfy a tax withholding obligation. In addition, the number of shares of our Common Stock that will be reserved for issuance under the Equity Incentive Plan will automatically increase on January&#160;1 of each year for a period of ten years, beginning on January&#160;1, 2023 and ending on (and including) January&#160;1, 2032, in an amount equal to the lesser of (1) 4% of the total number of shares of our Common Stock outstanding on December&#160;31 of the immediately preceding year, (2) 7,311,356 shares of Common Stock (subject to adjustment for recapitalizations, stock splits, stock dividends and similar transactions), and (3)&#160;such number of shares of our Common Stock determined by our Board or the Compensation Committee of our Board prior to January&#160;1 of a given year. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&#160;1, 2023, the authorized number of shares of our Common Stock referenced in the preceding clause&#160;(i) was increased to&#160;20,276,666 based on the foregoing provisions. Notwithstanding anything to the contrary in the foregoing sentence, the aggregate maximum number of shares of our Common Stock that may be issued on the exercise of ISOs under the Equity Incentive Plan was initially&#160;14,622,712 shares, which amount was to increase commencing on January&#160;1, 2023 and ending on (and including) January&#160;1, 2032, in an amount </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">201 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
equal to the lesser of (i) 4% of the total number of shares of Common Stock outstanding on December&#160;31 of the preceding year, (ii) 7,311,356 shares of Common Stock (subject to adjustment for recapitalizations, stock splits, stock dividends and similar transactions), and (iii)&#160;such number of shares of our Common Stock determined by our Board or the Compensation Committee of our Board prior to January&#160;1 of a given year. On January&#160;1, 2023, the authorized number of shares of our Common Stock referenced in the preceding clause&#160;(i) regarding ISOs was increased to&#160;20,276,666 based on the foregoing provisions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;4, 2023, our stockholders approved an amendment to the Equity Incentive Plan to (i)&#160;increase the number of shares authorized for issuance thereunder by&#160;10,000,000 shares to&#160;30,276,666 shares, (ii)&#160;increase the number of shares authorized for issuance thereunder pursuant to the exercise of incentive stock options to&#160;30,276,666 shares, and (iii)&#160;modify the commencement date of the automatic increase in the number of shares authorized for issuance thereunder pursuant to the exercise of incentive stock options to January&#160;1, 2024. All of the foregoing share numbers are subject to adjustment as necessary to implement any changes in our capital structure (as described below). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares subject to awards that will be granted under the Equity Incentive Plan that expire or terminate without being exercised in full will not reduce the number of shares available for issuance under the Equity Incentive Plan. The settlement of any portion of an award in cash will not reduce the number of shares available for issuance under the Equity Incentive Plan. Shares of Common Stock withheld under an award to satisfy the exercise, strike or purchase price of an award or to satisfy a tax withholding obligation will not reduce the number of shares that will be available for issuance under the Equity Incentive Plan. With respect to a stock appreciation right, only shares of Common Stock that are issued upon settlement of the stock appreciation right will count towards reducing the number of shares available for issuance under the Equity Incentive Plan. If any shares of our Common Stock issued pursuant to an award are forfeited back to or repurchased or reacquired by us (i)&#160;because of a failure to meet a contingency or condition required for the vesting of such shares; (ii)&#160;to satisfy the exercise, strike or purchase price of an award; or (iii)&#160;to satisfy a tax withholding obligation in connection with an award, the shares that are forfeited or repurchased or reacquired will revert to and again become available for issuance under the Equity Incentive Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Plan Administration </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board, or a duly authorized committee of our Board, administers the Equity Incentive Plan. Our Board, or a duly authorized committee of our Board, may, in accordance with the terms of the Equity Incentive Plan, delegate to one or more of our officers the authority to (i)&#160;designate employees (other than officers) to be recipients of specified awards, and to the extent permitted by applicable law, the terms of such awards; and (ii)&#160;determine the number of shares of Common Stock to be subject to such awards granted to such employees. Under the Equity Incentive Plan, our Board, or a duly authorized committee of our Board, will have the authority to determine: award recipients; how and when each award will be granted; the types of awards to be granted; the provisions of each award, including the period of exercisability and the vesting schedule applicable to an award; the number of shares of Common Stock or cash equivalent subject to each award; the fair market value applicable to an award; and the terms of any performance award that is not valued in whole or in part by reference to, or otherwise based on, Common Stock, including the amount of cash payment or other property that may be earned and the timing of payment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Equity Incentive Plan, (i)&#160;our Board will not, without stockholder approval, (a)&#160;reduce the exercise or strike price of an option or stock appreciation right (other than in connection with a capitalization adjustment), and (b)&#160;at any time when the exercise or strike price of an option or stock appreciation right is above the fair market value of a share of our Common Stock, cancel and <span style="white-space:nowrap">re-grant</span> or exchange such option or stock appreciation right for a new award with a lower (or no)&#160;purchase price or for cash, and (ii)&#160;a participant&#8217;s rights under any award will not be materially adversely impaired by any amendment without the participant&#8217;s written consent. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">202 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will also designate a plan administrator to administer the <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> operations of the Equity Incentive Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stock Options </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Options will be granted under stock option agreements adopted by our Board. Each option will be designated in writing as an ISO or an NSO. Our Board will determine the exercise price for stock options, within the terms and conditions of the Equity Incentive Plan, except the exercise price of a stock option generally will not be less than&#160;100% (or&#160;110% in the case of ISOs granted to a person who owns or is deemed to own stock possessing more than&#160;10% of our total combined voting power or that of any of our parent or subsidiary corporations, or a ten percent stockholder) of the fair market value of our Common Stock on the date of grant. Options granted under the Equity Incentive Plan will vest at the rate specified in the stock option agreement as will be determined by our Board. The terms and conditions of separate options need not be identical. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No option will be exercisable after the expiration of ten years (or five years in the case of ISOs granted to a ten percent stockholder) or a shorter period specified in the applicable award agreement. Unless the terms of an optionholder&#8217;s stock option agreement, or other written agreement between us and the recipient, provide otherwise, if an optionholder&#8217;s service relationship with us or any of our affiliates ceases for any reason other than disability, death or cause, the optionholder may generally exercise any vested options for a period of three months following the cessation of service. If an optionholder&#8217;s service relationship with us or any of our affiliates ceases due to death, or an optionholder dies within a certain period following cessation of service, the optionholder or a beneficiary may generally exercise any vested options for a period of&#160;18&#160;months following the date of death. If an optionholder&#8217;s service relationship with us or any of our affiliates ceases due to disability, the optionholder may generally exercise any vested options for a period of&#160;12&#160;months following the cessation of service. In the event of a termination for cause, options generally terminate upon the termination date. An optionholder may not exercise an option at any time that the issuance of shares upon such exercise would violate applicable law. Unless provided otherwise in the optionholder&#8217;s stock option agreement or other written agreement between an optionholder and us, if an optionholder&#8217;s service relationship with us or any of our affiliates ceases for any reason other than for cause and, at any time during the last thirty days of the applicable post-termination exercise period: (i)&#160;the exercise of the optionholder&#8217;s option would be prohibited solely because the issuance of shares of Common Stock upon such exercise would violate applicable law, or (ii)&#160;the immediate sale of any shares of Common Stock issued upon such exercise would violate our trading policy, then the applicable post-termination exercise period will be extended to the last day of the calendar month that begins after the date the award would otherwise expire, with an additional extension of the exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such extended exercise period. There is no limitation as to the maximum permitted number of extensions. However, in no event may an option be exercised beyond the expiration of its term. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Acceptable consideration for the purchase of Common Stock issued upon the exercise of a stock option will be determined by our Board and may include (i)&#160;cash or check, bank draft or money order payable to us; (ii)&#160;a broker-assisted cashless exercise; (iii)&#160;subject to certain conditions, the tender of shares of our Common Stock previously owned by the optionholder; (iv)&#160;a net exercise of the option if it is an NSO; or (v)&#160;other legal consideration acceptable to our Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless our Board provides otherwise, options or stock appreciation rights generally will not be transferable except by will or the laws of descent and distribution. Subject to approval of our Board or a duly authorized officer, an option may be transferred pursuant to a domestic relations order. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Limitations on ISOs </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate fair market value, determined at the time of grant, of our Common Stock with respect to ISOs that are exercisable for the first time by an optionholder during any calendar year under all of our stock plans or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">203 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
plans of our affiliates may not exceed $100,000. Options or portions thereof that exceed such limit will generally be treated as NSOs. No ISO may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than&#160;10% of our total combined voting power or that of any of our parent or subsidiary corporations unless (i)&#160;the option exercise price is at least&#160;110% of the fair market value of the stock subject to the option on the date of grant; and (ii)&#160;the term of the ISO does not exceed five years from the date of grant. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Restricted Stock Unit Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the Equity Incentive Plan, each restricted stock unit award will have such terms and conditions as determined by our Board. A restricted stock unit award represents a participant&#8217;s right to be issued on a future date the number of shares of our Common Stock that is equal to the number of restricted stock units subject to the award. A participant will not have voting or any other rights as a stockholder of ours with respect to any restricted stock unit award (unless and until shares are actually issued in settlement of a vested restricted stock unit award). A restricted stock unit award will be granted in consideration for a participant&#8217;s services to us or an affiliate, such that the participant will not be required to make any payment to us (other than such services) with respect to the grant or vesting of the restricted stock unit award, or the issuance of any shares of Common Stock pursuant to the restricted stock unit award. Our Board may determine that restricted stock unit awards may be granted in consideration for any form of legal consideration that may be acceptable to our Board and permissible under applicable law. A restricted stock unit award may be settled by cash, delivery of stock (or any combination of our Common Stock and cash), or in any other form of consideration determined by our Board and set forth in the restricted stock unit award agreement. At the time of grant, our Board may impose such restrictions or conditions on the award of restricted stock units that delay delivery to a date following the vesting of the award. Additionally, dividend equivalents may be paid or credited in respect of shares of Common Stock covered by a restricted stock unit award. Except as otherwise provided in the applicable award agreement, or other written agreement between us and the recipient, restricted stock unit awards that have not vested will be forfeited once the participant&#8217;s continuous service ends for any reason. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Restricted Stock Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restricted stock awards will be granted under restricted stock award agreements adopted by our Board. A restricted stock award may be awarded in consideration for cash, check, bank draft or money order, past services to us or any of our affiliates, or any other form of legal consideration that may be acceptable to our Board and permissible under applicable law. Our Board will determine the terms and conditions of restricted stock awards, including vesting and forfeiture terms. Dividends may be paid or credited with respect to shares subject to a restricted stock award, as determined by our Board and specified in the applicable restricted stock award agreement. If a participant&#8217;s service relationship with us ends for any reason, we may receive any or all of the shares of Common Stock held by the participant that have not vested as of the date the participant terminates service with us through a forfeiture condition or a repurchase right. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stock Appreciation Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock appreciation rights will be granted under stock appreciation right agreements adopted by our Board and denominated in shares of Common Stock equivalents. The terms of separation stock appreciation rights need not be identical. Our Board will determine the purchase price or strike price for a stock appreciation right, which generally will not be less than&#160;100% of the fair market value of our Common Stock on the date of grant. A stock appreciation right granted under the Equity Incentive Plan will vest at the rate specified in the stock appreciation right agreement as will be determined by our Board. Stock appreciation rights may be settled in cash or shares of our Common Stock (or any combination of our Common Stock and cash) or in any other form of payment, as determined by our Board and specified in the stock appreciation right agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board will determine the term of stock appreciation rights granted under the Equity Incentive Plan, up to a maximum of ten years. If a participant&#8217;s service relationship with us or any of our affiliates ceases for any </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">204 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reason other than cause, disability, or death, the participant may generally exercise any vested stock appreciation right for a period of three months following the cessation of service. If a participant&#8217;s service relationship with us or any of our affiliates ceases due to death, or a participant dies within a certain period following cessation of service, the participant or a beneficiary may generally exercise any vested stock appreciation rights for a period of&#160;18&#160;months following the date of death. If a participant&#8217;s service relationship with us or any of our affiliates ceases due to disability, the participant may generally exercise any vested stock appreciation rights for a period of&#160;12&#160;months following the cessation of service. In the event of a termination for cause, stock appreciation rights generally terminate upon the termination date. A holder of a stock appreciation right may not exercise a stock appreciation right at any time that the issuance of shares upon such exercise would violate applicable law. Unless provided otherwise in the stock appreciation right agreement or other written agreement between the participant and us, if a participant&#8217;s service relationship with us or any of our affiliates ceases for any reason other than for cause and, at any time during the last thirty days of the applicable post-termination exercise period: (i)&#160;the exercise of the participant&#8217;s stock appreciation right would be prohibited solely because the issuance of shares upon such exercise would violate applicable law, or (ii)&#160;the immediate sale of any shares issued upon such exercise would violate our trading policy, then the applicable post-termination exercise period will be extended to the last day of the calendar month that begins after the date the award would otherwise expire, with an additional extension of the exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such extended exercise period. There is no limitation as to the maximum permitted number of extensions. However, in no event may a stock appreciation right be exercised beyond the expiration of its term. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Performance Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Equity Incentive Plan will permit the grant of performance awards that may be settled in stock, cash or other property. Performance awards may be structured so that the stock or cash will be issued or paid only following the achievement of certain <span style="white-space:nowrap">pre-established</span> performance goals during a designated performance period. Performance awards that are settled in cash or other property are not required to be valued in whole or in part by reference to, or otherwise based on, our Common Stock. The performance goals may be based on any measure of performance selected by our Board. The performance goals may be based on company-wide performance or performance of one or more business units, divisions, affiliates, or business segments, and may be either absolute or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise by our Board at the time the performance award is granted, our Board will appropriately make adjustments in the method of calculating the attainment of performance goals for a performance period as follows: (i)&#160;to exclude restructuring and/or other nonrecurring charges; (ii)&#160;to exclude exchange rate effects; (iii)&#160;to exclude the effects of changes to generally accepted accounting principles; (iv)&#160;to exclude the effects of any statutory adjustments to corporate tax rates; (v)&#160;to exclude the effects of items that are &#8220;unusual&#8221; in nature or occur &#8220;infrequently&#8221; as determined under generally accepted accounting principles; (vi)&#160;to exclude the dilutive effects of acquisitions or joint ventures; (vii)&#160;to assume that any business divested by us achieved performance objectives at targeted levels during the balance of a performance period following such divestiture; (viii)&#160;to exclude the effect of any change in the outstanding shares of our Common Stock by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, <span style="white-space:nowrap">spin-off,</span> combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends; (ix)&#160;to exclude the effects of stock based compensation and the award of bonuses under our bonus plans; (x)&#160;to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles; and (xi)&#160;to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board retains the discretion to reduce or eliminate the compensation or economic benefit due upon attainment of performance goals and to define the manner of calculating the performance criteria it selects to use for the performance period. Partial achievement of the specified criteria may result in the payment or vesting corresponding to the degree of achievement as specified in the performance award agreement or the written terms </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">205 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of a performance cash award. Our Board will determine the length of any performance period, the performance goals to be achieved during a performance period and the other terms and conditions of such awards. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other Stock Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board will be permitted to grant other awards, based in whole or in part by reference to, or otherwise based on, our Common Stock, either alone or in addition to other awards. Our Board will have the sole and complete discretion to determine the persons to whom and the time or times at which other stock awards will be granted, the number of shares under the other stock award (or cash equivalent) and all other terms and conditions of such awards. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Non-Employee</span> Director Compensation Limit </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate value of all compensation granted or paid following the effective date of the Equity Incentive Plan to any individual for service as a <span style="white-space:nowrap">non-employee</span> director with respect to any fiscal year, including awards granted under the Equity Incentive Plan (valued based on the grant date fair value for financial reporting purposes) and cash fees paid by us to such <span style="white-space:nowrap">non-employee</span> director, will not exceed $750,000 in total value, except such amount will increase to $1,000,000 for the year in which a <span style="white-space:nowrap">non-employee</span> director is first appointed or elected to our Board. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes to Capital Structure </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event there is a specified type of change in our capital structure, such as a stock split, reverse stock split, or recapitalization, our Board will appropriately and proportionately adjust (i)&#160;the class(es) and maximum number of shares subject to the Equity Incentive Plan and the maximum number of shares by which the share reserve may annually increase pursuant to the Equity Incentive Plan; (ii)&#160;the class(es) and maximum number of shares that may be issued on the exercise of ISOs; and (iii)&#160;the class(es) and number of shares and exercise price, strike price, or purchase price, if applicable, of all outstanding awards granted under the Equity Incentive Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Corporate Transactions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a corporate transaction (as defined below), unless otherwise provided in a participant&#8217;s award agreement or other written agreement with us or one of our affiliates or unless otherwise expressly provided by our Board at the time of grant, any awards outstanding under the Equity Incentive Plan may be assumed, continued or substituted for, in whole or in part, by any surviving or acquiring corporation (or its parent company), and any reacquisition or repurchase rights held by us with respect to our Common Stock issued pursuant to awards may be assigned to the successor (or its parent company). If the surviving or acquiring corporation (or its parent company) does not assume, continue or substitute for such awards, then (i)&#160;with respect to any such awards that are held by participants whose continuous service has not terminated prior to the effective time of the corporate transaction, or current participants, the vesting (and exercisability, if applicable) of such awards will be accelerated in full (or, in the case of performance awards with multiple vesting levels depending on the level of performance, unless provided otherwise in the applicable award agreement, vesting will accelerate at&#160;100% of the target level) to a date prior to the effective time of the corporate transaction (contingent upon the effectiveness of the corporate transaction) as our board of directors determines (or, if our board of directors does not determine such a date, to the date that is five days prior to the effective time of the corporate transaction), and such awards will terminate if not exercised (if applicable) at or prior to the effective time of the corporate transaction, and any reacquisition or repurchase rights held by us with respect to such awards will lapse (contingent upon the effectiveness of the corporate transaction); and (ii)&#160;any such awards that are held by persons other than current participants will terminate if not exercised (if applicable) prior to the occurrence of the corporate transaction, except that any reacquisition or repurchase rights held by us with respect to such awards will not terminate and may continue to be exercised notwithstanding the corporate transaction. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">206 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event an award will terminate if not exercised prior to the effective time of a corporate transaction, our Board may provide, in its sole discretion, that the holder of such award may not exercise such award but instead will receive a payment, in such form as may be determined by our Board, equal in value to the excess (if any) of (i)&#160;the value of the property the participant would have received upon the exercise of the award, over (ii)&#160;any per share exercise price payable by such holder, if applicable. As a condition to the receipt of an award, a participant will be deemed to have agreed that the award will be subject to the terms of any agreement under the Equity Incentive Plan governing a corporate transaction involving us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Equity Incentive Plan, a &#8220;corporate transaction&#8221; generally will be the consummation, in a single transaction or in a series of related transactions, of (i)&#160;a sale or other disposition of all or substantially all, as determined by our board of directors, of the consolidated assets of us and our subsidiaries; (ii)&#160;a sale or other disposition of at least&#160;50% of our outstanding securities; (iii)&#160;a merger, consolidation or similar transaction following which we are not the surviving corporation; or (iv)&#160;a merger, consolidation or similar transaction following which we are the surviving corporation but the shares of our Common Stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Transferability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as expressly provided in the Equity Incentive Plan or the form of award agreement, awards granted under the Equity Incentive Plan may not be transferred or assigned by a participant. After the vested shares subject to an award have been issued, or in the case of a restricted stock award and similar awards, after the issued shares have vested, the holder of such shares is free to assign, hypothecate, donate, encumber or otherwise dispose of any interest in such shares provided that any such actions are in compliance with the provisions herein, the terms of our trading policy and applicable law. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Clawback/Recovery </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All awards granted under the Equity Incentive Plan will be subject to recoupment in accordance with any clawback policy that we are required to adopt pursuant to the listing standards of any national securities exchange or association on which our securities are listed or as is otherwise required by the Dodd-Frank Act or other applicable law and any clawback policy that we otherwise adopt, to the extent applicable and permissible under applicable law. In addition, our Board may impose such other clawback, recovery or recoupment provisions in an award agreement as our Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of cause. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Amendment or Termination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board may accelerate the time at which an award granted under the Equity Incentive Plan may first be exercised or the time during which an award grant under the Equity Incentive Plan or any part thereof will vest, notwithstanding the provisions in the award agreement stating the time at which it may first be exercised or the time during which it will vest. Our Board will have the authority to amend, suspend, or terminate the Equity Incentive Plan at any time, provided that such action does not materially impair the existing rights of any participant without such participant&#8217;s written consent. Certain material amendments will also require the approval of our stockholders. No ISOs may be granted after the tenth anniversary of the date our Board adopts the Equity Incentive Plan. No awards may be granted under the Equity Incentive Plan while it is suspended or after it is terminated. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Federal Income Tax Consequences Associated with the Equity Incentive Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a general summary under current law of the material federal income tax consequences to participants in the Equity Incentive Plan. This summary deals with the general tax principles that apply and is </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">207 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provided only for general information. Some kinds of taxes, such as state, local and foreign income taxes and federal employment taxes, are not discussed. Tax laws are complex and subject to change and may vary depending on individual circumstances and from locality to locality. The summary does not discuss all aspects of income taxation that may be relevant in light of a holder&#8217;s personal investment circumstances. This summarized tax information is not tax advice. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Nonstatutory Stock Options</span>. For federal income tax purposes, if an optionee is granted an NSO under the Equity Incentive Plan, the optionee will not have taxable income on the grant of the option, nor will we be entitled to any deduction. Generally, upon exercise of NSOs, the optionee will recognize ordinary income, and we will be entitled to a deduction, in an amount equal to the excess of the fair market value of a share of our Common Stock over the option exercise price on the date each such option is exercised. The optionee&#8217;s basis for the stock for purposes of determining gain or loss on subsequent disposition of such shares generally will be the fair market value of our Common Stock on the date the optionee exercises such option. Any subsequent gain or loss will be generally taxable as capital gains or losses. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Incentive Stock Options</span>. There is no taxable income to an optionee when an optionee is granted an ISO or when that option is exercised. However, the amount by which the fair market value of the shares at the time of exercise exceeds the option price will be an &#8220;item of adjustment&#8221; for the optionee for purposes of the alternative minimum tax. Gain realized by the optionee on the sale of an ISO is taxable at capital gains rates, and no tax deduction is available to us, unless the optionee disposes of the shares within (a)&#160;two years after the date of grant of the option or (b)&#160;within one year of the date the shares were transferred to the optionee. If the shares acquired upon exercise of the ISO are sold or otherwise disposed of before the end of the <span style="white-space:nowrap">two-year</span> and <span style="white-space:nowrap">one-year</span> periods specified above, the excess of the fair market value of a share of our Common Stock over the option exercise price on the date of the option&#8217;s exercise will be taxed at ordinary income rates (or, if less, the gain on the sale), and we will be entitled to a deduction to the extent the optionee must recognize ordinary income. If such a sale or disposition takes place in the year in which the optionee exercises the option, the income the optionee recognizes upon sale or disposition of the shares will not be considered an item of adjustment for alternative minimum tax purposes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An ISO exercised more than three months after an optionee terminates employment, for reasons other than death or disability, will be taxed as an NSO, and the optionee will recognize ordinary income on the exercise. We will be entitled to a tax deduction equal to the ordinary income, if any, realized by the optionee. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Restricted Stock</span><span style="font-weight:bold"><span style="font-style:italic">.</span></span> An individual to whom restricted stock is issued generally will not recognize taxable income upon such issuance, and we generally will not then be entitled to a deduction, unless an election is made by the participant under Section&#160;83(b) of the Code (&#8220;Section&#160;83(b)&#8221;). However, when restrictions on shares of restricted stock lapse, such that the shares are no longer subject to a substantial risk of forfeiture, the individual generally will recognize ordinary income, and we generally will be entitled to a deduction for an amount equal to the excess of the fair market value of the shares at the date such restrictions lapse over the purchase price. If a timely election is made under Section&#160;83(b) with respect to restricted stock, the participant generally will recognize ordinary income on the date of the issuance equal to the excess, if any, of the fair market value of the shares at that date over the purchase price of such shares, and we will be entitled to a deduction for the same amount. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Stock Appreciation Rights</span>. A participant will not be taxed upon the grant of a stock appreciation right. Upon the exercise of the stock appreciation right, the participant will recognize ordinary income equal to the amount of cash or the fair market value of the stock received upon exercise. At the time of exercise, we will be eligible for a tax deduction as a compensation expense equal to the amount that the participant recognizes as ordinary income. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Performance Awards and Other Stock Awards</span>. The participant will have ordinary income upon receipt of stock or cash payable under performance awards, dividend equivalents, restricted stock units and stock payments. We will be eligible for a tax deduction as a compensation expense equal to the amount of ordinary income recognized by the participant. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">208 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Section</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;162(m) of the Code</span>. Section&#160;162(m) of the Code generally limits to $1.0&#160;million the amount of compensation that we may deduct in any calendar year for certain current and former executive officers. For grants under the Equity Incentive Plan, we will not be able to take a deduction for any compensation in excess of $1.0&#160;million that is paid to a covered officer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Requirements of Section</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;409A of the Code</span>. Certain awards under the Equity Incentive Plan may be considered &#8220;nonqualified deferred compensation&#8221; for purposes of Section&#160;409A of the Code (&#8220;Section&#160;409A&#8221;), which imposes certain requirements on compensation that is deemed under Section&#160;409A to involve nonqualified deferred compensation. Among other things, the requirements relate to the timing of elections to defer, the timing of distributions and prohibitions on the acceleration of distributions. Failure to comply with these requirements (or an exception from such requirements) may result in the immediate taxation of all amounts deferred under the nonqualified deferred compensation plan for the taxable year and all preceding taxable years, by or for any participant with respect to whom the failure relates, the imposition of an additional&#160;20% income tax on the participant for the amounts required to be included in gross income and the possible imposition of penalty interest on the unpaid tax. Generally, Section&#160;409A does not apply to incentive awards that are paid at the time the award vests. Likewise, Section&#160;409A typically does not apply to restricted stock. Section&#160;409A may, however, apply to incentive awards the payment of which is delayed beyond the calendar year in which the award vests. Treasury regulations generally provide that the type of awards provided under the Equity Incentive Plan will not be considered nonqualified deferred compensation. However, to the extent that Section&#160;409A applies to an award issued under the Equity Incentive Plan, the Equity Incentive Plan and all such awards will, to the extent practicable, be construed in accordance with Section&#160;409A. Under the Equity Incentive Plan, the administrator has the discretion to grant or to unilaterally modify any award issued under the Equity Incentive Plan in a manner that conforms with the requirements of Section&#160;409A with respect to deferred compensation or voids any participant election to the extent it would violate Section&#160;409A. The administrator also has sole discretion to interpret the requirements of the Code, including Section&#160;409A, for purposes of the Equity Incentive Plan and all awards issued under the Equity Incentive Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Scilex Holding Company&#160;2022 Employee Stock Purchase Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;17, 2022, our Board adopted, subject to the approval by our stockholders, the ESPP. On November&#160;9, 2022, our stockholders approved the ESPP. The ESPP became effective on November&#160;9, 2022, the day immediately preceding the date on which the Closing occurred. As of the date of this prospectus, we have not commenced any offerings under the ESPP. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Purpose </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the ESPP is to secure and retain the services of new employees, to retain the services of existing employees, and to provide incentives for such individuals to exert maximum efforts toward our success and that of our related corporations. The ESPP includes two components. One component is designed to allow eligible U.S.&#160;employees to purchase our Common Stock in a manner that may qualify for favorable tax treatment under Section&#160;423 of the Code (the &#8220;423 Component&#8221;) and accordingly, it will be construed in a manner that is consistent with the requirements of Section&#160;423 of the Code. We intend (but make no undertaking or representation to maintain) the&#160;423 Component to qualify as an employee stock purchase plan, as that term is defined in Section&#160;423(b) of the Code. The other component will permit the grant of purchase rights that do not qualify for such favorable tax treatment (the <span style="white-space:nowrap">&#8220;Non-423</span> Component&#8221;) in order to allow deviations necessary to permit participation by eligible employees who are foreign nationals or employed outside of the U.S.&#160;while complying with applicable foreign laws, and except as otherwise provided in the ESPP or determined by our Board, it will operate and be administered in the same manner as the&#160;423 Component. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Share Reserve </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Initially, the maximum number of shares of our Common Stock that may be issued under the ESPP will not exceed&#160;1,462,271 shares of our Common Stock. On January&#160;1, 2023, the maximum number of shares of our </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">209 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Common Stock that may be issued under the ESPP was increased to&#160;2,875,759 based on the following provisions of the ESPP. The ESPP provides that the number of shares of our Common Stock that will be reserved for issuance will automatically increase on January&#160;1 of each year for a period of up to ten years, commencing on January&#160;1, 2023 and ending on (and including) January&#160;1, 2032, in an amount equal to the lesser of (i) 1% of the total number of shares of our Common Stock outstanding on December&#160;31 of the immediately preceding calendar year; (ii) 1,827,839 shares of our Common Stock; and (iii)&#160;such number of shares of our Common Stock determined by our Board or the Compensation Committee of our Board prior to January&#160;1 of a given year, provided however, that our Board may act prior to January&#160;1 of a given calendar year to provide that there will be no increase for such calendar year or the increase for such year will be a lesser number of shares than the amount set forth in clauses&#160;(i) to (iii)&#160;above. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, up to the maximum number of shares of our Common Stock reserved may be used to satisfy purchases of our Common Stock under the&#160;423 Component and any remaining portion of such maximum number of shares may be used to satisfy the purchases of our Common Stock under the <span style="white-space:nowrap">Non-423</span> Component. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any purchase right granted under the ESPP terminates without having been exercised in full, the shares of our Common Stock not purchased under such purchase right will again become available for issuance under the ESPP. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Common Stock purchasable under the ESPP will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by us on the open market. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Administration </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board administers the ESPP. Our Board may delegate some or all of the administration of the ESPP to a committee or committees of our Board. All references to our Board in summary of the ESPP will include a duly authorized committee of our Board except where the context dictates otherwise. Further, to the extent not prohibited by applicable law, our Board may, from time to time, delegate some or all of its authority under the ESPP to one or more of our officers or other persons or groups of persons as it deems necessary, appropriate or advisable under conditions or limitations that it may set at or after the time of the delegation. Our Board will have the authority to determine how and when purchase rights are granted and the provisions of each offering; to designate, from time to time, which of our related corporations will be eligible to participate in the&#160;423 Component or the <span style="white-space:nowrap">Non-423</span> Component, or which related corporations will be eligible to participate in each separate offering; to construe and interpret the ESPP and purchase rights thereunder, and to establish, amend and revoke rules and regulations for the ESPP&#8217;s administration; to settle all controversies regarding the ESPP and purchase rights granted thereunder; to amend, suspend or terminate the ESPP; to exercise such powers and to perform such acts as it deems necessary or expedient to promote the best interests of us and our related corporations and to carry out the intent of the ESPP to be treated as an employee stock purchase plan with respect to the&#160;423 Component; and to adopt such rules, procedures and <span style="white-space:nowrap">sub-plans</span> as are necessary or appropriate to permit or facilitate participation in the ESPP by employees who are foreign nationals or employed or located outside the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All determinations, interpretations and constructions made by our Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Offerings </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board may grant or provide for the grant of purchase rights to eligible employees under an offering (consisting of one or more purchase periods) on an offering date or offering dates selected by our Board. Each offering will be in the form and will contain those terms and conditions as our Board deems appropriate, and, with respect to the&#160;423 Component, will comply with the requirements of Section&#160;423(b)(5) of the Code. The </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">210 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provisions of separate offerings do not need to be identical, but each offering will include the period during which the offering will be effective, which period will not exceed&#160;27&#160;months beginning with the offering date, and the substance of the applicable provisions contained in the ESPP. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a participant has more than one purchase right outstanding under the ESPP, unless he or she otherwise indicates in forms delivered to us or a third party designee of ours: (i)&#160;each form will apply to all of his or her purchase rights under the ESPP, and (ii)&#160;a purchase right with a lower exercise price (or an earlier-granted purchase right, if different purchase rights have identical exercise prices) will be exercised to the fullest possible extent before a purchase right with a higher exercise price (or a later-granted purchase right if different purchase rights have identical exercise prices) will be exercised. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board will have the discretion to structure an offering so that if the fair market value of a share of our Common Stock on the first trading day of a new purchase period within that offering is less than or equal to the fair market value of a share of our Common Stock on the first day of that offering, then (i)&#160;that offering will terminate immediately as of that first trading day, and (ii)&#160;the participants in such terminated offering will be automatically enrolled in a new offering beginning on the first trading day of such new purchase period. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Eligibility </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, purchase rights may only be granted to employees, including executive officers, employed by us (or by any of our affiliates or related corporations as designated by our Board) on the first day of an offering if such employee has been employed by us or by one of our designated affiliates or related corporations for such continuous period preceding such date (not to exceed two years) as our Board may require. Our Board may (unless prohibited by applicable law) require that employees have to satisfy one or both of the following service requirements with respect to the&#160;423 Component: (i)&#160;being customarily employed by us, or any of our related corporations or affiliates, for more than&#160;20 hours per week and more than five months per calendar year; or (ii)&#160;such other criteria as our Board may determine consistent with Section&#160;423 of the Code with respect to the&#160;423 Component. Our Board may provide that each person who, during the course of an offering, first becomes an eligible employee will, on the date or dates specified in the offering which coincides with the day on which the person becomes an eligible employee or which occurs thereafter, receive a purchase right under that offering, and the purchase right will thereafter be deemed to be part of the offering with substantially identical characteristics. No employee will be eligible for the grant of any purchase rights under the ESPP if immediately after such rights are granted, such employee owns stock possessing five percent or more of the total combined voting power or value of all classes of our outstanding capital stock (or the stock of any related corporation) determined in accordance with the rules of Section&#160;424(d) of the Code. As specified by Section&#160;423(b)(8) of the Code, an eligible employee may be granted purchase rights only if such purchase rights, together with any other rights granted under all employee stock purchase plans of ours or any of our related corporations, do not permit such eligible employee&#8217;s rights to purchase our stock or the stock of any of our related corporations to accrue at a rate which, when aggregated, exceeds $25,000 (based on the fair market value per share of such common stock on the date that the purchase right is granted) for each calendar year such purchase rights are outstanding at any time. Our Board may also exclude from participation in the ESPP or any offering employees of ours, or of any of our related corporation, who are highly compensated employees, as within the meaning of Section&#160;423(b)(4)(D) of the Code, or a subset of such highly compensated employees. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything in the foregoing paragraph to the contrary, in the case of an offering under the <span style="white-space:nowrap">Non-423</span> Component, an eligible employee (or a group of eligible employees) may be excluded from participation in the ESPP or an offering if our Board has determined, in its sole discretion, that participation of such eligible employee is not advisable or practical for any reason. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Purchase Rights; Purchase Price </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the first day of each offering, each eligible employee, pursuant to an offering made under the ESPP, will be granted a purchase right to purchase up to that number of shares of our Common Stock purchasable either </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">211 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with a percentage or with a maximum dollar amount, as designated by our Board, which will not exceed&#160;15% of such employee&#8217;s earnings (as defined by our Board) during the period that begins on the first day of the offering (or such later date as our Board determines for a particular offering) and ends on the date stated in the offering, which date will be no later than the end of the offering. Our Board will establish one or more purchase dates during an offering on which purchase rights granted for that offering will be exercised and shares of Common Stock will be purchased in accordance with such offering. Each eligible employee may purchase of up to&#160;10,000 shares of our Common Stock in an offering (or such lesser number of shares determined by our Board prior to the start of the offering). Our Board may also specify (i)&#160;a maximum number of shares of our Common Stock that may be purchased by any participant on any purchase date during an offering, (ii)&#160;a maximum aggregate number of shares of our Common Stock that may be purchased by all participants in an offering and/or (iii)&#160;a maximum aggregate number of shares of our Common Stock that may be purchased by all participants on any purchase date under an offering. If the aggregate number of shares of our Common Stock issuable upon exercise of purchase rights granted under the offering would exceed any such maximum aggregate number, then, in the absence of any action by our Board otherwise, a pro rata allocation of the shares of our Common Stock (rounded down to the nearest whole share) available, based on each participant&#8217;s accumulated contributions, will be made in as nearly a uniform manner as will be practicable and equitable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purchase price of shares of our Common Stock acquired pursuant to purchase rights will not be less than the lesser of (i) 85% of the fair market value of a share of our Common Stock on the first day of an offering; or (ii) 85% of the fair market value of a share of our Common Stock on the date of purchase. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Participation; Withdrawal; Termination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An eligible employee may elect to participate in an offering and authorize payroll deductions as the means of making contributions by completing and delivering to us or our designee, within the time specified in the offering, an enrollment form provided by us or our designee. The enrollment form will specify the amount of contributions not to exceed the maximum amount specified by our Board. Each participant&#8217;s contributions will be credited to a bookkeeping account for the participant under the ESPP and will be deposited with our general funds except where applicable law requires that contributions be deposited with a third party. If permitted in the offering, a participant may begin such contributions with the first payroll occurring on or after the first day of the applicable offering (or, in the case of a payroll date that occurs after the end of the prior offering but before the first day of the next new offering, contributions from such payroll will be included in the new offering). If permitted in the offering, a participant may thereafter reduce (including to zero) or increase his or her contributions. If required under applicable law or if specifically provided in the offering, in addition to or instead of making contributions by payroll deductions, a participant may make contributions through payment by cash, check or wire transfer prior to a purchase date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During an offering, a participant may cease making contributions and withdraw from the offering by delivering to us or our designee a withdrawal form provided by us. We may impose a deadline before a purchase date for withdrawing. Upon such withdrawal, such participant&#8217;s purchase right in that offering will immediately terminate and we will distribute as soon as practicable to such participant all of his or her accumulated but unused contributions and such participant&#8217;s purchase right in that offering shall then terminate. A participant&#8217;s withdrawal from that offering will have no effect upon his or her eligibility to participate in any other offerings under the ESPP, but such participant will be required to deliver a new enrollment form to participate in subsequent offerings. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise required by applicable law, purchase rights granted pursuant to any offering under the ESPP will terminate immediately if the participant either (i)&#160;is no longer an employee for any reason or for no reason (subject to any post-employment participation period required by applicable law) or (ii)&#160;is otherwise no longer eligible to participate. We will distribute the individual&#8217;s accumulated but unused contributions as soon as practicable to such individual. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">212 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise determined by our Board, a participant whose employment transfers or whose employment terminates with an immediate rehire (with no break in service) by or between us and one of our designated companies designated to participate in an offering (or between such designated companies) will not be treated as having terminated employment for purposes of participating in the ESPP or an offering. However, if a participant transfers from an offering under the&#160;423 Component to an offering under the <span style="white-space:nowrap">Non-423</span> Component, the exercise of the participant&#8217;s purchase right will be qualified under the&#160;423 Component only to the extent such exercise complies with Section&#160;423 of the Code. If a participant transfers from an offering under the <span style="white-space:nowrap">Non-423</span> Component to an Offering under the&#160;423 Component, the exercise of the purchase right will remain <span style="white-space:nowrap">non-qualified</span> under the <span style="white-space:nowrap">Non-423</span> Component. Our Board may establish different and additional rules governing transfers between separate offerings within the&#160;423 Component and between offerings under the&#160;423 Component and offerings under the <span style="white-space:nowrap">Non-423</span> Component. Unless otherwise specified in the offering or as required by applicable law, we will have no obligation to pay interest on contributions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Purchase of Shares </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On each purchase date, each participant&#8217;s accumulated contributions will be applied to the purchase of shares of our Common Stock, up to the maximum number of shares of our Common Stock permitted by the ESPP and the applicable offering, at the purchase price specified in the offering. Unless otherwise provided in the offering, if any amount of accumulated contributions remains in a participant&#8217;s account after the purchase of shares on the final purchase date of an offering, then such remaining amount will not roll over to the next offering and will instead be distributed in full to such participant after the final purchase date of such offering without interest (unless otherwise required by applicable law). No purchase rights may be exercised to any extent unless the shares of our Common Stock to be issued upon such exercise under the ESPP are covered by an effective registration statement pursuant to the Securities Act and the ESPP is in material compliance with all applicable U.S.&#160;federal and state, foreign and other securities, exchange control and other laws applicable to the ESPP. If on a purchase date the shares of our Common Stock are not so registered or the ESPP is not in such compliance, no purchase rights will be exercised on such purchase date, and the purchase date will be delayed until the shares of our Common Stock are subject to such an effective registration statement and the ESPP is in material compliance, except that the purchase date will in no event be more than&#160;27&#160;months from the first day of an offering. If, on the purchase date, as delayed to the maximum extent permissible, the shares of our Common Stock are not registered and the ESPP is not in material compliance with all applicable laws, as determined by us in our sole discretion, no purchase rights will be exercised and all accumulated but unused contributions will be distributed to the ESPP participants without interest (unless the payment of interest is otherwise required by applicable law). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A participant will not be deemed to be the holder of, or to have any of the rights of a holder with respect to, shares of our Common Stock subject to purchase rights unless and until the participant&#8217;s shares of our Common Stock acquired upon exercise of purchase rights are recorded in our books (or the books of our transfer agent). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes to Capital Structure </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ESPP provides that in the event of a change in our capital structure through actions such as a merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure, or similar transaction, our Board will appropriately and proportionately adjust: (i)&#160;the class(es) and maximum number of securities subject to the ESPP; (ii)&#160;the class(es) and maximum number of securities by which the share reserve is to increase automatically each year; (iii)&#160;the class(es) and number of shares subject to, and purchase price applicable to, outstanding offerings and purchase rights; and (iv)&#160;the class(es) and number of securities that are subject to purchase limits under each ongoing offering. Our Board will make these adjustments, and its determination will be final, binding and conclusive. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">213 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Corporate Transactions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ESPP provides that in the event of a corporate transaction (as defined below), any then-outstanding rights to purchase our Common Stock under the ESPP may be assumed, continued, or substituted for by any surviving or acquiring corporation (or its parent company). If the surviving or acquiring corporation (or its parent company) elects not to assume, continue, or substitute for such purchase rights, then (i)&#160;the participants&#8217; accumulated payroll contributions will be used to purchase shares of our Common Stock (rounded down to the nearest whole share) within ten business days (or such other period specified by our Board) before such corporate transaction under the outstanding purchase rights, and such purchase rights will terminate immediately after such purchase, or (ii)&#160;our Board, in its discretion, may terminate outstanding offerings, cancel the outstanding purchase rights and refund the participants&#8217; accumulated contributions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the ESPP, a &#8220;corporate transaction&#8221; is generally the consummation, in a single transaction or in a series of related transactions, of: (i)&#160;a sale or other disposition of all or substantially all, as determined by our Board, of the consolidated assets of us and our subsidiaries; (ii)&#160;a sale or other disposition of at least&#160;50% of our outstanding securities; (iii)&#160;a merger, consolidation or similar transaction following which we are not the surviving corporation; or (iv)&#160;a merger, consolidation or similar transaction following which we are the surviving corporation but the shares of our Common Stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Transferability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During a participant&#8217;s lifetime, purchase rights will be exercisable only by a participant. Purchase rights are not transferable by a participant, except by will, by the laws of descent and distribution, or, if permitted by us, by a beneficiary designation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Tax Withholding </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each participant must make arrangements, satisfactory to us and any applicable related corporation, to enable us or our related corporation to fulfill any withholding obligation for taxes arising out of or in relation to a participant&#8217;s participation in the ESPP. In our sole discretion and subject to applicable law, such withholding obligation may be satisfied in whole or in part by (i)&#160;withholding from the participant&#8217;s salary or any other cash payment due to the participant from us or any related corporation; (ii)&#160;withholding from the proceeds of the sale of shares of our Common Stock acquired under the ESPP, either through a voluntary sale or a mandatory sale arranged by us; or (iii)&#160;any other method deemed acceptable by our Board. We will not be required to issue any shares of our Common Stock under the ESPP until such obligations are satisfied. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Amendment, Suspension or Termination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board will have the authority to amend, suspend or terminate the ESPP. Any benefits, privileges, entitlements and obligations under any outstanding purchase right granted before an amendment, suspension or termination of the ESPP will not be materially impaired by any such amendment, suspension or termination except (i)&#160;with the consent of the person to whom such purchase rights were granted, (ii)&#160;as necessary to facilitate compliance with any laws, listing requirements, or governmental regulations&#160;(including, without limitation, the provisions of Section&#160;423 of the Code), or (iii)&#160;as necessary to obtain or maintain favorable tax, listing, or regulatory treatment. Except with respect to certain changes in our capital structure, stockholder approval is required for any amendment to the ESPP if such approval is required by applicable law or listing requirements. No purchase rights may be granted under the ESPP while it is suspended or after it is terminated. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Scilex Holding Company&#160;2023 Inducement Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&#160;17, 2023, the Compensation Committee of our Board adopted the Inducement Plan and it became effective on the date of its adoption. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material terms of the Inducement Plan. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">214 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Purpose of the Inducement Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the Inducement Plan is to advance our interests by providing a material inducement for individuals to join us as employees and to provide a means by which such persons may be given an opportunity to benefit from increases in value of our Common Stock through the granting of awards under the Inducement Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Awards and Eligibility </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Inducement Plan provides for the grant of NSOs, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other forms of awards. We intend to grant awards pursuant to the Inducement Plan only to persons to whom we may issue shares of our Common Stock without stockholder approval under Section&#160;5635 of the Nasdaq Listing Rules. The Inducement Plan provides that awards may be granted to a natural person to whom we or one of our subsidiaries makes an offer of employment, provided that (i)&#160;such person was not previously an employee or us or one of our affiliates, or the person is returning to employment with us or one of our subsidiaries following a bona-fide period of <span style="white-space:nowrap">non-employment;</span> and (ii)&#160;the grant of an award under the Inducement Plan is a material inducement to the person&#8217;s decision to enter into employment with us or one of our subsidiaries. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Authorized Shares </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An aggregate of&#160;1,400,000 shares of our Common Stock have been reserved for issuance pursuant to awards granted under the Inducement Plan, subject to adjustment as necessary to implement any changes in our capital structure (as described below). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares subject to awards that will be granted under the Inducement Plan that expire or terminate without being exercised in full will not reduce the number of shares available for issuance under the Inducement Plan. The settlement of any portion of an award in cash will not reduce the number of shares available for issuance under the Inducement Plan. Shares of Common Stock withheld under an award to satisfy the exercise, strike or purchase price of an award or to satisfy a tax withholding obligation will not reduce the number of shares that will be available for issuance under the Inducement Plan. With respect to a stock appreciation right, only shares of common stock that are issued upon settlement of the stock appreciation right will count towards reducing the number of shares available for issuance under the Inducement Plan. If any shares of our Common Stock issued pursuant to an award are forfeited back to or repurchased or reacquired by us (i)&#160;because of a failure to meet a contingency or condition required for the vesting of such shares; (ii)&#160;to satisfy the exercise, strike or purchase price of an award; or (iii)&#160;to satisfy a tax withholding obligation in connection with an award, the shares that are forfeited or repurchased or reacquired will revert to and again become available for issuance under the Inducement Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Plan Administration </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board will delegate administration of the Inducement Plan to a duly authorized committee of our Board (the &#8220;Committee&#8221;) and to the extent required by applicable law, including the Nasdaq Listing Rules, each member of such Committee will be an &#8220;independent director&#8221;, as defined in Section&#160;5605(a)(2) of the Nasdaq Listing Rules. Under the Inducement Plan, the Committee will have the authority to determine: award recipients; how and when each award will be granted; the types of awards to be granted; the provisions of each award, including the period of exercisability and the vesting schedule applicable to an award; the number of shares of Common Stock or cash equivalent subject to each award; and the fair market value applicable to an award. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Inducement Plan, (i)&#160;the Committee will not, without stockholder approval, reduce the exercise or strike price of an option or stock appreciation right (other than in connection with a capitalization adjustment), </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">215 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and (ii)&#160;a participant&#8217;s rights under any award will not be materially adversely impaired by any amendment without the participant&#8217;s written consent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will also designate a plan administrator to administer the <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> operations of the Inducement Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Stock Options </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Options will be granted under stock option agreements adopted by the Committee and each option will be an NSO. The Committee will determine the exercise price for stock options, within the terms and conditions of the Inducement Plan, except the exercise price of a stock option will generally not be less than&#160;100% of the fair market value of our Common Stock on the date of grant. Options granted under the Inducement Plan will vest at the rate specified in the stock option agreement as will be determined by the Committee. The terms and conditions of separate options need not be identical. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No option will be exercisable after the expiration of ten years or a shorter period specified in the applicable award agreement. Unless the terms of an optionholder&#8217;s stock option agreement, or other written agreement between us and the recipient, provide otherwise, if an optionholder&#8217;s service relationship with us or any of our affiliates ceases for any reason other than disability, death or cause, the optionholder may generally exercise any vested options for a period of three months following the cessation of service. If an optionholder&#8217;s service relationship with us or any of our affiliates ceases due to death, or an optionholder dies within a certain period following cessation of service, the optionholder or a beneficiary may generally exercise any vested options for a period of&#160;18&#160;months following the date of death. If an optionholder&#8217;s service relationship with us or any of our affiliates ceases due to disability, the optionholder may generally exercise any vested options for a period of&#160;12&#160;months following the cessation of service. In the event of a termination for cause, options generally terminate upon the termination date. An optionholder may not exercise an option at any time that the issuance of shares upon such exercise would violate applicable law. Unless provided otherwise in the optionholder&#8217;s stock option agreement or other written agreement between an optionholder and us, if an optionholder&#8217;s service relationship with us or any of our affiliates ceases for any reason other than for cause and, at any time during the last thirty days of the applicable post-termination exercise period: (i)&#160;the exercise of the optionholder&#8217;s option would be prohibited solely because the issuance of shares of common stock upon such exercise would violate applicable law, or (ii)&#160;the immediate sale of any shares of common stock issued upon such exercise would violate our trading policy, then the applicable post-termination exercise period will be extended to the last day of the calendar month that begins after the date the award would otherwise expire, with an additional extension of the exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such extended exercise period. There is no limitation as to the maximum permitted number of extensions. However, in no event may an option be exercised beyond the expiration of its term. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Acceptable consideration for the purchase of common stock issued upon the exercise of a stock option will be determined by the Committee and may include (i)&#160;cash or check, bank draft or money order payable to us; (ii)&#160;a broker-assisted cashless exercise; (iii)&#160;subject to certain conditions, the tender of shares of our Common Stock previously owned by the optionholder; (iv)&#160;a net exercise of the option; or (v)&#160;other legal consideration acceptable to the Committee. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the Committee provides otherwise, options or stock appreciation rights generally will not be transferable except by will or the laws of descent and distribution. Subject to approval of the Committee or a duly authorized officer, an option may be transferred pursuant to a domestic relations order. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Restricted Stock Unit Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the Inducement Plan, each restricted stock unit award will have such terms and conditions as determined by the Committee. A restricted stock unit award represents a participant&#8217;s right to be issued on a future date the number of shares of our Common Stock that is equal to the number of restricted stock </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">216 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
units subject to the award. A participant will not have voting or any other rights as a stockholder of ours with respect to any restricted stock unit award (unless and until shares are actually issued in settlement of a vested restricted stock unit award). A restricted stock unit award will be granted in consideration for a participant&#8217;s services to us or an affiliate, such that the participant will not be required to make any payment to us (other than such services) with respect to the grant or vesting of the restricted stock unit award, or the issuance of any shares of common stock pursuant to the restricted stock unit award. The Committee may determine that restricted stock unit awards may be granted in consideration for any form of legal consideration that may be acceptable to the Committee and permissible under applicable law. A restricted stock unit award may be settled by cash, delivery of stock (or any combination of our Common Stock and cash), or in any other form of consideration determined by the Committee and set forth in the restricted stock unit award agreement. At the time of grant, the Committee may impose such restrictions or conditions on the award of restricted stock units that delay delivery to a date following the vesting of the award. Additionally, dividend equivalents may be paid or credited in respect of shares of Common Stock covered by a restricted stock unit award. Except as otherwise provided in the applicable award agreement, or other written agreement between us and the recipient, restricted stock unit awards that have not vested will be forfeited once the participant&#8217;s continuous service ends for any reason. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Restricted Stock Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restricted stock awards will be granted under restricted stock award agreements adopted by the Committee. A restricted stock award may be awarded in consideration for cash, check, bank draft or money order, past services to us or any of our affiliates, or any other form of legal consideration that may be acceptable to the Committee and permissible under applicable law. The Committee will determine the terms and conditions of restricted stock awards, including vesting and forfeiture terms. Dividends may be paid or credited with respect to shares subject to a restricted stock award, as determined by the Committee and specified in the applicable restricted stock award agreement. If a participant&#8217;s service relationship with us ends for any reason, we may receive any or all of the shares of common stock held by the participant that have not vested as of the date the participant terminates service with us through a forfeiture condition or a repurchase right. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Stock Appreciation Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock appreciation rights will be granted under stock appreciation right agreements adopted by the Committee and denominated in shares of Common Stock equivalents. The terms of separate stock appreciation rights need not be identical. The Committee will determine the purchase price or strike price for a stock appreciation right, which generally will not be less than&#160;100% of the fair market value of our Common Stock on the date of grant. A stock appreciation right granted under the Inducement Plan will vest at the rate specified in the stock appreciation right agreement as will be determined by the Committee. Stock appreciation rights may be settled in cash or shares of our Common Stock (or any combination of our Common Stock and cash) or in any other form of payment, as determined by the Committee and specified in the stock appreciation right agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee will determine the term of stock appreciation rights granted under the Inducement Plan, up to a maximum of ten years. If a participant&#8217;s service relationship with us or any of our affiliates ceases for any reason other than cause, disability, or death, the participant may generally exercise any vested stock appreciation right for a period of three months following the cessation of service. If a participant&#8217;s service relationship with us or any of our affiliates ceases due to death, or a participant dies within a certain period following cessation of service, the participant or a beneficiary may generally exercise any vested stock appreciation rights for a period of&#160;18&#160;months following the date of death. If a participant&#8217;s service relationship with us or any of our affiliates ceases due to disability, the participant may generally exercise any vested stock appreciation rights for a period of&#160;12&#160;months following the cessation of service. In the event of a termination for cause, stock appreciation rights generally terminate upon the termination date. A holder of a stock appreciation right may not exercise a stock appreciation right at any time that the issuance of shares upon such exercise would violate applicable law. Unless provided otherwise in the stock appreciation right agreement or other written agreement between the participant and us, if a participant&#8217;s service relationship with us or any of our affiliates ceases for any reason other than for </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">217 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cause and, at any time during the last thirty days of the applicable post-termination exercise period: (i)&#160;the exercise of the participant&#8217;s stock appreciation right would be prohibited solely because the issuance of shares upon such exercise would violate applicable law, or (ii)&#160;the immediate sale of any shares issued upon such exercise would violate our trading policy, then the applicable post-termination exercise period will be extended to the last day of the calendar month that begins after the date the award would otherwise expire, with an additional extension of the exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such extended exercise period. There is no limitation as to the maximum permitted number of extensions. However, in no event may a stock appreciation right be exercised beyond the expiration of its term. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Other Stock Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee will be permitted to grant other awards, based in whole or in part by reference to, or otherwise based on, our Common Stock, either alone or in addition to other awards. The Committee will have the sole and complete discretion to determine the persons to whom and the time or times at which other stock awards will be granted, the number of shares under the other stock award (or cash equivalent) and all other terms and conditions of such awards. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Changes to Capital Structure </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event there is a specified type of change in our capital structure, such as a stock split, reverse stock split, or recapitalization, the Committee will appropriately and proportionately adjust (i)&#160;the class(es) and maximum number of shares subject to the Inducement Plan; and (ii)&#160;the class(es) and number of shares and exercise price, strike price, or purchase price, if applicable, of all outstanding awards granted under the Inducement Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Corporate Transactions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a corporate transaction (as defined below), unless otherwise provided in a participant&#8217;s award agreement or other written agreement with us or one of our affiliates or unless otherwise expressly provided by the Committee at the time of grant, any awards outstanding under the Inducement Plan may be assumed, continued or substituted for, in whole or in part, by any surviving or acquiring corporation (or its parent company), and any reacquisition or repurchase rights held by us with respect to our Common Stock issued pursuant to awards may be assigned to the successor (or its parent company). If the surviving or acquiring corporation (or its parent company) does not assume, continue or substitute for such awards, then (i)&#160;with respect to any such awards that are held by participants whose continuous service has not terminated prior to the effective time of the corporate transaction, or current participants, the vesting (and exercisability, if applicable) of such awards will be accelerated in full (or, in the case of performance awards with multiple vesting levels depending on the level of performance, unless provided otherwise in the applicable award agreement, vesting will accelerate at&#160;100% of the target level) to a date prior to the effective time of the corporate transaction (contingent upon the effectiveness of the corporate transaction) as the Committee determines (or, if the Committee does not determine such a date, to the date that is five days prior to the effective time of the corporate transaction), and such awards will terminate if not exercised (if applicable) at or prior to the effective time of the corporate transaction, and any reacquisition or repurchase rights held by us with respect to such awards will lapse (contingent upon the effectiveness of the corporate transaction); and (ii)&#160;any such awards that are held by persons other than current participants will terminate if not exercised (if applicable) prior to the occurrence of the corporate transaction, except that any reacquisition or repurchase rights held by us with respect to such awards will not terminate and may continue to be exercised notwithstanding the corporate transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event an award will terminate if not exercised prior to the effective time of a corporate transaction, the Committee may provide, in its sole discretion, that the holder of such award may not exercise such award but instead will receive a payment, in such form as may be determined by the Committee, equal in value to the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">218 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
excess (if any) of (i)&#160;the value of the property the participant would have received upon the exercise of the award, over (ii)&#160;any per share exercise price payable by such holder, if applicable. As a condition to the receipt of an award, a participant will be deemed to have agreed that the award will be subject to the terms of any agreement under the Inducement Plan governing a corporate transaction involving us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Inducement Plan, a &#8220;corporate transaction&#8221; generally will be the consummation, in a single transaction or in a series of related transactions, of (i)&#160;a sale or other disposition of all or substantially all, as determined by the Committee, of the consolidated assets of us and our subsidiaries; (ii)&#160;a sale or other disposition of at least&#160;50% of our outstanding securities; (iii)&#160;a merger, consolidation or similar transaction following which we are not the surviving corporation; or (iv)&#160;a merger, consolidation or similar transaction following which we are the surviving corporation but the shares of our Common Stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Transferability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as expressly provided in the Inducement Plan or the form of award agreement, awards granted under the Inducement Plan may not be transferred or assigned by a participant. After the vested shares subject to an award have been issued, or in the case of a restricted stock award and similar awards, after the issued shares have vested, the holder of such shares is free to assign, hypothecate, donate, encumber or otherwise dispose of any interest in such shares provided that any such actions are in compliance with the provisions herein, the terms of our trading policy and applicable law. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Clawback/Recovery </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All awards granted under the Inducement Plan will be subject to recoupment in accordance with any clawback policy that we are required to adopt pursuant to the listing standards of any national securities exchange or association on which our securities are listed or as is otherwise required by the Dodd-Frank Act or other applicable law and any clawback policy that we otherwise adopt, to the extent applicable and permissible under applicable law. In addition, the Committee may impose such other clawback, recovery or recoupment provisions in an award agreement as the Committee determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of cause. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Amendment or Termination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee may accelerate the time at which an award granted under the Inducement Plan may first be exercised or the time during which an award grant under the Inducement Plan or any part thereof will vest, notwithstanding the provisions in the award agreement stating the time at which it may first be exercised or the time during which it will vest. The Committee will have the authority to amend, suspend, or terminate the Inducement Plan at any time, provided that such action does not materially impair the existing rights of any participant without such participant&#8217;s written consent. No awards may be granted under the Inducement Plan while it is suspended or after it is terminated. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Emerging Growth Company Status </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act. As an emerging growth company, we are exempted from certain requirements related to executive compensation, including the requirements to hold a nonbinding advisory vote on executive compensation and to provide information relating to the ratio of total compensation of our Chief Executive Officer to the median of the annual total compensation of all of our employees, each as required by the Investor Protection and Securities Reform&#160;Act of&#160;2010, which is part of the Dodd-Frank Act. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">219 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Director Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides information regarding the total compensation that was earned by or paid to each of our <span style="white-space:nowrap">non-employee</span> directors during the year ended December&#160;31, 2023. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:39%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Name</span>(1)(2)<span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Fees<br/>Earned&#160;or<br/>Paid&#160;in<br/>Cash&#160;($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br/>Awards&#160;($)(3)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">All Other<br/>Compensation&#160;($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total&#160;($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Current <span style="white-space:nowrap">Non-Employee</span> Directors</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jay Chun, M.D., Ph.D.(4)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">26,779.11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">250,650.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">277,429.11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dorman Followwill</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">150,001.52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">599,997.56</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">749,999.08</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Lemus</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">120,000.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">629,996.71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">749,996.71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yue Alexander Wu, Ph.D.(4)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">35,018.84</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">250,650.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">285,668.84</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Former <span style="white-space:nowrap">Non-Employee</span> Directors</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laura J. Hamill(5)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">665,935.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">665,935.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Tien-Li</span> Lee, M.D.(6)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">9,949.26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">614,998.96</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">624,948.22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tommy Thompson(7)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">28,387.10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">28,387.10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Dr.&#160;Ji, our Executive Chairperson, and Mr.&#160;Shah, our Chief Executive Officer and President, are not included in this table, as each of them was our employee and therefore receives no compensation for his service as a director. Dr.&#160;Ji&#8217;s and Mr.&#160;Shah&#8217;s compensation as named executive officers are included in the section titled &#8220;Executive and Director Compensation &#8212; Summary Compensation Table&#8221; below. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">In July and September 2023, the Company determined that the aggregate value of all compensation granted or paid to Mr.&#160;Followwill, Mr.&#160;Lemus, Ms.&#160;Hamill and Dr.&#160;Lee for the fiscal year ending December&#160;31, 2023 inadvertently exceeded the $750,000 annual compensation limit for <span style="white-space:nowrap">non-employee</span> directors (the &#8220;Compensation Limit&#8221;) under the Company&#8217;s 2022 Equity Incentive Plan, as amended (the &#8220;Equity Incentive Plan&#8221;). As a result, (a)&#160;Mr.&#160;Followwill voluntarily agreed to forfeit a combination of shares and cash compensation in excess of the Compensation Limit as follows: (i) 85,536 shares of Common Stock and (ii)&#160;an aggregate of $6,173.84 in cash compensation payable by the Company for his service as a director; (b)&#160;Ms.&#160;Hamill voluntarily agreed to forfeit a combination of shares and cash compensation in excess of the Compensation Limit as follows: (i) 67,462 shares of Common Stock and (ii)&#160;an aggregate of $84,062.50 in cash compensation payable by the Company for her service as a director; (c)&#160;Dr.&#160;Lee voluntarily agreed to forfeit 81,424 shares of Common Stock, which represents the number of shares awarded in excess of the Compensation Limit; and (d)&#160;Mr.&#160;Lemus voluntarily agreed to forfeit 77,313 shares of Common Stock, which represents the number of shares awarded in excess of the Compensation Limit. The compensation information in this table reflects such forfeitures. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">As of December&#160;31, 2023, each of our current <span style="white-space:nowrap">non-employee</span> directors held options to purchase the following number of shares of our Common Stock: Dr.&#160;Chun: 250,000; Mr.&#160;Followwill: 164,464; Mr.&#160;Lemus: 172,687 and Dr.&#160;Wu: 250,000. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Dr.&#160;Wu was appointed to our Board on September&#160;22, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Ms.&#160;Hamill resigned from our Board effective September&#160;21, 2023. As of December&#160;31, 2023, Ms.&#160;Hamill held options to purchase 182,538 shares of our Common Stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Dr.&#160;Lee resigned from our Board effective August&#160;27, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Mr.&#160;Thompson was not nominated for reelection to our Board at the 2023 annual meeting of stockholders held on May&#160;4, 2023, and his service on the Board ceased as of the date of such meeting. On January&#160;17, 2023, Mr.&#160;Thompson was granted a stock option to purchase 250,000 shares of our Common Stock, with an aggregate grant date fair value of $912,050. As Mr.&#160;Thompson&#8217;s service on the Board terminated on May&#160;4, 2023, all such options were forfeited in accordance with the terms of the Equity Incentive Plan. Accordingly, Mr.&#160;Thompson&#8217;s compensation for the fiscal year ending December&#160;31, 2023 did not exceed the Compensation Limit. The compensation information in this table reflects such forfeiture. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">220 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-Employee</span> Director Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to our <span style="white-space:nowrap">Non-Employee</span> Director Compensation Policy for the compensation of our <span style="white-space:nowrap">non-employee</span> directors, during&#160;2023, each of our <span style="white-space:nowrap">non-employee</span> directors received annual retainers, subject to proration, for service on our Board and its committees as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:83%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Annual Cash Compensation</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Amount</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board Members</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">82,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chairs of the Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee and Commercialization and Transaction Committee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">37,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Members of the Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee and Commercialization and Transaction Committee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">15,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Equity Compensation</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial Stock Options</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">250,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual Stock Options</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">100,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All annual cash compensation amounts for our <span style="white-space:nowrap">non-employee</span> directors are payable in equal quarterly installments in arrears, following the end of each quarter in which the service occurred, <span style="white-space:nowrap">pro-rated</span> for any partial months of service. The equity compensation paid to our <span style="white-space:nowrap">non-employee</span> directors will vest monthly over a period of 48 months from the date of grant with respect to the initial stock option grants and over a period of 12 months from the date of grant with respect to the annual stock option grants, in each case, subject to continued service through each vesting date. Additionally, we will reimburse each outside director for reasonable travel expenses related to such director&#8217;s attendance at Board and committee meetings. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Employee directors receive no additional compensation for their service as a director. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">221 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx759370_15">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a summary of transactions since January&#160;1, 2023 and any currently proposed transactions to which the Company was or is to be a participant in which the amount involved exceeded or will exceed $120,000, and in which any of the Company&#8217;s directors, executive officers or, to the Company&#8217;s knowledge, beneficial owners of more than 5% of the Company&#8217;s capital stock, or their immediate family members have had or will have a direct or indirect material interest, other than compensation and other arrangements that are described under the sections of this prospectus titled &#8220;<span style="font-style:italic">Executive and Director Compensation</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stockholder Agreement with Sorrento </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;12, 2022, Vickers entered into the Stockholder Agreement with Sorrento (the &#8220;Stockholder Agreement&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Stockholder Agreement, from and after the Effective Time, and for so long as the Sorrento Group beneficially owns any shares of Series A Preferred Stock, among other things, (i)&#160;Sorrento had the right, but not the obligation, to designate each director to be nominated, elected or appointed to our Board (each, a &#8220;Stockholder Designee&#8221; and collectively, the &#8220;Stockholder Designees&#8221;), regardless of whether such Stockholder Designee is to be elected to our Board at a meeting of stockholders called for the purpose of electing directors (or by consent in lieu of meeting) or appointed by our Board in order to fill any vacancy created by the departure of any director or increase in the authorized number of members of our Board or the size of our Board and (ii)&#160;we were required to take all actions reasonably necessary, and not otherwise prohibited by applicable law, to cause each Stockholder Designee to be so nominated, elected or appointed to our Board as more fully described in the Stockholder Agreement. Notwithstanding the foregoing, the parties previously agreed that our Board will continue to satisfy all applicable stock exchange requirements applicable to directors, including with respect to director independence. Sorrento also had the right to designate a replacement director for any Stockholder Designee that has been removed from our Board and the right to appoint a representative of Sorrento to attend all meetings of the committees of the Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Stockholder Agreement also provided that we shall not, and shall cause our subsidiaries not to, among others, without the prior written consent of Sorrento: (i)&#160;amend, alter, modify or repeal (whether by merger, consolidation, by operation of law or otherwise) any provisions of the Certificate of Incorporation (including the Certificate of Designations of Series A Preferred Stock, filed with the Secretary of State of the State of Delaware on November&#160;10, 2022 (our &#8220;Certificate of Designations&#8221;)) or our Bylaws that increase or decrease the authorized number of directors constituting our Board; (ii)&#160;take any action that would have the effect of increasing or decreasing the number of directors constituting our Board; (iii)&#160;amend, alter, modify or repeal (whether by merger, consolidation, reclassification, by operation of law or otherwise) any provisions of the respective charters (and any related organizational documents) of any of the committees of our Board; (iv)&#160;file any voluntary petition under any applicable federal or state bankruptcy or insolvency law on behalf of us or any of our subsidiaries; (v)&#160;(A) incur or permit any of our subsidiaries to incur any indebtedness in an aggregate principal amount in excess of $10,000,000) (with &#8220;principal amount&#8221; for purposes of this definition to include undrawn committed or available amounts) or (B)&#160;enter into, modify, amend or renew (or permit any of our subsidiaries enter into, modify, amend or renew) any contract or other agreement in respect of indebtedness in an aggregate principal amount in excess of $10,000,000 (with &#8220;principal amount&#8221; for purposes of this definition to include undrawn committed or available amounts); (vi) consummate or otherwise enter into any other contract or agreement to effect any change of control, joint venture or corporate reorganization by the Company or any of our subsidiaries; (vii)&#160;declare or pay any dividend or distribution on our Common Stock, other Junior Security (as defined below) or Parity Security (as defined below); or (viii)&#160;purchase, redeem or otherwise acquire for consideration by us, directly or indirectly, any Common Stock, other Junior Security or Parity Security (except as necessary to effect (A)&#160;a reclassification of any Junior Security for or into other Junior Securities, (B)&#160;a reclassification of any Parity Security for or into other Parity Securities with the same or lesser aggregate liquidation preference, (C)&#160;a reclassification of any Parity Security into a Junior Security, (D)&#160;the exchange or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">222 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conversion of any Junior Security for or into another Junior Security, (E)&#160;the exchange or conversion of any Parity Security for or into another Parity Security with the same or lesser per share liquidation amount, (F)&#160;the exchange or conversion of any Parity Security for or into any Junior Security or (G)&#160;the settlement of incentive equity awards (including any applicable withholdings and the net exercise of options) in accordance with the terms thereof). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Series A Preferred Stock ranks (i)&#160;senior to all of our Common Stock, and to all other classes or series of our capital stock, except for any such other class or series, the terms of which expressly provide that it ranks on parity with the Series A Preferred Stock as to dividend rights and rights on liquidation, dissolution or <span style="white-space:nowrap">winding-up</span> of the Company (&#8220;Junior Securities&#8221;); and (ii)&#160;on parity with each class or series of our capital stock, created specifically ranking by its terms on parity with the Series A Preferred Stock as to dividend rights and rights on liquidation, dissolution or <span style="white-space:nowrap">winding-up</span> of the Company (&#8220;Parity Securities&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After a hearing before the Bankruptcy Court (as defined below) on September&#160;12, 2023, the Bankruptcy Court entered a final order approving, among other things, the termination of the Stockholder Agreement, upon the closing of the Equity Repurchase Transaction. Accordingly, the Stockholder Agreement terminated on September&#160;21, 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our Relationship with Sorrento </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the Business Combination, Legacy Scilex was a majority-owned subsidiary of Sorrento. Following the closing of the Business Combination, Sorrento continued to beneficially own a significant percentage of our outstanding Common Stock. Following the consummation of the Equity Repurchase Transaction and as a result of the sale of the Purchased Securities (each as defined below), Sorrento no longer owns a significant percentage of our outstanding Common Stock. Sorrento retained 1,917,210 shares of our Common Stock, which are being held in abeyance for the benefit of certain holders of warrants to purchase shares of common stock of Sorrento who may be entitled to receive shares of our Common Stock pursuant to the terms of the applicable warrants as a result of the previously declared and announced dividend of shares of our Common Stock by Sorrento. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Intercompany Dividend </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;4, 2023, Scilex Pharma distributed $20,000,000 to Legacy Scilex (via a dividend) and Legacy Scilex distributed $20,000,000 to New Scilex (via a dividend). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap"><span style="white-space:nowrap">Junior&#160;Debtor-in-Possession&#160;Financing</span></span> with Sorrento </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Background </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our former controlling stockholder, Sorrento, together with its wholly owned direct subsidiary, Scintilla Pharmaceuticals, Inc. (together with Sorrento, the &#8220;Debtors&#8221;), commenced voluntary proceedings under Chapter&#160;11 of the United States Bankruptcy Code (the &#8220;Bankruptcy Code,&#8221; and such cases, the &#8220;Chapter&#160;11 Cases&#8221;) in the United States Bankruptcy Court for the Southern District of Texas (the &#8220;Bankruptcy Court&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After a hearing before the Bankruptcy Court on March&#160;29, 2023, the Bankruptcy Court entered a final order approving <span style="white-space:nowrap">a&#160;non-amortizing&#160;super-priority</span> senior secured term loan facility in an aggregate principal amount not to exceed $75,000,000 in term loan commitments (the &#8220;Senior DIP Facility&#8221;), provided to the Debtors by JMB Capital Partners Lending, LLC (the &#8220;Senior DIP Lender&#8221;), on a final basis. The Debtors then negotiated definitive financing documentation, including a Senior Secured, <span style="white-space:nowrap"><span style="white-space:nowrap">Super-Priority&#160;Debtor-in-Possession&#160;Loan</span></span> and Security Agreement and other documents evidencing the Senior DIP Facility. At the time of the entry of the Interim DIP Order (as defined below), the Debtors&#8217; liquidity was projected to last only until July&#160;7, 2023. The Senior DIP Facility matured on July&#160;31, 2023 and was not repaid on such date. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">223 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;30, 2023, the Debtors filed the Debtors&#8217;<span style="font-style:italic">&#160;Emergency Motion for Entry of Interim and Final Orders (I)</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;Authorizing the Debtors to (A)</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;Obtain Junior Secured Superpriority Postpetition Financing and (B)</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;Use Cash</span> <span style="font-style:italic">Collateral, (II)</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;Granting Liens and Providing Claims with Superpriority Administrative Expense Status, (III)</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;Modifying the Automatic Stay, (IV)</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;Scheduling a Final Hearing, and (V)</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;Granting Related Relief</span>&#160;(the &#8220;DIP Motion&#8221;), seeking the Bankruptcy Court&#8217;s approval of the Junior DIP Facility (as defined below) and certain related relief. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Terms of the Junior DIP Facility </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;5, 2023, the Company and the Debtors executed that <span style="white-space:nowrap"><span style="white-space:nowrap">certain&#160;Debtor-in-Possession&#160;Term</span></span> Loan Facility Summary of Terms and Conditions (the &#8220;Junior DIP Term Sheet&#8221;), pursuant to which the Company (or its designees or its assignees) agreed to provide the Debtors with <span style="white-space:nowrap">a&#160;non-amortizing&#160;super-priority</span> junior secured term loan facility in an aggregate principal amount not to exceed the sum of (i)&#160;$20,000,000 (the &#8220;Base Amount&#8221;), plus (ii)&#160;the amount of the commitment fee and the funding fee, each equal to 1% of the Base Amount, plus (iii)&#160;the amount of the DIP Lender Holdback (as defined in the Interim DIP Order) (the &#8220;Junior DIP Facility&#8221;), subject to the terms and conditions set forth in the Junior DIP Term Sheet. The Junior DIP Term Sheet granted to the Company a right of first refusal to provide <span style="white-space:nowrap"><span style="white-space:nowrap">any&#160;debtor-in-possession&#160;financing</span></span> during the course of the Chapter&#160;11 Cases to the Debtors occurring after the date of the Interim DIP Order until the Chapter&#160;11 Cases were concluded. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The interest rate under the Junior DIP Facility was 12.00% per annum payable in kind on the first day of each month in arrears and on the DIP Termination Date (as defined in the Junior DIP Term Sheet). Upon the occurrence and during the continuance of an event of default as defined in the Junior DIP Term Sheet, the interest rate on outstanding DIP Loans (as defined in the Junior DIP Term Sheet) would increase by 2.00% per annum (payable in kind). The commitment fee and the funding fee described above became payable upon the funding of the DIP Loans (as defined in the Junior DIP Term Sheet), in each case as set forth in the Junior DIP Term Sheet. Upon repayment or satisfaction of the DIP Loans (as defined in the Junior DIP Term Sheet) in whole or in part, the Debtors were to pay to the Company in cash an exit fee equal to 2.00% of the aggregate principal amount of the Junior DIP Facility on the date of the Draw (as defined below). The Junior DIP Facility terms state that it was required to be paid in full in cash under any Chapter&#160;11 plan of reorganization. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The interest rate return on the Senior DIP Lender was 14.0% on an annual basis. Based on the terms of the Junior DIP Facility and the Senior DIP Facility including the fees associated therewith, respectively, we believe that the annualized returns to the Senior DIP Lender exceeded the returns to the Junior DIP Lender as a result of the differences in the following between the Senior DIP Facility and the Junior DIP Facility, respectively: (i) non-default annualized interest rate of 14.0% as compared to 12.0%; (ii) maturity term of five months as compared to three months; (iii) a commitment fee of 2.5% as compared to 1.0%; (iv)&#160;a funding fee of 2.5% as compared to 1.0%; and (v)&#160;an exit fee of 7.0% as compared to 2.0%. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Junior DIP Facility was set to mature on the earliest of: (i)&#160;September&#160;30, 2023; (ii); the effective date of any Chapter&#160;11 plan of reorganization with respect to the Debtors; (iii)&#160;the consummation of any sale or other disposition of all or substantially all of the assets of the Debtors pursuant to section 363 of the Bankruptcy Code; (iv)&#160;the date of the acceleration of the DIP Loans and the termination of the DIP Commitments in accordance with the DIP Documents (each as defined in the Junior DIP Term Sheet); and (v)&#160;dismissal of the Chapter&#160;11 Cases or conversion of the Chapter&#160;11 Cases into cases under Chapter&#160;7 of the Bankruptcy Code. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Junior DIP Facility afforded us certain valuable protections. First, the Junior DIP Facility was secured by liens on and security interests in substantially all assets of Sorrento, other than certain excluded assets as described more fully in the Interim DIP Order, including (i)&#160;a first-priority security interest in and continuing lien on all proceeds of the DIP Facility in the DIP Accounts, and the Junior DIP Lender Holdback (each as defined in the Interim DIP Order) and (ii)&#160;subject to certain terms and exclusions, a second-priority security interest in and continuing lien on substantially all other assets, in each case, whether then owned or existing or thereafter acquired, created or arising and wherever located other than certain excluded assets as described in the Interim </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">224 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
DIP Order. The Junior DIP Facility was also granted super priority administrative expense priority ahead of certain other administrative expenses in Chapter&#160;11 and ahead <span style="white-space:nowrap">of&#160;pre-petition&#160;unsecured</span> claims, which means it had to be paid in full, in cash in order for the Debtors to emerge from bankruptcy under a Chapter&#160;11 Plan, unless otherwise agreed to by us. This priority status gave us a voice in Sorrento&#8217;s plan to emerge from Chapter&#160;11. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of that certain intercreditor and subordination agreement, dated as of September&#160;21, 2023, entered into by and among the Senior DIP Lender and the Company (the &#8220;Subordination Agreement&#8221;), the Debtors&#8217; obligations to the Company under the Junior DIP Facility were subordinated to the obligations of the Debtors to Senior DIP Lender on the terms and conditions set forth therein. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;5, 2023, at a hearing before the Bankruptcy Court, the Bankruptcy Court entered an interim order (the &#8220;Interim DIP Order&#8221;) approving the Junior DIP Facility among the Debtors (as borrowers) and the Company (as lender) on an interim basis. Upon entry of the Interim DIP Order and satisfaction of all applicable conditions precedent, as set forth in the Junior DIP Term Sheet, the Debtors were authorized to make a single draw under the Junior DIP Facility (the &#8220;Draw&#8221;) to be funded by the Company as the lender under the Junior DIP Facility. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bankruptcy Court entered the final order approving on the Junior DIP Facility on July&#160;27, 2023. Other definitive financing documentation was then negotiated, including a Junior Secured, Super Priority <span style="white-space:nowrap"><span style="white-space:nowrap">Debtor-in-Possession</span></span> Loan and Security Agreement, which was entered into on July&#160;28, 2023 between the Company and the Debtors (the &#8220;Junior DIP Loan Agreement&#8221;), which agreement memorialized the terms of the Junior DIP Term Sheet. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After a hearing before the Bankruptcy Court on August&#160;7, 2023, the Bankruptcy Court on August&#160;7, 2023, entered a final order (the &#8220;Replacement DIP Order&#8221;) approving <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">a&#160;non-amortizing&#160;super-priority&#160;debtor-in-possession&#160;term</span></span></span> loan facility in an aggregate principal amount of $100,000,000 (the &#8220;Replacement DIP Facility&#8221;) provided to the Debtors by Oramed Pharmaceuticals Inc. (&#8220;Oramed&#8221;) on a final basis. The Replacement DIP Facility was to be used to, among other things, refinance the existing Senior DIP Facility. The Replacement DIP Facility included certain milestones for the sale of the Company&#8217;s equity interests owned by the Debtors. The lender under the Replacement DIP Facility was permitted to use the loan to credit bid for the collateral securing the Replacement DIP Facility (including the equity interests of the Company), subject to the terms therein. The Replacement DIP Order provided that the liens securing the Junior DIP Facility were junior to the liens securing the Replacement DIP Facility and the Company was not permitted to exercise certain remedies until the payment in full of the Replacement DIP Facility (all as set forth in the Replacement DIP Order). Though junior to the Replacement DIP Facility, the Company would still have been treated as a secured creditor with priority over other claimants in the Chapter 11 Cases. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We funded the Junior DIP Facility with cash on hand, including from a portion of the net proceeds from the eCapital Credit Agreement (as defined below) that were distributed to us by our wholly owned subsidiary, Scilex Pharma. As noted below, the Junior DIP Facility was terminated on September&#160;21, 2023, pursuant to <span style="white-space:nowrap">the&#160;Pay-Off&#160;Letter</span> (as defined below). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The above description of the Junior DIP Facility is not complete and is qualified in its entirety by reference to the Junior DIP Term Sheet, the Junior DIP Loan Agreement and the Subordination Agreement, each of which are filed as an exhibit to the Current Report on Form <span style="white-space:nowrap">8-K,</span> filed with the SEC on July&#160;7, 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stock Purchase Agreement with Sorrento </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;21, 2023 (the &#8220;Oramed Closing Date&#8221;), we entered into, and consummated the transactions contemplated by, that certain Securities Purchase Agreement, dated as of such date, between us and Oramed (the &#8220;Scilex-Oramed SPA&#8221;). Pursuant to the Scilex-Oramed SPA, among other things, on September&#160;21, 2023, we (i)&#160;issued to Oramed (A)&#160;a senior secured promissory note due 18 months from the date of issuance in the principal amount of $101,875,000 (the &#8220;Oramed Note&#8221;), (B) a warrant to purchase up to an aggregate of 4,500,000 shares of Common Stock (the &#8220;Closing Penny Warrant&#8221;), with an exercise price of $0.01 per share and certain restrictions on exercisability, and (C)&#160;warrants to purchase up to an aggregate of 8,500,000 shares of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">225 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Common Stock (the &#8220;Subsequent Penny Warrants&#8221; and together with the Closing Penny Warrant, the &#8220;Penny Warrants&#8221;), each with an exercise price of $0.01 per share and each with certain restrictions on exercisability, and (ii)&#160;caused certain outstanding warrants to purchase up to an aggregate of 4,000,000 shares of Common Stock, with an exercise price of $11.50 per share, that we acquired from Sorrento pursuant to the Sorrento SPA (as defined below) to be transferred to Oramed (the &#8220;Transferred Warrants&#8221;). Pursuant to the terms and conditions contained in the Scilex-Oramed SPA, we also agreed to reimburse Oramed for up to $2,910,000 for its legal and other advisor costs, fees and expenses incurred by Oramed in connection with the Sorrento SPA, the Senior DIP Facility, the Scilex-Oramed SPA and certain other transaction documents, $1,910,000 of which was paid on the Oramed Closing Date, and $1,000,000 of which was included in the initial principal amount of the Oramed Note. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;21, 2023, in connection with the Scilex-Oramed SPA, we and Sorrento entered into and consummated the transactions contemplated by that certain Stock Purchase Agreement (the &#8220;Sorrento SPA&#8221;), dated as of such date, pursuant to which, among other things, we purchased from Sorrento (i) 60,068,585 shares of Common Stock, (ii) 29,057,097 shares of Series A Preferred Stock, and (iii)&#160;warrants exercisable for 4,490,617 shares of Common Stock, each with an exercise price of $11.50 ((i) through (iii)&#160;collectively, the &#8220;Purchased Securities&#8221;, and such transactions, the &#8220;Equity Repurchase Transaction&#8221;). The aggregate consideration for the Purchased Securities was (i) $100,000,000 (the &#8220;DIP Amount&#8221;), which such amount is satisfied by the Company&#8217;s assumption of the Debtors&#8217; outstanding obligations under the Senior DIP Facility (the &#8220;Oramed DIP Assumption&#8221;), (ii) a credit bid, <span style="white-space:nowrap"><span style="white-space:nowrap">on&#160;a&#160;dollar-for-dollar&#160;basis,&#160;pursuant</span></span> to Section&#160;363(k) of the Bankruptcy Code, in respect of any and all amounts of principal and accrued but unpaid interest outstanding, and any other obligations of the Debtors, in each case, under the Junior DIP Facility as of September&#160;21, 2023 (the &#8220;Credit Bid Amount&#8221;), (iii) $10,000,000 in cash (the &#8220;Cash Payment&#8221;) and (iv)&#160;the assumption and assignment of certain obligations of Sorrento for legal fees and expenses in the approximate amount of $12.25&#160;million (the &#8220;Legal Fee Assumption&#8221; and, together with the DIP Amount, the Credit Bid Amount and the Cash Payment, the &#8220;Purchase Price&#8221;). Following the sale of the Purchased Securities, Sorrento retained 1,917,210 shares of Common Stock in abeyance for the benefit of certain holders of warrants to purchase shares of common stock of Sorrento who may be entitled to receive shares of Common Stock pursuant to the terms of the applicable warrants as a result of the previously declared and announced dividend of shares of Common Stock by Sorrento. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The above description of the Scilex-Oramed SPA is not complete and is qualified in its entirety by reference to the full text of the Scilex-Oramed SPA, a copy of which is filed as an exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Oramed DIP Assumption and Assignment Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Oramed DIP Assumption, on September&#160;21, 2023, we entered into an assignment, assumption and release agreement (the &#8220;DIP Assignment Agreement&#8221;) with the Debtors. Pursuant to the DIP Assignment Agreement, the Debtors assigned and transferred to us all of their rights, title and interest and duties, liabilities and obligations under that certain Senior <span style="white-space:nowrap"><span style="white-space:nowrap">Secured,&#160;Super-Priority&#160;Debtor-In-Possession&#160;Loan&#160;and</span></span> Security Agreement entered into by the Debtors and Oramed on August&#160;9, 2023, to provide the Senior DIP Facility. On September&#160;21, 2023, the Debtors&#8217; aggregate outstanding obligation under the Senior DIP Facility was $101,875,000, comprised of $100,000,000 of principal, $875,000 accrued and unpaid interest and $1,000,000 in fees and expenses payable under the Senior DIP Facility. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The above description of the DIP Assignment Agreement is not complete and is qualified in its entirety by reference to the full text of the DIP Assignment Agreement, a copy of which is filed as an exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Credit <span style="white-space:nowrap">Bid&#160;Pay-Off&#160;Letter</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Sorrento SPA, in connection with acquiring the Purchased Securities, we made a credit bid, <span style="white-space:nowrap"><span style="white-space:nowrap">on&#160;a&#160;dollar-for-dollar&#160;basis,&#160;pursuant</span></span> to Section&#160;363(k) of the Bankruptcy Code, in respect of the obligations of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">226 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Debtors under the Junior DIP Loan Agreement, accrued and outstanding as of September&#160;21, 2023 for the Credit Bid Amount. As noted above, the Credit Bid Amount is part of the Purchase Price for the Purchased Securities. On September&#160;21, 2023, we entered into a letter agreement <span style="white-space:nowrap">(the&#160;&#8220;Pay-Off&#160;Letter&#8221;)&#160;with</span> the Debtors, pursuant to which, upon Closing (as defined in the Sorrento SPA), the Junior DIP Loan Agreement, that certain Intellectual Property Security Agreement, dated as of July&#160;28, 2023, by the Debtors in our favor, any other Loan Document (as defined in the Junior DIP Loan Agreement) and any other notes, security agreements, mortgages, pledge agreements, guarantees or other agreements, documents, certificates or instruments related thereto automatically terminated, and all obligations thereunder were paid and discharged in full. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The above description of the <span style="white-space:nowrap">Pay-Off&#160;Letter</span> is not complete and is qualified in its entirety by reference to the full text of the <span style="white-space:nowrap">Pay-Off&#160;Letter,</span> a copy of which is filed as an exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Legal Fee Assumption Letter Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Legal Fee Assumption in accordance with the Sorrento SPA, we and Sorrento entered into a letter agreement on September&#160;21, 2023, pursuant to which, among other things, we agreed to assume all of Sorrento&#8217;s obligations for certain legal fees and expenses in the aggregate amount of approximately $12.25&#160;million. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Subsidiary Guarantee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;21, 2023, in connection with the Scilex-Oramed SPA, we and each of our subsidiaries (collectively, the &#8220;Guarantors&#8221;) entered into a subsidiary guarantee (the &#8220;Subsidiary Guarantee&#8221;) with Oramed (together with its successors and permitted assigns, the &#8220;Holder&#8221;) and Acquiom Agency Services LLC, as the collateral agent for the holders of the Oramed Note (the &#8220;Agent&#8221;), pursuant to which, the Guarantors have agreed to guarantee and act as surety for payment of the Oramed Note and any additional notes issued by us after the closing date of the transactions contemplated by the Scilex-Oramed SPA in full or partial substitution of the Oramed Note (the &#8220;Additional Notes&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The above description of the Subsidiary Guarantee is not complete and is qualified in its entirety by reference to the full text of the Subsidiary Guarantee, a copy of which is filed as an exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Security Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;21, 2023, we and the Guarantors entered into a security agreement (the &#8220;Security Agreement&#8221;) with the Holder and the Agent, pursuant to which we and the Guarantors granted to the Agent (on behalf of and for the benefit of the holders of the Oramed Note and any Additional Notes) a security interest in all or substantially all of our and each Guarantor&#8217;s property, respectively, to secure the prompt payment, performance and discharge in full of all of our obligations under the Oramed Notes and Additional Notes and the Guarantors&#8217; obligations under the Subsidiary Guarantee, subject to certain customary limitations. The Security Agreement contains certain customary representations, warranties and covenants regarding the collateral thereunder, in each case as more fully set forth in the Security Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The above description of the Security Agreement is not complete and is qualified in its entirety by reference to the full text of the Security Agreement, a copy of which is filed as an exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Subordination Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;21, 2023, Scilex Pharma entered into a subordination agreement (the &#8220;Subordination Agreement&#8221;) with eCapital Healthcare Corp. (the &#8220;ABL Lender&#8221;) and the Agent. Pursuant to the Subordination agreement, the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">227 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
parties agreed that ABL Lender&#8217;s rights and interests under that certain Credit and Security Agreement, dated as of June&#160;27, 2023 (as may be amended, restated, supplemented or otherwise modified from time to time, the &#8220;eCapital Credit Agreement&#8221;) previously entered into between Scilex Pharma and ABL Lender will be secured by first priority liens on certain collateral (the &#8220;ABL Priority Collateral&#8221;) and the Agent&#8217;s rights and interests under the Subsidiary Guarantee shall be secured by first priority liens on certain other collateral and second priority liens on the ABL Priority Collateral. Among other customary interlender terms, the Subordination Agreement requires that the Facility Cap (as defined in the eCapital Credit Agreement) shall not exceed $30,000,000. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The above description of the Subordination Agreement is not complete and is qualified in its entirety by reference to the full text of the Subordination Agreement, a copy of which is filed as an exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Executive Officer and Director Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please see the sections titled &#8220;Executive Compensation&#8221; and <span style="white-space:nowrap">&#8220;Non-Employee</span> Director Compensation&#8221; for information regarding the compensation of our executive officers and <span style="white-space:nowrap">non-employee</span> directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Employment Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into offer letter agreements with our named executive officers, other than Dr.&#160;Ji and Mr.&#160;Ma, that, among other things, provide for certain compensatory benefits. In addition, we have also entered into severance and change of control agreements with our named executive officers which provide for severance payments upon certain terminations of employment as well as in connection with a change of control of the Company. For descriptions of such agreements, see the section titled &#8220;Executive Compensation.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Limitation of Liability and Indemnification of Officers and Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please see the section titled &#8220;Management &#8212; Limitation of Liability and Indemnification of Directors and Officers&#8221; for information regarding our arrangements to provide indemnification to our officers and directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Related Person Transaction Policy </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have adopted a related person transaction policy that sets forth our procedures for the identification, review, consideration and approval or ratification of related person transactions. For purposes of our policy, a related person transaction is a transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we and any related person are, were or will be participants in which the amount involved exceeds $120,000. Transactions involving compensation for services provided to us as an employee or director are not covered by this policy. A related person is any executive officer, director or beneficial owner of more than 5% of any class of our voting securities and any of their respective immediate family members and any entity owned or controlled by such persons. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the policy, if a transaction has been identified as a related person transaction, including any transaction that was not a related person transaction when originally consummated or any transaction that was not initially identified as a related person transaction prior to consummation, our management must present information regarding the related person transaction to our Audit Committee, or, if audit committee approval would be inappropriate, to another independent body of our Board, for review, consideration and approval or ratification. The presentation must include a description of, among other things, the material facts, the interests, direct and indirect, of the related persons, the benefits to us of the transaction and whether the transaction is on terms that are comparable to the terms available to or from, as the case may be, an unrelated third party or to or from employees generally. Under the policy, we will collect information that we deem reasonably necessary from each director, executive officer and, to the extent feasible, significant stockholder to enable us to identify any existing </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">228 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or potential related-person transactions and to effectuate the terms of the policy. In addition, under our code of conduct and ethics, our employees and directors have an affirmative responsibility to disclose any transaction or relationship that reasonably could be expected to give rise to a conflict of interest. In considering related person transactions, our Audit Committee, or other independent body of our Board, will take into account the relevant available facts and circumstances including, but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the risks, costs and benefits to us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the impact on a director&#8217;s independence in the event that the related person is a director, immediate family member of a director or an entity with which a director is affiliated; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the availability of other sources for comparable services or products; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the terms available to or from, as the case may be, unrelated third parties or to or from employees generally. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The policy requires that, in determining whether to approve, ratify or reject a related person transaction, our Audit Committee, or other independent body of our Board, must consider, in light of known circumstances, whether the transaction is in, or is not inconsistent with, our best interests and those of our stockholders, as our Audit Committee, or other independent body of our Board, determines in the good faith exercise of our discretion. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">229 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx759370_16">PRINCIPAL </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITYHOLDERS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding the beneficial ownership of our Common Stock as of March&#160;15, 2024 by: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each person or &#8220;group&#8221; known to be the beneficial owner of more than 5% of our outstanding Common Stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each of our current executive officers and directors; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">all of our executive officers and directors as a group. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security, including options and warrants that are currently exercisable or exercisable within 60 days. Shares subject to options and warrants that are currently exercisable or exercisable within 60 days of March&#160;15, 2024 are considered outstanding and beneficially owned by the person holding such options or warrants for the purpose of computing the percentage ownership of that person, but are not treated as outstanding for the purpose of computing the percentage ownership of any other person. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The beneficial ownership of our Common Stock is based on 166,189,835 shares of such common stock outstanding as of March&#160;15, 2024. Voting power is based on 166,189,835 shares of Common Stock and 29,057,097 shares of Series A Preferred Stock outstanding as of March&#160;15, 2024. Shares of Series&#160;A Preferred Stock are held solely by SCLX JV. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, we believe, based on information available to us, that all persons and entities named in the table have sole voting and investment power with respect to all shares shown as beneficially owned by them. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:43%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Common Stock</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Series A Preferred Stock</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&#160;</p></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name and Address</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">of Beneficial Owner<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Shares&#160;of&#160;Common<br/>Stock Beneficially<br/>Owned</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%&#160;of&#160;Total<br/>Common<br/>Stock</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Shares&#160;of&#160;Series&#160;A<br/>Preferred Stock<br/>Beneficially&#160;Owned</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%&#160;of&#160;Total<br/>Series A<br/>Preferred<br/>Stock</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%&#160;of&#160;Total<br/>Vote</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Directors and Named Executive Officers</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jaisim Shah<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">9,911,604</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5.63</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4.83</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Henry Ji, Ph.D.<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">5,093,288</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2.98</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2.55</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen Ma<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">217,752</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elizabeth Czerepak<sup style="font-size:75%; vertical-align:top">(5)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">498,889</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jay Chun, M.D., Ph.D.<sup style="font-size:75%; vertical-align:top">(6)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">71,052</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dorman Followwill<sup style="font-size:75%; vertical-align:top">(7)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">53,752</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Lemus<sup style="font-size:75%; vertical-align:top">(8)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">54,823</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yue Alexander Wu, Ph.D.<sup style="font-size:75%; vertical-align:top">(9)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">430,139</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">All Directors and Executive Officers as a Group (7 individuals)</span><sup style="font-size:75%; vertical-align:top">(10)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">15,832,410</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">8.73</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">7.52</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">5% Beneficial Owners</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SCLX Stock Acquisition JV LLC</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">60,559,202</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(11)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">36.33</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">29,057,097</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">100.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">45.78</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Less than 1%. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Unless otherwise indicated, the business address of each of the following individuals is 960 San Antonio Road, Palo Alto, CA 94303. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents 9,895,722 shares subject to options exercisable within 60 days of March&#160;15, 2024 and 15,882 shares held directly. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">230 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents 4,490,041 shares subject to options exercisable within 60 days of March&#160;15, 2024, 305,273 shares held directly, an aggregate of 70 shares held through an entity owned by Dr.&#160;Ji, 5,640 shares held by Dr.&#160;Ji&#8217;s spouse and an aggregate of 292,264 shares held by family trusts for the benefit of Dr.&#160;Ji, his spouse and children. This does not include 2,749 shares of Common Stock to which Dr.&#160;Ji is entitled to receive as a result of the exercise of a put option, as such shares have not yet been transferred to Dr.&#160;Ji due to <span style="white-space:nowrap">lock-up</span> restrictions on such shares, which <span style="white-space:nowrap">lock-up</span> is currently set to expire on the earlier of (i) September 30, 2024 or (ii) the date on which Sorrento and its Official Committee of Unsecured Creditors agree in writing or on the record in the Chapter 11 Cases that the Stock Clawback Claims should not be pursued, or on such date that the Bankruptcy Court deems just and proper. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents 217,752 shares subject to options exercisable within 60 days of March&#160;15, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents 498,889 shares subject to options exercisable within 60 days of March&#160;15, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents 26,041 shares subject to options exercisable within 60 days of March&#160;15, 2024, 45,000 shares of Common Stock held directly and 11 shares of Common Stock held by Dr.&#160;Chun&#8217;s child. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents 53,452 shares subject to options exercisable within 60 days of March&#160;15, 2024 and 300 shares of Common Stock held directly. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(8)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents 54,823 shares subject to options exercisable within 60 days of March&#160;15, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(9)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents 430,139 shares subject to options exercisable within 60 days of March&#160;15, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(10)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Excludes shares held by Ms.&#160;Czerepak as she is no longer an executive officer of the Company, but includes 217,752 shares subject to options held by Mr.&#160;Ma that are exercisable within 60 days of March&#160;15, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(11)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents (a) 60,068,585 shares of Common Stock and (b) 490,617 SPAC Warrants, all of which are currently exercisable, in each case, transferred to SCLX JV in connection with the Equity Repurchase Transaction. Does not include any shares of Series A Preferred Stock. The voting and dispositive power of the equity securities of the Company (including the Series A Preferred Stock) held by SCLX JV are subject to the control of an independent manager, Jack Wu, until such time as the Oramed Note and any Additional Notes are paid in full. The business address of SCLX Stock Acquisition JV LLC is 960 San Antonio Road, Palo Alto, CA 94303. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">231 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx759370_17">SELLING STOCKHOLDERS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to the offer and sale from time to time by the Selling Stockholders of up to an aggregate of 13,324,683 Resale Shares, consisting of: (i)&#160;up to 324,683 HB Shares, of which 110,392 shares of Common Stock are held by Cove Lane and 241,291 shares of Common Stock are held by HBC, in each case issued on September 25, 2023, pursuant to the Settlement Agreement; and (ii)&#160;up to 13,000,000 Penny Warrant Shares. For additional information regarding the issuances of Penny Warrants and the HB Shares, see the section titled &#8220;<span style="font-style:italic">Certain Relationships and Related Party Transactions</span>&#8221; respectively, above. We are registering the shares of Common Stock in order to permit the Selling Stockholders to offer the Resale Shares for resale from time to time. Except for the relationships described in the section titled &#8220;<span style="font-style:italic">Certain Relationships and Related Party Transactions</span>&#8221; the Selling Stockholders have not had any material relationship with us within the past three years. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below lists the Selling Stockholders and other information regarding the beneficial ownership of the shares of Common Stock by each of the Selling Stockholders. The second column lists the number of shares of Common Stock beneficially owned by each Selling Stockholder, based on its ownership of the Penny Warrants, as of March&#160;15, 2024, that are currently exercisable or that will become exercisable by the Selling Stockholders within 60 days of March&#160;15, 2024 without regard to any limitations on exercises. The beneficial ownership of Common Stock is based on 166,189,835 shares of such Common Stock outstanding as of March&#160;15, 2024. Voting power is based on an aggregate of 195,246,932 shares of our capital stock outstanding as of March&#160;15, 2024, comprised of 166,189,835 shares of Common Stock and 29,057,097 shares of Series A Preferred Stock. Shares of Series A Preferred Stock are held solely by SCLX JV. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The third column lists the shares of Common Stock being offered by this prospectus by the Selling Stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the terms of the Oramed RRA with Oramed, this prospectus generally covers the resale of the sum of the maximum number of shares of Common Stock issuable upon the exercise of the Penny Warrants, determined as if the outstanding Penny Warrants were exercised, as applicable, in full as of the trading day immediately preceding the date the registration statement of which this prospectus forms a part was initially filed with the SEC, each as of the trading day immediately preceding the applicable date of determination and all subject to adjustment as provided in the Oramed RRA, without regard to any limitations on the exercise of the Penny Warrants. The fourth column assumes the sale of all of the shares offered by the Selling Stockholders pursuant to this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of the Penny Warrants provide for certain limitations on the exercise of such Penny Warrants, including that Oramed may not exercise such Penny Warrants, as applicable, to the extent such conversion or exercise would cause Oramed, together with its affiliates, to beneficially own a number of shares of Common Stock which would exceed 9.9% of our then outstanding Common Stock following such conversion or such exercise, excluding for purposes of such determination shares of Common Stock issuable upon exercise of such Penny Warrants which have not been exercised. The number of shares in the second and fourth columns do not reflect any such limitations. The Selling Stockholders may sell all, some or none of their shares in this offering. See &#8220;<span style="font-style:italic">Plan of Distribution</span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot advise you as to whether the Selling Stockholders will in fact sell any or all of such shares of Common Stock. In particular, the Selling Stockholders identified below may have sold, transferred or otherwise disposed of all or a portion of their securities after the date on which they provided us with information regarding their securities in transactions exempt from registration under the Securities Act. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:47%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Name and Address of Selling<br/>Securityholder<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of&#160;shares&#160;of<br/>Common&#160;Stock<br/>Beneficially&#160;Owned<br/>Prior&#160;to&#160;Offering</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Maximum&#160;Number&#160;of&#160;shares&#160;of<br/>Common Stock to be<br/>Sold&#160;Pursuant<br/>to this Prospectus</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of&#160;shares&#160;of<br/>Common&#160;Stock<br/>Beneficially&#160;Owned<br/>After&#160;Offering<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oramed Pharmaceuticals Inc.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(2)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2.35</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">13,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2.35&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cove Lane Onshore Fund, LLC<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">110,392</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">110,392</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">232 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:54%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Name and Address of Selling<br/>Securityholder<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of&#160;shares&#160;of<br/>Common&#160;Stock<br/>Beneficially&#160;Owned<br/>Prior&#160;to&#160;Offering</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Maximum&#160;Number&#160;of&#160;shares&#160;of<br/>Common Stock to be<br/>Sold&#160;Pursuant<br/>to this Prospectus</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of&#160;shares&#160;of<br/>Common&#160;Stock<br/>Beneficially&#160;Owned<br/>After&#160;Offering<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HBC Investments LLC<sup style="font-size:75%; vertical-align:top">(5)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">214,291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">214,291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Less than 1% </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Beneficial ownership is determined in accordance with <span style="white-space:nowrap">Rule&#160;13d-3&#160;under</span> the Exchange Act. In computing the number of shares beneficially owned by a person and the percentage ownership of that person, shares of Common Stock subject to warrants, options and other convertible securities held by that person that are currently exercisable or exercisable (within 60 days of March&#160;15, 2024) are deemed outstanding. Shares subject to warrants, options and other convertible securities, however, are not deemed outstanding for the purpose of computing the percentage ownership of any other person. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents the Transferred Warrants, which are exercisable within 60 days of March&#160;15, 2024. The business address of Oramed Pharmaceuticals Inc. is 1185 Avenue of the Americas, Third Floor, New York, 10036. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Comprised of shares issuable upon the exercise of the Penny Warrants. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The business address of Cove Lane Onshore Fund, LLC is c/o Hudson Bay Capital Management LP, 28&#160;Havemeyer Place, 2nd Floor, Greenwich, CT 06830. Hudson Bay Capital Management LP, the investment manager of Cove Lane Onshore Fund, LLC, has voting and investment power over these securities. Sander Gerber is the managing member of Hudson Bay Capital GP LLC, which is the general partner of Hudson Bay Capital Management LP. Each of Cove Lane Onshore Fund, LLC and Sander Gerber disclaims beneficial ownership over these securities. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The business address of HBC Investments LLC is c/o Hudson Bay Capital Management LP, 28 Havemeyer Place, 2nd Floor, Greenwich, CT 06830. Hudson Bay Capital Management LP, the investment manager of HBC Investments LLC, has voting and investment power over these securities. Sander Gerber is the managing member of Hudson Bay Capital GP LLC, which is the general partner of Hudson Bay Capital Management LP. Each of HBC Investments LLC and Sander Gerber disclaims beneficial ownership of these securities. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">233 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx759370_18">PLAN OF DISTRIBUTION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Selling Stockholder of the securities and any of their pledgees, donees, transferees, distributees, assignees and <span style="white-space:nowrap"><span style="white-space:nowrap">successors-in-interest</span></span> may, from time to time, sell any or all of their securities covered hereby on the principal Trading Market or any other stock exchange, market or trading facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices. A Selling Stockholder may use any one or more of the following methods when selling securities: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an exchange distribution in accordance with the rules of the applicable exchange; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">privately negotiated transactions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">settlement of short sales; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in transactions through broker-dealers that agree with the Selling Stockholders to sell a specified number of such securities at a stipulated price per security; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a combination of any such methods of sale; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any other method permitted pursuant to applicable laws. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Stockholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if available, rather than under this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Broker-dealers engaged by the Selling Stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the Selling Stockholders (or, if any broker- dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in compliance with FINRA Rule 2121. It is possible that the Selling Stockholders will attempt to sell shares of our Common Stock in block transactions to market makers or other purchasers at a price per share which may be below the then existing market price. We cannot assure that all or any of the shares offered in this prospectus will be issued to, or sold by, the Selling Stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the sale of the securities or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The Selling Stockholders may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities to broker- dealers that in turn may sell these securities. The Selling Stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Stockholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the securities </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">234 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. To our knowledge, there are currently no plans, arrangements or understandings between the Selling Stockholders and any broker-dealer or agent regarding the sale of the securities by the Selling Stockholders. Upon our notification by a Selling Stockholder that any material arrangement has been entered into with an underwriter or broker-dealer for the sale of securities through a block trade, special offering, exchange distribution, secondary distribution or a purchase by an underwriter or broker-dealer, we will file, if required by applicable law or regulation, a supplement to this prospectus pursuant to Rule 424(b) under the Securities Act disclosing certain material information relating to such underwriter or broker-dealer and such offering. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required to pay certain fees and expenses incurred by us incident to the registration of the securities. We have agreed to indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We agreed to keep this prospectus effective until the earlier of (i)&#160;the date on which the securities may be resold by the Selling Stockholders without registration and without regard to any volume or <span style="white-space:nowrap"><span style="white-space:nowrap">manner-of-sale</span></span> limitations by reason of Rule 144, without the requirement for the Company to be in compliance with the current public information under Rule 144 under the Securities Act or any other rule of similar effect or (ii)&#160;all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market making activities with respect to the Common Stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the Selling Stockholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the Common Stock by the Selling Stockholders or any other person. We will make copies of this prospectus available to the Selling Stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">235 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx759370_19">MATERIAL U.S.&#160;FEDERAL INCOME TAX CONSEQUENCES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a discussion of certain material U.S.&#160;federal income tax considerations generally applicable to the purchase, ownership and disposition of our Common Stock. This discussion is based on provisions of the Code, the Treasury Regulations promulgated thereunder (whether final, temporary, or proposed), administrative rulings of the IRS, and judicial decisions, all as in effect on the date hereof, and all of which are subject to differing interpretations or change, possibly with retroactive effect. This discussion does not purport to be a complete analysis or listing of all potential U.S.&#160;federal income tax consequences relating to the purchase, ownership and disposition of our Common Stock. In addition, this discussion does not address all aspects of U.S.&#160;federal income tax consequences to particular holders nor does it take into account the individual facts and circumstances of any particular holder that may affect the U.S.&#160;federal income tax consequences to such holder, and accordingly, is not intended to be, and should not be construed as, tax advice. This discussion does not address the U.S.&#160;federal&#160;3.8% Medicare tax imposed on certain net investment income or any aspects of U.S.&#160;federal taxation other than those pertaining to the income tax (such as the gift or estate tax), nor does it address any tax consequences arising under any U.S.&#160;state and local, or <span style="white-space:nowrap">non-U.S.&#160;tax</span> laws. Holders should consult their own tax advisors regarding such tax consequences in light of their particular circumstances. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No ruling has been requested or will be obtained from the IRS with respect to the U.S.&#160;federal income tax consequences to a holder of the purchase, ownership or disposition of our Common Stock; thus, there can be no assurance that the IRS will not challenge the U.S.&#160;federal income tax treatment described below or that, if challenged, such treatment will be sustained by a court. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary is limited to considerations relevant to holders that hold our Common Stock as &#8220;capital assets&#8221; within the meaning of Section&#160;1221 of the Code (generally, property held for investment). This discussion does not address all aspects of U.S.&#160;federal income taxation that may be important to holders in light of their individual circumstances, including holders subject to special treatment under the U.S.&#160;tax laws, such as, for example: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">banks or other financial institutions, underwriters, or insurance companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">dealers or traders in securities who elect to apply a <span style="white-space:nowrap"><span style="white-space:nowrap">mark-to-market</span></span> method of accounting; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">real estate investment trusts and regulated investment companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">tax-exempt</span> organizations, qualified retirement plans, individual retirement accounts, or other <span style="white-space:nowrap">tax-deferred</span> accounts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expatriates or former long-term residents of the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">subchapter&#160;S corporations, partnerships or other pass-through entities or investors or beneficial owners in such entities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">dealers or traders in securities, commodities or currencies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">grantor trusts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons subject to the alternative minimum tax; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">U.S.&#160;persons whose &#8220;functional currency&#8221; is not the U.S.&#160;dollar; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons who received our Common Stock through the issuance of restricted stock under an equity incentive plan or through a <span style="white-space:nowrap">tax-qualified</span> retirement plan or otherwise as compensation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons who own (directly or through attribution) 5% or more (by vote or value) of the outstanding securities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons holding our Common Stock as a position in a &#8220;straddle,&#8221; as part of a &#8220;synthetic security&#8221; or &#8220;hedge,&#8221; as part of a &#8220;conversion transaction,&#8221; or other integrated investment or risk reduction transaction; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">236 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">controlled foreign corporations, passive foreign investment companies, or foreign corporations with respect to which there are one or more United States shareholders within the meaning of Treasury <span style="white-space:nowrap">Regulation&#160;Section&#160;1.367(b)-3(b)(1)(ii);</span> or </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As used in this discussion, the term &#8220;U.S.&#160;Holder&#8221; means a beneficial owner of our Common Stock that is, for U.S.&#160;federal income tax purposes: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an individual who is a citizen or resident of the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a corporation (or other entity that is classified as a corporation for U.S.&#160;federal income tax purposes) that is created or organized in or under the laws of the United States or any State thereof or the District of Columbia; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an estate the income of which is subject to U.S.&#160;federal income tax regardless of its source; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a trust (i)&#160;if a court within the United States is able to exercise primary supervision over the administration of the trust and one or more U.S.&#160;persons have the authority to control all substantial decisions of the trust, or (ii)&#160;that has a valid election in effect under applicable Treasury Regulations to be treated as a U.S.&#160;person for U.S.&#160;federal income tax purposes. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <span style="white-space:nowrap">&#8220;Non-U.S.&#160;Holder&#8221;</span> means a beneficial owner of our Common Stock, that is neither a U.S.&#160;Holder nor a partnership (or an entity or arrangement treated as a partnership) for U.S.&#160;federal income tax purposes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a partnership, including for this purpose any entity or arrangement that is treated as a partnership for U.S.&#160;federal income tax purposes, holds our Common Stock, the U.S.&#160;federal income tax treatment of a partner in such partnership will generally depend on the status of the partner and the activities of the partnership. A holder that is a partnership and the partners in such partnership should consult their own tax advisors with regard to the U.S.&#160;federal income tax consequences of the ownership and disposition of our Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is based on the Code, and administrative pronouncements, judicial decisions and final, temporary and proposed Treasury Regulations as of the date hereof, which are subject to change, possibly on a retroactive basis, and changes to any of which subsequent to the date of this prospectus may affect the tax consequences described herein. This discussion does not address any aspect of state, local or <span style="white-space:nowrap">non-U.S.</span> taxation, or any U.S. federal taxes other than income taxes (such as gift and estate taxes). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">THIS SUMMARY DOES NOT PURPORT TO BE A COMPREHENSIVE ANALYSIS OR DESCRIPTION OF ALL POTENTIAL U.S.&#160;FEDERAL INCOME TAX CONSEQUENCES OF THE OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK. IN ADDITION, THE U.S.&#160;FEDERAL INCOME TAX TREATMENT OF THE BENEFICIAL OWNERS OF OUR COMMON STOCK MAY BE AFFECTED BY MATTERS NOT DISCUSSED HEREIN AND DEPENDS IN SOME INSTANCES ON DETERMINATIONS OF FACT AND INTERPRETATIONS OF COMPLEX PROVISIONS OF U.S.&#160;FEDERAL INCOME TAX LAW FOR WHICH NO CLEAR PRECEDENT OR AUTHORITY MAY BE AVAILABLE. HOLDERS OF OUR COMMON STOCK SHOULD CONSULT WITH THEIR TAX ADVISORS REGARDING THE PARTICULAR TAX CONSEQUENCES TO THEM OF THE OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK INCLUDING THE APPLICABILITY AND EFFECTS OF U.S.&#160;FEDERAL, STATE, LOCAL, AND OTHER TAX LAWS. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">U.S.&#160;Holders </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Taxation of Distributions </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we pay distributions or make constructive distributions (other than certain distributions of our stock or rights to acquire our stock) to U.S.&#160;Holders of shares of our Common Stock, such distributions generally will constitute dividends for U.S.&#160;federal income tax purposes to the extent paid from our current or accumulated </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">237 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
earnings and profits, as determined under U.S.&#160;federal income tax principles. Distributions in excess of our current and accumulated earnings and profits will constitute a return of capital that will be applied against and reduce (but not below zero) the U.S.&#160;Holder&#8217;s adjusted tax basis in our Common Stock. Any remaining excess will be treated as gain realized on the sale or other disposition of the Common Stock and will be treated as described under &#8220;<span style="font-style:italic">U.S.</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;Holders-Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock</span>&#8221; below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends we pay to a U.S.&#160;Holder that is a taxable corporation will generally qualify for the dividends received deduction if the requisite holding period is satisfied. With certain exceptions (including dividends treated as investment income for purposes of investment interest deduction limitations), and provided certain holding period requirements are met, dividends we pay to a <span style="white-space:nowrap">non-corporate</span> U.S.&#160;Holder will generally constitute &#8220;qualified dividends&#8221; that will be subject to tax at the preferential tax rate accorded to long-term capital gains. <span style="white-space:nowrap">Non-corporate</span> U.S.&#160;Holders that do not meet a minimum holding period requirement or that elect to treat the dividend income as &#8220;investment income&#8221; pursuant to Section&#160;163(d)(4) of the Code (dealing with the deduction for investment interest expense) will not be eligible for the reduced rates of taxation applicable to qualified dividends. In addition, the rate reduction will not apply to dividends if the recipient of a dividend is obligated to make related payments with respect to positions in substantially similar or related property. This disallowance applies even if the minimum holding period has been met. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the holding period requirements are not satisfied, a corporation may not be able to qualify for the dividends received deduction and would have taxable income equal to the entire dividend amount, and <span style="white-space:nowrap">non-corporate</span> holders may be subject to tax on such dividend at ordinary income tax rates instead of the preferential rates that apply to qualified dividend income. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A U.S. Holder generally will recognize gain or loss on the sale, taxable exchange or other taxable disposition of our Common Stock, including on a redemption that is treated as a sale or exchange under </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&#160;302 of the Code. Any such gain or loss will be capital gain or loss, and will be long-term capital gain or loss if the U.S. Holder&#8217;s holding period for the Common Stock so disposed of exceeds one year. The amount of gain or loss recognized will generally be equal to the difference between (1)&#160;the sum of the amount of cash and the fair market value of any property received in such disposition and (2)&#160;the U.S. Holder&#8217;s adjusted tax basis in its Common Stock so disposed of. A U.S. Holder&#8217;s adjusted tax basis in its Common Stock will generally equal the U.S. Holder&#8217;s acquisition cost for such Common Stock, less any prior distributions treated as a return of capital. The deductibility of capital losses is subject to limitations. Long-term capital gains recognized by </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">non-corporate</span> U.S. Holders are generally eligible for reduced rates of tax. If the U.S. Holder&#8217;s holding period for the Common Stock so disposed of is one year or less, any gain on a sale or other taxable disposition of the shares would be subject to short-term capital gain treatment and would be taxed at ordinary income tax rates. The deductibility of capital losses is subject to limitations. Any gain or loss recognized by a U.S. Holder on the sale </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or exchange of our Common Stock will generally be treated as U.S. source gain or loss. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Exercise, Lapse, or Redemption of a Warrant </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as discussed below with respect to the cashless exercise of a Penny Warrant, a U.S. Holder generally will not recognize gain or loss upon the exercise of a Penny Warrant. A U.S. Holder&#8217;s tax basis in a share of our Common Stock received upon exercise of the Penny Warrant generally will be an amount equal to the sum of the U.S. Holder&#8217;s initial investment in the Penny Warrant and the exercise price. The U.S. Holder&#8217;s holding period for the share of the Common Stock received upon exercise of the Penny Warrant generally will commence on the date of exercise of the Penny Warrant or the date following the date of exercise of the Penny Warrant; however, in either case the holding period will not include the period during which the U.S. Holder held the Penny Warrant. If a Penny Warrant is allowed to lapse unexercised, a U.S. Holder generally will recognize a capital loss equal to such holder&#8217;s tax basis in the Penny Warrant. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">238 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The tax consequences of a cashless exercise of a Penny Warrant are not clear under current tax law. A cashless exercise may be <span style="white-space:nowrap">tax-free,</span> either because the exercise is not a gain realization event or because the exercise is treated as a recapitalization for U.S. federal income tax purposes. In either <span style="white-space:nowrap">tax-free</span> situation, a U.S. Holder&#8217;s basis in the share of the Common Stock received would equal the holder&#8217;s basis in the Penny Warrants used to effect the cashless exercise. If the cashless exercise is not treated as a gain realization event, a U.S. Holder&#8217;s holding period in the Common Stock generally would be treated as commencing on the date of exercise of the Penny Warrant or the date following the date of exercise of the Penny Warrant; however, in either case the holding period will not include the period during which the U.S. Holder held the Penny Warrant. If the cashless exercise were treated as a recapitalization, the holding period of the Common Stock would include the holding period of the Penny Warrant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is also possible that a cashless exercise could be treated in part as a taxable exchange in which gain or loss would be recognized. In such event, a portion of the Penny Warrants to be exercised on a cashless basis could, for U.S. federal income tax purposes, be deemed to have been surrendered in consideration for the exercise price of the remaining Penny Warrants, which would be deemed to be exercised. For this purpose, a U.S. Holder could be deemed to have surrendered Penny Warrants having an aggregate fair market value equal to the exercise price for the total number of Penny Warrants to be deemed exercised. The U.S. Holder would recognize capital gain or loss in an amount equal to the difference between the fair market value of the Penny Warrants deemed surrendered and the U.S. Holder&#8217;s tax basis in such Penny Warrants. In this case, a U.S. Holder&#8217;s tax basis in the Common Stock received would equal the sum of the U.S. holder&#8217;s initial investment in the Penny Warrants deemed exercised and the exercise price of such Penny Warrants. A U.S. Holder&#8217;s holding period for the Common Stock in such case generally would commence on the date following the date of exercise (or possibly the date of exercise) of the Penny Warrant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the absence of authority on the U.S. federal income tax treatment of a cashless exercise, there can be no assurance which, if any, of the alternative tax consequences and holding periods described above would be adopted by the IRS or a court of law. Accordingly, U.S. Holders should consult their tax advisors regarding the tax consequences of a cashless exercise. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Possible Constructive Distributions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of each Penny Warrant provide for an adjustment to the number of shares of Common Stock for which the Warrant may be exercised or to the exercise price of the Penny Warrant in certain events, as discussed in the section of this prospectus titled &#8220;<span style="font-style:italic">Description of Our Securities&#8212;Penny Warrants</span>&#8221;. An adjustment which has the effect of preventing dilution generally should not be a taxable event. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nevertheless, a U.S. Holder of Penny Warrants would be treated as receiving a constructive distribution from us if, for example, the adjustment increases the holder&#8217;s proportionate interest in our assets or earnings and profits (e.g., through an increase in the number of shares of Common Stock that would be obtained upon exercise) as a result of a distribution of cash to the holders of shares of our Common Stock which is taxable to such holders as a distribution. Such constructive distribution would be subject to tax as described above under &#8220;<span style="font-style:italic">U.S. Holders-Taxation of Distributions</span>&#8221; in the same manner as if such U.S. Holder received a cash distribution from us on Common Stock equal to the fair market value of such increased interest. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-U.S.</span> Holders </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Taxation of Distributions </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, any distributions (including constructive distributions) we make to a <span style="white-space:nowrap">Non-U.S.</span> Holder of shares of our Common Stock, to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles), will constitute dividends for U.S. federal income tax purposes and, provided such dividends are not effectively connected with the <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s conduct of a trade or business </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">239 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
within the United States, we will be required to withhold tax from the gross amount of the dividend at a rate of 30%, unless such <span style="white-space:nowrap">Non-U.S.</span> Holder is eligible for a reduced rate of withholding tax under an applicable income tax treaty and provides proper certification of its eligibility for such reduced rate (usually on an IRS Form <span style="white-space:nowrap">W-8BEN</span> or <span style="white-space:nowrap"><span style="white-space:nowrap">W-8BEN-E,</span></span> as applicable). Special certification and other requirements apply to certain <span style="white-space:nowrap">Non-U.S.</span> Holders that are pass-through entities rather than corporations or individuals. Any distribution not constituting a dividend will be treated first as reducing (but not below zero) the <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s adjusted tax basis in its shares of our Common Stock and, to the extent such distribution exceeds the <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s adjusted tax basis, as gain realized from the sale or other disposition of the Common Stock, which will be treated as described under &#8220;<span style="font-style:italic"><span style="white-space:nowrap">Non-U.S.</span> Holders-Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock</span>&#8221; below. In addition, if we determine that we are likely to be classified as a &#8220;United States real property holding corporation&#8221; (see &#8220;<span style="font-style:italic"><span style="white-space:nowrap">Non-U.S.</span> Holders-Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock</span>&#8221; below), we will withhold 15% of any distribution that exceeds our current and accumulated earnings and profits. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends we pay to a <span style="white-space:nowrap">Non-U.S.</span> Holder that are effectively connected with such <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s conduct of a trade or business within the United States (or, if a tax treaty applies, are attributable to a U.S. permanent establishment or fixed base maintained by the <span style="white-space:nowrap">Non-U.S.</span> Holder) will generally not be subject to U.S. withholding tax, provided such <span style="white-space:nowrap">Non-U.S.</span> Holder complies with certain certification and disclosure requirements (generally by providing an IRS Form <span style="white-space:nowrap">W-8ECI).</span> Instead, such dividends generally will be subject to U.S. federal income tax, net of certain deductions, at the same graduated individual or corporate rates applicable to U.S. Holders. If the <span style="white-space:nowrap">Non-U.S.</span> Holder is a corporation, dividends that are effectively connected income may also be subject to a &#8220;branch profits tax&#8221; at a rate of 30% (or such lower rate as may be specified by an applicable income tax treaty). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A <span style="white-space:nowrap">Non-U.S.</span> Holder generally will not be subject to U.S. federal income or withholding tax in respect of gain recognized on a sale, taxable exchange or other taxable disposition of our Common Stock, unless: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the gain is effectively connected with the conduct of a trade or business by the <span style="white-space:nowrap">Non-U.S.</span> Holder within the United States (and, if an applicable tax treaty so requires, is attributable to a U.S. permanent establishment or fixed base maintained by the <span style="white-space:nowrap">Non-U.S.</span> Holder); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the <span style="white-space:nowrap">Non-U.S.</span> Holder is an individual who is present in the United States for 183 days or more in the taxable year of disposition and certain other conditions are met; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we are or have been a &#8220;United States real property holding corporation&#8221; for U.S. federal income tax purposes at any time during the shorter of the five-year period ending on the date of disposition or the period that the <span style="white-space:nowrap">Non-U.S.</span> Holder held our Common Stock and, in the case where shares of our Common Stock are regularly traded on an established securities market, the <span style="white-space:nowrap">Non-U.S.</span> Holder has owned, directly or constructively, more than 5% of our Common Stock at any time within the shorter of the five-year period preceding the disposition or such <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s holding period for the shares of our Common Stock. There can be no assurance that our Common Stock will be treated as regularly traded on an established securities market for this purpose. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain described in the first bullet point above will be subject to tax at generally applicable U.S. federal income tax rates as if the <span style="white-space:nowrap">Non-U.S.</span> Holder were a U.S. resident. Any gains described in the first bullet point above of a <span style="white-space:nowrap">Non-U.S.</span> Holder that is a foreign corporation may also be subject to an additional &#8220;branch profits tax&#8221; at a 30% rate (or lower applicable treaty rate). Gain described in the second bullet point above will generally be subject to a flat 30% U.S. federal income tax. <span style="white-space:nowrap">Non-U.S.</span> Holders are urged to consult their tax advisors regarding possible eligibility for benefits under income tax treaties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the third bullet point above applies to a <span style="white-space:nowrap">Non-U.S.</span> Holder and applicable exceptions are not available, gain recognized by such holder on the sale, exchange or other disposition of our Common Stock will be subject to tax </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">240 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
at generally applicable U.S. federal income tax rates. In addition, a buyer of our Common Stock from such holder may be required to withhold U.S. income tax at a rate of 15% of the amount realized upon such disposition. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-U.S.</span> Holders are urged to consult their tax advisors regarding the application of these rules. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Exercise, Lapse, or Redemption of a Warrant </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The characterization for U.S. federal income tax purposes of the exercise, redemption or lapse of a Warrant held by a <span style="white-space:nowrap">Non-U.S.</span> holder will generally correspond to the characterization described under &#8220;U.S. Holders&#8212; Exercise, Lapse, or Redemption of a Warrant&#8221; above, although to the extent a cashless exercise or redemption results in a taxable exchange, the consequences would follow those described above in <span style="white-space:nowrap">&#8220;Non-U.S.</span> Holders&#8212; Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Possible Constructive Distributions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of each Penny Warrant provide for an adjustment to the number of shares of Common Stock for which the Penny Warrant may be exercised or to the exercise price of the Warrant in certain events, as discussed in the section of this prospectus titled &#8220;<span style="font-style:italic">Description of Our Securities&#8212;Penny Warrants</span>&#8221;. An adjustment which has the effect of preventing dilution generally should not be a taxable event. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nevertheless, a <span style="white-space:nowrap">Non-U.S.</span> Holder of Penny Warrants would be treated as receiving a constructive distribution from us if, for example, the adjustment increases the holder&#8217;s proportionate interest in our assets or earnings and profits (e.g., through an increase in the number of shares of Common Stock that would be obtained upon exercise) as a result of a distribution of cash to the holders of shares of our Common Stock which is taxable to such holders as a distribution. A <span style="white-space:nowrap">Non-U.S.</span> Holder would be subject to U.S. federal income tax withholding as described above under &#8220;<span style="font-style:italic"><span style="white-space:nowrap">Non-U.S.</span> Holders-Taxation of Distributions</span>&#8221; under that section in the same manner as if such <span style="white-space:nowrap">Non-U.S.</span> Holder received a cash distribution from us on Common Stock equal to the fair market value of such increased interest. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Foreign Account Tax Compliance Act </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Sections 1471 to 1474 of the Code and the Treasury Regulations and administrative guidance promulgated thereunder (commonly referred to as the &#8220;Foreign Account Tax Compliance Act&#8221; or &#8220;FATCA&#8221;) a </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">30% withholding tax generally applies with respect to certain dividends in respect of and, subject to the proposed Treasury Regulations described below, gross proceeds from a sale or disposition of, securities which are held by or through certain foreign financial institution (including investment funds), unless any such institution (a)&#160;enters into, and complies with, an agreement with the IRS to report, on an annual basis, information with respect to interests in, and accounts maintained by, the institution that are owned by certain U.S. persons and by certain </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">non-U.S.</span> entities that are wholly or partially owned by U.S. persons and to withhold on certain payments, or (b)&#160;if required under an intergovernmental agreement between the United States and an applicable foreign country, reports such information to its local tax authority, which will exchange such information with the U.S. authorities. An intergovernmental agreement between the United States and the applicable foreign country may modify these requirements. Accordingly, the entity through which our Common Stock are held will affect the determination of whether such withholding is required. Similarly, dividends in respect of, and (subject to the proposed Treasury Regulations discussed below) gross proceeds from the sale or other disposition of, Common Stock held by an investor that is a <span style="white-space:nowrap">non-financial</span> <span style="white-space:nowrap">non-U.S.</span> entity that does not qualify under certain exceptions will generally be subject to withholding at a rate of 30%, unless such entity either (i)&#160;certifies to the applicable withholding agent that such entity does not have any &#8220;substantial United States owners&#8221; or (ii)&#160;provides certain information regarding the entity&#8217;s &#8220;substantial United States owners,&#8221; which will in turn be provided to the U.S. Department of Treasury. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">241 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the applicable Treasury Regulations and administrative guidance, withholding under FATCA generally applies to payments of dividends. While withholding under FATCA generally would also apply to payments of gross proceeds from the sale or other disposition of securities (including Common Stock), proposed Treasury Regulations eliminate FATCA withholding on payments of gross proceeds entirely. Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued. All holders should consult their tax advisors regarding the possible implications of FATCA on their investment in our Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Information Reporting and Backup Withholding. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information returns will be filed with the IRS in connection with payments of dividends and the proceeds from a sale or other disposition of our shares of Common Stock. A <span style="white-space:nowrap">Non-U.S.</span> Holder may have to comply with certification procedures to establish that it is not a United States person in order to avoid information reporting and backup withholding requirements. The certification procedures required to claim a reduced rate of withholding under a treaty generally will satisfy the certification requirements necessary to avoid the backup withholding as well. Backup withholding is not an additional tax. The amount of any backup withholding from a payment to a <span style="white-space:nowrap">Non-U.S.</span> Holder will be allowed as a credit against such holder&#8217;s U.S. federal income tax liability and may entitle such holder to a refund, provided that the required information is timely furnished to the IRS. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">THE DISCUSSION ABOVE IS A GENERAL SUMMARY. IT DOES NOT COVER ALL TAX MATTERS THAT MAY BE IMPORTANT TO YOU. EACH PROSPECTIVE PURCHASER OF OUR COMMON STOCK SHOULD CONSULT ITS TAX ADVISOR ABOUT THE TAX CONSEQUENCES OF AN INVESTMENT IN OUR COMMON STOCK BASED ON YOUR CIRCUMSTANCES. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">242 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx759370_20">DESCRIPTION OF OUR SECURITIES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">General </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description summarizes the most important terms of our securities. The following summary does not purport to be complete and is subject to the Certificate of Incorporation, the Bylaws and the provisions of applicable law. A copy of the Certificate of Incorporation and a copy of the Bylaws are attached as exhibits to the registration statement of which this prospectus forms a part. The stockholders are encouraged to read the applicable provisions of the DGCL, the Certificate of Incorporation and the Bylaws in their entirety for a complete description of the rights and preferences of our securities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Authorized and Outstanding Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation authorizes the issuance of (i) 740,000,000 shares of Common Stock, $0.0001 par value per share and (ii) 45,000,000 shares of preferred stock, $0.0001 par value per share (the &#8220;Preferred Stock&#8221;), of which&#160;29,057,097 shares have been designated as Series A Preferred Stock. As of March&#160;15, 2024, there were 166,189,835 shares of Common Stock and&#160;29,057,097 shares of Series A Preferred Stock issued and outstanding. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Common Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides the following with respect to the rights, powers, preferences and privileges of our Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Dividend Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of our Common Stock are entitled to receive ratably those dividends, if any, that may be declared from time to time by our Board upon the shares of our capital stock, which dividends may be paid either in cash, in property or in shares of our capital stock, subject to preferences that may be applicable to preferred stock, if any, then outstanding. Subject to applicable law and the Certificate of Incorporation, our Board will have full power to determine whether any dividends shall be declared and paid to stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Voting Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each holder of our Common Stock will be entitled to one vote for each share of our Common Stock held of record by such holder on all matters on which stockholders generally are entitled to vote, except for any amendment to the Certificate of Incorporation that relates solely to the terms of one or more outstanding classes or series of our Preferred Stock if the holders of such affected classes or series are entitled, either separately or together with the holders of one or more other such classes or series, to vote thereon pursuant to the Certificate of Incorporation or the DGCL. Any action or matter presented to the stockholders at a duly called or convened meeting, at which a quorum is present, is decided by the affirmative vote of the holders of a majority of the votes cast affirmatively or negatively (excluding abstentions) at the meeting by the holders entitled to vote thereon, except that our directors will be elected by a plurality of the votes cast. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Right to Receive Liquidation Distributions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a liquidation, dissolution or winding up of the Company, the holders of our Common Stock will be entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of our Preferred Stock, if any, then outstanding. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">No Preemptive or Similar Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock have no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to our Common Stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">243 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Fully Paid and <span style="white-space:nowrap">Non-Assessable</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The outstanding shares of our Common Stock are fully paid and <span style="white-space:nowrap">non-assessable.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Preferred Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation authorizes our Board, subject to limitations prescribed by Delaware law, to issue up to&#160;45,000,000 shares of preferred stock in one or more series, to determine and fix from time to time the number of shares to be included in each such series and to fix the designations, powers, rights and preferences of the shares of each such series, and the qualifications, limitations and restrictions thereof, including voting rights (if any), dividend rights, dissolution rights, conversion rights, exchange rights and redemption rights, in each case without further vote or action by our stockholders. The number of authorized shares of our Common Stock and our Preferred Stock may be increased or decreased (but not below the number of the shares thereof then outstanding) by the affirmative vote of the holders of a majority in voting power of our outstanding stock entitled to vote thereon. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our Common Stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control and may adversely affect the market price of our Common Stock and the voting and other rights of the holders of our Common Stock. Other than the shares of Series A Preferred Stock, there are no other shares of Preferred Stock outstanding and we have no current plans to issue any other shares of preferred stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Number and Designation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We filed the Certificate of Designations, designating&#160;29,057,097 shares of our preferred stock as &#8220;Series A Preferred Stock&#8221;. As of the date of this prospectus, 29,057,097 shares of the Series A Preferred Stock are held by SCLX JV, which shares were repurchased from Sorrento pursuant to the terms of the Sorrento SPA and represent all of the shares of Series A Preferred Stock that were previously owned by Sorrento. The shares of Series A Preferred Stock have all of the rights, preferences and privileges set forth in the Certificate of Designations as more fully described below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Rank </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Series A Preferred Stock shall rank (i)&#160;senior to all of our Common Stock, and to all other classes or series of our capital stock, except for any such other class or series, the terms of which expressly provide that it ranks on parity with the Series A Preferred Stock as to dividend rights and rights on liquidation, dissolution or <span style="white-space:nowrap">winding-up</span> of the Company (&#8220;Junior Securities&#8221;); and (ii)&#160;on parity with each class or series of our capital stock, created specifically ranking by its terms on parity with the Series A Preferred Stock as to dividend rights and rights on liquidation, dissolution or <span style="white-space:nowrap">winding-up</span> of the Company (&#8220;Parity Securities&#8221;). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Dividend Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of the Series A Preferred Stock shall not be entitled to dividends unless we pay dividends to holders of the Common Stock and shall be entitled to receive, when, as and if declared by our Board, such dividends (whether in cash or other property) as are paid to holders of our Common Stock to the same extent as if such holders of Series A Preferred Stock had been deemed to convert their shares of Series A Preferred Stock into Common Stock and had held such shares of Common Stock on the record date for such dividends and distributions. Such payments will be made concurrently with the dividend or distribution to the holders of the Common Stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">244 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Liquidation Preference </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a change of control, liquidation, dissolution or <span style="white-space:nowrap">winding-up</span> of the Company, whether voluntary or involuntary, before any payment or distribution of our property or assets (whether capital or surplus) shall be made to or set apart for the holders of Junior Securities, the holders of Series A Preferred Stock shall be entitled to receive an amount per share of Series A Preferred Stock equal to the greater of (i)&#160;the sum of $10.00 (which amount shall be appropriately adjusted in the event of any stock split, stock combination or other similar recapitalization of the Series A Preferred Stock) and all accrued and unpaid dividends and (ii)&#160;the amount such share of Series A Preferred Stock would be entitled to receive pursuant to the change of control, liquidation, dissolution or <span style="white-space:nowrap">winding-up</span> of the Company assuming that such share had been converted into shares of Common Stock in a Deemed Conversion (as defined below). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Conversion and Redemption Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Series A Preferred Stock will not be convertible into Common Stock or any of our other securities and will not be redeemable by the Company; provided, however, a number of the rights, preferences and privileges of the Series A Preferred Stock set forth in the Certificate of Designations will be determined based on an <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">as-converted-to-Common</span></span></span> Stock basis or otherwise assume that the shares of Series A Preferred Stock are converted into shares of Common Stock. Accordingly, the number of shares of Common Stock that each share of Series A Preferred Stock is deemed to be (or otherwise being treated as) converted into for the purpose of affecting the various rights, preferences and privileges of the Series A Preferred Stock set forth in the Certificate of Designation (a &#8220;Deemed Conversion&#8221;), whether in connection with a change of control or otherwise, shall be equal to the result obtained by dividing (i)&#160;stated value by (ii) $10.00 (subject to anti-dilution adjustments). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Voting and Other Preferred Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise required by law or as set forth in the Certificate of Designations, the holders of shares of Series A Preferred Stock will be entitled to vote, together with the holders of shares of Common Stock and not separately as a class, on all matters upon which holders of shares of Common Stock have the right to vote. The holders of shares of Series A Preferred Stock will be entitled to one vote for each share of Common Stock that such share of Series A Preferred Stock would otherwise be convertible into pursuant to a Deemed Conversion on the record date for the determination of the stockholders entitled to vote. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As long as any shares of Series A Preferred Stock are outstanding, we shall not, without the affirmative vote of the holders of at least a majority of the outstanding shares of Series A Preferred Stock (a)&#160;change the Series A Preferred Stock (whether by merger, consolidation, reclassification or otherwise) into cash, securities or other property except in accordance with the terms of the Certificate of Designations; (b)&#160;create, authorize or issue any Parity Security or other equity security the terms of which provide that it ranks senior to the Series A Preferred Stock with respect to dividend rights or rights upon liquidation, dissolution or <span style="white-space:nowrap">winding-up</span> of the Company, or increase the authorized amount of any such other class or series; or (c)&#160;amend the Certificate of Incorporation or the Certificate of Designations in any manner that adversely affects the holders of Series A Preferred Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Registration Rights </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Registration Rights Agreement entered into in connection with the Closing of the Business Combination, certain of our stockholders are able to demand that we register their registrable securities under certain circumstances and each also have piggyback registration rights for these securities. In addition, we are required to file and maintain an effective registration statement under the Securities Act covering the resale of all such registrable securities. We have filed a registration statement on Form <span style="white-space:nowrap">S-1</span> (File <span style="white-space:nowrap">No.&#160;333-268603)</span> which was initially declared effective by the SEC on December&#160;27, 2022, in order to satisfy these obligations. The registration of these securities will enable the public sale of such securities, subject to certain contractual </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">245 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
restrictions imposed by the Registration Rights Agreement and the Merger Agreement. The presence of these additional shares of common stock trading in the public market may have an adverse effect on the market price of our securities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Anti-Takeover Matters in our Governing Documents and Under Delaware Law </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain provisions of Delaware law, along with the Certificate of Incorporation and the Bylaws, all of which are summarized below, may have the effect of delaying, deferring or discouraging another person from acquiring control of the Company. These provisions are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed, in part, to encourage persons seeking to acquire control of the Company to first negotiate with our Board. However, these provisions could have the effect of delaying, discouraging or preventing attempts to acquire the Company, which could deprive our stockholders of opportunities to sell their shares of our Common Stock at prices higher than prevailing market prices. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Authorized but Unissued Capital Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The authorized but unissued shares of our Common Stock and our Preferred Stock are available for future issuance without stockholder approval, subject to any limitations imposed by the rules of the Nasdaq Listing Rules. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved Common Stock and Preferred Stock could make more difficult or discourage an attempt to obtain control of the Company by means of a proxy contest, tender offer, merger or otherwise. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Impact of the Equity Repurchase Transaction or Provisions Related to a Sorrento Trigger Event </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain provisions of our Certificate of Incorporation related to the number of authorized directors, filling vacancies on the Board, removal of directors, stockholder actions by written consent, calling of special meetings of our stockholders, our election to not be governed by Section&#160;203 of the DGCL and amendments to our Certificate of Incorporation and our Bylaws lapse upon or are triggered by the Sorrento Trigger Event. Upon the closing of the equity repurchase transaction pursuant to the Sorrento SPA, a Sorrento Trigger Event occurred. The disclosures below related to the foregoing provisions are based on the occurrence of such event. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Classified Board of Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that our Board are divided into three classes, with the classes as nearly equal in number as practical and each class serving three-year staggered terms. The directors in each class serve for a three-year term (except that the term of our current Class&#160;II directors shall expire at our 2024 annual meeting of stockholders (with three-year terms subsequently)), with one class being elected each year by the stockholders. This system of electing and removing directors may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of the Company, because it generally makes it more difficult for stockholders to replace a majority of the directors. See the section of this prospectus titled &#8220;<span style="font-style:italic">Management</span>&#8221; for more information on the classified board. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation also provides that the total number of directors shall be determined from time to time exclusively by our Board. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Removal of Directors; Vacancies </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that, except as otherwise required by law or the Certificate of Incorporation, directors may be removed only for cause and only by the affirmative vote of the holders of at least&#160;66 2/3% in voting power of all the then-outstanding shares of our capital stock entitled to vote thereon, voting together as a single class, in each case subject to the rights of holders of any series of Preferred Stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">246 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Certificate of Incorporation provides that, except as otherwise provided therein or by law, any vacancy resulting from the death, resignation, removal or disqualification of a director or other cause, or any newly created directorship in our Board, shall be filled only by a majority of the directors then in office, although less than a quorum, and shall not be filled by our stockholders, in each case subject to the rights of the holders of any series of Preferred Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions may have the effect of deferring, delaying, or discouraging hostile takeovers, changes in control of the Company or changes in our management. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Delaware Anti-Takeover Law </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that we are governed by Section&#160;203 of the DGCL. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;203 of the DGCL prohibits persons deemed to be &#8220;interested stockholders&#8221; from engaging in a &#8220;business combination&#8221; with a publicly held Delaware corporation for three years following the date such persons become interested stockholders, unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#8217;s voting stock. Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions that are not approved in advance by our Board, including discouraging attempts that might result in a premium over the market price for the shares of Common Stock held by stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that the restrictions on business combination of Section&#160;203 of the DGCL will not apply to Sorrento or its current or future Affiliates (as defined in the Certificate of Incorporation) regardless of the percentage of ownership of the total voting power of all the then-outstanding shares of our capital stock entitled to vote generally in the election of directors beneficially owned by them. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">No Cumulative Voting </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Delaware law, the right to vote cumulatively does not exist unless the certificate of incorporation specifically authorizes cumulative voting. The Certificate of Incorporation does not authorize cumulative voting. Therefore, stockholders holding a majority of the shares of our capital stock entitled to vote generally in the election of directors will be able to elect all of our directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Special Stockholder Meetings </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that special meetings of stockholders may only be called by order of the Chairperson of our Board, our Board or the Chief Executive Officer, subject to the rights of the holders of any series of Preferred Stock with respect to such series of preferred stock. The Bylaws prohibits the conduct of any business at a special meeting other than as specified in the notice for such meeting. These provisions may have the effect of deferring, delaying, or discouraging hostile takeovers or changes in control or management. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Director Nominations and Stockholder Proposals </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bylaws establishes advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of our Board or a committee of our Board. In order for any matter to be &#8220;properly brought&#8221; before a meeting, a stockholder will have to comply with advance notice requirements and provide us with certain information. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">247 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, to be timely, a stockholder&#8217;s notice must be delivered to our secretary at our principal executive offices not earlier than the close of business on the&#160;120th day nor later than the close of business on the&#160;90th day prior to the first anniversary of the preceding year&#8217;s annual meeting; provided, however, that, if the date of the annual meeting is advanced more than&#160;30&#160;days prior to or delayed by more than&#160;60&#160;days after the anniversary of the preceding year&#8217;s annual meeting, or if no annual meeting was held in the preceding year, notice by the stockholder to be timely must be so delivered not earlier than the close of business on the&#160;120th day prior to such annual meeting and not later than the close of business on the later of the&#160;90th day prior to such annual meeting and the&#160;10th day following the day on which public announcement of the date of such meeting is first made by us. The Bylaws also specifies requirements as to the form and content of a stockholder&#8217;s notice. The Bylaws allows any previously scheduled stockholders meeting to be postponed, adjourned or canceled by resolution of our Board; provided, however, that with respect to any special meeting of stockholders scheduled at the request of Sorrento, our Board is not allowed to postpone, reschedule or cancel without the prior written consent of Sorrento. In addition, the Bylaws allows the chair of a meeting of the stockholders to adopt rules and regulations for the conduct of that meeting that may have the effect of precluding the conduct of certain business at that meeting if the rules and regulations are not followed. These provisions may also defer, delay, or discourage a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to influence or obtain control. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stockholder Action by Written Consent </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&#160;228 of the DGCL and the terms of the Certificate of Incorporation, any action required or permitted to be taken by our stockholders must be effected by a duly called annual or special meeting of such stockholders, subject to the rights of the holders of any series of Preferred Stock with respect to such series of preferred stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Amendment of Certificate of Incorporation or Bylaws </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The DGCL provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation&#8217;s certificate of incorporation or bylaws, unless a corporation&#8217;s certificate of incorporation or bylaws, as the case may be, requires a greater percentage. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that the affirmative vote of the holders of at least&#160;66 2/3% of the voting power of the then-outstanding shares of our capital stock entitled to vote thereon, voting together as a single class, will be required to alter, amend or repeal the following provisions of the Certificate of Incorporation: Article V (Board of Directors), Article&#160;VI (Consent of Stockholders in Lieu of Meeting; Special Meetings of Stockholders), Article&#160;VII (Limitation of Liability), Article&#160;VIII (Corporate Opportunities and Competition), Article&#160;IX (Exclusive Forum), Article&#160;X (Section&#160;203 of the DGCL) and Article&#160;XI (Amendment of Certificate of Incorporation and Bylaws), and no other provision may be adopted, amended or repealed that would have the effect of modifying or permitting the circumvention of the provisions set forth in any of such Articles. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation and the Bylaws provide that, our Board is authorized to make, alter and repeal the Bylaws, without the consent or vote of the stockholders, by an approval of a majority of the total authorized number of directors. The affirmative vote of the holders of at least&#160;66 2/3% of the voting power of the then-outstanding shares of our capital stock entitled to vote thereon, voting together as a single class, will be required to alter, amend or repeal the Bylaws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of the DGCL, the Certificate of Incorporation and the Bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our Common Stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of our Board and our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">248 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Exclusive Forum </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom shall, to the fullest extent permitted by law, be the sole and exclusive forum for (i)&#160;any derivative action or proceeding brought on behalf of the Company, (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers, employees or stockholders to us or our stockholders, (iii)&#160;any action asserting a claim against us or any of our current or former directors, officers, employees or stockholders arising pursuant to any provision of the DGCL or of the Certificate of Incorporation or the Bylaws, (iv)&#160;any claim or cause of action seeking to interpret, apply, enforce or determine the validity of the Certificate of Incorporation or the Bylaws, (v)&#160;any action or proceeding asserting a claim against us or any of our current or former directors, officers, employees or stockholders as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware, or (vi)&#160;any action asserting an &#8220;internal corporate claim,&#8221; as that term is defined in Section&#160;115 of the DGCL. The foregoing exclusive forum provisions will not apply to claims arising under the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Certificate of Incorporation provides that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we believe these provisions benefit us by providing increased consistency in the application of applicable law in the types of lawsuits to which they apply, the provisions may have the effect of discouraging lawsuits against our directors and officers. The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings and there is uncertainty as to whether a court would enforce such provisions. In addition, investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. It is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in the Certificate of Incorporation to be inapplicable or unenforceable in such action. We may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, operating results and financial condition. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and consented to the forum provisions in the Certificate of Incorporation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Limitation of Liability and Indemnification of Directors and Officers </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation and the Bylaws contain provisions that limit the liability of our directors for monetary damages to the fullest extent permitted by the DGCL. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any breach of their duty of loyalty to us or our stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">unlawful payments of dividends or unlawful stock repurchases or redemptions in violation of the DGCL; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any transaction from which the director derived an improper personal benefit. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation also provides that if the DGCL is amended to permit further elimination or limitation of the personal liability of directors, then the liability of our directors will be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">249 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bylaws provide that we shall indemnify any person who is or was a director or officer of the Company or who is or was serving at our request as a director, officer or trustee of another corporation, limited liability company, partnership, joint venture, employee benefit plan, trust, nonprofit entity or other enterprise (a &#8220;Covered Person&#8221;) and who is or was a party to, is threatened to be made a party to, or is otherwise involved (including as a witness) in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative, or investigative based on such person&#8217;s actions in his or her official capacity as a director or officer of the Company or as a director, officer or trustee of another corporation, limited liability company, partnership, joint venture, employee benefit plan, trust, nonprofit entity or other enterprise (to the extent serving in such position at our request), in each case against all liability and loss suffered (including, without limitation, any judgments, fines, excise taxes or penalties arising under the Employee Retirement Income Security Act of&#160;1974 and amounts paid in settlement consented to in writing by us) and expenses (including attorneys&#8217; fees), actually and reasonably incurred by such person in connection therewith, subject to certain conditions. In addition, the Bylaws provide that we may, to the fullest extent permitted by law, (i)&#160;advance costs, fees or expenses (including attorneys&#8217; fees) incurred by a Covered Person defending or participating in any proceeding in advance of the final disposition of such proceeding, subject to certain exceptions, and (ii)&#160;purchase and maintain insurance, at our expense, to protect us and any person who is or was a director, officer, employee or agent of the Company or is or was a director, officer, employee or agent of the Company serving at our request as a director, officer, employee or agent of another corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise against any liability, expense or loss, whether or not we would have the power or obligation to indemnify such person against such liability, expense or loss under the DGCL or the provisions of the Bylaws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors, executive officers and certain other employees as determined by our Board. These agreements, among other things, require us to indemnify our directors and executive officers against liabilities that may arise by reason of their status or service. These indemnification agreements also require us to advance all expenses actually and reasonably incurred by the directors and executive officers in connection with any proceeding. Our Board believes that these agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above description of the indemnification provisions of the Certificate of Incorporation, the Bylaws and the indemnification agreements is not complete and is qualified in its entirety by reference to these documents, each of which is filed as an exhibit to the registration statement of which this prospectus is a part. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our <span style="white-space:nowrap">non-employee</span> directors may, through their relationships with their employers, be insured or indemnified against certain liabilities incurred in their capacity as members of our Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitation of liability and indemnification provisions in the Certificate of Incorporation and the Bylaws may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and our stockholders. In addition, a stockholder&#8217;s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors or executive officers, we have been informed that in the opinion of the SEC, such indemnification is against public policy and is therefore unenforceable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Conflicts of Interest </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Delaware law permits corporations to adopt provisions renouncing any interest or expectancy in certain opportunities that are presented to the corporation or its officers, directors or stockholders. The Certificate of Incorporation provides that, to the fullest extent permitted by law, no Identified Person (as defined therein) will have any duty to refrain from (i)&#160;engaging in a corporate opportunity in the same or similar business activities or lines of business in which we or our affiliates are engaged or that are deemed to be competing with us or any of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">250 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our affiliates or (ii)&#160;otherwise investing in or providing services to any person that is engaged in the same or similar business activities as we or our affiliates or competes with us or our affiliates. In addition, to the fullest extent permitted by law, no Identified Person will have any obligation to offer to us or our subsidiaries or affiliates the right to participate in any corporate opportunity in the same or similar business activities or lines of business in which we or our affiliates are engaged or that are deemed to be competing with us or any of our affiliates. Subject to the preceding sentences and to the fullest extent permitted by applicable law, neither we nor any of our subsidiaries shall have any rights in any business interests, activities or ventures of any Identified Person, and we waive and renounce any interest or expectancy therein, except with respect to opportunities offered solely and expressly to our officers in their capacity as such. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Rights of Appraisal and Payment </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the DGCL, with certain exceptions, our stockholders will have appraisal rights in connection with a merger or consolidation of the Company. Pursuant to Section&#160;262 of the DGCL, stockholders who properly demand and perfect appraisal rights in connection with such merger or consolidation will have the right to receive payment of the fair value of their shares as determined by the Delaware Court of Chancery. However, appraisal rights are not available in all circumstances. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Stockholders&#8217; Derivative Actions </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the DGCL, any of our stockholders may bring an action in the Company&#8217;s name to procure a judgment in its favor, also known as a derivative action, provided that the stockholder bringing the action is a holder of our capital stock at the time of the transaction to which the action relates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">SPAC Warrants </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March 15, 2024, there are 10,958,309 outstanding SPAC Warrants. The &#8220;SPAC Warrants&#8221; include (i) 6,854,309 redeemable warrants with an exercise price of $11.50 per share that were previously included in the units issued in connection with the initial public offering of Vickers Vantage Corp. I (our predecessor company) (the &#8220;Public Warrants&#8221; and (ii) 4,104,000 warrants with an exercise price of $11.50 per share that were initially sold in a private placement to the sponsors of Vickers Vantage Corp. I (the &#8220;Private Warrants&#8221;). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Public Warrants </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Public Warrant entitles the registered holder thereof to purchase one share of our Common Stock at a price of $11.50&#160;per share, subject to adjustment as described in this prospectus. We may, in our sole discretion, lower the warrant exercise price at any time prior to the expiration date for a period of not less than&#160;20 business days and any such reduction will be applied consistently to all of the warrants, provided that we will provide at least&#160;20&#160;days&#8217; prior written notice to registered holders of the warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, no Public Warrants will be exercisable for cash unless we have an effective and current registration statement covering the issuance of the Common Stock issuable upon exercise of the warrants and a current prospectus relating to such Common Stock. Notwithstanding the foregoing, if a registration statement covering the issuance of the Common Stock issuable upon exercise of the Public Warrants is not effective within&#160;90&#160;days from the consummation of the Business Combination, warrantholders may, from the&#160;91st day after the consummation of the Business Combination until such time as there is an effective registration statement and during any period when we shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act. If an exemption from registration is not available, holders will not be able to exercise their warrants on a cashless basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrants will expire five years from the consummation of the Business Combination (i.e., November&#160;10, 2027) at&#160;5:00 p.m., New York City time or earlier upon redemption or liquidation. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">251 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may call the warrants for redemption (excluding the Private Warrants), in whole and not in part, at a price of $0.01&#160;per warrant: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">at any time while the warrants are exercisable, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">upon not less than&#160;30&#160;days&#8217; prior written notice of redemption to each warrantholder, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if, and only if, the closing price of the Common Stock equals or exceeds $18.00&#160;per share (as adjusted for share <span style="white-space:nowrap">sub-divisions,</span> share dividends, reorganizations and recapitalizations), for any&#160;20 trading days within a&#160;30 trading day period commencing after the warrants become exercisable and ending on the third trading day prior to the date on which notice of redemption is given, and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if, and only if, there is an effective registration statement covering the Common Stock issuable upon exercise of the Public Warrants, and a current prospectus relating thereto, available throughout <span style="white-space:nowrap">the&#160;30-day</span> redemption. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not exercise such redemption right if the issuance of the Common Stock upon exercise of the warrants is not exempt from registration or qualification under applicable state blue sky laws or we are unable to effect such registration or qualification. The right to exercise will be forfeited unless the warrants are exercised prior to the date specified in the notice of redemption. On and after the redemption date, a record holder of a warrant will have no further rights except to receive the redemption price for such holder&#8217;s warrant upon surrender of such warrant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The redemption criteria for our warrants have been established at a price which is intended to provide warrantholders a reasonable premium to the initial exercise price and provide a sufficient differential between the then-prevailing per share price of our Common Stock and the warrant exercise price so that if the per share price of our Common Stock declines as a result of our redemption call, the redemption will not cause the per share price of our Common Stock to drop below the exercise price of the warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we call the warrants for redemption as described above, our management will have the option to require all holders of warrants to exercise their warrants on a &#8220;cashless basis.&#8221; In such event, each holder would pay the exercise price by surrendering the warrants for that number of shares of Common Stock equal to the quotient obtained by dividing (x)&#160;the product of the number of shares of Common Stock underlying the warrants, multiplied by the difference between the exercise price of the warrants and the fair market value by (y)&#160;the fair market value. The &#8220;fair market value&#8221; for this purpose shall mean the average reported closing price of the shares of our Common Stock for the&#160;10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants. For example, if a holder held&#160;150 warrants to purchase&#160;150 shares of our Common Stock and the fair market value on the trading date prior to exercise was $15.00, that holder would receive&#160;35 shares of our Common Stock without the payment of any additional cash consideration. Whether we will exercise our option to require all holders to exercise their warrants on a &#8220;cashless basis&#8221; will depend on a variety of factors including the price of our Common Stock at the time the warrants are called for redemption, our cash needs at such time and concerns regarding dilutive share issuances. Requiring a cashless exercise in this manner will reduce the number of shares of our Common Stock to be issued and thereby lessen the dilutive effect of a warrant redemption. We believe this feature is an attractive option to use if we do not need the cash from the exercise of the Public Warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrants are issued in registered form under a warrant agreement (the &#8220;Warrant Agreement&#8221;) between Continental, as warrant agent, and us. The Warrant Agreement provides that the terms of the warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision, but requires the approval, by written consent or vote, of the registered holders of a majority of the then-outstanding warrants (including the Private Warrants) in order to make any change that adversely affects the interests of the registered holders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exercise price and number of shares of Common Stock issuable on exercise of the warrants may be adjusted in certain circumstances including in the event of (i)&#160;a stock dividend or split up, (ii)&#160;a consolidation, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">252 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
combination, reverse stock split or reclassification of the Common Stock, (iii)&#160;extraordinary dividend or (iv)&#160;reclassification or reorganization of the outstanding Common Stock or an merger or consolidation of us with or into another corporation. However, the warrants will not be adjusted for issuances of shares of Common Stock at a price below the par value per share issuable upon exercise of the warrants. Whenever the number of shares of Common Stock purchasable upon the exercise of the warrants is adjusted, the warrant exercise price will be adjusted by multiplying such warrant exercise price immediately prior to such adjustment by a fraction (x)&#160;the numerator of which will be the number of shares of Common Stock purchasable upon the exercise of the warrants immediately prior to such adjustment, and (y)&#160;the denominator of which will be the number of shares of Common Stock so purchasable immediately thereafter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price (or on a cashless basis, if applicable), by certified check or bank draft payable to the order of the warrant agent or wire transfer, for the number of warrants being exercised. The warrantholders do not have the rights or privileges of holders of shares of Common Stock and any voting rights until they exercise their warrants and receive shares of Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the issuance of shares of Common Stock upon exercise of the warrants, each holder will be entitled to one vote for each share of Common Stock held of record on all matters to be voted on by stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described above, no Public Warrants will be exercisable for cash and we will not be obligated to issue shares of Common Stock upon exercise of a warrant unless the shares of Common Stock issuable upon such warrant exercise have been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. Under the terms of the Warrant Agreement, we have agreed to use our best efforts to meet these conditions and to maintain a current prospectus relating to the Common Stock issuable upon exercise of the warrants until the expiration of the warrants. However, we cannot assure you that we will be able to do so and, if we do not maintain a current prospectus relating to the Common Stock issuable upon exercise of the warrants, holders will be unable to exercise their warrants and we will not be required to settle any such warrant exercise. If the prospectus relating to the Common Stock issuable upon the exercise of the warrants is not current or if the Common Stock is not qualified or exempt from qualification in the jurisdictions in which the holders of the warrants reside, we will not be required to net cash settle or cash settle the warrant exercise, the warrants may have no value, the market for the warrants may be limited and the warrants may expire worthless. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Warrantholders may elect to be subject to a restriction on the exercise of their warrants such that an electing warrantholder would not be able to exercise their warrants to the extent that, after giving effect to such exercise, such holder (together with such holder&#8217;s affiliates) would beneficially own in excess of&#160;9.8% of the Common Stock outstanding immediately after giving effect to such exercise. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No fractional shares will be issued upon exercise of the warrants. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest in a share, we will, upon exercise, round up to the nearest whole number of shares of Common Stock to be issued to the warrantholder. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Private Warrants </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Private Warrants are identical to the Public Warrants except that such Private Warrants are exercisable for cash (even if a registration statement covering the issuance of the Common Stock issuable upon exercise of such warrants is not effective) or on a cashless basis, at the holder&#8217;s option, and will not be redeemable by us, in each case so long as they are still held by the initial purchasers or their affiliates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary of the terms and conditions of the warrants does not purport to be complete and is qualified in its entirety by reference to the copy of the specimen warrant certificate and the Warrant Agreement that are filed as an exhibit to the registration statement of which this prospectus forms a part. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">253 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Penny Warrants </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the transactions contemplated by the Securities Purchase Agreement, dated September&#160;21, 2023, between us and Oramed Pharmaceuticals Inc. (&#8220;Oramed&#8221; and such Securities Purchase Agreement, the &#8220;Scilex-Oramed SPA&#8221;), we issued warrants to purchase Common Stock, having an exercise price of $0.01 per share, subject to adjustment as provided therein (such warrants, the &#8220;Penny Warrants&#8221;), to Oramed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrant to purchase up to an aggregate of 4,500,000 shares of our Common Stock, with an exercise price of $0.01 per share, which we issued to Oramed pursuant to the Scilex-Oramed SPA (the &#8220;Closing Penny Warrant&#8221;), will be exercisable upon the earliest of (i)&#160;March&#160;14, 2025, (ii) the date on which the senior secured promissory note due 18 months from the date of issuance in the principal amount of $101,875,000 issued by us to Oramed pursuant to the Scilex-Oramed SPA (the &#8220;Oramed Note&#8221;) has been repaid in full and (iii)&#160;the Management Sale Trigger Date (as defined therein), if any, and will expire on the date that is the fifth anniversary of the issuance date. For purposes of the Penny Warrants, the Management Sale Trigger Date is generally the first date on which either Dr.&#160;Henry Ji, our Executive Chairperson, or Mr.&#160;Jaisim Shah, our Chief Executive Officer and President and a member of the Board, engages in certain sales or other similar transfers of shares of Common Stock or other of our or any of our subsidiaries&#8217; securities, subject to certain exceptions as are customary for <span style="white-space:nowrap">lock-up</span> agreements executed by directors and officers in connection with financings or similar transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Scilex-Oramed SPA, we issued to Oramed four warrants (each a &#8220;Subsequent Penny Warrant&#8221;) to purchase up to an aggregate of 8,500,000 shares of our Common Stock, each with an exercise price of $0.01 per share, each for 2,125,000 shares of Common Stock, one of which shall vest and become exercisable on the date that is the later of (i)&#160;each of March&#160;19, 2024, June&#160;17, 2024, September&#160;15, 2024 or December&#160;14, 2024 (the &#8220;Subsequent Penny Warrant Vesting Date&#8221;) and (ii)&#160;the earliest of (A)&#160;March&#160;14, 2025, (B) the date on which the Oramed Note has been repaid in full and (C)&#160;the Management Sale Trigger Date (as defined therein), if any. Each Subsequent Penny Warrant will expire on the date that is the fifth anniversary of the issuance date; provided that, if the Oramed Note is repaid in full prior to the Subsequent Penny Warrant Vesting Date applicable to such Subsequent Penny Warrant, such Subsequent Penny Warrant will expire on the date the Oramed Note is repaid in full. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exercise price of the Closing Penny Warrant issued to Oramed pursuant to the Scilex-Oramed SPA is $0.01 per share, subject to adjustment as provided therein. The exercise price and number of shares of Common Stock issuable upon the exercise of the Penny Warrants will be subject to adjustment in the event of any stock dividend, stock split, recapitalization, reorganization or similar transaction, as described in the Penny Warrants; provided that there shall not be any adjustment to the exercise price of the Penny Warrants in the event we combine (by combination, reverse stock split or otherwise) our Common Stock into a smaller number of shares. Oramed may exercise the Penny Warrants by means of a &#8220;cashless exercise.&#8221; The Closing Penny Warrant and the Subsequent Penny Warrants utilize the same form of warrant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Penny Warrants may not be exercised if Oramed, together with its affiliates, would beneficially own in excess of 9.9% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise (the &#8220;Oramed Beneficial Ownership Limitation&#8221;); provided, however, that upon 61 days&#8217; prior notice to us, Oramed may increase or decrease the Oramed Beneficial Ownership Limitation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary of the terms and conditions of the Penny Warrants does not purport to be complete and is qualified in its entirety by reference to the copy of the form of Penny Warrants that is filed as an exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Transfer Agent and Registrar </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our Common Stock is Continental. The transfer agent&#8217;s address is&#160;1 State Street, 30th Floor, New York, New York&#160;10004. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">254 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Listing </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of our Common Stock and Public Warrants are listed on the Nasdaq Capital Market under the symbols &#8220;SCLX&#8221; and &#8220;SCLXW&#8221; respectively. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">255 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx759370_21">LEGAL MATTERS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the securities being offered by this prospectus will be passed upon for us by Paul Hastings LLP, Palo Alto, California. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx759370_22">EXPERTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Scilex Holding Company at December&#160;31, 2023 and&#160;2022, and for each of the three years in the period ended December&#160;31, 2023, appearing in this prospectus, have been audited by Ernst&#160;&amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon (which contains an explanatory paragraph describing conditions that raise substantial doubt about the Company&#8217;s ability to continue as a going concern as described in Note&#160;2 to the consolidated financial statements) appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx759370_23">WHERE YOU CAN FIND MORE INFORMATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed a registration statement on <span style="white-space:nowrap">Form&#160;S-1,</span> including exhibits, under the Securities Act, with respect to the securities offered by this prospectus. This prospectus does not contain all of the information included in the registration statement. For further information pertaining to us and our securities, you should refer to the registration statement of which this prospects is a part and the exhibits to such registration statement. The descriptions in this prospectus of the provisions of documents filed as exhibits to this prospectus are only summaries of those documents&#8217; material terms. You can read copies of such documents, along with copies of reports, proxy statements and other information filed by us with the SEC at the SEC&#8217;s website at <span style="font-style:italic">http://www.sec.gov</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also maintain a website at www.scilexholding.com. Through our website, we make available, free of charge, annual, quarterly and current reports, proxy statements and other information as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained on, or that may be accessed through, our website is not part of, and is not incorporated into, this prospectus and the inclusion of our website address in this prospectus is an inactive textual reference only. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">256 </p>

</div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>
<div style="display: none"><ix:header><ix:hidden><ix:nonNumeric name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="hidden107552736" contextRef="PAsOn12_31_2023">http://fasb.org/us-gaap/2023#DerivativeLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="hidden107552737" contextRef="PAsOn12_31_2022">http://fasb.org/us-gaap/2023#DerivativeLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric name="us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="hidden107553186" contextRef="PAsOn12_31_2023">http://fasb.org/us-gaap/2023#DerivativeLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric name="us-gaap:ServicingLiabilityAtFairValueOtherChangeInFairValueStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="hidden107552752" contextRef="P01_01_2023To12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis">http://fasb.org/us-gaap/2023#OperatingCostsAndExpenses</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="sclx-20231231.xsd"/></ix:references></ix:header></div><div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="index"><div id="tx759370_24" style="display:inline;"></div>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:96%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><a href="#del_fin741235_1">Report of Independent Registered Public Accounting Firm (PCAOB ID: 42)</a></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-2</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><a href="#del_fin741235_2">Consolidated Balance Sheets as of December&#160;31, 2023 and 2022</a></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-3</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><a href="#del_fin741235_3">Consolidated Statements of Operations for the Years ended December&#160;31, 2023, 2022 and 2021</a></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-4</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><a href="#del_fin741235_4">Consolidated Statements of Stockholders&#8217; (Deficit) / Equity for the Years ended December&#160;31, 2023, 2022 and 2021</a></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-5</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><a href="#del_fin741235_5">Consolidated Statements of Cash Flows for the Years ended December&#160;31, 2023, 2022 and 2021</a></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-6</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><a href="#del_fin741235_6">Notes to Consolidated Financial Statements</a></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-7</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-1 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="del_fin741235_1" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Report of Independent Registered Public Accounting Firm </div></div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the stockholders and the Board of Directors of </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scilex Holding Company </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Opinion on the Financial Statements </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying consolidated balance sheets of Scilex Holding Company (the Company) as of December&#160;31, 2023 and 2022, the related consolidated statements of operations, stockholders&#8217; (deficit)/equity and cash flows for each of the three years in the period ended December&#160;31, 2023, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2023, in conformity with U.S. generally accepted accounting principles. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">The Company&#8217;s Ability to Continue as a Going Concern </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has negative working capital, has suffered losses from operations, has recurring negative cash flows from operations, and has stated that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. Management&#8217;s evaluation of the events and conditions and management&#8217;s plans regarding these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Basis for Opinion </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst&#160;&amp; Young LLP </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#8217;s auditor since 2020. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&#160;11, 2024 </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-2 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">PART I&#8212;FINANCIAL INFORMATION </div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Item&#8201;1. Financial Statements </div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SCILEX HOLDING COMPANY </div></div><div id="del_fin741235_2" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">CONSOLIDATED BALANCE SHEETS </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(In thousands, except for par value and share amounts) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:77%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">ASSETS</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Current assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-25998">3,921</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-25999">2,184</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts receivable, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26000">34,597</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26001">21,236</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Inventory</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26002">4,214</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26003">1,378</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses and other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26004">4,049</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26005">4,810</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total current assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26006">46,781</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26007">29,608</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26008">722</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26009">772</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26010">2,943</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26011">1,131</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Intangibles, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26012">36,485</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26013">40,591</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Goodwill</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26014">13,481</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26015">13,481</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other long-term assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26016">897</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26017">944</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26018">101,309</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26019">86,527</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">LIABILITIES AND STOCKHOLDERS&#8217; (DEFICIT) EQUITY</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Current liabilities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26020">40,954</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26021">8,450</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued payroll</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26022">2,681</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26023">1,354</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued rebates and fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26024">89,658</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26025">30,893</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:AccruedExpenses" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26026">7,408</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:AccruedExpenses" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26027">3,136</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current portion of deferred consideration</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:CurrentPortionOfDeferredConsideration" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26028">491</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:CurrentPortionOfDeferredConsideration" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26029">264</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Debt, current</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26030">108,429</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26031">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current portion of operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26032">759</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26033">745</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total current liabilities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26034">250,380</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26035">44,842</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term portion of deferred consideration</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:LongTermPortionOfDeferredConsideration" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26036">2,895</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:LongTermPortionOfDeferredConsideration" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26037">3,387</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Debt, net of issuance costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherLongTermDebtNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26038">17,038</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherLongTermDebtNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26039">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Derivative liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26040">1,518</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26041">1,231</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26042">2,237</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26043">665</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other long-term liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26044">179</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26045">163</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total liabilities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26046">274,247</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26047">50,288</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Commitments and contingencies (See Note 11)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" xsi:nil="true" id="ixv-26048"/></td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" xsi:nil="true" id="ixv-26049"/></td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Stockholders&#8217; (deficit) equity:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Preferred stock, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-26050"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-26051">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-26052"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-26053">45,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-26054"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-26055"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-26056"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-26057">29,057,097</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2023 and December&#160;31, 2022, respectively</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26058">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26059">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-26060"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-26061">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-26062"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-26063">740,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-26064">160,084,250</ix:nonFraction> shares issued and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-26065">100,015,665</ix:nonFraction> shares outstanding as of December&#160;31, 2023; <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-26066"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-26067">141,348,856</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26068">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26069">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26070">407,813</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26071">412,136</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated deficit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26072">490,245</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26073">375,914</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Treasury stock, at cost; <ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-26074">60,068,585</ix:nonFraction> shares and <ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-26075">nil</ix:nonFraction> shares as of December&#160;31, 2023 and December&#160;31, 2022, respectively</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26076">90,522</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26077">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stockholders&#8217; (deficit) equity</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26078">172,938</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26079">36,239</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total liabilities and stockholders&#8217; (deficit) equity</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26080">101,309</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26081">86,527</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to audited consolidated financial statements </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-3 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SCILEX HOLDING COMPANY </div></div><div id="del_fin741235_3" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">CONSOLIDATED STATEMENTS OF OPERATIONS </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(In thousands, except for net loss per share amounts) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:72%"/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net revenue</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26082">46,743</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26083">38,034</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26084">31,317</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Operating costs and expenses:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cost of revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26085">15,681</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26086">10,797</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26087">3,634</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26088">12,746</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26089">9,054</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26090">9,201</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Selling, general and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26091">119,641</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26092">64,895</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26093">50,582</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Intangible amortization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26094">4,106</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26095">3,922</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26096">3,738</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total operating costs and expenses</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26097">152,174</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26098">88,668</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26099">67,155</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Loss from operations</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26100">105,431</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26101">50,634</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26102">35,838</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Other (income) expense:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss (gain) on derivative liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26103">512</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26104">8,310</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26105">300</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of debt and liability instruments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ChangeInFairValueOfDebtAndLiabilityInstruments" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26106">7,189</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ChangeInFairValueOfDebtAndLiabilityInstruments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26107">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ChangeInFairValueOfDebtAndLiabilityInstruments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26108">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">(Gain) loss on debt extinguishment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26109">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26110">28,634</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26111">12,463</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Scilex Pharma Notes principal increase</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:NotesPrincipalIncrease" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26112">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8194;<ix:nonFraction name="sclx:NotesPrincipalIncrease" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26113">&#8212;</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:NotesPrincipalIncrease" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26114">28,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest expense, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26115">1,068</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26116">9,604</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26117">11,764</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss on foreign currency exchange</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26118">118</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26119">66</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26120">54</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total other (income) expense</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26121">8,887</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26122">27,274</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26123">52,581</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Loss before income taxes</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26124">114,318</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26125">23,360</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26126">88,419</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26127">13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26128">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26129">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net loss</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26130">114,331</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26131">23,364</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26132">88,424</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per share attributable to common stockholders &#8212; basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-26133"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-26134">1.28</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-26135"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-26136">0.17</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-26137"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-26138">0.67</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average number of shares during the period &#8212; basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26139"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26140">130,298</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26141"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26142">134,226</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26143"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26144">132,858</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to audited consolidated financial statements </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-4 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SCILEX HOLDING COMPANY </div></div><div id="del_fin741235_4" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; (DEFICIT) / EQUITY </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(In thousands) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:42%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Preferred Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div><br/> Capital</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Treasury Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stockholders&#8217;</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Deficit)<br/> Equity</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance, December&#160;31, 2020</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26145">132,858</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26146">13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26147">122,430</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26148">264,126</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26149">141,683</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26150">5,822</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26151">5,822</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Adjustment to shares issued in Semnur Acquisition</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:AdjustmentToSharesIssuedInSemnurAcquisitionValue" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26152">409</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:AdjustmentToSharesIssuedInSemnurAcquisitionValue" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26153">409</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26154">88,424</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26155">88,424</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance, December&#160;31, 2021</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26156">132,858</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26157">13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26158">128,661</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26159">352,550</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26160">223,876</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock options exercised</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26161">202</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26162">96</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26163">96</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Aardvark <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> license transfer from Sorrento, net of discount</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="sclx:AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26164">4,127</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="sclx:AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26165">4,127</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Aardvark <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> discount amortization</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="sclx:Adjustmenttoadditionalpaidincapitaldiscountamortization" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26166">35</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="sclx:Adjustmenttoadditionalpaidincapitaldiscountamortization" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26167">35</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares issued pursuant to the terms of the Debt Exchange Agreement</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="P01_01_2022To12_31_2022_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26168">29,057</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="P01_01_2022To12_31_2022_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26169">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26170">2,906</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26171">289,730</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26172">289,733</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares issued as a result of the Business Combination, net of transaction activities</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26173">5,133</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26174">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26175">8,707</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26176">8,706</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares issued to Yorkville pursuant to Yorkville Purchase Agreement</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares" contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26177">250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26178">1,238</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26179">1,238</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26180">5,280</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26181">5,280</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26182">23,364</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26183">23,364</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance, December&#160;31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2022_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26184">29,057</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26185">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26186">141,349</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26187">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26188">412,136</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26189">375,914</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26190">36,239</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares issued under Standby Equity Purchase Agreements</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:SharesIssuedUnderStandbyEquityPurchaseAgreements" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26191">13,218</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ValueIssuedUnderStandbyEquityPurchaseAgreements" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26192">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ValueIssuedUnderStandbyEquityPurchaseAgreements" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26193">34,256</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ValueIssuedUnderStandbyEquityPurchaseAgreements" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26194">34,257</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Disbursement of funds to Sorrento</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="sclx:DisbursementOfFundsToSorrentoAmount" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26195">20,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="sclx:DisbursementOfFundsToSorrentoAmount" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26196">20,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repurchase of Treasury Stock, Preferred Stock, and warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="sclx:StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue" contextRef="P01_01_2023To12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26197">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="sclx:StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26198">53,196</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="sclx:StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares" contextRef="P01_01_2023To12_31_2023_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26199">60,069</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="sclx:StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue" contextRef="P01_01_2023To12_31_2023_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26200">90,522</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="sclx:StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26201">143,721</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Penny Warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:IssuanceOfPennyWarrants" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26202">10,401</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:IssuanceOfPennyWarrants" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26203">10,401</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock in connection with Settlement Agreement</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26204">475</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26205">750</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26206">750</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Conversion of Convertible Debentures into common stock</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ConversionOfConvertibleDebenturesIntoCommonStockShares" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26207">632</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ConversionOfConvertibleDebenturesIntoCommonStockValue" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26208">7,735</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ConversionOfConvertibleDebenturesIntoCommonStockValue" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26209">7,735</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Retainer shares issued</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:RetainerSharesIssued" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26210">4,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:RetainerSharesIssuedValue" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26211">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:RetainerSharesIssuedValue" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26212">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:RetainerSharesIssuedValue" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26213">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock upon warrants exercise</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:IssuanceOfCommonStockUponWarrantsExerciseShares" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26214">45</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:IssuanceOfCommonStockUponWarrantsExerciseValue" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26215">521</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:IssuanceOfCommonStockUponWarrantsExerciseValue" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26216">521</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock options exercised</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26217">365</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26218">614</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26219">614</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26220">14,596</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26221">14,596</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26222">114,331</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26223">114,331</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance, December&#160;31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal" id="ixv-26224">29,057</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26225">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26226">160,084</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26227">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26228">407,813</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26229">490,245</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2023_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26230">60,069</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2023_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26231">90,522</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26232">172,938</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to audited consolidated financial statements </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-5 </div></div></div></div><div></div></div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SCILEX HOLDING COMPANY </div></div><div id="del_fin741235_5" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">CONSOLIDATED STATEMENTS OF CASH FLOWS </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(In thousands) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:78%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Operating activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26233">114,331</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26234">23,364</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26235">88,424</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Adjustments to reconcile net loss to net cash used for operating activities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation and amortization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26236">4,146</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26237">3,961</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26238">3,779</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Amortization of debt issuance costs and debt discount</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26239">65</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26240">3,142</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26241">7,909</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Scilex Pharma Notes principal increase</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:NotesPrincipalIncrease" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26242">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:NotesPrincipalIncrease" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26243">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:NotesPrincipalIncrease" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26244">28,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt discount</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26245">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="sclx:PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26246">21,190</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="sclx:PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26247">12,487</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">(Gain) loss on debt extinguishment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26248">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26249">28,634</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26250">12,463</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> operating lease cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:NonCashOperatingLeaseCost" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26251">507</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:NonCashOperatingLeaseCost" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26252">492</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:NonCashOperatingLeaseCost" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26253">372</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26254">14,596</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26255">5,280</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26256">5,822</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of shares under Settlement Agreement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromInsuranceSettlementOperatingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26257">750</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromInsuranceSettlementOperatingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26258">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromInsuranceSettlementOperatingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26259">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss (gain) on derivative liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26260">512</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26261">8,310</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26262">300</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeitures of private warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ForfeituresOfPrivateWarrants" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26263">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ForfeituresOfPrivateWarrants" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26264">1,697</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ForfeituresOfPrivateWarrants" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26265">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of debt and liability instruments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ChangeInFairValueOfDebtAndLiabilityInstruments" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26266">7,189</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ChangeInFairValueOfDebtAndLiabilityInstruments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26267">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ChangeInFairValueOfDebtAndLiabilityInstruments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26268">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherOperatingActivitiesCashFlowStatement" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26269">57</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherOperatingActivitiesCashFlowStatement" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26270">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherOperatingActivitiesCashFlowStatement" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26271">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in operating assets and liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts receivables, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26272">13,361</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26273">6,968</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26274">1,142</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Inventory</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26275">2,838</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26276">1,184</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26277">1,417</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses and other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26278">441</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26279">2,629</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26280">1,479</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other long-term assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26281">855</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26282">350</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26283">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26284">19,880</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26285">2,806</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26286">3,836</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued payroll</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:IncreaseDecreaseInAccruedPayroll" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26287">1,327</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="sclx:IncreaseDecreaseInAccruedPayroll" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26288">2,379</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="sclx:IncreaseDecreaseInAccruedPayroll" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26289">21</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26290">2,310</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26291">123</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26292">664</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued rebates and fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:IncreaseDecreaseInAccruedRebatesAndFees" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26293">58,765</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:IncreaseDecreaseInAccruedRebatesAndFees" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26294">23,531</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="sclx:IncreaseDecreaseInAccruedRebatesAndFees" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26295">255</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26296">711</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26297">392</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26298">80</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Related party payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInNotesPayableRelatedPartiesCurrent" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26299">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInNotesPayableRelatedPartiesCurrent" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26300">30,125</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInNotesPayableRelatedPartiesCurrent" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26301">18,210</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other long-term liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:OtherLongTermLiabilities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26302">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:OtherLongTermLiabilities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26303">163</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:OtherLongTermLiabilities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26304">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net cash used for operating activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26305">20,707</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26306">21,258</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26307">28,664</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Investing activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquisition consideration paid in cash for Romeg intangible asset acquisition</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="sclx:AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26308">300</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="sclx:AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26309">2,060</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26310">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchase of property and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26311">30</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26312">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26313">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net cash used for investing activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26314">330</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26315">2,067</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26316">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Financing activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from issuance of shares under Standby Equity Purchase Agreements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26317">35,458</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26318">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26319">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from issuance of Convertible Debentures</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26320">24,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26321">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26322">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayment of Convertible Debentures</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26323">15,625</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26324">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26325">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from issuance of Revolving Facility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ProceedsFromIssuanceOfRevolvingFacility" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26326">86,354</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ProceedsFromIssuanceOfRevolvingFacility" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26327">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ProceedsFromIssuanceOfRevolvingFacility" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26328">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayment of Revolving Facility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="sclx:RepaymentOfRevolvingFacility" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26329">69,001</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:RepaymentOfRevolvingFacility" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26330">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:RepaymentOfRevolvingFacility" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26331">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayment of Oramed Note</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarlyRepaymentOfSeniorDebt" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26332">5,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EarlyRepaymentOfSeniorDebt" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26333">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EarlyRepaymentOfSeniorDebt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26334">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transaction costs paid related to the Business Combination</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="sclx:TransactionCostsPaidRelatedToTheRecapitalizationTransaction" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26335">1,372</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="sclx:TransactionCostsPaidRelatedToTheRecapitalizationTransaction" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26336">2,949</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:TransactionCostsPaidRelatedToTheRecapitalizationTransaction" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26337">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Payments of debt issuance costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26338">380</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26339">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26340">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Disbursement of funds to Sorrento</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="sclx:DisbursementOfFunds" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26341">20,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:DisbursementOfFunds" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26342">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:DisbursementOfFunds" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26343">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash consideration paid in connection with share repurchase</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AcceleratedShareRepurchasesAdjustmentToRecordedAmount" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26344">10,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AcceleratedShareRepurchasesAdjustmentToRecordedAmount" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26345">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AcceleratedShareRepurchasesAdjustmentToRecordedAmount" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26346">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transaction costs paid in connection with share repurchase</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="sclx:TransactionCostsPaidInConnectionWithShareRepurchase" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26347">1,987</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:TransactionCostsPaidInConnectionWithShareRepurchase" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26348">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:TransactionCostsPaidInConnectionWithShareRepurchase" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26349">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from the Business Combination</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ProceedsFromTheBusinessCombination" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26350">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ProceedsFromTheBusinessCombination" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26351">3,375</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ProceedsFromTheBusinessCombination" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26352">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from stock options and warrants exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26353">1,135</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26354">96</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26355">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from related party payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26356">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26357">51,900</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26358">47,850</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from related party note payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSecuredNotesPayable" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26359">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSecuredNotesPayable" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26360">62,500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSecuredNotesPayable" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26361">14,700</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from other loans</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromOtherShortTermDebt" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26362">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromOtherShortTermDebt" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26363">9,857</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromOtherShortTermDebt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26364">47,832</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayment of principal on the Scilex Pharma Notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:RepaymentOfPrincipalOnTheScilexPharmaNotes" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26365">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="sclx:RepaymentOfPrincipalOnTheScilexPharmaNotes" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26366">84,808</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="sclx:RepaymentOfPrincipalOnTheScilexPharmaNotes" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26367">33,387</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayment on other loans</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ProceedsFromRepaymentOfLoansToPurchase" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26368">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="sclx:ProceedsFromRepaymentOfLoansToPurchase" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26369">18,800</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="sclx:ProceedsFromRepaymentOfLoansToPurchase" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26370">48,832</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net cash proceeds from financing activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26371">23,582</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26372">21,171</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26373">28,163</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net change in cash, cash equivalents and restricted cash</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26374">2,545</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26375">2,154</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26376">501</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash, cash equivalents and restricted cash at beginning of period</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26377">2,184</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26378">4,338</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26379">4,839</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash, cash equivalents and restricted cash at end of period</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26380">4,729</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26381">2,184</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26382">4,338</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Supplemental disclosure:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash paid for interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InterestIncomeOperatingPaidInCash" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26383">1,426</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InterestIncomeOperatingPaidInCash" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26384">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InterestIncomeOperatingPaidInCash" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26385">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> investing and financing activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of shares to B. Riley pursuant to B. Riley Purchase Agreement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26386">1,869</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26387">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26388">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Conversion of Convertible Debentures into common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ConversionOfConvertibleDebenturesIntoCommonStock" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26389">7,735</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ConversionOfConvertibleDebenturesIntoCommonStock" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26390">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ConversionOfConvertibleDebenturesIntoCommonStock" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26391">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets obtained in exchange for operating lease liabilities with lease modification</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26392">2,523</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26393">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26394">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Oramed Note issuance at fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:OramedNoteIssuanceAtFairValue" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26395">106,252</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:OramedNoteIssuanceAtFairValue" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26396">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:OramedNoteIssuanceAtFairValue" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26397">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> consideration in connection with share repurchase</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:OtherNonCashConsiderationInConnectionWithShareRepurchase" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26398">26,154</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:OtherNonCashConsiderationInConnectionWithShareRepurchase" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26399">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:OtherNonCashConsiderationInConnectionWithShareRepurchase" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26400">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Excise tax in connection with share repurchase included in accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26401">1,310</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26402">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26403">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Related party debt converted to equity pursuant to Debt Exchange Agreement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26404">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26405">289,733</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26406">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred consideration for Romeg intangible asset acquisition</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:DeferredConsiderationForRomegIntangibleAssetAcquisition" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26407">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:DeferredConsiderationForRomegIntangibleAssetAcquisition" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26408">3,650</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:DeferredConsiderationForRomegIntangibleAssetAcquisition" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26409">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Promissory Note issued to Sorrento in exchange for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> license</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26410">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26411">4,162</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26412">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value adjustment to derivative liability in troubled debt restructuring</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26413">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26414">30,400</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26415">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Scilex Pharma Notes principal increase</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ScilexPharmaNotesPrincipalIncrease" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26416">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ScilexPharmaNotesPrincipalIncrease" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26417">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ScilexPharmaNotesPrincipalIncrease" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26418">28,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transaction costs obligation assumed by Sorrento</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:TransactionCostsObligationAssumedBySorrento" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26419">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:TransactionCostsObligationAssumedBySorrento" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26420">5,148</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:TransactionCostsObligationAssumedBySorrento" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26421">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to audited consolidated financial statements </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-6 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="del_fin741235_6" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SCILEX HOLDING COMPANY </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </div></div><ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_107552589" id="ixv-17768"><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">1. Nature of Operations and Basis of Presentation </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Organization and Principal Activities </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scilex Holding Company (&#8220;Scilex&#8221; and together with its wholly owned subsidiaries, the &#8220;Company&#8221;) is the successor entity to Vickers Vantage Corp. I (&#8220;Vickers&#8221;), a special purpose acquisition company. The Company is an innovative revenue-generating company focused on acquiring, developing and commercializing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-opioid</div> pain management products for the treatment of acute and chronic pain. The Company was originally formed in 2019 and currently has five wholly owned subsidiaries, Scilex Inc. (&#8220;Legacy Scilex&#8221;), Scilex Pharmaceuticals Inc. (&#8220;Scilex Pharma&#8221;), Semnur Pharmaceuticals, Inc. (&#8220;Semnur&#8221;), SCLX DRE Holdings LLC and SCLX Stock Acquisition JV LLC. The business combination with Vickers (the &#8220;Business Combination&#8221;) was closed in November 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company launched its first commercial product in October 2018, ZTlido (lidocaine topical system) 1.8% (&#8220;ZTlido&#8221;), a prescription lidocaine topical system that is designed with novel technology to address the limitations of current prescription lidocaine therapies by providing significantly improved adhesion and continuous pain relief throughout the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-hour</div> administration period. The Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> the exclusive right to commercialize GLOPERBA (colchicine USP) oral solution (&#8220;GLOPERBA&#8221;), a U.S. Food and Drug Administration (&#8220;FDA&#8221;)-approved prophylactic treatment for painful gout flares in adults, in the United States (&#8220;U.S.&#8221;). In February 2023, the Company acquired the rights related to ELYXYB (celecoxib oral solution) (&#8220;ELYXYB&#8221;) and the commercialization thereof in the U.S. and Canada. ELYXYB is a first-line treatment and the only <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ready-to-use</div></div> oral solution for the acute treatment of migraine, with or without aura, in adults. In April 2023, the Company launched ELYXYB in the U.S. The Company expects to commercialize GLOPERBA in the U.S. in the first half of 2024. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is currently developing three product candidates, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102</div> (10 mg, dexamethasone sodium phosphate viscous gel), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica for which the Company has completed a Phase 3 study <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;SP-102&#8221;</div> or &#8220;SEMDEXA&#8221;), <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div> (lidocaine topical system) 5.4% <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;SP-103&#8221;),</div> a next-generation, triple-strength formulation of ZTlido, for the treatment of chronic neck pain and for which the Company has recently completed a Phase 2 trial in low back pain, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> (4.5 mg, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-dose</div> naltrexone hydrochloride delayed-burst release low dose naltrexone hydrochloride capsules) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;SP-104&#8221;),</div> a novel <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-dose</div> delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia, for which Phase 1 trials were completed in the second quarter of 2022 and a Phase 2 clinical trial is expected to commence in 2024. Since inception, the Company has devoted substantially all of its efforts to the development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104,</div> and the commercialization of ZTlido. In 2024, the Company will also devote efforts on the commercialization of GLOPERBA and ELYXYB. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Sorrento Chapter 11 Filing </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;13, 2023, Sorrento Therapeutics, Inc. (&#8220;Sorrento&#8221;), the Company&#8217;s then-controlling stockholder, and Sorrento&#8217;s wholly owned direct subsidiary, Scintilla Pharmaceuticals, Inc. (&#8220;Scintilla&#8221; and together with Sorrento, the &#8220;Debtors&#8221;), commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code (the &#8220;Bankruptcy Code&#8221;) in the United States Bankruptcy Court for the Southern District of Texas (the &#8220;Bankruptcy Court&#8221;). The Debtors&#8217; Chapter 11 proceedings are jointly administered under the caption In re Sorrento Therapeutics, Inc., et al., Case Number <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">23-90085</div> (DRJ) (the &#8220;Chapter 11 Cases&#8221;). While the Company was majority-owned by Sorrento, the Company was not a debtor in the Chapter 11 Cases. As of December&#160;31, 2023, Sorrento no longer holds a majority of the voting power of the Company&#8217;s outstanding capital stock entitled to vote. As of December&#160;31, 2023, the Company had a $<ix:nonFraction name="us-gaap:ReceivablesNetCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26422">3.2</ix:nonFraction>&#160;million receivable from Sorrento, which was fully reserved. The Company evaluates the collectability of this receivable on a quarterly basis. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-7</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_107552589" continuedAt="TextSelectionAppend_107552589_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552589_1" continuedAt="TextSelectionAppend_107552589_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552589_2" continuedAt="TextSelectionAppend_107552589_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_107552589_3" continuedAt="TextSelectionAppend_107552589_4"><ix:nonNumeric name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17814"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position for the periods presented. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements include the accounts of the Company as well as its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17820"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Segments </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating segments are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assessing performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer, as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions. The Company is engaged primarily in the development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-opioid</div> products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single reportable segment. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17826"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of these consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17831"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Customer Concentration Risk </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to April 2022, sales to the Company&#8217;s sole distributor represented <ix:nonFraction name="sclx:PercentageOfNetRevenueSoleDistributors" contextRef="PAsOn04_30_2022_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-26424">100</ix:nonFraction>% of net revenue. In April 2022, the Company announced the expansion of its direct distribution network to national and regional wholesalers and pharmacies. The Company had three and four customers during the years ended December&#160;31, 2023 and 2022, respectively, each of which individually generated <ix:nonFraction name="sclx:PercentageOfNetRevenueSoleDistributors" contextRef="PAsOn12_31_2022_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-26425"><ix:nonFraction name="sclx:PercentageOfNetRevenueSoleDistributors" contextRef="PAsOn12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-26426">10</ix:nonFraction></ix:nonFraction>% or more of the Company&#8217;s total revenue. These customers accounted for <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2023To12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-26427">85</ix:nonFraction>% and <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2022To12_31_2022_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-26428">83</ix:nonFraction>% of the Company&#8217;s revenue for the years ended December&#160;31, 2023 and 2022, respectively, individually ranging from <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2023To12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-26429">22</ix:nonFraction>% to <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2023To12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-26430">32</ix:nonFraction>% and <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2022To12_31_2022_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-26431">19</ix:nonFraction>% to <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2022To12_31_2022_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-26432">24</ix:nonFraction>%, respectively. As of December&#160;31, 2023 and 2022, these customers represented <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2023To12_31_2023_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ThreeCustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-26433">91</ix:nonFraction>% and <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2022To12_31_2022_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ThreeCustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-26434">90</ix:nonFraction>% of the Company&#8217;s outstanding accounts receivable, respectively, individually ranging between <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2023To12_31_2023_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-26435">24</ix:nonFraction>% and <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2022To12_31_2022_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-26436">36</ix:nonFraction>% for both periods. Additionally, during the years ended December&#160;31, 2023 and 2022, the Company purchased ZTlido inventory from its sole supplier, Itochu Chemical Frontier Corporation (&#8220;Itochu&#8221;). This exposes the Company to concentration of customer and supplier risk. The Company monitors the financial condition of its customers, limits its credit exposure by setting credit limits, and has not experienced any credit losses during the years ended December&#160;31, 2023 and 2022. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_107552791" id="ixv-17836"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial assets and liabilities are recorded at fair value on a recurring basis in the consolidated balance sheets. The carrying values of the Company&#8217;s financial assets and liabilities, including cash and cash equivalents, restricted cash, prepaid and other current assets, accounts payable and accrued expenses approximate to their fair value due to the short-term nature of these instruments. The derivative warrant liability associated with the Private Warrants (as defined below) is valued using the Black-Scholes option pricing model, which is further discussed in Note 4. The Company elected the fair value option to account for the Convertible Debentures (as defined below) in an aggregate principal amount of up to $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_31_2023_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26437">25.0</ix:nonFraction>&#160;million that were issued in March and April 2023 </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-8</ix:exclude> </div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_107552791" continuedAt="TextSelectionAppend_107552791_1"><ix:continuation id="TextSelectionAppend_107552589_4" continuedAt="TextSelectionAppend_107552589_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552589_5" continuedAt="TextSelectionAppend_107552589_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552589_6" continuedAt="TextSelectionAppend_107552589_7"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_107552589_7" continuedAt="TextSelectionAppend_107552589_8"><ix:continuation id="TextSelectionAppend_107552791_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and for the Oramed Note (as defined below) in the principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn09_30_2023_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26439">101.9</ix:nonFraction>&#160;million that was issued in September 2023 (see Note 7 titled &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Debt&#8221; </div></div>below). These instruments are measured at fair value on a recurring basis using Level&#160;3 inputs. The Binomial Lattice Model valuation technique and a discounted cash flow model were employed to measure the fair value of the Convertible Debentures and the Oramed Note, respectively. The Revolving Facility (as defined below) in an aggregate principal amount of up to $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn06_30_2023_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26440">30.0</ix:nonFraction>&#160;million was issued in June 2023 (see Note 7 titled &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Debt&#8221; </div></div>below). The Company accounts for the Revolving Facility using the amortized cost basis and recognizes interest expense over the expected term using the effective interest rate method. The carrying value of the Revolving Facility approximates its fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. Assets and liabilities recorded at fair value are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels are directly related to the amount of subjectivity with the inputs to the valuation of these assets or liabilities as follows: </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1 - </div></div>Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2 - </div></div>Inputs (other than quoted prices included in Level&#160;1) that are either directly or indirectly observable inputs for similar assets or liabilities. These include quoted prices for identical or similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active; and </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3 - </div></div>Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </div></ix:continuation><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17875"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Cash, Cash Equivalents and Restricted Cash </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments that are readily convertible into cash without penalty and with original maturities of three months or less at the date of purchase to be cash equivalents. The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents are valued at cost, which approximate their fair value. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Restricted cash as of December&#160;31, 2023 consist of deposits placed in a segregated bank account as required under the terms of the Credit and Security Agreement, dated as of June&#160;27, 2023, between Scilex Pharma and eCapital Healthcare Corp., which is discussed further in Note 7. Restricted cash is recorded as other long-term assets within the Company&#8217;s consolidated balance sheet. </div><ix:nonNumeric name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17881"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that together reflect the same amounts shown in the consolidated statements of cash flows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:60%"/>
<td style="vertical-align:bottom;width:13%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:13%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26441">3,921</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26442">2,184</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted cash</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26443">808</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26444">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash, cash equivalents, and restricted cash</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26445">4,729</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26446">2,184</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric name="us-gaap:TradeAndOtherAccountsReceivablePolicy" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_107552793" id="ixv-17970"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Accounts Receivable, Net </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounts receivable are presented net of allowances for expected credit losses and prompt payment discounts. Accounts receivable consists of trade receivables from product sales to customers, which are generally unsecured. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for expected credit losses within accounts receivable, net. The Company reviews </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-9</ix:exclude> </div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_107552793" continuedAt="TextSelectionAppend_107552793_1"><ix:continuation id="TextSelectionAppend_107552589_8" continuedAt="TextSelectionAppend_107552589_9"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552589_9" continuedAt="TextSelectionAppend_107552589_10"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552589_10" continuedAt="TextSelectionAppend_107552589_11"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_107552589_11" continuedAt="TextSelectionAppend_107552589_12"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><ix:continuation id="TextSelectionAppend_107552793_1">reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for expected credit losses.</ix:continuation> </div><ix:nonNumeric name="us-gaap:InventoryPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17992"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Inventory </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company determines inventory cost on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-out</div> basis. The Company reduces the carrying value of inventories to a lower of cost or net realizable value for those items that are potentially excess, obsolete or slow- moving. The Company reserves for excess and obsolete inventory based upon historical experience, sales trends, and specific categories of inventory and expiration dates for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-hand</div> inventory. Inventory costs resulting from these adjustments are recognized as cost of sales in the period in which they are incurred. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#8217;s judgment, the Company capitalizes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-launch</div> inventory costs prior to regulatory approval. As of December&#160;31, 2023 and 2022, the Company&#8217;s inventory was primarily comprised of finished goods. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-18001"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment, Net </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment are carried at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally five to seven years. Leasehold improvements are amortized over the lesser of their estimated useful lives or the term of the respective lease on a straight-line basis.&#160;The cost of repairs and maintenance is expensed as incurred. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:BusinessCombinationsPolicy" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-18006"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Acquisitions </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for business combinations using the acquisition method of accounting, which requires that assets acquired, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development (&#8220;IPR&amp;D&#8221;) projects and liabilities assumed be recorded at their fair values as of the acquisition date on the Company`s consolidated balance sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When the Company determines net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the transaction is accounted for as an acquisition of assets and, therefore, no goodwill is recorded and contingent consideration such as payments upon achievement of various developmental, regulatory and commercial milestones generally is not recognized at the acquisition date. In an asset acquisition, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> payments allocated to IPR&amp;D projects at the acquisition date and subsequent milestone payments are charged to expense in the Company`s consolidated statements of operations unless there is an alternative future use. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates. Intangible assets acquired in a business combination that are used for IPR&amp;D activities are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Upon commercialization of the relevant research and development project, the Company amortizes the acquired IPR&amp;D over its estimated useful life. Capitalized IPR&amp;D is reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_107552797" id="ixv-18015"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill and Other Long-Lived Assets </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwill, which has an indefinite life, represents the excess cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if events occur </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-10</ix:exclude> </div></ix:nonNumeric></ix:continuation></div></div></div><ix:continuation id="TextSelection_107552797" continuedAt="TextSelectionAppend_107552797_1"><ix:continuation id="TextSelectionAppend_107552589_12" continuedAt="TextSelectionAppend_107552589_13"><div></div></ix:continuation></ix:continuation></div><ix:continuation id="TextSelectionAppend_107552797_1" continuedAt="TextSelectionAppend_107552797_2"><ix:continuation id="TextSelectionAppend_107552589_13" continuedAt="TextSelectionAppend_107552589_14"><div><div style="line-height:normal;background-color:white;display: inline;"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></div></div></ix:continuation></ix:continuation></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_107552589_14" continuedAt="TextSelectionAppend_107552589_15"><ix:continuation id="TextSelectionAppend_107552797_2"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">indicating the potential for impairment. The Company has one reporting unit. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company performs a quantitative goodwill impairment test. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative goodwill impairment test.</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluates its long-lived and intangible assets with definite lives, such as property and equipment, patent rights, and acquired technology, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-generic</div> and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of useful life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets&#8217; book value to future net undiscounted cash flows that the assets are expected to generate to determine if a write-down to the recoverable amount is appropriate. If such assets are written down, an impairment will be recognized as the amount by which the book value of the asset group exceeds the recoverable amount. </div></ix:continuation><ix:nonNumeric name="us-gaap:ContingentLiabilityReserveEstimatePolicy" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-18046"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Contingent Consideration </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of contingent consideration liabilities assumed in business combinations is recorded as part of the purchase price consideration of the acquisition, and is determined using a discounted cash flow model or Monte Carlo simulation model. The significant inputs of such models are not observable in the market, such as certain financial metric growth rates, volatility rates, projections associated with applicable milestones, discount rates and the related probabilities and payment structure in the contingent consideration arrangement. Fair value adjustments to contingent consideration liabilities are recorded through operating expenses in the consolidated statement of operations. Other than contingent consideration that is accounted for in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480, Distinguishing Liabilities from Equity, and Topic 815, Derivatives and Hedging, contingent consideration arrangements assumed in an asset acquisition will be measured and accrued when such contingency is resolved. </div></ix:nonNumeric><ix:nonNumeric name="sclx:PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_107552701" id="ixv-18051"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Public Warrants and Private Warrants </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon completion of the Business Combination, the Company assumed public and private placement warrants to purchase Common Stock, each with an exercise price of $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-26450">11.50</ix:nonFraction> per share (&#8220;Public Warrants&#8221; and &#8220;Private Warrants&#8221;, respectively, and collectively, the &#8220;SPAC Warrants&#8221;) that were issued by Vickers in connection with its initial public offering (declared effective by the Securities and Exchange Commission (&#8220;SEC&#8221;) on January&#160;11, 2021) whereby holders of the public and private placement warrants are entitled to acquire ordinary shares of Vickers. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to the Business Combination, the Public Warrants were accounted for as equity per FASB ASC Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;815-40,</div> Contracts on an Entity&#8217;s Own Equity. Warrants classified as equity are recorded at their issuance cost and are not subject to remeasurement at each subsequent balance sheet date. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to the Business Combination, the Private Warrants were accounted for as liabilities per ASC Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40.</div> The Private Warrants are not considered indexed to the Company&#8217;s stock per ASC Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40</div> as the fair value calculation applicable upon a cashless exercise of a Private Warrant changes based upon the holder of the instrument, which is not an input to a valuation model for a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">fixed-for-fixed</div></div> option contract. Therefore, Private Warrants are recognized as derivative liabilities at their estimated fair value on November&#160;10, 2022, the date of the closing of the Business Combination, and are revalued at each subsequent balance sheet </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-11</ix:exclude> </div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_107552701" continuedAt="TextSelectionAppend_107552701_1"><ix:continuation id="TextSelectionAppend_107552589_15" continuedAt="TextSelectionAppend_107552589_16"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552589_16" continuedAt="TextSelectionAppend_107552589_17"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552589_17" continuedAt="TextSelectionAppend_107552589_18"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_107552589_18" continuedAt="TextSelectionAppend_107552589_19"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><ix:continuation id="TextSelectionAppend_107552701_1">date, with fair value changes recognized in the statement of operations. The Company estimates the value of these warrants using a Black-Scholes option pricing formula.</ix:continuation> </div><ix:nonNumeric name="us-gaap:DebtPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-18080"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Debt </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may enter into financing arrangements, the terms of which involve significant assumptions and estimates. This involves estimating future net product sales, determining interest expense, determining the amortization period of the debt discount, as well as determining the classification between current and long-term portions. </div></ix:nonNumeric><ix:nonNumeric name="sclx:ConvertibleDebenturesAndTheOramedNotePolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-18085"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Convertible Debentures and the Oramed Note </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has elected the fair value option to account for the Convertible Debentures (as defined in Note 2 &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidity and Going Concern</div></div>&#8221; below) that were issued in March and April 2023, as discussed further in Note 7. The Company has also elected the fair value option to account for the Oramed Note (as defined in Note 4 &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements</div></div>&#8221; below). The Company recorded the Convertible Debentures and the Oramed Note at fair value upon issuance with changes in fair value recorded as change in fair value of debt and liability instruments in the consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. Interest expense related to these financial instruments is included in the changes in fair value. As a result of applying the fair value option, direct costs and fees related to the Convertible Debentures and the Oramed Note were expensed as incurred. The weighted-average interest rates for the short-term loans, including the Convertible Debentures and the Oramed Note, were <ix:nonFraction name="us-gaap:DebtWeightedAverageInterestRate" contextRef="PAsOn12_31_2022_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-26453"><ix:nonFraction name="us-gaap:DebtWeightedAverageInterestRate" contextRef="PAsOn12_31_2023_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-26454">13.55</ix:nonFraction></ix:nonFraction>% and nil for the years ended December&#160;31, 2023 and 2022, respectively. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:DerivativesPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-18094"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Derivative Liabilities </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Derivative liabilities are recorded on the Company&#8217;s consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-18099"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Research and Development Costs </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company expenses the cost of research and development as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and preclinical materials as well as other contracted services, license fees and other external costs.&#160;Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with FASB ASC Topic 730, Research and Development. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_107552696" id="ixv-18104"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The provisions of the FASB ASC Topic 740, Income Taxes, address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">740-10,</div> the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position.&#160;The Company has determined that it has uncertain tax positions. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-12</ix:exclude> </div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_107552696" continuedAt="TextSelectionAppend_107552696_1"><ix:continuation id="TextSelectionAppend_107552589_19" continuedAt="TextSelectionAppend_107552589_20"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552589_20" continuedAt="TextSelectionAppend_107552589_21"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552589_21" continuedAt="TextSelectionAppend_107552589_22"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_107552589_22" continuedAt="TextSelectionAppend_107552589_23"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><ix:continuation id="TextSelectionAppend_107552696_1">will be realized. As of December&#160;31, 2023 and 2022, the Company maintained a full valuation allowance against its deferred tax assets.</ix:continuation> </div><ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-18132"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Leases </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company determines if an arrangement is a lease at inception. Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (&#8220;ROU&#8221;) assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and is reduced by lease incentives. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term in selling, general and administrative expenses. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_107552685" id="ixv-18139"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Revenue Recognition </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s revenue is generated from product sales within the United States. The Company does not incur significant direct costs to obtain contracts with its customers. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from product sales is comprised of sales of ZTlido and ELYXYB. The Company&#8217;s performance obligation with respect to sales of ZTlido and ELYXYB is satisfied at a point in time, when control is transferred upon delivery of product to the customer. The Company considers control to have transferred upon delivery because the customer has legal title to the product, physical possession of the product has been transferred to the customer, the customer has significant risks and rewards of ownership of the product, and the Company has a present right to payment at that time.&#160;Invoicing typically occurs upon shipment and the length of time between invoicing and when payment is due is not significant. The aggregate dollar value of unfulfilled orders as of December&#160;31, 2023 and 2022 were not material. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenues from product sales are recorded net of reserves established for commercial and government rebates, fees and chargebacks, wholesaler and distributor fees, sales returns and prompt payment discounts. Such variable consideration is estimated in the period of the sale and is estimated using a most likely amount approach based primarily upon provisions included in the Company&#8217;s customer contract, customary industry practices and current government regulations. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rebates and Chargebacks </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rebates are discounts which the Company pays under either government or private health care programs.&#160;Government rebate programs include state Medicaid drug rebate programs, the Medicare coverage gap discount programs and the Tricare programs. Commercial rebate and fee programs relate to contractual agreements with commercial healthcare providers, under which the Company pays rebates and fees for access to and position on that provider&#8217;s patient drug formulary. Rebates and chargebacks paid under government programs are generally mandated under law, whereas private rebates and fees are generally contractually negotiated by the Company with commercial healthcare providers. Both types of rebates vary over time. The Company records a reduction to gross product sales at the time the customer takes title to the product based on estimates of expected rebate claims. The Company monitors the sales trends and adjusts for these rebates on a regular basis to reflect the most recent rebate experience and contractual obligations. Reserves for rebates and chargebacks are now separately presented as accrued rebates and fees under current liabilities within the Company&#8217;s consolidated balance sheet. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Prompt Payment Discounts </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company provides its customers with prompt payment discounts which may result in adjustments to the price that is invoiced for the product transferred, in the case that payments are made within a defined period. The </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-13</ix:exclude> </div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_107552685" continuedAt="TextSelectionAppend_107552685_1"><ix:continuation id="TextSelectionAppend_107552589_23" continuedAt="TextSelectionAppend_107552589_24"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552589_24" continuedAt="TextSelectionAppend_107552589_25"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552589_25" continuedAt="TextSelectionAppend_107552589_26"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_107552589_26" continuedAt="TextSelectionAppend_107552589_27"><ix:continuation id="TextSelectionAppend_107552685_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">prompt payment discount reserve is based on actual gross sales and contractual discount rates. Reserves for prompt payment discounts are included in accounts receivable, net on the consolidated balance sheets. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Service Fees </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company compensates its customer and others in the distribution chain for wholesaler and distribution services. The Company has determined such services received to date are not distinct from the Company&#8217;s sale of products to the customer and, therefore, these payments have been recorded as a reduction of revenue. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Returns </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is obligated to accept the return of products sold that are expiring within six months, damaged or do not meet certain specifications. The Company may authorize the return of products sold in accordance with the term of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company estimates the amount of its product sales that may be returned by its customer and records this estimate as a reduction of revenue in the period the related product revenue is recognized. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Payment</div> Assistance </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients who have commercial insurance or pay cash and meet certain eligibility requirements may receive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-</div> payment assistance. The Company accrues for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payment</div> assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators. </div></ix:continuation><ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-18187"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Stock-Based Compensation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, Compensation &#8211; Stock Compensation which establishes accounting for equity instruments exchanged for employee and consulting services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee&#8217;s requisite service period (generally the vesting period of the equity grant) or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee&#8217;s</div> vesting period. The Company accounts for forfeitures as incurred. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of determining the inputs used in the calculation of stock-based compensation, the Company determines the expected life assumption for options issued using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period since the Company does not have historic exercise behavior. Then the Company determines an estimate of option volatility based on an assessment of historical volatilities of comparable companies whose share prices are publicly available. The Company uses these estimates as variables in the Black-Scholes option pricing model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in our consolidated statement of operations. </div></ix:nonNumeric><ix:nonNumeric name="sclx:TreasuryStockPolicyTextblock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-18194"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Treasury Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company uses the cost method to account for repurchases of its stock. In the computation of net (loss) income per share, treasury shares are not included as part of the outstanding shares. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_107553205" id="ixv-18199"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Net Loss per Share </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share attributable to common stockholders is presented in conformity with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method required for participating securities. Net loss per share has been retrospectively adjusted for all periods presented prior to the Business Combination. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-14</ix:exclude> </div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_107553205" continuedAt="TextSelectionAppend_107553205_1"><ix:continuation id="TextSelectionAppend_107552589_27" continuedAt="TextSelectionAppend_107552589_28"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552589_28" continuedAt="TextSelectionAppend_107552589_29"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552589_29" continuedAt="TextSelectionAppend_107552589_30"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_107552589_30"><ix:continuation id="TextSelectionAppend_107553205_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method, basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share attributable to common stockholders adjusts basic earnings per share for the potentially dilutive impact of stock options and warrants. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the Company has reported losses for all periods presented, all potentially dilutive securities are antidilutive and accordingly, basic net loss per share equals diluted net loss per share. </div></ix:continuation><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-18228"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Recently Adopted Accounting Pronouncements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2021, FASB issued Accounting Standards Updates (&#8220;ASU&#8221;) 2021-08, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Combinations (Topic&#160;805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;ASU&#160;2021-08&#8221;)</div></div></div>, which requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities in accordance with ASC Topic 606. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2021-08</div> is effective for fiscal years beginning after December&#160;15, 2022. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2021-08</div> should be applied prospectively to business combinations occurring on or after the adoption date. The Company adopted this guidance as of January&#160;1, 2023 and the adoption did not have a material impact on the Company&#8217;s consolidated financial statements. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2022, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2022-03,</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2022-03&#8221;),</div> </div></div>which clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered when measuring fair value. Recognizing such a restriction as a separate unit of account is also not permitted. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2022-03</div> is effective for fiscal years beginning after December&#160;15, 2023, with early adoption permitted. The Company elected to early adopt this guidance as of January&#160;1, 2023 and the adoption did not have a material impact on the Company&#8217;s consolidated financial statements. </div></ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_107553156" id="ixv-18244"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">2. Liquidity and Going Concern </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Management has assessed the Company&#8217;s ability to continue as a going concern for at least one year after the issuance date of the accompanying consolidated financial statements. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;17, 2022, the Company entered into a standby equity purchase agreement (the &#8220;Original Purchase Agreement&#8221;) with YA II PN, Ltd., a Cayman Islands exempt limited partnership (&#8220;Yorkville&#8221;). On February&#160;8, 2023, the Company entered into an amended and restated standby equity purchase agreement with Yorkville (the &#8220;A&amp;R Yorkville Purchase Agreement&#8221;), amending, restating and superseding the Original Purchase Agreement. On January&#160;8, 2023, the Company entered into a standby equity purchase agreement (the &#8220;B. Riley Purchase Agreement&#8221; and together with A&amp;R Yorkville Purchase Agreement, the &#8220;Standby Equity Purchase Agreements&#8221;) with B. Riley Principal Capital II, LLC (&#8220;B. Riley&#8221;). Pursuant to each of the Standby Equity Purchase Agreements, the Company has the right, but not the obligation, to sell to each of Yorkville and B. Riley up to $<ix:nonFraction name="sclx:RightToSellMaximumNumberOfCommonStockShares" contextRef="P11_17_2022To11_17_2022_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26459">500.0</ix:nonFraction>&#160;million of shares of the Company&#8217;s common stock, par value $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn11_17_2022_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-26460">0.0001</ix:nonFraction> per share (the &#8220;Common Stock&#8221;) at its request any time during the 36 months following the date on which the registration statement related to each such purchase agreement was initially declared effective by the SEC, subject to certain conditions, which are discussed further in Note 9. On, and effective as of, February&#160;16, 2024, the Company and B. Riley mutually agreed to terminate the B. Riley Purchase Agreement. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for Yorkville&#8217;s and B. Riley&#8217;s respective commitment to purchase shares of Common Stock at the Company&#8217;s direction, the Company issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-26461">250,000</ix:nonFraction> commitment shares to each of Yorkville (the &#8220;Yorkville Commitment Shares&#8221;) and B. Riley (the &#8220;B. Riley Commitment Shares&#8221;). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March 21, 2023, the Company entered into a securities purchase agreement with Yorkville (the &#8220;Yorkville SPA&#8221;), pursuant to which the Company would issue and sell to Yorkville convertible debentures in an aggregate </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-15</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_107553156" continuedAt="TextSelectionAppend_107553156_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107553156_1" continuedAt="TextSelectionAppend_107553156_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107553156_2" continuedAt="TextSelectionAppend_107553156_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_107553156_3"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">principal amount of up to $<ix:nonFraction name="sclx:Convertibledebentureprincipalamount" contextRef="P03_21_2023To03_21_2023_EquityUnitPurchaseAgreementsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26463">25.0</ix:nonFraction>&#160;million (the &#8220;Convertible Debentures&#8221;). As of December&#160;31, 2023, Convertible Debentures in the principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentIssuedPrincipal" contextRef="P01_01_2023To12_31_2023_EquityUnitPurchaseAgreementsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26464">25.0</ix:nonFraction>&#160;million (for net cash proceeds of $<ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="PAsOn12_31_2023_EquityUnitPurchaseAgreementsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26465">24.0</ix:nonFraction> million) were issued and sold pursuant to the Yorkville SPA, which is discussed further in Note 7. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;27, 2023, Scilex Pharma entered into a Credit and Security Agreement (the &#8220;eCapital Credit Agreement&#8221;) with eCapital Healthcare Corp. (the &#8220;Lender&#8221;), pursuant to which the Lender shall make available loans (the &#8220;Revolving Facility&#8221;) in an aggregate principal amount of up to $<ix:nonFraction name="sclx:PrincipalLaonAmount" contextRef="P06_27_2023To06_27_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26466">30.0</ix:nonFraction>&#160;million (the &#8220;Facility Cap&#8221;). The proceeds of the Revolving Facility will be used for (i)&#160;transaction fees incurred in connection with the eCapital Credit Agreement, (ii)&#160;working capital needs of Scilex Pharma and (iii)&#160;other uses not prohibited under the eCapital Credit Agreement. As of December&#160;31, 2023, the Company has an outstanding balance of $<ix:nonFraction name="sclx:OutstandingBalanceOfRevolvingFacility" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26467">17.0</ix:nonFraction>&#160;million under the Revolving Facility. See Note 7 for additional discussion of the terms of the eCapital Credit Agreement. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;22, 2023, the Company entered into a Sales Agreement (the &#8220;ATM Sales Agreement&#8221;) with B. Riley Securities, Inc., Cantor Fitzgerald&#160;&amp; Co. and H.C. Wainwright&#160;&amp; Co., LLC (the &#8220;Sales Agents&#8221;). Pursuant to the ATM Sales Agreement, the Company may offer and sell (the &#8220;Offering&#8221;) shares of Common Stock up to $<ix:nonFraction name="sclx:CommonStockIssuableValue" contextRef="PAsOn12_22_2023_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis_CommonStockMemberusgaapStatementClassOfStockAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-26468">170,000,000</ix:nonFraction> (the &#8220;ATM Shares&#8221;), through or to the Sales Agents as part of the Offering. The Company has no obligation to sell any shares of Common Stock under the ATM Sales Agreement and may suspend offers thereunder at any time. The Offering will terminate upon (i)&#160;the election of the Sales Agents upon the occurrence of certain adverse events, (ii)&#160;three business days&#8217; advance notice from the Company to the Sales Agents or a Sales Agent to the Company, or (iii)&#160;the sale of all $<ix:nonFraction name="sclx:ValueOfStockSoldForTerminationOfOffering" contextRef="PAsOn12_22_2023_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis_CommonStockMemberusgaapStatementClassOfStockAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-26469">170,000,000</ix:nonFraction> of shares of Common Stock thereunder. As of December&#160;31, 2023, <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2023_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-26470">no</ix:nonFraction> sales of Common Stock had been made under the ATM Sales Agreement. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, the Company&#8217;s negative working capital was $<ix:nonFraction name="sclx:WorkingCapital" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26471">203.6</ix:nonFraction>&#160;million, including cash and cash equivalents of approximately $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26472">3.9</ix:nonFraction>&#160;million. During the year ended December&#160;31, 2023, the Company had operating losses of $<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-26473">105.4</ix:nonFraction>&#160;million and cash flows used for operations of $<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26474">20.7</ix:nonFraction>&#160;million. The Company had an accumulated deficit of $<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-26475">490.2</ix:nonFraction>&#160;million as of December&#160;31, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has plans to obtain additional resources to fund its currently planned operations and expenditures for at least twelve months from the issuance of these consolidated financial statements through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions. The Company&#8217;s plans are also dependent upon the success of future sales of ZTlido and ELYXYB, among which ELYXYB is still in the early stages of commercialization, and the future commercialization of GLOPERBA. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although the Company believes such plans, if executed, should provide the Company with financing to meet its needs, successful completion of such plans is dependent on factors outside the Company&#8217;s control. As a result, management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company&#8217;s ability to continue as a going concern for one year after the date the consolidated financial statements are issued. </div></ix:continuation><ix:nonNumeric name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_107552817" id="ixv-18272"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">3. Acquisitions </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> Acquisition </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2022, the Company acquired the Delayed Burst Release Low Dose Naltrexone asset and intellectual property rights for the treatment of chronic pain, fibromyalgia and chronic post-COVID syndrome (collectively, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;SP-104</div> Assets&#8221;). Pursuant to the acquisition provisions, the Company is obligated to pay Aardvark Therapeutics, Inc. (&#8220;Aardvark&#8221;) (i) $<ix:nonFraction name="sclx:AmountDueForNewDrugApplication" contextRef="P05_31_2022To05_31_2022_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_SorrentoMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26476">3.0</ix:nonFraction>&#160;million upon initial approval by the FDA of a new drug application for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> Assets (which amount may be paid in shares of Common Stock or cash, in the Company&#8217;s sole discretion) (the &#8220;Development Milestone Payment&#8221;) and (ii) $<ix:nonFraction name="sclx:PaymentUponTheAchievementOfNetSales" contextRef="P05_31_2022To05_31_2022_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_SorrentoMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26477">20.0</ix:nonFraction>&#160;million in cash, upon achievement of certain net sales by the Company of a commercial product that uses the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> Assets (the &#8220;Sales Milestone Payment&#8221;). The Company will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by the Company of a commercial product that uses the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> Assets. </div><ix:exclude><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-16 </div></ix:exclude></ix:nonNumeric></div></div><ix:continuation id="TextSelection_107552817" continuedAt="TextSelectionAppend_107552817_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552817_1" continuedAt="TextSelectionAppend_107552817_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552817_2" continuedAt="TextSelectionAppend_107552817_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_107552817_3" continuedAt="TextSelectionAppend_107552817_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sales Milestone Payment and sale volume-based future royalties were determined to meet a scope exception for derivative accounting and will not be recognized until the contingencies are realized. The Development Milestone Payment represents a liability, which will be measured at fair value for each reporting period. As of December&#160;31, 2023 and December&#160;31, 2022, the contingent consideration associated with the Development Milestone Payment was $<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" contextRef="PAsOn12_31_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26478"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" contextRef="PAsOn12_31_2023_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26479">0.2</ix:nonFraction></ix:nonFraction>&#160;million, recorded in the other long-term liabilities. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">GLOPERBA License Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2022, the Company entered into a license agreement (the &#8220;Romeg License Agreement&#8221;) with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.) (&#8220;Romeg&#8221;). Pursuant to the Romeg License Agreement, among other things, Romeg granted the Company (a)&#160;a transferable license, with a right to sublicense, to (i)&#160;commercialize the pharmaceutical product comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans (the &#8220;Initial Licensed Product&#8221; or &#8220;GLOPERBA&#8221;) in the United States (including its territories) (the &#8220;GLOPERBA Territory&#8221;), (ii) develop other products comprising the Initial Licensed Product as an active pharmaceutical ingredient (the &#8220;Licensed Products&#8221;) and commercialize any such products and (iii)&#160;manufacture Licensed Products anywhere in the world, solely for commercialization in the GLOPERBA Territory; and (b)&#160;an exclusive, transferable license, with a right to sublicense, to use the trademark GLOPERBA and logos, designs, translations, and modifications thereof in connection with the commercialization of the Initial Licensed Product solely in the GLOPERBA Territory. The Initial Licensed Product, GLOPERBA, was approved and made available in the United States in 2020. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for the license under the Romeg License Agreement, the Company paid Romeg an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> license fee of $<ix:nonFraction name="sclx:Upfrontlicensefee" contextRef="P06_14_2022To06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26480">2.0</ix:nonFraction>&#160;million, and has agreed to pay Romeg (a)&#160;upon the Company&#8217;s achievement of certain net sales milestones, certain milestone payments in the aggregate amount of up to $<ix:nonFraction name="sclx:PaymentUponTheAchievementOfNetSales" contextRef="P06_14_2022To06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26481">13.0</ix:nonFraction>&#160;million, (b)&#160;certain royalties, at rates that do not exceed ten percent, based on annual net sales of the Licensed Products by the Company during the applicable royalty term under the Romeg License Agreement, and (c)&#160;minimum quarterly royalty payments totaling $<ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="P06_14_2022To06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26482">7.1</ix:nonFraction>&#160;million commencing on the first year anniversary of the effective date of the Romeg License Agreement and ending on the later of (i)&#160;expiration of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">last-to-expire</div></div> of the licensed patents covering the Licensed Products in the GLOPERBA Territory or (ii)&#160;the tenth anniversary of the effective date of the Romeg License Agreement. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Romeg License Agreement, the Company recorded an intangible asset for acquired licenses of $<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="PAsOn06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26483">5.7</ix:nonFraction>&#160;million, which is comprised of the upfront license fee of $<ix:nonFraction name="sclx:Upfrontlicensefee" contextRef="P06_14_2022To06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26484">2.0</ix:nonFraction>&#160;million and deferred consideration of $<ix:nonFraction name="sclx:Deferredconsiderationliabilities" contextRef="PAsOn06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26485">3.7</ix:nonFraction>&#160;million that is the present value of the future minimum royalty payments and immaterial transaction costs. <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen" id="ixv-26486"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn12_31_2023_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen" id="ixv-26487">No</ix:nonFraction></ix:nonFraction> contingent consideration was recognized as a liability or included in the fair value of the assets as of December&#160;31, 2023 or December&#160;31, 2022. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">ELYXYB Acquisition </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;12, 2023, the Company entered into an asset purchase agreement (the &#8220;ELYXYB APA&#8221;) with BioDelivery Sciences International, Inc. (&#8220;BDSI&#8221;) and Collegium Pharmaceutical, Inc. (&#8220;Collegium&#8221;, and together with BDSI, the &#8220;Sellers&#8221;) to acquire the rights to certain patents, trademarks, regulatory approvals, data, contracts, and other rights related to ELYXYB and its commercialization in the United States and Canada (the &#8220;ELYXYB Territory&#8221;). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for the acquisition, the Company assumed various rights and obligations under the asset purchase agreement between BDSI and Dr.&#160;Reddy&#8217;s Laboratories Limited, a company incorporated under the laws of India (&#8220;DRL&#8221;), dated August&#160;3, 2021 (the &#8220;DRL APA&#8221;), including an irrevocable, royalty-free, exclusive license to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and patents of DRL related to ELYXYB and necessary or used to exploit ELYXYB in the ELYXYB Territory. No cash consideration was or will be payable to the Sellers for such acquisition; however, the obligations under the DRL APA that were assumed by the Company include contingent sales and regulatory milestone payments and sales royalties. The Company is also obligated to make quarterly royalty payments to </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-17</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_107552817_4" continuedAt="TextSelectionAppend_107552817_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552817_5" continuedAt="TextSelectionAppend_107552817_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552817_6" continuedAt="TextSelectionAppend_107552817_7"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><ix:continuation id="TextSelectionAppend_107552817_7">DRL on net sales of ELYXYB in the ELYXYB Territory. In April 2023, the Company launched ELYXYB in the U.S. As of December&#160;31, 2023, the Company had ending balances of accrued royalty payables of $<ix:nonFraction name="sclx:AccruedRoyaltyPayables" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal" id="ixv-26490">5.0</ix:nonFraction>&#160;thousand. As of December&#160;31, 2023, <ix:nonFraction name="sclx:PaymentToAcquireLicense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen" id="ixv-26491">no</ix:nonFraction> sales or regulatory milestone payments had been accrued as there were no potential milestones yet considered probable of achievement.</ix:continuation> </div><ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_107552723" id="ixv-18334"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">4. Fair Value Measurements </div></div><ix:nonNumeric name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-18337"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the Company&#8217;s financial assets and liabilities that are measured at fair value on a recurring basis and the level of inputs used in such measurements (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:42%"/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices<br/> in Active<br/> Markets<br/> (Level 1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs&#160;(Level&#160;2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable<br/> Inputs&#160;(Level&#160;3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Oramed Note</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26492">104,089</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26493">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26494">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26495">104,089</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Convertible Debentures</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ConvertibleDebtFairValueDisclosures" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26496">4,340</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ConvertibleDebtFairValueDisclosures" contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26497">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ConvertibleDebtFairValueDisclosures" contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26498">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ConvertibleDebtFairValueDisclosures" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26499">4,340</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-hidden:hidden107552736;display:inline;">Derivative liabilities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26500">1,518</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26501">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26502">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26503">1,518</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other long-term liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26504">179</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26505">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26506">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26507">179</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities measured at fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26508">110,126</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26509">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26510">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26511">110,126</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:44%"/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices<br/> in Active<br/> Markets<br/> (Level&#160;1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs&#160;(Level&#160;2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable<br/> Inputs&#160;(Level&#160;3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-hidden:hidden107552737;display:inline;">Derivative liabilities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26512">1,231</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26513">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26514">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26515">1,231</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other long-term liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26516">163</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26517">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26518">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26519">163</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities measured at fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26520">1,394</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26521">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26522">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26523">1,394</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">The Oramed Note </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2023, the Company issued a senior secured promissory note to Oramed Pharmaceuticals Inc. (&#8220;Oramed&#8221;) in the principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentIssuedPrincipal" contextRef="P09_30_2023To09_30_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26524">101.9</ix:nonFraction>&#160;million (the &#8220;Oramed Note&#8221;) (see Note 7). The Company elected the fair value option to account for the Oramed Note with any changes in the fair value of the note recorded in the consolidated statements of operations. The Company uses a discounted cash flow model to determine the fair value of the Oramed Note based on Level&#160;3 inputs. This methodology discounts the interest and principal payments using a risk-adjusted discount rate. The fair value as of December&#160;31, 2023 was determined to be $<ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn12_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26525">104.1</ix:nonFraction>&#160;million by applying a discount rate of <ix:nonFraction name="sclx:SecuredNoteDiscountRate" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-26526">13.05</ix:nonFraction>%. For the year ended December&#160;31, 2023, the Company recorded $<ix:nonFraction name="sclx:ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense" contextRef="P01_01_2023To12_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26527">2.8</ix:nonFraction>&#160;million in change in fair value of the Oramed Note. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Convertible Debentures </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March and April 2023, the Company issued the Convertible Debentures in the principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentIssuedPrincipal" contextRef="P04_30_2023To04_30_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26528">25.0</ix:nonFraction>&#160;million (see Note 7). The Convertible Debentures are measured at fair value on a recurring basis using Level&#160;3 inputs. The Company uses the Binomial Lattice Model valuation technique to measure the fair value of the Convertible Debentures with any changes in the fair value of the Convertible Debentures recorded in the consolidated statements of operations. Interest expense related to the Convertible Debentures is included in the changes in fair value. For the year ended December&#160;31, 2023, the Company recorded $<ix:nonFraction name="sclx:ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26529">4.4</ix:nonFraction>&#160;million in change in </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-18</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_107552723" continuedAt="TextSelectionAppend_107552723_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552723_1" continuedAt="TextSelectionAppend_107552723_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552723_2" continuedAt="TextSelectionAppend_107552723_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_107552723_3" continuedAt="TextSelectionAppend_107552723_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">fair value of the Convertible Debentures. <ix:nonNumeric name="us-gaap:ScheduleOfDebtTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_107552721" id="ixv-26531">A summary of inputs used in valuing the Convertible Debentures is as follows: </ix:nonNumeric></div><ix:continuation id="TextSelection_107552721"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:80%"/>
<td style="vertical-align:bottom;width:17%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk -Free Rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" contextRef="PAsOn12_31_2023" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-26532">5.31</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate Bond Yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:CorporateBondYield" contextRef="PAsOn12_31_2023" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-26533">15.60</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Coupon Interest Rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:CouponInterestRate" contextRef="PAsOn12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-26534">7.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-26535">70.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend Yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" contextRef="PAsOn12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-26536">0.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Conversion Price</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-26537">8.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:continuation><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Derivative Liabilities </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recorded a gain of $<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2023To12_31_2023_WarrantsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26538">0.5</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2022To12_31_2022_WarrantsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26539">8.3</ix:nonFraction>&#160;million and a loss of $<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2021To12_31_2021_WarrantsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-26540">0.3</ix:nonFraction>&#160;million for the years ended December&#160;31, 2023, 2022 and 2021, respectively, on derivative liabilities which was attributed to the Private Warrants that the Company assumed from Vickers in November 2022 in connection with the Business Combination and compound derivative liabilities associated with the senior secured notes issued by Scilex Pharma in September 2018 (the &#8220;Scilex Pharma Notes&#8221;), respectively. The fair value of the derivative liability associated with the Scilex Pharma Notes decreased by $<ix:nonFraction name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="P06_02_2022To06_02_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26541">30.4</ix:nonFraction>&#160;million immediately after entry into Amendment No.&#160;4 to the Scilex Pharma Notes on June&#160;2, 2022 (&#8220;Amendment No.&#160;4&#8221;). The fair value of the derivative liability associated with the Scilex Pharma Notes was estimated using the discounted cash flow method combined with a Monte Carlo simulation model including consideration of the terms of Amendment No.&#160;4. Significant Level&#160;3 assumptions used in the measurement included a <ix:nonFraction name="sclx:RiskAdjustedNetSalesForecast" contextRef="PAsOn06_30_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-26542">6.1</ix:nonFraction>% risk adjusted net sales forecast and an effective debt yield of <ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleWeightedAverageYield" contextRef="PAsOn06_30_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-26543">21.5</ix:nonFraction>%. The Scilex Pharma Notes were fully extinguished in September 2022 and, as such, there were no remaining loan derivative liabilities associated with the Scilex Pharma Notes as of December&#160;31, 2022. At the closing of the Business Combination in November 2022, the Company assumed a derivative warrant liability of $<ix:nonFraction name="sclx:DerivativeWarrantLiabilityPrivateWarrants" contextRef="P11_30_2022To11_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26544">2.5</ix:nonFraction>&#160;million related to the Private Warrants. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-26545">3,613,383</ix:nonFraction> Private Warrants were outstanding, and the fair value of derivative warrant liability related to the Private Warrants was $<ix:nonFraction name="sclx:DerivativeWarrantLiabilityPrivateWarrants" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26546">1.5</ix:nonFraction>&#160;million. </div><ix:nonNumeric name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-18840"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table includes a summary of the derivative liabilities measured at fair value during the three years ended December&#160;31, 2023, 2022 and 2021 (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:84%"/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26547">35,400</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> of fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ReMeasurementOfFairValue" contextRef="P01_01_2021To12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26548">300</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26549">35,700</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Private warrant liability acquired as part of the Business Combination</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:PrivatePlacementWarrantLiabilityAcquired" contextRef="P01_01_2022To12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26550">2,545</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeiture of Private Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ForfeitureOfPrivateWarrants" contextRef="P01_01_2022To12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26551">1,696</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value measurement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="sclx:ChangeInValuationInputsOrOtherAssumptions" contextRef="P01_01_2022To12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26552">38,710</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26553">1,231</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value measurement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ChangeInValuationInputsOrOtherAssumptions" contextRef="P01_01_2023To12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26554">512</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeiture of Private Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="sclx:ForfeitureOfPrivateWarrants" contextRef="P01_01_2023To12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26555">225</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26556">1,518</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Warrant Liability Measurement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The derivative warrant liability was valued using the Black-Scholes option pricing model, which is considered to be Level&#160;3 fair value measurement. The primary unobservable input utilized in determining the fair value of the </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-19</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_107552723_4" continuedAt="TextSelectionAppend_107552723_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552723_5" continuedAt="TextSelectionAppend_107552723_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552723_6" continuedAt="TextSelectionAppend_107552723_7"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_107552723_7"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">warrant is the expected volatility of the Common Stock. The expected volatility assumption is based on historical volatilities of comparable companies whose share prices are publicly available as well as the implied volatility of the Public Warrants (see Note 9). A summary of the inputs used in valuing the derivative warrant liabilities is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="us-gaap:FairValueConcentrationOfRiskTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-18981">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:65%"/>
<td style="vertical-align:bottom;width:13%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Equity value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:EquityValue" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-26558">2.04</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:EquityValue" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-26559">3.99</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise price</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-26560">11.50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-26561">11.50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Term, in years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:duryear" id="ixv-26562">3.86</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:duryear" id="ixv-26563">4.86</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-26564">76.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-26565">35.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-26566">3.90</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-26567">3.94</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-26568">0.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-26569">0.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Call option value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:CallOptionValue" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-26570">0.42</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:CallOptionValue" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-26571">0.30</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Contingent Consideration Related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> Acquisition </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Development Milestone Payment related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> Assets represents an obligation to potentially settle a fixed value in a variable number of shares of Common Stock and requires remeasurement at fair value through settlement. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the achievement of FDA approval for a new drug application for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104,</div> the Company will transfer $<ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26572">3.0</ix:nonFraction>&#160;million in cash or shares of Common Stock, at the discretion of the Company. The fair value of the contingent consideration liability associated with the Development Milestone Payment was estimated using a probability-weighted discounted cash flow method. Significant unobservable inputs assumptions included the likelihood of receiving FDA approval for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104,</div> expected timing for receipt of FDA approval for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104,</div> and a discount rate of <ix:nonFraction name="us-gaap:ProductLiabilityContingencyAccrualDiscountRate" contextRef="PAsOn12_31_2023" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-26573">10.2</ix:nonFraction>%. As of December&#160;31, 2023 and December&#160;31, 2022, the fair value of contingent consideration related to the Development Milestone Payment was $<ix:nonFraction name="sclx:FairValueOfContingentConsideration" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26574"><ix:nonFraction name="sclx:FairValueOfContingentConsideration" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26575">0.2</ix:nonFraction></ix:nonFraction>&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no transfers between fair value measurement levels during the years ended December&#160;31, 2023, 2022 and 2021. </div></ix:continuation><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_107552757" id="ixv-19095"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">5. Balance Sheet Components </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment, Net </div></div></div><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-19101"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment, net, consists of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:66%"/>
<td style="vertical-align:bottom;width:13%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:13%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Construction in progress</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26576">689</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26577">689</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26578">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26579">118</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computers and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26580">36</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26581">77</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26582">50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26583">55</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, gross</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26584">780</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26585">939</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Accumulated depreciation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26586">58</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26587">167</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26588">722</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26589">772</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognized depreciation expense of $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal" id="ixv-26590">40.0</ix:nonFraction>&#160;thousand, $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal" id="ixv-26591">40.0</ix:nonFraction>&#160;thousand and $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal" id="ixv-26592">39.0</ix:nonFraction>&#160;thousand for the years ended December&#160;31, 2023, 2022 and 2021, respectively. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-20</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_107552757" continuedAt="TextSelectionAppend_107552757_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552757_1" continuedAt="TextSelectionAppend_107552757_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552757_2" continuedAt="TextSelectionAppend_107552757_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_107552757_3"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Accrued Expenses </div></div></div><ix:nonNumeric name="sclx:AccruedExpensesTextblock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-19270"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued expenses consists of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:66%"/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional service fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26594">2,029</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26595">2,024</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued sales and marketing costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedMarketingCostsCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26596">1,601</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedMarketingCostsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26597">574</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued research and development costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:AccruedResearchAndDevelopmentCosts" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26598">1,546</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:AccruedResearchAndDevelopmentCosts" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26599">459</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued tax payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TaxesPayableCurrentAndNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26600">1,452</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TaxesPayableCurrentAndNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26601">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued others</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26602">780</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26603">79</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:AccruedExpenses" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26604">7,408</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:AccruedExpenses" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26605">3,136</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_107552777" id="ixv-19392"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">6. Goodwill and Intangible Assets </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023 and 2022, the Company had recorded goodwill of $<ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26606"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26607">13.5</ix:nonFraction></ix:nonFraction>&#160;million. <ix:nonFraction name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-26608"><ix:nonFraction name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-26609"><ix:nonFraction name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-26610">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> goodwill impairment was recognized for the years ended December&#160;31, 2023, 2022 and 2021. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amortization of the intangible assets that have finite useful lives is generally recorded on a straight-line basis over their useful lives. <ix:nonNumeric name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_107552779" id="ixv-26611">A summary of the Company&#8217;s identifiable intangible assets as of December&#160;31, 2023 and December&#160;31, 2022 is as follows (in thousands): </ix:nonNumeric></div><ix:continuation id="TextSelection_107552779"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:55%"/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross&#160;Carrying<br/> Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intangibles,<br/> net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Patent rights</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2023_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26612">32,630</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2023_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26613">15,591</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2023_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26614">17,039</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired technology</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2023_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26615">21,940</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2023_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26616">7,679</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2023_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26617">14,261</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired licenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2023_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26618">5,711</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2023_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26619">551</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2023_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26620">5,160</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Assembled workforce</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2023_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26621">500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2023_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26622">475</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2023_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26623">25</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26624">60,781</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26625">24,296</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26626">36,485</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:55%"/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross&#160;Carrying<br/> Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intangibles,<br/> net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Patent rights</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2022_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26627">32,630</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2022_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26628">13,415</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2022_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26629">19,215</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired technology</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2022_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26630">21,940</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2022_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26631">6,216</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2022_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26632">15,724</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired licenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2022_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26633">5,711</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2022_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26634">184</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2022_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26635">5,527</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Assembled workforce</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2022_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26636">500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2022_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26637">375</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2022_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26638">125</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26639">60,781</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26640">20,190</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26641">40,591</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:continuation><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, the weighted average remaining life for identifiable intangible assets was <ix:nonNumeric name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:duryear" id="ixv-26642">9.4</ix:nonNumeric> years. Aggregate amortization expense was $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26643">4.1</ix:nonFraction>&#160;million, $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26644">3.9</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26645">3.7</ix:nonFraction>&#160;million for the years ended December&#160;31, 2023, 2022 and 2021, respectively. Patent rights and acquired technology are amortized over a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15-year</div> period. Assembled workforce is amortized over a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-year</div> period. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-21</ix:exclude> </div></ix:nonNumeric></div></div></div><ix:continuation id="TextSelection_107552777" continuedAt="TextSelectionAppend_107552777_1"><div></div></ix:continuation></div><div><div style="line-height:normal;background-color:white;display: inline;"><ix:continuation id="TextSelectionAppend_107552777_1" continuedAt="TextSelectionAppend_107552777_2"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552777_2" continuedAt="TextSelectionAppend_107552777_3"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552777_3" continuedAt="TextSelectionAppend_107552777_4"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_107552777_4"><ix:nonNumeric name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-19736"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Estimated future amortization expense related to intangible assets as of December&#160;31, 2023 is as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:85%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26647">4,031</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26648">4,006</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26649">4,006</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26650">4,006</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2028</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26651">4,006</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Thereafter</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26652">16,430</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26653">36,485</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:DebtDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_107552740" id="ixv-19818"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">7. Debt </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Convertible Debentures </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;21, 2023, the Company entered into the Yorkville SPA, pursuant to which the Company would issue and sell to Yorkville Convertible Debentures in an aggregate principal amount of up to $<ix:nonFraction name="us-gaap:DebtInstrumentIssuedPrincipal" contextRef="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26654">25.0</ix:nonFraction>&#160;million. <ix:nonNumeric name="us-gaap:DebtInstrumentDescription" contextRef="P01_01_2023To12_31_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis" id="ixv-19825">The Yorkville SPA provides that the Convertible Debentures would be issued and sold at a purchase price equal to <ix:nonFraction name="sclx:ConvertibleDebenturesIssuedPercent" contextRef="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-26655">96</ix:nonFraction>% of the applicable principal amount in three tranches as follows: (i) $<ix:nonFraction name="us-gaap:DebtInstrumentIssuedPrincipal" contextRef="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26656">10.0</ix:nonFraction>&#160;million upon the signing of the Yorkville SPA, which was funded on March&#160;21, 2023; (ii) $<ix:nonFraction name="us-gaap:DebtInstrumentIssuedPrincipal" contextRef="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26657">7.5</ix:nonFraction>&#160;million upon the filing of a registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</div> with the SEC to register the resale by Yorkville of any shares of Common Stock issuable upon conversion of the Convertible Debentures under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), which was funded on April&#160;11, 2023; and (iii) $<ix:nonFraction name="us-gaap:DebtInstrumentIssuedPrincipal" contextRef="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ShareBasedCompensationAwardTrancheThreeMemberusgaapVestingAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26658">7.5</ix:nonFraction>&#160;million at the time such registration statement was declared effective by the SEC, which was funded on April&#160;20, 2023.</ix:nonNumeric> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Convertible Debentures bear interest at an annual rate of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-26659">7.00</ix:nonFraction>% and were initially set to mature on <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis" format="ixt:date-monthname-day-year-en" id="ixv-26660">December 21, 2023</ix:nonNumeric>. On <div style="display:inline;">October&#160;11, 2023</div>, the Company and Yorkville amended the Convertible Debentures. The Default Conversion Price (as defined therein) was originally set not to fall below $<ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="PAsOn10_11_2023_MaximumMembersrtRangeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-26661">2.00</ix:nonFraction> per share and such floor price has been amended to mean a price per share of Common Stock equal to 95% of the lowest daily VWAP (as defined therein) during the five consecutive trading days immediately preceding the conversion date, but not lower than $<ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="PAsOn10_11_2023_MinimumMembersrtRangeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-26662">0.50</ix:nonFraction> per share. The maturity date of the Convertible Debentures was also extended from December&#160;21, 2023 to <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P01_01_2023To12_31_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis" format="ixt:date-monthname-day-year-en" id="ixv-26663">March 15, 2024</ix:nonNumeric>. The outstanding principal amount is to be repaid in equal installments that are due every 30 days beginning on May&#160;20, 2023, which is 60 days after the date on which the first Convertible Debenture was issued to Yorkville. The Convertible Debentures provide a conversion right, in which any portion of the outstanding and unpaid principal and any accrued but unpaid interest may be converted into shares of Common Stock, at a conversion price of $<ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="PAsOn03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-26664">8.00</ix:nonFraction> per share at the option of the holder of the Convertible Debentures. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><ix:nonNumeric name="us-gaap:DebtInstrumentPaymentTerms" contextRef="P01_01_2023To12_31_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis" id="ixv-26665">The Company has the option to repay either (i)&#160;in cash, with premium equal to&#160;<ix:nonFraction name="sclx:DebtInstrumentPrincipalAmountPercentage" contextRef="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-26666">5</ix:nonFraction>% in respect of the principal amount of such payment, or (ii)&#160;by submitting a notice for an advance under the A&amp;R Yorkville Purchase Agreement, or a series of advances thereunder, or any combination of (i)&#160;or (ii) as determined by the Company. In the case of (ii), the proceeds from the shares sold to Yorkville are applied against the outstanding amounts.</ix:nonNumeric> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><ix:nonNumeric name="us-gaap:DebtInstrumentRedemptionDescription" contextRef="P01_01_2023To12_31_2023" id="ixv-26667">The Company has the right, but not the obligation, in its sole discretion, to redeem, upon five business days&#8217; prior written notice to Yorkville (the &#8220;Redemption Notice&#8221;), all or any portion of the amounts outstanding under the Convertible Debentures; provided that the trading price of the Common Stock is less than the Conversion Price at the time of the Redemption Notice. The redemption amount shall be equal to the outstanding principal balance being redeemed by the Company, plus the redemption premium of <ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentage" contextRef="P01_01_2023To12_31_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-26668">10</ix:nonFraction>% of the principal amount being redeemed, plus all accrued and unpaid interest in respect of such redeemed principal amount.</ix:nonNumeric> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has elected the fair value option for the Convertible Debentures and records the changes in the fair value within the consolidated statements of operations at the end of each reporting period. Pursuant to the </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-22</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_107552740" continuedAt="TextSelectionAppend_107552740_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552740_1" continuedAt="TextSelectionAppend_107552740_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552740_2" continuedAt="TextSelectionAppend_107552740_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_107552740_3" continuedAt="TextSelectionAppend_107552740_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yorkville SPA, the Company issued additional Convertible Debentures in an aggregate principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentIssuedPrincipal" contextRef="P04_30_2023To04_30_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26670">15.0</ix:nonFraction>&#160;million in April 2023 for $<ix:nonFraction name="sclx:NetCashProceeds" contextRef="P04_30_2023To04_30_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26671">14.4</ix:nonFraction>&#160;million in net cash proceeds. In April 2023, Yorkville elected to convert $<ix:nonFraction name="us-gaap:PrincipalAmountOutstandingOfLoansHeldInPortfolio" contextRef="PAsOn12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26672">5.0</ix:nonFraction>&#160;million of the outstanding principal and accrued interest of the first Convertible Debentures issued to Yorkville, resulting in the issuance of <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-26673">632,431</ix:nonFraction> shares of Common Stock at a conversion price of $<ix:nonFraction name="us-gaap:CommonStockConvertibleConversionPriceIncrease" contextRef="P01_01_2023To12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-26674">8.00</ix:nonFraction>&#160;per share and reducing the outstanding Convertible Debentures fair value balance by $<ix:nonFraction name="sclx:DebtInstrumentOutstandingPrincipal" contextRef="P01_01_2023To12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26675">4.4</ix:nonFraction>&#160;million. The Company repaid $<ix:nonFraction name="us-gaap:DebtInstrumentRepaidPrincipal" contextRef="P01_01_2023To12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26676">15.6</ix:nonFraction>&#160;million of the Convertible Debentures during the year ended December&#160;31, 2023. <div style="-sec-ix-hidden:hidden107552752;display:inline;">Interest expense related to the Convertible Debentures and included in the changes in fair value</div> was $<ix:nonFraction name="us-gaap:ServicingLiabilityAtFairValueOtherChangesInFairValue" contextRef="P01_01_2023To12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26677">0.7</ix:nonFraction>&#160;million for the year ended December&#160;31, 2023. </div><ix:nonNumeric name="us-gaap:ConvertibleDebtTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-19852"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a summary of the changes in the balance and the estimated fair value of the Convertible Debentures (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:80%"/>
<td style="vertical-align:bottom;width:13%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beginning Balance as of January&#160;1, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="PAsOn12_31_2022_ConvertibleDebtSecuritiesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26678">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Convertible Debentures</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NotesIssued1" contextRef="P01_01_2023To12_31_2023_ConvertibleDebtSecuritiesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26679">24,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayment of Convertible Debentures</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="sclx:RepaymentOfConvertibleDebenture" contextRef="P01_01_2023To12_31_2023_ConvertibleDebtSecuritiesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26680">15,625</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of Convertible Debentures</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ChangeInFairValueOfConvertibleDebentures" contextRef="P01_01_2023To12_31_2023_ConvertibleDebtSecuritiesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26681">3,700</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Conversion of Convertible Debentures into Common Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="sclx:ConversionOfConvertibleDebenturesIntoCommonStock" contextRef="P01_01_2023To12_31_2023_ConvertibleDebtSecuritiesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26682">7,735</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="PAsOn12_31_2023_ConvertibleDebtSecuritiesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26683">4,340</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Revolving Facility </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;27, 2023, Scilex Pharma entered into the eCapital Credit Agreement, pursuant to which the Lender shall make available the Revolving Facility in an aggregate principal amount of up to $<ix:nonFraction name="us-gaap:FinancingReceivableRevolvingConvertedToTermLoan" contextRef="PAsOn06_27_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26684">30.0</ix:nonFraction>&#160;million. The Facility Cap may, at the request of Scilex Pharma and with the consent of the Lender, be increased in increments of $<ix:nonFraction name="sclx:DebtInstrumentOutstandingPrincipal" contextRef="P06_27_2023To06_27_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-26685">250,000</ix:nonFraction>&#160;at such time as the outstanding principal balance under the eCapital Credit Agreement equals or exceeds <ix:nonFraction name="sclx:ExistingFacilityCapMaximum" contextRef="P06_27_2023To06_27_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-26686">95</ix:nonFraction>% of the then-existing Facility Cap. The amount available to Scilex Pharma under the Revolving Facility at any one time is the lesser of the Facility Cap and <ix:nonFraction name="sclx:ExistingFacilityCapMinimum" contextRef="P06_27_2023To06_27_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-26687">85</ix:nonFraction>% of the Net Collectible Value of Eligible Receivables (each as defined therein) minus the amount of any reserves or adjustments against receivables required by the Lender, in its discretion. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the eCapital Credit Agreement, interest will accrue daily on the principal amount outstanding at a rate per annum equal to the Wall Street Journal Prime Rate plus <ix:nonFraction name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" contextRef="P07_01_2023To07_01_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-26688">1.5</ix:nonFraction>%, based on a year consisting of 360 days, and which shall be payable by Scilex Pharma monthly in arrears, commencing July&#160;1, 2023. The eCapital Credit Agreement provides for an early termination fee of <ix:nonFraction name="sclx:TerminationFees" contextRef="PAsOn12_31_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-26689">0.5</ix:nonFraction>% of the Facility Cap if Scilex Pharma voluntarily prepays and terminates in full the Revolving Facility prior to the first anniversary of the closing of the Revolving Facility. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the eCapital Credit Agreement, Scilex Pharma and the Lender entered into blocked account control agreements with respect to Scilex Pharma&#8217;s collections and eCapital Credit Agreement funding accounts, which permit the Lender to sweep all funds in the collections account to an account of the Lender for application to the outstanding amounts under the Revolving Facility, and to exercise customary secured party remedies with respect to the eCapital Credit Agreement funding account. All indebtedness incurred and outstanding under the eCapital Credit Agreement will be due and payable in full on July&#160;1, 2026, unless the eCapital Credit Agreement is earlier terminated. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The eCapital Credit Agreement contains a financial covenant requiring Scilex Pharma to maintain cash on hand of at least $<ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn12_31_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26690">1.0</ix:nonFraction>&#160;million at all times. Scilex Pharma&#8217;s obligations under the eCapital Credit Agreement are secured by a continuing security interest in Scilex Pharma&#8217;s accounts receivable, arising from customers in the ordinary </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-23</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_107552740_4" continuedAt="TextSelectionAppend_107552740_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552740_5" continuedAt="TextSelectionAppend_107552740_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552740_6" continuedAt="TextSelectionAppend_107552740_7"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_107552740_7" continuedAt="TextSelectionAppend_107552740_8"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">course of business. The eCapital Credit Agreement contains customary events of default and also provides that an event of default includes a change of control of Scilex Pharma and the failure by the Company to issue at least $<ix:nonFraction name="us-gaap:DebtInstrumentIssuedPrincipal" contextRef="P01_01_2023To12_31_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26692">75.0</ix:nonFraction>&#160;million of debt or equity by September&#160;30, 2023, which condition was satisfied by the issuance of the Oramed Note. As of December&#160;31, 2023, Scilex Pharma has an outstanding balance of $<ix:nonFraction name="us-gaap:PrincipalAmountOutstandingOfLoansHeldInPortfolio" contextRef="PAsOn12_31_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26693">17.0</ix:nonFraction>&#160;million under the Revolving Facility, which is classified as a long-term liability in the consolidated balance sheet. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;21, 2023, Scilex Pharma signed a subordination agreement (the &#8220;Subordination Agreement&#8221;) with the Lender and Acquiom Agency Services LLC (the &#8220;Agent&#8221;). Pursuant to the Subordination Agreement, the rights and interests of the Lender under the eCapital Credit Agreement would be secured by first priority liens on the ABL Priority Collateral (as defined therein). The ABL Priority Collateral consists of all of the Company&#8217;s properties identified in the description of collateral in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">UCC-1</div> Financing Statement filed with the Delaware Secretary of State on June&#160;27, 2023. The Agent&#8217;s rights and interests under that certain Subsidiary Guarantee, dated as of September&#160;21, 2023, entered into by us and each of our subsidiaries with Oramed and the Agent (the &#8220;Subsidiary Guarantee&#8221;), would be secured by first priority liens on certain other collateral and second priority liens on the ABL Priority Collateral. The Subordination Agreement also includes other standard interlender terms and requires that the Facility Cap (as defined therein) shall not exceed $<ix:nonFraction name="us-gaap:FinancingReceivableRevolvingConvertedToTermLoan" contextRef="PAsOn09_21_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26694">30.0</ix:nonFraction>&#160;million. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">The Oramed Note </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;21, 2023, the Company entered into a securities purchase agreement with Oramed (the &#8220;Scilex-Oramed SPA&#8221;), pursuant to which the Company issued the Oramed Note. The Oramed Note, which has a principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentIssuedPrincipal" contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26695">101.9</ix:nonFraction>&#160;million, matures on <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P09_21_2023To09_21_2023_FristInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-26696">March 21, 2025</ix:nonNumeric>. It is payable in six principal installments, with the first installment of $<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P09_21_2023To09_21_2023_FristInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26697">5.0</ix:nonFraction>&#160;million payable on <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P09_21_2023To09_21_2023_SecondInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-26698">December 21, 2023</ix:nonNumeric>, the second installment in the principal amount of $<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P09_21_2023To09_21_2023_SecondInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26699">15.0</ix:nonFraction>&#160;million payable on <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_ThirdInstallmentMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en" id="ixv-26700">March 21, 2024</ix:nonNumeric>, the next three installments each in the principal amount of $<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ThirdInstallmentMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26701">20.0</ix:nonFraction>&#160;million payable on each of <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P09_21_2023To09_21_2023_FourthInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-26702">June 21, 2024</ix:nonNumeric>, <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P09_21_2023To09_21_2023_FiveInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-26703">September 21, 2024</ix:nonNumeric> and <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SixInstallmentMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en" id="ixv-26704">December 21, 2024</ix:nonNumeric> and the last installment in the entire remaining principal balance of the Oramed Note payable on <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-26705">March 21, 2025</ix:nonNumeric>. <ix:nonNumeric name="us-gaap:DebtInstrumentDescription" contextRef="P01_01_2023To12_31_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" id="ixv-19957">Interest under the Oramed Note accrues at a fluctuating per annum interest rate equal to the sum of (1)&#160;greater of (x) <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-26706">4</ix:nonFraction>% and (y)&#160;Term SOFR (as defined in the Oramed Note) and (2) <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="P09_21_2023To09_21_2023_MonthlyBasisMemberSCLXDebtPayableAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-26707">8.5</ix:nonFraction>%, payable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-kind</div> on a monthly basis. If the outstanding principal has not been fully repaid by March&#160;21, 2024, an exit fee of approximately $<ix:nonFraction name="sclx:DebtRepaymentExitFee" contextRef="PAsOn09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26708">3.1</ix:nonFraction>&#160;million becomes due upon repayment. Upon the occurrence and during the continuance of an event of default under the Oramed Note, holders of more than <ix:nonFraction name="sclx:DebtInstrumentOwnedPercentage" contextRef="PAsOn09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-26709">50</ix:nonFraction>% of the aggregate unpaid principal amount of the Oramed Notes may elect to accrue interest at a default rate equal to the lesser of (i)&#160;Term SOFR plus <ix:nonFraction name="sclx:DebtInstrumentDefaultInterestRate" contextRef="PAsOn09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-26710">15</ix:nonFraction>% or (ii)&#160;the maximum rate permitted under applicable law. Voluntary prepayments made before the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> anniversary of the closing date of the Scilex-Oramed SPA must include a make-whole amount equal to <ix:nonFraction name="sclx:DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount" contextRef="PAsOn09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-26711">50</ix:nonFraction>% of the additional interest that would accrue on the principal amount so prepaid from the date of such prepayment through and including the maturity date. If the Oramed Note is accelerated upon an event of default, repayment is required at a mandatory default rate of <ix:nonFraction name="sclx:DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount" contextRef="PAsOn09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-26712">125</ix:nonFraction>% of the principal amount (together with <ix:nonFraction name="sclx:DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest" contextRef="PAsOn09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-26713">100</ix:nonFraction>% of accrued and unpaid interest thereon and all other amounts due in respect of the Oramed Note). The Oramed Note contains mandatory prepayment provisions requiring use of <ix:nonFraction name="sclx:PercentageOfUsageOfCashProceedsFromCashSweepFinancing" contextRef="PAsOn09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-26714">70</ix:nonFraction>% of net cash proceeds from any Cash Sweep Financing (as defined in the Oramed Note) or advances under the ELOCs (as defined in the Oramed Note) to prepay the outstanding principal after the earlier of April&#160;1, 2024 or full repayment of Acceptable Indebtedness (as defined in the Oramed Note).</ix:nonNumeric> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Oramed Note contains affirmative and negative covenants binding on the Company and its subsidiaries, which restrict, among other things, the Company and its subsidiaries from incurring indebtedness or liens, amending charter and organizational documents, repaying or repurchasing stock, repaying, repurchasing, or acquiring indebtedness, paying or declaring cash dividends, assigning, selling, transferring or otherwise disposing of assets, making or holding investments, entering into transactions with affiliates, and entering into settlement agreements, in each case as more fully set forth in, and subject to certain qualifications and exceptions set forth in, the Oramed Note. The Company was in compliance with all of the covenants as of December&#160;31, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Oramed Note, the Company and each of its subsidiaries (collectively, the &#8220;Guarantors&#8221;) entered into a security agreement (the &#8220;Security Agreement&#8221;) with Oramed (together with its successors and </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-24</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_107552740_8" continuedAt="TextSelectionAppend_107552740_9"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552740_9" continuedAt="TextSelectionAppend_107552740_10"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552740_10" continuedAt="TextSelectionAppend_107552740_11"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_107552740_11"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">permitted assigns, the &#8220;Holder&#8221;) and the Agent, which acts as the collateral agent for the holders of the Oramed Note. Under this agreement, the Company and the Guarantors granted to the Agent (on behalf of and for the benefit of the holders of the Oramed Note and any Additional Notes as defined thereunder) a security interest in all or substantially all of the properties of the Company and each of the Guarantors. This was done to ensure the timely payment, performance, and full discharge of all obligations under the Oramed Note. The Security Agreement contains certain customary representations, warranties and covenants regarding the collateral thereunder, all of which are detailed in the Security Agreement. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At issuance, the Company concluded that certain features of the Oramed Note would be considered derivatives that would require bifurcation. In lieu of bifurcating such features, the Company has elected the fair value option for this financial instrument and records the changes in the fair value within the consolidated statements of operations at the end of each reporting period. As of December&#160;31, 2023, the fair value of the Oramed Note was $<ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn12_31_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26716">104.1</ix:nonFraction>&#160;million, which is classified as a current liability in the consolidated balance sheet. </div><ix:nonNumeric name="sclx:ScheduleOfTheOramedNoteTableTextBlock" contextRef="P01_01_2023To12_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis" escape="true" id="ixv-19982"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a summary of the changes in the balance and the estimated fair value of the Oramed Note (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:80%"/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beginning Balance as of January&#160;1, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="PAsOn12_31_2022_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26717">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Oramed Note</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NotesIssued1" contextRef="P01_01_2023To12_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26718">106,252</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of Oramed Note</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:ChangeInFairValueOfConvertibleDebentures" contextRef="P01_01_2023To12_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26719">2,837</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayment of Oramed Note</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="sclx:RepaymentOfConvertibleDebenture" contextRef="P01_01_2023To12_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26720">5,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="PAsOn12_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26721">104,089</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_107552717" id="ixv-20051"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">8. Junior DIP Facility and Sorrento Stock Purchase Agreement </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Junior DIP Facility </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2023, the Company entered into an agreement to provide Sorrento with a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-amortizing</div> super-priority junior secured term loan facility (&#8220;Junior DIP Facility&#8221;) in an aggregate principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn07_05_2023_JuniorDipFacilityMemberusgaapLongtermDebtTypeAxis_SorrentoMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26722">20.0</ix:nonFraction>&#160;million (the &#8220;Junior DIP Loan Agreement&#8221;), which was funded in the same month. The Junior DIP Facility bears interest at a per annum rate of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="P07_05_2023To07_05_2023_JuniorDipFacilityMemberusgaapLongtermDebtTypeAxis_SorrentoMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-26723">12.0</ix:nonFraction>% payable in kind on the first day of each month in arrears and on the DIP Termination Date (as defined in the Junior DIP Loan Agreement). Upon repayment or satisfaction of the DIP Loans (as defined in the Junior DIP Loan Agreement) in whole or in part, Sorrento is required to pay to the Company in cash an exit fee equal to <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn07_05_2023_JuniorDipFacilityMemberusgaapLongtermDebtTypeAxis_SorrentoMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-26724">2.00</ix:nonFraction>% of the aggregate principal amount of the Junior DIP Facility. <ix:nonNumeric name="us-gaap:DebtInstrumentDescription" contextRef="P07_05_2023To07_05_2023_JuniorDipFacilityMemberusgaapLongtermDebtTypeAxis_SorrentoMemberusgaapBusinessAcquisitionAxis" id="ixv-26725">The Junior DIP Facility was to mature on the earliest of: (i)&#160;September&#160;30, 2023; (ii) the effective date of any Chapter 11 plan of reorganization with respect to Sorrento; (iii)&#160;the consummation of any sale or other disposition of all or substantially all of the assets of Sorrento; (iv)&#160;the date of the acceleration of the DIP Loans and the termination of the DIP Commitments (as defined in the Junior DIP Loan Agreement) in accordance with the DIP Documents (as defined in the Junior DIP Loan Agreement); and (v)&#160;dismissal of the Chapter 11 Cases or conversion of the Chapter 11 Cases into cases under Chapter 7 of the Bankruptcy Code.</ix:nonNumeric> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;21, 2023, Sorrento&#8217;s obligations under the Junior DIP Facility were waived and deemed to be fully settled in conjunction with the Sorrento SPA as described below. Consequently, the transfer of funds associated with the Junior DIP Facility was deemed and accounted for as a capital distribution to Sorrento. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sorrento Stock Purchase Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;21, 2023, the Company entered into a Stock Purchase Agreement with Sorrento (&#8220;Sorrento SPA&#8221;), pursuant to which the Company purchased from Sorrento (i) <ix:nonFraction name="sclx:SharesPurchasedUnderStockPurchaseAgreement" contextRef="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-26726">60,068,585</ix:nonFraction> shares of Common Stock, (ii)&#160;<ix:nonFraction name="sclx:SharesPurchasedUnderStockPurchaseAgreement" contextRef="PAsOn09_21_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-26727">29,057,097</ix:nonFraction> shares of Series A Preferred Stock, par value $<ix:nonFraction name="sclx:SharesPurchasedAtParValueUnderStockPurchaseAgreement" contextRef="PAsOn09_21_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-26728">0.0001</ix:nonFraction> per share, of the Company (the &#8220;Preferred </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-25</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_107552717" continuedAt="TextSelectionAppend_107552717_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552717_1" continuedAt="TextSelectionAppend_107552717_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552717_2" continuedAt="TextSelectionAppend_107552717_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_107552717_3" continuedAt="TextSelectionAppend_107552717_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock&#8221;) and (iii) <ix:nonFraction name="sclx:SharesPurchasedUnderStockPurchaseAgreement" contextRef="PAsOn09_21_2023_PublicWarrantsMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-26730">1,386,617</ix:nonFraction> Public Warrants and <ix:nonFraction name="sclx:SharesPurchasedUnderStockPurchaseAgreement" contextRef="PAsOn09_21_2023_PrivateWarrantsMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-26731">3,104,000</ix:nonFraction> Private Warrants (collectively, the &#8220;Purchased Securities&#8221;). On the same day, the Company and Oramed entered into the Scilex-Oramed SPA. The Company concluded that the Sorrento SPA and the Scilex-Oramed SPA were entered in contemplation of each other and the issuance of the Oramed Note was accounted as part of the consideration payable for the Purchased Securities acquired from Sorrento. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Scilex-Oramed SPA, the Company issued the Oramed Note (see Note 7), which replaced Sorrento&#8217;s outstanding obligations to Oramed, warrants to purchase up to an aggregate of <ix:nonFraction name="sclx:IssueOfWarrantsToPurchaseShares" contextRef="PAsOn09_21_2023_ClosingPennyWarrantMemberusgaapClassOfWarrantOrRightAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-26732">4,500,000</ix:nonFraction> shares of Common Stock (the &#8220;Closing Penny Warrant&#8221;) with an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn09_21_2023_ClosingPennyWarrantMemberusgaapClassOfWarrantOrRightAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-26733">0.01</ix:nonFraction> per share and restrictions on exercisability, and warrants to purchase up to an aggregate of <ix:nonFraction name="sclx:IssueOfWarrantsToPurchaseShares" contextRef="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-26734">8,500,000</ix:nonFraction> shares of Common Stock (the &#8220;Subsequent Penny Warrants&#8221; and together with the Closing Penny Warrant, the &#8220;Penny Warrants&#8221;), each with an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-26735">0.01</ix:nonFraction> per share and each with restrictions on exercisability. Additionally, the Company agreed to transfer to Oramed <ix:nonFraction name="sclx:TransferOfWarrants" contextRef="PAsOn09_21_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-26736">4,000,000</ix:nonFraction> SPAC Warrants, which were acquired by the Company under the Sorrento SPA. There was no change in the terms for the warrants transferred to Oramed as a result of the transactions described above. The remaining consideration for the Purchased Securities was comprised of a credit bid for all amounts of principal and accrued but unpaid interest outstanding under the Junior DIP Facility, a $<ix:nonFraction name="sclx:CashPayment" contextRef="P09_21_2023To09_21_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26737">10.0</ix:nonFraction>&#160;million cash payment, and the assumption and assignment of certain obligations of Sorrento for legal fees and expenses amounting to approximately $<ix:nonFraction name="us-gaap:LegalFees" contextRef="P09_21_2023To09_21_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26738">12.3</ix:nonFraction>&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company allocated the total consideration between the repurchased instruments by allocating to the repurchased Private Warrants their full value, with the remaining consideration allocated to the Common Stock, Preferred Stock, and Public Warrants based on their relative fair values as of September&#160;21, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before the closing of the Sorrento SPA transactions and in connection with the transactions contemplated by the Sorrento SPA, the Company formed two entities: (a)&#160;Scilex DRE Holdings LLC (&#8220;Holdco&#8221;), a single purpose entity that is the Company&#8217;s direct wholly owned subsidiary and (b)&#160;Scilex Stock Acquisition Joint Venture LLC, a single purpose bankruptcy-remote entity that is the Company&#8217;s indirect wholly owned subsidiary (&#8220;SCLX JV&#8221;), which was formed to hold the Purchased Securities. Holdco was formed to hold all of the equity interests in SCLX JV. Holdco and SCLX JV are parties to the Security Agreement and Subsidiary Guarantee (see Note 7). </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preferred Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Sorrento SPA, the Company repurchased all of the outstanding Preferred Stock. The Preferred Stock is classified in equity and does not have any bifurcated features. Therefore, the repurchase of the Preferred Stock by the Company is treated as a redemption of shares and viewed as a deemed dividend. The fair value of Preferred Stock as of the repurchase date of September&#160;21, 2023 was $<ix:nonFraction name="sclx:FairValueOfSharesRepurchased" contextRef="P09_21_2023To09_21_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26739">52.6</ix:nonFraction>&#160;million. The Company derecognized the carrying value of the Preferred Stock, with any excess amount allocated as the reduction in additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital. The Preferred Stock is currently held as collateral for the Oramed Note. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Treasury Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Common Stock that has been repurchased by the Company under the Sorrento SPA is not intended for constructive retirement, and is being held as collateral for the Oramed Note. In accordance with treasury stock accounting guidance, the consideration allocated to Common Stock is presented under a separate caption of Treasury Stock as a reduction of equity. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Penny Warrants </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Closing Penny Warrant will be exercisable upon the earliest of (i)&#160;<ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" contextRef="P01_01_2023To12_31_2023_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt:date-monthname-day-year-en" id="ixv-26740">March 14, 2025</ix:nonNumeric>, (ii) the date on which the Oramed Note has been repaid in full and (iii)&#160;the Management Sale Trigger Date (as defined therein), if any, and will expire on the date that is the fifth anniversary of the issuance date. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-26</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_107552717_4" continuedAt="TextSelectionAppend_107552717_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552717_5" continuedAt="TextSelectionAppend_107552717_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552717_6" continuedAt="TextSelectionAppend_107552717_7"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_107552717_7"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company issued four Subsequent Penny Warrants, each for <ix:nonFraction name="sclx:IssueOfWarrantsToPurchaseShares" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants2MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-26742"><ix:nonFraction name="sclx:IssueOfWarrantsToPurchaseShares" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants3MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-26743"><ix:nonFraction name="sclx:IssueOfWarrantsToPurchaseShares" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants4MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-26744"><ix:nonFraction name="sclx:IssueOfWarrantsToPurchaseShares" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants1MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-26745">2,125,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;shares of Common Stock, one of which shall vest and become exercisable on the date that is the later of (i)&#160;each of <ix:nonNumeric name="sclx:WarrantVestingDate" contextRef="P01_01_2023To12_31_2023_SubsequentPennyWarrants1MemberusgaapClassOfWarrantOrRightAxis" format="ixt:date-monthname-day-year-en" id="ixv-26746">March 19, 2024</ix:nonNumeric>, <ix:nonNumeric name="sclx:WarrantVestingDate" contextRef="P01_01_2023To12_31_2023_SubsequentPennyWarrants2MemberusgaapClassOfWarrantOrRightAxis" format="ixt:date-monthname-day-year-en" id="ixv-26747">June 17, 2024</ix:nonNumeric>, <div style="display:inline;"></div><ix:nonNumeric name="sclx:WarrantVestingDate" contextRef="P01_01_2023To12_31_2023_SubsequentPennyWarrants3MemberusgaapClassOfWarrantOrRightAxis" format="ixt:date-monthname-day-year-en" id="ixv-20116"><div style="display:inline;">September 15</div>, 2024</ix:nonNumeric> or <ix:nonNumeric name="sclx:WarrantVestingDate" contextRef="P01_01_2023To12_31_2023_SubsequentPennyWarrants4MemberusgaapClassOfWarrantOrRightAxis" format="ixt:date-monthname-day-year-en" id="ixv-26748"><ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" contextRef="P01_01_2023To12_31_2023_MinimumMembersrtRangeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt:date-monthname-day-year-en" id="ixv-26749">December 14, 2024</ix:nonNumeric></ix:nonNumeric> (the &#8220;Subsequent Penny Warrant Vesting Date&#8221;) and (ii)&#160;the earliest of (A)&#160;<ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" contextRef="P01_01_2023To12_31_2023_MaximumMembersrtRangeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt:date-monthname-day-year-en" id="ixv-26750">March 14, 2025</ix:nonNumeric>, (B) the date on which the Oramed Note has been repaid in full and (C)&#160;the Management Sale Trigger Date (as defined therein), if any. Each Subsequent Penny Warrant will expire on the date that is the fifth anniversary of the issuance date; provided that, if the Oramed Note is repaid in full prior to the Subsequent Penny Warrant Vesting Date applicable to such Subsequent Penny Warrant, such Subsequent Penny Warrant will expire on the date the Oramed Note is repaid in full. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exercise price of the Penny Warrants is $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn09_21_2023_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-26751">0.01</ix:nonFraction> per share, subject to adjustments provided therein. The exercise price and number of shares of Common Stock issuable upon the exercise of the Penny Warrants will be subject to adjustment in the event of any stock dividend, stock split, recapitalization, reorganization or similar transaction, as described in the Penny Warrants; provided that there shall not be any adjustment to the exercise price of the Penny Warrants in the event the Company combines (by combination, reverse stock split or otherwise) its Common Stock into a smaller number of shares. Oramed may exercise the Penny Warrants by means of a &#8220;cashless exercise.&#8221; The Closing Penny Warrant and the Subsequent Penny Warrants utilize the same form of warrant. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Penny Warrants may not be exercised if Oramed, together with its affiliates, would beneficially own in excess of <ix:nonFraction name="sclx:NumberOfShareOutstanding" contextRef="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-26752">9.9</ix:nonFraction>% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise (the &#8220;Oramed Beneficial Ownership Limitation&#8221;); provided, however, that upon 61 days&#8217; prior notice to the Company, Oramed may increase or decrease the Oramed Beneficial Ownership Limitation. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounted for the Penny Warrants as an equity classified instrument as they are indexed to the Company&#8217;s own stock and meet the conditions to be classified in equity under FASB ASC 815, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Derivatives and Hedging,</div></div> including sufficient available shares for the Company to settle the exercise of the warrants in shares. The Penny Warrants are recognized in additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital in the Company&#8217;s consolidated balance sheets. The fair value of Penny Warrants as of September&#160;21, 2023, the date of issuance, was $<ix:nonFraction name="sclx:FairValueOfWarrants" contextRef="PAsOn09_21_2023_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26753">10.4</ix:nonFraction>&#160;million. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Excise Tax </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2022, the Department of the Treasury and the Internal Revenue Service (the &#8220;IRS&#8221;) issued guidelines on the implementation of the new code section added by the Inflation Reduction Act of 2022, which imposes a 1% excise tax on the total fair market value of stock repurchases during the tax year, subject to adjustments. Pursuant to the terms of the Sorrento SPA, the Company repurchased the Purchased Securities from Sorrento. The total fair market value of the Purchased Securities was offset by the fair market value of the shares issued during the year ended December&#160;31, 2023. The Company has accrued $<ix:nonFraction name="us-gaap:SalesAndExciseTaxPayableCurrent" contextRef="PAsOn12_31_2023_SorrentoMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26754">1.3</ix:nonFraction>&#160;million of the excise tax liability, which is recorded as accrued expenses under current liabilities on the consolidated balance sheet. The excise tax will be adjusted based on any new guidance that the IRS may release. </div></ix:continuation><ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_107552724" id="ixv-20128"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">9. Stockholders&#8217; Equity </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">SPAC Warrants </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the completion of the Business Combination, the Company assumed the SPAC Warrants. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of the SPAC Warrants are entitled to acquire shares of Common Stock. The SPAC Warrants will expire five years after the completion of the Business Combination or earlier upon redemption or liquidation. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the reported last sale price of the Common Stock equals or exceeds $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-26755">18.00</ix:nonFraction> per share for any 20 trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-trading</div> day period ending three business days before the Company sends the notice of redemption to the warrant holders, the Company may redeem all the Public Warrants at a price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2023_WarrantsMemberusgaapAwardTypeAxis_WarrantTransferAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-26756">0.01</ix:nonFraction> per warrant upon not less than 30 days&#8217; prior written notice. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-27</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_107552724" continuedAt="TextSelectionAppend_107552724_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552724_1" continuedAt="TextSelectionAppend_107552724_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552724_2" continuedAt="TextSelectionAppend_107552724_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_107552724_3" continuedAt="TextSelectionAppend_107552724_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company calls the Public Warrants for redemption, the Company will have the option to require all holders that wish to exercise the Public Warrants to do so on a cashless basis. The Company will not be required to net cash settle the SPAC Warrants. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Public Warrants are equity-classified warrants and recognized in additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital in the accompanying consolidated balance sheets. The Private Warrants are liability-classified warrants and are recognized as liabilities (refer to Notes 1 and 4). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&#160;31, 2023, the SPAC Warrants held by Sorrento were repurchased, and certain of such warrants transferred to Oramed, as a result of the Sorrento SPA (refer to Note 8). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023 and 2022, there were <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-26758">6,854,309</ix:nonFraction>&#160;and <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-26759">6,899,988</ix:nonFraction> Public Warrants outstanding, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023 and 2022, there were <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2023_WarrantsMemberusgaapAwardTypeAxis_WarrantTransferAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-26760">3,613,383</ix:nonFraction>&#160;and <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2022_WarrantsMemberusgaapAwardTypeAxis_WarrantTransferAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-26761">4,104,000</ix:nonFraction> Private Warrants outstanding, respectively. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Preferred Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023 and 2022, there were <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2022_PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-26762"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2023_PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-26763">29,057,097</ix:nonFraction></ix:nonFraction> shares of Preferred Stock outstanding. On September&#160;21, 2023, the Preferred Stock was repurchased and derecognized for accounting purposes. The Preferred Stock is currently held as collateral for the Oramed Note. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Treasury Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, there were <ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="PAsOn12_31_2023_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-26764">60,068,585</ix:nonFraction> shares of Treasury Stock. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">A&amp;R Yorkville Purchase Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the A&amp;R Yorkville Purchase Agreement, the Company has the right, but not the obligation, in its sole and absolute discretion, to sell to Yorkville up to $<ix:nonFraction name="sclx:RightToSellMaximumNumberOfCommonStockShares" contextRef="P01_01_2023To12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26765">500.0</ix:nonFraction>&#160;million of shares of Common Stock at its request and subject to certain conditions by delivering written notice to Yorkville at any time until the first day of the month following the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">36-month</div> anniversary of the date on which the Company&#8217;s registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</div> registering such shares has been declared effective by the SEC. Pursuant to the A&amp;R Yorkville Purchase Agreement, the shares of Common Stock, if any, that the Company elects to sell to Yorkville pursuant to a sale of Common Stock will be purchased at a price equal to <ix:nonFraction name="sclx:PurchaseOfStockPercentage" contextRef="PAsOn12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-26766">98</ix:nonFraction>% of the VWAP (as defined below) during the applicable pricing period for such advance, which shall be the period commencing upon receipt by Yorkville of an advance notice from the Company (or the open of regular trading hours, if later) and ending on 4:00 p.m. on the same day. For purposes of the A&amp;R Yorkville Purchase Agreement, &#8220;VWAP&#8221; means, for a specified period, the volume weighted average price of the Common Stock on the Nasdaq Capital Market for such period as reported by Bloomberg L.P. through its &#8220;AQR&#8221; function. Pursuant to the terms of the Original Purchase Agreement, the Company filed a registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</div> (File <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-268607)</div> (as it may be amended or supplemented from time to time, the &#8220;Yorkville Registration Statement&#8221;) related to the Original Purchase Agreement with the SEC on November&#160;30, 2022 (following the execution of the Original Purchase Agreement). The Yorkville Registration Statement was initially declared effective by the SEC on December&#160;9, 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the execution of the Original Purchase Agreement, the Company issued to Yorkville <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2023To12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis_CommonStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-26767">250,000</ix:nonFraction> shares of Common Stock. During the year ended December&#160;31, 2023, the Company sold <ix:nonFraction name="sclx:CommonStockSold" contextRef="P01_01_2023To12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-26768">11,552,074</ix:nonFraction> shares of Common Stock pursuant to the A&amp;R Yorkville Purchase Agreement for aggregate net proceeds of&#160;$<ix:nonFraction name="sclx:ProceedsFromSaleOfCommonStock" contextRef="P01_01_2023To12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26769">32.3</ix:nonFraction>&#160;million. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">B. Riley Purchase Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the B. Riley Purchase Agreement, the Company has the right, but not the obligation, to sell to B.&#160;Riley up to $<ix:nonFraction name="sclx:RightToSellMaximumNumberOfCommonStockShares" contextRef="P11_17_2022To11_17_2022_BRileyPurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26770">500.0</ix:nonFraction>&#160;million of shares of Common Stock, subject to certain limitations and conditions set forth </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-28</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_107552724_4" continuedAt="TextSelectionAppend_107552724_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552724_5" continuedAt="TextSelectionAppend_107552724_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552724_6" continuedAt="TextSelectionAppend_107552724_7"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_107552724_7" continuedAt="TextSelectionAppend_107552724_8"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">therein, from time to time at the Company&#8217;s sole and absolute discretion, during the term of the B. Riley Purchase Agreement. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s right to sell shares of Common Stock pursuant to the B. Riley Purchase Agreement shall end on the first day of the month following the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">36-month</div> anniversary of the date on which the B. Riley Registration Statement (as defined below) was initially declared effective by the SEC. Pursuant to the terms of the B. Riley Purchase Agreement, the Company filed a registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</div> (File <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-269205)</div> (as it may be amended or supplemented from time to time, the &#8220;B. Riley Registration Statement&#8221;) related to the B. Riley Purchase Agreement with the SEC on January&#160;12, 2023 (following the execution of the B. Riley Purchase Agreement). The B. Riley Registration Statement was initially declared effective by the SEC on January&#160;20, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares of Common Stock, if any, that the Company elects to sell to B. Riley pursuant to an advance under the B. Riley Purchase Agreement will be purchased at a price equal to <ix:nonFraction name="sclx:PurchaseOfStockPercentage" contextRef="PAsOn12_31_2023_BRileyPurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-26772">98</ix:nonFraction>% of the VWAP (as defined in such agreement) during the pricing period prescribed therein. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the execution of the B. Riley Purchase Agreement, the Company issued to B. Riley <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2023_BRileyPurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-26773">250,000</ix:nonFraction> shares of Common Stock. During the year ended December&#160;31, 2023, the Company sold an aggregate of <ix:nonFraction name="sclx:CommonStockSold" contextRef="P01_01_2023To12_31_2023_BRileyPurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-26774">1,414,554</ix:nonFraction> shares of Common Stock for aggregate net proceeds of $<ix:nonFraction name="sclx:ProceedsFromSaleOfCommonStock" contextRef="P01_01_2023To12_31_2023_BRileyPurchaseAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26775">3.2</ix:nonFraction>&#160;million. On, and effective as of, February&#160;16, 2024, the Company and B. Riley mutually agreed to terminate the B. Riley Purchase Agreement. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Stock Issued under Settlement Agreement with Hudson Bay Parties </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2023, the Company, along with Hudson Bay Capital Management LP (&#8220;Hudson Bay&#8221;), Cove Lane Onshore Fund, LLC (&#8220;Cove Lane&#8221;), and HBC Investments LLC (&#8220;HBC&#8221; and collectively, the &#8220;Hudson Bay Parties&#8221;), entered into several agreements. Under these agreements, the Company agreed to issue and sell up to $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="P08_31_2023To08_31_2023_HudsonBayMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26776">118.6</ix:nonFraction>&#160;million in securities and warrants to the Hudson Bay Parties. However, on September&#160;15, 2023, a settlement agreement was reached and released all claims related to the previous agreements. The Company acknowledged payments of $<ix:nonFraction name="us-gaap:PaymentsOfDividends" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-4" scale="6" format="ixt:num-dot-decimal" id="ixv-26777">8.65</ix:nonFraction>&#160;million made to the Hudson Bay Parties as properly earned. To satisfy remaining obligations, the Company agreed to issue shares of Common Stock to Cove Lane and HBC worth $<ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2023_CoveLaneMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26778">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2023_HudsonBayMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26779">0.5</ix:nonFraction>&#160;million, respectively. This resulted in the issuance of an aggregate of <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn09_25_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-26780">474,683</ix:nonFraction>&#160;shares of Common Stock on September&#160;25, 2023. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">At-the-Market</div></div> Sales Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;22, 2023, the Company entered into a Sales Agreement (the &#8220;ATM Sales Agreement&#8221;) with B. Riley Securities, Inc., Cantor Fitzgerald&#160;&amp; Co. and H.C. Wainwright&#160;&amp; Co., LLC (the &#8220;Sales Agents&#8221;). Pursuant to the ATM Sales Agreement, the Company may offer and sell (the &#8220;Offering&#8221;) shares of Common Stock up to $<ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P12_22_2023To12_22_2023_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis_MaximumMembersrtRangeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-26781">170,000,000</ix:nonFraction> (the &#8220;ATM Shares&#8221;), through or to the Sales Agents. The Company has no obligation to sell any shares of Common Stock under the ATM Sales Agreement and may suspend offers at any time. The Offering will terminate upon (i)&#160;the election of the Sales Agents upon the occurrence of certain adverse events, (ii)&#160;three business days&#8217; advance notice from the Company to the Sales Agents or a Sales Agent to the Company, or (iii)&#160;the sale of all $<ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P12_22_2023To12_22_2023_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-26782">170,000,000</ix:nonFraction> of shares of Common Stock thereunder. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ATM Shares offered and sold in the Offering will be issued pursuant to the Company&#8217;s shelf registration statement on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;S-3&#160;(the</div> &#8220;Shelf <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3</div> Registration Statement&#8221;), filed with the SEC on December&#160;22, 2023, and declared effective by the SEC on January&#160;11, 2024. The ATM Shares may be offered only by means of a prospectus forming a part of the Shelf <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3</div> Registration Statement. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sales Agents are entitled to a commission equal to <ix:nonFraction name="sclx:ProceedSOfSaleOfCommonSharesPercentage" contextRef="P01_01_2023To12_31_2023_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-26783">3.0</ix:nonFraction>% of the gross proceeds from each sale of shares of Common Stock. The Company will also reimburse the Sales Agents for certain expenses and has agreed to </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-29</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_107552724_8" continuedAt="TextSelectionAppend_107552724_9"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552724_9" continuedAt="TextSelectionAppend_107552724_10"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552724_10" continuedAt="TextSelectionAppend_107552724_11"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_107552724_11"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provide indemnification and contribution to the Sales Agents against certain civil liabilities, including liabilities under the&#160;Securities Act. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, no sales of Common Stock had been made under the ATM Sales Agreement. </div></ix:continuation><ix:nonNumeric name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_107553159" id="ixv-20237"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">10. Stock Incentive and Employee Benefit Plan </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">2017 Scilex Pharmaceuticals Inc. Equity Incentive Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2017, the Board of Directors of the Company adopted the Scilex Pharmaceuticals Inc. Equity Incentive Plan (the &#8220;Scilex Pharma 2017 Plan&#8221;). In connection with the corporate reorganization in March 2019, the Scilex Pharma 2017 Plan was terminated. Accordingly, after such time, no additional awards were granted under the Scilex Pharma 2017 Plan. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Scilex Holding Company 2019 Stock Option Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2019, the Board of Directors of the Company adopted the Scilex Holding Company 2019 Stock Option Plan (the &#8220;2019 Stock Option Plan&#8221;), which subsequently was amended in December 2020. The 2019 Stock Option Plan was terminated at the closing of the Business Combination, and no further awards have been granted under the 2019 Stock Option Plan thereafter. However, the 2019 Stock Option Plan will continue to govern outstanding awards granted thereunder. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Scilex Holding Company 2022 Equity Incentive Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2022, the Board of Directors of the Company adopted the Scilex Holding Company 2022 Equity Incentive Plan (the &#8220;Equity Incentive Plan&#8221;). The total number of shares of Common Stock for which incentive stock options (&#8220;ISOs&#8221;) may be granted under the Equity Incentive Plan is not to exceed <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2022_MaximumMembersrtRangeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-26785">20,276,666</ix:nonFraction> shares, which was increased from <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-26786">14,622,712</ix:nonFraction> as a result of the automatic annual increase on January&#160;1, 2023 pursuant to the Equity Incentive Plan provisions. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&#160;4, 2023, the Company&#8217;s stockholders approved the amendment to the Equity Incentive Plan to (i)&#160;increase the number of shares authorized for issuance thereunder by <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="PAsOn05_04_2023_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-26787">10,000,000</ix:nonFraction> shares from <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="PAsOn05_04_2023_MinimumMembersrtRangeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-26788">20,276,666</ix:nonFraction> shares to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="PAsOn05_04_2023_MaximumMembersrtRangeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-26789">30,276,666</ix:nonFraction> shares, (ii)&#160;increase the number of shares authorized for issuance thereunder pursuant to the exercise of ISOs to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="PAsOn05_04_2023_MaximumMembersrtRangeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-26790">30,276,666</ix:nonFraction> shares, and (iii)&#160;modify the commencement date of the automatic increase in the number of shares authorized for issuance thereunder pursuant to the exercise of ISOs to January&#160;1, 2024. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, options to purchase <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2023_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-26791">33,123,798</ix:nonFraction> shares of Common Stock were outstanding under all equity incentive plans. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div>recently determined that the aggregate value of all compensation granted or paid to each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director for the fiscal year ending December&#160;31, 2023 (when aggregated with any remaining compensation payable for the remainder of such fiscal year) would inadvertently exceed the $<ix:nonFraction name="sclx:Sharebasedcompensationpayable" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-26792">750,000</ix:nonFraction> annual compensation limit for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors (the &#8220;Compensation Limit&#8221;) under the Equity Incentive Plan, as a result of the previously disclosed equity grants made thereunder to such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors in January 2023 (the &#8220;Awards&#8221;). As a result, the Company&#8217;s current <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors, David Lemus and Dorman Followwill, and the Company&#8217;s former <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Tien-Li</div> Lee and Laura Hamill, each voluntarily agreed to forfeit (i)&#160;a number of shares of Common Stock subject to their Awards or (ii)&#160;a combination of shares of Common Stock subject to their Awards and cash compensation payable by the Company for such person&#8217;s service as a director for the remainder of 2023, in each case in an amount that would bring each such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director&#8217;s aggregate compensation for the fiscal year ending December&#160;31, 2023 below the Compensation Limit. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors forfeited an aggregate of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="P01_01_2023To12_31_2023_NonEmployeeDirectorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-26793">311,735</ix:nonFraction> shares of Common Stock and an aggregate of approximately $<ix:nonFraction name="us-gaap:DeferredCompensationCashBasedArrangementsLiabilityCurrent" contextRef="PAsOn12_31_2023_NonEmployeeDirectorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-26794">107,424</ix:nonFraction> in cash compensation. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-30</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_107553159" continuedAt="TextSelectionAppend_107553159_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107553159_1" continuedAt="TextSelectionAppend_107553159_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107553159_2" continuedAt="TextSelectionAppend_107553159_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_107553159_3" continuedAt="TextSelectionAppend_107553159_4"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Scilex Holding Company 2023 Inducement Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;17, 2023, the compensation committee of the Board of Directors of the Company adopted the Scilex Holding Company 2023 Inducement Plan (the &#8220;Inducement Plan&#8221;). The Inducement Plan provides for the grant of equity-based awards in the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-statutory</div> stock options, stock appreciation rights, restricted stock, restricted stock units, and other awards solely to prospective employees of the Company or an affiliate of the Company, provided that certain criteria are met. The initial maximum number of shares available for grant under the Inducement Plan is <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="PAsOn01_17_2023_TwoThousandTwentyThreeInducementPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-26796">1,400,000</ix:nonFraction> shares of Common Stock (subject to adjustment for recapitalizations, stock splits, reorganizations and similar transactions). No awards were granted under the Inducement Plan during the year ended December&#160;31, 2023. </div><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-20288"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes stock option activity during the year ended December&#160;31, 2023 (shares in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:48%"/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Exercise&#160;Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Remaining<br/> Contractual&#160;Life,<br/> in years</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> Intrinsic&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding as of December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-26797">16,939</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-26798">1.68</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:duryear" id="ixv-26799">7.0</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26800">38,942</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-26801">17,610</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-26802">7.02</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-26803">365</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-26804">1.68</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited/Cancelled</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-26805">1,060</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-26806">6.36</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding as of December&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-26807">33,124</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-26808">4.38</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:duryear" id="ixv-26809">7.5</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26810">7,459</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable as of December&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-26811">18,990</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-26812">2.78</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:duryear" id="ixv-26813">6.3</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26814">5,600</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the Common Stock for the options that had exercise prices that were lower than the per share fair value of the Common Stock as of the measurement date of the intrinsic value. The weighted-average grant date fair value per share of stock options granted during the year ended December&#160;31, 2023 was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-26815">3.24</ix:nonFraction> per share. The total intrinsic values of options exercised during the years ended December&#160;31, 2023, 2022, and 2021 were $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26816">1.1</ix:nonFraction>&#160;million, $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26817">0.3</ix:nonFraction>&#160;million, and nil, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total stock-based compensation recorded within operating expenses was $<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2023To12_31_2023_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26818">14.6</ix:nonFraction>&#160;million, $<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26819">5.3</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2021To12_31_2021_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26820">5.8</ix:nonFraction>&#160;million for the years ended December&#160;31, 2023, 2022 and 2021, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total unrecognized compensation costs related to unvested employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> stock option grants as of December&#160;31, 2023 were $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26821">42.4</ix:nonFraction>&#160;million, which the Company expects to recognize over a weighted-average period of approximately <ix:nonNumeric name="sclx:WeightedAveragePeriodOverGrant" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:duryear" id="ixv-26822">3.1</ix:nonNumeric> years. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Scilex Holding Company 2022 Employee Stock Purchase Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2022, the Board of Directors of the Company adopted the Scilex Holding Company 2022 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The purchase price of the Common Stock is equal to&#160;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" contextRef="P10_01_2022To10_31_2022_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-26823">85</ix:nonFraction>% of the lesser of the market value of such shares at the beginning of an offering period or the date of purchase. As of December&#160;31, 2023, the total number of shares of Common Stock that may be issued under the ESPP shall not exceed <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2023_MaximumMembersrtRangeAxis_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-26824">2,875,759</ix:nonFraction>, which was increased from <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2023_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-26825">1,462,271</ix:nonFraction> shares as a result of automatic annual increase on January&#160;1, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total stock-based compensation recorded as operating expense for the ESPP was $<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2023To12_31_2023_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal" id="ixv-26826">21.0</ix:nonFraction>&#160;thousand and <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-26827">nil</ix:nonFraction> for the year ended December&#160;31, 2023 and 2022, respectively. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-31</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_107553159_4" continuedAt="TextSelectionAppend_107553159_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107553159_5" continuedAt="TextSelectionAppend_107553159_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107553159_6" continuedAt="TextSelectionAppend_107553159_7"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_107553159_7"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Valuation Assumptions </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company calculates the fair value of stock options and ESPP awards granted to employees and nonemployees using the Black-Scholes option-pricing method. The Black-Scholes option-pricing method requires the use of subjective assumptions. </div><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-20541"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following assumptions were used in the Black-Scholes options pricing model to estimate stock-based compensation on the date of grant for stock options and ESPP: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:72%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> December&#160;31, 2023</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock options:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2023To12_31_2023_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_StockOptionMemberusgaapFinancialInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-26829">0.00</ix:nonFraction>%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2023To12_31_2023_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_MinimumMembersrtRangeAxis_StockOptionMemberusgaapFinancialInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-26830">40.00</ix:nonFraction>%&#160;-&#160;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2023To12_31_2023_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_MaximumMembersrtRangeAxis_StockOptionMemberusgaapFinancialInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-26831">77.00</ix:nonFraction>%</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="P01_01_2023To12_31_2023_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_StockOptionMemberusgaapFinancialInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-26832">3.59</ix:nonFraction>%&#160;-&#160;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="P01_01_2023To12_31_2023_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_StockOptionMemberusgaapFinancialInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-26833">4.74</ix:nonFraction>%</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Term of options (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2023To12_31_2023_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_StockOptionMemberusgaapFinancialInstrumentAxis" format="ixt-sec:duryear" id="ixv-26834">6.25</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Employee stock purchase plan:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2023To12_31_2023_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_EmployeeStockPurchasePlanMemberusgaapFinancialInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-26835">0.00</ix:nonFraction>%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2023To12_31_2023_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_EmployeeStockPurchasePlanMemberusgaapFinancialInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-26836">117.57</ix:nonFraction>%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="P01_01_2023To12_31_2023_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_EmployeeStockPurchasePlanMemberusgaapFinancialInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-26837">5.33</ix:nonFraction>%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected life (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2023To12_31_2023_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_EmployeeStockPurchasePlanMemberusgaapFinancialInstrumentAxis" format="ixt-sec:duryear" id="ixv-26838">0.50</ix:nonNumeric></td></tr></table></ix:nonNumeric><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Employee Benefit Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company maintains a defined contribution 401(k) plan available to eligible employees. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company made matching contributions to the 401(k) plan totaling $<ix:nonFraction name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26839">0.5</ix:nonFraction>&#160;million, $<ix:nonFraction name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26840">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26841">0.3</ix:nonFraction>&#160;million for the years ended December&#160;31, 2023, 2022 and 2021, respectively. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Retainer Shares </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;13, 2023, the Company entered into a Stock Issuance Agreement (the &#8220;SIA&#8221;) with a law firm for the provision of legal services to the Company. Under the SIA, the Company issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="P02_13_2023To02_13_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-26842">4,000,000</ix:nonFraction> shares of Common Stock to the law firm (the &#8220;Retainer Shares&#8221;). The Retainer Shares are held by the law firm as collateral for the current and future outstanding legal fees due from the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the option of the law firm, the Retainer Shares may be sold and the net proceeds may be applied against the outstanding legal fees. The Retainer Shares not applied against the outstanding legal fees due will be returned to the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, it was <ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-26843">no</ix:nonFraction>t probable that any of the Retainer Shares would be applied against any outstanding legal fees. </div></ix:continuation><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_107553191" id="ixv-20618"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">11. Commitments and Contingencies </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Product Development Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2013, Scilex Pharma became a party to a product development agreement (as amended, the &#8220;Product Development Agreement&#8221;) with Itochu and Oishi Koseido Co., Ltd. (&#8220;Oishi,&#8221; and together with Itochu, the &#8220;Developers&#8221;), pursuant to which the Developers will manufacture and supply lidocaine tape products, including ZTlido and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div> (the &#8220;Products&#8221;), for Scilex Pharma. The Developers initially developed and have intellectual property rights relating to the Products. Pursuant to the Product Development Agreement, Scilex Pharma acquired an exclusive right to develop and commercialize the Products worldwide except for Japan. The Developers are responsible for sourcing and supplying lidocaine for development and commercialization purposes. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-32</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_107553191" continuedAt="TextSelectionAppend_107553191_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107553191_1" continuedAt="TextSelectionAppend_107553191_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107553191_2" continuedAt="TextSelectionAppend_107553191_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_107553191_3" continuedAt="TextSelectionAppend_107553191_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Product Development Agreement, Scilex Pharma is required to make aggregate royalty payments between <ix:nonFraction name="sclx:RoyaltyPaymentPercentageRelatedToFutureYears" contextRef="P02_01_2013To02_28_2013_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MinimumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-26845">25</ix:nonFraction>% and <ix:nonFraction name="sclx:RoyaltyPaymentPercentageRelatedToFutureYears" contextRef="P02_01_2013To02_28_2013_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MaximumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-26846">35</ix:nonFraction>% to the Developers based on net profits. For the years ended December&#160;31, 2023 and 2022, Scilex Pharma made royalty payments in the amount of $<ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="P01_01_2023To12_31_2023_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26847">8.3</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="P01_01_2022To12_31_2022_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26848">2.3</ix:nonFraction>&#160;million. As of December&#160;31, 2023 and 2022, Scilex Pharma had ending balances of accrued royalty payables of $<ix:nonFraction name="us-gaap:RoyaltyGuaranteesCommitmentsAmount" contextRef="PAsOn12_31_2023_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26849">2.4</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:RoyaltyGuaranteesCommitmentsAmount" contextRef="PAsOn12_31_2022_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26850">2.2</ix:nonFraction>&#160;million, respectively. Total royalty expense recorded within cost of revenue was $<ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="P01_01_2023To12_31_2023_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26851">8.5</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="P01_01_2022To12_31_2022_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26852">4.5</ix:nonFraction>&#160;million for the years ended December&#160;31, 2023 and 2022, respectively. Net profits are defined as net sales, less cost of goods and marketing expenses. Net sales are defined as total gross sales of any Product, less all applicable deductions, to the extent accrued, paid or allowed in the ordinary course of business with respect to the sale of such Product, and to the extent that they are in accordance with GAAP. If Scilex Pharma were to sublicense the licensed technologies, the Developers will receive the same proportion of any sublicensing fees received therefrom. The Product Development Agreement will continue in full force and effect until <ix:nonNumeric name="sclx:AgreementMaturityDate" contextRef="P02_01_2013To02_28_2013_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" format="ixt:date-monthname-day-year-en" id="ixv-26853">October 2, 2028</ix:nonNumeric>, the date that is ten years from the date of the first commercial sale of ZTlido. <ix:nonNumeric name="sclx:MaturityRenewalDescription" contextRef="P02_01_2013To02_28_2013_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" id="ixv-20645">The Product Development Agreement will renew automatically for subsequent successive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> renewal periods unless Scilex Pharma or the Developers terminate it upon <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-month</div> written notice.</ix:nonNumeric> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;16, 2017, Scilex Pharma entered into a Commercial Supply Agreement (as amended, the &#8220;Supply Agreement&#8221;) with the two Developers to provide commercial supply of ZTlido and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div> to Scilex Pharma. The Supply Agreement contains standard terms regarding term, termination, payment, product quality and supply. In addition, the agreement provides additional terms regarding the calculation and amount of marketing expenses that may be deducted from net sales for purposes of determining the amount of net profit under the Product Development Agreement. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Litigation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the normal course of business, the Company may be named as a defendant in one or more lawsuits. Other than the following four lawsuits, the Company is not a party to any outstanding material litigation and management is not aware of any legal proceedings that, individually or in the aggregate, are deemed to be material to the Company&#8217;s financial condition or results of operations. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time the Company may become involved in various legal proceedings, including those that may arise in the ordinary course of business. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc. Litigation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;23, 2021, the Company filed an action (the &#8220;Action&#8221;) in the U.S. District Court for the Northern District of California against Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc., two manufacturers of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">over-the-counter</div></div> (&#8220;OTC&#8221;) lidocaine patch products, alleging, among other things, false and deceptive advertising and unfair competition under the Lanham Act and California state laws by those companies regarding their respective OTC patch products. This lawsuit sought, among other relief, damages and an injunction enjoining the defendants from continuing to make false or misleading statements of fact about their respective OTC lidocaine patch products. The defendants filed motions to dismiss, which narrowed slightly the Company&#8217;s claims, but which motions the court largely rejected. Discovery was proceeding. On January&#160;26 and February&#160;2, 2024, Scilex Pharma entered into two separate settlement agreements and mutual releases with the two manufacturers that resolve the Action. The terms of those agreements are confidential. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Former Employee Action </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;12, 2021, Scilex Pharma and Sorrento (the &#8220;Plaintiffs&#8221;) filed an action (the &#8220;Former Employee Action&#8221;) in the Delaware Court of Chancery against the former President of Scilex Pharma, Anthony Mack, and Virpax Pharmaceuticals, Inc. (&#8220;Virpax&#8221;, together with Mr.&#160;Mack, the &#8220;Defendants&#8221;), a company founded and then headed by Mr.&#160;Mack, alleging, among other things, breach by Mr.&#160;Mack of a restrictive covenant agreement with Sorrento related to his sale of his Scilex Pharma stock to Sorrento, tortious interference with that agreement </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-33</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_107553191_4" continuedAt="TextSelectionAppend_107553191_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107553191_5" continuedAt="TextSelectionAppend_107553191_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107553191_6" continuedAt="TextSelectionAppend_107553191_7"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_107553191_7" continuedAt="TextSelectionAppend_107553191_8"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">by Virpax, breach of Mr.&#160;Mack&#8217;s fiduciary duties to Scilex Pharma, aiding and abetting of that breach by Virpax, and misappropriation of Scilex Pharma&#8217;s trade secrets by Mr.&#160;Mack and Virpax. Such lawsuit sought, among other relief, damages and various forms of injunctive relief. The case was tried from September&#160;12, 2022 to September&#160;14, 2022. On September&#160;1, 2023, the court found in favor of the Plaintiffs on all but three counts deemed to have been waived. In its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">95-page</div> opinion, the court instructed the parties to submit supplemental briefing on the appropriate remedy to implement its rulings. On October&#160;18, 2023, the Plaintiffs submitted a supplemental brief on remedies. On November&#160;29, 2023, Defendants submitted a supplemental brief on remedies. On December&#160;21, 2023, the Plaintiffs submitted a supplemental reply brief on remedies. On February&#160;26, 2024, the Company and Virpax entered into a term sheet regarding a mutual release and settlement agreement, pursuant to which the parties have agreed to resolve the ongoing disputes. On February&#160;29, 2024, the Company and Virpax entered into a definitive settlement agreement, which provides for, among other things, that Virpax will be obligated to make the following payments to the Company to settle the Former Employee Action: (i) $<ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="P01_01_2023To12_31_2023_FormerEmployeeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26855">3.5</ix:nonFraction>&#160;million (the &#8220;Initial Payment&#8221;) by two business days after the Effective Date (as defined therein); (ii) $<ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="P01_01_2023To12_31_2023_FormerEmployeeOneMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26856">2.5</ix:nonFraction>&#160;million by July&#160;1, 2024 and (iii)&#160;to the extent any of the following drug candidates are ever sold, royalty payments of (a) <ix:nonFraction name="sclx:RoyaltyPaymentPercentageOnNetSale" contextRef="P01_01_2023To12_31_2023_EpoladermMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-26857">6</ix:nonFraction>% of annual Net Sales (as defined therein) of Epoladerm; (b) <ix:nonFraction name="sclx:RoyaltyPaymentPercentageOnNetSale" contextRef="P01_01_2023To12_31_2023_ProbudurMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-26858">6</ix:nonFraction>% of annual Net Sales of Probudur and (c) <ix:nonFraction name="sclx:RoyaltyPaymentPercentageOnNetSale" contextRef="P01_01_2023To12_31_2023_EnveltaMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-26859">6</ix:nonFraction>% of annual Net Sales of Envelta during the Royalty Term (as defined therein). The Company and Virpax provide mutual releases of all claims that exist as of the Effective Date, whether known or unknown, arising from any allegations set forth in the Former Employee Action. Plaintiffs&#8217; release relates to claims against Virpax only, which does not affect its claims against Mr.&#160;Mack. Plaintiffs have not released Mr.&#160;Mack, and litigation against him remains ongoing. Plaintiffs&#8217; release as to Virpax is conditioned upon Virpax&#8217;s Initial Payment. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ZTlido Patent Litigation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2022, the Company filed a complaint against Aveva Drug Delivery Systems, Inc. (&#8220;Aveva&#8221;), Apotex Corp., and Apotex, Inc. (together, &#8220;Apotex&#8221;) in the U.S. District Court for the Southern District of Florida (the &#8220;ZTlido Patent Litigation&#8221;) alleging infringement of certain Orange Book listed patents covering ZTlido (the &#8220;ZTlido Patents&#8221;). The ZTlido Patent Litigation was initiated following the submission by Apotex, in accordance with the procedures set out in the Hatch-Waxman Act, of an abbreviated new drug application (&#8220;ANDA&#8221;). Apotex&#8217;s ANDA seeks approval to market a generic version of ZTlido prior to the expiration of the ZTlido Patents and alleges that the ZTlido Patents are invalid, unenforceable, and/or not infringed. The Company is seeking, among other relief, an order that the effective date of any FDA approval of Apotex&#8217;s ANDA be no earlier than the expiration of the asserted patents listed in the Orange Book, the latest of which expires on May&#160;10, 2031, and such further and other relief as the court may deem appropriate. Apotex is subject to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-month</div> stay preventing it from selling a generic version of ZTlido during that time. The stay should expire no earlier than November&#160;11, 2024. The two Apotex entities were recently dismissed from the litigation without prejudice, as they no longer have an interest in the generic product that Aveva seeks to market. Trial in the ZTlido Patent Litigation has been scheduled for July&#160;8, 2024. The Company cannot make any predictions about the final outcome of this matter or the timing thereof. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">GLOPERBA Patent Litigation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;6, 2023, Takeda Pharmaceuticals U.S.A., Inc. (&#8220;Takeda&#8221;) filed a complaint against the Company in the U.S. District Court for the District of Delaware (the &#8220;GLOPERBA Patent Litigation&#8221;) alleging that the Company&#8217;s filing with the FDA of an application for approval of a proposed revision to the product label for its GLOPERBA product infringed certain Orange Book listed patents covering Takeda&#8217;s colchicine product, Colcrys<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#160;</div>(the &#8220;Colcrys Patents&#8221;). Takeda is seeking an order that the effective date of any FDA approval of the Company&#8217;s labeling revision be no earlier than the expiration date of the asserted patents listed in the Orange Book, and such further and other relief as the court may deem appropriate. The filing of the complaint subjects the Company to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-month</div> stay, preventing it from selling GLOPERBA under a revised label (but not from selling GLOPERBA under its current label) during that time. The Company cannot make any predictions about the final outcome of this matter or the timing thereof. The stay could last as long as until May&#160;6, 2026, unless the </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-34</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_107553191_8" continuedAt="TextSelectionAppend_107553191_9"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107553191_9" continuedAt="TextSelectionAppend_107553191_10"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107553191_10" continuedAt="TextSelectionAppend_107553191_11"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_107553191_11" continuedAt="TextSelectionAppend_107553191_12"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">litigation is resolved before that time. As of December&#160;31, 2023, the Company accrued $<ix:nonFraction name="sclx:DueFromRelatedParty" contextRef="PAsOn12_31_2023_GloperbaMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26861">0.5</ix:nonFraction>&#160;million with respect to the GLOPERBA Patent Litigation. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Operating Leases </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company leases administrative and research and development facilities under various <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancelable</div> lease agreements. Facility leases generally provide for periodic rent increases and may include options to extend. As of December&#160;31, 2023, the Company&#8217;s leases have remaining lease terms of approximately <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" contextRef="PAsOn12_31_2023_MinimumMembersrtRangeAxis_NonCancelableLeaseAgreementsMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentFacilitiesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear" id="ixv-26862">0.7</ix:nonNumeric> to <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" contextRef="PAsOn12_31_2023_MaximumMembersrtRangeAxis_NonCancelableLeaseAgreementsMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentFacilitiesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear" id="ixv-26863">3.8</ix:nonNumeric> years. The terms of the Company&#8217;s leases, ranging from <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="PAsOn12_31_2023_MinimumMembersrtRangeAxis_NonCancelableLeaseAgreementsMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentFacilitiesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear" id="ixv-26864">3</ix:nonNumeric> to <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="PAsOn12_31_2023_MaximumMembersrtRangeAxis_NonCancelableLeaseAgreementsMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentFacilitiesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear" id="ixv-26865">5</ix:nonNumeric> years, include extension options that were not reasonably certain to be exercised. Many of the Company&#8217;s leases are subject to variable lease payments. Variable lease payments are recognized in the period in which the obligations for those payments are incurred, are not included in the measurement of the ROU assets or lease liabilities, and are immaterial. Additionally, the Company subleases certain properties to third parties. Sublease income is recognized on a straight-line basis and is immaterial. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company calculates the associated lease liability and corresponding ROU asset upon lease commencement using a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. As of December&#160;31, 2023, the Company has <ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-26866">no</ix:nonFraction> <div style="-sec-ix-hidden:hidden107553186;display:inline;">finance leases</div>. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2023, the Company modified the lease term for its principal executive offices located in Palo Alto, California. The modification extended the lease term for an additional three years, with the lease term expiring in September 2027. As a result of the modification, the Company recognized additional ROU assets and corresponding lease liabilities of $<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn04_30_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26867"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn04_30_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26868">2.5</ix:nonFraction></ix:nonFraction>&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lease expense was $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26869">1.1</ix:nonFraction>&#160;million, $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26870">0.5</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26871">0.6</ix:nonFraction>&#160;million for the years ended December&#160;31, 2023, 2022 and 2021, respectively, and was primarily comprised of operating lease costs. The lease expense also included variable lease costs and sublease income, which were immaterial for the periods presented. </div><ix:nonNumeric name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-20722"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Supplemental quantitative information related to leases includes the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:78%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash paid for amounts included in the measurement of lease liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating cash flows from operating leases (in thousands)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26872">1,021</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26873">746</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average remaining lease term in years &#8212; operating leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2023" format="ixt-sec:duryear" id="ixv-26874">3.6</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2022" format="ixt-sec:duryear" id="ixv-26875">1.8</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average discount rate &#8212; operating leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-26876">11.1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-26877">11.8</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-35</ix:exclude> </div></ix:continuation></div></div></div><ix:continuation id="TextSelectionAppend_107553191_12" continuedAt="TextSelectionAppend_107553191_13"><div></div></ix:continuation></div><div><div style="line-height:normal;background-color:white;display: inline;"><ix:continuation id="TextSelectionAppend_107553191_13" continuedAt="TextSelectionAppend_107553191_14"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107553191_14" continuedAt="TextSelectionAppend_107553191_15"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107553191_15" continuedAt="TextSelectionAppend_107553191_16"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_107553191_16"><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-20819"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approximate future minimum lease payments under operating leases were as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:86%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26879">1,042</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26880">916</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26881">944</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26882">724</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26883">3,626</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less imputed interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26884">630</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26885">2,996</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less current portion of lease liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26886">759</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liability, net of current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:LeaseLiabilityNetOfCurrentPortion" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26887">2,237</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_107553203" id="ixv-20933"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">12. Income Taxes </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total loss before income taxes for the years ended December&#160;31, 2023, 2022 and 2021 did not include a foreign component. </div><ix:nonNumeric name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-20937"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of the provision expense (benefit) were as follows for the years ended December&#160;31, 2023, 2022 and 2021 (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:64%"/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current income tax expense (benefit):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26888">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26889">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26890">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26891">13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26892">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26893">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26894">13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26895">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26896">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred income tax expense (benefit):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26897">16,514</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26898">10,396</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26899">12,981</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26900">11,247</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26901">1,851</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26902">2,472</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26903">27,761</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26904">12,247</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26905">15,453</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in tax rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26906">1,471</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26907">1,347</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26908">31</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26909">29,232</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26910">10,900</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26911">15,422</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total income tax expense from continuing operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26912">13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26913">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26914">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-36</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_107553203" continuedAt="TextSelectionAppend_107553203_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107553203_1" continuedAt="TextSelectionAppend_107553203_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107553203_2" continuedAt="TextSelectionAppend_107553203_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_107553203_3" continuedAt="TextSelectionAppend_107553203_4"><ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-21243"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of the Company&#8217;s net deferred tax liabilities and related valuation allowance are as follows as of December&#160;31, 2023 and 2022 (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:72%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating loss carryforwards</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26916">71,434</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26917">48,984</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Debt related interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:DeferredTaxAssetsDebtRelatedInterest" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26918">16,898</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:DeferredTaxAssetsDebtRelatedInterest" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26919">15,272</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capitalized research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26920">4,936</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26921">2,014</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Tax credit carryforwards</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26922">3,960</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26923">1,630</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock based compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26924">525</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26925">1,602</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expense and reserves</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:DeferredTaxAssetsAccruedExpenseAndReserves" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26926">1,584</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:DeferredTaxAssetsAccruedExpenseAndReserves" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26927">568</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:DeferredTaxAssetsOperatingLeaseLiabilities" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26928">774</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:DeferredTaxAssetsOperatingLeaseLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26929">315</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26930">159</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26931">77</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26932">100,270</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26933">70,462</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26934">96,776</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26935">67,543</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26936">3,494</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26937">2,919</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26938">2,734</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26939">2,666</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26940">760</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26941">253</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26942">3,494</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26943">2,919</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net deferred tax liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26944">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26945">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-21550"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The reconciliation between U.S. federal income taxes at the statutory rate and the Company&#8217;s provision for income taxes are as follows for the years ended December&#160;31, 2023, 2022 and 2021 (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:65%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax benefit at federal statutory rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26946">24,007</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26947">4,905</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26948">19,150</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26949">29,232</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26950">10,900</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26951">15,422</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Debt discount and interest limitation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:EffectiveIncomeTaxRateReconciliationDebtDiscountAmount" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26952">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="sclx:EffectiveIncomeTaxRateReconciliationDebtDiscountAmount" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26953">9,293</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:EffectiveIncomeTaxRateReconciliationDebtDiscountAmount" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26954">8,954</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Compensation expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26955">3,798</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26956">2,469</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26957">224</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquisition related charges</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:IncomeTaxReconciliationAcquisitionRelatedCharges" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26958">260</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:IncomeTaxReconciliationAcquisitionRelatedCharges" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26959">992</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:IncomeTaxReconciliationAcquisitionRelatedCharges" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26960">75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prior year <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">true-up</div> and carryback</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26961">5,079</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26962">713</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26963">3,968</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State, net of federal tax benefit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26964">5,127</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26965">174</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26966">2,545</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of Convertible Debentures</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26967">1,752</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26968">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26969">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in tax rates</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="sclx:EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-26970">1,471</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26971">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26972">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26973">655</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26974">728</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26975">993</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26976">13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26977">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26978">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has evaluated the available evidence supporting the realization of its gross deferred tax assets, including the amount and timing of future taxable income, and has determined that it is more likely than not that the deferred tax assets will not be realized. Due to such uncertainties surrounding the realization of the deferred tax assets, the Company maintains a valuation allowance of $<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26979">96.8</ix:nonFraction>&#160;million against its deferred tax assets as of December&#160;31, 2023. Realization of the deferred tax assets will be primarily dependent upon the Company&#8217;s ability to generate sufficient taxable income prior to the expiration of its net operating losses. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, the Company had $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26980">278.7</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26981">114.0</ix:nonFraction>&#160;million of federal and state net operating loss carryforwards, respectively. The net operating loss carryforwards begin to expire in <ix:nonNumeric name="sclx:OperatingLossCarryforwardsExpirationYear" contextRef="P01_01_2023To12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" id="ixv-26982">2035</ix:nonNumeric> and <ix:nonNumeric name="sclx:OperatingLossCarryforwardsExpirationYear" contextRef="P01_01_2023To12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" id="ixv-26983">2034</ix:nonNumeric> for federal and state, respectively. As of December&#160;31, 2023, the Company had a total of $<ix:nonFraction name="sclx:IndefiniteOperatingLossCarryforwards" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26984">265.9</ix:nonFraction>&#160;million of federal net operating losses </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-37</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_107553203_4" continuedAt="TextSelectionAppend_107553203_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107553203_5" continuedAt="TextSelectionAppend_107553203_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107553203_6" continuedAt="TextSelectionAppend_107553203_7"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_107553203_7"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">that have an indefinite life and will not expire, and had federal research and development income tax credits of $<ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26986">3.4</ix:nonFraction>&#160;million which will begin to expire in <ix:nonNumeric name="sclx:IncomeTaxCreditsExpirationYear" contextRef="P01_01_2023To12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" id="ixv-26987">2035</ix:nonNumeric>. As of December&#160;31, 2023, the Company had California research and development income tax credits of $<ix:nonFraction name="sclx:TaxCreditCarryforwardNotSubjectToExpireAmount" contextRef="PAsOn12_31_2023_ResearchMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-26988">1.9</ix:nonFraction>&#160;million that have an indefinite life and will not expire. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Internal Revenue Code Section&#160;382 rules apply to limit a corporation&#8217;s ability to utilize existing net operating loss and tax credit carryforwards once the corporation experiences an ownership change as defined in Section&#160;382. For the years ended December&#160;31, 2023 and 2022, there was no impact of such limitations on the Company&#8217;s income tax provision. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to taxation in U.S. federal and state tax jurisdictions. All of the Company&#8217;s tax years will remain open for three years for examination by the federal and state tax authorities from the date of utilizations of net operating loss. There are no active tax compliance audits as of December&#160;31, 2023. </div><ix:nonNumeric name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-21818"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reconciliation of the beginning and ending amount of unrecognized tax expense (benefits) is as follows for the years ended December&#160;31, 2023, 2022 and 2021 (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:74%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beginning balance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26989">408</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26990">408</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26991">406</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Increase related to prior year tax positions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26992">536</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26993">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26994">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Increases related to current year tax positions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26995">127</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26996">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-26997">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending balance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26998">1,071</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-26999">408</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-27000">408</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, 2022 and 2021, the Company had $<ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-27001">1.1</ix:nonFraction>&#160;million, $<ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-27002">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-27003">0.4</ix:nonFraction>&#160;million in total unrecognized tax benefits, respectively. If these were to be recognized, they would affect the effective tax rate, however given the full valuation allowance in the jurisdiction in which the unrecognized tax benefits relate to, the impact on the effective tax rate would be nil. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense. <ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-27004"><ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-27005"><ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-27006">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> interest or penalties have been recognized as of and for the periods ended December&#160;31, 2023, 2022 and 2021. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company believes that <ix:nonFraction name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-27007">no</ix:nonFraction> material amount of the liabilities for uncertain tax positions are expected to reverse within 12 months of December&#160;31, 2023. </div></ix:continuation><ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_107552591" id="ixv-21956"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">13. Net Loss Per Share </div></div><ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-21959"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the reconciliation of basic and diluted loss per share for the years ended December&#160;31, 2023, 2022 and 2021 (in thousands except per share data): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:60%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-27008">114,331</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-27009">23,364</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-27010">88,424</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Premium on redemption of Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PreferredStockRedemptionPremium" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-27011">52,645</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockRedemptionPremium" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-27012">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockRedemptionPremium" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-27013">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss for basic and diluted loss per share available to common stockholders</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-27014">166,976</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-27015">23,364</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-27016">88,424</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average number of shares outstanding - basic</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-27017">130,298</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-27018">134,226</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-27019">132,858</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effect of dilutive securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:EffectOfDilutiveSecurities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-27020">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:EffectOfDilutiveSecurities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-27021">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="sclx:EffectOfDilutiveSecurities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-27022">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average number of shares and assumed conversions - diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-27023">130,298</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-27024">134,226</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-27025">132,858</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss per share</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-27026"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-27027">1.28</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-27028"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-27029">0.17</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-27030"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-27031">0.67</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-38</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_107552591" continuedAt="TextSelectionAppend_107552591_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552591_1" continuedAt="TextSelectionAppend_107552591_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552591_2" continuedAt="TextSelectionAppend_107552591_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_107552591_3"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic net loss per share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding during the period. Premium paid on redemption of Preferred Stock was added to the net loss to arrive at loss available for common stockholders as it represents a dividend to the preferred stockholder. Diluted earnings per share is computed using the weighted average number of Common Stock and, if dilutive, potential Common Stock outstanding during the period. Potential Common Stock consists of the incremental Common Stock issuable upon the exercise of stock options and warrants (using the treasury stock method). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the computation of net loss per share, treasury shares are not included as part of the outstanding shares. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with FASB ASC 260, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Earnings Per Share, </div></div>Penny Warrants are warrants that would be exercised for no or little consideration and therefore should be included in the calculation of weighted average shares outstanding for purposes of calculating basic and diluted net income (loss) per share. The Closing Penny Warrants become exercisable upon the passage of time and are included in basic and diluted net income (loss) per share from the closing date of September&#160;21, 2023. The Subsequent Penny Warrants to purchase up to an aggregate of <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn09_21_2023_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-27033">8,500,000</ix:nonFraction> shares of Common Stock are not vested as of the closing date of September&#160;21, 2023 and the vesting is based on the passage of time, the Company&#8217;s repayment of the Oramed Note or the occurrence of the Management Sale Trigger Date (as defined therein). Therefore, these Subsequent Penny Warrants are included in the computation for diluted net income per share once all other exercise contingencies are removed except for the passage of time. </div><ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-22204"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:55%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock options</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_StockOptionsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-27034">33,123,798</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022_StockOptionsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-27035">16,939,093</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To12_31_2021_StockOptionsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-27036">18,967,724</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-27037">6,854,309</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022_PublicWarrantsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-27038">6,899,988</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To12_31_2021_PublicWarrantsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-27039">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Private Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_PrivateWarrantsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-27040">3,613,383</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022_PrivateWarrantsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-27041">4,104,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To12_31_2021_PrivateWarrantsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-27042">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Retainer Shares</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_RetainerSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-27043">4,000,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022_RetainerSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-27044">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To12_31_2021_RetainerSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-27045">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares Issuable pursuant to ESPP</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_SharesIssuablePursuantToEsppMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-27046">29,806</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022_SharesIssuablePursuantToEsppMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-27047">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To12_31_2021_SharesIssuablePursuantToEsppMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-27048">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Convertible Debentures</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_ConvertibleDebenturesMemberusgaapDebtInstrumentAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-27049">546,921</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022_ConvertibleDebenturesMemberusgaapDebtInstrumentAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-27050">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To12_31_2021_ConvertibleDebenturesMemberusgaapDebtInstrumentAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-27051">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-27052">48,168,217</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-27053">27,943,081</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-27054">18,967,724</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_107552590" id="ixv-22387"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">14. Subsequent Events </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Termination of B. Riley Purchase Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><ix:nonNumeric name="us-gaap:SubsequentEventDescription" contextRef="P02_16_2024To02_16_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="ixv-27055">On February&#160;16, 2024, the Company and B. Riley mutually agreed to terminate the B. Riley Purchase Agreement. The termination is effective as of February&#160;16, 2024.</ix:nonNumeric> </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Underwritten Offering </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;29, 2024, the Company entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Rodman&#160;&amp; Renshaw LLC and StockBlock Securities LLC, as the representatives (the &#8220;Representatives&#8221;) of the underwriters named in Schedule A (the &#8220;Underwriters&#8221;). Pursuant to the Underwriting Agreement, the Company agreed to sell, in an underwritten offering (the &#8220;Bought Deal Offering&#8221;), <ix:nonFraction name="sclx:CommonStockSold" contextRef="P02_29_2024To02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-27056">5,882,353</ix:nonFraction>&#160;shares (the &#8220;Firm Shares&#8221;) of the Common Stock, and accompanying common warrants to purchase up to an aggregate of <ix:nonFraction name="sclx:PurchaseOfCommonWarrants" contextRef="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-27057">5,882,353</ix:nonFraction>&#160;shares of Common Stock (the &#8220;Firm Warrants&#8221;). Pursuant to the Underwriting Agreement, the Company also granted the Underwriters an option for a period of 30 days from the date of the Underwriting Agreement to purchase up to <ix:nonFraction name="sclx:PurchaseOfCommonShares" contextRef="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-27058">882,352</ix:nonFraction> additional shares of Common Stock (the &#8220;Optional Shares&#8221;, and together with the Firm Shares, the &#8220;Shares&#8221;) and/or common warrants to purchase up to <ix:nonFraction name="sclx:PurchaseOfCommonWarrants" contextRef="PAsOn02_29_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-27059">882,352</ix:nonFraction> shares of Common Stock (the &#8220;Optional Warrants&#8221;, and together with the Firm Warrants, the &#8220;Common Warrants&#8221;) that may be purchased </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-39</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_107552590" continuedAt="TextSelectionAppend_107552590_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552590_1" continuedAt="TextSelectionAppend_107552590_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_107552590_2" continuedAt="TextSelectionAppend_107552590_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_107552590_3"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">by the Underwriters, at a price per Optional Share of $<ix:nonFraction name="sclx:PricePerOptionalShare" contextRef="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-27061">1.5548</ix:nonFraction>&#160;and a price per Optional Warrant of $<ix:nonFraction name="sclx:PricePerOptionalWarrant" contextRef="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-27062">0.0092</ix:nonFraction>, which amounts reflect the public offering price of $<ix:nonFraction name="sclx:PublicOfferingPerOptionalShare" contextRef="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-27063">1.69</ix:nonFraction> per Optional Share and $<ix:nonFraction name="sclx:PublicOfferingPerOptionalWarrant" contextRef="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-27064">0.01</ix:nonFraction>&#160;per Optional Warrant, less underwriting discounts and commissions, as applicable (the &#8220;Underwriters&#8217; Option&#8221;).&#160;Each Firm Share was sold together with a Firm Warrant at a combined public offering price of $<ix:nonFraction name="sclx:PublicOfferingPriceSold" contextRef="PAsOn02_29_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-27065">1.70</ix:nonFraction>. The combined price per Firm Share and accompanying Firm Warrant paid by the Underwriters was $<ix:nonFraction name="sclx:CombinedPricePaidOfWarrant" contextRef="PAsOn02_29_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:num-dot-decimal" id="ixv-27066">1.564</ix:nonFraction>, which amount reflects the combined public offering price of $<ix:nonFraction name="sclx:PublicOfferingPrice" contextRef="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-27067">1.70</ix:nonFraction>, less underwriting discounts and commissions. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to certain ownership limitations, the Common Warrants are exercisable immediately from the date of issuance, will expire on the five-year anniversary of the date of issuance and have an exercise price of $<ix:nonFraction name="sclx:ExercisePriceOfCommonWarrant" contextRef="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-27068">1.70</ix:nonFraction>&#160;per share. The exercise price of the Common Warrants is subject to certain adjustments, including (but not limited to) for stock dividends, stock splits, combinations and reclassifications of the Common Stock. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Bought Deal Offering, the Company agreed, pursuant to the Underwriting Agreement, to issue the Representatives warrants (the &#8220;Representative Warrants&#8221;, and together with the Common Warrants, the &#8220;Warrants&#8221;) to purchase up to an aggregate of <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn02_29_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-27069">470,588</ix:nonFraction> shares of Common Stock (which represents <ix:nonFraction name="sclx:CommonShareSold" contextRef="PAsOn02_29_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-27070">8.0</ix:nonFraction>% of the aggregate number of Firm Shares sold in the Bought Deal Offering), or up to an aggregate of <ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="PAsOn02_29_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-27071">541,176</ix:nonFraction> shares of Common Stock if the Underwriters exercise the Underwriters&#8217; Option in full. The Representative Warrants are immediately exercisable and have the same terms as the Common Warrants described above, except that the exercise price of the Representative Warrants is $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn02_29_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:num-dot-decimal" id="ixv-27072">2.125</ix:nonFraction> per share, which represents <ix:nonFraction name="sclx:PublicOfferingPriceCombined" contextRef="PAsOn02_29_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-27073">125</ix:nonFraction>% of the combined public offering price per Firm Share and accompanying Firm Warrant. The Company also agreed to pay certain expenses of the Representatives in connection with the Bought Deal Offering, including their legal fees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> expenses up to $<ix:nonFraction name="us-gaap:LegalFees" contextRef="P02_29_2024To02_29_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-27074">200,000</ix:nonFraction> and up to $<ix:nonFraction name="sclx:OutOfPocketExpense" contextRef="PAsOn02_29_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-27075">15,950</ix:nonFraction> for clearing expenses. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Shares, the Warrants and the shares of Common Stock issuable upon exercise of the Warrants were offered and sold by us pursuant to an effective shelf registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3,</div> which was originally filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on December&#160;22, 2023, as amended, and was declared effective on January&#160;11, 2024 (File <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-276245),</div> a base prospectus dated January&#160;11, 2024, and a final prospectus supplement dated February&#160;29, 2024. </div></ix:continuation><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-40 </div></div></div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">PART II </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">INFORMATION NOT REQUIRED IN THE PROSPECTUS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;13. Other Expenses of Issuance and Distribution. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth all expenses to be paid by Scilex Holding Company (the &#8220;Registrant&#8221;) in connection with the sale of the Common Stock being registered. The security holders will not bear any portion of such expenses. All amounts shown are estimates except for the registration fee. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:83%"/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,480</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">75,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing, transfer agent fees and miscellaneous expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">203,480</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;14. Indemnification of Directors and Officers. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;102 of the General Corporation Law of the State of Delaware (&#8220;DGCL&#8221;) permits a corporation to eliminate or limit the personal liability of directors and officers of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director or officer, except where the director or officer breached his or her duty of loyalty to the corporation or its stockholders, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase or redemption in violation of the DGCL or derived an improper personal benefit, or, with respect to any officer, any action by or in the right of the corporation. The Registrant&#8217;s restated certificate of incorporation (the &#8220;Certificate of Incorporation&#8221;) contains provisions that limit the liability of our directors and officers for monetary damages to the fullest extent permitted by the DGCL. Consequently, the Registrant&#8217;s directors and officers will not be personally liable to the Registrant or its stockholders for monetary damages for any breach of fiduciary duty as a director or officer, except liability for the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any breach of their duty of loyalty to the Registrant or its stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">with respect to any director, unlawful payments of dividends or unlawful stock repurchases or redemptions in violation of the DGCL; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any transaction from which the director or officer derived an improper personal benefit; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">with respect to any officer, any action by or in the right of the corporation. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation also provides that if the DGCL is amended to permit further elimination or limitation of the personal liability of directors or officers, then the liability of the Registrant&#8217;s directors and officers will be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he or she was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
indemnification shall be made with respect to judgments, fines and amounts paid in settlement in connection with such action, suit or proceeding or with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. The Certificate of Incorporation permits the Registrant to indemnify its directors, officers, employees and other agents to the maximum extent permitted by the DGCL, and the Registrant&#8217;s bylaws (the &#8220;Bylaws&#8221;) provide that the Registrant will indemnify its directors and officers and permit the Registrant to indemnify its employees and other agents, in each case to the extent not prohibited by the DGCL or any other applicable law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Registrant has entered, and expects to continue to enter, into indemnification agreements with its directors and officers, that may be broader than the specific indemnification provisions contained in the DGCL. These agreements, among other things, require the Registrant to indemnify its directors and officers against liabilities that may arise by reason of their status or service. These indemnification agreements also require the Registrant to advance all expenses actually and reasonably incurred by the directors and executive officers in connection with any proceeding. The Registrant also maintains directors&#8217; and officers&#8217; liability insurance. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;15. Recent Sales of Unregistered Securities. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following list sets forth information as to all of the Registrant&#8217;s securities sold in the last three years which were not registered under the U.S.&#160;Securities Act of&#160;1933, as amended (the &#8220;Securities Act&#8221;). Capitalized terms used and not defined in this Item&#160;15 have the meaning given to them in the prospectus which forms a part of this registration statement. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On July&#160;16, 2020, the Registrant issued an aggregate of&#160;3,593,750 Vickers Ordinary Shares to an affiliate of Venture Fund VI (Plan)&#160;Pte Ltd (&#8220;Sponsor One&#8221;) and Vickers Venture Fund VI Pte Ltd (&#8220;Sponsor Two&#8221; and, together with Sponsor One, the &#8220;Sponsors&#8221;) for an aggregate purchase price of $25,000, or approximately $0.007&#160;per share. In August&#160;2020, the affiliate transferred his founder shares to the Sponsors for the same price paid for such shares. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On January&#160;11, 2021, the Registrant consummated the sale of&#160;6,840,000 private placement warrants at a price of $0.75&#160;per private placement warrant in a private placement to the Sponsors, generating gross proceeds of $5,130,000. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On October&#160;17, 2022, the Registrant issued an aggregate of&#160;533,057 shares of common stock, par value $0.0001 per share, of the Registrant (the &#8220;Common Stock&#8221;) to the Sponsors pursuant to the Debt Contribution Agreement (the &#8220;Debt Contribution Agreement&#8221;), dated as of October&#160;17, 2022, between the Sponsors and the Registrant, in exchange for the Sponsors&#8217; contribution to the Registrant of approximately $5.3&#160;million of indebtedness described in the Debt Contribution Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On November&#160;17, 2022, the Registrant issued&#160;250,000 shares of Common Stock to YA II PN, Ltd., a Cayman Islands exempt limited partnership (&#8220;Yorkville&#8221;), in consideration for Yorkville&#8217;s irrevocable commitment to purchase shares of Common Stock pursuant to the standby equity purchase agreement the Registrant entered into with Yorkville on November&#160;17, 2022 (the &#8220;Original Purchase Agreement&#8221;), as amended and restated on February&#160;8, 2023 (the &#8220;A&amp;R Yorkville Purchase Agreement&#8221;). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On January&#160;11, 2023, the Registrant issued&#160;250,000 shares of Common Stock to B. Riley Principal Capital II, LLC, a Delaware limited liability company (&#8220;B. Riley&#8221;), in consideration for B. Riley&#8217;s irrevocable commitment to purchase shares of Common Stock pursuant to the standby equity purchase agreement the Registrant entered into with B. Riley on January&#160;8, 2023 (the &#8220;B. Riley Purchase Agreement&#8221;). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On February&#160;13, 2023, the Registrant issued&#160;4,000,000 shares of Common Stock (the &#8220;Retainer Shares&#8221;) to Paul Hastings LLP, pursuant to a stock issuance agreement dated as of such date, as a </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
retainer for legal services to be provided by Paul Hastings LLP to the Registrant and its affiliates following such date, and as payment for prior services provided to the Registrant, to be held by Paul Hastings LLP until such time as the Retainer Shares are applied against the outstanding legal fees or returned to the Registrant, in each case in accordance with the terms of such agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Between February&#160;15, 2023 and March&#160;15, 2024, the Registrant has sold 1,414,554 shares of Common Stock pursuant to advances under the B. Riley Purchase Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Between February&#160;16, 2023 and March&#160;15, 2024, the Registrant sold 11,649,056 shares of Common Stock pursuant to advances under the A&amp;R Yorkville Purchase Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On March&#160;21, 2023, the Registrant entered into a securities purchase agreement with Yorkville, pursuant to which the Registrant sold and issued to Yorkville convertible debentures in the following aggregate principal amounts on the specified dates: (i) $10,000,000, on March&#160;21, 2023, (ii) $7,500,000, on April&#160;11, 2023, and (iii) $7,500,000, on April&#160;20, 2023, each of which is convertible into shares of the Registrant&#8217;s Common Stock. In April&#160;2023, Yorkville elected to convert $5.0&#160;million of the outstanding principal and accrued interest of the convertible debentures, resulting in the issuance of&#160;632,431 shares of the Registrant&#8217;s Common Stock at a conversion price of $8.00&#160;per share. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On September&#160;15, 2023, the Registrant entered into a settlement agreement with Cove Lane Onshore Fund, LLC (&#8220;Cove Lane&#8221;), HBC Investments LLC (&#8220;HBC&#8221;)&#160;and Hudson Bay Capital Management LP, pursuant to which the Registrant issued, on September&#160;25, 2023, an aggregate of&#160;474,683 shares of Common Stock, consisting of&#160;161,392 shares of Common Stock to Cove Lane and&#160;313,291 shares of Common Stock to HBC. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On September&#160;21, 2023, the Registrant entered into the Securities Purchase Agreement, dated as of such date, with Oramed Pharmaceuticals Inc. (&#8220;Oramed&#8221;), pursuant to which, among other things, the Registrant issued to Oramed (i)&#160;a senior secured promissory note due&#160;18&#160;months from the date of issuance in the principal amount of $101,875,000 (ii)&#160;a warrant to purchase up to an aggregate of&#160;4,500,000 shares of Common Stock, with an exercise price of $0.01&#160;per share and restrictions on exercisability, and (iii)&#160;warrants to purchase up to an aggregate of&#160;8,500,000 shares of Common Stock, each with an exercise price of $0.01&#160;per share and each with restrictions on exercisability. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Registrant issued the foregoing securities in transactions not involving an underwriter and not requiring registration under Section&#160;5 of the Securities Act in reliance on the exemption afforded by Section&#160;4(a)(2) thereof. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;16. Exhibits and Financial Statements Schedules. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left"><span style="font-weight:bold">(a)</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Exhibits </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following exhibits are filed as part of this registration statement: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:89%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;2.1#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex2d1.htm">Agreement and Plan of Merger, dated as of March&#160;18, 2019, by and among Scilex Holding Company, Sigma Merger Sub, Inc., Semnur Pharmaceuticals, Inc., Fortis Advisors LLC, solely as the representative of the Equityholders and, solely with respect to Section&#160;1.8(a), Section 3.11 and Article X, Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 2.1 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No. <span style="white-space:nowrap">333-264941),</span> filed with the SEC on June&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;2.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex2d2.htm">Amendment No.&#160;1 to Agreement and Plan of Merger, dated as of August 7, 2019, by and among Semnur Pharmaceuticals, Inc., Scilex Holding Company, Sigma Merger Sub, Inc., Fortis Advisors, LLC, solely as the representative of the Equityholders and, solely with respect to Section 1.8(a), 3.11 and Article X of the Agreement and Plan of Merger, Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 2.2 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on October June&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;2.3#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex2d3.htm">Bill of Sale and Assignment and Assumption Agreement, dated May 12, 2022, by and between Scilex Holding Company and Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 2.3 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on June&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;2.4&#x5E;#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex2d4.htm">Asset Purchase Agreement, dated April 23, 2021, between Sorrento Therapeutics, Inc. and Aardvark Therapeutics, Inc., as assumed by Scilex Holding Company on May 12, 2022, pursuant to the Bill of Sale and Assignment and Assumption Agreement, dated as of such date, by and between Scilex Holding Company and Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 2.4 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on June&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;2.5#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000121390022013697/ea157097ex2-1_vickers1.htm">Agreement and Plan of Merger, dated as of March&#160;17, 2022, by and among Vickers Vantage Corp. I, Vickers Merger Sub, Inc. and Scilex Holding Company (incorporated by reference to Exhibit 2.1 of Vickers&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on March&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;2.6#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922099785/tm2225830d1_ex2-1.htm">Amendment No.&#160;1 to Agreement and Plan of Merger, dated as of September 12, 2022, by and among Vickers Vantage Corp. I, Vickers Merger Sub, Inc. and Scilex Holding Company (incorporated by reference to Exhibit 2.1 of Vickers&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on September&#160;14, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;3.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex31.htm">Restated Certificate of Incorporation of Scilex Holding Company (incorporated by reference to Exhibit 3.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on November&#160;17, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;3.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex32.htm">Certificate of Designations of Scilex Holding Company (incorporated by reference to Exhibit 3.2 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on November&#160;17, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;3.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex33.htm">Bylaws of Scilex Holding Company (incorporated by reference to Exhibit 3.3 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on November&#160;17, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000121390021001411/ea133037ex4-1_vickers1.htm">Warrant Agreement, dated as of January&#160;6, 2021, by and between Vickers Vantage Corp. I and Continental Stock Transfer &amp; Trust Company (incorporated by reference to Exhibit 4.1 of Vickers&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on January 11, 2021). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000121390020042745/fs12020ex4-3_vickers1.htm">Specimen Warrant Certificate of Scilex Holding Company (f/k/a Vickers Vantage Corp. I) (incorporated by reference to Exhibit 4.3 of Vickers&#8217;s Form <span style="white-space:nowrap">S-1</span> (File <span style="white-space:nowrap">No.&#160;333-251352),</span> filed with the SEC on December&#160;15, 2020).</a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:90%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523242508/d537034dex41.htm">Senior Secured Promissory Note issued to Oramed Pharmaceuticals, Inc. on September&#160;21, 2023 (incorporated by reference to Exhibit 4.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on September&#160;26, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523242508/d537034dex42.htm">Form of Scilex Holding Company Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.2 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on September&#160;26, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.5</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524059255/d772929dex41.htm">Form of Common Warrant (incorporated by reference to Exhibit 4.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on March&#160;5, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.6</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524059255/d772929dex42.htm">Form of Representative Warrant (incorporated by reference to Exhibit 4.2 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on March&#160;5, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;5.1&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523259945/d536627dex51.htm">Opinion of Paul Hastings LLP. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.1*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex102.htm">Form of Indemnification Agreement of Scilex Holding Company (incorporated by reference to Exhibit 10.2 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on November&#160;17, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.2*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d7.htm">Scilex Pharmaceuticals, Inc. Amended and Restated 2017 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on June&#160;27, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.3*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d8.htm">Form of Option Agreement and Stock Option Grant Notice under the Scilex Pharmaceuticals Inc. 2017 Equity Incentive Plan (incorporated by reference to Exhibit 10.8 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on June&#160;27, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.4*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d9.htm">Scilex Holding Company 2019 Stock Option Plan, as amended (incorporated by reference to Exhibit 10.9 of Amendment No. 1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on June&#160;27, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.5*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d10.htm">Form of Option Agreement and Stock Option Grant Notice under the Scilex Holding Company 2019 Stock Option Plan, as amended (incorporated by reference to Exhibit 10.10 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on June&#160;27, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.6*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523137199/d327950dex101.htm">Scilex Holding Company 2022 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on May&#160;5,&#160;2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.7*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex106.htm">Form of Stock Option Grant Notice and Stock Option Agreement under the Scilex Holding Company 2022 Equity Incentive Plan (incorporated by reference to Exhibit 10.6 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on November&#160;17, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.8*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex107.htm">Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the Scilex Holding Company 2022 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on November&#160;17, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.9*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex108.htm">Scilex Holding Company 2022 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.8 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on November&#160;17,&#160;2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.10*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523009256/d426852dex101.htm">Scilex Holding Company 2023 Inducement Plan (incorporated by reference to Exhibit 10.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on January&#160;17, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.11*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523009256/d426852dex102.htm">Form of Stock Option Grant Notice and Stock Option Agreement under the Scilex Holding Company 2023 Inducement Plan (incorporated by reference to Exhibit 10.2 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on January&#160;17, 2023).</a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:89%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.12*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523009256/d426852dex103.htm">Form of Restricted Stock Unit Award Grant Notice and Award Agreement under the Scilex Holding Company 2023 Inducement Plan (incorporated by reference to Exhibit 10.3 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on January&#160;17, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.13*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d17.htm">Offer Letter, dated as of April&#160;19, 2019, between Scilex Pharmaceuticals Inc. and Jaisim Shah (incorporated by reference to Exhibit 10.17 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> <span style="white-space:nowrap">(File&#160;No.&#160;333-264941),</span> filed with the SEC on June&#160;27, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.14*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523240648/d440182dex101.htm">Consulting Agreement, dated as of September&#160;20, 2023, by and between Scilex Holding Company and Elizabeth Czerepak (incorporated by reference to Exhibit 10.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on September&#160;22, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.15&#x5E;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-59.htm">Office Lease, dated as of August&#160;8, 2019, by and between Scilex Pharmaceuticals Inc. and 960 San Antonio LLC (incorporated by reference to Exhibit 10.59 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No. <span style="white-space:nowrap">333-264941),</span> filed with the SEC on July&#160;21, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.16&#x5E;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-60.htm">First Amendment to Office Lease, dated as of September&#160;15, 2019, by and between Scilex Pharmaceuticals Inc. and 960 San Antonio LLC (incorporated by reference to Exhibit 10.60 of Amendment No. 2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21,&#160;2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.17&#x5E;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523177931/d378841dex1039.htm">Amended and Restated Industrial Lease, dated as of April&#160;12, 2023, by and between Scilex Pharmaceuticals, Inc. and 960 San Antonio LLC (incorporated by reference to Exhibit 10.39 of Amendment No. 4 of Scilex&#8217;s Form <span style="white-space:nowrap">S-1</span> (File <span style="white-space:nowrap">No.&#160;333-271401),</span> filed with the SEC on June&#160;29,&#160;2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.18&#x5E;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-61.htm">Sublease Agreement, dated as of May 18, 2022, by and between Scilex Holding Company and Live Action, Inc. (incorporated by reference to Exhibit 10.61 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.19&#x5E;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-22.htm">Commercial Supply Agreement, dated as of February&#160;16, 2017, by and among Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.22 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.20&#x5E;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-23.htm">First Addendum to Commercial Supply Agreement, dated as of August&#160;31, 2017, by and among Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.23 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.21&#x5E;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-24.htm">Second Addendum to Commercial Supply Agreement, dated as of May&#160;9, 2018, by and among Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.24 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.22</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-25.htm">Third Addendum to Commercial Supply Agreement, dated as of August&#160;30, 2018, by and among Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.25 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> <span style="white-space:nowrap">(File&#160;No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.23#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922099735/vcka-20220623xex10d26.htm">Exclusive Distribution Agreement, dated as of August&#160;6, 2015, by and among Scilex Pharmaceuticals Inc. and Cardinal Health 105, Inc. (incorporated by reference to Exhibit 10.26 of Amendment No.&#160;4 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on September&#160;13, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.24</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922099735/vcka-20220623xex10d27.htm">Amendment to Exclusive Distribution Agreement, dated as of May&#160;24, 2018, by and among Scilex Pharmaceuticals Inc. and Cardinal Health 105, Inc. (incorporated by reference to Exhibit 10.27 of Amendment No.&#160;4 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on September&#160;13, 2022).</a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:88%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.25#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922099735/vcka-20220623xex10d28.htm">Second Amendment to Exclusive Distribution Agreement, dated as of September&#160;19, 2018, by and among Scilex Pharmaceuticals Inc. and Cardinal Health 105, Inc. (incorporated by reference to Exhibit 10.28 of Amendment No.&#160;4 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on September&#160;13, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.26</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922099735/vcka-20220623xex10d29.htm">Third Amendment to Exclusive Distribution Agreement, dated as of October&#160;1, 2021, by and among Scilex Pharmaceuticals Inc. and Cardinal Health 105, LLC (f/k/a Cardinal Health 105, Inc.). (incorporated by reference to Exhibit 10.29 of Amendment No.&#160;4 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on September&#160;13, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.27#&#x5E;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-33.htm">Supply Agreement, dated as of December&#160;17, 2015, by and between Genzyme Corporation and Semnur Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.33 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.28&#x5E;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-34.htm">Product Development Agreement, dated as of May&#160;11, 2011, by and between Scilex Pharmaceuticals, Inc. (as successor to Stason Pharmaceuticals, Inc.), Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation. (incorporated by reference to Exhibit 10.34 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.29</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-35.htm">First Amendment to Product Development Agreement, dated as of April&#160;2, 2013, by and between Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.35 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.30&#x5E;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-36.htm">Second Amendment to Product Development Agreement, dated as of February&#160;20, 2017, by and between Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.36 of Amendment No.&#160;2 of Vickers&#8217;s <span style="white-space:nowrap">Form&#160;S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.31&#x5E;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-37.htm">Third Amendment to Product Development Agreement, dated as of August&#160;29, 2018, by and between Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.37 of Amendment No.&#160;2 of Vickers&#8217;s <span style="white-space:nowrap">Form&#160;S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.32</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-38.htm">Fourth Amendment to Product Development Agreement, dated as of December&#160;13, 2019, by and between Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.38 of Amendment No.&#160;2 of Vickers&#8217;s <span style="white-space:nowrap">Form&#160;S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.33</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-39.htm">Fifth Amendment to Product Development Agreement, dated as of April&#160;30, 2021, by and between Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.39 of Amendment No.&#160;2 of <span style="white-space:nowrap"><span style="white-space:nowrap">Vickers&#8217;s&#160;Form&#160;S-4&#160;(File&#160;No.&#160;333-264941),&#160;filed</span></span> with the SEC on July&#160;21, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.34#&#x5E;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d40.htm">Master Services Agreement - <span style="white-space:nowrap">SP-102,</span> dated as of January&#160;27, 2017, by and between Semnur Pharmaceuticals, Inc. and Lifecore Biomedical, LLC (incorporated by reference to Exhibit 10.40 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on June&#160;27,&#160;2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.35</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d41.htm">Amendment No.&#160;1 to Master Services Agreement, dated as of April&#160;26, 2018, by and between Semnur Pharmaceuticals, Inc. and Lifecore Biomedical, LLC (incorporated by reference to Exhibit 10.41 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on June&#160;27, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.36</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d42.htm">Novation Agreement re Master Services Agreement, dated as of June&#160;15, 2022, by and among Scilex Holding Company, Tulex Pharmaceuticals Inc. and Aardvark Therapeutics Inc. (incorporated by reference to Exhibit 10.42 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> <span style="white-space:nowrap">(File&#160;No.&#160;333-264941),</span> filed with the SEC on June&#160;27, 2022).</a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:88%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.37#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d43.htm">Master Services Agreement, dated as of November&#160;23, 2020, by and between Aardvark Therapeutics Inc. and Tulex Pharmaceuticals Inc. as assumed by Scilex Holding Company on May&#160;12, 2022, as novated to Scilex Holding Company, pursuant to the Novation Agreement re Master Services Agreement, dated as of June&#160;15, 2022, by and among Scilex Holding Company, Tulex Pharmaceuticals Inc. and Aardvark Therapeutics Inc. (incorporated by reference to Exhibit 10.43 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on June&#160;27, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.38#&#x5E;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d44.htm">License and Commercialization Agreement, dated as of June&#160;14, 2022, by and between Scilex Holding Company and RxOmeg Therapeutics LLC, a/k/a Romeg Therapeutics, LLC (incorporated by reference to Exhibit 10.44 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on June&#160;27, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.39#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523075731/d280460dex101.htm">Securities Purchase Agreement, dated as of March<span style="text-decoration:underline"></span>&#160;21, 2023, by and between Scilex Holding Company and YA II PN, LTD. (incorporated by reference to Exhibit 10.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-39852),</span> filed with the SEC on March<span style="text-decoration:underline"></span>&#160;21, 2023. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.40</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523075731/d280460dex41.htm">Convertible Debenture, dated as of March&#160;21, 2023, executed by Scilex Holding Company (incorporated by reference to Exhibit 4.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File No. <span style="white-space:nowrap">001-39852),</span> filed with the SEC on March&#160;21, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.41</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523097796/d429390dex101.htm">Convertible Debenture, dated as of April&#160;11, 2023, executed by Scilex Holding Company (incorporated by reference to Exhibit 10.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File No. <span style="white-space:nowrap">001-39852),</span> filed with the SEC on April&#160;11, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.42</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523108354/d498999dex101.htm">Convertible Debenture, dated as of April&#160;20, 2023, executed by Scilex Holding Company (incorporated by reference to Exhibit 10.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File No. <span style="white-space:nowrap">001-39852),</span> filed with the SEC on April&#160;20, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.43</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523254137/d439599dex101.htm">Amendment to Convertible Debenture, dated as of October 11, 2023, by and between Scilex Holding Company and YA II PN, Ltd. (incorporated by reference to Exhibit 10.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File No. <span style="white-space:nowrap">001-39852),</span> filed with the SEC on October&#160;11, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.44&#x5E;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523176273/d443585dex101.htm">Credit and Security Agreement, dated as of June 27, 2023, by and between Scilex Pharmaceuticals Inc. and eCapital Healthcare Corp. (incorporated by reference to Exhibit 10.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File No. <span style="white-space:nowrap">001-39852),</span> filed with the SEC on June&#160;27, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.45&#x5E;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523176273/d443585dex102.htm">Guaranty Agreement, dated as of June&#160;27, 2023, executed by Scilex Holding Company (incorporated by reference to Exhibit 10.2 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File No. <span style="white-space:nowrap">001-39852),</span> filed with the SEC on June&#160;27, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.46</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex101.htm">Amended and Restated Registration Rights Agreement, dated as of November&#160;10, 2022, by and among Scilex Holding Company, Vickers Venture Fund VI Pte Ltd, Vickers Venture Fund VI (Plan) Pte Ltd, Sorrento Therapeutics, Inc. and certain security holders set forth on the signature pages thereto (incorporated by reference to Exhibit 10.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on November&#160;17, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.47</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523030002/d802493dex101.htm">Amended and Restated Standby Equity Purchase Agreement, dated as of February 8, 2023, by and between Scilex Holding Company and YA II PN, LTD. (incorporated by reference to Exhibit 10.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on February&#160;9, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.48</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523075731/d280460dex102.htm">Registration Rights Agreement, dated as of March 21, 2023, by and between Scilex Holding Company and YA II PN, LTD. (incorporated by reference to Exhibit 10.2 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on March&#160;21, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.49</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523239551/d554572dex101.htm">Settlement Agreement, dated September&#160;15, 2023, by and among Scilex Holding Company, Cove Lane Onshore Fund, LLC, HBC Investments LLC and Hudson Bay Capital Management LP (incorporated by reference to Exhibit 10.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on September&#160;21, 2023).</a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:89%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.50</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523242508/d537034dex102.htm">Registration Rights Agreement, dated September&#160;21, 2023, by and between Scilex Holding Company and Oramed Pharmaceuticals Inc. (incorporated by reference to Exhibit 10.2 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on September&#160;26, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.51#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523242508/d537034dex101.htm">Securities Purchase Agreement, dated September&#160;21, 2023, by and between Scilex Holding Company, Oramed Pharmaceuticals Inc. and Acquiom Agency Services LLC (incorporated by reference to Exhibit 10.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on September&#160;26, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.52#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523242508/d537034dex103.htm">Subsidiary Guarantee, dated September&#160;21, 2023, made by certain of the Company&#8217;s subsidiaries in favor of the holders of that certain Senior Secured Promissory Note dated as of the date thereof due March&#160;21, 2025 in the original aggregate principal amount of $101,875,000 (incorporated by reference to Exhibit 10.3 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on September&#160;26, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.53</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523242508/d537034dex104.htm">Security Agreement, dated September&#160;21, 2023, by and among Scilex Holding Company, the Subsidiaries of the Company party thereto, Oramed Pharmaceuticals Inc. and Acquiom Agency Services LLC (incorporated by reference to Exhibit 10.4 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on September&#160;26, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.54</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523242508/d537034dex105.htm">Subordination Agreement, dated September&#160;21, 2023, by and among eCapital Health Corp., Scilex Pharmaceuticals Inc. and Acquiom Agency Services LLC (incorporated by reference to Exhibit 10.5 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on September&#160;26,&#160;2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.55#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523242508/d537034dex106.htm">Stock Purchase Agreement, dated September&#160;21, 2023, by and between Scilex Holding Company and Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 10.6 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on September&#160;26, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.56</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523242508/d537034dex107.htm">Assignment, Assumption and Release Agreement, dated September&#160;21, 2023, by and among Scilex Holding Company, Oramed Pharmaceuticals Inc., Sorrento Therapeutics, Inc. and Scintilla Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.7 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on September&#160;26, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.57#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523242508/d537034dex108.htm">Letter Agreement, dated September&#160;21, 2023, by and among Scilex Holding Company, Sorrento Therapeutics, Inc. and Scintilla Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.8 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on September&#160;26, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.58#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523242508/d537034dex109.htm">Letter Agreement, dated September&#160;21, 2023, by and between Scilex Holding Company and Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 10.9 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on September&#160;26, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.59#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524059255/d772929dex11.htm">Underwriting Agreement, dated February&#160;29, 2024, among Scilex Holding Company, Rodman&#160;&amp; Renshaw LLC and StockBlock Securities LLC. (incorporated by reference to Exhibit 1.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on March&#160;5, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.60*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000095017023063810/sclx-ex10_12.htm">Severance and Change of Control Agreement, dated as of November&#160;8, 2023, by and between Jaisim Shah and Scilex Holding Company (incorporated by reference to Exhibit 10.12 of our Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on November&#160;14, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.61*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000095017023063810/sclx-ex10_13.htm">Severance and Change of Control Agreement, dated as of November&#160;9, 2023, by and between Henry Ji and Scilex Holding Company (incorporated by reference to Exhibit 10.13 of our Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on November&#160;14, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.62*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000095017023063810/sclx-ex10_14.htm">Severance and Change of Control Agreement, dated as of November&#160;8, 2023, by and between Stephen Ma and Scilex Holding Company (incorporated by reference to Exhibit 10.14 of our Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on November&#160;14, 2023).</a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:87%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.63</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312524046890/d795466dex101.htm">Settlement Term Sheet, dated February<span style="text-decoration:underline"></span>&#160;26, 2024, by and between Scilex Pharmaceuticals Inc., Sorrento Therapeutics, Inc. and Virpax Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-39852),</span> filed with the SEC on February<span style="text-decoration:underline"></span>&#160;27, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.64+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d759370dex1064.htm">Settlement Agreement and Mutual Release, dated February&#160;29, 2024, by and between Scilex Pharmaceuticals Inc., Sorrento Therapeutics, Inc. and Virpax Pharmaceuticals, Inc. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;21.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523259945/d536627dex211.htm">List of Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 of our Form <span style="white-space:nowrap">S-1</span> (File <span style="white-space:nowrap">No.&#160;333-275117),</span> filed with the SEC on October&#160;20, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;23.1+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d759370dex231.htm">Consent of Ernst&#160;&amp; Young LLP, independent registered public accounting firm. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;23.2&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523259945/d536627dex51.htm">Consent of Paul Hastings LLP (included in Exhibit&#160;5.1). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;24.1&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d759370dposam.htm#sig">Power of Attorney (included on the signature page to this Registration Statement). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.INS+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Instance Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.SCH+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Schema Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.CAL+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.DEF+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Definition Linkbase Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.LAB+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Labels Linkbase Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.PRE+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit&#160;101).</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">107&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523259945/d536627dexfilingfees.htm">Filing Fee Table. </a></td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">+</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Filed herewith. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Indicates management contract or compensatory plan or arrangement. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">&#x5E;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Certain identified information has been omitted pursuant to Item 601(b)(10) of Regulation <span style="white-space:nowrap">S-K</span> because such information is both (i)&#160;not material and (ii)&#160;information that the Registrant treats as private or confidential. The Registrant hereby undertakes to furnish supplemental copies of the unredacted exhibit upon request by the SEC. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">#</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation <span style="white-space:nowrap">S-K</span> Item 601. The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">&#8224;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Previously filed. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;17. Undertakings. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To include any prospectus required by Section&#160;10(a)(3) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td align="left" style="vertical-align:top">
deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">provided, however</span>, that: Paragraphs&#160;(a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to Section&#160;13 or Section&#160;15(d) of the Securities and Exchange Act of&#160;1934, as amended (the &#8220;Exchange Act&#8221;), that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule&#160;424(b) that is part of the registration statement. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">That, for the purpose of determining liability under the Securities Act to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(iv)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="sig">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, the registrant has duly caused this Post-Effective Amendment No.&#160;1 to the registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Palo Alto, State of California, on the 27th day of March&#160;2024. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:7%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:92%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">Scilex Holding Company</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By:</p> <p style="font-size:2pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jaisim Shah</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Name: Jaisim Shah</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Title: &#8194;Chief Executive Officer and President</td></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each person whose signature appears below constitutes and appoints each of Jaisim Shah and Stephen Ma, acting alone or together with another <span style="white-space:nowrap"><span style="white-space:nowrap">attorney-in-fact,</span></span> as his true and lawful <span style="white-space:nowrap"><span style="white-space:nowrap">attorney-in-fact</span></span> and agent, with full power of substitution and resubstitution, for such person and in his name, place and stead, in any and all capacities, to sign any or all further amendments (including post-effective amendments) to this registration statement&#160;(and any additional registration statement related hereto permitted by Rule&#160;426(b) promulgated under the Securities Act of&#160;1933, as amended (and all further amendments, including post-effective amendments thereto)), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said <span style="white-space:nowrap"><span style="white-space:nowrap">attorneys-in-fact</span></span> and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said <span style="white-space:nowrap"><span style="white-space:nowrap">attorney-in-fact</span></span> and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, this Post-Effective Amendment No.&#160;1 to the registration statement has been signed by the following persons in the capacities and on the dates indicated. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:35%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:18%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Signature</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date</p></td></tr>


<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jaisim Shah</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Jaisim Shah</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Chief Executive Officer, President and Director</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">(Principal Executive Officer)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">March 27, 2024</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Stephen Ma</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Stephen Ma</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Chief Financial Officer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">(Principal Financial and Accounting Officer)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">March 27, 2024</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Henry Ji, Ph.D.</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Henry Ji, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Executive Chairperson and Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">March 27, 2024</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dorman Followwill</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Dorman Followwill</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">March 27, 2024</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Yue Alexander Wu, Ph.D.</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Yue Alexander Wu, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">March 27, 2024</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jay Chun, M.D., Ph.D.</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Jay Chun, M.D., Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">March 27, 2024</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Lemus</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">David Lemus</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">March 27, 2024</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-13 </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.64
<SEQUENCE>2
<FILENAME>d759370dex1064.htm
<DESCRIPTION>EX-10.64
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.64</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.64 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SETTLEMENT AGREEMENT AND MUTUAL RELEASES </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Settlement Agreement and Mutual Releases (the &#147;Agreement&#148;) is entered into as of February&nbsp;29, 2024 by and among Sorrento
Therapeutics, Inc. and Scilex Pharmaceuticals Inc., on the one hand, and Virpax Pharmaceuticals, Inc. on the other hand. They are collectively referred to herein as &#147;the Parties&#148; and each individually as a &#147;Party.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS,</B> Sorrento and Scilex filed the lawsuit captioned <I>Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals Inc. v. Anthony Mack
and Virpax Pharmaceuticals, Inc.</I>, Case No. <FONT STYLE="white-space:nowrap">2021-0210-PAF</FONT> (the &#147;Action&#148;), in which Sorrento and Scilex asserted claims for breach of contract against Mack and tortious interference against Virpax,
breach of fiduciary duty against Mack and aiding and abetting against Virpax, and trade secret misappropriation against Mack and Virpax (the &#147;Asserted Claims&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS,</B> on February&nbsp;13, 2023, Sorrento filed for chapter 11 bankruptcy protection in the United States Bankruptcy Court for the
Southern District of Texas (the &#147;Bankruptcy Court&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS,</B> on September 1, 2023, the Delaware Court of Chancery
issued a memorandum opinion (the &#147;Opinion&#148;) finding: (1)&nbsp;Mack breached the RCA with Sorrento; (2)&nbsp;Virpax is liable for tortious interference with that contract; (3)&nbsp;Plaintiffs waived their claims for breach of Mack&#146;s
employment contract and for tortious interference with prospective economic advantage; (4)&nbsp;Mack breached his fiduciary duty of loyalty to Scilex; (5)&nbsp;Virpax aided and abetted Mack&#146;s breach of fiduciary duty; and (6)&nbsp;Mack
misappropriated certain Scilex trade secrets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS,</B> in the Opinion, the Court instructed the parties to submit supplemental
briefing on the appropriate remedy to implement its rulings. On October&nbsp;18, 2023, Plaintiffs submitted a supplemental brief on remedies. On November&nbsp;29, 2023, Defendants submitted a supplemental brief on remedies. On December 21, 2023,
Plaintiffs submitted a supplemental reply brief on remedies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS,</B> the Parties desire to settle, discharge and terminate all
claims, controversies and potential claims and controversies which may exist whether known or unknown, against each other as of the Effective Date (as defined below) without resort to further claim or dispute of any nature whatsoever in any way
arising out of, or in any way related to, the Action, the Asserted Claims, and any other claims, including any counterclaims, that could have been asserted in the Action, upon the terms and conditions set forth herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW THEREFORE,</B> in consideration of the mutual promises and representations contained herein, and other good and valuable consideration,
the receipt of which is hereby acknowledged, and intending to be legally bound thereby, the Parties agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TERMS OF
AGREEMENT </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Bankruptcy Court Approval.</U> Notwithstanding any other terms of this Agreement to the contrary, the obligations
and representations of the Parties under this Agreement are expressly conditioned on and subject to the entry by the Bankruptcy Court of an order approving this Agreement (the &#147;Settlement Order&#148;). If the Settlement Order is not entered by
April&nbsp;1, 2024 (or such other date as agreed to in writing by the Parties), this Agreement shall terminate automatically. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sorrento covenants that it will seek expedited/emergency approval from the Bankruptcy Court
in getting this Agreement approved by the Bankruptcy Court, and it further covenants that it will request that any such settlement order be immediately effective and will oppose any attempt to stay the Settlement Order. If there are no objections to
Sorrento&#146;s motion for approval of the Agreement, the date the Settlement Order is entered shall be and is referred to herein as the &#147;Effective Date.&#148; If there are objections, the date the Settlement Order becomes <FONT
STYLE="white-space:nowrap">non-appealable</FONT> shall be the &#147;Effective Date.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Settlement Consideration.</U> Virpax will
pay Sorrento and Scilex a total of $6&nbsp;million. Virpax will pay that amount as follows: No later than two business days after the Effective Date, Virpax will wire $3.5&nbsp;million to Scilex (the &#147;Initial Payment&#148;). By or on
July&nbsp;1, 2024, Virpax will wire the remaining $2.5&nbsp;million to Scilex. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Royalty Payments.</U> Virpax shall pay a 6% royalty
to Sorrento and Scilex on worldwide Net Sales of all Products sold during the Royalty Term by Virpax or any Selling Party. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Products&#148; shall mean the drug candidates referred to in the Action as Epoladerm, Probudur, and
Envelta (and individually, a &#147;Product&#148;), and shall incorporate by reference the definition of &#147;Product&#148; from the June&nbsp;6, 2017 License Agreement between MedPharm Limited and Virpax Pharmaceuticals, LLC, &#147;Licensed
Product&#148; from the March 19, 2018 License and Sublicense Agreement between LipoCureRx, Ltd. and Virpax Pharmaceuticals, Inc., and &#147;Licensed Product&#148; from the April&nbsp;11, 2019 Collaboration and License Agreement between Nanomerics
Ltd. and Virpax Pharmaceuticals, Inc. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Royalty Term&#148; shall mean the period of time commencing on the date of the first commercial sale of a
Product and ending on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis with respect to each Product upon the later of: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="22%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">expiration of the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> valid patent claim of Virpax or its licensor covering the manufacture, use or sale of such Product in such country; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="22%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">expiration of any period of regulatory exclusivity for such Product in such country. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Selling Party&#148; shall mean any affiliate <FONT STYLE="white-space:nowrap">sub-licensee,</FONT> <FONT
STYLE="white-space:nowrap">co-marketer,</FONT> collaborator, joint venturer or other partner of Virpax. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Net Sales&#148; shall mean with respect to any Product, the gross amount invoiced with respect thereto by
Virpax or a Selling Party in an arm&#146;s length transaction exclusively for money or, where the sale is not at arm&#146;s length or not exclusively for money, the price that would have been so invoiced if it had been at arm&#146;s length
exclusively for money, less the following to the extent allowed, paid or accrued with respect to such sales consistent with relevant accounting standards: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="22%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">normal and customary trade, cash and/or quantity discounts allowed and taken, and wholesaler and inventory
management fees paid, with respect to sales of such product or products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="22%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">amounts paid, repaid or credited by reason of defects, rejection, recalls, returns and allowances with respect
to such product or products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="22%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any applicable sales, use or value-added taxes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="22%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iv.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">charges, chargebacks, rebates, discounts and amounts under rebate programs paid or accrued on sale or
dispensing of the such product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="22%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">v.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all transportation charges, including freight, postage and insurance related directly to such product, in each
case to the extent included in the invoice price to a buyer; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="22%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">vi.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all other deductions allowed by relevant accounting standards, as consistently applied by Virpax and its
affiliates (or their licensees or <FONT STYLE="white-space:nowrap">sub-licensees,</FONT> as applicable) in determining net product sales. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">For clarification, sale of a Product by a selling party to another selling party for resale by such entity to a third party shall not be
deemed a sale for purposes of this definition of &#147;Net Sales,&#148; provided that the subsequent resale is included in the computation of Net Sales. Further, transfers or dispositions of Product, without consideration: (A)&nbsp;in connection
with patient assistance programs; (B)&nbsp;for charitable or promotional purposes; (C)&nbsp;for preclinical, clinical, regulatory or governmental purposes or under <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;named patient&#148; or other
limited access programs; or (D)&nbsp;for use in any tests or studies reasonably necessary to comply with applicable law, regulation or request by a regulatory authority, shall not, in each case of (A)&nbsp;through (D), be deemed sales of such
product for purposes of this definition of &#147;Net Sales.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Destruction of Scilex Information.</U> Within 30 days of the
Effective Date, Virpax shall perform a search of its systems for Scilex&#146;s nonpublic information, including all documents identified in the pleadings and alleged to be Scilex&#146;s confidential information. Virpax shall destroy all hard copies
of such information and shall remove any such information from its computing systems but shall create a preservation copy of such information on a hard drive that shall be maintained by Virpax&#146;s counsel Ballard Spahr during the pendency of this
Action until there is a binding settlement or final, <FONT STYLE="white-space:nowrap">non-appealable</FONT> decision as to all parties to the Action. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Affidavit regarding Scilex&#146;s Confidential Information.</U> Within 30 days of the
Effective Date, Virpax will provide Scilex with an affidavit from its CEO confirming that that Virpax has complied with its obligation to destroy Scilex confidential information and confirming that no Scilex confidential information remains in
Virpax&#146;s possession. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Release by Sorrento and Scilex</U>. Upon payment of the Initial Payment, and in exchange for the
consideration set forth in this Agreement, Sorrento and Scilex, on behalf of themselves, their parents, subsidiaries, affiliates, directors, managers, officers, shareholders, members, employees, attorneys, agents, representatives, predecessors,
successors and assigns, knowingly and voluntarily releases and forever discharges Virpax and its respective parents, subsidiaries, affiliates, directors, managers, officers, shareholders, members, employees, attorneys, agents, representatives,
predecessors, successors and assigns (as applicable), of any and all causes of action, claims, demands, damages, debts, liabilities, attorneys&#146; fees and all other manner of actions (&#147;Claims&#148;) that were asserted in the Action, that
could have been asserted in the Action, and/or that arise from or are related to the facts and circumstances alleged in the Action, and existed as of the Effective Date and could have been asserted against such released persons. For the avoidance of
doubt, Defendant Anthony Mack, Virpax&#146;s former CEO and Chairman, is not included in this release and Sorrento and Scilex reserve the ability to pursue all Claims against Mr.&nbsp;Mack. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Release by Virpax.</U> Upon the Effective Date, and in exchange for the consideration set forth in this Agreement, Virpax, on behalf of
itself and its attorneys, agents, representatives, predecessors, successors, and assigns, knowingly and voluntarily releases and forever discharges Sorrento and Scilex, and their respective parents, subsidiaries, affiliates, directors, managers,
officers, shareholders, members, employees, attorneys, agents, representatives, predecessors, successors and assigns, of any and all Claims, that could have been asserted in the Action and/or that arise from or are related to the facts and
circumstances alleged in the Action, and existed as of the Effective Date and could have been asserted against such released persons. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.
<U>Releases Include Unknown Claims.</U> The Parties acknowledge that the releases in this Agreement may include a release of Claims, whether fixed or contingent, at law or in equity that are unknown or unsuspected up to the Effective Date. The
releases in this Agreement are to be interpreted as broadly as the law allows. The Parties hereby waive any common law or statutory doctrine or provision that limits the effect of a release of unknown or unsuspected claims, counterclaims, demands,
damages, debts, liabilities, attorneys&#146; fees, actions, causes of action, obligations, covenants, contracts, agreements, promises, disputes, demands, and all other manner of actions whatsoever, whether fixed or contingent, at law or in equity,
including any law or principle of common law which is similar, comparable or equivalent to Cal. Civ. Code &#167; 1542, which provides: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:Times New Roman"><B>A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR
RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Enforcement of Releases.</U> All of the persons and entities receiving releases in this Agreement have the right to enforce those
releases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Representations and Warranties of All Parties. </U>The Parties represent and warrant: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">each Party has the legal right, capacity and authority to enter into this Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">each Party has taken all necessary corporate and legal actions, as applicable, to duly approve the making and
performance of this Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">this Agreement has been validly executed and delivered by the Party and constitutes a valid and binding
obligation, enforceable against the Party in accordance with the terms hereof; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">neither the execution nor performance of this Agreement by such Party constitutes or will constitute a
violation or breach of such Party&#146;s charter or bylaws (or comparable documents, as applicable); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">neither the execution nor the performance of this Agreement will constitute a violation or breach of any law,
order, injunction, judgment, statute or regulation applicable to such Party or constitutes or will constitute a material default (or would, with the passage of time or the giving of notice, or both, constitute such a default) under any material
contract, agreement or other instrument to which such Party is a party or by which it is bound; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">each Party has not relied upon any document, statement, representation, promise, inducement, understanding or
information made or provided by any other Party or its representatives except as expressly set forth in this Agreement, and such Party has relied solely upon its own due diligence and independent judgment concerning this Agreement and the
Party&#146;s decision to enter into this Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">each Party has read this Agreement and fully understands all of its terms, covenants, conditions, provisions
and obligations; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the language, terms, conditions and provisions of this Agreement are the result of negotiations between the
parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">each Party specifically acknowledges that this Agreement shall not be subject to any claim of mistake of fact,
that it expresses a full and complete settlement between the Parties, and that regardless of the adequacy or inadequacy of the consideration described herein, this Agreement is intended to avoid litigation and to be a final and complete settlement
of claims and obligations between the Parties described herein as covered by this Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">each Party has not assigned or transferred any Claim or interest in any Claim that is the subject of the
releases in this Agreement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">each Party is not presently aware of any other Claim it has against any other party arising from or relating to
the facts alleged in the Action other than those asserted in the Action or referenced herein. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Enforcement
Actions.</U> Notwithstanding the foregoing, nothing contained herein shall be interpreted as preventing any Party from filing suit to enforce any portion of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Dismissal.</U> No later than two business days after Scilex receives the Initial Payment, Sorrento and Scilex will stipulate to the
dismissal of the Action with prejudice by filing the Stipulation of Dismissal substantially in the form attached hereto as Exhibit A. The Parties will cooperate on any requested changes to the form and manner of such Stipulation of Dismissal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Choice of Law.</U> The parties agree that the terms of the Settlement Agreement will be interpreted and construed under Delaware law,
without regard to otherwise applicable conflict of law rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Jurisdiction.</U> The Delaware Court of Chancery will retain
jurisdiction over enforcement of the Settlement Agreement and the promises made therein. Jurisdiction is retained solely for that purpose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Notice/Cure/Settlement Conference.</U> Before raising any potential breaches of this Agreement with the Court, the Parties will meet
and confer within five (5)&nbsp;business days of notice of the breach to negotiate a resolution. Notice pursuant to this requirement shall be in writing and shall be deemed duly given: (i)&nbsp;upon actual receipt; (ii)&nbsp;five (5) business days
after mailing by first class, certified, or registered U.S. mail, postage prepared and addressed as indicated in Paragraph 26, return receipt requested; (iii)&nbsp;if given by email, once such notice or other communication is transmitted to the
email address(es) specified in this Agreement, or (iv)&nbsp;if sent through a nationally-recognized overnight delivery service that guarantees next day delivery and addressed as indicated in this Agreement, the business day following its delivery to
such service in time for next day delivery. The Party alleged to be in breach shall have seven (7)&nbsp;business days in which to cure the breach. If no resolution can be negotiated or if the breach is not cured within seven (7)&nbsp;business days,
or cannot be cured, the <FONT STYLE="white-space:nowrap">non-breaching</FONT> Party may file an action seeking to enforce this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>No Admission and No Precedential Value</U>. This settlement and the terms of this
Agreement constitute a compromise of the Asserted Claims and any Claims (as defined above) and is made solely to avoid the uncertainties associated with litigation and further expenditures of time, fees, and costs by the Parties. Neither the offer
nor acceptance of the terms and conditions of this Agreement shall be used as evidence of, or be deemed or asserted to be, an admission of liability or fault on the part of any Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <U>Costs and Attorney&#146;s Fees.</U> The Parties shall each individually bear all attorneys&#146; fees, costs, and disbursements of its
own counsel and consultants in connection with this Agreement and the matters and documents referred to herein, and all related matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <U>Modification.</U> No modification of this Agreement shall be valid unless made in a writing signed by all Parties hereto, wherein
specific reference is made to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. <U>Integration.</U> The terms of this Agreement constitute the full and complete
understanding, agreement, and arrangement of the Parties with respect to the matters set forth herein and the integrated memorial of their agreement with regard to settlement, and supersede all prior agreement, except as set forth herein and as with
respect to any protective/confidentiality order entered into by the Parties in the Action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. <U>Construction.</U> The headings
contained in this Agreement are for convenience only and do not constitute part of and shall not be used to interpret this Agreement. The language in all parts of this Agreement shall be construed according to its fair meaning and not strictly for
or against any Party because that Party or that Party&#146;s legal representative drafted it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. <U>Severability</U>. If any terms or
provision of this Agreement or any portion thereof is declared illegal or unenforceable by any court of competent jurisdiction, such provision or portion thereof shall be deemed modified so as to render it enforceable, and to the extent such
provision or portion thereof cannot be rendered enforceable, this Agreement shall be considered divisible as to such provision which shall become null and void, leaving the remainder of this Agreement in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22. <U>Jointly Drafted.</U> The Agreement has been reviewed by counsel for all Parties. The Parties, through their respective legal counsel,
have participated in the drafting and negotiation of this Agreement. The Agreement shall be deemed to have been jointly drafted by each of them for the purposes of applying any rule of contract construction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23. <U>Cooperation with Respect to this Agreement.</U> The Parties agree to cooperate fully and execute all supplementary documents and to
take all action that may be necessary or appropriate to give full force and effect to the terms and conditions of this Agreement, and which are not inconsistent with the terms set forth herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24. <U>Successors and Assigns.</U> This Agreement is binding upon and inures to the benefit
of the Parties hereto and their respective parents, subsidiaries, directors, officers, agents, employees, stockholders, heirs, executors, administrators, legal representatives, predecessors, successors and assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">25. <U>Counterparts and Execution.</U> This Agreement may be executed in counterparts, and each counterpart, when executed, shall have the
efficacy of a signed original and may be delivered via mail, email (.pdf) or facsimile, any of which shall be deemed an original, and such counterparts will together constitute but one Agreement. The Parties agree that this Agreement may be
accepted, executed or agreed to through the use of an electronic signature in accordance with the Electronic Signatures in Global and National Commerce Act <FONT STYLE="white-space:nowrap">(&#147;E-Sign</FONT> Act&#148;), Title 15, United States
Code, Sections 7001 et seq., the Uniform Electronic Transaction Act (&#147;UETA&#148;) and any applicable state law. Any document accepted, executed or agreed to in conformity with such laws will be binding on the Parties the same as if it were
physically executed and the Parties hereby consents to the use of any third party electronic signature capture service providers as may be chosen by any other Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">26. <U>Notice.</U> Any notice required or permitted to be given to the Parties will be deemed to have been properly given if delivered in
person or by certifiable mail, return receipt requested, or if delivered by one of the means set forth in this Agreement, if addressed to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For Sorrento: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Sorrento
Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">4955 Directors Place </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">San Diego, California 92121 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>HJi@sorrentotherapeutics.com</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With a copy to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Steve Feldman
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Latham&nbsp;&amp; Watkins LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">1271 Avenue of the Americas </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New
York, New York 10020 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>steve.feldman@lw.com</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For Scilex: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Scilex
Pharmaceuticals Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">960 San Antonio Road, Suite 11 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Palo Alto, CA 94303 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>jshah@scilexholding.com</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With a copy to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Steve Feldman </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Latham&nbsp;&amp;
Watkins LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">1271 Avenue of the Americas </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York, New York 10020 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>steve.feldman@lw.com</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For
Virpax: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Virpax Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">1055 Westlakes Drive, Suite 300 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Berwyn, PA 19312 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>gbruce@virpaxpharma.com</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With a copy to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Elizabeth A.
Sloan </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Ballard Spahr LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">919
N. Market Street, Suite 11 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Wilmington DE 19801 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>sloane@ballardspahr.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of page intentionally left blank] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have signed this Agreement on the date set
forth below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Sorrento Therapeutics, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mohsin Meghji</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">February&nbsp;29, 2024</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#8195;&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: Mohsin Meghji</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Its: &#8195;&#8201;Chief Restructuring Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Scilex Pharmaceuticals Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jaisim Shah</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">February&nbsp;29, 2024</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: Jaisim Shah</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Its: &#8195;&#8201;Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">February&nbsp;29, 2024</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Virpax Pharmaceuticals, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Gerald W. Bruce</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: Gerald W. Bruce</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Its: &#8195;&#8201;Chief Executive Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>d759370dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the caption &#147;Experts&#148; and to the use of our report dated March&nbsp;11, 2024, in the Post-Effective
Amendment No.&nbsp;1 to the Registration <FONT STYLE="white-space:nowrap">Statement&nbsp;(Form&nbsp;S-1</FONT> <FONT STYLE="white-space:nowrap">No.&nbsp;333-275117)</FONT> and related prospectus of Scilex Holding Company dated March 27, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst&nbsp;&amp; Young LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March 27, 2024 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>sclx-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 28-March-2024 [02:31:15] {AM}-->
<schema targetNamespace="http://www.vickersvantagecorp.com/20231231" elementFormDefault="qualified" xmlns:sclx="http://www.vickersvantagecorp.com/20231231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
<link:definition>1002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals" id="CondensedConsolidatedBalanceSheetsParentheticals">
<link:definition>1003 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations" id="CondensedConsolidatedStatementsOfOperations">
<link:definition>1004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity" id="CondensedConsolidatedStatementsOfStockholdersDeficitEquity">
<link:definition>1005 - Statement - Condensed Consolidated Statements of Stockholders' (Deficit) / Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows" id="CondensedConsolidatedStatementsOfCashFlows">
<link:definition>1006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentation" id="NatureOfOperationsAndBasisOfPresentation">
<link:definition>1007 - Disclosure - Nature of Operations and Basis of Presentation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcern" id="LiquidityAndGoingConcern">
<link:definition>1008 - Disclosure - Liquidity and Going Concern</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/Acquisitions" id="Acquisitions">
<link:definition>1009 - Disclosure - Acquisitions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurements" id="FairValueMeasurements">
<link:definition>1010 - Disclosure - Fair Value Measurements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/BalanceSheetComponents" id="BalanceSheetComponents">
<link:definition>1011 - Disclosure - Balance Sheet Components</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssets" id="GoodwillAndIntangibleAssets">
<link:definition>1012 - Disclosure - Goodwill and Intangible Assets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/Debt" id="Debt">
<link:definition>1013 - Disclosure - Debt</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreement" id="JuniorDipFacilityAndSorrentoSharePurchaseAgreement">
<link:definition>1014 - Disclosure - Junior DIP Facility and Sorrento Share Purchase Agreement</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/StockholdersEquity" id="StockholdersEquity">
<link:definition>1015 - Disclosure - Stockholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlans" id="StockIncentiveAndEmployeeBenefitPlans">
<link:definition>1016 - Disclosure - Stock Incentive and Employee Benefit Plans</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1017 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>1018 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/NetLossPerShare" id="NetLossPerShare">
<link:definition>1019 - Disclosure - Net Loss Per Share</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>1020 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationPolicies" id="NatureOfOperationsAndBasisOfPresentationPolicies">
<link:definition>1021 - Disclosure - Nature of Operations and Basis of Presentation (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationTables" id="NatureOfOperationsAndBasisOfPresentationTables">
<link:definition>1022 - Disclosure - Nature of Operations and Basis of Presentation (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
<link:definition>1023 - Disclosure - Fair Value Measurements (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/BalanceSheetComponentsTables" id="BalanceSheetComponentsTables">
<link:definition>1024 - Disclosure - Balance Sheet Components (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsTables" id="GoodwillAndIntangibleAssetsTables">
<link:definition>1025 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/DebtTables" id="DebtTables">
<link:definition>1026 - Disclosure - Debt (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansTables" id="StockIncentiveAndEmployeeBenefitPlansTables">
<link:definition>1027 - Disclosure - Stock Incentive and Employee Benefit Plans (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
<link:definition>1028 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>1029 - Disclosure - Income Taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/NetLossPerShareTables" id="NetLossPerShareTables">
<link:definition>1030 - Disclosure - Net Loss Per Share (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails" id="NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails">
<link:definition>1031 - Disclosure - Nature of Operations and Basis of Presentation (Additional Information) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationScheduleOfCashAndCashEquivalentsDetails" id="NatureOfOperationsAndBasisOfPresentationScheduleOfCashAndCashEquivalentsDetails">
<link:definition>1032 - Disclosure - Nature of Operations and Basis of Presentation - Schedule of Cash and Cash Equivalents (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails" id="LiquidityAndGoingConcernAdditionalInformationDetails">
<link:definition>1033 - Disclosure - Liquidity and Going Concern (Additional Information) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/AcquisitionsAdditionalInformationDetails" id="AcquisitionsAdditionalInformationDetails">
<link:definition>1034 - Disclosure - Acquisitions (Additional Information) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsAdditionalInformationDetails" id="FairValueMeasurementsAdditionalInformationDetails">
<link:definition>1035 - Disclosure - Fair Value Measurements (Additional Information) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis" id="FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis">
<link:definition>1036 - Disclosure - Fair Value Measurements  (Details) - Schedule of fair value assets measured on a recurring basis</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements" id="FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements">
<link:definition>1037 - Disclosure - Fair Value Measurements (Details) - Schedule of quantitative information regarding Level 3 fair value measurements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue" id="FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue">
<link:definition>1038 - Disclosure - Fair Value Measurements (Details) - Schedule Of The Derivative Liabilities Measured at Fair Value</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities" id="FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities">
<link:definition>1039 - Disclosure - Fair Value Measurements (Details) - Schedule of The Inputs Used In Valuing The Derivative Warrant Liabilities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails" id="BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails">
<link:definition>1040 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetails" id="BalanceSheetComponentsScheduleOfAcrcuedExpensesDetails">
<link:definition>1041 - Disclosure - Balance Sheet Components - Schedule of Acrcued expenses (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/BalanceSheetComponentsAdditionalInformationDetails" id="BalanceSheetComponentsAdditionalInformationDetails">
<link:definition>1042 - Disclosure - Balance Sheet Components (Additional Information) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails" id="GoodwillAndIntangibleAssetsAdditionalInformationDetails">
<link:definition>1043 - Disclosure - Goodwill and Intangible Assets (Additional Information) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails" id="GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails">
<link:definition>1044 - Disclosure - Goodwill and Intangible Assets - Summary of identifiable intangible assets (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails" id="GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails">
<link:definition>1045 - Disclosure - Goodwill and Intangible Assets - Estimated future amortization expense of intangible assets (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails" id="DebtAdditionalInformationDetails">
<link:definition>1046 - Disclosure - Debt (Additional Information) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/DebtSummeryOfOutstandingConvertibleDebentureDetails" id="DebtSummeryOfOutstandingConvertibleDebentureDetails">
<link:definition>1047 - Disclosure - Debt - Summery of Outstanding Convertible Debenture (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails" id="JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails">
<link:definition>1048 - Disclosure - Junior DIP Facility and Sorrento Share Purchase Agreement (Additional Information) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails" id="ShareholdersEquityAdditionalInformationDetails">
<link:definition>1049 - Disclosure - Shareholders' Equity (Additional Information) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails" id="StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails">
<link:definition>1050 - Disclosure - Stock Incentive and Employee Benefit Plans - Schedule of Stock Options Outstanding Activity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails" id="StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails">
<link:definition>1051 - Disclosure - Stock Incentive and Employee Benefit Plans - Schedule of estimate stock-based compensation on the date of grant for stock options and ESPP (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails" id="StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails">
<link:definition>1052 - Disclosure - Stock Incentive and Employee Benefit Plans (Additional Information) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesScheduleOfLeasesSupplementalQuantitativeInformationDetails" id="CommitmentsAndContingenciesScheduleOfLeasesSupplementalQuantitativeInformationDetails">
<link:definition>1053 - Disclosure - Commitments and Contingencies - Schedule of Leases Supplemental Quantitative Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails" id="CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails">
<link:definition>1054 - Disclosure - Commitments and Contingencies - Schedule of Lease Maturities of Lease Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" id="CommitmentsAndContingenciesAdditionalInformationDetails">
<link:definition>1055 - Disclosure - Commitments and Contingencies (Additional Information) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails" id="IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails">
<link:definition>1056 - Disclosure - Income Taxes - Schedule of Components of Benefit for Income Taxes (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails" id="IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails">
<link:definition>1057 - Disclosure - Income Taxes - Schedule of Deferred Tax Liabilities and Related Valuation Allowance (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
<link:definition>1058 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails" id="IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails">
<link:definition>1059 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesAdditionalInformationDetails" id="IncomeTaxesAdditionalInformationDetails">
<link:definition>1060 - Disclosure - Income Taxes (Additional Information) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/NetLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails" id="NetLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails">
<link:definition>1061 - Disclosure - Net Loss Per Share - Schedule of the reconciliation of basic and diluted loss per share (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails" id="NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails">
<link:definition>1062 - Disclosure - Net Loss Per Share - potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/NetLossPerShareAdditionalInformationDetails" id="NetLossPerShareAdditionalInformationDetails">
<link:definition>1063 - Disclosure - Net Loss Per Share (Additional Information) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails" id="SubsequentEventsAdditionalInformationDetails">
<link:definition>1064 - Disclosure - Subsequent Events (Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="sclx-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="sclx-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="sclx-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="sclx-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
<import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
<import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
<import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
<import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
<element name="AccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_AccruedExpenses" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CurrentPortionOfDeferredConsideration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_CurrentPortionOfDeferredConsideration" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LongTermPortionOfDeferredConsideration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_LongTermPortionOfDeferredConsideration" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ChangeInFairValueOfDebtAndLiabilityInstruments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ChangeInFairValueOfDebtAndLiabilityInstruments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NotesPrincipalIncrease" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_NotesPrincipalIncrease" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="Adjustmenttoadditionalpaidincapitaldiscountamortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_Adjustmenttoadditionalpaidincapitaldiscountamortization" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AdjustmentToSharesIssuedInSemnurAcquisitionValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AdjustmentToSharesIssuedInSemnurAcquisitionValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ConversionOfConvertibleDebenturesIntoCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ConversionOfConvertibleDebenturesIntoCommonStockShares" substitutionGroup="xbrli:item" />
<element name="ConversionOfConvertibleDebenturesIntoCommonStockValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ConversionOfConvertibleDebenturesIntoCommonStockValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DisbursementOfFundsToSorrentoAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_DisbursementOfFundsToSorrentoAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IssuanceOfCommonStockUponWarrantsExerciseShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_IssuanceOfCommonStockUponWarrantsExerciseShares" substitutionGroup="xbrli:item" />
<element name="IssuanceOfCommonStockUponWarrantsExerciseValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_IssuanceOfCommonStockUponWarrantsExerciseValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IssuanceOfPennyWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_IssuanceOfPennyWarrants" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RetainerSharesIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_RetainerSharesIssued" substitutionGroup="xbrli:item" />
<element name="RetainerSharesIssuedValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_RetainerSharesIssuedValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares" substitutionGroup="xbrli:item" />
<element name="SharesIssuedUnderStandbyEquityPurchaseAgreements" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_SharesIssuedUnderStandbyEquityPurchaseAgreements" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ValueIssuedUnderStandbyEquityPurchaseAgreements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ValueIssuedUnderStandbyEquityPurchaseAgreements" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ConversionOfConvertibleDebenturesIntoCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ConversionOfConvertibleDebenturesIntoCommonStock" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredConsiderationForRomegIntangibleAssetAcquisition" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_DeferredConsiderationForRomegIntangibleAssetAcquisition" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OramedNoteIssuanceAtFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_OramedNoteIssuanceAtFairValue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OtherNonCashConsiderationInConnectionWithShareRepurchase" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_OtherNonCashConsiderationInConnectionWithShareRepurchase" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ScilexPharmaNotesPrincipalIncrease" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ScilexPharmaNotesPrincipalIncrease" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TransactionCostsObligationAssumedBySorrento" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_TransactionCostsObligationAssumedBySorrento" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DisbursementOfFunds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_DisbursementOfFunds" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProceedsFromIssuanceOfRevolvingFacility" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ProceedsFromIssuanceOfRevolvingFacility" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProceedsFromRepaymentOfLoansToPurchase" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ProceedsFromRepaymentOfLoansToPurchase" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProceedsFromTheBusinessCombination" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ProceedsFromTheBusinessCombination" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RepaymentOfPrincipalOnTheScilexPharmaNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_RepaymentOfPrincipalOnTheScilexPharmaNotes" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RepaymentOfRevolvingFacility" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_RepaymentOfRevolvingFacility" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TransactionCostsPaidInConnectionWithShareRepurchase" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_TransactionCostsPaidInConnectionWithShareRepurchase" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TransactionCostsPaidRelatedToTheRecapitalizationTransaction" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ForfeituresOfPrivateWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ForfeituresOfPrivateWarrants" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseDecreaseInAccruedPayroll" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_IncreaseDecreaseInAccruedPayroll" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseDecreaseInAccruedRebatesAndFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_IncreaseDecreaseInAccruedRebatesAndFees" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OtherLongTermLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_OtherLongTermLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NonCashOperatingLeaseCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_NonCashOperatingLeaseCost" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ConvertibleDebenturesAndTheOramedNotePolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ConvertibleDebenturesAndTheOramedNotePolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="TreasuryStockPolicyTextblock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_TreasuryStockPolicyTextblock" substitutionGroup="xbrli:item" />
<element name="AccruedExpensesTextblock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AccruedExpensesTextblock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfTheOramedNoteTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ScheduleOfTheOramedNoteTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DescriptionofOrganizationandBusinessOperationsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DescriptionofOrganizationandBusinessOperationsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" substitutionGroup="xbrli:item" />
<element name="PercentageOfNetRevenueSoleDistributors" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PercentageOfNetRevenueSoleDistributors" substitutionGroup="xbrli:item" />
<element name="ThreeCustomersMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ThreeCustomersMember" substitutionGroup="xbrli:item" />
<element name="LiquidityAndGoingConcernTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_LiquidityAndGoingConcernTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="LiquidityAndGoingConcernLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_LiquidityAndGoingConcernLineItems" substitutionGroup="xbrli:item" />
<element name="CommonStockIssuableValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_CommonStockIssuableValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="Convertibledebentureprincipalamount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_Convertibledebentureprincipalamount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OutstandingBalanceOfRevolvingFacility" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_OutstandingBalanceOfRevolvingFacility" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PrincipalLaonAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PrincipalLaonAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RightToSellMaximumNumberOfCommonStockShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_RightToSellMaximumNumberOfCommonStockShares" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ValueOfStockSoldForTerminationOfOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_ValueOfStockSoldForTerminationOfOffering" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="WorkingCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_WorkingCapital" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PurchaseAgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PurchaseAgreementAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="PurchaseAgreementDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PurchaseAgreementDomain" substitutionGroup="xbrli:item" />
<element name="ARYorkvillePurchaseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ARYorkvillePurchaseAgreementMember" substitutionGroup="xbrli:item" />
<element name="AtmSalesAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_AtmSalesAgreementMember" substitutionGroup="xbrli:item" />
<element name="AccruedRoyaltyPayables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AccruedRoyaltyPayables" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AmountDueForNewDrugApplication" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AmountDueForNewDrugApplication" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="Deferredconsiderationliabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_Deferredconsiderationliabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PaymentToAcquireLicense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PaymentToAcquireLicense" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PaymentUponTheAchievementOfNetSales" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PaymentUponTheAchievementOfNetSales" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="Upfrontlicensefee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_Upfrontlicensefee" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RomegLicenseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_RomegLicenseAgreementMember" substitutionGroup="xbrli:item" />
<element name="SorrentoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SorrentoMember" substitutionGroup="xbrli:item" />
<element name="LicenseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_LicenseAgreementMember" substitutionGroup="xbrli:item" />
<element name="WarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_WarrantsMember" substitutionGroup="xbrli:item" />
<element name="ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DerivativeWarrantLiabilityPrivateWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_DerivativeWarrantLiabilityPrivateWarrants" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FairValueOfContingentConsideration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_FairValueOfContingentConsideration" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RiskAdjustedNetSalesForecast" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_RiskAdjustedNetSalesForecast" substitutionGroup="xbrli:item" />
<element name="SecuredNoteDiscountRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_SecuredNoteDiscountRate" substitutionGroup="xbrli:item" />
<element name="CorporateBondYield" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_CorporateBondYield" substitutionGroup="xbrli:item" />
<element name="CouponInterestRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_CouponInterestRate" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" substitutionGroup="xbrli:item" />
<element name="ChangeInValuationInputsOrOtherAssumptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ChangeInValuationInputsOrOtherAssumptions" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ForfeitureOfPrivateWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ForfeitureOfPrivateWarrants" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PrivatePlacementWarrantLiabilityAcquired" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PrivatePlacementWarrantLiabilityAcquired" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ReMeasurementOfFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ReMeasurementOfFairValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract" substitutionGroup="xbrli:item" />
<element name="CallOptionValue" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_CallOptionValue" substitutionGroup="xbrli:item" />
<element name="EquityValue" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_EquityValue" substitutionGroup="xbrli:item" />
<element name="AccruedResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_AccruedResearchAndDevelopmentCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AcquiredLicensesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_AcquiredLicensesMember" substitutionGroup="xbrli:item" />
<element name="AcquiredTechnologyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_AcquiredTechnologyMember" substitutionGroup="xbrli:item" />
<element name="AssembledWorkforceMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_AssembledWorkforceMember" substitutionGroup="xbrli:item" />
<element name="PatentRightsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PatentRightsMember" substitutionGroup="xbrli:item" />
<element name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FiveInstallmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_FiveInstallmentMember" substitutionGroup="xbrli:item" />
<element name="FourthInstallmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_FourthInstallmentMember" substitutionGroup="xbrli:item" />
<element name="FristInstallmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_FristInstallmentMember" substitutionGroup="xbrli:item" />
<element name="SecondInstallmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SecondInstallmentMember" substitutionGroup="xbrli:item" />
<element name="SixInstallmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SixInstallmentMember" substitutionGroup="xbrli:item" />
<element name="ThirdInstallmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ThirdInstallmentMember" substitutionGroup="xbrli:item" />
<element name="ConvertibleDebenturesIssuedPercent" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ConvertibleDebenturesIssuedPercent" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentDefaultInterestRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_DebtInstrumentDefaultInterestRate" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentOutstandingPrincipal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_DebtInstrumentOutstandingPrincipal" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DebtInstrumentOwnedPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_DebtInstrumentOwnedPercentage" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentPrincipalAmountPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_DebtInstrumentPrincipalAmountPercentage" substitutionGroup="xbrli:item" />
<element name="DebtRepaymentExitFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_DebtRepaymentExitFee" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest" substitutionGroup="xbrli:item" />
<element name="DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount" substitutionGroup="xbrli:item" />
<element name="ExistingFacilityCapMaximum" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ExistingFacilityCapMaximum" substitutionGroup="xbrli:item" />
<element name="ExistingFacilityCapMinimum" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ExistingFacilityCapMinimum" substitutionGroup="xbrli:item" />
<element name="NetCashProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_NetCashProceeds" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PercentageOfUsageOfCashProceedsFromCashSweepFinancing" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PercentageOfUsageOfCashProceedsFromCashSweepFinancing" substitutionGroup="xbrli:item" />
<element name="TerminationFees" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_TerminationFees" substitutionGroup="xbrli:item" />
<element name="DebtPayableAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_DebtPayableAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="DebtPayableDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_DebtPayableDomain" substitutionGroup="xbrli:item" />
<element name="MonthlyBasisMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_MonthlyBasisMember" substitutionGroup="xbrli:item" />
<element name="SecuritiesPurchaseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SecuritiesPurchaseAgreementMember" substitutionGroup="xbrli:item" />
<element name="ChangeInFairValueOfConvertibleDebentures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ChangeInFairValueOfConvertibleDebentures" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RepaymentOfConvertibleDebenture" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_RepaymentOfConvertibleDebenture" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ClosingPennyWarrantMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ClosingPennyWarrantMember" substitutionGroup="xbrli:item" />
<element name="PennyWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PennyWarrantsMember" substitutionGroup="xbrli:item" />
<element name="SubsequentPennyWarrants1Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SubsequentPennyWarrants1Member" substitutionGroup="xbrli:item" />
<element name="SubsequentPennyWarrants2Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SubsequentPennyWarrants2Member" substitutionGroup="xbrli:item" />
<element name="SubsequentPennyWarrants3Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SubsequentPennyWarrants3Member" substitutionGroup="xbrli:item" />
<element name="SubsequentPennyWarrants4Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SubsequentPennyWarrants4Member" substitutionGroup="xbrli:item" />
<element name="SubsequentPennyWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SubsequentPennyWarrantsMember" substitutionGroup="xbrli:item" />
<element name="JuniorDipFacilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_JuniorDipFacilityMember" substitutionGroup="xbrli:item" />
<element name="PrivateWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PrivateWarrantsMember" substitutionGroup="xbrli:item" />
<element name="PublicWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PublicWarrantsMember" substitutionGroup="xbrli:item" />
<element name="CashPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_CashPayment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FairValueOfSharesRepurchased" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_FairValueOfSharesRepurchased" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FairValueOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_FairValueOfWarrants" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IssueOfWarrantsToPurchaseShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_IssueOfWarrantsToPurchaseShares" substitutionGroup="xbrli:item" />
<element name="NumberOfShareOutstanding" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_NumberOfShareOutstanding" substitutionGroup="xbrli:item" />
<element name="SharesPurchasedAtParValueUnderStockPurchaseAgreement" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_SharesPurchasedAtParValueUnderStockPurchaseAgreement" substitutionGroup="xbrli:item" />
<element name="SharesPurchasedUnderStockPurchaseAgreement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_SharesPurchasedUnderStockPurchaseAgreement" substitutionGroup="xbrli:item" />
<element name="TransferOfWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_TransferOfWarrants" substitutionGroup="xbrli:item" />
<element name="WarrantVestingDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_WarrantVestingDate" substitutionGroup="xbrli:item" />
<element name="StockPurchaseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_StockPurchaseAgreementMember" substitutionGroup="xbrli:item" />
<element name="ShareholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ShareholdersEquityDetailsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="CoveLaneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_CoveLaneMember" substitutionGroup="xbrli:item" />
<element name="HudsonBayMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_HudsonBayMember" substitutionGroup="xbrli:item" />
<element name="AtTheMarketSalesAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_AtTheMarketSalesAgreementMember" substitutionGroup="xbrli:item" />
<element name="BRileyPurchaseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_BRileyPurchaseAgreementMember" substitutionGroup="xbrli:item" />
<element name="ShareholdersEquityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ShareholdersEquityDetailsLineItems" substitutionGroup="xbrli:item" />
<element name="CommonStockSold" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_CommonStockSold" substitutionGroup="xbrli:item" />
<element name="ProceedsFromSaleOfCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ProceedsFromSaleOfCommonStock" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProceedSOfSaleOfCommonSharesPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ProceedSOfSaleOfCommonSharesPercentage" substitutionGroup="xbrli:item" />
<element name="PurchaseOfStockPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PurchaseOfStockPercentage" substitutionGroup="xbrli:item" />
<element name="WarrantTransferAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_WarrantTransferAgreementMember" substitutionGroup="xbrli:item" />
<element name="EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_EmployeeStockPurchasePlanMember" substitutionGroup="xbrli:item" />
<element name="BlackScholesOptionPricingMethodMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_BlackScholesOptionPricingMethodMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandTwentyThreeInducementPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_TwoThousandTwentyThreeInducementPlanMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandTwentyTwoEquityIncentivePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_TwoThousandTwentyTwoEquityIncentivePlanMember" substitutionGroup="xbrli:item" />
<element name="NonEmployeeDirectorMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_NonEmployeeDirectorMember" substitutionGroup="xbrli:item" />
<element name="Sharebasedcompensationpayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_Sharebasedcompensationpayable" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="WeightedAveragePeriodOverGrant" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_WeightedAveragePeriodOverGrant" substitutionGroup="xbrli:item" />
<element name="LeaseLiabilityNetOfCurrentPortion" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_LeaseLiabilityNetOfCurrentPortion" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CommitmentsAndContingenciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_CommitmentsAndContingenciesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_CommitmentsAndContingenciesLineItems" substitutionGroup="xbrli:item" />
<element name="AgreementMaturityDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AgreementMaturityDate" substitutionGroup="xbrli:item" />
<element name="DueFromRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_DueFromRelatedParty" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="MaturityRenewalDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_MaturityRenewalDescription" substitutionGroup="xbrli:item" />
<element name="RoyaltyPaymentPercentageOnNetSale" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_RoyaltyPaymentPercentageOnNetSale" substitutionGroup="xbrli:item" />
<element name="RoyaltyPaymentPercentageRelatedToFutureYears" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_RoyaltyPaymentPercentageRelatedToFutureYears" substitutionGroup="xbrli:item" />
<element name="ResearchAndDevelopmentFacilitiesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ResearchAndDevelopmentFacilitiesMember" substitutionGroup="xbrli:item" />
<element name="DevelopersMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_DevelopersMember" substitutionGroup="xbrli:item" />
<element name="FormerEmployeeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_FormerEmployeeMember" substitutionGroup="xbrli:item" />
<element name="FormerEmployeeOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_FormerEmployeeOneMember" substitutionGroup="xbrli:item" />
<element name="GloperbaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_GloperbaMember" substitutionGroup="xbrli:item" />
<element name="EnveltaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_EnveltaMember" substitutionGroup="xbrli:item" />
<element name="EpoladermMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_EpoladermMember" substitutionGroup="xbrli:item" />
<element name="ProbudurMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ProbudurMember" substitutionGroup="xbrli:item" />
<element name="ScilexPharmaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScilexPharmaMember" substitutionGroup="xbrli:item" />
<element name="NonCancelableLeaseAgreementsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_NonCancelableLeaseAgreementsMember" substitutionGroup="xbrli:item" />
<element name="ProductDevelopmentAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ProductDevelopmentAgreementMember" substitutionGroup="xbrli:item" />
<element name="DeferredTaxAssetsAccruedExpenseAndReserves" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_DeferredTaxAssetsAccruedExpenseAndReserves" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxAssetsDebtRelatedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_DeferredTaxAssetsDebtRelatedInterest" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxAssetsOperatingLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_DeferredTaxAssetsOperatingLeaseLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="EffectiveIncomeTaxRateReconciliationDebtDiscountAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncomeTaxReconciliationAcquisitionRelatedCharges" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_IncomeTaxReconciliationAcquisitionRelatedCharges" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_IncomeTaxDisclosureLineItems" substitutionGroup="xbrli:item" />
<element name="IncomeTaxCreditsExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_IncomeTaxCreditsExpirationYear" substitutionGroup="xbrli:item" />
<element name="IndefiniteOperatingLossCarryforwards" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_IndefiniteOperatingLossCarryforwards" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_OperatingLossCarryforwardsExpirationYear" substitutionGroup="xbrli:item" />
<element name="TaxCreditCarryforwardNotSubjectToExpireAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_TaxCreditCarryforwardNotSubjectToExpireAmount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="EffectOfDilutiveSecurities" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_EffectOfDilutiveSecurities" substitutionGroup="xbrli:item" />
<element name="ConvertibleDebenturesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ConvertibleDebenturesMember" substitutionGroup="xbrli:item" />
<element name="RetainerSharesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_RetainerSharesMember" substitutionGroup="xbrli:item" />
<element name="SharesIssuablePursuantToEsppMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SharesIssuablePursuantToEsppMember" substitutionGroup="xbrli:item" />
<element name="StockOptionsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_StockOptionsMember" substitutionGroup="xbrli:item" />
<element name="RodmanRenshawLlcMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_RodmanRenshawLlcMember" substitutionGroup="xbrli:item" />
<element name="CombinedPricePaidOfWarrant" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_CombinedPricePaidOfWarrant" substitutionGroup="xbrli:item" />
<element name="CommonShareSold" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_CommonShareSold" substitutionGroup="xbrli:item" />
<element name="ExercisePriceOfCommonWarrant" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_ExercisePriceOfCommonWarrant" substitutionGroup="xbrli:item" />
<element name="OutOfPocketExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_OutOfPocketExpense" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PricePerOptionalShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PricePerOptionalShare" substitutionGroup="xbrli:item" />
<element name="PricePerOptionalWarrant" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PricePerOptionalWarrant" substitutionGroup="xbrli:item" />
<element name="PublicOfferingPerOptionalShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PublicOfferingPerOptionalShare" substitutionGroup="xbrli:item" />
<element name="PublicOfferingPerOptionalWarrant" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PublicOfferingPerOptionalWarrant" substitutionGroup="xbrli:item" />
<element name="PublicOfferingPrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PublicOfferingPrice" substitutionGroup="xbrli:item" />
<element name="PublicOfferingPriceCombined" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PublicOfferingPriceCombined" substitutionGroup="xbrli:item" />
<element name="PublicOfferingPriceSold" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PublicOfferingPriceSold" substitutionGroup="xbrli:item" />
<element name="PurchaseOfCommonShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PurchaseOfCommonShares" substitutionGroup="xbrli:item" />
<element name="PurchaseOfCommonWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PurchaseOfCommonWarrants" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>5
<FILENAME>sclx-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 28-March-2024 [02:31:15] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#NatureOfOperationsAndBasisOfPresentationScheduleOfCashAndCashEquivalentsDetails" roleURI="http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationScheduleOfCashAndCashEquivalentsDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#BalanceSheetComponentsScheduleOfAcrcuedExpensesDetails" roleURI="http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails" roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails" roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" />
<calculationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetails">
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AccruedExpenses" xlink:label="loc_SCLX_AccruedExpenses" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_SCLX_AccruedExpenses" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_TaxesPayableCurrentAndNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_SCLX_AccruedExpenses" xlink:to="loc_us-gaap_TaxesPayableCurrentAndNoncurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AccruedResearchAndDevelopmentCosts" xlink:label="loc_SCLX_AccruedResearchAndDevelopmentCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_SCLX_AccruedExpenses" xlink:to="loc_SCLX_AccruedResearchAndDevelopmentCosts" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_SCLX_AccruedExpenses" xlink:to="loc_us-gaap_AccruedMarketingCostsCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_SCLX_AccruedExpenses" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent" use="optional" order="5" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_TreasuryStockValue" use="optional" order="6" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_LongTermPortionOfDeferredConsideration" xlink:label="loc_SCLX_LongTermPortionOfDeferredConsideration" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_SCLX_LongTermPortionOfDeferredConsideration" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermDebtNoncurrent" xlink:label="loc_us-gaap_OtherLongTermDebtNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OtherLongTermDebtNoncurrent" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DebtCurrent" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_CurrentPortionOfDeferredConsideration" xlink:label="loc_SCLX_CurrentPortionOfDeferredConsideration" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_SCLX_CurrentPortionOfDeferredConsideration" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AccruedExpenses" xlink:label="loc_SCLX_AccruedExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_SCLX_AccruedExpenses" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedSalariesCurrent" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" use="optional" order="20" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_Goodwill" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="26" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_InventoryNet" use="optional" order="28" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" use="optional" order="29" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="30" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" xlink:label="loc_SCLX_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_SCLX_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories" use="optional" order="8" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" use="optional" order="10" weight="-1" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_NotesPrincipalIncrease" xlink:label="loc_SCLX_NotesPrincipalIncrease" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SCLX_NotesPrincipalIncrease" use="optional" order="11" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" use="optional" order="12" weight="-1" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount" xlink:label="loc_SCLX_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SCLX_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount" use="optional" order="13" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" use="optional" order="15" weight="-1" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_IncreaseDecreaseInAccruedPayroll" xlink:label="loc_SCLX_IncreaseDecreaseInAccruedPayroll" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SCLX_IncreaseDecreaseInAccruedPayroll" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_NonCashOperatingLeaseCost" xlink:label="loc_SCLX_NonCashOperatingLeaseCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SCLX_NonCashOperatingLeaseCost" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_IncreaseDecreaseInAccruedRebatesAndFees" xlink:label="loc_SCLX_IncreaseDecreaseInAccruedRebatesAndFees" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SCLX_IncreaseDecreaseInAccruedRebatesAndFees" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet" use="optional" order="23" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ForfeituresOfPrivateWarrants" xlink:label="loc_SCLX_ForfeituresOfPrivateWarrants" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SCLX_ForfeituresOfPrivateWarrants" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_OtherLongTermLiabilities" xlink:label="loc_SCLX_OtherLongTermLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SCLX_OtherLongTermLiabilities" use="optional" order="26" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ChangeInFairValueOfDebtAndLiabilityInstruments" xlink:label="loc_SCLX_ChangeInFairValueOfDebtAndLiabilityInstruments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SCLX_ChangeInFairValueOfDebtAndLiabilityInstruments" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" use="optional" order="28" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="29" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt" use="optional" order="31" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt" use="optional" order="32" weight="-1" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ProceedsFromIssuanceOfRevolvingFacility" xlink:label="loc_SCLX_ProceedsFromIssuanceOfRevolvingFacility" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SCLX_ProceedsFromIssuanceOfRevolvingFacility" use="optional" order="33" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RepaymentOfRevolvingFacility" xlink:label="loc_SCLX_RepaymentOfRevolvingFacility" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SCLX_RepaymentOfRevolvingFacility" use="optional" order="34" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarlyRepaymentOfSeniorDebt" xlink:label="loc_us-gaap_EarlyRepaymentOfSeniorDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_EarlyRepaymentOfSeniorDebt" use="optional" order="35" weight="-1" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction" xlink:label="loc_SCLX_TransactionCostsPaidRelatedToTheRecapitalizationTransaction" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SCLX_TransactionCostsPaidRelatedToTheRecapitalizationTransaction" use="optional" order="36" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts" use="optional" order="37" weight="-1" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DisbursementOfFunds" xlink:label="loc_SCLX_DisbursementOfFunds" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SCLX_DisbursementOfFunds" use="optional" order="38" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount" use="optional" order="39" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_TransactionCostsPaidInConnectionWithShareRepurchase" xlink:label="loc_SCLX_TransactionCostsPaidInConnectionWithShareRepurchase" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SCLX_TransactionCostsPaidInConnectionWithShareRepurchase" use="optional" order="40" weight="-1" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ProceedsFromTheBusinessCombination" xlink:label="loc_SCLX_ProceedsFromTheBusinessCombination" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SCLX_ProceedsFromTheBusinessCombination" use="optional" order="41" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised" use="optional" order="42" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt" use="optional" order="43" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSecuredNotesPayable" xlink:label="loc_us-gaap_ProceedsFromSecuredNotesPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromSecuredNotesPayable" use="optional" order="44" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromOtherShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromOtherShortTermDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromOtherShortTermDebt" use="optional" order="45" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RepaymentOfPrincipalOnTheScilexPharmaNotes" xlink:label="loc_SCLX_RepaymentOfPrincipalOnTheScilexPharmaNotes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SCLX_RepaymentOfPrincipalOnTheScilexPharmaNotes" use="optional" order="46" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ProceedsFromRepaymentOfLoansToPurchase" xlink:label="loc_SCLX_ProceedsFromRepaymentOfLoansToPurchase" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SCLX_ProceedsFromRepaymentOfLoansToPurchase" use="optional" order="47" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaap_OperatingCostsAndExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingCostsAndExpenses" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="loc_us-gaap_CostOfRevenue" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_Revenues" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ChangeInFairValueOfDebtAndLiabilityInstruments" xlink:label="loc_SCLX_ChangeInFairValueOfDebtAndLiabilityInstruments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_SCLX_ChangeInFairValueOfDebtAndLiabilityInstruments" use="optional" order="12" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_NotesPrincipalIncrease" xlink:label="loc_SCLX_NotesPrincipalIncrease" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_SCLX_NotesPrincipalIncrease" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestExpense" use="optional" order="15" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" use="optional" order="16" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive" xlink:label="loc_SCLX_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_SCLX_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive" use="optional" order="6" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" use="optional" order="8" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsNet" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsGross" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DeferredTaxAssetsDebtRelatedInterest" xlink:label="loc_SCLX_DeferredTaxAssetsDebtRelatedInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_SCLX_DeferredTaxAssetsDebtRelatedInterest" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DeferredTaxAssetsAccruedExpenseAndReserves" xlink:label="loc_SCLX_DeferredTaxAssetsAccruedExpenseAndReserves" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_SCLX_DeferredTaxAssetsAccruedExpenseAndReserves" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="loc_SCLX_DeferredTaxAssetsOperatingLeaseLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_SCLX_DeferredTaxAssetsOperatingLeaseLiabilities" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOther" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" use="optional" order="11" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxLiabilities" use="optional" order="12" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" use="optional" order="14" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount" xlink:label="loc_SCLX_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_SCLX_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_IncomeTaxReconciliationAcquisitionRelatedCharges" xlink:label="loc_SCLX_IncomeTaxReconciliationAcquisitionRelatedCharges" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_SCLX_IncomeTaxReconciliationAcquisitionRelatedCharges" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount" xlink:label="loc_SCLX_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_SCLX_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount" xlink:label="loc_SCLX_EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_SCLX_EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" use="optional" order="10" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationScheduleOfCashAndCashEquivalentsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents" use="optional" order="2" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>6
<FILENAME>sclx-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 28-March-2024 [02:31:15] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#CoverPage" roleURI="http://www.vickersvantagecorp.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#CondensedConsolidatedStatementsOfStockholdersDeficitEquity" roleURI="http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#DebtTables" roleURI="http://www.vickersvantagecorp.com/role/DebtTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails" roleURI="http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#LiquidityAndGoingConcernAdditionalInformationDetails" roleURI="http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#AcquisitionsAdditionalInformationDetails" roleURI="http://www.vickersvantagecorp.com/role/AcquisitionsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#FairValueMeasurementsAdditionalInformationDetails" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#GoodwillAndIntangibleAssetsAdditionalInformationDetails" roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails" roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#DebtAdditionalInformationDetails" roleURI="http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#DebtSummeryOfOutstandingConvertibleDebentureDetails" roleURI="http://www.vickersvantagecorp.com/role/DebtSummeryOfOutstandingConvertibleDebentureDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails" roleURI="http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#ShareholdersEquityAdditionalInformationDetails" roleURI="http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails" roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails" roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#CommitmentsAndContingenciesAdditionalInformationDetails" roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#IncomeTaxesAdditionalInformationDetails" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails" roleURI="http://www.vickersvantagecorp.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#NetLossPerShareAdditionalInformationDetails" roleURI="http://www.vickersvantagecorp.com/role/NetLossPerShareAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#SubsequentEventsAdditionalInformationDetails" roleURI="http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesLineItems" xlink:label="loc_dei_EntityAddressesLineItems_1410" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_1390" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_DocumentType_1390" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_1391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_AmendmentFlag_1391" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_EntityRegistrantName_1392" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_1395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_EntityFilerCategory_1395" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1396" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_1397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_EntityAddressAddressLine1_1397" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_1398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_EntityAddressCityOrTown_1398" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_1399" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_EntityAddressStateOrProvince_1399" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_1400" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_EntityAddressPostalZipCode_1400" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_1401" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_EntityTaxIdentificationNumber_1401" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_1402" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_EntitySmallBusiness_1402" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_1403" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_EntityEmergingGrowthCompany_1403" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_1404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_EntityExTransitionPeriod_1404" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber_1405" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_EntityPrimarySicNumber_1405" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesTable" xlink:label="loc_dei_EntityAddressesTable_1406" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_EntityAddressesTable_1406" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1407" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntityAddressesTable_1406" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1407" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1408" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1407" xlink:to="loc_dei_AddressTypeDomain_1408" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1408_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1407" xlink:to="loc_dei_AddressTypeDomain_1408_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1409" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_1408" xlink:to="loc_dei_BusinessContactMember_1409" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_1411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_EntityCentralIndexKey_1411" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_1412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_CityAreaCode_1412" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_1414" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_ContactPersonnelName_1414" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_1416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_AmendmentDescription_1416" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_1413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_LocalPhoneNumber_1413" use="optional" order="24" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_238" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_227" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_StatementTable_227" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_227" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_232" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_232" xlink:to="loc_us-gaap_EquityComponentDomain_231" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_231_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_232" xlink:to="loc_us-gaap_EquityComponentDomain_231_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_231" xlink:to="loc_us-gaap_PreferredStockMember_234" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_231" xlink:to="loc_us-gaap_CommonStockMember_237" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_240" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_231" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_240" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_242" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_231" xlink:to="loc_us-gaap_RetainedEarningsMember_242" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockPreferredMember" xlink:label="loc_us-gaap_TreasuryStockPreferredMember_244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_231" xlink:to="loc_us-gaap_TreasuryStockPreferredMember_244" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_227" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_235" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_235" xlink:to="loc_us-gaap_RelatedPartyDomain_230" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_230_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_235" xlink:to="loc_us-gaap_RelatedPartyDomain_230_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_250" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AdjustmentToSharesIssuedInSemnurAcquisitionValue" xlink:label="loc_sclx_AdjustmentToSharesIssuedInSemnurAcquisitionValue_251" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_sclx_AdjustmentToSharesIssuedInSemnurAcquisitionValue_251" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue" xlink:label="loc_sclx_AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue_254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_sclx_AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue_254" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_IssuanceOfPennyWarrants" xlink:label="loc_sclx_IssuanceOfPennyWarrants_255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_sclx_IssuanceOfPennyWarrants_255" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ConversionOfConvertibleDebenturesIntoCommonStockValue" xlink:label="loc_sclx_ConversionOfConvertibleDebenturesIntoCommonStockValue_256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_sclx_ConversionOfConvertibleDebenturesIntoCommonStockValue_256" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ConversionOfConvertibleDebenturesIntoCommonStockShares" xlink:label="loc_sclx_ConversionOfConvertibleDebenturesIntoCommonStockShares_257" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_sclx_ConversionOfConvertibleDebenturesIntoCommonStockShares_257" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_IssuanceOfCommonStockUponWarrantsExerciseValue" xlink:label="loc_sclx_IssuanceOfCommonStockUponWarrantsExerciseValue_260" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_sclx_IssuanceOfCommonStockUponWarrantsExerciseValue_260" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_IssuanceOfCommonStockUponWarrantsExerciseShares" xlink:label="loc_sclx_IssuanceOfCommonStockUponWarrantsExerciseShares_261" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_sclx_IssuanceOfCommonStockUponWarrantsExerciseShares_261" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DisbursementOfFundsToSorrentoAmount" xlink:label="loc_sclx_DisbursementOfFundsToSorrentoAmount_262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_sclx_DisbursementOfFundsToSorrentoAmount_262" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_Adjustmenttoadditionalpaidincapitaldiscountamortization" xlink:label="loc_sclx_Adjustmenttoadditionalpaidincapitaldiscountamortization_267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_sclx_Adjustmenttoadditionalpaidincapitaldiscountamortization_267" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_233" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_SharesOutstanding_236" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ValueIssuedUnderStandbyEquityPurchaseAgreements" xlink:label="loc_sclx_ValueIssuedUnderStandbyEquityPurchaseAgreements_239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_sclx_ValueIssuedUnderStandbyEquityPurchaseAgreements_239" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SharesIssuedUnderStandbyEquityPurchaseAgreements" xlink:label="loc_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreements_241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreements_241" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_243" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_245" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_246" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_247" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement" xlink:label="loc_sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement_248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement_248" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares" xlink:label="loc_sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares_249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares_249" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_252" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_253" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RetainerSharesIssuedValue" xlink:label="loc_sclx_RetainerSharesIssuedValue_258" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_sclx_RetainerSharesIssuedValue_258" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RetainerSharesIssued" xlink:label="loc_sclx_RetainerSharesIssued_259" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_sclx_RetainerSharesIssued_259" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_263" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_264" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue" xlink:label="loc_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue_265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue_265" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares" xlink:label="loc_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares_266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares_266" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_ProfitLoss_268" use="optional" order="41" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/DebtTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1415" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_463" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1415" xlink:to="loc_us-gaap_DebtInstrumentTable_463" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_462" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_463" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_462" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_465" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_462" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_465" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_465_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_462" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_465_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_464" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_465" xlink:to="loc_us-gaap_SeniorNotesMember_464" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_466" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1415" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_466" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ScheduleOfTheOramedNoteTableTextBlock" xlink:label="loc_sclx_ScheduleOfTheOramedNoteTableTextBlock_467" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1415" xlink:to="loc_sclx_ScheduleOfTheOramedNoteTableTextBlock_467" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:label="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_537" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:label="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_499" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_537" xlink:to="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_499" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_511" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_499" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_511" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_494" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_511" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_494" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_494_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_511" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_494_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_494" xlink:to="loc_us-gaap_ConvertibleDebtMember_506" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_499" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_520" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_520" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_504" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_504_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_520" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_504_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_499" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_524" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_503" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_524" xlink:to="loc_us-gaap_EquityComponentDomain_503" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_503_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_524" xlink:to="loc_us-gaap_EquityComponentDomain_503_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaap_TransactionTypeAxis_527" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_499" xlink:to="loc_us-gaap_TransactionTypeAxis_527" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaap_TransactionDomain_510" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TransactionTypeAxis_527" xlink:to="loc_us-gaap_TransactionDomain_510" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaap_TransactionDomain_510_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TransactionTypeAxis_527" xlink:to="loc_us-gaap_TransactionDomain_510_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_529" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_499" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_529" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_493" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_529" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_493" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_493_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_529" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_493_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_493" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_512" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_499" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_531" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_505" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_531" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_505" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_505_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_531" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_505_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_502" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_505" xlink:to="loc_us-gaap_SalesRevenueNetMember_502" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_505" xlink:to="loc_us-gaap_AccountsReceivableMember_517" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_499" xlink:to="loc_us-gaap_TypeOfArrangementAxis_533" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_496" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_533" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_496" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_496_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_533" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_496_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_535" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_499" xlink:to="loc_srt_RangeAxis_535" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_501" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_535" xlink:to="loc_srt_RangeMember_501" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_501_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_535" xlink:to="loc_srt_RangeMember_501_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_500" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_501" xlink:to="loc_srt_MinimumMember_500" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_516" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_501" xlink:to="loc_srt_MaximumMember_516" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_536" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_499" xlink:to="loc_srt_MajorCustomersAxis_536" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_508" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_536" xlink:to="loc_srt_NameOfMajorCustomerDomain_508" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_508_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_536" xlink:to="loc_srt_NameOfMajorCustomerDomain_508_default" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ThreeCustomersMember" xlink:label="loc_sclx_ThreeCustomersMember_518" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_508" xlink:to="loc_sclx_ThreeCustomersMember_518" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_498" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_537" xlink:to="loc_us-gaap_ReceivablesNetCurrent_498" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_515" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_537" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_515" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_537" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_522" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_526" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_537" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_526" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_528" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_537" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_528" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PercentageOfNetRevenueSoleDistributors" xlink:label="loc_sclx_PercentageOfNetRevenueSoleDistributors_534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_537" xlink:to="loc_sclx_PercentageOfNetRevenueSoleDistributors_534" use="optional" order="41" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_LiquidityAndGoingConcernLineItems" xlink:label="loc_sclx_LiquidityAndGoingConcernLineItems_579" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_LiquidityAndGoingConcernTable" xlink:label="loc_sclx_LiquidityAndGoingConcernTable_557" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_579" xlink:to="loc_sclx_LiquidityAndGoingConcernTable_557" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_552" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_557" xlink:to="loc_us-gaap_DebtInstrumentAxis_552" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_569" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_552" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_569" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_569_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_552" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_569_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_565" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_557" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_565" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_553" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_565" xlink:to="loc_us-gaap_RelatedPartyDomain_553" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_553_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_565" xlink:to="loc_us-gaap_RelatedPartyDomain_553_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_568" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_557" xlink:to="loc_srt_RangeAxis_568" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_555" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_568" xlink:to="loc_srt_RangeMember_555" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_555_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_568" xlink:to="loc_srt_RangeMember_555_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_554" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_555" xlink:to="loc_srt_MaximumMember_554" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_571" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_557" xlink:to="loc_us-gaap_TypeOfArrangementAxis_571" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_549" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_571" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_549" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_549_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_571" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_549_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PurchaseAgreementAxis" xlink:label="loc_sclx_PurchaseAgreementAxis_573" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_557" xlink:to="loc_sclx_PurchaseAgreementAxis_573" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PurchaseAgreementDomain" xlink:label="loc_sclx_PurchaseAgreementDomain_558" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_PurchaseAgreementAxis_573" xlink:to="loc_sclx_PurchaseAgreementDomain_558" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PurchaseAgreementDomain" xlink:label="loc_sclx_PurchaseAgreementDomain_558_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_PurchaseAgreementAxis_573" xlink:to="loc_sclx_PurchaseAgreementDomain_558_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ARYorkvillePurchaseAgreementMember" xlink:label="loc_sclx_ARYorkvillePurchaseAgreementMember_547" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PurchaseAgreementDomain_558" xlink:to="loc_sclx_ARYorkvillePurchaseAgreementMember_547" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AtmSalesAgreementMember" xlink:label="loc_sclx_AtmSalesAgreementMember_562" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PurchaseAgreementDomain_558" xlink:to="loc_sclx_AtmSalesAgreementMember_562" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_557" xlink:to="loc_us-gaap_StatementClassOfStockAxis_575" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_566" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_575" xlink:to="loc_us-gaap_ClassOfStockDomain_566" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_566_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_575" xlink:to="loc_us-gaap_ClassOfStockDomain_566_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_566" xlink:to="loc_us-gaap_CommonStockMember_548" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_557" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_577" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_560" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_577" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_560" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_560_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_577" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_560_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityUnitPurchaseAgreementsMember" xlink:label="loc_us-gaap_EquityUnitPurchaseAgreementsMember_559" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_560" xlink:to="loc_us-gaap_EquityUnitPurchaseAgreementsMember_559" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_551" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_579" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_551" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_WorkingCapital" xlink:label="loc_sclx_WorkingCapital_564" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_579" xlink:to="loc_sclx_WorkingCapital_564" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_567" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_579" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_567" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_570" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_579" xlink:to="loc_us-gaap_OperatingIncomeLoss_570" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_572" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_579" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_572" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_579" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_574" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_Convertibledebentureprincipalamount" xlink:label="loc_sclx_Convertibledebentureprincipalamount_576" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_579" xlink:to="loc_sclx_Convertibledebentureprincipalamount_576" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PrincipalLaonAmount" xlink:label="loc_sclx_PrincipalLaonAmount_578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_579" xlink:to="loc_sclx_PrincipalLaonAmount_578" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_579" xlink:to="loc_us-gaap_ConvertibleDebt_580" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="loc_us-gaap_DebtInstrumentIssuedPrincipal_581" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_579" xlink:to="loc_us-gaap_DebtInstrumentIssuedPrincipal_581" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_OutstandingBalanceOfRevolvingFacility" xlink:label="loc_sclx_OutstandingBalanceOfRevolvingFacility_582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_579" xlink:to="loc_sclx_OutstandingBalanceOfRevolvingFacility_582" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_583" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_579" xlink:to="loc_us-gaap_CommonStockSharesIssued_583" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_CommonStockIssuableValue" xlink:label="loc_sclx_CommonStockIssuableValue_584" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_579" xlink:to="loc_sclx_CommonStockIssuableValue_584" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ValueOfStockSoldForTerminationOfOffering" xlink:label="loc_sclx_ValueOfStockSoldForTerminationOfOffering_585" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_579" xlink:to="loc_sclx_ValueOfStockSoldForTerminationOfOffering_585" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RightToSellMaximumNumberOfCommonStockShares" xlink:label="loc_sclx_RightToSellMaximumNumberOfCommonStockShares_588" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_579" xlink:to="loc_sclx_RightToSellMaximumNumberOfCommonStockShares_588" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_589" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_579" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_589" use="optional" order="43" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/AcquisitionsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_641" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_626" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_641" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_626" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_624" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_626" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_624" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_629" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_624" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_629" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_629_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_624" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_629_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_LicenseAgreementMember" xlink:label="loc_sclx_LicenseAgreementMember_632" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_629" xlink:to="loc_sclx_LicenseAgreementMember_632" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_634" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_626" xlink:to="loc_dei_LegalEntityAxis_634" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_638" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_634" xlink:to="loc_dei_EntityDomain_638" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_638_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_634" xlink:to="loc_dei_EntityDomain_638_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RomegLicenseAgreementMember" xlink:label="loc_sclx_RomegLicenseAgreementMember_625" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_638" xlink:to="loc_sclx_RomegLicenseAgreementMember_625" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_636" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_626" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_636" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_633" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_636" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_633" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_633_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_636" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_633_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_628" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_633" xlink:to="loc_us-gaap_PatentsMember_628" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_639" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_626" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_639" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_630" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_639" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_630" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_630_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_639" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_630_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_627" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_630" xlink:to="loc_sclx_SorrentoMember_627" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_631" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_641" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_631" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_Upfrontlicensefee" xlink:label="loc_sclx_Upfrontlicensefee_635" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_641" xlink:to="loc_sclx_Upfrontlicensefee_635" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PaymentUponTheAchievementOfNetSales" xlink:label="loc_sclx_PaymentUponTheAchievementOfNetSales_637" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_641" xlink:to="loc_sclx_PaymentUponTheAchievementOfNetSales_637" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaap_PaymentsForRoyalties_640" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_641" xlink:to="loc_us-gaap_PaymentsForRoyalties_640" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_642" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_641" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_642" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_Deferredconsiderationliabilities" xlink:label="loc_sclx_Deferredconsiderationliabilities_643" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_641" xlink:to="loc_sclx_Deferredconsiderationliabilities_643" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_644" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_641" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_644" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PaymentToAcquireLicense" xlink:label="loc_sclx_PaymentToAcquireLicense_645" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_641" xlink:to="loc_sclx_PaymentToAcquireLicense_645" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AccruedRoyaltyPayables" xlink:label="loc_sclx_AccruedRoyaltyPayables_646" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_641" xlink:to="loc_sclx_AccruedRoyaltyPayables_646" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AmountDueForNewDrugApplication" xlink:label="loc_sclx_AmountDueForNewDrugApplication_647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_641" xlink:to="loc_sclx_AmountDueForNewDrugApplication_647" use="optional" order="27" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_704" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_696" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_704" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_696" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_690" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_696" xlink:to="loc_us-gaap_TypeOfArrangementAxis_690" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_689" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_690" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_689" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_689_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_690" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_689_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_697" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_696" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_697" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_693" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_697" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_693" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_693_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_697" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_693_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_694" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_693" xlink:to="loc_us-gaap_PrivatePlacementMember_694" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_699" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_696" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_699" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_695" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_699" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_695" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_695_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_699" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_695_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_692" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_695" xlink:to="loc_us-gaap_SeniorNotesMember_692" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_702" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_696" xlink:to="loc_us-gaap_AwardTypeAxis_702" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_700" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_702" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_700" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_700_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_702" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_700_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_WarrantsMember" xlink:label="loc_sclx_WarrantsMember_706" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_700" xlink:to="loc_sclx_WarrantsMember_706" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_691" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_704" xlink:to="loc_us-gaap_DebtInstrumentFairValue_691" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SecuredNoteDiscountRate" xlink:label="loc_sclx_SecuredNoteDiscountRate_698" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_704" xlink:to="loc_sclx_SecuredNoteDiscountRate_698" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="loc_us-gaap_DebtInstrumentIssuedPrincipal_701" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_704" xlink:to="loc_us-gaap_DebtInstrumentIssuedPrincipal_701" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_703" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_704" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_703" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense" xlink:label="loc_sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense_705" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_704" xlink:to="loc_sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense_705" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_707" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_704" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_707" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_708" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_704" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_708" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RiskAdjustedNetSalesForecast" xlink:label="loc_sclx_RiskAdjustedNetSalesForecast_709" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_704" xlink:to="loc_sclx_RiskAdjustedNetSalesForecast_709" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleWeightedAverageYield" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleWeightedAverageYield_710" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_704" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleWeightedAverageYield_710" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_711" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_704" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_711" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductLiabilityContingencyAccrualDiscountRate" xlink:label="loc_us-gaap_ProductLiabilityContingencyAccrualDiscountRate_712" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_704" xlink:to="loc_us-gaap_ProductLiabilityContingencyAccrualDiscountRate_712" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_FairValueOfContingentConsideration" xlink:label="loc_sclx_FairValueOfContingentConsideration_713" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_704" xlink:to="loc_sclx_FairValueOfContingentConsideration_713" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DerivativeWarrantLiabilityPrivateWarrants" xlink:label="loc_sclx_DerivativeWarrantLiabilityPrivateWarrants_714" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_704" xlink:to="loc_sclx_DerivativeWarrantLiabilityPrivateWarrants_714" use="optional" order="29" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_729" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_723" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_729" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_723" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_722" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_723" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_722" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_724" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_722" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_724" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_724_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_722" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_724_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_721" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_724" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_721" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_728" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_724" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_728" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_732" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_724" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_732" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_725" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_729" xlink:to="loc_us-gaap_LiabilitiesAbstract_725" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotes" xlink:label="loc_us-gaap_SeniorNotes_720" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_725" xlink:to="loc_us-gaap_SeniorNotes_720" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_727" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_725" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_727" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_731" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_725" xlink:to="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_731" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_733" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_725" xlink:to="loc_us-gaap_DerivativeLiabilities_733" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_734" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_725" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_734" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_735" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_725" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_735" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_753" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_750" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_753" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_750" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_748" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_750" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_748" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_751" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_748" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_751" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_751_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_748" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_751_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_749" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_751" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_749" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_747" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_753" xlink:to="loc_us-gaap_DerivativeLiabilities_747" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PrivatePlacementWarrantLiabilityAcquired" xlink:label="loc_sclx_PrivatePlacementWarrantLiabilityAcquired_752" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_753" xlink:to="loc_sclx_PrivatePlacementWarrantLiabilityAcquired_752" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ReMeasurementOfFairValue" xlink:label="loc_sclx_ReMeasurementOfFairValue_754" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_753" xlink:to="loc_sclx_ReMeasurementOfFairValue_754" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ForfeitureOfPrivateWarrants" xlink:label="loc_sclx_ForfeitureOfPrivateWarrants_755" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_753" xlink:to="loc_sclx_ForfeitureOfPrivateWarrants_755" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ChangeInValuationInputsOrOtherAssumptions" xlink:label="loc_sclx_ChangeInValuationInputsOrOtherAssumptions_756" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_753" xlink:to="loc_sclx_ChangeInValuationInputsOrOtherAssumptions_756" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_785" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_785" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_778" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_782" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_778" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_782" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_780" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_782" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_780" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_780_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_782" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_780_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_780" xlink:to="loc_us-gaap_ConstructionInProgressMember_781" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_780" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_784" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_787" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_780" xlink:to="loc_us-gaap_ComputerEquipmentMember_787" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_788" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_780" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_788" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_779" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_785" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_779" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_783" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_785" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_783" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_785" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_786" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_813" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_813" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_807" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_804" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_807" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_804" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_802" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_804" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_802" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_802_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_804" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_802_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_810" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_807" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_810" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_810" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_805" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_805_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_810" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_805_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_808" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_813" xlink:to="loc_us-gaap_Goodwill_808" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_811" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_813" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_811" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_814" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_813" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_814" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_815" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_813" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_815" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_824" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_821" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_824" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_821" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_820" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_821" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_820" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_818" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_820" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_818" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_818_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_820" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_818_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PatentRightsMember" xlink:label="loc_sclx_PatentRightsMember_819" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_818" xlink:to="loc_sclx_PatentRightsMember_819" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AcquiredTechnologyMember" xlink:label="loc_sclx_AcquiredTechnologyMember_823" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_818" xlink:to="loc_sclx_AcquiredTechnologyMember_823" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AcquiredLicensesMember" xlink:label="loc_sclx_AcquiredLicensesMember_826" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_818" xlink:to="loc_sclx_AcquiredLicensesMember_826" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AssembledWorkforceMember" xlink:label="loc_sclx_AssembledWorkforceMember_828" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_818" xlink:to="loc_sclx_AssembledWorkforceMember_828" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_822" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_824" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_822" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_824" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_825" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_824" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_827" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_884" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_848" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_DebtInstrumentTable_848" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_846" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_848" xlink:to="loc_us-gaap_CreditFacilityAxis_846" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_860" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_846" xlink:to="loc_us-gaap_CreditFacilityDomain_860" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_860_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_846" xlink:to="loc_us-gaap_CreditFacilityDomain_860_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_855" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_860" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_855" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PurchaseAgreementAxis" xlink:label="loc_sclx_PurchaseAgreementAxis_862" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_848" xlink:to="loc_sclx_PurchaseAgreementAxis_862" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PurchaseAgreementDomain" xlink:label="loc_sclx_PurchaseAgreementDomain_856" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_PurchaseAgreementAxis_862" xlink:to="loc_sclx_PurchaseAgreementDomain_856" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PurchaseAgreementDomain" xlink:label="loc_sclx_PurchaseAgreementDomain_856_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_PurchaseAgreementAxis_862" xlink:to="loc_sclx_PurchaseAgreementDomain_856_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ARYorkvillePurchaseAgreementMember" xlink:label="loc_sclx_ARYorkvillePurchaseAgreementMember_845" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PurchaseAgreementDomain_856" xlink:to="loc_sclx_ARYorkvillePurchaseAgreementMember_845" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_867" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_848" xlink:to="loc_us-gaap_VestingAxis_867" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_858" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_867" xlink:to="loc_us-gaap_VestingDomain_858" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_858_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_867" xlink:to="loc_us-gaap_VestingDomain_858_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_844" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_858" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_844" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_861" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_858" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_861" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_866" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_858" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_866" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_871" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_848" xlink:to="loc_us-gaap_TypeOfArrangementAxis_871" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_847" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_871" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_847" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_847_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_871" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_847_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SecuritiesPurchaseAgreementMember" xlink:label="loc_sclx_SecuritiesPurchaseAgreementMember_843" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_847" xlink:to="loc_sclx_SecuritiesPurchaseAgreementMember_843" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_874" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_848" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_874" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_874" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_859" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_859_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_874" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_859_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_851" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_859" xlink:to="loc_us-gaap_SeniorNotesMember_851" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_877" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_848" xlink:to="loc_us-gaap_DebtInstrumentAxis_877" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_870" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_877" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_870" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_870_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_877" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_870_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_FristInstallmentMember" xlink:label="loc_sclx_FristInstallmentMember_854" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_870" xlink:to="loc_sclx_FristInstallmentMember_854" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SecondInstallmentMember" xlink:label="loc_sclx_SecondInstallmentMember_864" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_870" xlink:to="loc_sclx_SecondInstallmentMember_864" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ThirdInstallmentMember" xlink:label="loc_sclx_ThirdInstallmentMember_868" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_870" xlink:to="loc_sclx_ThirdInstallmentMember_868" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_FourthInstallmentMember" xlink:label="loc_sclx_FourthInstallmentMember_872" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_870" xlink:to="loc_sclx_FourthInstallmentMember_872" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_FiveInstallmentMember" xlink:label="loc_sclx_FiveInstallmentMember_875" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_870" xlink:to="loc_sclx_FiveInstallmentMember_875" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SixInstallmentMember" xlink:label="loc_sclx_SixInstallmentMember_878" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_870" xlink:to="loc_sclx_SixInstallmentMember_878" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_880" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_848" xlink:to="loc_srt_RangeAxis_880" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_853" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_880" xlink:to="loc_srt_RangeMember_853" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_853_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_880" xlink:to="loc_srt_RangeMember_853_default" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_852" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_853" xlink:to="loc_srt_MaximumMember_852" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_863" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_853" xlink:to="loc_srt_MinimumMember_863" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DebtPayableAxis" xlink:label="loc_sclx_DebtPayableAxis_882" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_848" xlink:to="loc_sclx_DebtPayableAxis_882" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DebtPayableDomain" xlink:label="loc_sclx_DebtPayableDomain_849" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_DebtPayableAxis_882" xlink:to="loc_sclx_DebtPayableDomain_849" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DebtPayableDomain" xlink:label="loc_sclx_DebtPayableDomain_849_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_DebtPayableAxis_882" xlink:to="loc_sclx_DebtPayableDomain_849_default" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_MonthlyBasisMember" xlink:label="loc_sclx_MonthlyBasisMember_850" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DebtPayableDomain_849" xlink:to="loc_sclx_MonthlyBasisMember_850" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="loc_us-gaap_DebtInstrumentIssuedPrincipal_857" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_DebtInstrumentIssuedPrincipal_857" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaap_DebtInstrumentDescription_865" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_DebtInstrumentDescription_865" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_NetCashProceeds" xlink:label="loc_sclx_NetCashProceeds_869" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_sclx_NetCashProceeds_869" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_TerminationFees" xlink:label="loc_sclx_TerminationFees_873" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_sclx_TerminationFees_873" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_876" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_RepaymentsOfDebt_876" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_879" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_DebtInstrumentFairValue_879" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DebtRepaymentExitFee" xlink:label="loc_sclx_DebtRepaymentExitFee_881" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_sclx_DebtRepaymentExitFee_881" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepaidPrincipal" xlink:label="loc_us-gaap_DebtInstrumentRepaidPrincipal_883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_DebtInstrumentRepaidPrincipal_883" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:label="loc_us-gaap_CommonStockConvertibleConversionPriceIncrease_885" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_CommonStockConvertibleConversionPriceIncrease_885" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ExistingFacilityCapMaximum" xlink:label="loc_sclx_ExistingFacilityCapMaximum_886" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_sclx_ExistingFacilityCapMaximum_886" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ExistingFacilityCapMinimum" xlink:label="loc_sclx_ExistingFacilityCapMinimum_887" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_sclx_ExistingFacilityCapMinimum_887" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DebtInstrumentOutstandingPrincipal" xlink:label="loc_sclx_DebtInstrumentOutstandingPrincipal_888" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_sclx_DebtInstrumentOutstandingPrincipal_888" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" xlink:label="loc_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue_889" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue_889" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServicingLiabilityAtFairValueOtherChangeInFairValueStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="loc_us-gaap_ServicingLiabilityAtFairValueOtherChangeInFairValueStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_890" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_ServicingLiabilityAtFairValueOtherChangeInFairValueStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_890" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_891" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_891" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_892" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_892" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_893" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_893" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DebtInstrumentPrincipalAmountPercentage" xlink:label="loc_sclx_DebtInstrumentPrincipalAmountPercentage_894" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_sclx_DebtInstrumentPrincipalAmountPercentage_894" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="loc_us-gaap_DebtInstrumentPaymentTerms_895" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_DebtInstrumentPaymentTerms_895" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ConvertibleDebenturesIssuedPercent" xlink:label="loc_sclx_ConvertibleDebenturesIssuedPercent_896" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_sclx_ConvertibleDebenturesIssuedPercent_896" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_897" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_Cash_897" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_898" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_898" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionDescription" xlink:label="loc_us-gaap_DebtInstrumentRedemptionDescription_899" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_DebtInstrumentRedemptionDescription_899" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio" xlink:label="loc_us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio_900" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio_900" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_902" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_CommonStockSharesIssued_902" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableRevolvingConvertedToTermLoan" xlink:label="loc_us-gaap_FinancingReceivableRevolvingConvertedToTermLoan_903" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_FinancingReceivableRevolvingConvertedToTermLoan_903" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_904" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_904" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DebtInstrumentOwnedPercentage" xlink:label="loc_sclx_DebtInstrumentOwnedPercentage_905" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_sclx_DebtInstrumentOwnedPercentage_905" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DebtInstrumentDefaultInterestRate" xlink:label="loc_sclx_DebtInstrumentDefaultInterestRate_906" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_sclx_DebtInstrumentDefaultInterestRate_906" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount" xlink:label="loc_sclx_DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount_907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_sclx_DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount_907" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount" xlink:label="loc_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount_908" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount_908" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest" xlink:label="loc_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest_909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest_909" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PercentageOfUsageOfCashProceedsFromCashSweepFinancing" xlink:label="loc_sclx_PercentageOfUsageOfCashProceedsFromCashSweepFinancing_910" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_sclx_PercentageOfUsageOfCashProceedsFromCashSweepFinancing_910" use="optional" order="74" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/DebtSummeryOfOutstandingConvertibleDebentureDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_929" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_925" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_929" xlink:to="loc_us-gaap_DebtInstrumentTable_925" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_924" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_925" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_924" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_927" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_924" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_927" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_927_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_924" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_927_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_926" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_927" xlink:to="loc_us-gaap_SeniorNotesMember_926" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_930" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_927" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_930" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_923" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_929" xlink:to="loc_us-gaap_ConvertibleDebt_923" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesIssued1" xlink:label="loc_us-gaap_NotesIssued1_928" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_929" xlink:to="loc_us-gaap_NotesIssued1_928" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RepaymentOfConvertibleDebenture" xlink:label="loc_sclx_RepaymentOfConvertibleDebenture_932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_929" xlink:to="loc_sclx_RepaymentOfConvertibleDebenture_932" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ChangeInFairValueOfConvertibleDebentures" xlink:label="loc_sclx_ChangeInFairValueOfConvertibleDebentures_931" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_929" xlink:to="loc_sclx_ChangeInFairValueOfConvertibleDebentures_931" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ConversionOfConvertibleDebenturesIntoCommonStock" xlink:label="loc_sclx_ConversionOfConvertibleDebenturesIntoCommonStock_933" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_929" xlink:to="loc_sclx_ConversionOfConvertibleDebenturesIntoCommonStock_933" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_977" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_947" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_977" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_947" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_944" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_947" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_944" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_951" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_944" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_951" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_951_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_944" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_951_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_946" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_951" xlink:to="loc_sclx_SorrentoMember_946" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_955" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_947" xlink:to="loc_srt_RangeAxis_955" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_942" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_955" xlink:to="loc_srt_RangeMember_942" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_942_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_955" xlink:to="loc_srt_RangeMember_942_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_941" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_942" xlink:to="loc_srt_MaximumMember_941" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_954" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_942" xlink:to="loc_srt_MinimumMember_954" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_960" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_947" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_960" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_949" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_960" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_949" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_949_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_960" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_949_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_JuniorDipFacilityMember" xlink:label="loc_sclx_JuniorDipFacilityMember_940" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_949" xlink:to="loc_sclx_JuniorDipFacilityMember_940" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_953" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_949" xlink:to="loc_us-gaap_SeniorNotesMember_953" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_965" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_947" xlink:to="loc_us-gaap_TypeOfArrangementAxis_965" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_938" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_965" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_938" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_938_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_965" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_938_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_StockPurchaseAgreementMember" xlink:label="loc_sclx_StockPurchaseAgreementMember_937" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_938" xlink:to="loc_sclx_StockPurchaseAgreementMember_937" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_968" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_947" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_968" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_963" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_968" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_963" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_963_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_968" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_963_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ClosingPennyWarrantMember" xlink:label="loc_sclx_ClosingPennyWarrantMember_948" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_963" xlink:to="loc_sclx_ClosingPennyWarrantMember_948" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SubsequentPennyWarrantsMember" xlink:label="loc_sclx_SubsequentPennyWarrantsMember_958" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_963" xlink:to="loc_sclx_SubsequentPennyWarrantsMember_958" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PennyWarrantsMember" xlink:label="loc_sclx_PennyWarrantsMember_962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_963" xlink:to="loc_sclx_PennyWarrantsMember_962" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SubsequentPennyWarrants1Member" xlink:label="loc_sclx_SubsequentPennyWarrants1Member_967" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_963" xlink:to="loc_sclx_SubsequentPennyWarrants1Member_967" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SubsequentPennyWarrants2Member" xlink:label="loc_sclx_SubsequentPennyWarrants2Member_970" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_963" xlink:to="loc_sclx_SubsequentPennyWarrants2Member_970" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SubsequentPennyWarrants3Member" xlink:label="loc_sclx_SubsequentPennyWarrants3Member_973" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_963" xlink:to="loc_sclx_SubsequentPennyWarrants3Member_973" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SubsequentPennyWarrants4Member" xlink:label="loc_sclx_SubsequentPennyWarrants4Member_976" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_963" xlink:to="loc_sclx_SubsequentPennyWarrants4Member_976" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaap_AwardDateAxis_971" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_947" xlink:to="loc_us-gaap_AwardDateAxis_971" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaap_AwardDateDomain_950" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardDateAxis_971" xlink:to="loc_us-gaap_AwardDateDomain_950" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaap_AwardDateDomain_950_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardDateAxis_971" xlink:to="loc_us-gaap_AwardDateDomain_950_default" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_974" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_947" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_974" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_943" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_974" xlink:to="loc_us-gaap_EquityComponentDomain_943" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_943_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_974" xlink:to="loc_us-gaap_EquityComponentDomain_943_default" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_939" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_943" xlink:to="loc_us-gaap_CommonStockMember_939" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_952" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_943" xlink:to="loc_us-gaap_PreferredStockMember_952" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PrivateWarrantsMember" xlink:label="loc_sclx_PrivateWarrantsMember_959" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_943" xlink:to="loc_sclx_PrivateWarrantsMember_959" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PublicWarrantsMember" xlink:label="loc_sclx_PublicWarrantsMember_964" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_943" xlink:to="loc_sclx_PublicWarrantsMember_964" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_945" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_977" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_945" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_956" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_977" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_956" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_961" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_977" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_961" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaap_DebtInstrumentDescription_966" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_977" xlink:to="loc_us-gaap_DebtInstrumentDescription_966" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SharesPurchasedUnderStockPurchaseAgreement" xlink:label="loc_sclx_SharesPurchasedUnderStockPurchaseAgreement_978" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_977" xlink:to="loc_sclx_SharesPurchasedUnderStockPurchaseAgreement_978" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SharesPurchasedAtParValueUnderStockPurchaseAgreement" xlink:label="loc_sclx_SharesPurchasedAtParValueUnderStockPurchaseAgreement_979" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_977" xlink:to="loc_sclx_SharesPurchasedAtParValueUnderStockPurchaseAgreement_979" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_IssueOfWarrantsToPurchaseShares" xlink:label="loc_sclx_IssueOfWarrantsToPurchaseShares_980" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_977" xlink:to="loc_sclx_IssueOfWarrantsToPurchaseShares_980" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_981" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_977" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_981" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_NumberOfShareOutstanding" xlink:label="loc_sclx_NumberOfShareOutstanding_982" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_977" xlink:to="loc_sclx_NumberOfShareOutstanding_982" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_TransferOfWarrants" xlink:label="loc_sclx_TransferOfWarrants_983" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_977" xlink:to="loc_sclx_TransferOfWarrants_983" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_984" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_977" xlink:to="loc_us-gaap_LegalFees_984" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_CashPayment" xlink:label="loc_sclx_CashPayment_985" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_977" xlink:to="loc_sclx_CashPayment_985" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_FairValueOfSharesRepurchased" xlink:label="loc_sclx_FairValueOfSharesRepurchased_986" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_977" xlink:to="loc_sclx_FairValueOfSharesRepurchased_986" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_FairValueOfWarrants" xlink:label="loc_sclx_FairValueOfWarrants_987" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_977" xlink:to="loc_sclx_FairValueOfWarrants_987" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_988" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_977" xlink:to="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_988" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_WarrantVestingDate" xlink:label="loc_sclx_WarrantVestingDate_989" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_977" xlink:to="loc_sclx_WarrantVestingDate_989" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_990" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_977" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_990" use="optional" order="56" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ShareholdersEquityDetailsLineItems" xlink:label="loc_sclx_ShareholdersEquityDetailsLineItems_1046" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ShareholdersEquityDetailsTable" xlink:label="loc_sclx_ShareholdersEquityDetailsTable_1008" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1046" xlink:to="loc_sclx_ShareholdersEquityDetailsTable_1008" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1011" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1008" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1011" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1009" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1011" xlink:to="loc_us-gaap_EquityComponentDomain_1009" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1009_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1011" xlink:to="loc_us-gaap_EquityComponentDomain_1009_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaap_TreasuryStockCommonMember_1004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1009" xlink:to="loc_us-gaap_TreasuryStockCommonMember_1004" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1019" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1008" xlink:to="loc_us-gaap_AwardTypeAxis_1019" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1024" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1019" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1024" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1024_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1019" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1024_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_WarrantsMember" xlink:label="loc_sclx_WarrantsMember_1034" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1024" xlink:to="loc_sclx_WarrantsMember_1034" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1027" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1008" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1027" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1003" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1027" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1003" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1003_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1027" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1003_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_WarrantTransferAgreementMember" xlink:label="loc_sclx_WarrantTransferAgreementMember_997" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1003" xlink:to="loc_sclx_WarrantTransferAgreementMember_997" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PurchaseAgreementAxis" xlink:label="loc_sclx_PurchaseAgreementAxis_1032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1008" xlink:to="loc_sclx_PurchaseAgreementAxis_1032" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PurchaseAgreementDomain" xlink:label="loc_sclx_PurchaseAgreementDomain_1010" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_PurchaseAgreementAxis_1032" xlink:to="loc_sclx_PurchaseAgreementDomain_1010" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PurchaseAgreementDomain" xlink:label="loc_sclx_PurchaseAgreementDomain_1010_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_PurchaseAgreementAxis_1032" xlink:to="loc_sclx_PurchaseAgreementDomain_1010_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ARYorkvillePurchaseAgreementMember" xlink:label="loc_sclx_ARYorkvillePurchaseAgreementMember_1000" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PurchaseAgreementDomain_1010" xlink:to="loc_sclx_ARYorkvillePurchaseAgreementMember_1000" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_BRileyPurchaseAgreementMember" xlink:label="loc_sclx_BRileyPurchaseAgreementMember_1022" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PurchaseAgreementDomain_1010" xlink:to="loc_sclx_BRileyPurchaseAgreementMember_1022" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AtTheMarketSalesAgreementMember" xlink:label="loc_sclx_AtTheMarketSalesAgreementMember_1031" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PurchaseAgreementDomain_1010" xlink:to="loc_sclx_AtTheMarketSalesAgreementMember_1031" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1035" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1008" xlink:to="loc_dei_LegalEntityAxis_1035" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1028" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1035" xlink:to="loc_dei_EntityDomain_1028" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1028_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1035" xlink:to="loc_dei_EntityDomain_1028_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_HudsonBayMember" xlink:label="loc_sclx_HudsonBayMember_1018" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1028" xlink:to="loc_sclx_HudsonBayMember_1018" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_CoveLaneMember" xlink:label="loc_sclx_CoveLaneMember_1026" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1028" xlink:to="loc_sclx_CoveLaneMember_1026" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1038" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1008" xlink:to="loc_srt_TitleOfIndividualAxis_1038" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_1038" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1012" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1012_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_1038" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1012_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1040" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1008" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1040" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1025" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1040" xlink:to="loc_us-gaap_ClassOfStockDomain_1025" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1025_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1040" xlink:to="loc_us-gaap_ClassOfStockDomain_1025_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1017" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1025" xlink:to="loc_us-gaap_CommonStockMember_1017" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_1023" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1025" xlink:to="loc_us-gaap_PreferredStockMember_1023" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1042" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1008" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1042" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1001" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1042" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1001" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1001_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1042" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1001_default" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1044" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1008" xlink:to="loc_srt_RangeAxis_1044" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1007" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1044" xlink:to="loc_srt_RangeMember_1007" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1007_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1044" xlink:to="loc_srt_RangeMember_1007_default" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1006" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1007" xlink:to="loc_srt_MaximumMember_1006" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_998" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1046" xlink:to="loc_us-gaap_CommonStockSharesIssued_998" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1015" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1046" xlink:to="loc_us-gaap_SharePrice_1015" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1021" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1046" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1021" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1030" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1046" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1030" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_1036" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1046" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_1036" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaap_TreasuryStockCommonShares_1039" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1046" xlink:to="loc_us-gaap_TreasuryStockCommonShares_1039" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1045" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1046" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1045" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PurchaseOfStockPercentage" xlink:label="loc_sclx_PurchaseOfStockPercentage_1047" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1046" xlink:to="loc_sclx_PurchaseOfStockPercentage_1047" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_CommonStockSold" xlink:label="loc_sclx_CommonStockSold_1048" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1046" xlink:to="loc_sclx_CommonStockSold_1048" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ProceedsFromSaleOfCommonStock" xlink:label="loc_sclx_ProceedsFromSaleOfCommonStock_1049" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1046" xlink:to="loc_sclx_ProceedsFromSaleOfCommonStock_1049" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1050" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1046" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1050" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividends" xlink:label="loc_us-gaap_PaymentsOfDividends_1052" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1046" xlink:to="loc_us-gaap_PaymentsOfDividends_1052" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_1053" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1046" xlink:to="loc_us-gaap_CommonStockValue_1053" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RightToSellMaximumNumberOfCommonStockShares" xlink:label="loc_sclx_RightToSellMaximumNumberOfCommonStockShares_1054" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1046" xlink:to="loc_sclx_RightToSellMaximumNumberOfCommonStockShares_1054" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1055" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1046" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1055" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ProceedSOfSaleOfCommonSharesPercentage" xlink:label="loc_sclx_ProceedSOfSaleOfCommonSharesPercentage_1056" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1046" xlink:to="loc_sclx_ProceedSOfSaleOfCommonSharesPercentage_1056" use="optional" order="55" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1114" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1114" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1105" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis_1103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1105" xlink:to="loc_us-gaap_ValuationTechniqueAxis_1103" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_1106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_1103" xlink:to="loc_us-gaap_ValuationTechniqueDomain_1106" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_1106_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_1103" xlink:to="loc_us-gaap_ValuationTechniqueDomain_1106_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_BlackScholesOptionPricingMethodMember" xlink:label="loc_sclx_BlackScholesOptionPricingMethodMember_1099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_1106" xlink:to="loc_sclx_BlackScholesOptionPricingMethodMember_1099" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1105" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1110" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1110" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1104" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1104_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1110" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1104_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_1098" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1104" xlink:to="loc_us-gaap_StockOptionMember_1098" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_EmployeeStockPurchasePlanMember" xlink:label="loc_sclx_EmployeeStockPurchasePlanMember_1107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1104" xlink:to="loc_sclx_EmployeeStockPurchasePlanMember_1107" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1105" xlink:to="loc_srt_RangeAxis_1112" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1112" xlink:to="loc_srt_RangeMember_1102" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1102_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1112" xlink:to="loc_srt_RangeMember_1102_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1102" xlink:to="loc_srt_MinimumMember_1101" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1102" xlink:to="loc_srt_MaximumMember_1109" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1114" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1108" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1114" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1111" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1114" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1113" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_1115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1114" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_1115" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1114" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1116" use="optional" order="20" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1161" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1161" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1132" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1132" xlink:to="loc_us-gaap_PlanNameAxis_1131" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1125" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1131" xlink:to="loc_us-gaap_PlanNameDomain_1125" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1125_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1131" xlink:to="loc_us-gaap_PlanNameDomain_1125_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:label="loc_sclx_TwoThousandTwentyTwoEquityIncentivePlanMember_1140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1125" xlink:to="loc_sclx_TwoThousandTwentyTwoEquityIncentivePlanMember_1140" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_TwoThousandTwentyThreeInducementPlanMember" xlink:label="loc_sclx_TwoThousandTwentyThreeInducementPlanMember_1146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1125" xlink:to="loc_sclx_TwoThousandTwentyThreeInducementPlanMember_1146" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" xlink:label="loc_sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember_1150" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1125" xlink:to="loc_sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember_1150" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1139" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1132" xlink:to="loc_srt_RangeAxis_1139" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1139" xlink:to="loc_srt_RangeMember_1130" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1130_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1139" xlink:to="loc_srt_RangeMember_1130_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1130" xlink:to="loc_srt_MaximumMember_1129" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1130" xlink:to="loc_srt_MinimumMember_1138" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1132" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1145" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1145" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1133" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1133_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1145" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1133_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1132" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1149" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1123" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1149" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1123" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1123_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1149" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1123_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1132" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1154" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1154" xlink:to="loc_us-gaap_RelatedPartyDomain_1128" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1128_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1154" xlink:to="loc_us-gaap_RelatedPartyDomain_1128_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_NonEmployeeDirectorMember" xlink:label="loc_sclx_NonEmployeeDirectorMember_1155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1128" xlink:to="loc_sclx_NonEmployeeDirectorMember_1155" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1157" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1132" xlink:to="loc_us-gaap_AwardTypeAxis_1157" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1141" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1141_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1141_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1159" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1132" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1159" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1159" xlink:to="loc_us-gaap_ClassOfStockDomain_1143" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1143_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1159" xlink:to="loc_us-gaap_ClassOfStockDomain_1143_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1143" xlink:to="loc_us-gaap_CommonStockMember_1122" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1161" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1127" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_1137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1161" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_1137" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1144" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1161" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1144" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1161" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1148" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1161" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1152" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1161" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1156" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_1158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1161" xlink:to="loc_us-gaap_ShareBasedCompensation_1158" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1160" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1161" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1160" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_1162" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1161" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_1162" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1163" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1161" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1163" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_1164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1161" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_1164" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_Sharebasedcompensationpayable" xlink:label="loc_sclx_Sharebasedcompensationpayable_1165" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1161" xlink:to="loc_sclx_Sharebasedcompensationpayable_1165" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationCashBasedArrangementsLiabilityCurrent" xlink:label="loc_us-gaap_DeferredCompensationCashBasedArrangementsLiabilityCurrent_1166" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1161" xlink:to="loc_us-gaap_DeferredCompensationCashBasedArrangementsLiabilityCurrent_1166" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_WeightedAveragePeriodOverGrant" xlink:label="loc_sclx_WeightedAveragePeriodOverGrant_1167" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1161" xlink:to="loc_sclx_WeightedAveragePeriodOverGrant_1167" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1161" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1168" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1161" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1169" use="optional" order="45" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_CommitmentsAndContingenciesLineItems" xlink:label="loc_sclx_CommitmentsAndContingenciesLineItems_1228" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_CommitmentsAndContingenciesTable" xlink:label="loc_sclx_CommitmentsAndContingenciesTable_1198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1228" xlink:to="loc_sclx_CommitmentsAndContingenciesTable_1198" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1205" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CommitmentsAndContingenciesTable_1198" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1205" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1205" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1195" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1195_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1205" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1195_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ProductDevelopmentAgreementMember" xlink:label="loc_sclx_ProductDevelopmentAgreementMember_1193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1195" xlink:to="loc_sclx_ProductDevelopmentAgreementMember_1193" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_NonCancelableLeaseAgreementsMember" xlink:label="loc_sclx_NonCancelableLeaseAgreementsMember_1208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1195" xlink:to="loc_sclx_NonCancelableLeaseAgreementsMember_1208" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_1213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CommitmentsAndContingenciesTable_1198" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_1213" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1200" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1213" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1200" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1200_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1213" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1200_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CommitmentsAndContingenciesTable_1198" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1217" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1217" xlink:to="loc_us-gaap_SegmentDomain_1197" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1197_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1217" xlink:to="loc_us-gaap_SegmentDomain_1197_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ScilexPharmaMember" xlink:label="loc_sclx_ScilexPharmaMember_1199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1197" xlink:to="loc_sclx_ScilexPharmaMember_1199" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_EpoladermMember" xlink:label="loc_sclx_EpoladermMember_1211" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1197" xlink:to="loc_sclx_EpoladermMember_1211" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ProbudurMember" xlink:label="loc_sclx_ProbudurMember_1216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1197" xlink:to="loc_sclx_ProbudurMember_1216" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_EnveltaMember" xlink:label="loc_sclx_EnveltaMember_1220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1197" xlink:to="loc_sclx_EnveltaMember_1220" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1221" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CommitmentsAndContingenciesTable_1198" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1221" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1201" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1221" xlink:to="loc_us-gaap_RelatedPartyDomain_1201" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1201_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1221" xlink:to="loc_us-gaap_RelatedPartyDomain_1201_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DevelopersMember" xlink:label="loc_sclx_DevelopersMember_1196" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1201" xlink:to="loc_sclx_DevelopersMember_1196" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_GloperbaMember" xlink:label="loc_sclx_GloperbaMember_1210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1201" xlink:to="loc_sclx_GloperbaMember_1210" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_FormerEmployeeMember" xlink:label="loc_sclx_FormerEmployeeMember_1215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1201" xlink:to="loc_sclx_FormerEmployeeMember_1215" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_FormerEmployeeOneMember" xlink:label="loc_sclx_FormerEmployeeOneMember_1219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1201" xlink:to="loc_sclx_FormerEmployeeOneMember_1219" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CommitmentsAndContingenciesTable_1198" xlink:to="loc_srt_RangeAxis_1224" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1203" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1224" xlink:to="loc_srt_RangeMember_1203" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1203_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1224" xlink:to="loc_srt_RangeMember_1203_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1202" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1203" xlink:to="loc_srt_MinimumMember_1202" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1203" xlink:to="loc_srt_MaximumMember_1212" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CommitmentsAndContingenciesTable_1198" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1226" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1226" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1204" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1204_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1226" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1204_default" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ResearchAndDevelopmentFacilitiesMember" xlink:label="loc_sclx_ResearchAndDevelopmentFacilitiesMember_1206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1204" xlink:to="loc_sclx_ResearchAndDevelopmentFacilitiesMember_1206" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RoyaltyPaymentPercentageRelatedToFutureYears" xlink:label="loc_sclx_RoyaltyPaymentPercentageRelatedToFutureYears_1194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1228" xlink:to="loc_sclx_RoyaltyPaymentPercentageRelatedToFutureYears_1194" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_1209" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1228" xlink:to="loc_us-gaap_LitigationSettlementExpense_1209" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RoyaltyPaymentPercentageOnNetSale" xlink:label="loc_sclx_RoyaltyPaymentPercentageOnNetSale_1214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1228" xlink:to="loc_sclx_RoyaltyPaymentPercentageOnNetSale_1214" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_1218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1228" xlink:to="loc_us-gaap_RoyaltyExpense_1218" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_1222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1228" xlink:to="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_1222" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AgreementMaturityDate" xlink:label="loc_sclx_AgreementMaturityDate_1225" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1228" xlink:to="loc_sclx_AgreementMaturityDate_1225" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_MaturityRenewalDescription" xlink:label="loc_sclx_MaturityRenewalDescription_1227" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1228" xlink:to="loc_sclx_MaturityRenewalDescription_1227" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DueFromRelatedParty" xlink:label="loc_sclx_DueFromRelatedParty_1230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1228" xlink:to="loc_sclx_DueFromRelatedParty_1230" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_1231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1228" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_1231" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_1232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1228" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_1232" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability_1233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1228" xlink:to="loc_us-gaap_FinanceLeaseLiability_1233" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_1234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1228" xlink:to="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_1234" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_1235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1228" xlink:to="loc_us-gaap_OperatingLeaseExpense_1235" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1228" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1236" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1228" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1237" use="optional" order="47" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/IncomeTaxesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_IncomeTaxDisclosureLineItems" xlink:label="loc_sclx_IncomeTaxDisclosureLineItems_1300" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_1294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1300" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_1294" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1290" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1294" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1290" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1293" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1290" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1293" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1293_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1290" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1293_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_1291" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1293" xlink:to="loc_us-gaap_DomesticCountryMember_1291" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_1298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1293" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_1298" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_1297" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1294" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_1297" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_1292" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1297" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_1292" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_1292_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1297" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_1292_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_1295" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1292" xlink:to="loc_us-gaap_ResearchMember_1295" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1300" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1289" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1296" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1300" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1296" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_IndefiniteOperatingLossCarryforwards" xlink:label="loc_sclx_IndefiniteOperatingLossCarryforwards_1299" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1300" xlink:to="loc_sclx_IndefiniteOperatingLossCarryforwards_1299" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_OperatingLossCarryforwardsExpirationYear" xlink:label="loc_sclx_OperatingLossCarryforwardsExpirationYear_1301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1300" xlink:to="loc_sclx_OperatingLossCarryforwardsExpirationYear_1301" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1302" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1300" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1302" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_TaxCreditCarryforwardNotSubjectToExpireAmount" xlink:label="loc_sclx_TaxCreditCarryforwardNotSubjectToExpireAmount_1303" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1300" xlink:to="loc_sclx_TaxCreditCarryforwardNotSubjectToExpireAmount_1303" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_IncomeTaxCreditsExpirationYear" xlink:label="loc_sclx_IncomeTaxCreditsExpirationYear_1304" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1300" xlink:to="loc_sclx_IncomeTaxCreditsExpirationYear_1304" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_1305" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1300" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_1305" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_1306" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1300" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_1306" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1307" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1300" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1307" use="optional" order="20" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1331" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1331" xlink:to="loc_us-gaap_StatementTable_1323" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1323" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1325" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1325" xlink:to="loc_us-gaap_ClassOfStockDomain_1330" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1330_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1325" xlink:to="loc_us-gaap_ClassOfStockDomain_1330_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_StockOptionsMember" xlink:label="loc_sclx_StockOptionsMember_1322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1330" xlink:to="loc_sclx_StockOptionsMember_1322" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PublicWarrantsMember" xlink:label="loc_sclx_PublicWarrantsMember_1327" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1330" xlink:to="loc_sclx_PublicWarrantsMember_1327" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PrivateWarrantsMember" xlink:label="loc_sclx_PrivateWarrantsMember_1329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1330" xlink:to="loc_sclx_PrivateWarrantsMember_1329" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RetainerSharesMember" xlink:label="loc_sclx_RetainerSharesMember_1334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1330" xlink:to="loc_sclx_RetainerSharesMember_1334" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SharesIssuablePursuantToEsppMember" xlink:label="loc_sclx_SharesIssuablePursuantToEsppMember_1335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1330" xlink:to="loc_sclx_SharesIssuablePursuantToEsppMember_1335" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1323" xlink:to="loc_us-gaap_DebtInstrumentAxis_1328" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1332" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1328" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1332" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1332_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1328" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1332_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ConvertibleDebenturesMember" xlink:label="loc_sclx_ConvertibleDebenturesMember_1324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1332" xlink:to="loc_sclx_ConvertibleDebenturesMember_1324" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1331" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1326" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/NetLossPerShareAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1343" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1339" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1343" xlink:to="loc_us-gaap_StatementTable_1339" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1339" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1341" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1341" xlink:to="loc_us-gaap_EquityComponentDomain_1340" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1340_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1341" xlink:to="loc_us-gaap_EquityComponentDomain_1340_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1340" xlink:to="loc_us-gaap_WarrantMember_1338" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1342" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1343" xlink:to="loc_us-gaap_CommonStockSharesIssued_1342" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1366" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_us-gaap_SubsequentEventTable_1348" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1355" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1348" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1355" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1355" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1346" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1346_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1355" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1346_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1354" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1346" xlink:to="loc_us-gaap_SubsequentEventMember_1354" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1359" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1348" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1359" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1352" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1359" xlink:to="loc_us-gaap_EquityComponentDomain_1352" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1352_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1359" xlink:to="loc_us-gaap_EquityComponentDomain_1352_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1352" xlink:to="loc_us-gaap_WarrantMember_1347" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1348" xlink:to="loc_dei_LegalEntityAxis_1362" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1361" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1362" xlink:to="loc_dei_EntityDomain_1361" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1361_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1362" xlink:to="loc_dei_EntityDomain_1361_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RodmanRenshawLlcMember" xlink:label="loc_sclx_RodmanRenshawLlcMember_1349" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1361" xlink:to="loc_sclx_RodmanRenshawLlcMember_1349" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1364" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1348" xlink:to="loc_srt_RangeAxis_1364" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1351" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1364" xlink:to="loc_srt_RangeMember_1351" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1351_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1364" xlink:to="loc_srt_RangeMember_1351_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_CommonStockSold" xlink:label="loc_sclx_CommonStockSold_1363" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_sclx_CommonStockSold_1363" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PurchaseOfCommonWarrants" xlink:label="loc_sclx_PurchaseOfCommonWarrants_1365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_sclx_PurchaseOfCommonWarrants_1365" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PurchaseOfCommonShares" xlink:label="loc_sclx_PurchaseOfCommonShares_1367" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_sclx_PurchaseOfCommonShares_1367" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1368" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1368" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PricePerOptionalShare" xlink:label="loc_sclx_PricePerOptionalShare_1369" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_sclx_PricePerOptionalShare_1369" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PricePerOptionalWarrant" xlink:label="loc_sclx_PricePerOptionalWarrant_1370" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_sclx_PricePerOptionalWarrant_1370" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PublicOfferingPerOptionalShare" xlink:label="loc_sclx_PublicOfferingPerOptionalShare_1371" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_sclx_PublicOfferingPerOptionalShare_1371" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PublicOfferingPerOptionalWarrant" xlink:label="loc_sclx_PublicOfferingPerOptionalWarrant_1372" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_sclx_PublicOfferingPerOptionalWarrant_1372" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PublicOfferingPrice" xlink:label="loc_sclx_PublicOfferingPrice_1373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_sclx_PublicOfferingPrice_1373" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ExercisePriceOfCommonWarrant" xlink:label="loc_sclx_ExercisePriceOfCommonWarrant_1374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_sclx_ExercisePriceOfCommonWarrant_1374" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_CommonShareSold" xlink:label="loc_sclx_CommonShareSold_1375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_sclx_CommonShareSold_1375" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_1377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_1377" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1378" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PublicOfferingPriceCombined" xlink:label="loc_sclx_PublicOfferingPriceCombined_1379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_sclx_PublicOfferingPriceCombined_1379" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_1381" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_us-gaap_LegalFees_1381" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_OutOfPocketExpense" xlink:label="loc_sclx_OutOfPocketExpense_1382" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_sclx_OutOfPocketExpense_1382" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PublicOfferingPriceSold" xlink:label="loc_sclx_PublicOfferingPriceSold_1383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_sclx_PublicOfferingPriceSold_1383" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_CombinedPricePaidOfWarrant" xlink:label="loc_sclx_CombinedPricePaidOfWarrant_1384" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_sclx_CombinedPricePaidOfWarrant_1384" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventDescription" xlink:label="loc_us-gaap_SubsequentEventDescription_1387" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_us-gaap_SubsequentEventDescription_1387" use="optional" order="35" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaap_OperatingCostsAndExpenses" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_OperatingCostsAndExpenses" order="1.0" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent" order="1.0" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_DerivativeLiabilities" order="2.0" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>sclx-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 28-March-2024 [02:31:15] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesTable" xlink:label="loc_dei_EntityAddressesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressesTable" xml:lang="en-US">Entity Addresses [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesTable" xlink:to="lab_dei_EntityAddressesTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AddressTypeDomain" xml:lang="en-US">Address Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_BusinessContactMember" xml:lang="en-US">Business Contact [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember" xlink:to="lab_dei_BusinessContactMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesLineItems" xlink:label="loc_dei_EntityAddressesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressesLineItems" xml:lang="en-US">Entity Addresses [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesLineItems" xlink:to="lab_dei_EntityAddressesLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentDescription" xml:lang="en-US">Amendment Description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentDescription" xlink:to="lab_dei_AmendmentDescription" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelName" xml:lang="en-US">Contact Personnel Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName" xlink:to="lab_dei_ContactPersonnelName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod" xml:lang="en-US">Entity Ex Transition Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPrimarySicNumber" xml:lang="en-US">Entity Primary SIC Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPrimarySicNumber" xlink:to="lab_dei_EntityPrimarySicNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventory, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xml:lang="en-US">Other Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses and other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xml:lang="en-US">Assets, Noncurrent, Other than Noncurrent Investments and Property, Plant and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xml:lang="en-US">Other long term assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xml:lang="en-US">Intangibles, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease right-of-use asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Additional ROU assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and stockholders' (deficit) equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' DEFICIT</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies (See Note 11)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xml:lang="en-US">Derivative Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xml:lang="en-US">Derivative liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AccruedExpenses" xlink:label="loc_sclx_AccruedExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AccruedExpenses" xml:lang="en-US">Accrued expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AccruedExpenses" xml:lang="en-US">Accrued expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_sclx_AccruedExpenses" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AccruedExpenses" xlink:to="lab_sclx_AccruedExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AccruedExpenses" xml:lang="en-US">Accrued expenses</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xml:lang="en-US">Accrued Salaries, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xml:lang="en-US">Accrued payroll</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_CurrentPortionOfDeferredConsideration" xlink:label="loc_sclx_CurrentPortionOfDeferredConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CurrentPortionOfDeferredConsideration" xml:lang="en-US">Current portion of deferred consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CurrentPortionOfDeferredConsideration" xml:lang="en-US">Current portion of deferred consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CurrentPortionOfDeferredConsideration" xlink:to="lab_sclx_CurrentPortionOfDeferredConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CurrentPortionOfDeferredConsideration" xml:lang="en-US">Current portion of deferred consideration</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtCurrent" xml:lang="en-US">Debt, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtCurrent" xml:lang="en-US">Debt, current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Current portion of operating lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Less current portion of lease liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Accrued rebates and fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_LongTermPortionOfDeferredConsideration" xlink:label="loc_sclx_LongTermPortionOfDeferredConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LongTermPortionOfDeferredConsideration" xml:lang="en-US">Long-term portion of deferred consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_LongTermPortionOfDeferredConsideration" xml:lang="en-US">Long-term portion of deferred consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LongTermPortionOfDeferredConsideration" xlink:to="lab_sclx_LongTermPortionOfDeferredConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LongTermPortionOfDeferredConsideration" xml:lang="en-US">Long-term portion of deferred consideration</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Corresponding lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other long-term liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermDebtNoncurrent" xlink:label="loc_us-gaap_OtherLongTermDebtNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLongTermDebtNoncurrent" xml:lang="en-US">Other Long-Term Debt, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLongTermDebtNoncurrent" xml:lang="en-US">Debt, net of issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermDebtNoncurrent" xlink:to="lab_us-gaap_OtherLongTermDebtNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' (deficit) equity:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.0001 par value, 740,000,000 shares authorized; 160,084,250 shares issued and 100,015,665 shares outstanding as of December 31, 2023; 141,348,856 shares issued and outstanding as of December 31, 2022</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock Issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, $0.0001 par value, 45,000,000 shares authorized; 29,057,097 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Equity, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' (deficit) equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury Stock, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury stock, at cost; 60,068,585 shares and nil shares as of September 30, 2023 and December 31, 2022, respectively</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Offer and sell shares of Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaap_TreasuryStockCommonShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xml:lang="en-US">Treasury Stock, Common, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xml:lang="en-US">Treasury stock shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xml:lang="en-US">Treasury Stock Common Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Basic (Loss) income Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Net loss per share attributable to common stockholders - basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Net loss per share attributable to common stockholders - diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other (income) expense:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ChangeInFairValueOfDebtAndLiabilityInstruments" xlink:label="loc_sclx_ChangeInFairValueOfDebtAndLiabilityInstruments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ChangeInFairValueOfDebtAndLiabilityInstruments" xml:lang="en-US">Change In Fair Value Of Debt And Liability Instruments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ChangeInFairValueOfDebtAndLiabilityInstruments" xml:lang="en-US">Change in fair value of debt and liability instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ChangeInFairValueOfDebtAndLiabilityInstruments" xlink:to="lab_sclx_ChangeInFairValueOfDebtAndLiabilityInstruments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ChangeInFairValueOfDebtAndLiabilityInstruments" xml:lang="en-US">Change In Fair Value Of Debt And Liability Instruments</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Loss (gain) on derivative liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">(Gain) loss on derivative liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, before Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">Loss on foreign currency exchange</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">(Gain) loss on debt extinguishment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Loss before income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest expense, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total other (income) expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_NotesPrincipalIncrease" xlink:label="loc_sclx_NotesPrincipalIncrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NotesPrincipalIncrease" xml:lang="en-US">Notes principal increase</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_sclx_NotesPrincipalIncrease" xml:lang="en-US">Scilex Pharma Notes principal increase</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NotesPrincipalIncrease" xlink:to="lab_sclx_NotesPrincipalIncrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NotesPrincipalIncrease" xml:lang="en-US">Notes principal increase</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating costs and expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization of Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Intangible amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfRevenue" xml:lang="en-US">Cost of Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostOfRevenue" xml:lang="en-US">Cost of revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaap_OperatingCostsAndExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xml:lang="en-US">Operating Costs and Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xml:lang="en-US">Total operating costs and expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="lab_us-gaap_OperatingCostsAndExpenses" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">Selling, General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">Selling, general and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Net revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted average number of shares during the period -diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted average number of shares and assumed conversions - diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted average number of shares during the period-basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted average number of shares outstanding - basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockMember" xml:lang="en-US">Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockMember" xml:lang="en-US">Preferred Stock Member</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockPreferredMember" xlink:label="loc_us-gaap_TreasuryStockPreferredMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockPreferredMember" xml:lang="en-US">Treasury Stock, Preferred [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TreasuryStockPreferredMember" xml:lang="en-US">Treasury Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockPreferredMember" xlink:to="lab_us-gaap_TreasuryStockPreferredMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_Adjustmenttoadditionalpaidincapitaldiscountamortization" xlink:label="loc_sclx_Adjustmenttoadditionalpaidincapitaldiscountamortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_Adjustmenttoadditionalpaidincapitaldiscountamortization" xml:lang="en-US">AdjustmentToAdditionalPaidInCapitalDiscountAmortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_Adjustmenttoadditionalpaidincapitaldiscountamortization" xml:lang="en-US">Aardvark SP-104 license transfer from Sorrento</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_Adjustmenttoadditionalpaidincapitaldiscountamortization" xlink:to="lab_sclx_Adjustmenttoadditionalpaidincapitaldiscountamortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_Adjustmenttoadditionalpaidincapitaldiscountamortization" xml:lang="en-US">AdjustmentToAdditionalPaidInCapitalDiscountAmortization</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue" xlink:label="loc_sclx_AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue" xml:lang="en-US">Adjustment To Additional Paid In Capital License Transfer Net Of Discount, value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue" xml:lang="en-US">Aardvark SP-104 license transfer from Sorrento, net of discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue" xlink:to="lab_sclx_AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue" xml:lang="en-US">Adjustment To Additional Paid In Capital License Transfer Net Of Discount, value</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AdjustmentToSharesIssuedInSemnurAcquisitionValue" xlink:label="loc_sclx_AdjustmentToSharesIssuedInSemnurAcquisitionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AdjustmentToSharesIssuedInSemnurAcquisitionValue" xml:lang="en-US">Adjustment to shares issued in Semnur Acquisition value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AdjustmentToSharesIssuedInSemnurAcquisitionValue" xml:lang="en-US">Adjustment to shares issued in Semnur Acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AdjustmentToSharesIssuedInSemnurAcquisitionValue" xlink:to="lab_sclx_AdjustmentToSharesIssuedInSemnurAcquisitionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AdjustmentToSharesIssuedInSemnurAcquisitionValue" xml:lang="en-US">Adjustment to shares issued in Semnur Acquisition value</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ConversionOfConvertibleDebenturesIntoCommonStockShares" xlink:label="loc_sclx_ConversionOfConvertibleDebenturesIntoCommonStockShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ConversionOfConvertibleDebenturesIntoCommonStockShares" xml:lang="en-US">Conversion of Convertible Debentures Into Common Stock, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ConversionOfConvertibleDebenturesIntoCommonStockShares" xml:lang="en-US">Conversion of convertible debentures into common stock, (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ConversionOfConvertibleDebenturesIntoCommonStockShares" xlink:to="lab_sclx_ConversionOfConvertibleDebenturesIntoCommonStockShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ConversionOfConvertibleDebenturesIntoCommonStockShares" xml:lang="en-US">Conversion of Convertible Debentures Into Common Stock, Shares</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ConversionOfConvertibleDebenturesIntoCommonStockValue" xlink:label="loc_sclx_ConversionOfConvertibleDebenturesIntoCommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ConversionOfConvertibleDebenturesIntoCommonStockValue" xml:lang="en-US">Conversion of Convertible Debentures Into Common Stock, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ConversionOfConvertibleDebenturesIntoCommonStockValue" xml:lang="en-US">Conversion of convertible debentures into common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ConversionOfConvertibleDebenturesIntoCommonStockValue" xlink:to="lab_sclx_ConversionOfConvertibleDebenturesIntoCommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ConversionOfConvertibleDebenturesIntoCommonStockValue" xml:lang="en-US">Conversion of Convertible Debentures Into Common Stock, Value</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DisbursementOfFundsToSorrentoAmount" xlink:label="loc_sclx_DisbursementOfFundsToSorrentoAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DisbursementOfFundsToSorrentoAmount" xml:lang="en-US">Disbursement of funds to Sorrento Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DisbursementOfFundsToSorrentoAmount" xml:lang="en-US">Disbursement of funds to Sorrento Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DisbursementOfFundsToSorrentoAmount" xlink:to="lab_sclx_DisbursementOfFundsToSorrentoAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DisbursementOfFundsToSorrentoAmount" xml:lang="en-US">Disbursement of funds to Sorrento Amount</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_IssuanceOfCommonStockUponWarrantsExerciseShares" xlink:label="loc_sclx_IssuanceOfCommonStockUponWarrantsExerciseShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_IssuanceOfCommonStockUponWarrantsExerciseShares" xml:lang="en-US">Issuance of Common Stock Upon Warrants Exercise, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_IssuanceOfCommonStockUponWarrantsExerciseShares" xml:lang="en-US">Issuance of common stock upon warrants exercise, (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_IssuanceOfCommonStockUponWarrantsExerciseShares" xlink:to="lab_sclx_IssuanceOfCommonStockUponWarrantsExerciseShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_IssuanceOfCommonStockUponWarrantsExerciseShares" xml:lang="en-US">Issuance of Common Stock Upon Warrants Exercise, Shares</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_IssuanceOfCommonStockUponWarrantsExerciseValue" xlink:label="loc_sclx_IssuanceOfCommonStockUponWarrantsExerciseValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_IssuanceOfCommonStockUponWarrantsExerciseValue" xml:lang="en-US">Issuance of Common Stock Upon Warrants Exercise, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_IssuanceOfCommonStockUponWarrantsExerciseValue" xml:lang="en-US">Issuance of common stock upon warrants exercise</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_IssuanceOfCommonStockUponWarrantsExerciseValue" xlink:to="lab_sclx_IssuanceOfCommonStockUponWarrantsExerciseValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_IssuanceOfCommonStockUponWarrantsExerciseValue" xml:lang="en-US">Issuance of Common Stock Upon Warrants Exercise, Value</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_IssuanceOfPennyWarrants" xlink:label="loc_sclx_IssuanceOfPennyWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_IssuanceOfPennyWarrants" xml:lang="en-US">Issuance of Penny Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_IssuanceOfPennyWarrants" xml:lang="en-US">Issuance of penny warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_IssuanceOfPennyWarrants" xlink:to="lab_sclx_IssuanceOfPennyWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_IssuanceOfPennyWarrants" xml:lang="en-US">Issuance of Penny Warrants</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RetainerSharesIssued" xlink:label="loc_sclx_RetainerSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RetainerSharesIssued" xml:lang="en-US">Retainer shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RetainerSharesIssued" xml:lang="en-US">Retainer shares issued (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RetainerSharesIssued" xlink:to="lab_sclx_RetainerSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RetainerSharesIssued" xml:lang="en-US">Retainer shares issued</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RetainerSharesIssuedValue" xlink:label="loc_sclx_RetainerSharesIssuedValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RetainerSharesIssuedValue" xml:lang="en-US">Retainer Shares Issued Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RetainerSharesIssuedValue" xml:lang="en-US">Retainer shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RetainerSharesIssuedValue" xlink:to="lab_sclx_RetainerSharesIssuedValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RetainerSharesIssuedValue" xml:lang="en-US">Retainer shares issued value</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement" xlink:label="loc_sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement" xml:lang="en-US">Shares issued to Yorkville pursuant to Yorkville Purchase Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement" xml:lang="en-US">Shares issued to Yorkville pursuant to Yorkville Purchase Agreement, Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement" xlink:to="lab_sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement" xml:lang="en-US">Shares issued to Yorkville pursuant to Yorkville Purchase Agreement</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares" xlink:label="loc_sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares" xml:lang="en-US">Shares issued to Yorkville pursuant to Yorkville Purchase Agreement (In Shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares" xml:lang="en-US">Shares issued to Yorkville pursuant to Yorkville Purchase Agreement, Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares" xlink:to="lab_sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares" xml:lang="en-US">Shares issued to Yorkville pursuant to Yorkville Purchase Agreement (In Shares)</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SharesIssuedUnderStandbyEquityPurchaseAgreements" xlink:label="loc_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreements" xml:lang="en-US">Shares issued under Standby Equity Purchase Agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreements" xml:lang="en-US">Shares issued under Standby Equity Purchase Agreements (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreements" xlink:to="lab_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreements" xml:lang="en-US">Shares issued under Standby Equity Purchase Agreements</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares" xlink:label="loc_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares" xml:lang="en-US">Stock Issued During Period Repurchase of Treasury Stock, Preferred Stock, and warrants, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares" xml:lang="en-US">Repurchase of Treasury Stock, Preferred Stock, and warrants, (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares" xlink:to="lab_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares" xml:lang="en-US">Stock Issued During Period Repurchase of Treasury Stock, Preferred Stock, and warrants, Shares</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue" xlink:label="loc_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue" xml:lang="en-US">Stock Issued During Period Repurchase Of Treasury Stock Preferred Stock And Warrants Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue" xml:lang="en-US">Repurchase of Treasury Stock, Preferred Stock, and warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue" xlink:to="lab_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue" xml:lang="en-US">Stock Issued During Period Repurchase Of Treasury Stock Preferred Stock And Warrants Value</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xml:lang="en-US">Shares issued pursuant to the terms of the Debt Exchange Agreement, (In shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Issuance of common stock in connection with Settlement Agreement, (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Stock issued for services, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xml:lang="en-US">Stock Issued During Period, Shares, Purchase of Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xml:lang="en-US">Shares issued as a result of the Business Combination, net of transaction activities, Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Stock options exercised (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Options Outstanding, Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xml:lang="en-US">Shares issued pursuant to the terms of the Debt Exchange Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Issuance of common stock in connection with Settlement Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xml:lang="en-US">Stock Issued During Period, Value, Purchase of Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xml:lang="en-US">Shares issued as a result of the Business Combination, net of transaction activities, Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock options exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ValueIssuedUnderStandbyEquityPurchaseAgreements" xlink:label="loc_sclx_ValueIssuedUnderStandbyEquityPurchaseAgreements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ValueIssuedUnderStandbyEquityPurchaseAgreements" xml:lang="en-US">value issued under Standby Equity Purchase Agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ValueIssuedUnderStandbyEquityPurchaseAgreements" xml:lang="en-US">Shares issued under Standby Equity Purchase Agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ValueIssuedUnderStandbyEquityPurchaseAgreements" xlink:to="lab_sclx_ValueIssuedUnderStandbyEquityPurchaseAgreements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ValueIssuedUnderStandbyEquityPurchaseAgreements" xml:lang="en-US">value issued under Standby Equity Purchase Agreements</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xml:lang="en-US">Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental disclosure:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Supplemental disclosure of non-cash financing activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ConversionOfConvertibleDebenturesIntoCommonStock" xlink:label="loc_sclx_ConversionOfConvertibleDebenturesIntoCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ConversionOfConvertibleDebenturesIntoCommonStock" xml:lang="en-US">Conversion of Convertible Debentures into Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ConversionOfConvertibleDebenturesIntoCommonStock" xml:lang="en-US">Conversion of Convertible Debentures into common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_sclx_ConversionOfConvertibleDebenturesIntoCommonStock" xml:lang="en-US">Conversion of Convertible Debentures into common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ConversionOfConvertibleDebenturesIntoCommonStock" xlink:to="lab_sclx_ConversionOfConvertibleDebenturesIntoCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ConversionOfConvertibleDebenturesIntoCommonStock" xml:lang="en-US">Conversion of Convertible Debentures into Common Stock</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DeferredConsiderationForRomegIntangibleAssetAcquisition" xlink:label="loc_sclx_DeferredConsiderationForRomegIntangibleAssetAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DeferredConsiderationForRomegIntangibleAssetAcquisition" xml:lang="en-US">Deferred Consideration for Romeg Intangible Asset Acquisition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DeferredConsiderationForRomegIntangibleAssetAcquisition" xml:lang="en-US">Deferred consideration for Romeg intangible asset acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DeferredConsiderationForRomegIntangibleAssetAcquisition" xlink:to="lab_sclx_DeferredConsiderationForRomegIntangibleAssetAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DeferredConsiderationForRomegIntangibleAssetAcquisition" xml:lang="en-US">Deferred Consideration for Romeg Intangible Asset Acquisition</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses" xlink:label="loc_sclx_ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses" xml:lang="en-US">Excise tax in connection with share repurchase included in accrued expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses" xml:lang="en-US">Excise tax in connection with share repurchase included in accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses" xlink:to="lab_sclx_ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses" xml:lang="en-US">Excise tax in connection with share repurchase included in accrued expenses</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring" xlink:label="loc_sclx_FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring" xml:lang="en-US">Fair value adjustment to derivative liability in troubled debt restructuring</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring" xml:lang="en-US">Fair value adjustment to derivative liability in troubled debt restructuring</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring" xlink:to="lab_sclx_FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring" xml:lang="en-US">Fair value adjustment to derivative liability in troubled debt restructuring</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_OramedNoteIssuanceAtFairValue" xlink:label="loc_sclx_OramedNoteIssuanceAtFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_OramedNoteIssuanceAtFairValue" xml:lang="en-US">Oramed Note issuance at fair value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_OramedNoteIssuanceAtFairValue" xml:lang="en-US">Oramed Note issuance at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_OramedNoteIssuanceAtFairValue" xlink:to="lab_sclx_OramedNoteIssuanceAtFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_OramedNoteIssuanceAtFairValue" xml:lang="en-US">Oramed Note issuance at fair value</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_OtherNonCashConsiderationInConnectionWithShareRepurchase" xlink:label="loc_sclx_OtherNonCashConsiderationInConnectionWithShareRepurchase" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_OtherNonCashConsiderationInConnectionWithShareRepurchase" xml:lang="en-US">Other non-cash consideration in connection with share repurchase</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_OtherNonCashConsiderationInConnectionWithShareRepurchase" xml:lang="en-US">Other non-cash consideration in connection with share repurchase</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_OtherNonCashConsiderationInConnectionWithShareRepurchase" xlink:to="lab_sclx_OtherNonCashConsiderationInConnectionWithShareRepurchase" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_OtherNonCashConsiderationInConnectionWithShareRepurchase" xml:lang="en-US">Other non-cash consideration in connection with share repurchase</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount" xlink:label="loc_sclx_PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount" xml:lang="en-US">Promissory Note issued to Sorrento in exchange for the SP-104 license</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount" xlink:to="lab_sclx_PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount" xml:lang="en-US">Promissory Note issued to Sorrento in exchange for the SP-104 license, net of discount</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement" xlink:label="loc_sclx_RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement" xml:lang="en-US">Related party debt converted to equity pursuant to Debt Exchange Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement" xml:lang="en-US">Related party debt converted to equity pursuant to Debt Exchange Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement" xlink:to="lab_sclx_RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement" xml:lang="en-US">Related party debt converted to equity pursuant to Debt Exchange Agreement</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification" xlink:label="loc_sclx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease liabilities with lease modification</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease liabilities with lease modification</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification" xlink:to="lab_sclx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease liabilities with lease modification</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ScilexPharmaNotesPrincipalIncrease" xlink:label="loc_sclx_ScilexPharmaNotesPrincipalIncrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScilexPharmaNotesPrincipalIncrease" xml:lang="en-US">Scilex Pharma Notes principal increase</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_sclx_ScilexPharmaNotesPrincipalIncrease" xml:lang="en-US">Scilex Pharma Notes principal increase</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScilexPharmaNotesPrincipalIncrease" xlink:to="lab_sclx_ScilexPharmaNotesPrincipalIncrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ScilexPharmaNotesPrincipalIncrease" xml:lang="en-US">Scilex Pharma Notes principal increase</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssued1" xml:lang="en-US">Stock Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssued1" xml:lang="en-US">Issuance of shares to B.Riley pursuant to B. Riley Purchase Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_TransactionCostsObligationAssumedBySorrento" xlink:label="loc_sclx_TransactionCostsObligationAssumedBySorrento" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TransactionCostsObligationAssumedBySorrento" xml:lang="en-US">Transaction costs obligation assumed by Sorrento</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TransactionCostsObligationAssumedBySorrento" xml:lang="en-US">Transaction costs obligation assumed by Sorrento</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TransactionCostsObligationAssumedBySorrento" xlink:to="lab_sclx_TransactionCostsObligationAssumedBySorrento" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TransactionCostsObligationAssumedBySorrento" xml:lang="en-US">Transaction costs obligation assumed by Sorrento</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOperatingPaidInCash" xlink:label="loc_us-gaap_InterestIncomeOperatingPaidInCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeOperatingPaidInCash" xml:lang="en-US">Interest Income, Operating, Paid in Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestIncomeOperatingPaidInCash" xml:lang="en-US">Cash paid for interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperatingPaidInCash" xlink:to="lab_us-gaap_InterestIncomeOperatingPaidInCash" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash and cash equivalents at beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash and cash equivalents at end of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Total cash, cash equivalents, and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount" xml:lang="en-US">Accelerated Share Repurchases, Adjustment to Recorded Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount" xml:lang="en-US">Cash consideration paid in connection with share repurchase</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount" xlink:to="lab_us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DisbursementOfFunds" xlink:label="loc_sclx_DisbursementOfFunds" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DisbursementOfFunds" xml:lang="en-US">Disbursement Of Funds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DisbursementOfFunds" xml:lang="en-US">Disbursement of funds to Sorrento</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DisbursementOfFunds" xlink:to="lab_sclx_DisbursementOfFunds" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DisbursementOfFunds" xml:lang="en-US">Disbursement Of Funds</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarlyRepaymentOfSeniorDebt" xlink:label="loc_us-gaap_EarlyRepaymentOfSeniorDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarlyRepaymentOfSeniorDebt" xml:lang="en-US">Early Repayment of Senior Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_EarlyRepaymentOfSeniorDebt" xml:lang="en-US">Repayment of Oramed Note</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarlyRepaymentOfSeniorDebt" xlink:to="lab_us-gaap_EarlyRepaymentOfSeniorDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash proceeds from financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xml:lang="en-US">Payments of Debt Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xml:lang="en-US">Payments of debt issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Proceeds from Convertible Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Proceeds from issuance of Convertible Debentures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from issuance of shares under Standby Equity Purchase Agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ProceedsFromIssuanceOfRevolvingFacility" xlink:label="loc_sclx_ProceedsFromIssuanceOfRevolvingFacility" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ProceedsFromIssuanceOfRevolvingFacility" xml:lang="en-US">Proceeds from Issuance of Revolving Facility</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ProceedsFromIssuanceOfRevolvingFacility" xml:lang="en-US">Proceeds from issuance of Revolving Facility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ProceedsFromIssuanceOfRevolvingFacility" xlink:to="lab_sclx_ProceedsFromIssuanceOfRevolvingFacility" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ProceedsFromIssuanceOfRevolvingFacility" xml:lang="en-US">Proceeds from Issuance of Revolving Facility</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromOtherShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromOtherShortTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromOtherShortTermDebt" xml:lang="en-US">Proceeds from Other Short-Term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromOtherShortTermDebt" xml:lang="en-US">Proceeds from other loans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromOtherShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromOtherShortTermDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt" xml:lang="en-US">Proceeds from Related Party Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt" xml:lang="en-US">Proceeds from related party payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="lab_us-gaap_ProceedsFromRelatedPartyDebt" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ProceedsFromRepaymentOfLoansToPurchase" xlink:label="loc_sclx_ProceedsFromRepaymentOfLoansToPurchase" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ProceedsFromRepaymentOfLoansToPurchase" xml:lang="en-US">Proceeds From Repayment Of Loans To Purchase</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ProceedsFromRepaymentOfLoansToPurchase" xml:lang="en-US">Repayment on other loans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ProceedsFromRepaymentOfLoansToPurchase" xlink:to="lab_sclx_ProceedsFromRepaymentOfLoansToPurchase" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ProceedsFromRepaymentOfLoansToPurchase" xml:lang="en-US">Proceeds From Repayment Of Loans To Purchase</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSecuredNotesPayable" xlink:label="loc_us-gaap_ProceedsFromSecuredNotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSecuredNotesPayable" xml:lang="en-US">Proceeds from Secured Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSecuredNotesPayable" xml:lang="en-US">Proceeds from related party note payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSecuredNotesPayable" xlink:to="lab_us-gaap_ProceedsFromSecuredNotesPayable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from stock options and warrants exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ProceedsFromTheBusinessCombination" xlink:label="loc_sclx_ProceedsFromTheBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ProceedsFromTheBusinessCombination" xml:lang="en-US">Proceeds from the Business Combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ProceedsFromTheBusinessCombination" xml:lang="en-US">Proceeds from the Business Combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ProceedsFromTheBusinessCombination" xlink:to="lab_sclx_ProceedsFromTheBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ProceedsFromTheBusinessCombination" xml:lang="en-US">Proceeds from the Business Combination</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RepaymentOfPrincipalOnTheScilexPharmaNotes" xlink:label="loc_sclx_RepaymentOfPrincipalOnTheScilexPharmaNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RepaymentOfPrincipalOnTheScilexPharmaNotes" xml:lang="en-US">Repayment of principal on the Scilex Pharma Notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RepaymentOfPrincipalOnTheScilexPharmaNotes" xlink:to="lab_sclx_RepaymentOfPrincipalOnTheScilexPharmaNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RepaymentOfPrincipalOnTheScilexPharmaNotes" xml:lang="en-US">Repayment of principal on the Scilex Pharma Notes</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RepaymentOfRevolvingFacility" xlink:label="loc_sclx_RepaymentOfRevolvingFacility" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RepaymentOfRevolvingFacility" xml:lang="en-US">Repayment of Revolving Facility</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_sclx_RepaymentOfRevolvingFacility" xml:lang="en-US">Repayment of Revolving Facility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RepaymentOfRevolvingFacility" xlink:to="lab_sclx_RepaymentOfRevolvingFacility" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RepaymentOfRevolvingFacility" xml:lang="en-US">Repayment of Revolving Facility</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xml:lang="en-US">Repayments of Convertible Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xml:lang="en-US">Repayment of Convertible Debentures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_TransactionCostsPaidInConnectionWithShareRepurchase" xlink:label="loc_sclx_TransactionCostsPaidInConnectionWithShareRepurchase" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TransactionCostsPaidInConnectionWithShareRepurchase" xml:lang="en-US">Transaction costs paid in connection with share repurchase</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_sclx_TransactionCostsPaidInConnectionWithShareRepurchase" xml:lang="en-US">Transaction costs paid in connection with share repurchase</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TransactionCostsPaidInConnectionWithShareRepurchase" xlink:to="lab_sclx_TransactionCostsPaidInConnectionWithShareRepurchase" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TransactionCostsPaidInConnectionWithShareRepurchase" xml:lang="en-US">Transaction costs paid in connection with share repurchase</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction" xlink:label="loc_sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction" xml:lang="en-US">Transaction costs paid related to the recapitalization transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction" xml:lang="en-US">Transaction costs paid related to the Business Combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction" xlink:to="lab_sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction" xml:lang="en-US">Transaction costs paid related to the recapitalization transaction</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" xlink:label="loc_sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" xml:lang="en-US">Acquisition Consideration Paid In Cash for Romeg Intangible Asset Acquisition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" xml:lang="en-US">Acquisition consideration paid in cash for Romeg intangible asset acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" xlink:to="lab_sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" xml:lang="en-US">Acquisition Consideration Paid In Cash for Romeg Intangible Asset Acquisition</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash used for investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchase of property, plant, and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used for operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US">Amortization of debt issuance costs and debt discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ForfeituresOfPrivateWarrants" xlink:label="loc_sclx_ForfeituresOfPrivateWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ForfeituresOfPrivateWarrants" xml:lang="en-US">Forfeitures of Private Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ForfeituresOfPrivateWarrants" xml:lang="en-US">Forfeitures of private warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ForfeituresOfPrivateWarrants" xlink:to="lab_sclx_ForfeituresOfPrivateWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ForfeituresOfPrivateWarrants" xml:lang="en-US">Forfeitures of Private Warrants</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Accounts receivables, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_IncreaseDecreaseInAccruedPayroll" xlink:label="loc_sclx_IncreaseDecreaseInAccruedPayroll" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_IncreaseDecreaseInAccruedPayroll" xml:lang="en-US">Increase Decrease In Accrued payroll</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_IncreaseDecreaseInAccruedPayroll" xml:lang="en-US">Accrued Payroll</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_IncreaseDecreaseInAccruedPayroll" xlink:to="lab_sclx_IncreaseDecreaseInAccruedPayroll" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_IncreaseDecreaseInAccruedPayroll" xml:lang="en-US">Increase Decrease In Accrued payroll</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_IncreaseDecreaseInAccruedRebatesAndFees" xlink:label="loc_sclx_IncreaseDecreaseInAccruedRebatesAndFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_IncreaseDecreaseInAccruedRebatesAndFees" xml:lang="en-US">Increase (Decrease) in Accrued Rebates and Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_IncreaseDecreaseInAccruedRebatesAndFees" xml:lang="en-US">Accrued rebates and fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_IncreaseDecreaseInAccruedRebatesAndFees" xlink:to="lab_sclx_IncreaseDecreaseInAccruedRebatesAndFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_IncreaseDecreaseInAccruedRebatesAndFees" xml:lang="en-US">Increase (Decrease) in Accrued Rebates and Fees</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Increase (Decrease) in Inventories</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent" xml:lang="en-US">Increase (Decrease) in Notes Payable, Related Parties, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent" xml:lang="en-US">Related party payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent" xlink:to="lab_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xml:lang="en-US">Other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xml:lang="en-US">Other long-term assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xml:lang="en-US">Increase (Decrease) in Prepaid Expenses, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xml:lang="en-US">Prepaid expenses and other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used for operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_OtherLongTermLiabilities" xlink:label="loc_sclx_OtherLongTermLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_OtherLongTermLiabilities" xml:lang="en-US">Other long-term liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_OtherLongTermLiabilities" xml:lang="en-US">Other long-term liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_OtherLongTermLiabilities" xlink:to="lab_sclx_OtherLongTermLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_OtherLongTermLiabilities" xml:lang="en-US">Other long-term liabilities</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_NonCashOperatingLeaseCost" xlink:label="loc_sclx_NonCashOperatingLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NonCashOperatingLeaseCost" xml:lang="en-US">Non Cash Operating Lease Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NonCashOperatingLeaseCost" xml:lang="en-US">Non-cash operating lease cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NonCashOperatingLeaseCost" xlink:to="lab_sclx_NonCashOperatingLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NonCashOperatingLeaseCost" xml:lang="en-US">Non cash operating lease cost.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount" xlink:label="loc_sclx_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount" xml:lang="en-US">Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_sclx_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount" xml:lang="en-US">Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount" xlink:to="lab_sclx_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount" xml:lang="en-US">Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt discount</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xml:lang="en-US">Proceeds from Insurance Settlement, Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xml:lang="en-US">Issuance of shares under Settlement Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:to="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Nature of Operations and Basis of Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xml:lang="en-US">Liquidity and Going Concern</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="loc_us-gaap_DisclosureTextBlockAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureTextBlockAbstract" xml:lang="en-US">Disclosure Text Block [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract" xlink:to="lab_us-gaap_DisclosureTextBlockAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xml:lang="en-US">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xml:lang="en-US">Acquisitions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Balance Sheet Components</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xml:lang="en-US">Goodwill and Intangible Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Debt Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Junior DIP Facility and Sorrento Share Purchase Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Equity [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">STOCKHOLDERS EQUITY</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xml:lang="en-US">Stock Incentive and Employee Benefit Plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Net Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Basis of Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xml:lang="en-US">Acquisitions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Customer Concentration Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:label="loc_us-gaap_ContingentLiabilityReserveEstimatePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContingentLiabilityReserveEstimatePolicy" xml:lang="en-US">Contingent Liability Reserve Estimate, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContingentLiabilityReserveEstimatePolicy" xml:lang="en-US">Contingent Consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:to="lab_us-gaap_ContingentLiabilityReserveEstimatePolicy" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ConvertibleDebenturesAndTheOramedNotePolicyTextBlock" xlink:label="loc_sclx_ConvertibleDebenturesAndTheOramedNotePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ConvertibleDebenturesAndTheOramedNotePolicyTextBlock" xml:lang="en-US">Convertible Debentures and the Oramed Note [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ConvertibleDebenturesAndTheOramedNotePolicyTextBlock" xml:lang="en-US">Convertible Debentures and the Oramed Note</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ConvertibleDebenturesAndTheOramedNotePolicyTextBlock" xlink:to="lab_sclx_ConvertibleDebenturesAndTheOramedNotePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ConvertibleDebenturesAndTheOramedNotePolicyTextBlock" xml:lang="en-US">Convertible Debentures and the Oramed Note</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xml:lang="en-US">Debt, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xml:lang="en-US">Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivative Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Net Loss per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value Measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xml:lang="en-US">Goodwill and Other Long-Lived Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xml:lang="en-US">Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recently Adopted Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and Equipment, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock" xlink:label="loc_sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock" xml:lang="en-US">Public Warrant And Private Placement Warrants [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock" xml:lang="en-US">Public Warrants and Private Placement Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock" xlink:to="lab_sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock" xml:lang="en-US">Public Warrant And Private Placement Warrants [Policy Text Block]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Stock-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xml:lang="en-US">Accounts Receivable [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xml:lang="en-US">Accounts Receivable, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_TreasuryStockPolicyTextblock" xlink:label="loc_sclx_TreasuryStockPolicyTextblock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TreasuryStockPolicyTextblock" xml:lang="en-US">Treasury Stock Policy TextBlock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TreasuryStockPolicyTextblock" xml:lang="en-US">Treasury Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TreasuryStockPolicyTextblock" xlink:to="lab_sclx_TreasuryStockPolicyTextblock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TreasuryStockPolicyTextblock" xml:lang="en-US">Treasury Stock Policy TextBlock</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xml:lang="en-US">Schedule of Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Schedule of fair value assets measured on a recurring basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueConcentrationOfRiskTextBlock" xlink:label="loc_us-gaap_FairValueConcentrationOfRiskTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueConcentrationOfRiskTextBlock" xml:lang="en-US">Fair Value, Concentration of Risk [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueConcentrationOfRiskTextBlock" xml:lang="en-US">Schedule of quantitative information regarding Level 3 fair value measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueConcentrationOfRiskTextBlock" xlink:to="lab_us-gaap_FairValueConcentrationOfRiskTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xml:lang="en-US">Schedule of Debt [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xml:lang="en-US">Schedule of convertible debentures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xml:lang="en-US">Schedule of the derivative liabilities measured at fair value using significant unobservable inputs Level 3</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AccruedExpensesTextblock" xlink:label="loc_sclx_AccruedExpensesTextblock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AccruedExpensesTextblock" xml:lang="en-US">Accrued expenses Textblock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AccruedExpensesTextblock" xml:lang="en-US">Schedule of Acrcued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AccruedExpensesTextblock" xlink:to="lab_sclx_AccruedExpensesTextblock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AccruedExpensesTextblock" xml:lang="en-US">Accrued expenses Textblock</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Schedule of Property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xml:lang="en-US">Estimated future amortization expense related to intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xml:lang="en-US">Summary of identifiable intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xml:lang="en-US">Convertible Debt [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xml:lang="en-US">Schedule of convertible debentures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ScheduleOfTheOramedNoteTableTextBlock" xlink:label="loc_sclx_ScheduleOfTheOramedNoteTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScheduleOfTheOramedNoteTableTextBlock" xml:lang="en-US">Schedule of The Oramed Note Table Text Block</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ScheduleOfTheOramedNoteTableTextBlock" xml:lang="en-US">Schedule of The Oramed Note</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScheduleOfTheOramedNoteTableTextBlock" xlink:to="lab_sclx_ScheduleOfTheOramedNoteTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ScheduleOfTheOramedNoteTableTextBlock" xml:lang="en-US">Schedule of The Oramed Note Table Text Block</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xml:lang="en-US">Long-Term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xml:lang="en-US">Long-Term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeniorNotesMember" xml:lang="en-US">Senior Notes [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeniorNotesMember" xml:lang="en-US">Oramed Note</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule of Stock Options Outstanding Activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of estimate stock-based compensation on the date of grant for stock options and ESPP</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Schedule of Lease Maturities of Lease Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xml:lang="en-US">Schedule of Leases Supplemental Quantitative Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule of Components of Benefit for Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Liabilities and Related Valuation Allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of the reconciliation of basic and diluted loss per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:label="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xml:lang="en-US">Description of Organization and Business Operations (Details) [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:to="lab_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xml:lang="en-US">Descriptionof Organizationand Business Operations Details Table</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableMember" xml:lang="en-US">Accounts Receivable [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SalesRevenueNetMember" xml:lang="en-US">Revenue Benchmark [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xml:lang="en-US">Concentration Risk Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xml:lang="en-US">Concentration Risk Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xml:lang="en-US">Customer Concentration Risk [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:label="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xml:lang="en-US">Description of Organization and Business Operations (Details) [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="lab_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xml:lang="en-US">Descriptionof Organizationand Business Operations Details Line Items</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xml:lang="en-US">Concentration Risk, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xml:lang="en-US">Concentration risk, percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt principal amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Initial principal amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xml:lang="en-US">Debt, Weighted Average Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xml:lang="en-US">Debt Weighted Average Interest Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PercentageOfNetRevenueSoleDistributors" xlink:label="loc_sclx_PercentageOfNetRevenueSoleDistributors" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfNetRevenueSoleDistributors" xml:lang="en-US">Percentage of net revenue, sole distributors</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfNetRevenueSoleDistributors" xml:lang="en-US">Percentage of net revenue, sole distributor</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfNetRevenueSoleDistributors" xlink:to="lab_sclx_PercentageOfNetRevenueSoleDistributors" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfNetRevenueSoleDistributors" xml:lang="en-US">Percentage of net revenue, sole distributors</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xml:lang="en-US">Receivables, Net, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xml:lang="en-US">Receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xml:lang="en-US">Exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MajorCustomersAxis" xml:lang="en-US">Customer [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_NameOfMajorCustomerDomain" xml:lang="en-US">Customer [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ThreeCustomersMember" xlink:label="loc_sclx_ThreeCustomersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ThreeCustomersMember" xml:lang="en-US">Three Customers [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ThreeCustomersMember" xml:lang="en-US">Three Customers [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ThreeCustomersMember" xlink:to="lab_sclx_ThreeCustomersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ThreeCustomersMember" xml:lang="en-US">Three Customers [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-Term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-Term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtMember" xml:lang="en-US">Convertible Debt [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtMember" xml:lang="en-US">Convertible Debentures [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaap_TransactionTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransactionTypeAxis" xml:lang="en-US">Transaction Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransactionTypeAxis" xlink:to="lab_us-gaap_TransactionTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaap_TransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransactionDomain" xml:lang="en-US">Transaction [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransactionDomain" xlink:to="lab_us-gaap_TransactionDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xml:lang="en-US">Restricted Cash and Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_LiquidityAndGoingConcernTable" xlink:label="loc_sclx_LiquidityAndGoingConcernTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LiquidityAndGoingConcernTable" xml:lang="en-US">Liquidity and Going Concern [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LiquidityAndGoingConcernTable" xlink:to="lab_sclx_LiquidityAndGoingConcernTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LiquidityAndGoingConcernTable" xml:lang="en-US">Liquidity and Going Concern [Table]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityUnitPurchaseAgreementsMember" xlink:label="loc_us-gaap_EquityUnitPurchaseAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityUnitPurchaseAgreementsMember" xml:lang="en-US">Equity Unit Purchase Agreements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityUnitPurchaseAgreementsMember" xml:lang="en-US">Equity Purchase Agreement with Yorkville and B. Riley [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityUnitPurchaseAgreementsMember" xlink:to="lab_us-gaap_EquityUnitPurchaseAgreementsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_LiquidityAndGoingConcernLineItems" xlink:label="loc_sclx_LiquidityAndGoingConcernLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LiquidityAndGoingConcernLineItems" xml:lang="en-US">Liquidity and Going Concern [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems" xlink:to="lab_sclx_LiquidityAndGoingConcernLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LiquidityAndGoingConcernLineItems" xml:lang="en-US">Liquidity and Going Concern [Line Items]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_CommonStockIssuableValue" xlink:label="loc_sclx_CommonStockIssuableValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CommonStockIssuableValue" xml:lang="en-US">Common Stock Issuable Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CommonStockIssuableValue" xml:lang="en-US">Common stock issuable, value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CommonStockIssuableValue" xlink:to="lab_sclx_CommonStockIssuableValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CommonStockIssuableValue" xml:lang="en-US">Common Stock Issuable Value</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_Convertibledebentureprincipalamount" xlink:label="loc_sclx_Convertibledebentureprincipalamount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_Convertibledebentureprincipalamount" xml:lang="en-US">ConvertibleDebentureprincipalAmount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_Convertibledebentureprincipalamount" xml:lang="en-US">Convertible Debenture principal Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_Convertibledebentureprincipalamount" xlink:to="lab_sclx_Convertibledebentureprincipalamount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_Convertibledebentureprincipalamount" xml:lang="en-US">ConvertibleDebentureprincipalAmount</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebt" xml:lang="en-US">Convertible Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConvertibleDebt" xml:lang="en-US">Convertible Debenture</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ConvertibleDebt" xml:lang="en-US">Convertible debentures, beginning period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ConvertibleDebt" xml:lang="en-US">Convertible debentures, ending period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt" xlink:to="lab_us-gaap_ConvertibleDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="loc_us-gaap_DebtInstrumentIssuedPrincipal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentIssuedPrincipal" xml:lang="en-US">Debt Instrument, Issued, Principal</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentIssuedPrincipal" xml:lang="en-US">Aggregate Principle amount of issued debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentIssuedPrincipal" xlink:to="lab_us-gaap_DebtInstrumentIssuedPrincipal" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_OutstandingBalanceOfRevolvingFacility" xlink:label="loc_sclx_OutstandingBalanceOfRevolvingFacility" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_OutstandingBalanceOfRevolvingFacility" xml:lang="en-US">Outstanding balance of revolving facility</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_OutstandingBalanceOfRevolvingFacility" xml:lang="en-US">Outstanding balance of revolving facility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_OutstandingBalanceOfRevolvingFacility" xlink:to="lab_sclx_OutstandingBalanceOfRevolvingFacility" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_OutstandingBalanceOfRevolvingFacility" xml:lang="en-US">Outstanding balance of revolving facility</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PrincipalLaonAmount" xlink:label="loc_sclx_PrincipalLaonAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PrincipalLaonAmount" xml:lang="en-US">Principal laon amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PrincipalLaonAmount" xml:lang="en-US">Principal laon amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PrincipalLaonAmount" xlink:to="lab_sclx_PrincipalLaonAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PrincipalLaonAmount" xml:lang="en-US">Principal laon amount</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RightToSellMaximumNumberOfCommonStockShares" xlink:label="loc_sclx_RightToSellMaximumNumberOfCommonStockShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RightToSellMaximumNumberOfCommonStockShares" xml:lang="en-US">Right to Sell Maximum Number of Common Stock Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RightToSellMaximumNumberOfCommonStockShares" xml:lang="en-US">Right to sell maximum number of common stock shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RightToSellMaximumNumberOfCommonStockShares" xlink:to="lab_sclx_RightToSellMaximumNumberOfCommonStockShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RightToSellMaximumNumberOfCommonStockShares" xml:lang="en-US">Right to Sell Maximum Number of Common Stock Shares</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Shares issued, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ValueOfStockSoldForTerminationOfOffering" xlink:label="loc_sclx_ValueOfStockSoldForTerminationOfOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ValueOfStockSoldForTerminationOfOffering" xml:lang="en-US">Value Of Stock Sold For Termination Of Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ValueOfStockSoldForTerminationOfOffering" xml:lang="en-US">Value of stock sold for termination of offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ValueOfStockSoldForTerminationOfOffering" xlink:to="lab_sclx_ValueOfStockSoldForTerminationOfOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ValueOfStockSoldForTerminationOfOffering" xml:lang="en-US">Value Of Stock Sold For Termination Of Offering</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_WorkingCapital" xlink:label="loc_sclx_WorkingCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WorkingCapital" xml:lang="en-US">Working Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_WorkingCapital" xml:lang="en-US">Negative working capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WorkingCapital" xlink:to="lab_sclx_WorkingCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_WorkingCapital" xml:lang="en-US">Working Capital</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PurchaseAgreementAxis" xlink:label="loc_sclx_PurchaseAgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PurchaseAgreementAxis" xml:lang="en-US">Purchase Agreement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PurchaseAgreementAxis" xlink:to="lab_sclx_PurchaseAgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PurchaseAgreementAxis" xml:lang="en-US">Purchase Agreement Axis</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PurchaseAgreementDomain" xlink:label="loc_sclx_PurchaseAgreementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PurchaseAgreementDomain" xml:lang="en-US">Purchase Agreement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PurchaseAgreementDomain" xlink:to="lab_sclx_PurchaseAgreementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PurchaseAgreementDomain" xml:lang="en-US">Purchase Agreement Domain</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ARYorkvillePurchaseAgreementMember" xlink:label="loc_sclx_ARYorkvillePurchaseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ARYorkvillePurchaseAgreementMember" xml:lang="en-US">A R Yorkville Purchase Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ARYorkvillePurchaseAgreementMember" xml:lang="en-US">A&amp;R Yorkville Purchase Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ARYorkvillePurchaseAgreementMember" xlink:to="lab_sclx_ARYorkvillePurchaseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ARYorkvillePurchaseAgreementMember" xml:lang="en-US">A R Yorkville Purchase Agreement.</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AtmSalesAgreementMember" xlink:label="loc_sclx_AtmSalesAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AtmSalesAgreementMember" xml:lang="en-US">ATM Sales Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AtmSalesAgreementMember" xml:lang="en-US">ATM Sales Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AtmSalesAgreementMember" xlink:to="lab_sclx_AtmSalesAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AtmSalesAgreementMember" xml:lang="en-US">ATM Sales Agreement [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xml:lang="en-US">Business Combinations [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xml:lang="en-US">Business Acquisition [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AccruedRoyaltyPayables" xlink:label="loc_sclx_AccruedRoyaltyPayables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AccruedRoyaltyPayables" xml:lang="en-US">Accrued Royalty Payables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AccruedRoyaltyPayables" xml:lang="en-US">Accrued Royalty Payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AccruedRoyaltyPayables" xlink:to="lab_sclx_AccruedRoyaltyPayables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AccruedRoyaltyPayables" xml:lang="en-US">Accrued Royalty Payables</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AmountDueForNewDrugApplication" xlink:label="loc_sclx_AmountDueForNewDrugApplication" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AmountDueForNewDrugApplication" xml:lang="en-US">Amount due for New Drug Application</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AmountDueForNewDrugApplication" xml:lang="en-US">Amount due for New Drug Application</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AmountDueForNewDrugApplication" xlink:to="lab_sclx_AmountDueForNewDrugApplication" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AmountDueForNewDrugApplication" xml:lang="en-US">Amount due for New Drug Application</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xml:lang="en-US">Contingent consideration, liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Intangible asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xml:lang="en-US">Development milestones payment was recognized under other long-term liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_Deferredconsiderationliabilities" xlink:label="loc_sclx_Deferredconsiderationliabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_Deferredconsiderationliabilities" xml:lang="en-US">DeferredConsiderationLiabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_Deferredconsiderationliabilities" xml:lang="en-US">Deferred consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_Deferredconsiderationliabilities" xlink:to="lab_sclx_Deferredconsiderationliabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_Deferredconsiderationliabilities" xml:lang="en-US">DeferredConsiderationLiabilities</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaap_PaymentsForRoyalties" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRoyalties" xml:lang="en-US">Payments for Royalties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsForRoyalties" xml:lang="en-US">Payments for royalties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRoyalties" xlink:to="lab_us-gaap_PaymentsForRoyalties" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PaymentToAcquireLicense" xlink:label="loc_sclx_PaymentToAcquireLicense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PaymentToAcquireLicense" xml:lang="en-US">Payment to Acquire License</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PaymentToAcquireLicense" xml:lang="en-US">Payment to acquire license</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PaymentToAcquireLicense" xlink:to="lab_sclx_PaymentToAcquireLicense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PaymentToAcquireLicense" xml:lang="en-US">Payment to Acquire License</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PaymentUponTheAchievementOfNetSales" xlink:label="loc_sclx_PaymentUponTheAchievementOfNetSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PaymentUponTheAchievementOfNetSales" xml:lang="en-US">Payment upon the achievement of net sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PaymentUponTheAchievementOfNetSales" xlink:to="lab_sclx_PaymentUponTheAchievementOfNetSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PaymentUponTheAchievementOfNetSales" xml:lang="en-US">payment upon the achievement of net sales</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_Upfrontlicensefee" xlink:label="loc_sclx_Upfrontlicensefee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_Upfrontlicensefee" xml:lang="en-US">UpFrontLicenseFee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_Upfrontlicensefee" xml:lang="en-US">Up-front license fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_Upfrontlicensefee" xlink:to="lab_sclx_Upfrontlicensefee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_Upfrontlicensefee" xml:lang="en-US">UpFrontLicenseFee</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PatentsMember" xml:lang="en-US">Patents [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RomegLicenseAgreementMember" xlink:label="loc_sclx_RomegLicenseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RomegLicenseAgreementMember" xml:lang="en-US">Romeg License Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RomegLicenseAgreementMember" xlink:to="lab_sclx_RomegLicenseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RomegLicenseAgreementMember" xml:lang="en-US">Romeg License Agreement [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xml:lang="en-US">Related Party Transaction [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xml:lang="en-US">Related Party Transaction [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SorrentoMember" xml:lang="en-US">Sorrento [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SorrentoMember" xml:lang="en-US">Sorrento</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SorrentoMember" xlink:to="lab_sclx_SorrentoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SorrentoMember" xml:lang="en-US">Sorrento [Member]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_LicenseAgreementMember" xlink:label="loc_sclx_LicenseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LicenseAgreementMember" xml:lang="en-US">License Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_LicenseAgreementMember" xml:lang="en-US">License Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LicenseAgreementMember" xlink:to="lab_sclx_LicenseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LicenseAgreementMember" xml:lang="en-US">License Agreement [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">us-gaap_AwardTypeAxis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_WarrantsMember" xlink:label="loc_sclx_WarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WarrantsMember" xml:lang="en-US">Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_WarrantsMember" xml:lang="en-US">Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WarrantsMember" xlink:to="lab_sclx_WarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_WarrantsMember" xml:lang="en-US">Warrants [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Contingent Consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xml:lang="en-US">Common stock upon conversation of cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense" xlink:label="loc_sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense" xml:lang="en-US">Change In Fair Value Of Convertible Debentures Include Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense" xml:lang="en-US">Change in fair value of debt and liability instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense" xlink:to="lab_sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense" xml:lang="en-US">Change In Fair Value Of Convertible Debentures Include Interest Expense</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Warrants outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xml:lang="en-US">Estimated fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleWeightedAverageYield" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleWeightedAverageYield" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleWeightedAverageYield" xml:lang="en-US">Debt Securities, Available-for-Sale, Weighted Average Yield</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleWeightedAverageYield" xml:lang="en-US">Debt Securities, Available-for-Sale, Weighted Average Yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleWeightedAverageYield" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleWeightedAverageYield" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DerivativeWarrantLiabilityPrivateWarrants" xlink:label="loc_sclx_DerivativeWarrantLiabilityPrivateWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DerivativeWarrantLiabilityPrivateWarrants" xml:lang="en-US">Derivative Warrant Liability Private Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DerivativeWarrantLiabilityPrivateWarrants" xml:lang="en-US">Derivative warrant liability private warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DerivativeWarrantLiabilityPrivateWarrants" xlink:to="lab_sclx_DerivativeWarrantLiabilityPrivateWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DerivativeWarrantLiabilityPrivateWarrants" xml:lang="en-US">Derivative warrant liability private warrants.</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_FairValueOfContingentConsideration" xlink:label="loc_sclx_FairValueOfContingentConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FairValueOfContingentConsideration" xml:lang="en-US">Fair value of contingent consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_FairValueOfContingentConsideration" xml:lang="en-US">Development Milestone Payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FairValueOfContingentConsideration" xlink:to="lab_sclx_FairValueOfContingentConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FairValueOfContingentConsideration" xml:lang="en-US">Fair value of contingent consideration.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesFairValueAdjustment" xml:lang="en-US">Liabilities, Fair Value Adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueAdjustment" xlink:to="lab_us-gaap_LiabilitiesFairValueAdjustment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductLiabilityContingencyAccrualDiscountRate" xlink:label="loc_us-gaap_ProductLiabilityContingencyAccrualDiscountRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProductLiabilityContingencyAccrualDiscountRate" xml:lang="en-US">Product Liability Contingency, Accrual, Discount Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProductLiabilityContingencyAccrualDiscountRate" xml:lang="en-US">Discount rate of FDA</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductLiabilityContingencyAccrualDiscountRate" xlink:to="lab_us-gaap_ProductLiabilityContingencyAccrualDiscountRate" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RiskAdjustedNetSalesForecast" xlink:label="loc_sclx_RiskAdjustedNetSalesForecast" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RiskAdjustedNetSalesForecast" xml:lang="en-US">Risk Adjusted Net Sales Forecast</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RiskAdjustedNetSalesForecast" xlink:to="lab_sclx_RiskAdjustedNetSalesForecast" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RiskAdjustedNetSalesForecast" xml:lang="en-US">Risk adjusted net sales forecast</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SecuredNoteDiscountRate" xlink:label="loc_sclx_SecuredNoteDiscountRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SecuredNoteDiscountRate" xml:lang="en-US">Secured Note Discount Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SecuredNoteDiscountRate" xml:lang="en-US">Oramed note discount rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SecuredNoteDiscountRate" xlink:to="lab_sclx_SecuredNoteDiscountRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SecuredNoteDiscountRate" xml:lang="en-US">Secured Note Discount Rate</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAbstract" xml:lang="en-US">Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAbstract" xml:lang="en-US">Liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xml:lang="en-US">Convertible debenture</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilities" xml:lang="en-US">Derivative Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLiabilities" xml:lang="en-US">Derivative liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_DerivativeLiabilities" xml:lang="en-US">Fair value, beginning</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_DerivativeLiabilities" xml:lang="en-US">Fair value, ending</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xml:lang="en-US">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xml:lang="en-US">Liabilities, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xml:lang="en-US">Total liabilities measured at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotes" xlink:label="loc_us-gaap_SeniorNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeniorNotes" xml:lang="en-US">Senior Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeniorNotes" xml:lang="en-US">Oramed Note</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotes" xlink:to="lab_us-gaap_SeniorNotes" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Level 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Level 2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Level 3 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_CorporateBondYield" xlink:label="loc_sclx_CorporateBondYield" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CorporateBondYield" xml:lang="en-US">Corporate Bond Yield</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CorporateBondYield" xml:lang="en-US">Corporate Bond Yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CorporateBondYield" xlink:to="lab_sclx_CorporateBondYield" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CorporateBondYield" xml:lang="en-US">Corporate Bond Yield</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_CouponInterestRate" xlink:label="loc_sclx_CouponInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CouponInterestRate" xml:lang="en-US">Coupon Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CouponInterestRate" xml:lang="en-US">Coupon Interest Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CouponInterestRate" xlink:to="lab_sclx_CouponInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CouponInterestRate" xml:lang="en-US">Coupon Interest Rate</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Conversion Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Debt conversion price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" xlink:label="loc_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" xml:lang="en-US">Dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" xlink:to="lab_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate1</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" xlink:label="loc_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" xml:lang="en-US">Risk-free rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" xlink:to="lab_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate1</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xml:lang="en-US">Volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ChangeInValuationInputsOrOtherAssumptions" xlink:label="loc_sclx_ChangeInValuationInputsOrOtherAssumptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ChangeInValuationInputsOrOtherAssumptions" xml:lang="en-US">ChangeInValuationInputsOrOtherAssumptions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ChangeInValuationInputsOrOtherAssumptions" xml:lang="en-US">Change in fair value measurement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ChangeInValuationInputsOrOtherAssumptions" xlink:to="lab_sclx_ChangeInValuationInputsOrOtherAssumptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ChangeInValuationInputsOrOtherAssumptions" xml:lang="en-US">Change in valuation inputs or other assumptions.</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ForfeitureOfPrivateWarrants" xlink:label="loc_sclx_ForfeitureOfPrivateWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ForfeitureOfPrivateWarrants" xml:lang="en-US">Forfeiture of Private Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ForfeitureOfPrivateWarrants" xml:lang="en-US">Forfeiture of Private Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ForfeitureOfPrivateWarrants" xlink:to="lab_sclx_ForfeitureOfPrivateWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ForfeitureOfPrivateWarrants" xml:lang="en-US">Forfeiture of Private Warrants</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PrivatePlacementWarrantLiabilityAcquired" xlink:label="loc_sclx_PrivatePlacementWarrantLiabilityAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PrivatePlacementWarrantLiabilityAcquired" xml:lang="en-US">Private placement warrant liability acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PrivatePlacementWarrantLiabilityAcquired" xml:lang="en-US">Private Warrant liability acquired as part of the Business Combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PrivatePlacementWarrantLiabilityAcquired" xlink:to="lab_sclx_PrivatePlacementWarrantLiabilityAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PrivatePlacementWarrantLiabilityAcquired" xml:lang="en-US">Private placement warrant liability acquired</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ReMeasurementOfFairValue" xlink:label="loc_sclx_ReMeasurementOfFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ReMeasurementOfFairValue" xml:lang="en-US">Re-measurement of fair value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ReMeasurementOfFairValue" xml:lang="en-US">Re-measurement of fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ReMeasurementOfFairValue" xlink:to="lab_sclx_ReMeasurementOfFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ReMeasurementOfFairValue" xml:lang="en-US">Re-measurement of fair value</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract" xlink:label="loc_sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract" xml:lang="en-US">Schedule of derivative component of the obligation is initially valued and classified as a derivative liability [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract" xlink:to="lab_sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract" xml:lang="en-US">Schedule Of Derivative Component Of The Obligation Is Initially Valued And Classified As A Derivative Liability Abstract</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_CallOptionValue" xlink:label="loc_sclx_CallOptionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CallOptionValue" xml:lang="en-US">Call option value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CallOptionValue" xml:lang="en-US">Call option value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CallOptionValue" xlink:to="lab_sclx_CallOptionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CallOptionValue" xml:lang="en-US">Call option value</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_EquityValue" xlink:label="loc_sclx_EquityValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_EquityValue" xml:lang="en-US">Equity Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_EquityValue" xml:lang="en-US">Equity Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_EquityValue" xlink:to="lab_sclx_EquityValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_EquityValue" xml:lang="en-US">Equity Value</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Dividend yield</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Term, in years</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Term of options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Volatility</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected stock -price volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computers &amp; equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConstructionInProgressMember" xml:lang="en-US">Construction in Progress [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConstructionInProgressMember" xml:lang="en-US">Construction in progress [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xml:lang="en-US">Leaseholds and Leasehold Improvements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xml:lang="en-US">Leasehold improvements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less: Accumulated depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property and equipment, gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilities" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilities" xml:lang="en-US">Accrued others</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedMarketingCostsCurrent" xml:lang="en-US">Accrued Marketing Costs, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedMarketingCostsCurrent" xml:lang="en-US">Accrued sales and marketing costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedMarketingCostsCurrent" xlink:to="lab_us-gaap_AccruedMarketingCostsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued Professional Fees, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued professional service fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AccruedResearchAndDevelopmentCosts" xlink:label="loc_sclx_AccruedResearchAndDevelopmentCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AccruedResearchAndDevelopmentCosts" xml:lang="en-US">Accrued research and development costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AccruedResearchAndDevelopmentCosts" xml:lang="en-US">Accrued research and development costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AccruedResearchAndDevelopmentCosts" xlink:to="lab_sclx_AccruedResearchAndDevelopmentCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AccruedResearchAndDevelopmentCosts" xml:lang="en-US">Accrued research and development costs</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_TaxesPayableCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxesPayableCurrentAndNoncurrent" xml:lang="en-US">Taxes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxesPayableCurrentAndNoncurrent" xml:lang="en-US">Accrued tax payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_TaxesPayableCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xml:lang="en-US">Weighted average remaining life for identifiable intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xml:lang="en-US">Goodwill and Intangible Asset Impairment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xml:lang="en-US">Goodwill impairment charges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US">Accumulated amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xml:lang="en-US">Gross carrying amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Intangibles, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AcquiredLicensesMember" xlink:label="loc_sclx_AcquiredLicensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AcquiredLicensesMember" xml:lang="en-US">Acquired licenses [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AcquiredLicensesMember" xml:lang="en-US">Acquired licenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AcquiredLicensesMember" xlink:to="lab_sclx_AcquiredLicensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AcquiredLicensesMember" xml:lang="en-US">Acquired licenses [Member]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AcquiredTechnologyMember" xlink:label="loc_sclx_AcquiredTechnologyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AcquiredTechnologyMember" xml:lang="en-US">Acquired technology [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AcquiredTechnologyMember" xml:lang="en-US">Acquired technology</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AcquiredTechnologyMember" xlink:to="lab_sclx_AcquiredTechnologyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AcquiredTechnologyMember" xml:lang="en-US">Acquired technology [Member]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AssembledWorkforceMember" xlink:label="loc_sclx_AssembledWorkforceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AssembledWorkforceMember" xml:lang="en-US">Assembled workforce [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AssembledWorkforceMember" xml:lang="en-US">Assembled workforce</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AssembledWorkforceMember" xlink:to="lab_sclx_AssembledWorkforceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AssembledWorkforceMember" xml:lang="en-US">Assembled workforce [Member]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PatentRightsMember" xlink:label="loc_sclx_PatentRightsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PatentRightsMember" xml:lang="en-US">Patent rights [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PatentRightsMember" xml:lang="en-US">Patent rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PatentRightsMember" xlink:to="lab_sclx_PatentRightsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PatentRightsMember" xml:lang="en-US">Patent rights [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Amortization Expense, Rolling Maturity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract" xml:lang="en-US">As of March 31,2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive" xlink:label="loc_sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization,after Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive" xml:lang="en-US">Thereafter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive" xlink:to="lab_sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization,after Year Five</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xml:lang="en-US">2028</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xml:lang="en-US">2027</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xml:lang="en-US">2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xml:lang="en-US">2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityAxis" xml:lang="en-US">Credit Facility [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityDomain" xml:lang="en-US">Credit Facility [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xml:lang="en-US">Revolving Credit Facility [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_FiveInstallmentMember" xlink:label="loc_sclx_FiveInstallmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FiveInstallmentMember" xml:lang="en-US">Five Installment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_FiveInstallmentMember" xml:lang="en-US">Five Installment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FiveInstallmentMember" xlink:to="lab_sclx_FiveInstallmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FiveInstallmentMember" xml:lang="en-US">Five Installment [Member]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_FourthInstallmentMember" xlink:label="loc_sclx_FourthInstallmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FourthInstallmentMember" xml:lang="en-US">Fourth Installment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_FourthInstallmentMember" xml:lang="en-US">Fourth Installment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FourthInstallmentMember" xlink:to="lab_sclx_FourthInstallmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FourthInstallmentMember" xml:lang="en-US">Fourth Installment [Member]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_FristInstallmentMember" xlink:label="loc_sclx_FristInstallmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FristInstallmentMember" xml:lang="en-US">Frist Installment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_FristInstallmentMember" xml:lang="en-US">First installment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FristInstallmentMember" xlink:to="lab_sclx_FristInstallmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FristInstallmentMember" xml:lang="en-US">Frist Installment [Member]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SecondInstallmentMember" xlink:label="loc_sclx_SecondInstallmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SecondInstallmentMember" xml:lang="en-US">Second Installment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SecondInstallmentMember" xml:lang="en-US">Second Installment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SecondInstallmentMember" xlink:to="lab_sclx_SecondInstallmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SecondInstallmentMember" xml:lang="en-US">Second Installment [Member]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SixInstallmentMember" xlink:label="loc_sclx_SixInstallmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SixInstallmentMember" xml:lang="en-US">Six Installment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SixInstallmentMember" xml:lang="en-US">Six Installment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SixInstallmentMember" xlink:to="lab_sclx_SixInstallmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SixInstallmentMember" xml:lang="en-US">Six Installment [Member]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ThirdInstallmentMember" xlink:label="loc_sclx_ThirdInstallmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ThirdInstallmentMember" xml:lang="en-US">Third Installment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ThirdInstallmentMember" xml:lang="en-US">Third Installment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ThirdInstallmentMember" xlink:to="lab_sclx_ThirdInstallmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ThirdInstallmentMember" xml:lang="en-US">Third Installment [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash on hand</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:label="loc_us-gaap_CommonStockConvertibleConversionPriceIncrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockConvertibleConversionPriceIncrease" xml:lang="en-US">Common Stock, Convertible, Conversion Price, Increase</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockConvertibleConversionPriceIncrease" xml:lang="en-US">Common Stock at a conversion price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:to="lab_us-gaap_CommonStockConvertibleConversionPriceIncrease" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ConvertibleDebenturesIssuedPercent" xlink:label="loc_sclx_ConvertibleDebenturesIssuedPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ConvertibleDebenturesIssuedPercent" xml:lang="en-US">Convertible Debentures Issued Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ConvertibleDebenturesIssuedPercent" xml:lang="en-US">Convertible Debentures Issued Percent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ConvertibleDebenturesIssuedPercent" xlink:to="lab_sclx_ConvertibleDebenturesIssuedPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ConvertibleDebenturesIssuedPercent" xml:lang="en-US">Convertible Debentures Issued Percent</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DebtInstrumentDefaultInterestRate" xlink:label="loc_sclx_DebtInstrumentDefaultInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DebtInstrumentDefaultInterestRate" xml:lang="en-US">Debt Instrument, Default Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DebtInstrumentDefaultInterestRate" xml:lang="en-US">Debt instrument, default interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DebtInstrumentDefaultInterestRate" xlink:to="lab_sclx_DebtInstrumentDefaultInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DebtInstrumentDefaultInterestRate" xml:lang="en-US">Debt Instrument, Default Interest Rate</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaap_DebtInstrumentDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentDescription" xml:lang="en-US">Debt Instrument, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentDescription" xml:lang="en-US">Debt instrument, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentDescription" xlink:to="lab_us-gaap_DebtInstrumentDescription" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xml:lang="en-US">Debt Instrument, Interest Rate During Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xml:lang="en-US">Debt instrument, interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Debt Instrument, Maturity Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Debt maturity date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DebtInstrumentOutstandingPrincipal" xlink:label="loc_sclx_DebtInstrumentOutstandingPrincipal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DebtInstrumentOutstandingPrincipal" xml:lang="en-US">Debt Instrument Outstanding Principal</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DebtInstrumentOutstandingPrincipal" xml:lang="en-US">Outstanding debt instrument</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DebtInstrumentOutstandingPrincipal" xlink:to="lab_sclx_DebtInstrumentOutstandingPrincipal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DebtInstrumentOutstandingPrincipal" xml:lang="en-US">Debt instrument outstanding principal</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DebtInstrumentOwnedPercentage" xlink:label="loc_sclx_DebtInstrumentOwnedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DebtInstrumentOwnedPercentage" xml:lang="en-US">Debt Instrument, Owned, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DebtInstrumentOwnedPercentage" xml:lang="en-US">Debt instrument, owned, percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DebtInstrumentOwnedPercentage" xlink:to="lab_sclx_DebtInstrumentOwnedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DebtInstrumentOwnedPercentage" xml:lang="en-US">Debt Instrument, Owned, Percentage</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="loc_us-gaap_DebtInstrumentPaymentTerms" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentPaymentTerms" xml:lang="en-US">Debt Instrument, Payment Terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentPaymentTerms" xml:lang="en-US">Debt payment terms</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPaymentTerms" xlink:to="lab_us-gaap_DebtInstrumentPaymentTerms" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount" xlink:label="loc_sclx_DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount" xml:lang="en-US">Debt Instrument, Percentage of Interest Accrued on Principal Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount" xml:lang="en-US">Debt instrument, percentage of interest accrued on principal amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount" xlink:to="lab_sclx_DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount" xml:lang="en-US">Debt Instrument, Percentage of Interest Accrued on Principal Amount</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DebtInstrumentPrincipalAmountPercentage" xlink:label="loc_sclx_DebtInstrumentPrincipalAmountPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DebtInstrumentPrincipalAmountPercentage" xml:lang="en-US">Debt Instrument Principal Amount, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DebtInstrumentPrincipalAmountPercentage" xml:lang="en-US">Debt Instrument Principal Amount, Percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DebtInstrumentPrincipalAmountPercentage" xlink:to="lab_sclx_DebtInstrumentPrincipalAmountPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DebtInstrumentPrincipalAmountPercentage" xml:lang="en-US">Debt Instrument Principal Amount, Percentage</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionDescription" xlink:label="loc_us-gaap_DebtInstrumentRedemptionDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionDescription" xml:lang="en-US">Debt Instrument, Redemption, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentRedemptionDescription" xml:lang="en-US">Debt Instrument Redemption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionDescription" xlink:to="lab_us-gaap_DebtInstrumentRedemptionDescription" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xml:lang="en-US">Redemption Premium</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepaidPrincipal" xlink:label="loc_us-gaap_DebtInstrumentRepaidPrincipal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRepaidPrincipal" xml:lang="en-US">Debt Instrument, Repaid, Principal</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentRepaidPrincipal" xml:lang="en-US">Convertible Debentures Repaid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepaidPrincipal" xlink:to="lab_us-gaap_DebtInstrumentRepaidPrincipal" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DebtRepaymentExitFee" xlink:label="loc_sclx_DebtRepaymentExitFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DebtRepaymentExitFee" xml:lang="en-US">Debt Repayment Exit Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DebtRepaymentExitFee" xml:lang="en-US">Debt Repayment Exit Fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DebtRepaymentExitFee" xlink:to="lab_sclx_DebtRepaymentExitFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DebtRepaymentExitFee" xml:lang="en-US">Debt Repayment Exit Fee</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest" xlink:label="loc_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest" xml:lang="en-US">Debt Repayment, Percentage of Mandatory Default Rate of Accrued and Unpaid Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest" xml:lang="en-US">Debt repayment, percentage of mandatory default rate of accrued and unpaid interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest" xlink:to="lab_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest" xml:lang="en-US">Debt Repayment, Percentage of Mandatory Default Rate of Accrued and Unpaid Interest</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount" xlink:label="loc_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount" xml:lang="en-US">Debt Repayment, Percentage of Mandatory Default Rate of Principal Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount" xml:lang="en-US">Debt repayment, percentage of mandatory default rate of principal amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount" xlink:to="lab_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount" xml:lang="en-US">Debt Repayment, Percentage of Mandatory Default Rate of Principal Amount</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ExistingFacilityCapMaximum" xlink:label="loc_sclx_ExistingFacilityCapMaximum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ExistingFacilityCapMaximum" xml:lang="en-US">Existing Facility Cap Maximum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ExistingFacilityCapMaximum" xml:lang="en-US">Facility cap maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ExistingFacilityCapMaximum" xlink:to="lab_sclx_ExistingFacilityCapMaximum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ExistingFacilityCapMaximum" xml:lang="en-US">Existing Facility Cap Maximum</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ExistingFacilityCapMinimum" xlink:label="loc_sclx_ExistingFacilityCapMinimum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ExistingFacilityCapMinimum" xml:lang="en-US">Existing Facility Cap Minimum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ExistingFacilityCapMinimum" xml:lang="en-US">Facility cap minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ExistingFacilityCapMinimum" xlink:to="lab_sclx_ExistingFacilityCapMinimum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ExistingFacilityCapMinimum" xml:lang="en-US">Existing facility cap minimum</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableRevolvingConvertedToTermLoan" xlink:label="loc_us-gaap_FinancingReceivableRevolvingConvertedToTermLoan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancingReceivableRevolvingConvertedToTermLoan" xml:lang="en-US">Financing Receivable, Revolving, Converted to Term Loan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinancingReceivableRevolvingConvertedToTermLoan" xml:lang="en-US">Accounts receivable revolving loan facility in an aggregate amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableRevolvingConvertedToTermLoan" xlink:to="lab_us-gaap_FinancingReceivableRevolvingConvertedToTermLoan" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xml:lang="en-US">Line of Credit Facility, Interest Rate During Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xml:lang="en-US">Line Of Credit Facility Interest Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_NetCashProceeds" xlink:label="loc_sclx_NetCashProceeds" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NetCashProceeds" xml:lang="en-US">net cash proceeds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NetCashProceeds" xml:lang="en-US">Net cash proceeds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NetCashProceeds" xlink:to="lab_sclx_NetCashProceeds" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NetCashProceeds" xml:lang="en-US">net cash proceeds</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PercentageOfUsageOfCashProceedsFromCashSweepFinancing" xlink:label="loc_sclx_PercentageOfUsageOfCashProceedsFromCashSweepFinancing" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfUsageOfCashProceedsFromCashSweepFinancing" xml:lang="en-US">Percentage of Usage of Cash Proceeds from Cash Sweep Financing</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfUsageOfCashProceedsFromCashSweepFinancing" xml:lang="en-US">Percentage of usage of cash proceeds from cash sweep financing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfUsageOfCashProceedsFromCashSweepFinancing" xlink:to="lab_sclx_PercentageOfUsageOfCashProceedsFromCashSweepFinancing" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfUsageOfCashProceedsFromCashSweepFinancing" xml:lang="en-US">Percentage of Usage of Cash Proceeds from Cash Sweep Financing</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio" xlink:label="loc_us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio" xml:lang="en-US">Loan, Held-in-Portfolio, Principal Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio" xml:lang="en-US">Outstanding principal amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio" xlink:to="lab_us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfDebt" xml:lang="en-US">Repayments of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RepaymentsOfDebt" xml:lang="en-US">Repayment of debt prinnciple installment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServicingLiabilityAtFairValueOtherChangeInFairValueStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="loc_us-gaap_ServicingLiabilityAtFairValueOtherChangeInFairValueStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ServicingLiabilityAtFairValueOtherChangeInFairValueStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xml:lang="en-US">Servicing Liability, Fair Value, Change in Fair Value, Other, Statement of Income or Comprehensive Income [Extensible Enumeration]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServicingLiabilityAtFairValueOtherChangeInFairValueStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_ServicingLiabilityAtFairValueOtherChangeInFairValueStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" xlink:label="loc_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" xml:lang="en-US">Servicing Liability at Fair Value, Other Changes in Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" xml:lang="en-US">Change in fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" xlink:to="lab_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_TerminationFees" xlink:label="loc_sclx_TerminationFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TerminationFees" xml:lang="en-US">termination fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TerminationFees" xml:lang="en-US">Termination fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TerminationFees" xlink:to="lab_sclx_TerminationFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TerminationFees" xml:lang="en-US">termination fees</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DebtPayableAxis" xlink:label="loc_sclx_DebtPayableAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DebtPayableAxis" xml:lang="en-US">Debt Payable [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DebtPayableAxis" xlink:to="lab_sclx_DebtPayableAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DebtPayableAxis" xml:lang="en-US">Debt Payable [Axis]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DebtPayableDomain" xlink:label="loc_sclx_DebtPayableDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DebtPayableDomain" xml:lang="en-US">Debt Payable [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DebtPayableDomain" xlink:to="lab_sclx_DebtPayableDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DebtPayableDomain" xml:lang="en-US">Debt Payable [Domain]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_MonthlyBasisMember" xlink:label="loc_sclx_MonthlyBasisMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MonthlyBasisMember" xml:lang="en-US">Monthly Basis [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_MonthlyBasisMember" xml:lang="en-US">Monthly Basis [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MonthlyBasisMember" xlink:to="lab_sclx_MonthlyBasisMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_MonthlyBasisMember" xml:lang="en-US">Monthly Basis [Member]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SecuritiesPurchaseAgreementMember" xlink:label="loc_sclx_SecuritiesPurchaseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SecuritiesPurchaseAgreementMember" xml:lang="en-US">Securities Purchase Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SecuritiesPurchaseAgreementMember" xml:lang="en-US">Securities Purchase Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SecuritiesPurchaseAgreementMember" xlink:to="lab_sclx_SecuritiesPurchaseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SecuritiesPurchaseAgreementMember" xml:lang="en-US">Securities Purchase Agreement [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingAxis" xml:lang="en-US">Vesting [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingDomain" xml:lang="en-US">Vesting [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xml:lang="en-US">Tranche One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xml:lang="en-US">Tranche Three</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xml:lang="en-US">Tranche Two</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xml:lang="en-US">Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="lab_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ChangeInFairValueOfConvertibleDebentures" xlink:label="loc_sclx_ChangeInFairValueOfConvertibleDebentures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ChangeInFairValueOfConvertibleDebentures" xml:lang="en-US">Change in fair value of Convertible Debentures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_sclx_ChangeInFairValueOfConvertibleDebentures" xml:lang="en-US">Change in fair value of Convertible debentures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ChangeInFairValueOfConvertibleDebentures" xlink:to="lab_sclx_ChangeInFairValueOfConvertibleDebentures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ChangeInFairValueOfConvertibleDebentures" xml:lang="en-US">Change in fair value of Convertible Debentures</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesIssued1" xlink:label="loc_us-gaap_NotesIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesIssued1" xml:lang="en-US">Notes Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NotesIssued1" xml:lang="en-US">Issuance of Convertible Debentures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesIssued1" xlink:to="lab_us-gaap_NotesIssued1" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RepaymentOfConvertibleDebenture" xlink:label="loc_sclx_RepaymentOfConvertibleDebenture" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RepaymentOfConvertibleDebenture" xml:lang="en-US">Repayment of Convertible Debenture</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RepaymentOfConvertibleDebenture" xml:lang="en-US">Repayment of Convertible Debentures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RepaymentOfConvertibleDebenture" xlink:to="lab_sclx_RepaymentOfConvertibleDebenture" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RepaymentOfConvertibleDebenture" xml:lang="en-US">Repayment of Convertible Debenture</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xml:lang="en-US">Convertible Debt Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xml:lang="en-US">Convertible Debentures [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaap_AwardDateAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardDateAxis" xml:lang="en-US">Award Date [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateAxis" xlink:to="lab_us-gaap_AwardDateAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaap_AwardDateDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardDateDomain" xml:lang="en-US">Award Date [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateDomain" xlink:to="lab_us-gaap_AwardDateDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ClosingPennyWarrantMember" xlink:label="loc_sclx_ClosingPennyWarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ClosingPennyWarrantMember" xml:lang="en-US">Closing Penny Warrant [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ClosingPennyWarrantMember" xlink:to="lab_sclx_ClosingPennyWarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ClosingPennyWarrantMember" xml:lang="en-US">Closing Penny Warrant [Member]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PennyWarrantsMember" xlink:label="loc_sclx_PennyWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PennyWarrantsMember" xml:lang="en-US">Penny Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PennyWarrantsMember" xlink:to="lab_sclx_PennyWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PennyWarrantsMember" xml:lang="en-US">Penny Warrants [Member]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SubsequentPennyWarrants1Member" xlink:label="loc_sclx_SubsequentPennyWarrants1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SubsequentPennyWarrants1Member" xml:lang="en-US">Subsequent Penny Warrants 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SubsequentPennyWarrants1Member" xlink:to="lab_sclx_SubsequentPennyWarrants1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SubsequentPennyWarrants1Member" xml:lang="en-US">Subsequent Penny Warrants 1 [Member]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SubsequentPennyWarrants2Member" xlink:label="loc_sclx_SubsequentPennyWarrants2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SubsequentPennyWarrants2Member" xml:lang="en-US">Subsequent Penny Warrants 2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SubsequentPennyWarrants2Member" xlink:to="lab_sclx_SubsequentPennyWarrants2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SubsequentPennyWarrants2Member" xml:lang="en-US">Subsequent Penny Warrants 2 [Member]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SubsequentPennyWarrants3Member" xlink:label="loc_sclx_SubsequentPennyWarrants3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SubsequentPennyWarrants3Member" xml:lang="en-US">Subsequent Penny Warrants 3 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SubsequentPennyWarrants3Member" xlink:to="lab_sclx_SubsequentPennyWarrants3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SubsequentPennyWarrants3Member" xml:lang="en-US">Subsequent Penny Warrants 3 [Member]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SubsequentPennyWarrants4Member" xlink:label="loc_sclx_SubsequentPennyWarrants4Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SubsequentPennyWarrants4Member" xml:lang="en-US">Subsequent Penny Warrants 4 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SubsequentPennyWarrants4Member" xlink:to="lab_sclx_SubsequentPennyWarrants4Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SubsequentPennyWarrants4Member" xml:lang="en-US">Subsequent Penny Warrants 4 [Member]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SubsequentPennyWarrantsMember" xlink:label="loc_sclx_SubsequentPennyWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SubsequentPennyWarrantsMember" xml:lang="en-US">Subsequent Penny Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SubsequentPennyWarrantsMember" xlink:to="lab_sclx_SubsequentPennyWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SubsequentPennyWarrantsMember" xml:lang="en-US">Subsequent Penny Warrants [Member]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_JuniorDipFacilityMember" xlink:label="loc_sclx_JuniorDipFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_JuniorDipFacilityMember" xml:lang="en-US">Junior DIP Facility [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_JuniorDipFacilityMember" xml:lang="en-US">Junior DIP Facility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_JuniorDipFacilityMember" xlink:to="lab_sclx_JuniorDipFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_JuniorDipFacilityMember" xml:lang="en-US">Junior DIP Facility [Member]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PrivateWarrantsMember" xlink:label="loc_sclx_PrivateWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PrivateWarrantsMember" xml:lang="en-US">Private Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PrivateWarrantsMember" xml:lang="en-US">Private Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PrivateWarrantsMember" xlink:to="lab_sclx_PrivateWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PrivateWarrantsMember" xml:lang="en-US">Private Warrants [Member]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PublicWarrantsMember" xlink:label="loc_sclx_PublicWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PublicWarrantsMember" xml:lang="en-US">Public Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PublicWarrantsMember" xml:lang="en-US">Public Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PublicWarrantsMember" xlink:to="lab_sclx_PublicWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PublicWarrantsMember" xml:lang="en-US">Public Warrants [Member]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_CashPayment" xlink:label="loc_sclx_CashPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CashPayment" xml:lang="en-US">Cash payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CashPayment" xml:lang="en-US">Cash payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CashPayment" xlink:to="lab_sclx_CashPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CashPayment" xml:lang="en-US">Cash payment</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xml:lang="en-US">Class of Warrant or Right, Date from which Warrants or Rights Exercisable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xml:lang="en-US">Warrants exercisable date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="lab_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Price per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Exercise price of the Representative Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Exit fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_FairValueOfSharesRepurchased" xlink:label="loc_sclx_FairValueOfSharesRepurchased" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FairValueOfSharesRepurchased" xml:lang="en-US">Fair value of Shares Repurchased</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_FairValueOfSharesRepurchased" xml:lang="en-US">Fair Value of stock repurchased</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FairValueOfSharesRepurchased" xlink:to="lab_sclx_FairValueOfSharesRepurchased" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FairValueOfSharesRepurchased" xml:lang="en-US">Fair value of Shares Repurchased</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_FairValueOfWarrants" xlink:label="loc_sclx_FairValueOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FairValueOfWarrants" xml:lang="en-US">Fair Value Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_FairValueOfWarrants" xml:lang="en-US">Fair Value Of Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FairValueOfWarrants" xlink:to="lab_sclx_FairValueOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FairValueOfWarrants" xml:lang="en-US">Fair Value Of Warrants</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_IssueOfWarrantsToPurchaseShares" xlink:label="loc_sclx_IssueOfWarrantsToPurchaseShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_IssueOfWarrantsToPurchaseShares" xml:lang="en-US">Issue of Warrants to Purchase Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_IssueOfWarrantsToPurchaseShares" xml:lang="en-US">Issue of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_IssueOfWarrantsToPurchaseShares" xlink:to="lab_sclx_IssueOfWarrantsToPurchaseShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_IssueOfWarrantsToPurchaseShares" xml:lang="en-US">Issue of Warrants to Purchase Shares</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LegalFees" xml:lang="en-US">Legal Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LegalFees" xml:lang="en-US">Legal fees and expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalFees" xlink:to="lab_us-gaap_LegalFees" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_NumberOfShareOutstanding" xlink:label="loc_sclx_NumberOfShareOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NumberOfShareOutstanding" xml:lang="en-US">Number Of Share Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NumberOfShareOutstanding" xml:lang="en-US">Number Of Share Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NumberOfShareOutstanding" xlink:to="lab_sclx_NumberOfShareOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NumberOfShareOutstanding" xml:lang="en-US">Number Of Share Outstanding</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xml:lang="en-US">Sales and Excise Tax Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xml:lang="en-US">Excise tax liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:to="lab_us-gaap_SalesAndExciseTaxPayableCurrent" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SharesPurchasedAtParValueUnderStockPurchaseAgreement" xlink:label="loc_sclx_SharesPurchasedAtParValueUnderStockPurchaseAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SharesPurchasedAtParValueUnderStockPurchaseAgreement" xml:lang="en-US">Shares Purchased At Par Value Under Stock Purchase Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SharesPurchasedAtParValueUnderStockPurchaseAgreement" xml:lang="en-US">Shares Purchased At Par Value Under Stock Purchase Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SharesPurchasedAtParValueUnderStockPurchaseAgreement" xlink:to="lab_sclx_SharesPurchasedAtParValueUnderStockPurchaseAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SharesPurchasedAtParValueUnderStockPurchaseAgreement" xml:lang="en-US">Shares Purchased At Par Value Under Stock Purchase Agreement</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SharesPurchasedUnderStockPurchaseAgreement" xlink:label="loc_sclx_SharesPurchasedUnderStockPurchaseAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SharesPurchasedUnderStockPurchaseAgreement" xml:lang="en-US">Shares Purchased Under Stock Purchase Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SharesPurchasedUnderStockPurchaseAgreement" xml:lang="en-US">Shares Purchased Under Stock Purchase Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SharesPurchasedUnderStockPurchaseAgreement" xlink:to="lab_sclx_SharesPurchasedUnderStockPurchaseAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SharesPurchasedUnderStockPurchaseAgreement" xml:lang="en-US">Shares Purchased Under Stock Purchase Agreement</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_TransferOfWarrants" xlink:label="loc_sclx_TransferOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TransferOfWarrants" xml:lang="en-US">Transfer of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TransferOfWarrants" xml:lang="en-US">Transfer of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TransferOfWarrants" xlink:to="lab_sclx_TransferOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TransferOfWarrants" xml:lang="en-US">Transfer of Warrants</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_WarrantVestingDate" xlink:label="loc_sclx_WarrantVestingDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WarrantVestingDate" xml:lang="en-US">Warrant Vesting Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_WarrantVestingDate" xml:lang="en-US">Warrant vesting date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WarrantVestingDate" xlink:to="lab_sclx_WarrantVestingDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_WarrantVestingDate" xml:lang="en-US">Warrant Vesting Date</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_StockPurchaseAgreementMember" xlink:label="loc_sclx_StockPurchaseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_StockPurchaseAgreementMember" xml:lang="en-US">Stock Purchase Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_StockPurchaseAgreementMember" xml:lang="en-US">Sorrento Stock Purchase Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_StockPurchaseAgreementMember" xlink:to="lab_sclx_StockPurchaseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_StockPurchaseAgreementMember" xml:lang="en-US">Stock Purchase Agreement [Member]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ShareholdersEquityDetailsTable" xlink:label="loc_sclx_ShareholdersEquityDetailsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ShareholdersEquityDetailsTable" xml:lang="en-US">Shareholders' Equity (Details) [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ShareholdersEquityDetailsTable" xlink:to="lab_sclx_ShareholdersEquityDetailsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ShareholdersEquityDetailsTable" xml:lang="en-US">Shareholders Equity Details Table</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_CoveLaneMember" xlink:label="loc_sclx_CoveLaneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CoveLaneMember" xml:lang="en-US">Cove Lane [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CoveLaneMember" xml:lang="en-US">Cove Lane [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CoveLaneMember" xlink:to="lab_sclx_CoveLaneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CoveLaneMember" xml:lang="en-US">Cove Lane [Member]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_HudsonBayMember" xlink:label="loc_sclx_HudsonBayMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_HudsonBayMember" xml:lang="en-US">Hudson Bay [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_HudsonBayMember" xml:lang="en-US">Hudson Bay [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_HudsonBayMember" xlink:to="lab_sclx_HudsonBayMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_HudsonBayMember" xml:lang="en-US">Hudson Bay [Member]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AtTheMarketSalesAgreementMember" xlink:label="loc_sclx_AtTheMarketSalesAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AtTheMarketSalesAgreementMember" xml:lang="en-US">At-the-Market Sales Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AtTheMarketSalesAgreementMember" xml:lang="en-US">ATM Sales Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AtTheMarketSalesAgreementMember" xlink:to="lab_sclx_AtTheMarketSalesAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AtTheMarketSalesAgreementMember" xml:lang="en-US">At-the-Market Sales Agreement [Member]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_BRileyPurchaseAgreementMember" xlink:label="loc_sclx_BRileyPurchaseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_BRileyPurchaseAgreementMember" xml:lang="en-US">B Riley Purchase Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_BRileyPurchaseAgreementMember" xml:lang="en-US">B. Riley Purchase Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_BRileyPurchaseAgreementMember" xlink:to="lab_sclx_BRileyPurchaseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_BRileyPurchaseAgreementMember" xml:lang="en-US">B Riley Purchase Agreement.</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ShareholdersEquityDetailsLineItems" xlink:label="loc_sclx_ShareholdersEquityDetailsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ShareholdersEquityDetailsLineItems" xml:lang="en-US">Shareholders' Equity (Details) [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems" xlink:to="lab_sclx_ShareholdersEquityDetailsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ShareholdersEquityDetailsLineItems" xml:lang="en-US">Shareholders Equity Details Line Items</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_CommonStockSold" xlink:label="loc_sclx_CommonStockSold" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CommonStockSold" xml:lang="en-US">Common stock sold</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CommonStockSold" xml:lang="en-US">Common stock sold</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CommonStockSold" xlink:to="lab_sclx_CommonStockSold" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CommonStockSold" xml:lang="en-US">Common stock sold.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividends" xlink:label="loc_us-gaap_PaymentsOfDividends" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfDividends" xml:lang="en-US">Payments of Dividends</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsOfDividends" xml:lang="en-US">Payment made to Investor</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceed from Securities and Warrants issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ProceedsFromSaleOfCommonStock" xlink:label="loc_sclx_ProceedsFromSaleOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ProceedsFromSaleOfCommonStock" xml:lang="en-US">Proceeds from sale of common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ProceedsFromSaleOfCommonStock" xml:lang="en-US">Proceeds from sale of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ProceedsFromSaleOfCommonStock" xlink:to="lab_sclx_ProceedsFromSaleOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ProceedsFromSaleOfCommonStock" xml:lang="en-US">Proceeds from sale of common stock.</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ProceedSOfSaleOfCommonSharesPercentage" xlink:label="loc_sclx_ProceedSOfSaleOfCommonSharesPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ProceedSOfSaleOfCommonSharesPercentage" xml:lang="en-US">Proceed s of sale of common shares percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ProceedSOfSaleOfCommonSharesPercentage" xml:lang="en-US">Proceeds from sale of common shares percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ProceedSOfSaleOfCommonSharesPercentage" xlink:to="lab_sclx_ProceedSOfSaleOfCommonSharesPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ProceedSOfSaleOfCommonSharesPercentage" xml:lang="en-US">Proceed s of sale of common shares percentage</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PurchaseOfStockPercentage" xlink:label="loc_sclx_PurchaseOfStockPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PurchaseOfStockPercentage" xml:lang="en-US">Purchase of stock, percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PurchaseOfStockPercentage" xml:lang="en-US">Purchase of stock, percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PurchaseOfStockPercentage" xlink:to="lab_sclx_PurchaseOfStockPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PurchaseOfStockPercentage" xml:lang="en-US">Purchase of stock, percentage</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Number sale of common stock shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaap_TreasuryStockCommonMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xml:lang="en-US">Treasury Stock, Common [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xml:lang="en-US">Treasury Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title of Individual [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_WarrantTransferAgreementMember" xlink:label="loc_sclx_WarrantTransferAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WarrantTransferAgreementMember" xml:lang="en-US">Warrant Transfer Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_WarrantTransferAgreementMember" xml:lang="en-US">Warrant Transfer Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WarrantTransferAgreementMember" xlink:to="lab_sclx_WarrantTransferAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_WarrantTransferAgreementMember" xml:lang="en-US">Warrant Transfer Agreement [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Options Outstanding, Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Exercisable, Weighted-average Remaining Contractual Life, (in Years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US">Options Outstanding, Forfeited/Cancelled</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Forfeited/Cancelled</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Options Outstanding, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Options Outstanding, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Options Outstanding, Ending Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of option outstanding to purchase common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Outstanding, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Outstanding, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Outstanding, Weighted-average Remaining Contractual Life, (in Years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xml:lang="en-US">Financial Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Financial Instruments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_EmployeeStockPurchasePlanMember" xlink:label="loc_sclx_EmployeeStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_EmployeeStockPurchasePlanMember" xml:lang="en-US">Employee Stock Purchase Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_EmployeeStockPurchasePlanMember" xlink:to="lab_sclx_EmployeeStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_EmployeeStockPurchasePlanMember" xml:lang="en-US">Employee Stock Purchase Plan [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockOptionMember" xml:lang="en-US">Equity Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockOptionMember" xml:lang="en-US">Stock Option [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xml:lang="en-US">Risk-free interest rate, maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xml:lang="en-US">Risk-free interest rate, minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xml:lang="en-US">Valuation Approach and Technique [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xml:lang="en-US">Valuation Approach and Technique [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_BlackScholesOptionPricingMethodMember" xlink:label="loc_sclx_BlackScholesOptionPricingMethodMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_BlackScholesOptionPricingMethodMember" xml:lang="en-US">Black-Scholes Option Pricing Method [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_BlackScholesOptionPricingMethodMember" xlink:to="lab_sclx_BlackScholesOptionPricingMethodMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_BlackScholesOptionPricingMethodMember" xml:lang="en-US">Black-Scholes Option Pricing Method</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_TwoThousandTwentyThreeInducementPlanMember" xlink:label="loc_sclx_TwoThousandTwentyThreeInducementPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TwoThousandTwentyThreeInducementPlanMember" xml:lang="en-US">Two Thousand Twenty Three Inducement Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TwoThousandTwentyThreeInducementPlanMember" xml:lang="en-US">2023 Inducement Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TwoThousandTwentyThreeInducementPlanMember" xlink:to="lab_sclx_TwoThousandTwentyThreeInducementPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TwoThousandTwentyThreeInducementPlanMember" xml:lang="en-US">Two Thousand Twenty Three Inducement Plan [Member]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" xlink:label="loc_sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" xml:lang="en-US">2022 Employee Stock Purchase Plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" xml:lang="en-US">2022 Employee Stock Purchase Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" xlink:to="lab_sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" xml:lang="en-US">Two Thousand Twenty Two Employee Stock Purchase Plan [Member]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:label="loc_sclx_TwoThousandTwentyTwoEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TwoThousandTwentyTwoEquityIncentivePlanMember" xml:lang="en-US">Two Thousand Twenty Two Equity Incentive Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TwoThousandTwentyTwoEquityIncentivePlanMember" xml:lang="en-US">2022 Equity Incentive Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:to="lab_sclx_TwoThousandTwentyTwoEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TwoThousandTwentyTwoEquityIncentivePlanMember" xml:lang="en-US">Two Thousand Twenty Two Equity Incentive Plan [Member]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_NonEmployeeDirectorMember" xlink:label="loc_sclx_NonEmployeeDirectorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NonEmployeeDirectorMember" xml:lang="en-US">Non Employee Director [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NonEmployeeDirectorMember" xlink:to="lab_sclx_NonEmployeeDirectorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NonEmployeeDirectorMember" xml:lang="en-US">Non Employee Director [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xml:lang="en-US">Accrued Professional Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xml:lang="en-US">Accrued legal fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common stock shares reserved for future issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Aggregate shares purchase common warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationCashBasedArrangementsLiabilityCurrent" xlink:label="loc_us-gaap_DeferredCompensationCashBasedArrangementsLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCompensationCashBasedArrangementsLiabilityCurrent" xml:lang="en-US">Deferred Compensation Cash-Based Arrangements, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredCompensationCashBasedArrangementsLiabilityCurrent" xml:lang="en-US">Cash compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationCashBasedArrangementsLiabilityCurrent" xlink:to="lab_us-gaap_DeferredCompensationCashBasedArrangementsLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xml:lang="en-US">Employee benefit plan contributions by employer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Unrecognized compensation cost related to unvested stock option grants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US">Number of shares authorized under the plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Number of shares available for grant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Total intrinsic value of option exercise</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Number of common stock shares forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Options granted weighted-average grant date fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_Sharebasedcompensationpayable" xlink:label="loc_sclx_Sharebasedcompensationpayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_Sharebasedcompensationpayable" xml:lang="en-US">ShareBasedCompensationpayable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_Sharebasedcompensationpayable" xml:lang="en-US">Stock Based Compensation expense cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_Sharebasedcompensationpayable" xlink:to="lab_sclx_Sharebasedcompensationpayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_Sharebasedcompensationpayable" xml:lang="en-US">ShareBasedCompensationpayable</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_WeightedAveragePeriodOverGrant" xlink:label="loc_sclx_WeightedAveragePeriodOverGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WeightedAveragePeriodOverGrant" xml:lang="en-US">Weighted average period over grant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WeightedAveragePeriodOverGrant" xlink:to="lab_sclx_WeightedAveragePeriodOverGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_WeightedAveragePeriodOverGrant" xml:lang="en-US">Weighted average period over grant</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xml:lang="en-US">Cash Flow, Operating Activities, Lessee [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Operating Lease, Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Operating cash flows from operating leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Weighted average discount rate - operating leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Weighted average remaining lease term in years - operating leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_LeaseLiabilityNetOfCurrentPortion" xlink:label="loc_sclx_LeaseLiabilityNetOfCurrentPortion" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LeaseLiabilityNetOfCurrentPortion" xml:lang="en-US">Lease liability, net of current portion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_LeaseLiabilityNetOfCurrentPortion" xml:lang="en-US">Lease liability, net of current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LeaseLiabilityNetOfCurrentPortion" xlink:to="lab_sclx_LeaseLiabilityNetOfCurrentPortion" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LeaseLiabilityNetOfCurrentPortion" xml:lang="en-US">Lease liability, net of current portion</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Total lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">2027</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Less imputed interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating Lease, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Total lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_CommitmentsAndContingenciesTable" xlink:label="loc_sclx_CommitmentsAndContingenciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CommitmentsAndContingenciesTable" xml:lang="en-US">Commitments and Contingencies [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CommitmentsAndContingenciesTable" xlink:to="lab_sclx_CommitmentsAndContingenciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CommitmentsAndContingenciesTable" xml:lang="en-US">Commitments and Contingencies [Table]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_CommitmentsAndContingenciesLineItems" xlink:label="loc_sclx_CommitmentsAndContingenciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CommitmentsAndContingenciesLineItems" xml:lang="en-US">Commitments and Contingencies [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems" xlink:to="lab_sclx_CommitmentsAndContingenciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CommitmentsAndContingenciesLineItems" xml:lang="en-US">Commitments and Contingencies [Line Items]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AgreementMaturityDate" xlink:label="loc_sclx_AgreementMaturityDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AgreementMaturityDate" xml:lang="en-US">Agreement Maturity Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AgreementMaturityDate" xml:lang="en-US">Agreement maturity date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AgreementMaturityDate" xlink:to="lab_sclx_AgreementMaturityDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AgreementMaturityDate" xml:lang="en-US">Agreement Maturity Date</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DueFromRelatedParty" xlink:label="loc_sclx_DueFromRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DueFromRelatedParty" xml:lang="en-US">Due From Related Party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DueFromRelatedParty" xlink:to="lab_sclx_DueFromRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DueFromRelatedParty" xml:lang="en-US">Due From Related Party</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiability" xml:lang="en-US">Finance Lease, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseLiability" xml:lang="en-US">Finance lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xml:lang="en-US">Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xml:lang="en-US">Operating lease, remaining lease term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xml:lang="en-US">Operating lease, lease term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LitigationSettlementExpense" xml:lang="en-US">Litigation Settlement, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LitigationSettlementExpense" xml:lang="en-US">Agreement settlement payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_MaturityRenewalDescription" xlink:label="loc_sclx_MaturityRenewalDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MaturityRenewalDescription" xml:lang="en-US">Maturity Renewal Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_MaturityRenewalDescription" xml:lang="en-US">Agreement maturity renewal description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MaturityRenewalDescription" xlink:to="lab_sclx_MaturityRenewalDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_MaturityRenewalDescription" xml:lang="en-US">Maturity Renewal Description</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseExpense" xml:lang="en-US">Operating Lease, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseExpense" xml:lang="en-US">Lease Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RoyaltyExpense" xml:lang="en-US">Royalty Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RoyaltyExpense" xml:lang="en-US">Royalty expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xml:lang="en-US">Royalty Guarantees, Commitments, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xml:lang="en-US">Accrued royalty payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:to="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RoyaltyPaymentPercentageOnNetSale" xlink:label="loc_sclx_RoyaltyPaymentPercentageOnNetSale" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RoyaltyPaymentPercentageOnNetSale" xml:lang="en-US">Royalty Payment Percentage On Net Sale</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RoyaltyPaymentPercentageOnNetSale" xml:lang="en-US">Percentage on net sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RoyaltyPaymentPercentageOnNetSale" xlink:to="lab_sclx_RoyaltyPaymentPercentageOnNetSale" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RoyaltyPaymentPercentageOnNetSale" xml:lang="en-US">Royalty Payment Percentage On Net Sale</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RoyaltyPaymentPercentageRelatedToFutureYears" xlink:label="loc_sclx_RoyaltyPaymentPercentageRelatedToFutureYears" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RoyaltyPaymentPercentageRelatedToFutureYears" xml:lang="en-US">Royalty Payment Percentage Related To Future Years</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RoyaltyPaymentPercentageRelatedToFutureYears" xml:lang="en-US">Royalty payment percentage related to future years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RoyaltyPaymentPercentageRelatedToFutureYears" xlink:to="lab_sclx_RoyaltyPaymentPercentageRelatedToFutureYears" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RoyaltyPaymentPercentageRelatedToFutureYears" xml:lang="en-US">Royalty Payment Percentage Related To Future Years</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xml:lang="en-US">Liability Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xml:lang="en-US">Fair Value by Liability Class [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ResearchAndDevelopmentFacilitiesMember" xlink:label="loc_sclx_ResearchAndDevelopmentFacilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ResearchAndDevelopmentFacilitiesMember" xml:lang="en-US">Research and Development Facilities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ResearchAndDevelopmentFacilitiesMember" xlink:to="lab_sclx_ResearchAndDevelopmentFacilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ResearchAndDevelopmentFacilitiesMember" xml:lang="en-US">Research and Development Facilities [Member]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DevelopersMember" xlink:label="loc_sclx_DevelopersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DevelopersMember" xml:lang="en-US">Developers [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DevelopersMember" xlink:to="lab_sclx_DevelopersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DevelopersMember" xml:lang="en-US">Developers [Member]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_FormerEmployeeMember" xlink:label="loc_sclx_FormerEmployeeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FormerEmployeeMember" xml:lang="en-US">Former Employee [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FormerEmployeeMember" xlink:to="lab_sclx_FormerEmployeeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FormerEmployeeMember" xml:lang="en-US">Former Employee [Member]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_FormerEmployeeOneMember" xlink:label="loc_sclx_FormerEmployeeOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FormerEmployeeOneMember" xml:lang="en-US">Former Employee One[Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FormerEmployeeOneMember" xlink:to="lab_sclx_FormerEmployeeOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FormerEmployeeOneMember" xml:lang="en-US">Former Employee One[Member]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_GloperbaMember" xlink:label="loc_sclx_GloperbaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_GloperbaMember" xml:lang="en-US">GLOPERBA [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_GloperbaMember" xlink:to="lab_sclx_GloperbaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_GloperbaMember" xml:lang="en-US">GLOPERBA [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xml:lang="en-US">Segments [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentDomain" xml:lang="en-US">Segments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_EnveltaMember" xlink:label="loc_sclx_EnveltaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_EnveltaMember" xml:lang="en-US">Envelta [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_EnveltaMember" xlink:to="lab_sclx_EnveltaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_EnveltaMember" xml:lang="en-US">Envelta Member</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_EpoladermMember" xlink:label="loc_sclx_EpoladermMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_EpoladermMember" xml:lang="en-US">Epoladerm [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_EpoladermMember" xlink:to="lab_sclx_EpoladermMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_EpoladermMember" xml:lang="en-US">Epoladerm Member</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ProbudurMember" xlink:label="loc_sclx_ProbudurMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ProbudurMember" xml:lang="en-US">Probudur [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ProbudurMember" xlink:to="lab_sclx_ProbudurMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ProbudurMember" xml:lang="en-US">Probudur Member</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ScilexPharmaMember" xlink:label="loc_sclx_ScilexPharmaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScilexPharmaMember" xml:lang="en-US">Scilex Pharma [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScilexPharmaMember" xlink:to="lab_sclx_ScilexPharmaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ScilexPharmaMember" xml:lang="en-US">Scilex Pharma</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_NonCancelableLeaseAgreementsMember" xlink:label="loc_sclx_NonCancelableLeaseAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NonCancelableLeaseAgreementsMember" xml:lang="en-US">Non-cancelable Lease Agreements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NonCancelableLeaseAgreementsMember" xlink:to="lab_sclx_NonCancelableLeaseAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NonCancelableLeaseAgreementsMember" xml:lang="en-US">Non-cancelable Lease Agreements [Member]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ProductDevelopmentAgreementMember" xlink:label="loc_sclx_ProductDevelopmentAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ProductDevelopmentAgreementMember" xml:lang="en-US">Product Development Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ProductDevelopmentAgreementMember" xlink:to="lab_sclx_ProductDevelopmentAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ProductDevelopmentAgreementMember" xml:lang="en-US">Product Development Agreement [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Current Federal Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Federal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US">Total current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US">State</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xml:lang="en-US">Deferred income tax expense (benefit):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">Federal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xml:lang="en-US">State</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Total deferred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Changes in valuation allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Changes in tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DeferredTaxAssetsAccruedExpenseAndReserves" xlink:label="loc_sclx_DeferredTaxAssetsAccruedExpenseAndReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DeferredTaxAssetsAccruedExpenseAndReserves" xml:lang="en-US">Deferred Tax Assets, Accrued Expense and Reserves</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DeferredTaxAssetsAccruedExpenseAndReserves" xml:lang="en-US">Accrued expense and reserves</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DeferredTaxAssetsAccruedExpenseAndReserves" xlink:to="lab_sclx_DeferredTaxAssetsAccruedExpenseAndReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DeferredTaxAssetsAccruedExpenseAndReserves" xml:lang="en-US">Deferred tax assets, accrued expense and reserves.</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DeferredTaxAssetsDebtRelatedInterest" xlink:label="loc_sclx_DeferredTaxAssetsDebtRelatedInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DeferredTaxAssetsDebtRelatedInterest" xml:lang="en-US">Deferred Tax Assets, Debt Related Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DeferredTaxAssetsDebtRelatedInterest" xml:lang="en-US">Debt related interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DeferredTaxAssetsDebtRelatedInterest" xlink:to="lab_sclx_DeferredTaxAssetsDebtRelatedInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DeferredTaxAssetsDebtRelatedInterest" xml:lang="en-US">Deferred tax assets, debt related interest.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Total deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xml:lang="en-US">Capitalized research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Deferred Tax Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Net deferred tax liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Total deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="loc_sclx_DeferredTaxAssetsOperatingLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DeferredTaxAssetsOperatingLeaseLiabilities" xml:lang="en-US">Deferred Tax Assets Operating Lease Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DeferredTaxAssetsOperatingLeaseLiabilities" xml:lang="en-US">Operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="lab_sclx_DeferredTaxAssetsOperatingLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DeferredTaxAssetsOperatingLeaseLiabilities" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liabilities</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Net operating loss carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Deferred Tax Assets, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xml:lang="en-US">Tax credit carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Stock based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Less valuation allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred tax assets, valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xml:lang="en-US">Deferred Tax Liabilities, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xml:lang="en-US">Total deferred tax liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xml:lang="en-US">Deferred tax liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xml:lang="en-US">Intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xml:lang="en-US">Operating lease right-of-use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount" xlink:label="loc_sclx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Fair Value of Convertible Debentures, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount" xml:lang="en-US">Change in fair value of Convertible Debentures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount" xlink:to="lab_sclx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Fair Value of Convertible Debentures, Amount</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount" xlink:label="loc_sclx_EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Tax Rates, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount" xml:lang="en-US">Change in tax rates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount" xlink:to="lab_sclx_EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Tax Rates, Amount</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount" xlink:label="loc_sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount" xml:lang="en-US">Effective Income Tax Rate Reconciliation Debt Discount Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount" xml:lang="en-US">Debt discount and interest limitation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount" xlink:to="lab_sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount" xml:lang="en-US">Effective income tax rate reconciliation debt discount amount.</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_IncomeTaxReconciliationAcquisitionRelatedCharges" xlink:label="loc_sclx_IncomeTaxReconciliationAcquisitionRelatedCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_IncomeTaxReconciliationAcquisitionRelatedCharges" xml:lang="en-US">Income Tax Reconciliation Acquisition Related Charges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_IncomeTaxReconciliationAcquisitionRelatedCharges" xml:lang="en-US">Acquisition related charges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_IncomeTaxReconciliationAcquisitionRelatedCharges" xlink:to="lab_sclx_IncomeTaxReconciliationAcquisitionRelatedCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_IncomeTaxReconciliationAcquisitionRelatedCharges" xml:lang="en-US">Income tax reconciliation acquisition related charges.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Income tax benefit at federal statutory rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xml:lang="en-US">Compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xml:lang="en-US">Prior year true-up and carryback</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">State, net of federal tax benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized Tax Benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xml:lang="en-US">Increases related to current year tax positions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xml:lang="en-US">Increase related to prior year tax positions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xml:lang="en-US">Operating Loss Carryforwards [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DomesticCountryMember" xml:lang="en-US">Domestic Tax Authority [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DomesticCountryMember" xml:lang="en-US">Federal [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_IncomeTaxDisclosureLineItems" xlink:label="loc_sclx_IncomeTaxDisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_IncomeTaxDisclosureLineItems" xml:lang="en-US">Income Tax Disclosure [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems" xlink:to="lab_sclx_IncomeTaxDisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_IncomeTaxDisclosureLineItems" xml:lang="en-US">Income Tax Disclosure [Line Items]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xml:lang="en-US">Research and development income tax credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_IncomeTaxCreditsExpirationYear" xlink:label="loc_sclx_IncomeTaxCreditsExpirationYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_IncomeTaxCreditsExpirationYear" xml:lang="en-US">Income Tax Credits Expiration Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_IncomeTaxCreditsExpirationYear" xml:lang="en-US">Income tax credits, expiration year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_IncomeTaxCreditsExpirationYear" xlink:to="lab_sclx_IncomeTaxCreditsExpirationYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_IncomeTaxCreditsExpirationYear" xml:lang="en-US">Income Tax Credits Expiration Year</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xml:lang="en-US">Income Tax Examination, Penalties and Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xml:lang="en-US">Income tax expense, interest and penalties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_IndefiniteOperatingLossCarryforwards" xlink:label="loc_sclx_IndefiniteOperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_IndefiniteOperatingLossCarryforwards" xml:lang="en-US">Indefinite Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_IndefiniteOperatingLossCarryforwards" xml:lang="en-US">Indefinite net federal operating loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_IndefiniteOperatingLossCarryforwards" xlink:to="lab_sclx_IndefiniteOperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_IndefiniteOperatingLossCarryforwards" xml:lang="en-US">Indefinite Operating Loss Carryforwards</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent" xml:lang="en-US">Liability for Uncertainty in Income Taxes, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent" xml:lang="en-US">Liabilities for uncertain tax positions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating loss carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_OperatingLossCarryforwardsExpirationYear" xlink:label="loc_sclx_OperatingLossCarryforwardsExpirationYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_OperatingLossCarryforwardsExpirationYear" xml:lang="en-US">Operating Loss Carryforwards Expiration Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_OperatingLossCarryforwardsExpirationYear" xml:lang="en-US">Operating loss carryforwards, expiration year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_OperatingLossCarryforwardsExpirationYear" xlink:to="lab_sclx_OperatingLossCarryforwardsExpirationYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_OperatingLossCarryforwardsExpirationYear" xml:lang="en-US">Operating Loss Carryforwards Expiration Year</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_TaxCreditCarryforwardNotSubjectToExpireAmount" xlink:label="loc_sclx_TaxCreditCarryforwardNotSubjectToExpireAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TaxCreditCarryforwardNotSubjectToExpireAmount" xml:lang="en-US">Tax Credit Carryforward, Not Subject to Expire, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TaxCreditCarryforwardNotSubjectToExpireAmount" xml:lang="en-US">Tax credit, not subject to expire</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TaxCreditCarryforwardNotSubjectToExpireAmount" xlink:to="lab_sclx_TaxCreditCarryforwardNotSubjectToExpireAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TaxCreditCarryforwardNotSubjectToExpireAmount" xml:lang="en-US">Tax Credit Carryforward, Not Subject to Expire, Amount</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xml:lang="en-US">Tax Credit Carryforward [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchMember" xml:lang="en-US">Research Tax Credit Carryforward [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchMember" xml:lang="en-US">Research and Development Income Tax Credits [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_EffectOfDilutiveSecurities" xlink:label="loc_sclx_EffectOfDilutiveSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_EffectOfDilutiveSecurities" xml:lang="en-US">Effect of Dilutive Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_EffectOfDilutiveSecurities" xml:lang="en-US">Effect of dilutive securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_EffectOfDilutiveSecurities" xlink:to="lab_sclx_EffectOfDilutiveSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_EffectOfDilutiveSecurities" xml:lang="en-US">Effect of Dilutive Securities</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US">Net loss for basic and diluted loss per share available to common stockholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockRedemptionPremium" xlink:label="loc_us-gaap_PreferredStockRedemptionPremium" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockRedemptionPremium" xml:lang="en-US">Preferred Stock Redemption Premium</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PreferredStockRedemptionPremium" xml:lang="en-US">Premium on redemption of Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockRedemptionPremium" xlink:to="lab_us-gaap_PreferredStockRedemptionPremium" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ConvertibleDebenturesMember" xlink:label="loc_sclx_ConvertibleDebenturesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ConvertibleDebenturesMember" xml:lang="en-US">Convertible Debentures [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ConvertibleDebenturesMember" xml:lang="en-US">Convertible Debentures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ConvertibleDebenturesMember" xlink:to="lab_sclx_ConvertibleDebenturesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ConvertibleDebenturesMember" xml:lang="en-US">Convertible Debentures [Member]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RetainerSharesMember" xlink:label="loc_sclx_RetainerSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RetainerSharesMember" xml:lang="en-US">Retainer Shares [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RetainerSharesMember" xml:lang="en-US">Retainer Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RetainerSharesMember" xlink:to="lab_sclx_RetainerSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RetainerSharesMember" xml:lang="en-US">Retainer Shares [Member]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SharesIssuablePursuantToEsppMember" xlink:label="loc_sclx_SharesIssuablePursuantToEsppMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SharesIssuablePursuantToEsppMember" xml:lang="en-US">Shares Issuable pursuant to ESPP [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SharesIssuablePursuantToEsppMember" xml:lang="en-US">Shares Issuable pursuant to ESPP</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SharesIssuablePursuantToEsppMember" xlink:to="lab_sclx_SharesIssuablePursuantToEsppMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SharesIssuablePursuantToEsppMember" xml:lang="en-US">Shares Issuable pursuant to ESPP [Member]</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_StockOptionsMember" xlink:label="loc_sclx_StockOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_StockOptionsMember" xml:lang="en-US">Stock Options [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_StockOptionsMember" xml:lang="en-US">Stock Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_StockOptionsMember" xlink:to="lab_sclx_StockOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_StockOptionsMember" xml:lang="en-US">Stock Options [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Penny Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RodmanRenshawLlcMember" xlink:label="loc_sclx_RodmanRenshawLlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RodmanRenshawLlcMember" xml:lang="en-US">Rodman &amp; Renshaw LLC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RodmanRenshawLlcMember" xml:lang="en-US">Rodman &amp; Renshaw LLC</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RodmanRenshawLlcMember" xlink:to="lab_sclx_RodmanRenshawLlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RodmanRenshawLlcMember" xml:lang="en-US">Rodman &amp; Renshaw LLC [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_CombinedPricePaidOfWarrant" xlink:label="loc_sclx_CombinedPricePaidOfWarrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CombinedPricePaidOfWarrant" xml:lang="en-US">Combined Price Paid Of Warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CombinedPricePaidOfWarrant" xml:lang="en-US">Combined Price Paid Of Warrant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CombinedPricePaidOfWarrant" xlink:to="lab_sclx_CombinedPricePaidOfWarrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CombinedPricePaidOfWarrant" xml:lang="en-US">Combined Price Paid Of Warrant</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_CommonShareSold" xlink:label="loc_sclx_CommonShareSold" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CommonShareSold" xml:lang="en-US">Common Share Sold</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CommonShareSold" xml:lang="en-US">Sold of common share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CommonShareSold" xlink:to="lab_sclx_CommonShareSold" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CommonShareSold" xml:lang="en-US">Common Share Sold</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ExercisePriceOfCommonWarrant" xlink:label="loc_sclx_ExercisePriceOfCommonWarrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ExercisePriceOfCommonWarrant" xml:lang="en-US">Exercise Price Of Common Warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ExercisePriceOfCommonWarrant" xml:lang="en-US">Exercise Price Of Warrant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ExercisePriceOfCommonWarrant" xlink:to="lab_sclx_ExercisePriceOfCommonWarrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ExercisePriceOfCommonWarrant" xml:lang="en-US">Exercise Price Of Common Warrant</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_OutOfPocketExpense" xlink:label="loc_sclx_OutOfPocketExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_OutOfPocketExpense" xml:lang="en-US">Out-Of-Pocket Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_OutOfPocketExpense" xml:lang="en-US">Out Of Pocket Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_OutOfPocketExpense" xlink:to="lab_sclx_OutOfPocketExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_OutOfPocketExpense" xml:lang="en-US">Out-Of-Pocket Expense</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PricePerOptionalShare" xlink:label="loc_sclx_PricePerOptionalShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PricePerOptionalShare" xml:lang="en-US">Price Per Optional share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PricePerOptionalShare" xml:lang="en-US">Price of Optional Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PricePerOptionalShare" xlink:to="lab_sclx_PricePerOptionalShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PricePerOptionalShare" xml:lang="en-US">Price Per Optional share</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PricePerOptionalWarrant" xlink:label="loc_sclx_PricePerOptionalWarrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PricePerOptionalWarrant" xml:lang="en-US">Price Per Optional Warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PricePerOptionalWarrant" xml:lang="en-US">Price of optional warrant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PricePerOptionalWarrant" xlink:to="lab_sclx_PricePerOptionalWarrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PricePerOptionalWarrant" xml:lang="en-US">Price Per Optional Warrant</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PublicOfferingPerOptionalShare" xlink:label="loc_sclx_PublicOfferingPerOptionalShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PublicOfferingPerOptionalShare" xml:lang="en-US">Public Offering Per Optional Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PublicOfferingPerOptionalShare" xml:lang="en-US">Public Offering Price Per Optional Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PublicOfferingPerOptionalShare" xlink:to="lab_sclx_PublicOfferingPerOptionalShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PublicOfferingPerOptionalShare" xml:lang="en-US">Public Offering Per Optional Share</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PublicOfferingPerOptionalWarrant" xlink:label="loc_sclx_PublicOfferingPerOptionalWarrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PublicOfferingPerOptionalWarrant" xml:lang="en-US">Public Offering Per Optional Warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PublicOfferingPerOptionalWarrant" xml:lang="en-US">Public Offering Per Optional Warrant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PublicOfferingPerOptionalWarrant" xlink:to="lab_sclx_PublicOfferingPerOptionalWarrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PublicOfferingPerOptionalWarrant" xml:lang="en-US">Public Offering Per Optional Warrant</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PublicOfferingPrice" xlink:label="loc_sclx_PublicOfferingPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PublicOfferingPrice" xml:lang="en-US">Public Offering Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PublicOfferingPrice" xml:lang="en-US">Public Offering Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PublicOfferingPrice" xlink:to="lab_sclx_PublicOfferingPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PublicOfferingPrice" xml:lang="en-US">Public Offering Price</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PublicOfferingPriceCombined" xlink:label="loc_sclx_PublicOfferingPriceCombined" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PublicOfferingPriceCombined" xml:lang="en-US">Public Offering Price Combined</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PublicOfferingPriceCombined" xml:lang="en-US">Combined public offering price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PublicOfferingPriceCombined" xlink:to="lab_sclx_PublicOfferingPriceCombined" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PublicOfferingPriceCombined" xml:lang="en-US">Public Offering Price Combined</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PublicOfferingPriceSold" xlink:label="loc_sclx_PublicOfferingPriceSold" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PublicOfferingPriceSold" xml:lang="en-US">Public Offering Price Sold</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PublicOfferingPriceSold" xml:lang="en-US">Sold Of Public Offering Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PublicOfferingPriceSold" xlink:to="lab_sclx_PublicOfferingPriceSold" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PublicOfferingPriceSold" xml:lang="en-US">Public Offering Price Sold</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PurchaseOfCommonShares" xlink:label="loc_sclx_PurchaseOfCommonShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PurchaseOfCommonShares" xml:lang="en-US">Purchase Of Common Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PurchaseOfCommonShares" xml:lang="en-US">Purchase Of Common Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PurchaseOfCommonShares" xlink:to="lab_sclx_PurchaseOfCommonShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PurchaseOfCommonShares" xml:lang="en-US">Purchase Of Common Shares</label>
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PurchaseOfCommonWarrants" xlink:label="loc_sclx_PurchaseOfCommonWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PurchaseOfCommonWarrants" xml:lang="en-US">Purchase Of Common Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PurchaseOfCommonWarrants" xml:lang="en-US">Common Warrants Purchase</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PurchaseOfCommonWarrants" xlink:to="lab_sclx_PurchaseOfCommonWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PurchaseOfCommonWarrants" xml:lang="en-US">Purchase Of Common Warrants</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xml:lang="en-US">Common stock underwriters exercise, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventDescription" xlink:label="loc_us-gaap_SubsequentEventDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventDescription" xml:lang="en-US">Subsequent Event, Description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventDescription" xlink:to="lab_us-gaap_SubsequentEventDescription" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>sclx-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 28-March-2024 [02:31:15] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#CoverPage" roleURI="http://www.vickersvantagecorp.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#CondensedConsolidatedBalanceSheetsParentheticals" roleURI="http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#CondensedConsolidatedStatementsOfStockholdersDeficitEquity" roleURI="http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#NatureOfOperationsAndBasisOfPresentation" roleURI="http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentation" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#LiquidityAndGoingConcern" roleURI="http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcern" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#Acquisitions" roleURI="http://www.vickersvantagecorp.com/role/Acquisitions" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#FairValueMeasurements" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#BalanceSheetComponents" roleURI="http://www.vickersvantagecorp.com/role/BalanceSheetComponents" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#GoodwillAndIntangibleAssets" roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssets" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#Debt" roleURI="http://www.vickersvantagecorp.com/role/Debt" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#JuniorDipFacilityAndSorrentoSharePurchaseAgreement" roleURI="http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreement" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#StockholdersEquity" roleURI="http://www.vickersvantagecorp.com/role/StockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#StockIncentiveAndEmployeeBenefitPlans" roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlans" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#CommitmentsAndContingencies" roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#IncomeTaxes" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#NetLossPerShare" roleURI="http://www.vickersvantagecorp.com/role/NetLossPerShare" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#SubsequentEvents" roleURI="http://www.vickersvantagecorp.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#NatureOfOperationsAndBasisOfPresentationPolicies" roleURI="http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationPolicies" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#NatureOfOperationsAndBasisOfPresentationTables" roleURI="http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#FairValueMeasurementsTables" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#BalanceSheetComponentsTables" roleURI="http://www.vickersvantagecorp.com/role/BalanceSheetComponentsTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#GoodwillAndIntangibleAssetsTables" roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#DebtTables" roleURI="http://www.vickersvantagecorp.com/role/DebtTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#StockIncentiveAndEmployeeBenefitPlansTables" roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#CommitmentsAndContingenciesTables" roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#IncomeTaxesTables" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#NetLossPerShareTables" roleURI="http://www.vickersvantagecorp.com/role/NetLossPerShareTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails" roleURI="http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#NatureOfOperationsAndBasisOfPresentationScheduleOfCashAndCashEquivalentsDetails" roleURI="http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationScheduleOfCashAndCashEquivalentsDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#LiquidityAndGoingConcernAdditionalInformationDetails" roleURI="http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#AcquisitionsAdditionalInformationDetails" roleURI="http://www.vickersvantagecorp.com/role/AcquisitionsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#FairValueMeasurementsAdditionalInformationDetails" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#BalanceSheetComponentsScheduleOfAcrcuedExpensesDetails" roleURI="http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#BalanceSheetComponentsAdditionalInformationDetails" roleURI="http://www.vickersvantagecorp.com/role/BalanceSheetComponentsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#GoodwillAndIntangibleAssetsAdditionalInformationDetails" roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails" roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails" roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#DebtAdditionalInformationDetails" roleURI="http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#DebtSummeryOfOutstandingConvertibleDebentureDetails" roleURI="http://www.vickersvantagecorp.com/role/DebtSummeryOfOutstandingConvertibleDebentureDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails" roleURI="http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#ShareholdersEquityAdditionalInformationDetails" roleURI="http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails" roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails" roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails" roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#CommitmentsAndContingenciesScheduleOfLeasesSupplementalQuantitativeInformationDetails" roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesScheduleOfLeasesSupplementalQuantitativeInformationDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails" roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#CommitmentsAndContingenciesAdditionalInformationDetails" roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#IncomeTaxesAdditionalInformationDetails" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#NetLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails" roleURI="http://www.vickersvantagecorp.com/role/NetLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails" roleURI="http://www.vickersvantagecorp.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#NetLossPerShareAdditionalInformationDetails" roleURI="http://www.vickersvantagecorp.com/role/NetLossPerShareAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20231231.xsd#SubsequentEventsAdditionalInformationDetails" roleURI="http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails" />
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_1389" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesTable" xlink:label="loc_dei_EntityAddressesTable_1406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1389" xlink:to="loc_dei_EntityAddressesTable_1406" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesTable_1406" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1407" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1407" xlink:to="loc_dei_AddressTypeDomain_1408" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_1408" xlink:to="loc_dei_BusinessContactMember_1409" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesLineItems" xlink:label="loc_dei_EntityAddressesLineItems_1410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesTable_1406" xlink:to="loc_dei_EntityAddressesLineItems_1410" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_1390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_DocumentType_1390" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_1391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_AmendmentFlag_1391" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_EntityRegistrantName_1392" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_1395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_EntityFilerCategory_1395" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1396" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_1397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_EntityAddressAddressLine1_1397" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_1398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_EntityAddressCityOrTown_1398" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_1399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_EntityAddressStateOrProvince_1399" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_1400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_EntityAddressPostalZipCode_1400" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_1401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_EntityTaxIdentificationNumber_1401" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_1402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_EntitySmallBusiness_1402" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_1403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_EntityEmergingGrowthCompany_1403" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_1404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_EntityExTransitionPeriod_1404" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber_1405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_EntityPrimarySicNumber_1405" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_1411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_EntityCentralIndexKey_1411" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_1412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_CityAreaCode_1412" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_1413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_LocalPhoneNumber_1413" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_1414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_ContactPersonnelName_1414" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_1416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_1410" xlink:to="loc_dei_AmendmentDescription_1416" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_146" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_146" xlink:to="loc_us-gaap_AssetsAbstract_152" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_152" xlink:to="loc_us-gaap_AssetsCurrentAbstract_149" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_149" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_148" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_149" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_154" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_149" xlink:to="loc_us-gaap_InventoryNet_160" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_149" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_166" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_152" xlink:to="loc_us-gaap_AssetsCurrent_155" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_152" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_161" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_152" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_167" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_152" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_172" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_152" xlink:to="loc_us-gaap_Goodwill_176" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment_180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_152" xlink:to="loc_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment_180" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_152" xlink:to="loc_us-gaap_Assets_183" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_146" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_158" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_158" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_151" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_151" xlink:to="loc_us-gaap_AccountsPayableCurrent_147" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_151" xlink:to="loc_us-gaap_AccruedSalariesCurrent_153" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_151" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_159" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AccruedExpenses" xlink:label="loc_sclx_AccruedExpenses_165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_151" xlink:to="loc_sclx_AccruedExpenses_165" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_CurrentPortionOfDeferredConsideration" xlink:label="loc_sclx_CurrentPortionOfDeferredConsideration_171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_151" xlink:to="loc_sclx_CurrentPortionOfDeferredConsideration_171" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_151" xlink:to="loc_us-gaap_DebtCurrent_175" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_151" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_185" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_158" xlink:to="loc_us-gaap_LiabilitiesCurrent_157" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_LongTermPortionOfDeferredConsideration" xlink:label="loc_sclx_LongTermPortionOfDeferredConsideration_163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_158" xlink:to="loc_sclx_LongTermPortionOfDeferredConsideration_163" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermDebtNoncurrent" xlink:label="loc_us-gaap_OtherLongTermDebtNoncurrent_169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_158" xlink:to="loc_us-gaap_OtherLongTermDebtNoncurrent_169" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_158" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_174" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_158" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_178" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_158" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_181" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_158" xlink:to="loc_us-gaap_Liabilities_184" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_158" xlink:to="loc_us-gaap_CommitmentsAndContingencies_186" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_146" xlink:to="loc_us-gaap_StockholdersEquityAbstract_164" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_164" xlink:to="loc_us-gaap_PreferredStockValue_150" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_164" xlink:to="loc_us-gaap_CommonStockValue_156" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_164" xlink:to="loc_us-gaap_AdditionalPaidInCapital_162" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_164" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_168" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_164" xlink:to="loc_us-gaap_TreasuryStockValue_173" use="optional" order="36" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_164" xlink:to="loc_us-gaap_StockholdersEquity_177" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_146" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_170" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_188" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_188" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_189" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_188" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_190" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_188" xlink:to="loc_us-gaap_PreferredStockSharesIssued_191" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_188" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_192" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_188" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_193" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_188" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_194" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_188" xlink:to="loc_us-gaap_CommonStockSharesIssued_195" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_188" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_196" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaap_TreasuryStockCommonShares_197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_188" xlink:to="loc_us-gaap_TreasuryStockCommonShares_197" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_199" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_199" xlink:to="loc_us-gaap_Revenues_202" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_199" xlink:to="loc_us-gaap_OperatingExpensesAbstract_207" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_207" xlink:to="loc_us-gaap_CostOfRevenue_200" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_207" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_205" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_207" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_210" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_207" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_213" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_207" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_216" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_207" xlink:to="loc_us-gaap_OperatingIncomeLoss_219" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_199" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_211" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_211" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_204" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ChangeInFairValueOfDebtAndLiabilityInstruments" xlink:label="loc_sclx_ChangeInFairValueOfDebtAndLiabilityInstruments_209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_211" xlink:to="loc_sclx_ChangeInFairValueOfDebtAndLiabilityInstruments_209" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_211" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_212" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_NotesPrincipalIncrease" xlink:label="loc_sclx_NotesPrincipalIncrease_215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_211" xlink:to="loc_sclx_NotesPrincipalIncrease_215" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_211" xlink:to="loc_us-gaap_InterestExpense_218" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_211" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_221" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_211" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_222" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_211" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_223" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_211" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_224" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_199" xlink:to="loc_us-gaap_NetIncomeLoss_214" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_199" xlink:to="loc_us-gaap_EarningsPerShareAbstract_217" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_217" xlink:to="loc_us-gaap_EarningsPerShareBasic_201" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_217" xlink:to="loc_us-gaap_EarningsPerShareDiluted_206" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_199" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_220" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_220" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_203" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_220" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_208" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_226" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_226" xlink:to="loc_us-gaap_StatementTable_227" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_227" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_232" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_232" xlink:to="loc_us-gaap_EquityComponentDomain_231" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_231" xlink:to="loc_us-gaap_PreferredStockMember_234" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_231" xlink:to="loc_us-gaap_CommonStockMember_237" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_231" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_240" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_231" xlink:to="loc_us-gaap_RetainedEarningsMember_242" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockPreferredMember" xlink:label="loc_us-gaap_TreasuryStockPreferredMember_244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_231" xlink:to="loc_us-gaap_TreasuryStockPreferredMember_244" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_227" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_235" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_235" xlink:to="loc_us-gaap_RelatedPartyDomain_230" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_227" xlink:to="loc_us-gaap_StatementLineItems_238" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_233" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_SharesOutstanding_236" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ValueIssuedUnderStandbyEquityPurchaseAgreements" xlink:label="loc_sclx_ValueIssuedUnderStandbyEquityPurchaseAgreements_239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_sclx_ValueIssuedUnderStandbyEquityPurchaseAgreements_239" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SharesIssuedUnderStandbyEquityPurchaseAgreements" xlink:label="loc_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreements_241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreements_241" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_243" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_245" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_246" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_247" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement" xlink:label="loc_sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement_248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement_248" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares" xlink:label="loc_sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares_249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares_249" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_250" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AdjustmentToSharesIssuedInSemnurAcquisitionValue" xlink:label="loc_sclx_AdjustmentToSharesIssuedInSemnurAcquisitionValue_251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_sclx_AdjustmentToSharesIssuedInSemnurAcquisitionValue_251" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_252" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_253" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue" xlink:label="loc_sclx_AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue_254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_sclx_AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue_254" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_IssuanceOfPennyWarrants" xlink:label="loc_sclx_IssuanceOfPennyWarrants_255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_sclx_IssuanceOfPennyWarrants_255" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ConversionOfConvertibleDebenturesIntoCommonStockValue" xlink:label="loc_sclx_ConversionOfConvertibleDebenturesIntoCommonStockValue_256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_sclx_ConversionOfConvertibleDebenturesIntoCommonStockValue_256" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ConversionOfConvertibleDebenturesIntoCommonStockShares" xlink:label="loc_sclx_ConversionOfConvertibleDebenturesIntoCommonStockShares_257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_sclx_ConversionOfConvertibleDebenturesIntoCommonStockShares_257" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RetainerSharesIssuedValue" xlink:label="loc_sclx_RetainerSharesIssuedValue_258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_sclx_RetainerSharesIssuedValue_258" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RetainerSharesIssued" xlink:label="loc_sclx_RetainerSharesIssued_259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_sclx_RetainerSharesIssued_259" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_IssuanceOfCommonStockUponWarrantsExerciseValue" xlink:label="loc_sclx_IssuanceOfCommonStockUponWarrantsExerciseValue_260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_sclx_IssuanceOfCommonStockUponWarrantsExerciseValue_260" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_IssuanceOfCommonStockUponWarrantsExerciseShares" xlink:label="loc_sclx_IssuanceOfCommonStockUponWarrantsExerciseShares_261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_sclx_IssuanceOfCommonStockUponWarrantsExerciseShares_261" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DisbursementOfFundsToSorrentoAmount" xlink:label="loc_sclx_DisbursementOfFundsToSorrentoAmount_262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_sclx_DisbursementOfFundsToSorrentoAmount_262" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_263" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_264" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue" xlink:label="loc_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue_265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue_265" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares" xlink:label="loc_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares_266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares_266" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_Adjustmenttoadditionalpaidincapitaldiscountamortization" xlink:label="loc_sclx_Adjustmenttoadditionalpaidincapitaldiscountamortization_267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_sclx_Adjustmenttoadditionalpaidincapitaldiscountamortization_267" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_ProfitLoss_268" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_269" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_238" xlink:to="loc_us-gaap_SharesOutstanding_270" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_272" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_272" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_275" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_275" xlink:to="loc_us-gaap_NetIncomeLoss_276" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_275" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_284" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_284" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_274" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_284" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_282" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_NotesPrincipalIncrease" xlink:label="loc_sclx_NotesPrincipalIncrease_290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_284" xlink:to="loc_sclx_NotesPrincipalIncrease_290" use="optional" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount" xlink:label="loc_sclx_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount_296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_284" xlink:to="loc_sclx_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount_296" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_284" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_302" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_NonCashOperatingLeaseCost" xlink:label="loc_sclx_NonCashOperatingLeaseCost_308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_284" xlink:to="loc_sclx_NonCashOperatingLeaseCost_308" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_284" xlink:to="loc_us-gaap_ShareBasedCompensation_313" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_284" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_318" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_284" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_322" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ForfeituresOfPrivateWarrants" xlink:label="loc_sclx_ForfeituresOfPrivateWarrants_326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_284" xlink:to="loc_sclx_ForfeituresOfPrivateWarrants_326" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ChangeInFairValueOfDebtAndLiabilityInstruments" xlink:label="loc_sclx_ChangeInFairValueOfDebtAndLiabilityInstruments_330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_284" xlink:to="loc_sclx_ChangeInFairValueOfDebtAndLiabilityInstruments_330" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_284" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_334" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_284" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_337" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_337" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_273" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_337" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_281" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_337" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_289" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_337" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_295" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_337" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_301" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_IncreaseDecreaseInAccruedPayroll" xlink:label="loc_sclx_IncreaseDecreaseInAccruedPayroll_307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_337" xlink:to="loc_sclx_IncreaseDecreaseInAccruedPayroll_307" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_337" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_312" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_IncreaseDecreaseInAccruedRebatesAndFees" xlink:label="loc_sclx_IncreaseDecreaseInAccruedRebatesAndFees_317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_337" xlink:to="loc_sclx_IncreaseDecreaseInAccruedRebatesAndFees_317" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_337" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_321" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent_325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_337" xlink:to="loc_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent_325" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_OtherLongTermLiabilities" xlink:label="loc_sclx_OtherLongTermLiabilities_329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_337" xlink:to="loc_sclx_OtherLongTermLiabilities_329" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_337" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_333" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_272" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_283" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition" xlink:label="loc_sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition_279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_283" xlink:to="loc_sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition_279" use="optional" order="30" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_283" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_287" use="optional" order="31" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_283" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_305" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_272" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_291" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_291" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_277" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_291" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_285" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_291" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_292" use="optional" order="36" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ProceedsFromIssuanceOfRevolvingFacility" xlink:label="loc_sclx_ProceedsFromIssuanceOfRevolvingFacility_298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_291" xlink:to="loc_sclx_ProceedsFromIssuanceOfRevolvingFacility_298" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RepaymentOfRevolvingFacility" xlink:label="loc_sclx_RepaymentOfRevolvingFacility_304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_291" xlink:to="loc_sclx_RepaymentOfRevolvingFacility_304" use="optional" order="38" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarlyRepaymentOfSeniorDebt" xlink:label="loc_us-gaap_EarlyRepaymentOfSeniorDebt_310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_291" xlink:to="loc_us-gaap_EarlyRepaymentOfSeniorDebt_310" use="optional" order="39" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction" xlink:label="loc_sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction_315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_291" xlink:to="loc_sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction_315" use="optional" order="40" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_291" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_319" use="optional" order="41" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DisbursementOfFunds" xlink:label="loc_sclx_DisbursementOfFunds_323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_291" xlink:to="loc_sclx_DisbursementOfFunds_323" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount_327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_291" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount_327" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_TransactionCostsPaidInConnectionWithShareRepurchase" xlink:label="loc_sclx_TransactionCostsPaidInConnectionWithShareRepurchase_331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_291" xlink:to="loc_sclx_TransactionCostsPaidInConnectionWithShareRepurchase_331" use="optional" order="44" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ProceedsFromTheBusinessCombination" xlink:label="loc_sclx_ProceedsFromTheBusinessCombination_335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_291" xlink:to="loc_sclx_ProceedsFromTheBusinessCombination_335" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_291" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_338" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_291" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_339" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSecuredNotesPayable" xlink:label="loc_us-gaap_ProceedsFromSecuredNotesPayable_340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_291" xlink:to="loc_us-gaap_ProceedsFromSecuredNotesPayable_340" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromOtherShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromOtherShortTermDebt_341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_291" xlink:to="loc_us-gaap_ProceedsFromOtherShortTermDebt_341" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RepaymentOfPrincipalOnTheScilexPharmaNotes" xlink:label="loc_sclx_RepaymentOfPrincipalOnTheScilexPharmaNotes_342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_291" xlink:to="loc_sclx_RepaymentOfPrincipalOnTheScilexPharmaNotes_342" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ProceedsFromRepaymentOfLoansToPurchase" xlink:label="loc_sclx_ProceedsFromRepaymentOfLoansToPurchase_343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_291" xlink:to="loc_sclx_ProceedsFromRepaymentOfLoansToPurchase_343" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_291" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_344" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_272" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_297" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_272" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_303" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_272" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_309" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_272" xlink:to="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_314" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOperatingPaidInCash" xlink:label="loc_us-gaap_InterestIncomeOperatingPaidInCash_278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_314" xlink:to="loc_us-gaap_InterestIncomeOperatingPaidInCash_278" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_314" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_286" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_286" xlink:to="loc_us-gaap_StockIssued1_280" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ConversionOfConvertibleDebenturesIntoCommonStock" xlink:label="loc_sclx_ConversionOfConvertibleDebenturesIntoCommonStock_288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_286" xlink:to="loc_sclx_ConversionOfConvertibleDebenturesIntoCommonStock_288" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification" xlink:label="loc_sclx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification_294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_286" xlink:to="loc_sclx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification_294" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_OramedNoteIssuanceAtFairValue" xlink:label="loc_sclx_OramedNoteIssuanceAtFairValue_300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_286" xlink:to="loc_sclx_OramedNoteIssuanceAtFairValue_300" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_OtherNonCashConsiderationInConnectionWithShareRepurchase" xlink:label="loc_sclx_OtherNonCashConsiderationInConnectionWithShareRepurchase_306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_286" xlink:to="loc_sclx_OtherNonCashConsiderationInConnectionWithShareRepurchase_306" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses" xlink:label="loc_sclx_ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses_311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_286" xlink:to="loc_sclx_ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses_311" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement" xlink:label="loc_sclx_RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement_316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_286" xlink:to="loc_sclx_RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement_316" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DeferredConsiderationForRomegIntangibleAssetAcquisition" xlink:label="loc_sclx_DeferredConsiderationForRomegIntangibleAssetAcquisition_320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_286" xlink:to="loc_sclx_DeferredConsiderationForRomegIntangibleAssetAcquisition_320" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount" xlink:label="loc_sclx_PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount_324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_286" xlink:to="loc_sclx_PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount_324" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring" xlink:label="loc_sclx_FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring_328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_286" xlink:to="loc_sclx_FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring_328" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ScilexPharmaNotesPrincipalIncrease" xlink:label="loc_sclx_ScilexPharmaNotesPrincipalIncrease_332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_286" xlink:to="loc_sclx_ScilexPharmaNotesPrincipalIncrease_332" use="optional" order="69" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_TransactionCostsObligationAssumedBySorrento" xlink:label="loc_sclx_TransactionCostsObligationAssumedBySorrento_336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_286" xlink:to="loc_sclx_TransactionCostsObligationAssumedBySorrento_336" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentation">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_346" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_346" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_347" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcern">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_349" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_349" xlink:to="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_350" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/Acquisitions">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="loc_us-gaap_DisclosureTextBlockAbstract_352" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_352" xlink:to="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_353" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_355" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_355" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_356" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/BalanceSheetComponents">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_358" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_358" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_359" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_361" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_361" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_362" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/Debt">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_379" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_379" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_380" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreement">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_382" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_382" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_383" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/StockholdersEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_385" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_385" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_386" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlans">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_388" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_388" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_389" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_394" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_394" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_395" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_373" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_373" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_374" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/NetLossPerShare">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_400" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_400" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_401" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_403" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_403" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_404" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_406" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_406" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_410" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_406" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_436" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_406" xlink:to="loc_us-gaap_UseOfEstimates_412" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_406" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_413" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_406" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_416" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_406" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_417" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_406" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_418" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_406" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_419" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_406" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_420" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_406" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_421" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_406" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_424" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:label="loc_us-gaap_ContingentLiabilityReserveEstimatePolicy_422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_406" xlink:to="loc_us-gaap_ContingentLiabilityReserveEstimatePolicy_422" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock" xlink:label="loc_sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock_425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_406" xlink:to="loc_sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock_425" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock_428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_406" xlink:to="loc_us-gaap_DebtPolicyTextBlock_428" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ConvertibleDebenturesAndTheOramedNotePolicyTextBlock" xlink:label="loc_sclx_ConvertibleDebenturesAndTheOramedNotePolicyTextBlock_408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_406" xlink:to="loc_sclx_ConvertibleDebenturesAndTheOramedNotePolicyTextBlock_408" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_406" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_430" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_406" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_431" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_406" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_432" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_406" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_433" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_406" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_434" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_406" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_435" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_TreasuryStockPolicyTextblock" xlink:label="loc_sclx_TreasuryStockPolicyTextblock_429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_406" xlink:to="loc_sclx_TreasuryStockPolicyTextblock_429" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_406" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_437" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_406" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_438" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_440" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_441" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_440" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_441" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_447" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_447" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_448" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_447" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_449" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_450" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_447" xlink:to="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_450" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueConcentrationOfRiskTextBlock" xlink:label="loc_us-gaap_FairValueConcentrationOfRiskTextBlock_451" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_447" xlink:to="loc_us-gaap_FairValueConcentrationOfRiskTextBlock_451" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/BalanceSheetComponentsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_453" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_453" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_454" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AccruedExpensesTextblock" xlink:label="loc_sclx_AccruedExpensesTextblock_455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_453" xlink:to="loc_sclx_AccruedExpensesTextblock_455" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_457" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_457" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_458" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_457" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_459" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/DebtTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_461" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_463" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_461" xlink:to="loc_us-gaap_DebtInstrumentTable_463" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_463" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_462" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_465" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_462" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_465" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_464" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_465" xlink:to="loc_us-gaap_SeniorNotesMember_464" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_463" xlink:to="loc_us-gaap_DebtInstrumentLineItems_1415" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1415" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_466" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ScheduleOfTheOramedNoteTableTextBlock" xlink:label="loc_sclx_ScheduleOfTheOramedNoteTableTextBlock_467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1415" xlink:to="loc_sclx_ScheduleOfTheOramedNoteTableTextBlock_467" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_469" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_470" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_469" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_470" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_471" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_469" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_471" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_473" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_475" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_473" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_475" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_476" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_473" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_476" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_478" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_479" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_478" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_479" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_480" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_478" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_480" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_478" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_481" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_478" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_482" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/NetLossPerShareTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_484" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_484" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_485" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_484" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_486" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_491" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:label="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_499" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_491" xlink:to="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_499" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_499" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_511" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_511" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_494" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_494" xlink:to="loc_us-gaap_ConvertibleDebtMember_506" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_499" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_520" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_520" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_504" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_499" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_524" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_503" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_524" xlink:to="loc_us-gaap_EquityComponentDomain_503" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaap_TransactionTypeAxis_527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_499" xlink:to="loc_us-gaap_TransactionTypeAxis_527" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaap_TransactionDomain_510" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransactionTypeAxis_527" xlink:to="loc_us-gaap_TransactionDomain_510" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_499" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_529" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_529" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_493" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_493" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_512" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_499" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_531" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_531" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_505" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_505" xlink:to="loc_us-gaap_SalesRevenueNetMember_502" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_505" xlink:to="loc_us-gaap_AccountsReceivableMember_517" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_499" xlink:to="loc_us-gaap_TypeOfArrangementAxis_533" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_533" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_496" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_499" xlink:to="loc_srt_RangeAxis_535" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_535" xlink:to="loc_srt_RangeMember_501" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_501" xlink:to="loc_srt_MinimumMember_500" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_501" xlink:to="loc_srt_MaximumMember_516" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_536" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_499" xlink:to="loc_srt_MajorCustomersAxis_536" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_536" xlink:to="loc_srt_NameOfMajorCustomerDomain_508" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ThreeCustomersMember" xlink:label="loc_sclx_ThreeCustomersMember_518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_508" xlink:to="loc_sclx_ThreeCustomersMember_518" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:label="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_537" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_499" xlink:to="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_537" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_498" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_537" xlink:to="loc_us-gaap_ReceivablesNetCurrent_498" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_537" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_515" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_537" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_522" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_537" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_526" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_537" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_528" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PercentageOfNetRevenueSoleDistributors" xlink:label="loc_sclx_PercentageOfNetRevenueSoleDistributors_534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_537" xlink:to="loc_sclx_PercentageOfNetRevenueSoleDistributors_534" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationScheduleOfCashAndCashEquivalentsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_539" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_541" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_539" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_541" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_539" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_542" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_543" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_539" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_543" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_545" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_LiquidityAndGoingConcernTable" xlink:label="loc_sclx_LiquidityAndGoingConcernTable_557" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_545" xlink:to="loc_sclx_LiquidityAndGoingConcernTable_557" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_557" xlink:to="loc_us-gaap_DebtInstrumentAxis_552" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_552" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_569" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_565" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_557" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_565" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_565" xlink:to="loc_us-gaap_RelatedPartyDomain_553" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_568" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_557" xlink:to="loc_srt_RangeAxis_568" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_568" xlink:to="loc_srt_RangeMember_555" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_555" xlink:to="loc_srt_MaximumMember_554" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_557" xlink:to="loc_us-gaap_TypeOfArrangementAxis_571" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_571" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_549" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PurchaseAgreementAxis" xlink:label="loc_sclx_PurchaseAgreementAxis_573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_557" xlink:to="loc_sclx_PurchaseAgreementAxis_573" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PurchaseAgreementDomain" xlink:label="loc_sclx_PurchaseAgreementDomain_558" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PurchaseAgreementAxis_573" xlink:to="loc_sclx_PurchaseAgreementDomain_558" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ARYorkvillePurchaseAgreementMember" xlink:label="loc_sclx_ARYorkvillePurchaseAgreementMember_547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PurchaseAgreementDomain_558" xlink:to="loc_sclx_ARYorkvillePurchaseAgreementMember_547" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AtmSalesAgreementMember" xlink:label="loc_sclx_AtmSalesAgreementMember_562" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PurchaseAgreementDomain_558" xlink:to="loc_sclx_AtmSalesAgreementMember_562" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_557" xlink:to="loc_us-gaap_StatementClassOfStockAxis_575" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_575" xlink:to="loc_us-gaap_ClassOfStockDomain_566" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_566" xlink:to="loc_us-gaap_CommonStockMember_548" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_557" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_577" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_577" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_560" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityUnitPurchaseAgreementsMember" xlink:label="loc_us-gaap_EquityUnitPurchaseAgreementsMember_559" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_560" xlink:to="loc_us-gaap_EquityUnitPurchaseAgreementsMember_559" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_LiquidityAndGoingConcernLineItems" xlink:label="loc_sclx_LiquidityAndGoingConcernLineItems_579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_557" xlink:to="loc_sclx_LiquidityAndGoingConcernLineItems_579" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_579" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_551" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_WorkingCapital" xlink:label="loc_sclx_WorkingCapital_564" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_579" xlink:to="loc_sclx_WorkingCapital_564" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_579" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_567" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_579" xlink:to="loc_us-gaap_OperatingIncomeLoss_570" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_579" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_572" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_579" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_574" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_Convertibledebentureprincipalamount" xlink:label="loc_sclx_Convertibledebentureprincipalamount_576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_579" xlink:to="loc_sclx_Convertibledebentureprincipalamount_576" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PrincipalLaonAmount" xlink:label="loc_sclx_PrincipalLaonAmount_578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_579" xlink:to="loc_sclx_PrincipalLaonAmount_578" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_579" xlink:to="loc_us-gaap_ConvertibleDebt_580" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="loc_us-gaap_DebtInstrumentIssuedPrincipal_581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_579" xlink:to="loc_us-gaap_DebtInstrumentIssuedPrincipal_581" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_OutstandingBalanceOfRevolvingFacility" xlink:label="loc_sclx_OutstandingBalanceOfRevolvingFacility_582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_579" xlink:to="loc_sclx_OutstandingBalanceOfRevolvingFacility_582" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_579" xlink:to="loc_us-gaap_CommonStockSharesIssued_583" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_CommonStockIssuableValue" xlink:label="loc_sclx_CommonStockIssuableValue_584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_579" xlink:to="loc_sclx_CommonStockIssuableValue_584" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ValueOfStockSoldForTerminationOfOffering" xlink:label="loc_sclx_ValueOfStockSoldForTerminationOfOffering_585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_579" xlink:to="loc_sclx_ValueOfStockSoldForTerminationOfOffering_585" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RightToSellMaximumNumberOfCommonStockShares" xlink:label="loc_sclx_RightToSellMaximumNumberOfCommonStockShares_588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_579" xlink:to="loc_sclx_RightToSellMaximumNumberOfCommonStockShares_588" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_579" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_589" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/AcquisitionsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_623" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_626" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_623" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_626" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_624" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_626" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_624" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_629" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_624" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_629" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_LicenseAgreementMember" xlink:label="loc_sclx_LicenseAgreementMember_632" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_629" xlink:to="loc_sclx_LicenseAgreementMember_632" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_626" xlink:to="loc_dei_LegalEntityAxis_634" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_634" xlink:to="loc_dei_EntityDomain_638" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RomegLicenseAgreementMember" xlink:label="loc_sclx_RomegLicenseAgreementMember_625" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_638" xlink:to="loc_sclx_RomegLicenseAgreementMember_625" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_626" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_636" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_633" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_636" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_633" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_628" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_633" xlink:to="loc_us-gaap_PatentsMember_628" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_639" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_626" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_639" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_639" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_630" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_627" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_630" xlink:to="loc_sclx_SorrentoMember_627" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_626" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_641" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_631" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_641" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_631" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_Upfrontlicensefee" xlink:label="loc_sclx_Upfrontlicensefee_635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_641" xlink:to="loc_sclx_Upfrontlicensefee_635" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PaymentUponTheAchievementOfNetSales" xlink:label="loc_sclx_PaymentUponTheAchievementOfNetSales_637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_641" xlink:to="loc_sclx_PaymentUponTheAchievementOfNetSales_637" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaap_PaymentsForRoyalties_640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_641" xlink:to="loc_us-gaap_PaymentsForRoyalties_640" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_641" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_642" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_Deferredconsiderationliabilities" xlink:label="loc_sclx_Deferredconsiderationliabilities_643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_641" xlink:to="loc_sclx_Deferredconsiderationliabilities_643" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_641" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_644" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PaymentToAcquireLicense" xlink:label="loc_sclx_PaymentToAcquireLicense_645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_641" xlink:to="loc_sclx_PaymentToAcquireLicense_645" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AccruedRoyaltyPayables" xlink:label="loc_sclx_AccruedRoyaltyPayables_646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_641" xlink:to="loc_sclx_AccruedRoyaltyPayables_646" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AmountDueForNewDrugApplication" xlink:label="loc_sclx_AmountDueForNewDrugApplication_647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_641" xlink:to="loc_sclx_AmountDueForNewDrugApplication_647" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_687" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_696" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_687" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_696" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_696" xlink:to="loc_us-gaap_TypeOfArrangementAxis_690" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_690" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_689" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_697" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_696" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_697" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_693" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_697" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_693" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_694" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_693" xlink:to="loc_us-gaap_PrivatePlacementMember_694" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_696" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_699" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_695" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_699" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_695" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_695" xlink:to="loc_us-gaap_SeniorNotesMember_692" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_702" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_696" xlink:to="loc_us-gaap_AwardTypeAxis_702" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_702" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_700" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_WarrantsMember" xlink:label="loc_sclx_WarrantsMember_706" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_700" xlink:to="loc_sclx_WarrantsMember_706" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_696" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_704" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_704" xlink:to="loc_us-gaap_DebtInstrumentFairValue_691" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SecuredNoteDiscountRate" xlink:label="loc_sclx_SecuredNoteDiscountRate_698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_704" xlink:to="loc_sclx_SecuredNoteDiscountRate_698" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="loc_us-gaap_DebtInstrumentIssuedPrincipal_701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_704" xlink:to="loc_us-gaap_DebtInstrumentIssuedPrincipal_701" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_703" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_704" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_703" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense" xlink:label="loc_sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense_705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_704" xlink:to="loc_sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense_705" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_707" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_704" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_707" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_708" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_704" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_708" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RiskAdjustedNetSalesForecast" xlink:label="loc_sclx_RiskAdjustedNetSalesForecast_709" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_704" xlink:to="loc_sclx_RiskAdjustedNetSalesForecast_709" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleWeightedAverageYield" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleWeightedAverageYield_710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_704" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleWeightedAverageYield_710" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_711" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_704" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_711" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductLiabilityContingencyAccrualDiscountRate" xlink:label="loc_us-gaap_ProductLiabilityContingencyAccrualDiscountRate_712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_704" xlink:to="loc_us-gaap_ProductLiabilityContingencyAccrualDiscountRate_712" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_FairValueOfContingentConsideration" xlink:label="loc_sclx_FairValueOfContingentConsideration_713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_704" xlink:to="loc_sclx_FairValueOfContingentConsideration_713" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DerivativeWarrantLiabilityPrivateWarrants" xlink:label="loc_sclx_DerivativeWarrantLiabilityPrivateWarrants_714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_704" xlink:to="loc_sclx_DerivativeWarrantLiabilityPrivateWarrants_714" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_717" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_723" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_717" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_723" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_723" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_722" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_722" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_724" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_721" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_724" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_721" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_724" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_728" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_724" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_732" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_729" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_723" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_729" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_725" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_729" xlink:to="loc_us-gaap_LiabilitiesAbstract_725" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotes" xlink:label="loc_us-gaap_SeniorNotes_720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_725" xlink:to="loc_us-gaap_SeniorNotes_720" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_725" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_727" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_731" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_725" xlink:to="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_731" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_725" xlink:to="loc_us-gaap_DerivativeLiabilities_733" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_725" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_734" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_725" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_735" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_737" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" xlink:label="loc_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1_738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_737" xlink:to="loc_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1_738" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_CorporateBondYield" xlink:label="loc_sclx_CorporateBondYield_739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_737" xlink:to="loc_sclx_CorporateBondYield_739" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_CouponInterestRate" xlink:label="loc_sclx_CouponInterestRate_740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_737" xlink:to="loc_sclx_CouponInterestRate_740" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_741" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_737" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_741" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" xlink:label="loc_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1_742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_737" xlink:to="loc_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1_742" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_737" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_743" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_746" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_746" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_750" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_748" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_750" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_748" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_751" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_748" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_751" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_749" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_751" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_749" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_753" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_750" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_753" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_753" xlink:to="loc_us-gaap_DerivativeLiabilities_747" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PrivatePlacementWarrantLiabilityAcquired" xlink:label="loc_sclx_PrivatePlacementWarrantLiabilityAcquired_752" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_753" xlink:to="loc_sclx_PrivatePlacementWarrantLiabilityAcquired_752" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ReMeasurementOfFairValue" xlink:label="loc_sclx_ReMeasurementOfFairValue_754" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_753" xlink:to="loc_sclx_ReMeasurementOfFairValue_754" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ForfeitureOfPrivateWarrants" xlink:label="loc_sclx_ForfeitureOfPrivateWarrants_755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_753" xlink:to="loc_sclx_ForfeitureOfPrivateWarrants_755" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ChangeInValuationInputsOrOtherAssumptions" xlink:label="loc_sclx_ChangeInValuationInputsOrOtherAssumptions_756" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_753" xlink:to="loc_sclx_ChangeInValuationInputsOrOtherAssumptions_756" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_757" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_753" xlink:to="loc_us-gaap_DerivativeLiabilities_757" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities">
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract" xlink:label="loc_sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract_759" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_EquityValue" xlink:label="loc_sclx_EquityValue_760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract_759" xlink:to="loc_sclx_EquityValue_760" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_761" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract_759" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_761" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract_759" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_762" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract_759" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_763" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract_759" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_764" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_765" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract_759" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_765" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_CallOptionValue" xlink:label="loc_sclx_CallOptionValue_766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract_759" xlink:to="loc_sclx_CallOptionValue_766" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_777" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_777" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_778" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_778" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_782" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_782" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_780" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_780" xlink:to="loc_us-gaap_ConstructionInProgressMember_781" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_780" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_784" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_780" xlink:to="loc_us-gaap_ComputerEquipmentMember_787" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_780" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_788" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_778" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_785" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_785" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_779" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_785" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_783" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_785" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_786" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_790" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_790" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_791" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent_792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_790" xlink:to="loc_us-gaap_AccruedMarketingCostsCurrent_792" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AccruedResearchAndDevelopmentCosts" xlink:label="loc_sclx_AccruedResearchAndDevelopmentCosts_793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_790" xlink:to="loc_sclx_AccruedResearchAndDevelopmentCosts_793" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_TaxesPayableCurrentAndNoncurrent_794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_790" xlink:to="loc_us-gaap_TaxesPayableCurrentAndNoncurrent_794" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilities_795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_790" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilities_795" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AccruedExpenses" xlink:label="loc_sclx_AccruedExpenses_796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_790" xlink:to="loc_sclx_AccruedExpenses_796" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/BalanceSheetComponentsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_798" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_798" xlink:to="loc_us-gaap_Depreciation_799" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_801" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_801" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_807" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_807" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_804" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_802" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_804" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_802" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_807" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_810" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_810" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_805" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_807" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_813" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_813" xlink:to="loc_us-gaap_Goodwill_808" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_813" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_811" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_813" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_814" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_813" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_815" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_817" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_817" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_821" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_821" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_820" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_818" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_820" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_818" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PatentRightsMember" xlink:label="loc_sclx_PatentRightsMember_819" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_818" xlink:to="loc_sclx_PatentRightsMember_819" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AcquiredTechnologyMember" xlink:label="loc_sclx_AcquiredTechnologyMember_823" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_818" xlink:to="loc_sclx_AcquiredTechnologyMember_823" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AcquiredLicensesMember" xlink:label="loc_sclx_AcquiredLicensesMember_826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_818" xlink:to="loc_sclx_AcquiredLicensesMember_826" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AssembledWorkforceMember" xlink:label="loc_sclx_AssembledWorkforceMember_828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_818" xlink:to="loc_sclx_AssembledWorkforceMember_828" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_821" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_824" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_824" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_822" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_824" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_825" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_824" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_827" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_830" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract_832" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_830" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract_832" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract_832" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_833" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract_832" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_834" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract_832" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_835" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract_832" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_836" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract_832" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_837" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive" xlink:label="loc_sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive_839" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract_832" xlink:to="loc_sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive_839" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract_832" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_840" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_842" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_842" xlink:to="loc_us-gaap_DebtInstrumentTable_848" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_848" xlink:to="loc_us-gaap_CreditFacilityAxis_846" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_860" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_846" xlink:to="loc_us-gaap_CreditFacilityDomain_860" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_860" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_855" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PurchaseAgreementAxis" xlink:label="loc_sclx_PurchaseAgreementAxis_862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_848" xlink:to="loc_sclx_PurchaseAgreementAxis_862" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PurchaseAgreementDomain" xlink:label="loc_sclx_PurchaseAgreementDomain_856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PurchaseAgreementAxis_862" xlink:to="loc_sclx_PurchaseAgreementDomain_856" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ARYorkvillePurchaseAgreementMember" xlink:label="loc_sclx_ARYorkvillePurchaseAgreementMember_845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PurchaseAgreementDomain_856" xlink:to="loc_sclx_ARYorkvillePurchaseAgreementMember_845" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_867" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_848" xlink:to="loc_us-gaap_VestingAxis_867" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_867" xlink:to="loc_us-gaap_VestingDomain_858" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_858" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_844" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_858" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_861" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_866" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_858" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_866" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_871" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_848" xlink:to="loc_us-gaap_TypeOfArrangementAxis_871" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_871" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_847" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SecuritiesPurchaseAgreementMember" xlink:label="loc_sclx_SecuritiesPurchaseAgreementMember_843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_847" xlink:to="loc_sclx_SecuritiesPurchaseAgreementMember_843" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_874" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_848" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_874" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_874" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_859" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_851" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_859" xlink:to="loc_us-gaap_SeniorNotesMember_851" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_848" xlink:to="loc_us-gaap_DebtInstrumentAxis_877" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_870" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_877" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_870" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_FristInstallmentMember" xlink:label="loc_sclx_FristInstallmentMember_854" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_870" xlink:to="loc_sclx_FristInstallmentMember_854" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SecondInstallmentMember" xlink:label="loc_sclx_SecondInstallmentMember_864" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_870" xlink:to="loc_sclx_SecondInstallmentMember_864" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ThirdInstallmentMember" xlink:label="loc_sclx_ThirdInstallmentMember_868" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_870" xlink:to="loc_sclx_ThirdInstallmentMember_868" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_FourthInstallmentMember" xlink:label="loc_sclx_FourthInstallmentMember_872" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_870" xlink:to="loc_sclx_FourthInstallmentMember_872" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_FiveInstallmentMember" xlink:label="loc_sclx_FiveInstallmentMember_875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_870" xlink:to="loc_sclx_FiveInstallmentMember_875" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SixInstallmentMember" xlink:label="loc_sclx_SixInstallmentMember_878" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_870" xlink:to="loc_sclx_SixInstallmentMember_878" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_880" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_848" xlink:to="loc_srt_RangeAxis_880" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_853" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_880" xlink:to="loc_srt_RangeMember_853" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_852" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_853" xlink:to="loc_srt_MaximumMember_852" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_863" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_853" xlink:to="loc_srt_MinimumMember_863" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DebtPayableAxis" xlink:label="loc_sclx_DebtPayableAxis_882" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_848" xlink:to="loc_sclx_DebtPayableAxis_882" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DebtPayableDomain" xlink:label="loc_sclx_DebtPayableDomain_849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DebtPayableAxis_882" xlink:to="loc_sclx_DebtPayableDomain_849" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_MonthlyBasisMember" xlink:label="loc_sclx_MonthlyBasisMember_850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DebtPayableDomain_849" xlink:to="loc_sclx_MonthlyBasisMember_850" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_848" xlink:to="loc_us-gaap_DebtInstrumentLineItems_884" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="loc_us-gaap_DebtInstrumentIssuedPrincipal_857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_DebtInstrumentIssuedPrincipal_857" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaap_DebtInstrumentDescription_865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_DebtInstrumentDescription_865" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_NetCashProceeds" xlink:label="loc_sclx_NetCashProceeds_869" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_sclx_NetCashProceeds_869" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_TerminationFees" xlink:label="loc_sclx_TerminationFees_873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_sclx_TerminationFees_873" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_876" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_RepaymentsOfDebt_876" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_879" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_DebtInstrumentFairValue_879" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DebtRepaymentExitFee" xlink:label="loc_sclx_DebtRepaymentExitFee_881" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_sclx_DebtRepaymentExitFee_881" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepaidPrincipal" xlink:label="loc_us-gaap_DebtInstrumentRepaidPrincipal_883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_DebtInstrumentRepaidPrincipal_883" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:label="loc_us-gaap_CommonStockConvertibleConversionPriceIncrease_885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_CommonStockConvertibleConversionPriceIncrease_885" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ExistingFacilityCapMaximum" xlink:label="loc_sclx_ExistingFacilityCapMaximum_886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_sclx_ExistingFacilityCapMaximum_886" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ExistingFacilityCapMinimum" xlink:label="loc_sclx_ExistingFacilityCapMinimum_887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_sclx_ExistingFacilityCapMinimum_887" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DebtInstrumentOutstandingPrincipal" xlink:label="loc_sclx_DebtInstrumentOutstandingPrincipal_888" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_sclx_DebtInstrumentOutstandingPrincipal_888" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" xlink:label="loc_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue_889" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue_889" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServicingLiabilityAtFairValueOtherChangeInFairValueStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="loc_us-gaap_ServicingLiabilityAtFairValueOtherChangeInFairValueStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_890" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_ServicingLiabilityAtFairValueOtherChangeInFairValueStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_890" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_891" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_892" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_893" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_893" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DebtInstrumentPrincipalAmountPercentage" xlink:label="loc_sclx_DebtInstrumentPrincipalAmountPercentage_894" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_sclx_DebtInstrumentPrincipalAmountPercentage_894" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="loc_us-gaap_DebtInstrumentPaymentTerms_895" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_DebtInstrumentPaymentTerms_895" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ConvertibleDebenturesIssuedPercent" xlink:label="loc_sclx_ConvertibleDebenturesIssuedPercent_896" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_sclx_ConvertibleDebenturesIssuedPercent_896" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_897" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_Cash_897" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_898" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_898" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionDescription" xlink:label="loc_us-gaap_DebtInstrumentRedemptionDescription_899" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_DebtInstrumentRedemptionDescription_899" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio" xlink:label="loc_us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio_900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio_900" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_CommonStockSharesIssued_902" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableRevolvingConvertedToTermLoan" xlink:label="loc_us-gaap_FinancingReceivableRevolvingConvertedToTermLoan_903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_FinancingReceivableRevolvingConvertedToTermLoan_903" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_904" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DebtInstrumentOwnedPercentage" xlink:label="loc_sclx_DebtInstrumentOwnedPercentage_905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_sclx_DebtInstrumentOwnedPercentage_905" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DebtInstrumentDefaultInterestRate" xlink:label="loc_sclx_DebtInstrumentDefaultInterestRate_906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_sclx_DebtInstrumentDefaultInterestRate_906" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount" xlink:label="loc_sclx_DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount_907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_sclx_DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount_907" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount" xlink:label="loc_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount_908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount_908" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest" xlink:label="loc_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest_909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest_909" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PercentageOfUsageOfCashProceedsFromCashSweepFinancing" xlink:label="loc_sclx_PercentageOfUsageOfCashProceedsFromCashSweepFinancing_910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_884" xlink:to="loc_sclx_PercentageOfUsageOfCashProceedsFromCashSweepFinancing_910" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/DebtSummeryOfOutstandingConvertibleDebentureDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_922" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_925" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_922" xlink:to="loc_us-gaap_DebtInstrumentTable_925" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_924" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_925" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_924" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_927" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_924" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_927" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_926" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_927" xlink:to="loc_us-gaap_SeniorNotesMember_926" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_930" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_927" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_930" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_925" xlink:to="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_929" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_923" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_929" xlink:to="loc_us-gaap_ConvertibleDebt_923" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesIssued1" xlink:label="loc_us-gaap_NotesIssued1_928" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_929" xlink:to="loc_us-gaap_NotesIssued1_928" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RepaymentOfConvertibleDebenture" xlink:label="loc_sclx_RepaymentOfConvertibleDebenture_932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_929" xlink:to="loc_sclx_RepaymentOfConvertibleDebenture_932" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ChangeInFairValueOfConvertibleDebentures" xlink:label="loc_sclx_ChangeInFairValueOfConvertibleDebentures_931" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_929" xlink:to="loc_sclx_ChangeInFairValueOfConvertibleDebentures_931" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ConversionOfConvertibleDebenturesIntoCommonStock" xlink:label="loc_sclx_ConversionOfConvertibleDebenturesIntoCommonStock_933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_929" xlink:to="loc_sclx_ConversionOfConvertibleDebenturesIntoCommonStock_933" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_934" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_929" xlink:to="loc_us-gaap_ConvertibleDebt_934" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_936" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_947" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_936" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_947" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_947" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_944" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_951" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_944" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_951" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_946" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_951" xlink:to="loc_sclx_SorrentoMember_946" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_947" xlink:to="loc_srt_RangeAxis_955" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_942" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_955" xlink:to="loc_srt_RangeMember_942" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_942" xlink:to="loc_srt_MaximumMember_941" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_954" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_942" xlink:to="loc_srt_MinimumMember_954" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_960" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_947" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_960" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_949" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_960" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_949" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_JuniorDipFacilityMember" xlink:label="loc_sclx_JuniorDipFacilityMember_940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_949" xlink:to="loc_sclx_JuniorDipFacilityMember_940" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_949" xlink:to="loc_us-gaap_SeniorNotesMember_953" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_965" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_947" xlink:to="loc_us-gaap_TypeOfArrangementAxis_965" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_938" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_965" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_938" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_StockPurchaseAgreementMember" xlink:label="loc_sclx_StockPurchaseAgreementMember_937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_938" xlink:to="loc_sclx_StockPurchaseAgreementMember_937" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_947" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_968" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_968" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_963" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ClosingPennyWarrantMember" xlink:label="loc_sclx_ClosingPennyWarrantMember_948" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_963" xlink:to="loc_sclx_ClosingPennyWarrantMember_948" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SubsequentPennyWarrantsMember" xlink:label="loc_sclx_SubsequentPennyWarrantsMember_958" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_963" xlink:to="loc_sclx_SubsequentPennyWarrantsMember_958" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PennyWarrantsMember" xlink:label="loc_sclx_PennyWarrantsMember_962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_963" xlink:to="loc_sclx_PennyWarrantsMember_962" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SubsequentPennyWarrants1Member" xlink:label="loc_sclx_SubsequentPennyWarrants1Member_967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_963" xlink:to="loc_sclx_SubsequentPennyWarrants1Member_967" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SubsequentPennyWarrants2Member" xlink:label="loc_sclx_SubsequentPennyWarrants2Member_970" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_963" xlink:to="loc_sclx_SubsequentPennyWarrants2Member_970" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SubsequentPennyWarrants3Member" xlink:label="loc_sclx_SubsequentPennyWarrants3Member_973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_963" xlink:to="loc_sclx_SubsequentPennyWarrants3Member_973" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SubsequentPennyWarrants4Member" xlink:label="loc_sclx_SubsequentPennyWarrants4Member_976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_963" xlink:to="loc_sclx_SubsequentPennyWarrants4Member_976" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaap_AwardDateAxis_971" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_947" xlink:to="loc_us-gaap_AwardDateAxis_971" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaap_AwardDateDomain_950" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateAxis_971" xlink:to="loc_us-gaap_AwardDateDomain_950" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_947" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_974" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_943" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_974" xlink:to="loc_us-gaap_EquityComponentDomain_943" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_939" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_943" xlink:to="loc_us-gaap_CommonStockMember_939" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_952" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_943" xlink:to="loc_us-gaap_PreferredStockMember_952" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PrivateWarrantsMember" xlink:label="loc_sclx_PrivateWarrantsMember_959" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_943" xlink:to="loc_sclx_PrivateWarrantsMember_959" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PublicWarrantsMember" xlink:label="loc_sclx_PublicWarrantsMember_964" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_943" xlink:to="loc_sclx_PublicWarrantsMember_964" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_947" xlink:to="loc_us-gaap_StatementLineItems_977" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_977" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_945" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_956" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_977" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_956" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_977" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_961" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaap_DebtInstrumentDescription_966" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_977" xlink:to="loc_us-gaap_DebtInstrumentDescription_966" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SharesPurchasedUnderStockPurchaseAgreement" xlink:label="loc_sclx_SharesPurchasedUnderStockPurchaseAgreement_978" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_977" xlink:to="loc_sclx_SharesPurchasedUnderStockPurchaseAgreement_978" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SharesPurchasedAtParValueUnderStockPurchaseAgreement" xlink:label="loc_sclx_SharesPurchasedAtParValueUnderStockPurchaseAgreement_979" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_977" xlink:to="loc_sclx_SharesPurchasedAtParValueUnderStockPurchaseAgreement_979" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_IssueOfWarrantsToPurchaseShares" xlink:label="loc_sclx_IssueOfWarrantsToPurchaseShares_980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_977" xlink:to="loc_sclx_IssueOfWarrantsToPurchaseShares_980" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_977" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_981" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_NumberOfShareOutstanding" xlink:label="loc_sclx_NumberOfShareOutstanding_982" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_977" xlink:to="loc_sclx_NumberOfShareOutstanding_982" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_TransferOfWarrants" xlink:label="loc_sclx_TransferOfWarrants_983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_977" xlink:to="loc_sclx_TransferOfWarrants_983" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_984" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_977" xlink:to="loc_us-gaap_LegalFees_984" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_CashPayment" xlink:label="loc_sclx_CashPayment_985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_977" xlink:to="loc_sclx_CashPayment_985" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_FairValueOfSharesRepurchased" xlink:label="loc_sclx_FairValueOfSharesRepurchased_986" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_977" xlink:to="loc_sclx_FairValueOfSharesRepurchased_986" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_FairValueOfWarrants" xlink:label="loc_sclx_FairValueOfWarrants_987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_977" xlink:to="loc_sclx_FairValueOfWarrants_987" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_977" xlink:to="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_988" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_WarrantVestingDate" xlink:label="loc_sclx_WarrantVestingDate_989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_977" xlink:to="loc_sclx_WarrantVestingDate_989" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_990" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_977" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_990" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_996" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ShareholdersEquityDetailsTable" xlink:label="loc_sclx_ShareholdersEquityDetailsTable_1008" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_996" xlink:to="loc_sclx_ShareholdersEquityDetailsTable_1008" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1008" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1011" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1009" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1011" xlink:to="loc_us-gaap_EquityComponentDomain_1009" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaap_TreasuryStockCommonMember_1004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1009" xlink:to="loc_us-gaap_TreasuryStockCommonMember_1004" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1008" xlink:to="loc_us-gaap_AwardTypeAxis_1019" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1019" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1024" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_WarrantsMember" xlink:label="loc_sclx_WarrantsMember_1034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1024" xlink:to="loc_sclx_WarrantsMember_1034" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1027" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1008" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1027" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1027" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1003" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_WarrantTransferAgreementMember" xlink:label="loc_sclx_WarrantTransferAgreementMember_997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1003" xlink:to="loc_sclx_WarrantTransferAgreementMember_997" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PurchaseAgreementAxis" xlink:label="loc_sclx_PurchaseAgreementAxis_1032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1008" xlink:to="loc_sclx_PurchaseAgreementAxis_1032" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PurchaseAgreementDomain" xlink:label="loc_sclx_PurchaseAgreementDomain_1010" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PurchaseAgreementAxis_1032" xlink:to="loc_sclx_PurchaseAgreementDomain_1010" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ARYorkvillePurchaseAgreementMember" xlink:label="loc_sclx_ARYorkvillePurchaseAgreementMember_1000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PurchaseAgreementDomain_1010" xlink:to="loc_sclx_ARYorkvillePurchaseAgreementMember_1000" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_BRileyPurchaseAgreementMember" xlink:label="loc_sclx_BRileyPurchaseAgreementMember_1022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PurchaseAgreementDomain_1010" xlink:to="loc_sclx_BRileyPurchaseAgreementMember_1022" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AtTheMarketSalesAgreementMember" xlink:label="loc_sclx_AtTheMarketSalesAgreementMember_1031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PurchaseAgreementDomain_1010" xlink:to="loc_sclx_AtTheMarketSalesAgreementMember_1031" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1008" xlink:to="loc_dei_LegalEntityAxis_1035" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1035" xlink:to="loc_dei_EntityDomain_1028" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_HudsonBayMember" xlink:label="loc_sclx_HudsonBayMember_1018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1028" xlink:to="loc_sclx_HudsonBayMember_1018" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_CoveLaneMember" xlink:label="loc_sclx_CoveLaneMember_1026" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1028" xlink:to="loc_sclx_CoveLaneMember_1026" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1038" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1008" xlink:to="loc_srt_TitleOfIndividualAxis_1038" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_1038" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1012" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1040" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1008" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1040" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1040" xlink:to="loc_us-gaap_ClassOfStockDomain_1025" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1025" xlink:to="loc_us-gaap_CommonStockMember_1017" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_1023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1025" xlink:to="loc_us-gaap_PreferredStockMember_1023" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1042" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1008" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1042" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1042" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1001" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1044" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1008" xlink:to="loc_srt_RangeAxis_1044" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1044" xlink:to="loc_srt_RangeMember_1007" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1007" xlink:to="loc_srt_MaximumMember_1006" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ShareholdersEquityDetailsLineItems" xlink:label="loc_sclx_ShareholdersEquityDetailsLineItems_1046" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsTable_1008" xlink:to="loc_sclx_ShareholdersEquityDetailsLineItems_1046" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1046" xlink:to="loc_us-gaap_CommonStockSharesIssued_998" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1046" xlink:to="loc_us-gaap_SharePrice_1015" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1046" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1021" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1046" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1030" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_1036" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1046" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_1036" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaap_TreasuryStockCommonShares_1039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1046" xlink:to="loc_us-gaap_TreasuryStockCommonShares_1039" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1046" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1045" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PurchaseOfStockPercentage" xlink:label="loc_sclx_PurchaseOfStockPercentage_1047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1046" xlink:to="loc_sclx_PurchaseOfStockPercentage_1047" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_CommonStockSold" xlink:label="loc_sclx_CommonStockSold_1048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1046" xlink:to="loc_sclx_CommonStockSold_1048" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ProceedsFromSaleOfCommonStock" xlink:label="loc_sclx_ProceedsFromSaleOfCommonStock_1049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1046" xlink:to="loc_sclx_ProceedsFromSaleOfCommonStock_1049" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1046" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1050" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividends" xlink:label="loc_us-gaap_PaymentsOfDividends_1052" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1046" xlink:to="loc_us-gaap_PaymentsOfDividends_1052" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_1053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1046" xlink:to="loc_us-gaap_CommonStockValue_1053" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RightToSellMaximumNumberOfCommonStockShares" xlink:label="loc_sclx_RightToSellMaximumNumberOfCommonStockShares_1054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1046" xlink:to="loc_sclx_RightToSellMaximumNumberOfCommonStockShares_1054" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1046" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1055" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ProceedSOfSaleOfCommonSharesPercentage" xlink:label="loc_sclx_ProceedSOfSaleOfCommonSharesPercentage_1056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ShareholdersEquityDetailsLineItems_1046" xlink:to="loc_sclx_ProceedSOfSaleOfCommonSharesPercentage_1056" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1079" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1080" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1080" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1081" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1079" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1082" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1083" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1084" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1084" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1085" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1085" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1086" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1086" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1087" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1087" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1088" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1089" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1090" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1090" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1091" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1091" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1092" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1079" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1092" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1093" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1079" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1093" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1094" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1095" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1079" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1095" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1097" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1097" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1105" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis_1103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1105" xlink:to="loc_us-gaap_ValuationTechniqueAxis_1103" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_1106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_1103" xlink:to="loc_us-gaap_ValuationTechniqueDomain_1106" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_BlackScholesOptionPricingMethodMember" xlink:label="loc_sclx_BlackScholesOptionPricingMethodMember_1099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_1106" xlink:to="loc_sclx_BlackScholesOptionPricingMethodMember_1099" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1105" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1110" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1110" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1104" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_1098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1104" xlink:to="loc_us-gaap_StockOptionMember_1098" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_EmployeeStockPurchasePlanMember" xlink:label="loc_sclx_EmployeeStockPurchasePlanMember_1107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1104" xlink:to="loc_sclx_EmployeeStockPurchasePlanMember_1107" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1105" xlink:to="loc_srt_RangeAxis_1112" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1112" xlink:to="loc_srt_RangeMember_1102" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1102" xlink:to="loc_srt_MinimumMember_1101" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1102" xlink:to="loc_srt_MaximumMember_1109" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1105" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1114" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1114" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1108" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1114" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1111" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1114" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1113" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_1115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1114" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_1115" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1114" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1116" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1120" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1120" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1132" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1132" xlink:to="loc_us-gaap_PlanNameAxis_1131" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1131" xlink:to="loc_us-gaap_PlanNameDomain_1125" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:label="loc_sclx_TwoThousandTwentyTwoEquityIncentivePlanMember_1140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1125" xlink:to="loc_sclx_TwoThousandTwentyTwoEquityIncentivePlanMember_1140" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_TwoThousandTwentyThreeInducementPlanMember" xlink:label="loc_sclx_TwoThousandTwentyThreeInducementPlanMember_1146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1125" xlink:to="loc_sclx_TwoThousandTwentyThreeInducementPlanMember_1146" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" xlink:label="loc_sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember_1150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1125" xlink:to="loc_sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember_1150" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1132" xlink:to="loc_srt_RangeAxis_1139" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1139" xlink:to="loc_srt_RangeMember_1130" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1130" xlink:to="loc_srt_MaximumMember_1129" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1130" xlink:to="loc_srt_MinimumMember_1138" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1132" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1145" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1145" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1133" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1132" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1149" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1149" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1123" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1132" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1154" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1154" xlink:to="loc_us-gaap_RelatedPartyDomain_1128" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_NonEmployeeDirectorMember" xlink:label="loc_sclx_NonEmployeeDirectorMember_1155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1128" xlink:to="loc_sclx_NonEmployeeDirectorMember_1155" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1132" xlink:to="loc_us-gaap_AwardTypeAxis_1157" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1141" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1132" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1159" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1159" xlink:to="loc_us-gaap_ClassOfStockDomain_1143" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1143" xlink:to="loc_us-gaap_CommonStockMember_1122" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1132" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1161" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1161" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1127" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_1137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1161" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_1137" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1161" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1144" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1161" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1148" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1161" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1152" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1161" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1156" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_1158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1161" xlink:to="loc_us-gaap_ShareBasedCompensation_1158" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1161" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1160" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_1162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1161" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_1162" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1161" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1163" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_1164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1161" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_1164" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_Sharebasedcompensationpayable" xlink:label="loc_sclx_Sharebasedcompensationpayable_1165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1161" xlink:to="loc_sclx_Sharebasedcompensationpayable_1165" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationCashBasedArrangementsLiabilityCurrent" xlink:label="loc_us-gaap_DeferredCompensationCashBasedArrangementsLiabilityCurrent_1166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1161" xlink:to="loc_us-gaap_DeferredCompensationCashBasedArrangementsLiabilityCurrent_1166" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_WeightedAveragePeriodOverGrant" xlink:label="loc_sclx_WeightedAveragePeriodOverGrant_1167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1161" xlink:to="loc_sclx_WeightedAveragePeriodOverGrant_1167" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1161" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1168" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1161" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1169" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesScheduleOfLeasesSupplementalQuantitativeInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1174" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_1175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1174" xlink:to="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_1175" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_1176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_1175" xlink:to="loc_us-gaap_OperatingLeasePayments_1176" use="optional" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_1175" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1178" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_1175" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1179" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1181" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1181" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1182" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1181" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1183" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1181" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1184" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1181" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1185" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1181" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1186" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1181" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1187" use="optional" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_1188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1181" xlink:to="loc_us-gaap_OperatingLeaseLiability_1188" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1181" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_1189" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_LeaseLiabilityNetOfCurrentPortion" xlink:label="loc_sclx_LeaseLiabilityNetOfCurrentPortion_1190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1181" xlink:to="loc_sclx_LeaseLiabilityNetOfCurrentPortion_1190" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1192" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_CommitmentsAndContingenciesTable" xlink:label="loc_sclx_CommitmentsAndContingenciesTable_1198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1192" xlink:to="loc_sclx_CommitmentsAndContingenciesTable_1198" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesTable_1198" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1205" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1205" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1195" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ProductDevelopmentAgreementMember" xlink:label="loc_sclx_ProductDevelopmentAgreementMember_1193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1195" xlink:to="loc_sclx_ProductDevelopmentAgreementMember_1193" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_NonCancelableLeaseAgreementsMember" xlink:label="loc_sclx_NonCancelableLeaseAgreementsMember_1208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1195" xlink:to="loc_sclx_NonCancelableLeaseAgreementsMember_1208" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_1213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesTable_1198" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_1213" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1213" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1200" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesTable_1198" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1217" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1217" xlink:to="loc_us-gaap_SegmentDomain_1197" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ScilexPharmaMember" xlink:label="loc_sclx_ScilexPharmaMember_1199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1197" xlink:to="loc_sclx_ScilexPharmaMember_1199" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_EpoladermMember" xlink:label="loc_sclx_EpoladermMember_1211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1197" xlink:to="loc_sclx_EpoladermMember_1211" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ProbudurMember" xlink:label="loc_sclx_ProbudurMember_1216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1197" xlink:to="loc_sclx_ProbudurMember_1216" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_EnveltaMember" xlink:label="loc_sclx_EnveltaMember_1220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1197" xlink:to="loc_sclx_EnveltaMember_1220" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesTable_1198" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1221" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1221" xlink:to="loc_us-gaap_RelatedPartyDomain_1201" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DevelopersMember" xlink:label="loc_sclx_DevelopersMember_1196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1201" xlink:to="loc_sclx_DevelopersMember_1196" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_GloperbaMember" xlink:label="loc_sclx_GloperbaMember_1210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1201" xlink:to="loc_sclx_GloperbaMember_1210" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_FormerEmployeeMember" xlink:label="loc_sclx_FormerEmployeeMember_1215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1201" xlink:to="loc_sclx_FormerEmployeeMember_1215" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_FormerEmployeeOneMember" xlink:label="loc_sclx_FormerEmployeeOneMember_1219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1201" xlink:to="loc_sclx_FormerEmployeeOneMember_1219" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesTable_1198" xlink:to="loc_srt_RangeAxis_1224" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1224" xlink:to="loc_srt_RangeMember_1203" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1203" xlink:to="loc_srt_MinimumMember_1202" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1203" xlink:to="loc_srt_MaximumMember_1212" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesTable_1198" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1226" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1226" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1204" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ResearchAndDevelopmentFacilitiesMember" xlink:label="loc_sclx_ResearchAndDevelopmentFacilitiesMember_1206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1204" xlink:to="loc_sclx_ResearchAndDevelopmentFacilitiesMember_1206" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_CommitmentsAndContingenciesLineItems" xlink:label="loc_sclx_CommitmentsAndContingenciesLineItems_1228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesTable_1198" xlink:to="loc_sclx_CommitmentsAndContingenciesLineItems_1228" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RoyaltyPaymentPercentageRelatedToFutureYears" xlink:label="loc_sclx_RoyaltyPaymentPercentageRelatedToFutureYears_1194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1228" xlink:to="loc_sclx_RoyaltyPaymentPercentageRelatedToFutureYears_1194" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_1209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1228" xlink:to="loc_us-gaap_LitigationSettlementExpense_1209" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RoyaltyPaymentPercentageOnNetSale" xlink:label="loc_sclx_RoyaltyPaymentPercentageOnNetSale_1214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1228" xlink:to="loc_sclx_RoyaltyPaymentPercentageOnNetSale_1214" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_1218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1228" xlink:to="loc_us-gaap_RoyaltyExpense_1218" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_1222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1228" xlink:to="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_1222" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_AgreementMaturityDate" xlink:label="loc_sclx_AgreementMaturityDate_1225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1228" xlink:to="loc_sclx_AgreementMaturityDate_1225" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_MaturityRenewalDescription" xlink:label="loc_sclx_MaturityRenewalDescription_1227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1228" xlink:to="loc_sclx_MaturityRenewalDescription_1227" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DueFromRelatedParty" xlink:label="loc_sclx_DueFromRelatedParty_1230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1228" xlink:to="loc_sclx_DueFromRelatedParty_1230" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_1231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1228" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_1231" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_1232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1228" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_1232" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability_1233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1228" xlink:to="loc_us-gaap_FinanceLeaseLiability_1233" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_1234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1228" xlink:to="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_1234" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_1235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1228" xlink:to="loc_us-gaap_OperatingLeaseExpense_1235" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1228" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1236" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsAndContingenciesLineItems_1228" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1237" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1239" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1239" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1240" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1239" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1241" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1239" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1242" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_1243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1239" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_1243" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_1243" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1244" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_1243" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1245" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1239" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1246" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_1247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1239" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_1247" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1239" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1248" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1239" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1249" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_1251" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1251" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1252" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DeferredTaxAssetsDebtRelatedInterest" xlink:label="loc_sclx_DeferredTaxAssetsDebtRelatedInterest_1253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1251" xlink:to="loc_sclx_DeferredTaxAssetsDebtRelatedInterest_1253" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1251" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1254" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_1255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1251" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_1255" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1251" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1256" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DeferredTaxAssetsAccruedExpenseAndReserves" xlink:label="loc_sclx_DeferredTaxAssetsAccruedExpenseAndReserves_1257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1251" xlink:to="loc_sclx_DeferredTaxAssetsAccruedExpenseAndReserves_1257" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="loc_sclx_DeferredTaxAssetsOperatingLeaseLiabilities_1258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1251" xlink:to="loc_sclx_DeferredTaxAssetsOperatingLeaseLiabilities_1258" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_1259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1251" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_1259" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1251" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_1260" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1251" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1261" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1251" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_1262" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_1263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1251" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_1263" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_1264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_1263" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_1264" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_1265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_1263" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_1265" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_1266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1251" xlink:to="loc_us-gaap_DeferredTaxLiabilities_1266" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1251" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1267" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1269" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1269" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1270" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1269" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1271" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount" xlink:label="loc_sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount_1272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1269" xlink:to="loc_sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount_1272" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_1273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1269" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_1273" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_IncomeTaxReconciliationAcquisitionRelatedCharges" xlink:label="loc_sclx_IncomeTaxReconciliationAcquisitionRelatedCharges_1274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1269" xlink:to="loc_sclx_IncomeTaxReconciliationAcquisitionRelatedCharges_1274" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_1275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1269" xlink:to="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_1275" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_1276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1269" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_1276" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount" xlink:label="loc_sclx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount_1277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1269" xlink:to="loc_sclx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount_1277" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount" xlink:label="loc_sclx_EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount_1278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1269" xlink:to="loc_sclx_EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount_1278" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_1279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1269" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_1279" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1269" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1280" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1282" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1282" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1283" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_1284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1282" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_1284" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_1285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1282" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_1285" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1282" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1286" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/IncomeTaxesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1288" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_1294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1288" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_1294" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1294" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1290" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1290" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1293" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_1291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1293" xlink:to="loc_us-gaap_DomesticCountryMember_1291" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_1298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1293" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_1298" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_1297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1294" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_1297" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_1292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1297" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_1292" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_1295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1292" xlink:to="loc_us-gaap_ResearchMember_1295" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_IncomeTaxDisclosureLineItems" xlink:label="loc_sclx_IncomeTaxDisclosureLineItems_1300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1294" xlink:to="loc_sclx_IncomeTaxDisclosureLineItems_1300" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1300" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1289" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1300" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1296" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_IndefiniteOperatingLossCarryforwards" xlink:label="loc_sclx_IndefiniteOperatingLossCarryforwards_1299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1300" xlink:to="loc_sclx_IndefiniteOperatingLossCarryforwards_1299" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_OperatingLossCarryforwardsExpirationYear" xlink:label="loc_sclx_OperatingLossCarryforwardsExpirationYear_1301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1300" xlink:to="loc_sclx_OperatingLossCarryforwardsExpirationYear_1301" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1300" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1302" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_TaxCreditCarryforwardNotSubjectToExpireAmount" xlink:label="loc_sclx_TaxCreditCarryforwardNotSubjectToExpireAmount_1303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1300" xlink:to="loc_sclx_TaxCreditCarryforwardNotSubjectToExpireAmount_1303" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_IncomeTaxCreditsExpirationYear" xlink:label="loc_sclx_IncomeTaxCreditsExpirationYear_1304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1300" xlink:to="loc_sclx_IncomeTaxCreditsExpirationYear_1304" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_1305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1300" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_1305" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_1306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1300" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_1306" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_1300" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1307" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/NetLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1310" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1310" xlink:to="loc_us-gaap_NetIncomeLoss_1311" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockRedemptionPremium" xlink:label="loc_us-gaap_PreferredStockRedemptionPremium_1312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1310" xlink:to="loc_us-gaap_PreferredStockRedemptionPremium_1312" use="optional" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1310" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1313" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1310" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1315" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_EffectOfDilutiveSecurities" xlink:label="loc_sclx_EffectOfDilutiveSecurities_1316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1310" xlink:to="loc_sclx_EffectOfDilutiveSecurities_1316" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1310" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1317" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_1318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1310" xlink:to="loc_us-gaap_EarningsPerShareBasic_1318" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1310" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1319" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1321" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1321" xlink:to="loc_us-gaap_StatementTable_1323" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1323" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1325" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1325" xlink:to="loc_us-gaap_ClassOfStockDomain_1330" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_StockOptionsMember" xlink:label="loc_sclx_StockOptionsMember_1322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1330" xlink:to="loc_sclx_StockOptionsMember_1322" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PublicWarrantsMember" xlink:label="loc_sclx_PublicWarrantsMember_1327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1330" xlink:to="loc_sclx_PublicWarrantsMember_1327" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PrivateWarrantsMember" xlink:label="loc_sclx_PrivateWarrantsMember_1329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1330" xlink:to="loc_sclx_PrivateWarrantsMember_1329" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RetainerSharesMember" xlink:label="loc_sclx_RetainerSharesMember_1334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1330" xlink:to="loc_sclx_RetainerSharesMember_1334" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_SharesIssuablePursuantToEsppMember" xlink:label="loc_sclx_SharesIssuablePursuantToEsppMember_1335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1330" xlink:to="loc_sclx_SharesIssuablePursuantToEsppMember_1335" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1323" xlink:to="loc_us-gaap_DebtInstrumentAxis_1328" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1328" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1332" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ConvertibleDebenturesMember" xlink:label="loc_sclx_ConvertibleDebenturesMember_1324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1332" xlink:to="loc_sclx_ConvertibleDebenturesMember_1324" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1323" xlink:to="loc_us-gaap_StatementLineItems_1331" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1331" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1326" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/NetLossPerShareAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1337" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1337" xlink:to="loc_us-gaap_StatementTable_1339" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1339" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1341" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1341" xlink:to="loc_us-gaap_EquityComponentDomain_1340" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1340" xlink:to="loc_us-gaap_WarrantMember_1338" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1339" xlink:to="loc_us-gaap_StatementLineItems_1343" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1343" xlink:to="loc_us-gaap_CommonStockSharesIssued_1342" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1345" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1345" xlink:to="loc_us-gaap_SubsequentEventTable_1348" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1355" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1348" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1355" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1355" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1346" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1346" xlink:to="loc_us-gaap_SubsequentEventMember_1354" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1348" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1359" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1359" xlink:to="loc_us-gaap_EquityComponentDomain_1352" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1352" xlink:to="loc_us-gaap_WarrantMember_1347" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1348" xlink:to="loc_dei_LegalEntityAxis_1362" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1362" xlink:to="loc_dei_EntityDomain_1361" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_RodmanRenshawLlcMember" xlink:label="loc_sclx_RodmanRenshawLlcMember_1349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1361" xlink:to="loc_sclx_RodmanRenshawLlcMember_1349" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1348" xlink:to="loc_srt_RangeAxis_1364" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1364" xlink:to="loc_srt_RangeMember_1351" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1348" xlink:to="loc_us-gaap_SubsequentEventLineItems_1366" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_CommonStockSold" xlink:label="loc_sclx_CommonStockSold_1363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_sclx_CommonStockSold_1363" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PurchaseOfCommonWarrants" xlink:label="loc_sclx_PurchaseOfCommonWarrants_1365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_sclx_PurchaseOfCommonWarrants_1365" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PurchaseOfCommonShares" xlink:label="loc_sclx_PurchaseOfCommonShares_1367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_sclx_PurchaseOfCommonShares_1367" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1368" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PricePerOptionalShare" xlink:label="loc_sclx_PricePerOptionalShare_1369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_sclx_PricePerOptionalShare_1369" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PricePerOptionalWarrant" xlink:label="loc_sclx_PricePerOptionalWarrant_1370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_sclx_PricePerOptionalWarrant_1370" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PublicOfferingPerOptionalShare" xlink:label="loc_sclx_PublicOfferingPerOptionalShare_1371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_sclx_PublicOfferingPerOptionalShare_1371" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PublicOfferingPerOptionalWarrant" xlink:label="loc_sclx_PublicOfferingPerOptionalWarrant_1372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_sclx_PublicOfferingPerOptionalWarrant_1372" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PublicOfferingPrice" xlink:label="loc_sclx_PublicOfferingPrice_1373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_sclx_PublicOfferingPrice_1373" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_ExercisePriceOfCommonWarrant" xlink:label="loc_sclx_ExercisePriceOfCommonWarrant_1374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_sclx_ExercisePriceOfCommonWarrant_1374" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_CommonShareSold" xlink:label="loc_sclx_CommonShareSold_1375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_sclx_CommonShareSold_1375" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_1377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_1377" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1378" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PublicOfferingPriceCombined" xlink:label="loc_sclx_PublicOfferingPriceCombined_1379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_sclx_PublicOfferingPriceCombined_1379" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_1381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_us-gaap_LegalFees_1381" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_OutOfPocketExpense" xlink:label="loc_sclx_OutOfPocketExpense_1382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_sclx_OutOfPocketExpense_1382" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_PublicOfferingPriceSold" xlink:label="loc_sclx_PublicOfferingPriceSold_1383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_sclx_PublicOfferingPriceSold_1383" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20231231.xsd#sclx_CombinedPricePaidOfWarrant" xlink:label="loc_sclx_CombinedPricePaidOfWarrant_1384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_sclx_CombinedPricePaidOfWarrant_1384" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventDescription" xlink:label="loc_us-gaap_SubsequentEventDescription_1387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1366" xlink:to="loc_us-gaap_SubsequentEventDescription_1387" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g759370g00a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g759370g00a01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[29,4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )C"^EW8X0DE-! 0      &D< 5H  QLE1QP!6@ #&R5'' (   (  !P"
M4  (<G(R.30T.#<< @4 0$UI8W)O<V]F="!7;W)D("T@4V-I;&5X("T@4&]S
M="!%9F9E8W1I=F4@06UE;F1M96YT($YO+C$@3W)A;65D(%, .$))300E
M   0><QB;UM-CX&D2<YE<S.\6CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!=LB]
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  $Y   "[0         !                          $
M NT   $Y                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   $Y     %)G:'1L;VYG   "[0    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   !.0    !29VAT
M;&]N9P   NT    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     ,X0DE-! P     &Y(    !    H    $,   '@  !]H   &W8
M&  !_]C_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A9
M6B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M 0  ]M8  0    #3+4A0("
M                         !%C<')T   !4    #-D97-C   !A    &QW
M='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "+
M !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D   #
M3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T96-H
M   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/   " QT
M97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M
M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M !)S4D="($E%0S8Q.38V+3(N,0
M                                6%E:(        /-1  $    !%LQ8
M65H@                     %A96B        !OH@  ./4   .06%E:(
M     &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M%DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P.B\O
M=W=W+FEE8RYC:
M              !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@
M4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y-C8M
M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N
M9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC92!6
M:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                 '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>
M     5A96B       $P)5@!0    5Q_G;65A<P         !
M             H\    "<VEG(     !#4E0@8W5R=@        0     !0 *
M  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '<
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M=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&>J5[
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #] ET# 1$  A$! Q$!_\0
M'@   0,% 0$               $"!@,$!0<("0K_Q !T$  !! $"! ,#!0<*
M#0X* Q$! @,$!08'$0 ($B$3%#$505$)%B)A<1<9(S*!D:$*&"0F0I:QP='P
M)2<S-D124U165]+A\1HT-3=#149'8F9VAI/5*%588X.4E<+3UDAD<G1UA:)E
MAY*SMM2FLK2UP\3%_\0 '0$! 0 " P$! 0            $" P0%!@<("?_$
M %\1  $" P4#!@@)!P<)!@8# 0$"$0 #(00%$C%!!E%A$R)Q@9'P!Q05%Z&Q
MP=$6(S)"4E62D^$()%-4E-+Q)3,T0T5B<C5$8V1S@J+"TQAE=(.$XB8V5J.D
MLD:SP^/_V@ , P$  A$#$0 _ ._.<"5S399S+\S]_@O-OF> 8UB&L;V#X_IE
M3S["7<*8C8OIQ.DV6+T3%E$C2:*I&8+LLJ=2XPNCKZ]^>&+!$PM1_D-[VN]Y
MUNOBT62]E66S6"U^*)D+)2I0Y*424@T9E$*SH<3NK#'[W\&%@V)D[+;)V&\=
MDO*-OOBP)M,Z\C)1,E!:YMLE\G,62%8\4A'))#!9H2G"I8XIS?-N:S"(.K\V
M?SPZS*>T8L(]7?P+>%85]EDCN0VEC2XM*Q)=?EEW GP;*]HY[%FJSEU<NEB-
MLR_*3$O.PT>?M5NO2R2[2$WY,4F3,0E4N@*UJ2LA03C6[%!27(*:%CB('U>[
M]E-B[7-NFSIV&L!D7E+F3Q.$I!$A4I'* 3%<F@X%2R%2B'"U@I6F6#SI_@+7
M-3G$:C2S\H3J) R&TP'3G4*=BCSS*K*OBZE?,E-+#3,LM0JFO4B+,S(Q'46#
MU1?6DBH>:I<:GB=&2UML]KO.>E/\O*"U2T**6!*3,PJ!JL$N%$#)1(#I(,=+
M>MW[&W.!/G>#N2JR&\+58T3TRY?)S.0-M22&EJ(<V19PE 0$XCRJ,"@,<'N<
MY<.RF_KTM67FZ&IJ+NR\JC(UIR.+=8U<97'K-(53K^M>U'R2KCTZHF543C&+
MNXS)4\7WY4>ODGC6I5])Q#RO/6$I)*D(!2OFXFENIU$,R@0C"Q"E5<<GR?X/
M!:K-99>P5A'C^,NJ5A38\$TREF\#@/BR9Q3CDK09Q7*6F8$)!*(G,K"N>F)'
MJVG.=?4YJ[L+]N!)JI4Q]M-)1'-WL7?R*Z7#S>RLJUJLIH<S)[):ZD8]7(KG
MJ&1D[4]<0R=B1?N(%-Z34S H,#A)8KPA3N1D"I3N 62%DL%<&=+\'$J9/P["
MW;:+.F1,6FTRK-,,BU3D2S,Y.2M<D!1*PF6"DF8I:L7)8>54,VK27GRC:?ZM
M:F?KZLX>H-,(.H=TI35E9/?.:FQ3%ZC,,.GU#K64N-F+J-26KKD>1',]B@,*
M677+II:5J["98MHD2ID\WR7LR5*35W*D@H+L:$%RXIO(8QU*;Q\'!O*Z;K\W
MEGFS;WM-WR)*A9T\C*$^TB3; I9EA6*Q+2E! 8S)AY)TJ#1QYJYKCSA:/9-2
MX_)YL-8LB8R'$ZO+X%F;:QQ]2XME-M:TLBK=LK&6TTW*IY*H[DU<28^RXAQ^
MNAN%3*?-WK?FT5VSA)5>4\O+3,!! "PM\1R>A<%]V22X'V'9/P=^#S:&1/FS
M=E;NDS)-KG6>9+Y!*N36AE)2Y2 <4I4M9*72A2S+=10HG6(YQ^;8_P#TD]82
M02/Z\;#\W<[^FW'4_"R_Q_:-HK4.L:CHRW=N<>P3X&O!N0WP9NXD$@D6>6 X
MX$9LQ+/[(/UY'-K_ .4EK'^_"Q_EXHVMVAR\IV@=*TTZ>:\3S->#=R/@Q=]/
M]61WIKNU:&KYR.;<I(3S):Q%1V"=\PL" =^Q.Y]WQ]WKL>'PKOTGGWE/*00?
ME)JQ<%@'?*GX1BKP->#K#\7LQ=V)3 ?FR&&+?3)LW&56BC+YR.;R)%=4[S,:
MR-OAM2T.M9E.0$I2GK42-PDD $IZ@>DC?8!)XR3M5?LU:6O">0% $$ZDL&8/
MGGZ,XXUL\#/@ZD6*:)^S5W8Q+4I*T24 )"4DJ<D#-.+4;]"8ZKYRN;#FAQ_F
M#R>FQ_7O5*HI8&*Z<O,U-=E$N'":E3L H)<UUN,P.A#DJ:Z]*?)^DN0ZXLC=
M0/'=;1;17Q9[>),J\9Z4*D651R "E2916>FM35]3I'@_!CX)]A;;=%X6JU;-
MW=:IDJ^;[E(7,LZ%K,N7>%KD2)8YJDLA$M*4L.;DV<:.T[YFN;[43.L*P>/S
M3:MT2LQR&%1IMY&3V%@Q5JD**%2U0C(C>.&"E)4TF1'0KHW<=1N5#J;)M#?<
MVTID"\IR<92DJ)HRJ.6JS.:$.[9-'K;[\%G@\NNZYUY2]DKNF*2E1Y-%GEE2
ME(2KF,4_**F0V$L'4Q)"8Z\Q?'>:7.JN'9XE\H_GUTU-EJK4IAQY,B3 FPK3
M":2TKYL:+GLJ9-EU,W-(K,N=2P[?'(ACI79Y'!5,84/5RU7DL!2+^6I.3A!(
M+%*2P"B RE %G&O-JWR!=BV)D6U5@F[ 661-3(7-"U2I:T)^*F3DA^2(8RI2
M%8C@4 LD)6:3-9-7G.2AZ"PCG$Y@2FVS5["ZYY=18/,P9D5['P_99A.J,NLX
MV+5DP9"V<>>+MHU=+@R8DX4I*-^'/ME[R4DHO><I2Y@ED!!R!0ZED*4$IYYP
M9XB*L#3OK/L]X/)LTRK3LE=DN7+L4RVS5+LZ#,5A1:52464<BGE%JY+%,"C)
M$M"E**24 JV-I3A'/9JMCTN[7SMZB8#9P<BNZ)G%LSE9!4V%L*"\9KI[T"1,
MLHRG)[M2;#(:NH<BMFR9KUPHLM4E]MP;;&J^[59U+5>\U!,R8@(6%%PEF.:3
M5)<'/1Z1Y?::U^#;9^U7;*3L'*MEEMUCD6L3K+99"@@6A,P 3<3G".3 )?"
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M=L7R_BZ #,LBU\A9R2$A"ILJ2J8#,6A)4J2E14J89DK&:Y6W.AHAAL/,K#G
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M\-HFV25L5=LFT6:TBQVJ9;)")=EL]J5+7,5*F+$N8Y3(DR9H4F0M*A/2DD+
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M]L'&CI JW]@*G %XUWM0"Q\L5 B2D$';T],K:*^/@V)BK=.,Y=N*&<.$B4%
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M[6V[,>#^S6ZWV5>Q=S$W>+'(DS.10"J;;$6,I7,"97,LLI5I'C,[$KDBF:G
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M21!2H?4001O^?'S772:KMUK.?S)7I<%^-*Q4_EF[;RW$NX+G2GA.M(4D;TD
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M[?(")UJ8S):)B&-:.)AJ*O6AC70_4[6@O0I*M==5B21N1!QCN/>3O!/?X#L
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M?]3KZ E.RM=M5QL>Q%=C!.WN&YB;C;X;G\W'#3X,KJ!+VRUD')A+[30=]8]
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M#K?@_9W]T/.;:1_9:*;YS>DJ/J,*?EC[;WZ&0S]F=O#X?#%3_/\ +MEYD/\
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MJ]EQ*Z3<L6E9U,V<N0)M!<Q$LK?B$<0VH"H2:.&<Z J&G7D'S8&A<@26Q"O
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M*N_E6%WVPRRD$$81,*VM"YB<).$!"9!"58E8G#@5(V#9&U*!:?+!#DCGL$G
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M>$>RKEJ%IL,\VD6B9($NS +24I5/J"3B=*9)=)2"I=$EB#$M&R$Q*D\E;$L
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MBQP9Z74P[^WF,2ZNYH,?<B27VT7O[H[DT?U9D:J?/53^+RL93B>3PZ*()5I
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M65D!AC*PYJ'(!(;/0CRFA*;1RLX$D)1+YQ7+2.:!AS"2#0$#+>8R;.INH;"
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MJO1,;KWVWA)"@]";L;#RSC3I\$RY 24)>6%Y)NJY4I4E-AN\)4%!0")("@H
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M.!<.Q.FK5C$N'YISH7;H/R=<],C#O:TWJ"2Y'W42 !#B$[#=1/26@L>J6]B
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M0%0\N5=-Q&(?LA!CW%NVAV(SR%2E*Y)E$ ()<FA+I</JP+M6NF_#E E0:@*
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MYLN^=X%O].&KE^#U/3#SB[05:?8ONS[Q[(/OJW-4-]QIC]?[3[??_P#:O?\
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MVI74L> ZON$MN]"SNH)!W/'S:WIQ6N>HI26F*-3EHX%3F2WXQ[2S*:0A+J8
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MP^U7K8OVQ*9-3B@MZ&X:::P]=S4-^;"[2"E4  S0N=&08:2/HF5NH&/O[O%
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M. I*OND+*DI*$J.(Y0%)2KU0%&H)2@_VF_2-AL!L (?!9MH_^1Y=*?TJR?\
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M,_*.H(_N85[)WZ._XGXNWNX>:O;//R0B@;^E60L/O6/2'XYQ/A]LS5K>H?\
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MU_H[_D]/AQ&+$5:A9F]+=&0WO3G12:C*A.9R?@_:YW-7FP;CXC\^W8_S[<4
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MYQO.T@%AD,#A\VJ[;X^:[>(5Y6D%(!3R$L8>I6F\M3<W9Y[ [_623ON=_?\
MEV[?D_/Q]0&M6H>OAUQX.85@RW#G G3(D"M<ZE^$+Q(IQAZ#V]-?;7A!P@TS
M@<_1T-OU]<&X^/U?E^'"*TQQ099-OU.IST)@X0^,JP#/FP]#Y[V+[R&@X1/C
M-0.+MD[5#[\PW4T!('KP@$K.24EN K[VUA-Q_I[?P\(<\:)#58,Q["U-SC=P
MA=Q_/^?YOC[N$&F<--VZO"FN[H>$4??N1MN=P.K\4?VI['TVV/;?8'MOQD$D
M@EQ3-SOU[\8Q"Q*5R:D8GJS5/1J,ADV[6-@4NE6<Y!A%QJ#4TKD_&*.ZK,?L
M)+3S2YHL;=;;<1N) 0I4F6VAR5#;F2&$!$=V7'![$D=+:[_NZPV^3=]KM E3
MYLI<V65I/)D)(#*7A(!+J* HAPE3.<NRE7?.M-G,^SV>8E/*(2IEX",25$,E
M)!(=/.9P* U(>^D:)ZLQ7)S4K3S*&'*MI+]BAVJ=;,9M;L]@%P@J*5%ZML62
MTDJ>;=A2$*;*F?PFH;47 IL-YV904X20I5:IJ^$ AUI&(T.)+9TS%U7A5Y$\
M,6+%18AQ5U4+I):E07$-=T8U5C>.F1@&4MK81$=?:]E/!QEJ:VT[%4ID*4\A
M<AA]J0A" 2F.M,A\-L*#AV#:.Y"E)\HV5E8@EU!W25)4*I!.%8()(T9+FD:5
MW1>#E7)3<A0J6#D""0#J&-#D7RK%$Z0ZH)BR)JL!RE$:-',I]XU,M01&;F2X
M*G$MH2IU1;DUD]E\I;.QBS'U(0PVAWC([27("$^4;(2580 H?*(2H G"!4+0
M0"792 [D@A<=X-BY.>0Q)(5,.1T!-2Z2^3,<HSK&@NI[F3XOAKE)'KLDRW'[
M3)JN!:V+$-4>FIW+E,Z1<*4EQ-4]'33S'3'?"W7 AM*5#J0AOAKVLN1,N?.\
M949=FFRI$PID3%$S9R9)0B6"D!>,SD)!<#$2P)%>4FX;2K DI6#,EJ6!C 44
MI*P5%C0 H42"W- +,T861H_JA"8G2I&#Y"W"KX#EI+G+@N-PF:QMQEDSG)3Y
M2VTPIR0SL7.E](DQR4*\5KCF2MHKDG*0A-OLYF+F\@B7B(F&=7F!(2,184*2
M4G"IC0MQIES6R65+*)Z4I!45$'"0,(Q8B62"2 Q9R:Q;0-*=2+:OJK.NPK))
MM==M2G:J?'KGEPYK,5IQ^0MN22VTCPV4K65NK8"0IIQ)6%-@YS+^NB3,5)FV
MZS2YB5)"I:U#E 2 W-(*R-5  M4'5\$W7;%I$T2YBD9%22M*&8ER$G"&' $T
MU-<G4:)ZIWDI42'A5PAP19,]3LQI,!A,2-76ULXZ7Y"FV>M4&EL5Q&^DKF+B
M.H::W0>O5:-I;DLN#E;?9P5K,I(2"LF8%RY9#)22!BF)!)^3B<$Z;)=QWC:
M\N7.6$AW2HT"4J+DK().$8@0"[%GBTB:0ZCRLFJL/5B=A7Y%>0)5G4PKE/LE
M$F%"B/SIKX>F%ML-L,15+<2M1>:<2MEQI'6$JV*V@NE-DF6T6N4JSRUHE+7+
M25E*YBDRY:2@)Q.HJ8%@""%/E&I%S6Q4Y$A29YF*"U %1#I0"5%RJH#'7,:0
MQ_1_5.)'=F/X)DC<9E,%;CSE8\I*4VGA*@]0;"B@R6Y458;* XPS)9D/I89<
M;<<UIVDN5:4E-OL[J*F&1YJL*A5(/-4"'/RF88F('(\D6E*L!E6D @$A)-&
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M/?X;>OQ]?J]/3OQBQ&8/9V>F-F'_ $G87/8"3Z(7O[Q_/MZ_7Z^G^F4TZ^F
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MV-UOT>#ZY )0'CAY*6):29J#0(DRR",#.1)0HD,7R.39'::\B%/:;(.4.(C
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M0Q<,IQ+*J7,+I,1DY7>*<1B=/ 3 IXTZLBV59'LW?:U^]&5Y!S*6EG4)H(J
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M*0P:AYMG!KNJ7JV9C,WEL64OY#G$DD843UDT#U:8 U3F6RZE&L/R:GJKE8U
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MA(H8IO/8<@_R+/24J!(5.FAB02:\IEP(WY5A/NP?)JGM^M8S_?X?.RV![_\
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M/$RNTJ[^V3<H<L:RBOZ2J:@34Q(<V+6LIR2UDRX<Z1;!2!&AP4UT!L,*S$D
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M3R%=/ZA9ONTY?Q]W&&M\NVE:1!\73W3IQ3"RJ<H8%CZ//I)^B@)#1$7H'[I
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M%+G3GDY;C-YEM.]7JK%385E%538Y;.2IL"7)AQ'V&V'7_$?92MXTD$<T"N=
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MS.HR&\%[J1'R-,7'(DR7;Q\R9?L?;V1RFY1;QZ-UBQD1$K:9;6U @+4WC\6
M&!T#!@U:Z,.@4IP$:AXR2,2P7.>\T8FM6T/N$;BT[JN4_.Y6%:EZ:Z?L6[\C
M/:VIP/*A43:QW&)N/T\[+)\G"'[94=W'\4CQ7K%S*Z['UP:F]GSYM?;1+-Z6
M\E_8CD14@C5BQ(R+.VIZ0YH7(@4S=5,=!O 8'IIDQ WFL6E[S0:5V3BI^=XW
MEV'S=-,JL,LK*(16)Z;^+CE581:G++:365SB:G&#/FHC5EFZ7*I%VJ"ANPF"
M+(:8SQ(2?DN[C)V>N3ESV9Y:C((4SXR3H"U3V.V?2:,X .39^4 Y?)E\**IL
M,CM4PW[:OMK&+C=FF'67-2[41T8^EM;(ESKNX5=P%44*+&(L4/?@G04$\9<N
MD/S2S9',@AZD994]-'?$R)I(< :OVL0*TK5QT:-NW3/F(TMU>RK+\'PJXFR<
MJP.NI;7**:QIK*GE5L.]>F18:U)L([(=6W-@RH,MMO<QI;+C2B2@DY)FI66
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M]+9*_"T@MV[$9%%H/0^=@^ 8QHR2"ISK\PG9('<]?LMMO\#K;>RA8/'$VLH
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M?3LIG ?D;[/8_P!/5DI!['YEKV^';]L6_KV]=MMS\.)Y\9S_ .049?K(;_\
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MH(69X+*((!;DD@E^D;P0*[AX+I,O $7B0G$,82E3D [RLMUZ\,O6_0G0_"=
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MBF94[)6Y*L 'XPB]#=S:H0AM) 2XTTF4AF/(&WTI4=MJ0H]UN*)WXZ]*B%3
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M)*N$9^ST=P>R$;J8:3!*9-LH0D.M-!=Q:K0\%A6YG(,PIGN@DJ0],2^XE12
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MUOB?^S)ZLE@=6L/.I;/JI'WI_=ZO52#[\3E/^)>C_?;*_P"ZN,?,=8OKJ?\
MLZ?WXOG3MGU7*^^X?X>KIX0??B<H_P 2]'^^R5_W5W[;>[UW'#S'6+ZZG_<)
M/_,(>=.V_5<K[[TY'/09^P^_$Y3_ (EZ/]]LKZ_?[*_G^;AYCK%]=3_V=/[\
M/.G;'_R7*^^/KP]^L0#Y8G*?\2]'^^V5_ :H>_\ EX>8ZQ?74_\ 9T_OP\Z=
ML^JY7WS>M(@^_$Y3_B7H_P!]LK^'V5^CAYCK%]=3_N$_O1?.G;/JN5]\6_\
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MG*LRP"<+[V#.PKKH7>-$P2D42,GJ%%W;/KW<-S1)F]:N85#G,_#@:=Q\TO\
M"79"-#:"OQ_(\3CV[S;=XD5N09!G;>+T60V$:%7PLG><QNU363:^='I8-F;R
M4Q$2,V8 >:0P=F!TR(#YNSEPD_W744L(4[I=DE0.(AB,BSC+4:M6,%I;KKS,
MR]7L1PG5C2)==AF8T:+5K+**FM&D8S:3</Q_(&L;RMY4BPJJR52/JN$W,@63
MD0RY];35L^QL8%FRSC+G+Y8):AEAPS%ZEQJ_00&8AZ1FL(Y%,UOC"L))+Y#@
M>:-^3Z$")/\ *MD?-;E<.Q'33YX4A22E:3Y?! .H+"5 [; @I'IOMOL>/?\
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M0<(0?Q>G"$( !Z #[ /J_D'YA\.$(-A\!\?3W^N_Y^_"$+L/@/\ 2=S^GO\
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M+:25@@@I[<.5G?I)GVU>^'BLFOYM*R?Y U?^[PA5JQU"7EK<J$HCNI8D+4[
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MT;CJ\+JZ=QOMPA#!;591X@LH!:#WEO%\Y&\/S([&-U^+MXX][._6/[7A#O\
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M=]RZA(0 ATGU<2 LG;<GA$;OPW0JJ^"KQ.J'%4'U!;X5':4'U@ )<=W3LXL
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MRP4^U)G6.KI=ZDA7XB2-VP6R%V[4V^__ "@F:19#)*,$U<MC-,\?,(^@'=Z
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MV1EZ%8./.M0V8$61:(EJCLI+Z)7IIT5_&.X]+-3:;57'9N0TR/#8@9%=XY(
M>1)97)IY?@"3%E-@-R(LV,N-,CN( '1("%?20247OWSC9?"$'"$'"$'"$'"$
M>$?--1<ULKF7]N:+29#F$0*-A3M0^8QQ>;D\:YRER\CY A>55<AI$RJ=QV/#
MZL;R5$E]*V&)V/=#T]SZ#9Q/-BL "D!D!Z$<T@-FX-,G8C.N4>,M ^-M1(!9
M9"2V3&K$99^VM6U5E5S\H):0W9>-X]C&,BZNL@KX=#*J\5<NL:QH4:W*6_LK
MU>06D-=\J[D]$JEC17X:E0$A-C"9<<5(YI-I)="@0%)H"69CIV,[:$9&..L
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M!F]=3661Y3?R(.3I2@-/U08U)HVV+7);TSDM5%4SB0LXQKE0OZ*MR2_XL=#
MD<8WM,VQ\;O6?8DVF7)LY0;.A *I<Z4JSJYLA!1SYAFK"BNI3AR=P-MD1L^B
M6B5-4E:UD\Y:D8T.H!U*Q$@ )KTDZ@Q*I6BO+#/C9E>,Y_"K(Y;JIN/TL7,Z
MQ^75OE;DBR@=$YN*9T*6T#&A.E4F1&=0&WV4--B1*TRK_P!LI4V1)F7<9B I
M:)D]5F6H3$A*@%E2!A27 -&!+D."$#;Y*V?F$K-IY-.%TI,Y'RBRB 2H.&)
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M,H!5E4RZ'STTUG9"_0)>&[UN@AV2H*;7"XPY/F>W6E^LNYJ" #HCFHV]=HT
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9@X0@X0@X0@X0@X0@X0@X0@X0@X0@X0C_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g759370g00a02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g759370g00a02.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1;(4&AO=&]S:&]P(#,N,  X0DE-! 0
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M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q >&FZ8         IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              .U   )GP         !
M      $             "9\   .U                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     0X0DE-! P     #"P    !    H
M #X   '@  !T0   #!  &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( #X H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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M/_.V*N>K5-;O--^PN<T.]-QG:-SG0/<UO[NY
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M     /_A0>9H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME
M="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^
M"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L]
M(D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@,C Q,B\P,B\P
M-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H
M='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*
M(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @
M(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(CX*
M(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C0M,#,M,C94,3$Z,C@Z,3<K
M,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4
M;V]L/E!38W)I<'0U+F1L;"!697)S:6]N(#4N,BXR/"]X;7 Z0W)E871O<E1O
M;VP^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(T+3 S+3(V5#$R.C U
M.C0X*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A
M9&%T841A=&4^,C R-"TP,RTR-E0Q,CHP-3HT."LP-3HS,#PO>&UP.DUE=&%D
M871A1&%T93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D
M9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^"B @(" @(" @(#QP
M9&8Z4')O9'5C97(^06-R;V)A="!$:7-T:6QL97(@,3 N,2XQ-B H5VEN9&]W
M<RD\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @
M('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^
M"B @(" @(" @(#QD8SIT:71L93X*(" @(" @(" @(" @/')D9CI!;'0^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^36EC
M<F]S;V9T(%=O<F0@+2!38VEL97@@+2!0;W-T($5F9F5C=&EV92!!;65N9&UE
M;G0@3F\N,2!/<F%M960@4RTQ7S$Q.3(P.#,R,E\W("@Q*2YD;V-X/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L
M93X*(" @(" @(" @/&1C.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q
M/@H@(" @(" @(" @(" @(" \<F1F.FQI/G)R,CDT-#@W/"]R9&8Z;&D^"B @
M(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]D8SIC<F5A=&]R/@H@
M(" @(" @(" \9&,Z9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @
M(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS
M=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U
M<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(^"B @(" @
M(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z,D(X,$,Y,$4S0D5"144Q
M,4$U-$)%,3)",D$Y,C1%,C,\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @
M(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z,C@X,$,Y,$4S0D5"144Q,4$U
M-$)%,3)",D$Y,C1%,C,\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX
M;7!-33I/<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#HR.#@P0SDP13-"14)%
M13$Q034T0D4Q,D(R03DR-$4R,SPO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$
M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI3
M97$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T
M86YC94E$/GAM<"YI:60Z,C@X,$,Y,$4S0D5"144Q,4$U-$)%,3)",D$Y,C1%
M,C,\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IW:&5N/C(P,C0M,#,M,C94,3(Z,#4Z,S<K,#4Z,S \+W-T179T.G=H96X^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC
M:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HR
M.3@P0SDP13-"14)%13$Q034T0D4Q,D(R03DR-$4R,SPO<W1%=G0Z:6YS=&%N
M8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R-"TP,RTR
M-E0Q,CHP-3HT,2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N
M861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E
M<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F
M<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O
M97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T
M86YC94E$/GAM<"YI:60Z,D$X,$,Y,$4S0D5"144Q,4$U-$)%,3)",D$Y,C1%
M,C,\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IW:&5N/C(P,C0M,#,M,C94,3(Z,#4Z-#$K,#4Z,S \+W-T179T.G=H96X^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC
M:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HR
M0C@P0SDP13-"14)%13$Q034T0D4Q,D(R03DR-$4R,SPO<W1%=G0Z:6YS=&%N
M8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R-"TP,RTR
M-E0Q,CHP-3HT."LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @
M(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/'AM<$U-.D1E<FEV961&
M<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T
M4F5F.FEN<W1A;F-E240^>&UP+FEI9#HR.3@P0SDP13-"14)%13$Q034T0D4Q
M,D(R03DR-$4R,SPO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T
M4F5F.F1O8W5M96YT240^>&UP+F1I9#HR.#@P0SDP13-"14)%13$Q034T0D4Q
M,D(R03DR-$4R,SPO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T
M4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C(X.#!#.3!%,T)%0D5%
M,3%!-31"13$R0C)!.3(T13(S/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^
M"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(#PO<F1F.D1E
M<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB
M(@H@(" @(" @(" @("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B
M92YC;VTO<&AO=&]S:&]P+S$N,"\B/@H@(" @(" @(" \<&AO=&]S:&]P.D-O
M;&]R36]D93XT/"]P:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @(" \+W)D9CI$
M97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_
M/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! ?_  !$( .D"70,!$0 "$0$#$0'_Q  >  $  00# 0$
M!00&!P@! @,)"O_$ &00  $$ @$! @8+"0P'! <%"04" P0& 0< "!$2$Q05
M%B&6"1DB,3545G65T]47-D%15W2SM+88,U5A8G&4H;&RU-8C,C1R<X&1)"67
MT29"4E.CP? G.$-'X45&9(:'DI/#\?_$ !T! 0 !!0$! 0             !
M @,$!08'" G_Q !6$0 !! $! P,."P8#!@0%!0 !  (#! 41!A(A$Q0Q!Q=!
M45-AD9.4T=+3U/ 5&")25%56<96AL18R@9*BP2/A\0@D,T)#1$:#Q-4E17*"
MA31C='7"_]H # ,!  (1 Q$ /P#]Y8H<V18ERY<LLIY1FP,?Z(V9C-(9AGB4
M.,VVQ&G-,-H:CL--XPVVG&<)[5=JLY5DH(U[?A(_12?D&%\8->L1_P"T^$T'
M?\)\Z>087Q@UZQ'_ +3X30=_PGSIY!A?&#7K$?\ M/A-!W_"?.GD&%\8->L1
M_P"T^$T'?\)\Z>087Q@UZQ'_ +3X30=_PGSIY!A?&#7K$?\ M/A-!W_"?.GD
M&%\8->L1_P"T^$T'?\)\Z>087Q@UZQ'_ +3X30=_PGSIY!A?&#7K$?\ M/A-
M!W_"?.GD&%\8->L1_P"T^$T'?\)\Z>087Q@UZQ'_ +3X30=_PGSIY!A?&#7K
M$?\ M/A-!W_"?.GD&%\8->L1_P"T^$T'?\)\Z>087Q@UZQ'_ +3X30=_PGSI
MY!A?&#7K$?\ M/A-!W_"?.GD&%\8->L1_P"T^$T'?\)\Z>087Q@UZQ'_ +3X
M30=_PGSIY!A?&#7K$?\ M/A-!W_"?.GD&%\8->L1_P"T^$T'?\)\Z>087Q@U
MZQ'_ +3X30=_PGSIY!A?&#7K$?\ M/A-!W_"?.GD&%\8->L1_P"T^$T'?\)\
MZ>087Q@UZQ'_ +3X30=_PGSIY!A?&#7K$?\ M/A-!W_"?.GD&%\8->L1_P"T
M^$T'?\)\Z>087Q@UZQ'_ +3X30=_PGSIY!A?&#7K$?\ M/A-!W_"?.GD&%\8
M->L1_P"T^$T'?\)\Z>087Q@UZQ'_ +3X30=_PGSIY!A?&#7K$?\ M/A-!W_"
M?.GD&%\8->L1_P"T^$T'?\)\Z>087Q@UZQ'_ +3X30=_PGSIY!A?&#7K$?\
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MY 6%S=6.<T[KG :K&P;JQTV:ZC;7TKLF"$/;]2 P;%*%$A^(8PL/G"!!WP8
MFJ0I!.=$%FH<R9 2TU);CHFOM(>8@RW6LI^(O,Q,&:,;30GF? U[7@O8]CG,
MUE9P+&.<QP8XDAQX=) 6LAVLPD^TEO9-MDMS52M':?!(T-9+%)%%-_@2;QY1
M[(YF.>S=:X-#W %K'$77J#?5#W=]TGS(R95]RK:-JU#:\EAV!^$W"G+B(,H'
M=LA[,P<E4UGQ:;V-9?QE6? HQC';:O8^SCS5%D,'/*D5V#DWMDU@FWMPNW==
MUWR3JT]&H67A\[0SGPCS!TKO@O)VL3;Y6)T6[<J%HF:S74/8-YNZ\<' ] 69
M,/(RG*L9]&.SMSVI]';CMQZ.WM_B][W_ .;/9@:\-?UX?KHMS_G^7OYUU3(;
M5WN[G.>[V8SV=F??_FSGWOP_B_Z=K7M<?N_3_73I">_^7?/>6&]E[]H&J+?J
M.D6QPNDYNRVR:72$C1V)T59N+$:FNI*OXD-*'Q? .I[LCP;V%+PI/<QV=N<^
MIC[-V"_9A#.3QT#;-G?=N$1.?N:LU&CR'=(U'#B-5ILEG:&*N8>A;=*)\Y<?
M1HB.,R,-AD1F(E<".2:6 Z.((UX'3I4SL?;0+63E&:,!+B95?KT%U^+S4ZW,
ML2!90ZB4N,5LJH:O^Y*U&Q$<P1.2<9BPE+82[CM=3RW5J/M\X+)((^;5Y++^
M7E;%OLBZ60[W_%F=T-B;JX]G0<5?R.4@QAHB:&W-\(7H:$7-*S[')2S!Q;+9
MW.,%9NZ>4G<-QA+0>)"R5XTSV]G>QVX[.WTI]';_ *O;[KM]UZ<XQ[^<8SZ/
M>[<37^'3TZ=@Z=O3B==/N*V.HUTU&NNFG9U/0/O*A+9:15+JEDN9M3Z0E5 &
M+(67%9\8DH& ATDI/6PQA2<O/)B1'LM-84G+CF$HQG&5=N+L,3[$T,$8!DGD
MCBC!( +Y'!C03T ;SAJ>@=*LVK,5.M8MSDB&K!+8E(&I$<,;I'D#AJ0UIT&H
MU/95JZBVW4-W:UJ6UZ,X1>J-U&9+ WBD'(^>N&F3)B95)A*<=5'7X6*][A2U
M>YQC.<X[>SEZ_3GQUNQ2M!K9ZS^3E#'![-[=#ODO'R7#0CCT:\%AX?+4\[C*
M>7H.>ZE>B$U=TK.3>8RYS07,).Z26GAJ>&G;7EK3;8':3%Q?#!;@$32;U8-?
MDDW&MS*TX0*5Q4=,LJ!3.5_WO6IF9*,BSD;/BL_"'LM?O>>+=1],P-DD@>9Z
M\=EIAE;*&LEUW6R%O[DHT(<P\6G@5..RD.3;<=##<AYE=L4)!;K25G22URT/
MD@$FAFKNWAR4S?D2<=.@J'%;\H!G>EDZ>(;A?[HE5H8S8Q5#H[" F*V6(LBX
MBXQ3$A6'IOC3[?A8N8Z/!M=KGA,^C&;C\=99CH<HX,YI/9?5C(=J\RQM+W M
M T#=T:@ZZ\1PXJQ%GL?-G;6SC'2_"=.C#D9V&,B(5IY!'&6RZZ.?O$;S- 6C
M0D\1KF9#J%Y4E.?2GW_3C_Y9S^/'_7',#7CI[_Y_P_BMSX/"%T\8;[>S&<YS
MVYQV8[,YQV>_V^G_ /[^#@$'L\>UJ-? B>,M]O9Z>W\7:GM_Z=O&H[8\(3LZ
M?Q_AV^VL9U3;@&WWS96OH(2Y#BFKW:RR9+':U,$U@UFTC7RD)=0/2,^)V1N$
MRPI@NN%GL&S%M1GO](O'9ES57PUJMITL#H[8E+&1RM?+'R3@UPGC'&(N)!8'
M?O#4CH.FMK92"U?R..9#<CFQAKB:6>K+#5F-EAD9S2P\".T&!N[*8B1&\ACC
MO'19-P^WGWL^GT^C&4YSZ,=N?1C.>ST>GT_@[,^]G',7W]]5LO['3AQX]/8[
MW]NVF'VU>]G/O9S^#MQV?C]/O_Q<C4'[^G3L@=LC\D/#7O:_=V>ST=CL][71
M:^]2'4[K?I:J]8MFRX]LF0+A<QU! 0:97G;,9G68L.+$Q\)H6Q(CR'<RF0TM
MEG#'A77):XT=MI2WL=FVQ.'MYJQ+7IF%KH:\EJ5]B40Q,AB+0][I""&AN\"=
M=!IJ=>"YS:7:C&;*5*US*-MOCMW8J$#*59UJ>2S,R1\;&PL<'NW^3<T;H<2X
MM ''461HOK@TAO\ NYG658\^ZIL<&%39)-&V=1S-#L<D!X5AAPL/AET=R9%8
M>DQD/I:>\90EY#^(ZHV%O(OY/9_(XN!EJ<5YZDDAB;:IV([4 ET)Y-SX_P!U
MY ) <!J.@E86!VXP>T%Z;&5>?T\E#7%HT,K0L8ZS)6U:TS1,G:!(QCGM:\-=
MOM))+=T%PVX\8;[.WT^]V^CNY[?YO=>GFC78?<0?N.JQUK/<&O-Q!S%@UQ86
M+.#!V<S3IQ6(Q):A*/UY;+)B+#>E-,8G,0Y#V(_C\3#L&2ZAS,21(:QAQ61:
MJ6:4C(K4+H9'PQ3ACRW>Y*9@DB<="= ]A#AWBM?C<K0R\,MC'6&VH(;,]1\S
M X1F>L_DYV,<YK0\,?JS?9JQQ!W7.&A-+NC<M,T+K&U[<OJRB*A3(<2<:6&@
MX)$4,324(2SXM"\.QX=?C<^/A:?"H[K>5+[<]WLS7CZ4^3N04*H8;%AY9&)'
MAC-X,<\ZN/1\EIT&A)/0"K6:S%+ 8NYF,@Z1M*C&)9W0QF:0-=(V(;D;>+B7
MO:--1T\2%?@$] L88.=&Y=S!-BQY>%X="6WO%"45F9&\,WA:_!N^!?1X1O"E
M=Q?:GMSV=O,9[3'))&[]Z-[V.[6K'%AT/9&H.A6P@F98@AL1$F.>*.9FO [D
MK&O;J 3H=UPU&O \%-<I5U.$3A$X1.$3A$X1.$3A% 0OOC._F +^\7X1<USX
M/D?/UJ_:<QPBGN$3A$X1.$3A$X1.$3A%J?UU]G[C7J?S^'[AFRNS\?WK$?XL
M_P!F<?CQV<W.SFHV@PY'2,A6([Q$T>AZ1IH>/2%R6WNHV*VJ(UU^ <GIIQ/_
M .EDZ!H=? ?N*^<73[T=;^ZA=+]&1/<N^ZI)T%KD'IO;--UA4M<MB[)*S7JG
M <J 6P7)Z>I]7B(N6L<5FQ6G$S4.RW&HC,QR).@]7E<]C,7D=H68S%S1Y*U)
M>I3W+%SE8FB69_+OB@$9:-\[KF[SCNEH .FNOF^SFQF?VAPFQ$F<V@J/P&+K
MX;*T\51QC8+$AJU&<RBLW'RND'(L.Y(Y@_Q07N#6/+'LH=1:\/7';OLA^Z8!
MJ]VC9&@MO[7<T!3,6P^JIP;DY0CBXB'*FS,\FF\E9R@4)B#,8>C,J&QDL,XP
M](2[;R%F.O0V7HF*K#5R6/K#)SBM";#X3:C+M)RW?CW0QQWF$.(>07;IT56#
MQ]BYF^J-FFV,C:R. S.1&S](W+/,X;)QCBP\S$K8;#I7\DQK9&EC3& P#><5
MJWK:WU0-6^BS:6D-Z7J^=9^S]TU0+N^FS=CV*SDK,"+RBF-EB+_0)Q&3$KE<
MK>(\>.+*N"AJ&1V%&H[S[D9D@/W-R"9\VT-/(8^M5V?IT9GXVS'5BC:R5C6<
MPDKVFAK[$DY.LC=]Y=J=X<#IR>+O58JNPN5PN?O9#;;*YFG#GZ3\C:LOL5Y7
M3G+PWL=+*Z.M7IGY,;^2AW&M,L1=NZ"T-V%M>6[4OL@%NWKMFU"^JT'N^VT2
MC4.9L4\(?1K>(: MUNLA-9LE6!5BID\5DTZ2F.!"46%$'L'<2X4AI$Z3D8QE
MF#(;*P8VE$[#248+-BRVO$\.M%D@GEEMN9OQ3QR;K6,+PXM) !WN&%M!-C[N
M%ZHUO/YFW#M7!F[M"ACW9*Q!NXZ.6-M.M!C&RLALU9X&V'SR.@E8 T2ES!&U
MQW:U]N.MZCZL,9V9?X=(IY?V-K5$VL(LU@P(!$3<-0EN0D#&G2F(<VPOM19K
M<>,.;=+3DPY#49I_+:D8Y^W0DN8/_=*G.+$>UE]EAT,7*2LB<'[O*O8TEL)<
MX$%[@P$DG35=SC\S!A]L'_"N2;2I3]3;%2TV6K)B@?-"Z)LKH(WO#'3D;PTB
M:97AA #M M5=<7.:=Z;O8RJAO'8EJK?3?L6\=2+&\+6]=#E88,&P%NMKFMZY
M<;Q%(1"0T-+(>'8\"^5AQWHS4B2MYGR(Q*@;FU59!E]KY<?4AERU6MC!CZXK
MLF,<4L4?/)8*Q:Z-TC&;I)$;G#>WF]))Y:A?EGV;ZF-;.Y.U4V<R5[:,9VX^
M[-5$T]:U9^#:MV^V1DD4$CC(-'3,:X1\3I'JRY.IFN].)OIDH$G6^T]I[)U9
MKCKI"TI5JO=M/N5VGUBQJSFW :9;^P9D]1@T(4*?K]MFDK!,#+ERWQ=AC*G2
MD*L867+0YBZ+5*G4NV]FIY^1@KQ"2>6%KN0?/!\KDII2YW*0MC9RA ,C"-7C
M*VLK[,V-EL9)0R^5R&*QNWM:D;MZW8->I!8E_P!]@K7"UG.:,38F"O;>^PZ&
M1V]#8826KZ^]2N[:ITS=%-DV%K\HV3'!M; ZYIZ>R759/+9.PCH%>UY-BEY,
MF;(LB/\ ML X_/<E39!,=#ESW)#^5+=SQ&'Q\V5SM>G8;N.DM/EN!S1&(XX7
M.EL!S= (@&M<P#0!A(&F@7KVU.<K;-;%W<E1D;*V#&1P8ES9#8Y>>Q&VOCRR
M0N<ZQO/?')OESC(UKG%W$E?$K5XO=G1/?>CW<.Q.F\]I:F@$3-([SV<4V-2;
M4QL:'MVPD+&Q8; 'KTEPU7EUH\0)',.EUS^V,,#AGY;$B)&8E^@7)<?M%7V@
MHU,I'>GD(R.+J"M+!S0XZ+DC#&^3Y$G*0,CC(807%SWM'87A^+@S>PV0V+S6
M1V<DP]* 2X/:'*29"C:&1;F[3K3+,\5?26$5K3Y)BZ4$[K8(G.:YNZ[QWF7U
M_;J5[([:M];:M ?J:K&X;=1-4T-[8AX,K[D[+XAJG!J_KE@G'%6:HV 4Z6R;
MENB2L9@7"C65UV#)?43G58R.W7L[)Q8VC#)B9:<%FY9YO')K=WGF=\UHL+XI
MH)"WDX^4#B2&M!#MT49^;'WL;U3+.T&8N0;45<M?Q^)H#(3PGX( B..AK8QD
MI@L5+,&\Z>1U>1A8TSR.:1RCMB*1IFG[UZU-74F]2;(FK^UDZ@)SQM9MEBI[
MQ9UHF'BPXI,E62(PC('1'YB"N!JY>8;Y* .D2FGFXO@5ZZU?EQ^ MS5A7Y<;
M8WVL?+!%,6MW9"2V.9KV-UTW==PD->X#3>U/24</3SNVV)IW7VQ5;U+L1+(R
MM:LT^6)GB9&)9JLD4KFQZF01.D#7O$9>W1FAUEA[6VQ9^FCV/NH7:VR#&I[3
M?]\UV_SKSMBRZIKELDTFQRXNMZAL#;H,>;. P\>&J8@:TY'=;(>)1HSCL5L:
MR1';)U.A!EMIYJ\/)WH*F-L5&UZ,-Y\#)HXGW+$%*5[(I9'.<TN =JS><YHT
M)!YEN7S-K9CJ>4[]LS8B[D,]4R<M[+V\57N24;$L6+I9#,Q16+,$6Z'%FH E
M,+6N=HT.&49Q&[D^CJ767NIC7L"F0^L3 #7D<IL;>%AUM8*='AO.+Z>+AOB!
M3*=8EU: 2?S)@77,Z+6IPZ'[JT#H[$>6-Q&-K-SS7C#VY+#L$9;1CIT8K,,^
MO#+5\:9IXA(8V@/@#7/:YSG!FK@MR]V2DV+D@.TV/CIQ[7\CC^5R69M8ZS0#
M7']GKF?92IVQ69+KNY$/; Z-NYR\;0-VTRNU7&>A;K.HE:&62BG=8;/T2Y*D
M57>1'<6KHSMPOU;4N+J:\JE2R@T?F+"<R=K[UDL"XSTQOP\]$IZ= C7HJ33M
M%@IYI(;,=RA?<T3XV+'VB(89='7:X:&.?K_PY6QQ[P&NZ?WCA2YAXV$VQHUH
MK5"SBLM@@^2IG)LUC ZW>K$,Q&1<]TK(=UI=- ^:9XY0:O!)C;L3NDIJ^^=7
M/4O5NLC<ELU;3=::FUV7Z:Q,/8IS7PA]DG5G9]NO5;;&$!;%NNXRS-M1H(]>
M2DJ<\Y+%^32#8=IF!JZ#+5;"8F7 T8;MFW>M19=QJQVI&[E@"M6D;(U_(0.A
M#G%S S?Z2Y=#FIL9>VOVFJ[99JYBJ6-Q%"?9B"/)6,9!(Q]-LER_ ZO+";=R
M.V>38QSWG0.8(WE@#,<Z^G[4W^<]BFK&]K3L"([LND]3C%U6-M5DJ!Z\TZO#
M,3*B^>) YHPHO-AK8P4B:1;D-SRPJ;)F8FX>+OR%Y=R+'XR/;&7'5ZK^9VL2
M*V]%'/%4L3%IG$;7M<P\E,96L:X%K7-!T=N +68Z7,9V?J4T\]<R;#E,=M+\
M(<C:LTI\C2KQ%U)UE]>2.36S7C@,C]_E'-<[Y;72N<M_?8S<D .>K[523I\Q
M3]/]5VQ*5KR'8S1"P3:_5(K<#$4*P3*ORB#D..IGPR&WY#F,RGYDK/;(ER%K
MYO:S<D?A;G)QLGNX2I9MNCC9$V6P]TF])R<;6L:X@ $-:. ;KT #T'J:<K S
M:[%\O9FJ8C:[)4<<VU/+9DKTXXZ_)P":=SYG,:[><W>>[]XG7>+EICN.5)B]
M27LMJX.SWM-2G-4].;#>R&(5GF^;F':[4D/8DXIHTO9H< NUX0"0*"!TJ4)B
M%7B26\^+9[=[4T.)V(WJG/VB_E2ZH'QM,FDG #EBV,N;PD8QYT>6[I!WEQ65
M,C=I>J^8\H<*\XC9G<R>Y9>VO_N\8=O\T:^PR.0'D7R1-WHFR&0?NJV>EJ],
MTZP=0>IVBD36Y\OTIVB[-[6T/O>X]0>DPC8WOC&=C.5 C(N5UJUYBOS$DTIP
M>R2>'-(9:K4)V7$F/U9NLZ6'&7W-=8A9EXZ_,LCC8,9?DW_\0UF31MBCGK;K
M"S>W0&.T)<[756MD\@:MG:'"AS,?9DV5L7VY?"9V[M%A(6PAU=EYU64V+E6_
MOR<J6<H))&L(9 PJFZ"+I%H?4CI6G$,AKL7VQ0[6S'V9HWJ*N>P:Q=<"0&3T
MBS;NU%L"03L=5L,E+/8S-E1Z/Y-//2HC%;4AF;''W-IH><XF]89RE9M*W#O4
MLABJ]2>N9';@@H7:K8XYHP=7EIY;5C"[E!O-W[.P-XT-IL+0EY#(RYG&W-S+
M8/:2]DJ=OD(63NMYK$9%\LU.Q(T;C)=*K(9'\B("==S&;.^8+70)JW7+NTGT
M[K&]9S<([6?.V3G8,0/&V.>?D>5H&)V3T8"W$GBXN7YJ$"\N/Q1^',R%-Q\9
MCL8#M-<L,HM^#CL[+-%(*[!5>]V/&CH]6"-TF\''Y(W@03V"5K8-HF];_%X\
MYA[L\S;B.">MSQ[LDR)F8DD>)V;_ "T<387QM=RNZS5S(_WB&COU#W&[6'?G
M622N^QZWKV_ZOV!71&DK)<NH?8VLC&L:JEZ-FJ%==Z@IU(M$;94*UQEQ)-F7
MA#[V,3GI#[$1+ZB;M.,@KQ8S9]L-:2S4MUII<E%!BJUQMJ;?D9,RS>L6(33=
M''IR6A:&:!XX@*=H+N0L;0[:NNY*OC\CB\A4AP5BYM%D<6_&5'<F:4]'#TJ-
MEN39:>#SC4R<K\H.$8<YP^WE+BZYF[XUS8+A?YJNIZ1TVAVB^OQYTG&J\VK/
MDHTH];XM1F#8*4N^=BI4",4F-0R3,+*(3P]C*%H1Y].;;<?9;!5'P2W*2;EE
MT4;I6S%A$<#K <X_\$!Q8TEF\"[7B''W*FW'/S>/EMWW':4[.Q<M0CM3BK)5
M=)&;%IE-S(XG_P"]!S&6'L;,(SN%K6G=&F/LDUUNFR=U=.'2WK#6I#<TT2:B
M]1NTM;"[(!JJ[!3Z05;A5L$4/V%W @:)+%,EG":)J<NNYC!L16G9$J-E/0;*
MPUJE#*YBY:%$.B=B:-IT3YC'9M,=RLK(H_\ $<Z.(:!P(!U>TGCQX;JEV[V3
MS6S.RF,QLF:,=EFTF7QL=B"J+%+'RAE:M+8L@PQQ33N?(_>^4[DF-9J7+2NJ
M[ V%IS0'LB?2Y?:6:T98H=7,=0NG**NT"34^JT>[V*)', @EJJ\E(Z=" 37
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M5:'QO8]OR2R/=L#7,T%K+HUNK-%O-BJ<L]UHUK774_.KEW./6J@]/C5GM4*
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MQ(8W7CNMT&O85$5:O Z9\,$,+[$AEG=%%'&Z:4C0R3.8UIDD( &^\N=H -5
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M%I)!D=V7D;Q[)5YE2K'()F5H&3-A;7;*V)C9! TZM@$@:'"%IT+8]=P$#1O
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MG")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+YM>RX__ ' MZ?\
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MK*V9L!Z4-FS1DU420SB<,FS!TS#\*4^PX15];UU0Z;-R0J=0KM:E^:U9I"'
M8J&,2S3Z8\:?J=8CM0VF68P*NO6(XX(&1VVHD%129X!I'AE<(HPSJ+65BK=E
MJ!RCUTG6KB>=M-F#RQS+D4Q9G9T0GBPR_1ASRY')#QY"$6;<;GCYP^!+@R([
M\*,XT16F2Z9]!%JU7*?.U/3'*[47RTJMCF13</ =^P.+=LKL25#5'FI5:77'
M7;7E<E?G.XZZL]Y14XO*B*T:-TBZ6IUO/7Z32ZJ=N!*^8N@0P]6A\'-3CBZY
M7:?2J^%AQU+AHA4*LU<6.JSZF4K"NJ(3 K(ITC+2X17HGIOT.@U:[$G4](P:
MNX^SB[1/\AQ?"E(%W2I-UCY3E/@H>+GE7A;<Y ;BNV:0E$HXY/DMH=217'8-
M/:NM48]#L=#K)F+9ZK7J0?8GBXS[9.IU(@6+5<#(PM&>R!7BITL4"MM^#4,(
MS79T-;,K#;J"*TE],73\Y5%4?.I*4BK*M"KMD4R);83BY.#&PLBV)ELJ;GHL
MDP.WY*GFT2DDR YV5"FR7X\N4V\17-C2FI$""]?:US4(X(]KX;J@L&B@X,07
M,UH'P=P+HBX$9IJ*BK0$V>P)C!FFFX3:"\U&&NZ]G'"*)L/3QI*URK//L&M*
ML1GW$O7;#8R"X'@2!"Q5(.JO5NQ)GQELRX5@# %9!PC@YZ(5;#X2,S+5"0AA
M)%=</6&O!U7KM)@4RNPJA4B 8M6JW%&1F X8K7BS)\(2@P6T)8:GC3L=DU&E
M]W+Z2S:2.7%3.U[)% E-&:F*7S&U7]?U%S9S"&'(5VE!(TLK&)01KX@687W\
MH;D%Q8N0\*@EG,8+10[SXB(0CP'W&<D6.-,](6D--TP+6H-(K-A-L:WAZVMM
MR, (#A:^#7!<"!;)1V(YB3!0J_RX#9>YPXR$QK!/PRZ7P07$BK;(L@U/0.EZ
M+&CQ:EK6J!&XMC@6YIR*,;7+S91(R2%$&'ITC+TV3,#!YD@2&5(D.H$#%X@#
M418K;32"*G(=.NC2LVTD"6K:=.E79ZR2;6N2)9<0=D7$''K5L?GL*_T#KME
MQ619US#:5E(B5HF9>R\]EPBA=RZ""[/KMC@!G*S6+!:TTF%9#!R@U_8(BUUV
MA%"I:O5&WUPVN(LI71TXZ7("\"#5=-@R\O)4(<'R<O\ C!%4:&T!5-$ZRDZV
M&('EXIH];;1:Y#8 8"%&S=U)22!I$>L#TK%B@3++[(02&2J9F*!'P(D^<4F)
ME$99/?PKR#]+'3H %'0@G3="BC+/6\4ZPQ<@HTG!FJ-R$RHE<(.R\/O20HU]
MMI08<XYF,%0Q':$MPF8[*$$4K%Z<M$PJ:<UY'U12<4BSV 7;++6'0<22)L5H
M"YKZAMB.QI*'DES4=RJUUY1,AF1,DOB8C\IY]U*EJ(I:V:0U%>[6$O-QUW5;
M);:XV/:#G2PF/+G1F@Y)PT%:<4XG+<UH$:=>- FI[<EL(9>>*BTQ"#KDE1-!
MVEZ'M+ZJL]9DT\]1*Z2KDNTD;PX-?@IPENYEC,VPD+7#DM9;F0+'(-$IY'RU
M!D1B+4B7(4S);2ZM.2*UIW2_T\$XM3@S]-Z^EPJ.Q*B5>&]6QZXHV).*I/3X
M:X^6O!$(1"P(18B$,FB9%G6%"3TMEXNG$SA%D*^ZXHVT 6*SL"L"K4#1.B%&
M()2/X3$,H/<RY!*#WVU-RAI.&O*\Q2,!^--CI<=0T^A#SJ5D44C36IVA^O1+
M6NJ>R+U,4;-:T',@1S,&C%V8$\8R2K,5IA# J:W")SV428J$.IS*>=POPRO"
M<(J->B]/.;!?VLO7%2SL:2K+SUPR(C>653<ATUU1;#_=[B#CE<0BNN'FVTF7
M*^A -R>H6A$3!$EZ+T].KXZJ3=;U&56Q.NC&I!@20&BNC8.L[ V#;-TB-%6C
M+35>*(K5?Q-'I3AF1D,-4YC*HC.4$5!%Z=](0;4(O$7654:M@)H,V,.8')7,
M9>KH=FO "3WA%+:FG H&.P%%6":U(.#Q++8Z(09B(PS@B]-A]/FDMLDEEME:
MQI]V(/ 5U>5(L(A@AY0KJGI<EH,4:=QEDH/@RR$^>)C$6Y388C.FD1.(4Z4_
M(<(O21H'2LRY3M@S-84V9<2B97E(W+"1)3\]^>!S5"!"6P^AR'(,$*KGS6(&
MW8RB\ZM)37Y4UT0E,/!% 0NEGIX'5TM4X6H:4P -R04LC"2+3EQ;]5=>>J:X
MLY2U$1R:B[)D.5)L=+B-U=<B1D"@?X=WOD5:7Z:= G:S6J:6U#0IE5IZB>:V
M <KL!(P6@ZYEZPQVHS;2$.PK,\I3UI@R?#0[.\K+IY@BYGO<(JD]T[:-L_@O
M+^K*:4RT?*6C"I(>/E3AH[!'"SLE]2,(5)CG1@@2--C9&71A@>,'PB,.3&A1
MFFB+P3TV:$1#<')U+1L#GM<B]1/#_(,/,%[68.6N>#I3L-2,QW0(.:XN4%B.
M-J\DON..#E1LN+[Q%RYTW:(=IP^@.:KIZZ@+L2[?!#*%HRVS:WFI3$NRJE95
MX^^?(19TZ$4,2)3I J/GSAY&1*@S),=TBO@9K>A!:'C5PFH !NND@YM:32X0
MV-'KB:^2:D,3P^!;2$Q<#YC,N2U(C81X-U#[N%XSWU=I%;6=#Z9S%G0ON94S
M$4G0JYJV>PD%"0W*UQ4'ITBLT=U*&D]M8"/$Y[@\/CLA,JE.=C6<9QC!%7!=
M-ZLKMHG74'1:Z+M1$T<L<PW$@(;FNGK/"@#[&72OMRA@@=B#(+1:5'0T[/4S
MEZ2IQYZ0XZ126=9:^S0F]79J '[G;8MH(BF^(->;^!#"TN-CLC^SP*HF%H2I
M3*L*2YGM\)A7>5VD5IV3IWT;<&&XUHU93#K+5CL5N2@B&CO]ZPV['9:R+RLX
MPN1FS)PAL_&?4Y#,-,QFB$>0W&CI:(O.=TXZ()SZB3GZHI$J90Q%; 5-QT%#
MR@.#IKWC-.$MQ\(Q&DCZC,[9]5B36I+-;(K<(A409KCCZB*K?Z?])2K38KK+
MU;29=HMH\J+LA>6!@RGS,$\+CA+ U-:D-.1G%V$+#AA[!(PPF2<%0H0XJ],A
MPXS#1%&UOIIT+4'\2JYJFG"YOC=3GND&1;;I*5.H<PH0I,V>1DJ>G$)=2EFB
M;E=D3I$AT0F5X""MB.S'::(KGB:<U5!' 1$77U30*J]#*ZOKXQ0:&\/%:[.M
M!&3=,B0GVW(R:Z79K8%DF,4VJ//:%0VY2'4-8QPB[Z[U%K34@T@)UI2P%,AE
M9+4PF@+!1'>)2H\9J#$>(2U97+G9@P(\<</3*?=0.'1XX^"F/"CLL((L8:KZ
M3=*ZO#QV6*-4S=IE5>=6;9<)E=A-SK:V?2A=QDSX3BID:.FY24(=L;#:G5&6
M(\"&8DDFAT3+9%(Q.D_IO@A3E>BZ;I#0FS0*Z,L#'DK"Y!B#4#:+'48\\@XX
MLC(Q5#C3!*L..2\NU^1&B>2'(:(<5#)-!VO<='@4Q/Z;M#%35LL1+4](G&KT
M), [=/D@XKKIT78H,498XLU"DY9SBQC(,$=8GFFVI!Z#!@Q"SLQB%%0T17D5
MUAKXV2F&"]/!$"A"32)<Z=*@M.2)<C6IF78J N0YG':[BH'ITTP ;7VM#B4J
M1,80E]YQ:B*(NVKH%SN^J[RX0<@$=8E+<^EA,1$IH\#NE++U4P D+4^PN$VN
M9)!G4S&L2%>&K[<-4?*)JI$8BG &MJ#5GJS(KE1!!7Z92T:ZJ;@^ S&57:(V
MH.M%3#]Q.,006%5X$K(]C"&%9$#N\G/BC/<(KVSC&??_ !9Q_P L\(L7#M.:
M_#':.<# 8@C[G(JXBJ@+&L1HHL2F^31<ZR3666V/&,39SHM.%KQ*2POQR<[(
MCOR76GV"*7F:QUZ0"72MSJ=7Y@#8LXB3O0B2.CO0+61+080PC-.1W$*1/DRQ
MXZ!#<>>PIS#$*(VA2,1V>X110C2^J055%T@30JY#J@:T"[L/"('MKB-W$*>C
M6H9:G_"^$=G6*+98<0^DS/<DD5F8S!)V0Y+:0\DB[QM:0L[6([:+D7C!MNJ-
M4>G0G(Z8\&EUB5-AFK0R/QAYY<LM<CPX3*L!5S$=+PVLU(4Q"8R'ESBY%DSA
M$X1.$3A$X1.$3A$X1.$4!"^^,[^8 O[Q?A%S7/@^1\_6K]IS'"*>X1.$3A$X
M1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3
MA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$4!"^^,[^8 O[Q?A%
MS7/@^1\_6K]IS'"*>X1.$3A$X1.$3A$X1.$3A$X14)0F/"#")DM+9@"Q$"63
M)3I"NY'A#X$=R5,EOKS_ *C,:.TX\ZK_ -5"%9_!PBQAKO?>GML3WQ6O;^!L
MI6.*:/."HSST4HH$\\U&;.1QI!F'.E!E27V(WE:+'>'IDOL1U2<//-H419;[
MZ/\ VD__ -V/_/A%"#K,!+%CX(:4B3"]6D08MA@,N85($2"8]@J/9FH__"<E
MC9,>:PGMSWX[J%^C&>$4L_)C16'I,E]EB/':<???>=0VRRPTG*W7G7%J2AMM
MM"5*6M:L)0G&5*SC&,YX16\2NM1$4Z9L(E8PT6C#ZZ];9EK7/CJ LUE@=DLX
M=\I-N+BN#,#$YG)EM.+:=C=CK2EI4GM(NKUWJ4>F/;$=L Q-'CUERYNVA,IM
MP/BJM"LFUGTS&\J;6,P(QY1Q*1E2%1.QY.<ISC.2*K 6FNVEDA(KQ>$69%&"
M  DY#>PZF&:%.):(C7_>[DJ&XM*'F_\ U<JQZ<]O"*>[R?\ VL?]<<(HR 9&
M$Y!:)!E(?D R"!95O"7$YAD'!H\NB*M2T)2MS(TJ/E]K2EHPW*;QE6%X6E)%
M)]N/QX_ZXX108^S@"IBP5\<6ARS55>&L6(:R[A4H0\7'ME1C<UOLQEI4T<ZU
M,8QZ>^PM*_P\(IOO)_\ :3_UQ_Y\(N>\G_VD_P#7'"+GW_>X1:.;7Z\-*Z'O
MY_7>P%7%9^ ]%GXP' -$8*!Y*#&?BI;DJ)1LY5VX=4XCP7N%*SCM5V\ZO#;%
MYW.U!>Q\=9U<R/B#I; 8_>CW0_\ PPQS@ 7<"1H>WJ=%YCM7U6]D-C<L[#9J
M6^RZVO#9(K4^<1B*?>Y,F03, /R':M(!'2= 03CSVU3I<_%L;U19^V.;?K8[
M4=SI^4/]2N:^,-U.^[Y?\+/M*>VJ=+GXMC>J+/VQQUL=J.YT_*'^I3XPW4[[
MOE_PL^TI[:ITN?BV-ZHL_;''6QVH[G3\H?ZE/C#=3ON^7_"S[2GMJG2Y^+8W
MJBS]L<=;':CN=/RA_J4^,-U.^[Y?\+/M*>VJ=+GXMC>J+/VQQUL=J.YT_*'^
MI3XPW4[[OE_PL^TJA@>RG],S2'\2E[%=RJ9+<9SBILJ[D9Q]:H[?;Y7QV=QK
M*4]WLSW?>[<]G'6QVH[G3\H?ZE/C#=3H]$^7_#"?_4*N]M4Z7/Q;&]46?MCC
MK8[4=SI^4/\ 4I\8;J=]WR_X6?:4]M4Z7/Q;&]46?MCCK8[4=SI^4/\ 4I\8
M;J=]WR_X6?:4]M4Z7/Q;&]46?MCCK8[4=SI^4/\ 4I\8;J=]WR_X6?:4]M4Z
M7/Q;&]46?MCCK8[4=SI^4/\ 4I\8;J=]WR_X6?:4S[*GTN=F?1L;WODBS]L<
M=;+:CN=/RA_J4^,-U.^S/E_PL^TJ/&^RG=,[+#J9B]BNNJG$G4*34V583%=(
MRG8+?;DOCTLP5QV<X[/<^#[O:KL[V76RVI[E3'1_W+_X_P#0\_WI\8;J=GHG
MR_2?_EA.HUX?]P/?M*0]M4Z7/Q;&]46?MCCK8[4=SI^4/]2GQANIWW?+_A9]
MI3VU3I<_%L;U19^V..MCM1W.GY0_U*?&&ZG?=\O^%GVE/;5.ES\6QO5%G[8X
MZV.U'<Z?E#_4I\8;J=]WR_X6?:4]M4Z7/Q;&]46?MCCK8[4=SI^4/]2GQANI
MWW?+_A9]I3VU3I<_%L;U29^V..MCM1W.GY0_U*?&&ZG?=\O^%GVE4(WV4_IF
M9@QVIB]BO24(SAUS%395A:N\K.,X5DNGM]SG&.WLQ_-QULMJ>Y4_*'^H3XPW
M4[.FD^7Z/JLG]+/G^]5WMJG2Y^+8WJBS]L<=;':CN=/RA_J4^,-U.^[Y?\+/
MM*>VJ=+GXMC>J+/VQQUL=J.YT_*'^I3XPW4[[OE_PL^TI[:ITN?BV-ZHL_;'
M'6QVH[G3\H?ZE/C#=3ON^7_"S[2GMJG2Y^+8WJBS]L<=;':CN=/RA_J4^,-U
M.^[Y?\+/M*XS[*ITN=F?1L;';C./34F?MCCK8[4=SI^4/]2GQANIV.F?+_A9
M'_J51C?93^F5D?!9FKV,[,:AQFY;N*FRK#DE#*$OKPKRNGO86[A2NWNI[>WM
M[,>]QUL=J.YT_*'^I3XPW4[[OEQ_^+)_]0JWVU3I<_%L;U19^V..MCM1W.GY
M0_U*?&&ZG?=\O^%GVE/;5.ES\6QO5%G[8XZV.U'<Z?E#_4I\8;J=]WR_X6?:
M4]M4Z7/Q;&]46?MCCK8[4=SI^4/]2GQANIWW?+_A9]I3VU3I<_%L;U19^V..
MMCM1W.GY0_U*?&&ZG?=\O^%GVE4\OV5'IA<BR&V,[%;?6PZEA>:FRGNNJ1G#
M:NWROG..ZO.,]N,9[/Q<=;':CN=/RA_J4^,-U.QTSY?O#X+(U\-E=HWLJ/3"
MB.PA_.QEO(9;2ZOS29]TXE"<+5V^6,=O:K&<]O9CM[?>XZV6U'<Z?E#_ %*?
M&&ZG?8GR_P"%D_\ J O;VU3I<_%L;U19^V..MCM1W.GY0_U*?&&ZG?=\O^%G
MVE/;5.ES\6QO5%G[8XZV.U'<Z?E#_4I\8;J=]WR_X6?:4]M4Z7/Q;&]46?MC
MCK8[4=SI^4/]2GQANIWW?+_A9]I3VU3I<_%L;U19^V..MCM1W.GY0_U*?&&Z
MG?=\O^%GVE49'V4_IE>'SFH:MBM3'(<E$1W-393AJ2ME:6'.]Y7SW>X[E*N]
MV9[.SM[,^]EUL=J.YT_*'^I3XPW4[[,^7_"S[2JI'LJ?2[A"<9QL;.<8QC.<
M5)G[8XZV6U'<J?E#_4I\8;J=GHGR^G_]63_ZA=O;5.ES\6QO5%G[8XZV.U'<
MZ?E#_4I\8;J=]WR_X6?:4]M4Z7/Q;&]46?MCCK8[4=SI^4/]2GQANIWW?+_A
M9]I3VU3I<_%L;U19^V..MCM1W.GY0_U*?&&ZG?=\O^%GVE<9]E4Z7?Q;%Q_/
M46?MG'(/4RVH )Y.EP[=HM[!/2Z)H[';4C_:&ZG?9GS![6F+/M!6[];OPO8>
MKA^Q:NJ8R(L]5Q8@:YK*8TY$29 S*AN2(Z7'DL/XPI*E-X<<PA6.SO9YP]VI
M-C[=FE9W!/5FD@F#'![!)&XM< [0!P!&FHX=I>PXC*5<WBZ&7HEYIY*I!<JN
MD:&/=!8C;)&7-#G;KBUPU;J2#P/%=VMO:I>F78<SLN@.3]9Q_&MC0$7&NKFT
M&+AAV3F3=(J267ZM'Q&8?D9>.MP&\,,//=[P;:U8QEL55M;0UH]1?NH,["I#
MNM?$\D?NA-VL"ND>3TR?$LSO.M,_('Q+$S_LN97E#P&)'^ARYASW/"*"!;XT
MA:8XN76-PZNL<4Y8E5 +* 7^IF(Y>V(A,DEU@6^.+R6B%A2.DQYZ@L1;I),.
M0S)S&PRZVM1%D468%&X[LL.1A%(K,XD,>DCY3$R.V2#D90@P/6]'<<;1.$EH
M,T63B*5A^ 1B2H4IMJ3'>:0127"*(-O.L0FELKRVO)4$SE2??RU(.#H[Z/3V
M^AQEUQM7\E><>CA%+\(H"%]\9W\P!?WB_"+FN?!\CY^M7[3F.$4]PB<(G")P
MB<(G")PB<(G")PBL/:8,C9M8[&K8=E,@O8:';P8J.MUIA#Y$M7R$""RM]]2&
M64NR9#2%.O+0TWA65N*2A.<X(M)3G2';)6JZ@HAL+:%]VD/K&G=;-K-6.D5#
MS%UTO;6F+;N@%4B6KJIKC"?*837+*9!<E.-V.9%K\$<)+)7-?;GD6-K+TY]0
MK+]JKFL(=DI]GCEM\K@;FE;04FKV/4]HUQ?*[I/4P84S92MP F*(;*ZNS@I+
MI8Z#6)% -6\#83)NQ3F#)1I_?\_R\.JDZ/J?;NOM@RMG4W1%XK]2D;8A%5:E
M>V;09]JE5YWIZDZ\=,27I6RR-,:&C[^U%)2!'GG*GKA.KL\$;*//2 ^"E4=
MT#NN&(KE>VEKZQWBS3M<:OKC%]7N1$&J:W#BM%#Z1LFD'AT:Q+.VJ>8OZ;A8
M7$C*@<KEZS:PKUELH=RK#GQQ0/-[]G\]?O*S%.T]M.R=,/3GHX"#B:TD0EZO
M@[758$@[7#JP/6(M%DEC7Q(&W,Q[="NUYJM=KDR 'LC;,BIV$Q((28G@71[A
M2M7+OTQ=1J=<6W4)JH$MP5<#K;>FJ],R*9=0^M10V=?< [#K>[%Z^7V!#=&
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MS&?RA.3'SG?T^BF<JQ[_ &_\^W_Y^_R" ?\ E:/N:/[@J0S3H<?X[OHI[O\
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MH>UOUF!Q/_9TNWPZ:_\ '^/:T @=0WJ9#_P\\_?E<O\ VO ?W[:E/:W.C?\
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MX1$L2([Y*$CMDP67V79332'6U*(O6X[0J-"-U8):)V!6+7%MD^,9F.PX@ 3
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M)PBA;)][QSYI(?JKO"*:X1.$3A$X1.$4)8/@]GYYKG[1"^$4WPB@(7WQG?S
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M\HFL$5ZE>M^^AP@DE+$U!IJM3=B)W%.G5RVCBE+CT<C1_!-676:3TZ_4X7(
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#?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g759370g00a03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g759370g00a03.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[25F4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )4J^E48X0DE-! 0      &D< 5H  QLE1QP!6@ #&R5'' (   (  !P"
M4  (<G(R.30T.#<< @4 0$UI8W)O<V]F="!7;W)D("T@4V-I;&5X("T@4&]S
M="!%9F9E8W1I=F4@06UE;F1M96YT($YO+C$@3W)A;65D(%, .$))300E
M   0><QB;UM-CX&D2<YE<S.\6CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!8&Q#
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  &0   "8          !                          $
M F    &0                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   &0     %)G:'1L;VYG   "8     9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   !D     !29VAT
M;&]N9P   F     #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     ,X0DE-! P     &JL    !    H    &D   '@  #$X   &H\
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M_]'L,S[3]JL
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M)C0V1%-6<I8G0T5&9&:B5%5E=8*3I+32_\0 ' $!  ,! 0$! 0
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MV:[-_A9C,)B9G'>U\[A>(1B%RI,M.$4L3I F%*%DA\I4DATDT8%F$)R=SO\
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M'*JN ;+L XS1Q#M 9*\_"P%O2Q&FH((L-.ITC>?V7_"!/$D2I';3&3<(M/\
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MKBSV$]YILD$2V<-&R@M&$NFX>+E4>N6K<2-T2BHH!3BH(?40 ./G^T>%FXK
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MTZF66T2;%_)1T##OI1^RBVQWC]9DS1,LZ%NU(('6,D@118Q"CL2)G$-ZUQ9
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MVI&ZGR?\13E8Q!<7=%O>1FT-9(U)FL_CE8Z35.B#Y!-RV$5&[19(/&1624(
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MT^TS51G\J-&<Q7)1[ S#52+E3G9RD8Y5:2"!U$F)DE ;JIJ%5,F;PR^'OJ$
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M1REBFN:5JQ891KZ+ZO&&-F@2N,:2:!TX"XD0C4USLVQ$E8EF5L*:J3$H 8Y
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M%4#D8E.0Y3 !BF =E-H2Z'BTSC&.F2^[,]1 !HVC$,:4'(_YQE=A> R9O?#
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M0YQ ./DD\1Q25&8)RLRJ.[#DS%]];MM'[0OL[PF9+$E?#\,927RH,J44AZL
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MN!I5.)G:2JE(0T-.Q#I0MMBB/G:B[1-8J1N/OT3DC R5*']4 *F'=A4/8ZD
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M)*'2C)-13I.4 .&"\24X=,UCFG3 ,H!S)"G)!<N& U:^QCBE^+$S9+L)#L;
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M\I$_<;=4*O'P<]D.0;S-QE&9G/CV*2;MB-$'SXBJZB/CIMDDT0,@FD D* &
M3!QL!E&06!MSKK[#[Q5(2H]X*J*6?_M+%KLQ9]3SAR.$:1 KG!$ L%-$0_\
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MU[C5+)3):U3J4K&N(QM\HEH=I!RPFCTUES.6Z'6004(=,M5+2F5G6QJ ;:J
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MX][L]PQ?$\:B2A64,V87#BA'D#MMK'YK^)/:F5V3X1_J,W"HQ4M*TG(MB')
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MWW_/?",#Y\O)W-N0?W)BWJWH.^@]->O;T_7\O]N$718[?'^T7 )A$"@&^^@
M=CL0'T[!_?U].$4&[6J2=:[_ !R]Z"&]R=AS'&<(5C1,L6\E)J4G-,G#V;/)
M,(LK=9IXJS1/S4@HBV)XZA1+TJ& PCH $1[<>UP''XO!XM2\+([Q=P@!\URS
M $M<%@=QR^$_$'L_P?M#PO\ (\9QB<'A)RTE2U+0A(JX\2E "H #FKB](EQR
MQ8*E< XZ1HW++>(.]XV2D).3;SCR6C)18\O)./&E&_F6"B[4P-W  0I14ZR=
MP,4-ZXCC>,Q.+Q'>XJ3W,RV4 @ES1@0#;32YCI[#<!X7P'ADO!<)QIQ>$E?H
M4E2%()(=7B02"22-?:)0.$N8KY!'E;J0GST)!V+XQCH^"+$"%%J!1$NA,8W5
MU: ->F^_;QH^XLYM]]K?3VWVM;)G?Y+9PL)HCYN=D0:WX)T12*]!<G6582
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M2@S$>DN^@!ZM^PZ#8ZWP^:^OG^]!2*M,HQ5YM5P[<M@?O&OC$^9;YM'#**0
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MUDOC(\L-W85.?>5**Q['MY.S-H]VK"QRI RJ0R#J1(F+=!73U(#)J* )0<)
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M\]HY=_%MJMFM_*D[AZO"2ECDS7ZC.?ED0T7?/#MV\TDHLN""!%%!2;I@)U3
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M(/,(SNF&9*(JM.C:.^KYI+]N%F(SZLQ!SK=RVE:XHV6\JZC9=6-/&R;%4H>
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M)(  !<.*4%2/)CIRTEJ3,S %B$E5:"C4<\G](Z*P[\LK&L9(A1(1^S:O"D,
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M .2,-8DKF6_\WFU@^CQV/X^.C]R@X0@X0@X0@X0@X0@V'U#TW^GU_+A"#8;
M-AL?0/<=>NORX0@X0@X0BTW\)O\ [4?M[?78?YA^?"%[7TCC5G6%Y<7/Q2<
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MGS>"Q\@7)[;489O8L 8_DD:_$-H"(!6*T+.':>,1LS2,@HF<2I X7Z3*"=4
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M./)I)RUE:R5JHI'O&KTG0Z14\<ZJP)JD_ <A%2%$OX0  XNM*9H2E8+2B,M
M&(#O;0&].4602A2E)+$WIOT ?3IJ2T-VRY!.4".BF\0RP+0T8]M+)SR+8(TX
MD2E4&Y&J;THG6.H"GE44D#@)Q3523(10AP*4."I:9A2I9)6B@4":<O?E](G,
MK+E>CO\ *CX=GCSG_A^\G=JL2MNG<!4)_8EI)&6-*&C!07^8(';J).@!NHDF
M"I%&C543 31U$$CG QR (24I4G*10&QT(\_.\9J2%!C47H6=M'\W&G2\*2=Y
M/L+2TF[DF%>)733\W#35V)#%!(UY_9Y0KB%C;$X6\5=2+8.RE=E:-S))JKD*
M94IND.+!PP!9(%N>FF@Y_P @D 4J2&)>I'G[;[W,2@;H)MDB((%!-!(A$DDR
M@!2)D3#H A"@ :*   ![:T =N+$DES4_!$I2$AA\\K>T>_$1:#A"#8?4.WK]
MM>O\N$(.$(/3UX0@X0@X0B!7.&&YVG=Q#4/(CVW_ /MR'KKV[?\ IKB"]6+'
MG\]^HTI55BU_YB!<_D**KUKJ%/?)K [N1WZ3)V7PP:-G;)L+Y-BY4,('3._0
M;+D:](&$3#TB F'7'=A<#,Q4HS98\F=PV_M5O)H^<XAV@D\/QF&PLT) G?K4
MH@97?]3D,2*N6?78H3(G,!7Z#-*P8M/G;M&MS-D<_+))H/DR0JK%%TP?)E,J
MJU<F2D4ETR+@10^@T @.^.K \(F8I)4K,$I-R*/I4AG^7CR^+]M,'PS$X7#N
MA:L0'("TE5KT(8[>EV!<N(N]8DX:)FPL$0W9RW@)-E%Y6/Z1?K)D,,8!Q<>&
MH_2\8$E&93"N4X@04P-H!Y)F!Q")AEA"U,Y<)+,!JP-.C^T>K@^T7#,1AQ-7
MB$()<95+2";5 <"[5J'Z1X.K]7"2S"':2D1).'SQQ'N"LYN)%2-6:HK.%R.6
MOFQ<@9(Z)RJHI$,JD0HB<"E#BHP<\W0H?^E57\A&DWCG#D3<HQ"5;@3 3U9R
M2-3:K7K&2:]4<B:*A[A54T7"BR3=4]@B2IK*MP_XA-)0SP"**(@&UDR")D_^
ML"ZV!6"Q0KW*G_\ *;>0&]--*/%QQWA!+'%2@38&8A_3,/>N\*@ATU"IG(8I
MR'*4Q!3$I@.4X%,0Q3%$0.!RF*)1*(@.P$.P\<Q24EB""SL00>=#5AO'K2YB
M)LH*0M"DG]*@H$$.&J/2CQ<'\0=]^H '?M] '8=O]/R]8B0-2"W2^WD;4U9]
M(IV 2[["4>_O_8A^O;A$$%JAO+W//KOI2*F]0 !$?30!OZ=A#].$!1B*U?71
MSLS,SZQ7N E'?J'5W'ML=[^G?OZ>O?A&F=//T@$/Q@/KO0E^X[]-_?\ /Z?J
MBX(-B_2L-7F/ <#S&5QIC.RW-"B1\O,1[Q>>="T(5L9B=1RFB)GJB:!3+F#P
M_P 1Q,(!V[]P]W@'$)W#\49DE"IBS4! ))UJ![>W+\W_ !)[+8#M1PD8#B.+
M3@I,U:<\Q:DH0"%!0S%12'?1W+VB9G)_@.[\K6)D\9XDL%6R=6&\U+RY+([>
M-R*G>RS@%W374<95L!&BH 0NE.OOHWT"O'N(S^(8GO9TDH6:LH%)%=BUA7SI
M&_X>]G,)V8X..&X'%HQF&E*)ES990H*S'Q.I*B"0>=*#2LN%I7/GR5F=&!JP
MS1GKDKU(SE3P",P(46QB=M"<QNKJ$!]@X\2/T!^1H-OI&Q@Y/-"L9/J3D-7D
MI)%FF> 3:K&,BN\\4@*$<B8 $I 2$X@(!Z@'ZHC,^AI>G\^?\D1K8*6SXK+,
M"3D!5D8DZY2OE6[I45TT1*8#&3#H[B!P*&@[Z'>_?A$9KT52]+1@J2W,8#DP
M)UZI&:^9$I3"Z/XOE_$$ .(: .KP]#^?J \(N.7[1O;9(YM0DT4ZG#UUS'&8
MLS*J/UQ*MYT4BB]*3I+KPR*CHG5H1+L0].Z$83B5SU\CC#MH.L#.'<2 2B1W
M*@-TVP>$,<= >C^,X"H"P"/80[:UP:Q>[T_?[14*<_I4-*AJ4YV#QL(62S2>
M&L2DU"UQ*90;)&KZ39=06SER*P L1T80Z@(1+J,42AH3: .W")-.=^OS_%28
MUT%+9Z4F(]*>@:LE$&6#Y@LW<*BNDW\,0$R.BB G,IK0=_H.@X?/C1!5=@KE
M2G[U^-&O-+<Q@*%#]GJB*0J:$P.SB<$Q/_$8HE !.!=: H@ CZ^G")WY,/5C
MI79](4-MD<UMY?PJC"UMU#^39F\9^NH1P#L42"[(4I1T*95NHI!-ZE /3OQ6
MN96U&_BG7;ILT?5GI](P7<IG<82(4:PE7"95<2X322JZ@-F[0IX_Y0=N80'J
M%0AY#S.P$2@DF;7<-V-CTTK](A*@34*9ZT9@+U\C'-?*^"[-9.>3$N=)J%9A
MD^IUIG&U]-I9(E"MG:))6T"B_B'"A)AVL V*32\5H@9,3^6$# 5!;I^4Q_#I
M$[CV%QRIP$^2E 1+*@%$)5F<)<*(<ER0P!Z$?N/9OMCQ;!?AEQCLWA\'.F</
MQ<W$?F<2F5,5+E=Y**%$S4I*$E*$YF)=]#>.DL!*Y[5EF!)Z"JR,09R!7RS5
MRH9<C8>L#'3 0WUB;H$.P]O4-[W]4+![L/IRIZ1^&DJ"EL1E"Z4ID>K%G/G4
M$%^>M1F.8WQD2K5VH@D*B8*B1TH(E2V J:_"'XP*( 4 ["8="(:WQ,6)'UMR
MTZQOK7*9N1FU4JG"5MS"E;M!27?+J%<BY.W*9X0X>@%3<[(D(!W+W,'X=\/I
MZGYY1&9J,3Y#D*;U-6>M(PW<KGD(>).R@ZR:955E/FJ*C@X-T42':C&"D;H#
M9U$Q=>*&PT8" /<.$,SZ%C0./5^77GM&RB)'-1Z]/*R\-74K D1N,"W07.9L
MNH8P N5R;L!2$+W =;$?3MPB3\_CF?MI&#7I7.ZTLU)8(*LMX<QC>:5;.3F<
M%+T")!3+T?Q&-H-#H [;]^'SY\](KF N".HM\K&J;3',6+AN5U7JF" KE!P9
M-T<3E0V7J,0.C0J"4W;0@&P'T#U1+W !?1Q3_&O2-[:9'.",RLG5H:M.88J3
M845GRYR.3*F2 7)1* " $*KOI'W  ].$6C&>2N> C(@64#6/FB@/?FR:KDX(
M)=*B?DO -K0B=/QA.'<-E+O6^$15SMI]_G6+D9//(P3U5>#JY9PCQ K-$KHX
MMS,]#XYS#T;ZP[=._I[<17>!-'KT KZ7C-J<CFM=XY"UPU<:L CW)VIV;HQE
MC/\ PS"U(H'1H$A4Z0./T$>_$Q!-"0X+&_+Y3>(2\Y&.\F9FP\M3<F04,6N*
M66N2JAX*>90\DFYCI(KAJ)'4H9)MX7BE#QTS&%14@]*91-QXO&<.G%2>ZF%*
M4%@2LA(<D$,32XJ'%N9$?>_AYQ?%<'XVC&8.3,G8E,F8$2D(6LDD *"DH!)#
M.: L+7B2U6'.\-6X**A(2K&BHV#B6,4+IZ8[D[5JP021,LHF3PSJB0FS=.TS
MB.RB(" \>IAI8ER9<L$-+EH"31BPHQ<N&VUUK'R7&)Z\3Q3&SYJ<DR=C,1,6
MD!PE:IRB4DEBDU-&TJ :0X=EDLUHA%?LU#5YR)XU$\KYQ<Q?"DA#2R:&B]T0
M'0@;Z>FQXUK[=:^UO>. &^K'YZ6W]8UY97/7R RQH*L?/_F?05OY@X-!C11+
MI3KZ1,"OC=0" ^VO7B1\Y_2O+7VB"IFH2-Q7X.;[QL:U(9J62F!LD/7&RB<8
MH>&*T<&,"TG_ /@DW ]'X4==A'V'7;OOA$O:AKOIUC21TMS"'D&!9& JA(X[
MI#SRB+HXK),Q4("QR@)-"J"?6)0+O8ZU]00);<]+Q1_*\PQ9%V2/@:HHP*NJ
M#119R<%#MRG'PS'T7?4=/IV'L;8#Z<(J5%BP4_3^8W=HD<UHK1Y:O#UYRB>+
M:FD3O%S$%*4, @Z(C^'NB0VA+O>R@.N^N$"3E)#N*6!)8L:6K7ITC7FD\]C
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M UV=MA]85 JI@<J0J$!4Q1,5,3E YBEULQ2;ZA*&PV( (!L-CQ,6B_A"*"(
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M@LHMBYD72O2Z,813;-47"JH% !,.DC@ !^(-!Q]CV+GHD\2"YJT(1D)=:DI
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M_/*\+JB<PV)[Q2*Q>T;E7:]%VJ.9R#%C9[#7XB49B\0(N1A(-5)95-&13*<
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M*_0D)J38:[<O=XZ#N4S+-UTB]'4HDH0HJ%,8G48ABAUE*8AC$V/XBE,41#8
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M)?92&E2'2>.UDV3$R3Q)L1PR<<LJ09<F9)2NDU6<G3,:&HV]WY4LI064DZ)
MYBI- 2]:[=(;*I_"RL\+G'!V:9C-4=)_X3%2;K4B,@[S7JH@VC;];;C _L:Q
MCLCD!HZ32MSB*G#W@;VA,(L6.VS4C<$N.O#J$A?B\3RRFMGRD-6[OR)J'L(Q
MFYIDE4L$AU4((<.07#6H *.Q#DQHN8K)&.X+XK'+W5)3$\9-79WC]J_C\EGE
M'J<M L@0R<J:.;0R6VKSQ/(.R)*#LQ?F;@#%**9!#\[XOQ+!X;M+($[#)F*2
ME#3!50((V)#/4"[ASK']4=ANSW&,=^!W:7B4GBN)P_#Y?$,1(5@LTL2)DQ6&
M4"5N<S$.DU8)4X30/,R,^(GRV2<.E--)FW&;+DKBZ2)Z5.(NA0L[RP,F*AFZ
MC</#2;N*E8$914Y@*Q69'(H)#JI$'[N7/2O#R\19$T)4@%J9BR1?IS?7;^6%
M$)Q,["N#,D*.<BH\-"VMA?G9C31NOB2<L<HSRPUIE^+-V[&<@A67$&UKTA-O
MI*UR4D^A(>.B(6-<(R,__P!O,'4>[;LG#51,&3L_F4"E\8LSYN225I!4#0$
MD6<^(4!ZF+)RF;E*DOD)9P&#/N[ULT2!Y5,M6'.6!L=93M3&+C)ZVQ#A[)LH
M5C(QL4FY0E9"/$[-A,/I.49)+"S!4K-[(.G3<RADEEU!(&NI26$M5'7+!Z/<
M;4/QW?&3,,PS 11,Q0%[ T\R:^1B17%8V-C1^6\-1F7,%2P;19;(=W&63K,(
M0JDFYAHM>6<LT!'\;M5JW.0Y6K<H"=97J#H* C[=\)LT)*4W*CE85+EZ7NU0
M+TBX22"19(<]!?TCEA<?BKOX3F,BJ76L<N[-@A57%4:_N+6K6X]F>.LO,?G%
M=GX*00<FKXPK.*$5WT<ZC?.+F*KX+Y R1D.$N:E*5+61E!(<D $V()MF?3>P
MC.=X1+R>)2B' \12[.[.4C>A>V\2EI'Q+N5+)-BB*M1K?-6J:F[,\J44WA*S
M(R .IIDS>/U$@4;E5(B@=FP>+MUUA(58C9<1!/PCE#:2>_S&6#E37,06(TJ
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M6Y,VS\M8Y42,LTS,P+FH^:APU?W/0Q4 $A@'0B/H CK8AW#7W#6P[#K6Q 0
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MO&ZYC*_B!W\7'ENDK#=K+'9+1Q^R1@Z>TK[9U 2K,"90Z'#V;-()KMSD(:5
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M<R9I9/!,\1430(.<S/-0LLH969!%2<P#M<M6VP:Q;I6.[0"@@J*%%@Q8D,Q
MJY=FJ=+WTE*Y]>=6HQ4528?EM?RM%IW+Y17<;8;-0<H.;O*SI:=6P>6)^D5\
MU5FT(B1<R:-AJ1(N-LZAHE<8QTZ<.0*ATXM3RYTP#Q)[D)":D@I9; .%,Y>Y
M!V+$\F%3,"4(4]2MRK1G(.AK05W  <B.C/PY9NP3.#K,XL:4B22',&2G!5'5
M&M^/&3MH_G =L7D)5;L"\W$PKM)07+1NJ]D$2>*<2O!V=,@(",-+.:N4DC5+
M,6:A&@#L?:)E+6J=."DJ "J%25 *! 8@D %FJQ(J'+WYZ9@RQGK'O.MG'(U;
MKSZS+UVPTFB4BP2F'\]3%?I=0E,>/9&8:^3J%LB(.]1\W:BMH5=TTCW#>"FW
MK:9=N$?(BD/G2I\WO >[6>\40H!)+ 6<5:C$58-1Z1M-0 "4J&9(HQ%*.03H
M]@/74'H;R4\P7,%GN4RD?,=,@Z"PISZNQT/7"4*]UV;65FJE SSM9Q8;+*.(
M2:;1DF]DXA92!9J$5<M_Q*,Q:*)./96A"9:% NI5V4/#1V4+U%F ZZ1E(6M6
M;.0X+ &AIK9VY^<(/FZYK^8/ >8*I6*51H^ST"RM*TX^8HXFR;<G[9VYN<1"
MV-L[FZ9,GC(XC6OR#N7:J/(50Z(LCG.D](4Y X9"U+FXA*G9 \!(8$@$AE4!
M>PW?>D=$U.5,G*7*E.L"I <U-#R-1S<WB.U]Y^^=: <U"(IF!86U.)/(DE7K
M#:EL793B*<VBVZJ2L9'1RSF;-*^(\9*F24MCEF:/*Y1$OR9#?&V'>:4)4"EL
MUW + L:V)L!7J\57X4+4ELWA8/4UJ6%3J[\[M'5[,60YJ@88MN1(V.>KSL%6
MEI9DPCZC+W9SY[RY5$T"5:$DHR6F2$6,!5&K*2;KJ%*8Q%R=M98Q1DC,A*EL
MI*0$>,NH@/X1H:NS 7B^''>EELDD$^+P@,' KKRJ33E'ST99S/S7\Q=FQI<)
M"-G:3/TW#EYMT?!QF#,]Q\;'Y$AKM$(1$LS6C;7'G:2TG72KNFL2]EI=0([S
M\>9N]\P14(0DRI,Z=,.::2C( '*4J4D*87YGD"-!&:DYW0HV8@W=B]*?1F)N
M(?V/^(7S[EMLK4W.#ZS%Q$99:C5HR=EL/9ED9*5923V/9N[*=G%V!1%1F\:.
M%I(7"[AG\G,D=N^3=#XCA/ID$3&SY4@@DJ42FK/K2].<<ZE34>$ F_\ ;X=Z
M4--*FI.EX[VPQ9$T6P/,+-'$F9JW\\X:-%H]JLYZ"F65;,7#I^NT2.ILR;=5
M\Z.F40*==0P=7"8 "H T!H7VK>-Y944NJYY,;_3SW;2.*V6.8W*. <N<Q[K$
MU&MMFFIO(%'181$AA7*%KJ<JT)$A^T18Z9B']>9Q1A0\0P2S5:5:*/2$0,S,
MH8-^>N;-*NZ2E651RE66C6)!VW;^3Z4],E.'E30H*F)0Y0"E2R= R25'R%?:
M&<CN;/G0P16<IM,6X&/D1HQG9*QM8.3Q7E"/=40;)-IJ(JNY%:;9,KM$*-'"
MCI..K0M7D44!*X46-M$.N<KNI,E" ZD%*' ! "G!-!0 U<@#=KQY,M4R9,*U
M A*TJ+*!=TE@*LQ(85&](P;;SD<U6/[1*90HN '4UEB_4C%+:\0YJ#E5]CRO
MG64?C(2K8R242[=N"E(@V613G%G4258#.D7/0 #R8'O4SL4F<7SJ"TJ(\) 8
M,"^H%A75GBL]:S-E=U1(20L:@NUG'_[@[-K=^\*\P>;,U<Y>-'N4L<R>.20U
M;O5=)"1N-<E(,4RJ-(-VPD9?(4H1:JRC";5!ZYAVA$H]S'^$HW<.%UA,!O6E
MHEY5E2DDM0.QZCRU(#<R8W6L]PE.4YC,02P>S@W-!8'?4B'M^*&O>W>.<45*
MIEEW\5<,J1L7<:[#T^]V->PP*<:_6^6.9.B2\,^J;11X+<@S;IP5LU>':N0,
MF9KU!YA*_P \E+'NDRU*! .4J!2VM:&Q+T]2Z2 0745)2P#G*4DO2P>CM=G>
ML1MQUSM<X)4<:TQEBF$81$OD&DX_<SLOA//(FJ$7*P\I\RC98DO9#R4D\J+U
MA&MG-T=.R0DN5[I8&I]O>.[#_P!:=-$SP@)4H9CE<BS.WZM!?2P:,IA5*EI[
ML.<R0:.P-R::-6GO'5/F.N^4,9<O^0[[C.)C;1DFI5D9F*AG-:F9YG,K1ZJ*
MLDR;UZ"FHR<<JNF0/0CD&DNLX1=';G%*0\,S5QRXF:J69:4 JS3$I40Y8'4L
MX&@+AF9ZUCHD)S!7>*8Y"0_AJ&9-:U<W)/)J1S!:_$*YLG<&UG8[#<?.+E?7
M:+0I[+".:XNPSKF+^;+UIR@>;DV3&#B%VS%D1Q).EWPOW+L?"9,$_ ,IK.\
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MH47;TAVJ1VZ"JCH!7+T'\#PME,H4P<F)G(DI"IC! (S%19(S*"0232A( W)
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M8,VB+U<&;!)K%65R73-NU*JZ;(NS(E,94@\^ E_D0I5%DT(>Q8UL;7]+1IB
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M6[(2M!_<"U52!!W*%,)O,(<?FO'YG>=I,-A>YE%<Y"):%U,P%0R!0J"+BMG
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ME<K4+:).U.Y)A:W5H9F<QY'*1JO'?LVOXP$;G;>;F&P]8'(] W[OC!<^4@*
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M81]G>PUTG((#OZ'((!_U%'0A]UV##\3ET)&10( =_":>AC^>_P#B)"CV/G$
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M@YB&D8A\H!1#JFRD34Y5M6UJ\J@^W6/"E3#)EF6% 2PK,YH'L[T\]^<:-O\
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MAJW._4=6BWN(AV#8>V_;V[".P#U[>GTX1*ZD-7^;>L5 -!U&$.D '0#_ #V
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MCF4D$@@@U-0S%@1;7E$;_B98Y86'E83J$?.4J@1S"XT4&#BR2*-:K3)K'RJ
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M%:637/4H6+CV#I.P-WH$)(Q;Z27AU'A4BHIF2,H!^<)FB1B 0\PS'1=R'54
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M1>)BZZ1$ +[  []/01'T#[_S^G"+18(#W$3:T4 #_P 7_P!KZ[]>_MVWKA&
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ME^4?SV2 55#)402#2U];D[/RO&O2YD\2**(I$L#PQUCE2* PDN  8^]=0^2
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MZ,U;ZGSC!'/V,0A2SXS;D(P\BI%>8+#RACB^2;H.#I AY3Q@ $5TC H9/PQ
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MX1 54#>U7^'VYQDUS.6.+9*IPL',.74@JDLNFFI$R;<@I()^*J;Q5VR:>RD
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M_>,9CS$8JD7[.-:3CQ1X^=-V;5(867("CARJ1%(@J'9%(0/$4* F,8I0WL1
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M5)DR)DW."B4  ,I 8U?GKJX%XG:?%^/SM$F!ZG#G9H*JKI-A;!X1%5@ %#@
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M$!]0'>A#UV(=O7T^WY\(A5C1_GRD5'J 1[B.AWW^W;\]"/\ /].R 'A /-X
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MEY7(YY I0+*.?OK7(0C*S03-FS?'@Y.>4:*IE^ZP^($U*04E*J9CHD.Q)+T
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M5R(*CY!_?YH[$\XW-Y9>62K4"P5^A0UM/=YEA$*'L-G>UN'C3/$TE2MS/XZ
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M%-U<=>#G]W*PP+]U,EI8EAD<.*AF=ZDBIT$? ]I$39?&.+]ZH+Q0XAB^^(#
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MLX3246*4 ?*/&[X7783?PDZ=2AYB9@)"DD'3G^]7^S0 "):D,Z2EC6I?[/\
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M%9,5'D XD/(M3N'#(K=Z\>=+!8S=(R?2DH2BI"#-3._N2YH+EB*T\Z:\XNI
MF(,M;D$,33=QSVN(V=B^')B&QUFO5!SD+-+*O4^6GY>K1L?8J?N%-88=] O6
M+9Z_H,A(NX]",D7[=@A).WJS;S)C N82I&)=:!,*%*N@@AV&KZ#]_>$J6F3+
M5+0&2L,6VV'IM$S<=4=ACBF5BC1#R4D(JJQ#.%8/)E9JO*+-&+<C=$[]9DTC
MVJSD2I@*BB3% HF$1!,H#WU4HK42= D/6K#J>6L1*E"4@)2[ D@.USY=:CRA
M<\5C6/!TB+ANLB"AT14()062Z/%2$?15+Q$U4P53'\:0G3.4#E*(E$ X@C,"
M"]0U+PB/\=RV4IK'7)I+3%NM4AD)]#.;M9+#*L3SUC95]5$8R#>*1,5$Q:,(
M1JB,<LS8Q;05X]15NLHH=518:&6DHEH-4RW*=QF2I);9\QB"Y>K5?30O[_M2
M[Z_#W*EB;"&1\G90HC"89V/*QX\;$B]E?-Q#-&/<2+Y)K!, ;HBR;F?RL@Y4
M\RL\<;7\%)PFS31;$N@Y9018.370^E/;9JQF)8[U4QJY0!]V^^OK$CW2(.&R
MZ!C&(59,R9CD-TG*4X=)A*8/0VA'0^F_7MQ5:<R2':U>3A_:->E]/E/J(B#:
M^2+!]O:XZC'R-I8L<;PP5MJVBITC5.U5P9J-M"T#=U%V+IS-L']DBF$X],BJ
MQ=+/6QB&= V=.6Z]4RD)*BD90L,IM>;_ $K]!$$9@ZP#5@]=6YZZ:6.L*/&G
M*7BS%4S<9ZIJV9%W;&,[#M$I&92D&M'@+-.R5JDZ_1D3LBC#PRMFF)"71:O%
M)0R"JQ6J2I8UNV9)0F6$2UH=@LBQ:K@VW)% -Z5BI3F4E3T2"&!W'[,7OZQ%
M=+X5.((-DS5KF4\X?-J^>"?UE.:L]+<12$I4GLY*U<DB5KCA"17CF<S89-TY
M!%V1VL1T<@+B)$A+CW*9:^\!=8=A4AU#*:,;[.-.L2I"9B<JOTD@G7])!K>Q
M#GI>-1@/D)G,<85O&/7M]J%GN?D;"VK'D$8G]F:O;[!4Y:J.[)+JQ-/@;"ZE
MW,7*K%/\X)(R#9)=P8)&06=J+)].+3W\F2A!*5H4"2]&"G+,-0X!)!>M*&)D
ME4N:LDGNRE@+N<I +=6<6LQ:-Y5?A>8N=8DJM*RK;+[8[8T4KTA=;#!V=LW9
M6J3JU=_9B 9+1[NM$CEJ] 1@%^2-%X=)ZU=AYQ5VLZ$5>(Q,M&([O,D ( %
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M6/2332 3!WAD]VDLV4)42;&]3HQO:WKY">]S39H)/A)#W4P!8#F W4](^D)
MYE44U!*)1.4IM&#1@ 0W^(!T)1$.PE$-E'8#]H5>C,_,TY?O;6/2024@EPX%
M#\'N!TU/MPBT'"$'"$'"$'"$6G_A'^_<.$0;'H8YD?%:I%MO_*\X@:97I&S3
M!;Y2'HQ<6W%=V9LTF$UG#@J?;J203#K5$0'I -Z'CYKM-)F3L")<L%2E*R@
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MO8B/OZ<8ZWZ?Q'<'H2&+5'^">>\7<(F#A"#A"#A"#A"#A"+3@/2.@ 1#N&P
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M!0- ?EXF*>8;B( "Z0B/H *$$1]M  #L1V(: .X^W$P<"YBHKH (@*R0"'J
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MW"!(%SRB@N$ ["LD ]AT*A '0@ @.A'W 0$.$'&X]8J*Z(%*<5D@*;^$PJ$
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M0AE!1420_O37U]>D;""P]"0+:=:H35E=)S\4,2X%Y+.%C-D1$!\9F83;07V
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MPA%-@'J(!K_7T_O\OKP@^GSY_.Q@V'U] W]]?77"$ " ^@@/OV$![?7A"*[
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M$H_U >.HAO;WK'4DY@#\<%C[B+^(B8.$(@/SB!N>IQ=ZZH>0 ?N'G2!K]1$
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MRAU:XY^V\J2>*9LH(2#84>VU:6VZ"GI?@(HGL5AB5*5XI@>8Y41FL2=JL[T
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MHYI_%,QM>LH\L+BMX]K<E:YXU[I+XL1%E3,[.S93*:[IP4JJJ)0(W2VHH;K
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M8R073DG"R"[R6=SCI0/&D%"'\:5D7[L05*<H*NE@ OAG,0<TRTH2E*1X4I*
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M(@(?I_L(CPAG5?1]AZ1<4?Q!ON !K8]@UW /37Y=Q'_9&K@T>]*'Z?+\XMT
M 4-" ZV(^O;T#>N$9Y32G7E[UW]JFUQ1T02F$ $1$0[=QT/V#6NP!^?Y#PBS
M%(+!W%W;>PY=>D&P$ ]^VM;]!#T']0_GZ=^$9L:.^M]AL_TIRO%4]!KJULPE
M[: 1#8A^G?MH!'7^@V+QHBU;.#Y%K:?*PPG,?S 77EIHW^*%&;QKBP0T]%M6
MJ,RB+AH*<@J9NX Z0" @H"8[*)1  #?Y<?0]FN&2>)XON9F<.*!)8LU3?E2N
MS5C\M_%;M;C.Q_ E<4PB9:U2EIRH6D$#Q@.0:,QTO$RN0S*V7><?"+?+]MNJ
M]1EW<_.P1HJJHD1B@;P[ORC=P*:@&/XRQ/\ G=RZ$ [>_%>T?#97#,6J3*4L
M#3.Q+/U',/6OOT?ACVGQW:[L_+XIB^Y"IRB"F6DIRE! .P).NWI$ZEL76Y2&
M9QI,FV--TW>.7"DAI/Q7":Y"E(@H&NQ$1 3%'ZCQX$?I9V9Q0 >KW8:4\MQ&
MPA<;V>,C)YB\R+.R;B7:D0:/%^@%8Q1-4B@N&P '_,,4O0;>PZ3#VWH>$2PI
M0-4-[_;:-=#XKM\;*L7[G*-BD6S58JJK%P"0)N2E(8GAJ"!?X>X#V#VWZ\(G
MY^_K&"?$5S,X.N3+5F!(ZYE00 $A(4AE?$!(HZWTE*(IE_\ #Z]^$0PMR:W0
M:-RV]HWUIQM:)Z11>1V19^#23:-4#-&8)"D=5!$J1W ]0#^\7,45%/;8CKVX
MBI9B16O-C:]C^T0>@/\ @[OK]2]B3AN,76U:%CHU/)UB0=LG#]9>3*"0KO2.
MC(BDDJ EUTM@2/T:_P#KG;WXF)85&C"E?KO[VY1G0^.+/&P\_'.\ASDDYET$
M$V;];H!:+416!4ZS8 #76L4!3.'IH1[<(@IH6V;Z,_1HUT%BNWQ4NPD7>4;'
M)-VJQ5%V+@$P2=$ @E%-3L.@$1]O;UV/?A #PM:A'2_,_6L:T,/W0%@4-ENS
M&3*KX@I=*?28IC@/28=?PZ#H,/KX8#[\(LS?/G\0HK5CBSS\KY^/R).P;86;
M1 6+,">"91LCX:C@=AV.X,/B'UKOU?7L-'.D0WK\ZGZQ@N\8VQ:%B8U+)UA:
MO(Y>67<2:8$!U(D?"S,@BX]M,O+*@ET^RQQ#L B!ZL+W&^GW\[UV,G^[]-CH
MPM0Z'8^D<<\X6B6K/Q/\%X;7:U^P2ULH\<_2RG+Q:2F0*T11'(J@MH!\ @F@
MS(>*43'K3$2DDW0".PUQ\!Q#&*3VHPV&R2R9B9:,[#-+=0 ()(-*DM<VJ#']
M5]C> 2<;^"''N/G$8F6.'XOB*?R2<01)F/A5!"YDL#*L%0# BH)!O'8F!Q=;
M(N782;O)UAE&K5P"RT>Y!+P7*?[PHI*" !HOX]F'V .WL ?>(\*$I<J:A(W.
MM:M9[\H_E2:"N;,4/!F7F"=@"[$.QW?H\8"6(;HDJD<V6K.H4ATSF2$$Q*H4
MFNHANV_Q]BC_ . /8>+P(&SO0]+_ %_>-U:<:VB>F59&/R+/0;55NV3!@S G
M@$4;MR(**[$-@=<X&5/VUU".N(*F+L1704&KCE]-=' 4:_WZ[TO&*\Q7;7<3
M%,$\H6-NY8FD3.9 GA^/(%>G:&1(X#6M-004 FM"(*CWX @U$& T%W'7YM&Q
MBL<6>/@9V*<9$G7SR5*B#246*F#J,%)3K,9N =NI0-E-] 'MW[<3 CSY;_YH
M[T+ '>/"LXRM,),(2;_),_--DDG:9X]V"?@*BNV502,?0;VW4.59/[ET/")^
M;?/AC0$P[=B"F(Y>M)@*8NRE!(2B4-!H1$-Z$.PC_P!W[APB&Y"_W?;?36,R
M1Q/<GKU=PWRO9&B2GAB1LF"7ADZ$B)F$HZ_ZS$$X_03" <(@ ;!V:FP+-O2C
MQZ/,57!TG'I)Y6LB!V3,K=8Y 2ZG2H*J'%P?M_&(& @@(:T0!].&G+VYQ- =
M 31N0=OGE%4,3VY*.?,SY3LBCATL@HD\'P_$;E1,)CE(&M?OM@!_;Z>W#5W^
M;[P:VPM_GI_F,VO8SMD,_.\?9)GIAN+1VAY)R"8)>*X1,FFN(@&^IN804)K7
MX@].$010M=F<N:&.<WQ&&MBPYR^#<)2;2R:V1OM,;FJ]U:$>U]87<L1$CEPD
M42F%=F8WBMQ 0 B@ (@/'S7:69W6%0O+FRK!RLX/B 8O\\VC];_"# X?BG:#
M_3IIG2IB\--;$2E95IRIS94L0JO(EAKI$TZ#CBW3U+K,RCDJ>B&\S5X)ZWBX
M\B)&,:#F.;+ T:DZ1$K9OU>"B41']T4O?CVL"3^6DK)_7*20FK)S"@N0&VUI
MJS?GO:66D<>XE*23DD8W$RDAQF)1/6.\4;DEJF[F'-L>-K/,_+!8Y%G8CR,<
MFS<"U*F(OEB!HSM78:\4X]]>F_MV#KCQ0DW));GUWY?>,,,76T((8H<G6'S@
MR'G D])>8! 403\H/80\,# *@"'_ %"/MPBS ^>XZ;] XY"VN97<;6>&"7![
MD2<EQD8T[)L9R! %BN;6GJ6@UXQ==O;N(?3A BC,_+^???SC3QN)[DTD&3QQ
ME6R/$6SI%=5JJ5(".4TU"F,BKH.Q5"E$HZ]C<(C*&:S.W+5_6+7^)+DZ?NG2
M.5[,U0<.5%TVJ8)>&@F8PF*B4=;Z"@/2'VW^8( :D 'ESO3>U:QO++CBS3:\
M<JPR'.0I6<:W9+IM ()7BZ)3%.[5V'_,6$0$_?UW]M(EGH0&TY!OKZ4C7ABV
MV_(0BO\ $ZQ><"44?_-/W8.104;I(@S-L!#PR'(=8->AU# ';A!@UN;4O]'C
M.K^-[3$(S";[(L[,&D8M5BU.Z!,!CW!Q 2O4=%_YI #I#VT(\!0@[1527!
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M)$BG45,5(HB7?0D4Y2I_8@=6^$0I+AM=#UOO]XS)G%ENDWOF6V3K!')>59H
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MQO9D*J_@3Y$GE9%W*)OTIP03\XV;E;)(&8$T&O ,<@J[]>HP_?A$W%??VO\
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M@C5',:FL==ZFA*K)E00.+=5<Y0(-UJR&6#_<M*:5_46J/.U^6HY@L*0I:?\
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MI6=*T,A82N/YMS"%"UUBN0KRQGBTK,DV0MD>\@3K1CUB1NP29R+Q S(7"AG
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MGT_7^72W89J>6K%)3UCQ.PQDQD[_ "4U8J7!G:L%HYS+1E09R,>$=YA%4_\
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MENE))C*&6K6,(=!%1U*)1#( >KRKD[DA&[0_3X)$5U5R'$"E#('^K,2LY>Y
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MP>X#Q/L]V6DX#BB%2\3+6LJ2H)=E*<?H)31GN14L(Z;!&LBE.F#1OX9S 8Q
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M0:-@*43"0H-T0* "&A$  FBF[@ F#1AT/<0WQ =U$WHQZ#0["E6TMI$,D!@
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MK3VB68T\3-T<N_44Z5KSIZ!TCL1'Z!Z>^OOH0_E[]N$&W>GL*O0W;ES=H-[
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M]Y).7LH/S#K?-W0HF;(J=#X#Z;%*L0.H_J(>NPXJM65"U$D )427T K )=0
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M#"+$B#@ ZA.43*=RF >(-BUP"W/:C&(()#9&<$;Y7 J69_4&AKMS+RKG'*E
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MN$2"20Z6%:O9MFT/6HT9X3B^%\NJ/U7*>6WY&QW)U0;BI) 'ABL)RIZ3>D*
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M+G6W-V^VK;1JH#$^58QP_4D,GNWZ;B(?,FY1/(=*#QP4H(N@ [TP 9(V]"4
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M-":*UPL-&DAWI':U1GEW/RQZW=O7;1]8&]G0;13])!B#=D Q2A7!S@ LP$P
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MQ=@M5WEZ_'3-P5I45\WJL['.G\J@++QGC=HY;)+J0J:<DR5/)^'X )+E4#J
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M!8N$E;FFA=&Z<]3+ ]2("R46VKCV"!5(7<H\(J"I/1P"@,/+E!BF7*04+_W
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M""GG8I- Q)9]-Z&,UX?O%=X4GV WH_DQ?ZQ-CS""?AIBH4!,  4!WK0=(?Q
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MDQT!@ ZI2B8#!L!( ZZ]@ B'1U=@$?0!X@2)QM*6:M1)-1TB58S"I_5/EI<
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MSD@L #<O36/()J),;H!^W$_<!+U_B#0&'N&MAV*(]]=M#Z&+N>XG,_=3&/\
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M $0DR)PO*6'L<I:[7ZEH@8O#&T^6=:*!H+GRBTLW$F4!('[43CZ!XR>A'>@
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M_P#<N$&'/U/[Q3_#O'__ -@M._\ N8A/_<>!H"=H,-AZ" ,=X_#L%&I_U_\
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MC'69>/3+"128@U(X*1!4BKD 5_$N"9.L2@)BB B XX3CN)PREJ"):BM1=TN
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M([08S"RDR B4HJ2P64@L"[:!C3_,:<2_#;@?%<7B,9/FXX*7,"RA&)5+0"D
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g759370g00a04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g759370g00a04.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2364&AO=&]S:&]P(#,N,  X0DE-! 0
M    )+J^E (X0DE-! 0      &D< 5H  QLE1QP!6@ #&R5'' (   (  !P"
M4  (<G(R.30T.#<< @4 0$UI8W)O<V]F="!7;W)D("T@4V-I;&5X("T@4&]S
M="!%9F9E8W1I=F4@06UE;F1M96YT($YO+C$@3W)A;65D(%, .$))300E
M   0><QB;UM-CX&D2<YE<S.\6CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!953K
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  $7   "8          !                          $
M F    $7                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   $7     %)G:'1L;VYG   "8     9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   !%P    !29VAT
M;&]N9P   F     #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     ,X0DE-! P     &AL    !    H    $D   '@  "(X   &?\
M&  !_]C_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A9
M6B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M 0  ]M8  0    #3+4A0("
M                         !%C<')T   !4    #-D97-C   !A    &QW
M='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "+
M !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D   #
M3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T96-H
M   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/   " QT
M97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M
M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M !)S4D="($E%0S8Q.38V+3(N,0
M                                6%E:(        /-1  $    !%LQ8
M65H@                     %A96B        !OH@  ./4   .06%E:(
M     &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M%DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P.B\O
M=W=W+FEE8RYC:
M              !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@
M4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y-C8M
M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N
M9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC92!6
M:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                 '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>
M     5A96B       $P)5@!0    5Q_G;65A<P         !
M             H\    "<VEG(     !#4E0@8W5R=@        0     !0 *
M  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '<
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M5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$!_\  $0@!" )  P$1  (1 0,1 ?_$ !X  0 !! ,! 0
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M/D35^RR6%E+\=X*0XE)&L+."8U[LK:8DG+$B\#RN!MRVV6UB.W/ ,.UCGXN
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MXA7" HH5QB'"\3F:"T-SU!3ZR;YB-=#UUF"MRKVHX53;4=WSG=W1-8EK7$$
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MT_A?G2CETIYZ",>C18S2I<N4U8,/M.-LL%8:CN.!(0A1'0Q/!J]+&C"M]X@
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M:!-DVP0Y&2H4L6)9PUR;8<PF _PIT+2I(.X/B@][.[!+20Z(,'3KYZ?.5/\
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MLUI:ZJ2ZTBYT F(\0?E 76Q'87"XC"\/HU7M>[ TF4!G9G:YHU<182)D$FQ
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M81-B1DI,D7D^]8&%DN[W1'/W8W6J-Q;#<VS9K**VPRZI<75$8<@U<S%7'G)
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MB68BM6+:0IM#H'N@&(O)UD<AO:ZU<5V\;@*O#<'PZG7X@,2ZH'UJC:A+FL<
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M,3O_ ._HB?.=EW_8&7_"8O?_ -_W?7HBI\Z67WAE_P )B?T]$5?G.R^\,O\
MA,7X_P#T^?3ZM$3YTLOO#+]/_G,3U^'[?1$^<[+[PR_X3%_%^W_%_+QHH\M_
M1]?-4^=++[PR_P"$Q?Z>BE5^<[+[PROX3%_IZ(J?.EE]X9?\)B?T_P _JT1/
MG2R^\,O^%1/Z>B)\Z67WAE_PF)_3T1/G2R^\,O\ A43^GHB?.EE]X9?\)B?T
M]$3YTLOO#+_A,3^F-$3YTLOO#+_A,3^GHBK\YV7WAE_PF+_3T1/G2R^\,O\
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M:*K3D![X-:0Z2"39Q&NAA?6[;[=OIUW_ %.T=ECM17Y:R"U:X1FU!$AY#"<
M/FLKC36%M24!7/+T1UYM2>"5)YXU^FNS_M"I<1[ME6K5X=BP"/T^(J'-F$9@
MV"6D;2YP.\:+\J]H_9F<"*E2K@,'Q3 M,C&X:DU]&"26YL],.:XZB&F]B3"\
M69_)^])V;K6^_M#C=)-?)<7<XBJ7AUL5 @>(6.+O54P*Y()(?'*N"?0 _0:?
M&\;#2ZMWK2) < X$&-]--(&EIB5\RQ/87L]7<7#A].B\D U*+GTBV]X:S*+[
MF(*TG-^3>?QOSG=E.J/J&VND)6'(]8WFB\FQQE/BY2V]6VS*;28VG@@)D7JP
M>>5$GUWF<>IN]VO@,)4@6<6>\.9BXGS&IUB5QJOL]JT7=YPWM#Q;!NU+16S4
MRV+,  :Z) F7.D;295K5M5\IQMMR[BF_^S^\]='3PFLW,V_FXS8/-M\%#;4S
M#Y<?QO.CQ>8_.L5CQ)22!XE^+)^HX'7)[RC5I.=!]QM,M!Z2^?EOI9:[^&^T
M#AQ!PO$,'Q&BPP&XIU5E5S=1F(H&2=_YITUE=[75=UN;?\(W4Z+).0Q8Z3[9
M>[/Y[37Q6E''B>:H+AJ$^T%)/B0RY<OND)7]/D$&!PSA=>]'&!D_TU+$@<@
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MD3(A\2;IMOEHK=04N!'C)4L_M/',Q7:KLD_NJ['<3X:QQ)J-DU:;8+@7%TR
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M(2/DN^FY2RY3O[C8Z2E*4JI=P\HC*2E)[A*7YTI"2L@A?T2>W/O(.5O'\2T
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M6K@\J\0Y''B)4=7;Q7ASH[[!S>3D $&YD>=@=8^)I_TCVGHD_I.TN(#;1WS
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MKF&Q^.BQZ/FF*2K^1B\?(*E[(HL=J7(IFYT==DS&>4I+;SL1+A?0VI22 M2
MGGW\=]930K-9WAIO#(G,6F(U_P!<]EJ,XC@7XAV$9B:+L0T NI![2\ _\9FV
M]K3)LLGUB6ZK#C(XIH@/Q?\ ^O<T]?%0/N?D56S^ZV.?ORP_P5+T4^O7K\J^
MZ(FB)HBA#O/>U.-=:/2Q=7DYJNJX>QW5H94M_P ?E,A[(NF*.T5^!*U<*==0
MGLD\$\GMJ=O,[^&WWW\D N3R VZP1/P4@HV_.S\QEI^-G]"ZT\XTTTH//)\;
MKP66D>%;*5!2PVLCD#LDGT&H43X_#U\_PO;&WIVIEM,OQ\\QU;4@,*969R4!
MQ,E10PI(<"#X7% A*N..4GDZ*?7HKUL;M;:24!QC.,86@E(Y-O$1SXU%"> X
MM)/B6%(! X)' ]1I]D7N:W)V]?27&LWQ,I!0GQ+OZQL>)UT,-I3YDE/B+CY#
M*0GDJ=(; *R!J#-HC7<?,=47K3F^&/DMM9?B[BP'0IMO(:I2TEAY4=\$(EE0
M\F0A4=P]O+>2IM?"P0$D?VZQRGESO\>B@B>?Q]?-$9!B$I:D(O\ '93G!\;8
MMJUXI'(0?$E,A1X!6$D\?ME)![E(-@Y[8+7%I$&Q($B3M?4ZW\%0TJ9_<QKM
MKB9\?4+YY=6_R>&P?5MF6%YI<7L/&;_'G6H5Q(H9%<7<FQYF2J6[43P'T /M
MNN++$X!3["'G&B%(+81Z7AG:;'<-HUJ+:CW-J Q[W]1 $DG:PM/X7RSMI[)N
M =L<9@\;B:8P]3#.:7FBV#5:UQ=!@CWI)$P201)M>0T'HYZ5FJ*IQU6S^VDR
M/5P(U;#7*H:>1/6Q%2EM"G)?DF6\XL@+=4MU:W%J*EJ)/.N=4XSQ![W/.(?<
MFVVJ]31[$]G:.'HX8<,PQ928U@<YL..40"X@B2?,[2 L9L?D]>DBR4M3FS&+
M1.5J<"JSYRK%E:^ZE>*OGQ5#Z7*D@*X1R D)';5F\:QK;%X=U< 7;[\KQ?4
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MA10OP <%:4A:>RAS#N!4#_XL=2<8)$S!^FFT3YW"NSVA8EA#<1P#B-+0$Y)
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M]G4J8VB2K:=82E,P)1'<,8^;&4J0MI#B?9U2"X&9^$[:;V]>*C(PD$L! O(
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MR*Q2OL."9(42R!X?+6LJ .1S2TM!_J;F\)C7?GM>+:+$U^8.(!LYS?&#K?\
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M$ R-EC/8#O6Y\'V@X+B6N_9&,:"?$ 0+R(D'Q%UL"BZU>G*\<0PK<>IH9*R
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M;2AVUZS,4ZN<HKH;D.UAG/\ *<;=VV^<KJ3&>K["QO)<<Y+B3+HLFEU-=+4
M6 \A[9-)F)P^,%,N:RI58]AL'->UL.%Q&7.':B>O.E)QPU2DZJT.<&%EYRD$
M6))N#<&V\ #19?8VVYG0Y6;4S<#P6TW0QA[.<BI,&<W J;=V7-<L+.(U=V%;
M5X3&K8E+E.<2)4EO$52:YNGKZJO=)KEB4M2:-Q+V.I4*C6C, V6@S M)$NBT
M7CPA5?A^[I5JS'%S@X.:QQEH+A(!@ P"=05^@VJE2)U97S)<94*3+AQI+\-?
M/CBO/,H<<CKY)/C96I3:N>_*3R >1K;< '$ R ;'_8'T5Z3G.IL<\ .+02!I
M,7W._P".IN&JK(K)%/-Y:CX1J\?^Z^?\>B@;^/V"J./T0J^/S3_)[6C\O^+Z
M]3L/$^.WH>:;GP'W5YXY!![@_D/NU&JE.!SSW^SU ^L? \=NW'J=-Y]>O1T"
M0.2XKX\)^U/V_MAQHH\(FT^O#10_Z<O]?OY0#MV_5*;:]_B?U%G2L3^+D=CZ
M<_7J=M]3X;?/GY*&ZGS_ /N=Z^*F'J%9-$31$T1-$5" 3R1SVX_G^W\.BB+@
M\O\ 'X7$MH/J.??P0".>W< @@'L!\ /0#40"((!%M0-1H?$?)(\[S>\>"H&D
M#GD%0[@!7T@ ?<.?0:E(!UOXQ^/I=52VA/9*4I!Y[  #N>3V';U[_;J" =0#
MXH&@:2!>TF+_ '\.:ZG(L=T>%QI"A\"D?7V]/0\]_CK#5PU"L"*M)CP=9'GL
M1;IHLC:E1AECW-.T'0\P-)]!81>[6;=Y.VXUD&'8_;H=Y\P3JN&^5<\$\J6R
M5\D@$GQ<_7KCXGLQP/%3WO#\.<UR0R'$VDDS))C77JNOA>T?','E_3\3Q; P
M0UO>N<UHB(#72!Y!:%O>A[IONWG)+>W\.DE+Y/M6.3;*AD(623XT.UDN.I*@
M?0CL/3CC7#Q/L_X'6G],QV$(/_P7!I^.4Q>?JNYA_:!VDHP*F+;B@-L2P/!'
M@"V?BL)<Z)8]'^N;>[T;OX6Z@DLLHR?Y[@-\J*N#'MF9#RD#TX,GG@\>O?7(
MJ>SRK0DX'BV/I&?_ )[3K_\ T@?K$6"ZC?:(ZK3[K&\$X5B&']Q_3M#G;R==
MQXZ:KYT]:U_U [0O4.W<G>JWSMJT"+]?EX\Q4SZMB!,:, RIM?(<7+#[[:U'
M]<;"RTOEOP+"1\4]I^*[7=G:F'P]#B-?%L<X%V5KRZ1E,9F.%B;'W1O/7[;[
M)L#V.[3#%XS%\,H\.?2::;VN[L4WYP6YJ;7&T&-;F(E2:V+ZG^K7+\*J[VKV
MHQC<BLC1_9)3L+(F\;O&W895'7[; GIDK=D.K:\0+#82XI7*?#KV_8_MCVTQ
MO#*-5_#17%&GE#&-<*CVBT0:EWD3!EOO;0O ]M.Q78KAG%L1A:?$\1@7U*N=
ME7$!KL,02">[:QH<T<I>Z(D"%OMCK&RBA#*-R>GW=+$B24R)D>M;NZYI0/TB
MVY"69;[8'<+1$'('9/)'/MJ?;SB% AN/X!CJ+B0"<EAU/O.@:77C*O8? U6Y
MN&]HN&XH18.J=TYSN36NU.HRR#(N;A9G4=;_ $_6)#=CESN+O]DJ8RFFM:-:
M5'CO_5T5OQ =P2D%)/'!.NIA_:!P0PW&53@WG1E5KA'B8  T@WG297,J=A./
MP]V&P[<6UF]"HQY<#NUL@DSJ)F.:W/0[W[3Y,VT[1Y]BUBEX<M^SW$/Q+')'
M(;6XET=P?5 ^/H.==O#]J>!XF#2Q] @R9+@VVVOD-=5QL1V<XYALW?<-Q-/*
M0"7TG  ^(GF(CF/+8L>U@2P%1ID1Y"ARE3;[;G//'!'A4>00?J_#KJTL?A*P
MFGB*+F[$5&F>5IE<M^'Q%(Q4I5&F+@TWB#O<C;T5[%*2H<I*5<$'OP?J[>O'
M;D'MSP3W&M@/IN$AS7 ':^QY+"0X1(CG((^$_3KKSXE*.W8<D?25QWX!YX!(
MYX\7)X[CD]Q[M"6N,$&XL38"),_'GR5=!/QBY,ST&Y7-OP$>)M0()5W200>5
M$D\CL>3SW^L]_A80XYM2/=D:;:<^7H*8 ENAU(T-SZ]%52A*>>.>_))/?DJ/
M)/'H.3WX  Y)[:D "VU[;7,FR1\8B=X\Y0MH(X*0>Q'< \\C@\\@@^[U'N&D
M"UA:PZ#D.G13>(D^OE;P5?"./CZ<$\<@#]J >.>W<CGD]SW[ZE1'YY_7K=4+
M:%<<@$@@\]N>1[^?7^7T[>FB@M!CH9ZSXZHIM"@0I((/J" >>2">>0?7CN/0
M]^>=1 &@ C3HI(D$$F#'R]?5/+3Z<#COVX '<\G@#T[]^1WY[\Z0)!Y3\]3Z
MMR"DW]>O6BJ$A)) XY]?KX]/7OV[\>[N=2H@7MKKU7+T]-%.BL6-'FFB'GGD
MO>[C^SN?6=% ^Y^O@/6YU5+/[K8Y^_)_^"Y?Y\^[3HAVZ'UZWTT*OO';CU'I
MW[\_;J (W)\3*G5"D'L1R.>>#W'IQ[_=Q[AQSWY]3S)N".:B!;IZO]3S.JZ9
M32GH[S2%%*W&UH2KDC@J!'?@CMK%7IFK2?3#BTN8YH/(N! ),$VG\K)3?DJ,
M>1FR.:Z.<&8N"/DO@AN5T!3%]36W.#S]TY4R;N[C^\VY;M\NA2F36R=M[;;A
MEVO\A-LHR/G@[E>,S!(BIABF:1Y4@S_UC\Y\5]A[L;QBIQ,8^:M6LZJT$MS-
M]XF6F-@;@WZ\OT;PSV\U,#P&GPD\,IO9AZ+:7=N< *@+@TDVBP]X.@$D3>!,
MRJ^XWXZ0Y;,;*46&\&QR4H2J_BLJ_11A32?"T$28OF27;&O;'AX6EQ3B$)(Y
MY"6SZ?"5>TG8>JRCBV5.(\*AK \2][ ;!TA^6&1>!I$WDKQF-;V<[<M=7P9I
M\'XV\DC#/CN<09]Z'   G:3R'53NP'<S#=S*&)DF&WD*ZJYB M#D9U)<://A
M6T^T2'6'FW I#C3J$.(4.%)&OJ?"N-\/XO1;6PE9KB0,U,F'L.X(,&W.%\TX
MGPGB'":[Z&.PU2@YKLH<YIR/W#FD6((OKS.BSWOSQQVX]?B?Q\_C'X==:;D0
M1]_7)<U5U*)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB*SY!>5^,TEMD-L^
MB+5TE=-M;&2X?"AB#7QG94IY1/ "6V6EJ))  '<C6'$5FX>DZJ[1HD#=QD"!
MU,V4M:7.#1:3KRL>7SZ2H[;!=6&VV_NSC^]-5\X8=C]=>91CU_69NVQ2W6-V
M>+V\FLE1;N,X^6X;LIEJ+90T+<\3L&QA.$!3BDIO4=W;*+]158'0+P2#8\M)
MZ6O$K&UQ+GM, M=$=+P?E\9VA:3V.^4FV,WSS9W":R%DF%OF-=28%SG35?1T
MERJES"=ABHU1-<FJ382YMC ==CQXX6ZEE;0=2EU8;-:-5M9]1C?W4P"1T=,?
M0_ZNJ5:S:19FTJ&&GPB?&9$>IF.]NYMA&D7<:3N#AS$C&G&F<ACNY!5MO4CK
MR_+9;LD*E>**XZX4H0ET)4I1  !/&LC7!P):9 ,3UO;Y+*2 X-) +A(&Y'VU
M$?YM;OTX\*9>R>197N/56-8RFH\W*9658XNLDKMHB9:$.M,V*YE2ID*2A/SL
MQ$$U*@]"+S'ZYJ"]H)!-Q \SLKN:YF4.$%PD#>)(GY3\IE>]&[^U[UA753&X
M6&/65PBO<J*]K(ZE<RS;M$R55QAL"7YC_MPAR_9 VE9?#+BFO$$*U+?>NVXT
MM>_QUOI$JA,9I_I$NZ"8!\"=+K8:4-N(_:CPK!)2>%!0/(^D""""#P0>Q!X(
MT  D1Y'X((< ?@1YB?AS7+RT>Y('''IV]/3TX]"21\"3QZGD&@ @6'3;P4D3
MK?\ PN*F4+/*N_O (20#VX(!'8C_ !GGGG496DR0"09!-X\)T\E$2(VMRO'K
M:(VA=NK*4T162+]W;;MQ_4M=W^/9_P!?L].^B@:F^_PL/]HG_5$O_@@=O?\
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MQEK3G9(%X%XWM9;:;>2X.0I)!("2DA0/;GU22/Y?RZ]"RHRH,S',<#^TM<'
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M[#<B(8,]SA7BE8[.<\#%Q"<\!<0N.M1\M0*2X$J4GH\ [:T*\8'C ?@>(4@
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M1-$31$T1-$5" 1P?0_G_ -_Q]--40 #L ./A]?)//V\DDGU)]=1 B-O$_E$
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M5ITRD%\H3 ?G-^TV;#J'$--Q(*Y,!KAYQ+C39#2L[@!3B  0;QXZB.MM9$K
M/_+F#C %H,1^V+S>_*\QJ)6TJWI]V?J(.3UT+":_V#+X[D2[A2)%A-C.0G9"
MYBX%:S-FOMTE>9KCDY,"F$"(B:XN6AE,A7F:JT1'2.=HY;@>$*Y$SK/D)^1G
MS\-)6<89@V+[?TZ*+$JI%57)=<D+1[1+G2I,AT\N2)MC8ORK&=(7V"GYDI]W
MPA* L)2D  !H /"RF!KOS@2HR;E_[.3I.';_ %C^KH^@]]WTR@\'C_S4\]^_
M ^'>T6!ZGZ#\IN? ?4J9&H4IHB:(FB*A /<@$_$@?G[S^/4$ Z@'Q332WK_
M49M[>F/!]W%LWS2I.(;@U8\^BSO&E)K;Z#(;X+8D28Z$N6$1) \463YB2DJ2
M@H\2B?$=HNQF&XL7XK"N_2\0$N97I 4WDR#!>R''<7<O6\![6XS@X_35FMQO
M#GN#JV$Q [VFX1!RLJ2P& -HD2;W4/;OJZW8Z9+W&]L=_P"IA9"],M8J*W<B
MD<:C1,DQ?SVH\N=+JUN*<K+6'XT(EH\?A<42XP!YB2/G.)]H?$>Q6-P?!^/L
M-45*C2S%%Q<#0<>Z >73[P=3<XD[.O>%]*P/L[X9VXP.-XUV;=5HNITG][@
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MT1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31%8<9^XT3[7O^O<T]<U
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MB)HD#DFB*V6E/6741Z#:0(D^(^@H=CRX[,EIQ"API"FGT+001\1Q\>/?IXO
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MHU3FLR5*4Y!/B?\ 9HRL/'LM3!1#<<2_Q6OA,A("%.I6>$V(BGE'[X(+N8@
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M=8^?KRW4FP)Y*G(^(]W\OI^/1%71%#C<O_9Q])_?_P AW5UV^'[.=,G?\/\
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M:(A('J0/MT1<0I)]XY'J.1V_ET1<M$5"0/P_A_)J"815Y[D?#\_S'K^ CF5
M,ST5%*"1R?3D#\?Q/H/PD?#U(T4JH//IHFJ:(FB)HB:(FB)HB:(FB)HB:(FB
M)HB:(FB)HB:(FB)HB:(FB)HBL>-@"FB<<]_./<<?V=SZAVT4"\WFY_TJ6?'S
MMCG[\G_X*E^[[>._NU'X/V]:(8MXV\?4JZS%NM1)3L=KSWVX[ZV6/&EKSG4-
MJ4VUYB_H-^8L)1XU?11XO$KL#JKY#'93<-)!/0*?%0OR?J+W%V[?SZHS/$,<
MF6M/2X-:XDYCLFQ16R;#/<@?QN!C5X[,6\I%A!GMIE.R8JV&Y$)U"TQ6/&CQ
M0U\Y&D'.X@'0C:;S//95(/O$B6-&;K]A&P!OSLMU[0;EW&:IR^FRZ'5UV58%
M>FDO33JD"GDE<1N;'G0Q-==E,-+CN_KC;[JRA:5'Q!)X&8M(;F,1)&MY'/E]
M]MXJVHUSBT9I !N-C\?"\*..1[C[>9MUV]+L/"\\PW+Y=7L9U;FSBXOD]+?O
MUH<R#II;;,]JIFRUP_-<9>;;]H2V5K8=2GDMJ KMUO\ :/NL@-W#_B#_ /Y#
M\J?>B*A].>.>.2/MX/\ B[:@F 3K )^"*#NXG7!B&W6:Y!AD_;;=>WET,IJ&
M]84F(/S*J6X]&8E)<@RP\@2&TH?2VM00 '0L=PGQ'YEQCVBT>$8JKAJO"\=6
M%,D!U*@YS3!BSF&3;8@"-YLOHO!O9[7XQ@Z>+I\6X?AQ4 /=UZN1XG8AP MI
M9QO:(@G2>6_*A[=XZ[5,?I<[C0GI<UH2F\@H_F5::ON)4N"E^052GF3P4-D-
MM*X5R\CCOY#B7MPX;P]]%E3AN*I.JD@BI2>TD0(RYMY-[B(\)]IPSV$\:XC3
MJ5:7$L ]C6RUS:@<TD3^XM<8!B-#-X6;L?*+X!)1'<9VKWH?:DM)=CO,81(>
M8>:6@.-.,NM2%H<:=;6AUIQM10M"DE)[]NQ1]K6$K4VN9P;B+P\!S7BD<I#B
M)@EUY !$CKR7&K>R+'4'OIU..<(8]CLCF.K00Z\3FB18@^4PL^N^IJ9E."[>
M76$0[/ GMS,X7A$:XSNE3'?Q=3"7E.SWZF6LQWY$HM%BL:EN%AUYQ)6A85X3
M]%X#QIG&J%/$LP]7#M>TC+5$.)L9N+;S,C;9?->-\(J<$QE7!U<11Q#J1$U,
M.0ZF9&C8)D6.H&H@<K*CK.PC;^PDX5EMSF&X&5L9I:8PZ_#P%6.RXCE154;T
MYB5%0F/ GNQG;%J8Y(JD>6J+9Q4I9X9<7KNEX#PP WW/4P#RZ'QZ%<9I.7,9
MTG3: 8C6=?SHO7(Z^=KX-(]<6.*YW 6J4W'JZUVN@O3KD*FV$!YV$W%GO@)C
MR*R4A2'RTMQ24I;!*QK)5;W5W0?=!M<WV-NNNBFF34)RZ &9M<29&NH&D[J]
M+ZPL2F0Q=#',ZHL?KL[AX;;7DFKJ%,)L%5 OA ?AOSUSVV)E<ZV\J0S&3(C$
MI;6&U%8%1)#76ATG6X$F+<C&OFJBHTN<VX+-20(.FFO,; WLLMR_=G([W8G-
MMP,-CWNWUQ505S:67D%33V;DAA*8\B-.CQ'7IU?,@SX[G#96H.M>(I4TAU)2
M*U<S#3,CWG;&01IRZ[7GG 2G4%0/-QEF+1-I%KF\'7?2=%QRO?>IVQHMKY6<
MW-E+>OJFZM+RUJJRG<:?<H\'GY-)CV$%#J)-;[6Q'<EP5UT8(4[&:8<<1'?<
M.KV[TTAK<S_2!(W\"#IS)NHS@4P]UY@&VLF(VM])W6J<5ZP6*B%=JSVJR2PF
M#(<@D0Z^)74#,_'L,IT5[S\^T5!GB!,1!18L!0@OS)SZ"%>6XOQ\0!G);8PX
MMDFQBQ,QX^KJ[G!H!.XD;_('GM,K84[J_P .BXG=9PSB67RL4JW$^Q711318
M^0QT)E*EO4S4NT9D/O04PWUR:]QIJ>$!+C4=Q"O$*U'"F--R!RG_ &C79A(F
M+7/7PG_/DK'.ZQL3II$GSL<SFY9?M[..T(D"A:161*NFKKR0^I7SFT\[$<J[
M)F:VMY*Y)"BUX?&/"+/.1H>9() @:ZQ,>, WA12<:DB"#>9T%IB1\.I'5;)V
MAZFL!WIR3)L;Q*)?H<QDH\VRL:Y4>LL 7%,NB')"E)#D=U/@=8?\I[N%(0I)
MYUE[IW=]Y;+,1>?I'7711WK<^2#FF-+6UO,QY*1>L:R)HB:(FB)HB:(FB)HB
M:(FB)HBIWY^KW?4?Q?X_RZCGH?6^JB\Q%N<_9<%MAQ*DD)X4"/3^7GUY_/O[
MZ/IA[7,<!#FQ8"Q(O$B_.ZL"6D$:@@^O)?-K<?Y-C!-R<YR3.[7<7,H]ADED
M[9/QH[%2IB*M?A#<=A;L<O%EE*0AL*5X@@ <]M?%N,>Q3A'%^*5N*5.(8NE6
MJ5&U0&90UKIEP&X VDROL_!_;7Q[@W"L/P>A@,#4PM&CW)-0U<U1H;ED@.#9
M.\0-[J=6VN#';K$:K$A>6>0MU$9F(S:6RFS/=8CLMLLI=+24H/@;:2.>.3W^
MT_5N"\*'!\#1P+*]2NVBUK ^K=Q#!E!)DW+0"=+[<_E/%^(GBW$*^/?AZ6'?
MB'OJO92G('O<7N@'F7'R F2LEB_=RU_>M?\ D?UUUS!J?'[!!_JA7_P3Z^[_
M $TC^?4[#Q/V3<^ ^I5AW!R"=C&,3KBKQ2SS6TAJ:77T-1&3)F/2G%^4TZE*
M@I3;<?QEQ]YM"GD,!PLH<<*4*QO-@,I.8Q.L3;T;*1$W\XUC?Z* DS;[,H3U
M?FF.;;9?;/W=-NO397&L*QFCLY>9;DO0KJ5E3-*Z\78%"JR\RJ9\T),.J980
MIQ_V=2I$^\"W+  ;$?\ +GX1: ;:WU6,B)DB,^8C3W;6C<SS,&=M%,;"MO,B
MI]C<<VY5EUQB620,1JJ5678U'QNPN:2Q8:8+DVKC9?091C+[["T%E"+C'K6(
M4$J,<N>!:+D@QKI>=RE,$ @\R1TN;D$<_'351VZ-L6N<1W4Z[*+(=P,KW/NJ
M_J9P5V7FV:0\,K<CN!-Z.^F*5'18P=NL4P3#D)K8DB/5PS6XI7K7"@17)ZYM
MAYLYUMYG[?Y5AJ3M>+FUX(^4[<KJ>VH5ECF6Y71X/CEKE>2SV:NAI(KDZTL)
M'B#,2(T/IO.%(*O"DD \ ^OIK3Q^.H</PS\5B'9*5,2XD$_3_6JV<)A*^.Q%
M+"X6F:E>L[+38"!F,$Q)@"P49U=<W3 >4C=?'"M("@/->(/TN$\*\HI)4""!
MSZ*[\:\4_P!I79ADC]:TO )+,K@;6UTUMSY KV(]F_:XEH/"W@N((]^F;'0_
MN\=.16HL6^49V9M]QLSQFZN(%)BM,U7KQS*Y+[BH=^M:7!9-MI#7ZR8SOE^4
M3])YM9X'+>O,X+VO<%Q'%<3@Z]3)2IM8:+W4W9#^_-#FR?[?W-FXO$+TN-]C
M_:&APK"8RA1-;%535_4X</8#1:T,+"03E.8EP,/)L+!;H@=:W39;3(-; W1H
M7IMA*9APV&W)!<?D2' U':2"VGZ;JU)"0HD\D<CL3KUF&]H?9W%UJ="CC&.J
MU'!H:UKB"28$6%CM&F]EY+$]@.U&#P[L37X<^G18USG.+V6#;'1T_=,8W%NJ
M_=+>^%DF?RK?'L68HW,:QR8C"ZY,!ZPK#*=B09<6FJ[*7)D2?"TPJWL)K39*
M04I3XE*]O3?-!U5TW>,D 26%HN+7O)O ^A\66N%5K2=6D.;>&NDB]O"#]M=&
MVO69'G2-II./JRN%4NSJ:QS]^Q1@\AR15W<&XE-8]+CLQG)C\M(KW%LSL6;8
M8:4RTU,F*=<6#E FFZK,!HS0=2-;1:8YQMSMC+W=X6 6@2=I(Y7,1\NH,\\\
MZX(L_ \GCXCCN6XMG@I'[BGD./X5,17US4-BSC7+LFQEV=%)9<8=;1*IVVY5
MJVEQYM,-N0D*1#"'M+OVVD!VNO21)\Q?7=7)][+K-Y&T 6-IF;Z_)7^/UZ8L
MFTGXVQ@F8W]C1W&-8S-M8RZ"#7V%S>3X-.MU@S+.,([#5E/8(#J6O-BK5(BI
M6PVI0BF14:YUVQ-G:F)%HG>-8U^-JGN$-C,3RG>.8TN/0M[ZKKKHIENBIM-L
M,MHEHN_F*?(E7F%RV8$A%TB@>>6(-_(<D,,V+K;:C&0XI:%^-I*TA1%Z;>\$
M@QK8ZVWU@:;E8JE7NR&EI)(%QI< Q<\CY>2G>A06A*QZ+2E0^Q0!'IV]#[M5
M64&0#!$['5<M%*:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBL6-<
M?,T0#W></M(?<[_5S\--->0/Q$J!IYN^I2S^ZV.?ONP_P5+T4^O!7>0AYR.^
MW'=0Q(6RZAA]QHOH9>4A0:=6P'&2\AM92M30>:+@!0'$<^(#<$<T&HW44G>G
M3-,AQK+<<S_=2GOE9(^S;,7>/;;G%[F/D\"RC65)=V4N;F^4+L44"HC$6IJX
M"J.(S&2H.%UU7F   6R"<I!%^6@T/3X7E5<'$/$@!PB!M/K\0ML;5;7O;=PK
MQRWR)679-E=JY=9/?KK$TT:PFJ:3':1$I4S;-%?%CQD(90T;"4XO@K=>65<"
M23EC7WIOU^_E?FJA@#LP@6CS'JYL3H9"C5E.#81B/73TMR,2PS$\8DV.QO5N
MFRDX]CU5229[;5_TT.,(ENUD2,J4AIUU]Q"9!<\"WG%H*5+7XHVGQ^4?E9!J
M[2S1?Q</E;_:GAHB::HO$N!&6X7#&CJ*P0M3C84I7P^D1SQZ=CVX[#6L[!X1
MSG/=AZ3GN ESF@DQSD'EJ+^*N*U=N5K:KPQNC0X@"QT@\S/E9:JSG8':#<B=
M'L\WP#&<CL(C!C195G6M/N,1ROQJ905<A+:E$^+P@$\GU[:X?$NR7 N*O;5Q
M?#\/4J-B"ZFUP:1J6B!$_.!R"[O#NU7:#A5-U'!<3Q-&D\$%C*C@+SN22=9$
MS&RV%68Q24U; J*RJ@0ZVLAQH$"&TPCRHT2&TVQ&8;)22E#3+3:$#N4A/')Y
M)/4I<)X?0HTZ%+"T&TZ;6M:!2IV#0($Y9^?D%R*V-QF)JU*U?$5:E2J]U2HY
MU1Y+GN).:Y@&YF!8Q"P#=N]VFQW&VHN[+%,K&KJ>Q 9AV=2Y8PI<Y7*V&?9V
M8S_+ZBDJ:)2%$@^%0(XUMMITJ;FM8QK/=.4-:&@#>,L=9UUG9:YS.ESCF,W)
M),[7DR;'JK#1[9].^285065%A& 3,+:=EY%1S&:>$U%8DSO"S.LFI!:;D-29
M"6$QY;KC@=4W&:C.\ML(;1D+9@Q#AH3KKOK,7UF%209N"--? 1TV^((U5BO-
MENES"ZUB=;;9;<U-?<3H%6U(./Q4B1-G2RY 9:6TRIQMQZ8ZIQIQ"D?KSJE^
M/EPDGDO+&&Y<0 )Y<]+:\IYA!#&N(!#1<QO/G<&!TT'17W(MJNGG$L<F6F08
M#@U?CL6]1ELM<FFBJCG(A%%8U<>2&UF1:KA\0VW$H7(>; ; 6K57.REK (+B
M8D<IM.H'3;HH ;)> !F DS8C0&"8^4GJ%C$:[Z6Y6R]A81X^&*V8FVQK;.(:
MXHHWK8V"89A2:Q;0<,GYP4EKV53 /FJ)#?!5J7G,*9-Y(RGE!(N1<7$^%U(
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M@B0=C>%JX=/NS(5S^EKA@^B$]J&!SVXX/=GCW#Z_?SSWUYUW8SLXX@_PO#2
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MQ=TG6QU)U5*3\[9B(D&\P02(T&VZE/K665-$5BQKM31?J+W_ %[FFG73U^5
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M;T_\I]IX'X>/\6B2/[F^M=_]=4_5_=%1Y_T3^S/;_P#;>G'XN9'?\'IHD_\
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M\^75OKI[ MV$%U+,R(M$5Q:7H[JD.)0XV4\I44*X^(]=5=8$C7Z7D_Y^>BD
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M^G(L/R?"D&VN%)>>BU55EE51V[L&"T&XJIZZYEJ7(;=?2%*<4$YW$PULB
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ME$DV)),E(]?+Z+R8T>::)_\ 7?\ 7.?C^T]]0H'W/U*67W6QS]]V'^"I??\
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M:*57V6\^^L7^+A_E]%!!V<1Y#\*GLMY]]HW\7)_R^B>?T^*K[+>=_P!E8O\
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IU\N-*F2YDQN4[*1'1PVP&$MI8"P. %K*O%XNY)''&B:?4\_&/Q"__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g759370g00a05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g759370g00a05.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1764&AO=&]S:&]P(#,N,  X0DE-! 0
M    %;J^56(X0DE-! 0      &D< 5H  QLE1QP!6@ #&R5'' (   (  !P"
M4  (<G(R.30T.#<< @4 0$UI8W)O<V]F="!7;W)D("T@4V-I;&5X("T@4&]S
M="!%9F9E8W1I=F4@06UE;F1M96YT($YO+C$@3W)A;65D(%, .$))300E
M   0><QB;UM-CX&D2<YE<S.\6CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!<WCU
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  $6   "8          !                          $
M F    $6                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   $6     %)G:'1L;VYG   "8     9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   !%@    !29VAT
M;&]N9P   F     #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     ,X0DE-! P     "QP    !    H    $D   '@  "(X   "P
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MLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@
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MWQZ'VZF/="STE9@TAEN8RFZ//3#8*X# =YZA[^QJ*+/+-7*!CFXPS>P"*0E
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M> 4>%FV\-W+3,*B8?!7Q5<+H)BYR(8HPX7.CB;!%*V%$155>IRJ\KK3C,4B
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M<5T,+&QB1==8AKR=%3KHCB7(LQ$SG_ONRGC]1]C8O8V,Z>.[/G&X![X+WL@
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M(_RC/Z[?MU)&X1.TC_VV?UF_;JJP=BG:1^'XQGCY?*;X_F\=)&ZD'93VC/\
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M0YTD-E5BSM9(^!D =N^"J-(@CE><V. <\9:-J8._*)@2!K/DO2YWTV-D$DM
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M1$]65O//J\'GW]T@Y_\ MZ2;S7=2!$0(VT3U96_#P?JD'[O15/5E;\/"]_\
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M-:BU/OYT/H-0H_!6]555:^;GW))$G"KROA\KV?,J>/A[-08;S-XO<D'I<:>
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M,#9 H9U@C69L#V-E5&JYKG<*G-C,9I)L0"W-,'+M.HBPL!U79W$\-2,H$YB
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M2ZCMHN.4D8OBB>"\K^I/'R^;4DWIEZ&?DJR-QYA<^LGAXIX_.B<?GY5-)/\
MK3<F/2_A=58CR[*<TJ-PL!QZI_!=]!EIED*6X^.T6W&2HJ"K<MX\D$C0G+-&
M-V,#'M56.>DDOR.-;@D%T2T1F(O\DB)I59+@*2T.K )VOS,:P%EU%Y54\/#G
MVI[_  \//R\_<NL2[0 <R?:JTIUJ0;&431$T1-$6-,MW-K\0R/&L8*QW++8_
M+92(*::AJ([ %TP<$Y9D11+C1^[/%"&G.F1T:\#1/<U7.ZK5"8)BVU>E:1.D
MJ3M6H&O72=[V626.ZS4=QQUD1>/:G*>2_.B\HO'A[N=0&1-E5RU431$T1-$3
M1$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1
M-$6!^DL1.+LGGLPYY5;/ZF='"0&C$?UWSPLCAFE>4$T4,ESD@,,[V-W,:62=
M)6K&CDXX@)=AAM"7M% "36QY4$<U10..S''T5O\ 12CR3_)4*1ED@:W4UC/'
M,-76%?:@!1@" UT,8IU=8VD,R%1BI8$=H3V["C9VOBBX:U?=Q#LQPQ !# #U
MGQVW\!KYL"3G<29S1:+>-1?01Y1L;WX+O+PT*'4QD:2O#2>+O38E5$21T'7[
M1&.Y3AZM1JHJ+SXZ\QF^@O\ ]CK2G6B[R) U(D#7R7$*P!L&R/!-$,9%(L4C
MA"(26QR-_E1R.A>]K9&^3FJ[E/:B+H)O)@U% *?F.J @D@&HN-ME[=55-$31
M$T1-$31$T1-$31$T1-$31$XY_MU")B]#-$3CQ5?'QX]OAX>Y/9\^D5)W_"*B
MWF.4635Y-5D-17W=89&L1-?:"0'!3QJBM5L@I,<D+TX<Y/E,7CE>/'7;!Q\;
MAWC$P,7$PGM((=AO<TT,W!$B=++CC\/@\2PLQ\)F*PB,N(T.'6#JOBWNIZ-_
MH?VW2JJ;87+[#;@BVKIGV&!83?#8S$)DZQU@],^N(&3UC4F7(UFA*!BJQ#)(
MVS1*QJR(_P#?\%_^)':O"]E'LS$;P_%.HQN+Q(^H[+6C@:&!229L>OX7C/T#
MV;C=HCC\/%Q.&8*G!P"YD$_ZEKJ"8.XMK(SY!Z+':D"1\U;O3TG 9GMZCI(M
MY+J?F/GE6=4H:=C4Y3Q5K4<O^UQX:^>?USQKI^IP'9F).@X;#;)\ /G.%ZV_
MHOAF1D[0[0$?[<3B.Z7<(A>UWHV01VK'4=*#I.UC(^>Z<[AQF*,OL55GJU63
MGE>>ORG/")K?_P!YAX Q.QNSW5!/]MK?&,I.]"3S5/Z2> 0SM7BVC_&7.)$D
M34O)MUV(-U3BO1W;B1N;ZFZ</2:K&*US9FK=49W:JO"-7DBL^1PG/\E$5>5\
M4XUT;^LN"'_J_I_@'5'[3D,5F@PC$@12Q)\.+OTEQH=+.V^+$"*@NFV^(+:4
MK"],?0<Z10"-?5]/?>=KXFHR%EICN(V$74XZJK.U8('2O5OBC^47GQ7E='_J
MOL7$.5_Z=X< U.7'CI3Z8,3I0?C8_3/:C ,G;>.#:K&F>9,&MJ]%,O1%Z9@S
M%CJ>GQE'4:SK0K:[6X@=*D_'/,KF&0))$CD;Q&G57JIU>?%5U!^H_P!,NH_]
M-M-8(;Q0 (G3^V"-><4E']@=O1_;[;<+$3AM-0-9:1<;P9(H*K5?<GHC>D/=
MOWLQ<MZ8-;?M26]B!OIL-CQZ"BG$JIS;"&7#:TLNLO(["OBEB2<@X>5'2N@D
M7L61J[[O"?J;]#L[/XK Q?T^]F+B2&M#@XN%/\R9%&Q,@\[+XG$_IW]6OX_A
M\4=L%[&#,7-#6@&QE@: 09)K-S20%M<W9[TE03%0+I1[.V?8_P PZSV@)'>5
MXI\DIPM\](D5%_E0J]5ZK?D)[/@GM/\ 1KW%P['XG##G&@QG4OI()\;1S*^]
M_P#3?U0QH [48]P$26,%*5HRYVH%XRL)]*V&YBUV[W1;LVO15E2QP?, DBZJ
M)U4B[J80LJO55Z_7:SJM;RU%7A4?U7Z(?^_@./81/[,5U=9,NTB@O6\RL.X7
M]7L@LXS >/\ S;A4@B )8+UDS?>H7HA&]*T"QK23^BA<R0>+WQ09P AG'*\-
M8^->P1W\E/E.5.$5>/%-8=B?H=Q@87:.&:?YET3')WC740MAGZQ .;$X5Q$U
M&03T&45Z^R]+LC]*>&B<;==&&WZ_DD659<"D"-3QZW:Q?CNO_J]5>4]Z^'.3
MA_HA\1Q':6',R?I%X'2PB\'6EET#_P!7MO@\&Z 0#]1H)BQ-+NY4&VWD9NAZ
M4H4I&%]&WH_V L+OQTH&Z=E!(2Q$\7#L('58G.\&M;(URHOFOCRE_HOT4_\
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MW1 K!/*U=Q[D!$1.?>GR?!>?SZL"(CH*1KI'VBODG>W'D?=3W.P\/XU?X?\
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M8%!J-)U/O.U@JX/9B.9)H*0XD$02!%/(")O58J.Z;_1#W'AL,;J-NLBMMO\
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MS'7[?XM66^7W U<UT^=&@6&2"DO4JM.L*ZL@J8CV@3(^"$J6N$"#*D:U.\1
MBH]/Q3578  ($@$DFIDDS-9FLG51W><USJEH#6R+  0(B* 7.YDJPF=&7H]1
MGU5JS9C;EEE1Y&5E]0<W%:I"J[)S9(9B[T2=!^TALIY1AY)"6N1[GP0NYYB8
MK:.[$4BWPJN[_P"ZOV\A3P5P$[(;/F9H7N,5MKAI&>'L"89ETU"!)?D-K989
M@.TLG0J2K@Y1AWCOZZ/B=#%U')U&\!W3F%#>1TC[4_XA[T36! Y#Y^=U1,DZ
M-FP6897<9UE.T& 7^8Y#3+CM[DUIC=>7<V]&HC@?55B?+"Z<P) W.&;!.][&
MQ+U&HB:R&M&: ._^[<^-QX0I I_XB!4T'Y\53)NBST?>O,17[48916)%$/BT
MEQ048%1<+C0SAU;0MLQ(&%QU<L0L0TX\<C4D&185<C5U0 ! M2DG_&WS755O
M<)+:$WY]9O;7HKBM]@]F<BQO$\1R/;?%LCQS!9XR<1J\BKFWL- 3$[K,( DM
MG&$1S)Y+*Z9[W,XC<JQHC=6ZH) < 2 []T4F23I:YM  ,"!16M'T2>C'"5WV
M+8?:Z(I;MN2.ECP^H8K[ULQ)#;21&C(R4MDYA<K))&NZLA,[FHBRO5S2-!2W
MYNL@ 5Y1K954+HR]'NN&8&#LUMT*+$6>?$-%B]6V"(RT*&-L28HNPZD4IA88
MA!#HT;VDHT+G<]FWC0<YMB1T^<EL.<)@W=F.O>@B:_\ N-+5F)5?#V/V@K\O
M"S\#;;#PLVKFV30<I$I A[L9MQ-,1:)'811L(X/G(GF*ZSU[:2:1[^7/<JY:
M<N;+3/.;G)DR351Q+R"ZI%M-9TC544?HV; "6MQ>#;.;=PW&07 .0W=E'BM4
MTRTO*P]UI6VQL_=NO.>!9/D/#*>JRC%RRD0N9++(YT8T,!#1 -]9UUG6O5'$
MN()).6U2(\H\-M%RAZ-^P@Z94D&T. 1-SE+9N8,9C=<D>1LOE:MRRVC['J%Q
MV?5:AL<C59.C6H]JHU$2D L^F1+-O+6^FZS'?&)_F*9I/2HL?$<UAQG0&Z+<
M.XM=N$+ME4AR5N/%XT/B(8P$&"=Q,'/%,=+CB!</E*&LS(R(&E-K"))%+GKY
M#N"M983E<-";7 J#(FHJJZ7$$W&T5ZS^(,+-N+]'S8_";RHR;$MJL&QW(:"I
M2AI;JJQ\ 2SJZ=&21)7!&1Q)- *D4LD:1L>B)&][$^2Y47<FO,08I(VHIE!B
M:P9$DT-:WO4^%+*V;'HD]&*WL#K6TV&VKL+*SN"+^Q-,PVE((-N2^W[U8DR2
MBN=*1.I)"RN<JH]9I'*U5<JZR  ( @6@+9<XW)/\3'E)53#Z.FT-7F6%9E3X
MC7T9VWJ9%-BM92P#U="!:Y6(+6W-ZZM#'B[>YFJA65L94TSH8Q)'M0=9DCFB
M-[N8"@-"(&H!/.N_PX-36IH;G_&(\J4MJJ;G_17V&W'&N&9#MMCD5I;U5_3O
MRBIK@J[)Q!<JGG*O7@7$<#YX"+$LH@HN25D\94T\RDQ31SS,DQD:V<HRYI+R
M#>(DF\^'C(6R]SOW&:S!_B/2%;5'T,.CW483MCMX5A,.28KM#<7.0XA793)#
M;CMO[^<LRQMSQ'#PU\Y/>SIR XX A Z]ZL8 ,/#%%$S;@'QFK (&E#4BG/Y"
MPTEH+10$ $4,UF\4J-#6- :WM1=&'H[XQ<SY%CNRNVU+>DV#;6>VK<3J1#Y;
M%A4YK#'DPC-D6>,LD@F-_6YCFGED9U72.5=-)8(:2T;!:S&"V:$01R_'A"N.
M[V1V@R5F+1Y!MOAUS%A-F5=8C!8T8)4&.VQI$A9=C4P2Q.A#,(*EE)DGB8CW
M3R/EYZ[E76"QI=G([T$3)L:D1,5Z*"C<HHW;^;^JLUG1-Z,L1D-A'L1M:PX>
M6UGA+;AU,A#);QZOMW]KW7KN4]ZJZ?KJY'*JJU&\ZTTY22VA,6Y"!TIM>YJL
MEH(@R1S)Z[S[65UQ;$[/C949G >WF- 9C8G4]C99-6A>K;JR+H'*ZHDL; !X
MY!\82JJ1CEOF&>WY$T,C$1NI%7'5Q+B229)))-=R257-#@ :AH %2( L)!FD
M:KRQ]'K8V',;+<*+:?!(LYN#)+"TRR+'*Z.^/.E&4.4LJR9"A,I$HKE@DE<]
M7OC7ARKIE;>!(L8$A5W>:&.DM%@2?^^R]N.[%[-XE>VV3XQMCA5#D-]5K2W5
MS5X_7AV%I4+%#"ZM.)AA;(0$^(>%CQY%=&](F*]KE3G1P#Q#JB(KM,]5D-#8
M#1$&1!-#!'V)5!__ "Q]'I*W'Z=-F=NVU6)GS6F-5[<8K&B4=@3#",076P-@
M2,6:: >"&5T;4Z\<,37(J,;QHDN()KE$#D-EL$AN4'NDS'/>;KS4/17Z-^+&
MAV..;([:49]>48:$95XG4ADC%V(8E><3%+ .Q[9BP0 1)Y.>M) (/$Y59"Q&
MW,Z(FATH LD2W*9+9F)-][\E[[#HU[ 6IE4?8[.[>&&T<""U!4^,5CYZX5M9
M#2M%%D[!'1C-J1X*YHZ+V+1(8X48C&-1,M&6K:5)\3M-O"BNLR9WD_-%<HVS
MNU85A:6HNWV)P65U3D8_;G1TH2%65(4C4)JS9NR5Y(1'49VT$JN9)U4ZZ+QJ
M. =.:N:IF:P9^ZI))S29$UF#7HK(Q[HP[)XEEN'9?B>#U6,$8$!DP6*TN/BB
MU.-U4^8O$=D=PRI#&A;/<V4(8XDAD\LK6",6.*%DCEDUH$C-'^3<KN;9#H\P
M*W6:F!)AKLP&S@(N9-09I&YJJ@;T:.CY8W&09 ?LSMN9>Y6): Y+<$8G3R65
M\'=OKY+@:V-<*I!T5G)4UDAK29)$(?7B.DZRP1JW#6AM!83 T$_?J9\ZK3G%
MUS/W\Q5=8W1CZ/(EB#;#;,[=Q6=;45U"":F,5BD#4U1(V6LK8Y'0*O= 7M:H
MT3NLD2-:UO#6HB:B_,@^(CV%+*1'SF3>YN5>TFU>VTL>/128/C#X\2KAZG&&
MNJ U]0U@B-08"J58N0A($8U(H(%8QB-1$1$300'EX SD$%T"8.G11S0YN4U:
M'9HDQ.]#7H:*PUZ+?1S6P$M?\BFVZ60#B7AFLQ6K80.XP"&K*[-[(&JB$5P\
M <K?%KX(F,5/#04<7 D.<,I,FUHO2FT+H<1[BTETEH@$@4'E7QE=)O12Z-=D
M9>6)^QNV)9^2DL+OS2,1J)"K<J.6&=LY\[AED(D68>"5[GN59)(HW2=96HNL
MAK187)-R1)H:$[+))-R?MYQ$^*["NBOT;S2W'%['[9$F.N4R)Q4V(T[YW7:0
MR#I9ND<,KG%=A(^/KN5>6]7E%5C%;H"*"@%AH),F!85Y<K*761Z7;C L<LV7
M5#B-!46T=<+4,L*^N'%*;5@P=V"KTEB8UR""#_B!H/YN&+Y$;6M\-63$318;
7AL:9 @UK)-[W)5ZZBVFB)HB:(FB+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g759370g00a06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g759370g00a06.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1A^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &&*^8D(X0DE-! 0      &D< 5H  QLE1QP!6@ #&R5'' (   (  !P"
M4  (<G(R.30T.#<< @4 0$UI8W)O<V]F="!7;W)D("T@4V-I;&5X("T@4&]S
M="!%9F9E8W1I=F4@06UE;F1M96YT($YO+C$@3W)A;65D(%, .$))300E
M   0><QB;UM-CX&D2<YE<S.\6CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!;=6T
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  %=   "1          !                          $
M D0   %=                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   %=     %)G:'1L;VYG   "1     9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   !70    !29VAT
M;&]N9P   D0    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     ,X0DE-! P     #<0    !    H    &    '@  "T    #:@
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M[&?U_P#"?0586])#3D8U3C]F(M](
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M]M%?4R+EO-OI#0#>VBOJ9%RWFWTAH!O;17U,BY;S;Z0T WMHKZF1<MYM](:
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M>:3,X;>+]65L.O0X?[;)_P#GY)/ZZSF]R]6:+ZJ@4 H!0"@% * 4 H!0"@%
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MPTN[;<=-V?-#+QI8NZTW-4U&L1>:<77,RC%],3".48>&SXNV4-"HG$XS!6^
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MNN=FYN9)):6['*VN5'*&5?SV.WIKW%$44)JXI/9;>-E'// Y'4 H!0"@% *
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MYV%OEYZ1B=C42!0YJ26U8*9M1B18I7'6IC )2$7*#"4]IIU_,V67&FE%6W"
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MV,#AA%ES7'E$\Q9.Q!<8PICQLGFL,OA,#N;[[IE:HAK"^/2Q"\EO\:*1$IT
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ML-X4S89SC'F-3J%X>QJ^,0"]!"U;#)WIN;&E0RQ)+B4] [K+7!*T)N@C5Y+
MD;;WD]"0"L^Y,"M.NOAZ_'GR9)IY1%**;VM;[]UBM.@@\_L-T.C$]8E$(91%
MI<1/8%B=%FDU*=')8SS4)W'72YJ<#U%I]J9R$YN<"+#;+5;4H.L+N)/OYY;
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MW^3K%*IZ6.NVS06Q!OT.G_19/Q&B)BE\Q#230)># \VE$HT^)S=B=>WW-NZ
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M4A6ZZUF1&-[2<MYBWGHMZ-0>J4%)+;LP) \^\X;0 ;QS$,AK.:UX;Z4<[9?
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M)?@DK^E-HR8;>+M:[L5L.O0V?[;,0/S\DE3-[EZXBE]50* 4 H!0"@% * 4
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MY:K.\^4[<]I<'8W2X.B?0_A'TB[R:B8S33Q*71VFB6=#AR7YODIO++OLT:"
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M5Z4P]',K;W*455.M7).K8/'GP\(ZN[GV>\%3O.M,*G3#&4*:UUVO@$GAQ/\
M&<4A=W!#EN)?<I;S.TKS%/7I^QG6/H,FMH" B ADW)@U[0X0'6&OC&ONOH^:
M_CIII-OH\5;*F##E'OXW.F?\.C_L?;:PM_QGU.N+#^MBJGA:2I1T;SI,'M_
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MUW_]/'^YA.F7\.G_ +'W_P#R74[1/Y>/W6G.<H/;_7.Q_%<4 H!0"@% * 4
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M2JRS4IBE+SY**DD\BTZXT@ZVP5.9K/#W>_T@N*A10"@% * 4 H!0"@% * 4
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M^*CJG%*'DZN\6#INB:2Q)=),8UWE#:NG$Y[#P"Z8A0)])W'%/SPTZTG%V66
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M'_47:D0YZKTDO_A=7$5M)^GL]?Z0ZK+K^&PM3OI%=9<9)'T,FG^2V[_(4G]
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MX<'ZZ&?PNRC:3C/<WZ N5O<D#LEL6MJLE:D-&X"U">\+RKQLN&V[F;@U#E<
M@/9"K<&MH"P,*_2\B?X*+V[?XTW;0SALO'U95PZ]#9_MLG_Y^22IF]RW9\OP
M-&K?X.Q25VCKVZ"[@NBZRU>T@W2!\:4?1-IQ)UHN#<V."5 [DA>07FF=4ZQ.
M-O-6"4-M]P#2.B<2^:;<O'.3 ZO1N,<$N)EJV4D7+IAC1%,;XLL(9S"QBLEA
M:N,.+&E567N5X/"05D8(!=>7N=<H1KEB8"[,[3!<U^_XDO=6?&C7"M\]$;ZR
M8!(6Q@ER-0X)U;_B'B(]3^6OES=8)A5\D-0)G1HC]IIIAC<25'6QNCR57<88
M880CM5JB33KQL 59:91;G3)WW;O@I@FEP=9"F<M[%_O2@[%)W(QN%O7JK'M]
M5/[DL>307K1<W=:L/( Y6'0R4@I&44@0(RS5-I]YY\7]PB^WW6>^GQDSC?98
M9;=9?99?9<&5UM]H76W .T+K1U" ]FH(RYK<TNYS?U"C\%)^!0HW.;^H4?@Q
M'P* ;G-_4*/P8CX% -SF_J%'X,1\"@&YS?U"C\&(^!0#<YOZA1^#$? H!N<W
M]0H_!B/@4 W.;^H4?@Q'P* ;G-_4*/P8CX% -SF_J%'X,1\"@&YS?U"C\&(^
M!0#<YOZA1^#$? H!N<W]0H_!B/@4!Y6/-R222-(6"VDE%DVCAB/UI)=MEO\
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MYRCZ&;5_);;EU D_U<O/QUT4Z3\YTG[>+]YG93HOS>#]E&OK!Y!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!C_"OTO(GEK^Q1?%P
M&F\7EQT?P]-O.E#.&WB_5E;#KT-G^VS$#\_))4S>Y>N(T7U5 H!0"@% * 4
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ME5+.;5 JN*QG>BKDTG2M<WK%9@*NVR?@ZYMSX4EVJ!VZFQ/5*VFQTUM14A4
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MG[>+]YG93HOS>#]E&OK!Y!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MT?0S:OY+;?\ ($G^KEUT3Z7\YTG[>/\ >9V4Z+\W@_91KZP>04 H!0"@% *
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MGP]X QF9^R4Y!_-J+>+['</9SI75</F!TLS/V2G+DS%O']CO<RI77?3TTGQ
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M\D!O<037YU&77M_<=FO;^FD8OM>2 WN()LZ567P.SMTC%]KR0 X<P0?N59?
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MHOS6#]E>AN%8/(* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M@#ILQ $1[4\DF8B/<[E3-[EZLOGPX9>?$O:\P0+&XNWF[AM$;+1'(+[N9$;
MYH '(+A  YK8 " U2/+;?9PX7N<(7'2@DT>EV)L%=$4&=)+'99@E#XLC9'5S
MM4V/.-<C.C:%+)$3BD3JA1L=Y93@8^-MIK:YV]&MR:^U<W*;+1,3B(S<-Z>3
MEWA;[V*]NE2]&/2V&$QUF*D<;F6+46E#TZ+5J.-6688$0Y:D!M$A.K5GOLP;
MIZPN+<R97&)4*&3J;C#RF,VXRT^//WYLF+$\,;=5ZQG1Z(S[A!B9;B.Q'+EI
M[ 0]6+G$3V-E<3' QH;B5=R9"2Z&'$I[RGGG-I1SRW\[ QF6JMRU/[<0-YDY
M\I+A;:<[:Y0O36L7X927K 0(U"P4RI4">P;Q3HR@.5&A;MM(*NOL R\>"T;[
M<^,*%E1.6N\LG?"+V##YT''FPEZNQJ7B&8<.68=G9G)>F>VW#;\Z,>#\OB!Q
M"+X(?.1_S"7\N\O<HEZ<8]T\SLEOA%]:$Z[6X)?R_+QT+X#?"+ZSYU^(2OE]
M)YA@;X1?6A.A_P PE^^OH/#GSMRQOA%]9\Z_$)?C_=^KRXZ#PYYY8WPB^M"=
M?B$O5_I_N4)73B_A/N)WPB\_0A.NWN"7E_K^?BJ3OX,5T\Z\+>9&^$7UGSK;
MZPE_+_=]W52=_!_ 5T\^?6^RHWPB^L^=?B(OL?\ +^WWJHKIYT^/E[XG?"*Z
MT)R/^82_?7!05TXOX21OA%]9\Z_$)7R^I._@_@*Z>?RYT&^$7UGSK\0E?+Z3
MOX,5T\^<_*NP;X1?6?.OQ"5\OJS\+/GQL*Z>?K3X[AOA%]9\Z_$)7R^A1OA%
M]9\Z_$1?R_R]Q/,-^A*Z<\^_9+?"+ZSYU^(2OE]!73@_DN<QOA%]:$Z_$)?R
M^I,Z^*:]173Y>GH3OA%=:$Z[>X)?RZJ/#GT\_@1OA%]9\Z_$)7R^@KISZ>?Q
M&^$7J\Y\ZUAG_()?CS7[:D[^#*3OA%]:$ZV>L)?>^W]OB[-4>'//W$;X1?6?
M.OQ"5\OJ3OUL_AY7%>7\AOA%]9\Z_$)7R^D[^#^!*Z5WTXQ/D Q"+X8?.@_S
M$7\OJSS#*-\(OK/G7XA*^7TGF'S\,R5V<?D3OA%]:$Z_$)?R^@KI\/CY>="-
M\(O/T'SH.SN$7\O_ $U)WUV/ST\173GQCW$CB$5UH3D>TPE_+JL^>Q\KQ$O1
M^,>YOWD;X1?6?.OQ"7\O]W*A>>>6!Q"+ZSYUM]82^_\ ;_EW\A*Z>?K\ISV2
MWPB^M"=?B$O5_I_N9T+X<Z<_<'$(L/N/G0_YA+\7[OSH*Y>OR9.^$5J\Z$ZU
M_P"(2]7;_=U">'//EMH1OA%]9\Z_$)7R^A1OA%]:$Z#_ #"7[R^@\.>??LEO
MA%]9\Z_$)7R_R]R3OX,5Y?R XA%Z_.?.AR_Q$7K_ -._7V*I)>GIS/E>MI;X
M1?6?.OQ"7\O]S/AH4;X1?6?.MGK"7WOM_P N]F'///RG?"+ZT)R/^82_EU"2
M]'Y?'FEZQ&^$7UGSK\0E_+_+@SIG'QCGS%=//F^5=\6&^$7UH3K\0E][[?\
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M%24J) TH<C"AO)OOMM-+$<C"[A"^P<@NM :&C<: 4 H!0"@% * 4 H!0"@%
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MU96PZ]#9_MLG_P"?DDK.;W+WE+ZJ@4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MPN)V//)UCF@WS(?U8Z\EI7\R4+IMYJ-\R']6.O):5_,E -\R']6.O):5_,E
M-\R']6.O):5_,E"357KY;QOF0_JQUY+2KYEI',H36(>^*<_?8;YD/ZL=>2TK
M^9*";T=(RO.GO&^9#^K'7DM*_F2@F]'39?<-\R']6.O):5_,E"C?-AP9?NQU
MU_\ -:5?,ON4(W&O@FQOF0_JQUY+2KYEJQNXH3:CKLMO&^9#^K'7DM*OF6H)
MK$/A2TWMLWC?,A_5CKR6E?S)03>CI&5YT]XWS(?U8Z\EI7\R4$UB'PIEGS9C
M?,A_5CKR6E?S)0)SJM]QOF0_JQUY+2OYDH)I,/=%> WS(?U8Z\EI7\R4#<:\
M\\T&^9#^K'7DM*OF6@;C7@-\R']6.O):5_,E!-[T\]PWS(?U8Z\EI5\RU8W<
M4$Y<0][4(;YD/ZL=>2TJ^9:D<RN5XB;T=-E[VYS&^;#NK'7/BZ5I5G__ $M!
M-)A\'/#S(WS8?U6[!_-:5>\RC5C=Q7Q$['P?O@G?,A_5CKR6E?S)4*-\R']6
M.O):5_,E -\R']6.W):5?,M6-W%$G8]\,;YD/ZL=>2TK^9*@FL5M,Y?>-\R'
M]6.O):5?,M(YE";T=-E]VOS&^9#^K'7DM*OF7@_JI',H3L>66O-8F,QOF0_J
MQUY+2KYEI'QNN?"XG8^'+^[=+?,A_5CKR6E?S)03L=IMS4;YD/ZL=>2TJ^9:
M";4==GKIZC?,A_5CKR6E?S)0HWS(?U8[<EI5\RTCF42=CX,;YD/ZL=>2TJ^9
M:!.8HU.J]=!OF0_JQUY+2KYEH4;YD/ZL=>2TK^9* ;YD/ZL=>2TJ^9:$FL0^
M%.?ANEOF0_JQUY+2KYEH)O1TV7G37:1OFP[9T8ZY\72M*]F>6?\ (M!.Q\N(
MYI%9@G?,A_5CKR6E7S+03OYYR^$M\V'A_NQUY+2OO_R)5C=Q0FDP^%>?+*Y2
MPJNOWNXCSPA21>+03<)*I,>E4%\U>9<%IR=264H)OR$!$LXNPRW/*ZT!J&>\
ML-*TV+.NS71&0J&L-EN7H*%% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
7"@% * 4 H!0"@% :?AN_^*[\H: __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g759370g00a07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g759370g00a07.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2!J4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ($Z^@G X0DE-! 0      '$< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M @   @  ' )0  AR<C(Y-#0X-QP"!0! 36EC<F]S;V9T(%=O<F0@+2!38VEL
M97@@+2!0;W-T($5F9F5C=&EV92!!;65N9&UE;G0@3F\N,2!/<F%M960@4P X
M0DE-!"4      !#&R:T%1Q1%R^Q1Q30C:6B!.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0%@            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE-! T
M      0   !X.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@             !JP   B$
M 0                         !              (A   !JP
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   !JP    !29VAT
M;&]N9P   B$    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M\/[T:NQMC=S>$Z&?',U&0)[*,*[N:S"ZZ0"_J#6D@2T5-=!  =M?MJ_.]_\
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M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M+4P^W_1P5;/) );4)Y1$'?((!&/(1O,&*V&^(V;CBFD7#2EH3J("TDE/A (
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M(FL,;Z=;&R.P;C:%C;+.P=/][+=5ZW2T8V0CC-CQ-BE8Q@ZO<G**N_HR/I$
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ML3(CQI'JVZ9(=%\YE^H39..:Q<V6LR3AYNG2FZ4?8Q,Y(,&_4-.B1E*$,R>
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MQ?"RDA22)/,S$YF9,>HQG((XG;/A]QQ%-DTS;O+"'2XM2$*)0"4J@*2,'*A
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M7>YS?9Z\V2"V7V2>[?;E1T G"'GJQ:G6UJ=0:,9%I-2T&T29DG7*Z9Y\\D2
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ME]P*=!3@J1WTQ*2%1M,.Y?$FVT18H1^_7=,FCCZ/EHP[HYDD@,,@)XO;YJ&
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M(!(2#(*52J3(Y$R#$$&:[5[8+7Q:VNK)0[Q_5;7B4D^ !.APK0"DE00I)*2
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M.W!BE*4@*& "XP<<+BE+49*E%1)).29.Y.!R.^*N891;MMLMB&VD);0G>$H
M2)QT ZQG.:]_M*./A*..0X <<@;(?_> #<>H /D UA5U3@.1P&1\C@.<^<_@
M&E*G2E1VE#& #@1,' <&'.1#[1[AR/D<CGR.E*CL)D!["Y 0$![0R AD $..
M! #&P/D,CCR.E* 0@#D"E ?F!0 ?&/0/EQ]W&ID]340.@]U.PF<]I<B @(]H
M9$!QD,X\#@,A]@?(-1RCE,QRGK'6D"9@3UY^^I[2\?"7@  . X ,8 /D 8#'
MW!IOOG,^WKZ_.I@=/+V=*"4HXR4!P.0R #@0'("'V@(B.?.1SI2!T\_;UH
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M\Z0)F,[3SCI4@ !G  &1R.  ,B(B(B./(Y$1^\1TI Z5/^_^_P"(Z4H  '@
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M2E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E,!\O\ ?_< _#2E-*4
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M()W^I)'NC'_QS/MF>9BLOP=_VBO=]_+[G =^%P_Q*GZ^7P\<<8'W8. '(CD
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M' \Y[1 3"(_BGX7>VEWQCB[O#V7RBUMG7F0T'%I;4&W%HU*0"$DD &5 DSG
M%>UX-P]"+=+Z@D+6I)"U ;1)$D8!@G!Y@<\8O$ /CO !'](<@ Y,(9$V#<%X
M_:'V^GQ-:4J$+"5*&#(! CI,DYF(P >0D5Z0QD#EZAL>F23OD;3R&*=A>."\
MCCD. Q\QQC 9SP(\#Z#Y=V.20 !@  $#D (/+&>?6,QI!G @3(B.NV^8'K]8
M!-.TN,_#D1\ './PQQR&..>>0P.I[H= (ZP1^R23C.??(IH&/#$^0/J$0,[;
M3SQ@@24">I2!@/(EY'("4!QR4<"("/&>,\CG.6A, :0=N0Y9.8!SD#EZL4*
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MC$]-M]A$SG.3U),XYX&X^N1G&)=H".0*&,Y\9[<<]PXR/ B(]V/F(<Y ,.Z
MY)Z<A[/D^0Q/+)YU'BZJW@22)_SY=.?6I$I, ':7Y"  &<8QCN[<8$/&.X!X
M]  -0&M/B(!!R)VR>GES!@@[SM4 *&=1(,Q*C DCS.VW( \S(%1VE\ ' B/D
MH<CGY<_?ZCW?LP*4S.E'," G$9P8W/7S\XJ23)SO//&/WF/;/*: 7(_WH"("
M.0[?&/40\> X'P'(X ,ZGNTX.F/*,R?_ (B-SG,G&])B)*O5)GZP!CGOT\ZG
MV0>@$-V^I?3/C&< (B.< 7(B(B' B&L>[&) $\B )CV$[;DQ$#E-0">:B,QD
MD?;'M'OS$  !XQC.? >1$!SCU'/GSSGUUDD!$@ )G<)@ QC.1'6?.8P*" 9B
M"3G;.=B9D;3/4SB :OS;FQ.(*PM<F_>3Q<K)T43"!<.#F*BKC^U]Z!@Y.(#V
M(G[<X$2A]/\ @J[6/<#X_;6A6M5O=OAI:-2N[$JTSIU!/A@[C$#$"N#QFS0\
MRMT1K1L8S@9 YQSQSD'>MV$S <A3!X$ $/V@ _Z]?O-I:7&T+3A*DI4!$0%
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MQ21(@@ G$ G3B)&0,@&#%7I<E( DF!S&HX@[$D@^PS.1->SP..W)@$ ^( *
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M"TZE)T)2Y<MI<:3+:E:GFM:7%-A0YJF7TAE:04N+5I61(60I0U JDZ@DP9D
M$;Y(&RWY5S:V+H_Y)G=/8RB1<W-2#2E[4TRDP4:P?6"XVJ1K=XHRCEU[E&)O
M9J:G'+2&E+)9I3W<JYU4W\V_632(N^>^4[#7K2^UMO<..6["#>%94ZIAE :C
MO5CQ%+2$@!12V @$Z4H02I(.Y>M'T,@"% J1("B2!C)C48QO.=R<A.SNVO39
ML[8)/9[J)NMKNN\=BVUK!WNV5AW*LC=:N[<GDX1-E9Y:!J4+#4NB0]I]T;?1
MTA8)^ =62!20,W&3CW"#LZO/XKVHNV[GB-I:=RAB[NT(?>90A"GD-/+[H*<0
M M34D*[LGNUJ0TI0*VFBC)JT2&TK4=2DH 1J)64D@?)!)(Q@0!^=&"16K7Y*
M B;2T_E$6;MO(QCRT_E).I'=&KMI:-?Q![7MW:%Z6A!76N#+-VB<Q5Y1W"KM
MHV:8/5X]RL0JA5@]X9F+T?A+?3>6W95+3[#Z6^SUBBX2RZATH6E]6M#A0I02
ML9[Q"H4A4I4DJU$XV"%)7<A<@+?=*5*!"BE2H3!.3(@R)D"08$5N[U,6?IUN
M[N6Z9=Z+9:8)YN#47LQ]$PD]NEMF%EK[I9[!N(F'W+I1J]'S4TY4;NVK[;9K
M9GDU)Q:[$9"O*QDK'2 ^1X 7N'J9XLDVS[:+E1[E[T=^% !2BY:N]X2@E8&M
MQGNUKEL*4M*@G8>E04T"9V!!4D[P,R(R)!"P9\4#=6!>F+;#K'J/2SMG3HC=
M6JPUAJ5KW*:0,[U-;:7#<RZ3.PS:[SS/8=&V1]:W*V9<UZ]-MMBUMQ9RSLG+
MNHU$48N523FFTQ[3TO'N)=E+WBHO;NVN$H<MF>]:LG$6;:>(*:9-TL2W?-+:
M%QZ1H#;+*2E2%(*$I"#K-(NVAI"T0"4G4).D2$A0D+U01J)E6K!!D$8:NVQ4
M4R_*)QN[?6%7:5N)MCN)T01&RL7N#*5-5#9&#W<INX;ZV7JJN*[9)VX0U&;7
M9A*MK'MXI;+'-D+*P\K#L;-*6"((JOT&^.6+?9-7#N%/+MEM<6N+H)=?!N5L
M.6Z%6JPXAMKOO1^[=#J]+24+>;6VB%N=W6JV<<N]:B5 - D'5I"H!5@GPA4@
MIYD"-HK-GY-JD;@4C;'=R#L2MP':]/JCWH7Z6V%W=3#N>B^FKZ6C$:!'@6SB
M-C0J:DY'65S2"6%3WYS0GL&JS-]$O&#D?/=M;KAUTYPU5FQ;MW#?#;4WQMT,
MI;>O.[!4[+202M;9;+Y<_*&Y[]2]]0W+5"AWJBHE.I1;"M6$J,Q[#J*(& $]
M3/T3<#W.5B@'<)E5A'^UCCXQ$0*(  %Y[@X^$ ^(H#D->(292%'$A)YC<<P,
M'!&WJQ%=  Z0<C"3B>>9DG?.,S]9KKB Y+_>@8 #["@/ AZ<8'NQGD# (B.1
M$<N1YD9]9Y?9ZQ@"(K.1RC$GUQF1$@;;Q!VV$5/Q"'D1 ," "&0' "/ B'@"
M_$!1QP(\"/F,3D#,^R2!D=9P2.8]T&#I'.<[SO&1UWGV&8KD:#E4GC^W!@ S
MCE4PB'GUS@?4?4<YSU>S0 XU8\@+OI_M3TK4NOZ/<D<VU3[ACU?OQL:^@4;_
M !)O_P";+_4&OZ-<%_\ ++3_ (+?_8FOF;O\XOUG/7SKO:ZE5TTI32E-*4TI
M32E-*4TI32E-*4TI32E-*4TI32E="1_BJN0R'LS^?' EX'_?YZY7&?Z!<_\
M >_[15C0EQ'^\/\ /V&/;6@CG +*X\95R ]P (@<X>0XP "   "'R$0U_.OC
MO_F]Z/\ ;W(Q$@=XKIY]<9VB:^FV7]';.9"$QM(.A &!YR(/40(FNMY[@$?A
M X"/C/:)A#@,"/&1'S@,^,CKBC$0,E,#UQ.<QF.DXWK9& ,<CS)S&?*)CSQ)
MVJ!#X@Q@,8$! "XP!AY\AD2XYR)LX$PF[0SJ>1GVS.Y Q[?(#<")Q4C;!]>^
M9C!]QB/VDTQ@PER 8SR =P#CGXL>0X#/& QR4!SIR!WF/*.6///7,[[4.W7F
M9F2)P<8WGF3!WS CT$,#QP<1 0X\X_OL")LAG'H7QDV1SO!Z;'V\I$0??OBA
M]<DY&.1)Z\N@SN<;&N0BJY"E*FLH0"B/:4BA@ IA4]I^Y@4?TC*_N@B0/TA
MXCD1$,@H@  D 9 !( F9) @ 1.^^<8I"9F$@F,P/DX!F0<"( )C:!@$RF<4<
MBG^Y&, $-V9)D!)[,0,!<9#V8B3M-\(%R7&  HP2H)*4J(29) .#@[]9YG)/
M.9)J%)!2 4@@ 1(&!,@).8C$01B,;FI!84^XI1,4!$!$"G$"B)1[@-@!\@(B
M(9Y*.>0$1[;$ON!O0'EA'A)1K(25)!2"4ZH) , D;$C:)QT)40HA)5$20DJ&
M#N=P-@=AG$XD9RJ80[U%3@ 8(!U#& I0$!*!2CP7!R@(8X 0_1$0#6#2E,J"
MD++90H*1H)24%)E)3I(((DQ$$2((VIH3&DI&=QI$>T'?R'J .(KBR&?/S HB
M A@H]OPB)<"(9*3/H7V1>WNP :R4ZI:BM1U*( )495"2-(\1,!. D<B1@166
ME($!*8  (@<L8!$8$8 GQ0<U64H$$#% H&R)N\N,Y,4"G'(8'XR_ 8?TC &!
MXQF\7MV$PEW2(  E<QL <Q(&_+/NJ+"#)TXS@# DY Q$#EF! C:JCJ'.8PJ"
M8YA%/N,81,8PI]PH@(&')C$%50R8B(=HG5%,>1$:%.%:@M:E*6,@DSIS)TDD
MZ0,@#, B=\9AM $!(P,B -MY, #;H>7J''D2@&!'XBB3&!Q[,I0*4H#G  0@
M !2ER! # C@ *&+AU&3)(0(),JYXZF?. >0YUEI3$!(  $  9)GH,SG..L$&
MJ ^WX@X#&1#G @ YY .W @'=Z>F/&*=P-H,;#:1B!OOF(S]<CER@[0,;1 QU
MS$<I$Q-9N>#%[<"(CD<CR8,X']7D<8(;D!$,Y-AL3!D;"!C$QCK@;D;\L4]1
MD1R!'0;;$^LYVYB:<X'D/O* !_>AY'(&P/ B;)?&?0PZGV^HYY^[&T0?K%#M
MOML.>?:001& < _2Y0SZ .!,(EXQ@!'(8\?"(><A@ $>/GBC^<1M,9YY@S/G
MT]E8G?EMG(.8(^LB1U,&>5;6[+8_-I4<Y'WYSGT_OB?+[@U^U_@._P#3"NO>
MC;;Y")]O^->"X]_35GU#WC_"LQZ^V5PZ:4II2FE*:4II2FE*:4II2FE*:4II
M2FE*:4II2FE*P[O7_P 4_P#K:&<!S^GQG[//J&1_;KXE\.O_ *2__73^_P!M
M=O@'].'J^W;[[36IH9 O CR 8#&0,;.!X$/..#=N0'(AW  @4?Q0GY*?)(D\
MP-,C;SVF#SB1->^2,)CYH/U3N#CRVY2#O3(  @&!#.<X\< 4HFR7D R.0[0'
MNYSD=91SR,==\DD"#@XZQ&.5921D<^1.=XP)U<LY/N%24#X,  (E$0 H"7'@
MV39#M4.; IF$0 Q2%R;' B XA#A5J1XR23 .H"<1'*,1B#MG$4K7I*H.1S!Z
M]#OOCSS!FHP8 #NQVB4<  E+W";X0/SG)2"7!N  #AD0R4-6*;=B=(DC,8B-
MXF"(F#($<MZD+$<A@2=Y) R(VD;@8(DX)JHYU3F 3@<2D)[%,XG(;M(8HE,F
M454P*5,Y#&*=/!2"!C F80QFH(<2HJ+;I,$:@3$;1@_)QS,1D#:L/ 23,YF
MJ-@=QB3J&.8P1'.1.<4O9',;V1S&[T0$_LA\!@R9C 4P#V@4!,.0*3 F'M "
MV E.H)E)(E0F"2=YB3(Q(,R8]9MTI(28! @I) ,$QF8/+F)R><R>0ZJIO[8<
MQS (_$83''N,(B..<Y$>1\9#(F 3<":=4A>M*E)*3"5)64E.D:=YD0G&#(&!
MB8P[I)DDJ*2HJTDB"1))TD$<S."<X,34"=3M*4#G[.TI0*)Q I2$,8R9>W'@
MAC=P=HCVCW@7 &Y@K'B$)@$8B9(." 3&(A.,8.XQF$MI&G2(B/D#, 8((B($
M00.6,8H%0_>*H&$I@X$P&$3Y,83\F[@$1[C'.&,B!Q'(>NLW''%A.MQ:_!X=
M2E$ :BLA(,P"LZB-BHE4ZB:G0@1"4_)D'2!@<H Q@=<\CN#R HH "('-W' 2
M_IB/M 4'"@";N 1[A44]H X PG-Y^(1-NE"-"%+0@^)24$H23DR4C&3D&">9
MR0!&A$SI!(/RH (/48QY1G!QL*XC8-@_(#D%!-D1,)LF#OY 1R4V1 1/QG@0
M,8=822HR9.HD3R.^\[D'>)G.0*%"9,I!)D9 )F0=^?GT.8KD*LL4QQ*HH'=@
M5!]H/<)B^S$IS=H@.0%)$<#W#E(@9$R9>W,*=3E"E+4KEK5!G!3G!\/ASC3
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MQM>\\7,33;<=U*6V7K#?;G;.IQUAV]4=ST42 >S4Y-.;&J^38KIFC:4]0C9
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MO4UT[I[F-J3U&=$FQ6^O2Q^4@GK=09)T]9TVP;>49^TEY^*6W&8=2MJ&/2V
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M1LU*(/)F42FK%<!.UKL=[QKX0KAABU2H*>]"X@BZM7+E9N';=BV6XD--N+A
M:=60X\E+2$.NMMJ"4P4GGFR0K49(U:M21X1XH,:1).D0$Y(2%09'BK,6R'3[
MU'5JMQ.WG4+U&5+?.@URK.*.BRK>SRVVMVO<6YA%JXW/N]:7&YNX+&=<$C%7
M *,ZI5*.I)SC5K,/Y-ZBE+0ZFGQOM%P!V[8XKP:UN+7B(N7'KM*WPY;*?<5K
M6EA*6T+;;"U+ 2XX\K3I!5K2HKR1;+6E:%JE*90%%)!(F-1.HRH@9TC?)$D
M8?C?R>\V3I41Z&[)NVTLG30REHYBDHK49!AN^MM!"W5I<6>TTI:OI_\ -U=R
MS!LSJ[C<)G2H.25I""S M/C+$HQNREWX:VR^+GC:+<,\24TI3J@5);5?F5+?
M0D0I/Y67@@J4V79):]&4+<!:RGNE$E"3H25!(.A(  )!5((&\3!WU2JLX;4]
M+5CVYZJNJ7J ?7:L3U<ZEZ_L_65=NV=#?PKBEM-E*O8:O!D&SC=9U&?+*M;.
ML,RB%5@Q R*(M6[,$S":.(=N&+KA7#[)AEU%Y;7SU]=O+<U)<>>#(<*$Z$E
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M9C!I[9<HF/[0Y#CR)NXP*',(@)N[ @)@''DP"&"@7.<Y;@))*DCE)*4QM$R
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M8$ CUI$&,^(Q)S/G5)55B!@BJH9$3"!3B'Q"9-43?"81Y5334,/&3I$.(]Y
M$F0P21@D:21()!(D$XD'2,9S'E,E*3DI28W)2,YC'F08Z '$ R8 #B/< F'@
MW( (Y$2@4X9#X3 < [3#D>\H8$!$0*->AL&="-76!(GSC4,>Z>DD3"?FIQRB
M-YYF#@1R@3R D5^V6Y$JIRYX "G.(*")@$0')A$1$2E$0, Y I,@'PYLDG<D
M]9.PCW1B,'U;&((2J)2"-I4$XWVP0!OZS,9DU0)S&R)C'R(@81$PY-@P&_OC
M#D04*40'XAR0IL )!S)4HX*B1M!),;?NS&,XYB("4B-(2/8,2(DXSMD0,G&X
MH!CD$.PY@ ! WPF'],$E$S"';D ,5-PN0#8X355* X.<#80DC(&\Y'4F"=M^
M?,ST-3I2<:4XYE(VU<YY8!C,D9SM AD!$V0,'SSR(B)N0] P/  '(B(^ -B1
MB -O+D (QU\R3@"-R)8$"!&"!&(V( ,]-S&V,4+D3  C@ +^B7@V#"'[H(@.
M3<ACM'(@'PAC]'6+27'7FV6_$MQX@')(\1\,[@ 1 'JYF:%N$(4.>H@$3( $
M@ DXY 9V@<ZW$VHC5H^J-#+$,4[M11T(" %$2+*'%,P@'  9$4S8SP(<@ @
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M9JOQXUG44TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E0( /D
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M<#D*WK%]EE3@?"BA;:DC3,RKV@1^R1M7FE5W7 , VIX  !Q])2PX\<<1H!@
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M+#( (\!X\:Z)'PC@G/ ]S_K;@<\'?U>V*K_D[_;>Y'V?Y;F!4>TW7S_$Z?\
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ME-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*5 F  $P\
M&<_LXU!( ). ))]E*QC>K1!!7;(Q"38F>!%R"1F_O:7M4U@;*![%0@*"H014
M @=O;\.? 9Y^8]O.V/9RRX-Q:QO.*6;+YMBCNENMI6%004%)4"5:A!$3/7>N
MC8V=PZZTMMIQ2%+@K2"0)QOB.>Q/F,&N:E6B!4@H%D669&<FCF"2:!7*7M%%
MBM$LIID!0#"(" @8HE#D!$0# CJ.P7;'L[=\&X78L<7M;BY%I:-]TVZA:PL6
M[84G2"5!14#J)$E4SF16?$;.X;N+A9:<"$NK&I22)'>*2"3$9WWP,\IK) >
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M]/E]W(^<<CRUK^<KZ1^V@0G/A3@_-!Y ]/,Q^RF _5 1Q@>/(9'(9 /N$/&
M'.1#.FM?SE?2/VU&E$_)$&?S1C;D1UD<\P.@#!0],A]W@ X'T\?=C ^.!'6.
M^] E)_-1,3LG<YCG CVD9P10>X2_N94U!# X.4A0'XB  Y((F$"@J".142 5
MBB)BF4X"QAJXN%*2R"H@P.@V!YC \R!,[9JM00@R5$"<B1C&PY>< #'EBH*8
MPER<$R)E PBHF5,X"!^T $#"F1+ ID.D4!,EE?((G25.#D+7F+M@?E4*0D3)
MG ((QJVVF=N0\Z@+;4<'R$$9.,8)(DP2(,#<5. P(B >!#]$,\^GD? Y#&<9
M]?GKA:R =2LB?E'[:MT)(20D&8)P,C?.,_OY]1(8\8 <<#P!?M#@0#T > '_
M +IUK^<KZ1^VFA$?)$9@@#U9.?7MCG,&H "CGX0$0X$1# " #\^?O$/7[=-:
M_G*^D?MIH3@A*0#)F >0Z[<_(1YP9 I?&,#@!\#QG[^/N#G Y\Z:U_.5](_;
M4E"=]*8QL!GIF/\  XR!-!   > #&., /X?8''H 9#SYTUK^<KZ1^VL0A$"$
M@SSCU\Q^\SZR *CM#N_1#(>1$/0,!Z<"(@.?LSC36OYROI'[:G2G)"4[$QI&
MX)WD2!B.0WB#%!#U[? #C(!YP&./&>1]/LQGPUK^<KZ1^VI"$[:4D\_",>77
MU'><[5. Y^$/Z 'D/N^89''KG&<8%K7\Y7TC]M1I21\E,Q/R0=CF/? !@\C4
M=H!SVAG(9P&,?/G/_=QSP'#6OYROI'[:%",C2!'D,\NA.^!S.XF@@ ^@>@\\
M  !]H 'J/VY ,_+36OYROI'[::4C\U)'.$B9]6<'?&<B>=2(%]0 /&,X^_.
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M[:;M;:BA*U(!@KS*8WA0,XB8$XC:8%2E(2K00F3,8$Y$8!@P!T'*<@$5 8,
M?"'(@/  ( & $," =HX' < &0YP CK6*E@P5J)&"2HR3S.35FE."4C8[IS)V
MD8,F<@[' BI' >@9^0A]OR !SCQD/(#P(B&FM?SE?2/VTT)&Z0<3L//J>?38
M;XFG:&?T2_AC)@Y'D ^P,^,B'CSAK7\Y7TC]M A$92-SB!.3 $_L,],\S.
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MDD%2* (^S(JF4&JQ0'@ ,FDF18<#W=QA$,"(B/X9^'?@EU9<>]."#W%RDDK
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M8.N-N%UY3+*&6W7%=[H+S:&TI3I2$N !3Z75E2ET(X<&5G\HH J*@ 4P 3(
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M&S??M05A*T!2I2E4)4"/#D &-\D$D@FOH%IQBSND:E*AQ4+4G!*5*RH>H&0
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M(J*"< _3]H<1 PF-E\3<1_J[^9)!85UYP/=]>:Q[]'-;)S.=&X @_5C]PBJ
M(8 ( '6+[,3&)R;!#'[04,00/@HF H=QN!.   B(@&GQ-Q$;6[_LMU>[;G]X
MJ>_1^D9,P#\GEM.!]SM4 EZ95P _(P9 <YX$<8#CUSC[>-/B?B7]7N/5W"NF
MVWL_PS3TA$_SC/\ TX\MIS]XJ/9\>5<]V,?&.!X'(X,/ "'.,YR XSD-3\3\
M1_J[_P#]!7V4](1)/>,_]/+EM/WW%3[ 1Y ZO["F\>G.>0S\A]!$?MD<&XE_
M5KC/_P"77^V#_C4=^C](URCY'O&.0QGEM3L,(X %1P&/A QN[QR)A$1*.<9
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M /U59?\ +M?W*GTI_P#2*^DK[:GZ"B?\Q;_^S)\_L#UU/X,< _55C_RS'_\
M#K$W+Y_UK@]2U?;3Z#B0X]P;#_ZHG]/'KY']NH_!?@&_Q59?\NU_<J?2;C]*
MOW_;4?0,3D1]Q0#(YX3)_P#L^/LT_!?@'ZJLL;?Q=K'_ $4])?\ TBSM^<J,
M<XF*?043_F+?QZI)C^/P\_TZ?@OP#]567_+M?W*GTI_](KWG[:CZ!B1\L4/_
M &:>/V!V\?@&GX+\ _55E_R[7]RH])?_ $B_I*^W[[;8J?H*)_S%OX_R2?\
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MG%JM&%:W&F5E22PB"24$P<0.4>^+RX>])> <4 '%P HX.L^<8V_QS5R%@8D
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MFV^]4J!K27 GO A)S!4=42H[)$<4X9Q'B+ZEN.)T!:M*"M6E()(&(B8@&!C
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MD,YU^+;F[<X@XMZX6I>I2EJ*U%8\2M>ZB9DDD;C<YP*^@(0A"4H0/"B$I*8
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M Y OB5,)'BT)B-BD Y/,1/.)/GN9J3"A  $0, !4^>!/O]LC("AP./& '@/
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M2%H+P4VM#JVWPW;:^];9+BBMXVCY-*WELJT%U1DKTJ.HE:25!) )$ 2F2!R
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M+]"#.UC9"0N-I=Q)&E@7B8^"3CIF"8N+$O(\S@G ;1[LQ=<7'Y>Z9O+=@MK
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M"?1CIXF=YV/X;=W2KFTMD,%'9:TXPJR;:UI7<NM62EAH.DK2A27W;@$!P)(
M!+<.)R1>.AL)4M2R+AQLK4KQ$)4Y ,23E*4Q@$$'<D'*'5+;>LOIHZ:NM^XR
M>_%28R=/JE:W+Z=F<([KNXVZ&V\(NY"#N$)N#+6_9RGURTU:4L!7Z^WTG(U[
M\ZFZ#>5BU[#/#7")GY_![/L]><:X#9#A#W>*N;9B_1<+FWN0NX6A*@E!2X-:
M#H<0  2V@I2HE85FZ_<I0\L*4 0I;9!(TXG2))$#& (G?!Q?W5"PZD=AMAB]
M1M2ZA]T=Q6=#OVW6]6[FWYJ_MBW0EM@63:''>^A408^EQLA#(1]92=7BOO'U
MEGK'&(Q,G&'G91[)/GSRKAAX1?<<NN!W'#;5C^+O\-LWTK*%KO\ 4XJV?6LK
MTI6I?=L.+PVADJ6&^\!<5FMRX%HBX0MQ1"PI>HDF,:Q@$D 20G<GR(36)H'J
M\O'U^;WP+.\V6X[7]3]#:?\ Z.NP.$X!"O2NXE=E&6VNYL-7G$7!(RC^&C]P
MK7%WJ)F;&:76':>(E[6U,_J\:SD5[^*=FK(<';N&;4-7O#7BSQ,-NA2U-E1(
M?>0JX +J2EQE2$MLH24-(<4JX?,8M7KQ6I+A/C)* < )D>$$)!"2/$"=1'B*
M0$IFME+3?=VMONM_HVV.+NI.6/;W<+8[?>4O\1-PE)25LUOVHAZ.WA[BK*1M
M<C)MC(2#ZT/9&6C869/5BN@:"SBVZ35,$>+;\-X?=]E>)WB6 E3?&[0)"-2D
MH0_;<4<=:$E4H+C3:AJ4I1+05J.E1-I=6F[2B"H!DDSG41W?B/,DRJ2!DDX
MQ6*=M^I+=2G;MU&D=2"6XT-8[G:-UYG:V^TE&L7WI@ZJZ,2#NEOV\H5*D(-B
M,GM%N+7ZC&QCN,@Y(D=.VEU 3*,C*W=S.Q:+#IL=D^'\1LK6ZX4];K1W%NGB
M#+J=%U:.?D&GWDH4H!3+ERLI;4VIY :4E2T6ZEH0BLWCK;A!21*U!!(&8*IS
MI!$)^< 9G*T@SXG3YNEU7]0>TO3#U7UW>/:2LTZX66OV#>6%FKLC.4^7H=CD
M74%9=H*S30V0K[VH;I4VS.X^N4>12W(GWKVW11JO9IJ]J3J2+2GC7".#<!N.
M+\-O^'W-PXAIYFQNVD=VE"V5#1=*1"@MMQM!6K(\#O>H4@I2#FV]<7"$.)=0
MD%T%2=4F%'*3I@@))&,X'B $UMMUY[^SW3ILW5;35%H:(>W/?+9S:.1O$\X0
MC:WM]$;BW5I"3]PEY9:*W!C(MM%PZ+MDQG)>O3D!"3;]@_EH*SH1<W##Y/L3
MP.VXSQ&[9N%EU%K97-XTVV4:G"Q;.OA+H6N5)@ N#"U +2V%NP*NO;IUE#81
M\E;B0I8*MB0#!"01XC$# \,@)()MRD4GJABMQ-T*YN;OE6X+;*_[8%E=KHB)
MN#"[[R[6W. 5:L[=>(>?G]F-N(69H1DI6%<K15Q:6IO$65_%1*)AB9\6$;V;
MT\)99X>GXF>3?M7RDWL.+0P[;%6I"5-I(#*@.\00VM 4@("4I6A:U8H4^IQU
M0="D%&I$D$B1@C_>D&2F$E*I,$3@7\GSOANANS?[IM?OIN])R.YNSE0:$KK!
MC!L(&O\ 4MM?/SEA_-#K*KS-W J*/8*X,WD-76U7J+IU5*G-1RBLFE87%VV[
MA*[U>UO!.'V]M9<2X-:A%G?7J@ZE<AVP<25*<X>Y*CEH.)'>/:UN(0UH+;B;
MELT6URXI*TO.*)2(U@D:Q,!P':"$G 4D S/A*55KT7=;JKG>C7JQZG4NKBX1
M.XG3/OMU0L*'#N*=LH3;NY538F]O&D73+U7V6W47(3DA;:ZQ-647M:LE?;H/
MG4;*L$47[*;EI;T X3P=GC? .%+X,P[:\5X/PPW%P%*2XQ<7MA;"X?96E2RE
MUM2S<MZT.I2I4]UIA%5%YY3+[H=<!8N'@WXC"T(=6$@S$I*$A)B"<&<R-CJS
M;%W'Y4>,NUQ8-:&Z=?DCXZX6F/FU!%"F/EM]&4_.(21W8M5DV];=IN"/2+=G
MP,G0+*MENXZO&N;"W3V;-DE3KK'X1(:1I*E*T: D)4?SI025DQJ4LDDYBP.*
M+P<5\HM)61/R2O)&",B8,0)'3!M/:'J-W>6W2_)V));IR>Y]&ZI@Z@(^[7B:
MJM>IU?W/CJCM9-[G4>[;;[7HJS-DVV@XTT#]'QWTBO$2TY O#GM%>=.'D'81
MM>[*V18[0CT46S_#65.VS:RA5Q;H8O46I:=< 2E:RVX ZM+3>IY*5,AADEI<
MB\7J:'>%6N K*H4HH*QS.,&))(3@DF2+&MG4UU%0W2=^54O33>68_/KI?ZD=
MSZ9L_<#U?;(92!I]4INUTS#P+R+1HJ-.F$BO)^4]O(.84]@6.X,N=TBJR;%3
MV$<#X8KC'8EISA[;K?$;*R5>(4XM33SKG$[IA:U)+A(46T(3I04I 2$I0E T
M'!-PX$WB@2"EQTI4""I&-0SD]8/(<SSV/IU\WCI?6YL)MS-;P67<BA]073'N
M=N#9ZG:H>E-XNJ7C;IWMVXCY:BKUFJUB7A(]1E<7D9(1<Y,S+=VR3:O'SY_,
M E+GY7&.%<+=[,<3N6[9#5SP_C%K:)?;20XXVMBYEMQ6K2I.JV"D% 0I14Z7
M5.#04V,N.!]H+4M274:PE2BH#44$1(F?'F9GPP!F>M^5$6L:=&Z-$:]=;=3T
MK#^4-Z5:G/!6))"+)+1$U>P>I$F *UD49%.)E(IA*Q+%X5[!%E&C9Y)1+X[1
MG[OQ_@Y;8N7N.!UEMQ3?9_C*V4.-MK*5IX>LI=0%2E+HE4+ U05$#4<W<2"D
MAK22B741I*DR-:1! @XZGU 'G9*NW=AMGY4[>6HQ&[%_VZ]V_)Y['IOK=3TZ
M8:Y2ZR&Z6Z;=LNK+VBIVJ";*'>*'EWY(BO,7LC((%5]M'LFECB''KK92&^QM
MDW=MMO,N=I[O\@I,I*#;\(5W92,02M16$PKQ3*2:TUI4+I6<]TG(@*!)6-4B
M#(.0=NDR"<0]/?6MOWNYM1^3KILQ8JRIN#U,U3J75N5XD)=CM:M>K!T[W :?
M&5* F8RB[EL(>R6B+][N-C:Q-.KTNN$$5O".:JD^=-E;>+]D+!I?$^)6K)4V
MR^V^.&L-ZRPQ=AQY*UG2"EAE7=LI44*2KO6P'5 I+MC5XZ4H0I:E'21J*B25
M(T\@?E$%2E"=0"3*<$I^E?2\PWXKT7?J5U [F43<VSU_<2;=U-_57Z;ZR5_:
MJ>!"2HU4W*=DH^VS"7N\0W*_3=V%E5X%>8@!AIE_",_;NWJOS#M2[PIQZQ^+
M;5=FL6UNF[:D=TNY0C2ZXA(2DI0XH)6I"RX4++FE0:*0G>LE.I2OO5*67%%3
M>HF4I5D)S,:9@8'(;X.LR3[>[=[KKZM.GU#J/W.VXVRH6RFQ-\I+2BP>T3><
MKD[N M?$9?V%@L>VUC4=PZ:U?9N09OCR$NHX:*M4Y4\6A-QZ_N.&VG#;7LUP
M7BKG"6W[IWBS]I<E:W>Z>MV[7AC@E.L(3'>N)2&N[(#A.GO"%G4<6ZJY>;[Q
M>$X"582J5IU;;DC4-6ZCO!(K%'3?U.[Q;N[?])->W+W7,]W3MMRZGZM9ZKMM
M28>%LG4M6=D)^;H\+NM$6I:0C(39VGPSE".M5G=,TT?SVE1:QM7338+2%73W
MN+]F^&(7<WW#K,KM;MGASJ4J<#J.%NWK+5VZPI1:&MY*5.,I"UI6E*'2L.N)
M#C=#%T\I,*61IU(U296$$MZADQ)\4B<D$:08-B/NK3J+<=!.V6[X[FJ1&Y;+
MKM2Z?;'.Q<'09(MVH).JF2VG6AY1)_4/=1?#3&2#8)^JP]7DG;UN$P?V1GRQ
M2[0[*\'M.)WC2&$D.=CWN(A')-RO@3MYWJ% I)T70+C>K6H)"0HK4 :@7+BF
MHDJ*;C3.Y* Z4C<8E.\<Q,"MI;1+[S[@_E"M\.FN/W]OVW6UT5TC;?;M5UC1
MX'; DY7+E8KU<ZB_<Q,_8:#8GJL.+* :29V,LG)2QGZ1R-I2.BV\W&K\[AW!
M^&)X)P^\/#VW+E[M&_9N%:E!#EDVQPM26X! 2!WR_"SH4"M2I"R%&QRX=#KB
M1JPT#@Q!.J2  !)TR,%,C&")RE^3KWHO74+T5=..\.Y\@UF+_>:,5>TS#)@S
MBTIF3BYJ6@%Y@8]@@A'M',BWBO?W9(QFRC4WRZIF;-L@4B1/!]N>&VG">T7$
M[6T1W3#=]>-LM\T(3<N!"#E144IA(6LZSIE2M1,]&P=4Y:-*6HE1TZB23DC(
MWR"<Q Z#%;JJ@7O/@H!^Z&XP7(<B)0$ * 9#@!P!0^0 '&O'  "($3)$8*N9
M/4SS.:Z8 U' Y\HQ.8Z8)-9 VB75;WAD5(WP.@=HK@'<&$2-U5  W.3I@= N
M $3%#M+C& U]A^ Y]Y':U"4*6 LJU!)(U#8Z@" 8ZD1RZUYGM)!LP2DR%JR0
M-A(CK '(1MMI%;SE_1+]P?U:_?R?DI_W1^ROG=3K*E-*4TI32E-*4TI32E-*
M4TI32E-*4TI32E-*4TI4"&0$/F A^.H(D$=01[Z5J/OC656DNG/HIF*U?%20
M7.0#B"3Q/)2J#VA@I54/9IEY#"B939 <:_&_P^]DWT<2'&;=E19=;4'=$@)4
M<DB! D9!ZSMR]KV;O6X]&<4!S&<GS/.1&XY;QSP27( F' !V)Y  '&1'G'CX
M>  0'(  AQK\RMB$(&1I0D&3)PD8/GG)@$D9Q$^Q$>(CQ *,'<D#;/,QYU8^
MY6VU)W=J,E0]R:^E;J;+B4DQ69!=\G$2[=,IB%:R[)FLT)*Q65D55(Y^+EBJ
MNT0<&2,=),Y-RPO7>'/IN;=QQMU#B5H<;6MM;:TKU(6E:%)4E2%@*2L$%)3(
M(.]3B4N)TE((.X(D'$%)!F2J#(,[\Q7O(5V%2KI:BHQ))5H\0M J1$^Z<V%L
M_AW;4[1Q$21IA5\K*1[IHJ=F[0>*.$56@@B8%$A !N^,KQ%P;ME\H<65.*6'
M%A<J,E*E A2LDA4G<$QN:P4VE0T%"8$ C0"/#S((C'F!.9C-6+-;([33U.I5
M!DZ'7UZEML-=4VZCT&XL7FWSFILR1U8DJ1*QY6,M3IB%CRE9Q4S7G<?)(-3'
M(DY(10X#LIX]Q/O+E9N7(NE+[\]\X%/I65*4'86-<DSXRJ3&J#DP64)2!W:!
MI$)&@ "! B".4") $ 5=%.H=2H#>3:5*OLX4TY)#.6-X4JR\U99E=JVCSR]H
MG7JKR?L\VYCV;..5FIQ\_?&BF;-BHY.V;I$3T;OB%Y=H2RXXDM-2&T*42VVD
MJ4O2@%2@@%:U* $)U*48*B2;&F&]"U3!DR<23OOZP.?*(@"+&W(Z=]E-V[%7
M+GN-MO7;5<*BT?,*];CMW#"U1T-)"L$C"?G#$?1TLK67XKK%D:T\?*0K\RRI
MG3)4%%!-T+/CO$[*T78MW3_HJUI6;8/N]PIQ(*0M;*5!M2PE2@DD$@*(D@D5
M@;9I:@=*%+PD**4E0SF%$:O61C @8%6F?H]Z8PI9-M6>QU#BZ*%R#<,U/@(<
ML!#.[V21"1:VR180:K!"4LL<^22?Q<L_!TYAE$T?HUTC[%(0V1VLXTMQ3R[M
MY3RK<V:W%7#Q<5:%!9-HM9<*E6Q9):+)/==T2WI*":P5:MH3I#;82"#A"0"H
M1D1!$D9._.08J]9C8?:>P/K-(SE-;RBUT"$_/I!])S:\9?4:VS9QT&2_0ZTL
M:+OB4<R9IH(DMC.;$  5.XQA[QT4\9ODK0M#N@MDEHH44]V-14 @@C2 HJ5
M(\2B1!)K$VS2\J"2"((A.,$1D;[# &D#20!('9L^R.U=PM)KW.4YF-[5@C5!
M[;85U(UFS3-0%4ST]2LLY6G\/)6:GI.3G=(5:>6D:\1XJLN1B)U#G/9\>\26
MT677UN([]=PE"W5E"'U0"\$%>D.%*4@N1K4$I25$)! VK4@P@F('AR,G8\@)
M,2>9.":\^8Z?=F["^VVDG^WD,1YLTF*>TI8<SROMMM 49_19QI#"#>1["M*N
M8T20[A6':MCJPA4XE8RC$ 1#)OCW%$(ND"Z='IFH7)#RTFX2IU+Q2\0O\L"Z
ME#I#FH%:4J^6@&L_1V82"E!T$%,I!C$3L,P2<#J"<@5U[_TX[&;IW&#W#ONV
M-9L=^KL6:O1MP7:JH64:RX4.Y4JTG+QKAA*3=-7<"Z]ZJ\RN\@P4?+J&9'.N
MH<T,]H>*,,"S[Y?H_?)N$VX=6&1<("DH?+:5! =2E:P'=.L!:@%1J!Q7;H.2
ME!.D@'2F2DQB2",D X$F,QFK1D^C3I3EMK6.RCSIYVK4VMC9\UMBZ6TJ,-'L
MHJVB=1=2UQ2S!!B^CK<J+IPFI9X]PC)+H++I"\%)8P'W$]L.T277'SQ.^+KK
M186YZ;<EQ; 2$=PMSOM2FM " TI1;T!*8TP*P39,:4_DV@$F0.[3"595( ]6
M#O/,UZ[WI1Z=7^W#+:1;:&H_5FQGVML2IK5JY80B]L9KLW+*US3=HY15GK$T
M<LHYRUG)DS^12=,F;D'HN$$E2ZK?:/BC+[EVBZ=0MYE=H5)?=2HM+26ELJ4%
MZU-K;*FU-DZ5-DI(*215IM65!.M*509 6$J ,G(!GF=Y'7$"L^()>[-V[5%1
MV=)LFFB4[QXZ?.3$2()"&<OG:[AR\7,03>U=.G"[E=0YU%5E%%5#FXZW2MQ3
MA/BU%2HR-8,\N22!&8 VG%7MI !3$"(," 8 $$"-X&".OG6OTITF].,RMN>N
M_P!GJFN?>=RH_P!U$RHO&[*]/'1F!9-Q.-&+E!FJ>>+&1A[,*3?V]D=1[1Q/
MB\6:HF2[3?:;BJ/1BFZ>*K1#:+59??ULI0HN([E>LEK2LJ='=Q^54IS"E$FE
M5FV2KPH&LJ401A15OJZDC&8 2.8S5T$V VB3LFVEP/3$5+3L[$O8/:V<=2L^
M[DJ+#2K8C"4BZZLM*G!BREV2#>-G6A#(IS$6U:PTD1PQ9MT$[$=I.*H0XA%V
MZVAYQ+SS:'W4(==1)0XZE*]+CB"I6E2P5#4J#DDUFU:D2E!*?"/")2-H!.PQ
MRQM-8M:="?1^RC&4+'].>V36)879'<6(C6D*FBSA;:DZD7996!(D825UNLXE
MI07,9$),ZZ[1?N4EV0E<*%-D]VMXT\ITJOKEQ;S";5Y:[NX4IZV1I+;#JRXI
M2V$E"2EE>IH%"0$@I!J!9M$  ("0=0 2 D*,R0,9,DD@SDYFLO5S9':2I;BW
M#=JJ[?U^"W$W!73>6^V1S,J#ZPR*31!F>1=$3.# DDZ8M6K:2E&R*<P^2012
MDW*_L@[>7>\7OKYIEFY?4XW;M]RRAUQ2TLHU+7W;*%E26T:E.+TH@:EK5NI4
MY--!!4$I2DDG44@"1( )(DK)CF"%'F2!7C[R=.6Q74*C $WIVKJ&XRU3>JR-
M8D9R/!2:KKMZ0A'QX:PMB-IJ+1D@;,BRC%L\39R9&C9-^1<J"8$V.&<>XIPU
MAZVMKMYAE^0MMBX<:;=2#J 6&UH2X)A0"@J" H' (EZV:<5J4E"E)) 4I*5*
M3&/">0SN""9/3'3M72YT[7:&VW@[+LS0G\/LXZ<NMK(U"";QJ% !TW0;22%:
M+#E;*1<9-()-6T[$IJ%BIH&R!9%!V1$G;>UVDXNUZ2@7MPE-XHJN$IN7DBXE
M:7 7M#@[WQA*ORFJ%09P#4*MFU! TH)2  2D$B! @F ,2)&Z20?E5;H=&?2X
MC$SD VV/I,? SVX37=>8AHEL[B(A[N/'.AD(^Y PAG+9DUF(M\<TG$.F:1 C
M)5127C#MW:YE1N/:OBZ%:A=O]Z+46/>>D/!1LPT6!::N\D6O<E3/H^6N[.@(
MT&!'H+/S4 R% 0GY1(.H C?5F3XA!B#FLGP^SNW$#N9/;Q1E7*RW1M$"QK%F
MO)Y&57GIVMQ(F4CX27<.'S@C^.C3"JYCV;LRI&;U==PW32<*J'-IO<>XC<V9
MLG7U>C!Q;K;!<664+6A+:W4M%9;2M;:4(4N I24)220E(3DAE+:]82C40!.D
M3SP%;D9(Z#,;R>[?-KJ#N6RA6=[JD=/A69EM9ZP_5!5G.U&QM"J$;6*IV"/,
MQG:I/(IJ.$49B ?LI/W=9=+WL4UE"FU;+B=]8,.,LO:4/)TK;0M24+22E<*2
MDPI.I(4 <:@A7RA(S6VA9"E(0HC*5*2%*$2 09D'VC<B(->!*;"[/3=!N&UT
MWMU6)RA[B'<N+_ S3,TH%V?/$&C=Q-W"2DA=2U@GOWG&F"QS$B\FT_HJ/(#X
M?=&HI;#''>*,W%N^U<NLK8*5-+:?<;4PH**AW2D*2MHH<)<!0I)"A*1),E,-
M."%)228*@4I,X ,DCQ2,$'<"#BO,A^F[9* M--NT/M_'QEMV\AWU>I=B;2,\
MG*U^'F3F5G8^/>A*BM[.><G.%G$ZOO,XX 7LJ=ZX$ZPW+[0<14EQLOK4RM[O
M5-*>6IM3J>\"75(*RE3B0ZZD+4-0[Q:01J4%5FV:"I 3(!3.GQ!($:9Z$ 0,
M@0.@CP7'2'TUO:/>]M)39>G3E"W.M3B^;@5:PL1GXFSWY\X!T^ODHA,JOP&[
M/WYD'[ZW-S)6)\^9-G;A^9PBDH39':_CC5PQ<,\0NFWF&$6K;Z+NX0\TRVWW
M26$.!U*D-);A ;2H(2B4!,&L#:,D%.E$%6HI* 0HR25$'G)WW\4DDS-;7I'Z
M;6NV4ULRVV<J2&V=D<,75KJ)$'23>W+Q_:2+&ZNA<EE;8BQ$&A&J%D=29&J$
M:P2((E9H"753VDXH'T7+=RZAYI16P\EYU+K!UK<'=N)<"VR%N+6"DIA2E*@*
M))M-LT4^+2H$9$ @X B/DG$ ^$"(VC.;F]8A&U90I@Q_OM73B#000LPZ7G45
MH91LI'_1;H\PY=N'S$&BBC#W9R=5%-AAL0HH )=<PW=UZ6F]2M/?!WO^\F'4
M.J)E0<G4%"2-0(*08$Q-9!I"4=W"0@& C2-)C'R8TR1$F)/,[$VQ'[3[9Q3;
M:]M&46L,F^RC4[':0K>*;I#MZT-6/S,7;U,R*!1CFYZG[*%7;MA;E6:-$4#@
MH"$:5#<7QWBSJKIQ=VZM=PI9N%*?<4I_6L+5WI*R7I7I40X3*DSDZ36/<-X)
M;0"-CW:, 8 $C$$\I@':<UU)?9K;6?W&J^[<O4VSO<BDLY&.I]M/(RJ<A7(^
M4(V":CXD[:1;M8^,FDVZ:-A8LT"HSR2+=&1(Z!%( 6O&^(6UJY9I>4FV<6'%
M6R7%)MU+0E24.*924ME2$K6E*BDJ"5K2" LU*V$%Q*M*28 G0 K2=@#@QMB8
MP.@KIUG8O:6FO:V_KU)81GYFO):0I3-5Y*/8:ER,ZB_9SLI3H%X[>0%4FI5E
M,SK"2DX&-C7[UE-2S1RH9&1=I*V-\=XDRI3C5PMM:T!"UMN+2M;8*"$*6E4J
M3*4G29$I!(! -#;I*B"VDPHG3H!@YB)V]F_GSLJH](/3!0]Q9+=>F[$;=UJ^
MR4PYL3FR1=>:-!)99 JQ9&R,(Y-(T'$V.13<.TGUCC(]G8)!-TX*\<F!94@W
M7?:?C5^RW;W%]<+2BW;M0AVY=='H[6DH9 6M0[ELI"D-QH2H2E(.:K%JVE2P
MEMM,K4LA+:,JR"H@ #41N029V/,YEO=$IVY]2G:#N158"^4BR,OHZP52V1+2
M?@99I[9!PFVDHV41%HX.BY:MEVYSHJ.&SILW72/[PW3.7G<,XA?<)N3=V5PJ
MVN K4';=Q;+@S*"'&E-K!00((4"D#!(S5KC:5H[LH2H<T*2E0)@@X((,YWYY
MK#M/Z1^F_;NC6/;>E;/5:L4RXQC>%MT3$INV;BQP#8IT6U=G9=-V%ADZ\V;N
M7S)O O'KFOBR>NVA&?NCI8A]NZ[0\6NGFGG+M]Q;3I>2XNX>6XAY2PM;J7%J
M*PZIQ(6IQ)U*4$JF4@BD6S:00&VP2-)"4!((R"#B"(P4SMR,@&^YC97;.:OE
M1W8?4ME([F[<0;Z"H]O7>2B$W"1CX"&?0Z4FT=.UV\5,JD*G.'<-7 RZ!2M9
M!O(I))DU<QVBO$,"Q??>7:+N1<NM(=<[HJ"EE+BVPK25I[U>E:P5)"U@$:E3
M6NU01X4)$2! "<;D3OF>1Y"2"(K3#I!Z(9':^(W-)O\ 5;;RRRULZE]T.H"$
M"M72Y7&H+?GIN"ZOU.4M=1L57I%2DK=1'Z[5*&M#^+EWT8Z9(.HJ1BCHH$2]
M1VI[9VEZKAIX0JY:5;<'LN'.N*):47&;!JS?2%)<)6AQ*%)45*2'$*TN(Q%8
M6EHIOO0X I*W'%H"L@!2]0("A@A,;#D"DD"MT'VR.UCO=&0WG<TUF[W-D:L[
MV]=W%V[DG4D\H+EV=^XHSHJDDLR=4U9\"DBZK2IEH@TJ)I,&QW>%A\HUVBXM
M;VK;"+Q]#2;A+X:%PZEL/I&D/AL.! >"1I[S^<TITA6D:3LFW;F5(05 :=10
M"J!&"82H)G883G(Z8GKG0]TE5%&FMJUL!MY!EV^L[JVT8[2*!NYJ4P]2D 74
MAG1%!?,(1="7D2FKJ1TZF!Y!V="-(*QQ-LN=K^-..7"GKZY<=O 47"W+E]:[
MAH*"DI?4727D:D(4$.E2"X@*PI*:@63, A+:8((   28Y8W'69C&Q,W&MTG]
M/CBO;EU1SM=&.JUO#.J6?=:#>2$\O&[BV)==NNXG;BS<R1TIV7?JM&9)&0D$
MG+M^BR9INE3IMT2DI_";BVNW=-RZ7;,)3:.%Y[O+9*%J=;3;KUZF AU:W4AL
MC2M2EB%*)H+9I,IA !)"@$B"3@E0V42G<F21$G$5=;;8K:IK<Z7N*E4BA>=N
M:\K4:1:G,M87<M6:TX[0<0$>Z6EUE$(Q^=!I](,CB"#SW1L+Y%4Z!1+KK[07
M[EN]:N.OI9>=#RVP\\&G'4:TH=+064*6@+6$N*!4D+5! 6H',,HD$H05)&E*
MH25  B "1,0 (F#$9Q'K[H;2;;[T5 M&W3I\5>:FE+P]A90LL@J<L;/P#DCR
M(FHEVV,V>1<W&+H][*1C%T5VJ0&1]X]GD#:O#^+W'#5NJMGGFEOMN-.%AUQE
M3C+R2VXRM;:DJ+;B#H<024*02E:=(-6N(2[ 4A*BD@^().1!U>*>>9WDR,R1
M;L1T_;/5Z[/=R*]2&]?O<A2D-MG=KA)6;B9A2AM"$!K447L?*(';0#%0J3R.
MC6RQ6L9)@,RR12D5CN WCVAXF+=-NEY:6$W2WTL!QSNTNJ*$J=#>O2'5(;:2
MIP#7I;;!/@2!0;9LDJ(!40 21*@$DD)*MS"MHW&#M)L>2Z+^E64VJ@=CY/8F
MB2&T]4L#BU5&DN(TZD52;&Y=G?NYJFB<XO:?).7;E^^5=5US&&<2$@_<J&%5
MXN<^Z.V''@^\^.(7?I#Z"R^_Z9<AUYF DM/.=[K<;4@!/=K44%,)(&!6*;5E
M, (; 29$(P"#RCSS]\YEV^VWH6U-<:4W;6FU^D5EHX6<HQ%=CF\>W.^=D+[[
M)OA0*"KV4=B0#/9%ZLZD'JG<H\=N%3&4-PKJ_N+U_OKI2W"(&I:RZ?"D)2)4
M50E*4A"<X0G2(2*O2VEO8"!LD  1/+D23F?:(Y:8P_2#;Y3K@Z@>HC<.+I\C
MMINSM3MEMI6 KVY&X,7N2P0H"=E"<"P1T34ZDS=U.YC:(IG+UL+K.13I.,8>
M]M9UPFT:,_=7':OAA[%67!;5MWXPM^(/W;KJDA*4!Q%JV"RL+4XH%+'C,-A*
M>[2G7$CG"U6;M;Q)T*5D:B 96LF>7,P)V!.(SLI<NF/I]O:6VI+7LY0I9+9L
MCIKM<BE L&"%$CG;)K&O(6O(Q!6K5G59*,CV#.1KC0#U]^W9M$G#=R@W;B7S
M;/:GC*$7#'IKX9NW5.NH%R]H>65J<0IU(="72%*D%>HZC(,DJ.\;9C?0V(!
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M8R=XC&V]9#,)A$1$PB(B81-P.1\B(E(!0QGD0 H  @'PER(:TTH"R4HA2C!
M,8GD-XQT]FU7 XDF)@F>4YB3(Y@"(YY)%9SV.K"SB6<V)RD<&K-,[=M[0I@
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M379^JV\!^C$N QD P\9A@,=H@ ^\!Z!VB >F YQC70/P.=K1(%@[&=A B=@
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M 8$<<9SE^)WM?C^(O8]?VX\]L^ZL?CZRDD+WYZ3)S.?VT':Z\B 9B7(]N0*
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M"3B3RQ,8Y$\L]<QQRPC^<]?@._GG)\ZI#:^]@.0BW08$  0>LP\& Q>T?>N
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MM'*!L/92F ^0?@&HTI^:/<*4P'R#\ TTIZ#W"E,!\@_ -('0>X4I@/D'X!I
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M/<*4P'R#\ TTIZ#W"E,!\@_ -('0>X4IVE_5#Y^ \_/4:4_-3[A]E*8#Y!^
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M-:/G)^D/MI!Z'W&G>3]8O\X--:/G)^D/MI!Z'W&J1,&!Y !'./C#QZ&#(A^
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M?V5%3J:4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E>).SK"
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M=8CX7NU@))XHO))@K=@=!\KD<$?<9?$ED<]TH Y&3CU^R@;EW7TG5?E_%VF
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MW/LI]9ET'_'YP'R/[W:C\_'[VYQX\B(AGY<A\+O:K]:.YVA3A^K5GZJL^);
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M_EZO/]\9/3$#N7=O6>.'H/[W:^!Q@?XOSY\>@\"&<X#X7>U9Q\:N3_O+_O\
M/EU]=0G@UB2997'+Q;#_  ]O.GUF73@ GS^H<-FO' YQ^]ONR'X\<:G\;O:J
M?_-'NF[DSS_/.W3Z^N?Q)8?H5#_Y'GM4AN9=1#B>5XP/\7:>,@'^0QR/X /C
M@1"!\+_:J2#Q19C;QN'/F N(]?EUK$\&L)([E0Y;G]Y'UU3]9ET$?^,"@?\
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M#4$P">@)I6I.^5E4=RJ,(BI^]HXI'#E,._!G2H_N93@ B41*B/>3(<%-P/D
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M9 (J0(7C)2^?U0#/CTQ]N.0_#.04Z[Y/4F(\R8Y'VF#(J@ #(@4  PYX-VF
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MJGNS_%FF4WBK!\-*>+!46U!OO@"2@*TZ0H:@I21G24E23"2'I34RE?F/&20
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M9BJ>PO/!1SCP!<!G[PSY^W.!X .-*3Y=8\P(V\\[>6].PN/!1]/ <8 >?VX
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MN9J<NR?US<BLL&<0V<MZ-*/HV*9[GR=>JK6P"61DG":!8YJ[4OM./=G7.T7
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M"F.'O.!U;':*TO$K6=2F+9# 0\E.M!\%VONRX$+3)M4EU*AH4G5>MEE]:TH
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MJ(;)D#4=.K !*=I@Q.#$20-]4!(=/M*<AB"0 (8N#)F 3#P.! IL%Y I39$
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M)1!RJ9 !WDG>NI:<7NK32 0XE( "7/&( @#.0! P#R]@L;Z@8H!P26E )X*
MF;_"7TSEL B8/F( (^1QG ?/5?Z.O!@HAN\>"9.F9D)G WY#D /*NI^$]R3)
M0D$Y.F0 >@SL-AC:I^H"*X_A61Y_Z;?[<_X-QG.<<?(!#&G\'7A/*]<'229C
MSSN-O?SI^$UST'O5]M!V"B_'TM)>N1$S<?\ _&_8/IC AZAI_!VX3_6W3']K
M?'O/41ZJC\);F?DIZ[*\_P"UR_?ZZ@=@8L<?PM)<?])OZ9_\6'T'QX\ZQ/\
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MFVW=#F"5(U(A//( 5)P09KE77%[N["@I:DI422E*B$[SE(P?(^>!630(0 *
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MH2IY"7%!,IG4 I0F I,I,;DS &)F8]G=C=QIME]70'2@7BFX.Y%;V_20F;O
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MZ.?E=ZOQ@>Z*(!)<44J(E0!68&HY R8@CS %=9/ TINFGPJ$H80TMM,)2I2
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MC40-H$=(I3M(&1[2AW#DPX#XAP 9$?4<  9'T  \ &D#H/=2H$4Q  $2"7T
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MHJ* 3I/(R8F9)(S-<:UNN)7CUVBW-TE=OQIY'>..K[GN&RJ$*"E'6CY)*$I
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M.%ODY/%>%G:Y&7HD+:HION# -48]^UI5QF(NP75&0]O JB@B*RN/H*5K=4"
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ML DI Q&KU0=2T_M=4'D0]N&Z$G [9=2);3&TJW2-'O<#%4/=J4H>W74D\=1
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M D2(TDY)S,''D#!GE<+XE=N\1*+CO$,J2\6U%2U-/!#BA*$JA+82D G,PD2
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MGLS!2Z#R'DE<*/F:_:4=2;Q\S*U9&VHD08C$P($^K: ,#!/![!(*4L )5&H
MJ 4!R(V(D#H><G<\SSI=V+?NW#]SM]%*O'&XS;=TZYC/B+DW/9MO<&E];*I/
M4S-;2S9>S9-YAL9%XDU:-6S=5-NV;D(]+>( *U #'RE9B(YC'JG!-8IX-8-K
M4M#("EK*U03E2E2I6X$DF>61B,U4UZ8]CV;YC(MJ#&HO8N^SFZ#!P*TB=1ON
M-9$SI6*Z%[WQB+6"=07=)3,D)1=OTW<HBX672D795@NWA$+5( 2#K4#I\C((
MB(W  Q&Y(\&L%$E3 5+A=(5*@73$N$$D%1@2H $D?*@)CK4/I5V!VPGX"T4/
M:ZKUF<J+*?BZW*1S51NZA8:SN$G4W#,%!5$&T,Y<-2.$8<A0BH]511Q'-6RJ
MBAC'+MUQ&@K64[D:CIU;_))C) SOL02*L8X7:6SA>:90E>?&<JC;Y1!(Q($$
M""<8%71-;$;6SUY>[E2-:,:]R->1J#^TM):>CIE>HH.1D"5,[R/DFZI:S[\H
M>2-7TQ"*6DEEWJC07*RJIJTO+" @$@3JTR0)VD@&-42"<=9G-6.6%LX_WZF_
MRI!25B=13&4D_-V\.0=H@0+YJE%IU%@&E6IE8@*G7&":R3*"K<.PA(AF5PNH
MZ<@UCXY!!LA[RZ66<N!(F!EW*RRZHG65.<V*G7%$%2U*(VU*4K_N)QTB(Y5>
MW;,-)*6VD(2H00E*4SUF )GG,UKTMT0=*JD;(0JFR=+&%?V$]M)%I1RB4?!V
M4SHKTT]46:#A-&DS"C@I3J2%.1AG*P$*1=0Z92E"[TQ_2$:U0 !E2LQ&^><9
MZUSSP3AVLN&V05$DSIG3)!A,?)C9.D  2, F<X/]K:!+45?;25JT1*T1TQ^C
M'E8DVQ)"*D6!ER.5V\HW= I]) \<D,M('?&<*R"QU%WIUUE5#FU]9U%6Q)G&
M"/4=P.6.6*Z'H[7=!G2.["=(21(TXP1SF,SZ]P(QQ+]+&Q%B8V)A9Z PM"5I
MBX.#G%K2ZE[._6A:U,I6*MPC"2G7TE(Q$)7K&@C8(:)A7;&/BYI).49MD'I"
MKA>FZ>2G0%JTDR0%J )G)4-6YYG$R9F:TSPFQ4HN%E)64!LK*05A @I;2J"4
MH20/ DZ<0<5TT>DKIX;+N'"&U\ V7<W*N;@K+M??6SAQ?*HQ29UVY&62=E,>
MSQ:20&0FA-])"\%>37=J/EUG!QNWB(UF(TP5$X B"9S $09!P()WP3P3AR2F
M+9 "5]XD $!+DD]X!D!4F=0 4#)U1BKK>;";2OKI,;AJU! +C8G-4>6&<;/)
M1LXL#BA+$=4LTT5L^192J=8<(E=0*+]%="+??OUJ1)X85QQ3<NI0H),),@@8
MDY!@ ^X^S<U>OAUJM[OE-GO2 "L*4%$ @P5 C'A B?.KDV^VNH^UL&M6J! ,
MZU!N966G31S,S@Z 2LV[4D9>0 KE9<_O$I(N7#^2."B9G4@[=O5>YRX.J."G
M5*TDJ48 P5&!  B)P!Y=<U<Q:,VZ5(:0E"2HJ@)&YY^LC!VY\HCJ[?[1;?;8
M*VI6BUU.O&NMD?6ZUBV>2"@6"UR8@:5LTD1V[< ZL,K[)N25F5@,_DB-6I73
MA8&Z($E;JUQJ,PD"2=1@" ).0 -D^PSM4,6C#!=+:"DN+*U&2-:U&2H]3N)C
M: ($U9).E?8 MJ+=2[75<EF1O;O<UM* Q[%&6X4@FZ3D[G'(%4]RCIZ8!ZNK
M-R#)L@K-NCBZE1=.Q%0+!=/)  6<)"1XE82!&F)B,;<N7*M8\(L"XIPL)UJ=
M+RC&[LDAS."H$B#!VC:1747Z2^G)>'4KZFT-/4A%MPE=T0BQBP*U1W 5=2SU
M2RM@)@63DZ\]83&2;>S9'^GY@A4"I2CTJ\>DO3.L@QN"08QB9]6![L4^*>'Z
M0CT9!0'0Z$: 4I=3@+ CPD"1J\R008->BMTR[(.9!W*KT&/-(/=PH_=ETX,K
M)95W*C$BMHR["FF],@6R1S8A&3:4133=-F*2+5NJDS003+/I3WSCL!\I0\,?
M)P1C;!F.<U!X18$DEG_6=]L?YV3#@'SY*O$(4 ?"4@YEITS[&L)%A*M*%&)/
MHC<*8W:8N"KRH':[EV$5QG;V'[\,0]EF"+/DY.44(+E\F^?HN%#I/W!%1NGB
M -40 G<@:0(@B8CZHK(<+LD*UAKQ!9<DE1/>%6HN$R?&2)*MR>>T7=9]H*#<
M[;3+W8J^E)6[;P[Y6DSCAT^1?UA:5;"QEUH91HZ229+3,?\ P7,J()E/*18%
MCWYG#/"(X(>4E)3L#J&,;[B 1@\B9QCEBYVS9=<;=6G4ML#05$RDB,@C )T@
M*@9@&9R;;M?3ALI=OK"_.3;V!DQW9/6S[E^\H*$"\_F>P+&5A*S$170++MX5
M@"2#!F[*LS3*W1[T?:ID,4V^I!U"9.=S/JR3RQ VF1M1^QMWTJ2M (44R#MX
M?DX$#PF"!M(VDDUV1Z?MJE)%&65K/O+YNO"O2J/96<>HN).N,4H^N3#UDZDU
M6,C,UUHV9EK\X]1<2T,LV17CGK9=),Y<Q=O DA1$R3!4)F)G,&8SC//.10>$
MV2H"F]6DITZBHQH24HTR<: ? 4D%,0#&*NS;O;.C[3U9I2-OJ\RJM3CE7RT=
M!1IUR1\>,@Y5>/!8H*K*^Z$</'3IVNFW,BF9VY<.?9^V7.H:E2E*,DDDQDDG
M)R8Z2?;^RMMBW9MF^Z:2$-B2$@P(./V;D1DSOFO!C=DML(HS)9C4V@.HFQ6R
MT1,@NN\?R<59+PE)(7*;C)1\[<2,>_LHR\HO..63ANO(2#^0?NC+.W2RY\P^
MXE.E)@0-B<F-R0<DYF>IYR:J]!MBHK+<J*UJ"C)(6N0M0R8)F"1!P<Z8JQ%N
MD/IP<5B.IZVU-;4KD3:W=WA8PZ3H%82W2*ZB\I8H1Z+@9&'E9%=RZ<2KR*<M
M%915TZ4?J.1<K&/8;M\?G' @P5$$;#8R1R@D@]*H^)^'D$=PG2I9<@C.L[G,
MY)$F!XH3)(2F.U:>DWIUN2JJL_M)47J;JK1-*D6:461@QEZA +BZ@*U,,(]1
MFPF(>#<&,K"Q\FW>-(HQE!9)-_:"(X(NG4C"B(\U#KYP=S.2(,#>:E?"+!:D
MJ+"!I &!$QM,$2<[J"IC,UE"Q[;U"U0\+!3$01[$UR3@)J&9%=/F2;&7JCEO
M(5M^B=BY;*F7A9)E'R,<*IU"-G[)F\2[7#9%1.LK4HZE&3)(WP3)Z@[YF9Y]
M9VC;-%"$!("6PD( QIT@!)!&T "('*! JS[/T];.7*U/;Q9:1&S%MDJ>O0)"
M?<J2 O'M'>G6<.JDN*;M-%6M+/%U)):($#LE9 YWQTC/3>W&T7+J4!&L]V"5
M!&HZ0J02O221J_M1//E5+G#K1Q9<4W+A3H*_$#I@PF01X023IF-P=XKS773)
MLD_*\%W3".W,H$VE-RB\U8SS5C;6>*K4)8F5LG?I;Z:M3"9@*C5X5]'6)])1
MCF&KD##N&IV$1'MT9-X^<ZSR(@G$;$9,>R-L159X181!82J9DF<A20E4D1,I
M! G&3(,U["?3[LZG/)6(E!@49-"796-$B#3V,46S1<0SKT9;#0*0A7SVV,@8
M^/@HVS*1QY]C"Q[&,;2";)H@@D-V^2%:U3$3J5,;QO,<HVWBI3PFP3 %LV %
M:TI"$A 6-EA(&@*G(( ,^(R9-3M_T_;-[4SM@LVWNW=7J,S9W+]W,.X6,09%
M57EW:4A+BT1( -(PDQ(I(OYA*-;,R2T@W;O7Z:[A!)0F#C[C@@DJQM)//;)^
MJ3OUJ]BRM[=2E-MI3)). !G)QL![!'*!BD-L!M' 7V6W,AZ% Q]UF)*;FWDV
MBW,94LY9FL0PLTTQ9***1T9-V9A PS*QSD>V:RLZWC&*4HY<IM$"ISZ0YH"
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M!S]X^=8_<^52#/3UCGY_X53[0H&$!.01SX 2@(!D0R.3^ $! > '(#@-3!Y
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MSF9FG9I3;*UT:,:3![G65W$/!6)[#SD$[@ER*&22FZI(>P=/^I9O!M)"@"F
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MM#9%WM=B8FEU=L%+TI1&I4'2C.HX,1YR3F)\A6TRSQ?ND=Z;D/'T?NBAUS2
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M=4K-JI_6DI0C43&D!)&K!P ($X]8Y 3M,?&2;$MK0XJY4VE(7J(2"@:"-:E
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M4(*4)&1K?1.HTETW<M=>7ZA049]8NQ,[MVFG<MTEH%/9M FWJF["$74CV/\
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M@3UC//G[3[S4@4H#D"E <8R !G > SYP'RU,F(DQTY>ZD"9@3UY^^H A $1
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M.  0 ,XS@ ,(8^0B'@1T  V$>JD"9C.T\XZ5/83';V%Q@0QVAC!AR8,8Q@1
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M -@    .0&*Y1*41R)2B//(@ CR @/IZ@(@/S 1#UU%3 Z"J3))&$1,FF81
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MZ2>IVC?ET]51 Z#>=N?7UU(  8P !CQ@ #'GQ\O(_B/SU%3 Z4 I0\  >O
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:97>  #P !R(\?,?(_>/KJ*RII2FE*:4K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g759370g00a08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g759370g00a08.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1>Z4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %YZ^8$8X0DE-! 0      &D< 5H  QLE1QP!6@ #&R5'' (   (  !P"
M4  (<G(R.30T.#<< @4 0$UI8W)O<V]F="!7;W)D("T@4V-I;&5X("T@4&]S
M="!%9F9E8W1I=F4@06UE;F1M96YT($YO+C$@3W)A;65D(%, .$))300E
M   0><QB;UM-CX&D2<YE<S.\6CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!8 .-
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  $5   "0@         !                          $
M D(   $5                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   $5     %)G:'1L;VYG   "0@    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   !%0    !29VAT
M;&]N9P   D(    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     ,X0DE-! P     #0     !    H    $T   '@  "08   #.0
M&  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)
M" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,
M# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( $T H ,!
M(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0         #  $"! 4&!P@)
M"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q   00! P($ @4'!@@%
M PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A
M\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%
MU>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!
M  (1 R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:B
MLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F
M=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$  A$#$0 _ /54SOHGX)TSOHGX
M)*6#6QP$^UO@/N2'"=)2VUO@$MK? ?<G224MM;X!+:WP"=<U]8/K:W#L?A=.
M#;<EOMMN.K*S^['^%N;^[]"O_"?Z).A"4S41:)2$19>@NLQZ*S9>YE58Y>\A
MK1_:<LVSZT?5VMVTY;'$=ZVOL'^=4Q[5Q-6+U?KMYM:VS.L!(-SR QIYVA[M
MM-7_ !5/^8M>GZB]2<)ORJ:O)C76?B30I_9Q1_G,FO:+'[DS\L?M>@J^L_U=
MM<&MRZVD_P"D:ZL?YP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MTPB,V1@C7R\WKIEDW=4X*4@B01((D$2")!$@B01((D$2")!$@BH;=]JY?O\
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M((D$2")!$@B01((D$2")!%LGJ24_KY@EX<?.. _'!4Q10PW*@3J"Y2'2SIY
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MPT)(DX>F@I2OV6^=&T5A'.CC%&8F[>[?GS#N.^F[CX!QX"&X<-Q#P'CMX\
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M>C/8NQQ(GSY46,QX]XF*+W0 Y#0EH(0'(L"1NN3$77.-I]*<=C9GJI1'LP+
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ME;=%Z@B"?2WZ '<H?5/.'G(!1/'J+AK]RZ&>BR+$&3C]N;OJR?=P+%RU7F5
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M$[#@%PP(,)J'M>H%V(M5EY\&=QV#N#8<B(8#'' AMN ^? #OC/PS)4QO5=8
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M<.5J= N5*EJ<U8P9,&:]2G2+ER]*2:L8,5YPDDD 9IA# C%4$N.9%#!+#DL
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M9QK9KU96L-R.L5>[:4#<-:6KO$>(;Y'S\!QD0R Y[AVX#P#;,0J6L:,.%P[
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MA&A(.#"NK&!S134I,H"!A2,F,S3".P=;Q&%V_M_![!P6(Q>+GG0#.A9@U2;
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MK 8;#X23[HPC,  PHP# TM9@S-:BXCB,3ZW$&;.^&H:E34EZC2[?$7S8T_F
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M^T&ZO!_FJ0BM[E A(2B3?FFN6D)U0VJ)CPZ3I0/FP-!GR<K!GK &>;QVR&
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M,NY;2-=3<3&6RB^2GFJ5J= S+0J@!Q,/=%T)BN15"58PGJ1;^^BQHV5VS-&
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MR++N2^:P3YB[=U7JD$*I6D]E19;4,FR4G1#5#IZ$RLY)UDP9SL=*IR0:P(
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MOY9NX-IW!+3 @[VZ=3J)J>D!BHE*LLLIE%62U&;832*L%4]6)CS@^JB<@C@
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M+W[.L67O!;^K.-6LS;@I[DH!-, ] 0>B)*GTBU, #%.C*=8ZB8E =\FYL;8
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MW&LYZ:L"XGG4*J?2I'/U='6>:K)*6L.%62B:P6*K\A,'"4)*I6XF;2BCA#
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M$1&09PA,0$44)F0PF+=BC$<8WE+*24))990X2@ 1CELP# !6H^69^X;N&/\
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M\FH"G)M=&-ZFX;6]^96_1_;EZV[GOC6=K9JHA:X-XW5<!!, IHA^6=.5375
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M9^$L\,<8)>@A@AA9\R=YW.7!7,G<N>3;;7%T$EP."=,3ZQN1#;*945UY4FE
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M4XG"J24&/K7H!T9E[!V3(];^D8HDXT/0$Y TH P#:!SO E<6Z0[5F[0QA/\
M\.P %7;>O<PB(U]U]TN6:@43@QD,;\=]O-Z>X<;;[!P#AT!8(NQ>EJ5X\LP]
M:5-S?8 AOD!'/HSY@#/$1';NWQB/&=-W))FC,V(<\32E+W5,N#?>@+16U( )
MO3/(5&067#R5&FN73_IJ3UQ<(]5?UXJI5_.66O($AL@D&R@2,] JB !7^H46
MJ"J8+&:4IDFL.%7+3[RXCY%](.W1MO;L\RV,C"_DL#-7=)$1=GH2(=VU =%V
MCHOLWV#! Q!ILQB;V +-7.IM\+&N5SV-'6SI!$@B01((D$4.]?WW'6HS_J<N
M+@?2TU7^H(R^POT^1G6&FM1V<*BK+3>G;_S<VBW]0?'/K9;M")DM1T@Z<))Z
M\H3_ *B]M91E'8 PS4;;AN/  QC?QB=MP1_A#$4S+D.[DDGLR 9E3T'FRAT;
MV5[X_1H&+W!AAJ>'<*9*7'7B?NFC_##]/@[XQ7JX_LE;AZZ5]N'M3KQ/W31^
M4E_KAZN/[)3ULK[</:G7B?NFE_##] \^>$/5Q_9*>NE?;A[4Z\3]TT?X8?UP
M]7']DIZZ5]N'M3KQ/W31_AA_7#U<?V2GKI7VX>U.NE/=-'^&'CC\L/5Q_9*>
MNE?;A[5Q&#I0:%8 KTA$:-3 !-N.91 .&^XCQ^'/? 2XW'NF]QYR5)G2F)WX
M30YW[*MR5/0CA65$1Y9J],)I$E/"8.=P$"M&4<Y .$VWZ!#U<?V2D,^480?6
M!F=S1P:O;L&BJG7B?NFE_##T_I\7&'JX_LE5>NE?;A[4Z\3]TTOX8>G]/BXP
M]7']DIZZ5]N'M6O7B?NFC_#"'JX_LE/72OMP]J=>)^Z:/\,/ZX>KC^R4]=*^
MW#VIUXG[IH_PY?ZX>KC^R4]=*^W#VJU'RRAFA/H>N'3DJR334UNW?/EW$, ^
M44!R R\!\1VYHB(>,;+T5AC_  @"+@'AIUV.5URKTM3I7\W8'FB$''8( C4S
M8QI8LW5<9W1DW'9Q#V0?817O']PD_P Z,%,_.3/WXO\ ,5TC#MZB1[P_,RLS
M]B'^\H4*&AFJ+KN Z6GJ,OA;P;BO9>?*PD,=>E04L%1?532F8DFHD9J'6^KB
M:$H7,F><9 M($HSC,(B%JYU=K.!3N\YK(#+YUX:?0YW"Y?H+GJ'#65JE_P#$
M _YN[K/#;8.[/'&T4]9YT^BEH?LP\F^]^]/H+GKO_LRM4F_C< _MX8^J@W#Q
M]&VP08ZGN^B-#]F'L[K_ '\5H.BUZC_[96J4 [P!_GP ?3]4^&WH (GK\*=W
MBH:'[([$^@M>NW^S*U2_/\_Q'C_?7G'S]V?&&XGN^F?\%+0_9A[/OR_BM0T6
MO4,@&LK5(&?^D!0VVQMDT/?OZ?-M!N)[OHH8:#L6GT%KU_RRM4G=Q?Y_&W_[
MKCP[_@'(Y,=3W?12T/V8>P_54Y)T8/&J4"I+K"U-4I0,GZ82EGT?I49@IGJ]
M*I4E #8YE,340K9V^N 1YV-Y+G,^>;\U1#"(0:"M3W:\A<:#(*I?07/7_+*U
M2?/\_MY_LKCOOGCWQ#'4]WT5;0_9A[/O3Z"UZ_Y96J3&!#'E^?[\?_>N[&WA
MD0QC&#<3W?10T/V1V)]!<]<?=E:I<AW_ *H!_P#)UK<?3\4&.I[OHI:'[,/8
M?JM/H+7K_EE:I,;\7^?_ !_56^^!\X\=A$!-Q/=]$:'[,/9]ZU^@N>O^65JD
MX^_\_P!^<A]E<. _ $&.I[OHH:'[,/9?G]S)]!:]?\LK5)C?;]4 _P 1'.=S
M(CMW9S!CJ>[Z*6A^S#V?>N*?1.\:DL\E36-J?GDJ2='/).^CD\D\G>%268R/
M.$>\<RB'=CC$JG=AT\5)2P]FT>PUM4>VB&KJ2XFHYI6,T5!6D*R'JHJJF;4Z
ME.J!.C0HXHU#4].40I@(RRYF]D(P)>^?T:S>(N[Z"((=T,/N^OTRS?V."K2"
M)!$@B01((D$5@3EI-*$[F;B-J;:*8%91:U LV+E%R=+I*AIL&*X2-YT5:,G,
M&:9OGS<Z4I&99#1SLI531FPF($P!V'T4=)Q@L=^!<43ZC%DG"UI#,(J!"]-X
M5#"^^2Q+KGW3/8_M$GVN4*AM]\JT+M\.58F#P@ 4?'< ?#B.,<X._8!'(;X#
M 8W[L>>/I6%X[,1PZJU;GG2C%<SW!#D0*FFE6N,[9U 8A, (A^@AW[]WFV^+
M.PU+PY:,""019A7O8$VH#12ST2:MG%I*NNG/ MUI48ZWU1$N*V*$U$95M""J
M-6FH$Z-:M3H"M-JK5,*".8&4KS@ZVD]:*%%8W&@].^B4GI)LXF B'%X4$P1U
M $3$!W#;I8")Q8@CWF(V/H]MB;LW$5#R"&(-283V%PP(((#@$@!9F%O7^U+G
MM!!?+&62*^UW,ET%=%5R%26K0-%:P8P$HRRU:-6C5":@;*F,&RAN4R4-2T*]
M 9!^2\7@YV!Q$["SY7J9TB(PQ0D,QJQ- #2O$,6"[/A<3+Q4F"=*B>&($V+W
M8NSEP;M$:O7-?=QXJZ2")!$@B01((D$2")!$@B01((D$2")!$@B018VG*Z:[
MJ"U74=,%JU?GHR:<EIW;<"96":FIJ16J,]%@$C5*8?J=,-40KNR:A[(50"C?
MFFP47R1GNGHOZ%38Y@V[CY!W6_(H2*NY)C)>[!H0&(A)OO#=YKTMV^P]CPQ<
M#XH@6WH@* NU(7+TO4,(038LXX'Q$ ]/-VV'.VX8$> AN ;Q]!P05OE6G7S:
MPTZRN:DB.:18 U)OF<FT8,;TNFV1VQMMOGSCP\0_3PE,B6-GNXZV<D$#-AD]
MFGGR:^E2IJ9OBC2K1'I[96U,$'<^JM6F-4HIC2,!,B-&KL(?ME4R=?K)81YH
MH*2O&1F X7*9YAZ3.E4&Q]E#"87$?E^+.Z*EQ#7>BM:&'>+&Y A=R"-KZ+;*
M..QIF$'V>%MZN3MNFKU>IK$ 20XMF3TJ<M*E)3   ))0#;8-N_N_\H^5HO><
MQ%WJ23UU*[/!"((0 & IV6S/BN2"J2")!$@B01((O);W6K3+U6LN!:I6/G$I
M/N TEQHFU--Z$%!/*+R6;2S)DD)BE7+@9+434U<N-:C/*%27<)I=@N<'BO9,
M1#.ONFHL]!8O<7^5EB-M[*E[8V?B,!,B,(Q,LRS$P+0FX8C/,&K.S7%L=$Y*
M=UMI+3T)O:Z-6Z A(A FEI:0D7),)J8EIQ*A0+$B! B1*4B90F2*4*!<L6I%
MP+E2P" !Q$-AF](,-.BWX\ "2SV!(U<5)#->O73FV&]&NU,'*$C#=*L5(DPP
MB&7 ()V[#" 0(86Q7NPL:0PM" *4 "K/ZV!<7?\ ^D"UF^;^RF<\!SGV._\
M5F/'\.X3^SH?/_#U?)7'^CW;7^UVT.R;_P!TGZV!<8./* ZR?_%51'\A??\
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M>M_OR*\YDV"4#%$6&9-!UYY4.= '=8\FOCE<"PT%JTNEM6J=#4&NE.*\);V
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M8X"U64%0 F$VE)0@D")0V<<!,?F#TB]-8]N8C\&8.+_P["Q&'>A-<1'"3?4
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MX<=P#XMML9#P\_@/&(5!?4&K-:U P>G.X#,;KD\X[YSX;=VX<!X[[;#M!7'
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$D$7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g759370g00a09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g759370g00a09.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1=&4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %RJ^63 X0DE-! 0      &D< 5H  QLE1QP!6@ #&R5'' (   (  !P"
M4  (<G(R.30T.#<< @4 0$UI8W)O<V]F="!7;W)D("T@4V-I;&5X("T@4&]S
M="!%9F9E8W1I=F4@06UE;F1M96YT($YO+C$@3W)A;65D(%, .$))300E
M   0><QB;UM-CX&D2<YE<S.\6CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!;C:,
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  %W   "+P         !                          $
M B\   %W                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   %W     %)G:'1L;VYG   "+P    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   !=P    !29VAT
M;&]N9P   B\    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     ,X0DE-! P     #(P    !    H    &L   '@  #(H   #'
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M//5<MN=]ELK8S<ZK&+YU<P>G9] ;F-]8.KW^_P#TB!)%4+M.G4TZ6G@[[_\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M=H26M,7A0D925&:3HZ;"&&)D@J3#\8.2I;*V_\0 ' $! 0 " P$!
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M1.VM\%VK8'Z\@#3JM+;6>MBIMCO0=J%4%0B!DR*&+BUP>*KFF6T2!4/^)<8
MXG3X0<T-BP&QJ3N<XSZ><?14"'Y06D<Y*3D4RNPB:D!'2TNZD)**FH> ?Q,
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MY0,W'GG (-Q,CSHJ$\_VD_E786P]EX/:#:S*HQE2C#*9!<UE0M!W@2T" ?$
M21:-XV78;$[&[6VSM#$X&G1?3J86G6WW.8XL+V2 VS3.\6G=.1%[3:T=3^4?
M9UH,;6<VY/.KA=S<BUZ>U"<>9CH<4TE7KI4&YS"FZ3*LD5% X^F5,(B&RF8!
MZ3M-_-6P=DT-EUL'796.*K4C7:T212>T6 +FY$',P+P05V>Q/X[VOM*MM&CB
M*5;#'"47N8ZJ"UKWM<8@ACB01-R 8BW#T^8U?TV@VULN%[ODW1+FD6L<T%C.
M&7,@J[("@*O0Z406Z"0&("QAVCIF4+DF\1KUM;^2^S%"C@*IQ['''.IAK&$;
MS35B"=YS1:;B71!C>714.R^V,2_&LIX2I."875=YI%F_XPTDD@2,I;&4@#Z7
MSJG9%A2UH1,K-SRBEWR18]NJWFE54V7/"F";IZ!5MH&IG"Z3?;(4^R=0ICX3
M QR[]M_R%L#8V*V9A*N*I/./J"'-<T[LQ=Y)$ [TVWLH "PV;V9VKM.AC:]"
M@\-P3-^H'@L+AENLM=PX&"(U,+V)**:K% Z<M-F*8 $!"6=" @(!@<@<0[<<
M>/#LS[BCB*&(8VI1J-J,>-X.:Z1%^?NW)>?<"PEKA!!@CG,?6RYC#H!N-*3A
M1W[AEG6=WM''WL9K:ZI38X-<]H<[X6S<VF -5!<2 8XVCUGWZ*2PR!Q$"RDX
M(AO'^^SO=PXCM8]H..X>ZJ"#:^5\Q&6?/]W1<NH4O"<[YW=_MU8YGK;\(G4*
M7A2=X8]5W?P_=<:1S.<_K+)$ZA2\)SOG=W^W2.9]1^$4]1)^$YSSL[_;J^_?
MZ1.HD_"<YYV=_M5(ZYSG[MR1.HD_"<YYV=_M543J)/PG.>=G?[5$3J)/PG.>
M=G?[52+C.WSZHH&!2'^,YWWI=V'_ *^VKY_3\(IZB3\)SGG9W^U4BT7]3**.
MH4O"<[YW=_M_7MI%YD]+1]/>B*>HD_"<YYV=_M4C/._/Z<$3J)/PG.>=G?[=
M")XCI[^J* @4P_C2='VY=T/_ *JJ*>HD_"<YYV=_MU")U(Z(G427A.<\[N_V
MZF[_ -SO7](HZA2W?WSG=W^5W?;W^G__ !5C.YOTTX6_VBGJ)/PG.>=G?[="
M)U/D3[^R)U$GX3G/.SO]JJB=1)^$YSSL[_:HB# IC_&<Z'M2[O/_ /:I%YD^
MMLHRRY]43J)/PG.>=G?[=(L;F^NODBCJ%+PG.^=W?B_]_P 7Y^^D<SZ_GKK]
M@BGJ)/PG.>=G?[5(YG3,\/=^*)U$GX3G/.SO]JJB=1)^$YSSL[_;J$<R-;'W
MZ9(G42?A.<\[._VZF[S<8Y_5$ZB3\)SGG9W^U62+M,XTC-4ZA7DBX$Y )L/'
MR[I,N!$=HJ:@B4I^P3!O$-W"B*I4145GZMS??S,3^C=X_74U/"!]Y^R+B ?X
M2F'_ "&F'_UZ@\::ZY>7^_?%%7*J)1$HB41*(E$4" " @/ :$39%Q @ .1'/
M#'O#D..=X;L8P&  ,<<O/]*0"N6R&<[\X$/>$<\.&0[!]OOJ18CC/S2/.Y/K
M/^E!2@4,!W 'O &  .X #<'QY'(TBT3YZY^^NH.2JZ[T<,G8]S5P/_A'K(9C
MJ/>BAR/0JAV5ZSK5_P W87Y.;^U^8*.S/4_557-41*(N)SE(43F$  H9$1$
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MJXLFC5S'23L9-O'RY6P0<H:#<-G2Z42L#E-LW=(MR<R8Y57:*28%<5T?9'^
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MAJU0TVEWQ B""6Z!P,@Y1>5E+SQ.\,]N_< XS@1QC=P^'Q9]EWC20 YKB3$
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M@U'X5M-I)YN+( $S&Z3$77P*KVO_ ))V$_$[7V0,!5QN'IO?2IUVOKOJ0?@
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MP .41&7%=P(YB#<C3HJ'14R$33;<T3F"$3  3*5+9V"E3 I0(4  H  !C<%
M2"2"07&2=2>/6RR[IFZUI +61NM(! C+,::+L@D0-V/2@ E N[9 !P    '
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M<D@MI%Y+@W>+C($$$DQ>W'[SB_Y#[*XCL^W9=;9YK5Z>'AKJC 0:S0&L<X-
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M1 M81H/O/"5KQDMIL+CX0!(D#/YZZVL;6D[EVHE%JV$@ !102V0 <@!>;+@
M'M  W /:&^MIL2#F"9632"T$90(7WJ+)*(E$2B)1%U7P99/ '=EJX#/=E(]4
M6(ZA0Y&."H5D^LZU/\W(7Y.;4=F>I^JJN>HBLK4.ZF=E69<=T/E$R-H6)>/S
M\X8"$,9%$YD2&-D,%45 A!'?@#9X!FNEV]C1@=F8BJ""2TL D3O/L+<B1_N%
MR,+1[^NRGD"9))@ "YDZ6!\UBMR&;8<GTXE]8YK:5N'76X7]]**K H+E"V07
M586:T.*I2G(1Q"(DGSHCN2>3KPH9'(FO9_!' [)P].H\5*U4NKU*@R/>DN !
MUW08//G,<#O!BL;B\=$=^\,:V#X64!W+>4.#"X3H1$!9O5W*WI1$HB41*(E$
M2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(K5O"R[8ON$>6[=L%%7%"2!
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MOV+B_P"JPLG?P&-<:@<"?$:=1[CNR<@X$#.<@.MI[RI)R,G&MCW 21MV[T5
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MY&L;F0BY-5@QC9%=:6!_&*J-'*BCETY.<RKD3&<#*(#:#Y'Q5"X6R FW"XN
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MS'499^2QNY*!@=Z5DEC&(HI-W7><L98HE/SQ5[DD4VZX'*8V1.T2;XVAV@*
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MR'"YU*]3MF^;5O!J#RW9IC)HX';!!7*Z!^U-RV.4CALJF.2J).$DU"& 2F*
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M=0VA6HPQQ%2G'_QO\0BV6].[8: <LET&T.SV#QI-5DX7$@ES<10)I5-[0N+
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M416;?T=>4K:DLQL"X8VUKN70*6'GI>'"?CHY;G4Q4<.8<SAH#\I404V$!=(
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MX-1+VDB%3VP2&"C[;LE@JH)<F1POJ2H1,YS<T8Q@ 4SF*%><[86[/U3,$XW
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MN]H:QSF_V^[@VWLGV!@^H7VC^->W'9K9%>OM7:.*-7#"EN4@QV\QKG;QJNJ
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MM?=E"2Y>5_JS-D6*NT_NDV7:*8ES]A-IKH_,3+A,3'V3#L2FI"IQ$H 4IE
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MDJ)AR)0   N_)BUMI,WZS6\7'[\C^S:0N-C:G=86N\9BF\@\('E_M83<AF)
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MV]=%E7OU3$P]^(7W)WY)/V)F?09Q2-CE$+.=SBYS(J0JLC'.58]VBT$[P>;
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MO,KZL&"=Z"T%[W9F #+B'<1>9/U"RKB=TN+C D9D'6+\FFT7%LELV0SS".2
MF;FR;1"CDI#;(;1"CV@4<@ ]P5L.9ZE9LG=;/ <K:6Z*554T2&45.4A"ADQC
M&*4  !P(B)A  P([\C4Y:\%E(X\O/@A%DS@!BF# @40'(8,!@ 0$H@(@8! 0
MWE$0SD,Y <)SY)]E*:A%0VB&*8,X$2F*8 ,'$HB41 #%'<(=@T4D7&HSY:KK
MOA#H3P-^1:..'8',GW_7MH#!'7H/7+W.2'(].JP*U](I.J\B*R450*>7UNLZ
MZ':'IL*Q>FVEM[7SDP9  V)F(@C[1C 4!V=G)@ *[/"'<H;0J9;N%K &<RZ8
M'URRS7D>TK7UL7L##TQO/_ZSAL2[@VGAF57/G@Z' @:@6,V.2&AWV:!N62$/
MLLK?=V.3&$0$3@24.W34'CG:213P.\=P]V1^9]AW&I@L56<0:C\9B6.,R?[=
M5PZZM(X@F=%]+V^.[KT*;0-UF$P\<R]F]]29NO<*]RNC2B)1$HB41*(E$2B)
M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1$HBHC/U;F_P 1$^W][=_4/?IKZ=-?9\DX\OP#]UQ#
MUS&]PD_E!2B*NT1*(NH_>LX]JL[D';=BT1*)UW3I9)NW1('$ZJZQB))E#_I'
M.4.P!SNJ.R/35/?O]K5S?TBJSU9GY5-/4RX]1I2?4<6'J!":K045H?:EJ<^B
ME&(RL8>ZF[5KU3&I;%Q1<E;;]]<4@F[49N#D=MSMYAQ)>TBYFX&]F )'0WY7
M XK7B7M:UAF(AI!D"<[\L]<\\R%M*1 3(I&,8#G,FF)E P('$"AZ8HAN$IQR
M8,8R!NS@&1&8RT/W68N >("P8U#Y.>J%Q35UV_:SW3Z%LC46_(&^;LO=TA-N
MM3F"T%)QLB@TA@.X4B2NVH1A&</(D,U+&MUCB#553;%288]PX&)#7N=G$[Q)
MCYWX90E0;[0! @ 7Y#E[U6=21!2233$QCBF0I!.;>8VR !M&'M$<9$>_LJG,
MZ(!  S@1.OR6'_*NV'3O0J%N($3::3FL$9':B)/BYAGD8,--+0<;< ' 6QX6
M0N%*,;O$WOVHX,9))QZ0PUQRYW?AL'=#*EYM.Z8RU!B,C.EE'P*5OB[RG')N
M^W>YP!I(X*I<E!P5YI"^C57"_H<+?FJT=8Q%G*S94^GC.^9]G;@1JP*).PBV
MD:4&L4X;*'(E'HL^BN!(FF8O+Q :*5( C>-!I?H0XDCQ<BTB<LYBX6J@YV_4
M#@1%4ALQ!&>\,H!(.L:3G%M<@U!FRT=NF,CE /'Q>N6NK"/*+]62.2.:ZIW2
MC'@=XX<.73C::)I&*NY645<%$%C**&.)QU4Y[JG/Q;M[0=(GR]-0%FV>]K<-
MYL="WAI]S/!9E2 @5D\-G[EJX$<C@ #FC )LCD P&1W ._L$=P@"Y\  FP M
M))MGI?Y:+-Q#07$P "XDY "YDZ6_*U!*<I_2"[N6#H/IHGJ-:83^EFG=Z$,F
MN#E**&_[FB;,A8NU"RJJI62]QE@RW(8S9%P4@.Q+'"<TBL5F'HL=LK'X7LYC
M,<:#PQYW;P)9#CO&3D2  8Z67S&GVPV#M+MU@MBTMHX9U?"M>YS=^QK5 UHI
M!UFE\.W@;B?#!=8["="VTZ&GD,X;J1()OUI23^S-W@J"H]DG"@F.)')0WCM;
ML&$>(G' "/RSL51[O9KR6D=YBL6^W_\ )4!'*!!]>*^U;?JMJXZ&1%.EAZ=C
M(/=L@D'@=!&E\U[+LW+[-!^3/_G=>Q\7_;\UTB@"W-VK07O-I#YU5,Z1Y@_E
M%.S<N?OT%C\F?Y^#I7ZZGBC_ (ST,>L_9$V;E]F@_)G_ ,[IX_\ M^:*-FYO
M9H+Q?:TAP[?X75ORYVUTU1!+<W8M!9\;:0X>5_%\=!O:Q'('/U^?R1 +<O:M
M!>\VD.'E=#O:1YSFB 6YLCE:"QV8;2&??^VZ7MES_7OT13LW+V+0?DS_ .=T
MORTU/GIZ(FS<OLT%X_M9_P"/_P"+]KXZGB_[>6?OBBC9N;V:"Q^32''RJK?B
M)Z'+U1-FYMWV:"[<_:TA[V/MOX:7OER^\HFS<V[[-!>/[6D/?Q]MT\5\N6?E
M*)LW-OPM!>+[6D/?S]MTO:8YY^4(IV;E]F@O)G_SJIXO^WT/Y11LW+[-!>32
M'SJKXN(]#^439N;/WZ"Q^32&?]J_HI>-)Z6^OY1-FYMWV:"\?VM(?%]M4\5\
MN5C\[HIV;E]F@\?DS_\ -TO]=3Q?]L]#]9^R*-FYO9H+Q?:TA\ZJWMESL?.+
MHIV;D]F@_)G_ ,[IXN7SRO\ JW6][% %N;M6@L>)M(?.]_Q4,Z1/,'\V^:)L
MW/O^S0/B^UI#X_MNE[9<_P!(FS<W:M!>32'=^5]^?>IXM(^?'\1YHFS<WLT%
MV?P:0X]O\+^ ?BIXN6NARTU]1\T39N;'WZ"S^32&/]KIXITCSE$V;E[5H+R:
M0]_^%_7AXZ>+2/0^6OO/DB"6YNQ:"]]M(?._:H)UCR'[ZHI MR]JT'GQ-G_S
MNH=[3=CG** +<O:M!>\VD/UN]WQUE?R]^OR\T02W-V+07OMI#YW]?>WR_+Z_
MCT^=[$V;F]F@O)I#YUW>W3Q<1Z'\\>B*=FY?9H/R9_\ .ZGB_P"WYHHV;F]F
M@L=OVM(?.^[%6]\IT_?G*)LW+[-!>32'#ROZ^_N>+EZ'/U]^5R 6YNU:"]YM
M(?.Z&=(\Y1-FYO9H+'Y-(#V_E8=GQTORGH1IU.OR1-FYNQ:"\FD/G7MTOK'H
M?ST13LW+C[]!9_)G^/AZ5^JIXI_XQT,^D_=% EN;L6@L=N6TA\[JC>UB=(!_
M*)LW-VK07#=]K2''ROA]?:&=(SO/#\^^I-FYNQ:"S^32'SJE]2(Z'\H@%N7M
M6@O>;2''RJE^(]/VBG9N7L6@\_DS_P"=T\7*/,_CT^91=MF$N"AAD%(XR6QZ
M0&:+DA^<V@WG,NNH42;.0P4H#M" YP&!"=8Y0/V451JHJ*S]6YO\3$_HW=37
MR%O7Z_92,^9GY ?9<0#_  D,/;U&F'_UZ@TU\N!^N7EFJJY51*(O/=4VFGK^
MR)ECJFG#+6*](W:SB,^!#12Z:SM K9%T4X"42J.^8*0-V3B4,AFL7 &),1^M
M=/?!#8$\ 3Z76&$S;_[G%:%PR%O2L1H7#73$OD6SR+0CF19QA+%YDZ)$VS1-
M1TG(%.J@JW*DF*Q1,B9$/N:R:X[\-@VSYGGEE]\\EIJ;A:W?M/F+Y2!?ES)R
M6PQ#FQ01%+'-"D04\9$-@2ALXR #C&.( /> <*',SGJMHB!&6G31?6BJ414J
M:@H6Y(UU#7#$1D[$/2<V\BYE@TE(YVGM ;8<L7R2[5<@& ! JJ1R@( (!NJ0
M)F+\?DD YB5U4K5MM$8XR4##)C$1[B)BQ3BF!!C8IVFDF[C&&RW#H<>Z(W0*
MY9-^;;+@BB"J9@2(!1$S)F1%]+1Z<E  -!Y"%\+8LNT+*:N&-GVM;EJ,WC@7
M;MK;4'&039V[$H%,[<H1;5JDNY.'W2ZI3JF#<)AJZ1H,AH$  ).IS/T]-%4I
MEJ5W%R*)C' JK!XD8"F$@B"C=0F-L! 2[C#O 0P.!R&*R8XLJ,<T"0X.G_Q(
M(MK,QQX+57IBK3>PDPYCVP#$[S2+GSY>:_-JS_<=9)IKDKJ7*7RZ_N!A;YM2
M2='?G1O4]R+()2)+1Z2('.1L+T5'JT_DRPL$D&"*)G:BCAIZ;M1VUICL?C,*
M^F!4IX<TR&SNP Z' DS.69@7Z+\_[#_@RJW^1\-MEN,?_P!.?6%?/^]W^^TB
MB<@6%TDN$^!I\0) 7Z%=(&!HW36S&AMK:);\88VV!@-M*M$EA'T_IAR*@CD<
M#WAV!\W[,MW=D88@$=X.]N(,U ''Z_-?I+'M%/%UJ8,BFXTP9GX/"!\N/JO2
M:] N&E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2
MB)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%16?JU-_B8G]&[J:GH
M/NBX!ZYC>X2?R@I515VB)1%U7C9L[1,W=MD72"@EVT7"2:R(B0Q3E$Z:@&((
ME,4#%$0$0.4H@&0"H1((].J?37W[_&H#4_5Z84U>U.A%-9K*L\L/>*D G9L5
MR9'^HG6+5O'Q*2"DCJF63%%G.2:*A6LF<8TR=MO$U6PI* SR9@O$7@@'Q&-)
MFT@7WA89WUYC3BH:QF[F0-)$DQ%\H$7B+YK<"T'+5N/>@D.<"&<D <X$ QGC
MC&[.*R=F>I6QGPMRR&67LYKL5%DE$2B)1$HBZC_]XO<<>B.,?]R>J,P>!^X_
M"9KQ&\7(LM W:X&#;3T\;D1*8/NE%(5!)(F>T3',   X 1$ R 9&O*]M#_\
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MIL3('.3<9D9+BUG&JUM,-D !SC%IDR).@$=)E;K6XB9!$P@ "9(AA ,8*(E
M1*&-V $<!X@XCQJ$R2>)E;FB&@<M,N?S7VJ+)*(E$2B)1%U7W[R>?DKCMQ_B
MC]O9[?9QJC,=1[T4.1Z'G\M5CC? BM8FB\;C))2[-,VZB>3 )DF*))I0,!D1
M^Q1:@XWX !-P*(UX7MN;[$9I4VW0:8S@TZECZ3'YMZ#8#07;4=(!9LK$.;,6
M/>46DBV8!.5_HLEB!@I0[BAP]JO:TANTV 6AH'H(_P!<ET&:Y5L10)B@&1,
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M:[55Z@P6*9D(QCH[9%8Q22@,1,9(R>Y7"84$N=NM!<8)( )(%KF,A^E ;22
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M)P VX\MYS)+7$NS;M5VZ*D4]%8SG;#2YQD_ X#*YW3 TBYB)'T*U.#CW(#;
M@NY&Q/,9 6/%7;$61RL"Q)%I1EJTHS,6W$M5[>-JBD-P7K+(2KP;BE]'YE.\
M0-8T.]8+-%21<9*V*D1)N9HR8L5AZ2IB!=DV -^5HYGT/JLR'%M4"SG-AI$>
M<:#C<1.O'IWA97*<2O!=S:UN:_*68AIA<5LM&I]8FJTW)23ZUGA;:?O#IZ@P
MS&/N6-GDV73IIJBK+)+'!0MQ/FVV4N+9[^J7 [A:=QTVWAD>.1.DS\];P_\
MIZ;&;PJ!PWG6G<U!(L=)MI$JW6-L<L-.;1D8"V->8:4?/'[51W=VJ,-/VQ&L
MGFDCF',Y4@'FI<ZP#9U(,PEVSAK$G?LTD%UVITDU5FSBP?Z;NR3WAJ%Q?P;(
M@:YW,<1T6TV+H:7$,;NNREWBWNF8$=8)7NEF6%K3'<E_5>VKK2U6O:\;AC95
MO!P=Y2MO/[M1>R42@S=LHF6?7[<352$&4%>08*2]T)J(HJ*)HL&3=-NQ3RQ
M:ZFUK(<0&@F#?*22Z,N0RY+72[QI)=(FX$@AO$#0>0'R7FE\Z ZM6U8-GR6D
M;'69?46Z5;?E]0I9UJ'#P=RL%[4@F<="P4PVMB=MBWI.+:MT7D>@Q2=RD:H+
MLQY9O*@9-5MB7/#J5-H)I@0XS82!:YFQS,0;^63& ,K.<":CAX Z"6NN)!X6
M$WS.HA?2&TBU@@;YO%XYM'70MJW3J?/W6]/9&KYH>2<NY:!MM2W)LI7.H:*
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MUHW- W%*7!,.1O$\."[]1K(J"4)V0D'D@(.G!4SN3*)[W[I+=VP(AP (#8L
M/(#*=;K"GO!CB1XB#H),$1.DD"?J95O:B6OK8CK/<%PV+IOJ(C'O[WT:?(SE
MO7';$%#OH2((_P#1D298(WQ%N9B-2!Z4KR+EHQZBZ7*JNV;+JD17'73W@^BU
MQBD*U0OX-:[> , 201%HUOS52_N7[C9J%K=T6^+7. ")S,]=5Y7;^G'*2:3U
MT3,G8FLH.9R"TT8Z@2J6J,4-PW>E;MY3SB]HW3FX$K^2E;-:R3&9:2$"PCG-
MJM$8]M(M4EHEVN5)?8"QN'JL#?$ZNUP%YW;ASI O()MG>(S6;H<6DBX81T.@
MU%_0Y],B]((V\U-1]+F$\M,O+BT\LO45M?SV:=A-2D7!7?(P;O3RSKDN3G'A
M)>ZTF+-O)/\ FY.0=II,.G/W2P2S9R\HW=VH9N0W=,&XWISC/4Y:\EI8'13#
M@;%Y,FXM$F"1?*W+SSFK!;UY=?UF7C<[J/7MG4*3LM%JBNFZ081,/)%?'4.F
M9)50THW7.F9$I3D*5$2@8%!$X")2X\OMW9&T=HNI'!XYV&#6N:X-D226D$QE
M$?..)7/P6)PV'WN_PK,1O$$%Q<-T 7%CJ86/VIFF&O;.TY$+6U3N.[)5R4&9
M(DT5:<059LY$".CG?D:MEF^P@*@$.W<$6*H<HD$,"8/F';'LOVT_Z+7H[(VA
M5Q6)J-(W15=3=!D?$YS6QG<F3)T7J^SFT^SS=KX:IM3 TJ6$8_??5_NU-TMN
MT]VW>WO%H6$'6T*S]#-)^4&TMU2$N&]YW3UE#K<U#QS9G:\VDJU5VUC8761=
MN2"FX.<P@HMZ<#&XYKI/X\[*=OV;/?AMM8_$X,TG'<#ZS:D@N+B :;WG.]S)
M.<KM^VFVNRN*QS<1L?#4L1WS *SN[J4H+6A@):6L$EHS S$YE9)VEI[J% 32
M$I.:KSMUQS=-V"T$Z@;<8(OA40.FB(N6#5NX2.@J8BZ0$4(4ZA (J/-YKZWL
MKL]M?!X@UL5M1^*IAI I$D ^I@$YG*_!>"Q.-PU:B*=/!MI/D$U 3.DBY,@\
M^)XK':TW^K4%:6K]K?W"-64I*]+[U+G8.79SVG\.BTB[B*L>+>MY:,U%+,,9
M+;(06Z31%JLDL=(PO6XBHJG[)X=W#&MD/%-H.A!DR)'(Q(.6IN#UC8WA(@7N
M<O2=="1;/)8\3FGW*MG5-.9)Y9&JCRZ[;-8+ZWI.3O\ M]];5K'86)(0T\-W
M6\O>ZS2>N=*]W2DTYN$[*X'SJ%623;R "DK&J\AI8ROWC06CN7,<(^)Q$"8O
M,\3:."T!KG4>[<(/>;USH"8.L<0+9Y6A>A,+$Y1G4[8).(UT-9+N4MOT:6<W
MU<*&J+B:+!2#:[+ALJ\ OU-Q%VBXN15E)L[<;7= MSM$CIH0C!H9:(7P(!W3
M)D&;3RCTCZ>68!WG6\,#A<ZZSRO;763:M\69RK@N74MW 6YKNYAY2PUX"UV[
M/6!DHKZ)&9[1>6U/('"_;<CXERDJUET9\\=#L!DA"1;R2DTQDP1&$F:>?AJA
MQC_$#/*_0VGR*KI ):/%!CWK["ZBMI\KTTI=+BS[>UUMYY<+35ENQ=WCJ?%3
M\+%-I1.UGEDI-XMQJ3,I1SYHX:78A&/6#3I$8:3:-A=I,"H]7Y^$MJC(NJ$M
M_P#$Z@9#@<CIP6)GO&$ D"D 2=79D&;YZ$1YE>Q3&G&L*O)#NFQW;75:^KTF
MY%$(EA<LC:ZE_1K%S,QSM1->3F+YN2,70ABINCQ[E_=DL\%N1 #)G.!4285P
M'/PY:+,<TN(R;&I%B3!),3G>3EA0;4:*A>3XC(:2)@:6R$@$23KR5I:CZ&:L
M6C(:?/M%(_5UX\G+C2U U1GSZA1T3*2L\5U:$<XC;PB(:?M.WI@2VI'.8R/2
M!G-0C=%@H@,>9RY)(G.+O[C /"T$4\H=O S OKQ&OKL:QOQF=XYS,W \K1U7
M5L/2'5ZT)X(^0M77,MH?W2=4KD;I6=JX5EB;F-27%QVS/S24G?@EE[0E+2<)
MQDO%/F[\RLF:4>O;?<2+PTNI6'=#21):T B]SE<VRF9G(9HX386WC)/2.1 G
MHK]Y)UHZOV9=+QE=EC:F6Q:TG;%Q/WJ-SW9!35MM[I>W_<$RR;PT(PO6?;PB
MJMORK<CD8B+8M7;E,YGRRJY05.I@=S6[PS4=4:6"3.[NN#A,;NMYY0%'-BHU
MS 0W<.\+7=(OH.,&VDY0KHC]"8:XU]5UY/26;@=/IPT7<$-IDZGD(-P\U(B'
M$DZ?7;;X6==)FUJ%GP<(-'P1TW'A,$5D>M694'[U%WB6M[NG#9?3=O 6D9:S
M%^NG,R#27O#A#'MW9S! Y"3,Y6'7C5].K?USL/5QE:06O#*Z..[<-*S5S,P9
M)'2N0C%F@SCV2BDQUJ5..!!*#8Q)((D4E",T7Q))-UM,3;&/=5%?OB02/[>9
MFP$&+$SQT!ODL7L+.X%(;PG^Y8"!))S(SY6OEF5XU<4;>[-W)6E&V#=5X7C"
M<J!/5J?0@!MIFX=6"O,)R,%.MW-S3]N(RK<8A-M;S8K%9X#20AEXQXHU%NEM
M:\-X:E)SA 8W$-)SNYL-B,]XR 1(XPLZ\/+PWQ780 (/A:T:\])TF2JCJDMR
ME+VOIS.65IIK/:%LNK!+#R\2KJ%;$2:2!E>L8\6)"L8G4!['VU><A;A)ULQG
MHT&CPB+IDBO<3<X(A'MV3!=#"2<KB?7E^"MCG_V6[K(JAYFP)W=#P-\LS TT
M\H@-+.4W%6^Z@X&U=7+6(M<FJTM8ZJ6I46W<V]=MQZC.;DM*[-3'+.]G"E]V
MZ-NO4V<VRFO10X=/49!5W#O';A*0-DV!38T@DAP);F  Z8G7U\PM#VO-:NX3
M#KL=-RXM(F#'YF%3[PTOY6KZZY6:C[>U1)=ZL9=,'.WQ'WY$.(9_;[O46#F$
M66FD4O?T0YLYP_L-BK%HA&(6HL>62,#N2;+K%FRUH8VO4<!#'MURD"1,"?BM
M,"QSS@YKC3H@MFHUY+G6^&'",X@@C*<HA569THY1(Q-X-D6W*DGI!EH_%-;"
MERZR'M%XK?XW2[+M/XFW]9DHSK&,MN19(.U)1>582+2*<K/W$K* B=W#NEH(
M!#Q5%CK3W'RXQ8D'=&<W' A;8D&<X,WXY@3],E];:;:V6+=*DW?MIZ]I:='>
MZM0TL6^M0XR\HA>S;A@(8NG<6O #J-<CF3GSW8:38H/$(I].HHO4(LCX\*1N
MR;9-+&L().\7&,]8$\#G!!-\^*T5!5=4EH.Z&B;@ @3IRS)SB-1;8YHI$SD#
MI-I[#7)S@3D;:D,TD2*E*19!=)DD'1EBE$2\\V)L-U1 QLJ)&$1$<U""#!SM
M]%MID%H@1R^?WY+U"HLU1&7JW-_B(GM_DW?9]<T_'#KKK]O-%Q#US&]PD_E!
M2B*NT1*(E$2B)1$HB@1  $1X!1% G#&=_#(ANR <-X"("' =X[MP[^\H3'F8
M4;9<"([L=^-_M;^ ]@C@![!QOH@,SR]]?7R7(! >'U^O8/ >(9"@ORZJKK/1
M &3L1X U<"/M<T?-%#<'H5CO' 5[?6C30WI@B],YF8$@;."J*MK4BTE#%,.=
MH"NET\E*)@!4P"(%..UX?:3FUNU^#PY</[>$J8C=.7A+6$6F\N$?46GNZ#"S
M8N(Q$$%V+I8<\)+'51E?=AI-B>BR1#. SQP&>S?[5>X&072J:(E$2B)1$HB4
M1*(E$2B)1$HB41*(E$2B)1$HBXB7(<1#?D<#QX_\!QPR%%,\U)0P  /=\'B#
M  & X!NX454T1!W@-")L47S AMK:,<1[BA]R&X ^'M#@ 9'<(CD"GOW8<_=E
M]**I1$HB5(X6Z(E5$HB41*(E$2B)1$HB41*(E$2I>=(^<HHP&0'&\.WM[0_6
M-5%-$2B)1$HB@0R)1_Z.1QNWY#';W<=V!SVXR HUX?=$  #AV[Q\8]X^,>VB
M*:(J*S]6YL?Y")^)-W_34UCD/G/X4&O,_8#[+@'KF-[A)_*"E555VB)1$HB4
M1*(E$6-?*RN6Y+5T-O&3M=ZYBI%12#BU9EFIS3F%BI><C8Z8ET5=P-U&$<Y<
MKE<"8 0V15V@V<AQJCW"M18 =U]1K2[1H,\CF1&AX:(1_;JN!\3*;G-'$@96
MOU5F:%OGD)=_*.M"#DI.XK2L1W9+NT#2DN]G1;2L[8:,K/0[65D7+ATNB+YN
MRD#MU'1R-598Y4SID5!-/E56Q2:6NN=Z8BV[%YMQ.>5PM5 2[>?/Q <HF_KK
M<V@W*\,T+F[A<W/R>)@;IN*6F]9K'U2D]6&JT[(NTD7<<]0%F^3C5G"S* =V
MQ)');K0T>DTYLN6ZA5E"Y#&D-]M5KR710+V&;;V^!NS%S!)$9Q81=6KX:K-W
M(U=UT2(!83SM#0+Y#G9>[\B)S+K:1W$UF)N;N%:'UHUN@6DE<,P[G94\5!ZH
M7/%12+J2?*JNEA;Q[-NB0J@E!,B8%*F0FR%2G/=4YS@^G ]+_:,E&&:E4:!S
M=(%QGU,">:RVD#89NRC@H"U7 3FV@(0#)&#:.(%'!0$<B(9W (XW8'76JMH4
MZE5QAM.D^H]W^+:;2Z8UU6]@+WM8 27.:T :EQB/SR6IZW>4,_B>4!'/'O1W
M%MQ4.WTS3 CQ0&::2(,FZLL1<S0%$T%9ABFNH<K4QSLLB0BB@MB'_'S/Y8J/
M_EB2U[L  [9K)+6MA[V#O23D&N:? 6R9NX+[W5[ L'\?NKMJM_K.\IX]X(<'
M"&5&=SNQ .ZX0XN@9$7$;4$7<^LF10D9"B0Y"F(8)]\(& Q0, @/H<X" @(#
MOS^?]A4:O?4V5 !NO:'"\V(!&G ^\U\#+2PEIL6DM(X$6/T7/G[C\%0G^L#_
M .C5;+\O7GTX?.W-13S]Q^"H3CX??</]6N/B^.E^ ]3^$3G[B\%0OG]]]&Z7
MX#U/X1.?N+P5"^?WWT;I?@/4_A%'/W'X*A/]8'_T:I?@/7](G/W'X*A/]8'_
M -&JM_9_2)S]Q^"H3S^^^C52_ >OZ13S]Q^"H3S^^^C5+\!ZG\(HY^X_!4)_
MK _^C5+\!Z_KC^>2*>?N/P5">?WWT:]OZCN7X#U_73WF4<_<?@J$_P!8'_T:
MI?EZ_KK[-BD%[B[8N% ?%//A^/T-A^:E^ ]?TB<_<7@J%\_OOHW2_ >OZ1.?
MN+P5"^?WWT;I?@/4_A$Y^XO!4+Y_??1OO_I\5+\!ZG\(G/W%X*A?/[[Z-TOH
M!Z_HHHY^X_!4)CW???F]#7ZZ7X#U_2*>?N+P5"^?WWT;I?@/7](G/W'X*A//
M[[Z-4OP'K^N/YY(G/W'X*A//[[Z-4OP'J?PBCG[C\%0GG]]]&J7X#U_2)S]Q
M^"H3_6!_]&J7X#U_2*>?N+MBH7S^^^C8>+ZAO7X#U_2)S]Q>"X7S\^^C=+\!
MZ_I$Y^X_!4)Y_??1KV_J.Y?@/7](G/W'X*A?/[[Z-4OP'J?PB<_<?@J$\_OO
MHU2_ >I_")S]Q^"H7S^^^C7=_1XZ7X#U/X1.?N/P5"^?WWT:]KZAO7X#U_2)
MS]Q^"H3S^^^C5+\!ZG\(G/W'X*A?/[[Z-4OP'K^D3G[C\%0OG]]]&J7X#U_2
M)S]Q^"H3S^^^C5+\!Z_I$Y^XO!<+Y^??1NE^7K^D3G[C\%0GG]]]&J7X#U_2
M)S]Q]D5"^?WWT:&E^ ]3^$3G[C\%0OG]]]&J7X#U_2)S]Q^"H3S^^^C5+\!'
M7[1]T4<_<?@J$\_OOHU2_+U_2*>?N/P5"^?WWT:I?@/7](G/W'X*A?/[[Z-4
MOP'K^D3G[C\%0OG]]]&J7X#U_2*.?N/P5">?WWT:I?@/4_A$Y^X_!4)_K _^
MC5+\O7](NVT5E#G,#]DP;)@3)#M))P],)\ADIR+14>!"[.1 X'..0P) SD%^
M7K^D50JHJ(S]6YO\1$_HW=-?3[_A%Q#US&]PD_E!2GOW[U15VB)1$HB41*(E
M$5.EHF,G8U]#S#%M)1<DV59OV#Q(B[9VV7(*:R"Z1P$ITU"")3 (>,," "$(
M!ST16; Z3Z=VO$L8*WK5C8>*C9@MP,VC %FY$YD@ !9!4Y%05=. *!2 +LZY
M>;(1/9V"$*5%HO%_*>"A MRCY9*8'2G3NV)F>N&!M*'BYNY@7";DFC8$W+TK
MI4R[HFT X;D<KF%=PFT*@19?[,H4ROIZ1X0W( 1;4><\/9ND"9S,S?32W"UN
MB^U@Z8V%I;'/HC3^V8^UHR2D%Y9\RC06*@YDW1A.Z?*%655'I+E0QE7"I1 R
MZICJJ[:AC&&Y #0" H&@$N N[,\?>7DKW61(NFHDID2*D,F8HX$-DP"4P8$!
M 0, X$!R A6#V-J,?3> 6O:6.'%KA!!Y03ZK($@@@D$$$$18@R#<&ZU\(N='
MC\H-720NA=K%CQGG-O)WGUP0\N:ZV=HA?JR:EH=3D33@#11#HEGB7(LZ&5*B
MW/!IMU =D\/3_C;L=4QM7%.V'@CB016%;NXJ;S3O @W&9N(DZ'>7?U^U?:*E
MAJ='_JV,.'JEM(T15=N &0 6S$:&+1>-%L(12302312(!$DR%(F0H8*0A"@4
MI0#L I0  #L *]Q3ILI,;38-UC &M:,@   !R   70EQ<2YQ)<XESB<R29)/
M,DKZ5FHN)S 0HF'@ 9'?CZ_'X@K%SMUI=P$HL?M(N4!"ZOWIJ;:\&Q9)QVG\
M@R8L)I&X&<DO<B:IWK-\^ZH;-RJ0S5I*1SQBWZ2[<K/B)%> FW060YW-@WZ#
M*X/A>YS0#F"W-4@@QT\K3Q^BR#J*)1%9>H=W>@.R;IO$6))(+:@Y&8"/4>IQ
MI7QF+8ZY&G3U4UTVW2#E*ESHMUS$$X"1!<X%2/A4<6B0!Y_['-9,;O.#;WX*
MR]!M6E]:-.HV^7,"SMIT[DIN+>0K.<6N!!FYA)5U%J@21=0EN/A%06P*BWD8
M"*>H<YL+MB>D.?9'A8[_ "$]+Q&OK/TDZP3O.;_B2,LXUS7M%19*!''OC@/;
M']7>/8%$7BU_ZL2%E7]IM92-JHR+/4,]VMO1.\N)O$L(1_;5LR%QH-7#(&$@
M^=I/RQYT'+TI&R$<B<')>GK@5BI@73O;N8 (G+69(/*V4Z9+%Q( XD@>9M]?
MDJIHYJ'+:FV@:Y)BW&5MN2S4U$I(Q4ZXN2%DVT4_59(34)-/(*V7;^+DBI<^
MV5<03 V\Q4RKI FY5V$0&R;EH+N ))D"YM91KB2\$?"8ZV!^LY3ZKU:HLTHB
MP]UBY5;O2.8OR*<:;/9GT+P5E2-NK-YTI5;ME+WN9O:K".!@PAY9[$LFDDY2
M!T_*C*2"B95S,H%T8C9-[I94<]E5P '=U&L$S<$@$GF!.1()^<<=TB02.[<]
MT9@-!-K:@?719"Z8WPCJ/8EKWLW29()7'%HR HQSQ\_9-U5-HJS9!W)PUOR+
M@&ZR:B"AWL)%.043,51DB8!(7D.;NF)FP/J%KI5.\;O1'B(])XF9XV_*OVL5
MM7R64%-,QRE Q@ =D#&V2B; X QL&V2B/W1MDVR&1P80 HPF >0)]$6 ,ORW
M)V!EGT3(:3P[H(VXIIDM,PVI3EY;TS:\"O;#"3G;1D7^GL4M/2S27N08=> <
M,HEAT^(DTD+F7*1,YKA_[[Q3! .X'DVW<W",\QNR>16K$5108VI!<US@T0)(
MGC^=;\%G\@J"Z**Q0$"K)$4 !W" '*!@ 0R.! !WAD<<*&Q(X+8TR >(GU7U
MHJK;NZ;<6Y;<W.-DXA5>*C';],D]+K0$.<[9(R@%D9EO%3B\:U-LX4=)1$BH
MF&\C58V"&UU'[@FWGUCWQ0:>_DL9[&Y5K:[[VTVL%[:;2!G[SM][,W"@O=;=
M<UKNQ8/I* C6#1>)CY.X@G6$:XD =K1\ +!@[AU%FRCJ2*S2WAN\"X9 --XG
MQ:??0"#-KK0:I!8-T>)SFSPW1(/GD,YG,:Y=%-M  ]X9^OQ?#VUA[]^[K<#,
M'2)]5RHJO']:=2IG2RU4;CA;=B+M>*2T;&)6V^N1Y;DK,*R+@K9)E;(M;:N4
MDK.J**%,VC7:<2Q43364=S+!!-1=/!S]US08W3,W\5N U]P#I0"0XC03[]^8
M5BZ)\H=;5V\=1K3<VFQMH;$DS,FSI"ZBSR\NV(^>QRCIRTZCB48\0<L%MCJU
M]<3$0^UUY%M().F3;93_ +E!M86#G%NZ9FQ(X#4>BU/>&UNYS.X'3;42-;Y^
M6<PLFJBV*!' "(]G=QHBQXU4UNF=-[ZTWMA.S6$G;]_OWD.M=LC<<G!MH"8(
MS6<QK5RF6SY6%61D#(G(<RMRL91),JB[*%E")*[&NG4#ZU2B006,+FD9$@ P
M21;7TSBZCY:QKQ!EX:0<X,R?QF.*O+1O426U/LXUS3%LMK8<!.S\0W1CIMQ<
M4+,,8:27CVMQP$T\@;8>2$)-$1%TP<.8*/.8@F!,CAN"+QSN<T-W8,RT'*(F
M;>\\UBQV]O3 @Q\AGSF?P%ZM6*S2B+"S53E;2FE%T:B6U,:8*O36S!VW,64Y
M9S\P"U\C<%Q(VTJB>/6L=-:/:Q#YRU4D)&W%+X1(DZ21YHK\4V2^HU8+ 1\5
M7NR> X@9D\M..<7=):]PR8V2-2> N9^6OGDQIG?#?4>Q+7O9JFS21N2(:R8(
MQ[IZ]9HF7('.I-W<G$P$@X215!1(%7D)%N3"0><8H' R8<BK3=2?N$BP!-KW
M$C4C(K11JBJS?%KD<-8UO,C_ &K[K!;EUW;E%DU</'"A$6[5!5PNJ<<$3113
M,HHH8<A@I"%,8V\-P#O#B&+W;K7.B8!,=%0"2 ,R0!U)A:[2?N@3&1?.TK=L
M")F8V-?RCU^]_NCLT7!K$8SEM0+.XXUFUMJ21>3TNM<[-\QM!V_C# P15Y^<
M2>*)-!RPDXICWM\.Y!((.1GIJ.&HR6G$U?Z:HVFX!Q.>Z01,93ESFXC@MC!#
M@H0IPS@Q0, "&!#( .! =X"&=X46P&0#Q7*BJ\\U0U$BM+K+F;RE@25;QB)"
MMVBKI!AUA).EBM(Z.*\=&*V:B^>J)-Q<KCS+8ACN%0,FF(#JJ5=S<@;V\XMM
M,VL>D'.;*M@F]O./J+^7V6/ND7*\@M6KLT]M..A8AJ[O#3EE>DRLUO2/E1MV
M=>13"7-9[1J2/:O)U9DT>F,^EN8BDVXIIE,QYQ8Z:'*=3C?@SN&,L_KQZ"+K
M4]Y8^FRQ[QN](G@#Y'B#ZVOF+6I;$HB\$Y06O$3H-;$3-O6#29DIV;;1$5#.
MIQK;Y'*8'36EWYY%VW=)I(1$9SSU0A6ZJCE8&S)("JNR'+K+RUP;;Q-<X9_\
M8F?4<.2S:PNFX &<F_(#F8*H.A?*&5UGN/4*#/:\= -[-?%2C'S.Z1N!2>C#
M3=P01))PV& AT&!5W%O.7#8T4_N:*6:N$2==%D$GK!IO##W+*I(\3BV!I !X
MG4D>2XXJ2\L RBY&OR$'0\C8S;)GX_KXJP6U45GZMS?XF)_1NZFIZ#[HN >N
M8WN$G\H*545=HB41*(E$2B)1$HB41*(E$2B*R2:;V"G>:NHJ=H6^2^UV0QJU
MW%C&Q9]5@()%%F>2!/I)FXD12(*8GV1(0I!]*&*@ :7$9N$'61:U\LADHX;P
M:'7#3+1P-_RKVJJI1%Q,4I@P8,AQ]H>\!X@._B%#<$<45OQ=H6K!R<E-0UN0
ML5+S";=&5DHZ-:,WDBDT,J9L1XX;I)J."H&76,D"IC; JG$/NAH##0T6:"2&
MC($YF,D5Q41*(J;,0T5<,6_A)R.9RT1*-E6<C&OT$W+)ZT7*)%F[ENJ4R:J2
MA!$IR'*)1 =X5" 1!$A4$@R+%4JT;*M*P81O;=E6[$6O -%'"S:(A&2,?'HK
M.UCN72J;9N4B95'"ZAUEC[.THH83F$3#FKHT:-$ <!]_-8@ $D"YN?>G065S
MT52B*P;KTLTXOF2B9B\;*MRYI6!(Y3A9"9C&[]W%IO2<V\(Q77(=1N5T01(X
M!,2\\01(IM%$0J  $D"YB=<IXZWS4<T.$'B#YA52SK&L_3V&3MVQ[;A[4@D5
M3K)1$&R1CX])50"@H=-L@4J1!,!2@.R4 W!NK(DF.5AR0  D@9F3U5U5%4HB
M\NG]$]([IEIN=N33FT)N9N2/;14])R<(R=O)>-9JMUVK%^NLD8[ALW6:MU44
ME!$J:B*9R !B@-8AK0'-  #G!Q U<,CUZ?<J0)G6")Y',*_8:%B+=BV,)!1K
M.(B(QLDRCHU@@FV9LFB!0(BW;-T@*FBBF4 *0A"@4 [*S))SX1Y!1K6L$-$"
M2?,W)54J+)?-5)-9,Z2I"J)J$,F<A@R4Q#ALG*(=Q@W#XJA -B)L1Y%%XVPY
M.6@T6G'I1^D=@-$HF7&?C$D;:C2IL)HP@8TFT)S E0>', '.LF!3'. '-DP
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M:=V(\F)&S++MRUWUPKE<SCJ#BFL<O*KE577*J]4;)IF7,59TY5+MY %%UC@
M&4.(T2&AH^$9 WOUS6&XPN+MT;Q$$WR5]T6:HK/U;F_Q$3^C=U-?(??W["+@
M'KF-[A)_*"E5%7:(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)
M1$HB41*(E$4#D $0#(@ X#O'NHBQ"O;6+7&W=3[+L!A8VG H:A2]Z,;5>RMX
MSR+HS*S[>Z\,]E6K*V7:+<TF4%$6[=LX7.@H0%%E.; Y:4Y>'$B-V9OPBXMJ
M2,["^9A8.WA<',@ >MS/KI,"^<UY'E*:?6XO/GU(U.L2">6^I:L#<=KM>DKK
M6?>DZ@X$EON)TBRI)YW**-UUF#1M$L7;-JT44=(F(<RB<#FN!(=,.#<CF9_'
M3.]KTA[7!IB"TNDB#$@9#+/Z*YX3E,Z(7%)1D3#W]'N'\M)2D(T27CIQ@0LY
M#D.L_A7KB0BVC>+ET6R2KM.*DUF;]TR+TQF@NV$%:JQ#P;2)X"_D9B]C&EKS
M"N6R-9M.=1Y"3BK*NAK-2,4V0>NF8,Y./7&/<+*MVTHR"49,@E(AVN@LDUEH
MP7D<N=,Y$71S%'!P<&%X$@&)TGA_N/D5EO#>W<C$P;3TXY'+@<[$8K7=RN;V
ML*8OE6X+-LE]:UAZNVAI:_)#7A('O)^%ZMH5W#R\?".8)%JY<IH3:(O(E-YS
MIQ:/%&JBB26V.JF_>8QSI!J$Q>UBYOE,9Y2+HZ8<1_QN??0V&IZ7R3;<H71U
M>X)2U/1[$)ST.A,KO$'*,@R9G"W"**7 G'RSMFE$2R\&FDH:8:14@^=1HIJ$
M=I(G(8I=CK!W*1G[\K7*-=(;K+001D; ^\X'563,\K?2&*>V R;R4[-&U$NX
MEH0YHRT;K$63T8A6<,M)MU85-X@B,>1-9$@-C*N$7!7:28LF[QRWH:36[DR'
MFD:S1)@M:)('7+A?D)Q[UG=FIO2T5&TSQWG6'ST^RR<3,)@ V_!@ 2\0SD,\
M!*40QP !]-QVN&:<O?OFLQ>XFXZ?(W]]%X+RCM5[DT8T]"]K;@H.XET;@MZ'
M=1\Y+/HA$$)^4;Q)'*#AC'21SK-G#M!8Z*B1"J(%5 %-L"%-KEQKTJ3;]XX,
M(X2"0?E_N(1QAKG?XB?GU'KIJK,8\H&Y;8U5A=+-7;7@;=-=]MRUS6?>EMW$
MYE+;?IP:*;F;C)-.7CXE[$NXYNJ9P"BI3MEFR9E 51$!*78-V7L+P'L,$'G)
MSG0<CY2L"7A@J;H+3,D3:]M;S-\HUT5YL^4_H9(L)*297^R70BU(@BS8D5<!
M99T$^N9O!KP\(I$DF)]E,*%'JM]!1\BS?D#G&JRR8[0H/WL=-?E-OH<LM]NM
MNH]/71=^0Y1FC,4:#)(WW&M@N+HYHU8S26,U(F\D5(EBI*NDX\[:!2?2J1HU
MFI.*QQ7;O[ W$ZH@ A=[F#XFY@9BT\KQH#;6$<\-;O'+G;WZ?93JEJ1+6[,V
M#8EH$C5KYU(DI9"&/,%66B8B&MR,&7N&X)%JT50=.FS1MT=BV;H+HF7DI)D
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H8+M'+Y=V_,_</>8 3 W(U*FFU Y"$(1,XAG*AA,839-N[  *J+__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g759370g00a10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g759370g00a10.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1IV4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &EJ^9T8X0DE-! 0      &D< 5H  QLE1QP!6@ #&R5'' (   (  !P"
M4  (<G(R.30T.#<< @4 0$UI8W)O<V]F="!7;W)D("T@4V-I;&5X("T@4&]S
M="!%9F9E8W1I=F4@06UE;F1M96YT($YO+C$@3W)A;65D(%, .$))300E
M   0><QB;UM-CX&D2<YE<S.\6CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!;PP_
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  %%   "8          !                          $
M F    %%                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   %%     %)G:'1L;VYG   "8     9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   !10    !29VAT
M;&]N9P   F     #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     ,X0DE-! P     #[P    !    H    %8   '@  "A0   #Z
M&  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)
M" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,
M# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( %8 H ,!
M(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0         #  $"! 4&!P@)
M"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q   00! P($ @4'!@@%
M PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A
M\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%
MU>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!
M  (1 R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:B
MLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F
M=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$  A$#$0 _ /0W-?U)^12ZVS'9
M19M8ZAQKL/M]WJ?2]F[^;_?1:*'&[+_36_SP(!=( ].D[&->';&?R57JQJ<S
M(ZEC/=8&>M6266.!G8RSVO8=S/=_@U:QJF^ME:N_G@?I._T5'FDI+Z-O:]_S
M##^1C4MF2.+6G^LS_P B]BEZ+/%W^>[_ ,DG])OB[_.=_P"2253",L=ZW?)S
M?^_/4+;,]E+G545VV@>UGJ%@)\-QJ=M1O19XN_SG?^22])GB[_.=_P"2217B
MCWY?^B9_VX?_ $DEOS/]$S_MP_\ I)$])OB[_.=_Y)+TF>+O\YW_ )))7U1[
M\S_1,_[</_I)+?F?Z%G_ &X?_22)Z+/%W^<[_P DEZ3/%W^<[_R22?JA]7/]
M4-^SU^ELDO\ 5,[ICT]GI?N>_?N4_5R9UIT\0\?QA2-+#W=_GN_\DEZ#/%_^
M>_\ \DDBO%CZUW>AWR+/_)A+U[(G[/9\)9_Z43^@SQ?_ )[_ /R27V=GB_\
MSW_^223]5OM)D TV"?(&/\UQ4*,^NVIMAJNKWB=EE3PX?UV[3M1/09XO_P ]
M_P#Y)/Z#/%_^>_\ \DDC5A]MQN2_;W]P+?\ JPU.,O%)@75D^&X?WI_09XO_
M ,]__DE0_P J"]X?BAV,UQ#=MSC8YI.UCV^H]E;=C??8Q_\ UO\ D)+I->QV
MK7!WP,J2P6GJY?MNZ.QS=@]S;VCW@'U&C<YVYEEG\S]#_AE;PL07N%F7@G%?
MCV!]
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0'_P  1" $9 @X# 1$  A$! Q$!_\0 '@ !  $$ P$!
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MR38YX Z/#-/5H:G?01]A+OF[Y@!3/2 <G"@:UJ,-.+\8RMOFO$[H#"CD"KF
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M-3K(^L!#]_7^E[3_ +#O^K4\]._'5H_2.7<-,H>163\WDTRZ":>$<I*Q74C
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M,-A/+2?!FNY_(X*!Q_IVJ8K>)"7X@*1:,U$3?(XJ#Q\2B B&K>523G9I>YV
M(ZC\#.E8P3=-O27\[VA6K%"2#OH2W;[-.XVQCG)FF*1-PCR0$#=:;B5QY3S.
M 'OPFK[J;Q391'YE(V15$.WG / ZHJ=9U4YG#E4 .U#DX#DOWQL+'>*<[<5
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M<@)/FVUJ>M!+.$9U^<'>''%P1!MN?I(DZY:KY0@.QA'WOCBUMP "]^1Z(Y4
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M&H4N.N]DG4Y-BU<,(R>E;%!PA(*&<&*[LZQ)*L/PGRQQP&":.XITY Y'Q #
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M@I1(BS%\/#8>2N$E"&*D'*Q>H .F4>0!!^SK]GQGH\<CO+N/F0/Q<V!)/W9
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M1[:0?@?K_IJ[-K%[K+N/F?O$7,^FD$5 -;._$6KT?(A'@D*V>CTMC=1514(
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M<P P>INFQT#@(G$JQ.HA1$0!!_CX[?AV.\\8=9IS3EW?X!N2MUN.MTVHJJX
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M5%.A4$@ G>0P;L<O&Z+0M"0D58$"OT5$DCJ)._[-8XKV$6Z DV\?DYGAO(-
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ME=&EU2@@ *)LR,?Z-5.*8F,=-J)'!TRF*B<JABB'+:2?FP* K3C.Y+]M14^
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M)<D:T8$O0&E&CW,2YDJ.::X[L512G&B<=*GB)&*LD2M"S;!X5!M(-1=,5#K
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MVZ1+CCW'QI3MB@B <\B <<<_5SZ<Z0<9N/CVQ;YA/]\7UX]=(C$G?[8>87L
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MD\2!D''T036AS>G&/QL?VA]MBDDVH@@/^"1Q&B<J$[VW%HN'Q<M[?2/]4*&
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MG<@@@I3F<LVJVAINC2P<MO*+;[=)NZ3-5Y7/F)1*E*D)2I6,X0.D  ZF *F
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MS$1$1Y[?QO(!]?PXU!V%NK\AD]7TRX#JUUR:*_[0^VP+>5E("7#24DD@@-0
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MT;'MB.G!UNEHP.JN9D@)C]9&QEUC(@8$Q4-TAK]$NV1-L]FDRIBD*4A QGG
MY+#B]"SAF>/Y7VEMEGO2]K9:K($HD39I4@(E3):4])^BE W$-V#A&$=(_P!<
M(](\CR' ]_4 $ X]/\W/ ]]>D"G$^*6V?X3*E7Z1[-QCYWFII+E1<DT"9V3Y
M@,PRZP]<ZV\'[?UP\\]N!#GMQP/U\<A\>/GP/.K8P*!4O-FYQVJ69SG3@=U<
MK<U:&<&C?BS'9FJR=S@9U?**@3U[#]?8> 'U]0 ./LY]..>X\ YP9.@N,N<
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MSD-N7A91>.ULMS6/L+P&.F\\>L'MEBBE(",4L19,T-[J0&8:,5W#M:33]B:
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M,N.]5R.:-AFD9O@6U2=PT:F_=OS'*#LB9@F*ORP @$,5827.*H(!+99"HI4
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M+[ZQ/RA;)&7*2J_+",$SG0<8<E@G5Z  4.8K5XA1(;;]D%J2C_NB[YL%9-)
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M*9JU;.GHD0/6;?EZ2Y@EF>O&D%6$3 10.*A6&N+(%ZY!J6D\G&Q\U)*;GL@
M)8X5(+NP Z1)?*G1-:EQ$:J/%;+W5GW'0-VVV5)XGAVR6)P5]CS'4I8C4_&\
M73XVTM+)D",5=I3:;QT9^J@WC8:/>O9!RB9-LP!-)5<E)=_WD;.9JIZP\W I
ME/51ID_K%WI0.[&.BT<F>R$J>):;JLA>6A6:D](IZ0(*@^8JQKD2S1F='0\,
MV[S,#C^ PJUF+7*_0"&<6H^&;1"TEE9<H5%6WTA&1>R9&Q4TY^-;G.D2/&4;
MM%A,U</4E"JF+HB^;T5SQ3.7\PH"8,0Z)*4J&98N% NEZEGH1&$WDXV/0M"%
M7/9,<Q&-"F*J8E#\>A!2:4-<JO$@L%;3=G^4Z]9/?&WG&["W42[V3'=SCV,2
MJ9BC8:\X( N8Y5;@5V,E&.X^30.4RJ:?M0H>:91$X!7S]>1EIF\_, 7B"3TJ
MX5%)=F(J"'( U<C./DZV01,4@W19B0V3BA3B#)"U 9Y.6-3F!&\@\/39M_<!
MH0?5[J)V_P#Y_3L'ZM0+]O,L3:5NVI4X\8D\F^QQ)/F:SU_;_FA^#SV:<]MO
M^/PX'D!"(('</D('Y#Y_#OH+^O7\NO=ZQ/O^V)^3K9#]$6?N5_-%WX/79N(\
MC@*@<_\ [I+]7S4'Y?G^WOJ?/EY,WE"^%2V;U#UA\G6R/Z'L_7TG_P#%%/P>
MNS;U^X%0O[TD#Z^W!@^SO\OSZ>?+RR\H5X]6^'R<[(?H>S]ROYH?@]=FW?\
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MEEJ@6VD1?/:VFF0J#=\U;(L5W'M!T3*\F/KH2%)DRTJ-'*@-0#O8#^N6I/.
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M<GR3U^5['I10H(.U( BC1)!DW13;F;B58ATRN%555Q,<<E[,7DN6E"D(Z*0
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MZ]9X:-:N7+DTI'RBB37R>5*2><.6).%([07%0U*;GW!W[Y,Q$LI*DE3*)(<
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M1&/;%DXU9HDE4*O'24E*OXZLPSTR1(I(RCML"#>/,M[800*G[.9,% 4.4!*
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M'RN:_C.ZM,?"^:U"I*K6RUO9T:XWBX"- _O)(ZDF50B:LPUCFZR"1UTE3I@
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MPYQ>%^=4&!22]07RRH*Y[[>9KJ*%J\W6(A"<3&S2BY)  J@U.E-#QCV<A2F
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MEVD+9B)/U6Z13@V]O*D"2XIE #&Z X[":!(]4$D:FN\ESU9'KCGE@XE%0Z9
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M;(JK*$(/C'::SH*0J[+&25   +!<N17$ W#JC[)/)9>*G;;+:)3))($R2XJ
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MKG2@H-_%HZ#;PT9QS+/()OOZW,.9N/;-7[Z+3O3)5\V:.3&!HZ=,RNSK(MW
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MZ5)4I0 <49QG4[@&CXK9#;C9N3/VDYR][)*YV_;9,EXI@ ,I24 *W85$%B2
MS/4QGMQIOA\VSWVVCM\,UCR!F\25["AJK0\MX80@XVB5F0+)LD(L]CQ_:)HL
MP[>^:ZDYIW+O9!T=TXX62*<I"^-YCO.OW),JH+-*N'PGL<M7@[/'W Y0=E0@
M(-^6!@"#\\DNY-2V>F@U>I>-U91ONQ/+=(QK3+7NXB2.L4OD9&KW6#RI0HJY
MF?%JLO3W+B3<(Q9H)VJ^@YI\F[!O76I3K"FJD1$$SE4A5PWDM?.*LLP$!0<
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MRC9RT<R)5#IN%A*LOYMA<UZ!2E>2SBZPH@A3%0.9';F*=@:(/*%LJH8//MB
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MJNVCA$X[2K[O68I/W3-252U+%1] J;<*@!0W U?(TM6P.RLD2FN2QJYQ6$C
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M\/JB?D_V2K]YK)7]5?\ /#[PG:./K@7''^#[?_+J//MZ/6U3.PM[F\(CY/\
M9)J7-8^V65/V%3>$ V$[1@_VA<;_ .#R'\Q@T-^WII:I@_=/_EBWH!LGK<MA
M[)(3_P"%0?M[&@.PG:,/^T)C</\ W?0_G,.GGR]'<VN9V$ :\*_9$'8#9/2Y
M;#VR<7M5X9'41<&PK:+P'.!<<<A_R=;#\?K'G4F_;T)?RN;WZC+3+AK$?)_L
MEK<E@)_^P!FSY:MWZ\'WA6T7^X'C<?7N->;\CS^_IIY]O.KVF87_ %OJ&?&
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MM43#K1=WW@NSRK.JS3%(E.W0*E*=J**:%VJ.)+B,QM%<:9JYPO6QXEY-:)0
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M '#*G;CN%VO@>GIP'TE[?OSSJ!M+>@_Q9?\ !E<?U.,6^2?8G]&3.RVVT?\
M[!SZSW$B+1\(C83QQ]QA7CY%NUZ#X\]_RC]0'X_8'H :D;3WN,IZ!^S)E)[V
M16)/)3L46'FR:P!;[MMIS9ZF>37ZXH7PA]A/'^HPI\>>;K>^1Y'G^V4?F ?F
M^7;4^D][ZST'KDR3_P#\\N 817Y)MB?T;,_XVV^'W1[7[(J/A$;"Q'_49,
M/( %TO8=^>>>UE /7CGL'(!P.@VGO7\K*.?^!*R_<A\DVQ+_ /)LQMWEMNW;
M_*=]8?@BMA7(_P!1=3N(<C],[T/H(#ZC9!'I[ / >H]QYY$!CTFO7\K+_@RA
M1\J(\<_9$CDHV*&5VS?^-MCOUF?#\$1L(^.%S#W[_EK?.X\#W[V40^/?MW$/
ML 'I->OY67_!E=OT/:[:-#Y*-BAE=DQF;^^VW_W#4ZJYEX#X0^PD>?ZC)^X
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M"-UO8B' \\\_27GGX /P#MJ#M->I_P 27V297CT*]<0>278@U\V3#UVVV_\
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M=+V''/'IQ9NP<% ./0   #3TFO;\LCLDRAWL@/VQ!Y*-BU9W=,+!O[Y;,O\
MB(?@B-A7H&&3<#SV&ZWL0[^O ?24 #\WIJQVHO:GSR*9?,RC[4&(/)-L5^C9
MG_&6WW6@10?"&V$F$1-A@X\_ +K>R@'IZ!])1 OH'IP//?GG53M->A8&9++%
MQ\S*#=R!$CDFV*&=VS#_ -MMO_N#X,>,7?@B-A/QPP8>X#S]-;WSVXX];(/I
MQV^7?YZMZ47MK-E?P97\IA\D^Q)/_)DS3_/6[N/W1V<&BGX(C85Z?<8-QZ"
M72]  A]?Y2<#Z?'GZ]4.TMZEGFR]/\&4,MS)#:C6A:+?)3L5^C9G#[LME.^>
M<M&;B\5_!$["@Y$,,J=_^6MZ'T] X&Q\?8'IR/'H&I])KU 83)8_W,JG"J/;
M%3R3[$U^]LUS_P#6VP\/RXWU[](M#PB=A/5S]Q=3GN//TTO " CV'@36,0 .
M/@ !^WF/2:]ORTK_ (>3_)$'DFV*TNR:>'EUM'CS_AXQ4/")V$]^,,*!\P-=
M;R)1 >XAP%C !#L'(#R'U .@VEO9W,Z6=WS$D-W(ZLW[ZP')/L57[V30='MU
ML/LGC+OXQ<;PB=A)^!/A@YA#T$;M>P'Y=^+('/VCR(]]3Z37K7YV76OX"3_Z
M<6/)1L46)NV;V6ZVC+_M'7QKG%OX(;8/_<7/\/[-KY\^1X_*7X_7S\O3MIZ3
MWN& GI W"5* [@@=\3\E.Q7Z-FL[MY;;-2YKS[M[(?@A]A/]Q@_^&M[^7']L
MG[AVT])KUUFRS_N93Z9G [FM>/5$'DHV+TNZ8/\ MMM_]P(M_!#;"AX <,F$
MH?ZWZ:7L/U_27GGZQ_1IZ37K^5E]7,2&/_\ 7\/$?)/L5^CIO_&V[_W.Z*AX
M0VP@/3#!P_\ ?:]C_P#F3[/\FGI->OY65VR).ZGT!E#Y)]B=;MFO_P#G6W_U
M]U(N'PB-A(@(?<8/Q_UVOG/Z?I+^S@1#MSH=IKUTFRQGE(E:\<#MP[(L.2C8
MH?\ -LS0?WVVT R_S&_?%OX(;81Z?<8/_AM>^?T_23G]^-2-IKU%>=EN,OF9
M6O4@#4P^2G8O]'3.VVVW_P!P.N*AX0VP@   PP<.!Y#\MKWZ_/\ E)S^;G4'
M::]3_BRQ_N97\G]8?)3L7^C9O_&VS_UXM'PAMA/]QD_^&M]^//J/TF]?K^7
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M@V5S5GF$0Z-% (1J")(\KJ/2:+J]<Q*4RY#-B,MUMO>C\=8P-9LT!\(6 G<
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9#2$-(0TA#2$-(0TA#2$-(0TA#2$-(1__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g759370g00a11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g759370g00a11.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2&Z4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (9Z^A@8X0DE-! 0      &D< 5H  QLE1QP!6@ #&R5'' (   (  !P"
M4  (<G(R.30T.#<< @4 0$UI8W)O<V]F="!7;W)D("T@4V-I;&5X("T@4&]S
M="!%9F9E8W1I=F4@06UE;F1M96YT($YO+C$@3W)A;65D(%, .$))300E
M   0><QB;UM-CX&D2<YE<S.\6CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!@ *O@
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  &7   "8          !                          $
M F    &7                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   &7     %)G:'1L;VYG   "8     9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   !EP    !29VAT
M;&]N9P   F     #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     ,X0DE-! P     %P     !    H    &L   '@  #(H   %N0
M&  !_]C_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A9
M6B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M 0  ]M8  0    #3+4A0("
M                         !%C<')T   !4    #-D97-C   !A    &QW
M='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "+
M !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D   #
M3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T96-H
M   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/   " QT
M97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M
M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M !)S4D="($E%0S8Q.38V+3(N,0
M                                6%E:(        /-1  $    !%LQ8
M65H@                     %A96B        !OH@  ./4   .06%E:(
M     &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M%DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P.B\O
M=W=W+FEE8RYC:
M              !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@
M4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y-C8M
M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N
M9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC92!6
M:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                 '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>
M     5A96B       $P)5@!0    5Q_G;65A<P         !
M             H\    "<VEG(     !#4E0@8W5R=@        0     !0 *
M  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '<
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MQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$HHBC4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $Q <@# 1$  A$! Q$!_\0
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MTUP^/==EZ5DOJDR,MB/<C/;KOW=.O4OOW"9]7C^QDFGH[EXI0
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M,NGS_ ,6FM5;M,E*+5TU;M+P,@
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M3KZ(LHBSZGLEY"CV+Q[$9^4A/N]?_A5/\K*L;A'IB*3[)HYTV=>O\B6PK_\
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M]RX@OA_LQC7DWZ?VNZ^3XPSX_&_R0'LA;[WN7$#W%M_9C&NOE_\ -W3;X>\
M/9"7V_YN7$#W]_X,8UY#/_YM^(OG  ^(6^(C/V.7$$9EXOP8QKK\7]KO'O\
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M>&=U:W7.#+-UK=5S.+<X1[=Q:U&1^V4I6(J4:BW/<SW,S/QF+_$,=E_M=?\
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MD)=DD_F<6SY/P+QLNGH[D                    'W\G[
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M&;13(   (Y?NLQ\G2OWF&!.+[%\661=O7.U\I% W_P!RY]_N8!:OM^2)0"@
M  [P!38MMO%W "H UZT__.#XAOD;1C_!LM O!=K^7U-A0(
M                     1DRDI[%Q#L^JKYKK:>5MR5#COK0G<SY4K<;4HD[
MF9\I'MU/IU/?BU\%@\3+?Q&%P]>=K;U:C3J22ULG.,FE?.VE\S?1Q.)P\7&A
MB*]&+=VJ56I33?-[LE=]9VH\.)$:2Q%C,1F4ELEF.VAEI)>1+;9)07S%W]1M
MI4:-&"IT:<*5-:0IQ4(KL44DC74J5*LG.K4G4F]95)RG)]KDVWWLZ-C04=NR
MJ/:U-?9,+WYV9\1F6VK?H>Z'T.)/<C/Q>,_*-%?9V!Q*:Q&$H5T]?:TXU/\
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M,O@'91E&7X6GV'!*C(                         $<OW68^3I?[S"^_S
M3\S[%\661?=*U^ H!?\ T%G_ ! +67;\D2@%        #7K3_P#.#XAOD;1C
M_!LM O!=K^7KO-A0(
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M[W;YEL7W2M?@*#_<+,.7KB]/6MPM7V_)$F!0        UZT__.#XAOD;1?\
MP;+0+P[WRY+O\>XV% @
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M;Y&T7_P;+0+P7:_EP]7[C84"
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M(VY
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M?(VC'^#9:!>'>[^$?$V% @
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M/_S@^(;Y&T7_ ,&RT"\%VOLX>GW&PH$
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MVS-HUFX   ->M/\ \X/B&^1M%_\ !LM O#AJ^W1:_(V% @
M
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MR 7X<OG;Z>N&P@
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M4F5N+CN2JR1)C-OH0XA:F?"FLDN)4I*240%]>O VF
M
M!'+]UF/DZ5^\PP)Q?8OB_J61?=.U^*!Y/_@+Z_PZ^3N\9OD%J^WY(E *:F\0
MNE>LFH,IE>):@V\/"6H;";+3S&Y\3"K:\EIDM*DN/YRB+*MG(3\(GX_K/%F8
M^A3SC;RK1)MEMC!+VN]4COTU:T;]E_/-7_O&FU92W7SM>QFC22DI\<P.DI:#
M&KC#ZJ B6S%QR]E.SK2N+MTE:TRYC\ZR=DJ><4M]#JITDUM.MF;J_P H;)2<
MFFTL^7+3XKQ?(PA%)RM?5K/K]+0D\YT]Q;42M9K,HKCFMQ%R7Z]YN7-AOP)4
MF(]!7)8=@R8SGA>S2'4$E:EM*)1DM!D>QZIQWEEE*S2DM5>V2[;:]1M3:O9V
MNK/K1@>JX3,1H<5J,/I;RUA5",2_ 3+4+::FNYABYVK]UV60[*=6[53$3)4M
MIN;#<=0B#.F14Q/;1W8V;;;6EDHJ2>:DXQ4;WUX/D\W9\\(K=3MF\\KZYM\=
M+WN;4)C1T1DPTLM]E2P48F%))31L$V31-&A6Y*;\'[0TJW(T[D>Y&&NJMZZL
MBVRMP66>>7KF:Y:75-73Z^\1$>IKX%9'74Z,.+C5\./"9-WUDRQ)N&U&;;0I
M2DDE/.9<VR"+H1$!;>;?R]=F7 V4
M                                               !'+]UF/DZ5^\P
MP,?S?X5\7U?/N?"V+[IVOQ0/[A?7^'S 5:R[?DB3 H %-C\OW^;8N_8^X_&7
MCZ!Z94    &O6G_YP?$-\C:+_P"#9:!>"[7\OH;"@0
M
M(Y?NLQ\G2_WF$!/S/L7Q?K^Y;%/^L[4O(4#^X7]_G +5]OR1)@4        -
M>M/_ ,X/B&^1M%_\&RT"\%VOY>O6>PH$
M                                                  ".7[K,?)TO
M]YA?\0)Q?8OBRR+OZYVNY^*!M\!> 7^O??YM@"X]OR1* 4        ->]/\
M\X/B&[O<;1CR;^XV6]_W\H%X=[^7D;" 0
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MP 7*RYW?AE;Y^F;"@0
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M2EDZ2#0DFRW&1MV
M                                  ".7[K,?)TK]YA_\0)Q?8OB[_*_
M<612_K.V/RE _N%]/X_.'R"U?;\D2@%        #7K3_ /.#XAOD;1?_  ;+
M0+P7:_A$V% @
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M\(I/A'W22HVV4<SB^57*D]CVH.P *;D7?TW/;KY?OW>7Q "/7[K,?)TO]YA
M3B^Q?%ED7W3MOA[!_<+_ $_SW +CV_)>'I\24 H        :]:?_ )P?$-\C
M:+_X-EH%X=[^1L*!
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M_/X"ZD6!L5[W>3W5==[](MB;^N=MOW;0"+_<+Z_I/]7Z!5J^WY(E *
M  &O6G_YP?$-\C:+_P"#9;]_T>/<!]>KDM']=.\V%
M                                  -OO_/R_. *$E);]"Z]_CW^/?O
M DI+N(BV/?IT\I?HZGT[@MZNR62[M 1$6^Q=X%'*6VVW3??Y_*!++EK_ &^
M-)'ON7?W]3Z_'Y0%D_AW<@22+N+;Q?KW_6?4_+X]P+;*W#0$1)(B(MB+N(@!
M0T)-/*9>U\G7KY=_+OX]^_QB-)JS2:>J:NGW,++-9,XTQF$&2DLMI47<9(21
M_IVW^^_>0UQH4(RWXT:49)64HPBFEU6617*35G*376W]3EV+X_CZ_M&VRY$!
M)(NXOUG]SV\7DV+;N(1)+0>O KL7Z104V+??;K_PV_9T^<_*8EEGUZ_ #8N_
MX_&?C^#N% (B(SV\9]>OC^_WZF!+)9\_6FA'K]UF/DZ5^\PP'YGV+XLMB^Z5
MI\4'^Y< +67:O@OH28%     &_?\  "75VN6O>#7K3_\X/B&^1M%_P#!LM%+
MP7:_A$V% @
M                   !16^Q[;[_  =^V_7;X=@!\QN*3C=U*T0UEM-,\%T]
MQ',JRGTNPS-KR[OK>WIBH\DSS4IG!,1Q>5(CM/0GY&4M,7DVJ82<=^*5-(DR
MW50/R./2JRJ8BI2?NQC4P\(MK55%4<WP?N[L?'D6I&4*,:D6I2E3KS4;_FHN
MG9.UK;V_QM>V5C(>I.N'%'C^>W-+A6ET"\Q.([6IK+<],]2,@.4W)K(,F8HK
MJER"'4SDLSGI3#;T6*TA"6DMNI-Q"UJWQOO3B_PQG*,7S2FTW;5:<LV\LC7&
M3<8NUFU%M6;LVKVRY/*][=9KCK!Q$Y[G7&CP_P"D%9)U%P? \.OL_P!1<ZHJ
MG#<GBVVIE=I=@-K+2\]+.I4ES"I.<6F+UU!7PIQ.Y!/B62;39CUICR=.'DZE
M6M6>2H0;A3>6^IITTU?DY;RXJV?)*KM1A37NRK5(QW]=UQE&;O:[6\DX_I6\
MKY79Z?A&UFSWB+XP]?,IOKC+Z/"=*--\$Q#'=++"BO,>J<=R#/[2[R6[5>>N
M5;#*YS6%C%%A2K1U;SS=4Y>R8-42H)JER&#4W1KUIRNJM51C!ZT_9.:DN?O;
M\=<LLBXC=56A3CDZ4)NHU>7M/:^SW6WPW=UM<?>RX)?4U76V8^3I7[S#&\O%
M]B^++(N_KG:_% V_W"_A_7T\GBW +CV_)>!* 4     TYUSSS,ZC(=044UO:
M4</3+2:)J/3Q("V&F,NOWK>=%<KK,GX[RIU7'C5S,)R#'<8,Y-NVZHUO)B^#
ML5>_O9J<8J'%WCO;U^UI+(Q>J6B:LY9NUWPCEU<;W7*YMBW8NE2HM784IQXJ
MM-@Y716R=FN.%%[0J%'96MI+DI:OQ#+:G&R6\:4FM!'S$E9-I:)NW9<1;:3:
MSMXZ\.'C;K-",%U^L6=>M?)1</\ Q"NE+J-($^ :PO'U28QQJC*D[RFSS$DM
MI?)PEQS2XLUH2LU$@T['._EEG?/N^-BWR67/BNK+7FG\[&>?9%6/O=N(_P"@
M^._;0!?J?E]1[(JQ][MQ'_0?'?MH N^3\OJ/9%6/O=N(_P"@^._;0!?J?E]1
M[(JQ][MQ'_0?'?MH OU/R^H]D38^]VXC_H/COVT H]D38^]VXC_H/COVT E^
MI^7U'LBK'WNW$?\ 0?'?MH OU/R^H]D58^]VXC_H/COVT 7?)^7U'LBK'WNW
M$?\ 0?'?MH N^3\OJ/9$V/O=N(_Z#X[]M %^I^7AK^W6#XBK$B,_8[<1_0C/
M_P #X[XNO_SH N^7BU\K^D0&+<64'-L<I<NQ70CB*N<<R*OCVM):L8'2-,V%
M;+03D66TW*R]B0EM]HTN()YIMPDF7.A)[D0I/^R*L?>[<1_T'QW[:!W_ !\=
M/WZB7?)^7U'LBK'WNW$?]!\=^V@"[Y/R^H]D58^]VXC_ *#X[]M %^I^7U'L
MB;'WNW$?]!\=^V@"_4_+ZCV15C[W;B/^@^._;0!=\GY?4>R*L?>[<1_T'QW[
M: +]3\OKW_OD/9%6/O=N(_Z#X[]M %^I^7U'LBK'WNW$?]!\=^V@"[Y/R^H]
MD58^]VXC_H/COVT 7ZGY?4>R*L?>[<1_T'QW[:!W_'QT_?J%WR?E]3SN6<6M
M?@N-W&799H3Q$TV.4$-=A<6LC!*1UB#";4E+DAUN+E[\A2$&M.Y-,N*Z[\NQ
M&9!?J?BK=^?B>B+B)L3(C]CMQ'==]B_ C'=]B/8C,CS0C+<NNQD7S@+OD_+Z
MKT^VSV15C[W;B/\ H/COVT 7?)^7U'LB;'WNW$?]!\=^V@"_4_+EV]W*X]D5
M8^]VXC_H/COVT 7?)^7U'LB;'WNW$?\ 0C'/MH OU/R^H]D58^]VXC_H/COV
MT 7?)^7U'LBK'WNW$?\ 0?'?MH N^3\OJ/9$V/O=N(_Z#X[]M!>]>?T%WR?E
M]1[(JQ][MQ'_ $'QW[:""_4_+ZCV1-C[W;B/^@^._;0!=\GY?4>R*L?>[<1_
MT'QW[: +OD_+ZGGYW%G!KLEH\0F:$<13.19)!NK.DK#P2D4Y/@X\=<5S(:=1
MERHR$P3M:\G$O/-K7VE'@4N;+Y OU/LRZ^OC:W:>@]D58^]VXC_H/COVT 7?
M)^7U'LBK'WNW$?\ 0?'?MH OU/LR^MO,>R*L?>[<1_T'QW[: +OD_+ZCV15C
M[W;B/^@^._;0!?J?E]1[(JQ][MQ'_0?'?MH N^3\OJ/9%6/O=N(_Z#X[]M %
M^I^7U'LBK'WNW$?]!\=^V@"_4_+ZCV15C[W;B/\ H/COVT 7?)^7U!\1-B?3
MV.W$?]!\=^8__&G>7>7P@.Y^7#O\#P5SF^#Y'*GSL@X-]7+R=:RL=FV<VVT@
MP.PE6,S$)#TK$Y<Y^5E#KLN5C,F1(?H'WUN.5+S[SD$V5N+4>*@E)3LMY.]T
MK9\'VI99W\D&DUI?)JV6CR=NIV7@N1[PN(BP21$7#MQ'[$6Q?V'QWH7D+^VG
M0NA="Z#+M(LK6B\E9::>)-:99U@VJV4Y/:MZ=Y!B.H>GS5?B]LK/L3K*C,(-
M1DD1K(H4:#91)MLIRALTH3+4Q'LB9.6P2I#"7TI,\5&S<N+2BWS2=^[CZUNM
MD_RMR6CME:_>N>>MLC+E1B^.T,R[L:6CJ:J?DM@FVR*;75T.%+O;1$9J$FQM
MY$9EIVRG)AQX\1,J8IY],:.RR3G@VTI*Q2BK+2\I6ZY//Y!I.3E;-I+PTRX'
M=5[K,?)TK]YABCCW+XOCZXED7W2M>OB@?-^(7_S#EZXOP]/B%J^WY(E *
M  >0R+ <0RV;6V.1446SF5*E'"?=7):/P:G&GE19:(S[+=C 5(8CR3KK%$J
M<J.Q*.-VAAIQ!*SNLG=._6E9/P%O5VO@>NV+;;;IY/%^@ 0<''J&OO+W((,"
M.Q>Y$U5,WLYM;AR)[5*U)9J42$*<4VE,-J9*0R;;;9F3R^<UGL9!Z]>!.@
M             "AD1D>_=X^IEW=>\C(]O+U[N_H //XIC./8;CE+BN)U\>IQ
MO'ZV+44M9$<==C0*V"V3,6(PM]UYTVV6R)!&XZM9[>W6H^H ]"
M      /-Y?C6-9AC%WC&8P(EIB]U =A7E?.<<9ARZ]>RGFI+K3K#C;)\A&M:
M7FS(BW-1%N ?7]":A28<R,U*@26)D1])+8DQI")3#R.XEM/MK<0XD]ORDK41
MGOUWW B7+2R_O?CE;P.T!0              #SLS&,<FY+297-KH[V34$"XK
M*.S<==*3!@7IP%7,:.T3J65(G'5UYOFMEQ9=E;Y%(]MS"9:^LK_5GH@*
M           4,R(C,S(B+J9F>Q$7E,S[@!YZOQS'*>XO<BKX$6)<Y6JJ.]L4
MNN&_;*I8)UU3X<W'5(4<."HX[)-)1N@]UDM?M@!Z( 1R_=9CY.E_O,("<>Y?
M%V^?'QX6Q?=*U^*#O_N%_P -@^86LNWY(DP*      !8X9DA1EW]/A\9??\
M89=XQG?=E;-V=NWAK;CU@T)TUL[YS5;#5(=4_F5AF>N4;5V,4A3BH.-UDTTX
M>B;&4[R1HC!G2HQ]Q3:7767Y1LF?A)IBQ:W:<8.\'#>J-Y.-;C%K7)MJZ37)
MY&GWKMRBE+?<89IWI)JU\[:-\GIV&_)'N6_E%77U_'+R-RT7#JY
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M\U%O\3BG47*H_P 27.SXZ&NEO+?4LTIM0=K7A^5VX96R;OU<\IB&T
M        T.UD@YBYJ^N'5LINKV]L=+WM.;*GOZ]FQT]@TETJ1G3%_0OS&9J:
MFWJE6<OUTC1)K-HS).IEJCG#BF[CAVU*\[;KG-N_Z7!VYO7+=SOK:YJJ1;=U
MDMR,;*^;NN"Z^Q67,WN01D1&?51I22C\ID7?N,N+?/L6E^7:;%HNQ%X%
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MLOB_75WED7W3MOA*!\_XA?7X"\6WP&?C#UV!<>WY+Q)0"@
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MQ0/)_P# 7\_Z?F#UZ],+67:O@O7]R4 H
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M9?%W^1;%]TK7XH/S?B%_\P^86LNWY(DP*
M
M   1R_=9CY.E?O,/_@+P[U\S'\W^%?%^O[ED4C]<[7KT,H&WP?B%D?\ #]?S
MSUZ\BK67:O@B4 H
M                                            !'*]UF/DZ5\7_>8?
M[>GZ# G'N7;J[>&=^U%D7W3M?B@?-^)<_GO]RV<LOW]=06LNWY(E *
M
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M$^US./QEFMUQ^,M*22PZZ9%RMK,U*V(NA=YB$5]YMVM9)<_VS\<B6 R
M
8                            #__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g759370g00a12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g759370g00a12.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2,.4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (O*^B48X0DE-! 0      &D< 5H  QLE1QP!6@ #&R5'' (   (  !P"
M4  (<G(R.30T.#<< @4 0$UI8W)O<V]F="!7;W)D("T@4V-I;&5X("T@4&]S
M="!%9F9E8W1I=F4@06UE;F1M96YT($YO+C$@3W)A;65D(%, .$))300E
M   0><QB;UM-CX&D2<YE<S.\6CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!=;OM
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  'T   "7          !                          $
M EP   'T                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   'T     %)G:'1L;VYG   "7     9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   !]     !29VAT
M;&]N9P   EP    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     ,X0DE-! P     &%0    !    H    (0   '@  #W@   &#@
M&  !_]C_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A9
M6B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M 0  ]M8  0    #3+4A0("
M                         !%C<')T   !4    #-D97-C   !A    &QW
M='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "+
M !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D   #
M3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T96-H
M   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/   " QT
M97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M
M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M !)S4D="($E%0S8Q.38V+3(N,0
M                                6%E:(        /-1  $    !%LQ8
M65H@                     %A96B        !OH@  ./4   .06%E:(
M     &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M%DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P.B\O
M=W=W+FEE8RYC:
M              !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@
M4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y-C8M
M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N
M9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC92!6
M:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                 '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>
M     5A96B       $P)5@!0    5Q_G;65A<P         !
M             H\    "<VEG(     !#4E0@8W5R=@        0     !0 *
M  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '<
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MR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M>)*CM]+A\4-$14=29VB&AZ;#0D9B8X+5<W>#LK2VQO_$ !P! 0 " P$! 0
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M%=R/L,C]T$T_KT[R2HD
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MN[.Y523;65UR:>6=GTTTU^-OMV]@DL
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MD?Z@%US7+7CR*@2
M     :[(]E9?XG ^4G@57ZI>'R+RL_?%M^45?(,@2N/5_1&6 D        (L
M-$?JV)Q^#U+U9_I4MN7ZOTB>'6_KIZ\J_N2ST\.-OK\"4X@L
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M73J/5<Z8;[?6_K)O_P#DEJ=^OZVMA-GR9%US7F5]5QIA_>]K)^9+4[V_[VA
MNN:\T>3Z7>ER2W50:QH3X5*T3U.2DB+M,S/&MB(BYF?@(";KGT\>0]6!HW_U
MA?FKU"_F\ *^J^T</?EJ'Y_ZU6H7M?WO><!ZTY>LO@?)SI<Z,.I4A:-05(6E
M25)/2G4'F1D?+GCO/GX-RY\]]R+==IJ2;33R:=K7\<[^/0JXQDG%Q333336M
M\GJO670YEA^K716P2_RS)<7Q7*Z>XS6R:M<@F0M',XCOSYC42-#)QU;.,-J,
ME-QDK4@U*(WU.2#/K75#UUL?BL13ITZM:I*%))0BYWMKUU][CT-1@MA;+V=B
M,3B<+A*-*MBI.=:<*44Y-I7NTEE=7LGK;C8Z.?2ST346QQ\][=]CTFSY2>S;
M<B^MSQ'RWY_K'E4YO-N2?65_"Z?B;1T:;5MR%M?T1OYM/KZU\*Z5FARONHN=
MJY&1D>DF>GN6^^V_UM[[;^(^>W:)]K4TO-9WRE;I_=U\+Y63*_R]%ZTX.]M:
M<7E?1Y<>7CPR^2^E-H.Z1DNNS91&6QDK2'/C]_\ J<+;EYM_.+>WK+2I43X6
MG;+PEY]]M"LL)AI9.A2=\\Z2?/5Z7[_)EBYTENCRX7V^DR]TD^N+K-',Z4E.
MW:>R\;5X.W8R,R%OYO$9+VU9?_J?:5[9:9F)[,P$KJ>$P\EP4J4';7+-/_>?
M4M7.D#T5Y*NM>KWU.*(B/K=+,J)Q/"G;A4E>-[I4GL-)\R/<NT2L9BEI6K9?
M]_\ _HQ2V-LJ3O+9^$;RS>'I7RZ[ES#R=9.A[+0MJ3CT9]"_7+0[I%D+B5&1
MDHC42\742N9%V[[F7/<QD6/QB:?\Q55N<W;Q2=LNG(QSV#L>::>S<&\N.'I/
M_P#K];7->F9UT'K(VSGX+12U-$9-&_HK=*4WQ$1*)*CQ,S3N9%]R9$>Q%SVY
MY/ZGCK6_F*GF_GKQ/-+LOL&>4MEX)KE_+TE?_P#:M5;*^7>C7Y,SZGS,6ZY)
MTMQ1YQXOMJW-#[A2ED9<)\9GBQ&K<N1^';W#)_4\=K_,5//C?N]:IF%]CNS;
M;;V1@KO_ .Q'Z67?EF:W)QWZFM*:ZE[1K#B3Q$LE,:)7L=7$DN1FMC&$*[>W
M=?/L/F+_ -7VA=-XB;X:W^[\<[>9B?8KLTTU_2L-&]G[D7&SYJSR?Q?2QKTS
M3KZF5,6AQ>D=,TMHD\'<VEN91"Y'Q$>T>D:+B(]SXE$H^>^_CNMM;067M$[/
M)O5KOY]Z\^&.787LU+_Y""_],IKG_P!UOGIF89S2'ZF6X;RBT\L&%ODLG%Q,
M6U0B+X5GS)"H\-I2$[]B4FDB,NPO#*VWCLKN'C%/F_GP5M;N^BH^PG9YW_Z:
MIGRJSR[L\C 6VA'U-F=5V%=7TV<TCDZ'+B]V5T36%+S)26%L=:EMYMZ.ZIM*
MN(D/,N-F9$2T*1N0RTMOXVG4C/\ XFHM.SIW32E>V6FFO?S2/)B_X=[ Q-"I
M14<53<XRBI0Q,TXMII2LW9VN]4[],R(O1_Z('1;P?+\AO-7]>+C)ZZ#&DT&"
M0,7Q;.<$L&*AZ0P^=CD<FLCE,=MS;93%7";<3!0XTY-5UKSK!1NDVSVYK;2P
MV%H4L-2I^RC'VF]'>WI*-FU=*W<N\X;LU_!S"[-QV+Q6/VAB*\/>IX949NC+
MV<I*6]5E&3;EP46VM?>>3)<EI/T V>M.%K%K?7+>2:%+A9]K TXA&Y&24'W,
MX@D>M))-F1DE.Q;[#G%M[%:2I89VOK2CQ>6G*_?;P1VK_AUL=O+%;666BVC7
MBEER4K9]':_+AY7IQT-&6D,U?2:Z2-8TA:UJ:CZAZJK0LU;=J7ZMPD=G/@VW
MY[GSW*RV]7O>5##/DO9KRT:>G&UFWPR*/^'6SHV]GM';45R6TJ[5[Y-W?FL[
M]#Y?6;T<VY/7P>FCTGX:4$74,*R_.)C+1DG8CX9F..DX1&?W+O&6Y;\P>VW+
M]6#PSN\_^-)Y<6TLOCIW%O\ P'&+WH;=V[&R24?ZA4DDE?12RZK2U\GP7R3C
M^E,5#J:[I]])6*MPTD3KR'K T(09GZQN;@K[:#/=6ZB3QJW+=6Y$(_K,+YX+
M#O\ PX]7D[?)IY/C*[$UXIJ':#;$4^>)<M'JKW2US5[O)O-'U;3C<1"$0/JB
M.OC9-%R.=B%7-6H^+<MUGIXVI7@(^,U'MX3,MQ*VMAFGO8&BVUP27.^6Z\_&
MVF>1+[([5C94.TNT()<:N[6=[Y/*45;FFGT2/"KBT8>=<@_5'-1>$B6F.W8Z
M0PIK:./8B4\3..03>-)<SX#8WVY^(X6TL \I;/6BNU/CEI97UY]^MB7V:[2)
M/<[45>*5\'!VZV51?3IFT>$9CJ+%8-J#]4:4IU3A+ZVSZ-,N<24DD]TMH8LH
M"DGOL9J-2O%P[=E_ZALIW?\ 37?+_P",UY/=5O@87V;[7QC[O:V-TEF]E4GH
MW=66)N^CMR=[(N4:K:NQR:2W]48TT,V-NL1;=&F?%F<23/8I$<\FX^%?@4:D
MFHMS(O"4_P [L62][9]2+R_36U\<FM+].+YXWL7MQ!K<[3X::C^ZILQ1;:6:
M:5:2:\<[Z.Q0M>ND!&-]3?3MZ/5F:4F4=B7H1D<1"S):32IU<6S6MHR21I,D
M]<6Y]I=HCVVPGI@L1H[_ //QSTR?AU,KP7;R.FW=GRR67]-=FN3]]V\'Q>6>
M7GU3?20B-(2UTLNBE9N\2C=<FZ9ZCP>$B3ZU+:8;CR%;&1J-2D),R,N1^ WL
M23RH5E%KC5O]%FUP:M9\PL/V[BE_[7P+E>[MLY[O"R5WI;OS/NKI?=).(I/5
MZW]#JR0A*=UKQS6&-UQ\',S+C2ILS5L6R-R/QEX)W=AM.T*R;5D]Z]M-<G=:
MY<K%M_MS2E_YN K06<KT9P<L]$V[QX*UDKG+]6^F[TJV=+L]56YYT:5VR<=L
MCKW\!9U*7EK1I96;[E!"NV9=?)NNYB>[ULOJ)*IAL)-"EF23]>SJ6P'C,.J]
M2?L_:0<KI[K5],E;=>EWERNC2[<Q_P#$"&S,;[#"8:,G0DHSI54JRNGG33F[
M2MDKJZ;YV-#^I/\ 2NU'R#+<CQ'4#4&=.P2UL:J%C$34IK)4YC+S&T=D'/BX
MV[)J2)^"]*-*)B+*2Q&CS'$)A.-)0\V>R[8T]AI4I;+W5-YRC#.-H[B6;TU;
MMJUFED:?^%5?M9[;%4MKSK2P/N2IK%J;K*K)U'5W7K).2BVVW%96:<DW_1>7
MTVY<_". 5\[VUX<NO4^Z+1?33P-<?]EIGXG7^#_YD[P^']@DCB_#C].'U+VL
M_=[;G_RBKY%GD 7'J_HE]#+ 2        $66N?37F^,NB]6$7,^P]5;;?EYO
M&!7]SS>G@N'+I?PXDI@+                  !0R(^TB BR;OQTXE=OIV@+
M)>  D "FQ>?WS+]1@0XIZKYE2+;D!*5LD  VW_WF7Z@(:3R8VV\?NF9_K ))
M:(;%^C;W )]?/[GCJV_O:/\ (3Z  ZMO[VC_ "4^@ .K;^]H_P E/H #JV_O
M:/\ )3Z  ZMO[VC_ "4^@ .K;^]H_P E/H #JV_O:/\ )3Z  ZMO[VC_ "4^
M@ >>H9^\M?!H]  =0Q]Y:^#1Z  ZAC[RU\&CT !U#'WEKX-'H #J&/O+7P:/
M0 '4,?>6O@T>@ .H8^\M?!H]  =0Q]Y:^#1Z !Y.+%/?>,P>Y[GNRWS/QGZW
MF8 =RQOY.Q\"W_J@!W+&_D['P+?^J '<L;^3L? M_P"J '<L;^3L? M_ZH =
MRQ?Y,Q\"W_J@"G<D3^2Q_@6_]4!9/5%>Y8O\F8^!;_U0!Y.%#,]SB1C,^TS8
M:,S]TT "G<,+^1Q?B[7^H '<,+^1Q?B[/^H!%ER7D.X87\CB_%VO]0"2BH$)
M1&7<<3S;QVC+<N9;EP<RWVW+P]@9\,GZ[B&DU9YKD>&:V!'X38@P6%),E$;,
M1AK96YF:BX$),C,SWW(]]]S[3!N36<MY\W>WS;66F=^I$80C^F$8_P#IBE\D
M7Q?3Z?3S; 6-=D>RLO\ $X'RD\"J_5+P^1>5O[XMOR@KP[_\ S^SEL'KO+<_
M5LE_OQ,L         "+#1GZMB<7@]2]6;_G4MMO#V^YRW\XGAX^N'?Q\"O[N
M]?)OUX$IQ!8
M                                     #79'LK+_$X'RD\"JUEWKY+\
M%U5_OBX_*2O_ ..P!;GZ\^9F          19:_AKS_\ %?J^7_BI;?3W0SMT
M^%RO[O\ 'Z^O(E,!8
M                                           #79'LK+_$X'RD\"%K
M+P^7KTR\K"V?MO#O8*/_ #+(!<>_Z(RP$@  !PGI%:E9#I-IA;9KCE?#EO54
MZH3:2["'*LH=%0RK&/'N,@?JX,J!+LFZ:$Z[,.%'F1G'NKV)U.RM\4YN$J44
MO=DVF^"266??SY<24KWSM97SXZ=.OF1MQSI,ZFYQ%QFHQ!> V-K=8]J+G4/,
MGZNV/'<CPG#I<>)02HE"Q>JETTS*9#YM24OW4U5,AI;JXSZEI93>;4;SU48W
M>>F:5[<VW\N%F8:<G*6[)Y[S3X-+=<KY65LDD]=;YY*8>EFH$+4C3+"]1VVD
MUL/+<6JLE5'?=+AKTV$!J;)CNOK)">"$XMUE3RN%)H:XU&7,QDG3]G+=Z1EQ
M?ZDGZ_(HU?:P4[6NY*W_ *6U==/3S(T8'J1IWJ;TPKC(--\_PG4"CK^CW$QF
M?:X3EE!E5?#R&+J7:2Y5+*E45A/:8LXL927I$-U27V&U$IU"",M]?#:6#GC)
M8&->F\3&.^Z2DM^UKO+HM5KQM;,V$L#BX858R5&K'#3:C&JX25.3SS4M'F[+
MG;4FX/<>0
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M#^GF\?+GR\!D.GO\3G4[\&N\J!(
M                                                  :[(]E9?XG
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MMJ2LU9IV:SXKCR9[%@
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M]8S5LI7U3MPR3NC@,?L_&;-Q$\+C:$Z%:#:<9+DVKK/-.V7/73,VH;'4\0
M
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M-K/=WKZG?B,C[#(_:,C\_P"KF.L.;NN?&WCR[^A4
M                                                         !KL
MCV5E_B<#Y2>!5:R\/D7=87]$6_GL5?(,_3P 2M7TM\K_ %^/EEP)
M"+37/IK3>WUO1>K",N6Q[ZJVQ^WRV\P%+>^^ZZZ<"4H%P   "&KW3LTUZ]9
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M
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M1-[N\K1G%-K>@\U*+:=FFUD;H7/Z?3W!M5G^3P
M                                                   !KLCV5E_B
M<#Y2>!5?JE_C\B[K"VD6WGL%&?9]X9\1G^GW@Y=?NR5K+O\ HC+@2
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MIIYY/EG)(NPN>_+M\?G'8)W7YN<KW@2
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M[I]47@]!0
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MBTTVUQ?(Z(3B#[#WYF78?:6WF\Y;'V&7,MRYC=FIOZ>7SU/?T\7ZP)
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M5&8-HID.,Z91'E&@VV>399'=M/AQ\N'#PX*Q,$DFEG9ORNVN_P"]WQN]W N
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MI'^Z,E)>:R/B4HS@W&<)1:OE)6T=M-?@?<7(
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MTNBS;7T./K4*N'J2I5H2IU(NSA.+C)=<UIH7Q=G/D?A+MV'H[S$
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MEQX>)L(]YY@
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MU):6?QR6^;EXQMS6@
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MW+GN>Q;<_"8W^\K7NK<UG\C2<;6?CE^?A8]B0
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MS("+K+K]?7Q7,J!)%EK^&O/_ ,5^K_TJVP%?W?XKYLE,!8
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M[>T.JC*,XJ4)*499IQ:::UO=9-/H<QQ:LU;+/+OZ^9[%@
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MCQE6$8C;4E4B-UC23X"4O=:1C]>O7S+_ +K]&K=SU^*\R=OT^G:!8
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MK+A]V9O<C[#W'NNGHTS !(
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M[GSZ+U;R\']U6U[/%XP]>O7R*?O>7#7UWV\NI*8"X
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MO!I,^_$7T\7C/;?8MN9;[#,46>94C(]]C[#V/S&7:7BW+P@/7^_]LJ
M                 UV0?]-I?;RAP/=^V3^P"$LV^=O@B\K2V?MN>_\ 3!1_
MYEKE[_Z0Y>N+]9CGWY>2,L!(        19:_AKSO-T7ZO;W=5;;T";Y6ZW]>
MN)7]_P#C]?7D2F$%@
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M<'%-+/)O*2SL[<;:71NY;;<CWY]N^_N#;1>\KIIK@UI8UQ46
M  :[(]E9?XG ^4G@57ZI>'R+RM/=^V\U@HO\RR!//O\ HO69E@)        "
M++7\->=Y^B_5[>?;52VW K^[_'Z^O6LI@+
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M66N?37F[=A=%^MWW\^JEKMP^\>_M@5_>_P#T_7CU^A*8"P
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MKTJT5*E4A-/.\)QE96O>\6UY7^9RTX5*<G&I3G"2=FI1<7?6UG9KQ2/L2M_
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MO&9><"Y4
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MN\J>P"P
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M?.YE@)        "++/\ #7G_ .*_5_Z5+<0]';D[<RO[O\?J2F!:+N6NOB6
MD
M                       !%D]4F )!KLCV5E_B<#Y2>!5?JEX?(O*S]\6W
MY15\@R)?#N^K)6LN_P"B,L()        "+#7\-B=R/\ @O5?/P?W5+;M^GZN
M4\/%]W"_#NX^!7]WA]7\.O/E?.4X@L
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MURSTS+?+M2,,PC&WLMR&ZCQJ)CO8;DR.ER>?!<2H\.M=)F&AYXV94B4PE#W
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M5:\<B9N<8-#SB%$A3KC)*AN',*8V]C5]8T,M;A,NLDA^37OLN/1S2Z:S86?
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M.+OQ\,EWD<>]?)_DE.!(
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M;_:!7]W^/AKG]"4P%@
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MU?\ I4M@]>O7T*_N_P ?J2F L
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M]"I=)J:?\7#I,]F^QZ=U7O?VU]H$7Z/RZ7OZSOP*>J;G?@W])KMV_N=U/O\
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MNIZ/O27E3L3M6Z6_83IQ6I57V;M?#M&XRU*RDD+4J#/BO\3:EI)+J2,R5N1
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MWOZ\3HX$FNR/9:7R_P")P/=^V3@*K]4L^7AD7E86S]MY[!1_YEGZ?H L98
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M-G>]FHK>L[_W7=N%[6MDL$HMU4][AE9:>\[77'G=Z6?C^CHH9P
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MNKRFJLB@0RL5,E&5/**P4U4<CW)A4HD=>;)'S)HW#01\R3N%ER%ER+P
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M_:>Y>_\ 3VR*7JUR=O7(R)MI-\3T!(
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MW8J0J4Q$D2H[#C;<E\EA962LK*V5N2:2OR5^O2V9LI%L6WT^GT("2H
M                               #79'LM+Y?\3@>[]LG 56LO#Y%Y6?N
M]M^45>/[RSX_V<@)Y]_T1E@)
M
M  #79'LK+_$X'RD\"J_5+_'Y%Y6_N]M^4%?(L_3P<O?,3?7H[?!/ZF6 D
M
M                                   -=D>RLO\ $X'RD\"J><ERM\5^
M"\K?WQ;?E _D&0Y>K9O_ 'XEN?J^2_UX&6
M
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B8L!"G&5$M!+XYRC3Q%RW(C29EOV&0$+63SS:^"\];W/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g759370g00a13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g759370g00a13.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1D44&AO=&]S:&]P(#,N,  X0DE-! 0
M    &/B^8Y(X0DE-! 0      &D< 5H  QLE1QP!6@ #&R5'' (   (  !P"
M4  (<G(R.30T.#<< @4 0$UI8W)O<V]F="!7;W)D("T@4V-I;&5X("T@4&]S
M="!%9F9E8W1I=F4@06UE;F1M96YT($YO+C$@3W)A;65D(%, .$))300E
M   0><QB;UM-CX&D2<YE<S.\6CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!@0
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  '(   "6P         !                          $
M EL   '(                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   '(     %)G:'1L;VYG   "6P    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   !R     !29VAT
M;&]N9P   EL    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     8X0DE-! P     #EH    !    H    'D   '@  #BX   #CX
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MY#=20*<0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! ?_  !$( 5$!O0,!$0 "$0$#$0'_Q  >  $  00# 0$
M        " $%!@<" PD$"O_$ &80   % P(# @8+"@@'#@,)  $" P0%  81
M!R$($C$30105(E%ADPDU4U5Q<X&QM-+4%A@C,G21EZ'6\!<D)3,X6';!)D)%
M4H:U\2@T-D-$5W*2EK*VT=7A&6/&)S='5(6'E:+$_\0 ' $!  (" P$
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MBBK2KV!FX>/>C*L0>I@Q4EV#(RRS4!,V?M1 ';%VFH@[1143$M"T@!TVDB/
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M:#Q6$R?"II'*.%'2L=--51?NW[7P"Y)9L2,%^24\-:QA"K"5FQ<K3,BZ59I
M")G+HZP  D2*3$, +'"Q8T@1UU,\>2D@.#FFX<9/C  /2(]25\C3A)TB8':&
M9M[H;I,U8M9%HG=\V#,IXB79S[,?!Q7$@!XY9(2"Y0P"RQ!YP$AS$J8):YI
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MH-A%AO-OKX<>)L1P(Y@07@ $@Q,.,6:9(\Q-I'M-MXP5TB\.&J@*+$(*D W
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MV@[B(]"+8KH2*B"#:X)6ZVQP/*/.=TC<<XV92LP1X<!<@_=-43K@<#D*4@$
M-BH#H2#+1>/[W(.M]510(W20(^,GCSG6/SS6-(Z"WJRM^]8-CJ/#@G?.H<M>
M4KX792R[56'F4FZ+JUED$;H:K*MEP;)D=O2.D#NFYEVPMR)KJ9J:P"FVF[X@
MV;W$R9TDQZJT"'.<#^X #IXGB#RM>Z^]EP]+)WE&W-(7CX3&HS<#=\M;S.!0
MCFLA>5NV^XMN/DVJZ;Y4T;%DCUDC&A2)+IBY9M%0<X3,53)H#2XZR! X-(XC
M7TL%#AO ";B)/..@B/NL*XX].;'N[02\9RZ+7A)^6L^.1E+8D)1BFZ=04@:;
MA0%Y&*GR+5P(I)")R=Y"F# E*(2LE,-F7E;D#X?/Y^[(C@/1G =U$7TT1*(E
M$2B)1$HB41*(E$2B*.VIG\L:K:66]CF(S7D;@7#.>4$$T@3.(8VQX*?&1VW'
M&];=#X,/B:D27%K!Z GZ"WA?@K668YW@.-[R/H18*1-:BJ2B)0Z'CTYHHUZK
M9MK433._"EY&YI!6VY54A1V;/1$&XG''+R\RR_E&$!# " @ ;;N&BI0KTB8=
MNA[0;R6@F 9L9&MYE9MN"TVF3YCI;Z^6JD<B/,7/P>4 Y V0 <]X=^V!Z8K2
M^O\ ?^RP7=1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2
MB)1$HB41*(E$2B)1%98?VL;_ !CSZ8O4G7R;] H&GF[ZE4:>W<I^217S/ZC[
M*?NKW1%#/C$/<A+?L4ELR;R,>/+S2C3^*+JMNS9]\$A'O46[&(GKCMNZ"(J+
M/0;"LV91Y%7*1>15=-(I@&F!W],V_;5U\S' Z^4_/)S=ZA4-_A<TP.A'2)MX
MF^MUN#A]+)_P4VL$T]D9"0%N]\(=2MQ,+KD#B61<E(1W/Q4?$Q\@ND0")**M
M8UD0IB"GX,D8@@.U4U'_ ,1\Y/R6O1'P$\R?(#3WTXK=> P =P8_5TJM7*M$
M4:>,'^C=JM_9]O\ Z\B*(I'ML=B3'F#\^ S^O-$7?1$HB41*(E$2B)1$HB41
M<#F$O+O@-\[9V ,Y^'; =V^_=4$P0.?]D4=6IAF>(^54'RD+7L=NU*8H@)2N
M9%9)00 ?Q>?LGBY1$0$<I\HY "XW70S @G6I6GT$:<K#AQ5I/\H"#<F>1 ),
MCD>%N$SP4C:TU4E$0>@_[/U]U$4>.)%=NAINL=5 RBWC:-(T5!0"^".2+@H1
M<O\ C' "I' 0*8H^5L(=:W< T.Q :3 +'@]9$1Y]/'JK*5WCY^%I_P K(=%=
M1SZB0#M=6/\  5H51E&K'\([?PM0695#+X[-,4<X_FQ$^,[&P&*QQF'_ $]7
M=W@X.EPZ#>(2K3--T<#<>'Y^2MS5J*M*(E$2B)1$HB41*(E$2B)1$HB41*(E
M$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB4166']K&_QCSZ8O4G7R;] H&GF
M[ZE4:>W<I^217S/ZA2KW1%$OBP;P2MK6XO<S]];4&TN4CF2OJ*DY&,E;1;I-
M'*B;N./&QTH9P\>N$T6:#=TV(S.8X]JLFKV(C0YK36I:[PWRT:2;D"=/GXB\
M+(N(HU18-=NAW.)AQ&IT\N$+,N&$T.&B=D'A8I]#1IV3Y1!&4=N7TB[!23>J
M&F'KIW_'%',X.9=4'94W)#NQ253*8G(7:J3O?%^Z!(_PJ*0:&0VX!-^?6($>
M'V6_A5('?\@ (B..X QD1W#Y1QUJL&1/-6JH*$'O[Q# @(#D-^F,]-_@WZ4!
M!)'+7S11KXP! >&_5; @.+?;Y_\ YN(']_/W5**2+?\ FB?]$O\ W0"B+NHB
M41*(E$2B)1$HB41*(NI4<<NV0R(COC  '4-P\K.,>C.P]*<NOY^>(11UTA$L
MM?6KESX$06FVL,B;J IQR2N0+D/Q  2@8,[<X><*W,5\%+#,U(82/_)Q.OST
MC56.D-:TVO/D;WC7@1_8*1]::K2B)^_[YHBQV?MF(NAB,9/1J$HQ[5-<&SG/
M9]JD8PD.'(8H@8H&'&W+YP$!J6N>QV\TP01'A:8Y'D9]%():9&JCK&-2Z&ZA
MGB^0$=/[^63%@L(@(0\TD4I"H**" 81'G%, -D01%$P9!$X5ON)QE'?_ /?I
M#XF_[F1^Z=.$1K,<)5CG%XD@#=@6TO\ 3IX0%*=-0HE+@<Y ,8R.<@&! 0ZA
M@0'.^P[CWUQ_Y<1]54NVB)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B
M)1$HB41*(E$2B)1$HB41*(E$5EA_:QO\8\^F+U)U\F_0*!IYN^I5&GMW*^AI
M%8](8?[^CSU"E7K( ( /4>GIQU_-M^>B*&O&+:[NZ[7L]C&H1<G)-KI7>-H"
M:MB#NJ+FTR1+]-RBX8W1>^G]MIF:IJ \26E+C1Y3H\K-LZ<B5,M-N_IEQT:\
M@1-Q,>'#KJCP32>+7CQM),>1/$>^T>'UDVC='[98-5HA5-NC))*'MV$;V[$M
MEB/W9'#>/B6,O<$>T39K=HW_ ),FY>.450.=@^=-Q(H:^N3SDEL6XV,F_$::
M]9)56' W3)L7'I[CE,=9TM$V(EM0W>FT VF[AU)" ;:IZS,[IN)F%Q*7D$>T
M6N(VFC/M&3/QT:+?.SQHMU&;!1JL5./:K&*DZ$BV!'P42R[C1_;_ +GM+IF]
MB; <!$#2%8P "MOS:H8X_"2 )FT6TCK8*\:82FNSF^;*5OK[KFEXC+P#:>MX
MQ7/W)$TY'3L59:;=@@8]N!,C>^$5^5T:92>91*W*S-D;*9$#> :74B7?\7\&
M_P#($<>'+@J3O_#O#1YW;\+@$]2 #XVDZK9/&_,7FQT"O5K;5G,+CC)",12N
M.2=74E .;>9%G(4"/6L<I#R(SRF!4_B:;J-$.S*4%Q%0,8J\_P!O53":&$R"
M8B42Y#H(" [;9W ,@.,@/00WHB^FB)1$HB41*(E$2B)1$HB^"4=%91[UX? )
MM6;EPH(CL!44C*"([#_FXV 1#.>Z@@N:.),#U$J0"3 N2M$\.C)4E@*RRW\Y
M<5PS$N8YMSF(=8C-/F'?('!H"@% 1P!AR "(XV\;_K-:#9C&6UN6W\-?E*R>
M"'$'6!Q!T OTF-.'A92%K46"41*(E$6%WY:+&]K=>P+XN!<)B=FY*!159/DP
M$6[I+(9*8A\ ?'XZ8G)C?>RE5=1J"H#$6(_(GU&G4J08/3B.?BM<:2W=(IG5
MTZO3+2\K>(8J/:&,<)F()RBVD&ZY>9%8Q$C$[0H+&5Y?+$OD+ E=B6 DUZ<.
M8\S\(C=)X$$VY<+@K)[?ZA<'Y"+?+HM]UJK!*(E$2B)1$HB41*(E$2B)1$HB
M41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HBLL/[6-_C'GTQ>I.ODWZ!0
M-/-WU*HT]NY3\DBOF?T/#POZE!Q\;>@5[P&0' 9#H/>&>N/AJ%*CUQ VS*W+
M;L8V;V:GJ#"MI8[J?LLA+:*\N!H1HN5JW:N[I L<S*D\,FJX6(LW>B0!!LN7
ME,12HB*@,3K!U(O<"UH-[:1='06.%IY<3/CK>+#E*RO1"(N:$TRM6)O")BH&
M<9,%$EH*'!IX%$-/"EACHT#L4D62R[*/%LV=KLTB-EG":BJ8"4X&-<X@QQL!
M>]XOKZ?Y5=($-@B#)M_BRVR)2CU* _" ?!\VU0+1%HTCA.L*Q4Y2YSRESY\!
MGYO0'YJ(HU\7X 7APU6$H<H_<^WW+M_EN)#?& [Q#?N$>X1HBD>VQV),>8.O
MGP&?UYQZ*(N^B)1$HB41*(E$2B)1$HBUMJY)>*M.[I= ?D.:+7;)F[P4=F(W
M*(><?PF #SC5V';OUZ8CC,\HB>!_P#"SIW>WQ7T:5Q18;3VTX_D HI1+=0P"
M 9YG',X-GOSE7 YWVIB';U:H9GXH'_B /LE3]YO.E]> _/?59L\>LV+9=V]=
M(-6K9(Z[ARNL1%%!%(HJ**JJG$")ID(43G,80*!0$3" ;U4UKGN#&@N<X@!H
M$DDF !U)L!Q.BIJ5*=%CZM5[:=.FTN>]Y#6M:!)<YQ@  7)T%^2M%L7=;%YP
M[6X+3GXBXX-Z43,Y:%D&TBP<E*82&,BZ:J*(* 4P"!A(<P (" XQ6=:E4H.+
M*S'4W#4/:6F^ECS5&$QN$QU(5\'B*6)HN)#:E%[:C"1J YI()'$3*R'F+_G!
M^<*JD6OKIUE;2K4HJ" #U !^$*0#J)1:(UDLN1?H,KVM0IT+OM)8'K44 $IY
M..((G=L% ()3+8+S*)I9,*@=JB4AA5*(;6$J .-&K!IU3%YAI)@$S:T_<:*R
MF0'03 ((OI?Y+8%@7JQONW&,ZT$$E%B"D]9B?*C)\D( X;*%$"B D,("0<#S
M)F 0$:JKTC1J%CIO=A(_<W@1TZK%[=TQJ#=IX$<QSY+.*J6*41*(E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B*RP_M8W^,>?3
M%ZDZ^3?H% T\W?4JC3V[E/R2*^9_4*5>Z(H?<7LL]A;2M:1BY651EVEX,WD7
M;\5%WM+C=#MBBJZ,P>LK!82,TX9-44UG;A%9HO'G(4QG9![,@EH?/>TF@Q)<
M3U&I'I/*>)4EP%)\@'2+3<@@6N;:R-(\%LWAP=2CS2*TG$U-2L]*JH/CO7LU
M"2UNR!5323LW@1H>?32FV3>. P,&990A79VK=)18I3'Y2[=0 $ #^D>9_+>2
MHHDEIDR0X_.#'Y'3D-Z56KDHBC5Q@?T;]5<!G_!]OMC/^6XFB*1S<<HD^  _
M, !^O&:(N^B)1$HB41*(E$2B)1%01$ V#/3;Y?[NM$4?^(I[RV=%PZ9A*M<%
MR1<:0 ZG+VP*JD#SA@F1 /\ -'N"MS!#^:YQT8QQ/I//I_C564[.F]N7F;^G
M(^L+>K% C1BU;)%\AN@FB0H8#R4B@0 #N_Q=JU"9)/,D^I6!,DGF2?5>;OLK
M=W0-G\&6I+F6EY^.?2H,;>MEE;4TZAI&=N*X5_%3"+5.S43._CN1TO(24<8%
M$EV;)4ZB9BI (]BV4INJ9K0^%IIL::E1SVAP:VFTOT(M.Z!-HD7"\H[9,92P
MFQ&937K4L1B0S"X2G1J&G4JXC$/;18T%I!+1OE[FR-X,@$%0 X>N#KV17A?T
MSMBZ-!-6+2GV-R1<;=%R:*WS&.V;5G)NV::YV<=(*O'B3)R9-0J#D&Y(S\(F
M(+*") $O9\SSC9O-,74HXO""BYCGT_U%+=)=< N(!$B6R 9UD=/*=D-A.U+9
M#)L)CLDSFGBVXNE3QM?)\9O !U1@=W4O%0,?NG=<6N9!D& %OQO[)GKOHLZ0
MC>+?@ZU*LUH400<7YI_VUZ6H<Y1*DH[,+)D9)FDL8#K$24DSJ]D \B:@@(UQ
M9V8P.-!=E>:4JAU#:P%,Z&PDZV(ZV(U*[:SM7VDR)PI[8;&9GAV-=NG%Y>'X
MJBZ(EX:UAD&>#XCHIEZ;^R.<(6IL(\F(?6"VHI2-8JOY&'NIV2UIIJD@14ZB
M01\\9BHZ<%*B?*+,SA0-N8I1,7/#8C9S-L.YK785[PX@-?3!>PSH0YLVY\EW
MS+.U+8O-*-2K3SC#X=]&F:E:AC'##5J8 NTLJ[LN%QNM+B39LJ7-E7S:VH=M
M1-WV=,L9ZWIMHD]CI./<H.FRZ"Q0,405044(!R[D4)S"9-0ATS@!RB%</7HU
M<-5=1K,--[2 0X$&>4$ _P![<%W;+\QP>:86EC<!B*6)PU9N]3JTGM>UPDC5
MI(X&W,08,QE(@4Q3&'R@, C@W3'P"(@&=NX*I.A.EO&/=;JBS-G+HMJ*C/)G
M%*PKV5%*4;)[)Q,OL=1XDB4##@2B*QQ(4OX)10,#R  \DP'%T.[ FK1 +=2Y
MS0#:?&+'R5P!J,C^IFG_ ,;V]?-2(MRYH.Z&!Y& DD91D1P=N9R@"H)@NF1,
MZB8BJ0@Y(50AA''*/. %&M!S',.Z]I:[4@Z\OMJJB"TP1'BLBK%0E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%98?VL;_&/
M/IB]2=?)OT"@:>;OJ4:[3<J'F:Q7S/Z'AU'W(^R#CT/V!^ZO50I4#>,M@1>V
M&"]VW%!QD2WO%HYMDH-=4?&*298)XA($<#IA-Q4\Z7.X5,HF8JZ,<@T-_&>9
M02EK7_;69-W$U(!TW;D<-8U\B(E2X$TG\@6]""9B\<3 \)6[>%L6PZ)V:+1T
M=ZV%"1%)PJE<R)S%\:O"@!D[R>R-SDY>7 %FGSE]@,K*&V&MNI (C_:%10!#
M23Q<3_?Q/$\=5?\ 6K6.-T7M^,GI*(=RQ)2:;PB!$73&-9-G#AH\>)K2DM)+
M(LHYNJ#([5LHL;+F07:LT@%5<E5;TO#.):X^E_\ '.>BN-FEW $ \[D"? 2L
M0@>)"!FIV#B$[8N5@VF'-MP[R3DDFC4(.ZKKMU6Z(BW))@*YG@.AC$1!ZX1(
M=NS=+(-SB<%.T+F!,]!/I_:3_D*OO!O1ND#GY?@7Q<83]LAPZ:H).%D4U'$(
M@F@D==%%58P341Y*1%#@94_E$$"I<XB)BE$ Y@$,1/'F?3\_)5ACG;B>O]M%
M)ML.4$Q'&Y2]!R'XH=!_?X1ZU*+OHB41*(E$2B)1$HB41<3?BCZ0QOGOV[MZ
M@Z&Y'4:HHY:LB$MJ)I!;Q<*)A,/9M=,P9*)&9$^0Q@ >8,!VX9QD-A#OK=PY
M H8BH")+6L!XB0XF#P.G7P*L:(!=Q!(\/[Z\;_-2,)^('=Z/E&M-5KP:XQ;P
MM[7_ (\](-$9Z5 VC'#M&CK)JT).T.W7NIL#DUMV\*;<04</%3A%ID:&.0QD
MG[\XD_BXE4YS';095L)LAF&T&;O[COJ;Z=-T N[NP.X)$DF0"#HO#LXRS%=I
M?:GD&Q^7M=BL#DQ;F>8M:)INQ3"_NJ+R"8#8IETQ#I=<0#[%:6ZLV1JM%N7U
MFO5%T(Q0C-TT<(&;.FANR 4040.(^0=,H<@@)B#C_/ P5YALCMUD6V]"OB\F
MQ)J]T^*S' ;[01(+H)G>(=!B=?+Z/SW9C--F*M'"YE0;1-2D'TMUV\TL!W8%
MA!'4:7"V<O',GJ)TG39!PFJ0Q#IJIIJ)G*8!*8IBF((&*8/Q@$! <C7=6O<T
MAS'N;&D$@7^?YXKKCZ%*HTMJ4V/#A!#F@SZS;D- H"\3_L;7#3Q&6O<2"UAV
M_9FH$FP62B-0[;C_ !7,QDD)0%LZ=)QJS)O+MB*E#M&,@19(Y#J"D":PE5+S
M^5[39EEM:BXUWUJ#'@FC4AX('!LB08G0\3Q*\VVP[*MEMJL#BZ+L!0P6/K4G
M-I8_#L-.HRH?VNJ"D6"HV0!#@=T$D &9\X='7>KGL1%UDT_U:%SJ+PFWW)M5
M8S4F%9.1=6#=3M!NG)*33 ZCGP*+?.!,H=(BW9F(0730RC@'+0_9L<<%M?2.
M*PVYALPIM<31= [R 2(  $F!$G40($+R?9XY]V)8IN4YTZKFVRF,JTJ=#,*3
M7..#JN@%KP;L8=XEQ,B!(DB%[\VA>=N7Y;L5=-H3,=/6_--$GD=*1CA)VS<M
MERB=,Z:J)C (&+U#J0P&*?E,&*\]Q&'KX:H^A68ZE4;((<(@@W'/EY&5],9=
MF.#S3"T<9@*]+$X:LT.IU:3VO:6G2X)N-")D&W58=JMIF&IL3&Q@RXQ 1S\7
MO:E: \%4#H&1!$2"N@!0\H#B<3F ,"7E$,XRPV).%?WD;TB")M/#AH+V U@G
MC/(L>6&1Z3!L>?K-M86J(>V=2=#DCA""E?%FG6,^D8Y%L#669KG(F1=PV( *
MJ'**2*62E55)D!'LBADP[52M0QKY<#1JF "3\)$SK',FY^ZL,573.[%H)$GP
MCJ>M@MY65J;:]\H_R0^(D^1 "O(AZ)6\DT4+LH11 YA,IR&*8O.ESE'&1Y1$
M*TZU&I1,%N\TZ/'[2TF X'D?PJMS'-F= =?6/6/#JMAE,(B.2X .@YR!@WW#
M]7GZU4L%RHBXG'!1$.OHP/ZA$,_!1%JF^]8K2T]?M(Z?/(^$/&QG20,69'92
MI$5,D/:F\(3[,XF*."" ^3@V<"%;%'"UJX+J;9 ,&\7Z+-K'/G=@Q''FOMB=
M6K"EXYI))W-&M$WB0+%;/UVS9XB F,7D<(&7,*2GDYY1$1P(#WUB_"XECBWN
M]#R/Y[J"QS2009'0JX!J38V?^%T#\ OVVX!N/141S@!$/.(8K']/B.-,^0]S
M^?-1!Y'T/LL'N'B&TYMV0\7KOW<B84DEP<Q#9-\T$BHC^#[<C@H"L7 @<G)D
MNVXYS5[,#B:@+FLL+$'GKP!X=5F*3S-M.?U6XXF2;S,7'RS3G\%DF;=ZW[4H
M$4[%RD55/G(!C 0W*8.8O,;E';(XK5<TM<6G5I(/B%@002#J#"N%0H2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$5EA_:QO\8\^F+U)U\F_0*!IYN^I
M5&GMW*?DD5\S^AX>'W*#4^/V"O=0I41^+.Y[5LNU;?N>^VK)>SHRXN::7-&/
MY><13<1S]NV;VVPCI.,64D'KA0C=141D"-T!.J>-7*/:(T$M[Y@T);4:"9LX
MZ_\ [=(X*28ID\C)'. 2L\X9!%312Q7(0S>"1>1BSUI'MW:[X2L7C]RX8.7;
MAR_DW R3YF=%Y*)*R#L6[Y==$%C 3-;=40X#>WH:)/7EY<>O@J*)!9-KDZ<O
M#AQ'DKMK-I*CJW$Q$6O,J11(>6&6!NO%-9Z$EA/'/XP[&=@GBC=&2:$2D%';
M3^-ME6DFW9O"*Y;@F>C=_F-J D%K7-@'4. OKPOKU@7E7F[2T@$$M)D _M,Q
MYVMHM=6IPMPMJ2]MO$+MN22B(!W;4\XAI,&KA28NZU;:<6M&3SV5 A'8$&-7
M SB,33%!9XW9K%5330,BIDUQ!(C@!)&O,S?\U6#F@@ %P$WN9N>D2+C72">2
ML?&_8%E79H#>TO=-HVW<,I:<4E(6S)S4.QDGT _-.0W,]AW+INJI'NC"DD(K
M-3)*"*9,B;E+4J0 +#@I@-@PB0-^@==Q'8-_EZ_W!THI7?1$HB41*(E$2B)1
M$HBX*?B#W9P&?A$ ]%09@QJBC:<#37$41+\="T;/!4P".R:\B5,VV<A@4W:0
MB.P@)N\,5NB*> M$U*A$0/Z/+4WXDJVW=CA)/R(]8!6>ZS:F0FC>F-[ZE7$N
M#>)LZWI6;=',8"B?P)L=9)N3)R@*[E3E21(!@$YSE*'E"7,9?A'XW&4<-3$N
MJU&B^D6\H.DFTRNO[19O1R+)\?FM<@4\'AJM6"0-YP;\#=1)<X@#4WMHO"WA
M1LV7N;1B?U%O*.1DM<>-#4Q>\F8/"@Y=0&GC9T=K$&0,H05T&Q41D3HG_%!J
ML59,,MR&+Y9_U)9MA,R9E?9S@*?>XK&/P]&6?&:;&O+J]9S08#88\.D1(N;J
MG_I6R/%X7"YSVH9T=RKC*V)QA<]NZ7TGAK<+AV/(G>J/>':B6@$0"0O1!/3J
M]>$]="[;,,ZO.QW:#8M^Q:C=/QHW%$V!?QX()EYB-RJ',4HCY 9*MS%'MD?&
ML#LEGG8PZAF>3E^99-B&4CG.'[O>JT7&&O>P 6IM!<XDV9 M\2^C<1G^7]I)
MJ8/-&T\OS2F:S\NQ.]\-1ANS#U XP3+0!S))B=9MV%J!;6HMNL;DMA^D^9.D
MB'$I5"@NU5,0IQ;ND0,847"61*HD;H8, )P #&^B=FMILMVGP%/&X"LUX+1W
MC-X%]-\?$U[026N!!L>$+R?-\HQF38JIA,;2--[20##MQ[=0YCB ' M((()U
M6>@)3=,#^L/W_P!E=D7%K"M0-/K3U-M>7LR]8&-N*VYUDLQDXN2;)N&SE!8H
ME$AR' 1 2B('(<G*=-0I5"& Y2B%^&Q-;"5F5J#RQ["#()$@<#&JX[-,JP.<
MX*O@,PPU+$X:O3+'TZC01!$2.+2.#@01J"#!7A[,0&L/L3%VK7'99+@U7X);
MBE -<=H*'<2=SZ0.WZYA/(PRQ\JJ1"8'YQ[0X-W0")'8MWJ8/G/=FU,'M31+
M*P;A\U8V:=1L!M8-$0X2!O.,7UB.:\ K87.^QW'?J<#WN9[$XE_\_!@/?7RU
M]5X._3<)BFP3$D,?<$!P!'M-I'JW8>M=DPVH>GD^QN&V9YH1PS?,U4U  Q@*
M)V[A(AC&;/$#&%)RV5 JJ"I1(8H#N;I>-P5? 5W4<33+7,)@F3;6;Z]")X0%
M[OD6>Y=M#E]',LLQ#:^'K-!!$2UPC>:\7+7M)AS2=>8@G: <A@R %$ R&P .
M/.'3]5:H(-Q^?D_-<RM-WMH_!W$Z^Z&#%2U[N:',Y8SD4(M@6<E$3D\8H)E$
MCA,QP_"* F542&, '.'X.MJEBGT@6OA]-PW7-=<AIL=TFX,<)@'U6;7EI)/Q
M3K)GQ_+>*U7+ZWWUIB*,+J#::<D\.4X,IJ/?@S:2J#?LRJ+E)X*NB*X=JF98
M"$0$HJ$ 4$^8I2[3,%3Q4NPSH _<QYNPGRT-XU,<#QRW&ONV?^5M)T@3X\8T
M5ZC]>+INEJV&R]-)>0=+I@*KIZX[&);J&,( 5-T0A1<ID'.390'R1  ,  8:
MGX.G2);6K, $6&L\=03-Y'&#SLH[L P7 'J(^Z^\]L:UW<F8]S7E'V1'& #C
M'VR@*CGD[RJO3X4+DO-S<K]0 -L*)0W#$5,-3(%.D:KI@;Y,'6T#6W$"_'K!
M>RF"ZPBY+C8 6XB+\#/'31>;'&1Q&<,_"O<%HP=WWK>5Y73<+])":8P:T+/2
M$)%E5PZG9,%5D56_8@</!8H#'<OAYP()2EYA[9DN49GF5.L^E1IT&- <W>WJ
M<N$EL2(BQF_7Q\IVV[9=G-AL3@\+B*SL1B*]9HJ4L'W=9U*D7;CGU!O  S<"
M9B20 0LDA>/7V-B-BH]E(W[$R+U%JEV[V0MZ=3>KG4+VQ3.B(-0236*0Y2'(
M0 Y!*(" & 0"BID.>E[B6M;<V#VVBVA=/K=9,[:MC*C6U!F+@'@.AV&K C>$
MF?A@1?PTLKI_\0/V,H0-F\K=$  ,@$'<(YW#N\&W .OR54<@STZ1K_O;[GZ+
M+_ZT;%\<RGPP]77S:;<S]U&G6/V0_@:CKQL=M9EP7#+0ETOR1\\]M:"*2*LU
MBB(HC./BS!47D@J=RLCVC)B!U4VA'+D1$2MF[GE,%LWG;J&(J5!3(8UQ +I+
MB&[T0R! Z7$]"%P&;?\ 4)LCEN+R["TZM?$-QN(;2?490+&T0YP:'/-0M+FZ
M$P(CQ@^LVF6J3FWD("W+K72>6S+,F2]C7NV I(V3B7"1%F*;LY1(FB)6ZJ10
M.8O.F8.1;F(4%AZAB\)\;WM^&JQSFU:<&0YI(= U@D6X"9U7M>%Q-+,L-1QV
M%<'T<33;5IO:06O:Y@>' BUQ?ZQQE:11(P 8ARF*<.<IBFYBF 0 0$I@$0$!
M# AC;Y1WXXVL;&8CC*S7,! =P_?(9^8:(JT1*(E$2B)1$HB41*(E$2B)1$HB
M41*(E$2B)1%98?VL;_&//IB]2=?)OT"@:>;OJ51I[=RGY)%?,_I&G43\R/LD
MZ]#'R!^ZO0CYM_/OT#SU"E0AXE;POI&;@X.VM.+K\.:R*BEIZB1T_I,C%!(K
M1;A21:J0^HTFW1,!& JI^$+MTOPX 5DY[0#%JC]U6G,""_D21)%K6)L1ZFVN
M3_AIVO,DC@+:&_G"W/PV2)972&UG_+)E<N2R9Y+QO(04H_/+%E7A)195[; C
M;RI%GP+J(!#_ ,1(D)4T#&(0##MU?WVT@1KIPU)_."HHF6G2Q.FGA;EYK?%5
MJU*(HT\8/]&[5;^S[?\ UY$44$P">0E2/;?S),^8/F#'ZJ*5WT1*(E$2B)1$
MHB41*(N)\\IL=<;>CT^G'7'?C%#X2BCEIB/C;5366X3#SE+(Q,(W4 <E,DR;
M B<O?@!39H&, ;\V1$ Z5N8B&8;"L@DN#JA O^X@ :VXG@+JQ\AK6\K]+@=)
M\>%UYP^RNWL[U&>:.\&5KRI&,AJS<;2[-1WA#GYHG3&U%3O9!5?L\\B;YPV5
M6+V@ "A(HZ10'M#B7D\OQV&V=RK--I\<\4\/@,.>[<XAO\TD0&S8NX".=IE>
M(=J'ZK:C,=GNSO*R]^+SW'TZF-ITI+QE],EI+BT@M#JES((.Z(,@J6_"A8+2
M7=J:H>*C1,'&1B%C:8Q"Y2XC;-AD$FK5PFF 8(HX32Y!4(80,<'!@*!51S\T
M[ X7%[9;19IVB9L'N.(J5,-E;:LN#,,'!P>T'0D%[=YI ,FUROJC/*6%V2V>
MR?8;*Q3ITL%A*+\<*5IK-!:*;B(WMW=:Z_0FY@3J6:$<)J(KE(JBJ0Z:B9P
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MG$)%];5K3DESHM9^/-'*-%(N+.X3;HI&!<AF[A0K0W;-E4@;>B937P.U%-N
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M,>*;W ;U1[08@$@AH(N3;B+"_P 0\9%BN")DAK<O.=<*I$4!..@W2A0$Z95
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MBV68G^"8C+Z-(N>,+AGN<VL)&]WA:3#MT1>! $<AWC9O9[L\.6X^D[-Z.-Q
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MG13W8=OAAT(C6 97KVP6W%+#XIN"VEJ-Q67=V11?B&BJ_#N;NAK07"2PMWP
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M#W2\;F$ $"@!6RK,5"9'!1;G3'_C#"&1\_;6[2MOW T15V6R=QW3+8Q%1EA
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MK,6[U=VBW,!%U!4!J)UG I(9P-:F;YR[/\;^M;1;A\.*;*>'I@ .:P"),<3
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MQ^?XRL:=6IA\O+SW&$9N4VL:6M!)[IK2XN<"\R3=Q"D65,A,<I>4 V  $0
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M8R&@OF[9@>(/SY6CS@+?35NRB8]NU0*FV9,&J:*10'LTDF[=,J88'(% I"%
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M="W(N9A#\BKI!)LH\7>"D@102@D94P"-+B[OJ31H0\FUSI _.O-29%)[AJ"
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MZA^4!.8P[U[-E.2Y;DF%IX/+<)1PM&FQK=VDW=#MUK6[SB27.<0 2YQ<=;Q
M75,;CL7F%=^)QF(JXBL]SG.?4=O7<2X@#1HDF T #E"O]<JM5*(E$2B)1$HB
M41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HBX&3*<<FR
M.P!C(XV'/3IOD0'T?)B" 1!N"BMH0D2"CA4(]F"KL0%RJ#9 %'&"B4.V/V?,
MK@HB <XF$ VZ5I_PW ;]2I^CP_>58[Q_=-WGQH28F>JM->L0&FK4W6_M;O&&
MWFP!L5HK4[A*X<-8VZC?4?2"S+E%4! SI6-\72.^YA)*1"D?)$,(^5S$=%,4
MP<Q1*8 $,\/A*>$J-JX-U7"O:X.'<UJK&R+CX _NR.A:0N&S+),HSBF^GF>6
MX/&-J AQK4&&H01!BJ *C3&A:\.&H-A$+KK]BWLBV4U7O#%JIJ=P_P JFD<4
MHEI<DK?=C/E!$1*E)VM?4C,LW")A$"B!SJ 7/-R"; AV:AM'F-*6XK<Q]/\
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M$0O:30[1FUM%+&B;1MIJDD5FU;$>NP3 JCMPD@FES#MY*)"$(FW2*;D33*4
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MY&-))DT.[!%B4'C,&\J[!5FN MU3]F<X"=(@A$B]]+'@FD>H^D_)9:3333,
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MLN&[F^G5I%E;E8V[%RJQ[?A%&1V=KGG'$5V#,S(4VRA5;@DBN54R@HXYD>U
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M623I<OBA5L$J,:>.;-3^&MY5&X#J%(99\*N=%H#7[Y .Y4L=2>\L==(Z$1Q
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MVEY)XB23NGH!;76^MEAIWAX/:+7L0")DD\;QRL>:] +1#L[<@B ]>210B(X
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M*'3&!R(8V[AV[@[O340!/75%4   P 8"I1! !# ]!^3YJ(N/9D_S?,/4>H8
M!Z^8 "H  L$7(   P'3X1']8[U*)@,8QM^;H.?GWHBIR%W\D-\9\XXZ;]?\
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MPX8MUY2,0=MXU^HB0[ABB^!$'I&RILF1\*!!$JPI\IE")@03<N0%NB0Z+@$
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$41?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g759370g00a14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g759370g00a14.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1KL4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &M"^:&0X0DE-! 0      &D< 5H  QLE1QP!6@ #&R5'' (   (  !P"
M4  (<G(R.30T.#<< @4 0$UI8W)O<V]F="!7;W)D("T@4V-I;&5X("T@4&]S
M="!%9F9E8W1I=F4@06UE;F1M96YT($YO+C$@3W)A;65D(%, .$))300E
M   0><QB;UM-CX&D2<YE<S.\6CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!85_;
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  $+   "9@         !                          $
M F8   $+                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   $+     %)G:'1L;VYG   "9@    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   !"P    !29VAT
M;&]N9P   F8    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     ,X0DE-! P     $#$    !    H    $8   '@  "#0   $!4
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M*QSE5EI.&&8WZ*S:RM@_2;-K#Z;?9:I= Z!TDX]E_IFSUFOH>'/+V.K=L?\
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M(CZ3G-Y.WE[@M[_FC]7?^X0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(5SLP=\LJ9,:,T>5>#7PI6/29[KO":F3>DI:DA)&J)Q& #4UGIJ@>5BVW<J
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M2W*\J #;P&)NV!J!A'>*01L 6$#%N)@$>T/(--A_M, !]8:V+]53GGT1]I>
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M?#W 6D83S0O0%N#4IN;;#X1]V?JM=?\ >YC%O)KWI#W>S+77ZBF8/I7IX/\
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M]>XWX (<POU!H-[6U]=L(F.%'!<!ZG.CFC&F;@AG81(W'>$+Z!80#2U]-.H
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MM?'-V*R)LEG1)2K6$M.J"14N2>TA]G/'2[_OM5]V^T7I,0):YLTK,L$4*F!
MK45)/26-!XCI$A+?I2  @ _7E 0UX:#?M\U\;K[?LV]^KARI(SI0T.#BH &5
M>K>8JZ1(1MTJ0<;B"A>5N6]QX=7,=<._/$Y0%L-K@AJ"AIQP-"U-\ HD(B *
MI:?ZX7G?70?D/'%I3'?3AA6O5E$"Q5B V_/,BIRPWOAD Z>MU4PX<3E$!$;A
MUZ6[.%\"PS?J[?5%Y05!8[SM-.P8@YN<(=(EQ%1*P7#Z\O,-!XW$+VX#VX-W
M]>S;#E "#3,.349 [#]O0!5(! >E2XC<!. 6  Y!<>5AX\1OUX=\A6G?KVQ-
M<' L#B">'7AG7F:)%5*PV52 0 ;B!RZV$0M:_, $=.=AP:O1EM[\\ L!\,B]
M,GH,>);8V<1TJ?UO2I /,.D+S[>&@!?3S<\&&]N&=6SW=HWPY5VJ'%*$,,,]
MH:N0+,QATJ-Q#IDKA<1$3EXZZ:C8?5?GB11,2,P6<N< QR9LQAT#%PJ(Z "J
M0CH 6.73K$=>WCU7ZL7IW9\V7?*'*)#,Q+G@*@AJT'97?$@=+B"R6EP$>D+K
M\/K#@(>?#.K^F+R@8!P[N22*L=_-7=2!E$^(*I6XW Y ^(=;<0Z^O"F;]_MB
M&8 "P%<:B@W5=\-@+,VV 43T#I4P$0O]>40'SZ\N/I#MQ._?JB<H* @!SK-3
M.K<&'90Y!53$; HG8P#?YH4 $+7TN-[ZVTMI>^*P8XN#@V6T[.^V)KBC$$5S
M#-@6.#G+KP>)Z9.P652N80U Y0$1X#?72W9Q](X-QP)[6KT9#,,\9&8EQ@Y)
M!8[:G' L^W=@&H*HF4+](B&\6^JA?0%K\0T'SX,-_13GV4R8X&L8A8H:"CXN
MQX8OU9-%72IZ@"J8CJ(AOE$1L/GT'6P7ZO..#5#N >[Y4[UB\H*X!GH"*@$E
MJ,:@X4?HB.D2_NJ? 1&YRAJ&EN/'^;KPIO>N60'?A6+R@-* 8ER7R%3OKS#"
M(!5(;""B8W&UP.6PCR#CQN(_+C(RUD[@HDYA^&/DGFKV<@B  (B(  !<1&P
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MZ(U%^!712:7F)GDU^.=K\=^.9I'.7N,FR@F5)-)WF:4B0%(B4*]F2@B4I3$
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M1>0FV>:X <%)U@"^;''!L:=7V1X'K@M=TZ-3['>-G*#-FET3I:D%22D DI6
M6Q!<;0:N(U^]TJ[F"M3DC/[0F0T09>'7!:0KBA6" F-'F, '<3<(DF41% PE
M,J]9)D#HC&%5/YF)]SG]&M+"D(L=K(?!"U*849ALH'.5!3./,_"UX'E+,^_[
MAEI9(5-M%C3+<  $J6@ 5% Z<0[X.!H(7W-X43'*4P!JF8P)'!0BH$.)M[RB
MG( CTA-+6MV8],Y4&4)Z2"D)Y2A=Z8!CU;SO?Y.79%JM*)"TF7,U]52&*?*"
MM6H(!=S@*X\^Y>CNXK9PUM25.U0RS%HY%O/Q,?+HHGBWYCI)/FJ;DB:B@.P(
M)R%7 HB4@ :PB&F.EVK3JRV>T+E<B2J65))(HX/IQ?'='T%=GL?KUO.[['>$
MFTR$"UV>7.U%J)("T)6D*8#RF4'9V<QZ,>X59VC_ &2:+O;[F/[<>H775Z<;
M?W?V7YHX?)'JZ\8WWP<;\^EV7I5WKGU1'N%>=VGU2:,[?H6^[+?JOE<;ASMI
MRP]\"R_,GZH'8.^[&)\'&_/I5EYR=V+'GIF^30'N%6=OOD45R#[%O^'I=>GT
M<,7WP;-\TJCM3/N_3G1K\'"^ZM:[+TFE>[NYXF'N%6=U]<R*+'M\&/PMYOGL
M-?6'7A[X-ERDD5?S>WGKMWQ/@XWXX_&K,1GY1RRQ>N'<P]PJSM'CF31?/C&/
MA_\ N?7U]F)[X-EPY(@888\:=\XOP<;[^E64<ZNNN6XP#N%6=@:^R11=_P!R
MWW"_$/GKY!ROH%]\&R_-*Z-F'1#X.-]_2K+CM._?@*';V0]PJSM]\BB^.H^#
M'^O/]E:6Z^-]<0^$"RG&4KZM<WKL+P^#C?=/QJS!CD2S-QPRZ& QA[A5G:/]
MDFBOO6_TX</GKC\M,/? LKOR2N#4.-&P;OC4O@XWV"?QJRL:U4HD;L<(>X59
MVW^V31G6%HQ_H-AX_/7 >H.&HC<</? LOS)QV; 0,>S++>/L<;[<-:K+G36+
M-OJY/#[WN%6=M_MDT9;0=8Q^(]NO?7'JTX8#P@65OR1^J#OS&V'P<;\^E67Z
MRF]??/)[A5G;[Y-%\/N6_P"V_P"JN>@C^' >$"RC]">.K7NV;U<P^#C?GTNR
MC#,GCT9<V;P]PJSMM]LFB[\_H8_L/7IWUSYZX>[^R_-*RRV=^?.'P<;[;^5V
M7BY];=4/<*L[N69-%^8(M_\ ]ZQ3X0+*?T1P9VKT[?7%/L<;Z8_C5FJU=8N^
M!/1A#W"O.[A[)%%_>M];M_5?/\>F)[X%D^9/%JC@3T?;6(/8XWW]*LVQR3TX
MYX9X5A[A5G=I]4FBPXW^A;[C<>IW^/4<7WP+)7\":_U<-C94^^)\'&_&_E=F
M%=N ;UX-S[ ]PJSMM]LFC+_N6^TN&H_GKKOUW#MUP]\&R_-'!O-'?9NH(OP<
M;\I^-67?Y1?/*@V8'IA[A7G=[Y-%_>Q__P!ZXCU\.RVF)[X%E^9.%:;WV=V%
M##X.-^?2K+F<58Y#'KW5A[A5G=?[9-& '+Z&/QX< _/?/MY<;X#P@67$R3PU
M:=@B?!QOSZ59J?UC5CQS W N06@'<*L[??(HO2]OH9(<1YC9WKS]?7A[X%E^
M:4. V8=&7-L$#[&^^B7\;L^=-8X'[.+YQ/N%6=H?V2**^]DCVV_5? .KAU6P
M]\"R_-*Z*X[6??O,/@WWVS>-V;&OE*X<<.8[H#W"K.P=?9(HOA]S9$.NW!WK
MH/9SP]\"S?-JVFG3S;L(?!NOKZ79_K'=L;8.@;(>X59VCQS(HJW.T9(_]\^/
M#WP++7\$H/L#=F'- ^QOOHXVNS=)]<1[A5G;;[9%%Z<+1DAQY<78_@\^+[X%
ME^:4<JC$;#F8#V.%]C"U64YXER>^;]4/<*<[=/JDT7Q"_P!"W_(=+?/06&VG
M\VF \(%E'Z(D,S$=.>>?W-3['&^R/Y790>*O6>?N\^X5YVWTS)HO2]A\&/[W
MZ]'7P?S8Q]W]E^:/U7INV'-\M^,/@X7V7>UV8.,E%MF>[+;#W"K.S7ZI%&<+
M!]#9#0+6_9?6'RMA[X%FH\HD?L[,-K[,:!VH6B?!OOK*UV<?WU=W?OM!W"K.
MP+_5(HOL^ALAYN;L>0VT\V!\(%F^;5@QH?7QZ>E\&^^OI=G^L>/:Q[O >X5Y
MVB/VR*+MU#&/QZK"'SUR&_'\&M]\"RX\DHEF?5];_=2*/8X7V*"UV9AA4DD4
M^T981'N%6=P!]LFB_,$6^X<OU5^'T!PP]\"RX\D7Q?5$/@XWVU;59CN<X8;1
MCC >X5YW<LR:,[1\%ON//]5AY@]&+[X%ESDD\4UB?!POP4%JLU <^C';W>IB
M0[A7G=H/LDT7IQ#P8_U_XU;LZL3WP++\R?JCO]YB_!QOO'QJR])?)QCFWVP]
MPKSMT'V2*,Z[>#'WJ_/7X1\_/#WP++7\"?J[F=NO[R(?!QOOZ59N8ESNJ6!/
M13&(#N%6=MM<R*+OJ ?0M]I:PA^JNL/5\#WP+*[\D:N_DXOWZL"Y,/@XWW]*
MLNXNJF_$Y8<:YP]PJSMX^R31@CKPC'P!P_\ 6M;_ ( OP"SWP+*&:4JF[OM/
M'; ^QQOO*TV4_P!Y0Z:]'7MA[A5G=K]4FBP_S6_U_P"-?'A[X%E^9+_LCHPP
M&5(?!QOSZ59<JNJNW/T5W0]PJSN /MDT7?LBWX:]?YZ^/U\POO@67YD_5%>/
MV-#X.%]_2[*><N>L;L\NF/<*L[;ZYD47;C]BWVO/]E"/,>6(/"!907Y)71U;
M6W880^#C?CMXU96VDGH ?MZ<(GW"O.ZXC[)%%A_FQ]<>R_?0_#@?"!96_(GH
M[M6M.RD/@XWXW\JLP(_K&NP8G'/#= .X59W>^318!R#P6^_ ZM\6NN*?"!93
M^A.\ZM3SOUP^#C?9_I5F&RIW;SO&/1G'N%6=UK>R118!^Y;_ %]3L?3U^O#W
MP;+\R3L<=_3$^#C?=?QJS"KXGT$[&J](D>X59VC_ &2*,],8^'B&OZJY<.=[
MX@\(%E'Z$Y?%P:N39^B+\'&_*?C5F%*^4=]>Q\GVAX!W"K.T/[)-%A;3[&/^
M'9\]#\/JP]\"RU_!*KNQ;:8?!QOSZ59:&GE*JW T?.'N%6=O'V2:+O?2T6_"
MP?\ "N5@\X:>=[X%E^:/U1M?9M]/.^#C??TJRGG4_:./HB?<*L[/?(HSEQC'
MX_\ W(#>VE^WU/? LN!D[6\DYY94#\2:TB_!QOOZ59<JZRME>O#=MA[A7G9[
MY%%ZCK]#']PX?X6%QX_C'G??!LU'DFF[[.QMT8GV.-^4_&K,*5\HXOZL6I0B
M(]PKSN]\BB^5_H6_UO:]_GOU_!?3#WP+)\R?JX8X=/>L4>QQOSZ59LLSZ\N&
M5!'F:O[BCG#1%+5!5K[,6CUV=.0TE-.4$XU\!U$8QHN^4*0PNA*0QDT!*0Q@
M$I3"%] QG9=.+-/G2Y E%UJ"4G#%0 ?#;5J[HV=X>Q\O>P6*T6Y=JLZS9Y<R
M:0%%RB4DJ+<0&&#'/9IS,8CA(2E$%!4*)  # 8?+ 2@!=W>WC"(AN@ #<1#0
M;X[URTL2N54P!#DEA1GJ^0YVJ]&)\ -EF*GS;++.NO7"$I2"3K$@ ,ERY+.
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MA"&$(80AA"&!H"=D(M!GXD*V2V:I"E,<QLO:N*4I WC&$T$_"P% #"(B Z
M#>_ =,;Z[%!-NLRED)2)J"HDA@ 02Y-&9PYCA-(I9FW-><M *EJL5H2E(!))
M5+4 S8YTWQ^?[N9?<QE)HU/Y]9]P9T(UN="3H6@GZ6Z+H4]UPTGZC:K@902&
M/N*L(XP (@ .76^82)AWS2+2IY(L5D(#!E+07!!I122U0]03NSCYT\%_@B3+
MM)OV_9*5E4TS;-9IB6(8ZR)DQ*@^J31*2*9Y ?I3:,T62"+=NDFBW0(1)%!$
MNZFF0M@* % +% H     !0   +!CSA:RM14HE147)./?MCZ@E2TR4I0A(0A
M"4I3@V0 W=P]8^W&$:T,(0PA#"$,(0PA#"$,(0PA"X=8?+^D/7A!QMAA"&$(
M80AA"&$(80AA".)=0J2*JIM"IIF4$>P@";\'/3KTOB@.0-I ZXQ6K50I1P2D
MJZ \6LR@SBH#.ZD6%<Y>3J4W"OCN6YC$'<=L7K58Z3MA*,S#T\>];*E$BK9<
MA!L9%0F\BJV.IKVBR3K*H":E2=< I*@0"#7R7 ID^#@AW$<==M[6*]9)GV.<
MB8E*U2Y@2I),M:35,P))U5 Y*(H0?C)?Q>UEKD#7P!J()0(B <0 *GA1$1[
M#41Y!KC;N-L<F2U3&D<0L:PW 0$P6$!N'E*#NCP&X !K>8>JV-[(E+F)UDH4
MIJ4!(?BS.=APK''3;5(DJY2=,EI2Y;66A+N2$L[.*CCB\4.R'!$PB40"X!J
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M:G_ [[HCW6';DU'V9U-./TC9<VOP']:>O#JYWTN%Y[C+JV+Z/M@?#QIICXX
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M$(80AA"&)K#:.F$,'&T=(A#%A#"$,(0PA#"$,(1@MGSGG.9,9W4BM=9[2,O
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M;H0ONF/:X1''<(<WF*/IADYDD;G ZB*\1MIA2:YW='VQ)]OZHR"(&ROC0$!
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M8;_)'XL(Q4'2>#]%8_!MMQ7':GVA[</9HKF^G/QDD./:.O6 7 .H,?06CO\
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M1E=F8SIJ4KFH(>=HJFJICHM8\] 22[(J<5(O7KN/!G%IPI'4JY>H)*+)$<H
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M!D910S<YV@J$4/<#@:XXR_!@&H<99XYBO-U4Q)FN0#4MLW'CSOT#"+B@V<%
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M[<3E99^-U'U0UD[<>_-SQ/0+V'YV<7$0M\[K><>).'] B.(9B''EB@)(K48
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M](Y8CAR-F//!AL'W8=$<(T_3-Q 82$ 0#>$!C60" ==A1#&)F2P=4K2"*L5
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MH?))9@"*U?,E@-RV/OF/F*&$(80AA"&$(80BG?+>U]?3U7\W +@',-0Q"0"
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M*0X]$03*%*.\4IE+[X[ABE$-X#%W1.&Z)C <E<[3W?UGI,5N;'9S'J'<169
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M=^F'N,N*GXJL-D+7:P/_ '?OS>)]H%LI^]>7^-M;_P#B+^G#VVMWSB?X:/\
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M(@H=V@0@@X,)6]C&4 H].8!*D #\T$! F]A!QCEMR^QM\?25ZU.NJV(NF==
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M-?D+L^DK',?5Z8TC;=+2P]K;"?\ \@\^5?3$#5VW/?7+#(S7GXYU/\/T,O\
M(,7D+L&-HF8_)--S-PQ+XXXP\=TMH/:RP9,\_P!8X]<2-6;<X#KE?D7_ !SJ
M?G_FSB-M/,.()%V4>T+:N /1S;><[(>.Z7#_ ,ML/_,*;H9L,F]<4A5VW,-_
MJ89%Z#;^K*I_Y,[<7D+LK^'F-3(^JA--K;\WCNEK-[6V'_F#VL\/&W;F$=WV
M,,C.7Z\JH#2XA<;1G +7'D 6'JPY"[ *SYCC-E=C8FNRK0\=TM_5MAK_ .H-
M<L&X1/C5MR&OOY99'!P"Q:SJ@ $!'41^A8A8+"!K:B V#M<C=F5H6QVI+AP-
MHZ,^#P\=TL_5EB.&%I(PPRRXQ)JDVW%4E$%<L\CE45"*)JD6J^I54E4S)B!B
M'(,48#)JAO)J$.40'>"Y1+O8<A=AQGJK@-4L<CEZX>.Z6X"[;#B];2HG@\?'
M&2NV;"LFT7#90[/L/&-"'3;1L74M0,&#1$ZIU-UNS:Q"39$IS&%0Q4DRW44.
M8 N)A&"1=88>,+<NS)->AA]T7QW2U_YML/\ S"O5]V64?7XR[<'UP9;Y(7$1
M "^.%3B%N C]C-+%N/'>#2W'&7(W9AXPNC/Y#'I[O&/CFESTNVQ-D/&5TW 8
M<,ZG'"(/4VW 80$V6V20;HAKXYU/:P!81MX+-K:Q;6UU&X!J+D;LRM"B^'D$
MUV;N9Z05;-+'?VNLA;Y-J4!Q+C+"HSBLM5;<(  !EKD?8;"!AK*IQ$  0#0!
MC-=!$==.74&)R%VO6>O BB#ZANSV9M 6W2T"EVV'<]I5VA^_52>J-N(1#ZF>
M1PZ>2):QJ@;;I5! NL7<1,?H!N(B4!*83:A8P2+K+O/7FX"#B^;BF&ZF&T7Q
MW2UZW;8>>T+]&76[;XK&J=N'C[&>1P" V( 5C5&Z<+&,&_\ 0O0"G*E:VOE&
M'@%L/%[K^D3*;$FAJ,W[\\7Q[2VCW;8=[6@A^@4;+'BU#(U1MPA>V6>1PE$2
MV,:L:HTL!Q*( $8&@'*33F!P$;V$N!D74?.M"]I 1F.;/II01!;-+<[ML)__
M "%"KX]\Z[HH&J]N.XD]C#(VP6 HC6%3B)@ 2V PC&#^A$P#H(B8!UL(#AR%
MV$.+1,:OQ"!G6HIWHV-\=TM+?[-L(;_U"SD1CNVYYOE!:KVY  "CEED:); )
MK5G4_'G:\9S$ UTL CH.'B]V.3XQ,X:AW] =^#<T3QW2X?\ EMAXFTJP+/EL
M9BX9]\5!5&W$8=XV6N1X&L( 4M8U18"A;=T&-M>^H:"&Z%AUMAR-VY3U4.:3
MUN#SC+C#QS2W'VNL(+8>,KWTP;L]0*IVW[V#+C)$2C?RAK"IK@ #8H!]"P$!
MN-Q&]Q +:X<A=3/RZJF@"":G!RQ<8BN_?%%MTKSNVR'>+26V9UPKAUQ1XU[<
MH"/U,,C3"4.(UC4]S@(@ !;P8!0N.\8!,&@"  '4\7NS*T+ W)/:V0'#%F9R
M\=TM_5MAQH]I6[;V#=%=E(Y2U9MP7L?+/(TOD@80\;ZH$0'A;[&;H[O&^H?6
M@ 7TPY"ZZ'QB9O9)V[=F(YB\3QW2UF%VV&F!\85]CCC]D<05;MQEN'L9Y'B)
M1L)AK&IA ;"/DV"++Y)0,)]  ;@!3&$0PY"["Y\86U69)9ZUPH>D5V1!;M+A
M3VLL#8#\96"W,,?11VAXV[<VMLK\CQ+<0 1K.I;Z#;6T8(Z" WMI<0"XZ8&3
M=KG\.OZJA3?1GS[O 6W2[]6V&IJ1:5;WR<\-I/&*O&O;H&_U+\C+ /[<ZFY?
MYLUZNW$Y&Z\[0NO]56!Y@V6.6.^^.Z6_JVPCA:"!U 0\;-N?WK\C/XY5/_)F
M*9%V?2%C:=4TV4]9[*WQ[2W]6V!]O+GU<T/&[;HM]K#(T+#;6LJHT_Y,^08<
MA=GTA?,DX9GMW4XQ/'-+'?VLL+_OSV,T/&S;G][#(L ZQK*I[<M?L9PUQ>0N
MOZ1,^H<WW[ _"+X]I=^K;#_'/JB!J[;I ;>Q?D9<.'TZ5-_)O5C3,J[$C6,^
M8S_(4>A@]3MKNSAXYI<7:[+ 2<N7(?>3JM]L8IU?MT;4=%U%-TO)Y-Y4+/8)
MZLQ=+-:SJ$4CJHB)!.B8T>)A(<Y1  -R !L-]/#M(O#-HG<%XSKMG3)O*2*+
M(2HD,HBA":X5 >M,8])N70G3N^+%*MDF[;(I$XM+(G5<[C@,GPS)CIZ!S,S4
MVOL\,DXO,O+V@8&D,NIJKJUET6$S)RJ\GT]!5-2C!F5L[:MD[H252M)#IM\#
M%,VN'U@WW-Q>$K0_3^7:+A3+F3TVD,M"@M(4 #BX &>TUH*QL;UT*TQN&];K
MOBV(D6.58%6HJ7+FI6IYZ A&J$U?68TX%VC9Q[ &4=A$:$@+\OG),;]?7CD?
M>MT+_5$GH'J[\8YX:::3@_SM:S_>1ANIZXH#(#*(?UAP7_ R]@WX\-?YQMB^
M]=H7^J)/1]D/=KI1C[;6O#;+XX:N/W94J]K]E#I](L%K_@1=//Y6'O7:%_JB
M3%]VNE#G_:]JH*514_4W8G:6BGV ,H_VAP6O^!$_'IZ,/>MT+_5$FG?N^Z)[
MM=*'_G:U],MO\/W[Q$^U_P H_P!HD#_P0GX\/>NT+_5$F'NTTH_6]KPVR^CS
M<>[P]@#*(-?$2 "UKCWH32W,=?3;#WKM"\[GD]^:!TTTGJ/;BU85JG/>4%AP
MH-T8D;3F0\:[>9?P.6])M6DA-2<HBY68M^A1(@DW:&!=ZJ2^X@ETBAO*XB&Z
M4+CCQCPH^"B[[9,L%BN"P<A,G39>LJ6&"996C6*E,!0.0[ L<,^]Z#^$"V6&
M=:Y]\6V9:9*)"E2T+)42M*%,D#R:J( Q?.F$9/Y&9&4]E!!$2:HD>U ](D>7
MEU"$Z=54!*)D$;A=%HD(W(F4;FW=]3?4'>QZMX-O!S=FA=W2@B4B9;9LL&=/
M4 5:_P D%L#@XHYW!NFZ7Z7V_2BVJFSE*19I:FD68%DA+MKD$@%6JV.5 V$7
M_#B.E@"UOERQZDQ>A#48-@W.(Z?$XL(P*VNYB*@LT=D23FI%E$1K;.YQWQ(2
M3I!DR;A['==6%=RX.FBD!A,4A1.< %0Q2@-QQREWI4JSSY:05J54!(?8W3WR
MCJ.D,V7)MUTKF*"$BU)=2BP'D*S-&VG",HR9UY1[I0',JAK\+^-D".OG\(>K
MF/5C:&R6ES^ F5V)/?LCFQ>UV@![99\'_*HP?]J.3V:LHO?+H7J_JK@N/5^?
M\3Q2T_,3/JF+[;W;],L_\5'3YV&^)]FC*/WS*$Y?KL@>?^[\/%+3\S,^J8R]
MMKL^G67^-+_U1XRNZHV;LSZ6E**S JG+&K*3FN]0EZ?EJFA%XV0[S=(OFH.D
M"R1 5*@\;-W*13&L5=!-7=WR%$!LEH^9F4J/)/?/.,?;>[/IUES=ITLG$L/.
MQ.S:<<8\16T%L;9D*QZ]>*9/54XB(1I3L4XEZ@A'"\="Q\W&5&PCV:WA4JK=
M-G.PT5+('3.55-]'M5RJ =$H@\4M/S$SZIB^VUW?3)'\1%=^,=!%Y<["T,U.
MQCX;(MLQ<4M-42[9)2E. P?TA/.Y%]*TY)L#2)FLI%.'4U,K)-7Z+E-GX1?@
MQ!J5XL4U\4M+!Y*^&J7YZ;6;[XGMM=S_ ,LD%Q4<M+H.&LX-=W3CVK>F=C!N
M\IR0*GDRH\I5A!1L(Z=ST$^=L65*3+^HJ6;"X=RBZCM* J&5D9Z*[^.Y.QG'
M!)9N8C]%%PE/%+3\Q,^J>_>L!>UW8^.6?-_PB=S?&; 5QW1[.A9C9?RV"5\0
MYG*2DO#:S=63+!S=-LN^0:&=G9-C=$^^9L8X\A(>#8]'HV$<1ZY(R;-R+JE,
M\4M/S$SZI@+VNX#RK9(_BHZZQ<#V:LH_?+H7^-<%_P!_P\4M/S$SZIA[;W9]
M-L_\5'^J'LU91:A[)="W#D%5P/\ W_#Q2T_,S/JF+[;7=],L_P#%17AY5>:(
M'.O*( N.9="@ <?IK@M//\_\N>'BEI^9F?5,0WO=H#FV6<#:9J /\48I$JRF
M*KVW:8<TS/PU0(-\DYL%UH:392:2(GJA(Q2JG9+K$3.8I1,!3B41 +VM?&_U
M%2[%JK!27=R&&(#5P]3UQCKXM,FTZ12U2)J)J19U$E"DJ%5#5<@EGR=HS[+P
M#S!\6.(CN43A"&$(QJVN+#D/67^5"!>W#Z8(O\(?!CR+PU_F%>G]SG_&)=.T
MQWGP<?GA='[V;_EYT:5-+$MU&O?37R/Z/1C\UE>>L;CLRF*[]Q'VLGXU7\H]
M)[X^N.)Q?HA'CRXAPO\ @OY[=F,I/Y65^\1_B$83?R:_V5=GIPC>WL[_ &G*
M$_<5#T>4?3'Z@>"O\R+E_LZ>P1\.Z;?G3?.^U.VPF6B+U8]$CJL,(0PA#"$,
M(0PA#"$,(0PA#"$,(0PA#"$4F+>W8/QZ7\X<?@YXA +;BXA&KO:4H6M<_=IB
M%RDBZ[\1X: RKDZR*X;0$=,.'4@O4T/#F14.^$-U#H5^D*! WRF)H(:CC@-)
M- KATMLLN9>]G3/,E)"-9+ZG*%).!!\K42^&%=IXRR:4Z073?1LETVU5C2N3
MRLPI^,0ID[2X"BST#\(\ZAW.?,5%9L[2VBWH+-U"+$WJ!I\0!9,Y5"G$-[RB
M[Y;B4W']%PUZ78O [H78[5)M2+OE<I)(4E12?.3@0'[?4W99^E^G%HD+DKO^
M<I$T*2I*DOY"L0"W.6&&V,CR9*[5B:::26U"W2313(D0 RLIC4I"@4M]U4-2
ME* =N/8[/.L<B1*DBS(U92$H3JIU0$I# 5?(#N\= F7;?\R8M?MOJ%:BHM*)
M)?%^?-N,5>POM8?ZJ9#_ .%E,_E<:_C=C^BI/'[ (Q]J]( W^V22?]T7[1U/
M'FZLRYVL*5@GTX.T>^G19=YD+%0>45-/95XH]?MF"9&S<7"8'*DHZ(LX.)R@
MBV367&X)" O&[']%3T]^_1$5=5_@%7MOK,U.2(H2V=:8QBOD%GUF?M"1)9VG
MMJ*8I:(=2D_3\,_KK)^CJ>0G)VF:ZELNYV*BQ<2)S.7D=5$4FS$H!NG+,P8%
M,+B69-U;XY8:-9!OK7-^//&F+LTA+ZU[84'X,%Q2N6TUP;ICUV4^:U=9NY74
MQFS$;:\/3E.U533RK6;.L\M*+IZ9804<O)HO'LM'NWXC'HH>!I=P<RJ@%[RB
MY-Z BTC7RS<+78:_B@W5;T%J5KOKLR%UW^<;V%,N2=A5L-N+.37FCKZDSIJF
ME\QLL\NI+;DIP7.:L7F/(TY5#?+VAE:,:+97+T4C4L7.U $D5I$2@'KVG19M
M'(@=TB\Z:R:! 5.\;L3_ ,D3GGU$_=MW&>U=_N?]K^2&<\B><,WI>N3%KORG
MLLPRLHC+[=5"1BT*^:QLLF]HJA&PQK]Z])'-63OIWZ8(.%)!9*-*DH(&!\HF
MSL#E0B1KXW8<[(.G)GYS]V.--V7]B+VHU'DG<.K=EEG'V0\?G//N89G![;M(
M2[RHF!92":1E"T2[<2K$Z3I8CABB@^.+@ITV#\Q2I;QS P?"!;,W IPVNQ96
M1+<:]Z=Z&*+KO_ 7PU782J99N!5^+T$?-)DS9AW4DQD]NJA63R(6(A*-7%&T
M*1PP64.5,"ND1?=(F)#G(5;?*'>XG)T_1[X7GC=C^BIP?'O7=CN@;KOX4-\$
MU8_@>MGR&[FC'F$V@\PJ@SQ:9!1>U//+UD_K.?H9D\#).EU*>=R]/T>A7+E=
M"52?'25C7$$N15F^3(9)PJ/1%Y&'(6JQ$/XJG/XVS<SYN:X#)Q& NS2 J_G8
M:K@.90WY%CO[L+@TO66?U39[UEL]'V@:UIZM*3I%G7;62J3(FG(^F*MI)Q*.
M(129I:7*^73=MFTNU<,S%=)LSG%,3D();B$-KL0/\D3@^)SV;:=>$9"Z[_=O
M;<-4@\GLJS...)SCJX'-ZM)ZOLR: :;;L$1UE='T?)5!42^7-$EI1TC6D9,2
M\:E$39) S61<-64!++RB2/YP0:*N5A!JDJLF\;L3#\52_%MW'%N-<!#VKO\
M!(-[,&^9QSPQ;!ZXALZW:.EF\F:1)[>.C3J1+ANUDTT:&HM46#IXA'.F;-P"
M3LW1NG;>7BEF;4;N'19.,Z!-0TDQ*XGC=C^BIIO[C?3L>+[67^P'MP1B?R+-
ME5S2O6#MKV,G"YWPC""E)G;9I2*CZG(BK3[R0H.BVK>71<*LT$W#%59X1-PT
MZ>1CD#/"&,U(O(QZ)EBJ/F15WC=C^BIS[X=]\7VKO]OYZ/-*Q?JI7#('<_F%
MI?,A,)P V\Z 56III(NZ@:DI*@C.XA&*EO $@$@V"1Z5LJTGQ2A7"2Q041E%
MT&)R [<()*A:[&[FRAGP<84K448G,Y1B;LO[]<ER/F3@2"-NQZ@XQY?*>N<U
MLW,H8S/&(VP6]/T)+S]7TTV>U5E924*J,M1=:S]!S*($6=F!1,\[3DCW@HD<
M0=,BI.2% AA KQNQ#"R!LNR@JW._0T479?YK[;L23^BSI@Q#[<_5<NH(7/*F
M8>*GYO;2IB/AYUN5S"R;F@J)182Z"C3OU%6.=JO2MW2"[82K).$3G1%)1-43
M]&8#8HM=BSLB<\VRIBWW;X*NN_L?;=Z./P3EJ[^.75&.&56T'6V:\>,S'[7I
MZ4@?!J[\LY7&55$TY'J+-*NGJ,5BBB\E>^/"*DK3\B=LF9 I7+8I%&ZBAS"F
M6^-V(U%D2PVJ .SF?[8GM9?PQO:C4:4[D>JNRN<7,CJQS3D)^H8DNV=!MHFG
MX.GZ@&LG- 4 2DI9E4B+U=F2(DR2QS.UFZ#!TX=?,"$20156!0Z:"QDYXW8L
M[(EQC7T]1#$XM6 NR_\ *]MGZ(N-O1MPWQ<.2AL[XB2CXF3VU*8:24O#EJ",
M9*Y?4<5U(P1G39D689-P="JZCC.GC-H1XF0Z N7"*6_TBJ8'>.6/Z(G#:^;\
MW;TP-UW]7_:[G:))+])[C@0+&$S?S36RB1S:)M7+]ZJ,XIYXH#ECE^-8I(R]
M0,J>:@HS+-F8IB91R1\)3R)3'8G(L0ICJHI*/&[#]$37>V'3M+.W/$]K+_*6
M-[\/P3$/C5F? MQP.'L&U:9IRF5V8^;].[8 U91>4[O,.-K1Q3.3M-R3]C*9
M4K23>O8ILT%PCWR_@WD/(-'*9#@4Z[<Y$CF"PB\;L3?R0;ZN">^^@.;B+[67
M]E>X.) ,KIS+=6]FCRQ,VLSS>U73+M8R(O=L 8[V*6!,F:;,[(A*Y551G T=
MU(4CDQ81 ]+TG(H) N8QG4H0[-N584'BK5XW8J?BJ>GCWRB>UE_BHO8UH2)5
M!@_$BNT%@V<=U5F8>9E%YO4CDO-;9<62KZL8UE(',GEI1IXVET:(IQ.JY4*P
M>&?D+ F/"*E>LB/"E.J@J@H8I$UT#J#:[$_\E3TAG:IV 8<6;:(GM9?]#[;%
MMO)"A!+4V@5&QAMK[QJOFN]5;H,]N>C'"[INZ=H(I4-19UC-6+XL8]<'0*\%
M5))C(F!@_,L1/O1X MW'1JB4HSQNQESXHEMY[GN:1J>UM_#&^#@/T1V;<.J.
MY&&SR"GUZK';4ID::;K@V6G2Y?4<:+*Y,5,Q&X.P==&=94BJ:B*)!,=9%1-9
M(#I*)G,\;L?T5/3ZZ]$#=M_?K@X?-$]AC%:HMJ.?IC-A;*:0VR%7#QL2E4G=
M61V4%*OZ/;RM<II+T?#'F6STZ2KVH$U#@PZ$AR"LV<HJG3.B("\<L7T0/QIC
MPV;^ VX&Z]('_G=+'/DZ/B7JYRYP(R(D9+,>&(JM,;?&7D4DD_4BE%I2D*"9
M)%D$DN^#LQ4<R"9!7!N45@3 1,9,ISEN4A]V&U6,I8V1(4?ZU&WD8'<.9GC4
M%V7\"_MNX# GD:DT?FV&+3U[LG2KNIW<A6^UY#Q=0U*F>?.BYI.D(\7;=<';
MH'K=L=T40:K$8OC-3$"SDK-Z+;I.\W0(^3W[X+=$+^MRK?:K!*$^829A"2 K
M$DD/B[L.JL=UNS273"Z;*+-9;[GRDI/D! \D%L@V#,P %#4U:.++3)$M$/?'
M*A-N*BUA\B$"0"#H618E"5CRS*28B#TR907ADBS*;DY@1\$)J28J%9HJK)[W
M1CP>:,:+6T6^[[&B7-#TU'#,1B2^9&6>,;:^;ZTOOF0+/:[Y7-2[@J2 [$BH
M /F^=Z(OG3,9G-6<S)T[2>W#1U13\*#X9:$AZ'HE_+1W@N46@Y0'<>W>G=(&
MBYMNM$20*I%,PD2 T=@BL=,A_3?&[%CXHGZW:&?LXUCJ1NN_*M>Q)9Q^"S8-
MUD!^B+89?YEYE9@-ZO58;9#*$=T;FQ7V33V,J?*^CXA_)UCEU-MZ?FDX5JN^
MWW[%S+.VD?%O";B<B\<MVB!>^E4T3/'+#]$&ZK9<*] YX)NR_P!G-ZD8-Y!K
M@ <0W"IZ*_)DYFM7&=F7<9F73.VU#1D/(+O&JT?4N7%%Q$W$N6=23E+ WE8Q
M5^9=J=Y*T[)I1XG 0>IHBHB)MU0$[XY8:-9!SJ;MHW67KA$]K+]9S>Q&'Z)V
MI1Z#H&[(Q[C*%]GSG8;,0E%;5"ZWL99A266E0JNLI*62;JST=$0DX+B*<D<J
MI2,2YC:@CEVKU$W1K](<"A8EQAMEB<_BB=W3FU-N&[**+LOXN/;4N-DOXN%'
M.&;8M5S%YAR7VKQN'MI6_HRLIF_9^F:?+CB>.6+Z(GKB^U-^_K@<.1+EL>OH
MSB!R9VLN>U(A;G?*VF->L!^:\![+8OCEAI^*C&N.&[?WXT77?N=[K-6;DPW#
M!R6RIG% Y*;5QCE4':@:@<EP3..55+'.0#"&^ &,<1 #;I!$H" #N@4V@CC1
M5/L"I@F&QRW3YKI!(&8UB'K3AE%%V7ZQ";W6EP[:B:BC/2HV@'*AK%NZR<;2
MN2E<9%+5)G@RKNGLP,WXW+Z=A3T#!PAN\7U(UE/F=H/F*AUTU$UZ=9H@0H;@
ME5.(Z -]Y)-DM4N>D2 @HE+6DCXI2"4]%=V(.,<9;5WW=$^[USK>+0BU7A9K
M*I&I4B8H:YRH$).KF:;#&Q],1$A!'B)"B/G$ $?AQP9H2-A,=^224@G$@&D5
M8D91X*NLLJ%S*9,HRNJ5A*I81SH9!BWFF*#])H^!)1N5RBFX(<I%00773WRA
MO;JA@W@ PAC5D3YUF),F8I#[.T[3U;!&QMMWV2\$!%JD(G!!=(6'8LP..0P?
M!G H(MP&RGL[ (7R=H$0M;^IYCZ_S+X]>T<;GVRMOSZZXU[-G-NV1QPT9N0?
M^768C,:C9C>>X X3[539VO?V'J"_B['W_P"BQ/;"V?/KZ8'1BXB"/:ZSU_J"
M*O:J[.@#ID[00?[WF%_7T6+[8VWY]>?7CWRRA[E[@_5=F^J?7#VJNSKRR=H(
M+_\ F^P] _F7(=<3VPMC-RZSS]Q$.B]PXB[+,#^PP'1GV8Y-%/M4]G;WGJ"_
MB['W_P"AX_+LP]L+9\^OI[=L/<Q<@_\ +K-GBA^&)^[?%/M4]G>X?4>H*W5X
MOL1ZM?S'L].'MC;/GE/A1A3HX-LB^YBX_P!7V;^&/7%7M4]G;WGJ"UX_2ZP_
M)8>V-L^?5B_/WRPB^YBXOU=9_J#OS9]KVJ>SM[SU!>BGF #_ -#IV<</;&V5
M_#KKWYN:(=&+CJUW6:O]3AZ'P:L!V4]G80^T_0E^VGV-O5T0_A\V+[96WY]7
M5#W,7'^KK-A\V,?5T13[5/9X ;AD_05P"P7I]B/_ /#U:6P]L;7@9RJXLP]&
MWM.V'N8N3]7V;^']L3[579YYY/4"(<P\7F.H=6J7/$]L+6Q'++W!Z<X;KZH'
M1BXR&5=UF*=G)T[8]?1>265.7LFM,T5E_2U,2CA#O99_#Q35DY4;B;?% RJ!
M"&,GO^5NCY-QO:]\:4RUVB:G46M2DGSG(RPYO36-W9+FNRQ3#-LUDDR9A#:R
M$L6V/PZ,HNKC;QRD,(0PA&-&UQ?V"*Q#^^A>S3QBBM1X:6OKV\;CCR+PU_F%
M>O\ PV_YB7T4>N<=Z\&_YX71^\G?Y:<W7&E<0MN6X;HZ\=! @"/R]&/S6/G+
MQPS_ &ST\=L?:@^-^T:".%P(@D8!"PWXC^#U<?5C*3^5E?O$?XA&,VLM;?)/
M8_9&]O9W^TW0G7X$0OY]X^/U \%?YDW-_9T]@CX<TU_.B^/[57CJ(?HPYGB]
M6/1(ZM#"$,(0PA#"$,(0PA#"$,(0PA#"$,(0PA#"$8--]-O5Q_\ A[>AJ/77
MM/\ +F/$0QRCCQ%6+D(8MN-#L!PCJ0)&DI:GXH#T*2-F;MQ;FSEQQ<=MAA"&
M$(H5!04U 2,4J@D,"9C (E*<0$"F, " B #81 ! 1MQPA&J++ON6=*T &5G2
M9DR=5IY:U5G+.FCZBI^'=1,XRS@S/B<XED%&!4B(Q\M2M=T_".Z?GF()R+=H
MTN*@O$VRZ+CWI2(7:AV5[<FZHL56'<@RT?L_Y_4KEC60YB9@5ELJY@904$PK
MV/AF3%IF'(4)G?1=(5)'SB3-=:D47$7G/)1-2$CFYVB[1MTB38 =OR+N$*]\
M^G#OS=C,=QS@LQ*8=KUCF9-0M65C3>;K.JD(F'IY:,A9/.*@L@:#=+4XV5C^
M]&+BDHC9UH\L<[:H(C)R4U4LG) LH\(!47N*[JOS]Z1=&KNY,T)5DY*S2^9E
M4HF<UL^K1FT5;,7[<5IW:$I?:1GXZ4*]25"5;J5E2S2"AUGG2KQ%+.73)J<J
MAB'+&[^JN+9XQ*]^'#;Z]T>UV:NYJ4GLXYAPN8+*N7U8.(N";QY6-2P<,N>,
ME6%19ASC"9IA^DB1Q39^\\S)^!>-([HFSF/0:#N%.*V^[\W=GVMP8?NJS[.D
MTCS===S%;U?258T&AG74$9!U;F-6M="_"F*5?5,@RKINJ::H]Y4+Q@I*/X1L
M_4*^C"KKF5;]&FB<QB))"2PKQV!VVGIR.X/NCM,E>YG0^4>;.7>:Q<V*CG)#
M+Z?5J)O&/(F)10DE%LL6F5ZK5THDATR:/@YDG(D414*KWX8Q#&%#=*$'%^/?
M;U4:&RG1@.SLC(>F-FFN8[-[-_,FL<\)NM8+-.GY&EX^C0H^DX%6C(1VFHBU
M81M7Q#%O4SUM%(*N#QR#YZHFD_<*OA*+@V_AO[Y=)IUP)Q85Y\=].LME5B\8
M+G[CU%MZ4E*4B\_JMC(V9I^D*/>)(4G2.^[IRC<NLP<NV9)!PI'F7<2CZ/KQ
MT^D7YE %=XQ22.!FKQ\DL!UMW$<"">VD#F6=A3;O'9%QZ6[G-'/BYNQ-8MTF
MD;5^6^3&4@*FF4Y5*N4\F)%)P&;3YHR8QBM*5K6\+$4/3,BLP<*RD(C0$'+1
M<F609L%6MAS<,-^%=G?&/4;07<XASXR4R2R5>9[UO"QF4&5-0Y9OIT(^$DIJ
MNE)=IE]X+J*<=NV@K-I*$ELOH^10+'F;HK*R2S@Y>_6$6NW0SR9N>I[#QRBU
M,YW(>DIFH*BJH^;%0MY6?J;,^K1!M!02+,)C,C:9R\VFBIRJ!6A23$5!5%EX
MQIU!B]!1-U R<D1R NS(K)QL>#<.?%N[[#^C.CG+[]HB\[_N?"7M7J<V9H[-
M^I(Z/B,S*OS%=U*C 4WWU*A7&8-7YBS=,'C"LBQ[>+3?U?(-&RC1)%R1HV9I
M"I8@VNWOS]?7$? D8BE*C,C%\GP&&9CTRFPHQ+2NRU AF+).G6S50!\L4SSD
M/"S<)75,NZ::TV\"<IV2;+QB4PFE'L7<?*-44W+19$Z)3=[+K)G=^:*,3@V6
MW)^U^??&.#'N0])L63"/5S=J!^@T=4^[W'=/P*J*YJ>S%JO,=)-1,[8X*)N7
M]6.H]<! 3 T;-SD$%A5,:!]O?//[NRQ]%']R4IVBI.C)R/SGJ)63H?Q10AT)
M&GZ?>T])QE.%JMD\BJ@@7+4S"59S$56+YB=)=,2L3(-SLRI=,Z*K8F>&>VI[
MM7<,\!G=F1LOY?YC9BY'YER*QX^J<CD9UC"C&),V3"?@)R.CT%Z6GVB290<4
M^UEXV$J!A&I@5NUE8]JND0IBDNA7L[:[<OOC7RAW'*BF=!#1#7.&K(P3TDSI
M%_-Q\?%-5*@81M7TO64-X?B2H^!W[J">TVLA&28M22;=I,/4.^10:QQ&QALA
MV[*,/37NV$9FY?;'D?EMD-G_ )#15=2#B'STJ_:#JHLPXB(E%[2?MB:AJFII
M]BS*W12))E@GU52Q(E>2*LJ+5)BBX,=- P8=QWV]G7&-'&& KA0;-F;[<,'(
MM:S[FI0+>K=CZNE,RLRBU+LDA02,8DUJ%RC35<M\N,I:CRCI\TQ3-QC(MTM#
MU*_D)9W$I-E'ZRC^*.(1$Q)-ET984=VYRW?N\>'S#[E[$5EF3FC7T/G55-*.
M<PJES7K-!NE TW+.X>;SFRGI#*.ID0DY=BY>NX:-BJ-8RL%&**&282+QTD4
M;"B0'V[-W/W.,-C<_,^8H[X@8X81\.5'<X$<N\P**"1EE*G@:*F<YJU/7[]]
M&(2M4.,ZVZH2N7<U232+21<TS!5(VC:V8/G$@L5Q)%%LJU  Z4[CV?; ^@\.
M<Y??%ST>Y]MXG9NFMF^D\UZGIJ'E\Q&=<MIE-NPEU:?8($C47=(0+*81=),8
M%R#%59!(@BM%B]7:QRB#--NDFAB< PZ=H.YO2_&S=#]R1I6C(4T.CF_4+]PC
M4&3E0,Y)S3=.*+H.LFI::?0R:B)FADED91K-*MGZ9P$$CMT#MMP"[N$"6QH-
MKG/LJV>&&%/7T3W+S+ZD9++!V^JX*G3RSSBG,ST"S])4XY>5>RE8Z?C&M*U@
M[.U.,RRB6\\X%DX,ETUF[8AA,0A@PA78.G[/2/3'M]J+8(@\\*UJ3-!A4<TP
MGG],4,@E3";I)")>R^4):^?4*T8NS)*+0$9+R-;=ZU.DR+T+IBP1(5&S^6*]
M0?AT\?5V[(Q$R"[D"#*A\CZCSAJP&F:5+4)EK2-?T4P8PU0Y9OH6ELBW624_
M2Z\8X9-FL^>0C):5DDZH=MB2AWH-"G,#3IVYX'SV84YN?;EL$ ]>.9.[COV#
MI>,E,O\ N7U!TGFE6F9$OF!5DD2N%]HQQ+P\"=&C5E%MH?:/IW:6D#$GJ>*S
MF@3I*IX M-0:)G9B+TRZ<H2(.%U-\+MW]_0(<>;O1CW>/!U'W)UC4$\_DT\]
MZPC(QYG;4^>!89*$I]=)"HJ@SQH;.]!LF^69C('1C9"CS4ZFJLN=56*D5C*B
M95%L=-"NS;GG]NWJCXV_<>LN62E'/VV9-0FE:!<P18+OB*B58.8BXO,:M,RY
M!A6<#T!651'EY.NY>([Y<D%:.BFK S$Z3M1\JN@._'OAZ(SQV:=F>(V;8_,N
M+@IQ:589A9@C7B;0\>RC6U/F"EZ=I1&%C&S!--(D>VCJ98&0 P"=,YU4RB"1
M4RE80KPX%^;#N\9081880AA",*]L UYW90((!KM04]Z0'+/-$ "]M!N/JYXY
M6[/Z27QL\P?]*M_!M\=0TK)>Y' 87U9.O62.MB/1EFD3ZPO^27X@QQ:L3Q/;
M';DX#@.R*L2+#"$,(0PA#"$,(0PA#"$,(0PA#"$,(0PA#"$,(0PA#"$8T;7-
MO8'K$;?HH4/->H(O7U_'YL>1>&L?^ KU/[O_ #$OUQWKP;_GA='[V;_EIWHC
M2O;ZP+ 'DFYAU$U$;<N?FQ^:Z_/7P/\ [BH^U$_&_;/<;N%'WQQ.+]$:X@-@
M"WFTL(#IQX=?X+)_*ROWB/\ $(QF5ES,/,5V%^JHC>UL[_:<H3]Q$->ORCZX
M_4#P5_F1<O\ 9T]@CX<TU#:47Q_:7KOEHB]6/1(ZM#"$,(0PA#"$,(0PA#"$
M,(0PA#"$,(0PA$"( %QOSX=@"/Q!^#"$8.M[>WS<F$0 OM>WFH\/ZO8'@//0
M.5QMPOPQR3$6%VHXQH7KU8Y<\=28>Z11=FL;;C^$2*.*NVW817#.+>+>UP 1
M"X (@ VZ_-\AQQA(#.6?#OSQVT%X (#P$.W4!MY[".+!P<"\3A"&$(80AA$/
MI'>L,(L,(1X/,Y1\EE]6JD9)R,+($I2?[QF8EHK(R<0\/&.4VTHPC42F6D'D
M>J<KQLS2'I5UD2)I64,40/CNX]S$.['NW-ZZ-'YR5:CVV#L,N<OJC)5KBJFV
M?61E./\ .+*ZHLSD\N,TJ"FJ9JA.0J&I(E=JN_H"HFSD&;W-J/!PNQ;3RD<5
MVJS>]$F3$*Q8*(?'CD [TX>F+WYXSJSE/M89/;#.;.64U,9HUGFGES0M,NZ:
MVBZ7DG*U29AU')UU''>04%3T ,A6(N(."<KLG+A^H]/)1[9194X@4^X*@ YH
M':OV/$KEU[7P/H9^IHQOD\R-K.,S_G7^84AG&SR2;)S(U2XHN/K%R^/DLEDO
M0#F$>4J%.,W4QXU25>NI1BW7B4C3*51.9L"][N$'2[2:X=W3JM3%QBY-&X=,
M9!+M7BY :O-1L<FYXSEV%LUBJY PN69\P,S:ZS33H^N:ZIR3S6HG,J(FQIWQ
MHFHN$BU93,:GH*3GSTLY2:PYU95-I*230K23,W[S?(.E*%)K7 /@?LSYXQ4#
MA3^Z=XP-,G=XUA93;6FWY35>939AS=-5YF7XYY#['E/9ET'4F7U=PD:E7]?9
MJ[0L-F@^@T!:1\-2U6TO#1V7YZPE7#15BE$DIQ[*IH1*K=1<%)85RWGT0W;"
M,&].SII2+PU9W1#;^89*TGF9"9"TT:IJHR<SXS34HH,M\X):<I^ILHLD<LZU
MBLI*BB%HN!?Q-5U'FY,9G9=Q[1LK-GD8BG(1&/>O*D:SSIXU@PKD^>WGKE38
M\9!!QQRJ1T@>G>&H1%Z-M',G:/IK:PRGJ?+**K^I:!I/97J[,5.AX!M5A:0<
M9F.L\,A*=9253N*>[V0J!S3V7<_7M0!2:RPO9BEX&KF;!M9\JY:-9+L^0.;U
MYME>G9&(':!1@=V+DU=\7??&'U6[1.VW6.T-3M6J4?G%34-'U#E2P:4M3,=6
MS>BZW@*2VMJHI)[5Q$$FAF#1EF3E;&14O40**)MAI^8:2@%3@7,8*373MV9=
M^?TF+JG"F)S%1LQ-*[L(R33VW>Z$3]#GGJ>V96;R0([RY9/8UW2U3HKL9W,6
MGZR6DJ:Z%PZ;].7*^I8.G(^K)<@';C'3JC@005.R.5K#;2O4._9B1!JAV?*H
M.._*,IJ[VA-JN#V2LI,TXO+V*A\[\QJ[RWIR<HN<H^I)UG0,96!PCJ@>3D-3
M[]"6,E3K]%P^%^9\S;)QJC0)$Z9S*'&ZP9W'?=CS1"*U9AU8U!'-GO#-7&"I
M=M/;OB#5/&.LGJ&))TSGG$Y0K'+0F:#Q=U".7$JB?,]C%MVYXU>DI&+382C)
M\A5S]!H[.X;O$P0,DF$UTG MS'TU]>4 #F7J[X<V-1CNX4BUK/NDVVFUH*H9
MBI<@C%K$E(TQ.TPRB,F<TUDG,T^RVS-J=[3,@D<[I5F):BHR'CU51#OCH9H8
MQ%%%^[9OF[73MPQH?5N/1&6J]*'BI/I,=,YVZMM>GV.:U4T9DK++25053FC5
MC&&JRB\X*H9D2H'9-RFS.I6"I>(=.TBP3>K,Q7E2Y<(-HA%M&OZ@:.T6# ]7
M)RBKAKIPUN^W"(U< *#,9$TH6^PX1\SW;LVVLOHG,:5H?)"4J S[,/:UK48N
MJ:+S@JU=PVRM1V;)?+:EJ7*L[M!LLR0S%KZ%@V42@G$**4J^<4S'=^,)E4LU
MT[=N1ZJ=/'+"(1MK1GRXMAB,GC-[9@VX\R<[]HK:&RO>%RID(?*6-SP3AZ6I
MU^^1S!E)S+#/6?RS@4V;*160<2-/N:,CJ9DJSES0[=&-KRIV\;"N75/N8I1:
MZZ26?)\\O77K@QHQ&)Q-,Q5MAZAC&#6>6TEMA5YE_E'FPR@:YC92IMG_ &AI
MZH<IJ%I#.*BGM.5VTRQI=\QRQK=9@#.87JRG,P25+"T?,1*["1>$0Z2*7.]4
M574:Z2[%VQQIQI%9GP#<,F'?<.CL,UMMW;5DJ9K6E"Y-S+J%2J:M*>I56E:3
MS?@JN694 ?)B3@9%6IX1\@^>DJX*RJR)2<LS-@DCTX[.BNX,UE$P:R<U/M+'
MU<\1ME.SH[:?9M!V><\L_P#.VD,Y9V2IR$H>JZ?D*ZIRBJ"J"CJOBI"%GZ9F
M)J.IIU/3$NHTCJHI^K8MO!SK5[!G3W6\JL1-R8B'D I)+ U@Q #<^_!\CW+O
MMP2J3:GVU&\IDC7ZN2CQ*N9_)_-&0DZ*?(U[!4K&U33-2-(15F_%H>2IIN_J
M%NQEY&CEZL9]\)MSL#%>(M'"JHY=^_?*@@&JWVYY'#=Z@(MK"[5^V=(9ANYN
M'HFMZ4AIS-F0<2<96-"YD/XB129;.L#45,1$B@!*F)2--#7J[J&EU:)*$8_?
MH*KB5:3(.,$LQJ#4N=^'/ATQ2EFP(:C-O!]5<MF$;E=D_-.O,Y,FX:N<SJ-?
MT%6BL[541+4U(LTV@LQ@*CD8=!PP<I+*-IV(?H,R.XBHVB31I/,5TY-HR9(N
M2-4\RX8,<ZC MC5_LZXP"DGXP)#9A@6:G'HC)@# ;@(#IY[>?\5\1ZLQXM3I
MC(GI+L^T>B*L6+#"$,(0PA#"$,(0Q'&T=(A&%.U\ GJ'91 H7W=IRG!$1^M
M!RTS3W;B%];@(6XB/#2XARMV5%I8X2)O&B33G8BM(Z?I6'-SM0B]["3_ !2
MV]R_#?2,TT_S,FM_(+KUZ!KR^(,<8K$\3VQV]/FIX#LBO$BPPA#"$,(0PA#"
M$,(0PA#"$,(0PA#"$,(0PA#"$,(0PA&-.UQ]H>L0'6YX3U>,$6/6' -;7[/-
MY'X:_P PKU_N?YB5'>O!O^>%T?O9O^6G=N$:5O[6^M@-PTY$Z^?GN(]8X_-5
M7G+RIN^<5L^R/M1/QOVSW[,M_'B< /1"'F&WG$.SB/6-[><,92?RLK]XC_$(
MQF-R<PBODJ[.S/817.-[6SP%LG*$_<1#_G'#'Z@>"O\ ,BY?[.GL$?#NFWYT
MWQ_:>/Z- -<ZB+U8]$CJL,(0PA#"$,(0PA#"$,(0PA#"$,(0PA#"$!"X" \!
MT'$-*Y $FF//EZ8A#]^_J.<:HML]7-/*K.RD\V\JZNI^&DIR@Y2BY!A/TLI/
MD!HWFHR9*[043FHW=5.LDFD!#)[I$P-8QATQYOX1?"G9M ;-9I5HLXG^-%1%
M Z2@I#@%207Y1E9BA#N8Y+1[P<WCI;>4ZV79:TV9=G0B5,"@%!8F%2DOY"V8
MH+, 6?$4C'=KM8;9+AXQ9ES%RX)WVZ3;[QLL7(E+TRA4^D/].!-_= ^\( <F
M\(<N(>579[)"[+;>,BRKLB4"?-1+'DI4K6)9VY0$!S@]-U([G;/ SI79;'.G
M>/H6J2E2R4@:A"7-7E!RPH&/%P <^V^7^VV\;MW:6T)E8=-RBDN4 R5>>1TA
M"G HC[(6HE V[>P7M<;X^I[!;[#;+'9[1R85RLI$V@9BH/G7MS&!IXK:+OTA
MDSILL6Z6=1927DI<:I9C@[$$%P.&SE]C;;?U_P!$%E;V?45>:=?]D+GV6].-
MWRMBK^"X5PZ^QO1&GXII%]-E<.237A1ASF Y;;;XZ>V"RNMV9*N^%]..8(ZA
M;KQ1.L6<H=_[P<TSQK$-DTB^G2F_<I>F>7$5XP]C;;?_ -4%E=_\%G@=M],P
M@UOV8IG6$_HSP!;/B<N)WF!L>D3#\>E.^'(IW'8*OC]\0&6VV^%_]$%E;KQ^
MHL\OZ_9"^6O7B<M8?FC];HS=]O52@"QZ0BOCLIR:CD4OZ1MA[&NV_P MH+*W
ML^HJ\]/]D+F%@[,.6L7S>W,ON!J.G?$%CTA&%ME4=OP2<2&?TL=G3(9;;;X!
M_I@LKAN-Q^HJ\#T7]D*]N'._HPY:Q8<G3C7_ !>H$;'C+Q/2'*W2MI>2FI'-
MF&IAD8GV-MMP2@ [0&5HCK<!R5>B00'B A[(8#KVB(;P%$P&( D%RUA^9!PQ
M->E^BCC(C.>):0,7MTIQ0-)2Q'VY\SX123+#;4*(VS\RK*7>$P$)DDX*4IA#
M4P6S!WMX1N(F 0$1$;W#3 S;%E++;S]M>?FAXE?_ --EC_@IPZ3D=IP,5'RT
MVV%"""F?V5IMX-2CDHZ$@#O#80OF"!OK=!N(W-K< $2B$VPC&6^TG$C9Y[-C
ME]CQ&_B*VU X2DY;Z8_?$&RPVTC$W#9]Y7B-[7]A5QH2P[A #Q_W;)''I2:6
M$Q2E4*=,3D/>6L.')!LL2<\3K@[#C0X8.7B5_?34[6Y)+=#MU1\H92;90.CO
MRYY92D?G;$9B\)D@X*Y%HDHLX1:BM[('2=[IN5E%NBW[ =0YR"10W2 ,VP8B
M5UYT;XQS%6;9A$-AOX@_CB-E)20=Q?*N&8-6>/K#+#;1 1MGSE840$PD$<E7
M0\1L7>*&8!0U 0,IN@!M])/H3HD%8BT,VP/^1#5I@>+N7)S?T C(6&_L[;+_
M (08NSTYAB"Q%,2\#ECMI7L&?.5IB=()[#DJX PD%1,YPTK_ '.F4*4]U1*)
M!455.9$WS$$;RUA (Y$=+[-[48-3#!LRK%?YJ+:@;N22Q;!PY=R33: Y.,0.
M66VN)0OG[E;TFYN;Y<E7("4!N)@(*E?J^2!MW<*?>L!E.D,J84S)PS;"3^2S
MW X@Y')J8-A@*SQ*_P -^/2R1F90R?<Q<ER^><4CE?MIC8?9ZRL Q; E]11R
M;H" 10"$3$<P \DAA1,7> 3!T!  =TRI3N5L/S0H2S%CNSIO^P1!8;_SMLN@
M^:'=\JX5+Y1R>QGMK@8VYG]E>0AC";<#)9T%Q$3"(F,&8 ;QQN4!/8!$2W "
M@82XIG6'YKI+N&;-6?#$DUI#Q+2!OY<A_P!TC''G8C.M3 V6NVT:X#G_ )6B
M6X"3>R4=CN:WT ,P@ =W3=$UQO<37OI#-L)_1 Y!\<ZU4>IGI@S118K_ !_3
MD#*DI-=[9 <<\(@V6.VF>_29]Y6&$V[<PY)N#"(A:XC?, ;V !*0+7( W 1&
MP Y6P4_!!MC,,Z^=CM% <(IL-_$N;=+S_1)W8TY@SQ Y7[9YA#ZN^5@ !A'3
M)5S<"AT($*0HU\)"F*4'  <Q3&^;!K8H@:B=813DJ##T.=9Z/@[$ 4B>(W\?
MZ:@4;\D,/0<Z<VP0.5^VD-Q'/K*PP]?L*. $+^3O7\?[W*7RRZV%0/**9,0(
M SK"[\D.S+]H^C/:8&Q7^?Z:C&OX)+\=F#TS( -! ,L-M+GGQE6(B4 &V2KD
MNZ8.F\H+5_<1+O('( B)042-O%,DH=(8)M@SE=F3Y%1V^G$Q/$=(*?CTO^$"
M1F[TP('"H ;'Q-.;,FT=2,X]J6E\P<@Z=GGQY_OB5AMGTK!\LG54TC4U3E6>
M-Z[([.I4E3-T9R;,"Y4G\B0KU= [TI'1'*V#YD.&;!GVFM>!?C6F*;NOY)4?
M'93J+G\$&P IL! JPQK5X]P.66VH-Q#/K*P!$PFO["CD;"8Y!.-AK\;B)2FU
M,(COG.(B(=&"3EK#7\$*M5V--X.X=#M6-3Q/2#*W2]GY).>9VL2K?@VV*397
M;:(FN&?.5P .HE')9S]=8;B42U^ [U]PP".\ F*/2%.00(6\M8?F^PXXYY##
M>Y#/&/B.D!(>W(;9R0Q&#U<N<:U:HBI/+/;93,8P9_96!O&WC 3)1V3>$ L6
MXES"*([@6W1XW +W#3$Y6P@_DLWJ:G"A\K*O5AD\1T@I^/2PPRE)9R:O@<&S
MVBHI V6&VD81$V?>5Q[CH4^2K@2E*/UP!]4 !,/$0$XG'@ B.HB,ZQ5_!"K$
MM2NW&E=C1?$;^I^/(IER2:\=I&UXI#+#;1 ?M]96@ 7N(Y*NM1 R@A>U>A<N
MZ8A *'E!N:*6,<#PS["D*4))H*X5 &51@[ \]&$1-@O]P#;D /CR2<'P+O\
M=G4QA/7>T)MB4%5E0TF&9^6DDG3L@YC>_4\JG+0K@4#)ID4*CXY*I(E,<#W*
M4X#80+O@<2'3^:-,O#W=VCE[S;N%D)Y$^4PKY)(=.M, =A@2,\<8]>T<\%.D
MU]V"7;I5ME*1.;4) 2H/FI*9*@'%:$FE0:1Z?)3.7;,S@JT*21S:RR@CFBW4
MD1V;*5V\+\ZBU &W0%K9MHJ*WUW3[]QT+<!QS/@\\,MWZ:7L+NY (=RR$I.
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M#X&-&TL"NT$L% ZV1V@;1AO&&<2.V9G9S>T^(?N44?@Z7Y!C/X0VF)^/(/\
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M=45;A>T-;:Z:]FFM\'0JF',!OH<H.QZ:Y;W^V(,4H=>O5;2UOYM?7QQ=4$
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MP +6$ #'5U*F+45E"G5K*53$DXX"M!M.,=G"$)2VLC((=7FI&0HQW8;,&CD
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M@@@TUP,*5<;\!7A'<MJ@J!E$J0K5=9NP7DV,LH@FIN@+Z/(NFT7N6Q@.0JH
M8 $"J=&D8Q1,F02<U8](+VL-E-DD39B9:IB%J'E5$O6*11B*E^:.#M=P7=;;
M2+7.E2YD]$B=)2=8,!.,L*)I6B"!AB^5>[C,PJWAYV0J2/DWB$I*.57;Q0IR
M"BX<*BK87#<Q125*B"HD1(8NZF4H%+;AC?V73&_;+;)ULES5<K:$:LZBAKD
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MMEHM-LM$VU3PI4V:HK620Y)/K.;&.=LUFD6.SR;+9RA$F1+3+EI*P=5*0P&
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MP2;-B'2&2OX0(L<$[N$W@F,"Q%1,!@XZ\=[9],[]LLJSR9*M67)2I.J1525
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<K=#>WN=K!_/UX[SJAPK,!N;AAT-' 15C*$?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g759370g00a15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g759370g00a15.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2!*4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ("Z^@C@X0DE-! 0      &D< 5H  QLE1QP!6@ #&R5'' (   (  !P"
M4  (<G(R.30T.#<< @4 0$UI8W)O<V]F="!7;W)D("T@4V-I;&5X("T@4&]S
M="!%9F9E8W1I=F4@06UE;F1M96YT($YO+C$@3W)A;65D(%, .$))300E
M   0><QB;UM-CX&D2<YE<S.\6CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!;0
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  $8   "6          !                          $
M E@   $8                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   $8     %)G:'1L;VYG   "6     9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   !&     !29VAT
M;&]N9P   E@    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     8X0DE-! P     %9     !    H    $L   '@  ",H   %70
M&  !_]C_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A9
M6B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M 0  ]M8  0    #3+4A0("
M                         !%C<')T   !4    #-D97-C   !A    &QW
M='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "+
M !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D   #
M3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T96-H
M   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/   " QT
M97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M
M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M !)S4D="($E%0S8Q.38V+3(N,0
M                                6%E:(        /-1  $    !%LQ8
M65H@                     %A96B        !OH@  ./4   .06%E:(
M     &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M%DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P.B\O
M=W=W+FEE8RYC:
M              !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@
M4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y-C8M
M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N
M9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC92!6
M:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                 '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>
M     5A96B       $P)5@!0    5Q_G;65A<P         !
M             H\    "<VEG(     !#4E0@8W5R=@        0     !0 *
M  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '<
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M'1=!%V47B1>N%](7]Q@;&$ 891B*&*\8U1CZ&2
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M          #_X4'I:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP
M86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y
M9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM
M<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ-#4V-C$L(#(P,3(O
M,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z4D1&('AM;&YS.G)D
M9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS
M(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @
M(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+R(^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#(T+3 S+3(V5#$Q.C(X
M.C$W*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A
M=&]R5&]O;#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO>&UP.D-R
M96%T;W)4;V]L/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R-"TP,RTR
M-E0Q,CHR.3HS-BLP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX
M;7 Z365T861A=&%$871E/C(P,C0M,#,M,C94,3(Z,CDZ,S8K,#4Z,S \+WAM
M<#I-971A9&%T841A=&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @
M(" @(" \<&1F.E!R;V1U8V5R/D%C<F]B870@1&ES=&EL;&5R(#$P+C$N,38@
M*%=I;F1O=W,I/"]P9&8Z4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T
M:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @
M(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S
M+S$N,2\B/@H@(" @(" @(" \9&,Z=&ET;&4^"B @(" @(" @(" @(#QR9&8Z
M06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+61E9F%U
M;'0B/DUI8W)O<V]F="!7;W)D("T@4V-I;&5X("T@4&]S="!%9F9E8W1I=F4@
M06UE;F1M96YT($YO+C$@3W)A;65D(%,M,5\Q,3DR,#@S,C)?-R H,2DN9&]C
M>#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO
M9&,Z=&ET;&4^"B @(" @(" @(#QD8SIC<F5A=&]R/@H@(" @(" @(" @(" \
M<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3YR<C(Y-#0X-SPO<F1F
M.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO9&,Z8W)E
M871O<CX*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M
M870^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @
M>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP
M92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B
M/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.D-&0T8X030Q
M,T5%0D5%,3%!-31"13$R0C)!.3(T13(S/"]X;7!-33I);G-T86YC94E$/@H@
M(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.C)&.#!#.3!%,T)%
M0D5%,3%!-31"13$R0C)!.3(T13(S/"]X;7!-33I$;V-U;65N=$E$/@H@(" @
M(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z,D8X,$,Y
M,$4S0D5"144Q,4$U-$)%,3)",D$Y,C1%,C,\+WAM<$U-.D]R:6=I;F%L1&]C
M=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @
M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C)&.#!#.3!%,T)%0D5%,3%!-31"13$R
M0C)!.3(T13(S/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z=VAE;CXR,#(T+3 S+3(V5#$R.C(P.C$Q*S U.C,P/"]S=$5V
M=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N
M=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A
M<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO
M<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM
M<"YI:60Z,S X,$,Y,$4S0D5"144Q,4$U-$)%,3)",D$Y,C1%,C,\+W-T179T
M.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P
M,C0M,#,M,C94,3(Z,C Z,C<K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO
M<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I
M;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP
M87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T
M:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV
M97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O
M(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C,Q.#!#.3!%,T)%0D5%,3%!-31"13$R
M0C)!.3(T13(S/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z=VAE;CXR,#(T+3 S+3(V5#$R.C(P.C(W*S U.C,P/"]S=$5V
M=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N
M=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A
M<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO
M<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM
M<"YI:60Z0T9#1CA!-#$S145"144Q,4$U-$)%,3)",D$Y,C1%,C,\+W-T179T
M.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P
M,C0M,#,M,C94,3(Z,CDZ,S8K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO
M<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q
M/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @(#QX;7!-33I$
M97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z,S X,$,Y,$4S0D5"144Q
M,4$U-$)%,3)",D$Y,C1%,C,\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @
M(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z,D8X,$,Y,$4S0D5"144Q
M,4$U-$)%,3)",D$Y,C1%,C,\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @
M(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#HR1C@P0SDP
M13-"14)%13$Q034T0D4Q,D(R03DR-$4R,SPO<W12968Z;W)I9VEN86Q$;V-U
M;65N=$E$/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" \
M+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O
M;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O(CX*(" @(" @(" @/'!H;W1O
M<VAO<#I#;VQO<DUO9&4^-#PO<&AO=&]S:&]P.D-O;&]R36]D93X*(" @(" @
M/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E
M;F0](G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0'_P  1" #W A # 1$  A$! Q$!_\0 '@ !  $% 0$! 0
M          4! @,&!P0("0K_Q !>$  ! P0 ! ($!PH*!0D&!04! @,$  4&
M$0<2(3$300@4(E$55&%Q@9&4"3-5=:&QM-'2TQ8C)3(U0I6SP? 7)#12U$-$
M4V5S=)+A\6)C<H*BI!@V15>%H[+"Q-;_Q  : 0$  P$! 0
M 0(#! 4&_\0 1!$  0,# @0#!P(% 0<"!@,  0 "$0,A,4%1!!)A<8&1\ 43
M(J&QP=$RX10C0E+Q8A4D,T-3<H(&DB5$5%5C<Z+"TO_:  P# 0 "$0,1 #\
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ML]@#1< EC>6+_I.29%R;+Z:O/W17TD\7XU9_BUTL>!RK7AG%_P!'C!X_"F+
M5(XCWNU\;;%%FWJ):[E;KM-@3[E@LM^0\_=(+<BTS8EO?D&2B-R2%\]!SJG(
MZ/Y;N,KT"_1K*;CRDZ?I Q,D@3<*:A+:E1@(YF\+2JAI,$N<QI/+ O))V\P%
MY>%GW4'CMG'"[C;Q8S#A<UPHPO'[ZK$<(O-]9Q6^3[7GG^DAS HN"W+#<>X@
MSLW?N-S9,2X(O696'!;/!FRR)3ZK:@2W)JPVBU^2XM;I8N/*#CJ#;KV.@',^
MHP& QCW21?X03UO:(N<>&B\,/3Y])WCOQ.]!JV2[UB^!6S*_2/\ 29X9<4UV
MZR27[-E X*VG((UF#;C\E"82<@8;7)B0?&=0+BW&F,"2AE**[!1:#5!=/)P[
M:@U^(D2!-Y DW Q8V6/$/Y!2#)/.0'.V)Q8&P)L;V!UP8[B9QDN_ _TXONFW
M$7"<R??OO!GT2.'O$C <3RG.\OOF"0LO7\//Y8VS@SF1FQ,S+O%A6Z',3;X2
M)%N+T=]MIHNZ=X.$?_(XDN_4>):&@V'(&U"9-Y,Q83&]@3Z%>DQU3A6C_P"G
M>YY _P"9+"V!<QRATDQ_3,K3+G]TLXV<7N!.?S+RC$3=\ XR>@69#^$S;Y83
M.Q_CMD>!R+W;3,MET:FMNV2]7?P9.I*XEQ@1)-KN,5UB0\A78RDUSZ$'F+VU
MR6"\"FUCA &MS&AP2!*X:CC3-4&/@+ "#DO+@).(D-OB^ME]*W+[IGZ143+O
M2RN5L]'6Z7;AAZ/4;B':)$A=PP6-=[9D&(1+#.QN?,L#&>R>)=YMV60IEXN4
MA3/#J';;?"MT9V'=IHD. 8-/,UKOTAT_KL1!(@@2 3:TG]0NKG0 @D@$@7@3
MG30$XVZA>+B-Z4/I1S<M^YZIMO&;A6,2]('-N(=XR+)L1QNX? #M@M'"I[)\
M:QF_&9<E)CSA-DS(ZT)D1B_,BPG4H+S"VA!'(^H'R3R@M Q$ @BTF23H8!ZK
MH:QKN&J.D<[:C&MQ:3\4Q)\(DZV !^>^"GW2/C7B/ _!4VJV6>9)C8]QJXCW
M2\Y5/O\ D?\ I/N>*<7T8>WPKP:?=;B[-1D_J-P3D#D8R)CL.WS;5&B0#&*R
MWH'![.&=$<]-I=IF<VL3'A(ZKC+?=NXD@SRU##9G08O@9F;WF,KK%C^ZF\<$
M>E_-X+9'$X=)P=OTK^'' YJ F%*@Y=#Q[B-P;:XD.2)T@SEL)N6(7Q]O&)SB
MF$HE2$%EQ#;QY:OPC!7:SF/*7,JDEUC+&DBVYC[SJM.(_E4V/;!ES X3>71:
M)-@<F9W&W]"R7$J"3TV=:'3?7S'7ML=Q62JTDBXC[K)162B)1$HB41*(E$2B
M)1$HB41*(H"[??[+^-5?W,FBD9\'?0J?HH6NWI'LVI.__P!<@I'3STX!L=>F
MP.8>XD5!$@B8GT=D7([7PQR^'Q+FYK)SAT6-Z9*>C8O&$]V*6GK9-@-A_P!;
MN,F.%&1+;GNEB,TE3\"*EM#:0X%Q3;R  F;DGQ^<^*J\$CX7$<IF8%[$01>U
M_DNQ8^_*D0.>8Z'WTOR65.AL->)X$AUD++:?825! )Y !OR\S<B#$SU1I+@"
M1!N/+4=%.5"LE$7-,PXH<,\"G,0\VSS$,3F3D)>BQLBOUKM$F2TN2B&EZ.S.
MDL.N-*E26(P="?#\=Q*$K*U%(J(<\M EP:";"[;YU@?,V4_%8S;0=9-_\;]5
M+(RW#7)*;>C)L87-<<#*(:+S:E2G%J *6_5TR5/*<(<(2UR!:TJ'L$]:@R .
M2,V(.+SO>^;_ +#_ *O&?*#C*^8Y/IFX*F#G_J^$YX]D>$<:V> L##Y<"TVN
M^9EGLRUVN\6I%A<N=UC6V):;K;KG&G1+M?)]IB(B 2)*F$\H-6N):T\OQ<Q!
M;8&1,ND^)B)%K[7-,M)$_"*8>7-O8Q\, [$:WV7:>"7%S%^.F$1\WQN%<[4@
M72]8_>[#?HC,>^8WD^.7!^SY!C]U:8<DQ%3;9<8S\=Q^%+EPI#80[%DO,N(5
M6I&#D2"" 0 =KY(,XLL0021J+=8QWTPNO>JHZ Z4 =@*2#R[/,2D^1WOKT/4
M[.ZJ 02;23D;;8'4?,W5Y]><$^?DN=\4^$6$\9<(NW#O/[:[=\3O893<[<U.
MG6Y<M##J'T-.2K=(C2"RXXCEDM!P(DLJ6R\E;:U)+ECE+26P[FL3??UNCB7!
MP<9YA!)]?A;=8,8LN+V.T8W8+=#M5BL-OAVFSVN$REB';[;;V$1H4.,RV EI
MF.RTVVVA( 0E">71 JSB2XNM)-_0V'148T,:&C 'KZJ6]53Y: )',->R==SK
MMS<WM;/<@$[ZU5S>:)."#M(V]9[*TD8MO?UZ^5?5F]\Q2D].Q2#H\I3L$[(W
MOJ>_LIZZ&JLB>K-C92$A1UL\H!.AH=1HC7<:[;.M FH$BTB--QCUNG77?UW*
MRI;Y2#L$#8'3J 0.@/4_[Q/4DD@].U2BR41*(E$2B)1$HB41*(E$2B)1$HB4
M1*(E$2B)1$HB@[T=,P3_ -=VK],:J1AW;[A0<M[_ &*FU=C\Q_-4*5 V]15=
MKT0.[EO!Z]N6&UOY^X]WY*(I^B)1%C<WT]GF[GY1K74'L/?U(WJH=,&,Z0BT
MN^X-@V176WWS(<-Q2^7JU<B;5=[UCUHNETM@:=+[8@7&=$D2H0;?/K"/5GV@
M'B5IVLDU4M:;P.8B#$?IGY@$G(SU4Z=!<:W.?,"V?NO$YPWX;2')C\C!,)>D
M7.Y-7JXO.8M8G'+A=V5%;5VEO+@^++N3:UEQJX/J7*25E3;VW!S2V;S:+"+$
M")B1WLCB3FX,$B]R+ W,6B!&D1$0OD_A#PM]%NS>D'Z1_&'"LN3EO%"1>+2.
M+D:ZW1F]P>'EWM%F\"WLV>,] "\:D(L:5-2!;9*E.QRX)!Y^8"*;C3X9S&DB
MD:]1_4/(AWA8GK;:5F6M?Q)=RS5%)C9_T@!H%]@ +GZKO'#2]<$^+=EOU[P?
M'+3<;+=KPE&0O7/A[,QL7VYQ?"?9GSHF36"TRKX&?XIR)=G(TMIP);=8E*2E
M*Q=S3#)N##A>8@V\3&F\Y"L'@N> ?BN''><WST./)=0C8-AT0PU0\3QB,;?<
MGKQ 5'L-K95#N\A"T2+M&+<5!CW)]*UH?FL\DEY*U)<>4DD$2^0>;<',QH,_
MM&B$ Y ,8E1,OA+PPGW"Z7:=PYP&;=+XTXQ>;C+P['Y$^[,.*;66+G->MZY,
M]E2VFEN-RW74+4TV2-H3JG(V  +2"1N0"+^=^DC56YB2"29 @'4#H5Q+BIZ%
MO 3BXC&(E\Q&+8+1CF48[ELBQX3&@8E:<HN>)7RU9+C+661;1"CB^0K'?K+;
MKG;6)*QZL^PI+:@VZZA>E,NI56U6&'-:YK1%@'"'>!$6Z*KP'L+2))+3)_TF
M1ZFVD97T2WAN+-7*YWIO';$B\7J*B#>;JFT01<;O":&FHETG!CUFX1FTZ0AB
M6XZTA)4$I&Z@_$(.)F,7M>,:>$"R8/,+&(F^-1;N5Y4</\(:A6ZVM8ABK5MM
M$AR;:K>WCUI3!M<YT.I<F6Z((@CP9+B'WD+?C-M/+2\ZE2R'%A52"YP<XS +
M8,FVER=-L*180+"9,;^I] +Q1^%W#N''MT2'@6$Q(EGGNW:T18N*V./&M=T?
M(\>XV]EJ"EN'.? 279D9+4EPI3SN*"0*EHY1$XQIZNAO,ZY6!WA'PO?NSE_?
MX<8"]?7+BF[+O3N&X\N[KN:5!P7)RY*MYF+N(='B)G%[UH*Y=.[ -2):(:8
MQ$X.1G7UA01S3-Y(-[W&#>UM%T()(Y=$= 0>G4C?3Z1^<DT4J^B)1$HB41*(
ME$2B)1$HB41*(E$4!=OO]E_&JO[F312,^#OH5/T4+7[Y_-MGX\A>>M'3VC]!
MZ^X]CTHBF%)!2GRVX!OST0?UDT10^-G<%W_OT\_^*8^3_P"5%5OZ1X_4K8**
MR41?F7Z9GH<\1O2#SV5EF$W7A39$R. V>\(TW#,;)>)N119^7W>UW%BZ1Y]J
M4"FW6H6Q1;C])'CS%EM0ZD94N9E=[C=KA&LP)QH)-IO(@=!=Q!93%I8_GF\D
MFW+B($]\K<,(^YZ<#K+=<2SJ^VMZ;Q)LB;+=KG>(3D$6R5DUMB1$29<1F79U
MSVXKTMI;S2'I:Y(1KF>*^91T_1S%H+IG.;[ 6GZJCCSF7 "2"0W%C.N?'.M[
MK6;GZ(W$/(H_I#,Y)<>'LM_BIQ^L?&7A]<;=(S*TW'AZ[8,:Q;%[=.]?@2X\
MES);>SBS-Q9<A.LP'),N;#>2N+RI52'$4R!'Q NC209CI>-X\59SW2XC5@9$
MVAN+YGK,;0%]=>C[P7LW ;AQ:\!M-QN%[?;G7B_9!D5T<4[<LERC(I[UUO\
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M>M#8J77YB,F8^:HP$!M[?$?"8 ]=5"8[<9W\)\TM,V=*E"--MUP@MOM%IF%
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M6ZQ8ZWU67G2WKV&+@VMS2EI0>4!DE?M*!4>P3H@[[P2!<HO2B9>-G5H;(T"
M;BUL;ZD;#&R03HCR['M4Y17F;>?*SM _+<$'\G@C\]$03+UYV=H_-/0/SLFB
M*U4Z\ _T2RD] .:XM#6SK?5D'Y/<3[^U)O'BBRPILB2N6W(A*BN1U)3I3@>;
M<2I'.%H6E* K0!20/YA(WWZ1(WZ(O/>^K4$@=!>+8!H:'^U( '7S\OE-2GW6
MP41:_ &KG?0KH"] )^8Q&>O0@Z-$7JEW)B*\AA3<IQYUM3B6XT=V00V@A/B+
M\-"@E)4H)V03LIT031%S:VWR*UQ%RF,(EP2XYCF*7%:DQ9;DA:7IV30T%<4\
MPCLI3;]-.)2GUA:G0HCP0#YS:D<<YCK'W4[?U@3DV!.8\@5W/9/!,>T@@5>5
MT'_0X@&0+@"^)M;;?OAQD[_U>[_)_)<H]/?_ #?\ZKT5PJHO31[1[O\ V5*_
M9HBQM9!%?2I3+5U<2EQYI11;)*@'&'5L/()"?YS;S:VU#R6DCRHBO^&V?B]W
M_LJ5^S1$^&V?B]W_ +*E?LT18W<ABL)"GF[JVDN-,@KMDD NON(990/9ZJ<<
M<0A(\RH>^B++\--:!]7N^C_U5*_-R[HBI\-L_%[O_94K]FB*OPVT?^;W?Z;7
M)'YTTF\:Y18OX01?%+'AW3Q@V'BU\&2>?PBLH"^7EWRE8*=^\419/AMGXO=_
M[*E?LT1/AMGXO=_[*E?LT1#>VAK<>[C?;=JE=?\ Z:(K&K_&>25M-75:0XZT
M5)MDD@.,.N,/(WRZYFWFG&U>Y:"/*B+)\-M#_F]V_LN2?_\ $T14^'&C_P W
MN_\ 94D?F31%8[D$9AI;[S5U;:;',XXNUR@E(]Y)31%D^&FOB]W[Z_HJ5W]W
M\VB*GPVS\7N_]E2OV:(GPVS\7N_]E2OV:(K#D$5+K;!:NH>=2XMMLVR2%K0T
M4)<4$\N](+C84?+G3[Z)MUL/JLGPVR-[C7CW?T7*&C\OL'_ T1/AMG0_U>[[
MZ[_DN5U_^C8^L_11%3X<9'_-[M]-JD_XIHB]L.<U.2MQKQ?XIY3+B'FS'=;<
M0A#A!;5I0)0XCHK6P4D;!%$7CNO5ZR'M_*AZ>[^(DT4C/@[Z%? /I_<;G>%6
M/8MB-IX@.8IE/&-=XX=V&TMV&5+EW*5D,-4%FXVO+8+1=PJ\6J7)87;+I/\
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MZS,@1&HOIM9?6=V/-$MY  !O5JT!V'^NM=.N_P _S=*D6! Q%O,),\I.3?\
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M#HMW$?'PLQ6WWU&[MXC+4TAY2%*C(<%C'B*;6CVD(*B$H)KEXJ *!F_OL?\
M@^^GE,ZRG#@-K5GD1-![0<&]6F8ZCX<]-+Q]*L !)(_K<I)'8G7R #8&@2.A
M&B?:YJZ1< [A/LL]2B41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1% 7;[_9?QJK^YDT4C/@[Z%?(OW0'+7\(]$KC'DL2\W.RR(%CC(9FV
MC$(N=7!U<JZ0HPM[>+34B)=F[D'3#DQY:V8WJ[K@D.MM!9/'Q9@4HR:M/3(#
MA(G/EVF"M^& +W"]Z;]_[3IC6<6RN1_<T,XA9GZ'?#V]P[SF-^MD'*+I;8EQ
MS?&;1C.3%BUSPA[Q\:QF.BWVM'K'K"H%LCQD.1HKL>$E"@VTI?J<0 #3C6DP
MYZ;:+@H8J=*KA$#3KW-]1'5?66/\=K7D&>#"8=GN+@<<=#5T0E9:0E%KN%S/
MKUO>CQ[G;7FV8+D>5&G1F'H\N1#CE"UO"N9DN!)T)L(P(]#)W5WN+>6WZI$Y
MT.@G;4;+KV*NH?MI>;YPAV5-<3XC;C+A"Y;YV6WD-N(ZDC2D)/OJQC3UWZ]K
M*6&6XBY$7WR)43Q*@N7#!\LBM<GBR,>N;;7,GF'B>JO<FQWUXBD$<I2>BMD]
M -*!#:U,G^Z//:\=^BPXUI=PM9HU8X&(%B-SX8OLM!P2[,KN6,R2XPJ7EW#:
MTSRH+?4^^YB<AJ+-?#82IA+:7,J82IPN-R%K+* '$(5R>=4/N_:-1I(YJ\N!
M&S(!L;#)$Q>%Z'#$U?9E%T_!P[0V!H7XOF+29) /FN[(ZH2=_P!4'Y.V^YV=
M?+]-=@,W"P @1Z^0"OHI2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2
MB)1$HB41*(E$2B)1$HB@[T2&81'?X;M7Z8U4C#NWW"@Y;W^Q4Y4*5 6W^E+Y
M_P!O _0V:(IQP;2?=L;ZZZ>?F/JJ" ;'UZZ(OF+CJY+C9]Z-\N,9J&O]*TZ%
M.5"=6QRPG>'^7SAZVMO05$<EP(S$AEPEMSQ4!0*P@C*JP/#73:F[FS:0",YG
M-YBX\<7U'4WL@2'_  &,@&]\G(Z"_0KZ9CG;8.R=^9T?E.M?/H^7-S$:!K1I
M!:"#(WM]ELL]61*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)
M1$HB@+M]_LOXU5_<R:*1GP=]"ORT^ZCW+TB'L-PW%.!>/<4<B:OIO+F36WAQ
MPQPOB7%N28K<1N!;LNMN<S[=:X=D<+DB4TN&MRX+N,>*M"4!@E7%5#CQ5)K@
M#3Y2X@B0' @2+&(TU^16S2UO#U2"0_2)F(=(!$&]I'A$3'6?N>EARO%_1BPZ
MP9KC>78Y?K=G=X0_'X@X7C'#_-)Z)%T7+;O.0X[A[LC'4W.>F0XIV5;GWA*;
MY5NN>,'$CUN)+7N86FS:;01@2/AQY&^N#,K@X<R'V@\Q.+&3NOT&#+2 5):;
M2I2EE2DH2E2B6R220 224IWL_P!5/N%<N(BTF\6FQRNF 9D P+3I<8VR5$XU
M_L3_ /W^X?ILC]0^JI51@=@O;=XJ9L";#40$RH4F.O9 VEYI:"/>2$E:M=1T
M/36ZECH>(S8_..ZI6;S4GC_2;;V^@7SEPS<3'QWA8\D*:3:;AD&)R&U1/%D>
M$E4MAMDOE07#:]<AQ)*SS%#W@-A8*FTZY/:%-S.-X>H+_"1)& YH)O>+"^08
MVNM/8U4O]E<53.CPW.E.HYMQT OG2-%]/( *$]!H@'6CKKU[*Z_772"" 0(Z
M(KZE$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HBM!]HC1[#KLZ^8#
MMOWZ^GO1%=1$HB41*(E$6,.HZ[4!UZ;.M_+U JI< 8.THKP01L$$?)4@@X10
M=[^\0OQW:OTUJK##NWW"@Y;W^Q4[4*5!0/Z6OO\ V\#]#9HBG:(OF;TD7$18
M_"RZ!N,X;?Q4L!29+CC;*'+A;[S;"I1:TOG4F84(Z@<ZD\W0'6'$6HOBPM,$
MBTB<;^.<*S #48" 2YP;)@P(._AOV7TC&_F ["MI3H@@G6CK>M?/[ALCH0:T
MI@!C8$?"-(T4.$$C8D?->BKJ$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2
MB)1$HB41*(E$2B* NWW^R_C57]S)HI&?!WT*^0_3_P",.;<"O12XJ<2^'5RC
M6;+L>CXZW:;E,_@VB/%5>,FL]H?6J3F%ZQ_%8:A&G.A-POMX@6R 2F3*=#+7
M*>+B*A9[HP9>]C"+@PYT&-08TMYF5T</1]Z:L'_ATJKP<?H:72-=-.VMM+^Y
M]<9>('';T8<*X@\2;XS?\LN&9W&#+N+%QX?7=HLP;AX<9E-PX99'EF'.J:;]
MA1ME\EN(*O#D!MU2TUZ==GNRS'Q4VN/W)V^D"Q7G<.\O:^9L]P!,X[D"2-=;
MWNOT%4H:2DK25>(-)!',!U[C>_R5@"#@@QF#*Z%$8V1\'N'8UZ].Z[Z=9;NN
MO:K'/@/H% ^Y^I4Q(Y5(Y?9/-H:[D[) (UW ]K?N!)-1,7F.J.N#V/T7RS8C
M.AVC/( ;\23BO%]^7%8;DHA!N!/FP[I'\1;BDA*4P;B'UH)'BCE WS#?-[9/
M-1I5!>'LQ?'PQ;7(."#$JO\ Z=+65N,H&  :H/-8?&WFU@29,3 .F3'U6TI*
MD(*2#M*3T(/<?)_DUNTRUIZ#RT^2T<(<1$02(VOA9*LH2B)1$HB41*(E$2B)
M1$HBH2!W(&^VSJB)S)V!S)V>PV-GRZ>_KTHBIS)_WD_6/UT1.9/^\GZQ[]>_
MW]/GZ5$B)D1OHG3794+C8Z%: >@T5)'4]AU/GY>^HYV?W-_]P_*F#L;XZKS+
MGPT!7B264  E14ZA'*!L$DE0T!H]?+1]U9FO2;)<]K0,DN:(UO)VNKMI57&&
MTWN)L &./T"B9&38]&YE/7RTQTI+:5J<GQ&^53NO""UJ=TGQ"I)1S:*]CEWO
MKD>-X6X]]3<9B.=AOYGNM1P?%''#UC,XIO.!)%@H-WB+@C3S45>6X^N7(=EQ
MV(;-TAR);TB""J:RS&8<<?<=C@?ZPAMLK:)2E8"EI!@<9PYD->R>A!QT%S<@
M  3O"@\+Q _51JM$@2ZF\#M=HQUA>1?$?'E:,1K)+BER*J8V[:L-RVZ1RT'4
ML=)<*R/Q"^E9V(CCXE+0EQT-%#2U)H[C@,4JKYQR4WNU FPUN>@!O:]QPCG6
M]Y19_P#LJLIR;Q',X'ZZ;JV1G+J2?5</S2>D/QV0IJTQX(Y9*'5JDE%WGVQ9
M8C!KEDDM^*%OM(;9=)7R4?[0+2(X7B2#'_*?J3>PQ&=EK_L^+GB>$DS^GB*;
MK",P[.TWUQ*S(R?)'TCU3";D-KE(_E&XVN*=,ALL+4&9$L:E*6I*.79:2@E0
M3L@!Q7$5 ',X<AI)CW@Y7;7:X2!,Z7&%0\-09^OB&DQ,,(?:]P08.,6@YM<U
M-RSM^,I;>,6V-(,-M;;4J[%] EE](6PM<>,--(9VYXB-E2P0$[/2PJ<9I1;$
M:F^L0=8\NNBLVGP!SQ%07F!3-O$QFUQVME7#_2 ]S L6&$!*:*% RY15"Y5>
M,E22E 2^'"0V0HIY#S:V=&I_CW993;XR1J8$0=KY(B39(X!L@.JNOGE !Q$D
M'%KB_@O/'M/$%:$B=D5J:7J2%*@V9>P5K48I D/K22P@I\0\VG%)) 3O5!1X
MQX^*J&F+F+S.Q)F!KX 905>%:"!2+[R XD ]#$$".HC57?P7RAU3QD9K<@'&
M8[:$1K;#8\!UM#8>=0LI<4HO+"E\I!2@'E2=]I'"5YEW%/M(@#3>9F_G,:!6
M/%\/! X.D-;N)M)."<_,YV5R<'DKDB4_EN7N@3E3DQ?A&*Q%;25\R8:6F8*%
MF(A.D^$IUQ1Y I*M]*M_!NOS5ZA&P)\<9V QIH%D>*9?EX>BW8@3.<\V\Y/B
M+J__ $>6,^&9#F03%MQGHG-(R7(BAQB0HJ=2]&:N341US^JT\N.IUA.DM.-Z
MZR> H.(+@YY @%TVO.L3_E1_&5A'*0S7X0+Z3BQRMKM=JA6:*F';XJ8\= &F
MT%Q?-R@-^TIQ2EK44^TI2R5+(YE$DDGJITVTF\K! DF.I[D_5<]2H^J[F>2Y
MT 2<P,+'?-!B !K0O-I&AY?ZZW6HP[M]PLSEO?[%39Z GW U"E0%NTJZ7LGJ
M?'@$?/ZFQU^BB+8/\_51%\S^E RO^"6&S&W R+?Q1P2:\YX")*BPBZA#R$,.
M(6AQQQM90G:24<W.DI4 H9UW,;P]8O\ [1'?F&//&TK%PJ'B.&]W/_%'-!CX
M>5^>DP?!?1D$\T9E?72V6EC8T=*0.XV2#[_=V'0"E*#381CE;MMT]:KH>(<X
M?ZC]5[*T54HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B*
M NWW^R_C57]S)HI&?!WT*^,/NC5XA6;T0.+<RX_ +L-R+CL*0UDWP,S9'$73
M*++ Y)MPR.UWJQ6=+BY"?"OEVM4Z#9W_  IST?PXY*>/B8+J+=?>TX$7_6#M
MTN9M/=;T"1[QP=R@4JA=U;RF0>GSUV4+Z 5H19/15P&VP[QP]GMIOLM4-[AI
M?<6RO&H;:Y82B(O(<)M%DQF]W.*X2+G,MULC,N/*##BGEI5(7ZO%'F<V-*3!
M>8D#%[B_UT"\WA@0U\P?YKC8W@[G!SUCNOH:Q<-N(MOSTY1=>(KUPLA4YXM@
M;AN,L/+-LFPO$2DRG(\=+DN1'NCS++24(>@--LD(>>#G'1!9S<X!)Q??]I&,
M&-HZ*@<\-AT$.YCL0 1!CK!ML+Z+KN+H<3:RT^X'EIESDN+Y>0K4)CVUE*?8
M05$;(1L;\ZN;].R,LT"9Z[W-UL"D'0"4@@ :!([CF![^9"OF&J@B1 Z?4?13
M:>U_,$#U_E?-[D"&UG''6QD;=OF.X1FRT/I?<CJ6];+]CB4H0T03H8(TZ^VP
M>?F6E:TDO(*X]H-#_9[3JPNQ-H(((M<R)U_/+[-+J?M7B08FH:+F1:9:6N-P
M0;V.N+B0N]8_.:N%EM4]*T+]<@1GN= 6&U<[#:R4!:4J" #L<P! /M:.P,N'
MJMJ4:;P9EH$P1<"XN!]+KT:["RM581!:]P(M:_0D:X!,*;K=8I1$HB41*(E$
M2B)1$)UUIA%9SHUS<W38&^O4GH-=-G>^FM[\J(H*^Y%9K%&,BYSFHX 4IMD!
M;TF24)*BW%B-)7(E.$#HW':<7YA.NM<]7B*=(27"=!!)\@"?EYX6U+AZM9P:
MQI,WDP !.KC8'H3/1:7ZUG.3O@VEEO%;*P^TM,ZZQFIUTO$=QI3BE,6U:D(M
M20LLC<XNS%)+B51HQ0DKX_><;Q!FE_*8#9S@"7!V#R@R!K\4$2NLT^#X>U1W
MOZA_4QG,&TB-"[#B<RTD*31B^3+:*)>97!QQ33[1=B0;?#5_&%/@N#E;<TN.
ME*@DD$%2ME)'0:BAQ)_XE8N.[1 C01T,S?KA8NKT"?AH -!$ F?EU[J]6%K?
M:\*7?LC?YFV&RI-R$96XX2"YS14,\KCY3SO*'1:E*T$I( @\#S$EU6II^DP+
M#]AXW6C>.-, ,HT3$W<P.=F<D>4$V Q"M:X?VA*UN./WR2I4V1- D7RXK;0\
M^LE;:4>M) CHYB&6 "TVD!*4A(%&>SJ322:E5TF8<[>^?7S4GVE6(@4Z B8_
MEMU^GJRHUPSP]I!2JRMR IAR,M$R5,F!;#A47&EF5(=Y@YSDJWY['\T];-X#
MAVQ(<_\ [G$[WS$18B\_)9GCN(N X-'1H! Z$+VQ\#Q&&ZY(CXMCS<ATM*>?
M19[>F0\8R$HCEQX,AQTLMI#;7B+]@ <A0.AU'"<,(BDRV/A'SM?>_P!++,\7
MQ)F:S[[.(\K@>)OU6Q-6]AG8;CM-;*E'PT(2.91VI0"=>TL]2>A.^JCJK#AJ
M(,A@!Z #;8= J&M5,S4<9M=Q.H.IOC65[4MA)T D#E4.V^I(UO8Z^?R5J&M&
M@\?7T69),7.9];*\) )Z#7370>[KV'^?*I@;#R"A5T =@ 'WZ&Z0-AY!%6I1
M*(E$2B)1$HB4105[^\0OQW:OTUJI&'=ON%!RWO\ 8J<5V/S'\U0I4!;01=;V
M"-'Q8!^@PV-?7HT1;!1%\Z^E" .%K[Q4X@1\AQI[;,A$1[8O$1"0U)<*4,N%
M2P$K)'<CSK'B&<]"J+_IFW1P/[^&UE#'M97I.<[E .;[.M:]^B[M9B%6V$H!
M0YH<51"UAQ>RPC^<H;!.M;5OJ=@=$@F:-Z3/^T?+ZJ[S+W$8)D6(L<9]>:E*
MU54HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B* NWW^R_
MC57]S)HI&?!WT*^#?3]]'Z9QDP>TWA7'G$>"&-8:ZIW.'^)^*8_F_">_8M,N
M-JD3(N9XUEURM^+R F5!B>IR;PIY+3CA;:2VZZEP<SFS58\X+FA@.?>2"T1D
M_%]@%HU\4WMT+'!YM :0>8R<P),V&]KKH_HE<+X/"/@?C6%V[,.'&<18^6RI
M3-]X587B_#O"G#+G)6J-;L4PZ3+L4!Z,0L2DQ7E*>>4IYW^,"A7?7>7N:2WE
M^ -@V-IN!X:0>D+EHM#0^X-Y'+,3:03K:2+G1?8AZIZ>:E_E;56*U4+C@/J3
MQZ:]>G_/TF/_ *Z*K/TCQ^I6P=?DUT_QW^36OIHK+AM]:DP^.F+K0&A;<DX:
MYG;+@5C:G;C9;[B4ZQLA/901!NF5.!&E=U'7*I93HY@J<+5:1/+.EK@YO?-_
M!</.:7M*@0+U6N /_86NS&Q.^+V6V\.'WU8K B2ERW)5I=GV60_-CB.\^_:9
MS\%U\LH2&T-O*8*FE)Y6W&EH4CHK0\O@+4&T_P"JFX@R",$@QKY@>(7M<<#[
M\O,#WP#X$B)$P9B?"=\771!V'ET%>@N-5HB41*(E$2B)1%87$C?7S">A!ZDZ
M\B==>GM:HB\,VZ0;<P])FR68C#*5*<>DN-LM)2D$J45N*"=  G?8A)UO1K.I
M5ITA-1[6VFYCUZ.%>FQ]5W+3:7'8"?7H+GJ<BR#*SK#X:8=J>80XUE=Y9=;9
M>7XY0XW!LKJ6)\E'A(6MN=(,:(YSMJC^LLK#AX75Z]<_R&13Q[QUFQ.FI^AQ
M8Y[30H<, [B'A[R+4:?Q&;W<XP&QL)D!35GP:WVV8;I,<>O=Z4M]T7>[*3*E
MQA(Y?$BP"6PF##]E(3'CA*=)'.IQ0YJV9PP!YJ@YGF[INW,VV/SZK*IQ=1S/
M=,_ETP9#6YQ!DB";$WUVU&[(1R=/+20.I(Z#W: 'T?776  ( @+D[J^I1*(K
M0.O,>_4#1.M;Z;'O]_>B*ZB)1$HB41*(E$2B)1$HBH#L CL0#]=$5:(J$Z&]
M$_,-GZJ(A(! /]8D#Z!NB*$O0VS! _#=J_3&JD8=V^X4'+>_V*FSV/S&H4J#
M@=;K>S_[RW)T>AZ0FNNO=UZ&B*=/3_/^?IHB^>_2?MB;MP=R6.I+:@R[;)@#
MW-X"E1+A&D)+Q;YEB.%(27E(!6$;Y$K4.6H<7!C^7):0)QXV.VWB,K"LP.+)
M) #VXSD^8O>XMLNMX5(];Q:P2/\ 5R';-;E[AEU40DL J]74\A#Q:V=H+J$K
MY"DJ2DG0QX<DTFR!:1;O?3UL%TN !@;#Z CY=HPMIK=52B)1$HB41*(E$2B)
M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(H"[??[+^-5?W,FBD9\'?0KXU^Z
M*VF[7[T0>,=LL^-LY7,?M=H4;6Y!OUQ4B''O]J>GW)B#C"',CDR[3";?GQ46
M=AV<F0RVXRTLI*:Y.()#^'.HKTB#L?>-@QF,:WT(6U$ ^\!$S3J B8D<AUBT
MW^4[KYK^YC7#,[9P]R3 ;MPPR'AWAF)Y=99F+NY1'R-R]7^3=K?$G9+>+A?,
MEY9]W7)O"I8:#C#+D&,Q&9<0$[6/3J#FILJ.LXD@";D?W1L;]=<+B@,JN;2N
MP0>Y),]1&<"1:)B?T]B<2<)GY&O$861VN3D+2UH<MS,IMYYMU,-^867/"*DI
M<]58?D!/-S*:9=6!RH41S-)<)B.GB!;>Y6CR&YUM:+6)SV!-I4_C2@JWN+!!
M"ILX@CL=S'SL>\$$:4.BDZ(/D)1GZ<S<W\3],>"V&BLN(\3UM0,QX2WQTJ'J
MN7R+.D!+A2H9%C]VMW*YRI*>0OF.L%71*VQO^<"G>FX^ZJM&7 : _+/7;>\1
MYG%CEXGA*T_HJ\A&X>TC;0@1W,76P88EV'>LZMKJ6VTMY(FYPDB4)#BXMWMT
M.0M]Q',I43GN;=S0VA26VRAO8"MUXO EPK<6QPB*A<#H>8Z  # [VDKZ/C8=
M2X.HTS-$,<(B"T"9)-Y^1E="5.80\W'6M >=*@VWXB.=SD 4LH22.?D"AS\N
M^4D[  W7>:K YK"X![P2&S<P 3&^<A<(:XM+@# R8,>>)SY6E>RM%5*(E$2B
M+&IP)5RZ\B22=?0.G4FHO)MV.Z6QKMT]>L+ ],:CH6X^I#3;:0I;CBTH0E)T
M"5*/0<I())('*=@E0*:JZHQ@+GN#0+R3IO;12UI<8:"3L!)\ESM[,I5[?=@8
M3;U7-X.3(DF_RD>%8;3+8;24HD)6XS.N2EN*0$,VMM;3B0XIZ7'\/2O/?Q9K
M.Y>'8Y^G.00T'0ZS,8U7<.%IT0#Q=0,)AS:3!S/<")_58";:.@R-97HMV"(7
M*;N643SD5T0XQ*:3*0E-M@S&VUM^-;;:5+:CE*5K*%.%UT>RKQ/$3SU:EP;G
M$/XEXJO:06@MAMH-Q)BXTM862KQLL]S08VE1$@<H'O")$<U0"7$$'0770&V
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MM"5/S"&^0*"([2'5MG.GPE6JX/XIQQ>F#_+Z  W,;SJ;E:.XME EO!M+!?\
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M<D.2EM%#TI;12I]QQ?5)5[7+OE2D"&^SZ#7<T.-KR]U[SB8Z=K+-W&<0^9>
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ML1;E%>CL2HEWM[2GGG$PI3;ZF%)4ZLLS8TN.5'D35N&XA[G.I53-1I@F")$
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M?HN6\%2V,)7':4A28.5YW;0I!'+_ ";FM_@!/*/O9"8PVCIR$E.ARZ'1Q/\
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M:E08,>,X4\RCR%UILK*=GF()/M+44J':J.JO<(<XF#.VD+II\+0I&64FM)U
M .^0 5M#0"=I  \]#RWOIUZZ T1OONLKR9-K1TA;@ 8$++4J4HB@+M]_LOXU
M5_<R:*1GP=]"I^BA:U?1XB;<@+4@NWF(VE:" M*E(> 4@J2I*5I/M(4I) 4
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M/MCX,L>X25\G5(-W]DZ"T BK\O#-'ZW/(O$&"=B1IG&FV3D:GM*M/+290:1
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MLL+!TI!   6$ GS^^=5,DCETV\([Z??*\2.%7#5N$[;48)BB8#]@:Q5Z&+)
M]6>QIAU3[-A=9\#D<M+3RUNMP%@QD.*4M+84HDE4 "P^I[K51Z/7 UF/)@,\
M)>'S<&8J J7$3B]J#$A=L+AMJGVC&Y%F&77!%4H'P/$64 <RMC\0:#<-,C2#
M,Z9O>\H !CUW6G6?T5>#%IR.^W].+1)S=]M_P5(L-PMN/JQZ-;2B,R+>PQ%L
MD6<_;VD1(R8UON5QGP(:F&G(42.ZVE8&^=Y\;7^0]2I72;SP2X09%!L5NOW#
M3";Q Q>.[&QN'<\=MDR/86'DI#K=J:D1UH@I<2D)7ZN&RI.TD\JE S)F=5$
M"!89@$B>^^5I^3^C=P<R2S72SMX59,=5=8%OMLNZXQ9+'#NCEKM<F%+B6U;D
MJU3X<JWH=@P]P9T*5!=;81S-;2-5,B.6T$6MC]D(#@01(((.<'J(*V2Q<%>&
MEILF'V!>)VF[Q,$FN73%'KW;;;,E62Z.+6ZY=+8&X<>-;)KCBU_QMLC0VFDG
MPF6FD'EJQ<7'F)DD1)S$1]/4J&L:T<H%I!R9D$$$GP'DK[UP%X*Y'/N-TOW"
MS!+Q<KL\)%TGW'&K7*EW!]*FEI=F2'HZG9#B7&6G$J=4HI=0EP:<]JJ@ 3&K
MN8W)O$3?%M!;HK1^/-2V'\(^%_#Z5+FX-@&)XE+GQ(\&;(Q^R0;4]*A1%.KC
M1'UPV6E.1V%O/+;942A*W7%A/,M1-R]SLF5'*VU@(F($1.8C$Z_NNAI2$C0&
MAW[DGZSL]!H#W  #0 %54KFV?8"SG+MC+V39ACOP#=&;LVG$\BF6!-R6T$<L
M*\B+H7"VK*0%Q7?845*!/<5Y?M#V=_'%D5ZU+E()%-W*._>W4B\1*[.$XL\-
MS_RJ53G$?&P.\YR+X-LWNM!' F&B# @?Z1^+Q1!>OD@2%9[=3-D_P@ANPW&9
MKZDI<D,6P.J?L;3@(MLQ")$<\Z0*\\^PQ '\7Q) )OSF\X.U^@&>JZQ[3/,7
M&A0),6+6X)TVZC018PH__P##M"$!< \4N-8\2T&T"4>)%X]="4W!%P,Y$@D*
M%T"V_5%3P/%-O4N(1X2BJLF_^FN5I'\=Q,P8/.9DXL;1TQJ;K0^V2?\ Y7A^
MG\MMOSWRI!7 J(8%S@?Z1N+@]?<L3WK2,^N:)D)-BC,Q4-6Z1KFA,7-+(=OC
M:!_*4A;C\@AQ6CLWV&64C2'%5W$\OQ.<?Z2"3B+@6R!((@A8GVF><5/<4;<P
M+>00>81,#K!\UNUOX486J(B+D%K;S9]J/?H2+KFK3&1W5%LR26B7=;*W/N##
MC[=F>4VRPFV@B,(L:.P4+;:!KV.$X<\-3:SF+BT9-SKKZD:+@KUC6>7EK6R;
M!H  %] -=>R]UYX1\+LBEQ)]]X?XC=IL"T.V"%*GV*WR7XMC>:6P[:6''&%*
M;M[C#KK"HB2&2PZZSR>$XM"NO#N;609ZC!VU6)N"#@]-\]5XCP2X0E"&U<-<
M+4VU:&+ TVO'[<MMJR1I,>9'M32%,%+4!B7%C268J EIMZ.RXA(4V@B9/,7S
M\1,SUB)V!C900""#@B#VS]E6]\$N$&2WUO)\@X:85>LB:CQ8C=[N6/6V9=$Q
M87)ZI&$U^.N1X$?PV_"9*RVGPT:3[*=0+<T ?&076R1B?QA3'Z/] AO0??QG
M38+G68^BUP;RM=M5_!2%CS5KOLC(%1\9M&.PX]RNDML-2)5R8GV.Y-+E.-:0
MBYPDP;JPAYY$>XLAU8,4RYCBX&+VMYZ=AX6W,/:'M@^.@Z8B/178F>'N#M7I
MO)DXI8SDB;$UC7\('+=&<O:[ TE01:';FMM4QV .=9,9;RFE%2B4DFK$R7'^
M_P#5%@;SC3P2!#1_8(;TM!^6\K0GO1G]'N0TEE_@QPV=:3XG*A6)6<A)=0TV
MZ1_JN]N(890X=[6EM 5O0J&GDGEM.; _65#FM? < 0,#'TA='Q'!\.P&V.6;
M"<9LF*6EV;)N+EML-NC6R"NX35!<N:J-$;::5*E* +[Y3XKI2GG4K0U))<9-
MSO;[=U( $QKFY]=]]5M-0I2B)1%"7C[U!_'=K_3&ZD8=V^X4'+>_V*F^]0I4
M#;B3=;X3W\: /H$-G0HBGJ(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41
M*(E$2B)1$HB41*(E$2B* NWW^R_C57]S)HI&?!WT*GZ*% W6-)D(B+B-I>=B
MW"+,#;SW@)4ADK)2'>1S2E<_+U0K?;0)!!$3)O1V?@B."='E^%3S =?]^&-@
M]SYCITHBN];O0[VAC1\S=-]>P'L0U'J3YZWY=:(K3+O![VMA!UU'PMR^9ZZ5
M"![?10=;(JB5>1VM3"OE^%5*_*F$4_5U]XHBM,F\?@U@?)\+@:^A4/F^OK1%
M?ZS>]?T2SK7?X63V^?U7\M$5GK5Y'46QA1_W?A=)W] ADGZ.M$5QF7CSM+ !
M_FGX54G?TJA)';Y0/GJ+SBVZ()=[\[1'(/8_"I/3_P"2&KO[^WRU*(9EZV/Y
M'8/RBZ+T/GW!!^H&E_1_9$$N\'1%IC'78BZ.'7OT?4*(J^/>#U^"&=]3L7;6
MM]];A CW'=1?8>)_8HADWOK_ "2SK\;)[?/ZH#]/2I18_'NVM?!D?7N^%T:\
MS\3]Y/UFB*J9%X!]FV,$]3H7=!V?,D>I]?GHBN,F]>=J93\OPLD?1_LE$5OK
M-X_!S']L)_X.B)ZS>/P<Q_;"?^#HBN$J\:_HF,KOU-T4K>^AV4P2D].G0GH-
M'MJB+&7[L2=VN,-DDCX63W/??-"WOH![77IUHH@;#R5WCW3RM,8=-#^5T=-=
MO^9^7D*B^P\S^%*H'[J"";7&.O(W9O7G[X1'F?RT/8'OZ*8Q97F7=R-"V1D]
M=]+NV/S0A2^H'G/V"*WUF\?@YC^V$_\ !U**X2KR.UK85\INJE:_\$(@?3JB
M*AE7@GK;&$_)\+<OY%PP?R418_6;P"=6N/U/4_##8W\I_P!3^4]Z(LOKEWUK
MX)CCIK^F$?\ "C_"HOL//]D5OK-X_!S']L)_X.I1/6;Q^#F/[83_ ,'1$]9O
M'X.8_MA/_!T1/6;Q^#F/[83_ ,'1%<)-ZUTM3*A[_A9)_P#]2B+QR1=IKD1I
MVW,QVV;C"E.NBX^,>6,^V[H-^K-[)T >5>NQWWVO?3[_ +>H1;1Y:WUUW^CO
M[Z(H&V@_"E\5[WX ^3:83&]#Y=[/RT3UZ\U/T1*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$4!=OO]E_&JO[F312,^#OH5/T4)
M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$5#V/S&B+7'(5S:F294.3#2W,6PHHE-/.+0MB.$$I4VL )
M4AOFUK^<2/.B++N^_&[5]FE_O*(F[[\;M7V:7^\HB;OOQNU?9I?[RB)N^_&[
M5]FE_O*(F[[\;M7V:7^\HB;OOQNU?9I?[RB)N^_&[5]FE_O*(F[[\;M7V:7^
M\HB;OOQNU?9I?[RB)N^_&[5]FE_O*(F[[\;M7V:7^\HB;OOQNU?9I?[RB)N^
M_&[5]FE_O*(F[[\;M7V:7^\HB;OOQNU?9I?[RB)N^_&[5]FE_O*(F[[\;M7V
M:7^\HB;OOQNU?9I?[RB)N^_&[5]FE_O*(F[[\;M7V:7^\HB;OOQNU?9I?[RB
M)N^_&[5]FE_O*(F[[\;M7V:7^\HB;OOQNU?9I?[RB)N^_&[5]FE_O*(F[[\;
MM7V:7^\HB;OOQNU?9I?[RB+SJ@W63)AN3)$$M1)!EI$9I]#BE%MU"0>=:D$*
*"^I/770^X$7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674083027744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">POS AM<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Scilex Holding Company<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">960 San Antonio Road<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Palo Alto<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">92-1062542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPrimarySicNumber', window );">Entity Primary SIC Number</a></td>
<td class="text">2836<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001820190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">516-4310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">Post-Effective Amendment No.&#160;1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">960 San Antonio Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Palo Alto<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">516-4310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Jaisim Shah<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPrimarySicNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Primary Standard Industrial Classification (SIC) Number for the Entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPrimarySicNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:sicNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674081646928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,921<span></span>
</td>
<td class="nump">$ 2,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">34,597<span></span>
</td>
<td class="nump">21,236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">4,214<span></span>
</td>
<td class="nump">1,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">4,049<span></span>
</td>
<td class="nump">4,810<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets:</a></td>
<td class="nump">46,781<span></span>
</td>
<td class="nump">29,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">722<span></span>
</td>
<td class="nump">772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">2,943<span></span>
</td>
<td class="nump">1,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangibles, net</a></td>
<td class="nump">36,485<span></span>
</td>
<td class="nump">40,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">13,481<span></span>
</td>
<td class="nump">13,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment', window );">Other long term assets</a></td>
<td class="nump">897<span></span>
</td>
<td class="nump">944<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">101,309<span></span>
</td>
<td class="nump">86,527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">40,954<span></span>
</td>
<td class="nump">8,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll</a></td>
<td class="nump">2,681<span></span>
</td>
<td class="nump">1,354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued rebates and fees</a></td>
<td class="nump">89,658<span></span>
</td>
<td class="nump">30,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AccruedExpenses', window );">Accrued expenses</a></td>
<td class="nump">7,408<span></span>
</td>
<td class="nump">3,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CurrentPortionOfDeferredConsideration', window );">Current portion of deferred consideration</a></td>
<td class="nump">491<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Debt, current</a></td>
<td class="nump">108,429<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">759<span></span>
</td>
<td class="nump">745<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities:</a></td>
<td class="nump">250,380<span></span>
</td>
<td class="nump">44,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LongTermPortionOfDeferredConsideration', window );">Long-term portion of deferred consideration</a></td>
<td class="nump">2,895<span></span>
</td>
<td class="nump">3,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermDebtNoncurrent', window );">Debt, net of issuance costs</a></td>
<td class="nump">17,038<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liabilities</a></td>
<td class="nump">1,518<span></span>
</td>
<td class="nump">1,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">2,237<span></span>
</td>
<td class="nump">665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">274,247<span></span>
</td>
<td class="nump">50,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (See Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' (deficit) equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value, 45,000,000 shares authorized; 29,057,097 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 740,000,000 shares authorized; 160,084,250 shares issued and 100,015,665 shares outstanding as of December 31, 2023; 141,348,856 shares issued and outstanding as of December 31, 2022</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">407,813<span></span>
</td>
<td class="nump">412,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(490,245)<span></span>
</td>
<td class="num">(375,914)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost; 60,068,585 shares and nil shares as of September 30, 2023 and December 31, 2022, respectively</a></td>
<td class="num">(90,522)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' (deficit) equity</a></td>
<td class="num">(172,938)<span></span>
</td>
<td class="nump">36,239<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' (deficit) equity</a></td>
<td class="nump">$ 101,309<span></span>
</td>
<td class="nump">$ 86,527<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CurrentPortionOfDeferredConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current portion of deferred consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CurrentPortionOfDeferredConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LongTermPortionOfDeferredConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term portion of deferred consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LongTermPortionOfDeferredConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets, excluding property, plant, and equipment and other property and investments, that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Charges and Other Assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674082044832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">45,000,000<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">29,057,097<span></span>
</td>
<td class="nump">29,057,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">29,057,097<span></span>
</td>
<td class="nump">29,057,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">740,000,000<span></span>
</td>
<td class="nump">740,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">160,084,250<span></span>
</td>
<td class="nump">141,348,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">100,015,665<span></span>
</td>
<td class="nump">141,348,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock shares</a></td>
<td class="nump">60,068,585<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674081580224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenue</a></td>
<td class="nump">$ 46,743<span></span>
</td>
<td class="nump">$ 38,034<span></span>
</td>
<td class="nump">$ 31,317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">15,681<span></span>
</td>
<td class="nump">10,797<span></span>
</td>
<td class="nump">3,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">12,746<span></span>
</td>
<td class="nump">9,054<span></span>
</td>
<td class="nump">9,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">119,641<span></span>
</td>
<td class="nump">64,895<span></span>
</td>
<td class="nump">50,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible amortization</a></td>
<td class="nump">4,106<span></span>
</td>
<td class="nump">3,922<span></span>
</td>
<td class="nump">3,738<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total operating costs and expenses</a></td>
<td class="nump">152,174<span></span>
</td>
<td class="nump">88,668<span></span>
</td>
<td class="nump">67,155<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(105,431)<span></span>
</td>
<td class="num">(50,634)<span></span>
</td>
<td class="num">(35,838)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (income) expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Loss (gain) on derivative liability</a></td>
<td class="nump">512<span></span>
</td>
<td class="num">(8,310)<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ChangeInFairValueOfDebtAndLiabilityInstruments', window );">Change in fair value of debt and liability instruments</a></td>
<td class="nump">7,189<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">(Gain) loss on debt extinguishment, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(28,634)<span></span>
</td>
<td class="nump">12,463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NotesPrincipalIncrease', window );">Scilex Pharma Notes principal increase</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="nump">1,068<span></span>
</td>
<td class="nump">9,604<span></span>
</td>
<td class="nump">11,764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Loss on foreign currency exchange</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (income) expense</a></td>
<td class="nump">8,887<span></span>
</td>
<td class="num">(27,274)<span></span>
</td>
<td class="nump">52,581<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(114,318)<span></span>
</td>
<td class="num">(23,360)<span></span>
</td>
<td class="num">(88,419)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (114,331)<span></span>
</td>
<td class="num">$ (23,364)<span></span>
</td>
<td class="num">$ (88,424)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders - basic</a></td>
<td class="num">$ (1.28)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.67)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders - diluted</a></td>
<td class="num">$ (1.28)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.67)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted Average Number of Shares Outstanding, Diluted [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares during the period-basic</a></td>
<td class="nump">130,298<span></span>
</td>
<td class="nump">134,226<span></span>
</td>
<td class="nump">132,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares during the period -diluted</a></td>
<td class="nump">130,298<span></span>
</td>
<td class="nump">134,226<span></span>
</td>
<td class="nump">132,858<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ChangeInFairValueOfDebtAndLiabilityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value Of Debt And Liability Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ChangeInFairValueOfDebtAndLiabilityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NotesPrincipalIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes principal increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NotesPrincipalIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674080969456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' (Deficit) / Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred Stock Member</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Treasury Stock</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2020</a></td>
<td class="num">$ (141,683)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 122,430<span></span>
</td>
<td class="num">$ (264,126)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,858,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">5,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AdjustmentToSharesIssuedInSemnurAcquisitionValue', window );">Adjustment to shares issued in Semnur Acquisition</a></td>
<td class="nump">409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(88,424)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(88,424)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2021</a></td>
<td class="num">(223,876)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">128,661<span></span>
</td>
<td class="num">(352,550)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,858,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Shares issued pursuant to the terms of the Debt Exchange Agreement, (In shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,057,000<span></span>
</td>
<td class="nump">2,906,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Shares issued pursuant to the terms of the Debt Exchange Agreement</a></td>
<td class="nump">289,733<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Shares issued as a result of the Business Combination, net of transaction activities, Amount</a></td>
<td class="num">(8,706)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(8,707)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Shares issued as a result of the Business Combination, net of transaction activities, Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,133,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement', window );">Shares issued to Yorkville pursuant to Yorkville Purchase Agreement, Amount</a></td>
<td class="nump">1,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares', window );">Shares issued to Yorkville pursuant to Yorkville Purchase Agreement, Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">5,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised</a></td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue', window );">Aardvark SP-104 license transfer from Sorrento, net of discount</a></td>
<td class="num">(4,127)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,127)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_Adjustmenttoadditionalpaidincapitaldiscountamortization', window );">Aardvark SP-104 license transfer from Sorrento</a></td>
<td class="num">(35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(23,364)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,364)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">36,239<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">412,136<span></span>
</td>
<td class="num">(375,914)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,057,000<span></span>
</td>
<td class="nump">141,349,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ValueIssuedUnderStandbyEquityPurchaseAgreements', window );">Shares issued under Standby Equity Purchase Agreements</a></td>
<td class="nump">34,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">34,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreements', window );">Shares issued under Standby Equity Purchase Agreements (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,218,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">14,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised</a></td>
<td class="nump">$ 614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (in shares)</a></td>
<td class="nump">365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IssuanceOfPennyWarrants', window );">Issuance of penny warrants</a></td>
<td class="nump">$ 10,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ConversionOfConvertibleDebenturesIntoCommonStockValue', window );">Conversion of convertible debentures into common stock</a></td>
<td class="nump">7,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ConversionOfConvertibleDebenturesIntoCommonStockShares', window );">Conversion of convertible debentures into common stock, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">632,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RetainerSharesIssuedValue', window );">Retainer shares issued</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RetainerSharesIssued', window );">Retainer shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IssuanceOfCommonStockUponWarrantsExerciseValue', window );">Issuance of common stock upon warrants exercise</a></td>
<td class="nump">521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IssuanceOfCommonStockUponWarrantsExerciseShares', window );">Issuance of common stock upon warrants exercise, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DisbursementOfFundsToSorrentoAmount', window );">Disbursement of funds to Sorrento Amount</a></td>
<td class="num">(20,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock in connection with Settlement Agreement</a></td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock in connection with Settlement Agreement, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue', window );">Repurchase of Treasury Stock, Preferred Stock, and warrants</a></td>
<td class="num">(143,721)<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53,196)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (90,522)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares', window );">Repurchase of Treasury Stock, Preferred Stock, and warrants, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60,069,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(114,331)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(114,331)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2023</a></td>
<td class="num">$ (172,938)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 407,813<span></span>
</td>
<td class="num">$ (490,245)<span></span>
</td>
<td class="num">$ (90,522)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,057,000<span></span>
</td>
<td class="nump">160,084,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60,069,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment To Additional Paid In Capital License Transfer Net Of Discount, value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AdjustmentToSharesIssuedInSemnurAcquisitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment to shares issued in Semnur Acquisition value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AdjustmentToSharesIssuedInSemnurAcquisitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_Adjustmenttoadditionalpaidincapitaldiscountamortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>AdjustmentToAdditionalPaidInCapitalDiscountAmortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_Adjustmenttoadditionalpaidincapitaldiscountamortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ConversionOfConvertibleDebenturesIntoCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of Convertible Debentures Into Common Stock, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ConversionOfConvertibleDebenturesIntoCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ConversionOfConvertibleDebenturesIntoCommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of Convertible Debentures Into Common Stock, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ConversionOfConvertibleDebenturesIntoCommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DisbursementOfFundsToSorrentoAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disbursement of funds to Sorrento Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DisbursementOfFundsToSorrentoAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_IssuanceOfCommonStockUponWarrantsExerciseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Common Stock Upon Warrants Exercise, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_IssuanceOfCommonStockUponWarrantsExerciseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_IssuanceOfCommonStockUponWarrantsExerciseValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Common Stock Upon Warrants Exercise, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_IssuanceOfCommonStockUponWarrantsExerciseValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_IssuanceOfPennyWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Penny Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_IssuanceOfPennyWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RetainerSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Retainer shares issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RetainerSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RetainerSharesIssuedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Retainer shares issued value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RetainerSharesIssuedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued to Yorkville pursuant to Yorkville Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued to Yorkville pursuant to Yorkville Purchase Agreement (In Shares)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SharesIssuedUnderStandbyEquityPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued under Standby Equity Purchase Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SharesIssuedUnderStandbyEquityPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Repurchase of Treasury Stock, Preferred Stock, and warrants, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Repurchase Of Treasury Stock Preferred Stock And Warrants Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ValueIssuedUnderStandbyEquityPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>value issued under Standby Equity Purchase Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ValueIssuedUnderStandbyEquityPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674081850464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (114,331)<span></span>
</td>
<td class="num">$ (23,364)<span></span>
</td>
<td class="num">$ (88,424)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used for operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">4,146<span></span>
</td>
<td class="nump">3,961<span></span>
</td>
<td class="nump">3,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">3,142<span></span>
</td>
<td class="nump">7,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NotesPrincipalIncrease', window );">Scilex Pharma Notes principal increase</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount', window );">Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(21,190)<span></span>
</td>
<td class="num">(12,487)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">(Gain) loss on debt extinguishment, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(28,634)<span></span>
</td>
<td class="nump">12,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NonCashOperatingLeaseCost', window );">Non-cash operating lease cost</a></td>
<td class="nump">507<span></span>
</td>
<td class="nump">492<span></span>
</td>
<td class="nump">372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">14,596<span></span>
</td>
<td class="nump">5,280<span></span>
</td>
<td class="nump">5,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities', window );">Issuance of shares under Settlement Agreement</a></td>
<td class="nump">750<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Loss (gain) on derivative liability</a></td>
<td class="nump">512<span></span>
</td>
<td class="num">(8,310)<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ForfeituresOfPrivateWarrants', window );">Forfeitures of private warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,697<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ChangeInFairValueOfDebtAndLiabilityInstruments', window );">Change in fair value of debt and liability instruments</a></td>
<td class="nump">7,189<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivables, net</a></td>
<td class="num">(13,361)<span></span>
</td>
<td class="num">(6,968)<span></span>
</td>
<td class="num">(1,142)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(2,838)<span></span>
</td>
<td class="nump">1,184<span></span>
</td>
<td class="num">(1,417)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Prepaid expenses and other</a></td>
<td class="num">(441)<span></span>
</td>
<td class="num">(2,629)<span></span>
</td>
<td class="nump">1,479<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="nump">855<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="nump">19,880<span></span>
</td>
<td class="nump">2,806<span></span>
</td>
<td class="num">(3,836)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IncreaseDecreaseInAccruedPayroll', window );">Accrued Payroll</a></td>
<td class="nump">1,327<span></span>
</td>
<td class="num">(2,379)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">2,310<span></span>
</td>
<td class="num">(123)<span></span>
</td>
<td class="nump">664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IncreaseDecreaseInAccruedRebatesAndFees', window );">Accrued rebates and fees</a></td>
<td class="nump">58,765<span></span>
</td>
<td class="nump">23,531<span></span>
</td>
<td class="num">(255)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="num">(711)<span></span>
</td>
<td class="num">(392)<span></span>
</td>
<td class="num">(80)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent', window );">Related party payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,125<span></span>
</td>
<td class="nump">18,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OtherLongTermLiabilities', window );">Other long-term liabilities</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used for operating activities</a></td>
<td class="num">(20,707)<span></span>
</td>
<td class="num">(21,258)<span></span>
</td>
<td class="num">(28,664)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition', window );">Acquisition consideration paid in cash for Romeg intangible asset acquisition</a></td>
<td class="num">(300)<span></span>
</td>
<td class="num">(2,060)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property, plant, and equipment</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used for investing activities</a></td>
<td class="num">(330)<span></span>
</td>
<td class="num">(2,067)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of shares under Standby Equity Purchase Agreements</a></td>
<td class="nump">35,458<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of Convertible Debentures</a></td>
<td class="nump">24,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of Convertible Debentures</a></td>
<td class="num">(15,625)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ProceedsFromIssuanceOfRevolvingFacility', window );">Proceeds from issuance of Revolving Facility</a></td>
<td class="nump">86,354<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RepaymentOfRevolvingFacility', window );">Repayment of Revolving Facility</a></td>
<td class="num">(69,001)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarlyRepaymentOfSeniorDebt', window );">Repayment of Oramed Note</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction', window );">Transaction costs paid related to the Business Combination</a></td>
<td class="num">(1,372)<span></span>
</td>
<td class="num">(2,949)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="num">(380)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DisbursementOfFunds', window );">Disbursement of funds to Sorrento</a></td>
<td class="num">(20,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount', window );">Cash consideration paid in connection with share repurchase</a></td>
<td class="num">(10,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TransactionCostsPaidInConnectionWithShareRepurchase', window );">Transaction costs paid in connection with share repurchase</a></td>
<td class="num">(1,987)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ProceedsFromTheBusinessCombination', window );">Proceeds from the Business Combination</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,375<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock options and warrants exercised</a></td>
<td class="nump">1,135<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">51,900<span></span>
</td>
<td class="nump">47,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSecuredNotesPayable', window );">Proceeds from related party note payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="nump">14,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherShortTermDebt', window );">Proceeds from other loans</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,857<span></span>
</td>
<td class="nump">47,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RepaymentOfPrincipalOnTheScilexPharmaNotes', window );">Repayment of principal on the Scilex Pharma Notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(84,808)<span></span>
</td>
<td class="num">(33,387)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ProceedsFromRepaymentOfLoansToPurchase', window );">Repayment on other loans</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(18,800)<span></span>
</td>
<td class="num">(48,832)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash proceeds from financing activities</a></td>
<td class="nump">23,582<span></span>
</td>
<td class="nump">21,171<span></span>
</td>
<td class="nump">28,163<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="nump">2,545<span></span>
</td>
<td class="num">(2,154)<span></span>
</td>
<td class="num">(501)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">2,184<span></span>
</td>
<td class="nump">4,338<span></span>
</td>
<td class="nump">4,839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">4,729<span></span>
</td>
<td class="nump">2,184<span></span>
</td>
<td class="nump">4,338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOperatingPaidInCash', window );">Cash paid for interest</a></td>
<td class="nump">1,426<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash financing activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of shares to B.Riley pursuant to B. Riley Purchase Agreement</a></td>
<td class="nump">1,869<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ConversionOfConvertibleDebenturesIntoCommonStock', window );">Conversion of Convertible Debentures into common stock</a></td>
<td class="nump">7,735<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification', window );">Right-of-use assets obtained in exchange for operating lease liabilities with lease modification</a></td>
<td class="nump">2,523<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OramedNoteIssuanceAtFairValue', window );">Oramed Note issuance at fair value</a></td>
<td class="nump">106,252<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OtherNonCashConsiderationInConnectionWithShareRepurchase', window );">Other non-cash consideration in connection with share repurchase</a></td>
<td class="nump">26,154<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses', window );">Excise tax in connection with share repurchase included in accrued expenses</a></td>
<td class="nump">1,310<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement', window );">Related party debt converted to equity pursuant to Debt Exchange Agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">289,733<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DeferredConsiderationForRomegIntangibleAssetAcquisition', window );">Deferred consideration for Romeg intangible asset acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,650<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount', window );">Promissory Note issued to Sorrento in exchange for the SP-104 license</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,162<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring', window );">Fair value adjustment to derivative liability in troubled debt restructuring</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,400<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ScilexPharmaNotesPrincipalIncrease', window );">Scilex Pharma Notes principal increase</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TransactionCostsObligationAssumedBySorrento', window );">Transaction costs obligation assumed by Sorrento</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,148<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquisition Consideration Paid In Cash for Romeg Intangible Asset Acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ChangeInFairValueOfDebtAndLiabilityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value Of Debt And Liability Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ChangeInFairValueOfDebtAndLiabilityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ConversionOfConvertibleDebenturesIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of Convertible Debentures into Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ConversionOfConvertibleDebenturesIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DeferredConsiderationForRomegIntangibleAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Consideration for Romeg Intangible Asset Acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DeferredConsiderationForRomegIntangibleAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DisbursementOfFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disbursement Of Funds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DisbursementOfFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Excise tax in connection with share repurchase included in accrued expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value adjustment to derivative liability in troubled debt restructuring</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ForfeituresOfPrivateWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Forfeitures of Private Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ForfeituresOfPrivateWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_IncreaseDecreaseInAccruedPayroll">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease In Accrued payroll</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_IncreaseDecreaseInAccruedPayroll</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_IncreaseDecreaseInAccruedRebatesAndFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Accrued Rebates and Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_IncreaseDecreaseInAccruedRebatesAndFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NonCashOperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash operating lease cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NonCashOperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NotesPrincipalIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes principal increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NotesPrincipalIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_OramedNoteIssuanceAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Oramed Note issuance at fair value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_OramedNoteIssuanceAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_OtherLongTermLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other long-term liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_OtherLongTermLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_OtherNonCashConsiderationInConnectionWithShareRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other non-cash consideration in connection with share repurchase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_OtherNonCashConsiderationInConnectionWithShareRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt discount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ProceedsFromIssuanceOfRevolvingFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance of Revolving Facility</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ProceedsFromIssuanceOfRevolvingFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ProceedsFromRepaymentOfLoansToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Repayment Of Loans To Purchase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ProceedsFromRepaymentOfLoansToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ProceedsFromTheBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from the Business Combination</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ProceedsFromTheBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Promissory Note issued to Sorrento in exchange for the SP-104 license, net of discount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party debt converted to equity pursuant to Debt Exchange Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RepaymentOfPrincipalOnTheScilexPharmaNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment of principal on the Scilex Pharma Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RepaymentOfPrincipalOnTheScilexPharmaNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RepaymentOfRevolvingFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment of Revolving Facility</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RepaymentOfRevolvingFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-of-use assets obtained in exchange for operating lease liabilities with lease modification</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ScilexPharmaNotesPrincipalIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Scilex Pharma Notes principal increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ScilexPharmaNotesPrincipalIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TransactionCostsObligationAssumedBySorrento">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs obligation assumed by Sorrento</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TransactionCostsObligationAssumedBySorrento</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TransactionCostsPaidInConnectionWithShareRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs paid in connection with share repurchase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TransactionCostsPaidInConnectionWithShareRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs paid related to the recapitalization transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The adjustment needed to reconcile previously recorded amounts to the actual aggregate amount paid, whether in cash or other consideration, to acquire all of the shares purchased under an Accelerated Share Repurchase arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarlyRepaymentOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the extinguishment of long-term borrowing, with the highest claim on the assets of the entity in case of bankruptcy or liquidation, before its maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarlyRepaymentOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the current portion (due within one year or one business cycle, whichever is longer) of the amount owed by the reporting entity in the form of loans and obligations (generally evidenced by promissory notes) made by the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperatingPaidInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income from investment paid in cash, classified as operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperatingPaidInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-21B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInsuranceSettlementOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from short-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSecuredNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings supported by a written promise to pay an obligation that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSecuredNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674083235264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of Operations and Basis of Presentation</a></td>
<td class="text"><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">1. Nature of Operations and Basis of Presentation </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Organization and Principal Activities </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scilex Holding Company (&#8220;Scilex&#8221; and together with its wholly owned subsidiaries, the &#8220;Company&#8221;) is the successor entity to Vickers Vantage Corp. I (&#8220;Vickers&#8221;), a special purpose acquisition company. The Company is an innovative revenue-generating company focused on acquiring, developing and commercializing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-opioid</div> pain management products for the treatment of acute and chronic pain. The Company was originally formed in 2019 and currently has five wholly owned subsidiaries, Scilex Inc. (&#8220;Legacy Scilex&#8221;), Scilex Pharmaceuticals Inc. (&#8220;Scilex Pharma&#8221;), Semnur Pharmaceuticals, Inc. (&#8220;Semnur&#8221;), SCLX DRE Holdings LLC and SCLX Stock Acquisition JV LLC. The business combination with Vickers (the &#8220;Business Combination&#8221;) was closed in November 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company launched its first commercial product in October 2018, ZTlido (lidocaine topical system) 1.8% (&#8220;ZTlido&#8221;), a prescription lidocaine topical system that is designed with novel technology to address the limitations of current prescription lidocaine therapies by providing significantly improved adhesion and continuous pain relief throughout the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-hour</div> administration period. The Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> the exclusive right to commercialize GLOPERBA (colchicine USP) oral solution (&#8220;GLOPERBA&#8221;), a U.S. Food and Drug Administration (&#8220;FDA&#8221;)-approved prophylactic treatment for painful gout flares in adults, in the United States (&#8220;U.S.&#8221;). In February 2023, the Company acquired the rights related to ELYXYB (celecoxib oral solution) (&#8220;ELYXYB&#8221;) and the commercialization thereof in the U.S. and Canada. ELYXYB is a first-line treatment and the only <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ready-to-use</div></div> oral solution for the acute treatment of migraine, with or without aura, in adults. In April 2023, the Company launched ELYXYB in the U.S. The Company expects to commercialize GLOPERBA in the U.S. in the first half of 2024. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is currently developing three product candidates, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102</div> (10 mg, dexamethasone sodium phosphate viscous gel), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica for which the Company has completed a Phase 3 study <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;SP-102&#8221;</div> or &#8220;SEMDEXA&#8221;), <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div> (lidocaine topical system) 5.4% <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;SP-103&#8221;),</div> a next-generation, triple-strength formulation of ZTlido, for the treatment of chronic neck pain and for which the Company has recently completed a Phase 2 trial in low back pain, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> (4.5 mg, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-dose</div> naltrexone hydrochloride delayed-burst release low dose naltrexone hydrochloride capsules) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;SP-104&#8221;),</div> a novel <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-dose</div> delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia, for which Phase 1 trials were completed in the second quarter of 2022 and a Phase 2 clinical trial is expected to commence in 2024. Since inception, the Company has devoted substantially all of its efforts to the development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104,</div> and the commercialization of ZTlido. In 2024, the Company will also devote efforts on the commercialization of GLOPERBA and ELYXYB. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Sorrento Chapter 11 Filing </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;13, 2023, Sorrento Therapeutics, Inc. (&#8220;Sorrento&#8221;), the Company&#8217;s then-controlling stockholder, and Sorrento&#8217;s wholly owned direct subsidiary, Scintilla Pharmaceuticals, Inc. (&#8220;Scintilla&#8221; and together with Sorrento, the &#8220;Debtors&#8221;), commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code (the &#8220;Bankruptcy Code&#8221;) in the United States Bankruptcy Court for the Southern District of Texas (the &#8220;Bankruptcy Court&#8221;). The Debtors&#8217; Chapter 11 proceedings are jointly administered under the caption In re Sorrento Therapeutics, Inc., et al., Case Number <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">23-90085</div> (DRJ) (the &#8220;Chapter 11 Cases&#8221;). While the Company was majority-owned by Sorrento, the Company was not a debtor in the Chapter 11 Cases. As of December&#160;31, 2023, Sorrento no longer holds a majority of the voting power of the Company&#8217;s outstanding capital stock entitled to vote. As of December&#160;31, 2023, the Company had a $3.2&#160;million receivable from Sorrento, which was fully reserved. The Company evaluates the collectability of this receivable on a quarterly basis. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position for the periods presented. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements include the accounts of the Company as well as its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Segments </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating segments are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assessing performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer, as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions. The Company is engaged primarily in the development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-opioid</div> products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single reportable segment. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of these consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Customer Concentration Risk </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to April 2022, sales to the Company&#8217;s sole distributor represented 100% of net revenue. In April 2022, the Company announced the expansion of its direct distribution network to national and regional wholesalers and pharmacies. The Company had three and four customers during the years ended December&#160;31, 2023 and 2022, respectively, each of which individually generated 10% or more of the Company&#8217;s total revenue. These customers accounted for 85% and 83% of the Company&#8217;s revenue for the years ended December&#160;31, 2023 and 2022, respectively, individually ranging from 22% to 32% and 19% to 24%, respectively. As of December&#160;31, 2023 and 2022, these customers represented 91% and 90% of the Company&#8217;s outstanding accounts receivable, respectively, individually ranging between 24% and 36% for both periods. Additionally, during the years ended December&#160;31, 2023 and 2022, the Company purchased ZTlido inventory from its sole supplier, Itochu Chemical Frontier Corporation (&#8220;Itochu&#8221;). This exposes the Company to concentration of customer and supplier risk. The Company monitors the financial condition of its customers, limits its credit exposure by setting credit limits, and has not experienced any credit losses during the years ended December&#160;31, 2023 and 2022. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial assets and liabilities are recorded at fair value on a recurring basis in the consolidated balance sheets. The carrying values of the Company&#8217;s financial assets and liabilities, including cash and cash equivalents, restricted cash, prepaid and other current assets, accounts payable and accrued expenses approximate to their fair value due to the short-term nature of these instruments. The derivative warrant liability associated with the Private Warrants (as defined below) is valued using the Black-Scholes option pricing model, which is further discussed in Note 4. The Company elected the fair value option to account for the Convertible Debentures (as defined below) in an aggregate principal amount of up to $25.0&#160;million that were issued in March and April 2023 </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and for the Oramed Note (as defined below) in the principal amount of $101.9&#160;million that was issued in September 2023 (see Note 7 titled &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Debt&#8221; </div></div>below). These instruments are measured at fair value on a recurring basis using Level&#160;3 inputs. The Binomial Lattice Model valuation technique and a discounted cash flow model were employed to measure the fair value of the Convertible Debentures and the Oramed Note, respectively. The Revolving Facility (as defined below) in an aggregate principal amount of up to $30.0&#160;million was issued in June 2023 (see Note 7 titled &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Debt&#8221; </div></div>below). The Company accounts for the Revolving Facility using the amortized cost basis and recognizes interest expense over the expected term using the effective interest rate method. The carrying value of the Revolving Facility approximates its fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. Assets and liabilities recorded at fair value are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels are directly related to the amount of subjectivity with the inputs to the valuation of these assets or liabilities as follows: </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1 - </div></div>Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2 - </div></div>Inputs (other than quoted prices included in Level&#160;1) that are either directly or indirectly observable inputs for similar assets or liabilities. These include quoted prices for identical or similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active; and </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3 - </div></div>Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Cash, Cash Equivalents and Restricted Cash </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments that are readily convertible into cash without penalty and with original maturities of three months or less at the date of purchase to be cash equivalents. The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents are valued at cost, which approximate their fair value. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Restricted cash as of December&#160;31, 2023 consist of deposits placed in a segregated bank account as required under the terms of the Credit and Security Agreement, dated as of June&#160;27, 2023, between Scilex Pharma and eCapital Healthcare Corp., which is discussed further in Note 7. Restricted cash is recorded as other long-term assets within the Company&#8217;s consolidated balance sheet. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that together reflect the same amounts shown in the consolidated statements of cash flows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:60%"></td>
<td style="vertical-align:bottom;width:13%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:13%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,921</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,184</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted cash</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">808</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash, cash equivalents, and restricted cash</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,729</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,184</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Accounts Receivable, Net </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounts receivable are presented net of allowances for expected credit losses and prompt payment discounts. Accounts receivable consists of trade receivables from product sales to customers, which are generally unsecured. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for expected credit losses within accounts receivable, net. The Company reviews </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for expected credit losses. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Inventory </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company determines inventory cost on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-out</div> basis. The Company reduces the carrying value of inventories to a lower of cost or net realizable value for those items that are potentially excess, obsolete or slow- moving. The Company reserves for excess and obsolete inventory based upon historical experience, sales trends, and specific categories of inventory and expiration dates for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-hand</div> inventory. Inventory costs resulting from these adjustments are recognized as cost of sales in the period in which they are incurred. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#8217;s judgment, the Company capitalizes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-launch</div> inventory costs prior to regulatory approval. As of December&#160;31, 2023 and 2022, the Company&#8217;s inventory was primarily comprised of finished goods. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment, Net </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment are carried at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally five to seven years. Leasehold improvements are amortized over the lesser of their estimated useful lives or the term of the respective lease on a straight-line basis.&#160;The cost of repairs and maintenance is expensed as incurred. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Acquisitions </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for business combinations using the acquisition method of accounting, which requires that assets acquired, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development (&#8220;IPR&amp;D&#8221;) projects and liabilities assumed be recorded at their fair values as of the acquisition date on the Company`s consolidated balance sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When the Company determines net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the transaction is accounted for as an acquisition of assets and, therefore, no goodwill is recorded and contingent consideration such as payments upon achievement of various developmental, regulatory and commercial milestones generally is not recognized at the acquisition date. In an asset acquisition, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> payments allocated to IPR&amp;D projects at the acquisition date and subsequent milestone payments are charged to expense in the Company`s consolidated statements of operations unless there is an alternative future use. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates. Intangible assets acquired in a business combination that are used for IPR&amp;D activities are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Upon commercialization of the relevant research and development project, the Company amortizes the acquired IPR&amp;D over its estimated useful life. Capitalized IPR&amp;D is reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill and Other Long-Lived Assets </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwill, which has an indefinite life, represents the excess cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if events occur </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div></div><div><div style="line-height:normal;background-color:white;display: inline;"></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">indicating the potential for impairment. The Company has one reporting unit. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company performs a quantitative goodwill impairment test. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative goodwill impairment test.</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluates its long-lived and intangible assets with definite lives, such as property and equipment, patent rights, and acquired technology, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-generic</div> and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of useful life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets&#8217; book value to future net undiscounted cash flows that the assets are expected to generate to determine if a write-down to the recoverable amount is appropriate. If such assets are written down, an impairment will be recognized as the amount by which the book value of the asset group exceeds the recoverable amount. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Contingent Consideration </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of contingent consideration liabilities assumed in business combinations is recorded as part of the purchase price consideration of the acquisition, and is determined using a discounted cash flow model or Monte Carlo simulation model. The significant inputs of such models are not observable in the market, such as certain financial metric growth rates, volatility rates, projections associated with applicable milestones, discount rates and the related probabilities and payment structure in the contingent consideration arrangement. Fair value adjustments to contingent consideration liabilities are recorded through operating expenses in the consolidated statement of operations. Other than contingent consideration that is accounted for in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480, Distinguishing Liabilities from Equity, and Topic 815, Derivatives and Hedging, contingent consideration arrangements assumed in an asset acquisition will be measured and accrued when such contingency is resolved. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Public Warrants and Private Warrants </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon completion of the Business Combination, the Company assumed public and private placement warrants to purchase Common Stock, each with an exercise price of $11.50 per share (&#8220;Public Warrants&#8221; and &#8220;Private Warrants&#8221;, respectively, and collectively, the &#8220;SPAC Warrants&#8221;) that were issued by Vickers in connection with its initial public offering (declared effective by the Securities and Exchange Commission (&#8220;SEC&#8221;) on January&#160;11, 2021) whereby holders of the public and private placement warrants are entitled to acquire ordinary shares of Vickers. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to the Business Combination, the Public Warrants were accounted for as equity per FASB ASC Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;815-40,</div> Contracts on an Entity&#8217;s Own Equity. Warrants classified as equity are recorded at their issuance cost and are not subject to remeasurement at each subsequent balance sheet date. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to the Business Combination, the Private Warrants were accounted for as liabilities per ASC Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40.</div> The Private Warrants are not considered indexed to the Company&#8217;s stock per ASC Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40</div> as the fair value calculation applicable upon a cashless exercise of a Private Warrant changes based upon the holder of the instrument, which is not an input to a valuation model for a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">fixed-for-fixed</div></div> option contract. Therefore, Private Warrants are recognized as derivative liabilities at their estimated fair value on November&#160;10, 2022, the date of the closing of the Business Combination, and are revalued at each subsequent balance sheet </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">date, with fair value changes recognized in the statement of operations. The Company estimates the value of these warrants using a Black-Scholes option pricing formula. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Debt </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may enter into financing arrangements, the terms of which involve significant assumptions and estimates. This involves estimating future net product sales, determining interest expense, determining the amortization period of the debt discount, as well as determining the classification between current and long-term portions. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Convertible Debentures and the Oramed Note </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has elected the fair value option to account for the Convertible Debentures (as defined in Note 2 &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidity and Going Concern</div></div>&#8221; below) that were issued in March and April 2023, as discussed further in Note 7. The Company has also elected the fair value option to account for the Oramed Note (as defined in Note 4 &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements</div></div>&#8221; below). The Company recorded the Convertible Debentures and the Oramed Note at fair value upon issuance with changes in fair value recorded as change in fair value of debt and liability instruments in the consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. Interest expense related to these financial instruments is included in the changes in fair value. As a result of applying the fair value option, direct costs and fees related to the Convertible Debentures and the Oramed Note were expensed as incurred. The weighted-average interest rates for the short-term loans, including the Convertible Debentures and the Oramed Note, were 13.55% and nil for the years ended December&#160;31, 2023 and 2022, respectively. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Derivative Liabilities </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Derivative liabilities are recorded on the Company&#8217;s consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Research and Development Costs </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company expenses the cost of research and development as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and preclinical materials as well as other contracted services, license fees and other external costs.&#160;Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with FASB ASC Topic 730, Research and Development. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The provisions of the FASB ASC Topic 740, Income Taxes, address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">740-10,</div> the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position.&#160;The Company has determined that it has uncertain tax positions. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">will be realized. As of December&#160;31, 2023 and 2022, the Company maintained a full valuation allowance against its deferred tax assets. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Leases </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company determines if an arrangement is a lease at inception. Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (&#8220;ROU&#8221;) assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and is reduced by lease incentives. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term in selling, general and administrative expenses. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Revenue Recognition </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s revenue is generated from product sales within the United States. The Company does not incur significant direct costs to obtain contracts with its customers. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from product sales is comprised of sales of ZTlido and ELYXYB. The Company&#8217;s performance obligation with respect to sales of ZTlido and ELYXYB is satisfied at a point in time, when control is transferred upon delivery of product to the customer. The Company considers control to have transferred upon delivery because the customer has legal title to the product, physical possession of the product has been transferred to the customer, the customer has significant risks and rewards of ownership of the product, and the Company has a present right to payment at that time.&#160;Invoicing typically occurs upon shipment and the length of time between invoicing and when payment is due is not significant. The aggregate dollar value of unfulfilled orders as of December&#160;31, 2023 and 2022 were not material. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenues from product sales are recorded net of reserves established for commercial and government rebates, fees and chargebacks, wholesaler and distributor fees, sales returns and prompt payment discounts. Such variable consideration is estimated in the period of the sale and is estimated using a most likely amount approach based primarily upon provisions included in the Company&#8217;s customer contract, customary industry practices and current government regulations. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rebates and Chargebacks </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rebates are discounts which the Company pays under either government or private health care programs.&#160;Government rebate programs include state Medicaid drug rebate programs, the Medicare coverage gap discount programs and the Tricare programs. Commercial rebate and fee programs relate to contractual agreements with commercial healthcare providers, under which the Company pays rebates and fees for access to and position on that provider&#8217;s patient drug formulary. Rebates and chargebacks paid under government programs are generally mandated under law, whereas private rebates and fees are generally contractually negotiated by the Company with commercial healthcare providers. Both types of rebates vary over time. The Company records a reduction to gross product sales at the time the customer takes title to the product based on estimates of expected rebate claims. The Company monitors the sales trends and adjusts for these rebates on a regular basis to reflect the most recent rebate experience and contractual obligations. Reserves for rebates and chargebacks are now separately presented as accrued rebates and fees under current liabilities within the Company&#8217;s consolidated balance sheet. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Prompt Payment Discounts </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company provides its customers with prompt payment discounts which may result in adjustments to the price that is invoiced for the product transferred, in the case that payments are made within a defined period. The </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">prompt payment discount reserve is based on actual gross sales and contractual discount rates. Reserves for prompt payment discounts are included in accounts receivable, net on the consolidated balance sheets. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Service Fees </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company compensates its customer and others in the distribution chain for wholesaler and distribution services. The Company has determined such services received to date are not distinct from the Company&#8217;s sale of products to the customer and, therefore, these payments have been recorded as a reduction of revenue. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Returns </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is obligated to accept the return of products sold that are expiring within six months, damaged or do not meet certain specifications. The Company may authorize the return of products sold in accordance with the term of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company estimates the amount of its product sales that may be returned by its customer and records this estimate as a reduction of revenue in the period the related product revenue is recognized. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Payment</div> Assistance </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients who have commercial insurance or pay cash and meet certain eligibility requirements may receive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-</div> payment assistance. The Company accrues for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payment</div> assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Stock-Based Compensation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, Compensation &#8211; Stock Compensation which establishes accounting for equity instruments exchanged for employee and consulting services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee&#8217;s requisite service period (generally the vesting period of the equity grant) or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee&#8217;s</div> vesting period. The Company accounts for forfeitures as incurred. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of determining the inputs used in the calculation of stock-based compensation, the Company determines the expected life assumption for options issued using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period since the Company does not have historic exercise behavior. Then the Company determines an estimate of option volatility based on an assessment of historical volatilities of comparable companies whose share prices are publicly available. The Company uses these estimates as variables in the Black-Scholes option pricing model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in our consolidated statement of operations. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Treasury Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company uses the cost method to account for repurchases of its stock. In the computation of net (loss) income per share, treasury shares are not included as part of the outstanding shares. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Net Loss per Share </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share attributable to common stockholders is presented in conformity with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method required for participating securities. Net loss per share has been retrospectively adjusted for all periods presented prior to the Business Combination. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method, basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share attributable to common stockholders adjusts basic earnings per share for the potentially dilutive impact of stock options and warrants. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the Company has reported losses for all periods presented, all potentially dilutive securities are antidilutive and accordingly, basic net loss per share equals diluted net loss per share. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Recently Adopted Accounting Pronouncements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2021, FASB issued Accounting Standards Updates (&#8220;ASU&#8221;) 2021-08, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Combinations (Topic&#160;805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;ASU&#160;2021-08&#8221;)</div></div></div>, which requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities in accordance with ASC Topic 606. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2021-08</div> is effective for fiscal years beginning after December&#160;15, 2022. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2021-08</div> should be applied prospectively to business combinations occurring on or after the adoption date. The Company adopted this guidance as of January&#160;1, 2023 and the adoption did not have a material impact on the Company&#8217;s consolidated financial statements. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2022, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2022-03,</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2022-03&#8221;),</div> </div></div>which clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered when measuring fair value. Recognizing such a restriction as a separate unit of account is also not permitted. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2022-03</div> is effective for fiscal years beginning after December&#160;15, 2023, with early adoption permitted. The Company elected to early adopt this guidance as of January&#160;1, 2023 and the adoption did not have a material impact on the Company&#8217;s consolidated financial statements. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674076132240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Going Concern<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Liquidity and Going Concern</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">2. Liquidity and Going Concern </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Management has assessed the Company&#8217;s ability to continue as a going concern for at least one year after the issuance date of the accompanying consolidated financial statements. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;17, 2022, the Company entered into a standby equity purchase agreement (the &#8220;Original Purchase Agreement&#8221;) with YA II PN, Ltd., a Cayman Islands exempt limited partnership (&#8220;Yorkville&#8221;). On February&#160;8, 2023, the Company entered into an amended and restated standby equity purchase agreement with Yorkville (the &#8220;A&amp;R Yorkville Purchase Agreement&#8221;), amending, restating and superseding the Original Purchase Agreement. On January&#160;8, 2023, the Company entered into a standby equity purchase agreement (the &#8220;B. Riley Purchase Agreement&#8221; and together with A&amp;R Yorkville Purchase Agreement, the &#8220;Standby Equity Purchase Agreements&#8221;) with B. Riley Principal Capital II, LLC (&#8220;B. Riley&#8221;). Pursuant to each of the Standby Equity Purchase Agreements, the Company has the right, but not the obligation, to sell to each of Yorkville and B. Riley up to $500.0&#160;million of shares of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;) at its request any time during the 36 months following the date on which the registration statement related to each such purchase agreement was initially declared effective by the SEC, subject to certain conditions, which are discussed further in Note 9. On, and effective as of, February&#160;16, 2024, the Company and B. Riley mutually agreed to terminate the B. Riley Purchase Agreement. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for Yorkville&#8217;s and B. Riley&#8217;s respective commitment to purchase shares of Common Stock at the Company&#8217;s direction, the Company issued 250,000 commitment shares to each of Yorkville (the &#8220;Yorkville Commitment Shares&#8221;) and B. Riley (the &#8220;B. Riley Commitment Shares&#8221;). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March 21, 2023, the Company entered into a securities purchase agreement with Yorkville (the &#8220;Yorkville SPA&#8221;), pursuant to which the Company would issue and sell to Yorkville convertible debentures in an aggregate </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">principal amount of up to $25.0&#160;million (the &#8220;Convertible Debentures&#8221;). As of December&#160;31, 2023, Convertible Debentures in the principal amount of $25.0&#160;million (for net cash proceeds of $24.0 million) were issued and sold pursuant to the Yorkville SPA, which is discussed further in Note 7. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;27, 2023, Scilex Pharma entered into a Credit and Security Agreement (the &#8220;eCapital Credit Agreement&#8221;) with eCapital Healthcare Corp. (the &#8220;Lender&#8221;), pursuant to which the Lender shall make available loans (the &#8220;Revolving Facility&#8221;) in an aggregate principal amount of up to $30.0&#160;million (the &#8220;Facility Cap&#8221;). The proceeds of the Revolving Facility will be used for (i)&#160;transaction fees incurred in connection with the eCapital Credit Agreement, (ii)&#160;working capital needs of Scilex Pharma and (iii)&#160;other uses not prohibited under the eCapital Credit Agreement. As of December&#160;31, 2023, the Company has an outstanding balance of $17.0&#160;million under the Revolving Facility. See Note 7 for additional discussion of the terms of the eCapital Credit Agreement. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;22, 2023, the Company entered into a Sales Agreement (the &#8220;ATM Sales Agreement&#8221;) with B. Riley Securities, Inc., Cantor Fitzgerald&#160;&amp; Co. and H.C. Wainwright&#160;&amp; Co., LLC (the &#8220;Sales Agents&#8221;). Pursuant to the ATM Sales Agreement, the Company may offer and sell (the &#8220;Offering&#8221;) shares of Common Stock up to $170,000,000 (the &#8220;ATM Shares&#8221;), through or to the Sales Agents as part of the Offering. The Company has no obligation to sell any shares of Common Stock under the ATM Sales Agreement and may suspend offers thereunder at any time. The Offering will terminate upon (i)&#160;the election of the Sales Agents upon the occurrence of certain adverse events, (ii)&#160;three business days&#8217; advance notice from the Company to the Sales Agents or a Sales Agent to the Company, or (iii)&#160;the sale of all $170,000,000 of shares of Common Stock thereunder. As of December&#160;31, 2023, no sales of Common Stock had been made under the ATM Sales Agreement. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, the Company&#8217;s negative working capital was $203.6&#160;million, including cash and cash equivalents of approximately $3.9&#160;million. During the year ended December&#160;31, 2023, the Company had operating losses of $105.4&#160;million and cash flows used for operations of $20.7&#160;million. The Company had an accumulated deficit of $490.2&#160;million as of December&#160;31, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has plans to obtain additional resources to fund its currently planned operations and expenditures for at least twelve months from the issuance of these consolidated financial statements through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions. The Company&#8217;s plans are also dependent upon the success of future sales of ZTlido and ELYXYB, among which ELYXYB is still in the early stages of commercialization, and the future commercialization of GLOPERBA. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although the Company believes such plans, if executed, should provide the Company with financing to meet its needs, successful completion of such plans is dependent on factors outside the Company&#8217;s control. As a result, management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company&#8217;s ability to continue as a going concern for one year after the date the consolidated financial statements are issued. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674166110096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Acquisitions</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">3. Acquisitions </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> Acquisition </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2022, the Company acquired the Delayed Burst Release Low Dose Naltrexone asset and intellectual property rights for the treatment of chronic pain, fibromyalgia and chronic post-COVID syndrome (collectively, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;SP-104</div> Assets&#8221;). Pursuant to the acquisition provisions, the Company is obligated to pay Aardvark Therapeutics, Inc. (&#8220;Aardvark&#8221;) (i) $3.0&#160;million upon initial approval by the FDA of a new drug application for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> Assets (which amount may be paid in shares of Common Stock or cash, in the Company&#8217;s sole discretion) (the &#8220;Development Milestone Payment&#8221;) and (ii) $20.0&#160;million in cash, upon achievement of certain net sales by the Company of a commercial product that uses the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> Assets (the &#8220;Sales Milestone Payment&#8221;). The Company will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by the Company of a commercial product that uses the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> Assets. </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sales Milestone Payment and sale volume-based future royalties were determined to meet a scope exception for derivative accounting and will not be recognized until the contingencies are realized. The Development Milestone Payment represents a liability, which will be measured at fair value for each reporting period. As of December&#160;31, 2023 and December&#160;31, 2022, the contingent consideration associated with the Development Milestone Payment was $0.2&#160;million, recorded in the other long-term liabilities. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">GLOPERBA License Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2022, the Company entered into a license agreement (the &#8220;Romeg License Agreement&#8221;) with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.) (&#8220;Romeg&#8221;). Pursuant to the Romeg License Agreement, among other things, Romeg granted the Company (a)&#160;a transferable license, with a right to sublicense, to (i)&#160;commercialize the pharmaceutical product comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans (the &#8220;Initial Licensed Product&#8221; or &#8220;GLOPERBA&#8221;) in the United States (including its territories) (the &#8220;GLOPERBA Territory&#8221;), (ii) develop other products comprising the Initial Licensed Product as an active pharmaceutical ingredient (the &#8220;Licensed Products&#8221;) and commercialize any such products and (iii)&#160;manufacture Licensed Products anywhere in the world, solely for commercialization in the GLOPERBA Territory; and (b)&#160;an exclusive, transferable license, with a right to sublicense, to use the trademark GLOPERBA and logos, designs, translations, and modifications thereof in connection with the commercialization of the Initial Licensed Product solely in the GLOPERBA Territory. The Initial Licensed Product, GLOPERBA, was approved and made available in the United States in 2020. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for the license under the Romeg License Agreement, the Company paid Romeg an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> license fee of $2.0&#160;million, and has agreed to pay Romeg (a)&#160;upon the Company&#8217;s achievement of certain net sales milestones, certain milestone payments in the aggregate amount of up to $13.0&#160;million, (b)&#160;certain royalties, at rates that do not exceed ten percent, based on annual net sales of the Licensed Products by the Company during the applicable royalty term under the Romeg License Agreement, and (c)&#160;minimum quarterly royalty payments totaling $7.1&#160;million commencing on the first year anniversary of the effective date of the Romeg License Agreement and ending on the later of (i)&#160;expiration of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">last-to-expire</div></div> of the licensed patents covering the Licensed Products in the GLOPERBA Territory or (ii)&#160;the tenth anniversary of the effective date of the Romeg License Agreement. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Romeg License Agreement, the Company recorded an intangible asset for acquired licenses of $5.7&#160;million, which is comprised of the upfront license fee of $2.0&#160;million and deferred consideration of $3.7&#160;million that is the present value of the future minimum royalty payments and immaterial transaction costs. No contingent consideration was recognized as a liability or included in the fair value of the assets as of December&#160;31, 2023 or December&#160;31, 2022. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">ELYXYB Acquisition </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;12, 2023, the Company entered into an asset purchase agreement (the &#8220;ELYXYB APA&#8221;) with BioDelivery Sciences International, Inc. (&#8220;BDSI&#8221;) and Collegium Pharmaceutical, Inc. (&#8220;Collegium&#8221;, and together with BDSI, the &#8220;Sellers&#8221;) to acquire the rights to certain patents, trademarks, regulatory approvals, data, contracts, and other rights related to ELYXYB and its commercialization in the United States and Canada (the &#8220;ELYXYB Territory&#8221;). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for the acquisition, the Company assumed various rights and obligations under the asset purchase agreement between BDSI and Dr.&#160;Reddy&#8217;s Laboratories Limited, a company incorporated under the laws of India (&#8220;DRL&#8221;), dated August&#160;3, 2021 (the &#8220;DRL APA&#8221;), including an irrevocable, royalty-free, exclusive license to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and patents of DRL related to ELYXYB and necessary or used to exploit ELYXYB in the ELYXYB Territory. No cash consideration was or will be payable to the Sellers for such acquisition; however, the obligations under the DRL APA that were assumed by the Company include contingent sales and regulatory milestone payments and sales royalties. The Company is also obligated to make quarterly royalty payments to </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>DRL on net sales of ELYXYB in the ELYXYB Territory. In April 2023, the Company launched ELYXYB in the U.S. As of December&#160;31, 2023, the Company had ending balances of accrued royalty payables of $5.0&#160;thousand. As of December&#160;31, 2023, no sales or regulatory milestone payments had been accrued as there were no potential milestones yet considered probable of achievement.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//805/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674082247696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">4. Fair Value Measurements </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the Company&#8217;s financial assets and liabilities that are measured at fair value on a recurring basis and the level of inputs used in such measurements (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:42%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices<br/> in Active<br/> Markets<br/> (Level 1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs&#160;(Level&#160;2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable<br/> Inputs&#160;(Level&#160;3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Oramed Note</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">104,089</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">104,089</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Convertible Debentures</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-hidden:hidden107552736;display:inline;">Derivative liabilities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,518</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,518</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other long-term liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities measured at fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">110,126</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">110,126</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:44%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices<br/> in Active<br/> Markets<br/> (Level&#160;1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs&#160;(Level&#160;2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable<br/> Inputs&#160;(Level&#160;3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-hidden:hidden107552737;display:inline;">Derivative liabilities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,231</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,231</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other long-term liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">163</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">163</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities measured at fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,394</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,394</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">The Oramed Note </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2023, the Company issued a senior secured promissory note to Oramed Pharmaceuticals Inc. (&#8220;Oramed&#8221;) in the principal amount of $101.9&#160;million (the &#8220;Oramed Note&#8221;) (see Note 7). The Company elected the fair value option to account for the Oramed Note with any changes in the fair value of the note recorded in the consolidated statements of operations. The Company uses a discounted cash flow model to determine the fair value of the Oramed Note based on Level&#160;3 inputs. This methodology discounts the interest and principal payments using a risk-adjusted discount rate. The fair value as of December&#160;31, 2023 was determined to be $104.1&#160;million by applying a discount rate of 13.05%. For the year ended December&#160;31, 2023, the Company recorded $2.8&#160;million in change in fair value of the Oramed Note. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Convertible Debentures </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March and April 2023, the Company issued the Convertible Debentures in the principal amount of $25.0&#160;million (see Note 7). The Convertible Debentures are measured at fair value on a recurring basis using Level&#160;3 inputs. The Company uses the Binomial Lattice Model valuation technique to measure the fair value of the Convertible Debentures with any changes in the fair value of the Convertible Debentures recorded in the consolidated statements of operations. Interest expense related to the Convertible Debentures is included in the changes in fair value. For the year ended December&#160;31, 2023, the Company recorded $4.4&#160;million in change in </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">fair value of the Convertible Debentures. A summary of inputs used in valuing the Convertible Debentures is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:17%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk -Free Rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.31</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate Bond Yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15.60</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Coupon Interest Rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">70.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend Yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Conversion Price</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Derivative Liabilities </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recorded a gain of $0.5&#160;million and $8.3&#160;million and a loss of $0.3&#160;million for the years ended December&#160;31, 2023, 2022 and 2021, respectively, on derivative liabilities which was attributed to the Private Warrants that the Company assumed from Vickers in November 2022 in connection with the Business Combination and compound derivative liabilities associated with the senior secured notes issued by Scilex Pharma in September 2018 (the &#8220;Scilex Pharma Notes&#8221;), respectively. The fair value of the derivative liability associated with the Scilex Pharma Notes decreased by $30.4&#160;million immediately after entry into Amendment No.&#160;4 to the Scilex Pharma Notes on June&#160;2, 2022 (&#8220;Amendment No.&#160;4&#8221;). The fair value of the derivative liability associated with the Scilex Pharma Notes was estimated using the discounted cash flow method combined with a Monte Carlo simulation model including consideration of the terms of Amendment No.&#160;4. Significant Level&#160;3 assumptions used in the measurement included a 6.1% risk adjusted net sales forecast and an effective debt yield of 21.5%. The Scilex Pharma Notes were fully extinguished in September 2022 and, as such, there were no remaining loan derivative liabilities associated with the Scilex Pharma Notes as of December&#160;31, 2022. At the closing of the Business Combination in November 2022, the Company assumed a derivative warrant liability of $2.5&#160;million related to the Private Warrants. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, 3,613,383 Private Warrants were outstanding, and the fair value of derivative warrant liability related to the Private Warrants was $1.5&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table includes a summary of the derivative liabilities measured at fair value during the three years ended December&#160;31, 2023, 2022 and 2021 (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:84%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">35,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> of fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">35,700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Private warrant liability acquired as part of the Business Combination</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,545</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeiture of Private Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,696</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value measurement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(38,710</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,231</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value measurement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">512</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeiture of Private Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(225</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,518</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Warrant Liability Measurement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The derivative warrant liability was valued using the Black-Scholes option pricing model, which is considered to be Level&#160;3 fair value measurement. The primary unobservable input utilized in determining the fair value of the </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">warrant is the expected volatility of the Common Stock. The expected volatility assumption is based on historical volatilities of comparable companies whose share prices are publicly available as well as the implied volatility of the Public Warrants (see Note 9). A summary of the inputs used in valuing the derivative warrant liabilities is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:65%"></td>
<td style="vertical-align:bottom;width:13%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Equity value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.04</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.99</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise price</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Term, in years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">76.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">35.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.90</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.94</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Call option value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Contingent Consideration Related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> Acquisition </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Development Milestone Payment related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> Assets represents an obligation to potentially settle a fixed value in a variable number of shares of Common Stock and requires remeasurement at fair value through settlement. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the achievement of FDA approval for a new drug application for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104,</div> the Company will transfer $3.0&#160;million in cash or shares of Common Stock, at the discretion of the Company. The fair value of the contingent consideration liability associated with the Development Milestone Payment was estimated using a probability-weighted discounted cash flow method. Significant unobservable inputs assumptions included the likelihood of receiving FDA approval for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104,</div> expected timing for receipt of FDA approval for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104,</div> and a discount rate of 10.2%. As of December&#160;31, 2023 and December&#160;31, 2022, the fair value of contingent consideration related to the Development Milestone Payment was $0.2&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no transfers between fair value measurement levels during the years ended December&#160;31, 2023, 2022 and 2021. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674083213232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Balance Sheet Components</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">5. Balance Sheet Components </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment, Net </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment, net, consists of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:13%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:13%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Construction in progress</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">689</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">689</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">118</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computers and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, gross</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">780</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">939</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Accumulated depreciation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(58</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(167</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">722</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">772</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognized depreciation expense of $40.0&#160;thousand, $40.0&#160;thousand and $39.0&#160;thousand for the years ended December&#160;31, 2023, 2022 and 2021, respectively. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Accrued Expenses </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued expenses consists of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional service fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued sales and marketing costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,601</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">574</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued research and development costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,546</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">459</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued tax payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,452</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued others</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">780</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">79</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,408</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674082247696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">6. Goodwill and Intangible Assets </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023 and 2022, the Company had recorded goodwill of $13.5&#160;million. No goodwill impairment was recognized for the years ended December&#160;31, 2023, 2022 and 2021. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amortization of the intangible assets that have finite useful lives is generally recorded on a straight-line basis over their useful lives. A summary of the Company&#8217;s identifiable intangible assets as of December&#160;31, 2023 and December&#160;31, 2022 is as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:55%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross&#160;Carrying<br/> Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intangibles,<br/> net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Patent rights</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,630</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,591</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,039</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired technology</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21,940</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,679</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,261</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired licenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">551</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Assembled workforce</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">475</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">60,781</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24,296</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,485</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:55%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross&#160;Carrying<br/> Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intangibles,<br/> net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Patent rights</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,630</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,215</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired technology</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21,940</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,216</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,724</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired licenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">184</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,527</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Assembled workforce</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">375</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">125</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">60,781</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,190</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40,591</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, the weighted average remaining life for identifiable intangible assets was 9.4 years. Aggregate amortization expense was $4.1&#160;million, $3.9&#160;million and $3.7&#160;million for the years ended December&#160;31, 2023, 2022 and 2021, respectively. Patent rights and acquired technology are amortized over a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15-year</div> period. Assembled workforce is amortized over a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-year</div> period. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Estimated future amortization expense related to intangible assets as of December&#160;31, 2023 is as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:85%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,006</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,006</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,006</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2028</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,006</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Thereafter</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,430</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,485</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674083213232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">7. Debt </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Convertible Debentures </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;21, 2023, the Company entered into the Yorkville SPA, pursuant to which the Company would issue and sell to Yorkville Convertible Debentures in an aggregate principal amount of up to $25.0&#160;million. The Yorkville SPA provides that the Convertible Debentures would be issued and sold at a purchase price equal to 96% of the applicable principal amount in three tranches as follows: (i) $10.0&#160;million upon the signing of the Yorkville SPA, which was funded on March&#160;21, 2023; (ii) $7.5&#160;million upon the filing of a registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</div> with the SEC to register the resale by Yorkville of any shares of Common Stock issuable upon conversion of the Convertible Debentures under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), which was funded on April&#160;11, 2023; and (iii) $7.5&#160;million at the time such registration statement was declared effective by the SEC, which was funded on April&#160;20, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Convertible Debentures bear interest at an annual rate of 7.00% and were initially set to mature on December 21, 2023. On <div style="display:inline;">October&#160;11, 2023</div>, the Company and Yorkville amended the Convertible Debentures. The Default Conversion Price (as defined therein) was originally set not to fall below $2.00 per share and such floor price has been amended to mean a price per share of Common Stock equal to 95% of the lowest daily VWAP (as defined therein) during the five consecutive trading days immediately preceding the conversion date, but not lower than $0.50 per share. The maturity date of the Convertible Debentures was also extended from December&#160;21, 2023 to March 15, 2024. The outstanding principal amount is to be repaid in equal installments that are due every 30 days beginning on May&#160;20, 2023, which is 60 days after the date on which the first Convertible Debenture was issued to Yorkville. The Convertible Debentures provide a conversion right, in which any portion of the outstanding and unpaid principal and any accrued but unpaid interest may be converted into shares of Common Stock, at a conversion price of $8.00 per share at the option of the holder of the Convertible Debentures. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has the option to repay either (i)&#160;in cash, with premium equal to&#160;5% in respect of the principal amount of such payment, or (ii)&#160;by submitting a notice for an advance under the A&amp;R Yorkville Purchase Agreement, or a series of advances thereunder, or any combination of (i)&#160;or (ii) as determined by the Company. In the case of (ii), the proceeds from the shares sold to Yorkville are applied against the outstanding amounts. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has the right, but not the obligation, in its sole discretion, to redeem, upon five business days&#8217; prior written notice to Yorkville (the &#8220;Redemption Notice&#8221;), all or any portion of the amounts outstanding under the Convertible Debentures; provided that the trading price of the Common Stock is less than the Conversion Price at the time of the Redemption Notice. The redemption amount shall be equal to the outstanding principal balance being redeemed by the Company, plus the redemption premium of 10% of the principal amount being redeemed, plus all accrued and unpaid interest in respect of such redeemed principal amount. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has elected the fair value option for the Convertible Debentures and records the changes in the fair value within the consolidated statements of operations at the end of each reporting period. Pursuant to the </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yorkville SPA, the Company issued additional Convertible Debentures in an aggregate principal amount of $15.0&#160;million in April 2023 for $14.4&#160;million in net cash proceeds. In April 2023, Yorkville elected to convert $5.0&#160;million of the outstanding principal and accrued interest of the first Convertible Debentures issued to Yorkville, resulting in the issuance of 632,431 shares of Common Stock at a conversion price of $8.00&#160;per share and reducing the outstanding Convertible Debentures fair value balance by $4.4&#160;million. The Company repaid $15.6&#160;million of the Convertible Debentures during the year ended December&#160;31, 2023. <div style="-sec-ix-hidden:hidden107552752;display:inline;">Interest expense related to the Convertible Debentures and included in the changes in fair value</div> was $0.7&#160;million for the year ended December&#160;31, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a summary of the changes in the balance and the estimated fair value of the Convertible Debentures (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:13%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beginning Balance as of January&#160;1, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Convertible Debentures</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayment of Convertible Debentures</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15,625</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of Convertible Debentures</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Conversion of Convertible Debentures into Common Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,735</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Revolving Facility </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;27, 2023, Scilex Pharma entered into the eCapital Credit Agreement, pursuant to which the Lender shall make available the Revolving Facility in an aggregate principal amount of up to $30.0&#160;million. The Facility Cap may, at the request of Scilex Pharma and with the consent of the Lender, be increased in increments of $250,000&#160;at such time as the outstanding principal balance under the eCapital Credit Agreement equals or exceeds 95% of the then-existing Facility Cap. The amount available to Scilex Pharma under the Revolving Facility at any one time is the lesser of the Facility Cap and 85% of the Net Collectible Value of Eligible Receivables (each as defined therein) minus the amount of any reserves or adjustments against receivables required by the Lender, in its discretion. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the eCapital Credit Agreement, interest will accrue daily on the principal amount outstanding at a rate per annum equal to the Wall Street Journal Prime Rate plus 1.5%, based on a year consisting of 360 days, and which shall be payable by Scilex Pharma monthly in arrears, commencing July&#160;1, 2023. The eCapital Credit Agreement provides for an early termination fee of 0.5% of the Facility Cap if Scilex Pharma voluntarily prepays and terminates in full the Revolving Facility prior to the first anniversary of the closing of the Revolving Facility. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the eCapital Credit Agreement, Scilex Pharma and the Lender entered into blocked account control agreements with respect to Scilex Pharma&#8217;s collections and eCapital Credit Agreement funding accounts, which permit the Lender to sweep all funds in the collections account to an account of the Lender for application to the outstanding amounts under the Revolving Facility, and to exercise customary secured party remedies with respect to the eCapital Credit Agreement funding account. All indebtedness incurred and outstanding under the eCapital Credit Agreement will be due and payable in full on July&#160;1, 2026, unless the eCapital Credit Agreement is earlier terminated. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The eCapital Credit Agreement contains a financial covenant requiring Scilex Pharma to maintain cash on hand of at least $1.0&#160;million at all times. Scilex Pharma&#8217;s obligations under the eCapital Credit Agreement are secured by a continuing security interest in Scilex Pharma&#8217;s accounts receivable, arising from customers in the ordinary </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">course of business. The eCapital Credit Agreement contains customary events of default and also provides that an event of default includes a change of control of Scilex Pharma and the failure by the Company to issue at least $75.0&#160;million of debt or equity by September&#160;30, 2023, which condition was satisfied by the issuance of the Oramed Note. As of December&#160;31, 2023, Scilex Pharma has an outstanding balance of $17.0&#160;million under the Revolving Facility, which is classified as a long-term liability in the consolidated balance sheet. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;21, 2023, Scilex Pharma signed a subordination agreement (the &#8220;Subordination Agreement&#8221;) with the Lender and Acquiom Agency Services LLC (the &#8220;Agent&#8221;). Pursuant to the Subordination Agreement, the rights and interests of the Lender under the eCapital Credit Agreement would be secured by first priority liens on the ABL Priority Collateral (as defined therein). The ABL Priority Collateral consists of all of the Company&#8217;s properties identified in the description of collateral in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">UCC-1</div> Financing Statement filed with the Delaware Secretary of State on June&#160;27, 2023. The Agent&#8217;s rights and interests under that certain Subsidiary Guarantee, dated as of September&#160;21, 2023, entered into by us and each of our subsidiaries with Oramed and the Agent (the &#8220;Subsidiary Guarantee&#8221;), would be secured by first priority liens on certain other collateral and second priority liens on the ABL Priority Collateral. The Subordination Agreement also includes other standard interlender terms and requires that the Facility Cap (as defined therein) shall not exceed $30.0&#160;million. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">The Oramed Note </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;21, 2023, the Company entered into a securities purchase agreement with Oramed (the &#8220;Scilex-Oramed SPA&#8221;), pursuant to which the Company issued the Oramed Note. The Oramed Note, which has a principal amount of $101.9&#160;million, matures on March 21, 2025. It is payable in six principal installments, with the first installment of $5.0&#160;million payable on December 21, 2023, the second installment in the principal amount of $15.0&#160;million payable on March 21, 2024, the next three installments each in the principal amount of $20.0&#160;million payable on each of June 21, 2024, September 21, 2024 and December 21, 2024 and the last installment in the entire remaining principal balance of the Oramed Note payable on March 21, 2025. Interest under the Oramed Note accrues at a fluctuating per annum interest rate equal to the sum of (1)&#160;greater of (x) 4% and (y)&#160;Term SOFR (as defined in the Oramed Note) and (2) 8.5%, payable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-kind</div> on a monthly basis. If the outstanding principal has not been fully repaid by March&#160;21, 2024, an exit fee of approximately $3.1&#160;million becomes due upon repayment. Upon the occurrence and during the continuance of an event of default under the Oramed Note, holders of more than 50% of the aggregate unpaid principal amount of the Oramed Notes may elect to accrue interest at a default rate equal to the lesser of (i)&#160;Term SOFR plus 15% or (ii)&#160;the maximum rate permitted under applicable law. Voluntary prepayments made before the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> anniversary of the closing date of the Scilex-Oramed SPA must include a make-whole amount equal to 50% of the additional interest that would accrue on the principal amount so prepaid from the date of such prepayment through and including the maturity date. If the Oramed Note is accelerated upon an event of default, repayment is required at a mandatory default rate of 125% of the principal amount (together with 100% of accrued and unpaid interest thereon and all other amounts due in respect of the Oramed Note). The Oramed Note contains mandatory prepayment provisions requiring use of 70% of net cash proceeds from any Cash Sweep Financing (as defined in the Oramed Note) or advances under the ELOCs (as defined in the Oramed Note) to prepay the outstanding principal after the earlier of April&#160;1, 2024 or full repayment of Acceptable Indebtedness (as defined in the Oramed Note). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Oramed Note contains affirmative and negative covenants binding on the Company and its subsidiaries, which restrict, among other things, the Company and its subsidiaries from incurring indebtedness or liens, amending charter and organizational documents, repaying or repurchasing stock, repaying, repurchasing, or acquiring indebtedness, paying or declaring cash dividends, assigning, selling, transferring or otherwise disposing of assets, making or holding investments, entering into transactions with affiliates, and entering into settlement agreements, in each case as more fully set forth in, and subject to certain qualifications and exceptions set forth in, the Oramed Note. The Company was in compliance with all of the covenants as of December&#160;31, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Oramed Note, the Company and each of its subsidiaries (collectively, the &#8220;Guarantors&#8221;) entered into a security agreement (the &#8220;Security Agreement&#8221;) with Oramed (together with its successors and </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">permitted assigns, the &#8220;Holder&#8221;) and the Agent, which acts as the collateral agent for the holders of the Oramed Note. Under this agreement, the Company and the Guarantors granted to the Agent (on behalf of and for the benefit of the holders of the Oramed Note and any Additional Notes as defined thereunder) a security interest in all or substantially all of the properties of the Company and each of the Guarantors. This was done to ensure the timely payment, performance, and full discharge of all obligations under the Oramed Note. The Security Agreement contains certain customary representations, warranties and covenants regarding the collateral thereunder, all of which are detailed in the Security Agreement. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At issuance, the Company concluded that certain features of the Oramed Note would be considered derivatives that would require bifurcation. In lieu of bifurcating such features, the Company has elected the fair value option for this financial instrument and records the changes in the fair value within the consolidated statements of operations at the end of each reporting period. As of December&#160;31, 2023, the fair value of the Oramed Note was $104.1&#160;million, which is classified as a current liability in the consolidated balance sheet. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a summary of the changes in the balance and the estimated fair value of the Oramed Note (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beginning Balance as of January&#160;1, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Oramed Note</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">106,252</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of Oramed Note</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,837</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayment of Oramed Note</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,000</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">104,089</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674076247056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Junior DIP Facility and Sorrento Share Purchase Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Junior DIP Facility and Sorrento Share Purchase Agreement</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">8. Junior DIP Facility and Sorrento Stock Purchase Agreement </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Junior DIP Facility </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2023, the Company entered into an agreement to provide Sorrento with a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-amortizing</div> super-priority junior secured term loan facility (&#8220;Junior DIP Facility&#8221;) in an aggregate principal amount of $20.0&#160;million (the &#8220;Junior DIP Loan Agreement&#8221;), which was funded in the same month. The Junior DIP Facility bears interest at a per annum rate of 12.0% payable in kind on the first day of each month in arrears and on the DIP Termination Date (as defined in the Junior DIP Loan Agreement). Upon repayment or satisfaction of the DIP Loans (as defined in the Junior DIP Loan Agreement) in whole or in part, Sorrento is required to pay to the Company in cash an exit fee equal to 2.00% of the aggregate principal amount of the Junior DIP Facility. The Junior DIP Facility was to mature on the earliest of: (i)&#160;September&#160;30, 2023; (ii) the effective date of any Chapter 11 plan of reorganization with respect to Sorrento; (iii)&#160;the consummation of any sale or other disposition of all or substantially all of the assets of Sorrento; (iv)&#160;the date of the acceleration of the DIP Loans and the termination of the DIP Commitments (as defined in the Junior DIP Loan Agreement) in accordance with the DIP Documents (as defined in the Junior DIP Loan Agreement); and (v)&#160;dismissal of the Chapter 11 Cases or conversion of the Chapter 11 Cases into cases under Chapter 7 of the Bankruptcy Code. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;21, 2023, Sorrento&#8217;s obligations under the Junior DIP Facility were waived and deemed to be fully settled in conjunction with the Sorrento SPA as described below. Consequently, the transfer of funds associated with the Junior DIP Facility was deemed and accounted for as a capital distribution to Sorrento. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sorrento Stock Purchase Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;21, 2023, the Company entered into a Stock Purchase Agreement with Sorrento (&#8220;Sorrento SPA&#8221;), pursuant to which the Company purchased from Sorrento (i) 60,068,585 shares of Common Stock, (ii)&#160;29,057,097 shares of Series A Preferred Stock, par value $0.0001 per share, of the Company (the &#8220;Preferred </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock&#8221;) and (iii) 1,386,617 Public Warrants and 3,104,000 Private Warrants (collectively, the &#8220;Purchased Securities&#8221;). On the same day, the Company and Oramed entered into the Scilex-Oramed SPA. The Company concluded that the Sorrento SPA and the Scilex-Oramed SPA were entered in contemplation of each other and the issuance of the Oramed Note was accounted as part of the consideration payable for the Purchased Securities acquired from Sorrento. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Scilex-Oramed SPA, the Company issued the Oramed Note (see Note 7), which replaced Sorrento&#8217;s outstanding obligations to Oramed, warrants to purchase up to an aggregate of 4,500,000 shares of Common Stock (the &#8220;Closing Penny Warrant&#8221;) with an exercise price of $0.01 per share and restrictions on exercisability, and warrants to purchase up to an aggregate of 8,500,000 shares of Common Stock (the &#8220;Subsequent Penny Warrants&#8221; and together with the Closing Penny Warrant, the &#8220;Penny Warrants&#8221;), each with an exercise price of $0.01 per share and each with restrictions on exercisability. Additionally, the Company agreed to transfer to Oramed 4,000,000 SPAC Warrants, which were acquired by the Company under the Sorrento SPA. There was no change in the terms for the warrants transferred to Oramed as a result of the transactions described above. The remaining consideration for the Purchased Securities was comprised of a credit bid for all amounts of principal and accrued but unpaid interest outstanding under the Junior DIP Facility, a $10.0&#160;million cash payment, and the assumption and assignment of certain obligations of Sorrento for legal fees and expenses amounting to approximately $12.3&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company allocated the total consideration between the repurchased instruments by allocating to the repurchased Private Warrants their full value, with the remaining consideration allocated to the Common Stock, Preferred Stock, and Public Warrants based on their relative fair values as of September&#160;21, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before the closing of the Sorrento SPA transactions and in connection with the transactions contemplated by the Sorrento SPA, the Company formed two entities: (a)&#160;Scilex DRE Holdings LLC (&#8220;Holdco&#8221;), a single purpose entity that is the Company&#8217;s direct wholly owned subsidiary and (b)&#160;Scilex Stock Acquisition Joint Venture LLC, a single purpose bankruptcy-remote entity that is the Company&#8217;s indirect wholly owned subsidiary (&#8220;SCLX JV&#8221;), which was formed to hold the Purchased Securities. Holdco was formed to hold all of the equity interests in SCLX JV. Holdco and SCLX JV are parties to the Security Agreement and Subsidiary Guarantee (see Note 7). </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preferred Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Sorrento SPA, the Company repurchased all of the outstanding Preferred Stock. The Preferred Stock is classified in equity and does not have any bifurcated features. Therefore, the repurchase of the Preferred Stock by the Company is treated as a redemption of shares and viewed as a deemed dividend. The fair value of Preferred Stock as of the repurchase date of September&#160;21, 2023 was $52.6&#160;million. The Company derecognized the carrying value of the Preferred Stock, with any excess amount allocated as the reduction in additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital. The Preferred Stock is currently held as collateral for the Oramed Note. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Treasury Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Common Stock that has been repurchased by the Company under the Sorrento SPA is not intended for constructive retirement, and is being held as collateral for the Oramed Note. In accordance with treasury stock accounting guidance, the consideration allocated to Common Stock is presented under a separate caption of Treasury Stock as a reduction of equity. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Penny Warrants </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Closing Penny Warrant will be exercisable upon the earliest of (i)&#160;March 14, 2025, (ii) the date on which the Oramed Note has been repaid in full and (iii)&#160;the Management Sale Trigger Date (as defined therein), if any, and will expire on the date that is the fifth anniversary of the issuance date. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company issued four Subsequent Penny Warrants, each for 2,125,000&#160;shares of Common Stock, one of which shall vest and become exercisable on the date that is the later of (i)&#160;each of March 19, 2024, June 17, 2024, <div style="display:inline;"></div><div style="display:inline;">September 15</div>, 2024 or December 14, 2024 (the &#8220;Subsequent Penny Warrant Vesting Date&#8221;) and (ii)&#160;the earliest of (A)&#160;March 14, 2025, (B) the date on which the Oramed Note has been repaid in full and (C)&#160;the Management Sale Trigger Date (as defined therein), if any. Each Subsequent Penny Warrant will expire on the date that is the fifth anniversary of the issuance date; provided that, if the Oramed Note is repaid in full prior to the Subsequent Penny Warrant Vesting Date applicable to such Subsequent Penny Warrant, such Subsequent Penny Warrant will expire on the date the Oramed Note is repaid in full. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exercise price of the Penny Warrants is $0.01 per share, subject to adjustments provided therein. The exercise price and number of shares of Common Stock issuable upon the exercise of the Penny Warrants will be subject to adjustment in the event of any stock dividend, stock split, recapitalization, reorganization or similar transaction, as described in the Penny Warrants; provided that there shall not be any adjustment to the exercise price of the Penny Warrants in the event the Company combines (by combination, reverse stock split or otherwise) its Common Stock into a smaller number of shares. Oramed may exercise the Penny Warrants by means of a &#8220;cashless exercise.&#8221; The Closing Penny Warrant and the Subsequent Penny Warrants utilize the same form of warrant. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Penny Warrants may not be exercised if Oramed, together with its affiliates, would beneficially own in excess of 9.9% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise (the &#8220;Oramed Beneficial Ownership Limitation&#8221;); provided, however, that upon 61 days&#8217; prior notice to the Company, Oramed may increase or decrease the Oramed Beneficial Ownership Limitation. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounted for the Penny Warrants as an equity classified instrument as they are indexed to the Company&#8217;s own stock and meet the conditions to be classified in equity under FASB ASC 815, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Derivatives and Hedging,</div></div> including sufficient available shares for the Company to settle the exercise of the warrants in shares. The Penny Warrants are recognized in additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital in the Company&#8217;s consolidated balance sheets. The fair value of Penny Warrants as of September&#160;21, 2023, the date of issuance, was $10.4&#160;million. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Excise Tax </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2022, the Department of the Treasury and the Internal Revenue Service (the &#8220;IRS&#8221;) issued guidelines on the implementation of the new code section added by the Inflation Reduction Act of 2022, which imposes a 1% excise tax on the total fair market value of stock repurchases during the tax year, subject to adjustments. Pursuant to the terms of the Sorrento SPA, the Company repurchased the Purchased Securities from Sorrento. The total fair market value of the Purchased Securities was offset by the fair market value of the shares issued during the year ended December&#160;31, 2023. The Company has accrued $1.3&#160;million of the excise tax liability, which is recorded as accrued expenses under current liabilities on the consolidated balance sheet. The excise tax will be adjusted based on any new guidance that the IRS may release. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674193766528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS EQUITY</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">9. Stockholders&#8217; Equity </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">SPAC Warrants </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the completion of the Business Combination, the Company assumed the SPAC Warrants. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of the SPAC Warrants are entitled to acquire shares of Common Stock. The SPAC Warrants will expire five years after the completion of the Business Combination or earlier upon redemption or liquidation. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the reported last sale price of the Common Stock equals or exceeds $18.00 per share for any 20 trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-trading</div> day period ending three business days before the Company sends the notice of redemption to the warrant holders, the Company may redeem all the Public Warrants at a price of $0.01 per warrant upon not less than 30 days&#8217; prior written notice. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company calls the Public Warrants for redemption, the Company will have the option to require all holders that wish to exercise the Public Warrants to do so on a cashless basis. The Company will not be required to net cash settle the SPAC Warrants. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Public Warrants are equity-classified warrants and recognized in additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital in the accompanying consolidated balance sheets. The Private Warrants are liability-classified warrants and are recognized as liabilities (refer to Notes 1 and 4). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&#160;31, 2023, the SPAC Warrants held by Sorrento were repurchased, and certain of such warrants transferred to Oramed, as a result of the Sorrento SPA (refer to Note 8). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023 and 2022, there were 6,854,309&#160;and 6,899,988 Public Warrants outstanding, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023 and 2022, there were 3,613,383&#160;and 4,104,000 Private Warrants outstanding, respectively. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Preferred Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023 and 2022, there were 29,057,097 shares of Preferred Stock outstanding. On September&#160;21, 2023, the Preferred Stock was repurchased and derecognized for accounting purposes. The Preferred Stock is currently held as collateral for the Oramed Note. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Treasury Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, there were 60,068,585 shares of Treasury Stock. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">A&amp;R Yorkville Purchase Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the A&amp;R Yorkville Purchase Agreement, the Company has the right, but not the obligation, in its sole and absolute discretion, to sell to Yorkville up to $500.0&#160;million of shares of Common Stock at its request and subject to certain conditions by delivering written notice to Yorkville at any time until the first day of the month following the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">36-month</div> anniversary of the date on which the Company&#8217;s registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</div> registering such shares has been declared effective by the SEC. Pursuant to the A&amp;R Yorkville Purchase Agreement, the shares of Common Stock, if any, that the Company elects to sell to Yorkville pursuant to a sale of Common Stock will be purchased at a price equal to 98% of the VWAP (as defined below) during the applicable pricing period for such advance, which shall be the period commencing upon receipt by Yorkville of an advance notice from the Company (or the open of regular trading hours, if later) and ending on 4:00 p.m. on the same day. For purposes of the A&amp;R Yorkville Purchase Agreement, &#8220;VWAP&#8221; means, for a specified period, the volume weighted average price of the Common Stock on the Nasdaq Capital Market for such period as reported by Bloomberg L.P. through its &#8220;AQR&#8221; function. Pursuant to the terms of the Original Purchase Agreement, the Company filed a registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</div> (File <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-268607)</div> (as it may be amended or supplemented from time to time, the &#8220;Yorkville Registration Statement&#8221;) related to the Original Purchase Agreement with the SEC on November&#160;30, 2022 (following the execution of the Original Purchase Agreement). The Yorkville Registration Statement was initially declared effective by the SEC on December&#160;9, 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the execution of the Original Purchase Agreement, the Company issued to Yorkville 250,000 shares of Common Stock. During the year ended December&#160;31, 2023, the Company sold 11,552,074 shares of Common Stock pursuant to the A&amp;R Yorkville Purchase Agreement for aggregate net proceeds of&#160;$32.3&#160;million. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">B. Riley Purchase Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the B. Riley Purchase Agreement, the Company has the right, but not the obligation, to sell to B.&#160;Riley up to $500.0&#160;million of shares of Common Stock, subject to certain limitations and conditions set forth </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">therein, from time to time at the Company&#8217;s sole and absolute discretion, during the term of the B. Riley Purchase Agreement. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s right to sell shares of Common Stock pursuant to the B. Riley Purchase Agreement shall end on the first day of the month following the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">36-month</div> anniversary of the date on which the B. Riley Registration Statement (as defined below) was initially declared effective by the SEC. Pursuant to the terms of the B. Riley Purchase Agreement, the Company filed a registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</div> (File <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-269205)</div> (as it may be amended or supplemented from time to time, the &#8220;B. Riley Registration Statement&#8221;) related to the B. Riley Purchase Agreement with the SEC on January&#160;12, 2023 (following the execution of the B. Riley Purchase Agreement). The B. Riley Registration Statement was initially declared effective by the SEC on January&#160;20, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares of Common Stock, if any, that the Company elects to sell to B. Riley pursuant to an advance under the B. Riley Purchase Agreement will be purchased at a price equal to 98% of the VWAP (as defined in such agreement) during the pricing period prescribed therein. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the execution of the B. Riley Purchase Agreement, the Company issued to B. Riley 250,000 shares of Common Stock. During the year ended December&#160;31, 2023, the Company sold an aggregate of 1,414,554 shares of Common Stock for aggregate net proceeds of $3.2&#160;million. On, and effective as of, February&#160;16, 2024, the Company and B. Riley mutually agreed to terminate the B. Riley Purchase Agreement. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Stock Issued under Settlement Agreement with Hudson Bay Parties </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2023, the Company, along with Hudson Bay Capital Management LP (&#8220;Hudson Bay&#8221;), Cove Lane Onshore Fund, LLC (&#8220;Cove Lane&#8221;), and HBC Investments LLC (&#8220;HBC&#8221; and collectively, the &#8220;Hudson Bay Parties&#8221;), entered into several agreements. Under these agreements, the Company agreed to issue and sell up to $118.6&#160;million in securities and warrants to the Hudson Bay Parties. However, on September&#160;15, 2023, a settlement agreement was reached and released all claims related to the previous agreements. The Company acknowledged payments of $8.65&#160;million made to the Hudson Bay Parties as properly earned. To satisfy remaining obligations, the Company agreed to issue shares of Common Stock to Cove Lane and HBC worth $0.3&#160;million and $0.5&#160;million, respectively. This resulted in the issuance of an aggregate of 474,683&#160;shares of Common Stock on September&#160;25, 2023. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">At-the-Market</div></div> Sales Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;22, 2023, the Company entered into a Sales Agreement (the &#8220;ATM Sales Agreement&#8221;) with B. Riley Securities, Inc., Cantor Fitzgerald&#160;&amp; Co. and H.C. Wainwright&#160;&amp; Co., LLC (the &#8220;Sales Agents&#8221;). Pursuant to the ATM Sales Agreement, the Company may offer and sell (the &#8220;Offering&#8221;) shares of Common Stock up to $170,000,000 (the &#8220;ATM Shares&#8221;), through or to the Sales Agents. The Company has no obligation to sell any shares of Common Stock under the ATM Sales Agreement and may suspend offers at any time. The Offering will terminate upon (i)&#160;the election of the Sales Agents upon the occurrence of certain adverse events, (ii)&#160;three business days&#8217; advance notice from the Company to the Sales Agents or a Sales Agent to the Company, or (iii)&#160;the sale of all $170,000,000 of shares of Common Stock thereunder. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ATM Shares offered and sold in the Offering will be issued pursuant to the Company&#8217;s shelf registration statement on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;S-3&#160;(the</div> &#8220;Shelf <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3</div> Registration Statement&#8221;), filed with the SEC on December&#160;22, 2023, and declared effective by the SEC on January&#160;11, 2024. The ATM Shares may be offered only by means of a prospectus forming a part of the Shelf <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3</div> Registration Statement. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sales Agents are entitled to a commission equal to 3.0% of the gross proceeds from each sale of shares of Common Stock. The Company will also reimburse the Sales Agents for certain expenses and has agreed to </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provide indemnification and contribution to the Sales Agents against certain civil liabilities, including liabilities under the&#160;Securities Act. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, no sales of Common Stock had been made under the ATM Sales Agreement. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674076247056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive and Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Stock Incentive and Employee Benefit Plans</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">10. Stock Incentive and Employee Benefit Plan </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">2017 Scilex Pharmaceuticals Inc. Equity Incentive Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2017, the Board of Directors of the Company adopted the Scilex Pharmaceuticals Inc. Equity Incentive Plan (the &#8220;Scilex Pharma 2017 Plan&#8221;). In connection with the corporate reorganization in March 2019, the Scilex Pharma 2017 Plan was terminated. Accordingly, after such time, no additional awards were granted under the Scilex Pharma 2017 Plan. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Scilex Holding Company 2019 Stock Option Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2019, the Board of Directors of the Company adopted the Scilex Holding Company 2019 Stock Option Plan (the &#8220;2019 Stock Option Plan&#8221;), which subsequently was amended in December 2020. The 2019 Stock Option Plan was terminated at the closing of the Business Combination, and no further awards have been granted under the 2019 Stock Option Plan thereafter. However, the 2019 Stock Option Plan will continue to govern outstanding awards granted thereunder. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Scilex Holding Company 2022 Equity Incentive Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2022, the Board of Directors of the Company adopted the Scilex Holding Company 2022 Equity Incentive Plan (the &#8220;Equity Incentive Plan&#8221;). The total number of shares of Common Stock for which incentive stock options (&#8220;ISOs&#8221;) may be granted under the Equity Incentive Plan is not to exceed 20,276,666 shares, which was increased from 14,622,712 as a result of the automatic annual increase on January&#160;1, 2023 pursuant to the Equity Incentive Plan provisions. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&#160;4, 2023, the Company&#8217;s stockholders approved the amendment to the Equity Incentive Plan to (i)&#160;increase the number of shares authorized for issuance thereunder by 10,000,000 shares from 20,276,666 shares to 30,276,666 shares, (ii)&#160;increase the number of shares authorized for issuance thereunder pursuant to the exercise of ISOs to 30,276,666 shares, and (iii)&#160;modify the commencement date of the automatic increase in the number of shares authorized for issuance thereunder pursuant to the exercise of ISOs to January&#160;1, 2024. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, options to purchase 33,123,798 shares of Common Stock were outstanding under all equity incentive plans. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div>recently determined that the aggregate value of all compensation granted or paid to each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director for the fiscal year ending December&#160;31, 2023 (when aggregated with any remaining compensation payable for the remainder of such fiscal year) would inadvertently exceed the $750,000 annual compensation limit for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors (the &#8220;Compensation Limit&#8221;) under the Equity Incentive Plan, as a result of the previously disclosed equity grants made thereunder to such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors in January 2023 (the &#8220;Awards&#8221;). As a result, the Company&#8217;s current <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors, David Lemus and Dorman Followwill, and the Company&#8217;s former <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Tien-Li</div> Lee and Laura Hamill, each voluntarily agreed to forfeit (i)&#160;a number of shares of Common Stock subject to their Awards or (ii)&#160;a combination of shares of Common Stock subject to their Awards and cash compensation payable by the Company for such person&#8217;s service as a director for the remainder of 2023, in each case in an amount that would bring each such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director&#8217;s aggregate compensation for the fiscal year ending December&#160;31, 2023 below the Compensation Limit. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors forfeited an aggregate of 311,735 shares of Common Stock and an aggregate of approximately $107,424 in cash compensation. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Scilex Holding Company 2023 Inducement Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;17, 2023, the compensation committee of the Board of Directors of the Company adopted the Scilex Holding Company 2023 Inducement Plan (the &#8220;Inducement Plan&#8221;). The Inducement Plan provides for the grant of equity-based awards in the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-statutory</div> stock options, stock appreciation rights, restricted stock, restricted stock units, and other awards solely to prospective employees of the Company or an affiliate of the Company, provided that certain criteria are met. The initial maximum number of shares available for grant under the Inducement Plan is 1,400,000 shares of Common Stock (subject to adjustment for recapitalizations, stock splits, reorganizations and similar transactions). No awards were granted under the Inducement Plan during the year ended December&#160;31, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes stock option activity during the year ended December&#160;31, 2023 (shares in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:48%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Exercise&#160;Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Remaining<br/> Contractual&#160;Life,<br/> in years</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> Intrinsic&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding as of December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,939</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38,942</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,610</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.02</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(365</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited/Cancelled</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,060</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding as of December&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33,124</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,459</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable as of December&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,990</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.78</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the Common Stock for the options that had exercise prices that were lower than the per share fair value of the Common Stock as of the measurement date of the intrinsic value. The weighted-average grant date fair value per share of stock options granted during the year ended December&#160;31, 2023 was $3.24 per share. The total intrinsic values of options exercised during the years ended December&#160;31, 2023, 2022, and 2021 were $1.1&#160;million, $0.3&#160;million, and nil, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total stock-based compensation recorded within operating expenses was $14.6&#160;million, $5.3&#160;million and $5.8&#160;million for the years ended December&#160;31, 2023, 2022 and 2021, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total unrecognized compensation costs related to unvested employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> stock option grants as of December&#160;31, 2023 were $42.4&#160;million, which the Company expects to recognize over a weighted-average period of approximately 3.1 years. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Scilex Holding Company 2022 Employee Stock Purchase Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2022, the Board of Directors of the Company adopted the Scilex Holding Company 2022 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The purchase price of the Common Stock is equal to&#160;85% of the lesser of the market value of such shares at the beginning of an offering period or the date of purchase. As of December&#160;31, 2023, the total number of shares of Common Stock that may be issued under the ESPP shall not exceed 2,875,759, which was increased from 1,462,271 shares as a result of automatic annual increase on January&#160;1, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total stock-based compensation recorded as operating expense for the ESPP was $21.0&#160;thousand and nil for the year ended December&#160;31, 2023 and 2022, respectively. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Valuation Assumptions </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company calculates the fair value of stock options and ESPP awards granted to employees and nonemployees using the Black-Scholes option-pricing method. The Black-Scholes option-pricing method requires the use of subjective assumptions. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following assumptions were used in the Black-Scholes options pricing model to estimate stock-based compensation on the date of grant for stock options and ESPP: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> December&#160;31, 2023</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock options:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">0.00%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">40.00%&#160;-&#160;77.00%</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3.59%&#160;-&#160;4.74%</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Term of options (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">6.25</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Employee stock purchase plan:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">0.00%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">117.57%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">5.33%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected life (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">0.50</td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Employee Benefit Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company maintains a defined contribution 401(k) plan available to eligible employees. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company made matching contributions to the 401(k) plan totaling $0.5&#160;million, $0.3&#160;million and $0.3&#160;million for the years ended December&#160;31, 2023, 2022 and 2021, respectively. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Retainer Shares </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;13, 2023, the Company entered into a Stock Issuance Agreement (the &#8220;SIA&#8221;) with a law firm for the provision of legal services to the Company. Under the SIA, the Company issued 4,000,000 shares of Common Stock to the law firm (the &#8220;Retainer Shares&#8221;). The Retainer Shares are held by the law firm as collateral for the current and future outstanding legal fees due from the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the option of the law firm, the Retainer Shares may be sold and the net proceeds may be applied against the outstanding legal fees. The Retainer Shares not applied against the outstanding legal fees due will be returned to the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, it was not probable that any of the Retainer Shares would be applied against any outstanding legal fees. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674082187808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">11. Commitments and Contingencies </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Product Development Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2013, Scilex Pharma became a party to a product development agreement (as amended, the &#8220;Product Development Agreement&#8221;) with Itochu and Oishi Koseido Co., Ltd. (&#8220;Oishi,&#8221; and together with Itochu, the &#8220;Developers&#8221;), pursuant to which the Developers will manufacture and supply lidocaine tape products, including ZTlido and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div> (the &#8220;Products&#8221;), for Scilex Pharma. The Developers initially developed and have intellectual property rights relating to the Products. Pursuant to the Product Development Agreement, Scilex Pharma acquired an exclusive right to develop and commercialize the Products worldwide except for Japan. The Developers are responsible for sourcing and supplying lidocaine for development and commercialization purposes. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Product Development Agreement, Scilex Pharma is required to make aggregate royalty payments between 25% and 35% to the Developers based on net profits. For the years ended December&#160;31, 2023 and 2022, Scilex Pharma made royalty payments in the amount of $8.3&#160;million and $2.3&#160;million. As of December&#160;31, 2023 and 2022, Scilex Pharma had ending balances of accrued royalty payables of $2.4&#160;million and $2.2&#160;million, respectively. Total royalty expense recorded within cost of revenue was $8.5&#160;million and $4.5&#160;million for the years ended December&#160;31, 2023 and 2022, respectively. Net profits are defined as net sales, less cost of goods and marketing expenses. Net sales are defined as total gross sales of any Product, less all applicable deductions, to the extent accrued, paid or allowed in the ordinary course of business with respect to the sale of such Product, and to the extent that they are in accordance with GAAP. If Scilex Pharma were to sublicense the licensed technologies, the Developers will receive the same proportion of any sublicensing fees received therefrom. The Product Development Agreement will continue in full force and effect until October 2, 2028, the date that is ten years from the date of the first commercial sale of ZTlido. The Product Development Agreement will renew automatically for subsequent successive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> renewal periods unless Scilex Pharma or the Developers terminate it upon <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-month</div> written notice. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;16, 2017, Scilex Pharma entered into a Commercial Supply Agreement (as amended, the &#8220;Supply Agreement&#8221;) with the two Developers to provide commercial supply of ZTlido and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div> to Scilex Pharma. The Supply Agreement contains standard terms regarding term, termination, payment, product quality and supply. In addition, the agreement provides additional terms regarding the calculation and amount of marketing expenses that may be deducted from net sales for purposes of determining the amount of net profit under the Product Development Agreement. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Litigation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the normal course of business, the Company may be named as a defendant in one or more lawsuits. Other than the following four lawsuits, the Company is not a party to any outstanding material litigation and management is not aware of any legal proceedings that, individually or in the aggregate, are deemed to be material to the Company&#8217;s financial condition or results of operations. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time the Company may become involved in various legal proceedings, including those that may arise in the ordinary course of business. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc. Litigation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;23, 2021, the Company filed an action (the &#8220;Action&#8221;) in the U.S. District Court for the Northern District of California against Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc., two manufacturers of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">over-the-counter</div></div> (&#8220;OTC&#8221;) lidocaine patch products, alleging, among other things, false and deceptive advertising and unfair competition under the Lanham Act and California state laws by those companies regarding their respective OTC patch products. This lawsuit sought, among other relief, damages and an injunction enjoining the defendants from continuing to make false or misleading statements of fact about their respective OTC lidocaine patch products. The defendants filed motions to dismiss, which narrowed slightly the Company&#8217;s claims, but which motions the court largely rejected. Discovery was proceeding. On January&#160;26 and February&#160;2, 2024, Scilex Pharma entered into two separate settlement agreements and mutual releases with the two manufacturers that resolve the Action. The terms of those agreements are confidential. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Former Employee Action </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;12, 2021, Scilex Pharma and Sorrento (the &#8220;Plaintiffs&#8221;) filed an action (the &#8220;Former Employee Action&#8221;) in the Delaware Court of Chancery against the former President of Scilex Pharma, Anthony Mack, and Virpax Pharmaceuticals, Inc. (&#8220;Virpax&#8221;, together with Mr.&#160;Mack, the &#8220;Defendants&#8221;), a company founded and then headed by Mr.&#160;Mack, alleging, among other things, breach by Mr.&#160;Mack of a restrictive covenant agreement with Sorrento related to his sale of his Scilex Pharma stock to Sorrento, tortious interference with that agreement </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">by Virpax, breach of Mr.&#160;Mack&#8217;s fiduciary duties to Scilex Pharma, aiding and abetting of that breach by Virpax, and misappropriation of Scilex Pharma&#8217;s trade secrets by Mr.&#160;Mack and Virpax. Such lawsuit sought, among other relief, damages and various forms of injunctive relief. The case was tried from September&#160;12, 2022 to September&#160;14, 2022. On September&#160;1, 2023, the court found in favor of the Plaintiffs on all but three counts deemed to have been waived. In its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">95-page</div> opinion, the court instructed the parties to submit supplemental briefing on the appropriate remedy to implement its rulings. On October&#160;18, 2023, the Plaintiffs submitted a supplemental brief on remedies. On November&#160;29, 2023, Defendants submitted a supplemental brief on remedies. On December&#160;21, 2023, the Plaintiffs submitted a supplemental reply brief on remedies. On February&#160;26, 2024, the Company and Virpax entered into a term sheet regarding a mutual release and settlement agreement, pursuant to which the parties have agreed to resolve the ongoing disputes. On February&#160;29, 2024, the Company and Virpax entered into a definitive settlement agreement, which provides for, among other things, that Virpax will be obligated to make the following payments to the Company to settle the Former Employee Action: (i) $3.5&#160;million (the &#8220;Initial Payment&#8221;) by two business days after the Effective Date (as defined therein); (ii) $2.5&#160;million by July&#160;1, 2024 and (iii)&#160;to the extent any of the following drug candidates are ever sold, royalty payments of (a) 6% of annual Net Sales (as defined therein) of Epoladerm; (b) 6% of annual Net Sales of Probudur and (c) 6% of annual Net Sales of Envelta during the Royalty Term (as defined therein). The Company and Virpax provide mutual releases of all claims that exist as of the Effective Date, whether known or unknown, arising from any allegations set forth in the Former Employee Action. Plaintiffs&#8217; release relates to claims against Virpax only, which does not affect its claims against Mr.&#160;Mack. Plaintiffs have not released Mr.&#160;Mack, and litigation against him remains ongoing. Plaintiffs&#8217; release as to Virpax is conditioned upon Virpax&#8217;s Initial Payment. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ZTlido Patent Litigation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2022, the Company filed a complaint against Aveva Drug Delivery Systems, Inc. (&#8220;Aveva&#8221;), Apotex Corp., and Apotex, Inc. (together, &#8220;Apotex&#8221;) in the U.S. District Court for the Southern District of Florida (the &#8220;ZTlido Patent Litigation&#8221;) alleging infringement of certain Orange Book listed patents covering ZTlido (the &#8220;ZTlido Patents&#8221;). The ZTlido Patent Litigation was initiated following the submission by Apotex, in accordance with the procedures set out in the Hatch-Waxman Act, of an abbreviated new drug application (&#8220;ANDA&#8221;). Apotex&#8217;s ANDA seeks approval to market a generic version of ZTlido prior to the expiration of the ZTlido Patents and alleges that the ZTlido Patents are invalid, unenforceable, and/or not infringed. The Company is seeking, among other relief, an order that the effective date of any FDA approval of Apotex&#8217;s ANDA be no earlier than the expiration of the asserted patents listed in the Orange Book, the latest of which expires on May&#160;10, 2031, and such further and other relief as the court may deem appropriate. Apotex is subject to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-month</div> stay preventing it from selling a generic version of ZTlido during that time. The stay should expire no earlier than November&#160;11, 2024. The two Apotex entities were recently dismissed from the litigation without prejudice, as they no longer have an interest in the generic product that Aveva seeks to market. Trial in the ZTlido Patent Litigation has been scheduled for July&#160;8, 2024. The Company cannot make any predictions about the final outcome of this matter or the timing thereof. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">GLOPERBA Patent Litigation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;6, 2023, Takeda Pharmaceuticals U.S.A., Inc. (&#8220;Takeda&#8221;) filed a complaint against the Company in the U.S. District Court for the District of Delaware (the &#8220;GLOPERBA Patent Litigation&#8221;) alleging that the Company&#8217;s filing with the FDA of an application for approval of a proposed revision to the product label for its GLOPERBA product infringed certain Orange Book listed patents covering Takeda&#8217;s colchicine product, Colcrys<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#174;</div><div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">&#160;</div>(the &#8220;Colcrys Patents&#8221;). Takeda is seeking an order that the effective date of any FDA approval of the Company&#8217;s labeling revision be no earlier than the expiration date of the asserted patents listed in the Orange Book, and such further and other relief as the court may deem appropriate. The filing of the complaint subjects the Company to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-month</div> stay, preventing it from selling GLOPERBA under a revised label (but not from selling GLOPERBA under its current label) during that time. The Company cannot make any predictions about the final outcome of this matter or the timing thereof. The stay could last as long as until May&#160;6, 2026, unless the </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">litigation is resolved before that time. As of December&#160;31, 2023, the Company accrued $0.5&#160;million with respect to the GLOPERBA Patent Litigation. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Operating Leases </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company leases administrative and research and development facilities under various <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancelable</div> lease agreements. Facility leases generally provide for periodic rent increases and may include options to extend. As of December&#160;31, 2023, the Company&#8217;s leases have remaining lease terms of approximately 0.7 to 3.8 years. The terms of the Company&#8217;s leases, ranging from 3 to 5 years, include extension options that were not reasonably certain to be exercised. Many of the Company&#8217;s leases are subject to variable lease payments. Variable lease payments are recognized in the period in which the obligations for those payments are incurred, are not included in the measurement of the ROU assets or lease liabilities, and are immaterial. Additionally, the Company subleases certain properties to third parties. Sublease income is recognized on a straight-line basis and is immaterial. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company calculates the associated lease liability and corresponding ROU asset upon lease commencement using a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. As of December&#160;31, 2023, the Company has no <div style="-sec-ix-hidden:hidden107553186;display:inline;">finance leases</div>. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2023, the Company modified the lease term for its principal executive offices located in Palo Alto, California. The modification extended the lease term for an additional three years, with the lease term expiring in September 2027. As a result of the modification, the Company recognized additional ROU assets and corresponding lease liabilities of $2.5&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lease expense was $1.1&#160;million, $0.5&#160;million and $0.6&#160;million for the years ended December&#160;31, 2023, 2022 and 2021, respectively, and was primarily comprised of operating lease costs. The lease expense also included variable lease costs and sublease income, which were immaterial for the periods presented. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Supplemental quantitative information related to leases includes the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:78%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash paid for amounts included in the measurement of lease liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating cash flows from operating leases (in thousands)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,021</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(746</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average remaining lease term in years &#8212; operating leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average discount rate &#8212; operating leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approximate future minimum lease payments under operating leases were as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:86%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,042</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">916</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">944</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">724</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,626</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less imputed interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(630</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,996</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less current portion of lease liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">759</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liability, net of current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,237</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674076247056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">12. Income Taxes </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total loss before income taxes for the years ended December&#160;31, 2023, 2022 and 2021 did not include a foreign component. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of the provision expense (benefit) were as follows for the years ended December&#160;31, 2023, 2022 and 2021 (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:64%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current income tax expense (benefit):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred income tax expense (benefit):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(16,514</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10,396</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12,981</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11,247</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,851</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,472</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(27,761</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12,247</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15,453</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in tax rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,471</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,347</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29,232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,900</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,422</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total income tax expense from continuing operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of the Company&#8217;s net deferred tax liabilities and related valuation allowance are as follows as of December&#160;31, 2023 and 2022 (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating loss carryforwards</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71,434</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">48,984</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Debt related interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,898</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,272</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capitalized research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,936</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,014</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Tax credit carryforwards</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,960</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,630</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock based compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">525</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,602</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expense and reserves</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,584</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">568</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">774</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">315</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">159</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100,270</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">70,462</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(96,776</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(67,543</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,494</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,919</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,734</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,666</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(760</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(253</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,494</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,919</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net deferred tax liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The reconciliation between U.S. federal income taxes at the statutory rate and the Company&#8217;s provision for income taxes are as follows for the years ended December&#160;31, 2023, 2022 and 2021 (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:65%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax benefit at federal statutory rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(24,007</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,905</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19,150</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29,232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,900</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,422</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Debt discount and interest limitation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9,293</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,954</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Compensation expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,469</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">224</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquisition related charges</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">260</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">992</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prior year <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">true-up</div> and carryback</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,079</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(713</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,968</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State, net of federal tax benefit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,127</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(174</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,545</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of Convertible Debentures</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,752</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in tax rates</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,471</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">655</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">728</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">993</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has evaluated the available evidence supporting the realization of its gross deferred tax assets, including the amount and timing of future taxable income, and has determined that it is more likely than not that the deferred tax assets will not be realized. Due to such uncertainties surrounding the realization of the deferred tax assets, the Company maintains a valuation allowance of $96.8&#160;million against its deferred tax assets as of December&#160;31, 2023. Realization of the deferred tax assets will be primarily dependent upon the Company&#8217;s ability to generate sufficient taxable income prior to the expiration of its net operating losses. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, the Company had $278.7&#160;million and $114.0&#160;million of federal and state net operating loss carryforwards, respectively. The net operating loss carryforwards begin to expire in 2035 and 2034 for federal and state, respectively. As of December&#160;31, 2023, the Company had a total of $265.9&#160;million of federal net operating losses </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">that have an indefinite life and will not expire, and had federal research and development income tax credits of $3.4&#160;million which will begin to expire in 2035. As of December&#160;31, 2023, the Company had California research and development income tax credits of $1.9&#160;million that have an indefinite life and will not expire. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Internal Revenue Code Section&#160;382 rules apply to limit a corporation&#8217;s ability to utilize existing net operating loss and tax credit carryforwards once the corporation experiences an ownership change as defined in Section&#160;382. For the years ended December&#160;31, 2023 and 2022, there was no impact of such limitations on the Company&#8217;s income tax provision. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to taxation in U.S. federal and state tax jurisdictions. All of the Company&#8217;s tax years will remain open for three years for examination by the federal and state tax authorities from the date of utilizations of net operating loss. There are no active tax compliance audits as of December&#160;31, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reconciliation of the beginning and ending amount of unrecognized tax expense (benefits) is as follows for the years ended December&#160;31, 2023, 2022 and 2021 (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beginning balance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">408</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">408</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">406</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Increase related to prior year tax positions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">536</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Increases related to current year tax positions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">127</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending balance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,071</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">408</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">408</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, 2022 and 2021, the Company had $1.1&#160;million, $0.4&#160;million and $0.4&#160;million in total unrecognized tax benefits, respectively. If these were to be recognized, they would affect the effective tax rate, however given the full valuation allowance in the jurisdiction in which the unrecognized tax benefits relate to, the impact on the effective tax rate would be nil. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense. No interest or penalties have been recognized as of and for the periods ended December&#160;31, 2023, 2022 and 2021. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company believes that no material amount of the liabilities for uncertain tax positions are expected to reverse within 12 months of December&#160;31, 2023. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674076304480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">13. Net Loss Per Share </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the reconciliation of basic and diluted loss per share for the years ended December&#160;31, 2023, 2022 and 2021 (in thousands except per share data): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:60%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(114,331</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(23,364</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(88,424</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Premium on redemption of Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(52,645</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss for basic and diluted loss per share available to common stockholders</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(166,976</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(23,364</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(88,424</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average number of shares outstanding - basic</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">130,298</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">134,226</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">132,858</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effect of dilutive securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average number of shares and assumed conversions - diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">130,298</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">134,226</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">132,858</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss per share</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1.28</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.17</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.67</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic net loss per share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding during the period. Premium paid on redemption of Preferred Stock was added to the net loss to arrive at loss available for common stockholders as it represents a dividend to the preferred stockholder. Diluted earnings per share is computed using the weighted average number of Common Stock and, if dilutive, potential Common Stock outstanding during the period. Potential Common Stock consists of the incremental Common Stock issuable upon the exercise of stock options and warrants (using the treasury stock method). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the computation of net loss per share, treasury shares are not included as part of the outstanding shares. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with FASB ASC 260, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Earnings Per Share, </div></div>Penny Warrants are warrants that would be exercised for no or little consideration and therefore should be included in the calculation of weighted average shares outstanding for purposes of calculating basic and diluted net income (loss) per share. The Closing Penny Warrants become exercisable upon the passage of time and are included in basic and diluted net income (loss) per share from the closing date of September&#160;21, 2023. The Subsequent Penny Warrants to purchase up to an aggregate of 8,500,000 shares of Common Stock are not vested as of the closing date of September&#160;21, 2023 and the vesting is based on the passage of time, the Company&#8217;s repayment of the Oramed Note or the occurrence of the Management Sale Trigger Date (as defined therein). Therefore, these Subsequent Penny Warrants are included in the computation for diluted net income per share once all other exercise contingencies are removed except for the passage of time. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:55%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock options</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33,123,798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,939,093</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,967,724</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,854,309</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,899,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Private Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,613,383</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,104,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Retainer Shares</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares Issuable pursuant to ESPP</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29,806</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Convertible Debentures</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">546,921</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">48,168,217</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,943,081</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,967,724</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674082726768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">14. Subsequent Events </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Termination of B. Riley Purchase Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;16, 2024, the Company and B. Riley mutually agreed to terminate the B. Riley Purchase Agreement. The termination is effective as of February&#160;16, 2024. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Underwritten Offering </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;29, 2024, the Company entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Rodman&#160;&amp; Renshaw LLC and StockBlock Securities LLC, as the representatives (the &#8220;Representatives&#8221;) of the underwriters named in Schedule A (the &#8220;Underwriters&#8221;). Pursuant to the Underwriting Agreement, the Company agreed to sell, in an underwritten offering (the &#8220;Bought Deal Offering&#8221;), 5,882,353&#160;shares (the &#8220;Firm Shares&#8221;) of the Common Stock, and accompanying common warrants to purchase up to an aggregate of 5,882,353&#160;shares of Common Stock (the &#8220;Firm Warrants&#8221;). Pursuant to the Underwriting Agreement, the Company also granted the Underwriters an option for a period of 30 days from the date of the Underwriting Agreement to purchase up to 882,352 additional shares of Common Stock (the &#8220;Optional Shares&#8221;, and together with the Firm Shares, the &#8220;Shares&#8221;) and/or common warrants to purchase up to 882,352 shares of Common Stock (the &#8220;Optional Warrants&#8221;, and together with the Firm Warrants, the &#8220;Common Warrants&#8221;) that may be purchased </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">by the Underwriters, at a price per Optional Share of $1.5548&#160;and a price per Optional Warrant of $0.0092, which amounts reflect the public offering price of $1.69 per Optional Share and $0.01&#160;per Optional Warrant, less underwriting discounts and commissions, as applicable (the &#8220;Underwriters&#8217; Option&#8221;).&#160;Each Firm Share was sold together with a Firm Warrant at a combined public offering price of $1.70. The combined price per Firm Share and accompanying Firm Warrant paid by the Underwriters was $1.564, which amount reflects the combined public offering price of $1.70, less underwriting discounts and commissions. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to certain ownership limitations, the Common Warrants are exercisable immediately from the date of issuance, will expire on the five-year anniversary of the date of issuance and have an exercise price of $1.70&#160;per share. The exercise price of the Common Warrants is subject to certain adjustments, including (but not limited to) for stock dividends, stock splits, combinations and reclassifications of the Common Stock. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Bought Deal Offering, the Company agreed, pursuant to the Underwriting Agreement, to issue the Representatives warrants (the &#8220;Representative Warrants&#8221;, and together with the Common Warrants, the &#8220;Warrants&#8221;) to purchase up to an aggregate of 470,588 shares of Common Stock (which represents 8.0% of the aggregate number of Firm Shares sold in the Bought Deal Offering), or up to an aggregate of 541,176 shares of Common Stock if the Underwriters exercise the Underwriters&#8217; Option in full. The Representative Warrants are immediately exercisable and have the same terms as the Common Warrants described above, except that the exercise price of the Representative Warrants is $2.125 per share, which represents 125% of the combined public offering price per Firm Share and accompanying Firm Warrant. The Company also agreed to pay certain expenses of the Representatives in connection with the Bought Deal Offering, including their legal fees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> expenses up to $200,000 and up to $15,950 for clearing expenses. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Shares, the Warrants and the shares of Common Stock issuable upon exercise of the Warrants were offered and sold by us pursuant to an effective shelf registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3,</div> which was originally filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on December&#160;22, 2023, as amended, and was declared effective on January&#160;11, 2024 (File <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-276245),</div> a base prospectus dated January&#160;11, 2024, and a final prospectus supplement dated February&#160;29, 2024. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674193367408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations and Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position for the periods presented. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements include the accounts of the Company as well as its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Segments </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating segments are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assessing performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer, as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions. The Company is engaged primarily in the development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-opioid</div> products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single reportable segment. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of these consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Customer Concentration Risk</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Customer Concentration Risk </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to April 2022, sales to the Company&#8217;s sole distributor represented 100% of net revenue. In April 2022, the Company announced the expansion of its direct distribution network to national and regional wholesalers and pharmacies. The Company had three and four customers during the years ended December&#160;31, 2023 and 2022, respectively, each of which individually generated 10% or more of the Company&#8217;s total revenue. These customers accounted for 85% and 83% of the Company&#8217;s revenue for the years ended December&#160;31, 2023 and 2022, respectively, individually ranging from 22% to 32% and 19% to 24%, respectively. As of December&#160;31, 2023 and 2022, these customers represented 91% and 90% of the Company&#8217;s outstanding accounts receivable, respectively, individually ranging between 24% and 36% for both periods. Additionally, during the years ended December&#160;31, 2023 and 2022, the Company purchased ZTlido inventory from its sole supplier, Itochu Chemical Frontier Corporation (&#8220;Itochu&#8221;). This exposes the Company to concentration of customer and supplier risk. The Company monitors the financial condition of its customers, limits its credit exposure by setting credit limits, and has not experienced any credit losses during the years ended December&#160;31, 2023 and 2022. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial assets and liabilities are recorded at fair value on a recurring basis in the consolidated balance sheets. The carrying values of the Company&#8217;s financial assets and liabilities, including cash and cash equivalents, restricted cash, prepaid and other current assets, accounts payable and accrued expenses approximate to their fair value due to the short-term nature of these instruments. The derivative warrant liability associated with the Private Warrants (as defined below) is valued using the Black-Scholes option pricing model, which is further discussed in Note 4. The Company elected the fair value option to account for the Convertible Debentures (as defined below) in an aggregate principal amount of up to $25.0&#160;million that were issued in March and April 2023 </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and for the Oramed Note (as defined below) in the principal amount of $101.9&#160;million that was issued in September 2023 (see Note 7 titled &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Debt&#8221; </div></div>below). These instruments are measured at fair value on a recurring basis using Level&#160;3 inputs. The Binomial Lattice Model valuation technique and a discounted cash flow model were employed to measure the fair value of the Convertible Debentures and the Oramed Note, respectively. The Revolving Facility (as defined below) in an aggregate principal amount of up to $30.0&#160;million was issued in June 2023 (see Note 7 titled &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Debt&#8221; </div></div>below). The Company accounts for the Revolving Facility using the amortized cost basis and recognizes interest expense over the expected term using the effective interest rate method. The carrying value of the Revolving Facility approximates its fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. Assets and liabilities recorded at fair value are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels are directly related to the amount of subjectivity with the inputs to the valuation of these assets or liabilities as follows: </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1 - </div></div>Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2 - </div></div>Inputs (other than quoted prices included in Level&#160;1) that are either directly or indirectly observable inputs for similar assets or liabilities. These include quoted prices for identical or similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active; and </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3 - </div></div>Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Cash, Cash Equivalents and Restricted Cash </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments that are readily convertible into cash without penalty and with original maturities of three months or less at the date of purchase to be cash equivalents. The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents are valued at cost, which approximate their fair value. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Restricted cash as of December&#160;31, 2023 consist of deposits placed in a segregated bank account as required under the terms of the Credit and Security Agreement, dated as of June&#160;27, 2023, between Scilex Pharma and eCapital Healthcare Corp., which is discussed further in Note 7. Restricted cash is recorded as other long-term assets within the Company&#8217;s consolidated balance sheet. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that together reflect the same amounts shown in the consolidated statements of cash flows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:60%"></td>
<td style="vertical-align:bottom;width:13%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:13%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,921</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,184</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted cash</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">808</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash, cash equivalents, and restricted cash</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,729</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,184</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable, Net</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Accounts Receivable, Net </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounts receivable are presented net of allowances for expected credit losses and prompt payment discounts. Accounts receivable consists of trade receivables from product sales to customers, which are generally unsecured. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for expected credit losses within accounts receivable, net. The Company reviews </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for expected credit losses.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Inventory </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company determines inventory cost on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-out</div> basis. The Company reduces the carrying value of inventories to a lower of cost or net realizable value for those items that are potentially excess, obsolete or slow- moving. The Company reserves for excess and obsolete inventory based upon historical experience, sales trends, and specific categories of inventory and expiration dates for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-hand</div> inventory. Inventory costs resulting from these adjustments are recognized as cost of sales in the period in which they are incurred. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#8217;s judgment, the Company capitalizes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-launch</div> inventory costs prior to regulatory approval. As of December&#160;31, 2023 and 2022, the Company&#8217;s inventory was primarily comprised of finished goods. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment, Net </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment are carried at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally five to seven years. Leasehold improvements are amortized over the lesser of their estimated useful lives or the term of the respective lease on a straight-line basis.&#160;The cost of repairs and maintenance is expensed as incurred. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Acquisitions </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for business combinations using the acquisition method of accounting, which requires that assets acquired, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development (&#8220;IPR&amp;D&#8221;) projects and liabilities assumed be recorded at their fair values as of the acquisition date on the Company`s consolidated balance sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When the Company determines net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the transaction is accounted for as an acquisition of assets and, therefore, no goodwill is recorded and contingent consideration such as payments upon achievement of various developmental, regulatory and commercial milestones generally is not recognized at the acquisition date. In an asset acquisition, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> payments allocated to IPR&amp;D projects at the acquisition date and subsequent milestone payments are charged to expense in the Company`s consolidated statements of operations unless there is an alternative future use. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates. Intangible assets acquired in a business combination that are used for IPR&amp;D activities are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Upon commercialization of the relevant research and development project, the Company amortizes the acquired IPR&amp;D over its estimated useful life. Capitalized IPR&amp;D is reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Other Long-Lived Assets</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill and Other Long-Lived Assets </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwill, which has an indefinite life, represents the excess cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if events occur </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div></div><div><div style="line-height:normal;background-color:white;display: inline;"></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">indicating the potential for impairment. The Company has one reporting unit. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company performs a quantitative goodwill impairment test. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative goodwill impairment test.</div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluates its long-lived and intangible assets with definite lives, such as property and equipment, patent rights, and acquired technology, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-generic</div> and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of useful life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets&#8217; book value to future net undiscounted cash flows that the assets are expected to generate to determine if a write-down to the recoverable amount is appropriate. If such assets are written down, an impairment will be recognized as the amount by which the book value of the asset group exceeds the recoverable amount. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentLiabilityReserveEstimatePolicy', window );">Contingent Consideration</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Contingent Consideration </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of contingent consideration liabilities assumed in business combinations is recorded as part of the purchase price consideration of the acquisition, and is determined using a discounted cash flow model or Monte Carlo simulation model. The significant inputs of such models are not observable in the market, such as certain financial metric growth rates, volatility rates, projections associated with applicable milestones, discount rates and the related probabilities and payment structure in the contingent consideration arrangement. Fair value adjustments to contingent consideration liabilities are recorded through operating expenses in the consolidated statement of operations. Other than contingent consideration that is accounted for in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480, Distinguishing Liabilities from Equity, and Topic 815, Derivatives and Hedging, contingent consideration arrangements assumed in an asset acquisition will be measured and accrued when such contingency is resolved. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock', window );">Public Warrants and Private Placement Warrants</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Public Warrants and Private Warrants </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon completion of the Business Combination, the Company assumed public and private placement warrants to purchase Common Stock, each with an exercise price of $11.50 per share (&#8220;Public Warrants&#8221; and &#8220;Private Warrants&#8221;, respectively, and collectively, the &#8220;SPAC Warrants&#8221;) that were issued by Vickers in connection with its initial public offering (declared effective by the Securities and Exchange Commission (&#8220;SEC&#8221;) on January&#160;11, 2021) whereby holders of the public and private placement warrants are entitled to acquire ordinary shares of Vickers. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to the Business Combination, the Public Warrants were accounted for as equity per FASB ASC Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;815-40,</div> Contracts on an Entity&#8217;s Own Equity. Warrants classified as equity are recorded at their issuance cost and are not subject to remeasurement at each subsequent balance sheet date. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to the Business Combination, the Private Warrants were accounted for as liabilities per ASC Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40.</div> The Private Warrants are not considered indexed to the Company&#8217;s stock per ASC Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40</div> as the fair value calculation applicable upon a cashless exercise of a Private Warrant changes based upon the holder of the instrument, which is not an input to a valuation model for a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">fixed-for-fixed</div></div> option contract. Therefore, Private Warrants are recognized as derivative liabilities at their estimated fair value on November&#160;10, 2022, the date of the closing of the Business Combination, and are revalued at each subsequent balance sheet </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>date, with fair value changes recognized in the statement of operations. The Company estimates the value of these warrants using a Black-Scholes option pricing formula.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Debt </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may enter into financing arrangements, the terms of which involve significant assumptions and estimates. This involves estimating future net product sales, determining interest expense, determining the amortization period of the debt discount, as well as determining the classification between current and long-term portions. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ConvertibleDebenturesAndTheOramedNotePolicyTextBlock', window );">Convertible Debentures and the Oramed Note</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Convertible Debentures and the Oramed Note </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has elected the fair value option to account for the Convertible Debentures (as defined in Note 2 &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidity and Going Concern</div></div>&#8221; below) that were issued in March and April 2023, as discussed further in Note 7. The Company has also elected the fair value option to account for the Oramed Note (as defined in Note 4 &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements</div></div>&#8221; below). The Company recorded the Convertible Debentures and the Oramed Note at fair value upon issuance with changes in fair value recorded as change in fair value of debt and liability instruments in the consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. Interest expense related to these financial instruments is included in the changes in fair value. As a result of applying the fair value option, direct costs and fees related to the Convertible Debentures and the Oramed Note were expensed as incurred. The weighted-average interest rates for the short-term loans, including the Convertible Debentures and the Oramed Note, were 13.55% and nil for the years ended December&#160;31, 2023 and 2022, respectively. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Liabilities</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Derivative Liabilities </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Derivative liabilities are recorded on the Company&#8217;s consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Research and Development Costs </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company expenses the cost of research and development as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and preclinical materials as well as other contracted services, license fees and other external costs.&#160;Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with FASB ASC Topic 730, Research and Development. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The provisions of the FASB ASC Topic 740, Income Taxes, address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">740-10,</div> the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position.&#160;The Company has determined that it has uncertain tax positions. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>will be realized. As of December&#160;31, 2023 and 2022, the Company maintained a full valuation allowance against its deferred tax assets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Leases </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company determines if an arrangement is a lease at inception. Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (&#8220;ROU&#8221;) assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and is reduced by lease incentives. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term in selling, general and administrative expenses. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Revenue Recognition </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s revenue is generated from product sales within the United States. The Company does not incur significant direct costs to obtain contracts with its customers. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from product sales is comprised of sales of ZTlido and ELYXYB. The Company&#8217;s performance obligation with respect to sales of ZTlido and ELYXYB is satisfied at a point in time, when control is transferred upon delivery of product to the customer. The Company considers control to have transferred upon delivery because the customer has legal title to the product, physical possession of the product has been transferred to the customer, the customer has significant risks and rewards of ownership of the product, and the Company has a present right to payment at that time.&#160;Invoicing typically occurs upon shipment and the length of time between invoicing and when payment is due is not significant. The aggregate dollar value of unfulfilled orders as of December&#160;31, 2023 and 2022 were not material. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenues from product sales are recorded net of reserves established for commercial and government rebates, fees and chargebacks, wholesaler and distributor fees, sales returns and prompt payment discounts. Such variable consideration is estimated in the period of the sale and is estimated using a most likely amount approach based primarily upon provisions included in the Company&#8217;s customer contract, customary industry practices and current government regulations. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rebates and Chargebacks </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rebates are discounts which the Company pays under either government or private health care programs.&#160;Government rebate programs include state Medicaid drug rebate programs, the Medicare coverage gap discount programs and the Tricare programs. Commercial rebate and fee programs relate to contractual agreements with commercial healthcare providers, under which the Company pays rebates and fees for access to and position on that provider&#8217;s patient drug formulary. Rebates and chargebacks paid under government programs are generally mandated under law, whereas private rebates and fees are generally contractually negotiated by the Company with commercial healthcare providers. Both types of rebates vary over time. The Company records a reduction to gross product sales at the time the customer takes title to the product based on estimates of expected rebate claims. The Company monitors the sales trends and adjusts for these rebates on a regular basis to reflect the most recent rebate experience and contractual obligations. Reserves for rebates and chargebacks are now separately presented as accrued rebates and fees under current liabilities within the Company&#8217;s consolidated balance sheet. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Prompt Payment Discounts </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company provides its customers with prompt payment discounts which may result in adjustments to the price that is invoiced for the product transferred, in the case that payments are made within a defined period. The </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">prompt payment discount reserve is based on actual gross sales and contractual discount rates. Reserves for prompt payment discounts are included in accounts receivable, net on the consolidated balance sheets. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Service Fees </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company compensates its customer and others in the distribution chain for wholesaler and distribution services. The Company has determined such services received to date are not distinct from the Company&#8217;s sale of products to the customer and, therefore, these payments have been recorded as a reduction of revenue. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Returns </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is obligated to accept the return of products sold that are expiring within six months, damaged or do not meet certain specifications. The Company may authorize the return of products sold in accordance with the term of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company estimates the amount of its product sales that may be returned by its customer and records this estimate as a reduction of revenue in the period the related product revenue is recognized. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Payment</div> Assistance </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients who have commercial insurance or pay cash and meet certain eligibility requirements may receive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-</div> payment assistance. The Company accrues for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payment</div> assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Stock-Based Compensation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, Compensation &#8211; Stock Compensation which establishes accounting for equity instruments exchanged for employee and consulting services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee&#8217;s requisite service period (generally the vesting period of the equity grant) or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee&#8217;s</div> vesting period. The Company accounts for forfeitures as incurred. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of determining the inputs used in the calculation of stock-based compensation, the Company determines the expected life assumption for options issued using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period since the Company does not have historic exercise behavior. Then the Company determines an estimate of option volatility based on an assessment of historical volatilities of comparable companies whose share prices are publicly available. The Company uses these estimates as variables in the Black-Scholes option pricing model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in our consolidated statement of operations. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TreasuryStockPolicyTextblock', window );">Treasury Stock</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Treasury Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company uses the cost method to account for repurchases of its stock. In the computation of net (loss) income per share, treasury shares are not included as part of the outstanding shares. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Net Loss per Share </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share attributable to common stockholders is presented in conformity with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method required for participating securities. Net loss per share has been retrospectively adjusted for all periods presented prior to the Business Combination. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method, basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share attributable to common stockholders adjusts basic earnings per share for the potentially dilutive impact of stock options and warrants. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the Company has reported losses for all periods presented, all potentially dilutive securities are antidilutive and accordingly, basic net loss per share equals diluted net loss per share. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Recently Adopted Accounting Pronouncements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2021, FASB issued Accounting Standards Updates (&#8220;ASU&#8221;) 2021-08, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Combinations (Topic&#160;805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;ASU&#160;2021-08&#8221;)</div></div></div>, which requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities in accordance with ASC Topic 606. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2021-08</div> is effective for fiscal years beginning after December&#160;15, 2022. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2021-08</div> should be applied prospectively to business combinations occurring on or after the adoption date. The Company adopted this guidance as of January&#160;1, 2023 and the adoption did not have a material impact on the Company&#8217;s consolidated financial statements. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2022, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2022-03,</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2022-03&#8221;),</div> </div></div>which clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered when measuring fair value. Recognizing such a restriction as a separate unit of account is also not permitted. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2022-03</div> is effective for fiscal years beginning after December&#160;15, 2023, with early adoption permitted. The Company elected to early adopt this guidance as of January&#160;1, 2023 and the adoption did not have a material impact on the Company&#8217;s consolidated financial statements. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ConvertibleDebenturesAndTheOramedNotePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Debentures and the Oramed Note</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ConvertibleDebenturesAndTheOramedNotePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public Warrant And Private Placement Warrants [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TreasuryStockPolicyTextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury Stock Policy TextBlock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TreasuryStockPolicyTextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479515/805-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentLiabilityReserveEstimatePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the claims loss reserve for insurance contracts with a life contingency (permanent life, some term life, accident and health, some annuities), describing the loss exposures and bases and methodologies for making the relevant accounting estimates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(13)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentLiabilityReserveEstimatePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674075958336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations and Basis of Presentation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that together reflect the same amounts shown in the consolidated statements of cash flows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:60%"></td>
<td style="vertical-align:bottom;width:13%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:13%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,921</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,184</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted cash</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">808</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash, cash equivalents, and restricted cash</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,729</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,184</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674082066576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of fair value assets measured on a recurring basis</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the Company&#8217;s financial assets and liabilities that are measured at fair value on a recurring basis and the level of inputs used in such measurements (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:42%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices<br/> in Active<br/> Markets<br/> (Level 1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs&#160;(Level&#160;2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable<br/> Inputs&#160;(Level&#160;3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Oramed Note</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">104,089</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">104,089</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Convertible Debentures</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-hidden:hidden107552736;display:inline;">Derivative liabilities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,518</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,518</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other long-term liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities measured at fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">110,126</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">110,126</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:44%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices<br/> in Active<br/> Markets<br/> (Level&#160;1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs&#160;(Level&#160;2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable<br/> Inputs&#160;(Level&#160;3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-hidden:hidden107552737;display:inline;">Derivative liabilities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,231</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,231</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other long-term liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">163</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">163</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities measured at fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,394</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,394</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of convertible debentures</a></td>
<td class="text">A summary of inputs used in valuing the Convertible Debentures is as follows: <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:17%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk -Free Rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.31</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate Bond Yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15.60</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Coupon Interest Rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">70.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend Yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Conversion Price</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of the derivative liabilities measured at fair value using significant unobservable inputs Level 3</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table includes a summary of the derivative liabilities measured at fair value during the three years ended December&#160;31, 2023, 2022 and 2021 (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:84%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">35,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> of fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">35,700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Private warrant liability acquired as part of the Business Combination</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,545</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeiture of Private Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,696</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value measurement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(38,710</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,231</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value measurement</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">512</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeiture of Private Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(225</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,518</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueConcentrationOfRiskTextBlock', window );">Schedule of quantitative information regarding Level 3 fair value measurements</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:65%"></td>
<td style="vertical-align:bottom;width:13%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Equity value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.04</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.99</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise price</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Term, in years</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">76.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">35.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.90</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.94</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Call option value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueConcentrationOfRiskTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-23<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueConcentrationOfRiskTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674076159312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and equipment</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment, net, consists of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:13%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:13%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Construction in progress</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">689</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">689</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">118</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computers and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, gross</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">780</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">939</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Accumulated depreciation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(58</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(167</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">722</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">772</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AccruedExpensesTextblock', window );">Schedule of Acrcued expenses</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued expenses consists of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional service fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued sales and marketing costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,601</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">574</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued research and development costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,546</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">459</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued tax payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,452</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued others</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">780</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">79</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,408</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AccruedExpensesTextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses Textblock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AccruedExpensesTextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674082936880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Summary of identifiable intangible assets</a></td>
<td class="text">A summary of the Company&#8217;s identifiable intangible assets as of December&#160;31, 2023 and December&#160;31, 2022 is as follows (in thousands): <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:55%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross&#160;Carrying<br/> Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intangibles,<br/> net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Patent rights</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,630</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,591</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,039</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired technology</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21,940</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,679</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,261</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired licenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">551</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Assembled workforce</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">475</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">60,781</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24,296</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,485</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:55%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross&#160;Carrying<br/> Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intangibles,<br/> net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Patent rights</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,630</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,215</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired technology</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21,940</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,216</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,724</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquired licenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">184</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,527</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Assembled workforce</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">375</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">125</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">60,781</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20,190</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40,591</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated future amortization expense related to intangible assets</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Estimated future amortization expense related to intangible assets as of December&#160;31, 2023 is as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:85%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,006</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,006</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,006</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2028</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,006</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Thereafter</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,430</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,485</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674076110800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of convertible debentures</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a summary of the changes in the balance and the estimated fair value of the Convertible Debentures (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:13%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beginning Balance as of January&#160;1, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Convertible Debentures</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayment of Convertible Debentures</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15,625</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of Convertible Debentures</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Conversion of Convertible Debentures into Common Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,735</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Oramed Note</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ScheduleOfTheOramedNoteTableTextBlock', window );">Schedule of The Oramed Note</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a summary of the changes in the balance and the estimated fair value of the Oramed Note (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beginning Balance as of January&#160;1, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Oramed Note</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">106,252</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of Oramed Note</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,837</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayment of Oramed Note</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,000</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending Balance as of December&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">104,089</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ScheduleOfTheOramedNoteTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of The Oramed Note Table Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ScheduleOfTheOramedNoteTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674078274912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive and Employee Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Options Outstanding Activity</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes stock option activity during the year ended December&#160;31, 2023 (shares in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:48%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Exercise&#160;Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Remaining<br/> Contractual&#160;Life,<br/> in years</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> Intrinsic&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding as of December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,939</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38,942</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,610</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.02</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(365</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited/Cancelled</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,060</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding as of December&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33,124</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,459</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable as of December&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,990</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.78</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of estimate stock-based compensation on the date of grant for stock options and ESPP</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following assumptions were used in the Black-Scholes options pricing model to estimate stock-based compensation on the date of grant for stock options and ESPP: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> December&#160;31, 2023</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock options:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">0.00%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">40.00%&#160;-&#160;77.00%</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3.59%&#160;-&#160;4.74%</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Term of options (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">6.25</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Employee stock purchase plan:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">0.00%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">117.57%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">5.33%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected life (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">0.50</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674081973040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Leases Supplemental Quantitative Information</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Supplemental quantitative information related to leases includes the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:78%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash paid for amounts included in the measurement of lease liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating cash flows from operating leases (in thousands)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,021</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(746</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average remaining lease term in years &#8212; operating leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average discount rate &#8212; operating leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Lease Maturities of Lease Liabilities</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approximate future minimum lease payments under operating leases were as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:86%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,042</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">916</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">944</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">724</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,626</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less imputed interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(630</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,996</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less current portion of lease liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">759</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liability, net of current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,237</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674075986864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Benefit for Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of the provision expense (benefit) were as follows for the years ended December&#160;31, 2023, 2022 and 2021 (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:64%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current income tax expense (benefit):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred income tax expense (benefit):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(16,514</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10,396</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12,981</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11,247</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,851</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,472</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(27,761</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12,247</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15,453</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in tax rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,471</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,347</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29,232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,900</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,422</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total income tax expense from continuing operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Liabilities and Related Valuation Allowance</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of the Company&#8217;s net deferred tax liabilities and related valuation allowance are as follows as of December&#160;31, 2023 and 2022 (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating loss carryforwards</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71,434</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">48,984</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Debt related interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,898</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,272</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capitalized research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,936</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,014</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Tax credit carryforwards</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,960</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,630</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock based compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">525</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,602</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expense and reserves</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,584</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">568</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">774</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">315</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">159</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100,270</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">70,462</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(96,776</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(67,543</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,494</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,919</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,734</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,666</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(760</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(253</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,494</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,919</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net deferred tax liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The reconciliation between U.S. federal income taxes at the statutory rate and the Company&#8217;s provision for income taxes are as follows for the years ended December&#160;31, 2023, 2022 and 2021 (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:65%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax benefit at federal statutory rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(24,007</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,905</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19,150</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29,232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,900</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,422</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Debt discount and interest limitation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9,293</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,954</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Compensation expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,469</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">224</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Acquisition related charges</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">260</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">992</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prior year <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">true-up</div> and carryback</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,079</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(713</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,968</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State, net of federal tax benefit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,127</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(174</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,545</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of Convertible Debentures</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,752</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in tax rates</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,471</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">655</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">728</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">993</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits Roll Forward</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reconciliation of the beginning and ending amount of unrecognized tax expense (benefits) is as follows for the years ended December&#160;31, 2023, 2022 and 2021 (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beginning balance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">408</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">408</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">406</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Increase related to prior year tax positions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">536</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Increases related to current year tax positions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">127</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending balance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,071</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">408</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">408</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674083190240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of the reconciliation of basic and diluted loss per share</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the reconciliation of basic and diluted loss per share for the years ended December&#160;31, 2023, 2022 and 2021 (in thousands except per share data): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:60%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(114,331</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(23,364</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(88,424</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Premium on redemption of Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(52,645</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss for basic and diluted loss per share available to common stockholders</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(166,976</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(23,364</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(88,424</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average number of shares outstanding - basic</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">130,298</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">134,226</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">132,858</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effect of dilutive securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average number of shares and assumed conversions - diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">130,298</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">134,226</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">132,858</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss per share</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1.28</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.17</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.67</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:55%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock options</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33,123,798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,939,093</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,967,724</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,854,309</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,899,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Private Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,613,383</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,104,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Retainer Shares</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares Issuable pursuant to ESPP</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29,806</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Convertible Debentures</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">546,921</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">48,168,217</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,943,081</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,967,724</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674080081280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations and Basis of Presentation (Additional Information) (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfNetRevenueSoleDistributors', window );">Percentage of net revenue, sole distributor</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Three Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Minimum [Member] | Three Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Maximum [Member] | Three Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Accounts Receivable [Member] | Three Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">91.00%<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Accounts Receivable [Member] | Minimum [Member] | Three Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debentures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt principal amount</a></td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101.9<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Debt Weighted Average Interest Rate</a></td>
<td class="nump">13.55%<span></span>
</td>
<td class="nump">13.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Descriptionof Organizationand Business Operations Details Line Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfNetRevenueSoleDistributors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of net revenue, sole distributors</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfNetRevenueSoleDistributors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=sclx_ThreeCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=sclx_ThreeCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674079653120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of Operations and Basis of Presentation - Schedule of Cash and Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,921<span></span>
</td>
<td class="nump">$ 2,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">808<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash</a></td>
<td class="nump">$ 4,729<span></span>
</td>
<td class="nump">$ 2,184<span></span>
</td>
<td class="nump">$ 4,338<span></span>
</td>
<td class="nump">$ 4,839<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674083171904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Going Concern (Additional Information) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 27, 2023</div></th>
<th class="th"><div>Apr. 30, 2023</div></th>
<th class="th"><div>Mar. 21, 2023</div></th>
<th class="th"><div>Nov. 17, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 22, 2023</div></th>
<th class="th"><div>Sep. 25, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity and Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WorkingCapital', window );">Negative working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 203,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,921,000<span></span>
</td>
<td class="nump">$ 2,184,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(105,431,000)<span></span>
</td>
<td class="num">(50,634,000)<span></span>
</td>
<td class="num">$ (35,838,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(490,245,000)<span></span>
</td>
<td class="num">$ (375,914,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PrincipalLaonAmount', window );">Principal laon amount</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Aggregate Principle amount of issued debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OutstandingBalanceOfRevolvingFacility', window );">Outstanding balance of revolving facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Offer and sell shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,084,250<span></span>
</td>
<td class="nump">141,348,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">474,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EquityUnitPurchaseAgreementsMember', window );">Equity Purchase Agreement with Yorkville and B. Riley [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity and Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_Convertibledebentureprincipalamount', window );">Convertible Debenture principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible Debenture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Aggregate Principle amount of issued debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseAgreementAxis=sclx_ARYorkvillePurchaseAgreementMember', window );">A&amp;R Yorkville Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity and Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Aggregate Principle amount of issued debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Offer and sell shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">632,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RightToSellMaximumNumberOfCommonStockShares', window );">Right to sell maximum number of common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseAgreementAxis=sclx_ARYorkvillePurchaseAgreementMember', window );">A&amp;R Yorkville Purchase Agreement | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity and Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseAgreementAxis=sclx_AtmSalesAgreementMember', window );">ATM Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity and Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Offer and sell shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | ATM Sales Agreement | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity and Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommonStockIssuableValue', window );">Common stock issuable, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ValueOfStockSoldForTerminationOfOffering', window );">Value of stock sold for termination of offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CommonStockIssuableValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Issuable Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CommonStockIssuableValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_Convertibledebentureprincipalamount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ConvertibleDebentureprincipalAmount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_Convertibledebentureprincipalamount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LiquidityAndGoingConcernLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity and Going Concern [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LiquidityAndGoingConcernLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_OutstandingBalanceOfRevolvingFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Outstanding balance of revolving facility</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_OutstandingBalanceOfRevolvingFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PrincipalLaonAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Principal laon amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PrincipalLaonAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RightToSellMaximumNumberOfCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right to Sell Maximum Number of Common Stock Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RightToSellMaximumNumberOfCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ValueOfStockSoldForTerminationOfOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value Of Stock Sold For Termination Of Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ValueOfStockSoldForTerminationOfOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuedPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of principal of debt issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuedPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EquityUnitPurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EquityUnitPurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchaseAgreementAxis=sclx_ARYorkvillePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchaseAgreementAxis=sclx_ARYorkvillePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchaseAgreementAxis=sclx_AtmSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchaseAgreementAxis=sclx_AtmSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674079884640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Additional Information) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 14, 2022</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PaymentToAcquireLicense', window );">Payment to acquire license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AccruedRoyaltyPayables', window );">Accrued Royalty Payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member] | Sorrento [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PaymentUponTheAchievementOfNetSales', window );">Payment upon the achievement of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AmountDueForNewDrugApplication', window );">Amount due for New Drug Application</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_LicenseAgreementMember', window );">License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Development milestones payment was recognized under other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_LicenseAgreementMember', window );">License Agreement | Romeg License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_Upfrontlicensefee', window );">Up-front license fee</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PaymentUponTheAchievementOfNetSales', window );">Payment upon the achievement of net sales</a></td>
<td class="nump">13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Payments for royalties</a></td>
<td class="nump">7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible asset</a></td>
<td class="nump">5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_Deferredconsiderationliabilities', window );">Deferred consideration</a></td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AccruedRoyaltyPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Royalty Payables</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AccruedRoyaltyPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AmountDueForNewDrugApplication">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due for New Drug Application</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AmountDueForNewDrugApplication</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_Deferredconsiderationliabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>DeferredConsiderationLiabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_Deferredconsiderationliabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PaymentToAcquireLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment to Acquire License</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PaymentToAcquireLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PaymentUponTheAchievementOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>payment upon the achievement of net sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PaymentUponTheAchievementOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_Upfrontlicensefee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>UpFrontLicenseFee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_Upfrontlicensefee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=sclx_SorrentoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=sclx_SorrentoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sclx_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_RomegLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_RomegLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674169449072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Apr. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Jun. 02, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SecuredNoteDiscountRate', window );">Oramed note discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Aggregate Principle amount of issued debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,854,309<span></span>
</td>
<td class="nump">6,899,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense', window );">Change in fair value of debt and liability instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">(Gain) loss on derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(512)<span></span>
</td>
<td class="nump">$ 8,310<span></span>
</td>
<td class="num">$ (300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Liabilities, Fair Value Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RiskAdjustedNetSalesForecast', window );">Risk Adjusted Net Sales Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleWeightedAverageYield', window );">Debt Securities, Available-for-Sale, Weighted Average Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Common stock upon conversation of cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyAccrualDiscountRate', window );">Discount rate of FDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_FairValueOfContingentConsideration', window );">Development Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DerivativeWarrantLiabilityPrivateWarrants', window );">Derivative warrant liability private warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sclx_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">(Gain) loss on derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">$ 8,300<span></span>
</td>
<td class="num">$ (300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Oramed Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Aggregate Principle amount of issued debt</a></td>
<td class="nump">$ 101,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense', window );">Change in fair value of debt and liability instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,613,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DerivativeWarrantLiabilityPrivateWarrants', window );">Derivative warrant liability private warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value Of Convertible Debentures Include Interest Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DerivativeWarrantLiabilityPrivateWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative warrant liability private warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DerivativeWarrantLiabilityPrivateWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_FairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_FairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RiskAdjustedNetSalesForecast">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risk adjusted net sales forecast</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RiskAdjustedNetSalesForecast</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SecuredNoteDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Secured Note Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SecuredNoteDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuedPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of principal of debt issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuedPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleWeightedAverageYield">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average yield of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (a)<br> -Publisher SEC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleWeightedAverageYield</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductLiabilityContingencyAccrualDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate applied to the undiscounted amount of estimated damages for product liability to arrive at the present value recorded as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480102/450-20-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductLiabilityContingencyAccrualDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sclx_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sclx_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674080302208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements  (Details) - Schedule of fair value assets measured on a recurring basis - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Oramed Note</a></td>
<td class="nump">$ 104,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible debenture</a></td>
<td class="nump">$ 4,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Derivative Liability, Noncurrent<span></span>
</td>
<td class="text">Derivative Liability, Noncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">$ 1,518<span></span>
</td>
<td class="nump">$ 1,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">110,126<span></span>
</td>
<td class="nump">1,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Oramed Note</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible debenture</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Oramed Note</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible debenture</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Oramed Note</a></td>
<td class="nump">104,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible debenture</a></td>
<td class="nump">4,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">1,518<span></span>
</td>
<td class="nump">1,231<span></span>
</td>
<td class="nump">$ 35,700<span></span>
</td>
<td class="nump">$ 35,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">$ 110,126<span></span>
</td>
<td class="nump">$ 1,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.16)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674081915472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Schedule of quantitative information regarding Level 3 fair value measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1', window );">Risk-free rate</a></td>
<td class="nump">5.31%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CorporateBondYield', window );">Corporate Bond Yield</a></td>
<td class="nump">15.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CouponInterestRate', window );">Coupon Interest Rate</a></td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price</a></td>
<td class="nump">$ 8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CorporateBondYield">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Corporate Bond Yield</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CorporateBondYield</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CouponInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Coupon Interest Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CouponInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674082687872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Schedule Of The Derivative Liabilities Measured at Fair Value - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value, beginning</a></td>
<td class="nump">$ 1,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value, ending</a></td>
<td class="nump">1,518<span></span>
</td>
<td class="nump">$ 1,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value, beginning</a></td>
<td class="nump">1,231<span></span>
</td>
<td class="nump">35,700<span></span>
</td>
<td class="nump">$ 35,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PrivatePlacementWarrantLiabilityAcquired', window );">Private Warrant liability acquired as part of the Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ReMeasurementOfFairValue', window );">Re-measurement of fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ForfeitureOfPrivateWarrants', window );">Forfeiture of Private Warrants</a></td>
<td class="num">(225)<span></span>
</td>
<td class="nump">1,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ChangeInValuationInputsOrOtherAssumptions', window );">Change in fair value measurement</a></td>
<td class="nump">512<span></span>
</td>
<td class="num">(38,710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value, ending</a></td>
<td class="nump">$ 1,518<span></span>
</td>
<td class="nump">$ 1,231<span></span>
</td>
<td class="nump">$ 35,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ChangeInValuationInputsOrOtherAssumptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in valuation inputs or other assumptions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ChangeInValuationInputsOrOtherAssumptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ForfeitureOfPrivateWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Forfeiture of Private Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ForfeitureOfPrivateWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PrivatePlacementWarrantLiabilityAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Private placement warrant liability acquired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PrivatePlacementWarrantLiabilityAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ReMeasurementOfFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Re-measurement of fair value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ReMeasurementOfFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674081770064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Schedule of The Inputs Used In Valuing The Derivative Warrant Liabilities - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract', window );"><strong>Schedule of derivative component of the obligation is initially valued and classified as a derivative liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_EquityValue', window );">Equity Value</a></td>
<td class="nump">$ 2.04<span></span>
</td>
<td class="nump">$ 3.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term, in years</a></td>
<td class="text">3 years 10 months 9 days<span></span>
</td>
<td class="text">4 years 10 months 9 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">76.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">3.94%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CallOptionValue', window );">Call option value</a></td>
<td class="nump">$ 0.42<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CallOptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Call option value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CallOptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_EquityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_EquityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Derivative Component Of The Obligation Is Initially Valued And Classified As A Derivative Liability Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674080697584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 780<span></span>
</td>
<td class="nump">$ 939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(58)<span></span>
</td>
<td class="num">(167)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">722<span></span>
</td>
<td class="nump">772<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">689<span></span>
</td>
<td class="nump">689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers &amp; equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674081924144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Acrcued expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional service fees</a></td>
<td class="nump">$ 2,029<span></span>
</td>
<td class="nump">$ 2,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedMarketingCostsCurrent', window );">Accrued sales and marketing costs</a></td>
<td class="nump">1,601<span></span>
</td>
<td class="nump">574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AccruedResearchAndDevelopmentCosts', window );">Accrued research and development costs</a></td>
<td class="nump">1,546<span></span>
</td>
<td class="nump">459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrentAndNoncurrent', window );">Accrued tax payable</a></td>
<td class="nump">1,452<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities', window );">Accrued others</a></td>
<td class="nump">780<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AccruedExpenses', window );">Accrued expenses</a></td>
<td class="nump">$ 7,408<span></span>
</td>
<td class="nump">$ 3,136<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AccruedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AccruedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(10)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedMarketingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedMarketingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674075993088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Additional Information) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="nump">$ 39,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674082355328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 13,481<span></span>
</td>
<td class="nump">$ 13,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Goodwill impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average remaining life for identifiable intangible assets</a></td>
<td class="text">9 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 4,106<span></span>
</td>
<td class="nump">$ 3,922<span></span>
</td>
<td class="nump">$ 3,738<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674081960752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Summary of identifiable intangible assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">$ 60,781<span></span>
</td>
<td class="nump">$ 60,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">24,296<span></span>
</td>
<td class="nump">20,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">36,485<span></span>
</td>
<td class="nump">40,591<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_PatentRightsMember', window );">Patent rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">32,630<span></span>
</td>
<td class="nump">32,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">15,591<span></span>
</td>
<td class="nump">13,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">17,039<span></span>
</td>
<td class="nump">19,215<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AcquiredTechnologyMember', window );">Acquired technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">21,940<span></span>
</td>
<td class="nump">21,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">7,679<span></span>
</td>
<td class="nump">6,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">14,261<span></span>
</td>
<td class="nump">15,724<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AcquiredLicensesMember', window );">Acquired licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">5,711<span></span>
</td>
<td class="nump">5,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">551<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">5,160<span></span>
</td>
<td class="nump">5,527<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AssembledWorkforceMember', window );">Assembled workforce</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">475<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_PatentRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_PatentRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AcquiredTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AcquiredTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AcquiredLicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AcquiredLicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AssembledWorkforceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AssembledWorkforceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674079677360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Estimated future amortization expense of intangible assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract', window );"><strong>As of March 31,2023</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 4,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">4,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">4,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">4,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2028</a></td>
<td class="nump">4,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive', window );">Thereafter</a></td>
<td class="nump">16,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 36,485<span></span>
</td>
<td class="nump">$ 40,591<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization,after Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674069991792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Additional Information) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 21, 2023</div></th>
<th class="th"><div>Jul. 01, 2023</div></th>
<th class="th"><div>Jun. 27, 2023</div></th>
<th class="th"><div>Apr. 30, 2023</div></th>
<th class="th"><div>Mar. 21, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Oct. 11, 2023</div></th>
<th class="th"><div>Sep. 25, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Aggregate Principle amount of issued debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionDescription', window );">Debt Instrument Redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company has the right, but not the obligation, in its sole discretion, to redeem, upon five business days&#8217; prior written notice to Yorkville (the &#8220;Redemption Notice&#8221;), all or any portion of the amounts outstanding under the Convertible Debentures; provided that the trading price of the Common Stock is less than the Conversion Price at the time of the Redemption Notice. The redemption amount shall be equal to the outstanding principal balance being redeemed by the Company, plus the redemption premium of 10% of the principal amount being redeemed, plus all accrued and unpaid interest in respect of such redeemed principal amount.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,084,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">474,683<span></span>
</td>
<td class="nump">141,348,856<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Oramed Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Aggregate Principle amount of issued debt</a></td>
<td class="nump">$ 101,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Aggregate Principle amount of issued debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Debt instrument, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Yorkville SPA provides that the Convertible Debentures would be issued and sold at a purchase price equal to 96% of the applicable principal amount in three tranches as follows: (i) $10.0&#160;million upon the signing of the Yorkville SPA, which was funded on March&#160;21, 2023; (ii) $7.5&#160;million upon the filing of a registration statement on Form S-1 with the SEC to register the resale by Yorkville of any shares of Common Stock issuable upon conversion of the Convertible Debentures under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), which was funded on April&#160;11, 2023; and (iii) $7.5&#160;million at the time such registration statement was declared effective by the SEC, which was funded on April&#160;20, 2023.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt instrument, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 21,  2023<span></span>
</td>
<td class="text">Mar. 15,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DebtInstrumentPrincipalAmountPercentage', window );">Debt Instrument Principal Amount, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPaymentTerms', window );">Debt payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company has the option to repay either (i)&#160;in cash, with premium equal to&#160;5% in respect of the principal amount of such payment, or (ii)&#160;by submitting a notice for an advance under the A&R Yorkville Purchase Agreement, or a series of advances thereunder, or any combination of (i)&#160;or (ii) as determined by the Company. In the case of (ii), the proceeds from the shares sold to Yorkville are applied against the outstanding amounts.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ConvertibleDebenturesIssuedPercent', window );">Convertible Debentures Issued Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption Premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | First installment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of debt prinnciple installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Second Installment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of debt prinnciple installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Third Installment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of debt prinnciple installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Oramed Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Aggregate Principle amount of issued debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Debt instrument, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Interest under the Oramed Note accrues at a fluctuating per annum interest rate equal to the sum of (1)&#160;greater of (x) 4% and (y)&#160;Term SOFR (as defined in the Oramed Note) and (2) 8.5%, payable in-kind on a monthly basis. If the outstanding principal has not been fully repaid by March&#160;21, 2024, an exit fee of approximately $3.1&#160;million becomes due upon repayment. Upon the occurrence and during the continuance of an event of default under the Oramed Note, holders of more than 50% of the aggregate unpaid principal amount of the Oramed Notes may elect to accrue interest at a default rate equal to the lesser of (i)&#160;Term SOFR plus 15% or (ii)&#160;the maximum rate permitted under applicable law. Voluntary prepayments made before the one-year anniversary of the closing date of the Scilex-Oramed SPA must include a make-whole amount equal to 50% of the additional interest that would accrue on the principal amount so prepaid from the date of such prepayment through and including the maturity date. If the Oramed Note is accelerated upon an event of default, repayment is required at a mandatory default rate of 125% of the principal amount (together with 100% of accrued and unpaid interest thereon and all other amounts due in respect of the Oramed Note). The Oramed Note contains mandatory prepayment provisions requiring use of 70% of net cash proceeds from any Cash Sweep Financing (as defined in the Oramed Note) or advances under the ELOCs (as defined in the Oramed Note) to prepay the outstanding principal after the earlier of April&#160;1, 2024 or full repayment of Acceptable Indebtedness (as defined in the Oramed Note).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DebtRepaymentExitFee', window );">Debt Repayment Exit Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt instrument, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 21,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DebtInstrumentOwnedPercentage', window );">Debt instrument, owned, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DebtInstrumentDefaultInterestRate', window );">Debt instrument, default interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount', window );">Debt instrument, percentage of interest accrued on principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount', window );">Debt repayment, percentage of mandatory default rate of principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest', window );">Debt repayment, percentage of mandatory default rate of accrued and unpaid interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfUsageOfCashProceedsFromCashSweepFinancing', window );">Percentage of usage of cash proceeds from cash sweep financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Oramed Note | Monthly Basis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt instrument, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Oramed Note | First installment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 21,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Oramed Note | Second Installment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 21,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Oramed Note | Third Installment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 21,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Oramed Note | Fourth Installment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 21,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Oramed Note | Five Installment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 21,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Oramed Note | Six Installment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 21,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Tranche One | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Aggregate Principle amount of issued debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Tranche Two | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Aggregate Principle amount of issued debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember', window );">Tranche Three | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Aggregate Principle amount of issued debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseAgreementAxis=sclx_ARYorkvillePurchaseAgreementMember', window );">A&amp;R Yorkville Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Aggregate Principle amount of issued debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NetCashProceeds', window );">Net cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepaidPrincipal', window );">Convertible Debentures Repaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceIncrease', window );">Common Stock at a conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DebtInstrumentOutstandingPrincipal', window );">Outstanding debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ServicingLiabilityAtFairValueOtherChangeInFairValueStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Servicing Liability, Fair Value, Change in Fair Value, Other, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Operating Costs and Expenses<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio', window );">Outstanding principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">632,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Aggregate Principle amount of issued debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TerminationFees', window );">Termination fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ExistingFacilityCapMaximum', window );">Facility cap maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ExistingFacilityCapMinimum', window );">Facility cap minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DebtInstrumentOutstandingPrincipal', window );">Outstanding debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash on hand</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio', window );">Outstanding principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableRevolvingConvertedToTermLoan', window );">Accounts receivable revolving loan facility in an aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Line Of Credit Facility Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ConvertibleDebenturesIssuedPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Debentures Issued Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ConvertibleDebenturesIssuedPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DebtInstrumentDefaultInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Default Interest Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DebtInstrumentDefaultInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DebtInstrumentOutstandingPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument outstanding principal</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DebtInstrumentOutstandingPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DebtInstrumentOwnedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Owned, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DebtInstrumentOwnedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Percentage of Interest Accrued on Principal Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DebtInstrumentPrincipalAmountPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Principal Amount, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DebtInstrumentPrincipalAmountPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DebtRepaymentExitFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Repayment Exit Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DebtRepaymentExitFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Repayment, Percentage of Mandatory Default Rate of Accrued and Unpaid Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Repayment, Percentage of Mandatory Default Rate of Principal Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ExistingFacilityCapMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Existing Facility Cap Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ExistingFacilityCapMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ExistingFacilityCapMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Existing facility cap minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ExistingFacilityCapMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NetCashProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>net cash proceeds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NetCashProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfUsageOfCashProceedsFromCashSweepFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Usage of Cash Proceeds from Cash Sweep Financing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfUsageOfCashProceedsFromCashSweepFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TerminationFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>termination fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TerminationFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConvertibleConversionPriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in conversion price of convertible common stock. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockConvertibleConversionPriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuedPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of principal of debt issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuedPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of debt redemption features under terms of the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -SubTopic 470<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -SubTopic 470<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepaidPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of principal of debt repaid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepaidPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableRevolvingConvertedToTermLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of revolving financing receivable converted to term loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 79<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479294/326-20-55-79<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-6A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableRevolvingConvertedToTermLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is the result of the principal amount outstanding of total loans managed or securitized less securitized loans and loans that are in the process of being securitized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (a)<br> -Paragraph 4<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481326/860-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ServicingLiabilityAtFairValueOtherChangeInFairValueStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes increase (decrease) in fair value classified as other for contract to service financial asset under which estimated future revenue from contractually specified servicing fee, late fee, and other ancillary revenues are not expected to adequately compensate servicer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481229/860-50-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ServicingLiabilityAtFairValueOtherChangeInFairValueStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from changes in fair value classified as other for a contract to service financial assets under which the estimated future revenues from contractually specified servicing fees, late charges, and other ancillary revenues are not expected to adequately compensate the servicer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(4)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481229/860-50-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sclx_FristInstallmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sclx_FristInstallmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sclx_SecondInstallmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sclx_SecondInstallmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sclx_ThirdInstallmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sclx_ThirdInstallmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DebtPayableAxis=sclx_MonthlyBasisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DebtPayableAxis=sclx_MonthlyBasisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sclx_FourthInstallmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sclx_FourthInstallmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sclx_FiveInstallmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sclx_FiveInstallmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sclx_SixInstallmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sclx_SixInstallmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchaseAgreementAxis=sclx_ARYorkvillePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchaseAgreementAxis=sclx_ARYorkvillePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674077206528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Summery of Outstanding Convertible Debenture (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ConversionOfConvertibleDebenturesIntoCommonStock', window );">Conversion of Convertible Debentures into common stock</a></td>
<td class="num">$ (7,735)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debentures, beginning period</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Issuance of Convertible Debentures</a></td>
<td class="nump">106,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RepaymentOfConvertibleDebenture', window );">Repayment of Convertible Debentures</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ChangeInFairValueOfConvertibleDebentures', window );">Change in fair value of Convertible debentures</a></td>
<td class="num">(2,837)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debentures, ending period</a></td>
<td class="nump">104,089<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debentures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debentures, beginning period</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Issuance of Convertible Debentures</a></td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RepaymentOfConvertibleDebenture', window );">Repayment of Convertible Debentures</a></td>
<td class="num">(15,625)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ChangeInFairValueOfConvertibleDebentures', window );">Change in fair value of Convertible debentures</a></td>
<td class="num">(3,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ConversionOfConvertibleDebenturesIntoCommonStock', window );">Conversion of Convertible Debentures into common stock</a></td>
<td class="num">(7,735)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debentures, ending period</a></td>
<td class="nump">$ 4,340<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ChangeInFairValueOfConvertibleDebentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of Convertible Debentures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ChangeInFairValueOfConvertibleDebentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ConversionOfConvertibleDebenturesIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of Convertible Debentures into Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ConversionOfConvertibleDebenturesIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RepaymentOfConvertibleDebenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment of Convertible Debenture</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RepaymentOfConvertibleDebenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of notes issued in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674082535920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Junior DIP Facility and Sorrento Share Purchase Agreement (Additional Information) (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 21, 2023</div></th>
<th class="th"><div>Jul. 05, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_PennyWarrantsMember', window );">Penny Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_FairValueOfWarrants', window );">Fair Value Of Warrants</a></td>
<td class="nump">$ 10.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrants exercisable date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 14,  2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrants1Member', window );">Subsequent Penny Warrants 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WarrantVestingDate', window );">Warrant vesting date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 19,  2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrants1Member', window );">Subsequent Penny Warrants 1 [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IssueOfWarrantsToPurchaseShares', window );">Issue of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,125,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrants2Member', window );">Subsequent Penny Warrants 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WarrantVestingDate', window );">Warrant vesting date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 17,  2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrants2Member', window );">Subsequent Penny Warrants 2 [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IssueOfWarrantsToPurchaseShares', window );">Issue of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,125,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrants3Member', window );">Subsequent Penny Warrants 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WarrantVestingDate', window );">Warrant vesting date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 15,  2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrants3Member', window );">Subsequent Penny Warrants 3 [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IssueOfWarrantsToPurchaseShares', window );">Issue of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,125,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrants4Member', window );">Subsequent Penny Warrants 4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WarrantVestingDate', window );">Warrant vesting date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 14,  2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrants4Member', window );">Subsequent Penny Warrants 4 [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IssueOfWarrantsToPurchaseShares', window );">Issue of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,125,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_StockPurchaseAgreementMember', window );">Sorrento Stock Purchase Agreement | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesPurchasedUnderStockPurchaseAgreement', window );">Shares Purchased Under Stock Purchase Agreement</a></td>
<td class="nump">60,068,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_StockPurchaseAgreementMember', window );">Sorrento Stock Purchase Agreement | Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesPurchasedUnderStockPurchaseAgreement', window );">Shares Purchased Under Stock Purchase Agreement</a></td>
<td class="nump">29,057,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesPurchasedAtParValueUnderStockPurchaseAgreement', window );">Shares Purchased At Par Value Under Stock Purchase Agreement</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_FairValueOfSharesRepurchased', window );">Fair Value of stock repurchased</a></td>
<td class="nump">$ 52.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_StockPurchaseAgreementMember', window );">Sorrento Stock Purchase Agreement | Private Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesPurchasedUnderStockPurchaseAgreement', window );">Shares Purchased Under Stock Purchase Agreement</a></td>
<td class="nump">3,104,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_StockPurchaseAgreementMember', window );">Sorrento Stock Purchase Agreement | Public Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesPurchasedUnderStockPurchaseAgreement', window );">Shares Purchased Under Stock Purchase Agreement</a></td>
<td class="nump">1,386,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Oramed Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees and expenses</a></td>
<td class="nump">$ 12.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CashPayment', window );">Cash payment</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Oramed Note | Closing Penny Warrant [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IssueOfWarrantsToPurchaseShares', window );">Issue of warrants</a></td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Oramed Note | Subsequent Penny Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TransferOfWarrants', window );">Transfer of warrants</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Oramed Note | Subsequent Penny Warrants [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IssueOfWarrantsToPurchaseShares', window );">Issue of warrants</a></td>
<td class="nump">8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Oramed Note | Penny Warrants [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NumberOfShareOutstanding', window );">Number Of Share Outstanding</a></td>
<td class="nump">9.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Subsequent Penny Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrants exercisable date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 14,  2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Subsequent Penny Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrants exercisable date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 14,  2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sclx_SorrentoMember', window );">Sorrento</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesAndExciseTaxPayableCurrent', window );">Excise tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sclx_SorrentoMember', window );">Sorrento | Junior DIP Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Initial principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt instrument, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Exit fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Debt instrument, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Junior DIP Facility was to mature on the earliest of: (i)&#160;September&#160;30, 2023; (ii) the effective date of any Chapter 11 plan of reorganization with respect to Sorrento; (iii)&#160;the consummation of any sale or other disposition of all or substantially all of the assets of Sorrento; (iv)&#160;the date of the acceleration of the DIP Loans and the termination of the DIP Commitments (as defined in the Junior DIP Loan Agreement) in accordance with the DIP Documents (as defined in the Junior DIP Loan Agreement); and (v)&#160;dismissal of the Chapter 11 Cases or conversion of the Chapter 11 Cases into cases under Chapter 7 of the Bankruptcy Code.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_FairValueOfSharesRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of Shares Repurchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_FairValueOfSharesRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_FairValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_FairValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_IssueOfWarrantsToPurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue of Warrants to Purchase Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_IssueOfWarrantsToPurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NumberOfShareOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Share Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NumberOfShareOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SharesPurchasedAtParValueUnderStockPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Purchased At Par Value Under Stock Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SharesPurchasedAtParValueUnderStockPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SharesPurchasedUnderStockPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Purchased Under Stock Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SharesPurchasedUnderStockPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TransferOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transfer of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TransferOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_WarrantVestingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Vesting Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_WarrantVestingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesAndExciseTaxPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesAndExciseTaxPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_PennyWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sclx_PennyWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrants1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrants1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrants2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrants2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrants3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrants3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrants4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrants4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=sclx_PrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=sclx_PrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=sclx_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=sclx_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_ClosingPennyWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sclx_ClosingPennyWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sclx_SubsequentPennyWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sclx_SorrentoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sclx_SorrentoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sclx_JuniorDipFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sclx_JuniorDipFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674085613760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Additional Information) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 22, 2023</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Nov. 17, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 25, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,084,250<span></span>
</td>
<td class="nump">474,683<span></span>
</td>
<td class="nump">141,348,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,854,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,899,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,057,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,057,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Stock Common Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,068,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Payment made to Investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred Stock Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,057,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,057,097<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_HudsonBayMember', window );">Hudson Bay [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceed from Securities and Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_CoveLaneMember', window );">Cove Lane [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseAgreementAxis=sclx_ARYorkvillePurchaseAgreementMember', window );">A R Yorkville Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">632,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseOfStockPercentage', window );">Purchase of stock, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommonStockSold', window );">Common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,552,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ProceedsFromSaleOfCommonStock', window );">Proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RightToSellMaximumNumberOfCommonStockShares', window );">Right to sell maximum number of common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseAgreementAxis=sclx_ARYorkvillePurchaseAgreementMember', window );">A R Yorkville Purchase Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseAgreementAxis=sclx_BRileyPurchaseAgreementMember', window );">B. Riley Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseOfStockPercentage', window );">Purchase of stock, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommonStockSold', window );">Common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,414,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ProceedsFromSaleOfCommonStock', window );">Proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RightToSellMaximumNumberOfCommonStockShares', window );">Right to sell maximum number of common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseAgreementAxis=sclx_AtTheMarketSalesAgreementMember', window );">ATM Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number sale of common stock shares</a></td>
<td class="nump">170,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ProceedSOfSaleOfCommonSharesPercentage', window );">Proceeds from sale of common shares percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseAgreementAxis=sclx_AtTheMarketSalesAgreementMember', window );">ATM Sales Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number sale of common stock shares</a></td>
<td class="nump">170,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sclx_WarrantsMember', window );">Warrants [Member] | Warrant Transfer Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,613,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,104,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember', window );">Treasury Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury Stock Common Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,068,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CommonStockSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CommonStockSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ProceedSOfSaleOfCommonSharesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceed s of sale of common shares percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ProceedSOfSaleOfCommonSharesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ProceedsFromSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ProceedsFromSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchaseOfStockPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase of stock, percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchaseOfStockPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RightToSellMaximumNumberOfCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right to Sell Maximum Number of Common Stock Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RightToSellMaximumNumberOfCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ShareholdersEquityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shareholders Equity Details Line Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ShareholdersEquityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_HudsonBayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_HudsonBayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_CoveLaneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_CoveLaneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchaseAgreementAxis=sclx_ARYorkvillePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchaseAgreementAxis=sclx_ARYorkvillePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchaseAgreementAxis=sclx_BRileyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchaseAgreementAxis=sclx_BRileyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchaseAgreementAxis=sclx_AtTheMarketSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchaseAgreementAxis=sclx_AtTheMarketSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sclx_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sclx_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_WarrantTransferAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_WarrantTransferAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674082285184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive and Employee Benefit Plans - Schedule of Stock Options Outstanding Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Beginning Balance</a></td>
<td class="nump">16,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Outstanding, Granted</a></td>
<td class="nump">17,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options Outstanding, Exercised</a></td>
<td class="num">(365)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options Outstanding, Forfeited/Cancelled</a></td>
<td class="num">(1,060)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Ending Balance</a></td>
<td class="nump">33,124<span></span>
</td>
<td class="nump">16,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Outstanding, Exercisable</a></td>
<td class="nump">18,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding, Beginning Balance</a></td>
<td class="nump">$ 1.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">7.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">1.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited/Cancelled</a></td>
<td class="nump">6.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding, Ending Balance</a></td>
<td class="nump">4.38<span></span>
</td>
<td class="nump">$ 1.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 2.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted-average Remaining Contractual Life, (in Years)</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, Weighted-average Remaining Contractual Life, (in Years)</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 7,459<span></span>
</td>
<td class="nump">$ 38,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674082344208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive and Employee Benefit Plans - Schedule of estimate stock-based compensation on the date of grant for stock options and ESPP (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock -price volatility</a></td>
<td class="nump">76.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term of options</a></td>
<td class="text">3 years 10 months 9 days<span></span>
</td>
<td class="text">4 years 10 months 9 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=sclx_BlackScholesOptionPricingMethodMember', window );">Black-Scholes Option Pricing Method [Member] | Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">3.59%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.74%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term of options</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=sclx_BlackScholesOptionPricingMethodMember', window );">Black-Scholes Option Pricing Method [Member] | Stock Option [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock -price volatility</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=sclx_BlackScholesOptionPricingMethodMember', window );">Black-Scholes Option Pricing Method [Member] | Stock Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock -price volatility</a></td>
<td class="nump">77.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=sclx_BlackScholesOptionPricingMethodMember', window );">Black-Scholes Option Pricing Method [Member] | Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock -price volatility</a></td>
<td class="nump">117.57%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">5.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term of options</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=sclx_BlackScholesOptionPricingMethodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=sclx_BlackScholesOptionPricingMethodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=sclx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=sclx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674165967248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive and Employee Benefit Plans (Additional Information) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 13, 2023</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 04, 2023</div></th>
<th class="th"><div>Jan. 17, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of option outstanding to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,124<span></span>
</td>
<td class="nump">16,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options granted weighted-average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of option exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,596,000<span></span>
</td>
<td class="nump">5,280,000<span></span>
</td>
<td class="nump">$ 5,822,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to unvested stock option grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Employee benefit plan contributions by employer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued for services, shares</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent', window );">Accrued legal fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WeightedAveragePeriodOverGrant', window );">Weighted average period over grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_Sharebasedcompensationpayable', window );">Stock Based Compensation expense cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_NonEmployeeDirectorMember', window );">Non Employee Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationCashBasedArrangementsLiabilityCurrent', window );">Cash compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of common stock shares forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">311,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,276,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sclx_TwoThousandTwentyTwoEquityIncentivePlanMember', window );">2022 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of option outstanding to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,123,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,622,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,600,000<span></span>
</td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sclx_TwoThousandTwentyTwoEquityIncentivePlanMember', window );">2022 Equity Incentive Plan | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,276,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,276,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sclx_TwoThousandTwentyTwoEquityIncentivePlanMember', window );">2022 Equity Incentive Plan | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,276,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sclx_TwoThousandTwentyThreeInducementPlanMember', window );">2023 Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember', window );">2022 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,462,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember', window );">2022 Employee Stock Purchase Plan | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,875,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_Sharebasedcompensationpayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ShareBasedCompensationpayable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_Sharebasedcompensationpayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_WeightedAveragePeriodOverGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over grant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_WeightedAveragePeriodOverGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationCashBasedArrangementsLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for deferred compensation arrangements payable within one year (or the normal operating cycle, if longer). Represents currently earned compensation under cash arrangements (such as a profit-sharing plan, rabbi trust, and employee contract--excluding equity-based arrangements) that is not actually paid until a later date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483043/710-10-30-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483070/710-10-25-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationCashBasedArrangementsLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_NonEmployeeDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_NonEmployeeDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sclx_TwoThousandTwentyTwoEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sclx_TwoThousandTwentyTwoEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sclx_TwoThousandTwentyThreeInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sclx_TwoThousandTwentyThreeInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674075984592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Leases Supplemental Quantitative Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="num">$ (1,021)<span></span>
</td>
<td class="num">$ (746)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term in years - operating leases</a></td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate - operating leases</a></td>
<td class="nump">11.10%<span></span>
</td>
<td class="nump">11.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674081731888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Lease Maturities of Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 1,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">3,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(630)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">2,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less current portion of lease liability</a></td>
<td class="nump">759<span></span>
</td>
<td class="nump">$ 745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LeaseLiabilityNetOfCurrentPortion', window );">Lease liability, net of current portion</a></td>
<td class="nump">$ 2,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LeaseLiabilityNetOfCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease liability, net of current portion</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LeaseLiabilityNetOfCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674082538096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2013</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Apr. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Derivative Liability, Noncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Additional ROU assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,943<span></span>
</td>
<td class="nump">1,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Corresponding lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,237<span></span>
</td>
<td class="nump">665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_GloperbaMember', window );">GLOPERBA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DueFromRelatedParty', window );">Due From Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_FormerEmployeeMember', window );">Former Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Agreement settlement payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_FormerEmployeeOneMember', window );">Former Employee One[Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Agreement settlement payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=sclx_EpoladermMember', window );">Epoladerm [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RoyaltyPaymentPercentageOnNetSale', window );">Percentage on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=sclx_ProbudurMember', window );">Probudur [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RoyaltyPaymentPercentageOnNetSale', window );">Percentage on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=sclx_EnveltaMember', window );">Envelta [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RoyaltyPaymentPercentageOnNetSale', window );">Percentage on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_ProductDevelopmentAgreementMember', window );">Product Development Agreement [Member] | Developers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount', window );">Accrued royalty payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AgreementMaturityDate', window );">Agreement maturity date</a></td>
<td class="text">Oct.  02,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_MaturityRenewalDescription', window );">Agreement maturity renewal description</a></td>
<td class="text">The Product Development Agreement will renew automatically for subsequent successive one-year renewal periods unless Scilex Pharma or the Developers terminate it upon 6-month written notice.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_ProductDevelopmentAgreementMember', window );">Product Development Agreement [Member] | Developers [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RoyaltyPaymentPercentageRelatedToFutureYears', window );">Royalty payment percentage related to future years</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_ProductDevelopmentAgreementMember', window );">Product Development Agreement [Member] | Developers [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RoyaltyPaymentPercentageRelatedToFutureYears', window );">Royalty payment percentage related to future years</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_ProductDevelopmentAgreementMember', window );">Product Development Agreement [Member] | Scilex Pharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,300<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_NonCancelableLeaseAgreementsMember', window );">Non-cancelable Lease Agreements [Member] | Minimum [Member] | Research and Development Facilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_NonCancelableLeaseAgreementsMember', window );">Non-cancelable Lease Agreements [Member] | Maximum [Member] | Research and Development Facilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AgreementMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement Maturity Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AgreementMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DueFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Due From Related Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DueFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_MaturityRenewalDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturity Renewal Description</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_MaturityRenewalDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RoyaltyPaymentPercentageOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Payment Percentage On Net Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RoyaltyPaymentPercentageOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RoyaltyPaymentPercentageRelatedToFutureYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Payment Percentage Related To Future Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RoyaltyPaymentPercentageRelatedToFutureYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount the entity has committed to make for future royalty guarantees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483119/928-440-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyGuaranteesCommitmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_GloperbaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_GloperbaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_FormerEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_FormerEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_FormerEmployeeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_FormerEmployeeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=sclx_EpoladermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=sclx_EpoladermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=sclx_ProbudurMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=sclx_ProbudurMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=sclx_EnveltaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=sclx_EnveltaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_ProductDevelopmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_ProductDevelopmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_DevelopersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_DevelopersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=sclx_ScilexPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=sclx_ScilexPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_NonCancelableLeaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_NonCancelableLeaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sclx_ResearchAndDevelopmentFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sclx_ResearchAndDevelopmentFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674081516816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Benefit for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred income tax expense (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(16,514)<span></span>
</td>
<td class="num">(10,396)<span></span>
</td>
<td class="num">(12,981)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(11,247)<span></span>
</td>
<td class="num">(1,851)<span></span>
</td>
<td class="num">(2,472)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="num">(27,761)<span></span>
</td>
<td class="num">(12,247)<span></span>
</td>
<td class="num">(15,453)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Changes in tax rate</a></td>
<td class="num">(1,471)<span></span>
</td>
<td class="nump">1,347<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowance</a></td>
<td class="nump">29,232<span></span>
</td>
<td class="nump">10,900<span></span>
</td>
<td class="nump">15,422<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674082814960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Liabilities and Related Valuation Allowance (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred Tax Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 71,434<span></span>
</td>
<td class="nump">$ 48,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DeferredTaxAssetsDebtRelatedInterest', window );">Debt related interest</a></td>
<td class="nump">16,898<span></span>
</td>
<td class="nump">15,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">4,936<span></span>
</td>
<td class="nump">2,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">3,960<span></span>
</td>
<td class="nump">1,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">525<span></span>
</td>
<td class="nump">1,602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DeferredTaxAssetsAccruedExpenseAndReserves', window );">Accrued expense and reserves</a></td>
<td class="nump">1,584<span></span>
</td>
<td class="nump">568<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">774<span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">100,270<span></span>
</td>
<td class="nump">70,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(96,776)<span></span>
</td>
<td class="num">(67,543)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">3,494<span></span>
</td>
<td class="nump">2,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(2,734)<span></span>
</td>
<td class="num">(2,666)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease right-of-use assets</a></td>
<td class="num">(760)<span></span>
</td>
<td class="num">(253)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(3,494)<span></span>
</td>
<td class="num">(2,919)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DeferredTaxAssetsAccruedExpenseAndReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets, accrued expense and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DeferredTaxAssetsAccruedExpenseAndReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DeferredTaxAssetsDebtRelatedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets, debt related interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DeferredTaxAssetsDebtRelatedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674081687632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax benefit at federal statutory rate</a></td>
<td class="num">$ (24,007)<span></span>
</td>
<td class="num">$ (4,905)<span></span>
</td>
<td class="num">$ (19,150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">29,232<span></span>
</td>
<td class="nump">10,900<span></span>
</td>
<td class="nump">15,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount', window );">Debt discount and interest limitation</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,293)<span></span>
</td>
<td class="nump">8,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Compensation expense</a></td>
<td class="nump">3,798<span></span>
</td>
<td class="nump">2,469<span></span>
</td>
<td class="nump">224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IncomeTaxReconciliationAcquisitionRelatedCharges', window );">Acquisition related charges</a></td>
<td class="nump">260<span></span>
</td>
<td class="nump">992<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes', window );">Prior year true-up and carryback</a></td>
<td class="num">(5,079)<span></span>
</td>
<td class="num">(713)<span></span>
</td>
<td class="num">(3,968)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State, net of federal tax benefit</a></td>
<td class="num">(5,127)<span></span>
</td>
<td class="num">(174)<span></span>
</td>
<td class="num">(2,545)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount', window );">Change in fair value of Convertible Debentures</a></td>
<td class="nump">1,752<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount', window );">Change in tax rates</a></td>
<td class="num">(1,471)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">655<span></span>
</td>
<td class="nump">728<span></span>
</td>
<td class="nump">993<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Change in Fair Value of Convertible Debentures, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Change in Tax Rates, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation debt discount amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_IncomeTaxReconciliationAcquisitionRelatedCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation acquisition related charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_IncomeTaxReconciliationAcquisitionRelatedCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674081876512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning Balance</a></td>
<td class="nump">$ 408<span></span>
</td>
<td class="nump">$ 408<span></span>
</td>
<td class="nump">$ 406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increase related to prior year tax positions</a></td>
<td class="nump">536<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases related to current year tax positions</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending Balance</a></td>
<td class="nump">$ 1,071<span></span>
</td>
<td class="nump">$ 408<span></span>
</td>
<td class="nump">$ 408<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674082344208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, valuation allowance</a></td>
<td class="nump">$ 96,776<span></span>
</td>
<td class="nump">$ 67,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IndefiniteOperatingLossCarryforwards', window );">Indefinite net federal operating loss</a></td>
<td class="nump">265,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development income tax credits</a></td>
<td class="nump">3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Income tax expense, interest and penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Liabilities for uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research and Development Income Tax Credits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TaxCreditCarryforwardNotSubjectToExpireAmount', window );">Tax credit, not subject to expire</a></td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 278,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards, expiration year</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IncomeTaxCreditsExpirationYear', window );">Income tax credits, expiration year</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 114,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards, expiration year</a></td>
<td class="text">2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_IncomeTaxCreditsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Credits Expiration Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_IncomeTaxCreditsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_IndefiniteOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indefinite Operating Loss Carryforwards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_IndefiniteOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards Expiration Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TaxCreditCarryforwardNotSubjectToExpireAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Not Subject to Expire, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TaxCreditCarryforwardNotSubjectToExpireAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674079650208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of the reconciliation of basic and diluted loss per share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (114,331)<span></span>
</td>
<td class="num">$ (23,364)<span></span>
</td>
<td class="num">$ (88,424)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPremium', window );">Premium on redemption of Preferred Stock</a></td>
<td class="num">(52,645)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss for basic and diluted loss per share available to common stockholders</a></td>
<td class="num">$ (166,976)<span></span>
</td>
<td class="num">$ (23,364)<span></span>
</td>
<td class="num">$ (88,424)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding - basic</a></td>
<td class="nump">130,298,000<span></span>
</td>
<td class="nump">134,226,000<span></span>
</td>
<td class="nump">132,858,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_EffectOfDilutiveSecurities', window );">Effect of dilutive securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares and assumed conversions - diluted</a></td>
<td class="nump">130,298,000<span></span>
</td>
<td class="nump">134,226,000<span></span>
</td>
<td class="nump">132,858,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders - basic</a></td>
<td class="num">$ (1.28)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.67)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders - diluted</a></td>
<td class="num">$ (1.28)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.67)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_EffectOfDilutiveSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effect of Dilutive Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_EffectOfDilutiveSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The excess of (1) fair value of the consideration transferred to the holders of the preferred stock over (2) the carrying amount of the preferred stock in the registrant's balance sheet, during the accounting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480408/260-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674165955344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</a></td>
<td class="nump">48,168,217<span></span>
</td>
<td class="nump">27,943,081<span></span>
</td>
<td class="nump">18,967,724<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_ConvertibleDebenturesMember', window );">Convertible Debentures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</a></td>
<td class="nump">546,921<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_StockOptionsMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</a></td>
<td class="nump">33,123,798<span></span>
</td>
<td class="nump">16,939,093<span></span>
</td>
<td class="nump">18,967,724<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_PublicWarrantsMember', window );">Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</a></td>
<td class="nump">6,854,309<span></span>
</td>
<td class="nump">6,899,988<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_PrivateWarrantsMember', window );">Private Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</a></td>
<td class="nump">3,613,383<span></span>
</td>
<td class="nump">4,104,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_RetainerSharesMember', window );">Retainer Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sclx_SharesIssuablePursuantToEsppMember', window );">Shares Issuable pursuant to ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</a></td>
<td class="nump">29,806<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sclx_ConvertibleDebenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sclx_ConvertibleDebenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sclx_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sclx_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sclx_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sclx_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sclx_PrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sclx_PrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sclx_RetainerSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sclx_RetainerSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sclx_SharesIssuablePursuantToEsppMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sclx_SharesIssuablePursuantToEsppMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674075987568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Net Loss Per Share (Additional Information) (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 25, 2023</div></th>
<th class="th"><div>Sep. 21, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">160,084,250<span></span>
</td>
<td class="nump">474,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,348,856<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Penny Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139674293819808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Additional Information (Details) - Subsequent Event [Member] - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Feb. 16, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommonShareSold', window );">Sold of common share</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Common stock underwriters exercise, shares</a></td>
<td class="nump">541,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees and expenses</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OutOfPocketExpense', window );">Out Of Pocket Expense</a></td>
<td class="nump">$ 15,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PublicOfferingPriceSold', window );">Sold Of Public Offering Price</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CombinedPricePaidOfWarrant', window );">Combined Price Paid Of Warrant</a></td>
<td class="nump">$ 1.564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventDescription', window );">Subsequent Event, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On February&#160;16, 2024, the Company and B. Riley mutually agreed to terminate the B. Riley Purchase Agreement. The termination is effective as of February&#160;16, 2024.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Rodman &amp; Renshaw LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommonStockSold', window );">Common stock sold</a></td>
<td class="nump">5,882,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseOfCommonWarrants', window );">Common Warrants Purchase</a></td>
<td class="nump">5,882,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseOfCommonShares', window );">Purchase Of Common Shares</a></td>
<td class="nump">882,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PricePerOptionalShare', window );">Price of Optional Share</a></td>
<td class="nump">$ 1.5548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PricePerOptionalWarrant', window );">Price of optional warrant</a></td>
<td class="nump">0.0092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PublicOfferingPerOptionalShare', window );">Public Offering Price Per Optional Share</a></td>
<td class="nump">1.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PublicOfferingPerOptionalWarrant', window );">Public Offering Per Optional Warrant</a></td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PublicOfferingPrice', window );">Public Offering Price</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ExercisePriceOfCommonWarrant', window );">Exercise Price Of Warrant</a></td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchaseOfCommonWarrants', window );">Common Warrants Purchase</a></td>
<td class="nump">882,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Aggregate shares purchase common warrants</a></td>
<td class="nump">470,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of the Representative Warrants</a></td>
<td class="nump">$ 2.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PublicOfferingPriceCombined', window );">Combined public offering price</a></td>
<td class="nump">125.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CombinedPricePaidOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Combined Price Paid Of Warrant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CombinedPricePaidOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CommonShareSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Share Sold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CommonShareSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CommonStockSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CommonStockSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ExercisePriceOfCommonWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise Price Of Common Warrant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ExercisePriceOfCommonWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_OutOfPocketExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Out-Of-Pocket Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_OutOfPocketExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PricePerOptionalShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price Per Optional share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PricePerOptionalShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PricePerOptionalWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price Per Optional Warrant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PricePerOptionalWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PublicOfferingPerOptionalShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public Offering Per Optional Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PublicOfferingPerOptionalShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PublicOfferingPerOptionalWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public Offering Per Optional Warrant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PublicOfferingPerOptionalWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PublicOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public Offering Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PublicOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PublicOfferingPriceCombined">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public Offering Price Combined</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PublicOfferingPriceCombined</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PublicOfferingPriceSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public Offering Price Sold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PublicOfferingPriceSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchaseOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Of Common Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchaseOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchaseOfCommonWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Of Common Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchaseOfCommonWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_RodmanRenshawLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_RodmanRenshawLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>89
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M)K;POXL.7\Y\)HUKR1:/WG/7\]P]\B[3,^@[=[1U$OTK%&AR+9XJ^%/7KG4
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MH&CK02WP06TR*#29X%;OPV;![W#C,MO7I!:(?^/Y)A)D:_E5E:Z%LF@$%?U
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M[>OD&_O>XR,;2=-V[0!<0NK0IC%%V3O;DIFSM-\[[YAT%/G.Z557$LK8]8%
M@.'']&8%22:-<(C_)02:$?(A<4*)*E09^WPR&5(")O_2R>18-GV4R<A%GR*F
M]Z&!L#[2ID& 0GC3ADOE4,CC$"N>G..-)J@"!+5B\9& 5<J9BE/WB$,*V*!8
MZW8#\8DRRL$[N(TM)/8O3>7+M?T6I!7SL &KI'82&)PD.E6?9\P%3:1!EJFF
M7%*B*5GEVN."#6,\&B6C^!^Q[1;-3Y+?)30=0VAU="T)D/GR4GBK^GH$Y_P'
M.25O\)*!!HE8'H'<L&U@U6RVMK;8&Y0_4D02*]:<D@UX6:AU7<ZXSOL4VHF:
M[<X&N=&0R-ZIQJ#8G>2W58D8=0T5A#$8=AX@BB#YM-6@OF4D4P"ZUA4+MX?)
MZ?( $SAIB65CG>G5"5$W72&_<E"/B'LFXGH7:O1:@C>^*-H H6=?YU=ST#6A
M21;V1XKL(*M%:HH]V$A4&.<>E8<8=W#O!C;U[?6'/ZMM_>*U])SU:8NP-3R>
M%S8RGV;'^+BE@$\ U;8NM0@#20@AZL)68:N\)0KA-AQ:C!G3\H1W,K/L4RVM
M*7'Y@TH@>7.]0S!_<B#BT^]D74:996^_7+^_6%2_<#9K"!..F+$5"8!'Z"PE
M_5,LU?#4O,^59 O!43*@9*N$!SZCNX*!D 8*E.3(&:VUU$Y,0[X#R4DR9MY<
MVER2*3F':S#20+'=FAYI8WV YH8=C"D@%C-(]%+ #"T)\&*6_35H(7CUGJ'R
M.P0#[W@C+T5RPDW!GFV4[P0*^\Z<F/1Y5^>S]+D(&(PTF)AF*U;'K%A"3\J_
M$=M4R\ZA[?F:Y.R0GJ<(^)^=HF"AF1SCL8EL8UYR0C>7,B!G'"AR(@$FTS"<
M]["P2$8CJ=MTQ GRZ4(*Y*6W<#WMLJ:A!&)OI/@'LDON"]HAMY-+9M3VMA]U
M68GP&!;PRDKS69<HLM*68(NC# S9;6*8'HC%"*4T)&$WD4\=QO6I:PJ+$2X<
MH],7QBF:[<2(@!C.OS+$GM Z\\8B!+1;D_<I7DXS%H03O6W>JN:S'ME^'^"P
M_._81J>%_J1<.LQTDAE<T9,KM&OTY57V9 BF@'=CFO#(DB:G'+ O(P<W\1_?
M!K0,P6>J6#_PRPGXL$"2H>C[)F:BRWOC]*AH(+Q"-$X+1JU?5GQ,5LF/C(2>
M);5T5G*0G"*ZJY5O:4L9F%(';R,5$,&UX5'?/,,?A:HPS!\ERW<;:"D*<#)#
M')'TF(P=(:?($M.U0Z8[@HNC&'Q"H*-E_667//'Y:N\K^C:_R=A6+?ND7VB/
M)'<8&B.\XW:A[V^I^_0H9RF":0*>8&0-(3,;&W@9/=*JXZ0W:C!WH9[/<(8T
M[:H'5%<#0/7Q0#I/8J]!U0+%>,$1QQ'R*,=4DRD.BAG3BTB#Z]$D 1.D*(JW
M<-##(?A;Q91"R'8@.2-9=1A]=&J3A*BFI%#&</S%V!;717J2[DE:"H57'!ZQ
M'/!=+AHQNT2HK23YRB2*C>JE)B>107=E;Y0(1(/WZ\;N2=H:Z7S<69#!=L?_
MXB&)]"6/2@\*5;.<I^U!ZB2N6X9(&@TDQ*01E\..AY"#01DD9S'ITUW'=YOK
M'-)[X*M;(B%I@D&J?E\A+6G^Q+>=)HTW,6=R;PH..Q,;7IRW;F(P3Q(1&G.'
M4<J19K>^3)?TS]^@(JR:PF6O+/V)5=$WES>O8@_;T?NO;,%B-2BF7MY<Q:<^
MHH$XNWAV-N&V1'J:Q'V#0=XE?..D%U(/[9UH@3SV;/X$2<90P9(=_ED7:P[2
MOF9'!PI\+'3)V.(ND53@8F8QJ,[MX8M8[N-D^9UOA;+E#B#NNEN2X/;E,M])
M/ZRA!3 ?XP-1_E?!HESU%F4$V#WUM<PBF1L9G!/Y+"_[, V\2[ Y-,*69KI!
MOZUOO!!%0ZH*,46T2UQDFL^>G,$U96X#(0Y;.5I=VDH;[ABMU=\R;B208$YR
M:?)+V[>DWEQ?7HT'>'18:",G$EK_I=>J\IFY>-2 LP#<YL]D6_3_0-:^*W1>
M<O^GYEXJN%O?J^>K%\%^_'0K(0GSC^9-Y?KFIUZNZ>>_J4KZIJ7<,G\DC80T
MKO0WN]X/?,WF*7%I4K%+@F.+CCK,PSO#@WHNS+*;CJPU0_U0&SXM4F-!9<X>
M9#4T*R%+ K0_(UW&+'P.(/O5SJ"3TPO2YC\T]5@?CL^=6E(0,)A;Y@WSD_.Y
MU<64'ISR)\Y/3$00$B\?PLLDM^%-[TEK.\!:L>T,CT3@(!@Z;ESPT?=6P 'Y
MR"_/N.YZ@#-1=VBDV.F]*D9,S-AD6($+_5,[&*&!<T^;!U/4Y'Q/BW\F!OA,
MF^ IQ*B#PL,D(A')UZ'%V[7!BPVO,I:1[((888^"O0H46'5PYI.TT7,\".DI
M:5WT*:%:&)LJT+41*W@<6O"VG:C[!\"0UM_'D>U_HL<@%"47L?;^CBO?QH/M
MOUHY345^N:E.]M3TKF_@+9.?3X(/^T<+FJ$X/NPZ\<.$@CD,L0HE%9G/UZ]1
M'X&/&8PISTF&C+UHTIXB]LY[HB*3VH=I@A(GB:'1O@2)&#>1'JOU4IANM]H/
M#J'E&G&?,'N=),RN+&IR _4/<*T=I-]/)-P&.?</)_-[L6S62,:PD>6O>()^
M""S<1XI8XNE98Z9RT,!4DD*A"D:XG(M8#B9D2PX+T7[GPS,74O_HVXN/^.I0
M_ [K@5%<JK6^TPD'>Q0K#X(& A/<LL9GJK*5]OHG]^K;6%%SR&_^:JM&KSK"
MD1RM%CL6FYCN!ET(B&6(,+K'!!ZR=;YQR-NOK^"1%SI?)=F'LH._@9&=9[J(
M9+Q#2.FK?5*UY+-BJH?G?'N(0)"R4D@1'4/AP;4*SGUZ3@[UE& BO<U2_%'=
MQ@9UNPOG!L2^C@>$ATX?FPP.Y 6;&R/1D&EKU2VMKR(CALQ,J<PVJJ:WD=(H
M$ZX@W8%G&DT[4*&_H"N+D'=E50SZ>Z1M?)9]XI+,P,T3Y=,Y$7^R3N55NF5F
M).4I ?9)3]]=J.UP\,8E15D\=X5KKNL'6\+.%6L/AXWNZ:E/X\^DJ5!:+":>
MI/Z4H*Y$09A-P1&/SVP008V_Y[!<Z;KE[R&-Q):.V!3SVK&1SZ>@:/C?XG&4
MI(.!!=^A2X7"+\@MRVK,H4TP.M>E]3%R L3S;6FLA4<3@4$U&RU%@J_L:$[
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M0-=7EK3!?\$$\27@+_\/4$L#!!0    ( ,B+>UA;&7WD, H  $<<   8
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MU?Y.R#P5OUF=+\7,YHDJ\Z,=#P6T;">)PLZ"L.DCPB93\=7F?N7$ISQ5:5_
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M5RR93-7V%#Z/LIK1,*=N08/F?6*EJ?W5=+P[.JBI:TCD;:HTK$+S)[#P!SJ
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M'4EXK@QZ;-:_5:6;41 '7ZO&(ZH$;'D!S,#S[AD_I"1 PZ\"H$JIZ=1;S6G
MHIL$D=H*H /(JLUGWA=<UFZXHTWK,_[3=2*;8\Y(;/H)8*?SXPY0L>2?L"@F
M&,K#[SS-T^97LM/PXU"[//S$AJ/P4B-11BVP%32V/PAW5O47;PO^J6ANO;<9
M?UPIM(R2%N#]PF*VC%](0?/;X<G_ 5!+ P04    " #(BWM8$VTE=Z4'  #
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MIJ]H1GER%*Q-\5I/2\K80^;?*,)[DO1 /Y@4NDI$.\=R^R-%9^<X9'W>T_E
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M/1\/J2)O/.Y\>!$ZEJ8TG@[SO(%?_7>^PJ[V4"T'79$W&D)5'PTW6/\0"3Y
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M'4*S$MNLTTORC,:>FTEK3M@?!B&DHS==6X],9853SY$<E.TU.0#29 A).ND
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M*_\3?[_<_Z$$F!GRV8E"Y=@ZG9R?'@CK__C /S2FYA_\%Z9I3,D?5TK"2+0
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M.#B>3C>LBT)O+); / ')4PA79]/5"_F-@L/!*!A-_?0X&(3C($0>W&AYSZ'
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MKEW%:'_%E1.^#JP6AA*1 Q#<FG-]1@B*POA>BX"GF"&<EP&$X4)E2=&L52:
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M?IGY5\;FBK:>)L[UJG8K>K89X#+;<2$WJ5[HL%R+:C+O.GEQK4AT"<^J>RC
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M\=[D_)+W498.X/.%04\=WQ"#YO<V;_\/4$L#!!0    ( ,B+>UC3*O*WY D
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MRFNXFAO$G#D^*7B',U-2E<+PV(=AW 6W0+C1>2'4$PB5K"3DI2M%EM%3EI"
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M[=/IPB#XPR7/%\DNGKUPR:3WUAEZTM, %3*V<)Z,+N;':Y:#AH%P%0JG,[B
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MNZ*BJG=@+E8& O8/G;B<13MF2!!1P7GSM_!!#D51A>#=/__KGZ_F@Q/O-+]
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M9I$N=3S:,W2";98<89,))^4J1C)I/V>O2 ]CS(HOXI4 L8?F^9,%ILD]0O5
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M)]-N''QJE:A,JQ 2",/)P"9B:U#I7VG!: QI.O@+J0Y+R7.H:H)[QMJE;!)
MD@PN&;13DAY-)P%,1U."T'H&JRQKZY8S@SF5,D4LJYCC>9-,X!9NPG$*MQ<1
MR45$/XTB.Z;1E0 G?8"3_QW@5::REGCA"S5@C?I<:*^CD77J%.&WA/,(2GXO
MR(?D+,;!)GI%7:1 M'&-AD$T/<QQKZ$9]1/G0VK_3VCLNYFT=,+A. @A2=]D
M;>TPE95./,=G^CRZ!#@J)/$8XF3:*QCV @U[M3V+;N,D@O?O)E$8W=,43N/[
M7E"2X:K+@_1-O7<117(8!Q.:1\-P-#X74_^DV]:H=NY/L<YMA>D:;W_:?UNK
MKEN_B7=_WA>F=I70P+$@U> NI8"J[A_I-D8VKG=OI:&?P"U+^GI160&Z+Z0T
MQXU]H/_,E_\!4$L#!!0    ( ,B+>U@\]8Z*A ,  .T(   9    >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;+56WX_;-@Q^SU\AN$6Q L;9\L_DF@3(W75=
M'PH<>K?M8=B#8M.)4%E*);FYVU\_2DZ<M$VR8M@>$E,R^9$?*8J>;I7^9-8
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MQN\1T$X!WS=*V?W".1B^<.9_ U!+ P04    " #(BWM8D S2S3T#  "I"0
M&0   'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6R]5EMOTS 4?N^OL#(T;5*U
MW'K;UE:B'8@B!M,VX 'QX":GC;7$#K;3;O^>8Z<-J6C#1;"7Q)=SOO,='W^V
MAVLA'U0"H,ECEG(U<A*M\PO755$"&55G(@>.,PLA,ZJQ*Y>NRB70V#IEJ1MX
M7L_-*./.>&C';N1X* J=,@XWDJ@BRZA\FD JUB/'=[8#MVR9:#/@CH<Y7<(=
MZ(_YC<2>6Z'$+ .NF.!$PF+DO/0O)GUC;PT^,5BK6IN83.9"/)C.+!XYGB$$
M*43:(%#\K6 *:6J D,:W#:93A32.]?86_;7-'7.94P53D7YFL4Y&SL A,2QH
MD>I;L7X#FWRZ!B\2J;)?LBYMPZY#HD)ID6V<D4'&>/FGCYMUJ#D,O ,.P<8A
ML+S+0);E%=5T/)1B3:2Q1C33L*E:;R3'N"G*G98XR]!/CZ]@KLG)/9VGH$Z'
MKD9(,^%&&_=)Z1X<</<#<BVX3A1YQ6.(=P%<Y%(1"K:$)D$CXA5$9R3TVR3P
M@K !+ZP2#"U>V)3@C"LM"]Q+FGQYAP9DIB%37_?E6Z)U]J,9B5RHG$8P<E #
M"N0*G/'QD=_S+ANX=BJNG2;T\1U*+BY2(&)!(L%7(#7#PN NFR/U @/N8]R,
M>9\ 68@4Q<?XDFA3:))+L6(Q*$*W8C01-5I&">5+G&#<=N<TI3P"0GEL^Z T
M0R5 3!:42;*B:0%;UVF-\%5%F)Q8*%$HQ%"G%RVL+V1SD*;&K0DL&>>&V&0;
M21F\MY07AM5F&Y 7Y/AH$/C!)?[\\\YE:Z948>W1^$#@H-/V/*]U"SE]LI4_
M;'KB=]N]H$M.6U.;OTE_-\$#CF&[CR'*27M,'39E7 N<RS*TNM,B>B G_78_
M-$%1.C\O07V=MHO0:8<=KV&?=:M]UFW<$Q\DS;"&[X6&?1NJT?DO)="KJ/7^
MJ5Q[_X%KO^+:_VVY&IG]8EF;P9Y-IS66SR#.>C3?Z[6#;G!09'7;H#T(^[OB
MW2'>->+^$^WX'IX'@_-]97=KUV<&<FD?"0I/X(+K\B:M1JMWR,OR^OUA7CYB
MKJG$15,DA06Z>F=]U)(L'P9E1XO<7L9SH?%JM\T$WU(@C0'.+P2FM^F8 -7K
M;/P=4$L#!!0    ( ,B+>UB)9\\Q[ ,  "P)   9    >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;*U6VV[C-A!]]U<,U&Z1 (ZNOL2N;<#.INT^+-:(TRZ*
MH@^T-)*)4*)*TG&\7[]#RE:<(C&"HB\V+W,Y,W.&H\E.J@>]033P5(I*3[V-
M,?4X"'2ZP9)I7]98T4TN5<D,;541Z%HARYQ2*8(X# =!R7CES2;N;*EF$[DU
M@E>X5*"W9<G4?H%"[J9>Y!T/[GBQ,?8@F$UJ5N *S>_U4M$N:*UDO,1*<UF!
MPGSJS:/QHF_EG< ?''?Z9 TVDK64#W;S*9MZH06$ E-C+3#Z>\0;%,(:(AC_
M'&QZK4NK>+H^6O_%Q4ZQK)G&&RF^\LQLIMZU!QGF;"O,G=S]AH=X',!4"NU^
M87>0#3U(M]K(\J!,"$I>-?_LZ9"']RC$!X78X6X<.90?F6&SB9([4%::K-F%
M"]5I$SA>V:*LC*);3GIFMC(R?8!/58J530^P*H/;LA9RCP@+K##G!I:"51HN
M[ME:H+Z<!(8<6_4@/3A9-$[B-YQ$,7R6E=EHN*TRS%X:" AQ"SL^PE[$9RU^
MQ-2').I"',;)&7M)FX;$V4O>2L.&*;Q:4'DS6+(]L<[ 7"E6%>C6?\W7VBBB
MT-^O1=_8[KUNV[;56-<LQ:E'?:-1/:(W^^F':!#^? 9YKT7>.V=]MJ(VS;8"
M0>;0%/-+;?FNX<O6:$/UY%4!<TM^;O:OH3]O_WZ#D$M!S6OM&$N!0P?S;ZA!
M.Y>R?FXQ\@+95CEITMTC4X"V[$!%PW*-JBT<7&B;=PV\(EFYU8167XX[QPB^
MNI["[.ID-2\*A04SV#F-CVD;_[\=Q! -NJ-D!#]"Y ^N8>B'M$RNNZ->W/F5
MJDL6(1IV!Y$]I]NX<_N$*N66!A?)H ^7!]4./0$Y<I(/;A@UBQ!6(NJ&@]#)
M#/QD\ Y "21)-XI[I-'S$PNH;QUW>_W1T;-+\%O:$4$?6:RQ/[RV3FG9[P["
M\ R1^BV1^N\F$FK#Z<7#IKQ7:]<7J2QI%&CF2BTK5]W,"I%"89-)/%$O"*&;
MYV2U7+[&N_-P7O*.:>+<P>8.%<+6(N(-B(5@!)+P2WJ>6M>UXJE5+66& HS\
M_X,:=_ZTY'9O6F=U*C*F:M8T=\A!1AV1$?]ASU%D$/IA^.'Y]E$*<BULS_3<
M%5S!<.AD[KA^N,H5/<.<>$I=8D!98(G?'UFQGC_L?>C<HRHMUB.V"\J);3E]
M2?2(^YWV+6]"J+<JW5#@4-.3_E]01A%Q=O@VNKZ?)">:@N=XBBGT^Z]R-3B9
M8"6JPLUI3=795J899NUI^RDP;R;@LWCS'?&9J8)3)@3FI!KZ0^*9:F9SLS&R
M=O-P+0U-5[?<T.<,*BM ][F4YKBQ#MH/I-EW4$L#!!0    ( ,B+>UCE0V="
MI0,  (4(   9    >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;)U6;6_;-A#^
M[E]Q4+LB 0S+DOQ>VX#C;%B!!$V;;L4P[ ,MG6RBI*B25)S\^QTI17$2Q\#V
MQ3Q2O.?>GN-YOE?ZA]DA6KB7HC"+8&=M.0M#D^Y0,M-3)1;T)5=:,DM;O0U-
MJ9%E7DF*,.[W1Z%DO B6<W]VHY=S55G!"[S18"HIF7ZX0*'VBR *'@^^\NW.
MNH-P.2_9%F_1_E'>:-J%+4K&)1:&JP(TYHM@%<TNANZ^O_ GQ[TYD,%%LE'J
MA]M\RA9!WSF$ E/K$!@M=[A&(1P0N?&SP0Q:DT[Q4'Y$_\W'3K%LF,&U$M]Y
M9G>+8!) ACFKA/VJ]K]C$X]W,%7"^%_8UW>'XP#2RE@E&V7R0/*B7ME]DX<#
MA4G_#86X48B]W[4A[^4ELVPYUVH/VMTF-"?X4+TV.<<+5Y1;J^DK)SV[7"LI
MN:4L6P.LR&"M"LN++18I1P-GW]A&H#F?AY9L.8TP;7 O:MSX#=PHAFN"VAGX
MM<@P>PX0DI.MI_&CIQ?Q2<1+3'N01%V(^W%R B]I(T\\7O*_(K_D)A7*5!KA
M[]7&6$WT^>=8&FHC@^-&7$O-3,E27 34,P;U'0;+#^^B4?_CB1 &;0B#4^C+
M6VK1K!((*H<K)&X:N*W*4J"+B@GX4C&*R3)'?/A4U"U,O7 LCI.6CL?QS-;/
M0UO\R19UKF 6,[ *1.TC+U)19238'4*N!#T,E/A9YR]DNJ9+Q]78%3KNK)G9
M0<EX1C<U,*DJ5[ &(B/!HTA"IEHY7UPRO"$0G&VXX);J.>M\+E$S5V!('6).
M1@WD6DE0[9?&OS,/JBI#M##G\![.HFX_CL"+X\$(SCO??;>3?79'REND*-T+
MV(* 12V=<P\4DX$/[R9Q%']\;2KIC2#J35[C9<0_%RK0?7Q;/XIZ$?SBE@DM
M)R@U;"DU_&^4@FMF*^V3^'1V]9398UPZ;6)5EEK=<^D"RROK6HP>-BXKV>2N
M9 ]U6U;$!?TZZ#V2"C,-=5[6ZY!'0(\&R@V!N(=CY<GCN#6@2E)-![';#&$:
MC9PP@NE@X(0QC.-!YYMRO'[A4M(=Q:/.%1KBH"PKZRE(Q49CX6R4](D;AWH'
M%(2X.YTVJFFEM:-JJ;3OD5>4?8#Q<-JY>G[6A0(]O5^JOR?L.!D?*W]X,!HD
MZJT?@.2 RT0])=K3=L:NZM'R=+T>T-=,;WEAR-.<5/N],959UT.OWEA5^D&S
M49;&EA=W]#\!M;M WW.E[./&&6C_>2S_!5!+ P04    " #(BWM8E32*3G(&
M  !#$0  &0   'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6S%6-MNVS@0?==7
M$&ZP<  UEJB;E1N02XL-T$N0I%TL%OM 2W0L5!)=DHJ3_?J=(259=ETW#POL
MBRW)G.&9RSE#^70EY#>UX%R3YZJLU=EHH?7R>#)1V8)73!V)):_AE[F0%=-P
M*Q\G:BDYRXU154ZHY\63BA7UZ/S4/+N5YZ>BT651\UM)5%-53+Y<\E*LSD;^
MJ'MP5SPN-#Z8G)\NV2._Y_K+\E;"W:3WDA<5KU4A:B+Y_&QTX1]?)KC>+/A:
M\)4:7!.,9";$-[RYR<]&'@+B)<\T>F#P]<2O>%FB(X#QO?4YZK=$P^%UY_V]
MB1UBF3'%KT3Y1Y'KQ=EH.B(YG[.FU'=B]3MOXXG07R9*93[)RJZ-TQ')&J5%
MU1H#@JJH[3=[;O,P,)AZ/S&@K0$UN.U&!N4UT^S\5(H5D;@:O.&%"=58 [BB
MQJ+<:PF_%F"GSV_J3%2</+!GKLCX@<U*K@Y/)QI<XX))UKJYM&[H3]SXE'P4
MM5XH\J[.>;[I8 *8>F"T W9)]WJ\YMD1"7R74(\&>_P%?:"!\1?\,E!R7:BL
M%*J1G/QU,5-:0FO\O2MFZS'<[1'I<JR6+.-G(^"#XO*)C\Y_>^/'WLD>O&&/
M-]SG_?P>Z)<W)2=B3JY$M10UK[7"NTM>\WFA"3"2#,NW*X+]>SPL.,DV?&MX
MLI3BJ3"DX\_ ?<7)>&:W/"0K#DEC"O8N@<[*8$";%\ZD(AQK3Z!RO)IQV5?/
M?%+"ZAPO?#(N:C 2C8(GZO#8^1.,;=]LV#IH:TW1S+EJI 2<I+ Q:ZCD#P"/
MG?<\YY*5Y(#\]F9*?7H"7WX:GOSZ@7.OF>;$#TA((N=!:/"2M7NV#Z_YG,.#
M_)48QG[L1GY(#N'*<X,T-E?43:<^.6RW&_N^2\/$_.).(Q\OJ!LF%%98#'FW
MZ9@F;A+[K9/.*'+#*(#%5PM6/P*),;D 2UKGX D-?#> Y8$_7/7$RH99:<1B
MLCKCA*8N#2@!M*GG$?1-:0MC1\AS*2IHH%H7=5/4CP1&A30>%2074G8 23L@
MT1XV1#T;HE>SH2\"<OE#P69%6>@"8L(&N^,E!)Z3KWUP%UUPN_BQ=]?=#-]-
M&J0HJU],1R4GBM0P3_O"8<[*+:"R!;JK"FR39$S9L+=HU1&*[B'4FD/KWD4T
M3"FNU;'S"6"V58/Z@2@JDC$I7X#7*R9SK&,"/11@'<,I-&X(?F:Z1U_4&A1!
M 4%B=YI.L6-H0ITKMBR@9XI_. :J $ZV,'!S_@3G@&6%G K=-(@)=3T_=+"4
M&8 #6=O</W#3&!K1C0,/"".R;V8&YZ8"T(,V<Q&-<(E'G8LLDPW\W'6HS;2I
MG((ET118'$^=S^N0.;C;*$Z2A)#BR/D,99404 I/MIFX3B%0Q8.0/9)X;AA3
MYP.'%.ZJZ3B-W20Q"A G;A0&/_)[X#5PPS2$W*1^NEFX =)CYZ;6P.8"9G9G
M!]*1!*'5D#B&W7X(5>(QY:V8OVU0LQ)(+BZ.?@)GF)BQ!65\ RXP^+2OR7^I
MMWMD(>YE(7ZU++R;S[DYX@V&(KE#%;SCH%$9X#(UV24#^W=!QLL-'V3&]8KS
MFGPYNC\B\U;NUPJ)'-=&%Q2(?*.%?+&"C/VX2R[6,Q<GZJ:C_V_BWJPEOQUN
M&%87[E9H!] 7H>MY.)7@&MCM1?;23UT_@CYSOKYVXAB-R>&8)AH0"@RC%YJR
MJ$!:C).M_AJ#IQ3ZF(!.1:%S-52(3@\"-P&5@OD:IX32$/3B>P-YU_85PVI:
MMF 21R0%;J0I)4GDW,H"THXI)QKTY6VS)./(]9(4V9#XN.D8E6K:C777# #H
MRBY9PQR"J4_M\$Y:/D5AU(]PG,US5D@C(^WYKW[B4ANB0VI /.'LBGJ61'0[
M"UMGFK7+[E"@UJ>"_:96 .,H(@F=0B:"83]T"7WEG$]Z0B>O)O27&DGW6)LI
M@F1N#[Z*W $7R'L[(G;1>?\>%]MD;D?XC#\6=8U*B0T'S#*7E6E!6-(,X>PZ
M^*E#4JC_G*I;E+SL0<Y8:0@$R?>F@\\8RR2MUK<=K04(S+J# ?M2V*97)((9
MO-4'M/>@ABZZL_ .)]C.^YOIG4WG&K0/]/&'X'=USV3P8EMQ8"6^OL,1!6MB
MWW'[I_T_!!?VQ7B]W/Z]\!%(70#4DL_!U#M*X.@G[2N[O=%B:5Z39T+#2[>Y
M7' &[,4%\/M<"-W=X ;]_R;G_P)02P,$%     @ R(M[6).:8KYT!   ,0L
M !D   !X;"]W;W)K<VAE971S+W-H965T,S N>&ULO5;?;^,V#'[/7R'XAD,+
M^!I;=AR[30+TU[ #[H:@Z58,PQX4FXF%RI8GR4G[WX^2DS3MTO2PA[W8DDQ^
M_$B1-$=KJ1YU"6#(4R5J/?9*8YKS?E_G)51,G\D&:ORRD*IB!K=JV=>- E8X
MI4KT:1 D_8KQVIN,W-E434:R-8+7,%5$MU7%U/,5"+D>>Z&W/;CCR]+8@_YD
MU+ ES,#\UDP5[OH[E()74&LN:Z)@,?8NP_.K@95W K]S6.N]-;&>S*5\M)NO
MQ=@++"$0D!N+P/"U@FL0P@(AC;\WF-[.I%7<7V_1?W:^HR]SIN%:B@=>F'+L
MI1XI8,%:8>[D^A?8^.,(YE)H]R3KC6S@D;S51E8;9610\;I[LZ=-''Y$@6X4
MJ./=&7(L;YAADY&2:Z*L-*+9A7/5:2,Y7MM+F1F%7SGJF<FO>._?I-9D"HK,
M2J: G-RSN0!].NH;-&#%^OD&[*H#H^^ A91\E[4I-;FM"RA> _21V8X>W=*[
MHD<1;R _(U'H$QK0Z A>M',W<GC1.WBW3-6\7NZ[^^?E7!N%V?'7(8<[N/@P
MG*V8<]VP',8>EH0&M0)O\OE3F 071\C&.[+Q,?3)#"NP: 40N2"F!*R!7-8Y
M%YRYA,93S$>>$U87I."B-5 08>^R0>>T=>Z01T=M'O;H'HTOI, "QM@18].#
M:# :#Y4I_R,WJ^Q4GX$I3<!F#,'[AFJ.(ML[=T_J8' 1DA->HY)L-9Z@TE,.
MC=G#++ &3L][?R!DEX.O$'L6L0.T8#V;_([43^0D#&,_BD)R:C=H-TKB;IVF
M?DQQW9LJJ'A;$=>-"JB:K:?X80$*S\C,R/R1G RHG\0#5/_\*:4AO<!7F,47
M;[8OYFTD/@P76S$N7.B-)+FL*C2NK;U2B@)4YT22^-DP.>+$@VM3B,Y6H+#K
MDKIUT4$WG!E-L'-K@SSL57_9T JCP*=9BN_8IS3!-_730=J[72RPNUIE1QK[
M*^9%WBIN."(=]?YM,#XF9F/#-/X]4 B3#<7LGT$CR6W$WJ/Y[54D>U?_"K4-
MW1E-NU@%9^%PNTKLZD@I#W:E//CA4FZD@=IP)L3S2]CVH[X7PC7@S6.6B];F
M\D+)RI4,7G_3FEVI;=VHMPEUM $<9_JZUO]/KF0..6LU6"VN"'2YM9:M*$B)
M68'? 7_C2.?+CLJVAR (E]@07,^J$?^\]ZJ5O+OI=24K73%K$D5^B'4SM$F$
MI11E?I!%)$S]+!GZ0QKWINU<8/(\,*60B28))A@VCB"SJRSSLS1]F]E3Q5?,
MP(M.Y"<AUF8:D=@/@]@/@N"MSAT8'*BV_RA-G- !P;=Z&_&O6":N532MPE5M
M;,^XG4VGA&9^&B0?H%R[ZC+<(MS ' /:6M1!C"'!'GQ<^5X:)DB<^F&2^A1+
MB0[]+([\( WW GFHIOI[8TP%:NF&-8T)U-:FFVAVI[MY\+(;@U[$NV'R.U-+
MCO<I8(&JP=D0DUYU UJW,;)Q0]%<&ARQW++$F1:4%<#O"XF9O]E8 [LI>?(/
M4$L#!!0    ( ,B+>UCFM'EZ)08  +(T   9    >&PO=V]R:W-H965T<R]S
M:&5E=#,Q+GAM;,6;VV[C-A"&7X5P%\4ND,8ZV,ZAB8'$$M$431LDW>[%HA>T
MQ-C$ZE22=M*B#U]24B13D;EV=@K?)#IP/E&<T2_IMWCQE/,O8DFI1,]IDHG+
MP5+*XGPX%-&2ID0<YP7-U)['G*=$JE6^&(J"4Q*706DR]!QG,DP)RP;3BW+;
M'9]>Y"N9L(S><216:4KXW]<TR9\N!^[@9<,]6RREWC"<7A1D01^H_%C<<;4V
M;"@Q2VDF6)XA3A\O!U?N.?9.=$#9X@]&G\3&,M*G,L_S+WKE)KX<.+I'-*&1
MU BB_JWIC":))JE^_%5#!\TQ=>#F\@L=ER>O3F9.!)WER2<6R^7EX'2 8OI(
M5HF\SY]^HO4)C34ORA-1_D5/=5MG@**5D'E:!ZL>I"RK_I/G>B V MS)E@"O
M#O"Z :,M 7X=X.\:,*H#1KL&C.N \:X!DSI@4HY]-5CE2 =$DND%SY\0UZT5
M32^4Z2JCU0"S3%?6@^1J+U-Q<OHKD2M.4?Z(?BLH)SK; I$L1M=$,*&WWW$J
M:";+7>C]51PSO402=)-5A:W6/J#W 96$)>(#^@%]? C0^W<?T#LT1&))5#QB
M&?J8,2F.U$:U?,N21!_I8BC5.>B>#*.ZO]=5?[TM_74]=)MG<BE0F,4T-@%#
M=?+-"'@O(W#M68D!C8Z1[QXAS_'\G@[-=@_W>L(#>_@#+52XL_7HH3W\YU5F
M#<?V\*N"-^&>92S]IIK\DN=O'0P1<5:4I:)+BB](QOZI2J<LJI50$4)L%EM;
M.9]_43O1C:2I^+.O,JICC_J/K27X7!0DHI>#0I<L7]/!]/OOW(GS8U]6(6$!
M)"R$A&$@F%$-HZ8:1C;Z])Y&E*W)/*&]%WH5?%8&ZQO@>NH?JR)<;V;)>H!]
MLP0)"R%A& AF9&G<9&ELS5+X3'G$!$4%9Q'M2]3X5:)<]WC<R=0NC0)K3_;-
M "0, \&,#$R:#$RL&9B5MWG*T2S/(G6KK901W3/Q!7V^I>F<\EX]M%+WU4-(
M6  )"R%A& AFY/FDR?/) >^.)Y#5  D+(&$A) P#P8QJ.&VJX=1ZU=\IV=7/
MU8ORZ3M3+Y&<KFFVHD=(Y E%,1.2L_E*YKPOW17<=38$USEV.Z*\2Z/ VLU]
MTP,)PSW=;SMO#/I9,^AGWRRUZ%]T7V4"7=,L6JHW;F/G[TM.*7HA":M$6WNS
M[T4)"0L@82$D# /!C/IPG?9]V#F@2-<'!RH(4%H 2@M!:1B*9A;%ADGBVF7#
M4 NNU.((%8U^]R;:[9/>T^Y3\Y9F?D>B[=W;.S60- Q%,U/CM:GQ_G=%OV49
M2U?I6T7>WL.]+VI(6@!*"T%I&(IF5D[K5;F'-*M<4+<*E!: TD)0&H:BF471
M6E:NW;-Z@]*/^B3<ZSI9_<W<LZ[2@YI4H#0,13-3T_I4KMVH E%Z\OQ-2@_I
M.<U :0$H+02E82B:63FMO^9.#JGTH#X<*"T I86@- Q%,XNB->-<J[OS%J4_
MZ9-P_Y72]S;S1EVE![7%0&D8BF:FIG7&7+LUMJ/27T51OLJD0.T/36\6=DC?
M:@9*"T!I(2@-0]',0FG=//?LD,(.ZMZ!T@)06@A*PU T\W..UL'SK&;0&X2]
M!G84^ZSKIF]IUM%U>^_VS0PH#4/1S,RT-IKW%1L-1->_T:VQ]W'?JQJ4%H#2
M0E :AJ*9M=/Z?)YW0*GW0"T\4%H 2@M!:1B*9A9%:^%Y5C?H+5+O[_)P/NMO
MYD^Z6@]JI('2,!3-3$UKI'E?-=+6E$NFQ3N@<Y61E?X0U*K,D&[5#)06@-)"
M4!J&HIF9;GTY;WQ(90:UW$!I 2@M!*5A*)I9%*WEYMF_:5.7O-1?%&81*TB"
M2*J?Z'KS6W'&&T+K=7\EM1]K[ZQ-7G^JZ+C=Y_BPIV.^8[;!4!TS![FUL#R[
MA54.\J=R\@2-T9726_TUT4TFJ3J:1/=$]M\#:X/*-7^*\,>OQGW'AH&]GWM?
M"*!>%A2MRM%P8ZJ%>M58E)-B!"I?6*HY!\W69N+-53G=I+/]VCV?5=-G6DPU
MF^>6\ 53&IG01X5TCD]4"?)J@DRU(O.BG- QSZ5ZWRD7EY3$E.L&:O]CGLN7
M%7V 9IK2]#]02P,$%     @ R(M[6/[WH5G$ @  FPD  !D   !X;"]W;W)K
M<VAE971S+W-H965T,S(N>&ULK59=;]HP%/TK5E9-K<2:3UK:0:264&T/VU!I
MMX=I#R:Y$*M.G-H.=/]^MI.F? 1&)5Z(/\XYN??<2^S^DO$GD0)(])+17 RL
M5,KBVK9%G$*&Q3DK(%<[,\8S+-64SVU1<,")(674]ASGPLXPR:VP;];&/.RS
M4E*2PY@C4689YG]O@;+EP'*MUX5[,D^E7K##?H'G, 'Y6(RYFMF-2D(RR 5A
M.>(P&U@W[O6HJ_$&\)/ 4JR,D<YDRMB3GGQ-!I:C P(*L=0*6#T6, 1*M9 *
MX[G6M)I7:N+J^%7]SN2N<IEB 4-&?Y%$I@.K9Z$$9KBD\IXMOT"=CPDP9E28
M7[2LL8Z%XE)(EM5D%4%&\NJ)7VH?5@ANL(/@U03O4()?$_Q#"4%-" XE=&N"
M2=VN<C?&15CBL,_9$G&-5FIZ8-PW;.47R76?3"17NT3Q9/@=RY(#8C/THP".
M=?$$PGF";K$@0J^/.0C(I=E"G]!$=6I24D,98I$:L!F,GDNRP%1A!3J-0&)"
MQ9EB/$XB='IRADX0R=%#RDJA**)O2Q6^#L*.ZU!OJU"]':%&$)\CW^T@S_'\
M%OKP<+K70H\.I[LM]-'A=&>=;JN2-77SFKIY1L_?H;?;^M\W4R&Y^@/^:;.X
M4@W:5?5'Z5H4.(:!5>BR\P58X<</[H7SN<WP8XI%QQ0;'4ELK31^4QI_G_I;
M:6(]@+?2M-6CDNH:*?U-7X3^E>ZOQ:K/VR#/[07KH&AO4._U[TAB:_X%C7_!
M7O_N0?4OB254#K:Y5@E<K!C2<WH;IFUCG W']H;Q7L>.)+;F6+=QK+O7L0<F
M,35F=;::KF-:D?_?T^Y6DP67WM6&J=N@EDYL4?+]C?*,6D ]_^UUE0_VRL&F
MKRW?,)\3=4!1F"F:<WZI^+RZ"E03R0ISUDV95">G&:;J]@1< ]3^C#'Y.M''
M9W,?"_\!4$L#!!0    ( ,B+>UC<FQ=Z?0D  )AJ   9    >&PO=V]R:W-H
M965T<R]S:&5E=#,S+GAM;+6=:V_;.!:&_PKA70Q:H(UU\;63&$BC.YJ9H-F9
MQ6*P'VB9CH7JXDJTTP+SXX>2%<NR:=::>=,/C67K/(>RWR-1?"7J^CG+OQ0K
MQCCYEL1I<=-;<;[^T.\7X8HEM+C*UBP5GRRS/*%<+.9/_6*=,[JH@I*X;VC:
MJ)_0*.W-KJOW'O+9=;;A<92RAYP4FR2A^?>/+,Z>;WIZ[^6-S]'3BI=O]&?7
M:_K$'AG_;?V0BZ7^GK*($I8649:2G"UO>K?ZA\ <E@'5&K]'[+DX>$W*39EG
MV9=RP5_<]+2R12QF(2\15/S9LCL6QR5)M.-K#>WM<Y:!AZ]?Z$ZU\6)CYK1@
M=UG\WVC!5S>]28\LV))N8OXY>_98O4%5 \,L+JK_R?-NW;'9(^&FX%E2!XL6
M)%&Z^TN_U5_$08 ^.!-@U '&I0%F'6!>&C"H P:7!@SK@.%QP.A,P*@.&%V:
M85P'C"\-F-0!DTL#IG7 ]-( 77OYY;1*0;N?O-*+13F=7>?9,\G+]06O?%&)
MKHH7,HG2LCX>>2X^C40<GWV*OFZB1<2_$YHNB)M%Z1.YR]*0Y2EY<[L0GP@5
MTYCXZ:X6Q=);\L9BG$9Q\9:\)[\]6N3-O]]>][EH3<GLAW5F9Y?9.)-9-\A]
MEO)50>QTP19M0%]LQGY;C)=M^6@HB<$FO2+&^!TQ-,.4-.A.'7Z[SJ^(J9T-
MM]3A]U2$&_K9<%L=_DNVO2+ZKO&&[-M4AULL%(T_G]V]/%R6W;L\7)>$^Q>$
M&\;9Q@?J\$>V%N%#67A+1^:^)LR*9_Z-FOCCDUB9^)PEQ?\E+?VX(P_DY/)@
M]Z%8TY#=],31K&#YEO5F/_U+'VD_R_2*A%E(F(V$.4B8BX1Y2)B/A 4@6*L^
M!OOZ&*CHL\<5%5 2%<6&+=Z1HEJ4%8,2T[48D# +";.1,&<'&U6PLG.[G1E#
M3?R[[F\/98[,Z2%A/A(6@& MF0_W,A\J9?X+>Z)EY[WJX9?'@)"N(TYCF=*5
MI*Y*1\(L),Q&PIP=;'BH=,T<:1*Q(]-Z2)B/A 4@6$OLH[W81TJQW]%B575W
MPO(%$QV@+8U9RJ7[=26JJ]J1, L)LY$P9W2R7S>GAGZJ]=%I5>B3P<EZ'K)Q
M/A(6@& M&8_W,AXK9?PI*PJRS+.$9&N65Z>K4@4K*5T5C(192)B-A#GC$P6_
MU[7AP)2(6++J4!N9$AF/3^3^WAQ.S,G)FCYR6P(0K*71R5ZCDQ_T*_AN+[LI
MV()$Z8M410^C&BV,>"3O3BNQ746+A%E(F(V$.9/3[K0VEO4QD%D]),Q'P@(0
MK"7\Z5[X4Z7P;\-PDVQBRH7L%VP9A1&7R5P)Z2IS),Q"PFPDS)F>[G '4\T8
M#$^%/I7L<<?#J2[9.2.;Z"-A 0C6DK&N-6/FFE+(#WF4AM&:QB2FI<>39)M4
M*N6:<_AEFYHFV?W<J3-V%2J49D-I#I3F0FD>E.9#:0&*UM;\@4^DJW?>3T]Y
M.2#"2*W^F-7")]FR'@L4>_6YO Z4[*[[])K6.D<:RJK*@N:UH30'2G.A- ]*
M\Z&T $5KUX'1U(&AK(-?-[S@-%V4W?4YC6D:LK( <K;-XFWYYI*&41SQ[](Z
M4+([UP&29D%I-I3FU+3#BM?'LHIWH7D]*,V'T@(4K5T'C4>J*RVFV:_+)<NK
M$<."Q7%M I65<)<EB>@4/?(L_"*M :A%"J594)H-I3DU[;"/+U;5)@-Q[#LN
M LFJ ]T<3";#T5$7']I&'TH+))LQ& ]&$W._#6WM-OZEKC8P:XD6I43?D37-
MR9;&&R95*]3#A-(L*,V&TIR:-C[X[;0KL;O6CZ5ZV7H>M'4^E!:@:&TU-S:E
MKO8I[:^;\EJ5ATT>KFC!R*WHJ+.$B8[Y<\17Y']9_F4;Q65W7>RL/UZ1SU',
MOI,_[EDR9[GT(A9UPLZBA_J94)H-I3E0F@NE>5":#Z4%*%J[@!KK4]]94J]Q
MO9<.]4*A- M*LZ$T!TISH30/2O.AM !%:Y=*8Z_J:G]5E,66Y3R:B\.)Q>;B
M(+/)&5GOQT-OSP^%0BU7*,W23UU(^8"2#<WK0&DNE.9!:3Z4%J!H[2)H_%M=
M;>!*BT"J>:AC"Z594)H-I3DUK56/ _EP#]2VA=)\*"U T=J:;ZQ;_0?>[3\:
M_H=:NE":!:794)JCGWJU\N.2"\WK06D^E!:@:.T[C!KKUU!;O[<_T63]\^>#
ML^K3\VY9":BQ74L 2K.@-!M*<Z T%TKSH#0?2@M0M':9-&ZQH;_:*;4!-8NA
M- M*LZ$T!TISH30/2O.AM !%:Y=*8R@;:D/Y'_6LU.S.M2*Q6>475D#SVE":
M Z6Y4)H'I?E06H"BM>N@,92-5S*4U=S.-0 UE*$T&TISC%-[=60: _/8HH-F
M]: T'TH+4+1V!32VM*&VI:O)20C/=@60T&]1LDE(NBE]NK(0P@/;6G'7K3I+
MYWJ 6M90FEW3#H]7]>'J^(#E7+ZJ"VVC!Z7Y4%J HK7UWAC7AMJX[G 9AIK4
M6=-01QI*LVO:CRZ(<*!972C-@])\*"U T=J:;[QF0WV?[27C1^3/5I]'>:F&
M.EWGPH#ZSU":#:4Y4)H+I7E0F@^E!2A:NWP:_]D8O]ZX$M2!AM(L*,V&TAPH
MS872/"C-A]("%*U=*HU+;:A=ZHMGZ5%S.M<%U*6&TFPHS3$D]Q;+INJ!9O6@
M-!]*"U"TMN(;C]KX@4?]GWOR2&,A>K45!W6CH30+2K.A- =*<Z$T#TKSH;0
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MXO-EEO&7A3+!_F%4L[\ 4$L#!!0    ( ,B+>UBY<@\%#04  -,?   9
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M,[U/:^^J5]O=#U1$<29)PI80ZER.H%U1[2!7)XKG>HMTSI7BJ3Y<,0JI*"O
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MD$O30E(]\L92;K6\$7M4;;H:T5UUW<-&1Q^C,[(LJ_XINL@F/23,1\(62%B
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M*[C@2C>6V>,&283"&.CW*\[586 6*/]^F/X'4$L#!!0    ( ,B+>UBG/"6
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M0IMNP0UWIJ%#:0W,]XT0^G5B-VA;Q/0?4$L#!!0    ( ,B+>UB_Q-=SI ,
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M"<#WJ1!ZWS$73O=]$?T%4$L#!!0    ( ,B+>UA:8XS"@ (  *(&   9
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M"FM2K2.V@9&-\XB9-.@X;ECA1P243<#W<RG--K +])^E["]02P,$%     @
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M&#?-3'TN =<%:CYE3#YU](G<?X!%_P!02P,$%     @ R(M[6*:EZ%V&&P
M9&H! !D   !X;"]W;W)K<VAE971S+W-H965T-#8N>&ULM=UM;]O(O8?AKS+P
MZ2X2P.OHT98WV0!9\YE-$R3;'A3%>4%+M$5$(E62LF.@'_[,D)2HD>F1M+G;
M%]U8-J\94?R+(^HWPW>/6?ZMF,=Q*;XO%VGQV]F\+%>_OGE33.?Q,BHNLE6<
MRM_<9?DR*N6/^?V;8I7'T:S::+EX,^CU+M\LHR0]>_^N>NQS_OY=MBX721I_
MSD6Q7BZC_.GW>)$]_G;6/]L\\"6YGY?J@3?OWZVB^_AK7/Y]]3F7/[W9*K-D
M&:=%DJ4BC^]^._O0_S7L]X9JB^I/_I'$C\7.OX5Z+K=9]DW]X,]^.^NI+L6+
M>%HJ(Y+_>8AOXL5"4;(C_V[4LVVC:L/=?V]TIWKV\MG<1D5\DRW^-YF5\]_.
M)F=B%M]%ZT7Y)7OTXN89C94WS19%]?_BL?G;WIF8KHLR6S8;RQXLD[3^;_2]
MV1,[&_1'+VPP:#88[&\P?F&#8;/!\-@61LT&HV,W&#<;C(_=X++9X/+8YW#5
M;'"UM\&+NW72;# YMDO7S0;7QV[0[VU>N=[1FVQ?[/J@JX^2ZA"SHC)Z_R[/
M'D6N_EYZZA_5<5IM+X^L)%4U];7,Y6\3N5WYWHIO2_'JPVR6J",\6@@_K0M5
M_O1:O++B,DH6Q6OQB_C[5TN\^LOK=V]*V:S:^,VT:<*KFQB\T$1_(#YF:3DO
MA)W.XID.O)']W79ZL.GT[P.C^#5>78AA[UP,>H-A1X=NCMA\T']Q<\N\>;!>
M7(C>RYO;AS9/9>M7+V[NF#?_L,J-S]TU;_XQRHW/W3-O;L53V?K+F_OFS3]-
MRPO1?WGSX)@7;OSBYN'QG1\8#L/AMG:&E3<TU8Z?%F6^EF>94OSKK_(/A%_&
MR^+_.GKW>ZV-NC5U\ORU6$73^+<S>78LXOPA/GO_\__T+WMONPYQ$K-(S"8Q
MA\1<$O-(S">Q@,1""-,*;+0ML)%)?__A_CZ/[Z,R%I_S))TFJT4LHF6VEK66
MW8FD*-;Q3(Z?;LNN:C/2IU8;B5DD9I.84V/C"E.C\8?W@W&O^M^[-P^[E42V
MZI&83V(!B840IE72>%M)8V,E5:>J:98^Q'GU:6B5)].XJVJ,S*E50V(6B=DD
MYI"82V+>^%D]3_1"]LGF A(+(4PKE\MMN5P>+I>=D=V7>!8O5^HS45?-&*U3
M:X;$+!*S2<PA,9?$//.1\<<\%C?9<A6E3V(>%:*4/^?JLLVYN%V7(LW*ZJ'L
M=I'<5Q^BST62BJ0L1)')T<LL*:9Y7#]>9B*7QU6\/!?KE7Q/ODL>8HD4LL6B
M$+/HJ?CY?R:#_M5;]6Z=Y>(Q3\HR3E4;\LU;;?[/+/_VD"RD^THUJOY\T'O;
M'JSB;]6?5H_WW[X^%]%B(:2D.K_*\NI/Y$!*;5L/JPJ1K<NBC-)9DMZ+M?RX
MGE>_O:G.'&5R*YN2M2%+8BWWI.I8]I#(S_3RCZ+ZB9=Y5&U;G6 VN-QA2]G4
MUS*;?I/#-K%03U!NDN[@U6GI<[75ADJ66^'9<[H0ZI7(VX>;<6$Q5\_Q-A;Q
MO]?10NVDZN78>5:K>B@I?WD;+:)4MG<;J\?KUT(^E]NG3:?5JWPN5HMU\SJW
MK<D#:9FLEZI[_=Y/FUZV=-,;76XHU<%H.LW5X%7V2>[F593,Y&%2QG*GENIX
MD?]=Q=-JE%NLI_.V;_LM7'0-@<AR"$@LA##M/?UJ^YY^9:S<YB LU$%XKHX3
MV43S&:+K3=V(G?JF3F(6B=DDYI"82V)>C5WN#(3D7_8F(_GQ9F] 1#8;/&]V
M=#6ZG SU-L..WHWZP]%D,K[<_J5VS$^VQ_S$>,Q_C+XG2_DV]:^/\?(VSCNO
M2AF%4P]T$K-(S"8QA\1<$O-(S">Q@,1""-.*ZGI;5-?H9=]KLL!(S"(QF\0<
M$G-)S",QG\0"$@LA3"NP?J_]4K+'7*XR.Z<6%ZI9J&:CFH-J+JIYJ.8WFG9-
M6Q]^!6B#(:7II;/S?7[?/.1+TH-#/C-Q<M60FH5J-JHYJ.:BFH=J/JH%J!92
MFEY@@[; !NCPK^&H8B,U"]5L5'-0S44U#]5\5 M0+:0TO=C:A$W?F"\X82"(
MAFM0S4(U&]4<5'-1S4,UO]&N=P:"O8OQ_E 0S<Y0FEX\;7JF;X[/?,HC]9W!
MW[*RNV30A RJ6:AFHYJ#:BZJ>:CFHUJ :B&EZ;75YFGZ8W84B 9K4,U"-1O5
M'%1S4<U#-1_5 E0+*4TOMC:-TS>'+GXH!]K8NQ> ^KW^=4>J\<;<C9/+"DW?
MH)J#:BZJ>:CFHUJ :B&EZ675!B+ZYD2$793)4E;53-Q%22X>HL6Z>Z"(9B%0
MS4(U&]4<5'-1S6LT_5UQU.]X5_31A@-4"RE-KZ V7M$WYRN^QM-UGI1)7(C/
MZWPZCXI8?)#GJK@>$YHNP:.Q"U2S4,U&-0?57%3S4,U'M0#50DK3RZX-8/39
M!$8?C6"@FH5J-JHYJ.:BFH=J/JH%J!92FC[5NLUB#,Q9C!_Z\&6V3ZT\5+-0
MS48U!]7<04<&HG->GX>VZZ-:@&HAI>E5U<8T!N:81G4*2[:GL'-90<4T3UZ<
M8V3F3BXD-+*!:C:J.:CFHIIWX!!1$US:&3Y?/W_83+<IVNDVW1-SQ&.V7LS4
M+)CF[5E-,RDR^9#<+!*KS4>5>I+.=J;,]>5V)DNT6BV2::389Y-:$C5M1W[&
M47-]TNE<-A<5XBY;+++'XE?Q*GDM_M+O7?3JY[V4G5=?W%8SG)1<)/>IFA33
M-*0]P7/Q.$^F<_&H0#7[:";D5A\CV=U:VRQ<\58VH]JYNAB_T,Q=LFA:B80\
M?26RT*KI6*(HY:FL&C7*']2J/.+K+WWQF)3S:KNO]DT],4MMTLQ^DGLTDAV\
M?=KIK8+3I\TT$OG3WARG8EWMO*H_.]]?;R=$=;YL[82KG0^6'^IY0/WKX?!<
M[>E(=E[MF=TI7_J?M_.]NG;G!_F"+NJ]UM_N3G6 R%W:N4]WIV,ULY$Z]Z=J
M9A9/%W*/S$1\=Q=7JR5MIE/)'7NP/X-F69/.64UH[06H%E*:?C)I(TD#8PKC
M^<ED.Y=,ODB=E_3,X,FG$S24A&HVJCFHYC::2HSN9!)Z5SWM?_W],1H:/D*U
M -5"2M/+J@T?#8X('RVC4KVU/HG92Z6$)H]0S4(U&]4<5',/OI33>MFKE]>]
M,@/5NEG]<0V,.@L)7<,'U4)*TPNI#2(-S$&DHU-\9N?D6D(C2:AFHYJ#:FZC
M&98-\= &?50+4"VD-+UTVIS1X(B%>W8N=7_>?AK[4'T:.Q>?XWPJ?Q/==U<4
MFCM"-0O5;%1S4,UMM/V!WGB_JM! $:H%J!92FEY5;:!H<,3Z/JOHJ2HI^5%I
M6736#KJP#ZI9J&:CFH-J+JIY!PZ,KN5]LGK)E^JJD#QF1)S(1W-UH:MN)DG%
M-"KFY_5%I%6S,LSFJEK]-^.?]I9UZ5PN9K/<2W-DGJNU>M2%KMJX?9*_O5TF
M9:FN;$6;=8#NJ@5]1#1[J!:S::\A??@Y6J[>?MFY:/4\HU U$0FYVY+Z,E;#
M5,\\CROL?+-DT#1;WB9IM%DV:+L#FEZ*ZOJ/JB:Y4_>7T;F0)['JYZEJO]HZ
M>7W>[(9L&L>S0MSEV;*^1EA?5:NN6&K+',F'ZTN3ZIKF?:0N>3Q;WZ=9R:C[
M&A(:!D.UD-+TM\0V##8XM#Q.YR5)O[Z W PR.M\ET708JEFH9J.:@VINH^V-
M,*XO]T<89*,^J@6H%E*:7DYM,FQ@3H;M+%CVN3XC=-8.F@)#-0O5;%1S4,U%
M-:_1]BIQ[R*NC[89H%I(:7KIM.FN@3'0<F2H4OQ'.$E>U-][1(O%P<2EN=63
M:PT-@:&:C6H.JKFHYJ&:CVH!JH64IM_HH V!#7MHXG*(YKY0S4(U&]4<5'-1
MS4,U']4"5 LI32^V-ALV- =_OL2;2U/R<_*LNE25)VD3O=PYW746'IH3:[3=
M;P(Z<X,6VJR-:@ZJN:CFH9J/:@&JA92FUU0;D1F:(S)'#RKE'V;IK#K7'3.J
M-#=[<KVA01I4LU'-0347U3Q4\U$M0+60TO2BW+E_%GP#+?8.6NPMM-A[:+$W
MT6+OHL7>1HN]CQ9[(RWV3EK_C1#.L WA#,TAG!\:5:*YG$;3UCM_85B)9FY0
MS4$U%]4\5/-1+4"UD-+THFKC.4-S/.?H8>4?\R0_852)IG90S4(U&]4<5'-1
MS4,U']4"5 LI3:_)-MPSO&1'E6C,!]4L5+-1S4$U%]4\5/-1+4"UD-+T8FMC
M(T-S;.2'1I5H<F3X_"XZ@U[WJ!)-A:":@VHNJGFHYJ-:@&HAI>E%U89'AL2R
M0G)4>6"%5W,S)Q<8&B]!-1O5'%1S4<U#-1_5 E0+*4TOPC:&,F07&1JB^1)4
MLU#-1C4'U5Q4\U#-1[4 U4)*TXIMU.9+1O_%18;,]JF5UVC:U<GN]6(MM&$;
MU1Q4<U'-0S4?U0)4"RE-+ZLV23)B5QDR<R=7$KK*$*K9J.:@FHMJWH%#Q-\L
M%=).'-KY5-'<J+JH%PZZ6ZRGY3JJYA^M8C4I*%TO]<5&]/MN%_4MLE_UFYE"
M\DT^4JOJJ,>^OQ:CG^J%9YZ:7_\1J^5X/CE?Q*MJ+M%=HB82)>E^KU[7FPU>
MB\G%^*=S-5^J6FTG27_YEJ35JC*16&9I.5\\B=NH2(H+X=\9[@2NIGJI6[??
MQG$J[M8+N9F:ZY54LYB>KS\T.E<SKN+O22GNXGHMH-4JS[Y7JRG+;?\RO.C7
M&VS6T+F-I]E2[L;9NED3*-]<-[D0?]^L691-Y<>^/%:SN-3SF\G/@+*7U:0I
M^5R2=%U-\*I6'A+QP_::RUVT7KSP\IV+>;:0CU=3NY99'M=W71^WMRR/MB?>
MYC;D79/2]M1"+-4TN(6:RB9?Z/H0:0^#ZE#9=.OY,:%N_MX< LFSU[VZ07I_
M_),^\TUMMFQN95R!*S7)K%0K5]=/>V>YJD7T>"'^D2UDUZ/\24W':W:TZO5,
MW>S]KMX/<D^F\2]/<50=QXE:FT!MT#S=Z2(KU-Y7JWYL'OLZ31;Q]U^:/:$6
MY%JNJP#Z=+&6LCSDHF_Q+X]REV\'+]MGOKO+9[-$O0'+7VSW6;6@5[UJ5[,[
MFV/BV<M19/5SDB_5=K[<II/UY,'M,U;+=&7K^WEU--6]W!Q0VJHFV^+8+?RD
M4#V1+W)>K1!>';0=Q]UY>R2K37+YA!.U_E-U$"QEPU&9R;VJ'0YJ-:O!^*<7
MIT&^*K/[N)IC6<VH[/?J?5?OF'HQL^9@W=E_\K]5#^7O%PN159LW4P&KJGL^
M_7+W#>5"_+'W_%7)J0F&.T]B9\]6*[&IM2PV3UGMV'4]L_&J[FX:E]6\T+WY
MC6HBY8UZ^.MC'*^$DZ2RJM76A][RU"3,S>3,MMCMOWZZ*0YN6S8'S9/A/3"Z
MVZQW)DMBD=0ENKM86/W6I_JAWB%W7G?U=_)06955 ?JI&J?'LU36^:&.=4[2
M1$]_ :J%E*:/Y]H4X\B<8CQVQ7XS<_(X#DTEHIJ-:@ZJN:CF-=HQ*_:C#0>H
M%E*:7D%MY'!TQ)I>[9=6MAK#.7%W$:%IPT;;??F&72^>A39KHYJ#:BZJ>:CF
MHUJ :B&EZ274!@E'YB#AZ:M-FL&3*ZG6]A?3&>W7$9H=1#4'U5Q4\U#-1[4
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MBHX7!^_%C63K_"AZSJ1D27ZY A("SSJHWQ>,R;>;S$'U]\?T7U!+ P04
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MYA*HL[<(:F_6:!/?@EH\32V>G5I:"Z'R7LTKNQA9;SSM].E\;TDT]*;S79=
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M\NE%AAE! K^@E.*'ZN'N3@M!P0-4+6K4C%G9UJ2LZ8SFB;!G)6*SZ/,WZG@
MOM,CT#U7H&H1E)IIIB:0T$X@=SD5%*=HS6@>T[7\A+.B[)Y1MDN-MM'?FY_V
M=F O@JK1-$>#2&@'D8@\"$1S+EBI9MG?R<^"R(H$8@=2OUUPM$6UFGJ&K37:
M=KU=E]X"(<+6<^5VA/CT0H5:I>GT W075*.VXX>SY\=;X$*H<2&TX\)>U"2$
MQXRNU0LV.CT"I8*>QOV^(EU9$SUCCF1*S; H)05*JA;R1()92E6X%\OWZ(2>
MUK4NR%I4@\CZJ^_4+[WX(,^@IW6YY9)4KX2IADAJZ@?+,>CM"LN"#+DN6J<X
M5X<9*=@CSNG_JK>/H&<J5O(87\O2JC6;3%]);ZI7%<1%7KWKIBK5R',LAV2R
M6X4\@:&$\G7!Z?:$-%5_XW)<+.E69;STM3ZXK%J,.2=R=">_M>M\:E6YZ4EU
M=AR3E+!M]>J8<O.7 N?U6J4Z(ON:T7SO)#5K086*#(Y.I.L)6<K?*%&O4Q'F
MCZ/D](KZJ3I#UERP!.<QJ<W:B$9%7!XA^:%J[,FFG]*TC')IY*:]K9_L%G/"
ME8?2^R?">*M7>V=1=7>.JX]EM4M@<\;9ILA'G']GY5K$,BR*A$P[[XR@1#IK
MO68G(^RQ>ET1E[V1-[OZC3O;H]M7(MU4+P*:Z=/K]RE)AGN4US=*R5(6=:9G
M,M^P^A5%]1=1K*N7]CP40A19]7%%L#1"G2#_OBP*L?FB*MB^*.KZ_U!+ P04
M    " #(BWM8P]9(;,4)  !F;P  &0   'AL+W=O<FMS:&5E=',O<VAE970T
M.2YX;6R]G6MOXS8:1O\*X1;;&6 VUM67:1(@B2@V0-,-)C-;+(I^T-A,+(PN
MKB0G#= ?O]0EIBDIC-1]O/,A8SOBH>SWL4B=Z'+ZE&;?\@WG!?DSCI+\;+(I
MBNW'Z31?;7@<Y"?IEB?B-_=I%@>%>)H]3/-MQH-UU2B.II9AS*9Q$":3\]/J
MM=OL_#3=%5&8\-N,Y+LX#K+G2QZE3V<3<_+RPJ?P85.4+TS/3[?! [_CQ9?M
M;2:>3?>4=1CS) _3A&3\_FQR87YDKE4VJ);X=\B?\H/'I'PK7]/T6_GD>GTV
M,<HUXA%?%24B$/\]\BL>125)K,<?#72R[[-L>/CXA>Y7;UZ\F:]!SJ_2Z-=P
M76S.)HL)6?/[8!<5G]*GGWCSAMR2MTJCO/I)GIIEC0E9[?(BC9O&8@WB,*G_
M#_YL/HB#!J;S2@.K:6 -;6 W#>RA#9RF@=-N,'NE@=LT<(?V,&L:S(8VF#<-
MYE6QZD^W*HT7%,'Y:98^D:Q<6M#*!U5]J]:B(F%21O&NR,1O0]&N.+_;!!G?
MI-&:9_D/A/ZQ"XMG\NYBO0[+I 01N4[JO(MG[\D[CQ=!&.7OR3_)ESN/O/O^
M/?F>3$E>4G(2)N1+$A;Y!_&B>/QYD^[R(%GGI]-"K&K9X735K!:M5\MZ9;5,
MB]RD2;')"4W6?*T"IN(][M^H]?)&+RTMT>.K$V)9'XAE6';/"EWIFU_L'DZ(
M;;[:W-,W_R5]/"'FO&IN]7T< U9>T[NO;W['M^*]NZ\V9\-[MS2EL/>9LRN>
M/2IS^VC]]K-8GEP7/,Y_[UG9RQKN],/+3??'?!NL^-E$;)MSGCWRR?D_OC-G
MQH]]54?"/"2,(F$^$L9 ,"4[SCX[CHY^?I7&L1C!Q'9Q]>W#?KN3Y[OV1J+.
MBA8V-BM(F(>$T1HVJV#EY./Q7"QI+!S+-4ZGCX=!Z"[IS)W9PE878SU Q[2=
MQ<*=[9=4ZN?NZ^=JZU=]]\DV"U>\KU[:QF/KA81Y2!BM8>[AQ[MH%0K9'P/!
ME(K/]A6?:2O^:Y!E05+D1$R$\T),!\+DH:_T6LK8TB-A'A)&9YUOUFSA.K:Q
M;-4?V2GKZW2Y7"X6_5_F^;ZT<VUI;\5N \\ROFYMC]^HM!8ZMM)(F(>$T7GG
M0[>6ACLWEO-6J9&]L@&]*K5>[&N]T-;ZL]C1S7?9,[DK2TV:<?BN+OB_] 77
MDL<6' GSD#"ZZ'[+#$-\NQ=NJ^#(7EFW5Z._TLM]I9=O#]$ODZJ7[W1?6;68
ML65%PCPDC"Z[WRC7$/]:147VR4 PI?ZF(9V H=^N!\\Q3PH2!VM.BI1<)X]<
M;.&SOA#H46-3 *5Y4!IM:(>SML6L,\&&]LE0-#4(!W+('+*W56_RKU_=R])3
M1F< 2?.@--K0E)G[K)T 9(^LKT>G?P-O6K*NUL")6UW:&QY_Y?U?;RUH=&F1
M- ]*HU":#Z4Q%$V-B_1UYE&%G0DU=E":!Z51*,V'TAB*IF9(>CM3+^[^YKZB
MGCHZ.U"%!Z51L^O<7ME?A/;+AO2KUERZ/E,O^W[:K7,Q?;@,GLEO]1#3OWV
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M5XJG67,)) 9A!NCW<\[5RX,Q4%ZSC?X'4$L#!!0    ( ,B+>UAMP5 7MP0
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M:Z'3N@)=6 H][M'AO 7=9\/7.RI"]-<O&A+=*4CDMZ8$Y_Y[S?Y-,[F2:QK
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MHN_[Q]P^0C*22C(2^Z':._83;R ,+/L(N^FIY-R#T_ $Q"I[22!1P#>IR@^
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MDX_DZQ>'O/O[^XMA(0ZN3#$,F@.YJ0_$/'(@!KE-DV*=$S=9\J4BWGDEWM0
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MWQ2R?E*DF^H6@XNT*-*X>KCF_I)G90'Q_BI-BY<G98+=K3GG_P=02P,$%
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M!Y@"YR82<ORJ@SI-3B/<OGZ*_MZ:1S-SJF J^#>VT.N)<^&0!2QIR?5GL?D
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MC:TR2+, [R^%T$\#TXPUS7?R!U!+ P04    " #(BWM8]R@#[7L)  "/70
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MF1^'/3";"D?A*Z/EG[0O_OCJ*0A[!--LK D5:*LK7=.\+#G;@E!TI7L973:
M*;T_VOL0?UBJXJA?]2RJ?LD;E9SCX2,>?B.>&2RS!=D9L&4,PMCO0PQE X@Q
MR3G$L57Q1_?OQ3^J &$-.QA\;!)%_:"'HAA/^V$/1<E)]3X/_-@9^..MP0-7
MI+0&/MRG^TMY:=$,%L50TE\0[DEK7X&NI^:()%&S [:];_>T.X9=-X>/WO,;
M<SQKC@Q'-^W9[JLNTY1)5,):N_0N8QV/:(]+[8WBF^8 L>)*'T>:RT(?,4$8
M@7Z_YEP=;LP'ND/KXC]02P,$%     @ R(M[6+D1%(P! P  'PD  !D   !X
M;"]W;W)K<VAE971S+W-H965T-3DN>&ULK59=;YLP%/TK5ZR:6FDK'TE(U25(
M3=FT/E2JFG9[F/;@P$VP:FQFFZ3=KY\-A.6#IGGH"]CFGL,Y%_M>1BLAGU2&
MJ.$Y9UR-G4SKXM)U59)A3M2Y*)";)W,A<Z+-5"Y<54@D:07*F1MX7NCFA'(G
M&E5K=S(:B5(SRO%.@BKSG,B7"3*Q&CN^LUZXIXM,VP4W&A5D@5/4C\6=-#.W
M94EICEQ1P4'B?.Q<^9?QT,97 3\HKM3&&*R3F1!/=G*3CAW/"D*&B;8,Q-R6
M>(V,62(CXT_#Z;2OM,#-\9K]6^7=>)D1A=>"_:2ISL;.A0,ISDG)]+U8?<?&
MS\#R)8*IZ@JK)M9S("F5%GD#-@IRRNL[>6[RL 'PPU< 00,(=@']5P"]!M [
M%M!O /TJ,[65*@\QT20:2;$"::,-FQU4R:S0QC[E]K-/M31/J<'IZ(8G(D=X
M(,^HX#-,S;9*2X8@YO#()29BP>E?3&T 3)#CG&H%]X(Q,&E?$9G":8R:4*;.
M#/QQ&L/IR1F< .7PD(E2$9ZJD:N-4OL^-VE436I5P2NJ_ !N!=>9@J\\Q72;
MP#466Y_!VN<D.,@88W(./?\3!%[0ZQ!T?3P\Z(#'Q\/] VYZ[5?K57R]-[\:
MQ%0E3*A2(ORZFBDMS4GZW97QFK'?S6BKRZ4J2()CQY0/A7*)3O3Q@Q]Z7[JR
M]9YD\3N1;66RWV:R?X@]FN""<D[Y B:$$9Y@5^IJBD%%8>OH,NI[%R-WN9F1
M(V+BKIBPC=G2/VCU#P[J-SO!5'N%I@0SHLU!U0(*286$%R02M-DAA5#4UMC.
M<UBSAQN2!KUPQ]I^C+=C;#\BZ+85MK;"HVRI35])*25R?:2S<$^3'PQWG.W'
M[#H[%+'E;-@Z&QYT9@K:&[MMN+=+?&_H[RC?#]K?;H=C:O7N1NO(42ZJ%JP@
M$277=75M5]LN?U4UMYWUB>G^=;/^3U/_.MP2:<Z8 H9S0^F=#XTB6;?C>J)%
M436HF="FW57#S/S!H+0!YOE<"+V>V!>T_T31/U!+ P04    " #(BWM8<3K%
M+/4$   A&P  &0   'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6RUF=MNXS80
MAE^%4!=% J21)9_BU#:01%TTP 8-<NA>+'I!2V.;78ET2=I.^O0='2)9D<+8
M6^;&EF3.3\XG<F9HCK="?E=+ $V>DIBKB;/4>G7NNBI<0D+5J5@!QU_F0B94
MXZU<N&HE@4:941*[?J<S<!/*N#,=9\]NY70LUCIF'&XE4>LDH?+Y$F*QG3B>
M\_+@CBV6.GW@3L<KNH![T(^K6XEW;JD2L02X8H(3"?.)<^&=!WYFD+7XD\%6
M[5R3U)69$-_3F^MHXG32$4$,H4XE*'YMX KB.%7"<?Q3B#IEGZGA[O6+^N?,
M>71F1A5<B?@KB_1RXIPY)((Y7<?Z3FQ_A\*A?JH7BEAEGV2;MQUV'1*NE19)
M88PC2!C/O^E3 6+'P!N\8> 7!OYK@]X;!MW"H+NO0:\PZ&5D<E<R#@'5=#J6
M8DMDVAK5THL,9F:-[C.>OO=[+?%7AG9Z>LU#D0!YH$^@R-%%%+'T=="87/-\
M4N'=,3D*0%,6JV/R"WF\#\C1IV/RB3!.'I9BK2B/U-C5.)I4TPV+GB_SGOTW
M>O9\<B.X7BKR&X\@J@NXZ$;IB__BRZ5O5 P@/"5=[X3X';_;,J"K_<W]%O-@
M?W//X$VW?#/=3*_[[ILA 5-A+-1: OGV!9N1:PV)^JN->:[9:]=,@\BY6M$0
M)@Y&"05R \[TYY^\0>?7-EXVQ0)+8C66O9)ESZ2.[V8.4D)$--*D2H%6)V1#
MXS7-@T^,X8_R$-J(YLK]3#F-HIOI:# <#L;N9A=5L]5@V.]UZZT"XRA_D$&_
M9- W,KC&539GG&D@'//)'"*0N,XQ@TBDP!<$9UCK,LYE!SNN^8/^J--Y1<#8
M^Z&3Q9)8#=2@!#4P@KI#12K#)<&XABED@[EQA9E.8[S+5F0ZAT*<3$RWXAHT
M<'5[#5C&$1P*RY)8#=:PA#5\9U:53. )BQ$%)\A) _:D,X#XC,::02NK88/5
M:U#OM@B&C957M:BY=%:Z=&9TZ0NC,Q:S=,P$<R!98V"0F/YXYN5*J"Q%MOIS
M]JX_QJX/??&6Q&J41B6ED9'2(Y<0B@5G_Q9A=08<XXM61"^IQFIO'4>$)=B_
M)C"?0U;?90TQW+0&VE$#GN<U%LZH\;8;BRLPMZEYZW6J.JFS?U0(=J+"3IZ^
MRJ,"^78#R0QD:X(V=W-HAK:J%MA2JR/>*46]#ZAX"E%;0&VJ!;;4ZD#]"JAO
MG+,/9:8Z(5QHW-S-_L:%2+1(@S63K<NPT*RMPV:V-_=\,"=+:G5.5:7M&8O/
MZ>>B%C*N6ZN5M56UP)9:'5]57'N]CUBWEHKA JA-M<"66AUH5:E[YE+]CUI-
M3D(JY3-6(ELJW]AH]QL9SQ^>#9N+UFJ-;DNM#JFJTCUSF6Z"=)+'MWQW]XQY
MNY6:6=_O=/NM,\UJ[6Y+K0ZQJMZ]O<OW8DNS'SJSZIOHC&8'H[.D5D=7[1(\
M\S;A7F,=:TX9-HO]*ZMJ@2VU.KQJ\^"-/B)E&+<D!P.UJ1;84JO_\UEM3WSS
M]N30E%'([:8,S\-MTNN48>[V4$BVU.J0J@V&;ZRW_W_*>$<?XUZO]7]GJYL*
M6VHY1'?G[" !N<C.8)"-6'.=__5>/BW/>2ZRTXU7SR^]\R _K:ED\L.C&RH7
MC"L2PQPE.Z=#G'4R/X_);[1892<4,Z&U2+++)5"LR=,&^/M<"/URDW90GHI-
M_P-02P,$%     @ R(M[6.@PP$_E P  :0T  !D   !X;"]W;W)K<VAE971S
M+W-H965T-C$N>&ULM5==C^(V%/TK5KJJ=J5=\DF *2#-3&;52KLKM'2Z#U4?
M3'(AUB0QM1W8_OM>.R$#C,D@=?L"B7/NB<\]]O7-=,_%D\P!%/E>%I6<.;E2
MVQO7E6D.)94#OH4*GZRY**G"6[%QY58 S4Q06;B!Y\5N25GES*=F;"'F4UZK
M@E6P$$3694G%/W=0\/W,\9W#P%>VR94><.?3+=W $M3C=B'PSNU8,E9")1FO
MB(#US+GU;Q+?!!C$'PSV\NB::"DKSI_TS6_9S/'TC*" 5&D*BG\[N(>BT$PX
MC[];4J=[IPX\OCZP?S3B4<R*2KCGQ3>6J7SFC!V2P9K6A?K*][]"*VBH^5)>
M2/-+]BW6<TA:2\7+-AAG4+*J^:??VT0<!?CQA8"@#0C. Z(+ 6$;$%X;$+4!
MD<E,(\7D(:&*SJ>"[XG0:&33%R:9)AKELTK[OE0"GS*,4_,ON+0^<2G) @19
MYE0 ^4"6N+JRN@#"UT3E@/ZFO$I9P:CQ"D<QU2PEM,I(QHI:048*3;)%$FE(
MWB:@*"OD.Z1[7";D[9MWY UQFZ>2L(H\5DS)]SB(U[_GO);()J>N0E%Z:F[:
M"KAK! 07!/@!^<PKE4OR4&60G1*XF(TN)<$A)7=!+V,"Z8"$_GL2>$%HF=#]
M]>&!)3RY/MSO41-V!H>&+[S ]T!%Q:K-L<%_WJZD$KCC_K*ENZ&+['2Z#-W(
M+4UAYF"=D2!VX,Q__LF/O5]LJ?J19,D/(CM)8]2E,>IC-_M$+W%;QIK(H8G4
M=78W_^#[41BB?;OC9%AP01C&T2DLL<#&XRAXAIT(&'8"AKT"%@)*5I?$E.L,
MRNUA*^.#-0@<(TO%TR>;P(8Y/I[1,(BCX9F^ES#O3%H?XD15W*F*K[*%X GX
M>E&B.RQ)=(6%37&2\K+$#$@M.N=%!L)J;FPQ-XXGH_A,O 5G,]<"ZS%WU*5A
MU)N&;^9X0\%T!P*/:U+5Y0IEH[UMP<4C7RI,#98"K,@F4S:UHQ<&^:$73,:>
M=V;EO0T9!4'\ IG8D,%X>,)YHGK<J1[WJGY8K[%[T"*-W]@_$ EI+9AB8/5R
M_-H"O7\5D?0A3E1,.A63_^B=7M%48F>&(#R($::[+HD^MNO<IG5RM9,VI-U)
M&[+72=][;D.\ZS;RT6Y52K!5K7HV;-]2;E\X/MFY@V!\IMX&\P;^Z$RZ'1:/
M+N@^:K_\_T=WC_7M*U]5;H'9E%MA+Y2[1SUH"6)C>GF)DZ\KU?1>W6CWO7!K
MNN2S\3O]'6%ZVV>:YB/D,Q4;ANN^@#52>H,1EE'1]/7-C>);T^FNN,*^V5SF
M^"T$0@/P^9IS=;C1+^B^KN;_ E!+ P04    " #(BWM8D($Q;!$$   U$P
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MSPW? #'>HB(5S_3X&5<)Z0-&-.7Z/SA6MI8!HH(+FE7.\@190LI/]%H1<>$
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MBI4SFO)!T%Q/+394")KIY1ZC&#-E(-]O*16G!Q6@GI0M?@%02P,$%     @
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M;"]W;W)K<VAE971S+W-H965T-C0N>&ULM9E=;^(X%$#_BL6.1AVI2V+S53J
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M8A-\ 7EU^W%=:H=S2=9A_]K?$,Q))YD6,J6R31/Z36@\Y#0#.Y+-%W!611D
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M;W!S+V%P<"YX;6Q02P$"% ,4    " #(BWM8W*4,1^\    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #(BWM8
MF5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( ,B+>U@>N4-CJP0  & 4   8              "
M@0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #(BWM8
M0-LI0P4'   ?'@  &               @('O#   >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L! A0#%     @ R(M[6)^_9O07 P  MPH  !@
M     ("!*A0  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (
M ,B+>U@78.ZKH08  /<<   8              " @7<7  !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"% ,4    " #(BWM8R-Y7'"0*  #15   &
M            @(%.'@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#
M%     @ R(M[6$9!"C,;#0  5D0  !@              ("!J"@  'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( ,B+>UB.\D0:3A\  !!<
M   8              " @?DU  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"% ,4    " #(BWM86QE]Y# *  !''   &               @(%]50
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ R(M[6!-M)7>E
M!P  P!(  !@              ("!XU\  'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;%!+ 0(4 Q0    ( ,B+>UB%U*4KT D  -L<   9              "
M@;YG  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ R(M[
M6)D1PS>1 P  (P@  !D              ("!Q7$  'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"% ,4    " #(BWM8+(?++E@$  #/"@  &0
M        @(&-=0  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0
M   ( ,B+>U@DN+LJ%@\  -XL   9              " @1QZ  !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ R(M[6#8A<UXR#   #2(
M !D              ("!:8D  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q0
M2P$"% ,4    " #(BWM8XU_C(3D*  !T'   &0              @('2E0
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( ,B+>U@*MD<)
M:PH  /(>   9              " @4*@  !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L! A0#%     @ R(M[6#2C9'>/#0  >R,  !D
M ("!Y*H  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " #(
MBWM8TRKRM^0)  !<&P  &0              @(&JN   >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( ,B+>U@&:X482 4  #4-   9
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M  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ R(M[6'V
MI-]"!0  "@\  !D              ("!9O   'AL+W=O<FMS:&5E=',O<VAE
M970R,RYX;6Q02P$"% ,4    " #(BWM8J'8+$6(#  #8!P  &0
M    @('?]0  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (
M ,B+>U@\]8Z*A ,  .T(   9              " @7CY  !X;"]W;W)K<VAE
M971S+W-H965T,C4N>&UL4$L! A0#%     @ R(M[6) ,TLT] P  J0D  !D
M             ("!,_T  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"
M% ,4    " #(BWM8B6?/,>P#   L"0  &0              @(&G  $ >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( ,B+>UCE0V="I0,
M (4(   9              " @<H$ 0!X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L! A0#%     @ R(M[6)4TBDYR!@  0Q$  !D              ("!
MI@@! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " #(BWM8
MDYIBOG0$   Q"P  &0              @(%/#P$ >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;%!+ 0(4 Q0    ( ,B+>UCFM'EZ)08  +(T   9
M      " @?H3 0!X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%
M  @ R(M[6/[WH5G$ @  FPD  !D              ("!5AH! 'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " #(BWM8W)L7>GT)  "8:@
M&0              @(%1'0$ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+
M 0(4 Q0    ( ,B+>UBY<@\%#04  -,?   9              " @04G 0!X
M;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ R(M[6)V?!)^I
M!P  UTD  !D              ("!22P! 'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6Q02P$"% ,4    " #(BWM84XN"(Y0%   E*P  &0
M@($I- $ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( ,B+
M>UAZ)CM1T@(  %8'   9              " @?0Y 0!X;"]W;W)K<VAE971S
M+W-H965T,S<N>&UL4$L! A0#%     @ R(M[6/2E&;GA P  BA   !D
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M=#0R+GAM;%!+ 0(4 Q0    ( ,B+>UC#I3"E(0,  ,@)   9
M  " @7E. 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @
MR(M[6& S<ETL!   -A8  !D              ("!T5$! 'AL+W=O<FMS:&5E
M=',O<VAE970T-"YX;6Q02P$"% ,4    " #(BWM8^([PD+L"  ","0  &0
M            @($T5@$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4
M Q0    ( ,B+>UBFI>A=AAL  &1J 0 9              " @299 0!X;"]W
M;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ R(M[6*03*LMR!
M"AD  !D              ("!XW0! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX
M;6Q02P$"% ,4    " #(BWM8N$7$@*0)   T2@  &0              @(&,
M>0$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( ,B+>UC#
MUDALQ0D  &9O   9              " @6># 0!X;"]W;W)K<VAE971S+W-H
M965T-#DN>&UL4$L! A0#%     @ R(M[6#"A"TN!!   <A,  !D
M     ("!8XT! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,B+>UCW* /M>PD  (]=   9              "
M@3RH 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ R(M[
M6+? 3YK( P  $PX  !D              ("![K$! 'AL+W=O<FMS:&5E=',O
M<VAE970U-BYX;6Q02P$"% ,4    " #(BWM8C 724SL$  " #P  &0
M        @('MM0$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0
M   ( ,B+>UB9S#ZU3@0  , .   9              " @5^Z 0!X;"]W;W)K
M<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ R(M[6+D1%(P! P  'PD
M !D              ("!Y+X! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q0
M2P$"% ,4    " #(BWM8<3K%+/4$   A&P  &0              @($<P@$
M>&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( ,B+>UCH,,!/
MY0,  &D-   9              " @4C' 0!X;"]W;W)K<VAE971S+W-H965T
M-C$N>&UL4$L! A0#%     @ R(M[6)"!,6P1!   -1,  !D
M ("!9,L! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    " #(
MBWM8[]4RCH0"  !K"   &0              @(&LSP$ >&PO=V]R:W-H965T
M<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( ,B+>U@)6I:53 4  /,9   9
M          " @6?2 0!X;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#
M%     @ R(M[6!XSP95? P  LA8   T              ( !ZM<! 'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    " #(BWM8EXJ[',     3 @  "P
M    @ %TVP$ 7W)E;',O+G)E;'-02P$"% ,4    " #(BWM8L/.*#>D$  "3
M*@  #P              @ %=W $ >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ R(M[6-))O&T1 @  %R8  !H              ( !<^$! 'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ R(M[6,"(;73I 0  ?B4
M !,              ( !O.,! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/ $@ 2 "O$P  UN4!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>252</ContextCount>
  <ElementCount>475</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>97</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Condensed Consolidated Statements of Stockholders' (Deficit) / Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' (Deficit) / Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Disclosure - Nature of Operations and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentation</Role>
      <ShortName>Nature of Operations and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - Liquidity and Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcern</Role>
      <ShortName>Liquidity and Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Junior DIP Facility and Sorrento Share Purchase Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreement</Role>
      <ShortName>Junior DIP Facility and Sorrento Share Purchase Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Stock Incentive and Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlans</Role>
      <ShortName>Stock Incentive and Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Nature of Operations and Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationPolicies</Role>
      <ShortName>Nature of Operations and Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Nature of Operations and Basis of Presentation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationTables</Role>
      <ShortName>Nature of Operations and Basis of Presentation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/FairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/BalanceSheetComponents</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssets</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/Debt</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Stock Incentive and Employee Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansTables</Role>
      <ShortName>Stock Incentive and Employee Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlans</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/IncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/NetLossPerShare</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Nature of Operations and Basis of Presentation (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Nature of Operations and Basis of Presentation (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Nature of Operations and Basis of Presentation - Schedule of Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationScheduleOfCashAndCashEquivalentsDetails</Role>
      <ShortName>Nature of Operations and Basis of Presentation - Schedule of Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Liquidity and Going Concern (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails</Role>
      <ShortName>Liquidity and Going Concern (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcern</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Acquisitions (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/AcquisitionsAdditionalInformationDetails</Role>
      <ShortName>Acquisitions (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/Acquisitions</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Fair Value Measurements (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/FairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Fair Value Measurements  (Details) - Schedule of fair value assets measured on a recurring basis</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis</Role>
      <ShortName>Fair Value Measurements  (Details) - Schedule of fair value assets measured on a recurring basis</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Fair Value Measurements (Details) - Schedule of quantitative information regarding Level 3 fair value measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements (Details) - Schedule of quantitative information regarding Level 3 fair value measurements</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Fair Value Measurements (Details) - Schedule Of The Derivative Liabilities Measured at Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue</Role>
      <ShortName>Fair Value Measurements (Details) - Schedule Of The Derivative Liabilities Measured at Fair Value</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Fair Value Measurements (Details) - Schedule of The Inputs Used In Valuing The Derivative Warrant Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities</Role>
      <ShortName>Fair Value Measurements (Details) - Schedule of The Inputs Used In Valuing The Derivative Warrant Liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Balance Sheet Components - Schedule of Acrcued expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Acrcued expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Balance Sheet Components (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/BalanceSheetComponentsAdditionalInformationDetails</Role>
      <ShortName>Balance Sheet Components (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/BalanceSheetComponentsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Goodwill and Intangible Assets (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails</Role>
      <ShortName>Goodwill and Intangible Assets (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Goodwill and Intangible Assets - Summary of identifiable intangible assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Summary of identifiable intangible assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Goodwill and Intangible Assets - Estimated future amortization expense of intangible assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Estimated future amortization expense of intangible assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - Debt (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails</Role>
      <ShortName>Debt (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/DebtTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure - Debt - Summery of Outstanding Convertible Debenture (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/DebtSummeryOfOutstandingConvertibleDebentureDetails</Role>
      <ShortName>Debt - Summery of Outstanding Convertible Debenture (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure - Junior DIP Facility and Sorrento Share Purchase Agreement (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails</Role>
      <ShortName>Junior DIP Facility and Sorrento Share Purchase Agreement (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreement</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure - Shareholders' Equity (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Shareholders' Equity (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure - Stock Incentive and Employee Benefit Plans - Schedule of Stock Options Outstanding Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails</Role>
      <ShortName>Stock Incentive and Employee Benefit Plans - Schedule of Stock Options Outstanding Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure - Stock Incentive and Employee Benefit Plans - Schedule of estimate stock-based compensation on the date of grant for stock options and ESPP (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails</Role>
      <ShortName>Stock Incentive and Employee Benefit Plans - Schedule of estimate stock-based compensation on the date of grant for stock options and ESPP (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure - Stock Incentive and Employee Benefit Plans (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails</Role>
      <ShortName>Stock Incentive and Employee Benefit Plans (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1053 - Disclosure - Commitments and Contingencies - Schedule of Leases Supplemental Quantitative Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesScheduleOfLeasesSupplementalQuantitativeInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Leases Supplemental Quantitative Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1054 - Disclosure - Commitments and Contingencies - Schedule of Lease Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Lease Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1055 - Disclosure - Commitments and Contingencies (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1056 - Disclosure - Income Taxes - Schedule of Components of Benefit for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Benefit for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1057 - Disclosure - Income Taxes - Schedule of Deferred Tax Liabilities and Related Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Liabilities and Related Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>1058 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>1059 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>1060 - Disclosure - Income Taxes (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/IncomeTaxesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>1061 - Disclosure - Net Loss Per Share - Schedule of the reconciliation of basic and diluted loss per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/NetLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of the reconciliation of basic and diluted loss per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>1062 - Disclosure - Net Loss Per Share - potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>1063 - Disclosure - Net Loss Per Share (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/NetLossPerShareAdditionalInformationDetails</Role>
      <ShortName>Net Loss Per Share (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/NetLossPerShareTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="d759370dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>1064 - Disclosure - Subsequent Events (Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events (Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/SubsequentEvents</ParentRole>
      <Position>64</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="POS AM" isDefinitelyFs="true" isUsgaap="true" original="d759370dposam.htm">d759370dposam.htm</File>
    <File>sclx-20231231.xsd</File>
    <File>sclx-20231231_cal.xml</File>
    <File>sclx-20231231_def.xml</File>
    <File>sclx-20231231_lab.xml</File>
    <File>sclx-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g759370g00a01.jpg</File>
    <File>g759370g00a02.jpg</File>
    <File>g759370g00a03.jpg</File>
    <File>g759370g00a04.jpg</File>
    <File>g759370g00a05.jpg</File>
    <File>g759370g00a06.jpg</File>
    <File>g759370g00a07.jpg</File>
    <File>g759370g00a08.jpg</File>
    <File>g759370g00a09.jpg</File>
    <File>g759370g00a10.jpg</File>
    <File>g759370g00a11.jpg</File>
    <File>g759370g00a12.jpg</File>
    <File>g759370g00a13.jpg</File>
    <File>g759370g00a14.jpg</File>
    <File>g759370g00a15.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="828">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>95
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d759370dposam.htm": {
   "nsprefix": "sclx",
   "nsuri": "http://www.vickersvantagecorp.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "d759370dposam.htm"
     ]
    },
    "schema": {
     "local": [
      "sclx-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "sclx-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sclx-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "sclx-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sclx-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 329,
   "keyCustom": 146,
   "axisStandard": 32,
   "axisCustom": 2,
   "memberStandard": 35,
   "memberCustom": 57,
   "hidden": {
    "total": 9,
    "http://fasb.org/us-gaap/2023": 4,
    "http://xbrl.sec.gov/dei/2023": 5
   },
   "contextCount": 252,
   "entityCount": 1,
   "segmentCount": 97,
   "elementCount": 723,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 828,
    "http://xbrl.sec.gov/dei/2023": 25
   },
   "report": {
    "R1": {
     "role": "http://www.vickersvantagecorp.com/role/CoverPage",
     "longName": "1001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
     "longName": "1002 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
     "longName": "1003 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Condensed Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations",
     "longName": "1004 - Statement - Condensed Consolidated Statements of Operations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity",
     "longName": "1005 - Statement - Condensed Consolidated Statements of Stockholders' (Deficit) / Equity",
     "shortName": "Condensed Consolidated Statements of Stockholders' (Deficit) / Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2020",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2020",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows",
     "longName": "1006 - Statement - Condensed Consolidated Statements of Cash Flows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentation",
     "longName": "1007 - Disclosure - Nature of Operations and Basis of Presentation",
     "shortName": "Nature of Operations and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcern",
     "longName": "1008 - Disclosure - Liquidity and Going Concern",
     "shortName": "Liquidity and Going Concern",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.vickersvantagecorp.com/role/Acquisitions",
     "longName": "1009 - Disclosure - Acquisitions",
     "shortName": "Acquisitions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.vickersvantagecorp.com/role/FairValueMeasurements",
     "longName": "1010 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.vickersvantagecorp.com/role/BalanceSheetComponents",
     "longName": "1011 - Disclosure - Balance Sheet Components",
     "shortName": "Balance Sheet Components",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssets",
     "longName": "1012 - Disclosure - Goodwill and Intangible Assets",
     "shortName": "Goodwill and Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.vickersvantagecorp.com/role/Debt",
     "longName": "1013 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreement",
     "longName": "1014 - Disclosure - Junior DIP Facility and Sorrento Share Purchase Agreement",
     "shortName": "Junior DIP Facility and Sorrento Share Purchase Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.vickersvantagecorp.com/role/StockholdersEquity",
     "longName": "1015 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlans",
     "longName": "1016 - Disclosure - Stock Incentive and Employee Benefit Plans",
     "shortName": "Stock Incentive and Employee Benefit Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.vickersvantagecorp.com/role/CommitmentsAndContingencies",
     "longName": "1017 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.vickersvantagecorp.com/role/IncomeTaxes",
     "longName": "1018 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.vickersvantagecorp.com/role/NetLossPerShare",
     "longName": "1019 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.vickersvantagecorp.com/role/SubsequentEvents",
     "longName": "1020 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationPolicies",
     "longName": "1021 - Disclosure - Nature of Operations and Basis of Presentation (Policies)",
     "shortName": "Nature of Operations and Basis of Presentation (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "21",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationTables",
     "longName": "1022 - Disclosure - Nature of Operations and Basis of Presentation (Tables)",
     "shortName": "Nature of Operations and Basis of Presentation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables",
     "longName": "1023 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.vickersvantagecorp.com/role/BalanceSheetComponentsTables",
     "longName": "1024 - Disclosure - Balance Sheet Components (Tables)",
     "shortName": "Balance Sheet Components (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsTables",
     "longName": "1025 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.vickersvantagecorp.com/role/DebtTables",
     "longName": "1026 - Disclosure - Debt (Tables)",
     "shortName": "Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansTables",
     "longName": "1027 - Disclosure - Stock Incentive and Employee Benefit Plans (Tables)",
     "shortName": "Stock Incentive and Employee Benefit Plans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesTables",
     "longName": "1028 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.vickersvantagecorp.com/role/IncomeTaxesTables",
     "longName": "1029 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.vickersvantagecorp.com/role/NetLossPerShareTables",
     "longName": "1030 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
     "longName": "1031 - Disclosure - Nature of Operations and Basis of Presentation (Additional Information) (Details)",
     "shortName": "Nature of Operations and Basis of Presentation (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:ReceivablesNetCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:ReceivablesNetCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationScheduleOfCashAndCashEquivalentsDetails",
     "longName": "1032 - Disclosure - Nature of Operations and Basis of Presentation - Schedule of Cash and Cash Equivalents (Details)",
     "shortName": "Nature of Operations and Basis of Presentation - Schedule of Cash and Cash Equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
     "longName": "1033 - Disclosure - Liquidity and Going Concern (Additional Information) (Details)",
     "shortName": "Liquidity and Going Concern (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "sclx:WorkingCapital",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.vickersvantagecorp.com/role/AcquisitionsAdditionalInformationDetails",
     "longName": "1034 - Disclosure - Acquisitions (Additional Information) (Details)",
     "shortName": "Acquisitions (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "sclx:PaymentToAcquireLicense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "sclx:PaymentToAcquireLicense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.vickersvantagecorp.com/role/FairValueMeasurementsAdditionalInformationDetails",
     "longName": "1035 - Disclosure - Fair Value Measurements (Additional Information) (Details)",
     "shortName": "Fair Value Measurements (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "sclx:SecuredNoteDiscountRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "sclx:SecuredNoteDiscountRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis",
     "longName": "1036 - Disclosure - Fair Value Measurements  (Details) - Schedule of fair value assets measured on a recurring basis",
     "shortName": "Fair Value Measurements  (Details) - Schedule of fair value assets measured on a recurring basis",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:SeniorNotes",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:SeniorNotes",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements",
     "longName": "1037 - Disclosure - Fair Value Measurements (Details) - Schedule of quantitative information regarding Level 3 fair value measurements",
     "shortName": "Fair Value Measurements (Details) - Schedule of quantitative information regarding Level 3 fair value measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue",
     "longName": "1038 - Disclosure - Fair Value Measurements (Details) - Schedule Of The Derivative Liabilities Measured at Fair Value",
     "shortName": "Fair Value Measurements (Details) - Schedule Of The Derivative Liabilities Measured at Fair Value",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2022",
      "name": "us-gaap:DerivativeLiabilities",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2022To12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis",
      "name": "sclx:PrivatePlacementWarrantLiabilityAcquired",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities",
     "longName": "1039 - Disclosure - Fair Value Measurements (Details) - Schedule of The Inputs Used In Valuing The Derivative Warrant Liabilities",
     "shortName": "Fair Value Measurements (Details) - Schedule of The Inputs Used In Valuing The Derivative Warrant Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "sclx:EquityValue",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueConcentrationOfRiskTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "sclx:EquityValue",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueConcentrationOfRiskTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails",
     "longName": "1040 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment (Details)",
     "shortName": "Balance Sheet Components - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetails",
     "longName": "1041 - Disclosure - Balance Sheet Components - Schedule of Acrcued expenses (Details)",
     "shortName": "Balance Sheet Components - Schedule of Acrcued expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sclx:AccruedExpensesTextblock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sclx:AccruedExpensesTextblock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.vickersvantagecorp.com/role/BalanceSheetComponentsAdditionalInformationDetails",
     "longName": "1042 - Disclosure - Balance Sheet Components (Additional Information) (Details)",
     "shortName": "Balance Sheet Components (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:Depreciation",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-2",
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:Depreciation",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-2",
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails",
     "longName": "1043 - Disclosure - Goodwill and Intangible Assets (Additional Information) (Details)",
     "shortName": "Goodwill and Intangible Assets (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:Goodwill",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:GoodwillAndIntangibleAssetImpairment",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetImpairment",
       "us-gaap:GoodwillAndIntangibleAssetImpairment",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails",
     "longName": "1044 - Disclosure - Goodwill and Intangible Assets - Summary of identifiable intangible assets (Details)",
     "shortName": "Goodwill and Intangible Assets - Summary of identifiable intangible assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails",
     "longName": "1045 - Disclosure - Goodwill and Intangible Assets - Estimated future amortization expense of intangible assets (Details)",
     "shortName": "Goodwill and Intangible Assets - Estimated future amortization expense of intangible assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails",
     "longName": "1046 - Disclosure - Debt (Additional Information) (Details)",
     "shortName": "Debt (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "P04_30_2023To04_30_2023",
      "name": "us-gaap:DebtInstrumentIssuedPrincipal",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:DebtInstrumentRedemptionDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.vickersvantagecorp.com/role/DebtSummeryOfOutstandingConvertibleDebentureDetails",
     "longName": "1047 - Disclosure - Debt - Summery of Outstanding Convertible Debenture (Details)",
     "shortName": "Debt - Summery of Outstanding Convertible Debenture (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "sclx:ConversionOfConvertibleDebenturesIntoCommonStock",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis",
      "name": "us-gaap:NotesIssued1",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "sclx:ScheduleOfTheOramedNoteTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
     "longName": "1048 - Disclosure - Junior DIP Facility and Sorrento Share Purchase Agreement (Additional Information) (Details)",
     "shortName": "Junior DIP Facility and Sorrento Share Purchase Agreement (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "PAsOn09_21_2023_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn09_21_2023_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails",
     "longName": "1049 - Disclosure - Shareholders' Equity (Additional Information) (Details)",
     "shortName": "Shareholders' Equity (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:SharePrice",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails",
     "longName": "1050 - Disclosure - Stock Incentive and Employee Benefit Plans - Schedule of Stock Options Outstanding Activity (Details)",
     "shortName": "Stock Incentive and Employee Benefit Plans - Schedule of Stock Options Outstanding Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2022",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails",
     "longName": "1051 - Disclosure - Stock Incentive and Employee Benefit Plans - Schedule of estimate stock-based compensation on the date of grant for stock options and ESPP (Details)",
     "shortName": "Stock Incentive and Employee Benefit Plans - Schedule of estimate stock-based compensation on the date of grant for stock options and ESPP (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueConcentrationOfRiskTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_StockOptionMemberusgaapFinancialInstrumentAxis",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails",
     "longName": "1052 - Disclosure - Stock Incentive and Employee Benefit Plans (Additional Information) (Details)",
     "shortName": "Stock Incentive and Employee Benefit Plans (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesScheduleOfLeasesSupplementalQuantitativeInformationDetails",
     "longName": "1053 - Disclosure - Commitments and Contingencies - Schedule of Leases Supplemental Quantitative Information (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Leases Supplemental Quantitative Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails",
     "longName": "1054 - Disclosure - Commitments and Contingencies - Schedule of Lease Maturities of Lease Liabilities (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Lease Maturities of Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
     "longName": "1055 - Disclosure - Commitments and Contingencies (Additional Information) (Details)",
     "shortName": "Commitments and Contingencies (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:FinanceLeaseLiability",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:FinanceLeaseLiability",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails",
     "longName": "1056 - Disclosure - Income Taxes - Schedule of Components of Benefit for Income Taxes (Details)",
     "shortName": "Income Taxes - Schedule of Components of Benefit for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails",
     "longName": "1057 - Disclosure - Income Taxes - Schedule of Deferred Tax Liabilities and Related Valuation Allowance (Details)",
     "shortName": "Income Taxes - Schedule of Deferred Tax Liabilities and Related Valuation Allowance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
     "longName": "1058 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails",
     "longName": "1059 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)",
     "shortName": "Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2022",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2020",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.vickersvantagecorp.com/role/IncomeTaxesAdditionalInformationDetails",
     "longName": "1060 - Disclosure - Income Taxes (Additional Information) (Details)",
     "shortName": "Income Taxes (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "sclx:IndefiniteOperatingLossCarryforwards",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.vickersvantagecorp.com/role/NetLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails",
     "longName": "1061 - Disclosure - Net Loss Per Share - Schedule of the reconciliation of basic and diluted loss per share (Details)",
     "shortName": "Net Loss Per Share - Schedule of the reconciliation of basic and diluted loss per share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:PreferredStockRedemptionPremium",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.vickersvantagecorp.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails",
     "longName": "1062 - Disclosure - Net Loss Per Share - potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share (Details)",
     "shortName": "Net Loss Per Share - potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.vickersvantagecorp.com/role/NetLossPerShareAdditionalInformationDetails",
     "longName": "1063 - Disclosure - Net Loss Per Share (Additional Information) (Details)",
     "shortName": "Net Loss Per Share (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn09_21_2023_WarrantMemberusgaapStatementEquityComponentsAxis",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails",
     "longName": "1064 - Disclosure - Subsequent Events (Additional Information (Details)",
     "shortName": "Subsequent Events (Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "PAsOn02_29_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis",
      "name": "sclx:CommonShareSold",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn02_29_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis",
      "name": "sclx:CommonShareSold",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d759370dposam.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "sclx_ARYorkvillePurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ARYorkvillePurchaseAgreementMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "A R Yorkville Purchase Agreement [Member]",
        "terseLabel": "A&amp;R Yorkville Purchase Agreement",
        "documentation": "A R Yorkville Purchase Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AcceleratedShareRepurchasesAdjustmentToRecordedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AcceleratedShareRepurchasesAdjustmentToRecordedAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 39.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accelerated Share Repurchases, Adjustment to Recorded Amount",
        "terseLabel": "Cash consideration paid in connection with share repurchase",
        "documentation": "The adjustment needed to reconcile previously recorded amounts to the actual aggregate amount paid, whether in cash or other consideration, to acquire all of the shares purchased under an Accelerated Share Repurchase arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndOtherAccruedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetails": {
       "parentTag": "sclx_AccruedExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Other Accrued Liabilities",
        "terseLabel": "Accrued others",
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r825"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 29.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r311"
     ]
    },
    "sclx_AccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "AccruedExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 17.0
      },
      "http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetails",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Accrued expenses",
        "documentation": "Accrued expenses"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_AccruedExpensesTextblock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "AccruedExpensesTextblock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/BalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses Textblock",
        "terseLabel": "Schedule of Acrcued expenses",
        "documentation": "Accrued expenses Textblock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedMarketingCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedMarketingCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetails": {
       "parentTag": "sclx_AccruedExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Marketing Costs, Current",
        "terseLabel": "Accrued sales and marketing costs",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetails": {
       "parentTag": "sclx_AccruedExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional service fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees",
        "terseLabel": "Accrued legal fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "sclx_AccruedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "AccruedResearchAndDevelopmentCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetails": {
       "parentTag": "sclx_AccruedExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued research and development costs",
        "terseLabel": "Accrued research and development costs",
        "documentation": "Accrued research and development costs"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_AccruedRoyaltyPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "AccruedRoyaltyPayables",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Royalty Payables",
        "terseLabel": "Accrued Royalty Payables",
        "documentation": "Accrued Royalty Payables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Salaries, Current",
        "terseLabel": "Accrued payroll",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r793"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r213",
      "r646"
     ]
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted average remaining life for identifiable intangible assets",
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "sclx_AcquiredLicensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "AcquiredLicensesMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired licenses [Member]",
        "terseLabel": "Acquired licenses",
        "documentation": "Acquired licenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_AcquiredTechnologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "AcquiredTechnologyMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired technology [Member]",
        "terseLabel": "Acquired technology",
        "documentation": "Acquired technology [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition Consideration Paid In Cash for Romeg Intangible Asset Acquisition",
        "negatedLabel": "Acquisition consideration paid in cash for Romeg intangible asset acquisition",
        "documentation": "Acquisition Consideration Paid In Cash for Romeg Intangible Asset Acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r825",
      "r950"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r489",
      "r490",
      "r491",
      "r684",
      "r865",
      "r866",
      "r867",
      "r926",
      "r952"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "sclx_AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To Additional Paid In Capital License Transfer Net Of Discount, value",
        "terseLabel": "Aardvark SP-104 license transfer from Sorrento, net of discount",
        "documentation": "Adjustment To Additional Paid In Capital License Transfer Net Of Discount, value"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_AdjustmentToSharesIssuedInSemnurAcquisitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "AdjustmentToSharesIssuedInSemnurAcquisitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to shares issued in Semnur Acquisition value",
        "terseLabel": "Adjustment to shares issued in Semnur Acquisition",
        "documentation": "Adjustment to shares issued in Semnur Acquisition value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used for operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_Adjustmenttoadditionalpaidincapitaldiscountamortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "Adjustmenttoadditionalpaidincapitaldiscountamortization",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AdjustmentToAdditionalPaidInCapitalDiscountAmortization",
        "terseLabel": "Aardvark SP-104 license transfer from Sorrento",
        "documentation": "AdjustmentToAdditionalPaidInCapitalDiscountAmortization"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_AgreementMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "AgreementMaturityDate",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement Maturity Date",
        "terseLabel": "Agreement maturity date",
        "documentation": "Agreement Maturity Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r496"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt issuance costs and debt discount",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r567",
      "r808",
      "r809",
      "r860"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Intangible amortization",
        "verboseLabel": "Amortization expense",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r58",
      "r63"
     ]
    },
    "sclx_AmountDueForNewDrugApplication": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "AmountDueForNewDrugApplication",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount due for New Drug Application",
        "terseLabel": "Amount due for New Drug Application",
        "documentation": "Amount due for New Drug Application"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "sclx_AssembledWorkforceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "AssembledWorkforceMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assembled workforce [Member]",
        "terseLabel": "Assembled workforce",
        "documentation": "Assembled workforce [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionConsiderationTransferredContingentConsideration",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Consideration Transferred, Contingent Consideration",
        "terseLabel": "Common stock upon conversation of cash",
        "documentation": "Amount of contingent consideration recognized as part of consideration transferred in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r922",
      "r923",
      "r924"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r216",
      "r242",
      "r279",
      "r299",
      "r305",
      "r345",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r533",
      "r537",
      "r554",
      "r638",
      "r729",
      "r825",
      "r837",
      "r882",
      "r883",
      "r935"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets:",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r223",
      "r242",
      "r345",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r533",
      "r537",
      "r554",
      "r825",
      "r882",
      "r883",
      "r935"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent, Other than Noncurrent Investments and Property, Plant and Equipment",
        "terseLabel": "Other long term assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets, excluding property, plant, and equipment and other property and investments, that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Charges and Other Assets."
       }
      }
     },
     "auth_ref": []
    },
    "sclx_AtTheMarketSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "AtTheMarketSalesAgreementMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "At-the-Market Sales Agreement [Member]",
        "terseLabel": "ATM Sales Agreement [Member]",
        "documentation": "At-the-Market Sales Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_AtmSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "AtmSalesAgreementMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ATM Sales Agreement [Member]",
        "terseLabel": "ATM Sales Agreement",
        "documentation": "ATM Sales Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Domain]",
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AwardTypeAxis",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r457",
      "r458",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484"
     ]
    },
    "sclx_BRileyPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "BRileyPurchaseAgreementMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "B Riley Purchase Agreement [Member]",
        "terseLabel": "B. Riley Purchase Agreement [Member]",
        "documentation": "B Riley Purchase Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "sclx_BlackScholesOptionPricingMethodMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "BlackScholesOptionPricingMethodMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Black-Scholes Option Pricing Method [Member]",
        "documentation": "Black-Scholes Option Pricing Method"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r816",
      "r817"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r529",
      "r816",
      "r817"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration, liability",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r91",
      "r530"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Intangible asset",
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other",
        "terseLabel": "Development milestones payment was recognized under other long-term liabilities",
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Acquisitions",
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r840"
     ]
    },
    "sclx_CallOptionValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "CallOptionValue",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Call option value",
        "terseLabel": "Call option value",
        "documentation": "Call option value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "terseLabel": "Cash on hand",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r640",
      "r695",
      "r724",
      "r825",
      "r837",
      "r855"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationScheduleOfCashAndCashEquivalentsDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationScheduleOfCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r211",
      "r791"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r177"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationScheduleOfCashAndCashEquivalentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationScheduleOfCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "totalLabel": "Total cash, cash equivalents, and restricted cash",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r138",
      "r239"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r138"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash financing activity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesScheduleOfLeasesSupplementalQuantitativeInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Operating Activities, Lessee [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_CashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "CashPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash payment",
        "terseLabel": "Cash payment",
        "documentation": "Cash payment"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ChangeInFairValueOfConvertibleDebentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ChangeInFairValueOfConvertibleDebentures",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtSummeryOfOutstandingConvertibleDebentureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of Convertible Debentures",
        "negatedLabel": "Change in fair value of Convertible debentures",
        "documentation": "Change in fair value of Convertible Debentures"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change In Fair Value Of Convertible Debentures Include Interest Expense",
        "terseLabel": "Change in fair value of debt and liability instruments",
        "documentation": "Change In Fair Value Of Convertible Debentures Include Interest Expense"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ChangeInFairValueOfDebtAndLiabilityInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ChangeInFairValueOfDebtAndLiabilityInstruments",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 12.0
      },
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 27.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change In Fair Value Of Debt And Liability Instruments",
        "terseLabel": "Change in fair value of debt and liability instruments",
        "documentation": "Change In Fair Value Of Debt And Liability Instruments"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ChangeInValuationInputsOrOtherAssumptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ChangeInValuationInputsOrOtherAssumptions",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ChangeInValuationInputsOrOtherAssumptions",
        "terseLabel": "Change in fair value measurement",
        "documentation": "Change in valuation inputs or other assumptions."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails",
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r218",
      "r219",
      "r220",
      "r242",
      "r263",
      "r264",
      "r267",
      "r269",
      "r276",
      "r277",
      "r345",
      "r388",
      "r390",
      "r391",
      "r392",
      "r395",
      "r396",
      "r425",
      "r426",
      "r428",
      "r431",
      "r438",
      "r554",
      "r676",
      "r677",
      "r678",
      "r679",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r696",
      "r716",
      "r738",
      "r758",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r842",
      "r861",
      "r868"
     ]
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Date from which Warrants or Rights Exercisable",
        "terseLabel": "Warrants exercisable date",
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Price per share",
        "verboseLabel": "Exercise price of the Representative Warrants",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ClosingPennyWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ClosingPennyWarrantMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Closing Penny Warrant [Member]",
        "documentation": "Closing Penny Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_CombinedPricePaidOfWarrant": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "CombinedPricePaidOfWarrant",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Price Paid Of Warrant",
        "terseLabel": "Combined Price Paid Of Warrant",
        "documentation": "Combined Price Paid Of Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (See Note 11)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r113",
      "r639",
      "r715"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r381",
      "r382",
      "r786",
      "r881"
     ]
    },
    "sclx_CommitmentsAndContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "CommitmentsAndContingenciesLineItems",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Line Items]",
        "documentation": "Commitments and Contingencies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_CommitmentsAndContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "CommitmentsAndContingenciesTable",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Table]",
        "documentation": "Commitments and Contingencies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_CommonShareSold": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "CommonShareSold",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Share Sold",
        "terseLabel": "Sold of common share",
        "documentation": "Common Share Sold"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock shares reserved for future issuance",
        "verboseLabel": "Aggregate shares purchase common warrants",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_CommonStockConvertibleConversionPriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockConvertibleConversionPriceIncrease",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Convertible, Conversion Price, Increase",
        "terseLabel": "Common Stock at a conversion price",
        "documentation": "Per share increase in conversion price of convertible common stock. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "sclx_CommonStockIssuableValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "CommonStockIssuableValue",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Issuable Value",
        "terseLabel": "Common stock issuable, value",
        "documentation": "Common Stock Issuable Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity",
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r827",
      "r828",
      "r829",
      "r831",
      "r832",
      "r833",
      "r834",
      "r865",
      "r866",
      "r926",
      "r948",
      "r952"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r716"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/NetLossPerShareAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "verboseLabel": "Offer and sell shares of Common Stock",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r125",
      "r716",
      "r735",
      "r952",
      "r953"
     ]
    },
    "sclx_CommonStockSold": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "CommonStockSold",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock sold",
        "terseLabel": "Common stock sold",
        "documentation": "Common stock sold."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value, 740,000,000 shares authorized; 160,084,250 shares issued and 100,015,665 shares outstanding as of December 31, 2023; 141,348,856 shares issued and outstanding as of December 31, 2022",
        "verboseLabel": "Common Stock Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r642",
      "r825"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Stock Incentive and Employee Benefit Plans",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r161"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "verboseLabel": "Computers &amp; equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r52",
      "r103",
      "r104",
      "r309",
      "r785"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r52",
      "r103",
      "r104",
      "r309",
      "r671",
      "r785"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r52",
      "r103",
      "r104",
      "r309",
      "r785",
      "r844"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Customer Concentration Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r194"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r52",
      "r103",
      "r104",
      "r309"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r52",
      "r103",
      "r104",
      "r309",
      "r785"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentLiabilityReserveEstimatePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContingentLiabilityReserveEstimatePolicy",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Liability Reserve Estimate, Policy [Policy Text Block]",
        "terseLabel": "Contingent Consideration",
        "documentation": "Disclosure of accounting policy for the claims loss reserve for insurance contracts with a life contingency (permanent life, some term life, accident and health, some annuities), describing the loss exposures and bases and methodologies for making the relevant accounting estimates."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r176"
     ]
    },
    "sclx_ConversionOfConvertibleDebenturesIntoCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ConversionOfConvertibleDebenturesIntoCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.vickersvantagecorp.com/role/DebtSummeryOfOutstandingConvertibleDebentureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Convertible Debentures into Common Stock",
        "terseLabel": "Conversion of Convertible Debentures into common stock",
        "negatedLabel": "Conversion of Convertible Debentures into common stock",
        "documentation": "Conversion of Convertible Debentures into Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ConversionOfConvertibleDebenturesIntoCommonStockShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ConversionOfConvertibleDebenturesIntoCommonStockShares",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Convertible Debentures Into Common Stock, Shares",
        "terseLabel": "Conversion of convertible debentures into common stock, (in shares)",
        "documentation": "Conversion of Convertible Debentures Into Common Stock, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ConversionOfConvertibleDebenturesIntoCommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ConversionOfConvertibleDebenturesIntoCommonStockValue",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Convertible Debentures Into Common Stock, Value",
        "terseLabel": "Conversion of convertible debentures into common stock",
        "documentation": "Conversion of Convertible Debentures Into Common Stock, Value"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ConvertibleDebenturesAndTheOramedNotePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ConvertibleDebenturesAndTheOramedNotePolicyTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debentures and the Oramed Note [Policy Text Block]",
        "terseLabel": "Convertible Debentures and the Oramed Note",
        "documentation": "Convertible Debentures and the Oramed Note"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ConvertibleDebenturesIssuedPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ConvertibleDebenturesIssuedPercent",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debentures Issued Percent",
        "terseLabel": "Convertible Debentures Issued Percent",
        "documentation": "Convertible Debentures Issued Percent"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ConvertibleDebenturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ConvertibleDebenturesMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debentures [Member]",
        "terseLabel": "Convertible Debentures",
        "documentation": "Convertible Debentures [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtSummeryOfOutstandingConvertibleDebentureDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt",
        "verboseLabel": "Convertible Debenture",
        "periodStartLabel": "Convertible debentures, beginning period",
        "periodEndLabel": "Convertible debentures, ending period",
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r181",
      "r945"
     ]
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtFairValueDisclosures",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt, Fair Value Disclosures",
        "terseLabel": "Convertible debenture",
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debentures [Member]",
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r398",
      "r399",
      "r409",
      "r410",
      "r411",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809"
     ]
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtSecuritiesMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtSummeryOfOutstandingConvertibleDebentureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt Securities [Member]",
        "terseLabel": "Convertible Debentures [Member]",
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtTableTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Schedule of convertible debentures",
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount."
       }
      }
     },
     "auth_ref": []
    },
    "sclx_Convertibledebentureprincipalamount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "Convertibledebentureprincipalamount",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ConvertibleDebentureprincipalAmount",
        "terseLabel": "Convertible Debenture principal Amount",
        "documentation": "ConvertibleDebentureprincipalAmount"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_CorporateBondYield": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "CorporateBondYield",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Bond Yield",
        "terseLabel": "Corporate Bond Yield",
        "documentation": "Corporate Bond Yield"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Revenue",
        "terseLabel": "Cost of revenue",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r242",
      "r345",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r554",
      "r882"
     ]
    },
    "sclx_CouponInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "CouponInterestRate",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Coupon Interest Rate",
        "terseLabel": "Coupon Interest Rate",
        "documentation": "Coupon Interest Rate"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_CoveLaneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "CoveLaneMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cove Lane [Member]",
        "terseLabel": "Cove Lane [Member]",
        "documentation": "Cove Lane [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r846",
      "r864",
      "r921"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r519",
      "r525",
      "r864"
     ]
    },
    "sclx_CurrentPortionOfDeferredConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "CurrentPortionOfDeferredConsideration",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of deferred consideration",
        "terseLabel": "Current portion of deferred consideration",
        "documentation": "Current portion of deferred consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r846",
      "r864",
      "r921"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r309"
     ]
    },
    "us-gaap_DebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, Current",
        "terseLabel": "Debt, current",
        "documentation": "Amount of debt and lease obligation, classified as current."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r240",
      "r397",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r413",
      "r420",
      "r421",
      "r423"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r122",
      "r123",
      "r179",
      "r181",
      "r245",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r404",
      "r409",
      "r410",
      "r411",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r568",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r862"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Conversion Price",
        "verboseLabel": "Conversion Price",
        "terseLabel": "Debt conversion price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r400"
     ]
    },
    "sclx_DebtInstrumentDefaultInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "DebtInstrumentDefaultInterestRate",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Default Interest Rate",
        "terseLabel": "Debt instrument, default interest rate",
        "documentation": "Debt Instrument, Default Interest Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentDescription",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Description",
        "terseLabel": "Debt instrument, description",
        "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r69",
      "r115",
      "r122",
      "r179",
      "r181"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Face Amount",
        "verboseLabel": "Debt principal amount",
        "terseLabel": "Initial principal amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r109",
      "r398",
      "r568",
      "r806",
      "r807"
     ]
    },
    "us-gaap_DebtInstrumentFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Estimated fair value",
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r553",
      "r806",
      "r807"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Debt instrument, interest rate",
        "documentation": "The average effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r107",
      "r416"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Exit fee",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r399"
     ]
    },
    "us-gaap_DebtInstrumentIssuedPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentIssuedPrincipal",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Issued, Principal",
        "terseLabel": "Aggregate Principle amount of issued debt",
        "documentation": "Amount of principal of debt issued."
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r404",
      "r409",
      "r410",
      "r411",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r422",
      "r568",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r862"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Maturity Date",
        "verboseLabel": "Debt maturity date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r805",
      "r927"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r245",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r404",
      "r409",
      "r410",
      "r411",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r568",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r862"
     ]
    },
    "sclx_DebtInstrumentOutstandingPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "DebtInstrumentOutstandingPrincipal",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Outstanding Principal",
        "terseLabel": "Outstanding debt instrument",
        "documentation": "Debt instrument outstanding principal"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_DebtInstrumentOwnedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "DebtInstrumentOwnedPercentage",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Owned, Percentage",
        "terseLabel": "Debt instrument, owned, percentage",
        "documentation": "Debt Instrument, Owned, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentPaymentTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentPaymentTerms",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Payment Terms",
        "terseLabel": "Debt payment terms",
        "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r116"
     ]
    },
    "sclx_DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Percentage of Interest Accrued on Principal Amount",
        "terseLabel": "Debt instrument, percentage of interest accrued on principal amount",
        "documentation": "Debt Instrument, Percentage of Interest Accrued on Principal Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_DebtInstrumentPrincipalAmountPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "DebtInstrumentPrincipalAmountPercentage",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Principal Amount, Percentage",
        "terseLabel": "Debt Instrument Principal Amount, Percentage",
        "documentation": "Debt Instrument Principal Amount, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRedemptionDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionDescription",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption, Description",
        "terseLabel": "Debt Instrument Redemption",
        "documentation": "Description of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Redemption Premium",
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_DebtInstrumentRepaidPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRepaidPrincipal",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Repaid, Principal",
        "terseLabel": "Convertible Debentures Repaid",
        "documentation": "Amount of principal of debt repaid."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/DebtSummeryOfOutstandingConvertibleDebentureDetails",
      "http://www.vickersvantagecorp.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r69",
      "r70",
      "r106",
      "r107",
      "r109",
      "r114",
      "r155",
      "r156",
      "r245",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r404",
      "r409",
      "r410",
      "r411",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r422",
      "r568",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r862"
     ]
    },
    "sclx_DebtPayableAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "DebtPayableAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Payable [Axis]",
        "documentation": "Debt Payable [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_DebtPayableDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "DebtPayableDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Payable [Domain]",
        "documentation": "Debt Payable [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Debt",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "sclx_DebtRepaymentExitFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "DebtRepaymentExitFee",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Repayment Exit Fee",
        "terseLabel": "Debt Repayment Exit Fee",
        "documentation": "Debt Repayment Exit Fee"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Repayment, Percentage of Mandatory Default Rate of Accrued and Unpaid Interest",
        "terseLabel": "Debt repayment, percentage of mandatory default rate of accrued and unpaid interest",
        "documentation": "Debt Repayment, Percentage of Mandatory Default Rate of Accrued and Unpaid Interest"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Repayment, Percentage of Mandatory Default Rate of Principal Amount",
        "terseLabel": "Debt repayment, percentage of mandatory default rate of principal amount",
        "documentation": "Debt Repayment, Percentage of Mandatory Default Rate of Principal Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleWeightedAverageYield": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleWeightedAverageYield",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Weighted Average Yield",
        "terseLabel": "Debt Securities, Available-for-Sale, Weighted Average Yield",
        "documentation": "Weighted average yield of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtSummeryOfOutstandingConvertibleDebentureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtWeightedAverageInterestRate",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, Weighted Average Interest Rate",
        "terseLabel": "Debt Weighted Average Interest Rate",
        "documentation": "Weighted average interest rate of debt outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCompensationCashBasedArrangementsLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCompensationCashBasedArrangementsLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Compensation Cash-Based Arrangements, Liability, Current",
        "terseLabel": "Cash compensation",
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for deferred compensation arrangements payable within one year (or the normal operating cycle, if longer). Represents currently earned compensation under cash arrangements (such as a profit-sharing plan, rabbi trust, and employee contract--excluding equity-based arrangements) that is not actually paid until a later date."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r74"
     ]
    },
    "sclx_DeferredConsiderationForRomegIntangibleAssetAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "DeferredConsiderationForRomegIntangibleAssetAcquisition",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Consideration for Romeg Intangible Asset Acquisition",
        "terseLabel": "Deferred consideration for Romeg intangible asset acquisition",
        "documentation": "Deferred Consideration for Romeg Intangible Asset Acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r864",
      "r920",
      "r921"
     ]
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Deferred income tax expense (benefit):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r167",
      "r200",
      "r524",
      "r525",
      "r864"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r864",
      "r920",
      "r921"
     ]
    },
    "sclx_DeferredTaxAssetsAccruedExpenseAndReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "DeferredTaxAssetsAccruedExpenseAndReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Accrued Expense and Reserves",
        "terseLabel": "Accrued expense and reserves",
        "documentation": "Deferred tax assets, accrued expense and reserves."
       }
      }
     },
     "auth_ref": []
    },
    "sclx_DeferredTaxAssetsDebtRelatedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "DeferredTaxAssetsDebtRelatedInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Debt Related Interest",
        "terseLabel": "Debt related interest",
        "documentation": "Deferred tax assets, debt related interest."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized research and development",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r919"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax liabilities",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Deferred Tax Assets, Operating Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r919"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r919"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credit carryforwards",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r919"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development income tax credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r919"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r919"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less valuation allowance",
        "verboseLabel": "Deferred tax assets, valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r918"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedLabel": "Intangible assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r919"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "Operating lease right-of-use assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r919"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfDeferredTaxLiabilitiesAndRelatedValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_Deferredconsiderationliabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "Deferredconsiderationliabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DeferredConsiderationLiabilities",
        "terseLabel": "Deferred consideration",
        "documentation": "DeferredConsiderationLiabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Employee benefit plan contributions by employer",
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r443",
      "r450",
      "r812",
      "r813",
      "r814",
      "r815"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/BalanceSheetComponentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r64"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r284"
     ]
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 11.0
      },
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "negatedLabel": "Loss (gain) on derivative liability",
        "verboseLabel": "(Gain) loss on derivative liability",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability",
        "terseLabel": "Derivative liabilities",
        "periodStartLabel": "Fair value, beginning",
        "periodEndLabel": "Fair value, ending",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r225",
      "r553",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r730",
      "r732",
      "r733",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r794",
      "r949"
     ]
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Derivative liabilities",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes derivative liability."
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "sclx_DerivativeWarrantLiabilityPrivateWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "DerivativeWarrantLiabilityPrivateWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Warrant Liability Private Warrants",
        "terseLabel": "Derivative warrant liability private warrants",
        "documentation": "Derivative warrant liability private warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Liabilities",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r95",
      "r96",
      "r97",
      "r98",
      "r244"
     ]
    },
    "sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "DescriptionofOrganizationandBusinessOperationsDetailsLineItems",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Organization and Business Operations (Details) [Line Items]",
        "documentation": "Descriptionof Organizationand Business Operations Details Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "DescriptionofOrganizationandBusinessOperationsDetailsTable",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Organization and Business Operations (Details) [Table]",
        "documentation": "Descriptionof Organizationand Business Operations Details Table"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_DevelopersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "DevelopersMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Developers [Member]",
        "documentation": "Developers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_DisbursementOfFunds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "DisbursementOfFunds",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 38.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disbursement Of Funds",
        "terseLabel": "Disbursement of funds to Sorrento",
        "documentation": "Disbursement Of Funds"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_DisbursementOfFundsToSorrentoAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "DisbursementOfFundsToSorrentoAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disbursement of funds to Sorrento Amount",
        "terseLabel": "Disbursement of funds to Sorrento Amount",
        "documentation": "Disbursement of funds to Sorrento Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Junior DIP Facility and Sorrento Share Purchase Agreement",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r455",
      "r486",
      "r487",
      "r488",
      "r819"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureTextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Text Block [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "sclx_DueFromRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "DueFromRelatedParty",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due From Related Party",
        "documentation": "Due From Related Party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarlyRepaymentOfSeniorDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarlyRepaymentOfSeniorDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 35.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Early Repayment of Senior Debt",
        "negatedLabel": "Repayment of Oramed Note",
        "documentation": "The cash outflow for the extinguishment of long-term borrowing, with the highest claim on the assets of the entity in case of bankruptcy or liquidation, before its maturity."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.vickersvantagecorp.com/role/NetLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic (Loss) income Per Share",
        "verboseLabel": "Net loss per share attributable to common stockholders - basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r260",
      "r263",
      "r267",
      "r268",
      "r269",
      "r273",
      "r549",
      "r550",
      "r635",
      "r652",
      "r797"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.vickersvantagecorp.com/role/NetLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Net loss per share attributable to common stockholders - diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r263",
      "r267",
      "r268",
      "r269",
      "r273",
      "r549",
      "r550",
      "r635",
      "r652",
      "r797"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r270",
      "r271",
      "r272"
     ]
    },
    "sclx_EffectOfDilutiveSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "EffectOfDilutiveSecurities",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NetLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Dilutive Securities",
        "terseLabel": "Effect of dilutive securities",
        "documentation": "Effect of Dilutive Securities"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Fair Value of Convertible Debentures, Amount",
        "terseLabel": "Change in fair value of Convertible Debentures",
        "documentation": "Effective Income Tax Rate Reconciliation, Change in Fair Value of Convertible Debentures, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Tax Rates, Amount",
        "terseLabel": "Change in tax rates",
        "documentation": "Effective Income Tax Rate Reconciliation, Change in Tax Rates, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationDebtDiscountAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation Debt Discount Amount",
        "terseLabel": "Debt discount and interest limitation",
        "documentation": "Effective income tax rate reconciliation debt discount amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost related to unvested stock option grants",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "sclx_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Purchase Plan [Member]",
        "documentation": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "sclx_EnveltaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "EnveltaMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Envelta [Member]",
        "documentation": "Envelta Member"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_EpoladermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "EpoladermMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Epoladerm [Member]",
        "documentation": "Epoladerm Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity",
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/NetLossPerShareAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r204",
      "r229",
      "r230",
      "r231",
      "r246",
      "r247",
      "r248",
      "r250",
      "r256",
      "r258",
      "r275",
      "r346",
      "r347",
      "r440",
      "r489",
      "r490",
      "r491",
      "r520",
      "r521",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r548",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r578",
      "r666",
      "r667",
      "r668",
      "r684",
      "r758"
     ]
    },
    "us-gaap_EquityUnitPurchaseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityUnitPurchaseAgreementsMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Unit Purchase Agreements [Member]",
        "terseLabel": "Equity Purchase Agreement with Yorkville and B. Riley [Member]",
        "documentation": "Contracts and securities that allow the holder to buy equity units from the entity."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "sclx_EquityValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "EquityValue",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Value",
        "terseLabel": "Equity Value",
        "documentation": "Equity Value"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Excise tax in connection with share repurchase included in accrued expenses",
        "terseLabel": "Excise tax in connection with share repurchase included in accrued expenses",
        "documentation": "Excise tax in connection with share repurchase included in accrued expenses"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ExercisePriceOfCommonWarrant": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ExercisePriceOfCommonWarrant",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Of Common Warrant",
        "terseLabel": "Exercise Price Of Warrant",
        "documentation": "Exercise Price Of Common Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ExistingFacilityCapMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ExistingFacilityCapMaximum",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Existing Facility Cap Maximum",
        "terseLabel": "Facility cap maximum",
        "documentation": "Existing Facility Cap Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ExistingFacilityCapMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ExistingFacilityCapMinimum",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Existing Facility Cap Minimum",
        "terseLabel": "Facility cap minimum",
        "documentation": "Existing facility cap minimum"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustment to derivative liability in troubled debt restructuring",
        "terseLabel": "Fair value adjustment to derivative liability in troubled debt restructuring",
        "documentation": "Fair value adjustment to derivative liability in troubled debt restructuring"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of fair value assets measured on a recurring basis",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r172"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r101",
      "r102"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r552",
      "r587",
      "r588",
      "r589",
      "r806",
      "r807",
      "r812",
      "r813",
      "r814"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r171"
     ]
    },
    "us-gaap_FairValueConcentrationOfRiskTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueConcentrationOfRiskTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Concentration of Risk [Table Text Block]",
        "terseLabel": "Schedule of quantitative information regarding Level 3 fair value measurements",
        "documentation": "Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r105",
      "r173",
      "r174"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r443",
      "r448",
      "r552",
      "r587",
      "r812",
      "r813",
      "r814"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r443",
      "r448",
      "r552",
      "r588",
      "r806",
      "r807",
      "r812",
      "r813",
      "r814"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r552",
      "r589",
      "r806",
      "r807",
      "r812",
      "r813",
      "r814"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r587",
      "r588",
      "r589",
      "r806",
      "r807",
      "r812",
      "r813",
      "r814"
     ]
    },
    "sclx_FairValueOfContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "FairValueOfContingentConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of contingent consideration",
        "terseLabel": "Development Milestone Payment",
        "documentation": "Fair value of contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r23"
     ]
    },
    "sclx_FairValueOfSharesRepurchased": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "FairValueOfSharesRepurchased",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of Shares Repurchased",
        "terseLabel": "Fair Value of stock repurchased",
        "documentation": "Fair value of Shares Repurchased"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_FairValueOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "FairValueOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Of Warrants",
        "terseLabel": "Fair Value Of Warrants",
        "documentation": "Fair Value Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability",
        "terseLabel": "Finance lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r570",
      "r577"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r422",
      "r436",
      "r546",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r600",
      "r601",
      "r602",
      "r603",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r651",
      "r803",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r871",
      "r872",
      "r873",
      "r874"
     ]
    },
    "us-gaap_FinancingReceivableRevolvingConvertedToTermLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancingReceivableRevolvingConvertedToTermLoan",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing Receivable, Revolving, Converted to Term Loan",
        "terseLabel": "Accounts receivable revolving loan facility in an aggregate amount",
        "documentation": "Amortized cost of revolving financing receivable converted to term loan."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r802"
     ]
    },
    "sclx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization,after Year Five",
        "terseLabel": "Thereafter",
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization,after Year Five"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedTerseLabel": "Accumulated amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r373"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2024",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2028",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2027",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2026",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2025",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r372",
      "r373",
      "r375",
      "r619",
      "r620"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross carrying amount",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r620"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r62"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails",
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangibles, net",
        "totalLabel": "Total",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r619"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNetAmortizationExpenseRollingMaturityAbstract",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Rolling Maturity [Abstract]",
        "terseLabel": "As of March 31,2023"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_FiveInstallmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "FiveInstallmentMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Five Installment [Member]",
        "terseLabel": "Five Installment [Member]",
        "documentation": "Five Installment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "negatedLabel": "Loss on foreign currency exchange",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r555",
      "r556",
      "r557",
      "r558",
      "r755"
     ]
    },
    "sclx_ForfeitureOfPrivateWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ForfeitureOfPrivateWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeiture of Private Warrants",
        "terseLabel": "Forfeiture of Private Warrants",
        "documentation": "Forfeiture of Private Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ForfeituresOfPrivateWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ForfeituresOfPrivateWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeitures of Private Warrants",
        "terseLabel": "Forfeitures of private warrants",
        "documentation": "Forfeitures of Private Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_FormerEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "FormerEmployeeMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Employee [Member]",
        "documentation": "Former Employee [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_FormerEmployeeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "FormerEmployeeOneMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Employee One[Member]",
        "documentation": "Former Employee One[Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_FourthInstallmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "FourthInstallmentMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fourth Installment [Member]",
        "terseLabel": "Fourth Installment [Member]",
        "documentation": "Fourth Installment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_FristInstallmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "FristInstallmentMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Frist Installment [Member]",
        "terseLabel": "First installment [Member]",
        "documentation": "Frist Installment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 13.0
      },
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "(Gain) loss on debt extinguishment, net",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r67",
      "r68"
     ]
    },
    "sclx_GloperbaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "GloperbaMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GLOPERBA [Member]",
        "documentation": "GLOPERBA [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill",
        "terseLabel": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r360",
      "r634",
      "r804",
      "r825",
      "r878",
      "r879"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Asset Impairment",
        "terseLabel": "Goodwill impairment charges",
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Other Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r56"
     ]
    },
    "sclx_HudsonBayMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "HudsonBayMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hudson Bay [Member]",
        "terseLabel": "Hudson Bay [Member]",
        "documentation": "Hudson Bay [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r131",
      "r183",
      "r279",
      "r298",
      "r304",
      "r306",
      "r636",
      "r648",
      "r799"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r378",
      "r741"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r741"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "sclx_IncomeTaxCreditsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "IncomeTaxCreditsExpirationYear",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Credits Expiration Year",
        "terseLabel": "Income tax credits, expiration year",
        "documentation": "Income Tax Credits Expiration Year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_IncomeTaxDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "IncomeTaxDisclosureLineItems",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Line Items]",
        "documentation": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r500",
      "r507",
      "r512",
      "r517",
      "r522",
      "r526",
      "r527",
      "r528",
      "r681"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "terseLabel": "Income tax expense, interest and penalties",
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails",
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "verboseLabel": "Income tax expense",
        "totalLabel": "Total",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r201",
      "r257",
      "r258",
      "r287",
      "r505",
      "r523",
      "r653"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r503",
      "r504",
      "r512",
      "r513",
      "r516",
      "r518",
      "r675"
     ]
    },
    "sclx_IncomeTaxReconciliationAcquisitionRelatedCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "IncomeTaxReconciliationAcquisitionRelatedCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Reconciliation Acquisition Related Charges",
        "terseLabel": "Acquisition related charges",
        "documentation": "Income tax reconciliation acquisition related charges."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails",
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Changes in valuation allowance",
        "verboseLabel": "Valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfComponentsOfBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "terseLabel": "Changes in tax rate",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r506"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Income tax benefit at federal statutory rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "terseLabel": "Compensation expense",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount",
        "terseLabel": "Prior year true-up and carryback",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State, net of federal tax benefit",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Accounts payable",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivables, net",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "sclx_IncreaseDecreaseInAccruedPayroll": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "IncreaseDecreaseInAccruedPayroll",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Accrued payroll",
        "terseLabel": "Accrued Payroll",
        "documentation": "Increase Decrease In Accrued payroll"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_IncreaseDecreaseInAccruedRebatesAndFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "IncreaseDecreaseInAccruedRebatesAndFees",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Rebates and Fees",
        "terseLabel": "Accrued rebates and fees",
        "documentation": "Increase (Decrease) in Accrued Rebates and Fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInNotesPayableRelatedPartiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Notes Payable, Related Parties, Current",
        "terseLabel": "Related party payable",
        "documentation": "The increase (decrease) during the reporting period in the current portion (due within one year or one business cycle, whichever is longer) of the amount owed by the reporting entity in the form of loans and obligations (generally evidenced by promissory notes) made by the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Current Liabilities",
        "terseLabel": "Other liabilities",
        "documentation": "Amount of increase (decrease) in current liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other long-term assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidExpensesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expenses, Other",
        "negatedLabel": "Prepaid expenses and other",
        "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r374"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r147"
     ]
    },
    "sclx_IndefiniteOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "IndefiniteOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite Operating Loss Carryforwards",
        "terseLabel": "Indefinite net federal operating loss",
        "documentation": "Indefinite Operating Loss Carryforwards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangibles, net",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r61"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense",
        "terseLabel": "Interest expense, net",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r185",
      "r232",
      "r283",
      "r566",
      "r742",
      "r835",
      "r951"
     ]
    },
    "us-gaap_InterestIncomeOperatingPaidInCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeOperatingPaidInCash",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income, Operating, Paid in Cash",
        "terseLabel": "Cash paid for interest",
        "documentation": "Amount of interest income from investment paid in cash, classified as operating."
       }
      }
     },
     "auth_ref": [
      "r739",
      "r776",
      "r777"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 28.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r792",
      "r825"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r210",
      "r221",
      "r357",
      "r358",
      "r359",
      "r617",
      "r795"
     ]
    },
    "sclx_IssuanceOfCommonStockUponWarrantsExerciseShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "IssuanceOfCommonStockUponWarrantsExerciseShares",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Common Stock Upon Warrants Exercise, Shares",
        "terseLabel": "Issuance of common stock upon warrants exercise, (in shares)",
        "documentation": "Issuance of Common Stock Upon Warrants Exercise, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_IssuanceOfCommonStockUponWarrantsExerciseValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "IssuanceOfCommonStockUponWarrantsExerciseValue",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Common Stock Upon Warrants Exercise, Value",
        "terseLabel": "Issuance of common stock upon warrants exercise",
        "documentation": "Issuance of Common Stock Upon Warrants Exercise, Value"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_IssuanceOfPennyWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "IssuanceOfPennyWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Penny Warrants",
        "terseLabel": "Issuance of penny warrants",
        "documentation": "Issuance of Penny Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_IssueOfWarrantsToPurchaseShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "IssueOfWarrantsToPurchaseShares",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue of Warrants to Purchase Shares",
        "terseLabel": "Issue of warrants",
        "documentation": "Issue of Warrants to Purchase Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_JuniorDipFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "JuniorDipFacilityMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Junior DIP Facility [Member]",
        "terseLabel": "Junior DIP Facility",
        "documentation": "Junior DIP Facility [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_LeaseLiabilityNetOfCurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "LeaseLiabilityNetOfCurrentPortion",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liability, net of current portion",
        "terseLabel": "Lease liability, net of current portion",
        "documentation": "Lease liability, net of current portion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdsAndLeaseholdImprovementsMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leaseholds and Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements [Member]",
        "documentation": "Asset held by lessee under finance lease and addition or improvement to asset held under lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LegalFees",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Fees",
        "terseLabel": "Legal fees and expenses",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Lease Maturities of Lease Liabilities",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Operating lease, remaining lease term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease, lease term",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r242",
      "r345",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r534",
      "r537",
      "r538",
      "r554",
      "r714",
      "r798",
      "r837",
      "r882",
      "r935",
      "r936"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' (deficit) equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r182",
      "r644",
      "r825",
      "r863",
      "r875",
      "r928"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' DEFICIT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities:",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r209",
      "r242",
      "r345",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r534",
      "r537",
      "r538",
      "r554",
      "r825",
      "r882",
      "r935",
      "r936"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Adjustment",
        "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure",
        "terseLabel": "Total liabilities measured at fair value",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_LiabilityForUncertainTaxPositionsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForUncertainTaxPositionsCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability for Uncertainty in Income Taxes, Current",
        "terseLabel": "Liabilities for uncertain tax positions",
        "documentation": "Amount recognized for uncertainty in income taxes classified as current."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "sclx_LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "LicenseAgreementMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement [Member]",
        "terseLabel": "License Agreement",
        "documentation": "License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityInterestRateDuringPeriod",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Interest Rate During Period",
        "terseLabel": "Line Of Credit Facility Interest Rate",
        "documentation": "The effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "sclx_LiquidityAndGoingConcernLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "LiquidityAndGoingConcernLineItems",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity and Going Concern [Line Items]",
        "documentation": "Liquidity and Going Concern [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_LiquidityAndGoingConcernTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "LiquidityAndGoingConcernTable",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity and Going Concern [Table]",
        "documentation": "Liquidity and Going Concern [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationSettlementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationSettlementExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Agreement settlement payment",
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "sclx_LongTermPortionOfDeferredConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "LongTermPortionOfDeferredConsideration",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term portion of deferred consideration",
        "terseLabel": "Long-term portion of deferred consideration",
        "documentation": "Long-term portion of deferred consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/DebtSummeryOfOutstandingConvertibleDebentureDetails",
      "http://www.vickersvantagecorp.com/role/DebtTables",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/DebtSummeryOfOutstandingConvertibleDebentureDetails",
      "http://www.vickersvantagecorp.com/role/DebtTables",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r66"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r309",
      "r811",
      "r885",
      "r946",
      "r947"
     ]
    },
    "sclx_MaturityRenewalDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "MaturityRenewalDescription",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity Renewal Description",
        "terseLabel": "Agreement maturity renewal description",
        "documentation": "Maturity Renewal Description"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r383",
      "r384",
      "r386",
      "r387",
      "r451",
      "r616",
      "r665",
      "r704",
      "r705",
      "r764",
      "r765",
      "r766",
      "r767",
      "r775",
      "r787",
      "r788",
      "r801",
      "r810",
      "r818",
      "r826",
      "r884",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942"
     ]
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/Acquisitions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]",
        "terseLabel": "Acquisitions",
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r168"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r383",
      "r384",
      "r386",
      "r387",
      "r451",
      "r616",
      "r665",
      "r704",
      "r705",
      "r764",
      "r765",
      "r766",
      "r767",
      "r775",
      "r787",
      "r788",
      "r801",
      "r810",
      "r818",
      "r826",
      "r884",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942"
     ]
    },
    "sclx_MonthlyBasisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "MonthlyBasisMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Monthly Basis [Member]",
        "terseLabel": "Monthly Basis [Member]",
        "documentation": "Monthly Basis [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r309",
      "r811",
      "r885",
      "r946",
      "r947"
     ]
    },
    "sclx_NetCashProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "NetCashProceeds",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "net cash proceeds",
        "terseLabel": "Net cash proceeds",
        "documentation": "net cash proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 29.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash proceeds from financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used for investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used for operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r139",
      "r140"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "terseLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r139",
      "r140"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      },
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.vickersvantagecorp.com/role/NetLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r140",
      "r184",
      "r207",
      "r226",
      "r227",
      "r231",
      "r242",
      "r249",
      "r251",
      "r252",
      "r253",
      "r254",
      "r257",
      "r258",
      "r265",
      "r279",
      "r298",
      "r304",
      "r306",
      "r345",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r550",
      "r554",
      "r650",
      "r737",
      "r756",
      "r757",
      "r799",
      "r835",
      "r882"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NetLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss for basic and diluted loss per share available to common stockholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r251",
      "r252",
      "r253",
      "r254",
      "r260",
      "r261",
      "r266",
      "r269",
      "r279",
      "r298",
      "r304",
      "r306",
      "r799"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "sclx_NonCancelableLeaseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "NonCancelableLeaseAgreementsMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cancelable Lease Agreements [Member]",
        "documentation": "Non-cancelable Lease Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_NonCashOperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "NonCashOperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Cash Operating Lease Cost",
        "terseLabel": "Non-cash operating lease cost",
        "documentation": "Non cash operating lease cost."
       }
      }
     },
     "auth_ref": []
    },
    "sclx_NonEmployeeDirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "NonEmployeeDirectorMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Employee Director [Member]",
        "documentation": "Non Employee Director [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "negatedTotalLabel": "Total other (income) expense",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other (income) expense:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtSummeryOfOutstandingConvertibleDebentureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Issued",
        "verboseLabel": "Issuance of Convertible Debentures",
        "documentation": "The fair value of notes issued in noncash investing and financing activities."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r47"
     ]
    },
    "sclx_NotesPrincipalIncrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "NotesPrincipalIncrease",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      },
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes principal increase",
        "negatedLabel": "Scilex Pharma Notes principal increase",
        "documentation": "Notes principal increase"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_NumberOfShareOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "NumberOfShareOutstanding",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Share Outstanding",
        "terseLabel": "Number Of Share Outstanding",
        "documentation": "Number Of Share Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingCostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Costs and Expenses",
        "totalLabel": "Total operating costs and expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating costs and expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "terseLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r298",
      "r304",
      "r306",
      "r799"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Expense",
        "terseLabel": "Lease Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "terseLabel": "Total lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesScheduleOfLeaseMaturitiesOfLeaseLiabilitiesDetails",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities",
        "verboseLabel": "Less current portion of lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Corresponding lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesScheduleOfLeasesSupplementalQuantitativeInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "negatedLabel": "Operating cash flows from operating leases",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r572",
      "r574"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset",
        "verboseLabel": "Additional ROU assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesScheduleOfLeasesSupplementalQuantitativeInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate - operating leases",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r576",
      "r824"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesScheduleOfLeasesSupplementalQuantitativeInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term in years - operating leases",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r824"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "sclx_OperatingLossCarryforwardsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Operating loss carryforwards, expiration year",
        "documentation": "Operating Loss Carryforwards Expiration Year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "sclx_OramedNoteIssuanceAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "OramedNoteIssuanceAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Oramed Note issuance at fair value",
        "terseLabel": "Oramed Note issuance at fair value",
        "documentation": "Oramed Note issuance at fair value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Nature of Operations and Basis of Presentation",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r170",
      "r672",
      "r673"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued rebates and fees",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_OtherLongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Long-Term Debt, Noncurrent",
        "terseLabel": "Debt, net of issuance costs",
        "documentation": "Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r713"
     ]
    },
    "sclx_OtherLongTermLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "OtherLongTermLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other long-term liabilities",
        "terseLabel": "Other long-term liabilities",
        "documentation": "Other long-term liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_OtherNonCashConsiderationInConnectionWithShareRepurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "OtherNonCashConsiderationInConnectionWithShareRepurchase",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other non-cash consideration in connection with share repurchase",
        "terseLabel": "Other non-cash consideration in connection with share repurchase",
        "documentation": "Other non-cash consideration in connection with share repurchase"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 28.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other",
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 27.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses and other",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r856",
      "r877"
     ]
    },
    "sclx_OutOfPocketExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "OutOfPocketExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Out-Of-Pocket Expense",
        "terseLabel": "Out Of Pocket Expense",
        "documentation": "Out-Of-Pocket Expense"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_OutstandingBalanceOfRevolvingFacility": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "OutstandingBalanceOfRevolvingFacility",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding balance of revolving facility",
        "terseLabel": "Outstanding balance of revolving facility",
        "documentation": "Outstanding balance of revolving facility"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PatentRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "PatentRightsMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent rights [Member]",
        "terseLabel": "Patent rights",
        "documentation": "Patent rights [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PatentsMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "sclx_PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt discount",
        "negatedLabel": "Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt discount",
        "documentation": "Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt discount"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PaymentToAcquireLicense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "PaymentToAcquireLicense",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment to Acquire License",
        "terseLabel": "Payment to acquire license",
        "documentation": "Payment to Acquire License"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PaymentUponTheAchievementOfNetSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "PaymentUponTheAchievementOfNetSales",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment upon the achievement of net sales",
        "documentation": "payment upon the achievement of net sales"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Royalties",
        "terseLabel": "Payments for royalties",
        "documentation": "The amount of cash paid for royalties during the current period."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 37.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Payments of debt issuance costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_PaymentsOfDividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDividends",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Dividends",
        "verboseLabel": "Payment made to Investor",
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property, plant, and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "sclx_PennyWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "PennyWarrantsMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Penny Warrants [Member]",
        "documentation": "Penny Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PercentageOfNetRevenueSoleDistributors": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "PercentageOfNetRevenueSoleDistributors",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of net revenue, sole distributors",
        "terseLabel": "Percentage of net revenue, sole distributor",
        "documentation": "Percentage of net revenue, sole distributors"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PercentageOfUsageOfCashProceedsFromCashSweepFinancing": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "PercentageOfUsageOfCashProceedsFromCashSweepFinancing",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of Usage of Cash Proceeds from Cash Sweep Financing",
        "terseLabel": "Percentage of usage of cash proceeds from cash sweep financing",
        "documentation": "Percentage of Usage of Cash Proceeds from Cash Sweep Financing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity",
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock Member",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r827",
      "r828",
      "r831",
      "r832",
      "r833",
      "r834",
      "r948",
      "r952"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r425"
     ]
    },
    "us-gaap_PreferredStockRedemptionPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockRedemptionPremium",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NetLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Redemption Premium",
        "negatedLabel": "Premium on redemption of Preferred Stock",
        "documentation": "The excess of (1) fair value of the consideration transferred to the holders of the preferred stock over (2) the carrying amount of the preferred stock in the registrant's balance sheet, during the accounting period."
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r716"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r425"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r716",
      "r735",
      "r952",
      "r953"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value, 45,000,000 shares authorized; 29,057,097 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r641",
      "r825"
     ]
    },
    "sclx_PricePerOptionalShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "PricePerOptionalShare",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Price Per Optional share",
        "terseLabel": "Price of Optional Share",
        "documentation": "Price Per Optional share"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PricePerOptionalWarrant": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "PricePerOptionalWarrant",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Price Per Optional Warrant",
        "terseLabel": "Price of optional warrant",
        "documentation": "Price Per Optional Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrincipalAmountOutstandingOfLoansHeldInPortfolio",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan, Held-in-Portfolio, Principal Outstanding",
        "terseLabel": "Outstanding principal amount",
        "documentation": "This is the result of the principal amount outstanding of total loans managed or securitized less securitized loans and loans that are in the process of being securitized."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "sclx_PrincipalLaonAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "PrincipalLaonAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal laon amount",
        "terseLabel": "Principal laon amount",
        "documentation": "Principal laon amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PrivatePlacementWarrantLiabilityAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "PrivatePlacementWarrantLiabilityAcquired",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private placement warrant liability acquired",
        "terseLabel": "Private Warrant liability acquired as part of the Business Combination",
        "documentation": "Private placement warrant liability acquired"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PrivateWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "PrivateWarrantsMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Warrants [Member]",
        "terseLabel": "Private Warrants",
        "documentation": "Private Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ProbudurMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ProbudurMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Probudur [Member]",
        "documentation": "Probudur Member"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ProceedSOfSaleOfCommonSharesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ProceedSOfSaleOfCommonSharesPercentage",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceed s of sale of common shares percentage",
        "terseLabel": "Proceeds from sale of common shares percentage",
        "documentation": "Proceed s of sale of common shares percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 31.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from issuance of Convertible Debentures",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ProceedsFromInsuranceSettlementOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromInsuranceSettlementOperatingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Insurance Settlement, Operating Activities",
        "terseLabel": "Issuance of shares under Settlement Agreement",
        "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r789"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of shares under Standby Equity Purchase Agreements",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "sclx_ProceedsFromIssuanceOfRevolvingFacility": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ProceedsFromIssuanceOfRevolvingFacility",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 33.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Revolving Facility",
        "terseLabel": "Proceeds from issuance of Revolving Facility",
        "documentation": "Proceeds from Issuance of Revolving Facility"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Proceed from Securities and Warrants issued",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromOtherShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromOtherShortTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 45.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Other Short-Term Debt",
        "terseLabel": "Proceeds from other loans",
        "documentation": "Amount of cash inflow from short-term debt classified as other."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromRelatedPartyDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 43.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Related Party Debt",
        "verboseLabel": "Proceeds from related party payable",
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "sclx_ProceedsFromRepaymentOfLoansToPurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ProceedsFromRepaymentOfLoansToPurchase",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 47.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds From Repayment Of Loans To Purchase",
        "terseLabel": "Repayment on other loans",
        "documentation": "Proceeds From Repayment Of Loans To Purchase"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ProceedsFromSaleOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ProceedsFromSaleOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of common stock",
        "terseLabel": "Proceeds from sale of common stock",
        "documentation": "Proceeds from sale of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSecuredNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSecuredNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 44.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Secured Notes Payable",
        "terseLabel": "Proceeds from related party note payable",
        "documentation": "The cash inflow from borrowings supported by a written promise to pay an obligation that is collateralized (backed by pledge, mortgage or other lien in the entity's assets)."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 42.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from stock options and warrants exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r19"
     ]
    },
    "sclx_ProceedsFromTheBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ProceedsFromTheBusinessCombination",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 41.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the Business Combination",
        "terseLabel": "Proceeds from the Business Combination",
        "documentation": "Proceeds from the Business Combination"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ProductDevelopmentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ProductDevelopmentAgreementMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Development Agreement [Member]",
        "documentation": "Product Development Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductLiabilityContingencyAccrualDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductLiabilityContingencyAccrualDiscountRate",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Liability Contingency, Accrual, Discount Rate",
        "terseLabel": "Discount rate of FDA",
        "documentation": "Rate applied to the undiscounted amount of estimated damages for product liability to arrive at the present value recorded as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r226",
      "r227",
      "r236",
      "r242",
      "r249",
      "r257",
      "r258",
      "r279",
      "r298",
      "r304",
      "r306",
      "r345",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r532",
      "r535",
      "r536",
      "r550",
      "r554",
      "r636",
      "r649",
      "r683",
      "r737",
      "r756",
      "r757",
      "r799",
      "r822",
      "r823",
      "r836",
      "r857",
      "r882"
     ]
    },
    "sclx_PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory Note issued to Sorrento in exchange for the SP-104 license",
        "documentation": "Promissory Note issued to Sorrento in exchange for the SP-104 license, net of discount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails",
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/BalanceSheetComponents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Balance Sheet Components",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r195",
      "r198",
      "r199"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r212",
      "r647"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 21.0
      },
      "http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r637",
      "r647",
      "r825"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r195",
      "r198",
      "r645"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/BalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails",
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "sclx_PublicOfferingPerOptionalShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "PublicOfferingPerOptionalShare",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Offering Per Optional Share",
        "terseLabel": "Public Offering Price Per Optional Share",
        "documentation": "Public Offering Per Optional Share"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PublicOfferingPerOptionalWarrant": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "PublicOfferingPerOptionalWarrant",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Offering Per Optional Warrant",
        "terseLabel": "Public Offering Per Optional Warrant",
        "documentation": "Public Offering Per Optional Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PublicOfferingPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "PublicOfferingPrice",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Offering Price",
        "terseLabel": "Public Offering Price",
        "documentation": "Public Offering Price"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PublicOfferingPriceCombined": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "PublicOfferingPriceCombined",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Offering Price Combined",
        "terseLabel": "Combined public offering price",
        "documentation": "Public Offering Price Combined"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PublicOfferingPriceSold": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "PublicOfferingPriceSold",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Offering Price Sold",
        "terseLabel": "Sold Of Public Offering Price",
        "documentation": "Public Offering Price Sold"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Warrant And Private Placement Warrants [Policy Text Block]",
        "terseLabel": "Public Warrants and Private Placement Warrants",
        "documentation": "Public Warrant And Private Placement Warrants [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PublicWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "PublicWarrantsMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Warrants [Member]",
        "terseLabel": "Public Warrants",
        "documentation": "Public Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PurchaseAgreementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "PurchaseAgreementAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement [Axis]",
        "documentation": "Purchase Agreement Axis"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PurchaseAgreementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "PurchaseAgreementDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement [Domain]",
        "documentation": "Purchase Agreement Domain"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PurchaseOfCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "PurchaseOfCommonShares",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Of Common Shares",
        "terseLabel": "Purchase Of Common Shares",
        "documentation": "Purchase Of Common Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PurchaseOfCommonWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "PurchaseOfCommonWarrants",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Of Common Warrants",
        "terseLabel": "Common Warrants Purchase",
        "documentation": "Purchase Of Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_PurchaseOfStockPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "PurchaseOfStockPercentage",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of stock, percentage",
        "terseLabel": "Purchase of stock, percentage",
        "documentation": "Purchase of stock, percentage"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r383",
      "r384",
      "r386",
      "r387",
      "r442",
      "r451",
      "r481",
      "r482",
      "r483",
      "r590",
      "r616",
      "r665",
      "r704",
      "r705",
      "r764",
      "r765",
      "r766",
      "r767",
      "r775",
      "r787",
      "r788",
      "r801",
      "r810",
      "r818",
      "r826",
      "r829",
      "r880",
      "r884",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r383",
      "r384",
      "r386",
      "r387",
      "r442",
      "r451",
      "r481",
      "r482",
      "r483",
      "r590",
      "r616",
      "r665",
      "r704",
      "r705",
      "r764",
      "r765",
      "r766",
      "r767",
      "r775",
      "r787",
      "r788",
      "r801",
      "r810",
      "r818",
      "r826",
      "r829",
      "r880",
      "r884",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942"
     ]
    },
    "sclx_ReMeasurementOfFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ReMeasurementOfFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfTheDerivativeLiabilitiesMeasuredAtFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Re-measurement of fair value",
        "terseLabel": "Re-measurement of fair value",
        "documentation": "Re-measurement of fair value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables, Net, Current",
        "verboseLabel": "Receivables",
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "sclx_RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party debt converted to equity pursuant to Debt Exchange Agreement",
        "terseLabel": "Related party debt converted to equity pursuant to Debt Exchange Agreement",
        "documentation": "Related party debt converted to equity pursuant to Debt Exchange Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r579",
      "r580",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r734",
      "r736",
      "r763"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r579",
      "r580",
      "r934"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r579",
      "r580",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r734",
      "r736",
      "r763",
      "r934"
     ]
    },
    "sclx_RepaymentOfConvertibleDebenture": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "RepaymentOfConvertibleDebenture",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtSummeryOfOutstandingConvertibleDebentureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayment of Convertible Debenture",
        "terseLabel": "Repayment of Convertible Debentures",
        "documentation": "Repayment of Convertible Debenture"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_RepaymentOfPrincipalOnTheScilexPharmaNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "RepaymentOfPrincipalOnTheScilexPharmaNotes",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 46.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayment of principal on the Scilex Pharma Notes",
        "documentation": "Repayment of principal on the Scilex Pharma Notes"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_RepaymentOfRevolvingFacility": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "RepaymentOfRevolvingFacility",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 34.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayment of Revolving Facility",
        "negatedLabel": "Repayment of Revolving Facility",
        "documentation": "Repayment of Revolving Facility"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfConvertibleDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 32.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Convertible Debt",
        "negatedLabel": "Repayment of Convertible Debentures",
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Debt",
        "verboseLabel": "Repayment of debt prinnciple installment",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r499",
      "r914"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r499",
      "r914"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r498",
      "r943"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "sclx_ResearchAndDevelopmentFacilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ResearchAndDevelopmentFacilitiesMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Facilities [Member]",
        "documentation": "Research and Development Facilities [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and Development Income Tax Credits [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationScheduleOfCashAndCashEquivalentsDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationScheduleOfCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r177",
      "r211",
      "r239",
      "r640"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r157",
      "r643",
      "r669",
      "r670",
      "r680",
      "r717",
      "r825"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r246",
      "r247",
      "r248",
      "r250",
      "r256",
      "r258",
      "r346",
      "r347",
      "r489",
      "r490",
      "r491",
      "r520",
      "r521",
      "r540",
      "r542",
      "r543",
      "r545",
      "r548",
      "r666",
      "r668",
      "r684",
      "r952"
     ]
    },
    "sclx_RetainerSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "RetainerSharesIssued",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retainer shares issued",
        "terseLabel": "Retainer shares issued (in shares)",
        "documentation": "Retainer shares issued"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_RetainerSharesIssuedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "RetainerSharesIssuedValue",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retainer Shares Issued Value",
        "terseLabel": "Retainer shares issued",
        "documentation": "Retainer shares issued value"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_RetainerSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "RetainerSharesMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retainer Shares [Member]",
        "terseLabel": "Retainer Shares",
        "documentation": "Retainer Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r739",
      "r790",
      "r796"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "terseLabel": "Net revenue",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r242",
      "r280",
      "r281",
      "r297",
      "r302",
      "r303",
      "r307",
      "r308",
      "r309",
      "r345",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r554",
      "r636",
      "r882"
     ]
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "sclx_RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use assets obtained in exchange for operating lease liabilities with lease modification",
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities with lease modification",
        "documentation": "Right-of-use assets obtained in exchange for operating lease liabilities with lease modification"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_RightToSellMaximumNumberOfCommonStockShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "RightToSellMaximumNumberOfCommonStockShares",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right to Sell Maximum Number of Common Stock Shares",
        "terseLabel": "Right to sell maximum number of common stock shares",
        "documentation": "Right to Sell Maximum Number of Common Stock Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_RiskAdjustedNetSalesForecast": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "RiskAdjustedNetSalesForecast",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk Adjusted Net Sales Forecast",
        "documentation": "Risk adjusted net sales forecast"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_RodmanRenshawLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "RodmanRenshawLlcMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rodman &amp; Renshaw LLC [Member]",
        "terseLabel": "Rodman &amp; Renshaw LLC",
        "documentation": "Rodman &amp; Renshaw LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_RomegLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "RomegLicenseAgreementMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Romeg License Agreement [Member]",
        "documentation": "Romeg License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Expense",
        "terseLabel": "Royalty expenses",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_RoyaltyGuaranteesCommitmentsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RoyaltyGuaranteesCommitmentsAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Guarantees, Commitments, Amount",
        "terseLabel": "Accrued royalty payables",
        "documentation": "The amount the entity has committed to make for future royalty guarantees."
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "sclx_RoyaltyPaymentPercentageOnNetSale": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "RoyaltyPaymentPercentageOnNetSale",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Payment Percentage On Net Sale",
        "terseLabel": "Percentage on net sale",
        "documentation": "Royalty Payment Percentage On Net Sale"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_RoyaltyPaymentPercentageRelatedToFutureYears": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "RoyaltyPaymentPercentageRelatedToFutureYears",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Payment Percentage Related To Future Years",
        "terseLabel": "Royalty payment percentage related to future years",
        "documentation": "Royalty Payment Percentage Related To Future Years"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number sale of common stock shares",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesAndExciseTaxPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesAndExciseTaxPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales and Excise Tax Payable, Current",
        "terseLabel": "Excise tax liability",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r843"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r529"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Leases Supplemental Quantitative Information",
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Benefit for Income Taxes",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of convertible debentures",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Liabilities and Related Valuation Allowance",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r75",
      "r76",
      "r77",
      "r78"
     ]
    },
    "sclx_ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ScheduleOfDerivativeComponentOfTheObligationIsInitiallyValuedAndClassifiedAsADerivativeLiabilityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of derivative component of the obligation is initially valued and classified as a derivative liability [Abstract]",
        "documentation": "Schedule Of Derivative Component Of The Obligation Is Initially Valued And Classified As A Derivative Liability Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]",
        "terseLabel": "Schedule of the derivative liabilities measured at fair value using significant unobservable inputs Level 3",
        "documentation": "Tabular disclosure of derivative liabilities at fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of the reconciliation of basic and diluted loss per share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r147"
     ]
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Summary of identifiable intangible assets",
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r454",
      "r456",
      "r457",
      "r458",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Options Outstanding Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r81"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of estimate stock-based compensation on the date of grant for stock options and ESPP",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "sclx_ScheduleOfTheOramedNoteTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ScheduleOfTheOramedNoteTableTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of The Oramed Note Table Text Block",
        "terseLabel": "Schedule of The Oramed Note",
        "documentation": "Schedule of The Oramed Note Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits Roll Forward",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r821",
      "r917"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Estimated future amortization expense related to intangible assets",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "sclx_ScilexPharmaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ScilexPharmaMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scilex Pharma [Member]",
        "documentation": "Scilex Pharma"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ScilexPharmaNotesPrincipalIncrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ScilexPharmaNotesPrincipalIncrease",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scilex Pharma Notes principal increase",
        "negatedLabel": "Scilex Pharma Notes principal increase",
        "documentation": "Scilex Pharma Notes principal increase"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SecondInstallmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "SecondInstallmentMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second Installment [Member]",
        "terseLabel": "Second Installment [Member]",
        "documentation": "Second Installment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SecuredNoteDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "SecuredNoteDiscountRate",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Secured Note Discount Rate",
        "terseLabel": "Oramed note discount rate",
        "documentation": "Secured Note Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Purchase Agreement [Member]",
        "terseLabel": "Securities Purchase Agreement [Member]",
        "documentation": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r309",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r379",
      "r380",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r804",
      "r845",
      "r946"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r308",
      "r800"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "us-gaap_SeniorNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeniorNotes",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueAssetsMeasuredOnARecurringBasis"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Notes",
        "terseLabel": "Oramed Note",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r945"
     ]
    },
    "us-gaap_SeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeniorNotesMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/DebtSummeryOfOutstandingConvertibleDebentureDetails",
      "http://www.vickersvantagecorp.com/role/DebtTables",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Notes [Member]",
        "terseLabel": "Oramed Note",
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ServicingLiabilityAtFairValueOtherChangeInFairValueStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ServicingLiabilityAtFairValueOtherChangeInFairValueStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Servicing Liability, Fair Value, Change in Fair Value, Other, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes increase (decrease) in fair value classified as other for contract to service financial asset under which estimated future revenue from contractually specified servicing fee, late fee, and other ancillary revenues are not expected to adequately compensate servicer."
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ServicingLiabilityAtFairValueOtherChangesInFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Servicing Liability at Fair Value, Other Changes in Fair Value",
        "terseLabel": "Change in fair value",
        "documentation": "Amount of increase (decrease) from changes in fair value classified as other for a contract to service financial assets under which the estimated future revenues from contractually specified servicing fees, late charges, and other ancillary revenues are not expected to adequately compensate the servicer."
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock-based compensation",
        "terseLabel": "Stock-based compensation expenses",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date",
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities",
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Exercise price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield",
        "verboseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1",
        "terseLabel": "Dividend yield",
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility",
        "verboseLabel": "Expected stock -price volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1",
        "terseLabel": "Risk-free rate",
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Volatility",
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r454",
      "r456",
      "r457",
      "r458",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized under the plan",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options Outstanding, Exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of option exercise",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Options Outstanding, Forfeited/Cancelled",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Forfeited/Cancelled",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "terseLabel": "Number of common stock shares forfeited",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options Outstanding, Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Options granted weighted-average grant date fair value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodStartLabel": "Options Outstanding, Beginning Balance",
        "periodEndLabel": "Options Outstanding, Ending Balance",
        "terseLabel": "Number of option outstanding to purchase common stock",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r461"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding, Beginning Balance",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding, Ending Balance",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r461"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r457",
      "r458",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Tranche One",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "terseLabel": "Tranche Three",
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Tranche Two",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r459",
      "r478",
      "r479",
      "r480",
      "r481",
      "r484",
      "r492",
      "r493",
      "r494",
      "r495"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "terseLabel": "Common stock underwriters exercise, shares",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "verboseLabel": "Share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfTheInputsUsedInValuingTheDerivativeWarrantLiabilities",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Term, in years",
        "verboseLabel": "Term of options",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable, Weighted-average Remaining Contractual Life, (in Years)",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, Weighted-average Remaining Contractual Life, (in Years)",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "sclx_Sharebasedcompensationpayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "Sharebasedcompensationpayable",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ShareBasedCompensationpayable",
        "terseLabel": "Stock Based Compensation expense cash",
        "documentation": "ShareBasedCompensationpayable"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ShareholdersEquityDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ShareholdersEquityDetailsLineItems",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) [Line Items]",
        "documentation": "Shareholders Equity Details Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ShareholdersEquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ShareholdersEquityDetailsTable",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) [Table]",
        "documentation": "Shareholders Equity Details Table"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SharesIssuablePursuantToEsppMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "SharesIssuablePursuantToEsppMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issuable pursuant to ESPP [Member]",
        "terseLabel": "Shares Issuable pursuant to ESPP",
        "documentation": "Shares Issuable pursuant to ESPP [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued to Yorkville pursuant to Yorkville Purchase Agreement",
        "terseLabel": "Shares issued to Yorkville pursuant to Yorkville Purchase Agreement, Amount",
        "documentation": "Shares issued to Yorkville pursuant to Yorkville Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued to Yorkville pursuant to Yorkville Purchase Agreement (In Shares)",
        "terseLabel": "Shares issued to Yorkville pursuant to Yorkville Purchase Agreement, Share",
        "documentation": "Shares issued to Yorkville pursuant to Yorkville Purchase Agreement (In Shares)"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SharesIssuedUnderStandbyEquityPurchaseAgreements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "SharesIssuedUnderStandbyEquityPurchaseAgreements",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under Standby Equity Purchase Agreements",
        "terseLabel": "Shares issued under Standby Equity Purchase Agreements (in shares)",
        "documentation": "Shares issued under Standby Equity Purchase Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodStartLabel": "Balance (in shares)",
        "periodEndLabel": "Balance (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SharesPurchasedAtParValueUnderStockPurchaseAgreement": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "SharesPurchasedAtParValueUnderStockPurchaseAgreement",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Purchased At Par Value Under Stock Purchase Agreement",
        "terseLabel": "Shares Purchased At Par Value Under Stock Purchase Agreement",
        "documentation": "Shares Purchased At Par Value Under Stock Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SharesPurchasedUnderStockPurchaseAgreement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "SharesPurchasedUnderStockPurchaseAgreement",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Purchased Under Stock Purchase Agreement",
        "terseLabel": "Shares Purchased Under Stock Purchase Agreement",
        "documentation": "Shares Purchased Under Stock Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Domain]",
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "sclx_SixInstallmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "SixInstallmentMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Six Installment [Member]",
        "terseLabel": "Six Installment [Member]",
        "documentation": "Six Installment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SorrentoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "SorrentoMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sorrento [Member]",
        "terseLabel": "Sorrento",
        "documentation": "Sorrento [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r309",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r377",
      "r379",
      "r380",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r804",
      "r845",
      "r946"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails",
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r218",
      "r219",
      "r220",
      "r242",
      "r263",
      "r264",
      "r267",
      "r269",
      "r276",
      "r277",
      "r345",
      "r388",
      "r390",
      "r391",
      "r392",
      "r395",
      "r396",
      "r425",
      "r426",
      "r428",
      "r431",
      "r438",
      "r554",
      "r676",
      "r677",
      "r678",
      "r679",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r696",
      "r716",
      "r738",
      "r758",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r842",
      "r861",
      "r868"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity",
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/NetLossPerShareAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r38",
      "r204",
      "r229",
      "r230",
      "r231",
      "r246",
      "r247",
      "r248",
      "r250",
      "r256",
      "r258",
      "r275",
      "r346",
      "r347",
      "r440",
      "r489",
      "r490",
      "r491",
      "r520",
      "r521",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r548",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r578",
      "r666",
      "r667",
      "r668",
      "r684",
      "r758"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity",
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/NetLossPerShareAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r275",
      "r618",
      "r674",
      "r696",
      "r706",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r716",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r725",
      "r726",
      "r727",
      "r728",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r736",
      "r739",
      "r740",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r758",
      "r830"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity",
      "http://www.vickersvantagecorp.com/role/NetLossPerShareAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r275",
      "r618",
      "r674",
      "r696",
      "r706",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r716",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r725",
      "r726",
      "r727",
      "r728",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r736",
      "r739",
      "r740",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r758",
      "r830"
     ]
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued",
        "terseLabel": "Issuance of shares to B.Riley pursuant to B. Riley Purchase Agreement",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r47"
     ]
    },
    "sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Repurchase of Treasury Stock, Preferred Stock, and warrants, Shares",
        "terseLabel": "Repurchase of Treasury Stock, Preferred Stock, and warrants, (in shares)",
        "documentation": "Stock Issued During Period Repurchase of Treasury Stock, Preferred Stock, and warrants, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Repurchase Of Treasury Stock Preferred Stock And Warrants Value",
        "terseLabel": "Repurchase of Treasury Stock, Preferred Stock, and warrants",
        "documentation": "Stock Issued During Period Repurchase Of Treasury Stock Preferred Stock And Warrants Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Units",
        "terseLabel": "Shares issued pursuant to the terms of the Debt Exchange Agreement, (In shares)",
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r69",
      "r124",
      "r125",
      "r157"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "verboseLabel": "Issuance of common stock in connection with Settlement Agreement, (in shares)",
        "terseLabel": "Stock issued for services, shares",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Shares issued, shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r124",
      "r125",
      "r157",
      "r676",
      "r758",
      "r779"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Purchase of Assets",
        "terseLabel": "Shares issued as a result of the Business Combination, net of transaction activities, Share",
        "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfStockOptionsOutstandingActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "verboseLabel": "Stock options exercised (in shares)",
        "negatedLabel": "Options Outstanding, Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r124",
      "r125",
      "r157",
      "r465"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Units",
        "terseLabel": "Shares issued pursuant to the terms of the Debt Exchange Agreement",
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r38",
      "r157"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Issuance of common stock in connection with Settlement Agreement",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Purchase of Assets",
        "negatedLabel": "Shares issued as a result of the Business Combination, net of transaction activities, Amount",
        "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Stock options exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r38",
      "r157"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Option [Member]",
        "terseLabel": "Stock Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "sclx_StockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "StockOptionsMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NetLossPerSharePotentiallyDilutiveOutstandingSecuritiesWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options [Member]",
        "terseLabel": "Stock Options",
        "documentation": "Stock Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_StockPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "StockPurchaseAgreementMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Purchase Agreement [Member]",
        "terseLabel": "Sorrento Stock Purchase Agreement",
        "documentation": "Stock Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "totalLabel": "Total stockholders' (deficit) equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r128",
      "r129",
      "r142",
      "r718",
      "r735",
      "r759",
      "r760",
      "r825",
      "r837",
      "r863",
      "r875",
      "r928",
      "r952"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' (deficit) equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93",
      "r94",
      "r204",
      "r205",
      "r230",
      "r246",
      "r247",
      "r248",
      "r250",
      "r256",
      "r346",
      "r347",
      "r440",
      "r489",
      "r490",
      "r491",
      "r520",
      "r521",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r548",
      "r559",
      "r560",
      "r564",
      "r578",
      "r667",
      "r668",
      "r682",
      "r718",
      "r735",
      "r759",
      "r760",
      "r783",
      "r836",
      "r863",
      "r875",
      "r928",
      "r952"
     ]
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "STOCKHOLDERS EQUITY",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r241",
      "r424",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r437",
      "r440",
      "r547",
      "r761",
      "r762",
      "r784"
     ]
    },
    "us-gaap_SubsequentEventDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventDescription",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event, Description",
        "documentation": "Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r565",
      "r582"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r565",
      "r582"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r565",
      "r582"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r565",
      "r582"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r565",
      "r582"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r583"
     ]
    },
    "sclx_SubsequentPennyWarrants1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "SubsequentPennyWarrants1Member",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Penny Warrants 1 [Member]",
        "documentation": "Subsequent Penny Warrants 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SubsequentPennyWarrants2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "SubsequentPennyWarrants2Member",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Penny Warrants 2 [Member]",
        "documentation": "Subsequent Penny Warrants 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SubsequentPennyWarrants3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "SubsequentPennyWarrants3Member",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Penny Warrants 3 [Member]",
        "documentation": "Subsequent Penny Warrants 3 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SubsequentPennyWarrants4Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "SubsequentPennyWarrants4Member",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Penny Warrants 4 [Member]",
        "documentation": "Subsequent Penny Warrants 4 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_SubsequentPennyWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "SubsequentPennyWarrantsMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Penny Warrants [Member]",
        "documentation": "Subsequent Penny Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "documentation": "Different names of stock transactions and the different attributes of each transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcern"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Substantial Doubt about Going Concern [Text Block]",
        "terseLabel": "Liquidity and Going Concern",
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "sclx_TaxCreditCarryforwardNotSubjectToExpireAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "TaxCreditCarryforwardNotSubjectToExpireAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Not Subject to Expire, Amount",
        "terseLabel": "Tax credit, not subject to expire",
        "documentation": "Tax Credit Carryforward, Not Subject to Expire, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxesPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxesPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetails": {
       "parentTag": "sclx_AccruedExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/BalanceSheetComponentsScheduleOfAcrcuedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes Payable",
        "terseLabel": "Accrued tax payable",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r180",
      "r944"
     ]
    },
    "sclx_TerminationFees": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "TerminationFees",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "termination fees",
        "terseLabel": "Termination fees",
        "documentation": "termination fees"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ThirdInstallmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ThirdInstallmentMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Third Installment [Member]",
        "terseLabel": "Third Installment [Member]",
        "documentation": "Third Installment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ThreeCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ThreeCustomersMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Three Customers [Member]",
        "terseLabel": "Three Customers [Member]",
        "documentation": "Three Customers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r870",
      "r933"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable, Net",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r312",
      "r313",
      "r314"
     ]
    },
    "sclx_TransactionCostsObligationAssumedBySorrento": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "TransactionCostsObligationAssumedBySorrento",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction costs obligation assumed by Sorrento",
        "terseLabel": "Transaction costs obligation assumed by Sorrento",
        "documentation": "Transaction costs obligation assumed by Sorrento"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_TransactionCostsPaidInConnectionWithShareRepurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "TransactionCostsPaidInConnectionWithShareRepurchase",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction costs paid in connection with share repurchase",
        "negatedLabel": "Transaction costs paid in connection with share repurchase",
        "documentation": "Transaction costs paid in connection with share repurchase"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_TransactionCostsPaidRelatedToTheRecapitalizationTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "TransactionCostsPaidRelatedToTheRecapitalizationTransaction",
     "crdr": "credit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 36.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction costs paid related to the recapitalization transaction",
        "negatedLabel": "Transaction costs paid related to the Business Combination",
        "documentation": "Transaction costs paid related to the recapitalization transaction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransactionDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction [Domain]",
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "us-gaap_TransactionTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransactionTypeAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Type [Axis]",
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "sclx_TransferOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "TransferOfWarrants",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transfer of Warrants",
        "terseLabel": "Transfer of warrants",
        "documentation": "Transfer of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r422",
      "r436",
      "r546",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r600",
      "r601",
      "r602",
      "r603",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r651",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r871",
      "r872",
      "r873",
      "r874"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Treasury Stock [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Common, Shares",
        "verboseLabel": "Treasury stock shares",
        "terseLabel": "Treasury Stock Common Shares Outstanding",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "sclx_TreasuryStockPolicyTextblock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "TreasuryStockPolicyTextblock",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock Policy TextBlock",
        "terseLabel": "Treasury Stock",
        "documentation": "Treasury Stock Policy TextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TreasuryStockPreferredMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockPreferredMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Preferred [Member]",
        "terseLabel": "Treasury Stock",
        "documentation": "Previously issued preferred shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_TreasuryStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockValue",
     "crdr": "debit",
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, at cost; 60,068,585 shares and nil shares as of September 30, 2023 and December 31, 2022, respectively",
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r71",
      "r72"
     ]
    },
    "sclx_TwoThousandTwentyThreeInducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "TwoThousandTwentyThreeInducementPlanMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Three Inducement Plan [Member]",
        "terseLabel": "2023 Inducement Plan",
        "documentation": "Two Thousand Twenty Three Inducement Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "TwoThousandTwentyTwoEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2022 Employee Stock Purchase Plan",
        "terseLabel": "2022 Employee Stock Purchase Plan",
        "documentation": "Two Thousand Twenty Two Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_TwoThousandTwentyTwoEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "TwoThousandTwentyTwoEquityIncentivePlanMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Two Equity Incentive Plan [Member]",
        "terseLabel": "2022 Equity Incentive Plan",
        "documentation": "Two Thousand Twenty Two Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r508"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increases related to current year tax positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Increase related to prior year tax positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate",
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "sclx_Upfrontlicensefee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "Upfrontlicensefee",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UpFrontLicenseFee",
        "terseLabel": "Up-front license fee",
        "documentation": "UpFrontLicenseFee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NatureOfOperationsAndBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r55",
      "r192",
      "r193",
      "r196",
      "r197"
     ]
    },
    "us-gaap_ValuationTechniqueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationTechniqueAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Approach and Technique [Axis]",
        "documentation": "Information by valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ValuationTechniqueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationTechniqueDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansScheduleOfEstimateStockBasedCompensationOnTheDateOfGrantForStockOptionsAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Approach and Technique [Domain]",
        "documentation": "Valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "sclx_ValueIssuedUnderStandbyEquityPurchaseAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ValueIssuedUnderStandbyEquityPurchaseAgreements",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "value issued under Standby Equity Purchase Agreements",
        "terseLabel": "Shares issued under Standby Equity Purchase Agreements",
        "documentation": "value issued under Standby Equity Purchase Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_ValueOfStockSoldForTerminationOfOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "ValueOfStockSoldForTerminationOfOffering",
     "crdr": "credit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value Of Stock Sold For Termination Of Offering",
        "terseLabel": "Value of stock sold for termination of offering",
        "documentation": "Value Of Stock Sold For Termination Of Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/NetLossPerShareAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "terseLabel": "Penny Warrant [Member]",
        "verboseLabel": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r827",
      "r828",
      "r831",
      "r832",
      "r833",
      "r834"
     ]
    },
    "sclx_WarrantTransferAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "WarrantTransferAgreementMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Transfer Agreement [Member]",
        "terseLabel": "Warrant Transfer Agreement [Member]",
        "documentation": "Warrant Transfer Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_WarrantVestingDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "WarrantVestingDate",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/JuniorDipFacilityAndSorrentoSharePurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Vesting Date",
        "terseLabel": "Warrant vesting date",
        "documentation": "Warrant Vesting Date"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "WarrantsMember",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.vickersvantagecorp.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Member]",
        "terseLabel": "Warrants [Member]",
        "documentation": "Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.vickersvantagecorp.com/role/NetLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "verboseLabel": "Weighted average number of shares during the period -diluted",
        "terseLabel": "Weighted average number of shares and assumed conversions - diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r269"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.vickersvantagecorp.com/role/NetLossPerShareScheduleOfTheReconciliationOfBasicAndDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Weighted average number of shares during the period-basic",
        "terseLabel": "Weighted average number of shares outstanding - basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r269"
     ]
    },
    "sclx_WeightedAveragePeriodOverGrant": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "WeightedAveragePeriodOverGrant",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average period over grant",
        "documentation": "Weighted average period over grant"
       }
      }
     },
     "auth_ref": []
    },
    "sclx_WorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vickersvantagecorp.com/20231231",
     "localname": "WorkingCapital",
     "crdr": "debit",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Working Capital",
        "terseLabel": "Negative working capital",
        "documentation": "Working Capital"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b),(d)",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "e",
   "SubTopic": "470",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(a)",
   "Paragraph": "4",
   "SubTopic": "20",
   "Topic": "860",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "710",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-15"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "710",
   "SubTopic": "10",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)-(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-22"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "855",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.16)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205-20/tableOfContent"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205-40/tableOfContent"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350/tableOfContent"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//710/tableOfContent"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//712/tableOfContent"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//805/tableOfContent"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-23"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(13)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r176": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r177": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r178": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r179": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r180": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r181": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r182": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r183": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r184": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r185": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r186": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
  },
  "r187": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15"
  },
  "r188": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21B"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480408/260-10-S99-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-6A"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-15"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483119/928-440-50-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(10)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-16"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "79",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-79"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-18"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>96
<FILENAME>0001193125-24-078991-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-078991-xbrl.zip
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MP)+7:7 S@YI@_H4!Z)D%Q;78E3QT]$ ,;K 42MCVK71'6'\YU#XZF3U5@AQ
MQXN0&QF_%K5!+Z"_A38XU+1"[A^+W \?N]'"J)E[9D8EL+XDPTB*'X&!>16"
M7!A:;]X29%JF.:P0Z3NI#OX#Q"/K/W:LTWG=@1QHPV$84=SVLTPR+P?KHFT;
MSS+'+_ K^<DZ[.[2@-"N7O,K53D!@^=C$@)KO0+^"IPR(P<&.1(Q#!V3J!=V
MNU0+1C]LNL0/.P=:Y<+VY0P^__ D2QN=V5)"/__'_>,K!A$\6 91N<'FF<.L
M*H[,0B0,^YQ'69+GUAD:Q@ TWP0SKZ'#&N.ETW;+\9LUO68<5%>:K1OTOT<F
M'F%^4J;C7+.KQ H\C B@P)LDL4%/IX?I!.+(),U*(F#HIIT;$-ZCZ-BBL7A/
M8-23DP1>OYX)O>=)O<EPB$&-L0XD*K]@LG9KR301.H7)$"/GL424*7;XB31,
MC5]CV#G5H'8BO'P_*^= FTCXA)R8%-[.Z75Y*C*8/H7OXOG@+!1/U5F0+S.;
M5JZ$_[M64TRU!YP84N88H@4MDK+3/.7K?(R_/ %<^ZL$K$&M$O.!$'-RBX^<
M%Z0OC61:7(\3P#S ODSR(U!\)YC]"/,#D,G;-32P*L1C;QY[K?>=T#@5W166
M(!_SURLT_?O9/RQ.+,YDQO) /^.@-GNS=<[V46 PF);C@Q(/Q8^8>D#?@389
M<_(0X3!FYS9=3!0K6N'??>'?@T3 F-(EP,ZAO#'B4I7O!M/)S+H.,'VXT)_,
M4AQ9V=;?"TFN'B".<*(LYL/2AX'V+XG?###>Y[FBDRNTZ#.GE_%#R&-&F9[D
M<SH>\#5V$&;M%B:K@K%-7GCVW;NL:L6>?BSF/43$HU0[M(K2).,L1E7A8IU,
M/,RHWA0,B"3' @K1S_(R0PE8)2X'(8C*(IJJ&1E(E5T8>&FW?*P=:UHG/$V=
M@2PVD;6<P$Y4@W)JLIM<V"L4_4XH^B %*";H<5ZI072B+#MK0Y#V=H-IZF%.
M1&W,1B*+^4U;O4/)AIC3:UV7.66T<I&2=5#FR%5OY=+,*^<DYL)6*L!CQ/3
M<(8K+C8V1:4NDGKP)0[V+TB7DJ\0BMN=E[?-ESI(J*X@"X>P;-:$J\!N%1G
MS':5B_,E)><+>7;XO)H_H,LB(P,/7R,&8=@T)"(OQF$6R*/L-4+7RL" V,),
M!RJ+T5*#EI89)FS6F=N+,E J5Y0GOBA*CR9-"]TQ+/X&.>:0QH5=69C/,20_
MF:1E4850JF$WU &GIWK,0H<FRVU)2)*'54IXY>.RY22-TH%M]:@K!6!<O!"S
MW=%N<24;/$0^G!PQF-BM%?6OU:-=>5/J++.P(!V3;0Y..L6J!X$6O+#GO) "
MMX;CP8P04#RJ3TY0*,'"ARN3Q5*)5(,]$^WC\_20K*/U9 )+"GPVL<83E<W)
M\5@G?;L5V7P?WT??5KUA>.31OK,%U**E@@:(MJ"%Y46)Y5%BU $\ID!@. XY
M*!(Z3OB.H.OHY9&^KO9.)YU5Z<6$Y Y8= GG"+">>C6B5C).D8B#8Z^.M1AG
M23D:X\H]3'L5=&ZX*]HMRP!NC][WE"[[C/(I]PV7^<G2)#/R,!ZB>ZC.F_T
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MY];9%-V\V<4(]_A!9QGF;;)\0$"(/-R@3D^N@*QT0T[BY!>WY^P,9V5;?\_
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M,Y%R;46IVBW?T2PFT@#KOKUT&"&%+G0HS^*R6(HV-1]E7BB1N+XADE=-)#J
M#9$\3I4@9:C:*EFF5WU'S9G_E<#?5]SW)RH8)%<S0EH&Y6^7(<4Q;SJ^SUBT
M,#S-W/@R;!*+Z;-34#/(M_=6D6_/(-^S(]_N6T6^N76/#/*M'/D:;Q7YYA;K
M,<A7GEYY_4<0_KAU/8^_B:RL^?M]H7",1^BYBEXW\,HW^3(A!EJDBGP]<4-N
MQT%H++(?*T_E90*Y'=SR<^;SU^&#S^_F94+DU\2) O\+F[P.D!2V\S)AT@W"
M$-81Z/SO2Q*Y/H\B*G 0N<@U-A4ZBME5+ED(KKE-OA! U1O?ZP2DQDV0 JSQ
MG<3>RS&Q\M<<P"@ -[7990,/ !3&)[ *!%]CNX[_I%.EOV4GZ&1C<Z!6ORP3
MU%=)#[98EN[X*H%=MMVW!.Y\BB[LHUCY$*,^SZADW":K$FG.?\EJI2A3N<^W
M!&X*AXG.HBA!7Q;H7O#!CV^"3C0>OWI:G[_YMX0*,D7K[7#ZLOV^)8!?\YB!
MO"I"XEX_O,NV^Y; ;;IW/&?WCDW&C+FU3#89YD^I2/+Z0&DJM*VM0MLFHT'+
M<<C\Q+PKYCIG?IN-W9AY"[N7-QD/%O3/SCR"MX0+4NYQ5!+$6T*"\KV_;N@W
M->@WC:5VA:!N/@#4S=6#VEAJWQ2XC:7V38';F.?>&,"->>Y-@=MX8I[/$[-A
MJ& LM1MCJ=TPS#"E!Y<59_K:2P]N,A8_!0F_=VW7X_=7<&&,6.F]J*+PNN+
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MP,TA74-?IA:OH3QS:;YZHC:U> U1;RA1KZT6[X81M:G%^VI :>JO/G_]U9>
M$J;^ZEM#@];U'T'XX];UJ,1-61I3MWW^^]1/FXH"L@I?Z6KIM_G[-=!?"/IS
M4[Y>0BVHE:++POQJQI&91#.,$R9&_<UWXRD8Y(53V*'C>@ER\RP[LW-O>XG#
MG=,P&&$>5Q*3:G+95V67KV2!MR^3\@DV%7E347>5VU8OF0^#MX21KX'W&>ZS
M8-K6M>OQR9L0CF9N]2W!_"+PE:IXXH;<CH-<[L(;K6U7>2IO"35F6*J37L3_
M2F!K5]SW)V7F,\EBY4^7X;4[&&XLNTBY?_6B12CHK'T;6^QRL*[:Z6FP;N58
M]U;=>F\+HQZ$1Z\/V!4$M?OJX3Y[XP8%HN9;18&F00%Y$HVWB@(-@P+R)/;>
M*@KLO3T4:,4W0_Z5A3]X3$%%K]KJ-6>S;PGN-R%G41).1'Q$R/L\#'FN,M5K
MK^@WZP3>$B:D6W]S-3W+=OZ6(&\Z\JZU(^^&05^E_+=A++/E3AWN=FA'+<<)
MX4>X(\6'38X$A45_G+=J'%.ZXU<)\E9TZ=?WON_61>OMIP;M;R+0UQ.R_C@<
M<'V - QO4AONO>W=;,_RE\=#]4!"=:I/1(Y[#X,POGE!!=\K%ES1'V+E4 .Z
M/5@JU(X-U-8"M>-E0:W1^-XX).X)EV;ZV031KC=8I+G=:&PW#A>Z/PMCGW1_
M5D#?! B]8I@CGS:4OD9*STE).3@^B7/7=[\WE;J3?39]E9XCTF]WN[FH\I,;
M^S1]=_D((/IC?X%G'#0H  Q(@Q"IAS 28%]HE/P;EHOU!V\4>Q9^?^Z8,K%R
MX<,V"+PT!+ZY"PP"KPN!T\,V"+P\!,8" 0:%UX;"V7&_)20V*6HF1>VY,/+@
M>_-0863Z^?LUOPV\6SC%=L@=-SYEMNO!5G*V_=POFXY#9:O-_'8S-KMJJ!]L
M-Q>S2Q3&/MTNT?S>;*J G=&# G4>G,%8G?>RB3BS0,Q/Z7D]X=Y<0[N]3<C4
MS!G6&\WM9G,YYIE]Z8%N A-+/W^_@@T7;M!3%Q@\/X=[P#GSX84#="2THHC'
MT9>)*!.%IR.DPR ,X?F<!E.1];:IF*RUQ5MTVUHHBWY\2T# F6<G)-/<B:_8
M(ES?USSC<RS"N;%/O6\;>PI5T\_?SUT;CJM<=\' 4A!?6#A!IJ-SU>M@Q ?E
MCSK</><#YG5$#,.&XB=&4$PMDU!AQM:6P0NKCE2^_:$O7@Y"'FPW]A9%2'WL
MT\,Z#"*^:43,QY;HJ/6T:SF-4 !>ET4K=+GO!N%%$//<U7P>^(/X!04JE*\W
M!6QQDZO6(_0HA7EZA#[V:;?9G@;A]+/Q<Z[=*;;W .CO+0OZC8:*!J2(!A49
M>!6ZMS#GE<?LQ:^0383[ DPZ"_LNV_/J8QH6A'IA[-,%!N,#7ZL//!^0IAO_
MGAQ&V*A_;\PK3K*)<%IW?8^\Z:(.!+42$%15ZG@I(%AEL8L5@L"8OM=@^BX&
M0S>7%)QUF.6B9)\-'-?FPCA</!TE-_;I8LAQ*H;(=.M2;\0K33?+;7FUM'J\
M3(E#@]K3HC>,'>%Q1J<-%FU7A6CS')9EE/8]5^?_=6@U"[*6!S@"EX-U,T[Z
M92+<(S/@WS#./2QSWJ!=.=HE/5AL6=$]@W9YM)-&W>GC,CCW8%9'MD^#=(LB
M7=EY&:Q[J$3G!1'HNWJMK9QJ7U6MZY&BX.O0->;5,*L\U"6@Y_KUG.4+NQM-
M$"O&:U,K>LFUH@UAK$D^>5/8NH8ZU!O,SQX.Z[=RM1O>]1*)P-S/K^A^WF1$
M,][2]7B]EP:_#'847&L\:L:C5N&>/WY 7NGQTO)*R]'S-'2C^ SQWO.*.(G@
MPI_"1$/(UQE<.+U5B2SEYV,P='T8"H<1^(Y!T4H4K3@@@Z-KQ=''7_(W0S=<
M'+]?)(J6;]%@Z#HQU$B2KQO"7V',T)M\89$K=X\Y77A05VS",+W\J;?C2T<B
MX@J% Y&\8OKP-LE.8=CALHG%1(.9:+ 7@ZQKU-%?.HM_/GW>,/N-I9]U6A!>
M/0&MSMI@*&B3*6@M%&%L(89^7B/]G 9)& _-#;0<$:[\, T%O6H*<F^YH9_E
MT$_941KJ><W4LS;YK>O>OV[IK6R#AG9>!^T<?J_O:V5+Q.?O_TKP\$_<<5D(
M7CD1E-0I5FUI6_9?B1NY+Z%&<>62'U0:^(DD0.^J ,&JL?!PN[Z_*!;J8Y]>
M1L5@W]O#OGQ8JHY/3PM+/5+-P(&KI9^__YHX4>!_87(S+[TH<&$[J^8,1XM6
M*B^,?5IUS[0_!+5XSWI%W SY5Q;^X/'#>D:\K.J"\UM S#R&)["(=1<V+"!;
MKBO#'&3+C=TD9'M;*/6"X4[BQ_[W^IZ ]\U=<#,,DHCYSLT=+'\"7X@X@3/?
MQNW<8HE=7Y<U\.\+-MI83I(&-.36*4SS#]GM:N___>WZ<FJ^%P#ZLIC^<Y:4
M73\(#+4]AMK>*A95%28V6+0V+%I;;>4E8U'C>^.PZG['AI]GOI.(LOFO&E&J
MMKI:4#:V&\LIL]RHR]+*V.VAGC99*R6(T=@+)ISG(BI?-6SG[GFETGL3JZ$O
M6(.9QBZKF5E3H$0#C3V@LAW1Y^\G_)9[ 4R4<^!4M'^+ODST7V:;"KY?A0$0
M4"S?0 K4BXZ*7D/?Q\7/76)W$7PK]O[,!>DJ2:<!'+*Y(.F(L<VCS2:=2CGM
M+9#.8A*2(1U#.B6D\]H(Q&#QAF-Q\QA%Z#V!Q>+S]^O &3'_&LYOR.[./;O*
M7Z95>^K<%C"T\-,F1X_-ZKM9=A!+0,7*TZD8L ;Y?8_PZG@A^;TP=A4X^#I0
MR\"[W!IC>,U;XS6:0:B 34^W[3V%:YBF30;#5HMA&XTPKQER +7&0299R,\&
M@FN1+!H'BTL6V=@G2Q:-9NH4: ?^+0]CM^=QC'#, KSGA9-N,KAG!\W/V?(*
MZ;:)\3B91?_I[6B;:=BF@>,:X;B[*CC6'U5+?9-!N(%%P.NK@U[+<2@@G7E7
MS'7._#8;NS'SWA(D9Q[!RX3J-8^9ZW.GPT+?]0>+]\UZ!> LW_O+A.,I<\/?
MF)?P,W^<Q-$YFK%W=6"F [Y,TH^_PCFST!Y.:/BF0W71'4R-GSZ2EPCCAH'Q
MIL"XL3H8&WZ\1GZ\0C@:6?<E0\_(NL\FZZX,JDW#6]?)6U=F#VH^MH[M*X#B
MP^K1;C(,S?WXDJ%G[L=GNQ]7"-574@-L<SKEK= G8N[ -=V!*_.'/*ZW["L
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MP?;>;F-J)\MFP)N "Y)T:A:H!%Y"U\U_W3$<F\-K%#H:<X^/\40MGXY4'\D
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M@UPE'JHER;/B<^4-T%9RQG0:5.\!D_YQ=RPM_24* 0C:!9P6Y?>I0$3V;B>
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MRL_G_?J1KNA6D29[M*R#)AX*WVG*Q<C#$*7Z>.K\BH)1RKBS<+),<L7+$ET
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M!$94'8\@"BZ0'8\"<9;N2FD=%*^79[=(^_)K>)-U*L8K&BT+M+TA/4+*%+G
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MTFE7YUKN=&7HG48CB-)I[@&54(DBXX,S&+L^C,UP<<'"?85Z?;NF9*K!V^?
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M$/(1T+70\$A,WI97+YXRLX=*XG)"V(1HH25+\R"H1YS'4E^UX12HO=? "WJ
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M$962UZ^;]#1[C^ .$DU2/I@'.3V'41.BKA7@5LWZ K<X2TA49<!S2'6K62W
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M=T %,&AG/D O G];.HJ9EYK$T-V?.P>T6%'V=DH>0B?5'<T4>B,\T S(\\\
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M\"*5#%78,+5X&%&G@ A C$9<36L/"_8UF#Q#''_J%6AG]8\?48+@:7S"MRZ
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M<#PK'2LB*>1FT>>A9_06^WY$N5YJ,89O<)$.28U#@N+5>%R3OJPSJG#E\ZS
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M#'!)NW7@E!/9\ ^?<^3ZJ]]7LGFQU:9NB5Y@UY=C.38'$IFN&@Q$Q=I4K-:
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M=Q0Y!X\9,9Q%Y%W5UEOGHI)A_H2,EG(GSW@UJ[*:5''\RF,6/=TGX9+KU@M
M'R<O,SP1C#11*G2)6]@H\&32.O]T_1?3+1$)C.!6C>ZY?"5>O:CFC95D2<HA
MWQ?]G("!+7D Y:N+F-/(>YA6)/I^H(:3>TA+M,<&2M5:I4>K<M=%O\U-_)T7
M%QF3M)OV\,G_?5;&,":L8!"QJ^%8N2*.0X'L$XZ>:38Q_QZT5O+RRC6T[6-_
M3^#VRHB 3_N-] "I5/=X4_-E!E<A0GDB$9B,^C[28L:XF+%72>P)/!YS3WH!
M!=A0[#D1E@%6FX5'F]:)D:"-!8:(AQ^F&#\Y#\3)L [F0I%+O68;_;?R8>I#
MSC&AI)2:\>/!=KS(Z>E+64$HBX1H^S@]1;LY1PY,L8-,N(M(5HN[W^PB7=!#
M>1Y8^-?'N'L7'H2H0TDG (8I*Z:6EVF-WE>!>1>[O1 QS;%!A6I#OF L;:B[
M66ICWOKMK-Z4:2*S'\14)#\'L2JVH^5$6AJVNVD-3&O@?M9 624%G-F095^)
M3:D'LB+9]QZG:6!C5T5J%:^F:,US9;.Z]V'RY^K:4:G"<*V:E7%C%6B-,E(P
MV5KU85K6T#^IS:)]10)=J^-/:=:I3==R,I;I8'%#YDT+F9(5*QF23'+"^Y$/
MP5P 01W>H,].'WT51[V7?A#>E!18T]'WX5512,TG]UKF$;D_*BBK^:G2^-]$
M102?_S!YHS98#=2F6;+FB,_I+[,-W#!YTQ3@P96;/EBRQPVM.W@,3O-)E9_4
M*M!1H\&2<!&2)%/7']+^-7""H/"ID10*?T7%SM+?#W?ODPG&.<$XORR,\PL*
M$]:NJB\@N%)$'O)^P%>S2![!Z[AR3I](/6IN+-9OL7X#)@I;2I^^*Y._P"82
MU+U8Z>J$-B-V$XQ9BFKKM(.HR\,_S##7H (G3 N^A]<R54<M0B[@#-:TU,:L
M5['WV>)HB^S:XS+.6Q$^?.7@SR2XN_=+DL,.7.CG\[QPGV"_+_1T:L*&AU??
M>4>H#-+AR(I!#ET0(]6<QB9KY4V_/TK.80Y>E&U5YA5<"O%A[[.B2EX4* _U
M$AP">+$RS^0'3TZ/3D,?;>L*M[Y$2Q)E2CA'/_K^[.CQS6'.V?'W!T].CX\.
M-<[!Y[]V,]AI4"=D4:/1PN5N2MI>7U\?-C03(K]T"/:CDA$)UKQS$P&@/3$^
M3F0-N*<7[C!CT8(&N77:RQJ%$KEBH,\D@+K(QF88C@E;/E;32%"+1B'@0<#[
M$ZIW3(.#"+XN*;TN)RXD$T#C77,C65_$$4Y-O!8H>Y<W_@.#TLU*.3,Q;K;L
MI?Z8@;0G)80:#:(-D:J&02%+4%(;HI&5#@2RV!H(]6*'VLH$'B;_4W44<"J8
MI@QZV=6\X^NPO"!+'48B@QGJEL%8-&T0WX*_^[J,-YOV1G.Y;-OU'__C/\AJ
MW/P00F1O@+^;6.9LBF6F6.;;C&4&1[D1 T_R!1C#IZ=GST^?'OU_9V!"?_XI
M>??Z]4\?WOSE3Y^S[=[MJ/F!,K0#N=???5FPE\P!"QY-2IT^^\.N),_ #LV?
MR Q/_A#'10<GMPV,SL?U>+4\(9):HZ4$G\F@%_O/OY(>\?%I>GKR)/W^V:F1
M^NUG,E-B'A'Y,E2!FO*66_.63XYN3%R>[$Q<DG>Z,7,Y?HUO)',)1G<DRMCO
M70G1DPA&BQ0UZTU-^?')SNYH9^K9_ORC6-974G41@]#KG)IM N]T<'+;-Y\V
M0%M:Y_B>SZ?O<&/$QM&F&YGBIQ@5CIGIH^/'<)+JUO_9WS6/O_\^/7[V/'UV
M>F8VS.A1'K'^WL_(ER+HN3/65']\^*^V<_Z>S"I;MI*#4Z.B?>HBOR)Q;D8.
M2F,Q"B%F4H RN]T6B^G;V-/G-]K8+&LH[R-*F/HU^[B3%7YS5OA+I%VB5M8S
MCZU8(8(B+!QWEKOD^M)QD]HEXWHV\H6\T;H9,5J/&]B(@G><[5N2HC.>%B=S
M^EK-Z:\\S8*T'IP 57T$L[6H!8L)=C0)_WV?G]2DP!9CV7'J-! "<8TDM,YE
M^BCXYZ2^^X2=4XVP(J!\1(J '>8X3WU'HSXN7Y!_$G!J(]=FK>-LA1V4^)5N
M+=GE[.*B1GY-^N%WQZ?DJ*E<S/VGT1W@*M30B&N'_V]XJ\/DIVQ^V3O84!6J
M<(S,YZ%AU!Q>HO(U:*IC<5FZ/\8D9._?\+NCPZ-C1%/PMRD-SM!:%H+AD2D)
M,]N?3/\VXR.EXT[_<5W5E*.?BZ0D;7BLGFZP&5**C\ 8>3DONH7SOZ2NN46.
M?-]-.D*\$7^^E6^N_[70U+M<9GG=].\3L1;W/C1@@$9%W%LWORRKHKI0?&.H
M/L OQ@J0_#5&E*VS#7X3'TPZAE&U!YRHH%L2<IIAMAF=,FO=@JY*(\_#U3 N
M]-RY?47-9;&_E_F60H""+ES1N.M+IW+OD2^?'/C7ZL!_9MR[]JGO"AK?]3^'
M*2YP"U\H0QQCNKPZK%P[5):;S6I6%;X@_/+MWTWY=[*/K]$^2,YX:>2,C4'<
MPG585>2>WYA!'%@220%2K2.:Z_C9EAJI>/Q1C#P3&T#H.>\:;>G2Y]Y4G=:-
MY["7B:Q#10FP6@_S6""F8XT'T2J/^U:H_A +_R]GR+=**.X!IZ6TR,/D_&Y?
M,@[=&X+?V!ZPQN=DB/24AKT?$(ZD>R@X,[_/(9)9Y,PZ O%951MRL77A%$1$
MIEC)D4X#I0 T\>?YX1- 1/KL27IR=K3]E/\*PN$ ^3EE/.5ILBX(EA%?$%[H
MZ"P]>[8UMX"Y"X354+ICRY7) Y3,&2^O/))I2![A&-04SL-='N6/^?/^(SW_
M/GW^[.2&YX&H"7,JC I97&%V!3N_%LYL80:V1%@*^%MYX#Y)Y8H&#;P"0D5:
MA N7HO6,C#(0M#W*\\?)\Y/TY/E-8V.?!>_[XI>?DW-L;0D<;W0YN-[I:?K\
M[*;K$4+&QN5VBALVV;5I:/T=4Y!^/^$])KS'E\5[_"XVZSO4X/[M47ZUQ1.?
MI<^>G:2G9Z<W.*P1-!_K E8-AV"X[9!?OJZQK:+T6U^\*P].-? ?9B/1C+6V
M\9N=>ED5176-%QS;>*Y%]9Q CK*?(0HW:.IN>3]PZ/]3U1^O\J)P0S?__V2K
M]0\?S#?>ZU$^<'L^$GZL+.+XC-_K1%\LJ73C*FFFT"Q?N1E<AP2-Y%IQF\_N
M)/^S:,C<)XK)FPFR,;6:W:&0_OW9:7JR.T(C(Z XII]CC.*7R'I]X":KXNCX
M:2) ]/?(EI?-74<OWB1OROEA\A,';O#?F$^%Y?V^ #?S"&\8P]CYU^:J^$4Y
MTCX6_;^$@6_H&6!\\60[3"1_=W3X]&E(L_[P=< 'II7T[:XDV*'.GC]/GV\O
M!M_?8GHN5WS'N6=:+'")M[#;SS>ZT.SJ&?_-YZR;X\.GI].ZF=;-_:V;[].G
MSY^E3X^??;%UDXSW0%'[U!Y;S^@W=.VDMUD\WQ\^?S8MGFGQW-OBZ13J_?3[
M)^D)A$-;EE"07\5\O8@S>RA36"BCIC[9Z62G]V*G)^FSIV?IT[/G=S73G?Y\
MM2ZJC7-R27^.'[KU\_?OU8M/)CZ9^'V8N*1JTB>[8:%WLW,]!IR<@J-&JB/*
M3@WLN_?99.J3J=]7R'Z4/C][EIX>;77DNT-V_+>BTC1^+D</F\>'9T<\)E/4
M/-GO%^A2^VS[C;&5.ZT8$9V3$4]&?+]&O%=!;[<-7RLRV *5QZ^VVTT?/AUZ
MZ:G3<S+R.QOYDZ='Z=FSS\P,WJ>)GQP>GYSU;/QW+1C\=$+K?!Y:YRLB'?G^
MW__SPYOS_TY>OWCYR[L/YP_.]743.OD-P7T):MFG?T(H<%5<(2HSN80W3A8.
M<1@XQW7>?#Q,?O2TU-RN:<FDE',JC1#(BCL.4&1T$ %M4AO(-;8))=?@Y_'_
M\6M#4'3#\/WV<@05G0ID&B^[0DT+Y/MFLC!%41.\.8*0&E UM10M]"#_$BP+
MH2WU)OE+U3K4A\QJNO;KJ@8'MSAX6U4?N3]+V:X\P/_-TK!8-8[>LA'-'61H
MG<.(I\@#AJT]JIHAFG8W2^6E29'_L\L7F#3>JIIWF+P(,AU[T?ZSE(<0_S/>
M!6>2_TR*O=2D57O&L@U>(%@ W-'C@8I-*OJ^].(EMCT*"2W=:^&:>9W/1M'M
MJ7;-Z<0TW7I=" J4/JJ:]L!+D289?+(@$T1Z->8/4^*P'91LV+V3EX(8HO]D
M7!#WTE5EL=GZ]*H&"';+O6(XC?@/BXC:^6.]E5#=P[T^EM5UR=UF@7SNVK/'
M%TCJYE8(CQ9S89;[L))"-T"CJX\XXS*%E_T#GL-0/**:H+>M'F,;=;NQQ@Q#
MM4:_Z3L49  /M\B>6)?W92A]1R76WB)_,?SS':\)&*(_YT@6#J;YVK_.RTA_
M4IMY/ECJ\MLS ]_M96YRX+]:HR!87GMM5?*\.E[RR,\T++%Z876%N;N1!ZO(
MP#(NU4,N\[IIX;K%$M>X@-]8F)C&B!6)?P 7U:I0J'D<EUWE9*O*$2TAHGF\
MIB,N1;RZZAV#OQ>AX[S1Y\C+O!6#NQ!@^:#+44CI/39Q ^Z-WP;>+!8>%X;L
MF55CYM;+UADE9)0M=&4GNDIKI#7L:;+L8>7W8!??VC3364!^3JH4T?C*H'[A
MB29)+^7"AE="\";\R,M>;].LE<=6)FRBV5QR!VM75^L,1G4.FQ[N$$U3S7-R
M,C3F[__\%^T]R7&WQ4"%6L1QAVHNP>?@2, @7#FZ@#?%&4039?2>Z)_D061<
M_EJ2^Z+P@@;K'41)V-^";T;OBN[.OO#)*;VP%SGAH4ZQT]F+_-&\'^ 6G[2P
M.7#LICZ?=KT;Z5E?OWIQH&*AJ6?(O.E7-WX!MZH-K)^#KG%^B?'%*VR0;JJB
M\TKIQ)P_[UK[%C#PJ_RBSBA\X351T_]78,-95V<IA0<+#)92/\J'Y[2%>VM2
M^RR3%Q I%;(Z3GOQ%'*X-J0$D\]1!PU%+<">.@)^PTI49M1(\TRTED7)E^I/
M&N8P]:JH:R R6[7?Q";@3>3!J&$?I8XUGD-JVG5+1:P,SM47R?IRTX WR["]
M!59J@0(;1,V>;2C*!HO.HZT>.Z[F%&&N5AU8W<88]1RC0VKYYEUUZ,CIR6EE
M%K+CHM>I<XJR7'F17<AAP_R4)#R"ZHW^L#:JJ,+S&KT,C!7N@C*:]#J'VGEK
MAL'O+,:3T7^&: E%='C*K;MD?T9R!IEI>_/G$W_ ^./OG\-QRJG=9T[-6"><
M0JQ1K[)_5!I?D)3&4F@6U,IEL8X9=;J751,7>I,M6>TQ')R"Y_R\K6^JITS+
MXH[+@K9QQF60WG?*3-YD^#YDH?94'QS"?H;*-;$%1\D?$HIB67'\$D6A:,82
M+T]F.YGM/9BM]Z.E'&8IG49''Q;RPZA$J.R0''\RN\GL[ME;\EF9D>^PS2_<
M/SML1<%TO<M7LZYNG#_>+6'@:_,[S *3&F558.:C$7Z/>G& Z=V-1-?,4$5:
M87RE#DY3G"^>['FRYWNPYS9?21NS'&=S%-O#C5K*-%P$0N8+A])#5V[:R"<+
MO$\+%'."@]/,$>$BDBMQ!8K^#L,,C]D$31SA9WS]ZL4$N)FL\-ZL$/.'E#,C
MY2<D^92M&LX_KD8$#8RSA)W[4*_O@S2X547B#59+"25?:>Y/V<5"'MOYHH[)
MNVDNPK,Y6'K-/>H2RE-:.BYEP(]59FP09^/G0G%)%)1Q3I%9'-;\?T)D%'WC
M,'GODS-4,2*J-"D,5U2PI<IU_S7!:?BW9'JVJZS.'<\@+^5O$I+T;((D?660
M)-)TS!IBKPI)#Q8C9&9>W^BB+#&(J1 GLNYF&/!CJF4-:Q9I?Q>4' 1+)6H7
MNBJ?)5KGCQ=,M6H/%:%R-KH&)*/8M;DOXC%W,M<L987R;LHA'IX[<B*292[@
M0-8RS^MYMVI:)BG#;F-<D7+D%G7FP^256W$VU%?T</F*+A^.F"-@A?Y1?<0R
ME%;,\U/6%/;[^4>4ND-8DE9OMI>3]3;T6*:.3#J3>+<14 >[P</D)_@V,C-?
M.W:MC(R1*S*B:7N5 YY;WF;K-T><<2IYBIQD#Y5_'V\X](K#6LS8 ,!/YU1T
M:[J&I?SDO7GFEWDK!]#/4L"\U1)!_E8][>*&H<D:8A6L5HCHVK5/T6Z3%4TE
M)2&BZY03,VN/6@@2([7"6JSBF[/1.^:<C@\R.0*(WI0>-\2RDF8G<_!+7(>C
M93HIX T.[8*YF,&#+?,V0EJ,O2PKAU-P"S'&19DOX38$A6C@:>:.BA0TU0CG
M:VNNIL.ZA0A8-,XY82N9!!HKCIUYK+6"3TL/ QN\5H@@=EK#EP$,[8&QH8IF
MYDN3E4<173**B+4 \$LP\;B>%]'@%15)YL+:G;-#P/\@O@06V2PAY,S7/+7L
M%,CFZ%HJ;>L6>ADMT.#&V3C'78Q407Y .,I-(P*A4\1>B4"%YVD//L.RYXAE
M[!B8PGJJ,5&1UI^1]0LQ%>P-SV'\B#T3+WS"=.(HO'K-6JR7%6$KK]$XFVX&
M>T2>X4.]*:/'N=88&EDC#.MZ3R>9&-(42''N5B4B-L>>ZK^ZTN&E3P^3\^%D
MIQZVLJSFG9"2RHW4F8"O7"[5;XC"L2%'7Q<940:G":R\QM#'@\M![$V^W' B
M3^LE-R(MRJH\@+T"#FP*L* 2'^["V7J#*(1%OD#42<IML2WC?6$#] 3P30NN
M3A9^S KO<^'J \+E./IN\*22$SIF.S$]NXNRP])[1T1W$!5"4%-Y%-;/6"B2
M6YG-%F]$8)P6GF;6M;HW<6;>8LYX%]=S""["WG=D%YC/2>5@28+8PWM2L _K
M'?;I5F0"LIJXZ@Y)MYCW4=IYFDN"DPT]22,; Z8=5ME'&BG\,RS]1J$M!C2B
M"#I\A:M<=QJP^7_(D<HZHH ^?8!M]TTD+CS+JW5$/.9MPDXU3!:"S7%\8"HZ
M'BW8(>89"B_DI/8  6U#B[K-V,:[];*&!QG50^!%93<R!)D+(?'&+)2!A?*,
M+^%N?(I<\7Y'JM,2$(LP$>6(-,:B! V'T!3F%!!I$D)G#'&&#P<O5ZTL*!)>
M'B>R8#@Q/84KR>[ VP4DL<<;X=);XIX=HD@&W-"^# 98; X(3S<R!VQH#/<'
ME[+.%W@%!/ZC32YS5RP:OSPBQ)T9D 6]?HAQ\)A [P2V>;GMB6W2@!>'#=%(
ME=R1?S0(>%AS"V>5,@*<L+D!K[,U(IO0.U."[E8)NGZV"XG(T5(O*A*4NFF_
MA8WS0#=)W7%W;:"4VV(Q]!$/PM&@!1G2L=?C"7N;[E0EF<S_CN:O82;E4XW,
M#^Z"-QH_ILK@F%MBY.KQO 2LQS/L5$B>#/2>_7-DK5L.(:)X $%AU8PY3:Q"
M5_?NV"=+GRS]CI:.*8"HS7#980!,XI18':/ G#6J2/S2G%"HMW RP<D$[PIE
M;^$$.&^E]9BB5'O^A&O </LD#GC:O,'PM779:C*_R?SN;'Z+14@G8Q(T]"9+
MTE#-+R(.V#2M6TFAPM4-JFT4MF;C_V@[/W7_3C\O%(@3F'1KS.4Z?UH;T>V4
MT@\Y<9\TGY;-M&SNN&P$96/;]S3;/9ZLQVJ'H\)\5J".+I,K1%EX:;+$+TTF
M.IGHG=,,U C>.JFP<PET#(=@2]Y$#I*[NNF5C/0OE, V5O]/5"#BSM. 1[$G
M/W.)!97L0P3M>Y/@(I1*)G2#"AMS8C"G<Z67<'K]2G 6C'$QZ;S:<$QL73S?
M)F;L^809^TS,V.3G_@7\7.,BKT(H($[J;\E622W 8_'X7"4%R1XJCV7I^Y"@
M:7>>K/;.'>R7.6QWX_#"T0SJ#M#:8!LW[68(,NM6%%).W163X=[9<!7AFBKP
MGZE8JM8)%0M\#+/AB)T//X!C-UHDG,.759%7OTFK!2&!A0XFJFXH3(+X!4M/
MN8K1$56CTQYZ0M#."BJN:@6?*""W<%\>%K03&#<*GRR=0BB%RB?\04CJGQR>
MLOW!+0NZX'<GIX=/HK_15'_W[%G_SPJGW+@,G Y26"VV2'.GK&^"UX'_@#_6
MCOAZ"-!%G$#;]<+Q1Z,?G<C++P1#U*TZ9JY;.*0A([@75?L_Y2M60O_NR?.C
MPY.1=SM]>G;XO#<.\2.^W@H=3>,^''_B8B@[=K.;"6$^!=?P>8S;<&)B-P/S
M5XR=AQCW>'B8:V0+]&]'1N+&+-SY^X/CHQ/-OSTZ/DI6%W#Q3]G*M9?8,P&^
MOEKDW2I9(YG0)0905WDSK[HFN7#%X^21*E_^]/.KG_[^(@B.[7?K4W]K'(!Y
M1C1;U9HADY2"?)R<'3[YP\V7\P]"E_7/H=>GG7&O1WKB'^G)X=GJ8H\W*:KK
M@T7E2;B2,BO:VGW"P;O<+.IJ?@EG+>S 6( I;-SB $R"^A[FV;I!./CC6[[>
M$WV]0[WE"$*:@/%JA(J5YGX+ PQ$4CHV8720DF856(VQ7)G>6PSCJ1UYR51X
M(EF'N&5XD)->Q9<<S9[3Y-\=SJ&-(OMZ2U26I<%!WH@/'P#O']SY_\KL@0:>
MRO! >!DJU3.W&#Y]SPM@_7XKA+2)^G "6+(K90Q*;RUIA$),)4\SYZQ2RE;<
MF"1-5S(9J\((R?SP+M)#A1U!@@(U6RVQ_L+C($&3A,I1SXMOF<'M> 9CHL!D
MZ96A_*H8=/1#1C?"8:^&]T.$.T)/2XQ59EF3-PRD1,PJF7JE4\SE.0Q^S&P+
MFV^^6F=YW>]3X=JR!Y=KW"1HYRW>6@H6J>W)]-%'%5H91E@TOS 4>:F\E:9!
MR;ZA;SU 5K^+')PS!B':,L=-IX%&5SH!>)^DC8D<$DOW20FJO(!EGY5--A==
M3)PX.-Y?H1-;%YD(0]&T:3.!=-:8U2%]1FF";VK,DOHNI(D")K#"9H*@6O67
MK%ED_TS>2D_K!_3#U.\&2^&C7$':>8@VA,?@*VR]059CQBZ(:W7*ROL2&_!:
MHPW/C4L-N-JYL#:K?6D0$=$OT@!RT)(UEST]L#Q"KL=6_.#<K[_L?&VK-[;U
M6R%R63!<F\83FU5$R>RI!K@SUUZCNXPZ<+A50R_^9V*1)!+)EU6]/HP>X<6/
M;Y.W&$/7X9Z(5 7G+KXSOC+MW3/TA0MG)J&HL./:7OB#!Z6_AH,R>BFOG4PT
MWTEV 6][08NKQMUDC37@%75KP+NR_.%WIT>J.Y3:529-$0J3X;P#HVK\VES*
M;7&UZ$)5'TVU 8YC8:_FMI#A"/HZ "8U9%O#?X8Q.TS^ZM?PULE,>Y=N+K%'
M%CM%Z/"*:P S*,Q7O0++PFX*8C2O\83#'6=X,7)@7>E?E0*F"]A:()QPW&6(
M+7OK-@TP9T87P_WD#H,WQ5DY?OH#&-@,CMWBH;J;WXH9S/6J4IFGDCV=%F]W
M,?+TU+%)E/;<")'I]H-&)%3WFS!D>;GE1:3G!T-&[)!&^TQ]^+APX'OS-GQ)
MRC]!L4 E!+!6"K?*"K%;7(1XQ"N#'L&.P8G:0G>_NS"Q-\D<@@EP(35%*#F!
M'ZYX!DM<*/D5=W27K,Y"C8>X&MDS4HNW\::&+:K7G6?6$5RW:ID7TGV2LSTL
M(!^L&J@:*EK,X(O>(9O/BMSQAHG]JMCX1"$%DL>BB2=PQ+S BA[&/@%_3/]>
MY WNA71FEM^MD;8A1P=$S2$UKQ2>&_@Z-X;Q<U(=A]&>T=;-JC0PA@6_&\-#
MFM1?+>P72!G1U2@CV7(@"Z.JWN6\PVQ@7O*F-.["MWQGW('['DCQXCY-02]"
M=H4AX&;@<\4/!<=#,_ "![-:P5TA@H8?N?J*BA%OW[Z,??Q%]$3D)[A=W_N5
M2_&'\79 RXF*7+I.>.WMN:8E5^!O?_/EXL&7)M#D3][%]49^\(4[#GLG38[4
M""^<@'J7W(E=O:NSE0 U_=NEXM1GSCHP9D-98ULMU9MUE>@K*CF6.AKACD'_
M/O(KG9[W^DGP4,FCH6_:8IB/#[]A/I.3HZDV_=7QF=PBY*?NR:JNB>^XT2.U
M>&1.@2BT#H]NE&"V:4RE09EKDD5+K['JSD3T/56;/A.@3YD"C#=1R"?>A<7,
MY#!NMP7J-L9"*<;;48(/RU!RH.53*YY4\#_P/L08UEK"63:P(.HDF343NOOH
MMQ(YBG!VJI9</<(PS9,=T#JJ'3&84%2XDJC7G]S@'MB%8!K;;3>V!=E>5_7'
MB,!@:_LVCQ%W_!:&I6'=U1CM38"&::7>=:7J ?/V2]6<6T:.5<NN%JP?GZ5\
M_[G7O)B,=S+>>]MF^JA3>_#W1AEU.IB$2^UH?Z'+R%<GXYR,\\Z(FX^L1I*L
M4"XTJ"1AH-TU _Y03_UAL^[,,W*Q2275HFGY"XC]P<SU8TG=(JD:YCCA4 Q?
M#10GUY>5%UNT!#G$4J(.>NJPF:S^'CIL,(FJF_T28HE<\J=8@14.+UP!*2=:
M,XX,VBJUW)V#HA6#IA8=F.IF D1.AGH/AHJ5:(YZAY24B[SQ<COL1NN@J*I?
M]* (5GU#4^4CX\RA[#+] PZAF$NF];#VR7JPX@I,?? 5. =F<T\,^K!8RSCP
MQ^,Q5@V(,J[-F^4F/D#[JM1>"6R*R+"DX<FFMQ[B4X-X6GCTFV>90US_#EB=
M*($1&0!]%R8=99(*+?H?)G^NKA$"U#_I*"2%4V5!")6O)82Y$<UK5M?HKYCY
MSC 1!!!$1248FRU 4-8^ U9YDCNTD,/D]?8WBL T@?(X8F6CK&**Q+IHZ<5N
MO,-]D:2'JIU!Y5"8OK$%83TO[C$L-GQGRA)#@CQ>PA1:Y%02H:Q;*75SM"G*
M!2W<,H,_<R&6_MJ8/VM9,15=26[T1#E1WK!8?H9N,WB.P^2OZVKT9G'UL&I1
MC-SVPFD>=YYQ44]+'8/'2SW^-&^#=#6?V&WQ>%!RW\L0Q>K1@+ "(N4:K-"H
M2>,4M A.15>Z]Q4)FY6OL"V"H;VX,D3.DO%X#[$\X=P'/\MIM$U1ELE;*9M.
M!)2PD K'='\*+TA#V2H,*-L8(8V0R0\A>'-'EQ\4W</\AMH3?PE+]!T) <1/
MI)V3.&2NEW?,VWV]2M8H*(61 6N" !+P)+OF!3!X(8$3Q&^%=Q+$Q":Z)!]L
MYC#\&[2-+>MRN)& :WZ!6%7Q%8/:K3\S]5W(;1$2IB22A<25$EJ6O1)(H%68
M1QKI[$FX<7P_.-]7@B.3JNM?*@7C10= '8"0Q*8-U0^"">@?"@7VKMQ6=XZJ
MV/)>+XN*R(%?P:(*1>QKQZS^[+X:&#FT)"U @W&7.6$$N>*,V!_X.K8GESA,
MZ)N.GS&BJ-'>0L<<NUA*:!#U,/>EMS$4UG?'1\?ILZ=G", :>VR<#@_K6F_#
M49B*!GQG3F#K+$19+J[#FR+[7F7\&!1 B^] 'N_\O>\!8"=AK6B5<<&B$H;I
MZ*IG2E MCAT'J<D_F4'"5 5L*.)6_;+FFK_Y<.?PGBFZ#3F<B?@I;CD)4 6\
MA$ #]KWXL;WZ1N.KX;L^\9M""5$: FN=BUZ/ 1&[;G5R-'8KQ5$8W*+<,=TR
MF4]&VFX&3UEDXR.,Q'&U$]@T4U[KH\ZR0IL=!\YDU]"<(9!+*F[!2=N?PRY;
M(YDMG<6618=]:*U0TA#2>Q5J=E0#P\9?CYEO.E*<?W3\F&][@?H-3(/[Z)/\
M;4G]-*CV@="C)W]X3 /Q:",?_P)>,CE_]_K#& C$/*G\[$1^1LY8V,8<*_;X
M>SP[//O#X]2/S#XDD1]AW_?\D B<5ARCH-R_=. >8[BB%Z<#!.VX)N2S9=/!
MG(*#DJ.)*RG8RFE "4;)O)GKB"J_;]L8-W^"S7OIR.*^.TV/SKY/3\Z./$J(
MXDA)GV9UJ;+,TOLU^A+?,&KG>$+M?'6HG7]C@("'K?4.,@HXXV"A%#C!]E44
M]H+^8J(]-"P@."'A,<&O#UQKM,[L:I#S)]UNSCS)HJRVX*.&@+(1'*Q^?>2P
M.NZRT^02 BG'8NU4XH!@I4S.COZ@CQ^0Z5U)S[['>W)"PQ4*4"?Z>])",N.E
MA\_QK01/?[2;A!V#=A5]F^'V@<D[V2WRP7:P+N#@L<R7+8ZN]^W'X-K1@SW*
M]1?4YY]]RE>P%S%* T_-;>L;5/JGK2_MR_$\=545,%*([5S3:7>EZ8/^H+%]
MB#&R3\:OW+AGP:YW@ W$H3&PS!%<AK>,;V-#<ZI&V7:BF6/K;JL+IMOB*BZ=
MP@]0U$23:&'BK*%Y:XJ UC+YC/#FLRS;1;4E!&LJ'J9\L<6T!L$_G=7#T(9N
M*HHO0[9*PF3, >!/J4UN9(7;7$.W-76$/WPI0AEY$XTCIS2VQ9>#H*NE(2X7
M3,84+1#X^O')V1_,2_:N]RB>*]P*: 9HB/FD)<O>S 3\O\K*X)JFG]OL*)&]
M\^8]?-Z1PP<Z+ZQVFK<PLT&)B88.MA:1YDM*/4@+'/>KHB!0)0?"68VD6E$4
M^0+&H>#_-'&*B2/'O?V+D(U]8S,[-\6:-+W6[Z<).L2GP?:1$H"RZ/"R2&[0
ML!/?)"_QC^?7SJV3US[K==/]*%O&K-!A!?ST]MW+FQ^UE<6S^:SMS1X^?_9S
M^3[,);U).(5^:>>YU=#V:"F9Y?S>6![98FQL&9IZB7++R A#8H7;?DM.B/DB
M"&#0RQ02T!VOZ$K51,2>6;Z6$7>"Z5A4\TX.WC30HOL+_\WI!<I&0C3W,7R>
M1I^FOA=E\"AT[I$++MR\R&I?^/%=*:@O2+AD:O1T14'_02TH2\=OIZG/:^Q9
MY2X74<K6/A?!6< 7,1[AQ_!=*=*;P'_=W=XB2=WX^W"+MA#0M69:"$?$AW)*
MSV<-AS\<>2&O%38#XT&?KSC2;T?4><O0?6V;AO GLA#@T/<1WE$;I^RE^PMH
MZ!HI;^O--EAG\(1V'Z&,M[0Z8T9,(K<%'#S+CU[^B7T"^F=\^BUM@\3A)0A5
MG"AN'],;;E_<J7FT\Y=O_Y[\U]_&$KX-_ IW*+)WN 0V99?:$LS/HJ^:<R?5
M=JOG5*[>-%IIFY0?XM6'GY(_LV%11U :#15E]^'FN%91OVJ-!@W.0$U1]*Q^
M0W^E)A>:XD9J2#Y4X0P<)NY#HS75NNJJ:0XT0,!*.&-"V1)H1XB]$#'ST'>B
M3V!I2C<K1#:FC P/HSD;.D5\=QSZ54EX%$M.S?CAA.*DY*6OQKV4:MPO8:WC
M$V$1%9TB5@7L1X_L8DY'NA/C".1<.D1)3HO)$9(V!R?A5^T>LHI1/<MV&?KV
M?&[BP.I6Z1 CAA/G_=$P="S9L\I8C%0FM8+4'SZ)V]7%],IEECP:'4*]\ 6J
MP3R$8.LF7V1N,"RW]A,XO<HG$Z%R_8XJ%2/E'Y,R9TX#:8?7EKE04-ZKNTU;
MPV4_-GUK]F$>V7/@-94?6;S4I^JY%3OJV,8@^]2G?!O8J=EE@E>&@" YY[V7
M]RE,AB''4"-DB902.SH\.J84*?TVBJ+>NQ+6X*_R)+9MD94VI2(2"B'K7NYO
M4 -(>Z?='6_YY"XO=7Q\>':TY:U^T>  'FG[N[7F6[=X09S4_^!#O7W/\5=@
M<RLVNK'%XXTK;NQ9]XX=AAO\UPS:B+>>!\):F/CE09 6-^,>XKK8?DB'_G9P
MS_"&433!?O@&>9NO ]<0):MN1#)$CWXS@B'<YALN#YQ,Y8&OKSPPVGY_VW[Y
M1[B<E,R0\W^R'<HUJ[JY9<M^!-*ARN@0DC.^^@9 G=O@<H;[Q,,C<>YELT2Z
M,;L'#&D] O->])DT:U/^AOAE9KFO6X9FN_"V9AP5QN@9TO#[5UV![:'A_.";
MNP.>7CM($?=0K?)YZL'TIFDV.L,+%\I]8OAQ^J/;,GW7/4*OF==U!_A:V>D&
M^F%],C3ZN=],><5Y&!7.+++RT9=X1OK=CGU2.;;,N+?G*T2+?54GTX<"F+T8
M>2B3)D0.RXL+%M+8NS(J7>/(*A3B8!XX^-/^U="T5Q +!4T/\O4!Z36[H7!V
MIF++,O6\DG+@]/$>OAP%J&3B0EQ#E5=#Z<DUWM%'VQ'5^FF7JX:DWRL9N!=2
M1+HIW?( AQZ;SJ@]"$IG.B2R]I[\WBIR)9<$?6A+(T.^RO-?BKA!B-]EX%IX
M7F5PM'4^C.SI,C?@77H$6CVWY*]"JU-?:Z0Z(^</VA4XX(8H.XUTF;OVDNAT
M4LW^A7QY<H&:#:7O"AONBD/'="N_=>@]!1>AOU;'VN/0I",8W $6-(+'?'E>
MIA%3;Y@#P62#@5J<NU79B0Q56<IJ]>&#9265IM A,[40_ZJ?DE-2G]>5HC@4
MVRB*/A>KN40N+-U7"#=Y&(\=N (C:'/,C_.^R.A=?R;2M'%T+ ]EFISG%ZM,
MOPD1>PJK9GZ8"@,WPB$0@H"LL]?HJ&R-X#5VCC?)"Q9XE I!4Q4TCG%]XLK%
M3M7.IE"H1A!<_N0G^D1^$8)\?,7SBI3/*RZYZ.+4TDNJ?D,BR. X*/<U<O4M
M&<KO3IX='1[%M.ML?1CW$:8>?0B2"<%Q7#<68H<4H(50 2OYBJ98O.DC^#_Y
M[LG@+GHF4;),ZI]"5\7N4C-OC!5697ARVAR@U=V%9@;XH?C=7[]ZX2G.__+*
M0YO5V\O02/.9+A+/+BB6#X\<XD>_= =/NN/UA?$>[0*+^%Z)+KX_%4D%F-!,
M1$Q3E^OM]&H04[YM66TST.]@VL86_!9[S7H6.[$(3&;[FYCMR=EDMI/9_K9F
M.S3!&\WV[([>=J+#F$SW/DSW^#-L]^F=7.YO073QRR6<Q\RIV]8IO"Y(%>OI
M1*GB"LN<!.U$216<.,R_"!L#83,E,4<Y&:\M'2H93/I]]\.V9FN%T%Y22-NJ
MP8;'HQG+.J3"QU$*F433U:(Y1,D<<]6N9*18OJ1[8WNI'GLB!@H^G"]A5=::
MYNJ8.SRBH?@VBZVG4['U*RNV?EY:3G+TE)3;MN2]Q0>QF@'C"AGW..]*9/ /
MTC(?B0RI^#?IB2[B=]3:@=#J-CGWL0L8F5Q,T-TR#-(DK&&*D,U:P.9604\J
M=KWTHT@E4<IJ-Y6/]"&,J.)Q*UN[32FXR+I21)KL_1GN,O*;)27XJ&+C!*WL
MHMRV9):0B(?J? C9&A4E&^P36=-4<Q9/X!1M(%8@N' 'N\\\H(35( FQHE8Y
M5J=4LF%?,.[1#C<R%&/4P@_0>;9#$)*SJMM9G*\=OG*L^WC:4W=4T;,[BD<R
M"DV*;U2BSE?27&#J%++Z8] 8S=+"X:#BHE]1M9^5TC#]NR)ORS9%*=A 5,2K
M0FB)0HO8K&O)J6@6MZVF7-\4PM\JA&?<72,44,$-]%T0^HR29'(_WSU/R9+)
M7._!7!?89Z2-M'.!1Z'EUKD32AUKHFBRDU%.1OEEC5+9)ADU)W@'G\/HVU]J
M)9TY%M/*7>(U4V?.G]OY$%]N)F.=C/4>C+690^1/4I/@21MJY&4\+)]^&CG=
ML5HK]_-VC+3'SR.=YB !-*8Z[G-0GZ$4O:?X\P\6OS.MC&EEW&EE^,-<(.OD
M]< ]J 0$2@V29.3 OVM%3/Y[LM)[.[ A@U)6=IA!X%ZIW5'&9)"307YAMTE%
MJD"K5&Y"R0ABC&J3%5B:TNQCP+\-H<J$<K6MMW@QS> &IG/J&)Q5JER.>,8Y
M)C ,CGBR\,G"[RIW%@/@/8^'*A,(!TR#II WEP@C31-1V:%$O3%2:I-"&[4\
M-=J9&[C8&:&J[5Q1%Q%U'L2\,I8R;.M2E"6SUXH,F@/#.TX+:EI0][!EH"8%
MNW:N>&P-7I079KGUE&D #A1[#Q+4*='D+:JUY&6(ZNYRT^3P'4X6=B4L[LFR
M)\N^AZU"L37NTUH#;VSG0+)BIE&UW3:3LN5D?%_D:.@)]GH!!_/<2=NGXLO0
MBV[!1;1N?EE6174QV>ADH_>T]0M;PU)[\XGN4\H?K*L]:HH<I KQ@/&BDUU.
M=GD?=EEVB#QBK[=9<^5.3DW>/*\]MFP(%9O,<#+#NR+J#=BPR#V:6P_H17;=
M=+DR&@:.$S7/R0(G"[R7L[G P!BJ3_G7MJTS;&R^)'0I<2BQOM3'O$ >T[6K
M&Z06*"8;G&SP_D")/1SBS%%RLX>!GDQN,KE[3-SDJ[72M_>404A#=].T3AC,
M\W)99TU;H_(8HOM#*CXD[]E7KI'R Y$T_.O)8B>+O<]L#XEH<+8'E0FD  1A
M(1*I\@$[HWR[839IA,>/JUGT6^8YU9\OW-(I46'KB$P2973@JK#9MYL##4+G
M19:C24\]Q9-9WV=MB'0P$*JHQ1^EI.1FV!48+=.T7X60];?H#OYKV>:%HABT
ML4^!P+8#3E'"5+)B1?FH'XPW#6?5='&9>GTH8?[TE%Q" %4MEZ0^@KW%$0<E
MD7_&Q6=F51-1XY)B>D.I'(K6WW"7[9.IR_8KZ[*%:UL-'6I9?-BF\1?#*R,Q
M*;4^2O,20NZE-1_7'SQVQH@,+^"6US>#DF_\PB+;P+ >P/_U^ =#*=#V# ]Z
M_GM@E*W)R"W5\EX[:F_$U:$HMYS?X@,K@'0F+/*B(\<K&2A+.)A*],#DNG)-
M0XR+]7J=OI0NJ&S[S KMQ<4C@2S:#8PO];2F% 1M9>EEUEEUH;$[Q,<++@\,
M)4?WVR@?=5XC-VDM4\+$"4QQB\\(41:\67.97&5%1V8G4B%Q3BY"*D@V69M%
MX-XN6S'^GNO#!,G/5LRW;RIO9,P7R-JM$+<F&+[O&)$%U5L(.C2X.W6E]$PM
MNT()EW4!>++>43:(T2[UZU&*RKCG&_[8S8E^?^Y;O_<DW?YM>#??4<%>E=**
M"LNCPM'A'SLU$F[8C+Q$HCT5[O*M\CU*$[D4#[+]WJ+J8*V 77:#]>T;XZGU
M6QLPP4KK\J&8 =Z4S.=Z<DO)HK<YF,0"WP/'Y4_TZ"_YT7L"0J'#N:F*?&$]
M#AZX6_B#RFX0G^(B<47CKI&KF*EW<Q)V(.Z4CLURD3?SHFID8VGYJ\V]C/J
M'!=):;&IVU&$A]I!1!DJ.2J10>.D0+T*[T Z-DB-+A*469W!"E]?J@(9)PV4
MU/[FP<D$(L@@*(RC46,UP0?KR[J'OGI1(FZYFL".Q&]\J ^,K\W/2Y\.!Y!0
MD,VMQY&[)$IYR&S9"COK0BG/]WCA6@6)**(@U^R7Y755?V3Q0"8SP'&A;[ (
MHHLWD\"$((LT5FD,2[SG!WS7M.A.Z?L&I47U'S(E&$<VSI$3Y=W [\CI/; 3
MB!&,SS:?FWHL"4_/!CP)VR]Q0NP'C3.T__?HSM[M->L+4N319201S#\ZT6X4
M&T9WKRSJ7G\7GF<N+ OD,KI26%7;!]#:>Q</A(C\9)ZW"2-9;X3S(-0;7 N3
MV,:7\:=,#2D()S'@!5^@ #*K7,/&O\Q)&GL?WF<;E)+U$)47Y^ +_#5K-<J]
MS6V:;LW>B^84HC2?)0UK%7U?,\Y"%<BQ+&N)- " W9*B!'(%#U>B,I:$8W.X
M+,6D],5>4!I85#0)3-(_VWBQ^D\4108Q'GN42WLWATV0+N1V]P&5C0)A4'24
M$W)C[#0$:8"38')\DJS -"\;7F(\[%E,781T_+&E4:.H--@'($2OI3E^<-+?
MXAU%P+NXY;8XK,J0G]4H689"'=)C.H#JDIG5KO<XXVJWO6?D<QO"@X219?"0
MOA7*K"'2FHJBWG6VJ6J3'^'S0(BULYJYD7"G+]O D.&E2W"(X["[Q]G?T^NB
M8Q'1Q]Q&L,8?AM42BLTH3YP(#X9@/3S.3G_\6KALQKPPGY8EQKJ7J(H&:[]5
M%R1BO'L*6AGTS-)#06>M%>E'WOT94\%.(F-[U=/<P<J.."P_QC@[\N2B.C:2
MW @<8&$IT*$I:ZIR*R'85W9B\@X==H*\ZAID^L*5RRJO6?!4UR[[*)*N$CE+
M4<T+NUQ%.D:^;J;V86@^S%@.KC^PAT@1&F6H8NWB4C")&.QQA0Y76O_I>A>-
M1#N,+ ?*;^A*A#"NYDA+H_DN?K_0=T]=-F-O@K<PPHCA.RL(?G5%>OZID<7Z
M@ ?%OKH$T7_"9MCN?\:SAY=FU^GEA(8-_N.89L)8G%H31\Y@+<9!+!S&_;P/
MJ"?5A]O;'$4O%MX%CL1=.V[DJ$\P8OGH5_R#B?))/[%O'YS$/_=_,C*C^-";
M67>RAO.(2G/Q9G9[@Y)(B<U^3>$?C@&)MK>\X9!PDZR$608[Y3=-W'DVE12^
MNI+"BT@%5V,1#A!>E"56JC_X#,KKJE[=G+P_/CKX;TW'WR*'\ED>"W\PXAV"
M$[OM%FDQH1 =^?U,?S>,E3)T"^8 EX; ROBC-)R:%O"T5YP247 J7FZ>=8TH
MJB9%-O_(U%P^P#4)L'"L8R5GS$6L:\1W13N[MIT0S0Q]T)*(7!6V:9AR]PFQ
M#2[LSC0R*I3RCVYQ(<+M\?7,X]  @)MF%]D8':O!S'!RAC+<)O PU_+X1W^
M\3 B?G/6/4,'OX*[T@G5GQ33$2K'%"^)<DY\VL:40.TNL9$'M2\Q,FC43]M7
M*A>^C*RC';-04B*,.H.TZ]<_.4W*^,R%6<CT4,\I"L9+8?,EYU@"I:A.56E.
M9Q@@PA+V4T8(E*I$=49Z^EZZH8.S(S.X(22@[@TY/Q,E/HTE<;%O7:'KRVUP
M:'<WH0RU42KE/^ T/Q<A5 Y;;&I)ETV0#4:3K1:-GW*&QE"TMRSX2K*,=Z>S
MATELSI*PO9$NT<O+W"V3U_XR[W"6'$EZ_0P!(GN7-GGK+K+Y1E3*.:[$,[*K
MK_BMMETF5L;VN1,O!4NNCG+?<K=3EHI:KZN\Y "(+_TBS(]<&Y/,E/#*5IS9
MW?$J(_<+N?8(*W'98[GM6?&XZ7J3<KL,ZK?FNKV6XY3Z#,=\ ..GJRUGG\\Z
M7<EE-S>=K2C0BT/K&\Y*FH"(DR&RWO![*S[;2,2XPNQ>/9 >A"]7]8):%>?D
MDYMN!5/!+,V*LC0OF".<;:693'\4HV?),8<4Y!)U)>/R\_LO$?MUA90#\%I>
M-^[\IY<&C#!(N+ 3HEA<18]9)T!K"C&)O_2T@0/3[:_.*#M0^!J:.%!8H. O
MDW,LMZ=)X;(%HP *I:*@S=AD*N!3RM' O"QQ?ID@DWTQ#E=T##,#EO:*\G-P
MS+RWS6NDF*!O4ROIA4G KAU\$/RW +9H1K>DJ&#SR 36$"G_CF3"'D#8<YF.
MG/']LKC%6FNVQVE(7Z,9".=:.97"_1>27E2S6D,P!=-#V=BN&2/_[B>;HXU>
M+36K9QD\[,&[3X7;@']NT]%4X+ZYBDHMAY=M;R$M40"T"7  5OUDH 68++A8
M$<X5YC3& +R6-=*3!#_G5 +[QR='3[:_DLI1(@6ZW_J+/K"D@5?QP(^>]0HM
M!*SKD-P;D2K-'>,I;O"05!2EHWW-M6BTAN!4U+A&O:)W^X%\920<O8/0N0P6
M!GJN_@W2B1_RYF,#A[.HA>VE3W\F[^*BSGLI;[PRA9 OFLGZO RH9/9C 0.J
M@Q4;J^ 8$YE($<.3:H;OCV.(V .'2]&JAP6F%M(D=!:3!QFK#&$U%+5&:4V"
MXT! -1\3Z-XYJU8O#+<<_(4BL5CBF"K;]*"E:I0V]AI5'5]",EVZ'>)I4<U;
M?]3_3=\?H :G\1O;$K"P&+B(7I!/YJPNO^(M\^P/D37]%7TA3CG&/]*"C ?H
MVTZ1V0LF%8 )=']KT'VT\+@@(:M2\UNC;DU+V::^JE7MJ<EI,LR',<SA[KDG
MX?3$'CU9ZC=AJ1//^62I]ZD X"-NC#07>;=*+C<9!.80#+=P, TQ/9[8\W7N
M2_-"Z3]U>TZV^"6\Y@Y'*9;WVW1X+@2>/I:,>*'4N)ZZUR0SSOGY_7?HT*HT
MU71Z]UU#@E;$$WHJV1LJ<\*IKN&4,:9EW^7-94X?OVFK^67GARPF@_?;CXG2
M;Z&K<7IH]YMO%+;Q_03;^.I@&_\VL%]NJ=.50 @ZAU5O0I+?QY(3*FO-FLWS
M>MZM$ PZ=S9K,@8Q_F/RZ/@QFV_NT;QY&1*R:!7S2]TKL\%CR>=Y0TDJS+#/
M.*^3+WN?ZV>2$]82 6&3XR2P_$8R[\?/CI(%&*/TT,!M<BGY"\^G7.2'Y-&)
M?Y4TD79;*GXMV&50#A^&7M_F'GR=*6Z9EI%,7XG*'8\R>2S,6+85(C9**H9A
M8X05%;R-^_)=M7 K[$J@L42! *POP6VQ/>**RGYS W:+A,<__Z9+RG1R29&P
M\P3:KQFOA*A!(N6 V\.#U:WF1A_-9!PHZH*O5:M\GESE1M/[\Q\)88 *!H_[
M,[,F<5=<&:1RS:*"U8' &5]$L-!I6U*5%*ZOI$<+*UF@#2!FJ*US >)@E0FE
MRKFGE@I::"I4 X"+4<\VIYDQ_H1)6O ^V'<9X6NT5,,7J4RN5^\551K4[Y$\
M%N&Y&_$+VI8E8.\""ZA-L$J\+DR-+*]366PP&1=5M0 WAXEIK/!T30.#PG'Q
MHU-=:;VL.55MLO)CW:W;.35:9PU.!_>9RT8^<Z5;,F1V7KL%@F,8I72#/N[]
MK1INI:NPN6_.%'#]U>)7RB$A/FITH,5F)#JYNW??X6!N&I72Y60A_%0EC(E_
M*JS1X56I6H+=EO1XZ/GD\:C@_.:>/"%9HW_Q!06!UU2%H^)\QBTL.#B7;IQM
M1PE]UG7NVJS>],(]@41PL=@RZG_.]'/KS9<OMP>E<'+]V'!_@,MW$U<VHE0*
MS3?<\3(T3SWB]]5B5P03$EEOK;OF=8-MK<42KP(V\N1QU!R$[CE;:R#&71L,
MJO:8N'^B(@WC'GW1*V@W2DD?OP*G9F9'"E8A5?X?DLOJFNE?* HP/ -<Y[J^
MK%;X&J'?#;M9>QZ-;B1,%>-QOT4#L,7%#6[<]B1%,K=[S!&S,'<&5K=P!?E!
MB'POJYH:N@Z37R]S>+AK=&'PNZNH^YHDK6DU:F/5SCOZ]H& W*2I4= I]6_X
MG]O7CN>$7CR0C6@02 ^FP X=-R_AXN&T&*Y<YNM&H9%8K%0$*^-Y*M]GBFU=
MIJ68!H@KFA*W]87>O_P"XW,KD3SH*7(D2.-FC-B''C]%'WI\ECS".9"._S^Y
M\G\WJ^$EI(__<<K#I%][6=5KU69Z%%_"_,(9273]9:]/U2<#XB;5,3NGC>^S
M,EH1&B.[)G/%XG9!L&:!Y9KZK/5'T54/_6M<2@OGEJUOVW#N?5X9 PV#1]'K
M+MP<+)R6"D%0I+,M]A>,+&3/B4L"!R6;<\2)H^,#T8@KA>OFGJW]BN[3R3(Y
M>2+]ICC+QT]_D#-)/"[X-\+9=32".<%AR;E@;+?W4,&5<B8JP-83_ E[M\]Z
MX=2T@3$R_N=L$\443R#B*-I+PL:*J00G+9N,;L7X5CT'@U,J_T1,;["A+V#P
MM\!&[$P&WXB9>$@W]G.&Y!K)N:NO<G3" R_V7S#7$!WQI)VP$WL*P3R8ZHHZ
M,_A,*M[H;;Y$2*G;?MV>:_,_^#&O$*4%<Y0F;]^^]/Y-O[#%P?G?][:O.-TI
MP85/>/I?W>!0;GZ=.[B6.Z5"AMF,.(EACE77==Z"'Q"G$64M\*[^7"8,"GE)
M!SNT '^ 9J(A[ACF9L2Q;MY'\_A*\ &,%C6O+=';K0E=>]'E!:./LV1^"89,
MV\)57A69-%PPPI'#!4ZWR*F#0EGQ@8T!Z^%9?R'W=N4%A$X$?D8B"PQ?A?O+
MXV41(0MQ*YTW*8+KDR*+G=A8P_Q,LSITIB$B4/M4"#1VF*$AQBG\1U+"2OG!
M'&&7-AVUSI"I!H+H!;&<7%5D7W3JD#E4IQ_/([_UD^B:M2-LIL'#0B0%5V+"
M<7B7?V 7/L-%\>1329=16$08Q"TJ)\DU_N:Y6Y5=[5]0'\-SGU C!#-9(1AZ
M#I_CD"GKCFX- @2?*T0UPK_1C?UCF'WVMNN1D)L+MJ/()T=%D5N@UM) T(9'
M%HA+'\H]XPMO]SLVC/REP]Z4&UVN/U='/:ET$B*SY\N\AS6Y@J-)1X6L!N9I
M?NB],7UEBROFGP<*/=@8D$VNAZL;]\S?<$WDZ503^?IJ(GMB0'Q-CFWWAFC@
MAF7V6X0"E!<?+N=](@0XBIHJ1PV'U7S-F4@N>-"1+/SJ$4;%^&^IYH0>'TP.
MP3[3, ]-&T#YIJ]O\(B/:?LZV9'5U3@$6_I#AA>I':OZ(BL]O0UW]'C!8GH1
M[(6YS-<]A#2W F!C)5%!W?WZ?#)Q.*N-[]N K9'&U;-D,0$;LE\PN8%0$M!@
MF@L,>_-PXXDM,)[X<C,R]3Z<P^=!/A;N7[(!!;9%P>_C> )'APW<5D[RE;1.
MP.1R)C3^431Q_'.DV,H;&EMB,*!5<8$Q1:8115YJ5\]8&+#/4MMB]W#O7DYX
MSQ/;=J#9;W]8>^&S7%@/& (3Y+"=.VE5@("NG_W=@7)/5EW3!I:>W0T"OB]7
MVX P@"4G@+R,95EU5/2B60__!,-?.\-43!4,=7Y1*R79>*C.W>8U(OH9Y4W#
M.B5>2VZ2^C] Q-_5F?;&TU\I=^*;7JE2<9O[>W>[J[T"WP__J%8I35#_ZWK3
MZ@G:;U3Q:R4[&XS I]T&#6EL^*-6W[.C8>NH;>/XY=+9KA,I/-ND>V\<S$9@
MC8F[IDRRUW>3L2H-'+B8@**D2F;HS/,A)/(C<[,6;['_D.,I_F-%+768Q"K9
MHW+#I6FHY(P[]F4VR'4O#AZ?>%%GUUGA"2*O( Z&K[G\?XEE@'<!&(JF-TVI
MZ=;WG,NZ;'R7IQ>1N(&M]UXBH0&WZH@1H:&P<*03ZC4^;8_W2GF3I**\K[-M
MM24B!J(+:L!/%B0%C+%,<&]AXY[ XZH:ZDH2^"<XP,,F86_\'NL@M%GHD67^
MIY_?^Q-0WY<9<LM95*KJO0YZ-*S,%@W22-#V*;5%-9!=>MJ^-ND%<7Q?^'CM
M1NF0\#=\0==S!RTS6/@\)IBC"V^D_8C*3%WP!!<XP^A_;@R/(: [T#?SB ?O
MQNE&QJO3EL/( 0>+ZS)N[O2[MBWZQ'-<U<:WVBW;D](SJYM$!Q1\#@95"N/X
M^EK7XB(O_G.>/P0GJ52W1_MZ>GV,H9SV<*V*TCN+D:ZR2X$'E!0NE6I+'/6R
M,OLC4UH-&O\:^C+18% N4'?<VE&3M31,BR'[D_X.L0'/ SE0'4!V>Z,Z("^
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MARD1R?AL$QNLM#+*X!0J,BT"J=)+?T/A*L\;6>?P."F%< >XR78K#=!]>X?
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MQ/K0T1A;DV9UE?E]-" ;\'2MR:<B2E>]K."[Y2:!\2NK%4Y%L3E,?O4[=RB
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M9@-$/.U57DB-;PZG1@HR-=V[&8272-M?(:(6KU9UQ-&!@>PMJDA.#P3]"]&
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M3O*73);C\J&6EA4CN8%DLH'1L84Q: "6[D[&F"A(U)3.K' LB!B'^7(.:^]
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MH'X8BR.?)2)Q/#YYPI)?F-#+&0X>=G T;+2Z[&P7*Q5U<L(_,F+;7A%Y!=J
M%D-:=T$T6 *IW!ZL(_8O),?U:T[1JB>])6R#Q-U3/&3!]!;7!0YHBL0[L76P
M>I3BZVOMH(I- 'U-XV35-T,Y>VJ^08TI\[/>HCHV0(+LMZ<N' FY$,KLR@[M
M_9YO3FDMRC;V$FLOOZ$'HZ@HPFM"=7@"'8(]B%<ACYFR^,'S:B:VCYBCW@D8
M#%^F[AZ<89C5V*&W+KB!&AC\9&+<7[B!,@-YB%%T'O.V5I\PTO\/6DHR8@,*
M06*!-@1!F,?Q,=!H"?D6NM81)&/L93_GL4MG-^&*R( 'QP*< 40V0*$QFJ9
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MPJ')$G=@U99$<!%,RZJ\*2LY*<*O2NB1(*&D;]3/&]&?E>&0T\WBV,<S)>C
M26C?71=UR;!@F:=P@7#'XAI9Z*+\5\^E#]V"S&R<P)*%F=[EH*+L+:]$J;ZR
M#[+,6RYNT>Z-^]#X)<-S/,:V&AOAL56Z:;@MVHE?"'G2A:CX O%Y1T)8RGR!
M!(**4P=\/2S]355&&GS+*4^:6A/9R'\5PRE;5P@0&PZ[;(]FPE:(7<9?2(PO
M<XF'7ZP:DZ7EC\U(#3K6B^0<-=*;C'QMH#=P."%G<<%H7C;/P_N9!Y*914VE
M8D^O/*Y[($&BA1'I-> $&H-%4#Q^0CXLE2!(YN1<%87O6%C%&!Z8X^F!HAR=
MTJ1'V[ PE%..\C<S4?#+QKALC =N#'5EER<4\MOQ.IQF353;/$M?MI&Z$#%2
MT(= _',GUA9@P=3;!R]B6UX.@<M:?^^'@%'L:W ?4U:7U799;>^A2Y%=Y(&J
M/47$>_78V1O>%3FC!(QPC6H5Y)!?N"XNJ_&]G/-BXCA3NP(M*P6+!4O\;JJ>
M_-6+[;NLMO=B^["TF/ZPMWS>(?ATFPU52-AY3!*BT1C>*<G,U]+\\C)OVU*$
M-9&4OZSARQI^'RUUA%Q(,(Y874F6[++4+DOM@V6GG+ PZS0BL<0XN551WN0@
ML5=<KA94]+#G*I0(8%S6Z66=/CBD(9#PKU*A&\ 3+)K60@4A%)OV25B*NR4Q
M!0N+[C7N>I=B<E=4FR?A(GK*7Q;R92&_GX6L?6>N&<X@.BD4A_+S$KO[>ODQ
M;X'C;]NF+;L=%\?M"GU-#@+E] ]X9=)W1X2JV6+9G%;A.:C-@WO4M.;.KD7T
M@Z/N3N)M7/@B+AO@O:7]!P@6\GD)#Y- 0X+OL6R:MUI/I@:C;@&AQ=@9SR5;
M5QN.?\^2[M [%9#1WXP]\$L?MM?:ZM$;KX6P9"".$/];:[B"+<-%H))HV$0!
M\BS0^<A2WDU:ZQ"NH*2C\S\5B=CO+_#XCPX>_XR+O(+/$Y30)DJ"44&,T6(I
M0FZ;MSONL&8(>(IGC,VJ26,,=FN&SJGB/WI -J$RD8M.I@#2_G,)Y_P$/+7J
MFFDE$MYKM=@5ZS)?[*O\0-:B0S,EXBV*]@6(R\B:$'I14NNQ8+5O_/C <^*4
MV9:%/,E:R7YZHH8Y4$,?M2/[AO5LNN#J*6CE/BL#^DG;.7DLW1SO.V,=9J]"
M166,4D#Y/-0#X22N%LG#[0V;*7C>9=GL:7F'8*!GC\I:*WTG>@&8W0CFY$7F
M 'F"$JU*R<!.+595F!H"#%-?-Q&78E'3!-.3];5$TM*$K_HQ]X2_:MR"HS5!
MWD:@J#1<Q,W&FXI5M5Q3OJ^QC] C Y$@T]$A2#4]?++4*3=;DRR7LD35!Z9"
M( D>*'N6)#@CU!--?=T [!C.6>*>,0ZB[M"OP?2*7C:!D:GL4)35O($NZ,_;
M0CB&PJ):55!OZ[B#7GOO2[2JF$2B].=H?_FNJ<L#$#'K.<AM<DLGYNR3S,2_
M,]G^&A5M'+:> 0S[/EQ@932"X?E*[NM@BUMP PGCT/.50?'3>&+8J2T:?4*$
MD;P?$?X;@F6/;E8Z(@:R?3Y%[/63S2F1@^2V@H,E=R".^#)@$*E!$!!A[SDQ
MPQ!#A]$+9?[5GOM56EU%G8Q)""%J>ZZZ.!R;]BWBIF(9[E&$!1MBGS#&74.=
M,XDP<D:](<&M4QM#?!WV3JQC8')I"^:$I*30LD.A6"?$1?Q[AS .8TR^S&02
M[':&"_6["7(K66*\)*B<NP&RA5'A-DWQSWGLOQH?.=R0=-P6S''1+D1G::OL
M8^CWEME6'R!VT!AV'&U$N?<BF((E3#9[^,Q4P6L_JGWIUIK93LY>.8%$:7DK
M+23&DA\;IRSVS?&,PEL9&;M/W;-X-610<(X6=^ 3ZPJZW%,IRER26=I*\&B]
M.JHA"HXQ(RTABYT0\'$?Y(F "4(^H1UH/37M)]KG:+P7:-?S'U_Y4IY"\YM6
M\]<UO5B08-+J3EF+[/(W9=N#**&O@_^];5IT5N?H8P\;X;2D+2 C%+HBKZAG
M?R/NJ#7W'L1X-NS)\)+VQ<',[S9< #D@.F ZH9/6/3N1*K*T3T9Y('SM4%1%
M],+TK*%?DA$/7Y?WW#D95R& .[A#=\T]WBI.G:X1#"\^G B_@>V)[$.(&1C@
M7<LR2[9_^/NXD=3I8(\YAJ:4N</OKMN<21_RA2I1 9^*Y%5'LD%\*/"KX+.&
M*5'=J3)P6,#:)Q<;R'"$9\N%Y4@8*D+X(DX)9CYX[L&=68_($4?D#\$K/'61
M.6T$620)\. R*)E5THRDPN.\"81]G%(A-VRY@[>!V9)>8QIT.(,;WO._'HR+
M+T]IW)IV]#KUI<6!^\D9<45A>NAEL.&.MI>^E>R>]*RGQ@&F$&'VK9GWE'"$
MZ9%*]QP=";:0N.84F0^9'Q!(4*%(#+?G#ZDVH-C(],FBTD]&CU^P$+"$O.<
MVYD0=%7Y26@Z.6)8NX!HV"<<&4YL%4S(B&9>0_1.\H.1S6$H*YP+):0Z\48+
MJ8&*JN(VK:,(T]9=;76[C>HRNA<JKPRG<3.PH>'ED67#>@3Q&8/2\-M,.O0P
M6G[C,%S.=ICG+=2"]>VG?/:.Q_Q[Z>$2WS/SUE2/"MX,Y4V^.H5CJ&$/B*>
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M#%.X5G'MUJ&:DKOG*<.;U5?DVH7.NM3(?O&=AUDH-K,3?3"1,^6])3Z'S_Z
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MQ*]QO&P=J'1X<6+%5.\+>=NQR[1!N\4MGI85YLYZO\;*!/>%,X=E_4M?<SW
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M=*(4,<.H^0CFV=K+D'#1D/--OR<?7YKNJ+VA[2M.':.?UO(U#,QCX [%]8*
M%FT>;@^RR$9)R)1L).);HJP1H>RE2R_U"L.,'HO\;5'KY:*HAL8&G*UW5S"
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MAO^?O6];CMO(LGV?KZCH&$=($2!;%U_;9TX$1<FV>FQ+(<KMF?.&*J!8L%
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MWI:/H!$&T)DB;;VQ=S)\/$'A1])RD/CO<V0^8Y*P/P+A'N:+F+?-O&T^0%)
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M3<*BSL_='385=[;Q  6C5@F2/F664]R;QBB%E'&(WE68(Z875&61!'<>?KM
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M80>Q+.=M6R"<1=6A$F+T4>G>??.7O%MMR"GZ!@4_'U!%_[3MG"6^K#KGHIV
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MR"W=U^D!C@0Q$GO^H5C\QW=>3FI.:QC<I%DM/SU_>7*2"0,A_)VK8/GB%&;
M/<$S:.:#=$6W>"*EJI.^;R$M4R[NY5R.H4(C7*(HUQ4!F>CR][, 69DC6AYN
MCHP:/<!+L.: Z\,SE6IS]M6F9>IXY,I -@JD0H'*Q(Z@%STZ)[VW[LL*50S<
M=#0TJH$4B+,4H3U%LP@C+1M)6U!*"WE7F3YM< ?Q9UQ$^.;!7$3XQ(H([MK
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M<#0AJ7^95S4N/_(TQ7_,O//(7N[IIJJ+S@AS_$3YI^>*6WI)7N;B'H7_/&P
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M/P((45FDLF/>-4GC*EO?**P)-:WZ8K#8\0X.H-T9;LMS\A@"57#C\(2DB4"
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M"Y1$5TBY$2ZL8*]+#M_KOHE&+R=:33TX<G+3B3C?8QUH3T4!AVU:YKI$^MW
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M'B.;CS<"C!_4U3QV7T87TLY'<WF\>&$1GWI(J@)T^=8=C3V?(R(DD\8$47&
MYN9:RZ(^7Z[M;02WN(/*65 ,PD&,.N&0C SGF^>!.KK)&*&Q]?*_5$H)'KHS
MNQ0.'GBQRI,AJ%<BGY6^*<$T']SS5(9;06=WD>O1UQMZV#&L""KID89Z5P96
M\QT>UY:-DH]+# TUMV=?;4HN7Y7[=W_6,VWL#IV4SSA[__6<O?_TLO=R/KE5
M!A97N508[^Y]DM3N"!R9==N%OKLW]K Y8[S# @#Q]O08']83Z3JW-<B'(#KH
MQ_$6WP*8Z0(+:*A> -M<[[[&GN+F'&B;D*"%MS447H5!-..?Q#B/<[R8FU5F
MG9#:&YD+%T_8PUF]D08YNNM1T?:4 85 GU*;UX,1Z:M#7WK "UZXIRZFH:EH
MFB!]YDP0>.)@5$+VGWB 3!Y.UNKA@R_02+=XK '*IP2&;K>\U'F)OT_X >>=
MPKV.%^'1HF+5(K8@+R-))H'MM]I?[CF^8&"/OB*#Y5; BM-9M++@>IPW]F $
MK:S3?1!ZX ZA\;.O:V%#7^)"M+T5X7JBWH,6&F1LP+\TC6;)W8%P,'P/&-]8
MSVSM @-J,>-NN'PEHKKBFWQL3P"\2Z:8?U4R5Q&NV3,!59^$Y3QA#_WIU9GR
MATX[SH:N:#<F#M60)(ITV&J$JJC3JR,F[<=%%TF#>(WUFD RM*C)RRLM'=&T
MIY_"*[L(/^%E8DP6..MDR\H('F*=+C04RA_E(\BIZ.V7D4.C;4D)KV8\S1(Q
MT_.WPTZ*4NK,P2N6^7#7:"A+C_Q[.R!<<1^ART9S2(0B/,'.XL!UN @[]MA9
MKTK."9NTE92$IOAVGKX%DR\WC^X\5$REON*5.H5+?XP>I'O=^!A->04-SUYH
M'I(!45[<F=^+ >&O?5L/P:XY>?I*-PV6@GI^#=04O-R/)G-RXDS3M:YG52V-
M,UYRE>#J^W#RM9T>5R.WFR$+2\_Y_V(@FBM#*,NY&AY_KIK/S*11>*"*BY2?
MO@*(9EE'M8@6$?M0/.M =AOQ73FTSF'? '?FN.\O,?9SQHIQQ@O/CN^L/:PZ
MN@7,:\E$=K!"Y(B))A&2)>[LA6A.JG*X(LP23"9_#.+&MY5[$#IPZ?B/<*K5
M8-!AJE$W0RV;G!HA<BPPA1HE<(*).U?"=((DP9'0+O#<(%N<,+1A!JIY!^<+
MVYT(_3=07'>";T;AA.X34%0Y!2*V:K>X![_B/1#\17=#-]2TF'GWH4_'+2/T
MF&?$AL@0:?<TJ: .RB36!#).E6:=%RW[1=P1X*XNXIR^STRX6J0DBR<#Z'G"
M.L1SJ0PPM)S4X,8A[1F#WTEI6'O<H>&++[OG[O6F'-V1>\K":40+/UR@0@F^
M=;?<8>+@C5RU4HW/>RYC7:A"8J/QYN&W=H9-A!M_0Q[=C;[\M**J/,5+M9O,
M*I<K?7Q/YG3*/_"F [26$[GV>]5]6E3**R.-S]Z)H#RW]$ 39:>'<W#ER+(1
M\MOW9BYS]YF\$3% @*:!.[-)K"W X@<4C<@(-/8T\09R!_"Y>VY[D 2][@L:
M.*7?@>H $GON&5&I#*.>>]7E]5,R]JOHR"_27@%#=L77%<JZBAJ-"1@2F"?*
MR9J.:S@1B(:34!/"KI%,H9P$G=7DRC"U2/!EZU1%'#ZF.5MAU%C(D7-' ?&&
M.B,M]40L5NG0*33\:B:F/+,[[D ZG#=3\TKZ4OGB&Q= BIV%Q842'8L&?.D4
M^'I7$=WC*"Y]ZN:R*=$O0&#1%?B?5#8*_T!X&TYM\Z8XSR_ C'H^Q>"2.P8W
MF6C11HD!C!9Y$8>F+Q'*YS:#/ILM0;C="33[/4$:@7H*(0B!D8F_>+SX#=<'
M:^!>B,SL9)BC$?.T(=--;TZ]WCAK,E&^[W4JK-;1$KN!<S>Q+A<CA1;/-8!^
M)4U9OMWET:/@W'_^R@A.O/SY^GS'PX??'#W\^CNE4P-P*#X>P2R#E2D-[F3:
M),*FLXG66CH+@K4:;" -K!/2--A(/(/Z6UU")8^T,F@M^AMQ>D#]+_:?U$2$
MR1-Y^^QW<X=L)'+V8K5KP1^A!/;X=?N;2^G69ANF,U,0'!Q^VL6]O!> H':@
M&F9JFN.B?'L_420VB3=*CDQ*:V; TDH*H&99NMMIS.ES)9"C*HM^8KQZ3#(O
M-/4TW8'3$5H0/*8XV>1C '7^,0;S'CF:JUJ22";DUP2(\2>N2@WG8\\""BQ2
M7HG%:*R+3QZEVX9!IJ#WGEW(B<)IH<^XU/#-7&KX]$H-L+A_&MR_?8I1<XH_
MG6D\"&:Y/&]W%=7#-&&5+\;1&B?&.9./+L<1NASCI+Y2H9X[7\!=-<KQ"[U^
MJRF3SN<(4_GOIXM[?5B(^/H^[E]V\>*_?GN?=J$?/(U1\X-5KP^(OFHC]Z'/
MP13 32!P9*+J:KTK)S[VS>3'S!"#;WPK1-[<= <-UOOKOO0=P72AX"^]GR^D
MGYSV_J/O,B[2N'>\ .3J@/0BA%KMU>^ Y_67IF- ED&E5,;M:C5TQ^CNF]>$
M%5<\T[YCL-$]+/-LG8T]VK9UZ0PA+XG[\-H?/K8?2U1W[BNW<-41]9\2$G:L
MYP"YG0(3,EU)C*!0=5%*8C-T2?<=+\Y@0'"_70EL]"(O2TJJR,\/G@5C?4@,
M11JVX;Y<J>%7XG[#;Z3G:)_>G_G>MP^^"#BYY7.TG+$SATX/A0(GHA$>IJ:9
M]5FEO?O1=Q2O(3*%R@'4/%O[:F)[")?AW:"/?VR_!%Z=G/ '(4UL)@&N'P\,
MD +^6&V@;1I6Z$"O/SY[,;U.69VC)0)U@N2B3][]XV3Q SM'9P.R.9^M-B6H
MH N8^'57A5U#D-28SFM.!1$"GX^:CX(Q!C4)>-5<I20<><\);MM6 L@(9"_B
MBH]_1B($CFH>6GSI8S\F,:>8ZQA1HT_-EI^IE%]*[>!A@02KAQ3QK*5!8>1@
MN<#' ]FV^1O8V+"74>Y(YZ+G_$*%RL?KO4_IV4>&%V>2R89H>L3P!H,8Z<Y[
MR%L*V0AQ!76]X6K3PG><BN)EY09R 4QUE$X/W@0((PO+"](S>\94POUG'/(L
M2^9M%TZN$";V;LBP#PYK_L3@\+\SQUE3,EISR2A^@/'B$1-T^0JWHG8&2Z;1
MIU6L\@8O4@AYRQJPI'W?KBK,K)&$#%(0R"&6I-RZ)7_>7:#(H;AHGA\B(TQ#
M%L2!3^"."4)8IG1)=53KH0VO(8WANF)V+12BH7HWG <U--9!FU'W!OO&M%:N
MEWSY^H4G$-[M+\#-J/="TTBX;&08P CNT+OVS81NG96@N:.'J"\>4V&W61,1
M/W5;2)8)+XD7\R/"E0"FOO5-#8G;0PJBV@D!*5EO^GV#B\JM8C?)M)9JS/@R
M&2E5!_$PD FF.W$)QI**'GAVKVU@;3@V_F 5MF:6M\O2#GIZ-4B3TC57P!N3
MK<-&'G@$R23RN+4SR2\$=BL\*"K-8,U=FZ.G(NFF@!@P@)T(5(/0Z$0"%AP^
MN;MA1;Q9B3=):3U\)LC P!>X,&XZ9/19B#X?LF2@7%HU3 KJ^['  G+!/FBE
M:BAAN0)J).FZX16 #=JB+:MM7\NA@C2*X2'E4=-S,:">TJM^?)4I8A#O";4I
M0\&L#KE#*7484SM:UM- B&ARY7R*)PMVTGDXE:9U?F IH].VZP:WTE^J\$SH
M4* NW8H^5*F2? X6%B27>EB4I%!,?=#T]Y4+\EKGG+#<G;8VJ7MBO!7?=Q$J
M4\A.3/6)[8SJS$0'ENHV*$6P:;92W3)GC) @V;0]1[HSV4=4QKB;L_'%6(7&
MSA-#F-,OVA\MN$5/7YYDURR.A=&?0=]=VL I18YOBXB(_;29;OBR@^,3LY2U
MBQ57>) "#H1/)C>"ZP: 61P\2P6] NZSM/.6;A6U^U+;M:'R!ZL QXB'\[)S
MWP$GE>2HEB3! ]%RCO)X>FSBM3UK4R UEH2R:$>B>\R>0?7L[:'CC?]211/W
MJ_-<6O#I>UZ"JX"4=GY>@LED,3?+%]'M&E4A!+OFAE!71'V**Z$D^^@S3H%*
M#KU#!#3D*M#E70E\":I<U$M':@1D7[5UG2];ZXQ;GJ2TH!6F.?*@B3_0XPYD
MW5)X.!P;I$1:HF$8KX^HJ?\JV35-G=+.=*W<?#&E9DDU+!7*4^!]$,&[<9'!
M@'D/2&;M)MRB[I"Q6&V:H4N/4Q*GDV\)N(R*P9V5-#O^G)/SW\[)^4\N.?\:
M[38#9IH6 DBFSA66>Z&=H#8R]/8]<!*21) 3E0-^I,@$;H1W,&]Z#'E;2L=U
MV%>MLJ;@#@:^">%0HU2&-6[&KG$2DDZ] P<.[-W1C:!D"9Y6MG@V@":.F[_?
M&DZ<\+5&&@*4"VDT!R+Q=R.-\8,(M=W*[0@J]OT&;WT%\<M-%+3>?T;20G2!
MA -[;59BSBC)F8,_[)9/.7+>0\4R\HHTB+$/.';P$J1--\M*^3?"G"1N#18H
M36!N?Y,,UF$G\9./*I294N@<C72O6T*G$$RVSL?/%X'*\7E)X653"*38'>7_
M,[2[G*+C99MW!3>O0!<YTOVLF1=FX46E-V5><,\?P47]#>],NPLJEQ>[<DO8
MC(??9O:I95K.W#^ Q_$)&,QO'WVM1<ZS)_"C1\+04O2.K);E1\\N188&'"]8
MU.5JH-X$\#K+T?PS8D^!*[LKY[.ZB!FJ8'Z2&\RQX_R'T\\]+;R9J(M!+K6F
M,@!_E%.0>A_L]_] =^JKM_Z3QPN:/=^KK+W!N!AHMWL .'O%C2%=?BP-H0AW
M'1 HTGE,JYD_0>>=0EB#5N/GUH7,[EXU,K?3$@0N@ Z6-F!?,68H .!+X\P6
M&[?-Z"QCDGPAX67H/9FL9PB#>>D5WT]K*P=L!G4*'&'5;J#NH-?A'\] ;08K
M/NZ+2,1#<ZF@^4W)@T7V.,X&ET#;VHM =+T7V# 6<76E\_1];:</OERCR!DB
M\!G#C65K8G8&<*=[X'U0/I!2;U<)=-]#HV%PLB58T83'??@Q,9B#* 3F#]Z!
MVAA!N7KU'5.](NZH"U,-E/>FQ53M)*.)DP[F\,EQJIXZRVAFZM!$7>;"@QBP
M8,-,^??C!OU#N>Q\*\ICJ:%#NM@]#WZ$7R! ]$ SOKCAJWW=<@IO5PK*C]J6
MAII1QJEQ@S)1M>L9*CYZ"^'^P3P.OA$!24+R*'PS4TG=0.C8YSW-JPO+C"IA
MI;1?O.(D:H0QDND@0O?>*PG< 1&&/D&]1Y+[:%<!43E1P2<.DI.^=Q]UDX$G
MR7???.>;B9[ CW=SDC#-G-&;HGQ"=&3C/N3A8:"N</:26"ZA1[4B/2(W:.>A
MZY?IN\Z<7O?UO3#G.@\0G$)_!= #Z<MZ?<19<%8=?%+GJS?9XF1-].S"TYXM
M?JK 7P"^^)^!MJ%UG^DK^,/+'!YRM7C>UWF#)NE7J@KX[_(O?LJO\@J_<U+G
M_9N<?Y\MSO,]*"+T2_SCLNK+MP,A1Y"%D?RAX\63?60WF/O?_9>0&?;5[=_U
MQ5WE(3E,Z ] 8\=H]J>G?7JPCU!&,C%2#S-=DU\,7*A7TO+:5(WU#R2T' ]X
M 1F0[;!%L^2<F&B]'5IH[)HD1X?W%V1,- XIT"8&@-[-.PR!P% 12\S']T#(
M.GQL#\0]VM^'IJ0G^]JO!A=7"APY.J#^5[H5\C)FM^*S<BN>T^KF^;$@]D)Z
MW>@)9*<^PX[^)FR%\V,_=Z9?VVUK():LUNL>ZYW;+3RSRG9BH"SLL$R838L(
MW\F ZJ&R#>%<H>!JG4/?U.MK1^)Q?=)E&[Q/70"!V)/OY9>16)*HNR0]S8E]
M59*2A*E:=4,%T*8=@:X4XH25%JIR5TBNKWX+G$E/,!S%*GQ9[@[F*:CR\&O>
M%_G_N'FA9/TK:+\4GE/SJD%OQV@\(Q=_2#])EAW/HTP9)_989.U++GOX_)%O
M!,(#+56;]"FJS[HP\-U<&/C$"@.)Q.&KJG_3@\"14$'" GQEM5'0R)ZU:%+:
M [;A ^3DWB.Q>>K)RV#DWIW#(Q*=Z:XW%&VK'7OOOGH ""MW+<KB>G;L<F4<
M)Z#C9@Z3/IR1N\I6_M(=TT;^>^X,_79QMLDWV>*I_/:GLG''SM^K;*$?? J8
M-N<DM$#_ R;>_BV_K(K%S^66J^QZG9.Z?(NATN+W 74)E!L;#>SQ(C6.\!)^
M*!#'(:\K0JO"$*>S*'1CRQ&5-4XM@A,A:_ >H0 HU\C=H8F[X^&L+PV@]N[%
M8D3IXO,-"'H]TS&]H#'A@YQN\@IG[D:CN7\'YR4JR_A##G*!L4_Q =\ZO!4O
MCUF"3XA-R_+T$K;#-N"W !$\^X7F;+1DO.!U.D/[!AH.B&<WJ,"GN,<Y<@:V
MW<0#'%KH!QZ.<9\=$D$+:MZKEG00\L/TWGCA'9IX^-S/95XX_]//XU.)U,-%
M]!R3VQP4V) C7RRQ5V:-' 'D-?2 )U3_$KRH[478ZAYT[#[A"YRY"_@TDSY6
M[RQM!A-Q6>YQ6GK6C,A%:V(-03'C<K'ZR^P%!!C,2-[*@W-8]3AO5($3<<S0
M@CJ /!^T=\+T 5L\$JB!2]25;R&1 3&74/F Q,=.+XNQPD!U 1=I.'^.\8JB
M0K/)"XP*@=@3/*H5!PP8_9VXG7.9=V^.%[]#"[H^?/0EUKLH)4CJL64\N$*V
M$ 8/\^%-WA'!F7Q*/?.S$F%*3\#\\#R>P4X0!#SWE/D!<9R/4-RWF 1UX_KN
M^,LODI=OKP U! >U3GV. TEF>!X?+TY@Y*;3M"<Z;"BN4T_!R)0N_FC9T$P9
M0QD5/ BOXH?'OXL\P [1,12V"=QIW MBKX$1&F%VD,-,Y@9^T,\IVMG< 5-
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MN320F/L9U9Z1$O6RK=T"0]I&T\=(R2IC@WC)!LB7Q9.\>0/-V:N]BT:<>QZ
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M&!XC%D*M<K=-][UPRZ2@.^;#IJV!4X$"J%T+0;<X6)YIA^B>Z3":N##AACH
M07K ([]2;.1? F5%AU@_YG"%#RR679L7!$C"B^+RP(^% E6 ?BO*?D6Z@97T
M^_/D X9P\0,O)7F@  Y9=#GHR:^(@#;&1GI-J*DIM*?NQV]6>SUV@-TCL^
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M;9]"%3HY]WUL;4&K$Z\QR]9$+EY13E] NI6<"6FNNA;<>6+0UM"2,6JF[%7
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M>TVB'Y/,#:!):J<"SV%[05<"@]4)'X\9&[S7";M[^^'NP7ZPP1.=JF WEO1
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M3'6+YH*X'%Z9)&]WVF#*E% P)+AC>/?0B98E<1H)?[;^Y!D3+.LA54W2BAT
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MFJ)IZ_[Q&W&+DBSYZ(OR8-XD5;],1SH85G]9L!;) )&$]@:K2 ?FK9PYS3?
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M?<R8'+ZOK31/[;TK_)@R,*/^-7;Y&D43G@2WJ4QND""X+I[:^%!^@]SE$2(
M E=+W4;M= ])U"R\AQIU%OHL,4S'41SDF&:72&Q7# ^B;UGN!0[J7"CZBY;6
MR[/"$)9H;1K)"]UVA#(82;Z; A6.;#YJR8.HKG\DFO@ZU)8,[3<?,3M3SKA+
MHC)+.;EUHRO^+/P\PTS8.#(^L %< J .*E#;B.1!/S]FD XHU28G*1I9_QG>
M'@%PQ3]/SSZ$P<:EC.'U_F;X4$SQDR9!,.^J,B@-;I;NJ^Y6;WN7QP!U+2.=
M$=W>_9:!D=M8:XR/F>!K$;PC$Y0A[!]1JG)@8#O&%L_ P%A/-QN@?K55<)UD
MY)I9B!0$UW<S,DDU"AC$30NYI3,F_\"D7NUW.KR>(2]2F@*9,S))0,YA@1Y<
M4+]E.C,8L1PG%J8*SY"E[T;/.7$_O4E/0ZIY+4;FJZZWY\CEEEHMS(CR]4 V
MZ'+CY!)HK"Z5@ 1SL@FA^?@7YW?CKE+!&LY1*/I1[N8N4",X#CS?<BX[L&,?
M#H;260F,C2\>'0/KEDA@V _5/F(\JB,*V23VS1: ,P5KX*9 03OA5")X'S)>
M##3<4 N"NF2@7.,&,&R39<LRDXWR6+@C^HQ"T\2Y@>5%72Z7&J^ZGTK00.%T
M$*S8P(.EW@V;I]!V.R9 XB3<\+FR+8"K:Z*FB*ZCCYBNE^8Y5%'L%+V6P6P+
M^!!9DH?R(LT L%=10R5/@'B?)-$H(^PB ZZ+'AX''\@$3#AIDK;5G/7[J(JC
M?V\%_RANL:]WZ+(21Q%=#+N*;2PWTUS9DL$\:Z@?3?7,=L%IFZ6CM[F +IR=
MP-S.-K9Q\=*=I,#<R;LKR(E#WG]KA=)73Y:(8)0^IT.<A3[!3;K-R?O!1DIT
M=84Z\C@)&Q#+JA8H=I579:,A"#=$XBS5'#;*7KS;3INDKG;>G-'#BUMP;7XH
M(U0$+LZ.N+>55 (\SQC!86<=(UB]&(&Y'EYK.=.+5Y+@R,-DTP$K3F[$.-M8
M@6 QZ5_83*/MKNV?Y>+>FA<#=5O\6[>;).D>,=U*-S^!.%0HS21]I*+;1"-M
MJ"0CYS-OV4A?!WN=L+-W$.X>[#KA$%<[#BF-).@=AIW=_;!SN.\\=X'I?E5P
M%)P9+!KY#>FG-I7CEAJFC$F/*?MI%6GR\4ZX<]@)][K[,]].B2E2!J _=](!
M7W6[6[L=[2CKPK6S1W@,_-CF0[B-KJ=+DDQS6S4$=*="LZ<1,\=N>-C=#WO=
M3GL[,[_C;&,P<E9>)A,2-,HOM:$Y_%@IQBEN--M'+4F$A.SK^OPZ 4D?F#>]
M#C;PB+7?F',>V'I,>].ROB04>&9(Q0:+A!+Y4%GY=<C>^[DTM3U/S"P_VD>5
MHJ?ZRK(XD9OE^&_GCN9(,:N?B%K"+9@%B$@&:Q:#$D2?4ZOFDP+E?(T=51]=
M<XR?KB;H0DW(26S#_B]B0[/>8_O'M*D?1NENZ,QB"SL:O.=77ZC(6)_<E'.*
M:-\FG7G;9]48/*6T&E<SM9[023JS/[LFCXWGP3+:D+&^\6M*1>=+FTUFJU;,
M#BR.PS6;R+ 9V$I%UV=>839;.C*H#LYE$((JV619^C8N_D*M;5A7#(:L-AM9
M3/@6!B<W=QG7;'M-J"H$K"PE+G(YF;$LP[TX/:-)P?ZX[4-0((3**8T#A?,F
M6Y_&"FW0_D8D3R@77BO=M(2EC:;LT>&1E60Q8B[C4Y_8XWL6^*X&[\0V/"?;
MQ86)^E+K1&FE:MS"#?>&PK4@X<=Q06?3Z0YRLJ9+([-W'F@!-,T8]$$RAPV[
M9*_\8E;VFG'1T:*2.X"931,3S1U;+=U;CKP;(XD*M=[JJR+.NIBQ;CU5%L%1
MQ?F"+<#NVV'+S9QA]$74P,0<"@M0%Z3>_@Z[M:?<BIW 9#$8$BYU&_F+-LY:
M-2? 18SH^R+O"+.L(8B.QK64(E>9Z-WF$QJ/^LQ)C=O<RFUM8S2"'LT]#A&*
M9#5.)Q<X E)N\T(Y"58^E7]29D[HM!"M<XV-H:])1'M>XZ1FWS_$@Y^.>-&=
M9E^(X_<@O8K=1.H\_0ULN8),9G8^RFKY_OFNO*HI[MN!-=!)9_);R/L''&VL
M!<W18(!EZMRZK=$7N\7CYZHB66:5N45;[#B 5M'K11O%F0NV<8XF+GBZJT5Y
MIB\\W^C$7@8GRX#&CA,2TMC_:!QQ/1]WQBP8;EZ8GE"SU.Z NOZ4@6U>O]L#
MCC*(0M<=:^O:?/QMOVUZG+*#6W)!:*,\][CLE(8(921)'Z'M9_Q>\D1Q<XS;
M*=^D2=F>$3<SXN./*36:)5=K=%QM$2</.IP9=*;D[B*.-]_"3?[DM5<\3P@+
M'9=Y3+8.3/G,7#Q*KW9= <XH\)77#$<[.;3G10EKEPUED:H?.6W*J4^'W, /
M/H$ZM8J4LYLGMJN%T&WD4:YM#:@TS <YBX(M3[M5^'+E7^VI7H7[NLPA"KQ:
MG-9&V N.N]V\66XM;P8EDE#,F4+$K/BS>Q-FOLE&J!5OU3@S>-[*$NR+[=57
MBN6$CN1S!&]/[K"Z&?6_5)F.'_'XDN@MU0[2%]$4PAF)8VKEG"1$_<PV_$IA
MI:51(-K;9 L#<$Z:-Y-FG#):=U53(TWJX(9G&DFGN48N06&[$[!8%I(I<>-%
M#9C*$?,RR/R&X-/BCO,LM5/)H$V[=@J7YU1<<\&^I!O(:=%2,;;+N6]\+Y@P
M07%+M$A50-HH""3VLO7Y$^.S^1PV/_0HQF @<,L$92]CO;<49RK$>2J<4<L7
ML,3>W3H;M&IHB>T,SL^GT_Q]0^AT$H]O:7FYHR9ZC==HR&G6Z/SC,%]:)2:A
M+QAE$7<RTHY=)^=GIF-7-0$]CEGN5$\ASCDQW:;I26K4" /H#ZD;]9B->];?
M,.(AR3?8%SG3NBN'>VK6J?(B5UR&SSE4T5V'*E8O5'%=PW]M?FL("KW*&$Y[
M\96T09VKUS9!8X8P>:2C34[9@R8<S5RGE#929"@B(V%Y1,%N\AX[,;W(NSRW
M4L[]*:$^E SFQ[R5I',R3KCO-B4-5U5B4NOZ24Q%"":6J&_3+E7VQDHG\K)N
M1.AKXU+BY]P8KDT9GI)LR "H$7A9CTQ2LY$.*7-5PY6D<JD6P!=W\2)I&HU>
MW*:DO%JPMX?WR1EP7;J-[EQXL_J88L0M=Q*',L3[3[_ GGB@B<-M\10SCC.9
MC9C:AV;V-9C&N;H28T?G\G*R71US3# F3U$'>-1FEXGU,*WM3">JX^5Q$D?1
MGU4*5(AKT:-2S0H>.[252NZ0M+H5F%0FU19;9\I-:-1Y@Q5]5:6RQ[LPN< V
M%;4DR?"R!",&*WXLM1GM0$'$^\F4:VY^,K(F&#4VE7I#8-*5E]B++PN*?/EI
M:2Z;H%?X/>JOT&.#KY1S=BQ41 X%W1"[PEQ31ZNFEVCJ?)RX#69Y2)T6.V2\
MA7JP9LK'R$J2:BEV^&'B(=4SC*N[G )S+-!!@/*OQ1CAZRLE(O 4%=U0@ACG
M,]OIJ<'FZCPQZN)<62&S< 2'VS:8%F9[*9-9E(TCTX<,[4GJ&P5Z,?IG;XOR
M$ZEBI#D3/?+MUWU@3QQF1_8G7T"09A%PRB-N.S_D!GKZ6T>(5)S4#(HBA36H
M))[-#@Z#(A4:![OEQI1CBLX.Z9'B6'=6VO'=L'<[TJGYZ?7R$,Z0'E/2&!1W
M6/;35$@WF^&2S#0Y?PP@(S[_H>10^ZWPY+CO=*(!HP3B-GX6X<;Z@>ML4N+1
MI#XY-E(2BHKQR]"&B=-(<0 0,)$=ZTJ9;NZFYJ71DK>"-];OVJ>$2R5,>5/8
M=-R1+8H,)QU,$&($& +ZSD&1S9GT"(Z!K6'J!6EU#BF1X>E*(8BX2IPY1S&W
M81L:2*Y9<@*K19>L SU/JT_!VXB=T>0'Z/UD,U%Y.2EU@I]:DB8^WH%D47^:
M'@>WP$7#&V"2*UKQL ?"U(!CU^@Q)F61A4/MOT/4G]*K^3+O&H)XT'J,*1O,
M*=5H%J22DY\!K18A>45NX82S<U/K521"GR&P!NZJ$HQ_Y]%\ O06FS!2PRD7
MQ<,T1Y0 @8*Q7*IH,',71-!(0O/]$YOSY)'0JMG0=U;F[A5U&ZW.C'6)A'?*
M>HB9@#TY9NP"6\5*6*R-9.5071LTH65=A]*S<@G/H9[]HK4V'- W$3>^]%.9
M:;9L)8$J3[$B=:^F)4,>84X8UV3VJ24F97TW"V32TLMWIB9[N RI=4D0C"_A
M6ZUY[5[.=&JBWL259%58M(2+LL+CLH@I+O_Q.ITV$412-@_)WB]GYQ4WEVPD
M,*8IM0</(T]0D&+C8E$%<\8ZH<QU=:>ZM&'F1^/JLCD9GYT[CC?(UHDVE/M$
MX0H7'*N&,<ASA$,:P6'WP0:4)-.][6Z;& A]YYM1/F<PJ1*FVM785ISN)^4W
MF]*06Y%%A81UH;SO]@O3%56=DHT=H1;2"VC<;9%*&J!]K?&K^>0$%[9)34KS
MT? R!8*D7VN(S%P%E[K9B\#G''JTRGWUC /5@&*V%,9;7"-;(]_7@FQ'[+ST
M0F ,#:&TKDNKK$QEL+%R'E/<?"I^UE*GG>B#+<583Q7?!.H&4TD5$<Q2J$"K
MN]/2Q$LB*(A+Q+Q9_<1[/JR')@'B,HTEG=5Y.M1L!5/A:TP?WKZ6C;N@V3C;
MZ[G@N'3=XFM:BI7BK3G8J3P0QE;2!F"JV2K'\U1A?))$KV1M3HU)K>Y]X-5;
M[$XIQC/(63%L.>PKN4YF8:$4GIM4K)S,$(EGV7XE@@\&NT=0Z[7 #F.IZ;0;
MH)5X;R5BI#TZ_;)!=(I0?WM-&$&N$2(#Q,WXCX8&W&[*I;%<J00PA7?%3I:E
MG_JLF-A3;R:.&H.-.R("HF[1.)[2C%!8*V6Y8-N"#[YD!:#NE^:RT;8U;DS;
M+FX]YZA';QWU6+&HQQ=(,8R6E\FUQ-"IRE!!9Q Y!PWQZ'-0<H;&#-^]$W5_
M*AEU+*%<PH__+.J61&OE*P-6!"9#66A]O-6&PB66@QS!R?*:%BRG.84)@&%0
M8X50+!*9 KV>X(:&4<RJFH,C(?-6QR7]@@!C62HU/)1%GU.NN"*=N-/3N,$^
M'O_SR&1Z8)P^YS8=,)5>I[NO%G5B%P&S]0B)* C+P4/CP'$M>\>[0$6$VNXA
M%]]/7,/96> BA2D+6?@XV>62"\+:DQ8MT(?P HR;A6(FC[EL*;'G/4ROW*X<
M)M/VMBBS&*Y\HDX1#:X-<%7&NP9J+VCD#/Z3E"6B=9!O16+GCWU,'_+@MP@T
M"BD7W*?\SP[9M_GF&2R<7#+!Q[(>C@)QY-(.(,X^D?O1^<F%BSAMSU1K06WN
MA!"NEY'->6)(*J^]Q !,;*DS36TAJL 2_F(X(=@MZC,OH9F%HO;XP[].WVQV
M#TW".!QF,DS[7O%&,D15LYRXK>L=NN14TB0:JS,L3\:./QOTSHH=(0*%YU.?
M2YY$2=$$T[!I1\0NWPK@,([JJ[H:"[;I'IU&+PSL0?R"_]&#(.2(\R-S(#;K
MA-*(G#.@UP@.G>?(<C1L%W%3E1W\'2RUN_L#7BKRU#!(A(.,1G<#L1DPAT1_
M0,]/5P-S'=#"\[JL)YN7"'X=ZHDQ7+3[EB:REKXL+NLK"<OB[49C1.B,VR9$
MHKUIA0R5UQ/"!'=[(:P34Y,&FGTA".]RKX?19]J: :KM--1TD3;2>"%UN^SD
MXG>JET)B ()GD>:#3%*SW[+N.'UEU.03@V-I4[D?5=?! )A=N]5L'+]31G-;
MWI>5Y\1CYX@W#_K.@?JBO$F:,?F*ZO(J:6UC(L$QDW&>NAF). T!^*FFR("L
MQPQCEYGU7) Q9GI\X.\):O+?-1:;2]W5C81"Q#V_XMT0T(7PAQ8P1I3-Z->
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MG;YIJR=#A "7TGI,W^88>\%Q;(?=W&FYL&,)&SO\-1?PPP!3NE/+EFF/&+E
M_N'S>.YUOK6)'.8UW-X+LPYCZW1O,Z#YWF):5&EN;YE,<2V2:9)S4FFQ3^2V
M-]$"2@,HZ$]2$^/,;DVM^UDG(.^LO5LKYMV:LA):SBU(8UCCY_W=P^W]SO_;
M__[GWX[._^?D8W#T_DUP^O[-[Q<?S_\,WAQ]//H2GDJO2PG[X,>='^Z:5*QM
M^IP:5YN%EPJ<@--VEHNM*LDY0SP"Y5?5N(ZII)(C=JID5G5YDTPJI^@5]*M(
M<,H4A)XTLDW$LYH$6G2G8(G%K8,+H;!A"IQ6)>@<=YIKJN>/<TC:QF6Y!^M(
MF8<;4SZ6I(_&DBT"%8,6&J0)D)=@(4L*K!67'"^-07DO)[S6N1LJ_,IA@EB\
MHLU)<)I&')1)BJEVJ",($IV_YJG=TOT)TLHL6.J4S%>(QLT%Z:#4F/5<3D@&
MNK@:O'];P?MBC)J_43U(3FF;>8-0(KNK[-BE+V,T3>^&I._I[KEMOSC'C\2"
M"S-*,@+D)[KX\/"\OK5((ACQU*)!ZGTH#0 X"MJ 0<?\)-N,6>' 'JH)LUM\
M[Q>>:YVP@\T4*0HX"ETNE]>,1RIJI9Q03:?$= Z^1P5#9B*.MEV!O364E&]T
M('NX"B6'$R 3Y5E+R=VUE'SV4O+@^Y]_OS@)/KP-SLX_')^<O+EX<N%H>S"2
MMHNA'!/F,67,9%F+!#GGW)<+5O05L0/,3#+1O'32CS.^X3>B$<S>0_@,\;C)
M44$]Q[G45'Y)B))5I>!DFK6%F<*404/F:\P9/]7(@]CVYZJ.'U-I+I&-"+:R
MQ&@41K"),4D",ZO]<=)/8^G9BSV4*3E:HED1NQJT9WF%\QXDB;9'E?>X<Q1H
M'=.0XDHJX*T/PI\T08PJ-,JT'*D,8"CF/88F@&-+&JB>QGL19IMG),<XXS]1
MH-\!M8?&?G,>QBN/,+TLP<=F@<[M#AR7RXS6YF88.*Q+Q* QF,,,%5?#T)D@
MN4[!7@FTA_&CH-^]8(\1COM%YOJ];L_"%#DOO8TT!0XJI-09%/;5XE?I#6R/
M7IAVZ4U[UW^AM"U0U',=TZ .SKS6<PQW<K::6(4W"?8-6ACTQNHI'NKDJ=UJ
MCW>=%[=+-3.C#-9M2CQU4!8;0< 9NXS+%:@9SN=T0]TMZ8A.*V^%[ 5SG2XR
MG!*ZO^B4EIT"PZU>%P4'\>:\/&25K^#8>DH]B\=;P4G4S)K47.'*>;WC;_33
M@UM3:V9Z^"7W^BL(&X6'+@C:DA-RFG0YG\3-+:)_(!";V\R(X$\$9<26-DE3
M%:^SH0+UM5<4DA^^Q(H<"1PTOC>V!?$RH)*L&%'XO?F8!>,8H*>K:KX'.'&*
M76_'5#+4*&OL_[M.N3T"]S&!K1PG_>L<%+$K564M[ K=?M.QTZ0E6^9;)M(5
M&R<F)4<H!QQG++E2+65QCX=+N%*,K-AH((:B04+)CHTF6 6#6JU;"[%*8H(.
M#VN4).U63!,_Q\1Z^4S6Q-''WR2[UF8[$)01U78ZF<-B!:,%I(L,I$B CKY*
M$H$4,/#M\-^M:=OF3H'1P(_H&/[EFM8,N,?M[9"C"Y 17@;%1V4E3)WRD5EI
MLYB* 1\,@>#9D(0'2=]W^Y5I"<DB\U^8(4]),&\<.],R>>ZA!&1=TK1#A[QH
M/!(XA'9N ,VQI)=P&,F'7! L&OZ2W,>N;+HU?M=EV<%T H9(4_+Y7)9%1+I&
M'SZ@7;H18K+(NI7E05LXN,&6=<!WS02I!DF-9]LO90I8B<2D^56:F^223=0:
M.<4*CJNV2.XFE:H![+&D[*&F6Y[HD4)W.;F6K'P""?7TEV@))0:3LTS'(KBR
MY%*_C*JT"C5-F(+CID4"W>LIT;\LMY?F(9QC\:PM]KVUQ?[L+?;#[W]^<_+Q
MY/RWT_=''T\_O$?;_</;MR?GI^]_!2/^]/CD:RA5PKI%9F03&VL3YB5(/%+Z
M@8*0U* Y2K_$RZCJ:XZ1;Z1SPS1]QM=T?WU-G_TU[79,_.GT_=L/Y[_Q985_
M(6KY[^>G'T\1&./]F^#-Z;].WYS /\X^O#L]_O.1 _XMZ792J'#J! _NGL)V
M+P;RH:T:KE$LRND6AK\(_!?\0LHNK))>38:7""^M=;W'[_[7(,_FL?OQ'T9?
ML(HCME<X<Q.5VKKDMM5>AIH6;8"Y/FBA+'O2L)U<JJ:_[Z! RWOY%?WK^'^.
MS,R=SWYO629^/FN91ZQKG9A>#W@PUH/GX+DI8EU4&E059K_2*QJKG"F5QTN7
MJ<#8*]G2@/N).]B75E*HI8ZE_6Q.82_CK N=#J=2RCS#LW"/XNA9)<XSRH/8
M?)E5(80% /@_V]U=5TW&-K5EW"K:J!1X]K-.D04)25%DXR*IM*4;^0U,*UGQ
M7Z*W^TV"#F@R]S^6""+N $XYR#7%;8ZOEM[<*H85KEW:[P9Y-%S@TWR<!. W
MDFX9G!7  B9/S8XTPY:+^$#S!T.36P^/HI3-9DT(I9#\3!V&FW^:)AW& ^#:
MAV(<$78V8VF =99+/CEY74."[Z[%Q'4]/>1JXJ80,H1Z7Q@57 947<R@2F'@
MPZ2T*BJ,WXQ;BV7$'G/M5Z<Y]59P.M:J(8R&XJ3($)UZTNG@B2N>7B.W 4L4
M8,6XD?SN.*%@8XBM;8<WE\/9;CXYQ@)WCDRAS@J<<,*^>]JHD'*%L<U"I7C&
MT_'INP6C?V>K\DS,\&8\^N*:+-+;1&,\'@R;R:<4=&F]K:8!2*-X8HEC)6!M
M!)2=1D;G($?%/G9VIH"=/"*&[XRJ$2KQXXG3U._-A^F.:9QB&H 7^O<Z5"*<
M$34^6[ .S9OC8@TT!3 BE2O3PZ--/J>V48'LG2N(/ _B+1DBA739TVERB.PK
M\+H+&Z8Z8K#D_TB<YE12S$41./DW%3H=NRU^$;:B>FKVN+@P5Z9ZFJ-JC(H%
MSM,XZ4XNSLX$_P+S:W-I:FT6-:)%\:+%2K1[)-J'2C4:)O+W30C@BJM73FQN
M/4]UV<E)]9+I?N,#%9U*Q3!"%1Y*)1XW7CW#!E,101C2T"[$H?: %GN6&Q;2
M_=+6Q8SF[?< ]@=&0)(ZE\7T" 0.P1()LT"*Z"1K:VP 3.I,T$M(;^D>A(%*
M!&9P37P1%_C-+V@0&89PC:0V\N_M5C2B9C/VQ !04IH-8Q<%T2TAF+L7E[0K
MH@1LV:CN]8PKZ>E]HE%]&)G[</_]]AOI%K@\V;[>0<AOQ9\YI[ 3"AVX"K9_
M)C",?V5Z78.F:,_B+HVZO8UNWXLOV></3<";??=J>^SG6%MMFHUV[J8Q@_#'
M<%_B6K!Z:&(N3DWC.PM3@PIM\X=>)MW\._J,74 ':Q?0BKF &.EC4" T+%T9
M6K0I=793+Z,Y G(JB-9V8SQ]!G,#J ,'VA\H&J>4%&<5/4O6,ZG<H^KO_LX+
MZ2=9AJ8SO/6_O^]\3W^/,*(I?\NK?OEP_N;D?//XP[MW1V<7)S_J/^93>'.?
MY9Q!\[BDOGX_=F26/W;T'+_#F94_TW]BGSYV]HD0O6^PB!:]"T(QO%A#N?@\
M/=[\SQ,/<CASC+__#19+2]9QG)N;Y@CO^F-T4X#UN?1.$__RIL:;K930W>H@
MRZO Q(Z#_^K0__TT8_8MGI6E+UK7OV@'=U>1B>\?8URY*"=(M;!;\<^+=UT)
M7<G=_ A8'=IA__U][_N ?@#<3YRX]]RJMAB]MY:-Z+4&Z2_+ORUZ^GUM.4@Q
MX/]:@X%&X$3[4X9\^!UL-_KTQ(8TZ>\/5MCS**PD5"%]ZV4EG5.!J\DDN--.
M/^>#N7S->T$?)O$F_77$[=6]/:4_SB2EJ;F[_'?;YM(?3[S!*[*U_;O3O&YM
M@]K/"<=&]_D(@>6T H(^881D7KS:S_3%[XX-31^XBBR?*,I6_N7&R6=Q6;3/
M89"IY2-#9?405-KH]>M[G"J) )%[#R8$2-PB5O9568!^ORE*7K^?@/GV_=PI
M COWN'S@L_F@5:%RM32D(-1!76?#IGYX)\U+3/86+X%K +C*_]^KND4]VM_]
MX:>@;9D;73RY>O3S0TB7A[S'>E5)R?W^Y^WML N6V/[AP?0 TT)ZUG5]&%X]
M_T>OOG"%.UO;]UK;70]^6P[^44_Q?H?>W0OW.KVPL[W]E!NS\WIC=WIO'D%/
M[7:F%-7GR(DH]O! W*CW\-SH_MQAZ1$:Y"O];^$_W<.=1YG9>D-6D&F%.PSI
M_D#KFV8\SKT=?9[/0&2\OSV>N+LK=Q)=FUQWJ&A_]A5MUT6S6G-X$N5AO9L/
M<X._R7U\)!7E^5M1'XMQE*T-G+6!LW*ZP@$H"BMKX+P4/6.;N6E<U.@P^THL
M_0Z36'5-X]O8SQ5;Q$I,8MIK"_^+;FCW_5F*J<?LV#[8ZBR*RV+@MN& ;ZH^
M&HGL_M :P7W0"*V)RSK!_ZF8<"-FO)32U6"@$M']H<G4D46KE$ U2%RTA@S<
MKQY2\_K"O V>XBGG95>27JJ9 N0?^G%V8EQH$L_FYTQIBEI[J@]G!5B:-"3Y
MK=!';^7IXSR1'&FFD$9FTS=_@-LK?X!'7(CAXO'A0=YJR#CB:'$+> I69$MB
M9IW+'YR170@&G9N.9RM_YC",-9OX(BK;67TJFYM?'05CM./QD2X8RKV]L+>_
M,[=57<+]69/RQD^05@AS+('"?YETM <G.DW)%93>Y+,C)_?"G<YVN+W?L45(
MVDL3:(2!=.;DE&-=A'3<DV194VL&D\JQ<;/IRC#5RI&+N#C/M'W\Z58F2R$-
MF^VF#& W2\'N^H)+SA4XS<*Y62O!65 EW@01P1@36?#<<5N2G+Y >)8$:#47
MF/:6W=AN(+EO> @IKUM^LMTC/"$\#&:/IETVK@VQ&7B[-HY>!SL_F/X<1,1+
M;:;+&:>RJ+>[.F(Z'"8Q]N+.$,T#'J(?X++#8..7U\%^N-WMAMN[>_/>M>&@
M7A(Q47\ DM&,\=W \E<$LVJ4I6/SERU>H?3R%.Y]5+J(*)7V/#U6E/3:7H_E
M0:PG3@&4;>K<EI]M\+.GR29BD'W:*6S,8E!6#-RHE$5J!TEIDF# 0>T6*1#F
MC7;M<7>GN3FVE$C WU*O8$EV>$MAZ-PW<@([%7AX\#SM%TF:J5.G)MP$S;8W
MA:Z7"8/-*;Y(BLA!L \.B!EJ:NW7_\MN-_.<*L$&5T.GQ]&H*+5T+I),?:K/
M( "3QYS.Q;Q>I^-K0G67S@8Z+VRG#F=4#29^BVD\Z#+]Q'@/6EWKP,C)SYD>
M9004:]%G?I54N=G:M,==>;/CJ!(M!O.3?AK95A$A%RO-N9S<VLFVX&*\.N^4
MJ99PQ@L$PXVXZ+A@*J<E*UKC@RWZ5/#\YF/NP0I<W< <':[0-C;&P(@@55O@
MKIC_)'@H08^LG4;:EPF#[1*3&, :I-R1:A,C*5NY2O*^=/;*N?9'^W3%%H$^
MX4SYPFMKZS:@<(AL?&<J;?:16)9BVVJJ9,C013LT!&.W<^XV2N4P]XPJ6+VX
M(I@I[IMP'VZD-75Y$60%;'Y)G<N$SU;.&+.40#F2M>'1:GCLOAS#HQ<>[.^&
M^[N'\Q@(E=!3E=;=C _R@\VV%[KA7J<3'NST%MD+6,CY@.8!#K>$-3"+R)]E
M%=KAN@KM"ZO07@13:XD!+<NWOGL JY@JL1_."*Y'Q!JL*>PT.OL:MG#WR6UA
MV#]8#&R--8J[X4%O/SS8GLO)OW&CV&E >&U+KJ7%,+^'$$;[XV5&] Z!T"YX
M<"-32H/MCIJ8H7;J+X<;X@]@.G\T'Z-O#8J+TM[4;II.5$*P8*S@&*"OH@J;
M100+"^1JU%]S.@0]BEK=RQ!VP$W7TF[%:JZ_ ':OB[![[X]^/?GMY/U'*:B^
M"-Z<7AS_?G&!"'P(N0</O/OSXO0"L3/?GKX_>G]\>O0N./[P_LWI1WWF_.3B
M]W<?Z9$/9R?G!-_W],TQ%N$+^37I"%I44Z,*%K%YE$VJU+!,@:(F7'(UJ 4J
MA#K>X&,6;:FZUL['0,JH5E\Q-KW7?1GS$PBXPHY-L",,#<2#9_1 7HP3:?]'
M&,6DTH-TS:J$F]2U]2ERFA-2L\<41$E)8.5.O7W(OYNU>.D+1:CM:']O9D5!
M@.W.1+D+<'Y39-AV+ZT^$5B?8D\KSKG3,FHK0,Q"8/DU-X"B_1L2;M&,ED$)
M,^=9,VA8*O)J;5!$0&*R0-.T2-'$%/3<;6+$3I-QF5[6BGF-$^#9)=BW%G]6
MW+*&,^<,ICLW>1+"0<:J%K=N<ELSM6 5'@,_08"7<H+MK[ /R55$4%_!6]FX
M=[)Q%V;CMG2<A<V7'PF_Z0/H S<I//#X;9\CZGH/VYX7-Q$Y;] 3E-?))O<;
M&#O@8# 8$(N 99/WB'#V!3U.L27<'@/XV4(\Q;S(-^'G8#,HHB),#N0=*8-P
M[G'=']OVD&/@'&/CWNXC*=);K\LB!P-\%&&GM3_<=G*B53E+_((IR3S(F0[,
M,2T(-(8PZ@K"IF.57!6OQ.!?XH3<!2&W M56#?X^P<\@MKST &(.=(/Z]@C5
M/RP&@P^0+D7T!!E\S==W# 204&L[;=O'K)1:J]7Y$+[+&> =MBC#A[7773'"
ME2!X*$Z%?O0%NV(7TWH\.G%Q5K8>%G-!0A2D1;"WA?H!]Y6D8"MP7S'OB4=$
MFP5]D[P+H%'F_>LD%H%45F.'",W)P:L^ )= 517AJISW&O+%WZ-D 8&(*1>C
M=)1@RATSYNDAP^#_?@1955!OWHC "OMERNY)_+P?$58UC-UWYN$6]%%(+(FI
MK\?;HF K]DU97P5',9@>MHO2AK"SMV^.%,K(;#EU&AQP)XVZ+&"+KLW>5E6!
MT0#R\L(1C(IJO EG-DK0686/1]E5&IGAS_[Q7H=7?QDM#:F2#A1_7UTC4B)"
M(Z+E+3>.=P(?J- JP-I%V%;87"36DCOZ13$(#!*[VNUC(JTC]-!C['Z'MV6B
M5J=M^<2MF:2!Q(R]AK4#(5 #+[Z))!'A!=B.(B*07Z:EQ)D-,RW"M,+NT[1Q
MLJ<"7HH!/9S,PAO2[6W"PZ5>C\@_1/8;$,G*+91=4XS4R+D$%;4$X=;<R.F0
M:CY3+T!8Q-XN#%:,L"<DLP!<9Y=JX]!>'**XZU-#WFO05X "T("FA5$CC AQ
M@>$3HA=LNE*9%MY9EC+[:?P<>_MX73KQGM.F#*._0'_BUHQ /^;2TSH7[AB:
M FD?6V^Y3(7=LQ6)(PIB 76X<B4)?GV'&O0O1\$&V#M]H%0\_M\OSEZ#FD+-
M4K):^H3EBR<!MVI3KZ7#\&'U&;H1^@Y7&S!B:SZHL^ *Z6*0D<V+ERU&C2U4
M%0;QB^$<2:T@VCV"Z</AFLOV^]:%T33D*NLW[D\M=)G7:&C&=BC8)W%!1"DF
MWWJGM\,-(FTOFX@@AK%C7<&M5O@.#FTKU!@I5Y0];A:"_(L4Z+?)98F^"''C
MXW :32*.1&@D#+LYYA8^< ?B! =OM ^B78\RM\NL_%J5?!CEY-V?__OG+W#4
MV X$;L&E?\BO64@P^'.COY$>!NPU/74,DCB.:!%'<%,RNP(C1>1M[B_G*!_#
M]*I$WL,8U]1E2[&N@;N&EC#H_ 8IJJX1*6'$YR_J2^D#:.CB_9L+P^-A\?](
ML!N13-S >7&@K)_4Y,*DL:K@C4 0PKZ%P2\U3+8F<QXU7F*W(>9B).45\^/W
M>OUQA(M^RCJ\KE6/!D?@+;EC-<S_^:_N/M8B8S4,>TYIP[P]U-UKW3S<.SVO
MQVY9CQ+>A4%6V4\6*?%'$DAE8BX"JFXQ6:I T@M9C(E27YQM=CL]Y3)ZYA<G
MO[TY^5\KVS>ZG6!(NO7G"+2X:^P(B'TKXK0> E<&6^@:LTUNJ+%D%5PE&0AL
M$KFA^R$);KQKFO\!^QNC "$UOH^)(=C?,2FQ=!&/*!FE,2H%L/5_J0F&EAYQ
M^ZP>7A95U,?OX3I+MR02*^@AI+2#?B0]EK"'8H+W]XRBX-L!=IF>++53WE9M
MFZV:5JFJ"<Q]^#K8W=KY 8.)_*H>"K;/8V/ D#4/ND*&>AUH#U?CZ^:^J![7
M>L]56\V3_B>KLE*;-FUQ3!J\7;*9B?0_@Y^\^^5,.0JUM@[^#?QSS&Y3B84N
M@SWOI W0[NR8W=G9VB6*63@$6.B;,1C=^LL<V$N9?$;ZNI[$9=&_SD">QZ@8
M9]$DB3>!$9,;N!^-JAJ4$G2IBWIWYY<UQYSY<O> Z%3<$QFDEV4QG)#N&CHG
MP;O>Y5V7/@CV5*QKH<B;^]]C!=6<6Z.!75J)Y&5Y)%$>\FUP./>QV9/P!S(Z
M*?ZMB6J#".0\"%<*6' 7-MPRL2U L6&$\W1@[(Y0G#J2W6&UA2]2D^#\L&,Y
MJ8RP,XN;)PP&FUD$>H@.8#B.LB'+>4RO HK#LRI-;6.IW5FWQ_< -BQC$/4A
M^=0P $\AO6DMC$3PU%T=I3<4+/,8%7,Q]$!:7YQIWN>@$_=Z.DO[E$)Y1:"7
M@D@QUK HYA2J(B+$OY(\'A4IZ<L+-\]GB$@+0.;%70D"[PNP(]H,LR0T?>_X
M?KTK"W\&UV 39:G^4'<*MO&HOL*&$B8PRLP7KYQL'NMU!<4*T>V!B9VP./2$
MDG>IB@;)F-H9@%ZC>.\"<8JV(WG^D@&:?WTR4>ZX2.3VI+8@ V^:T\.ZZF-
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MA7%=;'B&:_I04KED(Q61$O#,KO SS2U,':.)%R4F QCX.>J+F1;\4'%)I]O
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M[&2=-@L<DDH?1_O[\>/'!_'>TZ-U^^GCSQN5]K&.=Q:$1A1&:3KN+7,]6 D
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MV7<3MUGI6.OU3Y(I#--@V,*0@]:I%Z+H"]HA!A6=975+_ .1Y4H^QI]+:L)
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M1S/R"$"K1<*87*3C7;J@I(]ILJCA\SVZYO8=]6T?CL/UQ]H=TMJQ"_Q2C<M
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M<9MLL.<,VN*H[&;F8[N3/TR=5>'9WS3!&LHMK*"E$AJ&WF'K$@GI:+VF86_
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M@,$]9#YMF SMWI'F,=</?#\Y/O<,#@GFC8:<>? +2Z_(BB_3MSMD["IQCV.
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M76_!(M4ERI-1.Y,A>C2<:.W9 VCO'S6S81:0O 2J51?78W((LFEP^"H)H1A
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MK7'1CZ.H O0&#B4G&.W;N2=U9"Z)>LH@P$5)3ZL='=>S.8V]@X71C*.L/AN
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MC:GUTK=N&16@N#$+"^M0S]':N<@#3:]@&+!=;.(T@>.X>(<EH$Q77 !FZLU
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M$X^Z?\FC4I$O/'4R2J5'ZM&^@3,P^,B[BHF+I:QF8+5?CMY\/#.LFC=JKH3
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MJ=1+N"JG_.72UB0%]J"R-*IR9M'BO%:<G>9S?)'F4X\!!@9UL81+.YBIIR)
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M@Y2%C<5.954%[2A1JQY(3]AR6<<%.T+A->M 7\"6)J-WA9.C_P&AQ7N%]M5
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MD8TW?=UE$OB07R'_L5J']'UO?<NI\,RYKIT(WQ9WC3L  M*?@4T8T8E9]^)
MX7CM)X/#9/"32)3O#?#@M:F@^Y>Z[5Q(?S"D<B.5[.V?_L@O8O_JFSK#G'N9
M!LFB"3@VA?(7=XMG0BDY);_$#_I=^U<'.\_^U??J7YV$V_C,-JX[G([[-NMW
MXRGM/L4\RB-X%3'>ZU?!>SVVB['_9%R,Y9F;E2H4>@+8 ZSMB.P]N".2+L7\
M,5-1T4Q2)IK@=#(OGF_LLMQ:^- G6>6A4[ N@<+O!B(WX>(6CJJ5R"G2?S59
MV=0]+.;<I2;=UMFJ2$JN=EGA#*KKV2AE[G>A^ZYS6JMI0'?ER#I1KZE#_H6[
M#7]>3J]GJ_!RW/H%<#)LT?Z3=^+T1-W:OZX7V<R3T8KV*YR=(JML,D!,8Y3K
MS'(+SK"TWS%\RMYM[[H,'V*EQ7&#0^MN\$#.*W,<ZR@]'7UW..S(,_L/J ]?
MT7@<TSJH$-LNN]4EQQF*6#(U2R\)40T*!FX* +YG3WGWV5/^'^ I]_I;8?V2
M#>%WXT;O/44W6@FL6PZO !'?&  7W_@-J-QC!T)\/+=7@;GKNKW?C EAJ=];
M004"I,-C2ZIULFPURW&!H"S.NGE(3F*4XC<XNVV,C3ELXC:(_E(N6ZC.V%EB
M\K^4JW0X$I:XR5JM<I)Y!L!.P+I3UD"OT"49GHT1RB(I2@;DA?IA8)_*E$!
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M]*PRD$^S]$N+):]'B/P..X/E"LC[9<K7))HB\LH=L7MTYZ5+0,L))P-TZLY
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M$TJ\W8!.#-SRC9.SX[,C!D>089:( FX$O')SLBL0(6*6Y:0:93RMF);K+*U
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MJQ<K*&+VC>3-V=O:*&R765:[OR2\<>NK5(2T1UFU2%>51-)G;66T@NX=[)/
M4URY$G2#)W!/+D#2/O\UZ*C.C0=7<?C;(28?#8_FO!=HAH=ZW>BSG7ATW-&Q
MFQ890U&!IZ_X:O+5>I&['<]I<5R-:U]L-/ *&=;1L1XK97S*R438 D/.MJ9P
MFU8KUL-*8"2LV:M6*2A"F@+> S@Q+;APKVN_=@;EZJ;M%9K<L*H:9""6Y!3Z
M=U68,OG*G24+.F1<L=ZRX!&$=B/%!18H3\PU=6CA7?A,8"+PK'H]]&XF_#3A
M$M!5B^C\+E1Z8>ATPU+F3(YO]WL 9SE$5T@M@"-]Y?_CTT!%'E##C%,1=O W
MT@)BL3:WI/B(/C&*'NG+QF(ISS/^B[7MY153!P@+$#<P4;A1,+)5^H0T;U$M
MC[OMS0G71<IU:<>O/[UV5.ZH8Q8CX=R7>FPM](9 LI01;C)(J 07"'JA\N+/
M84:SQ^2SZ0OZ 1(A!EVDGQ7AWTMTV>D[+8=NZ6J;D'=S@H8A"\:X/ML=3>(W
MN99Y.KGOOO&+2\C@2ED<KDB4.?1_IU'UWO&"OJXU P9787OIB!RT6BA6;7EV
M$T>M=)$FW'(]P[SV"5/PJ$B K95AIF5C./J592A;2UY%M>1*22?YA+O(*^U[
M>WI'Y/68Z536)IM/173+JV-Z ?ZNT'7ICK2W(E^R]R6;S+G$NLJW!V>@/T->
MEQ8V8GNUGGZL]($=A9+4,V'ZUB2&Z=[:G]Y\P"KA19B@C.Q#E%Q0;'C+(*15
MA1SFS&M=L$%(HL YR/M]<E-N>44%T@0.DTC#T!ZLFMPM:H9=\U;S+8YA-Z_L
M&LN+DBFHRZ+(IG&",%)>4]&/W/:3M5I';;J][>81AEO6=K?#2#+V7**J@/MC
MQ'Z1H4BFO4J)^0]ZM(7Y;'7:1%_(2%12OW@Y73*^3(W0K06%, 8C1Y,<#8W]
M*#6;FE-U7]3,*C^XM!B;-)WL%K\I)5D<W+1DJ$Q3B&B.*#Z(@DK&VK0J]L1;
MLW,:20%1=JVWW4DPN^"C8Y2EDHY$8*<AG8-UTA-;MC8B+@(LP:BL%[:+<3QV
MO3B^PE7;(PN.%?:NY#MX6_H)UTM].-!/&'!3V!TUV/F,-W+B$3A4_N">4]=
M=/1:!KWG\-<3A _.PMC(Q"S=_R'Q)K -RTH$N@.P ,$U<9D+>!;=&"+ )?A6
M[JSLY/HG6I/$U2#]5HMWLQ+QA2)Y7:6O=2&><%G=J+HL>\&ZR)Q/1B?/"!K-
M[*PEG;>!APTV@/<KR"BI%[40/$T2<":RP^&(<BHW([QQ@I4:=QV+*!M'H+PX
ME"R/_:S[?_>H=0%B%OJK.)]X3<HV-:""( K"G@*?_I*L\*I9^[W5:6*[4G_K
M,A)6F445<KS*$6] .GHQC?'7)TX:;UYQZTPOSUGT\JWUHFVVJRR?#9NJ5J0G
MY^]\'X[W2CL,+8]#%='!4MUO ?<.:(WUFDH?%JTAKT]!@3>/BQTJ>0 \BCY5
M2$2KOR.'R;?+G;: AS?>0RB&_64$<3R6%D?^8^(/ZNFU(ON34,@IG6=!]>9[
M+J3L/A=2GEPAY3]\(3LHRZ\K:!ML&=T.=]\P=-;*$9^)-??D!N*")1PMQGPO
M67AA]OG/I^60(SS\!"V'"]#PXWTJC<%]G^5O"] '5(PGMY[AT ]#II0"_IR/
MJ3RKEUN*1.6'W2%5G-.W-W8W92,K0%\IH[@]EP]!\>D[:8-S=+&&&5 W:_A#
MB^QE8T]O8@QAZ:"6O+) Z\=EC<A;.I<F\>5J"E#EJV5_PH<NOZ^75PI]YRQ&
M1)AX$)ZB($)LB9!,\JEB>".QUF5W[CX[9F_CH#6:.--TZYZH:8*SK6;NG!T_
M<'DYW<19>QQ.E="M#IF_)4L@C0?,[BPHOO++$F&J2 ZT(O3./>DZ0W<=!M+9
M=8*IDPEF:=Y*QC9VS$H@[619E)#Y%"ZWC#8@#/9>%\+P9G'!6I-9W:$:Z;Z;
MD1^BCP!=EJ\[B<:JSY^8"$^\Z2PV&N5@E]N:27Y36ZMM2("<VXCB3"+<4EUT
M\=T?(DHPQB[O3HQ*RSK#^D$T:Y+R^PA9UJXN)(>-[0,D3%GYB>I$4S>^E60E
M(Y-P_B!0K$5SA>@Y-2!*]/]L&1[F*;W6%21][]SQ[P-,9']*\.@*8VK KJMJ
M"TN:L*L!-"RR[FO[%)M?3L?[FC*?0MRHB=,LZYFMB8[9CU;*ZC/1FK(WQMF-
M?Z);R/K/C+Z"-@K^;%&Z0!H72A4@W>^I:(@CS9N.D&YL"H N'_YT^RL]X52(
M=+_,<T_;)PLM(@Q?SS\^KU)N\F_J*(=%D7UY#=CDUH1^"5++H>0BA!G!4R%I
MAF*P<1.)T:9*G4&:7=-70@W$1:$ED:;Z(:Q"H+H2'3.%/WC7G<E[ 5IV:^R(
MRY1X5T$*-9X!)6^*<S;TL.=ZILG(5_.CO'68IX9S1K]GX<@:: WJQ#KEBKW#
M'_E9]NE_]1F#]S-DX71=L:!?\!<"4V<>]-FYIU9R">:E]T4[_#CXB<>\ZHZ;
M<!X(S:_CM++;A/H D98:(X# !CWEGM),%2[IV*0M0B>EN:=_T%W?E77M,=M6
MIU V*9A2^&VB],[OSW[#QD7[1E4$!IE*633=D3:\1^(K,/\/DXTE_&/Z%6H(
MIL' :3 6AC%Z%0Q?ZE7DJ(.CI@[9<D98XQ[W'G'28#:9]664.K@Z-]K]>G1T
MZKWSOZZZGC0MO2BEK<2_/-\/<Y?8 7//[XTQ YJ!YM3SA(\6>L-J$(WP0ZE4
M)U]QT[:X(*\U'(8EMQ,4H%/A]6,OLV.GW/'@#@8S?=GMD^ELQ0W<5VPL=$-P
MSKW;*YBX*?DVKT*Y%1=, )>-N8$V?@5N^ELIVTX2Y>NGYVNGIM "O@RMH(EQ
M0P.K'"X-2X99DS%R(<B=7FT$-*W^*].6S-A8^7K+)#,2"OP]S"*Z8RICSBZQ
M-&K-O6%VG6<X:\ )!#O/RB-D.J+;= WRP[B;=DAB@E8ZUUL$%V(*/XP6I2,4
MVF,^H5<!%0 NNKL#LU<48"#@0"\Z$L*>W52R,]:(=X1CX8J<=?-,XY'0Z,%_
MW- 4,&YNJKDVX"W(^DA_,J?4\7IOQV85V1:XDFSG\.7A+ CU$#TOF[$K08[$
MEL-OA'PA.I.W1Y;YERV*_Q87#IY3@=>YP&;-E;[)FF:3_KNBB++.%J3U[C(,
M#"45>"JOZKP6W3)-5",31V_0]&$Z1DX_IU_!MH!8FGTVU% GK2_HAZV?2JT'
M=\;>U8NP7@O]JCT,Y7W;?;4#*CCS%V2BF)U62(SYG*>K_.QS'!:YNG"I]LY*
MV&773G1<<3R"82$0H;UM47M<@](S.J4%AP.>KN+X QS#M3UWF 8"!KAP*(KQ
MN)(#,HM_WI+)&)/'"XJU(!"DKX.LX6>?=0F@4U[DUQI6+^3A78ZA_^QOS\57
MG.:=7-2:!S1]ZA(9X;7,H38V_L%E;K6AW,IJV;@%G,(9@50:TTA0'$<N?3.3
M ,Q1RCND5M2ECH;"XIIYK2NDR$9Y13\5GC6\%WI!2#HLJESS(,IBYR+Z,*BG
MBS5USZKP*\7]+%HF@/Y,]01FV$\510[(F9^7 OB =%/M7S,G6X:;NFWV=1,Q
MPKP<;\E*0BFU84K^GWW2+!S,!"2 / SLR%G#@51@&-B3OKHHW2DAU(XABT@(
M+;LHK_1)ZD7M5'[AL#-"^F=^]8<Z#K%^>O@'"M"M+35,B\]5 Y&F2FK58,,[
M+R)LZ)"L.JUR1GXP]Y^O"'ZG%9B]YPK,TZO Q(ZF(F;6/:MSMW\] \:M:>#@
MR][RTMX58YKGK8,QK^LF"X3)/V:3IA8+]DL^S2(*C^Z5S0[WH0=#_:P4&E)B
M?ER.3VQ^,UVT)+9"B]A&/.>+#B5W4P177 7R(K19F2,;^O353M55YJPCKKRL
M1+'T]:A[(R+U[!.V0J'"R\LY'2>!Z!19X4_L6]]"Y:*=L1Q##Y%47".UU?64
M/'7M. F[S0VW+QE!:2L1YNYL5D \1]Q7*5988J<5R$W59Y"C-J^MJE<&;C)^
MXWUA."R>&"9*X?((KA@=NE"XZITR?,YSQ9VQJI"'HG=EA]]$%>U#Z0@F?O45
MF6EZI:[3?N#G!>,NLG,:F7BL%9^]4,R=,7VB"'L\1/SI'191*VAFLR X="$
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M_'31;=WXW#@R0F2U@ZUQ%I.1:P\-7%L1I:8)\"?9A/1K5OR;7('':CCZ4+2
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M'! /KU,?4N:<0H+\XIM.)-PH9)O3L#9:K0ET5KJT%^-"A7<SDT F^\J5^1F
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M_OF%D0"@EH?^$/MP*>!NGE40>@+>)#_#N#M/LI0L:VI*#\PRLE%\K'0&L2
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M?@^?-I7DKP4+>CAREH-9OD+,5FDMI0J ZID17AYA>NKZ3'G>(<6B<KH&>LF
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M%TCU77'G1;:H7845XF*K34/AW\56610R"SPSJ@=%$51>L& LW1K<UU#,M(
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MT3.*?K"C ?%VM=496_A7>MMCT>+6.D1J)I )$][B5TICSIT?RP5)&[56 WZ
M$S47Y0+DS*MY.N3X1W)K%_RW)87V-\*EL>+%+QQ+Z:(4.0_J9[5=^HC^-5-
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MC\> %+TK)W&#""M#Q(,2;DFY+L0=9O47SJ8>R;>\:Q!O>NA.WX9#!];'//7
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M=,BJN*Z((ZQ7,]MIG2J2WD- #M<%,'W-$$6<SF*:M.$56"@K<Z078M\!T@"
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M,N\NC"G;Q>$@N/^0T\VB 3A!7[@1=""7-=M,^*RFK F%" LIXF5S67D3'&0
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M7+L;!6UZQP'>H1(V/EGDOXPJBI(SL/=800C9\1:80/R=Y]<+Q]*)G%*K- =
MC) HO:#&]W=NG=]T7EYN"4KQY[<5%_?]VK3I H9<UENOF[XS"O"(1HHQG'%V
MWJM!X+I$Z+K2UI39 _B8Y_@D"U&/ S-Z4L% $N*WA22<>(9GH% E< HYV9O:
M4'V6Y;^N4IW)6'<A,Q<0!UGV1!QKR8IX,\([2*!C@:A(H4&!G\AEND*F!MA4
MMS83FEJ4KW+V, GYKMZXKA:@1Y ^/8KV/%I0<Z:T,:(_)OZ<&A%*7Z WD4K
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M&Q>';&<8+U+S]]Z=G&/76M9N(:3B1J\'Z>.S2BC],J*B!6,4*,Y(20+3=7O
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M]&MZ[(M+C^7=[R*$*OC42B6WAU%@'^YCC"%0]%+LK-#OH1 U6VR(P"@X[N%
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MP* B1* 'P?2)%S6UL5RB?;@(DNLF5&(N,GBF=^+@+O5H6J?GNMD(<Z)W^[Y
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MH[W=?ZK,+?5?/W[MJ\![P2O=O-^3VODS2+DM^+M.DZU5^)0R6H?2H:B%;'&
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M#/8=J2'"G@>1+4:O%Q*X156R"21]R[BL=@MNO<'+G$KNU$LC0RV#_V2R=SH
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MB(XIP%]JC7=;(&N7@REP!_\I_,/4LF:S;O4F:+$DFTS U>UY-"ET:"IC>X$
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M 9IO_KB+?-ZJB:U&R9EI']<!V^OPUL*16'S]9UFUL*.3Y]__%+2!%W<&N]1
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M82U><5MM0J;;B&NMY3BT&Z+8R$G4-0F-&LM=OV* JF%,/L3T?OC+4PY(#/J
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MO'O-8^#D:4?N^;K&MD2JIC 6@@'Z;A!D=VT41$".]<$UHB86-3GTOI/&CV7
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MGGPSU\UD!$$[;(J!Q1 \OAU_&L*I9%E0=H1LH/WWA7CIOXRA%-,+!8FXI2X
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ML:1S8=6,*\H70K@-TX%WGJ)](M=VCI*M]&CK(-W>FD,#0" '(VT&.3P5N0[
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M[:"(^S^*(&+,?<8RK0<]R_ET%R,[.ZNQBZ!QV"0X ZT_T#0RCLJ$V3HVDE_
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M=,C,12 ^';:NILQQA<< HA%HAB:#PC$L#BUPC6,/;!7TOB1@"NM.Q)MP'Q3
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M06"/<*=]>Q?,C1;^]HB]UF:G%6*W_($R"Y%7?>-!H4B4]NDE[+6C%%3W-Q2
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MS__Z#JXT1R[W>Q^Q%7U$][WZF?*$V!?5[B7^AB7]DF+!Y0]$%_*DP@7Y#%4
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M#UBT;)9A2( 4KZ.D[(NQBA%B!. ?&36 M&30 GMC/!I3*H^G$S%+S8/ E,X
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MIH;O>0.Y*+QW#"^*TBC<:B/Y!'\9U;EMCUA.1WFRG1[L'O6U'S#K3HU#U!M
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M+PWT/JJ7%DSD?CPOXY"+4K9ZJUM<QP@(/Z&#Q'KZ^ZZ2D^N08'Y'"=:ME(5
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M.&.7$\DX]828P%3?>.W0&+![9AA'30 ]$.QNC)4J9:%)[>%;>A H,G$:8*,
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M=<XPJ^K98AR)W3]H/%'Z*,&!:375VUMA7*9HQGU/TCN\GGRR"2KUI8GR&^(
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M%4%&QU3#Z(7$?2X#D><LCL'B&#SQ&(3WPZ#(H# &+0_,V0$D/;E>A7X<$.!
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MP/)U21)[8]&:1UJ+33TMF94R0TO=4[GI-G!TQ!1W !FBQDFZ&?,X9TNY=!$
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MQ-[G"L&F#MI1 =PO4P+(#E#D=7SRM,RLWMBH^#8_N,K1Q6]!T-E>/%J0&^Z
M*9UJ^Y"7AND04"FF#O1&.[H-0RT;"[XS@P:18+*K\7/FP V;UZR )G^#+CBT
M0MI!T@06+B$/Z32T(^/;6E2E):'4*,R;'#<L1T(KDKKJ,):&<8[4B1#SNDWP
MS.5P[7H-WL>T?8E^ETC:Q&- ""I9 ]TSTPDYKHB7@>J/83/60DC&D@^*;EL_
M#M]MJM=%6MR 6D[OM-^SYEW@U=RZ(4UI'E33];OAP3!-N0Q66U'^%62D'/5@
M ,&1!&L,,6>-D[1E4IM3=$<T"YGZJ[-\CHG9:$OB>T0>>EJT9IUX:</1V85D
MLZKP&%?!\:K7WY%6KY3ZK!1G&&Q(>PG'"F U$<0V'5BS>0\F%6DTU%"D95'%
MFE>J*)IU61OHO=$GUGCW%7^*6I!Q;C4,PC>X6 >[99!L=!6J12:$:A(B1[ &
M1SYR=?4MH!X):6/2K=B/ F.;9:[6(L_?=-+@_2)I,']E)VU\'#XH#4F?,J03
M@S;P!6R?#$='-]2^SB#T87!+#C89PW,9>[M;ZW^'EJSH_^ 1>ZP^4@:#@T@)
M'$P*UE7S4-$;4Z/5%-X6OKCJN(YL<'S.R"HTY:.^^HK<":"GZ.T$[] @)&<,
MRV5>HEV,Z"MT-S^GV6#RE/]8W?MT>&(S'3ZY32@]<O70KW0(!>-*+\>*LJRX
MD[,[9214P:BW"^\5-*KX.H^^X"F(FX4MG:'4<IHJ1)O&,K5;5C-TQC&;,(<E
M5P(9\EHPJ_4[_2C+"S+[U2["AUM+E9ZJY]NA<6,L9;R@W(NV5ANIX8LO,TJ_
M7CZEE<"#"JAT8/G9:J@>*WNO5QSE%"U$6).K#1WVOXA\-8Z^AW2P !Y;H;T3
M>E&'/@D[LIH&\ZSUK*,B0UG.P_!'6=$5<TOI:VD#6.K[-5N9*V@$VOO \L=Y
MJ6M[[%VIM>L8Z_4IE_&TYFLK^]=RFE'8U[F)J1#&QY%+)P*)$' T1\F[6B_8
M1V )N8JC_$9JIOH1 #6!1\:#W!;',SCT^\B)KE0QCASJJA#O54V/JEOQV'T$
M7F>L#;JSZPCK5S7$&>,T+[/0O:^7+7#FB,?$*;8'&2>'^T<K>FQ'5+GB5SVF
M.@RONDIU9\SWDI" [T(U()4^( :%":1<*]DJ.:FKN6NA.9\ FAF9[):2V?$;
MG5=_@@'JU#+9U9$3#AQ/&(E\()?MKHU6\5>0%;G1CK%:']UZH&)28W8)UQ]0
M;AF7-IK*)##J\ 8!^/!X W@\P\ZB@.C9F>]:Q*L!@#OY"$$JH^+UH*FFJ9W8
M=--P<HVB?Y92)?+K%@SD"\+0!Q&&8@0!!!-\^O'QM0D&QM-N]S'V";I>F)=V
MKA1CK.2I7+70/CZ?%WMEP3J].)W/<#J?8B,UM1<8JF-BH7[<PP;!M(V]+:\7
MC')-X<N?E*N(BL+ZM0)'L1OIX@)MP57Y3&&Q8+A>'(FG'PD.TRA1,N#+IP9F
MIDM1%1C9*-2 !4M,L/$T*RA'AUE@=7VNX@EAA%N82/VX#3QSS+G,ABFC^_*4
M<X]0YN;X)1]DQ-7=(1)L7,03/5A@9<T@'@;W?8^CZ?K^!*=:0UTX^>T_;?1
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MBS[ "8,,2^(Y9(;K1LEX=8^C0R'=_S)Q]&E90 0)K2,I G_ULS9^.V3 =.3
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MRH7Y2CV^)?_$4!<B#C&GBY-7H'9[FH[Q@@"$1:!DM?I4_4'V3'U1 3ED[=1
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MEEC^#%.< M&[1H=^:VMK=7-W;W=]:T4>P=2%D$))(B9MU7D=LUCL1E\<[L-
M#\)N"-X70S_>84'TIN^0+%G$1> 17<71=<")C,LJ:4':KVTO,ZDF)(3H6ZE'
M=#U9=@91FNBBY3%HJ0.7)>@6I7!<O-%TQLXBG3%GZ0SU; >0"R0EN2F#&Z_
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MXOKQL_97[>K__>WZ<05$CF?SGZY=+9QX40!*>_!Y[4Y2;*Z6\-2U+#;+4D'
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M>53/T9<#?E D0SW&$"!V4&TI"TV=D+RK0-YQ0 [33NM4>JU\QY ?/WFHDZ)
MH4!Q8/RS&/;7+9+]J3C:6T;9V= $_&,<;<;<P$38*ZOLA!B% H4"A0+%SI*T
M[SB>!28!M\Z_(:^\2+'*JQ?\]9C#1+4J=CS6F_F.)#A^LE G1(%"@>(0^&8Q
M;,\HF.VI.-$N)LDM"S7'"U2W]U/B% H4"A0*% H4FX!BS;09J5;<^=[8#F]
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MCD##6<H#?6<*:/D(U 1(-7% $QYUWIR%7S?%[(:/68OR6HQQH2F+^XWS*FJ
M/!WZ+U7Z[^UPT!Z(8MO\WW+A?J(0KRF(EPQQHRB(Y\_Y.H?=H:I3?OG"8,9\
M,T2['4/&SW9HLV!W@;65R-\D)IS7-=LI(Q]A984<KE,Y0^_I\G9<Z2^PTVO7
M\J;L0)J3U(MO3G)R*4P;X;"6PF&M8!QB.55=K[=R+9Q0*#12*#0*1F&STNMT
M]$:M,!2>EG)7*TDP]4?_CH*01TU"3_,94(IE.TQSA<3"3_%WRPPF6H2#$P#E
MFK="R_NB%+R37ME1*GCUDL[1)9O!V;&IU;-FNB/-G&*R[W]V'B]RB/42KXN<
M- C@=X=1KK,[ZJ<@L;_VU_56I=?0C8:JL"L)I;OKAQNC%"<NZMV6FOA=$DIW
MUQ<W1FD'4=INYUJB=+)*8EG"+4T;F#(Q8L-0L\5P;*"5 )1'E'GT^<@.+ !%
M^#&$7AHT@_%WGHSD/ET@3.!470I@%. )V?A(X;@Y-9:V1)P6+_D:56231B/7
MJCR%UM?16KST:QB57EOO5H]*^IV*D'M M\>+=C<QX0/MEI).9[X--#(S'0W^
MQ3I==MI2+;"<ER^T]3NY\VNQ\6(%V)I>28V:ZI54"A;S$5GKL%A76"P%BR7Z
M\QL8DNGHU6KUF&35R5MJ=^8<??F:AXFW3%LETTS1?8"-J*;" I+"WVW1>$#S
MF6.*+_$1'\BFHQ,G(#AP'R>,@X]#CX#7CV'WZ/4%Y&3'AGL.MT</;KP$H$E]
M<C^"4S49W"5Z6BX%E& GMH!+&[K1S95+GV[GIW+Q7X)!B3T%:WJCDVL?VL*C
M[J<BC3_]:MKN9QY&!QHC40IOM=VGR XF2&0ZQM9/6ZI*]PO"(L!L%!8,W*L,
M% 9C/"[[$90=)2C?D6:T,U)+D'U=LE!:]:-.&CN>8UJB\=FL<K'6*JK]J3(^
MWULHD :[)N"N;5LY<NNY9YAW)HJPDZ0S![T@%'@\;=DI?$#N!0 A+JRXP<UC
MU&)_,<6F4>DUJ\<\W.# 45B\>&S6L"NP"B 6AL+BK;MFO=*KMXM"H;+L7@L6
M8I/7LZ$94#N:Z8RYP0?*]*3&V-]P\Q>IO>]1'#5 'VSHS:Y*[BP,BR5(I"8H
M%7JM4U1$22&Q#)G40B1V\NT7KBRS=XJK:YFKZ8TU/E< <#]BOO8 %IE#3=.T
M_I//Z+>/(</N? ]0/ J^^][TV@TB'^&3@"/6\_IQ?=,>Y5N[TFLW%5_<"WH+
M38UI*O?S02 Y'\&X#LG=DI"L3+979"#ZM+5/3Q21HV"<;S\#=3PSN-X<VHX=
MSC^&Y+N,=XZ^?@3+P$T^NV4%^!6W]O"WJJ!&&LH[M4TL;F>\%F_:M8Q*KZ/7
M#96&4LI!+3$4UZI5>G65!'I0DNZ[YX^9'49HYH'!-R.*8=I/TP<%*=Q/#Z)R
MG?4I" S&=WS__Q3;WTN:24NEP)>)RQ(D&KJ<]597Q4"+Q&.A9EFKK!QI99:]
M(JPN)J;[Q#3;U<:F[6O/IA.QN,8<B\ICZPRN"4(_FK*/(<,X8*[=[P"6?R!4
M>/I5WQW=2(A<)P#9GW.RU<*B5:-35-'JZ7'"?#!;J%^RU5;ZREZQ6ZSD*\OK
MK.RW743B()PP_[0EG'1QT%97^.DQU>J[X_V,1U_O4;YU*[VF4O/+1&JAHJU=
M5:)MC[@M5+"UC6,6;*<BO[@&%*!-E^H3&P1,M F3%IWJ&7OR*SLM!;!15K\]
MBW>BPG;,S'[&^6;!256*OA')E'U.+AG_]]J5$+F/ ;(_A;!=J_0,[$9_U ,%
MC@NKQ3OTV_5*KZ5W6QV%U+*06GPV<INB-#GW23SZ]@=EB;%K]QF>[ODGDU>U
M]5F0$-AK]G"[6>G5]$Y=<;9M#-V=D%GB3)QVBUA;)]?N!L>/U"*.: ER"OOT
MZ WCN-KTG+P==N>SF0E 82]86<6X]\([)>_\UL=%@.1*0(3<@7L4;9U*K]%0
M=EB)2"W!$L/&/7JKEFM"P0F@M4BLEI@QW*F2K#NN$1^G(M&("#3'<Y_.0N9/
MA5?^5*39MB>$H''KN5;D^P#T/@'C *I?.E@NT50S.\I#;HF&6P<K)E0Q;XG(
M+33DW"DKLU^9<.\*I<W,.?JB/ZJHDW"XXV!X],W1'D-H'?3+=_6.ZO52'E:+
M-]PZW-%<55V8\HF@;8+5,@VW%@X=Z]1S1:\*IFTNR/R(C5".^9[CG+8<HT3Z
ME0<#87#'0;!'\47N^GI-905OPNC>A<PR#;,.BJ]ZOHZI$_ [%H'6,L46NI,+
M"Q$HJ^P]PDP&UDY;FFVLZ>$8;@Z9FR1%>G]BKELEAIAOUY:3Y8?%8+E$^=<U
M<*I"KB,53D#ZE8GLXA--NK5*K]4J*F=(&7 ;R#R?#<U0Y)*,V:G+OM>UQ'L.
M"S@DW]E>)5V]TFMV]'9+Q=Q*PFGQWL@N3JBMZ\UZKKK_\>-T)W-N,Z26:-5U
MT=><;XA<F74Y99<DBLZIR+:M57Z"Q 4/3A=JRVU_<+!=CZ%2)LM%<)EF7+O2
MJ^<[V$DAN$#3;7L$=RJ]? /G*@BWH8 3$YZUF>F'\X^>4D+SL(6;0P#F#N""
MS4#XL=E+I]5N6<WVCY01EH;EPBV\>K6*O:=UHZ:L]OV@N'!_9;V*/NF.7BLL
M!J$,O3S*"$[0Y'O%2T*[OX'-/\+>#R%25Z]B2Q*5=E<4 DL0975$8%'CS!4&
MBRP!J%<;^RH!2/BZ,7MY5;B(IVW1*VP[^ME:;@T]?\1\?A$L7@L\!Z2L_S3\
M5-4U_-_G=<)'+FP;.;/OY>5S&@]T<P>^/ 7[PX#]47J6C)(TZO0JZ5D_^15#
MSQE]'=G!S#'G7VP7;X:K;UFH668PT2(<0 XB*MUH,^[)*G%Q&@KY&QY<  GV
MH+WSO6>@I-&W^6\ FFNWE#FNV[IPZU6,7E;U=K6PAB]'JO(5CN3R C'U:@L3
MC_5:4S7>*AG)Y05CZM4V(+FCYYQ3=Z"I"#MK%4<@4K$/6%"T -W=*#OV1M"'
MN[*C5$MKI26M_F]D!S9Q:>"U" UDPO 7-4:S7:Z&H@8*3V-/\$EHND_VT&&\
MMPR<IO@))ZZ)DF,J!;"+-+SN %S7+DU)\'P"U74,*>I>D;IQCW[D3N[37$]7
M7RD<WR6XG:G56K6E,+ZQY[E(A!?JI3;*FGMS0 KK$4G:N\BW)F; ^,1F=.>$
M<ZH184 V,YRH<^+B4YI_=^:<)N,]>G1B?'8GH''GF"Z.T;N2 -F?G#0,E).*
M:9:+U^+EH5&K])1+;IMLHO=CM5BAM[?N;"HT>R3+4^%!!?N/#ONC]($=IA]Y
M.31KE^%9/F3-;TU )_:X'U1HUFB :J]T^[(Q7&)<UFARIY=2]+=1]-^/XF(5
M_=;'\VZ=<CCVN^V:KJ7"L1]N94>IBI;F)/8]8 NC0!O[WE2S@R""0T(NXV!B
M^O <8"#,UQY"TQT-YQKZ7L*Y%KN6^T\^H^'L)UZE$SNG!+B^ [2N!; &XPMO
M.O7<A]"S_MRC!QFK])MZ(]_DL%-70G9&:#ZNXW6Z1T>5'.\!I\7JDV65D1^0
M/GD2@O#"<VE;F(%TR8:PAL@_]:K454<I!0< PQYCI37L(MO0J_FF%7TDKK@A
M*@N5<<!AE8PK$YN%2C>@CR.6;J<BQ.[9C$?/3U]NO>$_CB$1H.9W*((+:_*;
M>BO?]C(G[RC> 9?%2JZRJO,5-LN07,UCEEP?V"Z[9\^>\XP._>^FA=TZYJ<B
MVUY)%E_MVXA!(2&Q1QG7JO0Z+;W>+&HDP$DQQ3QP6JRL:RM9MQ^T%BOTRG(P
M*W-M4W/M=,79:]5N,0@.2XAU*[U65Z]655?SC=G=+I@L5'35RRI/4[@L7%[5
MRW(6*R/MW8)LX ,AC33L 7SB$DRZ-*Y,WYFGSLP#<VW/WZ^OL5ZK])IYQ\A.
M5H+MCLEB15A9Q68*F27(L+TU=54V5R*J'GW3#02Y6%X0!KSOC"_F<(2>%DZ8
M]BT*X.X@T"Z\Z=!VS8_2;"8%G0L$#O:@$ W\'[W'";MGECFS0WC@?P@FJ>OW
M*.J:E9ZAU]MJ0M%>$5U\,7T=^Q_JW497(7I32ZX /!<K),OR-RM#;Z=HG C=
MHITW D4J"<B1+#UQ$;G8HF(P1F52^O;I?.U1"F*GM>*FN)T4:WP'(HNU]]2H
ML7*Q6:@L:QQU?[13$5F7=C",_(!)]^08A'. =MZ#1Z/(O!,76J0&IH$P&']'
M$!Q 9X2&04WKE9-R"X5^"TP6*JH:925\?V@4%BN?]M;*3-E:&P@N;(ZQKD6V
MY[J,T]5/.YSP6FW-9S-1EWWB(DTJ?'U N(.P8:,'A,!]#("@/_IW%(1XPAZ]
M>V9AHZM1?PK$4D!(;GNYUZCT#"7WMM7O<T5WL<*QK)QRA>>W\%RL!#WJ'D&G
M(BC7A/24G%P; ;C&3O,",O\$P"P<L_TY,1MM#.5U.ZJ3VKLB/#OBMUB9J'J:
M' "*BQ6'JL7)(<O);"G=J:>Y;%B9\SAA$@HI(!0K =<<GZ9*6"\?H\5GK31Q
MM(=>;^=:]*^P6;YX:ZH>)P<GQ0+LYZ9Y,T1"0-.-?IH^J$M@!+(7YEMVP$:G
M+=%6=02B+G<##I0K"8;]675-['NB&W7% <O 9PD2K5'I=5L*F24@LUB!IEJ?
M'(^DDQ4*,Q/G^,W,N3ET3L:!N?GI$<G+=PB%XBOLUAV<LOS^)\\,-T5G"4*M
M7>DU#;VKNHH6C<M\9-JKN.Q4>HVVWFD6A4MEH>THMUPO9!]7>#TP*_+9"$OC
M@SL.A/W(+Y5G7CY&BQ=AK6JEUZKI327"2D!G\5*L951Z1D-O%X9.99:]7[QY
MX83YFN.9[LE4OVU^7 :X^8>)YX>/S)_NS1QKJ5STTA%:@C2K5WI=T.%SS052
MR-R3+&MPBZR>:Y,&99'MT)]KYMNN9<],1P/JP2R0!\MVV(MV-S'A<NK;=>*B
M;+''W9V$R,!]G# .#@X- L9^9)I*(=\YY?7]J"UQ>' +&V8W]$XUU[E])Y#S
M6BR&=Q=YVV,8)S/6]7IQ6<W*D'NG5'0_CAVWE&&5.DLWN/U'[ZZ4.H!U@D_E
MB>_,%M^'UC*%7K?2,SH@]%0%9%G8+5'@M:M@['7R-O9>%7B);#!F+YO,N-]B
M8OEV5+6U[!MB%://+X+%:X'G8$/*I^&GJJ[A_SZO$V!R8=N(JWTO+Q\.?*";
M._#E*=@?!NR/TE=EE*25IU=)S_K)KQAZSNCKR YFCCG_8KMX,UQ]RT+-PD89
MLTQ49FR[)EB%[I.&<N?9#NW$IW7*RKUT P-8L'T(: S/0$VC;_/? C:Z=K]+
ML/1CJ.PO*[R-W9_J>K-3E$OX2%7 HC%;?.2F70/,&KK1SG5\CL+L6Y@M/HS3
MK@-F.[K1JI<5QE&*_9$L3RF7"O8?'?:GY8<_8(U_8KI/C#K\@,34N07 _C>R
MGT&@8>TG%H+Z+ A]V\+<8_S^(ZG_J$?@_Z\2D-S'T, O^NXH^T'JRCOFVQXH
M'A:0;< N&?\7_G:B$:@A5R\<^O=FR*[&8V;M<<A5NX$#(9H-55BZB1/YL*BC
MQ&A#NXED8N0[DOIT@PV'12=EQBU:E5ZSN)FORNV7FQ)PL;'8U\Q0&S+8CXO>
M0$Q_(\)4VL"&YWCA6/:#@5NT]ZA-W+J3*[<^?F:])QP7Y$?" DV]7L\UYTWA
M>$<<5XO!<1=QW*GG.JU-N0I/S&6BW%4*]A\1]LI5>&A6 H./#\$^^*]34"F*
M\?=U,+%0;]>*4BG*4!M/ KW%6'X=X_@MOY- ;S%&7Z=6K-%WJ@9!'32/D1<-
M'7:8FE$>ZSM<M51!7T&_/.B7'R/8&0Q'8  \1+.90W,634>#;RW'"R*??<E=
MN]]=G.1US7:'\B.L[+0L[%*G3M+\+%#K-!LT1#253]X0OA8;O78M;\H&,YJX
MZ3Z)23L D_TEN72H>WJC=LP-MX\"E86.O^HT3JBL^2C066CK],Y1MT[_L IA
M^NHT.C2!#\UA(9 ;?0I$AAM[@6WP;;]\79&-ZKEG278IR,MG(%6J.W-'Y52A
M?5P%[W!7IE3/78[R=1!$<%X81F%H4FL )T_[=J[=VPZ;:[/(Q^_#S(>RZX'6
M?_(967HGKZK2_!"$%1L9>]1*6ZB5=EHJ%),?UHI50-M* 2T,<\7JFF5U1#K*
M!.72'",>Z'9^@/0!\HG_%=KH^+UD0WAOA/+*=D$X@9TRA:MH--W)2B/J2)3
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M(4$-3TR#G ,$*9S!09 [0 CBU1<@1T;FN7PCBD?. LX<.A@Q=.2C/=<I@)@
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M[SZ&3,A-[<^\A6IO?G$Z.YQ7]'C!<IC'RKBYJ46 <(#CVN4"-!_PFO5,3CW
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M374U>X#^)W+9\9^=5(- 84U*?KN"?!*K#&@#D/8?ZAD6A.(@\;P[RWMRX9N
MESN!62MM4<U[%GT/DIXW:&LF3V64Y8PV97POU:=@RS/97C)KELN3LF*Q*<.7
M>\*2\W6NI<:7VLF1, ,I0RPF>*87.7A41#" ']J *C9<;HAKO(GCB'=%,]T
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M3_%P_@0^CDP&Q-VSA\L@UB<^$1YC'JU;B.F9.(?3HM<FD1T]WC=_1*PR2@G
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M[)*H(X(X\N(-(H$SN9D'462'(23?"!D$,$^1/,L3?Y('\<W+%SV3E-0%U-:
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M=7UY=WO@B=KJP0Z"*VJ=6A48XIIK@$#X8-3T^-R'I..<9(48\7G ++Q[AEF
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MI(TBEBW5":>\)&#",;I7JO&-W2P5E*_D5!WOX;96.USTJ['TAGJ6IYX[@'#
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MJM?>!N!4U.]O/U=S(,! 1XH@U3@<,(P#892#QU8I$:3V1OK-$:3X.R6,5"'
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MX?J60>V(I._%C)XI> GV )O[9=LS>OBOEN/@_]*4NO'4L1/7?TO?#?H!@^%
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M:JM^<M:JY0AR?JQ^^7MKFRK/H#R#\@R2YC"'YR[G.@LS8PHC#_SE7@%K:)A
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M[_G&+<&@_8#'/[Q:SHOU'8C[O <XSU;WY*Q5J34/:R#6,<E$^]U7PR8(QO]
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M90W07DT#!&>6K0NJ&F",$_7[T/]EJ!IY':(L?)9.>!"?#LYU&6+G84LTCLQ
M:4Z6:'#!+I10J5H:]&Z5"_FX"-$]N!#3?65RK#UV9">N0$Z0=Y+L DJ'-5#M
M$@J1CU$.F<9;*-@Y@B,+KS&$:QC<CYF/[HL T@DF_82=Y4PG&=>*V(*>C7_
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MKMWV+)R8&T1C-KX*&7]5CKA*J%>6)/19U_']%C[T:6X/ WS7#/\[1 18DP#
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M8V?[7-4H;++/+L'H6$:]F[I-S9S'X_ ELS6V3(E5]?[:E*C5<3A)YE95'MK
MJ?&X[62*&8&KD3]!5M7PF[!&[R0;YVL7Z8;O]L0>S\>\2]^;W6'"? M%1IO0
MHQ^,;9!9B=CAQYAAE:) 0W #Y1FBK2Y:>B*4$3HO2D;HN_FK*$?47B5K].7-
M2:.+;:2,JL97M)>I/+&]9-)GB3?&#1ZT@.A^"9XGM%/"!U.7U*MP+E84.?:
MO 8<JSO/V%XE^\\9NU^R[IW5],1K;.E.+)QHMI=. <NA\K9HY; (M;BD'+:B
M#U VA_^>B]'..N>2^/#E783V-+5[3GHYN):.5F>32(03[/(IR6<GD_.)*Y,U
MG=:+*,LC.!YZD;SXKHA_@QMASW"DMKA_%,@_E2@2$&+UV,!OIJ?7$%7"8"CB
MM>&E1@2<:25<>[SO>N02 6WU0JQ7XV%]I_HE&X0*CPC 9'QXE/]0.T-]9.D$
M" WY_DB#E,/'(Z8V _,X<([1XZQ*J1^;BV#9":N%I8PMDVLB36EXL<S2P1MI
M^<VJ+,-/OYM176]IF25C/K/A,*V@*0\%@D(K_L3.5%%D74@B<>QROT/4^;+M
M*S[26I^/+F=%XDS3 8-&N:]T4R]N];-[37[0P8F2BYN@YB6'9H'U]=Q;ZE*W
M Q/8;IR<]:MQ-&:%UK94C^EU1/88#M3F EYSA/'X$R@?^ .CD2DKK 1&]T:%
M0'U1)VW<O$Y ;)_MJ7$-BHCGJTIW-- Q%>/9?44!K["V(7W:J6-+JB]*]83S
M $R(:B6,\U?1)=F>#/"2FD#,@%S\LV;CERQN]P6\(:2H!/6#E^RJ4BM4OA6,
M-B7?;4&U@ C<_BM48QLJ>$3!$U4#H(W&EC63E0)<,^,+B*W$.C$N#?AV?O_%
M.+^_,'KU=CB6W\,U_*4V<Q9W]$]K"$?S5 G=F=C4C<SS94=X^$2T%Q,L(YIO
M(1:2_O)DD-4)8BS1M+]JQDP:E 3-B4>BE3[MHSI)FMLH*Z0/./43*^QB;)E>
M25?1XJ&1-G1XC0*[U7J(MN*8OKTDKMVDWHS6VYH#CJ$LYNLO$I('\]?N<;-5
M*@5'!3(+7F(1TTPVNN!O5 F3],8(VQ6E\0[]T3F63WLO:&1TRW9U=Q_@4O,E
M(99:60YYJ\+[M\=3AWR+$%KE!-8X<(<6PF%S'=9P&)2774U& MO@3M51G0]H
MM;P+,;AXC#7N6&Y5_RMZ3>2J HW%F[GO@^05Z/@G*'4EMJSL@\(V</T)/)F_
M!X_ K$=:L%0UME"QG-HF%H%0>,C>2&:WF3L:@:Z61$W]OM#TX@0U0B 1#*[@
M2YY"$BYG?694">I26Q*-8PK'/Y\,63! +FX99N*"2T.73/O8,ZYXNP5Z;5G/
MD^I<"-A2#=/6!F_S['51TBUHI]K(V+.(SN*V ]G*FL;]$'ZYC+*9C^GCHFD(
MCP[%459)!N@D(-_D/7J6@PYC-;V@*"LW2NXT-G2 6\GQ!<8%P?"*O =2-%JA
M^P=$@BOR0(I^U= I)CU]IMPJ$R>,!,NQZTVDV5MA(->VMZ&^X1W;T-^F2MK0
ME.E63&H=5(%!5D97^=1B*M1]:!,[":G^R3RD+%.(BJ8GFL$<#HQ$!W9*/,P*
M)?P$/7D\PK+N!:/I4X2\.L4P*.4K%X^#7+W]Q0.]]Q_43#N+0Z]4AXSKH:($
MGWG&"."A[%TH64#X^01AC<D;:[@T'4UI&TH[9]JZG!/&;3!DO210>PU @1K3
M)SAZ!=.E%"]B!H*26ABX;3]>:]9.Q9M$R(:S&Z8TU@*]$?9./,LR'B4ST8(>
M@_Y2*7V^A6C5Y&]RBH1PX15S">]-!*V&T+AA 6;[A[U6U&3&_E8$QXW&>.P8
M 43SAY(BO7/8U% !18A/2"R*'$!9-^._3M:%A3P64@F89Z7,,C@G$Z-92\B"
MO8+G.[,FXJB/K+*[FQ],:V.->NY&Z[!@6FF]Z^RN8#"MM*)UUE_"M&ZYU)IH
MNLX)Y S3>A5&J :=Z_B)5@GM=F#KPD:-'#=J:::.:64-Q>0@LG3"&G(T^&K[
MS_B!\(U@Y(WP]Z%K^"X%E8:Z"X1 T_;#F0)ZO[@ZTZ<53:P90[5H*>;=>\T/
M23;>DR $I]HE@$IW,\Y<(1+:>'5"5)98(YG9[!B$"6Y4)2I2]QI)X)M^*#OQ
M@7I^\4#I!M"HTW=:2Z$4MG)ZEVODKRH)81%UH#XNM)F!EA>"?>$>- 4/-.*K
MOVR8J4H2SE2H939,,Z.W&V*=9XP8IFVJI#&";>%_-O!NLV^GTX.=K15^MWLG
M9YU*K]VJ-&OQ*V'>=3H8\S;VULAO;WW:6[]?Z?=ZRS&GM5OMBAR'1?C([X_=
M=ADW;>VX.S7$P.[4FY5F+RT#G3,K'R;=ZHA+N#IV^*9R4H@4\K:SK_N%!]JV
MT@BCS7 /U,J\OP)4C1 N^D"^/)W:1+B%K:Z$RK.[K38SYRAE00='F5>3;(+Z
MSRS6B'X9;U5#N%,TA$_SA"E;&B"/"!@V?U=8.$>I?O:*C9.E?=90.G(/M 51
MA;E"]V7"UU:NV\Q/&%NK3I +G]Q[Y-WS_V..IY_OC/]QO3]?;,>Q]C_>,5J\
MLLH2P^FC9XDOAH2L$"(Q)G,HEZ30<BN8D,"B9Q]G55/2X!%^G(.7!50:>)9(
M2V$]H4.SIX,%,/)^5DT<>:P/[CU\5?1%R8)HK<0Y4<)2NJO.[]3K4Q#E$%LR
M]J?<BDPZ[9.S=FTYLG%Z 3.V+\UX&KAL.];JF63^0JMQ?41$.@=;G-!TA:]3
MPN>#-UY8"PJL9:"E<T27E#9H'7_!<]9'8-#<5YF3V?YM88<;UD0V+*%)*]Z!
M%BWZ]*PGG#_+"6%?*E7\SC=L-=CZFN]/ZV*Y_&:F..61Q&&JOCC@#<=$ER$8
M?"WQ;;]>Q"O15A?FM+9U";2DJH#4N%?,>/O) JN/;37%N.P(.\H"),UY"NY-
ME\R?)Y&7&Q'^9N:L^7P$.]J:T-BH-:'3.3GKQU,UJC/A]S_.;T,=C328^:->
MF*<U "+]R-/D^_$132('/C*'+Z*Z6,,?>.24NOCL (['FM"W1=G%P+*G5"\8
MG"RU7,FG265 -8HZ;WP0GJH[M<3P]:>Y:+"B^_IG=XX7Z\!;Y-MRTZVXRX<W
MMS[5:L:T.J[*PC8Y>ZN* JB\:$FAU9A<%*DB.647$G4L5=A)-S"FY]0VTX/%
MX@5,U!A=.C0PR*2@3(#',FH_Q))_F/[0_(]Q(;+QW[G04IV'H#G'#UQ8 G3^
MXK@NLN"3<5V]K6)9@SM_XEXAL?SS_WLG5S\2P[R7U)_>@%FV\=YAF1D?V5CY
M8^Y1^WWX!DO8_@M^N%7AJ#>;('&]3JW[4;X1#L">454'%D..^7: #FDJZI3E
M&#.R;DA@^-_0:)B [>YTRBEG7-5$$Q![T'62<3#:?/:O%TCY'^Z+'G#4*.!H
M&!_"QM3Z90WF>GE5QBL^<@RZ;/$4XMJ@[;@E+=/\X$+#D1%C>#1V4Z>5C N_
M#DV2Q\'IAFU)%1<J (+7&?*UTRU).?N=L%3Z4_X.Z-*VOMWE:7#>=7NM<4Y5
M8_T;.U7?A3#Q6>-,M%@ /KKS2&!+0W4Z.&6C7FFW&Y5:-]Y.DQ8 3#?P#=DV
MJGEG>"$_]5PN:71'?!99<=FM^##"7F"1?R@>.]!(K ]!QEMGG!QE<N-+U;@#
M [XH7DXC8V4;I3*TH.>+\"WX^7EF*NKUGSBF&^PIR(?Z^><7>G,A1*-;>V.2
MHI*4DG!4WS$7FV@I"I]=:C#U1U7=V<L?MY<JT]:I8SLHW%Y:[SJ[*QAN+ZUH
MG?67N+V'B-M+![?.,:?WJFVEF'3&8#^5>,!KA)-_*E.:G<S7FV@MQFA98HUW
MC2P1I'SQ')5=7]&#SG)X.,,&QR<30H>3#E?;2DD))"0CU\@2+$E7K>RJO9=T
M5;]1:V\S7;7D=-.R55F\'LU6_<L$!>@M>!?UAJC-69:LRGB#2%8M8\PU<U6A
M939J.YQ]^+"="Q=%C]!]2Y">#\;Q9)_>?FYBMA.X;.<2IMM8\Q(& 6WH7D6Q
MJ&[M(K<P.#=( ,G-))Y>@3*B*ZO<(".JOK*DL#0:TG)R=!=\L;4<9K>Y^QPF
MRK!*NF4#OVV4TRP:B1%!H]*JMRKM]NKYS,S49&8.9@M9R2)E72 T;U8;R_*1
M-Q/N5 FL(4'"5(QOUJ.GF>L.(RQ'< O@BTKFQ_/9G"PL*3_V$,"%P_9]ZXT.
M_E'F19E=6?4)FWQ/#6UD?B-NU#_G0Q^X]0NX>+=B8NW.,:+.YT]SB%5BR@D8
MR'&Q%BBRT."26X$R7]\& Y+5!X/!P!<N\-^U.;& +?UG[-/_-D?H5GVPLOJ,
M-EL9P>N^7!A7$QR=P%"UH5G,7R[D[3AG"AU'%NJ'?. XD8-W4&: +#QY6B]4
M>JO,O%\U?I->%?!U\/N(O"C)()O)U5;HM64FB(,Z[4 _70E<N%2PMUI/*J4'
M-_CY)V\1=L@J:6C9-$O^*XU[SD\7=?!JJK=L[BFY3P$X%0UQT]I&D9+Q(\+)
MS@( TXW5:2/*(O.K*;I%&?0Q$"XJM3 'SZ),6X 8\:Q@"!3LL1\-><!M>['=
MN1\Z?;UOU1S\"4$>A*%/6#5B+I@AEX,^W(J/WHPN!6CQ:I?"RXZLM=&1=4_.
MX,#BA;OA$QN;0RO];-"6@/4%?Q?, C@\X"(#J4!^($3S1PMMW'UPC;)$9%*L
M/HWEE,I#ZH-7N@-8!K41V'B"3UPVZ.;%PG?L5GQZB("Q#$H,=[W5O>Y)5_1Q
MLTOX+MIM]?!,*&G8-QO <BO8?5&=MMQU7C] 03S-=KY]J;W:R5FKVZIT4EOY
MTK")XVTK[96R&4?I;FT](;?U!Y[/3H%M3[DF,'0!0D"(>[LVOXG6;S4:22%J
MR$,R8VO6(4'/'[Y'_ZX2C.1%JE AP*JL@'LWJ(*/".X A'C?[-E_G] )&_*:
MJ&H%UE)E[5^]J!I_@&UYI0Q^Y"/"H=06)!>#YE>N)*%L.K[L. R4.\(.?>79
MA3"^\4_ "FJO*8*[DC?($2I](83R+G35U>0A&%L0+1EH_&PT C="_/SS? 9>
M#',?(V^N6EB6.G,FITJG7AW<R2[E7I+S+S%>H_<&SKRLH-5&JF@,$,<KG;B:
M@Z)2K92723E!E6)-X!F&#P=6\>?^E*Z"D"]\O5^"ER#YA7.Q03!-==@?0K.(
MQ-6@ HW0MA.,V' 'W$C()E$64IA#'@]!(R7\2FC*40P_38)I+2OU3B"K0?74
MVF]B4/3P@<@(:-DC@-[XP<A#7ES?6,+UZ4T^E%XFGMS9/48@=LS>(KZB/*;P
MS\+L_6C)1'+T/C5VN_QL.:.,"[ZM&V:\,62>O#]M\@^H881QEB:$5I7#O6)3
MO"?[8JXB;CZCEVYIEIM[DM>Y"JMS8KK%NDD[7W'O*(_9G4"P%Q[\ C$@>>MS
M IP:XYG#+R%&5/IJ/\3;F32$]& ,4I5Z;(#Y<6TKW:QQ(N@>-)R>IJ;32+UF
M2ZNCW9*2V\Y EEX3D]9QW:9NW)Z D_P@HT]VAR:=2DN1A4L; A:#52*4F3U^
MG'L"JBQT2GB/($VDPMI&J2$ <Y65.*H*P_Y.*@Q[:Q4W]0^LPK"_'DYFK7 E
MAK"DM7:0 ?59W"+#@M?_$5%S+.D3TZ-HXM%X8H_L :],%%+///MQ+F.=F&8T
MGTP<H!0TA]LOMJ-#^U6TJ4$ZXI^*BH0S%:3ZSP>[L<79.!T3E\Q(W']^-H?<
M9TWI[LS@;L/Q!VB:P,30)W'BQ7CJN O+XHE;LUL'7*E\)R TZ^V^/@&AT>P6
M>P)"O29&(&!>"-VI%T[\2]*):64S XGW7B<B-&KUKG$_@,C@EW$+GM$8W&D0
M[ '"T&,Z30Z,"$@8I]8NKI9IZ#DNEO-I7US3&Y*DVAXPJ1L,)U#70D-W.I,3
M$];>7RCUIW^;UD"?";* *?52 ]>;NAZF8R*30T$C\M1C>%:_$E]A\ ZZ?51I
MG6$5U"#.>8&3Q8MI'I! Y61<K3EQ=;Q8$['T?$85>L([4E5%D/'&]YCX%Z3
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MYL5T'(WJ0.S,ADN@H NI+OIU8,UFI0XD[";T4Z8%.I3;TB-NYA_JH&?/)@B
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M6-$D#&8T"4SQA($SH@TS[DU/R5C'P?<3$X T2BCBJ+*UOX%_)"&>OB51![X
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M(9^YAG+/A?.OI"FICH=$<_G&>D//^7?,7:>*<J->?>UXMM=S,,LE!!6%EK^
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M_#ZA#<++8"'P+HJ&TW/_<7EY7]-N!CFA2]W!X%%A_ 2;(^Y#@4C^,[P%<^K
M&G]V$.)%7EY@5@Q]C'RU(W+HCOU AC41ELG#\5 H9BANHAAFP#  RQV+LWW]
M]#YI6N,F![%+0=\>=S"SP0!!!\+'<6?, TBIR :CQXDF!;W+MV7UK$?3*J%B
MV[7S$:QYB%L[[]N3<Z2X\US8L&F=723-[8GL.GE?HYZV<2,T JL?<$K0;Q(<
M5^>>#9P J"[UV"9HRAWWM1G ES!_8!Y[M=W/+.P%#@7!C^($E( BVN(+XFR
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M8W8 CU92FJ:A8(<A8*6"@0(AQ=DJJ*J+WE@1XZG^7+K0$QDYC7ZUI7I>1[:
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M>1&%; ,'W5QXM^:_>BP(A\X8VZUA*0+YGP;D? (2S6^EIETO/+E4SBPUB2J
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MV.F>733JQU^:<^"'MYV4P&Z].KP='%Y].X=GX.&UJO[(BL2Q=EA7 * (63(
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M!2!^4[I\$9:"A7)"EO5!7LFRQ-)A4Y[C[KH,**G7&?NNTZ.J( !PLC/8<@1
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M_2ZP,2+_U<>7\U;7?H^/B^\Q>=&OM@=/IML> 5K:-U!UG@&[/N.2W\%6^FP
MO$#0I..])P3BU*F+Z23EV)3'[3SW1HHLP/(4O7U<JNVZFH_O3Z45U[^>82>.
MX.X@\/P7E-V\&W<RJ2 +NH2K+]9%_1+>TI]*[?O"E=T^399.=S/=='U##=9-
MDT9O;'MP0MIA/5%.W$F:>YT1D0DL^&@:H?[W%7:4E='J(>=T5."7=@Q'"G<Y
M@9@2(^1&.HT"L,DY3Y:2'T,A-#W6?^--UYO-99JN6^MU3=_.[9N/F54]NQ,+
M>ZL]C*>[MS\%'RZTJI7WH1U'U>'[H(ZC:OQ]8/DZCZH;Y&VDKJZIYU[2$*J%
ME-P_"+IW'+B%!M^5"RK[W8"N6\S8*ZV1F6GJ@4IM6;IA6GJ[2H(],)3)Q.$/
M!V4PQ;*E=ZVN7N]:%<H<%,ID@N&'@S(M0)F.WFVU]?9FNTA5!2P+MTZ/GURG
MESBE*HF^88G.X2O!NU=J:Y]=M/1.LZ%;]6[%GP\*9[(B_8!PID,XT^WJW4ZE
M!AX6SF1E^FYQIJ2^WNKNJ[Z^LMX7')3BO&#LJA+WVQ+W',"'P+L;=;#A]99A
MZ5:GLL<."VER\OZ D,8XNVCH1KU1&..OD.: !/YND:9$XC?VUE&G,N-5P?[
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M BSVU_Q7#TAAZ(PUUQDY//LGU%7/:69DD#H[RQF-6-^Q(^9.IOUG-,_.ZS'
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M:S=34BJ]C_L7I[_.D8RN/5.*+1GLSR"#0ZE'DG[UMZ9N6+3"BF8JFEF?9N[
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MV2#:!*\P=\ KYMZ1G8*]$,,0Y885XYC!.*RC51TLSCD^.;P/#?;/X002AK"
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M0NV=SV\: 2^%:["\9@9?Y7UJWW,.37E4SHO3CT'QG>"2Q(J3]K0Z/'',0PC
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MEJ;<>:F7R(ED"UX_HQ#/,%QR<\$<TL\&3A!&6HQF#W?R)AS"8V%8PQ%C60M
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MKB,V:D?"&$O<T?G#)@9O2W;,R<S-Z0?8-P5[/ [GZX@AAH?:(0-09#8CP!Z
M!^#(/[X ,, 1@ $0 >& T%T5^M ?TM_-& <10W[WB!$9C@TB8D-V39+[=+O2
M)C;N5M^BH;LC#Y+_TXS9?YJQ72@1BPLAD+D\N_,*)89\GP1YDDC\CP[<CV#S
MQP@^Q.2/3@CQCXXU,HCPHV/K1XSXT3$+#C+]T2''\0_3QJA O]\#\<U! -S"
MV(3\1;';1H/!:%PXTA W!_A.%OB0O_&,@_XN9XQ'.SF'$,W%X$%$P$]D'(0&
M_XH/)P01=_GV44&&7JV*AM_8]!'DPL/A31%$Q(^JL/>S)WROBIWV[]\FNT'
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M"# #P !V "> .^ @  7P!P23GR0B ;& 8X#C@%1 !B '4 @X!R@'U  : :V
M"X#+@.N FX AP%W )& 6,$=^&EH%K ,V 9^ 0" -D G( >0#"@/%@;) %: 6
MT !H!K0&PH'N0!^@'S $& Z,!28 4X$D8"&P%%@#; %V :\#!X#W@#/ I\ 5
MX%O@1Q %B!'$"1("28 405H@(Y 5R GD!?(#A8$.@1)!Z:!\4!FH'M0)N@X:
M DV"YD"KH T*  4#!3>%"(4\A1:%"84=A0>%+P6>X@A%"D4N11E%(\4EBEL4
MXQ1S%"\IMBBI*3DHP93RE+J4EI3.E"C*,,HCE*<H"RFK*3LI^RC'*9]2KE-N
M4S%1"5+)4NE00:G<J/RH(JF.4^5255)U4/5335(M4FU24U-S4TM2:U);4KM3
M!U#'4)^B/D/=1'V-^A[U//4&#0T-'XTLC3Z-'0V"ADASG*: II[F*LT8S2+-
M!UH&6F%:%5IS6@_:$-IXVES:6MH>VC':9=I/=*QTXG0Z='9T:+IHNM-TY727
MZ.[0+=)]HF>CEZ37IW>B#Z _1I]/WTC?3_^0_AT# X,H@S:# P.6(8XAGZ&9
MX3;#4X8M1G9&&4831D_&<,9TQBK&:XPSC.^8F)@DF R9/)B(3.E,-4PWF!XS
M?6#F8%9@AC*CF8\R%S%W,H\QK['0L8BS&+$<9#G$DLO2QG*'Y24K':L$JPDK
M@O4(:Q%K%^M]U@TV#C9E-CNV8+93;+5L VS/V6G8)=C-V-'LB>SGV6^PSW-0
M<(AQF'"@.!(XRCGZ.18YJ3DE.:&< 9RIG V<HYSK7.Q<:EPN7%%<15Q7N.:X
M*;@EN*'<0=RGN5NYI[@_\@CQ&/%@>))Y&GG&>-[S"O :\F)X4WB;>"=Y/_*!
M^<SX ODR^2[P/>*GY)?A=^"/Y#_+W\__4H!30%< )9 BT"KP0! D*",(%XP1
M/"\X++@AM$_(0BA4J$#HAM#+?=S[#/<%[,O>U[-O19A#V$ 8*YPM?%7X!9@+
M; 0. N>#^\#K(H(BEB+A(J4BHR*?1"5%G47C19M$'XG1BVF)^8IEB_6*K4.$
M(3:06$@=Y($XG;B6N+]XGO@M\?<2DA*N$B<D+D@\E^25A$H>DJR3?"C%)+5?
M*DRJ3&I"FEI:2SI0^HST71F0C+J,OTR1S!U9D*R&+%;VC.P].2HY;;D0N3*Y
M^_*,\D;R$?)U\D\5N!6L%>(5+BBL*4(4/10S%6\I;BNI*P4IE2O-*K,KPY3C
ME2\IOU6144&I%*E,J#*IFJL>5;VH^D9-5@VC=E9M6IU#W4;]A'JO^A<-30V\
M1J/&BB9$TT>S6/.^%J>6O=8IK=O:5-K&VD>U+VMOZ6CH$'5:=5[KRNL&ZM;J
M/M>3U,/HE>O-ZXOJ(_1+]><,P 8^!B4&<_M%]B/VE^U_9BAFB#:L-%PVDC8*
M,*HW6C-6,L8;=QB_-]$Q.6QRS93"U,(TQ734C-W,V:S0[+&YJ+F?>9WYNH6Z
M18S%-4LJ2RO+3,O[4"$H"EH#78=IP@[#^JP8K1RM"JV>6<M8XZTOV8!L8#99
M-@]MQ6U#;"_8 >R@=EEVC^PE[</LNQVH'>P=BAR6X,KP6/@M1PY';\=:QTTG
M8Z?33K/.4L[ASKTN+"Z>+C4N[UU-74FN<VZ*;H?=AMSYW;'N%SUH/%P\*CTV
M#I@=R#FPZ*GN>=QSRDO2*\IKX"#_P:"#5[Q9O!'>;3Y4/JX^M3Z?$7:(,L0&
M$HHL1JZC3%!YJ%6T(3H;O8+1QY PR[[ZOB3?YW[Z?EE^*_[[_7/]7V)-L(78
M-P&6 ><"W@?:!58%?@UR#6H*I@WV">X*80\)#.G#[<-%X>Z%RH8>#YT+TPG+
M"5O'6^$K"4""%^$BD9-\,S4<+A6>%/XTPB"B*.)#I$MD6Q1;5$C4<+1,='+T
M\B'S0Q4Q_WRH[-$>[=$>[=$>[=$>[=$>[=$>[=$>[=$>[=$>_?^7OC[=#_O]
MKU0A! 4$&H?$**!PP8I1B%!%904E18#>_JA0!"H00P0C,7[8$'W1U]U71<%8
MM+ZHJ[J-DDVH"<8?:WD(CW$\9.N$.A2(TD:+[C>@UXO2B0H.#<80$>"HX* 0
M@DZ4ONBN<1UR>X>M* K>%2$&ZHL:[0R W6SLP28X/ :LKJ JCU)25@9K:"@H
MJZEK:"C+@564E%44E<B_&O+*:CKJ&CHJFN#?2=2 GORIAT?[ZL!-S7^'(_?T
M17_ZZUNDJ@(.[Z>HK*VMO6-&146>+"%/B XA(J+D0PABWXQ\MV.*(:#PV-VW
ML\ [?002%T[4%Q6E!_]$O\\K./0'T"\#^,/RCG&RM(X)'H,@8DS)EX&*DHJ:
MO)*JO(J&D[*RCHJ6CK*FK)*ZCJJ2GN)?)']E X=WPN&"#+Y%[X\W DT<-<!2
MKM@0-"Z2(/V3H=_%_V+)!H?&^D;_PALU31TU[9^]^4GRKS;(^40CB(C_EI6?
M9;_'7/$O0?_?)B/TIZS_*1GD 7(R5/^<##)3QQZ/0X>C,'@#(Q0>AT00P:98
M A$;%(3!@Y65%)05E/\4RS]I_*>=1Z-^^!X:C@_:K5<T2A$3A-EYVY) ]E_Y
MS_ZC43I$+#'HYW1\AS4*(OZ9^WT@"+N#IA.$"/'3%XV2__U%$5&#?_?U3WEE
M;V5E;14E+545%6]-L)2RM (:AXKZ%IP@[%]<5/R[CWJ*OYC.SA11WVKW%Y-T
MQ(3]TR0-OK_;^J\<^+/^K@-_!]MQP1>'#T80#;#!"#^,(B:4X+LK^SOW/UT&
MY$5B8_.OMY3@8,5?:1*(9A'$?ZU)V'G=1Q&.(>#"\2B,600YCV*_-@7'_,-2
M^K4ILKC87W<Z&QL=: B!B C9>5?,@,Q0P&+1.JH:IJK&ZEI&JEIFQF9FRLI&
MZFK&9LHJQBI&VBIJ9BJJN]O$GU7_9M84APK?J<'?S:+)9I75-914U#7-5#7_
MM=F?5/]F]MO+:8B@?\/\+TS\#<:2O,7@\-'_LXK>+9M0!)ZP^U:<ONCWP(O^
M36%'9[<4=!"HW4(D("(P:#W%/_'^60G[]Y3]UY/_F^H_VX_TQX3\]9!0TE'Z
M<?#])/7/1G9VJD@$'F/D1X[Q?W4"_DKEGTVC_,E[(P9MH/A=\3OC;XGYY=;R
M'\D8&H/'_D]R1D8A;\-$#)Y@@,*%[+PA2-Z3??&X8# B-#0(BT+LZ"M&A*!_
M7\>A/T)%Q(%_WM;^9N[_<-+_?IEJ[)7I_VF9_ML9^Z_/@G\S8S_???Y_/&._
MOF?YIQ/E^T'Y;2,QW]D*_GMYUML]^O^WI\!?5']E&?V_.5S_IOHKR[A_Y_C^
M1Q-_C_9/0?W//\%\K[5_>([Y/OSW1\L?0SJ[[W63G]8P!FIZBK]B_TNGOW')
M3]+DAWC%'T_QOZKK_SSM@>R![('L@>R![('L@>R![('L@>R![('L@>R![('L
M@>R![('L@>R![('L@>R![('L@>R![('L@>R![('L@>R![('L@>R![('L@>R!
M[('L@>R![('L@>R![('L@?R'0>C_^'?QF!"TOFBDZ'Z#K[, $P#PWZ0=(_^N
M#>#7:P V6L 7D!<%D T 8@-2L &_]@'V 0! "BK@S_\%,A!$34%)14-+1T\>
M)[("@)1 $"4%!14-/1,S/5D+1!ZEIF$#T+*+<' J<QDYT'&+(L)X^,14CF66
MTO-")(QS6Z[?6Q>75-4PA3LZN;B./7W#KZ:N:6)F;H'TC3B>-2GE[(9*R,[I
M'9^R1..)X4EEF!.DMLZ)RM;VCAM]_614(;*_ ! %\">_?H>EI2,/>[/M=*DH
MJ&GI:&CHJ*G)@B V (4()16[LA&U X)#-.Q8YCH-)Q=/*=D3;C$58[@S*>LI
M+<31*7OLC;BJFHD9$J]NBD(3XLMZQWDQQ(3$9Q(:+N?+6\W;;LQ_?0!@I"##
MLU&P ?8#7H^&BA-L<@F*PU^V&49Z_.)0;L=;KB3,?\38&?1Z]>:GI:[TK6BX
M7>'@=A"#EM7PQ;]LK8+/,YQO:CH2A;S.P>"P;1+SX'7TU.JS>^@K.9@V-_DC
M4@4,XC+V"Q7L<":^;..VTKZU>N5/3ZXG)2#1+SL'IG%"I+=I/1^:)<9UWJHX
MJ-A[+,V*OR5P6[KHP=D&($KNI=*]%>G2(^]" I5.ZES5.*JG,US5CNS5]_K,
M$.7"M>DNUL54D:8@+\ON=<0]$A0K(/M ^Z5[[:B7YR6WM#;%06NKT1L6YSH.
M-%E!NBUMMI2A6<IT3I= '36R(D9:4R_MX9[QA=Q:)X5=NS<=D:\((44Z$?S7
MT ?A2W8<B>5L(O#,0:"R9R$SE94(_&1H1WQ.I9O>RC;HOKIV7X!:V]O$%Q#&
MX^/ \3/&9U+TWLFT-J76>*LX6C&IRG705UZQ3%55418R2YCDF2+)[ O(XS\K
M:6YU(&BS>_20X^?+)1U6QBEN[%FJ],=JKRMP&@Z8QJV ;UD=>O1)@'#,(#*A
M2Z95H'<29?K;4-[ \ )3!^1X;IG@#'=H-B7E,[U:)2G&T)CBQ1NM11]_Z\ L
M/0\(4'AYN59%O4HL-3S-$Q.VJI;DV+1Z<"*6U*BO4X9QLE5.[3XUX-C_?M&B
MB10U5>$-[=-KTD=(0VIHJ627GF%#JAP8!RG%&%@KG&])#FRS4-6.8/*:7=CF
M/PS5NG!.K]NHY.(HXCZT^G'.D]KY^O&Y!<?H*,LD59H;#R$MZK"CX1O:==T,
MFW/0VASES7&H*2&R)?*M;,6-D9?U=1[UE2=4)5L]7ICK>Z8L5Z/1K^P\3221
M9I].<C[.<E224M*"(B^+V"Z@Z;/7@.@DTG5/OK'/@K""_<R]CSI3==#6'L$J
M]>.,J4X+5JK:VK*>&9RP7DP\R5<ZH'\ L>BD&C!V,/8\=KLAP&_UQ>B^DG%:
MG1/$"G4,^OUH0) C3_6PTLH&<T?VQ9G4ZHG<QJY]I@3]% IZ]_"ARMR<NN8"
MY ,(K$#OB?C+ 7B6*[X\/OZEOQ'^6=%ME! ,)TQ#_?92R%7-W.@V7(S-$U%8
MTAF]4Z4&8Y!94"XF"=DB+VT$/#5P@D2L5@M;:@P\K>6AGP6??QO=/"67?.H$
M1]W0G'M1H.!AJU2,QE1[J\RCUI;<<9O!*E+UFHTG]'3K,\$CEP22K*M&'E]8
MNN?5EIAST'%HR/J:$4!._HW@V:3KAV<@%X41,_MICK!H'#?=:HMP6<M2L6D,
M/XON,9)9F#H.AR^"!>$Y\NB*L22YH7!.J3-([5M+TU\!OV5-L1N)?7S3_/G1
MZ'91V,1GN:NW-M/*.IA;JI\/18:$O>28"[S>Q;3NNP9AI^..]M&:,P_J:_L$
M_A(M^. K8%&\_NA5!N'%9VD-#P0O5_D+R=KH1#=Q#-]/B!2;ZW]BMX&.K.SN
M\ _8NKWTL#SQG7B]F87/F7<,(."3%MUSD;<>K;8\76_\(GDNVDZ:4CB[L"74
MC2:VYH.YS+KZW"I+_\O^1\G6-$NW$:F'58(>8EQ25,AVWD)<G5ZK\M^>?=HA
MS]Q18&L(@Y_M8->D@P!@AXZMB!V.@\Y#7CE_4L<&]D8##5EMRYM]6<X>.36?
M%K2N.O?"+,7_7)MKA+(\#'9/'  1A]0,4*@]F\#=S7_1@^]J7CHAO,0B67EK
MX[53K;0/\A+^G;KZC.G%T,(<74!)GOK4O)(.ZT)-XQ7IMT=("SK/;C\R?/,H
MF/N>-W=,5);,F[/9,F8Y%F!0CH2#^TJ#C;=C>=1^:@.Z3>Y9XD'N.I>11U,U
MI*:B-3B/RFA2_5!>E,>"9:YVK94(^UAV\]+"S,WT\1[?KIX)ZU7ZZ_/O;.J(
ML&$\KQ/V0F;6M)NR2PV]E%.'L8I8U-/X[!RU K:[C6D/PP5RF"L'VC4?SL+0
M#(/XL.SRZD*5ZL7:X:5$W4Z;?9V?UMWGWJY>6CX(WX2MY9=76&29G76'9R?6
MY??OEZK)F+:B<60W1C4IQT86>KYH%#HK_O;T\GT;F]S:B4K!:!7(M2+Z<;KR
M]J8B?H48&?1,N"K!LG[HC!7S$\&3J(J(:$$N:X3)Y)#S0C-GZE: K2VKI1R<
M=$TJ;M">JCAPI"[V6(1\<F:P<WS(-7>TC772"(-33:#Q$1GTPHF%DR@9.-?)
M.7L&B+AOEGJ6:_%"Z7,YL6);'UAPFVOSI>4\!Y]W2KYF,<(L,[X<M2JK6M,=
MZ.L9G6'+J9UI7@J,^5E)TE)/3AC,Q Q I:XL2UOEBV>PXJF8*S(J**O.AOJ=
M3&E6>UW_27_N;="XS'BK*[H+_])1OLVI6X>Q'V%6 7? "*9$F]61^I6D!MCO
M5DB59X,:TBJT+/0+&TY;=7OK'DJ.F[E^N_%Y07^;MCN535)SR67?2S%W(=:M
MIZHDN^%!*OR73HAV!A4T>4JU3HIO/A0("NAYY1(N[WIY@D,%">+F]!3/7\IR
MRJ/1WY>YN%EX?V[6[Y5K4/E+P3I,[B-49B!'?:<[/2UWXC# IF^9=N&:^'I<
M>:O[!(J/TR"RMO6S"?.)49>V QZ^D4J(%C]WT,9GX^/G'U@;=;8,MYXKIJK'
M]Q;J!+6J3^HR+57,A\Y;VQ2I2*@+%1N_GNLQ/)@U8=R<?*I4G@Z*?,$,KP=G
M%+XSN1@K=IG'+Z'(YHG*&P$1GTP4*=X5/&.O2)=JW0Z_(RZ%)>5IP[(+BEO9
MRU86KG--';I>'?L*R\ZCOQ;0D2!;SM>P+<D@4MW1&9![F,A(H!NL?HM [>L=
M8U#"!PQ/:6;$HR\BN^DV'Q1(79P+;+CP>-8DL@(UZ#@I9V-/K&XEC4T4I'NJ
MO+$WR-:Q.#]C0UK'MD]U14C'2/MD:7EU!O:&OG$Z"[MG0-QR#%I= F5)#2S7
M'K,"L])*J"&6&8J:<[2651Y<&<O)CL-O#5*RFL\*IR\07S]II@R^91U1]M&=
MXE85*=#YV,%2A^G9U/;#+,--"0OB@2ZC7CXH4">Q*P)P E32$A+W9JSKB4;L
M/<W!_0J:IP@TM1D-K]0=O9\>]#0?**\<'.S)*6:8OHL9 .A\/C1AV_(V*.ON
M .G%\<78R,XS)3U, Y@S\^-Y2K.5I7I+(N4#8)(ZGC:L9EY8KCN6ZZ7Z^5ZO
M]Z@SH=/BTQ6>/.%5).OLFJ4BS%)R"DR 6329?>R#27:\M]12^;O4D?C<\1L%
M5Y!R\KT,1W7](-DY$;\!6(PCA??-IZ?%.!^MX_6Z%%UP+/DF?^FHE]',N_K#
MUE&\ZP$55L4*#,",FA/Y0;?[/.(O$D(-PR[W-/>_RQQ)M0JS>2=?WZA1GG&.
M0;'X;)G1R]:F,HWW65>#/[%U;E4%:B1#>W%\*^>EI&UUJNE>7^[L.DNCQU]2
M<Y2ZWC$CP[I%8?1T=L;3 :AM?#GU'6+$F8<&@4B[V]BPJ]FZ"K>;6CPKV_@&
MJB?1&T$O5G+;"PXO./?++T98N^V7YXT]/N?8^8YG;:N*1Z/UHJDC_(M3UX7Z
M ?PKVJO;2C52]C(B4!G8I&U,C6UFDAQ]K;O<O3><TYO2<,G9X'W,%8.FW5RU
M]R&I\@4!!1)W#&[Y]1JSG[61=:Z1O:F<^)31-?F&8,UR17T=YXV%=RTUN-D%
M'>_ PIZ4@HC(E+([U5QIE<O0^EZ\UCW>[L8"TGV+EDL=Y^R8=:_?7NIBUF77
MJ\_%=8SF%N0-WD^'9;N0;/F.64;;TB*+L<@R7C0=V/@.:CU28ZW]H$KGOC52
M@<N*AI-$>*&'L\8@J'#Z;$!VC=6U"LHAAC[.),6LO%-#:1B7S\^>\;\Y_CQV
M+5P=HXJO.\EIAXD8G;Y_M[<HF%GPY-JUTUZDA0A7QCS,!:9,Y5JG JC5JF<$
M[6&AX,HW5UYV;D4B<=@[6J+(I?NT,GZV_,\ "-1)?6I!2/YO[UT&@L2[?7%,
M-2[]C[9E48M]=7)U>HT>6! 2=LP#'M<,+RG7-D2:CMDG-N4_7GI2=&E PV&_
M9V?SQ05=OKMZB#PW-4]K.H5;85[ZMIP?>MBSLW.:JJI!%<%7A>1>U5QE4^W_
M7*%5"04S&I[ @T[0C*3;BCW/.WKL-4W$:H]9]<LK#\TJI(H3%8S9:_Q]RNBN
M+7QNO/9;&*>=MN!L8DATYI1)EY"X=MII>_U/GSK?O[Y9VJ'Y[MPB7TG>H2H&
M(2G--37_Q;IKMQ)\2)\4(_,0(VTE&9''S0\\U.1=.4R_-%XHP"2^S'^X2HF_
M2B-"L^SBJ[.Z!A%6$J:ULM(Z9Y*G+%OJPYY4<#LV2\".KXZPM@DML^L;S=][
M6&04>Z?UX*!S3]A"/8,;<]9EI1+ 8NYFZ6E2E/&Z5_/]\/<MK4%Y5,?OR,P<
MG7FYF=L6QP.>><7!26('B(Q1VUT<TPY.QVNWAN5I+ 6ZW8*!)KAR[8 'JJI?
MOX@Y%*G[,>;3N?VJV-=3N0G!YXY),K8GI8><XM6/Z@F/^GCJ',5!)E\K^/$[
MCSY40*0G,9;#($]6J!\XX(!4W<?UK79CBD:":MTU<1$OE'SS(ZEIH1.A1M.'
MUFA?'CK^J%G7[K#44^Z9I7RW>J:GU0+>7JC(@M,TEMF<W?$OKYFKQ+I#E&OP
MUY]OC=5'6MCZ\-U2B]X43T73+]^R#Y,[H5X[_"KLH<'C!R;)K8%TSJ4MZ0H.
MV:HZ*H]":@8&FW-.WRQ)H+,RR5VS"G;(>?)HLWMP4HRW)SMY=9&/ZE&&TUI)
M)#V)U^62Q<!FJE\$]_.>97?QJ/VM#T(^R:RM.,K#'<2A'#A !BOD:1_,J5F0
M4!PW29^L_S DJN6S^'#K49WHUR?KVSB:DHU :U->V9\E);=*F<?A8&7J*>LZ
M?GK!$XHAF?M&CTD7E4^-9O<]#[ *TUI6'#IIZ9KKG+RH)=Y5'M=QZHPT/ 'P
M&S]02#S%+B%P\&V[UXMI:3JGY(C^M]L*<8Q#HO=ONP^(B- 7R< J*93]H?#R
M"C-8OB_L9F#.!1U^D>,WANNUKTV]3.IZ5R\V89;"12WSS,A&X-2T^Y +P0#-
MZ7$!?T)V=;JV)2/QQOIR?GI.ZU11>.VG2^42=U-?!-S'NN>6EP-6H#".9+,
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M<<55]" ZO.$@^KA>^Q@Q3.F 0(X0ZT8:27='4[JH_VMS;/UO<,PY,X%SHL$
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MF V-9.RS)Y3B*6T-@>L6;PIIWBB;>P874([^ZZ\#S1U+/ZY%4NQ3E$"L..5
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M*2&]=_R=&R$N35N.J#%V^'!RK[:M?T./'19L4AN%WC$A]U6(JL5+9J/3H;G
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MT<W,"CCQ*V*H)S?(FVQ'=/M+N1(2 GT>\1]5:PF8!%0M%C%XU!FM&MC81]B
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M/ NZ&Q6.B?MXBKS":@E[SHSMUIHWQ&<>+9,O#*>_MZKN&;3FN]@4#=H\_@O
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MY/$FGR 'ID1['L,4>2&Z:9?+DQ=95JD"4E[DPX8ERGFL6&0;64A#767FD'0
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MG<A..H(FN='A2N[W"EX=^3PXWDO<5_?L"^$W54XZV ID6. -QMFEU./T%_;
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M38CQFD)(@0NN88'=>""3O0:'IOV0?6W LH6$;M9I3(T>)*'C=PF[9T-A*W5
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M7$Y_@FJ.I-2RZC798LKZ]@[#KZZ!\VDQO0Y"[XB'Z#D]'>=I93#,Y=E*1,Z
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MO05S(6JKT#AMBK'G>-VN9 0(>27F[:%\4#DBWW-VJ=%UHBE1B&E178DB2DO
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M!\DZA%LD[0:]$S5.BIP(TR2UV\+,72;2 S5A&QYTK6B<(.&]G[IR$!>"UE4
MB=KI_NUA><^"/+)=QT-P-:ZDZMNUM!F5P%\(E'0-,O*VK344H>+ FZ='1?A9
MD&I;\\R=_:&'C8L#B3H!K>Q::S%QI :/Z8V$?XA'ISW+*(NIF]XS-<B-,A!E
MPHQDS>-V_74Z\]7'$8#<V>80]WN4;D^5'^4E2:Q#S(Z=\%!]9DOW!Q)R[.]W
MMZ>/Q*2YE:YX<0VR^[4.@HQH,T#UAN/:[Q& FOB:U3>$DS[[PG=B83[P!].R
M_5R^S9-2+H$M<6PRZN^]L>QQ0$3<E&X]#Z3GEN]T3_"[C+.H]C ?*I*BP.F\
M2C2_,B064T[]H2B$9@2Y#O72IT+6H*6!1VF$Q9! WG6<3ONI*=B43%'D^RUJ
M05F%N!4K4V=9[F(F<1D5+>!\*;(2;\MS;IW.-3(R@QVVW=BR^ZE<6ZN4X:&:
MCJY9\A&YQ(6XQ;AX5/@):'B&DIT+X=HVA"?$=Y^A:X_GX:KU.F$@ELBIE))M
M"0N'MDI=]>U?P-*,N#P @(A-^ZKA#Y+QI1CF0W:=]UF0J\8^!&+7$("?=%Q%
M$J'@7X*S0/AR3TT,U<Q.0E4Q8HRK$258F-X,OY8;>,T1E4IP7I[&N1$F86[M
M$%8H ZH"9\W5@PQ<?V4]X<U-"P-(*2=R<N,/.#>D>=*)4P^JZC[91)G?S>'5
M*/@A')8Z?9$.*TJ@OXD&[Y"HK]I6^C0HE*;5[-4UR-J%NM!J33+SR.$>)IT\
M80Z"R@G2&[?J]Q""NK(^[<42>#!BB*$TLKXVR3A,HO#86Y!><]HM;Q6F$R97
M3-HW]Y47*UH\(:_()U?.&!Y\N5.P]@Z6C#E*"J.4-#((?587:M52[#6EJ,/^
MNJ+7%&;*/:@.9@&98R.B.5G*@WL.?K5KMMGW)**I6"/Z__+_0\C>4R!L56BS
ME!DQ7,AG6I.E8#W>EJ-@IF:>4/^F+IL[[H)DN>WN8(PI7WV_<(]MKFW.+\J0
M6C!\91&YS#9&V>PR5L2)T)5WQ$E>S>/3]P.4KPQ>Z%+;"$Y#;\84ZC;E$E3W
MQQ$&18HV^<F9S/VM>[5,-RZ?ZI4M$A0D\ H6D];K@\/VK#A> 1<Y1A:/]@2_
M7G"DW<19U'Z-T]56Y-X8"13O2MAS-;X:KD*H)KNBX2B,8^S);2D9KNX<HQ#!
M":[?%N0&CUS9T[7MHL1\82KV-(/JZGBBJ!E$E*UF=BN #203$ 5!S%QZ3,0?
M#U,</VJNJO"3 UFT,\NU7:?W:'>23$SS5'12?V:& 1!'$0;Y;$^)1G4Y%, .
MV?%?"OA74V$=KZ\Q,_BZG?@36&J/%K '*U@,W=BB?0A5Q1Q-$/5-UY,(^\EL
M$UNQOW'6S3$+%=%T3>LYVIA7_7+"XV1^]4W,](1H6^XMD4K<587#[U>!Q]+?
MRH5=J88("GH++(1Q ]5SW19O#D^ T3? )J9]6179)3G-)RK*G_=Y43$0G:K'
MH,BWAES5&R11W&?&SJ53^8FR\<4U:2KF7]((NC=TDXAO"@<<ZNI2$"E,Y$SZ
M7F8Z@?<N=RPRXM.$!)T%"%H$7_< &FU]-MII( G-&&%[Z:(-7<8,/H36#V7=
MB,0A-,-CKFK4X!*G@._,'Q<P?N. ?<GYY)79D@ '7AG,0%3$N4]5T@'ED2*D
M,)%D^K>3$P>YQ+-;*!D'4P;%RXD]N%^%9DNFWTN<PWX>T'+3A<04RIC?N$N,
M\65%V=4E-166[R61-?'190H;4?;N$/?I\7XH*?(X$5T#H#*PEKFLS'ZMBFJ%
M^O8FGDZ_ACEXQV$.OQ;V5T5R(N0Y;GX_(C!PB^R.^FF^O>=@JI7=EFFB@*$<
M87+%G2C N7+,KL)I*'*/8T8Y?9483/^9;2Y^1KYI25W5\6,WQZB>=4.->!5M
M2E VAR.5X*NK$][O]/VK>AIVD#F/NY[%!8M?M&.,6'P3;SY[/6H[+9DARVX<
M?YM<TR)MKR2D&TG.$,OXR?9:E0^0RXP2HRBFZ$S+08I\.W=?3G*2Q4&AVE/E
MCMILBJDK<WO"0^+E]?#$>D>VI,^HRAN RM, 4#I(C .XTV#$EQ![R/KBV)\2
MYS!.U-8YKLLF\A<R^N,#>],;Y1$QK =]-7RMN]Y_A4\T/R,D/>?4//)E6_#H
M=&E C [']+J\ZW]V;!C]!51H&SVEEZT^G?E<_PLW@35?Y]@_B-KZ0!*<3V!A
M:9W);GT>/O?E#\[\#R:[N'\!?ON$A+"A<D@^TD7YI;KP\M=%OX";Y].'A=IG
M$<8S_KH'DA[1&8C>R=596*9B[I-PF.A4.>1'+OS@<<X[H8C!&7J38R?MTXDU
MWME%88$WNC/"N6N( )F!=Q87D3OR!%U'84G3^X658755CJF0!.]'0"$_1%8>
M'J7'?_G%G5WRU\VZ&@+>^XG"A-?'[PJZZ2=Q143ZC3C2OE?E5]E7Q9:+8R49
MI7?]*59H]QL]]!N![9H\[LZL>!3_VAF&C#0_3]UA:2FHK6/^!5C@510\6LJ[
M -(ABMPA_](C_RU@#A]O@6T>7E;[[9Z2*G.WLV2S]!A=Q@R;KY967$8T4!37
M'%Z*4MA*4OCHI5<K97'='3D<1O\%/)4]8Y*_@/NL 3G=7[KS_<#G+?;0%^S7
MXI/ELS3Q4HE6M5*:[V65".RLVE[I9>^YGM&3$1\6/UBLH6]V9,\X^:1OK3&<
MXB?2MM9.B7=#[[]WE<4^V_SY@7E4>S]__A=04O*,=<?]^4X2\A>@; )_=3W3
MM1MT6NZL\525YAUVG>5X+[IN!+DZNQ2L@\G!E*^>8*Y>I=J>/<M8\ZRB7X-.
M#_;_16L=SA09_@7<D3DVP;JJ8)9/I%@!J\D/F@]^Q11AQ;Z-89G"N4^F/3>B
M."M7OU\$67:]/\/6)<I=)0R[+K]\]'D4&C]JGGY!$5;@KBZT88NZ?_2_BU]J
MP/;V4Y8N!3;]#"#=73!-J!_-Z,GP3):'[Q3$M^%P'>L?*-Y8BVY7-ZDB#Y!/
M1LO[*3T/XRU_ 3O5S9!J+.YV5E]7R.E _9W$/SRR7](@0AVN'M-J%3"'/5OH
M4R@__#=L/J+SW+X/VX5"Z\?_R4!4^:V>#-:_T*\S148=A['ESZ['-;>Q.X86
M;O\$?Q.3??^,Q9?QLCUF#G=Q;%-VH2@SY)//<TSJHVC%86R#;9.FX VT:^WR
M9NJ/N[EO$N0F[(;TDJ2QPHC/_=XOMO8OH"48\JA$=-/]]-(EL2<N Y->)@OD
MIYY/C3FQ>"\Y8679PV]7(5T^SO])?5ATF8K\Y]ODZM\M.3Y&Z94W^S,?C,X$
M8 N0QP/8A4^&CS)W!LM5Y;UO[=[^B<(_( \)*6J\N1_Y_H.ZR#'GW4U/E>A]
M]2,L(RSM'T-_ <L(UP\>/?^##/D#W^ _S?K9%!D\B5HMD#T+^B[_!039-L'Y
M/+.6U"Y?1J$&[\8-I?P/_S@5#CNRV!?Y7]A-8#=9CG\!8T9&V\=GZSO_2E[/
M]N6$%8=8GK^ BNS'5W/UI[BZNEE;Y*'YDV&G@'EST5\ ][^,#M=WG,V[DM;A
MTNU+_V&T+^C(5^3QS[]D*%;V4P9>&+UZNG8CZX09_I-+?8PKY"82,^LY&_N_
M&BCK*/:+;W$P!?/ OU3"_[WF[SG#%GJS^-(7.7=WGIE+1L7V3[D/Z4QG87ZQ
MAQ4]D7&@[ XJ./,Q*DQKI]SQRF7DX*E8W_U%QM60#G>*WR^:&*[=U3M\SIE*
M*?D'D(UES5/0W8+RCP__?@ WX#K^E[NP]\/S"T+2<_?9%F[:CX<]-P$]](.W
M^]DOIG-U\UYKR^(7YP1$[I\--C\:<#WMZMO")FTOJV$GQR>W;O] 2JO5FWC.
M];J\=OM?@>)@W,ZUECTO*'1"GV>JA/U\?%I>T+>X?^$+\G:>\2GNI>;WRC5/
MT1]7%PZP_ZW=_D3&=9>S[#H >6YTN]YXB;8'OW3(W;_$1:^BL!:/%SIU_OPW
MM2]:]@M[8CZ&0NP#A(RXV]FN*J]F^@5C8&H2X_0OEF$"1UV#_;ZP^,?2"YBQ
M'>X]+[4JW1N=_7/*OL4U5&_EY[=SV'>2RP"_0FUER?I##Z-_=F1?4"3<Q>?3
M<HVT\*,:@L6=\4%WC=17E'YO1""&V.ST7ZOTA9TDG0H/2#*\@%ALWS=#%G%]
MG^-X($C^%R  ]_$;ZGFQ[B[W /NK]?*4/]?"')=1#016-Q_:1<Z/_EF-.N^*
M5>P"7+D9]B+=SK\ WI<&SV U; ZPG;F]\O;*V\6S%-6NF7EZ7SZE:U\5%[:M
MO5,2,S1#L>8*\?T+N*KPPRI>]NBRX%'_ ??3OYQ+/56<BGL11/SC=>JY'#:J
MBH;WU^I6L7N%2NZ.7W^\GCF]+*IWI"WPAIE,AHM*\ HIT#3>O:YI:)"7 YU_
M#OK$16S6!F%^0%-C=USG6?@M5]5.74T219:O$"P$%^HSS4PL!'U[,]1-@DT\
M[;_A)UM/XFO+DV#2.9M8Z@Q($8X+%EBDPP2\41[BWY&EG%E:'+'MASK6@5($
MDI?CQ$&%)8CXKVFQQ4CPLT&",0.QX?ZU8ZGHFH% L;Q7>&#!-SXFS&)HP-=,
MVKVOV5];C(T:.'[E^]^'PT9O$<<P1 K*]2LG;-YM+A&4XZN_65M94!?T<65C
MX;0J536A%JAD,TO,0>S"]M)K_QZ:*(.,^02_DN!2&"#JR:6'L@WN<5J#1R,0
MVDE!&VV1&/7%%9\P.W&/MOIC2J=7'TFU?_^Z"BEE,F\FN)*C29D1%HVQU:]#
M]>&<_O0.)0RE?_R;8UA?64D9KQ:/O9G+:'=1,>[.9UY"-;*T[5P-M*3+#;1+
M_!5.KE?S&-N#$TW36%!=^Q5,U^_08L:^<AV7^,+"SC(O!_]6OJN/3#I-7,%5
MAH83:;WYA64+A</#-,\49#$$&VM<2<*:$6S1=V)C5@;<=@)N]C^WV7.-[\FD
M0IY0S*/65#5D:B*L7)7]5*VTM-CSI C/65DIY>-Q\<M2$.R&A8K?>R$^!Q?R
MY'J(+6J=K_7X'GS1[;ZHRJ?*L;71TT!FMFT<K<_"?64FL/'B?J5<V5;!+9N1
M\I;?J]W?M>D)QB&2O=):+7IH+FK](BD"PL[=E$-?"4$N!EL=R4J_G,0NIZT/
M5!(^MR24:+1G'S=&X77E4W5C>0>>)%C=E+AJ38=()1_.I?-C@? K!CLP3@UL
M)M@0OHE[(BTY$V4";2LRLE.+6S&'$BFVI5F&'H,V\-G^Y-&U]1O6J-&),)MP
M;37F<H01)HH_,72)P4\G-S!]0N%V!>^(8Y@NLV]:H9$*[KO(8AWM)29UA_.-
M!-06#:PLQ'+JS<42D8\N'_'! M&1@50??8O6#-+SDPJR/[I%O#_ZDZ_+LI)&
MAK=J#B0)-K14< QF>]MR05-J2&7>3"J.OR?[&>C/O'+<S>;S).PE52B_7/ZJ
MSXFLSRQYAVOS7,%JBAQ7QZI_V7%OV'8 :8QG8Q(:]1D(;%9!CP/3D5(C==1^
MM(4V+ A<??P&="<_AGOY80Z8HL!C_GB1XZ3X/AUB_I\'&PN1[PJ$O?;6V)(?
M<05N(CLM/7YC13^R?S]4]YALMF)!.U0T$(%!T6<JRG^G ^BL35X)A"O-P]:O
MF\G%;TB9IDR>T$?CR@E^TDG1):CDDZXK$B0TW7RC3AN(:4JZV)Y.R!"0^)%_
M3;GWENRR_*-E,_^G[K[OV^,[@?M]14V2+.Z[_ IILF5Y14WQ%L?H"TZ.IOU:
M*%VKT)68'[>$J4WV$XW>[ZNM!X8'ML%\D5G6?.I$IAHH9BAO\)( @.V"+&3I
M1"?_11U0W%8RC;=-ENQ;[>+PBYY"_D_"DI7<.S%CC[)I7XF+J@)\U,S16:MI
M\3"KB;B<B$Y_M?N4.!L%&GV#CJN,-9DV-8]4\KS9'JI+53"\'-=L',XK<37N
MS@^D9^TG9TA':G*AX?HU^S)&6T5>E(;N[Q3\X2\T_%;G>/NQT1,^*O 7P!I<
M5I&^K(BDL"S;^?/$B.PA2K"DAFYUN3]Q+@$]9JM8M]+NHX8<=6QAW3U38L?@
MJW4 Y^!\8EXY0H1N5N!G5 :D8A\2\ .11%6K<J^M\4R19KL:+WF=3,G,$!?G
MD4R[8K2.GKEF$$6(\;R>X;.4)^?*N/EW_4#6]!N+SYPFVAM-I?$<<O-F(Z7,
M]W+(]U+O\$N)G"GI^G0;OR(VUG.P$EV*;4[%.]VGV$[Y!%N)!%G%B 5/;[Q/
M^ F)FUHQLO#TE69ACV*@35&8=MY(W?<2VO<X^2#Q?N?FO-U@3D=W^L HIH4I
M\T$WMI8I.;'$5"!2E)=2>QTEL"L@H;]@6!B;D=DA]$K-87^"2P'W%O3=GFZ
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MF']$J,EI# 6J<=*9Y1+*FGS>S?Q3)U-F1EJTO_KI3>NI1;U!0XG322?G :S
M6CBJ!>ZI?VLQCE>HY!FRU)=K3>K2>Y9F>V_I*BQ6%=8@#QVY<4I,T^**80J7
M$P^>=AC%#>1HR$4$@D$5DBD[[;B%QVEU"S;(S&?BV@*MTR% 31D:,@ST]WST
M/Q?!QQ<%!<EI!"%//G.)0@(Y=$H?;_B."^GJZ<V^)VX"TS2@H+XXO<FE+S+%
MNF)O(F0M7WU9_2K=XU.00BV5Y<9AJU8XG-TN;L8FA?B]]I,B$U//N1W=NCN
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M,"F5:TWQ_47OJ>SD]QQZF>CPW)J[.P 3B5F!_TP%%PXXT+"8 N% &L(@T<@
MQ@.04IL !;U)<:]@=_'I?<YGW;F[[__OC8/]W996][8IU=W.VDZ5/AS&O,KN
MQ @C!;R"S4.^I-QL"9%+E1X>-C\F.#U2PAMK&J^R(AP+Y<I,%69'<'PCC-A_
M!0ZE5" AR^.;;<.!N*UG4PO51[0<L\1"Z0G1HR05J_?6!AOFMA0,><+H6W>=
MR238$KD3=OA@DU[!RJ*FOVT\M(XW,CQ8E=^Q&TU3/N"Q9T9]F#-V*[0*>R@K
M[CZ*D0@C3E5FX9E5$P$'4!5MRPNGYHU\(03SS#AF!% @@C3[0H2_KES3-GB>
MQSK\9.M)2F.**LG ]S5VCM+ZFS:YMGDPHN]%T#VJ-[@>?]F"NY]1;+/R';)9
M(,Z]%OZK8HJ"EK-*S#:"Y3P4Z/*M8D_-4X##9M#5"J71VG)C >4##=8LOK-Z
MA3+/PC\7KX03R\D&=Y(Y"ZVX-*N<[^6P337PPG#P-45+8%O;5T:7P6K9QHG\
M0.\?FJ39E[2S?$5#(E4^8[?L2*D-42FL$KH P-+VZ0=7XV0S%-BG(B).S9?X
M&NMWUT[&!.1I:\).*]+N<KL<Q&4PQF]\%X>SVS#C:+WJG/RQ<)A9L)H7JTSS
MOVVQ"._RHA&=MOA#WVP/I4538U8-FHP>>L5$.)L+FKH9E4Q[MG1PLK!)MIRP
MV&SDC",I#2^OJGR2=^Z?>YWF@P9'HDDN G4W,R4-,7/R&U^!. G(AR'FM+H_
M5B?,!K-J+3Z.>&U<>!$8\FXO;7,CONS_>)#I4Q"HHB>M)?''Y:[=Z3@P2/!*
M%" )K!L1Q36@T]&+NW>\1!V]SM[*R#U-,NKG[[_U<=3IQ:6UP.//@BH(ZCL^
M5@)E@7,:\]J4(?R,@QV,:=;&TH&SB(<%W5,3[QF*:$U2S9&9[]$MD[ XUHG2
M8FBPDOV_\_[T-V ?I[\R.>^V;:.">9$XXPY0C'44#]6="+?.6EO4(<AFH95O
MGB&'A8!P3G)KUIJ:^@)0I-(TD=N.63#HJN6LU*;C:J4PD)0&Q$R<\$>V3^:J
M@$03<Q181:&_ F;DQ*QE6]A^PT5YYY"T&9W*>F2N9*Z.QFF-@,^JT^NP<UM2
M;6A P3,I@ZV)F>DR4^OF^3<ZRK&(L,VQN\71Z+H]$'RN[8^I/6%C@Z:R(!DT
M@'%$Z0?;17D8M=%!"X.G#)30EDL_(CHC@N>8@(FMW8-K@C=N6B)Y8'ZOF-3%
M:C_$;%+\=G=")4Q7,960V84K,!#T3J:;L6VWP?\OK]/BC&!E 2M,+9M16";4
MW6F/A5_:+HGT>^LI_\MG Z^<PZOU]?4_*W!W\$/#Y1GEB61Y_#C'3EM_= IC
MV#XS@\B9L:JKF%+(,O=GL2=[&";C#GTKC9[:GB>_6#^-*()W?!=5:51&\?OZ
MZ(BW)Q)+L*=HD)RB#.QGJ=O]G'Z<=G[2OU4=M5EZKY<ZJJ9 I)N6R*'R4P*\
M9USM;RQC[]S.)]?27H,Z]GW6YJ-F:A(E[OL)N%Z'T%*BA IE5^-QI3$"CBRW
M:9); P&!]/E7 +EWKGOQ<(]MQ\W6,>,R)!F?>RXF'3/U'H A?'.0[3UE,_@T
M)MW!DI[RM6(;V*T7_,%F9*:0!Y-!YW><+M;OGAL9WPYO[\EU_0M'09+CC)>5
MVBNG NZGCSV8-ZKE^7$?WUOWWH0%D^1?"KS0<%S[I+#X^/;4^T5[.OJ2V.1-
M/M7&?K"HR>]BDQC7;]=U2X"ET>>7?N(9I^XC?9AJRSE[IFYX!3RGKO?TE&3<
MVM_$-&]Z\RX*U3 +>?+/W'T31%U?]&"?UK_R#"BKWI@I(J]"S3@[)\]]!1P7
MO[VV]RQX2H[AIG TCKD6/NNF;H$L-)J:ZE>@+61GWHPY'S9QNOS<?WGVG+R^
M\S+Z8AX):5O\(K:>2M[UX8O:F"T2XCTK3#< CD746JE5M<FLL%_U#;E(4L:I
MXZLB!B93U:_"RE8(C.]'U6$*/AT^+#>,]K[YOJ3'^2B#/@MDE>]/,#_"NXM4
MI&)FNH&>4P0UDPR:#2@((]E'/H/86(4WVNJC=GG5=IN_:?PCG#X!F>%IB^M*
MA,]2A4]7X\PXSMCT [-3%QOL^*4,.:;BN(A!6F*CEC2?X_[U&.-_F>2N6C K
M!T.!&HEJ13B[6LDXCC1)"<PD9[&BS?86LRCHD2N*=/CYH5B)X \49)%HC!PD
MXHI98^9?FY5I%A;VAPKD:C./(W#I0#67X)V19&]IS-'XJX+CL%SW@V];-<#A
MCR6IAQ#61.>$9FUR\T0:J6[612=P<AXE"K(4B+<,0,L, /@3IL-)1)O9=#WS
M&61QG;4 #1>M3 F8I9UV1C'NN_088A7NLTE)^0AR:&AI (P9<!0O?**=O8<8
M;H>TC?#-DY3]=?+K8=KT:6DV+$-&EB7**+7,7RLM^>E]$:VK81J*]8/Z54T"
MGH-"\UX3(TC+H@WYTSV25X0!4]*' L@X$KT)LTIM(HJD@:"6G]JV]1@AQ+NG
M2B(HTD-IT@!_$7-?1[RI3I7CE(=.RPRWY7<JB82TH $V6IC$+F;&&(F'\*Y-
M:5)^Q@9_B/UQJ(_("D.S/@6#2U$)U))4/QH$NO7F6V1\!; LZ'3D*+6/&LAL
M;^,F.2Q!4I?>XP7KWM0&)\AB")NMRD)"JX;@1]\&?3B4J8D3VT!/;569[_!.
MHD-C"0L),QV0%0WY4P0>E6K&YB,3M7?J/AIXF6AT!ISY"#&?"*BBD0LY))+J
MLT3]H3*UVKS.;+/U@8?X9G#I- #"*TP-\Z-ON^8F2?F:TQ3V\U;$Q S^*EW!
M@35%BO$%:?%-+$!'.Z:R*8OEJD0YA$M#FBDR<-F'=!&J@ BS3YK^>-A-VO2-
MN+M4)LLL33P 961YE!"Q)J(FYGN"^<]0I_Q?LC=_V;@EFHBL\>.C46Z@(CC8
M'Y 3GYI$PL-H3L@83;N/&]FG94#QC]5E##[#)&H97L9U3NKL3O;:71STGTGF
M:"U!J;7!,@-0&AS5 &01>IHBQ*_89C:G\_(@4V+:6AF0#AKK&"A<"AD/+I91
MD6%;IBMC^S$C8:XY=,^DQI5'%3S"1%\?@>Q<_WOS&,HBT%-^MF+'[U[OJ>]&
MP8W<R>F\9,%'C6=3/14X7JN-AT-*_TX$A:XDQ!4_?QWQ2&C7XMK5PNQ'@8)6
M>]GB:7<*!A235-(H'D=:4^E044EM9SI\N2J! MY'PQFA3?BW/-K][(Y$GL7
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MS!8?Q2MTBZ="QG7^X>&:@]J*C3! FH@96ECHFH7SQ\U]OYNUQ(^60,<7)J5
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M0\+CF'NKTZ77R3[RL%1P<KBL?=)FC8X:.68B+;HC 2J4!'LF/F[(OQMGDD;
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M\V><+2ER).+/"2TU7C\Z'\YM\(,5QH1&>T%@3E)ID(I*\M/DJ#\H8J6,>E$
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MNP#! !]5FBHAI15/V^9EQ[0W=!_R$5\!ZL8"-7Q53U2DW8L0ED/B5P!7KEY
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MCRK\G#A2G9SVB8:G;D1B1L?Y'8H],1-SO8[_'A*+XE"D="$T%;5!G/M_ 8%
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MK94=4B-9)6VVM:XCT5"I:W RM2&@XH I:<4G8K:BX\2Y?E"S\I+++0 0M*G
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M[BS4S&F57@X0(7GA2=,A7(4W]7%\PYPB%*P7PI#;FKF.FC%\NMX-_P"3\_\
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ML=(_\%G/M_<KYW76V_?U'W2-R#V]Y^&V_;BC9;PFL$C:R4U:! 85.9Y('7,
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M4YE)2QB&3\LN6XKJ%@V$3;FDFP\]R6HQ>HR2N><?BL6=E#H9TABP@+#<J*_
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M1Y%#K&54</2ZB4!LK9'\,K20Z43H+Q;\+[]IL+9S8<@-:'F!B(E'4*BISE\
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M_ZSUK^PXE_2OHV7)$H?+/.[5;]UZ(S3\CN](_*UJ[86)@O3N7W?"YV1_%'X
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MG"U2U%+QZ0HA773]5ILY36,S/KC1#%^&-(UD'D;5<K7I-0]<_O&BQ^X<N>]
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MC!P6TO@SZ5R\X@MC-4G5+K^%!.8&\7U39^!AOPSILQK*0 R-CL&S]W62_.U
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M[-Q7W3O[GY_Y<?:O^4O3 WC1+3*O>DWV5;WRW*E4M #QCYH(FR6\^D: P@<
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M@P(G>7]\J6L,#4,Q<,T6U'0]4(KZ+L&*Q\LLTI-[M#:5)N%8"/M0JQQ:W<)
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MWLC\K 4=7FN8H=^P?)/.P^A8;L-?9!_^[N_XN]N\S_1<M_TPG-%:$3YT3OP
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M%1=6<?D B&J$I;SM:@VJ^@BE9<P*. \+%RL4O\]H)">W@"V/'F0_$KL5>^)
MU<ZZR;8OY=@"@AJ.(&,PEJ>YC!8,X3Y6:4J^#+KE?F\1NHN,58CN16__RH.'
MZ)9^J!X"2JZ1"%/I0YLNE8/,]1(/-TK]Q>"Y4( <0F<%#4OT/#;W$X9DI^B'
M=_+M'19$&]$]P5G[\DLRA+)).X'C+Z:>,N*WAX%.;-;=EIWZ7?87.^%7+>RQ
MZH[0W0%/ISUIW>G"X!YL<7LV,A!JB:&=;1OZL9P8H#O,O];E?(RWA)E!?9;$
MVE5:UUFLH*5EC[68V9J0D1Y?DY"./?%9'C$6:QOT3Y?V!)H,]NCTW+O% >=(
M6\LU4-K^ X#\0&+^+Q .ZJP>O-'!*/)?CA^'P9<:4LPGPJJ^+.P1OHNGT;57
MI/Y7E<66;'L:(X$GK4>&^5"W/@)E52_&N)VB:MP<X_K$W3(MU;0!X]8&88]^
MQ%B64Z&XDC)SYEB2QUX(:9-_-B7C9A@>5[V*>:M/ /W.29$X*]CZ=UKZ=Z#-
M[E 0>SMP7VGHT,!+DZ=4<VK"AK L-RO;3V@ ).D-W%D8S.T]&*A-(W,2CU:(
M)X!7&]/B0(=TBE].=E/Z@>KBQ=&&11K)BC8 IZVK,<&[MZTF@! SI7O\Y$3.
MV4U3+1C[8X68()<S^@9A'/U=0ROF6X._BBV!>^V A <%U_>,F\/2[<5QM<6_
M_>EB))&WN!H+"\-QQ"3!F_"ZF,JC .PBE%\)+&VQB4I.S;(J^,*^H%!=F]GM
M4*:;L>\Z3AOBY;/Z!XIN])-5/^PVB^@2XG=928UOF=5V=7_!I[>=F417,&UR
M*<;5(.SWZ^G@&T?>\F[$W[BHZ*3*EN=C6I"US=R458M2)\3BA9"&P$PC [:.
M:R'Z<"B 3]#=_OB-%@0C#<>G#P22)%-/_H(;;HX[6@V[NK!55/+<+7@<CKKA
M:XXF%)-_F4OXDIK^A-53JW'@V./=_I)B^3-'>@FT@"437>EX,T471R!ZV1:/
M-UM/VD*GN]:)L>;44988/V8G^.M=CG;-.3!$KI#F0,)N]D+B8.J<E:PW5.06
MA8>&WI)A9_<MH)DG;B  E^@+#++N85\^,!O*FIA=IK]._^#W3$2UGO@Y6EO3
M>67RZ[DF5KF73>FI7@^%4'7YG^L"5>[Z=6-[$64!QCP:.+\5U8VA*YFK[_4N
M##5#2S E]SY/S?<SC)NIUX;+L1+J@5S&_=%1 M9>XIDXY- <;FI$,)>XQ)FF
M_<C[]5;>$S I*[SE3YL\:48WKG/T=6,,M,&:-"7OS'P:1MBEC"U).OK;UDY!
MPM84FCH=^A62J_D%G?"!C*'I4^CH?O*=T3FY[7PN*[FZT8&84]%)^4QJRV=Y
MLD6\@-V5IV]\/AD^M!6V[ +J?7ZKW:N#S#SFZ6YI7,SSTE+"J8O#:?SG6UJ.
M6)((C,:,*@__<J"AKM*8XU]G)Q+& XF+S5*$.#WZAS-E'&%J5_L19IN=9HKL
M-SCV*>3=O.G'+GWHMVVS*[_4@)I'Z:JLJLKW-/NZO$RU;8"V% U$>BX_1H.8
M6A[80 T[<I3Y28GF(+, 9K&H[&5HM4K]!DR^:!PZ2WA@1CV@CT;H;H>@++9H
M#FS2ZMO=TSI_%4]I3&H:_T;X;\/U-#HQ+1?=S;8M]XUMT)"^,8XMRKF[A%+&
M8J!X4BZ(G=#&8;D-3F1^/M[]B #]JPS]FGVSP\EO5)DD[LM5V234D RYAF 3
M.4UA-LUL=16NQSH(* MBO5[!E43;5M-V&UT^$TY:D"DM-YH")>P4#U']3FU.
M5O>FNT-I;58"N,?I3<O?[VV*Q)V=$G);H4 TN>F8A\,F'^U:?3*7"M)B4J4?
M.)K9$?!/'2W_L+Q$I=O9X>%T*N[Y7/H#@!$Q+,,WDNQEEO\\AYLQ)YSY?F51
MT+[YB#12^L)MT3.K]OX!4'M3"V@<QI--)N%._?4!8%05MG0'5NI66]3NH33V
M8DPJWMXT^M^UDQ#=OY>_OF\2!N=-C[XT>1>QX*9ST/MZGE TDB"__KA)\N\Q
M?\NUEP*_-YZ\6X214=RR=Y\1'P9.MU:DW.][U2<<!TTJOK]EW7NV$_@_3WP
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MB%]/381Z3\9ZH^,/RJ2D8 +%TY(.&#DNDX8*PKP&IAB^4IRZ)ZZGZ<"UZN@
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M@%P,>8+38/R(]$KB&X/-%S9P+VX9V9:%9\T"%@D@I(D[Z/HJ2W"?73K9)R7
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M@]C.BV(,65K2*"RI;AOZV.JNMY@C!6502=RV;8I2KB/INT&6K9V^3L=U6IL
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MQ"D_L11)1TQ9C/9A 596;$2A2^&*_*E51 -*GD$6Y:_(EE4(GW!HE8@CV,)
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M^Q"''I<U<%4ZA3XZM?UA\7MG-43V\VK8^O>_89^=8FF]D:F]-=U;!Y].HR_
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M<<PA[^F["G9[?]#OZ $JFP96@O[CE*6X8>7Q7VM#9M^ZXA\0K4Z  NL/#=N
M?@43]9J^.#TXLT30+TJAEE,TY8"Z.+P06#=QGL3DL7!9?1A8]NV- Z3'1AV!
MC<=$%*3F]_+RN[@VW*06 C7S&W?@"PE@EL<CJ\V5?^>LKLIR5#)AA[7$3 ($
MLD^5R ?YA)82MB# Z5PB=!)I7SP+8*SP(4AZ.Y.'-DD%-A^JGBDZ1BT24=QP
M)HZ).G&"\>&/[I1;M*L*HENH=M/(&T#IZP'U,23T!(!Q->H&B2V"8^+$)6P+
MHAVVH9^7;_6+V:CK2L$+-W6^.%(Q%,U2(Y\XI-:BR<!WF<3N%N)>$HX6XN+
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M@]"L*G1)?B/Y[O*%7"X_A61410P-3R!VA'5GA6VP,X0JLW0J//21DQ\TIUJ
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M!00>A64UC&$,+/4B?U?6U'Y"-ZQ+I<]/*8(IOSJ%?;U[HKY;A8.T$\EAF[[
M>TN\BP\Y0+<LZ$;8QL5KA@J2U#5/_E<)KTLL)C[(]137LKA99BJN6?^O/,%%
MBY!EB]%I$#T1)J4WD$T] ['4&T)+PM"=$>1XJ;X2MY,PVVS5M .-SW&DN0/E
MB9&LF!HW5_*WB#. -DA4HA/8"[>9F..N<0+CT%T-R]9P.9W7?A.P.L,)H8_!
M%]B^1PK.! ;G\I:OL'.>@M+9 _X%.'"WC0 O__N?ITIX0T=5\US+!0UO;=.X
MAV/L:2]N$#M6Y;0^NY#UB\W&^EO*/UJ4$NKY(M0:>DD5-;/JJP11M,)0DI8
MF.!\^6;KN#[PK+=[)P'X8\*&PH'()/HDTB#2Y#E5@3=:Q-BX'2*/[,("$-7&
M)==U!"RU19]<'#RAH+5K9:ZH15ZSRT9;8" @1/S!CI FJYG\7UGV.U*5_RT?
M. W!Y'^ ZL+\3Z\!@+/;G*^/ %ABU.3_:[YFP-J?+F?VH'\ $TMJPS=L>NVT
M(3Q:1B"AE27$-?CP \Q)?T+ZK0?B+KT[/"GDXZ0_BRN8?R.&8H17!:I:4@92
MWV28!EZN86X[%H#^]1;/N:M1.YW9U8J$E=5P @KP5,#Y;"8Q0212VC]=GUQF
M$@#!]:<;(/C3RE4+WJ\&Z*9.<3NJ(%30 51' GY\RE+VB<8HQ>IBX9-$,@;_
M)0HL:]?\Z1B>KL"_]D$H'-06 S>(?8')/G..8R=,TK+R>9@OOV(9UPP;M>TB
M<@J$[ E,8JU%H_A/XY/;SR_5E OVKW&X7$/>G/%/S/YHO_9#.3[?L*CT""TE
M8'8MH1TR*L*E K[^L$(B+A6U=]>04&@E7[::[DCHHY/?F693FZ9/K:K^@R)6
M6D5G;FS0RG527='_HRV\HQ9Z?*35QHFU3DJ1.;MMD-]_<8GK%]>(NU JAZ;;
MKR:VF?,(=1IG+&8B[( 0.# _?8J?Q)VG6@7#ZG&4"N,YF1Z:7 <9++B<328_
MA>TF2;6SARU(*XIKIG$[!\]U6HUI\<]_N#9F#< VL[>E#<^&/JMQ4U!E,+B8
M#^0I+O.[-5"Q)!Y7MW@0*L-'4/IA:PW=J6>F]4(W&. IA8E8R/E25PGQ?C!S
MML,NLXM4.@ K,F0TQFT15!HNK75LETJ,ZJY7'%,PXJ(1#"@[C(MQA2-8+0:/
MF:K!D;P]D+&$#H61RD:TF<HS/PJC*-/82WS%2_5$W1.T_O(^+@<+,XKI\^E2
M2"*QZ,-M%L,O-95;_&14)7,H9:*GY1EGD6G^J6 V?/]V2&7!8,;^EIK\AS(S
MO1OX2]1XZO0FLTTIRO/<G/H1:*B2+T"LM-R**(WI0!Y4 BX(4TZ?.T_/_AXK
M:1N:*-9'A21VOEQAD1 YP;<X!</8TO 2<YA9LUX;]H8\3FW_*=Y0:@T"TISF
MS^B>CVF9YZYJRJ ;*LY5[A!8;5Z'_!B9F24E#B6;).% %L^;BA0W@0YPSI)/
M32#9G]*H.7JGLF@CH7])/.P[O<"^[U+=_[N)4QZ]>UM]@)A $EHA[-:);[39
MZ-#X(%'FV!E)M_707O[#:4&^7'']EV@SMI2*#4U=PY%"$B-O-O-V6VVI/8AH
MA([^^%R:[7UY\I52]%X15?&OS#H408[TJQ>:.&3T&ZIW*+Y>3WPNJRPEJ1"X
M)H[)VE:(O2F46!05[$^2]H 47=YX"H0$/FF(IJ=++Q?<MY!^F^EMJ[<;11U"
M;'8>-Q6Y2XV [&]$C2SZG-!Z#32]SS5CY2?O)%^ /^7/[(J^[S!*L)Q7&P[$
MMD%@M ,/"]^*+O8(75+U/V#6_OC>,&U62H*;NEN<V./MZYJ%O O$\&_+A(.I
MYGKYL+7_%;W-V=DEJ:6]U_%6S2A83[24>U[ZRT,BTGX4D(ZO=M"./D-<I$"A
M7T!7/(HTW4RI8 U7&!7V H'K)C\.Q;N0ML39IG4JIK)+$K4.5??=>F']Z@M
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MFI$*KP#4_!*1M5ZL0PPBF-S2J9)*[YE3PJ),,I7J#1+X6H8*5GF($$/E"_:
MNJL=\_2I::3?K'XHIJPG"^!$#/_ 56M,^&[5ZT+JF7@F%7CKK!8AE32:PZC#
MP?=N"@0"Q23]!P,2<)<=-M *Q0>M%*H406BE(P.Y#5#QT"2)L4JAAJ-Y)# ,
M[?C$!_I,RZCI4Z2MYQ.,+',T^0</P,PT,T9MY87@O2&GU)DL[Z1T3Z]IHU_B
MSKUL$9 P$)0JG./>%YGSQ@=T#86R#:3P\'52R6GV/?%:PH>TO_0TAU/Y(0
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M['QWW^PL"7$">ME)I-!B"WZ/M<NL%<I/G9)]<&N,I:W+HQ1>>U!GY:I+5ZU
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M&)BOO/(#S#25PE_&^U07*GCV0O#UX2^K@'XR7&L5YV3*DS7:FUN+]O/<G@@
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M8;JG@1FIF!G] OMAH ^#0AT,P0@O#SU[%^ IFQ"@#X !H*<_#@!F@"$ #$
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MM!\K#R;Y>>ML0'_L50C/C7A^2UC&Z4ON]'01 $#(G_(O :@!:-^GON\""!5
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M@%R 7(!<@%R 7(!<@%R 7(!<@%R 7(!<@%R 7(!<@%R 7(!<@%R 7(!<@%R
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MY5U3EVE'5-7;N@V#J!B:!@<76E._D72DKAQ\DP/>S\5$7,+]''6IFO';M^\
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M+F>=7+Y^"N=*UP,[149.K%%&_7PE@7(4Q0-LV+V\^*E(<=H=8YX6@H,J5Z*
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ME"7[1Q$_VH7ERGA:DIK;P3E//S]7'M?J,'_)I.O(TDK-69<5?+XLB-V?Y)+
MG%/Q >+[S&+"H/%M_?M8Q_C$NK+.:=U(PI#Z[:\#>$P=()4*<VWCG>>SNR;P
M)<LQL:!YS4.[P]V,:^,@F%FZNM):Z@#41M^4W\E5"W7@,22^OJ#C$-RS79 =
M+C*ZBYWS'D]Q]M*Q!"Z#SMP)7WL5'E?)PP$Z?A^)U6M?O1-\8?[IMYQF"G'+
MN\CN2W;4T=[\4*=W(QZY0I#B%3[//M5G]LV9N\SX\/UB=$55N1AJ)3N^ S:
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MU%=)BYM0<5!^0[,8L[&RRLNY&QEGSV" Q;/DJ;G+A:121F[>="XZJ$A=PUJ
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M=RI:Y&^R%Y672/Q]X+.1XQL8=7(-("=BEQL7QK:<F[8_C/,LNKX]=I,,T@O
M%47Z6_%G2H.OLK.ROCK0B>$V*088PI5A/3H<#9?VUDZUQ]'J<V"/SN3*\1<
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MI?MN=Y("TKC1T)?N1[U@9]1C5+IEZ5%'ZS5_7MO)?FPQ.OHX;0MCJ@WL<E
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MA1>-A,5=Z U'Z>=*=#@2>ZW279A!7ZYX%\:@;B4M/SZ/QE^7P7MR'V!-];\
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MR0]'IFF.Q-()>UT0W4\XRSRH#)X#BMP\^\!P_4]B\&&UAY/EWV7;:YE<PS'
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M)65#6E2G"0ZQ_OGK@%B*=YC+LBGX=5^!"-]\*I%*F?;D66[+!3(5)&X3;]9
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M5[MV;]O+.Z.58(I4M4LR;E\T'$^LBRUBU??63]]E_^F823X'G^_FYB%FV:6
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M#2?"[<BWLHK<CZS,[$82[()"92)>+Z_JEVVJ@7E(,Q;_@])TV8:J&8-E-;(
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M]SAQ+BW2-],RQGPL1HH5/:Y+ET2S^*(LXCMJS&L,6/UV*7YFC%?I$-+#)UM
M:' 51BNNQG'T@UAZ7*9L*R^MW1:^-#Q%5QUG_ICYYN9$QOB7<B10\QI1563-
M:M3R+AIG!<?PEPG4QIYTG#UI?"!<*I \NRCVV)M1PRF3-I[!KET,KP&>;CDR
M++T3]O:.OA.QLR033'59_TA9I(HP?,[(=HCPJ:& 0O(S&JH.8)Y#.4/W [?(
M9%)KZR*T4+2?%.)-4SGI4^95PRIJ>WW+: J_DNK)K-4H_3PV>%MB[:-C&4A
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M$BL23S-T?KA9O>T^(E8JQF8:]/U,BB^2^K&MM]CTF=/1N6+\\HIH'SHLW'-
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MJ7H%$WK)K0Y#0_BTI4'85N7(R='S?]IT9H_:\B7^Q 93T4<@/?0_RY_\V7E
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M&?XN07FK_U[Q1O]>,7#R]/M5,7)!!_RJ:'IY:ORJ8.+XNVDU9P^7WP+QPT'
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MXDL Z,$<C-< >@!T-'>T!9"HPI!.\ OJA@#6T39 =E(#8.''>D?/@"B A("
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MIH=(<W/2M$]N@DH'A/@2Y/4[#E\AE@];[8O/.@+7CX KEE4C/0-^N9HCS:-
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M "P  ,+&!?WQ6_QX^ 3''^ FQ";"R*TI, PL  <'!QL/!QL7"Y<&].,#W)0
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M(5BX^IK#@]I@[FB=A*'RDE*BH"ESGGA-^X@,P%.=Y]LC&HUP3K)"RE<U['$
M_J4:(\/'VX]93!O$TFCU'@V<,5(9UI-/>0%R'4S(3LIW2LS07TNCW#;#/?<0
M<=\[KT7GD9P)S83LA/757;[P+I;V^\O4T?J"VALB3=@U5J-/[R;H7Q=V]].W
MYD"G%.DW4-_+>9JZQ.H4F1;"QL0JPO)9C0]U-\UU_BFQK%-+"IGY^<+4J*V,
M-Q04[&5\4?)O[72S2A-[!6GJLP\O+:?M@!%"INE0HIQX/DC,&?46I:=:[QP_
MD;_N=2X6N,VJ^H) ]<=:C/^CP",T4L;I@=IT=,FNU9-UY[MSTWT\_S7498>
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MYPN7P>$CRN.G+NA)V:9^K6?=1(N$T@>$!\0'OQ[L6MNF$W8"4Z1FE.FR\8^
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M$+2_=<[,)ZP''6 ;Z#8=R_>*,U=S_@D%LP7';GCW:,T9D;E+EQ0O+X1N7D[
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M;\>YP5CG&ISKV'[AII3W%K\D)\%<\7>Q*B9&"P:&C1+VXGX0Y$S#-+JJ@*!
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MGWBWE\=@L7YT@$3B=H259U&*C2C4]I"-/4H, =50AW^:^1*V%Q*;"T=8(XZ
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MO*' URLVR5R<U;PER)+*UIZ6,E3IR1(1=LVE!(4C,YB V7=(%$3E* ]8B&P
M1"4\!QJUE EI=+ N;/86##SK6FAK,_$+LY)PZ<5,Q9$J9F$M0E3/%D*0K^VX
M*A3RN#'LU^)5RE/J3,9#:Y,:&JL%*LH24DQC94$VLG( 8S1J=,68+&.J!3=R
MD$H!WXG_ $#B 4$"4')I4!^?[Q5/XB]FURESTXLE$L J_I31<<T.W3WC=XT^
M(1RL9?E9"$H>1&\W)QD(_L+]LG&R:0H1,8@=T]=@99LF50$D4SGZ"B)S=(@
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M\7_T#B!7D$L9C89@2U_)V]M-,U?B#V=3ADXHXI8DDE)4</. S ()'Z7'ZTW
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MHN5MYIFT;CZ<R*K8:FXK2<PP:6 (**"KSK5,[VOS#QF]:2<.N_15,R$IG8G
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M)(<,2XB>M,^)3RBWIS*M*YE)G(.8.OREHD4RQLF4R,)"()N)%X<5&A"Z124
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M-PW']B\+.QF#D8F8M<UYDR5+6HLL@ J4"::6:@-HZTN^6K K^&CJZ[P[C1S
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MZ"4\3Q<L,)RAF)>IJY<VI5]:>S3/[.<&Q2WQ'#\-,* E*>\DRU$) R@.I)H
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M\DW82I64RX?&EQ5\LL++PBM"]1S%F>I4I+(%2_/1@15Z'H+O4-#")3-"S-+
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M1ZJC%.4&BC!)=$ >%.JH1JLJ@!G*BIA*?\6]\8J2E9455#92*FE?2KFW.U]
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MJ0-S5S3R?5HN(  <!$0_"8N_3N&P^H]OO_+\QL6OI&R:!+BS.(A)\0R/D);
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MB[>]8B7,$S,U640=@PMO\\H7?"-(.$(.$(.(8;#TA!Q,(L4V!#=/KK^_8?\
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M,+IP"J-4FKX$W'Q"GR%"TVQ>3KBMN;P3NO0MTL#!M&MW#Z=C(UXY9IO$%$2
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MNOXUY9(?+L4M'.&+26F91ZZ:QL/"JR<@BX:A%1C8@$>)D)UNEU>D5$R@&^S
MK4M$O+_TNZ!2-@&V/^ (^)XZF9)XMCI4Y9FXA./Q0G3BX"UB<L%M*D%]3M9\
M/''Q-YV5J^.1?X@D)QU8WSBANYZ'MD'*MU,BQ31BN,8N#0YQ3&;9K+2*"Q@(
M4ADE4>G8 /'<HT+4.FPUJ?:MX\E!+JI5@=:[Z,]=*4TAE5?BCS['F%!ZC7W#
MRGVN"KU7A,9OKU6&Z[2RN+B_K:LZ#-3PG<:[.JU KV.<**+G0\-T5(A#AP#
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MF\,8KFYR25!:1F):AUA]*OE0;>3,H[?N8M5RY4.T'RYE%E3F,B/AF,*?;BQ
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M75T]R)2[# :_S+_7DBXF'3?-% CCRY(!/XD3CB^.H9>ZL*(*GL)#R4L(9S,
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M9?+J^4#UGO>>E[??SZ_P\[,72H4_0$!B4'!3<2-@AQSNZO[U.E()[$[Y^7@
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M5(D\XB%MTBE;%NI0*3C/&LR1%!S,<7#V7@S9N2)305=-2-9KYP:CSW?[/;2
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M! "0TKS<;G?>>/9]?-PEC6A7VG9MZR+'6BMX!\SYPGQ@3\N/8EN/Y%0OU/5
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M!1H/7BN-Z]R/\VI"BXDU22_.\:ZGBQ>+$W5DM;BUY75B2V8G?OQ 1J"LD0$
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M%KYFAES$VIG;H;^;88ZMT&3"JL;R^*K8RZ0(#S>2JV*%DRY&EAZ19(3#2M
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M5QB+_C%J@0YQL@CVJ*"6:KA&%&J:"-30EKC:.KTD1"K'XV[_.F:FKLLT\04
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M5*>.MOQ0'.-7[75Z6,Y4!\%]^*+&%T L:_2K5=50YG?_FK@^89@WR_1-%;X
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MY?'X87G'38*OS8>U";SFHEI:R8="::.'L##I!&*5<K%'N8'&A&54M+-&4\:
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M.3D:#XG/XR7"6V8L2L8E7:JD]PS<NS8E"GLCB4LO9?9Q0/*C?E3?Z$9$&)F
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M@5B"Y=*V=+MOII^H#FRU:CY3;1&]9C!H'NPUQ$%M=*E98#:O';55.B38@1J
M7VD:-0_&XKXI,'2W/P3*JU>92PT@%#U+2GH'.NGZ%-+::15.*#@#=YA4#V%Q
MNHC5OUI"VOW8XE\;SO6[YZ[0*&37?I.J$):8LS^ /PT*V%62YCD=B]!=ELJ_
MFABTPQ$6B!\L+Z4JL\ D?+4>?1VI)C"=::&9J6X;IE\2:8YBBX..N5BYO#9M
M4G[(G)=K\F#69HWMNQVBW*E@G",M) W])QFLE4L_+Z=3XJ'[6H\TNXS%AI$B
M5B'9$X\"YPM.R4^H>1 BYBTVLP$)U&UHY>8O,(4(M4)-;I3]FI&Y;-VQ@]LG
M,:Q+=5K8A/[:BQ49SEJE39ZO0!=+;<,6;45D=1^K32PG!#"GQK)Y:^8/M>Z_
MH_LOJ;>1;R]*E&'(8L]D10U3D8*D(8]%&RW-58/Q.J6#.\<6&+@GCIE^M,XY
MB8X,TN&KIVFT-3QDFM5-L'&UD795;[R&AY\$UF,M.TV#I^>]Z171BP!?]DFA
MHV*@6)7"==;EF;IUN\+%TIJD+96 Y%$W;VX66>R8C9L_[P<EN-2HZM=FQ*@(
MP7J_I64WKIJN(ME5 F/.(MKXSGZR<."*/'#/J([V) ? EUWDPBF9W=[^36N[
MT[(YX03\!UJ"8G :U:]F!:KMS-8;L=VKZLL0'ML^SZ,I9MWA?K>SD^]+W_N/
MOL>7UK Z8ZN:#M%K U[]30R3H>DY92A>JP3)A@JC^PV)6LRR#%_NY;6&M)RQ
M,RPZ3,#D+%<S_+X.18B^5]>2)57[2MWDL:C0[U512Q,^PG2K10&/4MYK3[4>
MF7RCW$S%YSX-E<YDMDYK2-7)R^>GH$CH^Y[.48Z1EEHB=0!50^$V/%NDA!8.
M37W!S7/S?I\UJ[D8O,.KY=).SP>\,JV!; H].W<._!MK3ISX^2HQ%;:]"W6[
M"^DKYHDC%7=:3ACD$OMS#";;O7C3DK-QF;S2TT_O0#/$FYMCG:Z"'J6#13><
M;"Q8!2AM!JK:=\5.DO_&W6V>_JJE332F9I*_=]NX=VFP3U/)B3H!FIS*$6WC
M,W*X&KD$3B##6LD.7 "CK!72!'/W_>#!G1X5B/HPLR4R36!0!Q5K/?F+!M?.
M7/.SYKK+%_=XGQ\^[S^F%;#'#/]Y") EI-/G6!R)226)U&!R^< +3-7%U@Z?
M?S,3?Q]SN<$"3%M2SG7/Y8+M'M'[P7>Y(G#%I]&8H:^[$X:'E7MBTT->RZN;
MLY-D4\5B VOD:'LR)=B'IT<,B&3@",/L.$:S2N$UU_T(4)[J*7L8GTRB!_2-
M &=]Q,-&@H#+9\:\YBG^:?SWF;NS6\UYH229(&?'12+7LGH/K7?%='LE=%;&
M# R2+P!7'B^:LQX6?+CJ:W');*GRBSC^@Y](W60X/@H@Q>XMG91?5HM'=A<,
M^8!MAQ+V]O=-JUS(OC:G_H>,5^,&ZLMC7'Q^6Z"=TUQ673[>9N4N&5V9-^JS
MX<-'H@K*'!R#6JW^D*.E#ZS6&2;2$,=J90M.N-<T9NFVL^S%UXM4GAE^%&+5
M411_M'=\CC\MY=WUU]<7'ESQ%6QF2#@HY3,F?-PSU%NQ9*J9#R@X?>TXY@F?
M7%8<MG^*&G:P8J_J58GAH+[]^B=7@+%<&"JJ#^_R,SW3X%;J5(:D6$=)8#PS
M9)#1QO;<JUO15WO5>?R>#271(U'H[VRO-4JR_7C"S?LPZAV$(XW)W!C/+E),
M\EU1+.$J+JOFGCN93T'V/^J P=M3TL!4R2A"D%S;0.&F^,./<KT%3*Q1:"-:
MI[_GM(2+_5W!&2D77/LJC.LET&7'@)4:!Y>9RW+B;^!6!@BP(IO_X[-<B,(^
M/+K(VXF&ZZM7>(1^0B8A^A-#FA#2_VE,7U3;>(24 8885EELSIL, =ARF8;4
M!>1.UUL&)?^P)-[D\;*7PZ, )X;YXT<32]Q\WMJ%#S3/?XTA<&SU':OF0FF-
M32C9BTZK .%'8YH_)G6 :DG?!L^H2AGUBS7IQV77<E%-G2@.+L9(-6S5W'KK
M'*VD.T,>?.'[AH:VO5?1NO6]K']T!2:;;3]0P95E.9@AF;E7RBC2TFDY">GF
M;U'JX!AV L6 T%5JP\?,)N?BMVN[F5,"Y3;U#3A?)21P;MU7;'HFNI<Z6/%#
M7M7T.%,T+_!&D)03*KVCLF)F,A:@1T?Y3I8KWI/!S-]GF#Y_ BM, A?2F%/M
MD[A?6^A%:N<";7A_Z_\4ZLBSY16?YH3MN-9FXS -ZJ6O*1.<4<0;2KHU$V(@
MSN)#3,HTI4;@8V L;-G&)-IVW/2( >S6Q?1B98S\+9[G.TJOI*5@S*:L1.[-
M-(NFS@@+4J9=HF_3>$U@)#5]W=]3-9=%G&F$Z^M7LB2V;R0^-NQEC]T'XOEP
MXCI5]7?K;2^>XB<'L8T*)S:O;O,5Q/%5LK]F 9HV"?^X<F^8TF#U<?NCFE9'
M]%5U:&>#N&CJUD.-#9:SDJ<X>IO ;^.NZADQ2T3&$&,Y[J=?8T&T2FV-BI:L
M M@S;),[+?S3,*E+61;12'T08&9TY;:2%?F;,ZMDS:*)4=_A*1XO,XX;/XV=
M,]V5_XJ$NN:KR+4T0TFH.;-JZ*M3UEE.OD%K(HU-W<R*T6^])S1^[K#7H0C&
MXI!E',QZRDQ9?;66>YA-I+YI7'3:G$BD/>]SR:!E5&&3Q99UV,JD123Y$H]W
MD8UG(33/*@RWJASO?MPE&^0BH5P&$/LOK!M.60EP4<F399-4$HX^[F*]7BV9
M:1>]%0@*N"X%_6DE"/\9?^3TR^R*^,T/M34[C/ Z'6;I] C<M&E2.:?>MK;R
M&OM6XIRV7G\#:+T%7#.0JM!(\)"Z@BTVX%<:T[26EH$C1I+PAR"I* >/\!&?
M5&2K7!DO63%&.R"3A(-@54 UB)"?Y!@#V?$ZXR@#NRNW7>@[-9W_6-(^?0DJ
MOGER\SC=:TR/1G%TCBL<$0_/I53E'H7I["9A;<L/EM7T!JF\T.FOC0*#EI48
M8E%=CR!(&<E4+IN33!AD(SOQNI6PFG>I0:^9NO;5SO&J4*>!8T:7X<-WHH.5
MCZ^A(SR?/"Y\.(T$(C,+6_N<%*)K=$<PF%91V  P^+#\WF+.YS]AE@..E?EW
M2SZQ2FG6967-0/*MX!^XFM6X=;,J!1-98WLJ=7/CNA6G;G/TZ[/30^!Q\D%%
M5*ULQ:98$7L#=&"A(8P>F)L'^.&Y0C>AC4G\ ,L"P*IVGJ*#,OK8O1/3JA,M
MFN_0/;Z)S'S9(<D@5UK):_V2-<F@4U3T@T(U.$*/B9,S>^0;AQZ&R<CT"R#V
M1RHV4XR-#SAG2L [%EO0O@KB$1I-,YFFS0MCM*&_%> VR4D/I'@=*3<-P*MA
MU&F458OV._G0IE:@]L#?<SGIV:M?>8D/WGGM6*_C.,E@/-ZBP[;$!B<[^I33
M!.OJ4*<3YH:&[=%8?$^V]^'&/L#=23MXE]CP)\U&J-37*%7HR[3^OEQ\J^K,
M0%?50Y7;RO,761( F!Q3AN$7JMAZE-O:MF#3J=CJ"#I -CX#-;DL%R3/O39U
M7N;90V,1[TZAO6.79LVQ=J3PD$D\.F+"P:_;F#ZZ*ZZ%J_S6B$W&>D)$O'J<
M]0&7R3P,^/'U?5OI[DJJ!>OU&?58G?7RNU3,2# (.Z<KO%HNV U%'5"]GI_5
M,R92EMTZ,L"WKX:RC;HSFH5#.#5G^<XC=T+Q!?#*J8LM?:5+RK!PO9F?RI]G
MHUSYHXT5X_HW#C)PO:YGW6E*B8/"_P,-0/*_2L;B*)6W))!RBG&PZA);I073
M<=J72% &BK^H(^GS3514HHS%\H/T(^IZQ-W+./F&6,8W_&4H\=1T??JA8*B\
M?L3@1XR;S\8XC57381_"*S<K@52%. D.8G0<.DP\8SY8F2\KL<R%)ZI6E0]T
MBU=FBZ%95.SAE)(Y*24GS8ECH:QSIO/(CF?*F+1I>0<TXQF['"Q>*J?3Y1/$
M\XTK3.FXUN$-;W1[!!$R$,C+VZWNJ[&1\U*L9R)A4&?FDXR!:'6,;BJ92DS^
M^)92T@*&OA'A<-OR'/2,E)0N6);#(A3BM.=7TJ[]-W8JD_"TSU6,DP60GG,!
MAIVSK]>M=18U-MA>Z)5M2IVN?MEB/'.FCS,+Y 7$$O;UFE:?HIHJQD>P;-2@
M9(ZY%$F2F2N?,-#B%)*G)H$$$ V_VU>O-XJM F!)!#IL6I;W#&@J*^N#3/A)
M9-J]5K]<6S=B:00K<9#Q+:''#EH&H3)FM0FJ/,V*QPKK*+A1[:#L)-.9@)5F
M^9?);$P:/5T9%L0S8VN(2)I05,"DIY,-2'=N3O01HDLD@$$, 2*ETWMY4:%-
M9O@[U^8N]9L\5EEPU90#*@H/F,I6DY=Y9G475U:#D5[8)%22(H_5OU+.>.(5
M=(Z,5*%3F%22+C90A(4)IF$@RRE0%@'*2!:ARD@NPL T%*69*923E4DI>[L%
M!W<TS,0"]6,/SRE<B5SY9<T3E^&^8T?4R7B\B1_[*U3'L_5Y<"7*\H7.(-(R
MSN^348]+5DD A8\I(%OIDY=]!TS*%!.<*\J3/E+5G*U@@C^UE L=:@;#Z1S3
M9.?$RIX+!""E0- H%+48W#$F]WIITW5 RB9@3, &]"F["!3 /\6A 0,)1W^$
M>PB&A$!]"PHI(064==HZNOO]?*\<=N9OX:N5N8'+F0\C-,W8\AXRWP;>O15=
MGL76&5-&Q2:L4Z43E74#D6LLYQTD\C158OW$<D\1;NU&RBJR29.G&5*4B7-0
M5!UEP=4F[DBO*]A$36F+EJT00VMAH' ^HZAXT3[X8&6W[:NG'->*".X&REG6
MT:.'K"O6H!JUNR-S8LZ-'KY,5D*TX$R9HF0=$E':;EDJ?P$&J@@/%L-)[A"D
MJ(6I1<+U%7:M_7<QE/0)I4=1E-JT+Z-IIY<X[.MB+D;I%6%(RYDTB+G2(HBF
M8X%TH=%)855"IB<1$B:BB@D(/2)C& 1'934YD,'^/T/UBZ/TMJ'%F_?>.=O.
MUR47'FDM^++-5;UC^FCC9A;D3DN5"G[BY>N[1'$CD73!Q"WBI$8#&  O6Y5$
M774^2;J=1"I]!N94HKF+*2 :6?0U>]P&+#?SUS 2E(-E$7M1JLS/0>H:([S/
MPHIZSNIYQ9,P5>4*\<JR\6\7Q[(JS$I+OSQJKYAD"1<6]<]IJK!2.$:[%I$C
M7\<580<2K_IV.ZQ^A(>BDDN+!)KH1H-KZ1S)EJ\3$92"PH2=KT?>]7TK'8:O
M0WR2 B(@2LBGC(UBS$D>W%G'B9HW32,+-J=1P=LV$Q!%%$RJIT4^E/Q3B F'
M28H*<FS 5.W.FO\ DWBTJ7W:6H.0Z_?Y6T)[URG7VQ91OM@KN3:["XTR\XJ3
MK)M4E:<^F+6NXIBR3E@6G6<EF8Q4&W?&021E"/ZW+J'0%3R:K14WBEY<DPI6
MDJ\"TJIK:GF#4&U';2.XXA0,HH.52$J3S(50@6THX?[Q O)/PB<O78^2HV"S
MOB&J5S)S]XI,@UP[=OVC)&GMB%JCTBRS+,3!H>38+(%9)/QC@2\N)C)-DE!Z
M^-Y2RC#RY ;*[GFP-B*;>@KMS()2N<K^]='U!54N[N.O[PM;)\+G,-AGJC.G
MS=B5I)5JAU2@*R[3#]J;3JC:M3KJ5&>C9%GE1L+&P.V[H8\7:J+Q,B28'5(X
M.8W4DGNT3Y8(99J=1K6HMYVZ1A,EE?=N00DN:"IH0;LP;^=LIS\(L;! 34=:
MLKP(SB[R"0BI>NT T8W5@8X[]&6<V1A(V&6^<W2?BY)U%NK*BX8)I(@B<D<*
MB?4.$N0$.0?$5.ST&XW?76H%=8NM*EJ!*SE"6 <ACIY=&VK1M/-_"6MJ>/\
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M_3MZZXF-8.HV]B&P'M]._P!AU]OKZ^W",'^??]_LP:IC" Z !_4._P!/0?\
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MS +>4E,I\HPL@ Z?I8@?J<BM+AS'Q?:=SQ'%JGA*<3_JF.,U*&)"A.66(<$
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MXF2N&SY=J)7*3-5--RH@)5B)F3$#\0%RP0D*2ZG( (];\M(@J2Q)4E@P))
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M89^\6B7*Z.E$D'Z;=91(04(42B \6'B3G3XD$MF%4N-,PHX>SO6# %J L2S
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M,1D]&/K\NK+RSJ#5<DG9BD-XLLA!R[88^PP\6]FR0[DPMW,GYTH,AXT8L'
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MXZJJL<S;G%9<PQK%;1!.X66:,$R-5 \,JWY1QO'3)7:K"R2II12@J#EB*O\
MW"K.!H*4:/[/["<"X9BO^'WM5Q)>&PIXA)QV+[N>01.2!A"M*DE3LE*@/$3E
M?,"H* (Z@8[Q]RG9CIS+(M+Q%B2?K=^++S(2LKA^'A7TPO,'>PUA7G(BSUF-
ML*,L_(5_$3C><CV\@[11<,9$H(G\,/TB4E&23-EADE"2DB]0"'-OJ19RU?Y"
MF+"ILZ4HA2DK4E9<$$@UZ@UM0@$TT7:W+IR[.'GGE\&X97?"C%MA>KXWI2SL
MK6 ,V4@FY7"L(=44895NT6C&YC E'J%359^&8H;T-2'J;C>]QJST]H!@DA)9
M)&4D&A<$,="XTH]36,^;P-@JQ2,G,S^'\43DM+K1KJ:E)F@5&4DI5>(5*K$N
M)5\_B7+F06CED$U(]9V==9HLDF=N=,Z91+58SY22^588T+$%F!8U=@VYL\0D
M)30,P%1R#N[:7YN_DVTS4N5..O-<P?(XNQJVL=U3F<B5ZMFPXR5@)%_5A9MY
M6R)S:=06IS>T1Z3YH"8OY9"QG:G*LQ;.6J3@2YRU2S,F(EL)B ZF =KN1UY-
M9R'B)@#I"VRK+)26OH6-^I869WJ[U3J-)P[474/7&:4/7FCF=L3IJT1.N?S$
MHZ7EI55LTCVX*J'4<+B9-!FS566V4B:!UE!,9B9Z)4M2YJ@P#5(<Z 5-22:<
M^0I:7+((2AVK1N=P P/75N=(X,H?DJR9CQEG1OAS'%QJ%J4E+,G9W'+RK.33
MI>/6D_FLK-0;JA.KG&R23F/D6[I6<BX^1,^0\H(E<JMTE93+E]T%!&5"D@D$
M$'+6]*!R;-0TI"6LSU$#Q+?)2BC4I8!W%JW=B8<K&.+^62TP5!RAC;%.)!BG
M<)$6''U@B\95R"D6$,\3-)Q+F)(K7XN6@1)YXRR;86[-PU54.91--<Z@!LE1
M2ED'*"&+!G&W372YTBBI:<Y!_4"7!-7%Z!JN=068="\%OH%*R P1BKS4:O<H
MMNZ2?(QUL@(NQ,47J B*#M%G+-7:"3I'J,*;E(I%2".BCH1#C-2 H@G0@A_\
MV_<QJ'%J4^MP6IZ?9X23G F$WGS,7>'\7.33,6V@Y87./ZFX^:0S$Q3L8F1%
M2*$7D6U,0AFT<L!F;<Y0,D@4Q2F A"994I(;,=GKZ'86;F](HI 4*@?3T(K>
MMJZB-Y7\4XSJLVZL]9QW1JY9GK%K%O;! 56"B9MY&,2%28Q[J6CX]H]79-$2
M)IM6BB@H-2%!-$@% -W!RN!3-?G I!REG*6R^VY9^=#][[5B_'%Z6*YNV/Z3
M<52,EXPA[35(.?6+'.C +I@"LO'NS^2<" &6::!%8P 90#B "&8E("RO*,QJ
M_.SQ))*:A^3G7:EWY1SU^)S8)7#/*8DOBIV3'XQ5VHT/%I59)*%:1T6XF$T#
MQS)E&@T;L&:B&T1;MDBH]'8R2A-DX^>[439LKA^=!4Z2[I>C$7K1-?E8_7_P
M2X=A.(=L)6%Q291DF3B%%*PDI)$LD9@JA+T"3<VK4L)S=6#F$N#'"U1@J1D2
M>HR4'B6[LYBBX8=9:3F+BWD&2\LYL5ACHB5=8^/7&8E?,7:2;(\L11P4%%T@
M6:I]O"US9DW"KF!>1,I!42[530YK%WH>3&A>/SGM=*3)XGQF3(2$%'$L;+"
M*I2)ZV9-P&W\+ZUA',N93XB8W)I2Y.NYIA$',O!Q:MI;<GEKG(1N@6;D6LR_
M+,1M+6KY6P0GRU\@Y=2!6?FNLB*R@"JF3OGF8<3+2@*$HJ<D!TT!-56%M3K'
MARR48?Q)49@0,K4((-:=-"'?2-<VYF>>^JR-7;A6\WK,(^5L'[9(-N1;(2+&
MU*(746;*3<2<-CU)M$%DZT;Y@Y?QZX(B5,72BP=]\Z)L_P#-S$K"NZRT7E9%
MM%$9::L6)%:"(5F3AT*2DF:5 J2SJ%0] #8$DD[:AXD9\/KF9SAS Y,RJXRA
MD5E(5IFH["BX_9XFM]2>1<>G).6YWLO;9G'E=K#IPFFDBB2'K-XOX(G%55Q:
M' &3:M/50D'#!6N8ZCI2H<'=C](B8IIJ /[D>-G8 U(JY'L8>;G_ ,E\X^.:
MSCUQRE4^-L#V5M2K*[S;^"N5G_9B'*@F>.55KE"Q?F2W.V$@Y\5"0<Q5&?G0
M(FF8\A!E,+@WGJ,[\Q+"5$RW.<#0%VS7(JUV!#@,08[$)092U$IS@ I22 _2
MM=;/T-#$&+?S+_$WA$\IMJA1<@7>52@&;K&RC[EEN=5JGC*3C%G<'4C8U<=O
MIX[VMM%'+BE1A,<S\E;H@H.SUEU*E5CD[I7-[W*4JRYB"<OA :E;C35J\Z8*
M.5)(OH *DVT!<ZTV]5?%9Y^(T]C[$YF8JW,'$34,3/7JU/Y7<B3;-!S:';QA
MD&;IJ>1<>XPL=SFZ<V;1TF:E$J#.4$TB^3)$.4&[9JGT304JEA)!!/B4D.WA
M_N(<&MJMN7K'-+,])49@*G<H#$Y;,"U0;OH:."(5#G-?.)%RV1RQ*&1+"M%/
M<2NX"V#R790JDEDJ)>UEJ>V5]@BXQY,)Q#I&665*=6VG;,*TH+UHXDHQJ"*J
M'/,3-224J=@6-Q95*U=SJSFVD;RR6)4DN"/" Q()  J'H'J& #L[-"\Y4N9#
MF\>Y-R$QYO*2&/ZF_M;&LXUAF>.\N.9-A*/)&2;QJ3JT,L,Q^,'D%*Q;=D\-
M(Q.5+J:.>&.C)R#(5RMT^C#$*DA*Z3"34N.8?W#&FKZQC/*Y<\*2%&40"<HS
M,;:"@ 9P.;[#I9D>9E*_C^YV&#BIZ:F8:J3\O$P]5C&<S9I&2813MVSCZ]$R
M+EI'2DZ\=$*WC(]ZY:M'SY1!HZ<MT53K$Y<8J9+E+7+2M2AE8)!)JL)(  T!
M)/G'9* 6I(4<H+N:48$FI<"S![=8X/1?-I\25JI!N9VD9N($:E(OW,*VY.\C
M6$;>BCD*KM8&)F)V.Q- $KSZ5H<E9'4T]CX2.3CGD,B*"27AF7E+X8+5+S*(
MS,/";O4 ,SDN=Q1R3>.2=,FHFA"$9D%_$ HD  FX;;:H?6),<F4KG2Y\YV7<
MDYHQODBG2-CPC 5L'4]A*7HE-C'E5R5<E$JK#W\S(65W,A7Y.!EF#Z2DE7:C
M5^Y19_O64D@WWDI_IS"JBF2PH"74'#$N6K8/J: QU3YJ9B,,B6DIRA7>>%9+
MY5$DU-U$5=F(  >.C/,7:,ETW"N0K+A^K.+ED:*@E%ZS7VC4)!Z[<F<((N5V
M$891()>0CF"CN28PWB%-+NF:4:39W10'EQ9G=U,$EPK*6(#G>G6B6#WC20$&
M:@3&R/XG.4, 3=PU6U$<(,<Y1YW\+14ZYHN.L^.J_;,QY.M<P@OR;6B/DY1_
M,Y(Q],A9S4^/J*KRO,KC0IN_2+@6:+<AYR(1,NA&W5],P:^O#PW#Y*5EIH4I
MP2R@*D9DEBQ:[7$<DU"O]3GJ3_T"Q!H4DU'A6+D [LW-Q"]M_,;\0J)Q=!7E
MC6<S3N0I,O,%%UR.2Y'+=(2U=4K5NDH_#LA)Q#:CFG(!+(U5:1J\T:66B(P4
MG2:G_!+MURFLI2DA;"U13=GTK?1R6J7:.D!)F+!("2*$:GQ&YHU!<D FCZZ&
MU\\7.,SLV-<>O;U/XH=.+Q,!:[;D3E5R?&3U@QNTGH4K6=BZ.SPO='R3A2-/
M8(ELXE&= K1%V[:5=6UTJT>1[N<"?S,TH46*0IPHY2EDJ-4MND.Y JY>C\V(
M494HJ#N5  LX+E*?"XJ!>E7YAH^@AZYDD(%RZCD#R<JE&*JLTENEF9^]\KU-
MP5(!2)-SNE@ GXB$(CU='8NRCEC"J6E9EN5#PI9U54H LSN6.P=O*-)!SY<U
M'(?,R2QJY!H']&C@FVYDOBJA79>5LU&FH*T-,FNF2%,H_+EE"^*-Z,DA.#+D
MD9::Q#4*J[=QK=G%N:&_H=VOD1/23L8N:M*R;A!1"BE34HD'*I9(5F 3F+D4
M)8*"6.[4 <&+967-J"+I+T)I9G]=2YC(D^9KXI"EWMB#?']E@Z,E9*0PIA#<
MON5;%=G]5DI>NH/K3,,&&"/\/(M96&>3CNRQ!<Q/)F!?-2%&#@TFYF[GHPX5
MD69RAFRJ4EZ5 <)O^I390"'<AJM'*I4TS $A64JJ0F@ NY(J-'OY4AYKKF'G
M.C1N8RS+(DN[K64:7!-\>-^3BV7JN3%#;V"%*KD*OY#K5:D8N;-*0AI"7L$6
MR;.)BLRS8$HUG'%;-T7N<M:URDE0*5$+S. EF2IG!MF+,'<DL'=CL0<Y!?*,
MI&H?,Y8V)'(T%*:(W(',7\2UBI4H['./I&2C#Y*D6%GR7;\+95@X9U E53=1
M<?'42N8%O>4&<&=FHHR<SDS0X1BFX1((9!#Q%E49D!:\N<A.5P06%6%R<OMT
MTBZT_P#48M8I(;0AM2]*-HWF>Q^/;W$Y$@$YR$4D%$$'KJ(?^?@;%75DIB-,
M1"1;D8V6+@9844W F!)RK&)-W*($51 0,4W&RPWZ2#8N#M4@\OXJSQE*S$.L
M%)%*AGK39WW9M U(YE<Y6>N<Z@9D) \O]*RQ(TEK3W!IN3C\'2N1:\M-/F,@
M:&?5%Y6*%8WLL^CY%!JWGV$U9X0&J+ALHSAI9 [IVU\^4N><4M*PKNR1E44^
M%KN"V6GJ*U:.J:$(E!2#F4U@74+ER YVO7<"PAWD+,G/+F#$*E R/BC.$O&)
MVPJSNT,N3VX?/K8FR4@)2%BW5-E*HV/5XQ)4\IU6^&CG"R"[(K=59!8Z8'[\
M5+2F9)[LA8"DDE)?*;DDAV%+.&U)>,"3W2RS**<H!+$N=!TU'F(^A6GJ*'J-
M<5.@[;*'@XL3-W[1XQ?(&%DAU).V;YNU?-7*1A$BK=TW0714*8BI"&*)03C?
M+5V%!RT Z5\WBLE^[2[VU=_-P"[OI:.(/,C8N;Z3YL L%5QMDUL^QC$9%0Q'
M*0'+Z[N=*,DZJ2B\4_<90;PSEHZ>6*114BUJQ*/6S5JLJCX9@<J(K<<$I<WO
M'*%54!^A@U7-AO<DG<VBRW <#-6P!)ZAB"(TD!S*?$(O#Z5@Y2O9QIC5*EW2
M<76DN2>X+-7DO%1S!U 5]!U*T4\([7FWYW\<5LBH[>NFI"_\.5P!7)^[$LD2
MPAE.M&=CF8$EW8*9F%V&MGCG0J<5DJ<H*2XRD:4REF)WJYV-(Q3<XW.A2EY6
M;G*[E^)I3"!=%0CICDRR'5J[!*%IR#TLP\L[JD1#-HBQLXKL2-7#MJB9'I(#
M=Z)4T5^.=-F"?W;E"%LRB$A)M0*("7;05)VK'1)1_2)-"%9F('Z7=VL!4!VI
M$^/AQYARYFK$,[:LT9#C;U:QLJR:+>(QK;\>,:Q#JMTG,=% -QQ[C:2L[DZ)
MP<+332!^6F4.*31R\(0'!_6FRT(ER&(4I2,RC<O:K%O8$E^<82IIFS)H<@)4
MPU%NE@26#@<K0W/-IF#GLJ',90ZIA:I(L\"/:RL\M5Y:T/(N2)M>6W($?1\=
M$T3"^3D&<Q&MTV#R&;VR=HL))N3J-#2[_P 4J2/F8<S9LZ<%^&6E\H4&!+!K
M@;;G36_H+[H210F85"J22<M= :5O0?6(?27,W\5%I7(%E!T"W/[,%W:-+-8K
M;RW9,JU895$&S9S"NF3.BX8R]:Y1:Q)&73N#6.HI$JK+%.R2L\,U(@[59EIG
MY4A118G*6%;NU=Z'2.=1\"J$EF  <YC:ENIL/*'MA\W\_$G*L$K*ID>G5:0R
M+9H1Y:HSD]N=R6@&\02,7K+(]8"-@[G*4BUE6G&Y[XTJR81ZL=&@^=1)7*IW
M^\[,Y2BQ0:@"X(8$AZD'J69JO'-(,\))G$J)6P&5B$UJ: L*?Y>,0V?.>B,K
MC)[1\>W>PV;YWDV/<4AURTW?'A;/(I/[ I6+=+62=H*-3BX)PV:11A(K9H65
MDU':KE%:QN73)L?-8F94,IF0QH'-0XH+L;UM81K)\*9A4"YF!AE8D%)8D) )
M9@Y(HX>E3*7D:SQG6VTYC7^;2-&!S-8)>T2,!%QN-\O5ID2I0RC$IT9Z4O6&
M\50Y)QHY?F0(,6T<1,JT(F\AY2632=."=1*2): 1GR>( AZ-IHP/UY"*I4H%
M:E A.<@..IW!(%:U UA\>;^ZY4HN#[%-88AKI,9%5<QT=64Z34V]S>-)!^X*
MB@\FX52OVYW^S"2@E)/2$55;!(1C!0[U*/,")U4>2>J8%2PA*CXP"0*,07<[
M6\PVL=: %!>8@,@D D5+A@*ARSO>CQR2K/-S\28LLD\>XHS#//W]&BUF^/I#
ME*R+7*\VO#O$;><DVY<CKU.+CTF\9D--Q%-6\[(Q<<\7<JQ:KV/;F:J1><E4
MY:Y@6%A.:Y2685H6;E0ERPLT<DXKEF49:2IU,H)!-"'#[5=P6'-P(G7\.MO=
M$XW.\C>Z]D6*FK/EIS:@ELA85F<(/+*E+U^%.YEFM8?1$9&E TPG*H+_ "TQ
MU#'2!X_3\T].[>>DI*42TA*DEE6!!-K]/G,Z DK!(59W(/\ [>1#[Z<Z=).,
MHTB!/.$.K!3@'L P[\-AL! 1>E]P_+MZ?KZ<1JW3;G^WORA$21Z^D [" "(:
M#L.O3?8._P!=;]_IQ,421E%1KKS, @&@$F^WKKU_GZ]^_MH/3A%5U(Z;_/G2
M+1#?H/8>_?W[ZUKZ^WJ/U[^G"*V:FGW/3IN+C2*D'\)0$![[[  _7^OWT/IZ
MAZ\0_6^Q_:WM$M4=6O=C4&I;RY;P%] $H#]!'6@ !UK8=]?F.O3OOOQ,;14.
ML1$!$OMKI ##V^@%[!K]?;T'@X-B\0PV'H(MZ0[C]1WW]!'[:[;]/^KVWKUX
M13*G_=[C7Y[171! #"80#M^6^V@'W /U]/7A%@$A\O)V+_>*FUZ"&AT&NPCO
M>^P &P#Z;]/?A\WBT>???KZ]A_7UV/T^N@]??7%4DV(((W#?#$.-QZB/311
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M80(6$?;IC\E'S?CS'";"G>KXX['\-]%1;D)J$:\%/T[<B>FO>^5*1CI;.QK
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M_=!AE:D*!(F9G41,JV2C_-B)EU^UG(\4XYS*SMG*8<FVX>7U\A*U>/X:CWN
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M=0X?/Q^-ARJ>@2*8;*J$_JMR*>F$* -7<XH:O:8+MHL@HSPQ.S?/HR;]=2Y
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M0=@@*6OL75/ M=!Z8F6B&P[E7]I"@"& WQ3N^VM/R%O6XQ[A_]\/ 4GJSP+
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M:(_PZ?EU_K74;,AFQLHLU0F'@.=J^,1:4$UZX3XJ;4@R.CQ 1A\[ H8],&^
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M- WB)'UKJ*(G$ '0B&Q >$#6,8,28V P'"FPG6!@/UBV$3=8& P'ZNO?4!@
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MAC.@%8FC JL.# 5P=BT!OI'S'0"?C=(&V!^@H%ZM^@?GPH:>;?/@](-KY/\
M.L>\?CVDQ97I8VMQ3,)!L+-[Y= "^9;&[F15'J'J(/N'$V+Z\Z^QI$%(4&(<
M?-HPFV*\=-7"3MK485%TV536273; "B:J8@<AP$3"'4!@ ?3N(=^(H:N_G]=
M_.   ;0=('&*\=N5U73BH0JSA90RRJJC;9CJ&'J,<WXM;$=CZ=A]-<3!@"X
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M@_E]N*I)L0>IB'&X]8KLO?11[#H1'?8?OKT'L ]O7N #Q>,6M\M>U6_G: 0
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M<Q3=7'7@Y_=RL,"_=3):6)89'#BH9G>I(J=!'P/:1$V7QCB_>J"\4.(8OOB
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M4SD,4=>GL'%RDI+$$?/GWB9:Q,2% @@[1N.(B\>2Y_#14/TF/TD$1(0.HY@
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M #>,7Q#L-03/DTA\65N>A*; 5:>Q[%0SVY2QV[1&/A)!LDV:NI)02F7?+I)
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M:($6*OS 0>@JV%(X/ !WOQ@ X: D6^@^:1F9:2:@FKWIKI]=_:'?2(!"%(4
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MY&:PA8HV5CB1DL=K'M)&LM'[R1ADY2( ))L^5*=MYH0;"8";.'3*6KNB5OF
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MV[CV =]@[CP@XWO2+?,MO_KZ/KK_ )I/4=?^+[A_,.$3%1<-P'I%=$#?052
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M"(['0:#??8AH/OVX0BIET2B)3+)%,4=& RA"B Z >X"("'80'\A >$(]0$!
M! 0$!#8"'<! ?00'W >$(@3SA /SZH"'8?DL@ ??3TNP_K[]O7BNI;84?4E3
M](1$OPQ#0=)@-V'I_P"KVU]PZA,70Z#?;I[[U+@V(/G%2@;$&MW^4_S%H[$
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MZ=A_O[^WUX?/6$'47>MA[^_T]?Y?[_0>#Z;?>$5_TX7A!L/7ZZ_KZ<0"#:$
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M1#2<*ZQ\5BB_23,0L7/V2/18O6@+$8RC-HSF$&R3Q%=079U2$ [E<I3KF4,
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MA16'S&H/L6/1[F)]E$I0 HGV8.G8CZCKI+]NPZ !'W$1^O$N'9P[.VK;MM
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MWWB*K)IFO"_T51Q%5A 5_%73;.5RGVH!E>DOFSL4HD)E^(]Y+!RC](*@#2]
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M-6XV5B8NM**GE59>$831[3$LV!G?3!G;O4W!4 ,9=),0*)1*&Q)FC$*R2BS
MN"7+A@1JU23U+<CGB2,,HA89TY@]'&FCFXU;I#HXIYH,KOLLI1UIEX"RXYL^
M<LAXD@"M*\6!GX;Y9!-[?57;CPW*P/DABSKQDB99-)45&Z+L0(*RB9:2YO\
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M+WD3(<=EFWXVC)S(T.=N>*M+R2GTGT<9J!"I"U39RS9HF'20I3@5MTK 4 6
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M>$B'3^4>RDO*V2QS\J<BDK8K%-NCN9*6D3D "^*H/A((I$TDW:(-FR0 D@0
MV'A0F6E\J7(>_F>;T^/"9;+5,-%*#'H&:VP#<S7H[/"-8.$(3ENJD#>*U,5&
MT1Q):O3[,\?+QJBSEN1ZR5,054#+,UF[E,# 4-F0724[: X;XJI(6DI-BS^1
M!^T':HN*TY5AKGO+AAB0Q:CA9>A1@8O1.97]D&[B29,SK*/%Y-=19TS?-Y%P
MJZ?O'3MVX6>G7<N5E%'"BHF'=9DM,U*4J%$J"AU#-]!\=X259EJ=C,#+-B=2
M/4G8BPI">B^4/EW@\2O\$1>,HIOB24.B=]1PD)PT0J+=-HBW*4QY0SY!!!%@
MS22;-GB+=))LFF1("F,!K3?ZN3/5*!0<@EA377FYVM1$I",Q2/U5+U^=+4W=
MUE!8"Q'6JY%5&$H\2TK<'%S,+%12IG;]!K%V(A4IQGUR+EVNJ213(5-<RRQS
MF2#P@.">RC"T)F,%)!RD$4&C$5Z^XBR4A)41_<235[W^IWA/CRQX?8X=<X,J
M]28TO'X@9:,BZR4S,825(]+)M)J,54,JLG)LI--!^V<G.<Y'""90$$R@4(GH
M,Y#$U 8'DS>[ES>$M(E%T4\04+W!=W=_I$?L<?#FP+68W(!<D0K3-MCR=/34
MU;K==XEJC,/DIETC(+1I$XU9)HR12>M4%2.8Y-H[5.FD994_ADZ2)83)ERP*
MI8NPN""!>WE>NT%9ES5S%.>\HIR[BM&Z_+Q(?'7+)@[%$])VC'V.X>KV&8K$
M939269*R"KQ]6895RO%0SA1V\7ZVS%9X[.B8-* *QQ$X]8[O49FH9C9C2C!Q
M[CI$M_T__P!)R@ZA[]?2MJVAN(CD'Y0H2<862.P-2F\['2LI.,Y,4I)9PVEY
MMXYDI9^F"\BLF9=^_>NW3@QR"!UG"XF*'BF V:9$M(8)U=S=W?X;Q:9,7.4I
M2RY4&+BXY/7G5P]K1FFY%N4Y2N1=2'!]+) 0<T-@B&2;9ZDI'S'25(KUH^2>
MIOTA(@4J"2(.O+)HE*B1$$@ H6FH[TI4HLI 9)I;RWK7G46 HA(EI*4V)<]7
M]N7O&=0N3O"N,[^SO5+@#P7RM:;E8JN-'#@\"RM%E;#'S]K\!TLX45FY&-'Y
M=XIE"IMVIE2I$ 53#QH2X +$BCM7Y?Y>2ZDE)+I<$#2A!WK47-0>31*@   T
M';B( ,&^?/OJ8KPB8L.7K  V(?B =@.AT \07HSW%MN?*%X:.7P1BF=R ;*D
MK2XUYD$U:=U ;,JL_!_^S;\# \B !)X1L#5QOJ.(-P5 >Y5 'N% @-,0WA7?
MT]V+:_817*.\3,_N2" =G]H3[?EBP@UQ6YPDVQ_&-\6NUG"SBGH/)=&/5.Z<
MG=N#>,G($?E!9RH=4Y2/"E$QA#72(@%3+!3+0Q(E$%/J-;]?CW2HHF*F)++4
M7)YLT;?%O+[B+"M7=TS&-)CJM5G[@7#B"15D'[ RIDQ2.<$I9X_,D!R=C$2.
M1/W @"(CQNL]X %6&G3?][\XHD%*US'.:8?$7>GG[UMO&;"80Q57(6(KD'0J
M]&P$ YE'<-$-F12L&#J:*L$JN@V,)DBJ/O,N 6.8IC#XQP 0 PZS6D3$Y%"@
M3E2]LI9Q[5=]]8D  J.JBY^>L))+E@PRPQC8\0UFD1E.I-E>NI5ZPKA3L5DI
MMR[)(%G6K@3JJHR;:021>-E@,8$542 4H$ "A29)3,E(E&B4-E.S;?6(EC(I
M98>,F]7??RZ>L,%CCX<^$*VKDQ_DMDUS=/Y3=N5++8[O"LD)!5BN9$Q(Q)*.
M5(T133%JV4%XW1;O5%T2KG6%0-A P\L)"6L07UH"&^<Z5I5*,JE$?I.G/YUN
M.<2#QCRMX(PU)2LSC+',+49>;A65=E'\<M)JN'T)&$53CHY<[Y^Y$R+,BRO@
MB&CD$X@!]:XZ"HF691_0H,0W*_7F7]XD2TB8)O\ >'8]6ITH/32$"UY"N4)G
M*QDVA@:E_-X1=TYC)!=.2<+(+O)9W..E \:04(?QI61?NQ!4IR@JZ6 "^&<Q
M!S3+2A*4I'A2DH _[202#NY BZB5J*E7=Q;34"PNW1K1D#R*<IGR-&N_X&TS
MY6WLPW)NB5!\59O9!3(A\R;OBO2/T3 @0B(()N2LR($(D1N!"%)Q5$E$M69#
M@]7IM]+O%5CO RW4+ARY'('ZUOT!C953E!PO2<AM\@U.NC +MIF<M8P;%RZ&
M'=WJQ-RQTO=GJ3IPX4<3CF((G&$.!B-T6Q!%)(#J'$;9$]YWK,O+E?5G!ZAV
M&O["@E)",@ RYLP&C]/H/+F92E "AH/3^_3_ #_7B\: ,/GSK%>$3!PA$".<
M,/\ Y04SN':'D-A^3]$0[_H8?T[]N(UYCZ$_QUVA$1S-T3 !])=7471Q3()P
M,4/Q!U &P#>^@?4-?0.^J)TY",@66U <#T>U3' K 868OO)DN6J:2?'E!.^K
MZ7-!]#3RJ0E 3>#WV)0$H"4-;$"B E_")S%*"A@_$)!T';?!,^>!68I^M&Z6
M^/!?#\"H$&1+V_18OTY;F+O+(B.@!'93= %Z"]( !NHI@$0[EWZ@(:+Z 7AW
M\[68IJ_W$GT;6G\Q*<!@4VD2A0?V@=-*;M3I%/+(F -@F43AVV0HZ  #L;10
MW_"70EUT  :[<0,1.39<P-MS\V^_H6*X;@5_JPTHNU2D;N]!]M!'@XC6CM!=
MF[20<-U4E$ET3)AT+)*I@54@Z HB"A?PB4!_B[]][&YQ$Y1<S%GSB!P_!)!"
M)$I+TH@?86J ^GHUL<P8Q3)K'1K=%DQ9HIH-&Z :2112)X:20%V( 5,@!V$1
M$QMB([XK,F+F%U'^/M2-96&1(3DE)RIT9@&+OSUY_OF 4IMB ].OJ/\ IZ_Z
M=M^W&<:A*CIU?5G W+L^E*<H V "&RZT/?8>NO3[_K^OL'"-,P=G$4#N'3KN
M'IK0>_?\OY?IVX1F25VMI^_S]XK^$0 0$0]M;'N =]>O^NN_UX>\1UH>M@19
MG=O4Z,28J0Q"F#?8H"4V^^PT(".]!WUW'M_7OQ!L6VC1(02^@(>X9O>(G<ZV
M,K]ES$#BH8XK$E;[._L<(NQAHDB1G;A%LNHLNH0%U4$Q*DF'6<14 0#V[AQ]
M9V/Q<G!<13-GS4RY8205*_2^4AK&]O<VC\8_&_L_Q#M%V;5@>'8>9B9\Q8")
M<H#.H9TF@+6!)9P=GCHI\)'$V1L-\JS&H90J<I2[.E;K0]4A9A-$CPC1Y)>*
MT<&!NLLGT+I_C)^\$1[@8 UQ7M;C)&-QZILE25((/B07#,YTV(KY4,=WX.<#
MXAV?[*8? <1DS)&(0I2E(F !0!-'(=VU]12AZD .^_'RT?K<'"$'"$4V&]>_
M_EO_ "'A:'SYZ0; /Z?U].%X17A"\&^V_P!>$(-AV^X;#\O['A$ @U$4V';O
MZZU^H@ ?U$.$3%?[_GPA%IAV0P@&P$@B ?7MO7U[\"6!(J14->!J"-_+ZQP9
MYC<FY!B/C$<LV/XRT3K:DS./X]U,5IN^63A7SA9#*RBBKQ@4W0X5(+*/$5.@
M>GRY1$=%V7\YXMBL2.UV"PDO.)"Q**V'A*LP#$T >SG<]8_K/L1P+@>(_P"'
M_M5Q3$R,,.*R<=C1AE+EH5.*$811S)61F24J8BKDA-([LE8M02*0J#<I0,(A
MI!, VIKJ-T].NHQ1 IMA_#LOH/;]#"0E+"A53S(:];?+Q_)9\1<T93BW4$%G
MNUB+10(QET] LV@D["!1;(CHP@(&]2:[ATAL  1 -#VX!*0'(!(J[!Z6;;]X
M*!(+FX:OW^;N\!8YB0I2^3:!TB8P!Y9'\!C].Q+HF@-L"]1@T)M (CV#0Y%4
M+%^7I[FQU@ !069FIZVO&F+3JP-D0N1X.-&T-HQ:(;37E2>>;1CA8KE=F@J(
M#X":ZQ04<>$!#JCHIS&(4I0G*,V=O%ERN;L"3?;:(R@-0.&T^?YK4PJ0$!]/
M[]_]>)S"E;VH>GVBT']_W_+B80?W_?\ /A"#8;$/IZ_KPA!PA!PA%IQT41WK
MMZ_3A>()8$[=?M\WI'+[XLESM=)Y5G$W3YR4KLL6_P!&9%D8AP=LZ!JYFDDU
MT_%2$#@FX((D4)ON B [ >WSO:69-EX!1E/F<,1<$J'T%FM2\?K?X,\/P/$N
MU\G#<03+5(.'G*5WN7+X4*(_4,KDMY^43]Q0Z<OL;4!X]447>.:?6EW*ZINI
M1=9:(:**JJ"/<QSG,)A,(;$1$=\>Q@2HX/#%?ZC*05.7+MN:]?>/SOM#+ER^
M.\6ER@!+E\1QB):4L$A GK (;0!J#_+C>G'5'DQ01  V/IPA%>$(.$(-A_?Z
M?[APA!_?\N$/M%-AK?MK?H/I^7KPA%>$(/\ 7A"*;#^NOUUO_+_;UX0BNP_K
MK]>$'_:*;#^NOUWK_/\ W].$(KPA!_KPA!PA%-A_E_4=!_7_ ,^$(KPA!_?\
M^%H0<(0;#8!]?3].$(IL._V]>$(!$ #8CV].$(KPA!PA>*;#>OMO].$ 7@$0
M -^W"$5]>$(.$(.$(-AO7OK?Z<(138=_MO?Z>O"!+5,5 =]PX0@X0@X.WTA!
MPA%!$ [B/OK]?[#A"*\(1 ?G$#_MZG>^X>0  ^O_ !I??V]?YZX@[ZT\V?U9
MR6%VA\]8B4(FT =@Z0WH/K]0_P!?R$>)CG;YT^W[& HZ_B[ 'IL.WUW^G^O"
M+$$,]S\+\Z\^L5Z=@8 T&]=P$?J Z].WIW].VN$']0/_ /H%J4^EVN(L 3";
M8]B@'J';L&NWJ';>^$6)7LW1COU^=8N,.A 0'M_T_D';O_K]>$5RD5(H+U'E
M[WZTBT=:UK8B.NPB A^G^PB/"&=5]'V'I%Q1_$&^X &MCV#7< ]-?EW$?]D:
MN#1[TH?I\OSBW0 !0T(#K8CZ]O0-ZX1GE-*=>7O7?VJ;7%'1!*80 1$1#MW'
M0_8-:[ 'Y_D/"+,4@L'<7=M[#EUZ0; 0#W[:UOT$/0?U#^?IWX1FQH[ZWV&S
M_2G*\53T&NK6S"7MH!$-B'Z=^V@$=?Z#8O&B+5LX/D6MI\K#"<Q_,!=>6FC?
MXH49O&N+!#3T6U:HS*(N&@IR"IF[@#I (""@)CLHE$  -_EQ]#V:X9)XGB^Y
MF9PXH$EBS5-^5*[-6/RW\5NUN,['\"5Q3")EK5*6G*A:00/& Y!HS'2\3*Y#
M,K9=YQ\(M\OVVZKU&7=S\[!&BJJB1&*!O#N_*-W IJ 8_C+$_P"=W+H0#M[\
M5[1\-E<,Q:I,I2P-,[$L_4<P]:^_1^&/:?'=KNS\OBF+[D*G*(*9:2G*4$ [
M DZ[>D3J6Q=;E(9G&DR;8TW3=XY<*2&D_%<)KD*4B"@:[$1$!,4?J/'@1^EG
M9G% !ZO=AI3RW$;"%QO9XR,GF+S(L[)N)=J1!H\7Z 5C%$U2*"X;  ?\PQ2]
M!M[#I,/;>AX1+"E U0WO]MHUT/BNWQLJQ?N<HV*1;-5BJJL7 ) FY*4AB>&H
M(%_A[@/8/;?KPB?G[^L8)\17,S@ZY,M68$CKF5!  2$A2&5\0$BCK?24HBF7
M_P /KWX1#"W)K=!HW+;VC?6G&UHGI%%Y'9%GX-)-HU0,T9@D*1U4$2I'<#U
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M)?JG8!:MF,_$!+O&)'HP)9>+<S;0AB$4.5PQ8O71RF3\0OB'2%1(=E.4YB"
M\ <R2I/B";D6U_:"O"K(JBC85?1OW_<5A!5#/M#MV0,C8T1<.XBSXP>Q#2<0
MGOET<212FV"\BSDH(P2"R[^-(@U<$=KJ(-A053$ITP*(&'+#K3-DF:E0*4K4
M@FH8@LS$ Z'3S+QFN8E$\2C112"*U(+EVY-MK<PX:>0J"L"8I7:I* KU>$8E
MBB#%4Z%2H'\,Q7@E/TK'(B;I$=*F!,?Q#KC5P;$'SC0D"IH-_P!]NL>Z]WIB
M .07MM;0\HNDT=BM-QJ?E72^O!;..MR4$7"W4'A(J=*A^HO04=AL"%%DD$[
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MVS9M5ZXF,,FDJX:OWPO2.6[I9)8BC8I&*J*H;#QBB  .960LH:@!4=PD7/\
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M"[%KZ1$K7T 1Z>QM>@>NPT/KL/\ 3B8C,&N/G+X\6E$0V.MAV 1WK7\_S_\
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MW-DY _C#^J*BD>@!+B'[*3Y\/P9>PF G]$O=N;N_W3MAK04!!5N$>@J?7[\
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MD#*AG# 2M03Q1$;N$)-^Y%*$>-=[**Z93#M!JYY8G/41#=WO;Z>G!;^EN&9
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M_H?.$=J*TQ? 3W][\S\K\(%<%%<[;Z^?(CO_J6+T[RXB&Q#*JH2!30.X?WQ
MBGT(K\R*!9/NU&ZT/NR\_@E6+1.NZ899%!<[>P3[ @B+(*/ZPQC5/1!_]/V+
MI[Q3O^[_$E/Z#VI/5[?\]@4@VS%:*6G][X\")#<?7P %TO69\5P/2=0Z2VJ,
M] YHGLRR84QT-)8/^8;PF&XW<G+B35S5?N@69$%RPAOYIN>5N8LC]R1;TIK,
M N)O9GSQI %]@GP3LT2&8.]47'U".9M(]APK9T>?I 2*A3XY]?E))>HE.^*C
M,BL%E,3 =O953?N##<8NU8'2/;P)C&PR3'4VOTX,C"(@/[0_@,<_#B$,R9!6
ML"5<"1Y1+.J]=RY?025 3*1V!D@45 ?CD.=W-KAT);^S5@!T:"6[ZUF'K7G<
MN"<1(5$TN/_P:4M+J_W_W>,]KQ]^.5^ C?]:/ZDBCZA2W0+W.2O*.''AIGZB
MOC\I<4YA;5M8!QK:("0D$*;M5 [_D^FF#J:FYR.HSO\#"K;F"W #@'[<A%@1
MV]D4AX1X?-K#U$:$:,QXB(03]_9'[O9CN;GX>+[:"!8]GS((.GE!<P+T$Z"(
MK.*T>3W=W&RT?F:1!HDBMUR4O7K]V@]EL<T#ZW:_A*@]!MLX%UX)5O(3IG4X
MZ](%)Z=B@77H^<RXV7E]1?DWJ!!$KG"U8('V+P&Y+<+.1\PSG?O2/->80:E3
MXIS7MU.Q%^^G/>BMLTOZ!VY[W:V\[3YX4F$1P/:;]Q?@:.<>R3$"$4BXW8+D
M4CPP7Y@6&>,O[M49:[^=__)JRWEQL2'2_RV=/[P.8N<[BN_KXV?W1[=P:@4%
MO?:(I@MQ,"H:C1(@(!@@0R[4'=3V ;/3ZU#;5I 7^%-?1[721SJ\=^K:<+2-
M'X?X.=J\O]<JNJZ_R8@<::,+<\&K/K,=5+U=<@:1+(H+*#"^Y-P4;'O-&=NE
M,OD;2#F-5XQ)MQ557.G5+>@P<8<R++1P2SSIYF;.'R:'?B*KXYP QZD%V;:*
MX4/[Y_Y.+_<.&714'6IUC)->L<V/LX+W.H[!=9:V[BH;DL;W![_!/M^4S"3F
M]!""I)B4[=P2.*0*!$NU=DS3A4%5BV93IT7OHPWA<:_$7O"RMB,B"1;,V]\J
MO%SG*47/B1BV4H+."PSA'*V\$JF#YON.!NK\7H[ZC?XEOVM!BJ$]T<XRU.M8
M)'K0I6D<":SR6$6&O ,LGX4^8X2L]5UL9+J,CKJ;5F^(:RY#6!,>WDW&JC#,
MV^X>1+8F5"6</((M=P9?(](A1ELLVO/JQ,'HGTD5[IX0'S=MJDAYU0")'*)I
M'1&ID+\V3C%$528_%=>> E1R&W>KY%?B<9JF+*,*3$ '.1(_8QEN=[0J-]?N
M"Q1C\.)1427I@>JM]SB)V'F+Q&N4R7U(4V+^])&;((_X;@WRH$/)Z0VH*GU7
ME/5I_66<YL)4]B(Q/Z$(]HV# 0\@$/ 3,[JL0LT_[X_L/!PL-9$X*I$MO"'J
MOF>OV%SU/.VC;<9R7L9%NY?0Z]P!^1?@>VY2EYBF2:,J_N1[]4]BR4446E-S
ML\Q!M$IIZ116TSB1@Y9@QPHSMR-*-6F*"BC>U[ Z' ZN.V.BU1>K)@,&  @2
M7I!DQAS+M]1RK6?(4T3G4D[%4V3#$_8Y04%_'&62;X?;E3:]@=Y5".*L7J8>
MHNRS@+@3F;[93'11&D EGCH+WT>U")#-4-+">.:OKVLR/ B'N\!BGCR'X6#I
M:LDBK0MJ[!M'[,1=N9V)^4=FO,8EYJGU.DX9I\:EVZ"4M"(I2T/SQ7FH$V8+
M%-3SZ:6IWBG!8;WBFZ.R]ULIH:DH0ZC.TBQEN;GM<E/D;3#,0!&C8WBZ>=?R
M45+@C2GTQ%(*:/3F="IHRB]1-?FWB! ;$K,W43Q>.;5N7MG&]&"FK';;+6LS
M>H5*NJQI4,;,O'9["[>):J-@A_!*X+F2( "QJ^L#;%*?,2Z7'IS4+# W:^![
M$;P>*8NC6"^S<=-&(JS&]FT,J%[Q?1B"O"L@%EN.( @R^CD/QW:+(XO9 6J=
M:B,$,![^$'[SMT7P;[:\SN&/HR9I2+ ]>"Y.".OE+X".):(-B;%MT7&[0:04
M=8?M)]/A_CRZ&?L-MD3E/0LV;!7I*2+Y8#@/X!PC2:[4.0TFG(O)$<%E/=H8
MEI)+TE'R11<^Q>(1.K33Y1O]"6$Y\*05_2X-_38A; PK5!5Z% 7-V1M2>IEJ
MJJ_YE]JTNN,<F49;O9_;GR)6_31D$5:OF=NT3T;3IRB$_LEV&[6'"4U?"96$
M$CKHEW#P:'NHS9$'8;->E+G!7OBV7MM0OI_I HS[9E._R>C1E]ATDQGI@')T
MI TB!66'043L5<:VE1B".!1TB=MC(^RN$EM2%84'6.-Z\'%GF8.NSA'!I4@!
MO<B#;N!@.Y<+KRH< "5B'2N2&1=HLTDZ1,P"%3O14N9),0.G_%EKU/XU3\XX
M9;FF1U'J!NNL0#:(AB3@.&J!1;]HP. P8%T'/([??07CV-? (&<.F #[S69'
MY=/O)(O>?K65<I617OJW::JC4YCI%+IDW$P'AG.0ZYR>TA]]<CU>7KGR!W!^
M(N0/\4_=;I_*FV7&J3P:YQD%.Y_N21L#8]V2?7ADWAX%MZT'YP5X89\54IHX
M^?-?B+\Y ;4R/HWD#)A\,63-7"3*,;TR4=#=VN4V36K'E90PB P*7O"KGC:6
MFR(F<G']U181?O%$W2FI%,82,K06@1[U\@K-T?JEDDI\$W\A!M1*E@<1]6XI
M$\LOO&Q\1D!QK\6D=F>-04=E1[A)D]J)I+9(IL=W_.EE#]^%I+6.D-\'E276
MJZ)</A_7@BPKG"OKK^I66F&$CWNU$C)4PIP4BZ@2^]N#(ZF-)F*C12M@>,7O
M -"TL'#^OT^\Q&%:07!2AOI[@Y[O0CN<X91S<Z):B]C684=_AL<UD<W"$I!U
MF\9O\%O45#$S,4V!1>@%XM,4\W\A;@D#?5S#;0?JD+$VOP Y\9SYXR35'=@?
M!0T\?HS\DAR_[C*7SSEB&32ER'*O#A+:](R<G6#ZJ(B#XEEF7Z$[G>"1_[%*
M@Y,3"D#Y%T">\9I6D/[;17UDZ\"+'FX$MK695*2 :Z/$=[[S^'-;-93%<AGR
MMTIK+S?4A\<G "96G;W>SXRD;<I D3R7^O(GS"\ 6F/I?E4F'+/%O2?=9J>1
MZ4MO$FLNK,<T 1[U!:#B\@A,1!GB1NRLX7D%W6_B!BP]K4A5*I]8-&ND2^3:
MY3+=('E2R#9G?_/7[NEW&V4)_PR&(0JUEZX('<_B '?K@OR-@"Y1U*M%"$*
MN!M8+4S,@3!-"((*.R4M<95.MR[_F]3I3FAV#E'Q06$(!08[8O'><K%<"E8:
M%04K2 E9VF@QDT/Z/(=W GO\73"]1]F%>'L""HTQ$1+LM&!@AM7^9J((3H!,
M)L&<-QQ(ZQH A- !'"SU?Q.(<,$+'K,R1/"'A503Q&7U4R8A&'$<0!JZ33,U
MMZ5FQZ"2,%LL"$GBY4N%BI4GFVX]0(SG00U B<\>_-E"!>W@A?P ]K;X!3@6
M4.UW3N]8?$U3X+ODOQJ1=V<]YO[&9_\ONSRNW_[S/YQSW%(LNFW6'S-YIA-9
M2NHXUO&)/LCW7/<\)X"J]26R\DW-)D3WJS,)X<N0VC^@__J]?%:XF5G$<E/M
M-D8J6-(UX05O\7>1T9()L4G4E507#P"BP:,6BP76':7/.!SPP>]83?CFP_!I
MO(P)MI;^D=TS,HT1S^/.R)K\R^."OMMCJO)I6H^#+4$0&57>D*WL5/_A3'R<
M\ET"=>UY1U<V^_,GS39#[2F1U5'IMV^@%E7DH]:&6KWF\9KU1L>K'[.VJJ,/
M!0D5<.-Q<22NN+#@4$BA8:5>*![5.;F\_I_*YDL!'(\77J*1!]'.:O=IQ63.
M#&WB:0/LAD<<T\_%&\N[I)T+'LQS<ZD8<,%(RT9(E^Z#LUJ9GA]V4SM)ZHM^
M=2YEW2T/Q9Z29:S4*IP61Q!)Q,%Y\G2DZ(%68,+Q[-2C-"2U C!_%K0YU3Y)
MKYWV!1XV]#A;-W3$PUKT](O8KY%\DT[GFBKVWQ,1?T7P_HPYUY,&29@<J/'F
MQD[DE!F'"]!$WYI@#M'" N*&4,^?E]L2I-MIJF3!#!G\CCE8VMP91N0'0#WC
M"H=X;(FQ'H^!8?'HO+9K\PP\-G]S(B K"]+GP5@A_W&IFG>U16Z6#T)<EFKN
MYO-O%K[)K+M? $2S4C:4K-8)%&61@9!%$1:!> G,F/SH=&&(7>8^_W2I/VG"
ML!\>&K$:G$+BOG.0/&3I[T/#(_.;@[:7:9GTLJ"7MJZ<:[IVK3I[6,R;D>H!
M#:M6/9>_]J/@R.H@;.)"7+$R<>^G_<'+)[N.%X+FBCFUO%#*8]*+EF2;F Q]
M"&/;$DZ-N+'#E8@)"H%7:6TC]C_JH!/620+N7V@,NZK]MAW(F*NT1*(U?1W;
M!^5/I7VT0NLRH?Y*<8?\@?27W/7, E<$.BDLHW71ME='=Q3E(<>D,R2X'6$_
MJ:-_NOSP'!S2M! :)P(J0P ^OY4JRY/UH(0Y>*\.J\,L/U3KY6XL_XY"RP\>
MY-47LJ=ZNRQY>8-.L",2-'811N%8@R$M&,7=]@!1J9.G98\*CZP"O$. 0C3<
MRGSMYB:C^+-+N=-Z:KP0+?LY>23WRRPY1E4]1_?)B1/?E.PKDU>DT<NIYA.L
MZ6GHH<![ .A@XD77) ^P%[,\V=]:2OHZ?5Y^-_(7YQQ=%(NA;'SGSTZ.13W"
MLZ+@BQV[/LA H+:$,)TB)^D6J0#5E($[)"(7+\J-VXI[Y[8Y5G-!YBI)7<E*
M\#=V7EW(SKULI[)VI Y[4EV)-L-/D/-8\*(W!2:X0.+D>9+SZ9D1)/4C=QG>
MG1$&(Y7GH\?:P?KW_'BYMUP*_=V$9/?B)5G!CGZ$78\QJ6_Z/)TCS66=Y%VO
M 90;$L^B;A@!8Y^NID]72/'W013J)V4[<7XE$<[Y$83 8N?[L^Z<K9RGEAJH
MM2:C<)CJXO1K?+=R.&M&/.IO&6V"*&ECLBJ8W#%];Q]%0VAPR;L(A$&NT*)E
M:)DA],F3W0=W\%L69RIFO-XXK]$+0<65V8+48/P<.MNP,H<XV*?_O],Z"46+
M*<Z=CP2#,75Q?WRKFLGZ1Z49*OOLI"8)^H: GYAJ7*4A4N#76"V%#H)Y1'R%
M-0@ZV3X 71WX9P<58HA70GDUHA?U&6SWF]OQ1N3[JS@M;=!N99!3-_W @95J
M<\8P'K%HJ4ZH13PQ>UHD>WY2,GVL^!VP?=+4_Q@&6!?X?>5 Z_4)R8G83\@Y
M"L=05*0S4ODU5DDXJ"IV<$V^2'P#!X]SH]1AP5H#>?J;_V1T9%]!@?)]OP^M
M8A]9W=73GH_BS.;-"2B,:TR^AN%PH/)<G[WL;R?52NE\0M;H=$EAY-J^M536
M#&2IMJL$93(*UGKPQ]S((/-$W8H=<IMXH#1R"E;E6HL=BLXOO#V>'IR)"F'U
M<4^[%P*BL27H_:(XF% &N/&<1"]1?S"8(F_WE=)>&/YW["B659N;M^'IL0BV
MK*+.UKETWDT73E" DJD$I8S:$&5X^B!DK(S2!:M<WB4B.<5.,.#T-=LW>=:J
M"_UO*GV/"?16B:+;G,>3Z-;KD4#H-C,-:Y<3">\BN4HXP/;WJ6 WS\\WSWE$
M+LS6X2([W /"A/5T5L@>"8]CJ\M"J>B2&(L<=B[+_-E&()JK65-!ARJP5;$N
MR=OJ_D"TH,^UE6Q\QSZ^NL;8MA3S<?R.EW,QD$%2V#+#V'V#(I42!:PO8BN+
M*Z"U&L=/!/ HH6 B.:'I_E1D.+0WV3"NSWG0U4AZ&R4-'9/5P)L;0<@M,H:M
MWA:0"^_#0"U6Q _RIB6XJMM;9D@J"H2X>[RPX^3 ^152BVF&-X'85*4@YXE$
M?/4[V0(_/A>+:RS34"4L^"%D#8"PD>=^R4?DN/T8I:FVH2*VR1G&?[HQDG5,
M/>XLMYO9,%:+6TF$&X53D:P-AE,C0XU%E*G(UT)*]06H@OESH?\N]//E##[5
M%<SGE^?Z%X#[5Z> 6?S&'.5%A:F4S4QGMJ1TT5VH]WZ38:9:@H '+#_68*AN
MF*8^2YSX&[J#'ON)D>+&Q9]!&AY#%>8?K=P.+=5-UGFL0NK1CA_2B#E7K_;D
M)&SVR@)A,BB$F'E1>1#=+& )7 ]4 .+L"[%5DYF<UK_DO[\ Z]"I6 3P-H?<
MT5JZ_,FK<A(]/BDD0J;S$E&MT;$GKWIY6_,,O/9&[ <XQ?W2Z<*[E] DP%7$
MGL?*S\]Z>&1<Q)(JG:GW!"D%UX'X 3S/B9,:G:/6J5F]]?."521**!$L!1/J
M=#X#?UA*U:3".@!QP-4FQ_W&NU^,OA*JB!N,[%Q&R49+YF!>A.U9DJX+=XW$
MP7"53JOK9;\1>RIL@?BR([D3:TM#"%O0HA%19EOX\SY4:'UIDTB,8YCJ$A+T
MU)U[QE4]DC#2$_+!.43M^R-^3M#-_;OX/]XJ/H &?-<3' =;] F3!HK+@+L@
M]\&#"X?ODZK<&),2_<W6R2F\L$QK HH#$8GS%_4LN2!J]GKWD?QCQLD)]O!J
MJJ:F"R?TZ\72O '0S]4V*[X].?D]ZR1^=C?!DNI60,](SO:7V*T:S*EJ?W_8
M,"48)0"85&];V$9+GRLAH9IG2V\74'I1Z?S@.\$7("TOZ;. B.H:W!$)1P<,
M#8WD%0C9+4G2#R#EOR;PSP.2CS<+1WY/TBTF1=<+D7\ZNL_Z/D^Q6D#T9EN"
M4M,-]'9_O6CU4WB7$V64#X+?<-&\>)IG1KVJQ5@4![CA$\&LM,'Z#-2%E2(,
MB:JW9 ;<I[%@PGB# 59NPYRV1^K\0[\ DQ _R?=X1;YIW)%P^P\!4*_Y=^R>
MMYMOSM[?'"-MI/S(3R;\N.N7Z5:!_0[[R%LC>A\0!@;R;F"O-QO!UG%]$*!V
MX0-20DAA5/=KP2<2W[VS4XC']]U%M#96450D'X:G*A&'\+8D3[\X%C#QW.8?
MU?X!_END#T I41'B@P>RL$574D*?$2-810S(%-/&K0AI)%DUKY%=DEO$Z*V8
MK$KD6T#SR"/Z [).JS&N:&WBI4_<7>I 283&\ ]OS(?SK'X!KZ8ALQQNCVXA
MLJ2UH?>#\,U?1C4#PK8)]*[9F::'.8QZ2118YV?$]AOY4M'%<L[-TN0!33@E
MZW??B,-V:>DNN?!(>6^H484?[PN5G#F-9<,][IC!_T;M(>@L"GTO<F;<1@H:
MB?@ET#3$ZJ6*KG$&GOT8P4#_--D=0Z"16\W7$"6)*&$^AYZ(U$*Q#(D*\B66
MSL'A9(<VI$8,&5+:F_H-@"E&CMX[>.8=DT[,4+:JTN-TD36W;2ZI7BK4%IR(
MY0,=E;^7(X%F$A>,0,/R2PU:W]K4GF:5"&AQ_NIJ7.F&[N%_A'0VHZ'J*&O1
M:C+..:]5M06,(M@PT2>Q:DMHLB2I$0ZXS]>Z"<T%JA2[FUN:@QB8+Z668RW(
MLP9Y'D>_171@Z;84KV.P*JQ%:)2P#D_N-NC3!5LW53ZB*?RFS&Q9@::G8P4$
MH.OH==[Z1R?JQ@922SA7B.A7,*B%DD9D[SI> AT/V/2#XG]!1"MQQZ&".(SM
M)Z_MEW!"%=RQWG6U>SP=*W*IV7+J$XF+G4G7;Z/O>D39,*<HP>OU7%(KE"%]
MIPT+]IUH-,*'8REBXII=Z'MC%JU(Y3#@OA]Z$002*!'V))-8+*#7W,)T(CKG
MPA;K]+6MZ/$VBE<.)0FY$KO\B+V#MAUY3L_XL&Y/-.P_GAZ(7"B08&EH+&/2
MY+"32[7 'FU/I$.BW)[9;4VQ1J>Q9\H=Y^#=P2FQ#D_EF4 N9#8'XA).R@ H
M_0GKG/L</(J:,9AU-&!Y$S0.,1R/?G,8G6F@KJY5]/[C;BG&Y3I1DWFCBLG7
M>PE&I91.ZCG3\P7#N\IY E:$.ZP+UM,5">K@;9*6I4W2BLD3P5@NFAY'2(G!
M$14R8/2W,H+[>OYI(GES45O^Z_%%O0N<XD=*!@\!E<6G8ORJ4CY6!=:9$G]3
M%^W^_J%;O3N)=5)V9E9KT#TOBA]D8W,6,>U>L]"I-M(0YJS[%1&2'NQ'J.%
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M:;J\9$RKQ4;,>[P"TXA%4LS).[ (.\PV:ZX?DI;M<LSHFXF0,[QA"K& MZ3
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MH+_VM V25%3G<+SL)5V(BK@,/)(=N U48*2B\5!?$Z811H5A(-*T1M  B:'
MX:% 3#22Q/:8+B+AELT$WQJ/=_@58=UX2<%6]=]R5UW8/"V?@!9ZY=:DBE/D
M[V!X;G$@NQRKE6<(CJ1L\;&L.K,%<Q=D0*\J&ZX!@7R14-\?UGZ$P^9+&:MV
MEIA(6SA]3"SJHA>OCP?7NQ//-B4%S?L]Y[<(O=0;G ''(.8%G<11<Y\%5$Q7
M)AQXJHH[""VA#2YW 48DL5)01$^3U3;NW*W91/&M9;V(&HV:VQL\6CJN.4_"
M33(W>5<AZ4_LM=&5L^4PK06% Q%QU*JVQ;@C'2< ^&<)6I"54<HF['LL;_;A
MA\O%C$X,:QE+SRC./^8UE@P%T HP4@O2H\V"I9YO*^^)U\O-G)T]X*FG_3_]
M;(]B,_*[ZC%I]+[P[O9+\F9M"<Q2631",PGMJS$\&4>-E'ST7%J[Y7K;8J)K
M/O#@LAV=.G^)4]EROJ?]\\*)-62P-\R)58&#F[HM6T.#GYJ2MA:#N;S.GTFE
M9HD-&LB[J$G;K,C5C<=$0D],R7L8P_.G3MP#O]8OD0FF00Z:@N?4*M7"E$.N
MQ@\15_4%U5.5!9U8+N)RS^8O&JGIK2CPV(EX:BNTJU@YG443U0$J>AGW%JJ,
M?RO_#U!+ P04    " #+BWM8FU&V6OY$ 0 /H $ $0   &<W-3DS-S!G,#!A
M,#0N:G!G[+P'5%-;TS]\$B#TWJNA2R?T+KWW7I60! B0!)+0Q *B%.E%!!$$
M! 44I#=1Z4U I3<1 5%I8N_7+^#5ZRW/\Y;G7?^UOK48.,GLV7OF-WMF]M[G
M+(Y^F_FV!#"9&YL9 R 0&!0)B@2 ;ULB4[;^."*.X(\+ABK*R@-J^F96Y.0
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MM(9)90-'$(*M'(P=]XK,R !*( T"_B"2C7=3W],T+F-J"X4"_S-B1@3C24D
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MU.^+) 0WG"1J .<P>:]"C\A>X[T>2,AUZ]]JME[2VM8YQVV-/6;&[%M76H)
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MII,XU-?0;I_EQ+QCSM/ 6T&&JUNI<Z]B/OJ;IOY,NG=!HU!=M@H=NGL<@_=
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MR7'/$56NH)S<G^H6O\.$JIT*DX60F;R+E5QVO0\-F7)(<<ZPV:)!Q!Q(\$Q
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M";>0V&I\#2/1704[\,,@MH0,+09/DPTO\M@F;\KNERVQW_C(*_?V>#UBUIN
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MH,*%)CN7P$-NU%M&UI$7E1%[;CTE"7PQ*,__PW-95:1)>QO7\4?4E(X)^S=
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M'JT)NRDKS]2;1R5/BH,)-]/H4<C0P9DSTE \WH5WVU[6='K]T-=1K)Y@<N>
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M>>-6A3'[[!)%=3I<.H>9Q?F@1:'K-X"S,8723\,R9=R_#LVOBFO6JHM%2_4
MH\KD!F,3,+) *2J^E95H+F*&$NB5A!2:T(/7KFCQKBC$^UO- B(*15\5(A*1
M9$:P6;6:2,JW]R'O<O R8W&*H7>8!7$B/\+UMSM-MR8+;*1.-K9S3BXQ+2G&
M7_$_W'/Z=E)>*)9-C$RQ*PGX*B@G5(9B>_H%>WX&V3;&+&R;!M Z#MR&O,&P
M,+H!FK/M0.A]/LJ&@MBASNS?;KPT]%XX#BO!HJ$H'LNFZHW9:S]^MW@E][Z/
MJJ7_-&34,YTI,9A]5ZN !\%C$/!EPNJHI<-*[1)[*;JL"V]XG; X(E)BTWZ
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MJ3B.LW5THD&H'/."<CNY^_48I!R%M,&0KXEX"Q%]O5&SQ@W;'Q665+=_X%;
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M14/76ANRU9<!%=J<@R6JGN%$;<[;:6<KT^'8)@>9+Y_=H*DBC5*N6O1VP7-
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ME++EU@VK+K[E-G%.5LDS@,T\F0M38#;U9W[[E!7DQQ-NC8)/Z0;1W%& 2'+
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MK^Y6#+^+RVWX& ^/DBG=Q0E15JF/.RQDW\]-.]L\]+:2,W,=('S(=>2,]SB
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M>EB,.EZDN'X=C'_6!;GBY>S%#PD9E@PQO$3(I;1_C@_0>J322H8:2;Q2H]$
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M-@)Q7Y7-9FXDB@(_LT.*3*V6SES9$I9&,UT=4*S9B/;SKMY[4 7)-G4<0AO
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MD'CC1OAB2N\7Q9&U):83"&!E,&MS5WW!VK>&G([F:?Z)-N%CZ-Z3FMF1YI\
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MZB@6M<_FK):8K'!,UN=G0T)3*93-S- X%/GB"V.WO&.5$L]S$]N0+3),A.\
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M<.Y4PHGB4;]>S#GUZG595L[86/HXZU]/B.*7YDO,YO$"M'=GQJH"!QM !+-
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M2PV"I0]JK KI[CF38]7MV"FFW5KIM)NI\+#O<"IOXZK"0$M=M+XJ-LR6LI9
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M'"D>N]?:QO7DIAS78!SM2O9;DVDK"3M6ZR. VB^=)[@EIISU8S]^KPJC2\_
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MH2!D\I"YCO?"VMY]ERO=HR\3F&L_O>_ZMJM@LC)N'+,EZ8>V7DJ42E4J%6+
M5&6HS7JKDX9?2R=+,_4EC(E*MC@?-U^:%GOS''8+0BD"$D4UG@44AO$>@)&>
MV+TZTIY1.&[L;QO2N'D$_,RIWOR+3*[??%9"54?%;[T$^PN?:AX?Z<X('C?T
M/P*&5,1I_XN9WW+*\4GVMGG8' IXBJ*N/!K7MVH$\<+UWC8G%1[:,WIN0-)S
M71,RQQ/!'56:MJ;OM[WC_4!20U529L'"K&_JS0$3^IHNA+DQA^RZ[PX:V8B,
M4'XZ-D")]H;?XARK;D[SR%$YN<5*R&S))+Z2[B[3X PAYQB0%4"UEG*7KY^G
MPC)E_,8'(O$14>\B?"*U[2\=EL(F%:YK5'P"MFUC_R)N,>"IN!(VR?&?H-W_
M#5HYL4P)^2Q4)8OR]N[W=\[YG5D-Q"_/JU*'R@V42C<V!)3T9WFP^"*@1"9!
MO;OB%M8O[)[%%^XDH*G]*HV7LK-M%I,KZ&Q?WDGBHM;V=(/<7!?=F']O<99?
MT'Q?V_2YZIQ0XR.(+Z1]MJ0%9I#JD2XR)$M/FP,Y<[F5_DP%Z=&D^!YA7GNF
M)-@G9,%0OXJL7E6=WC!<M/#+R9+D$-S2?%Q4K_0-   \%\)":X129L;"USLM
MC@LJ+C)])BQ,.:R3O5-_OBV9ZR#..*VM'>"H+4$0WH![FCU9,EZ /Z8^*PT/
MFQ6?198ZP]C[**U2GM@,3G)":DIUPJ^E,41T<^__N8B@JD:S9-:/.".);78M
M53,LSJ"UO)3+&MDUNZ#BRNLY+ZM"L'C8534?.LN%/D&UM#(WLB QK]NQH(FU
M980WCUI79:H^9 D7IP@]/3.6"KT/_"A">( DJOK<=!01I $,GGN5MR"4TGKK
M#13@Z4T5K4?:(\G,BG]0N=Q3+>7X?5%&5>NX]Q&PO2R.H.%V[P_W" A\(7B;
M!WH$]%O=/O@._^M0B,<$K9:^,Y<\R&ES?%:FKAYR:/%V=C*"3H+ 1JQ1IB#Z
M9ZT8B(=>"L18 \"+)C;QJA_SKP4\;^.>""5;S%-@LC?/X$S0>,^"2OD%S1R/
M[2WS0.&JU1S!BS+#X$JBHO#029R1MU,=X<!8[0C,FNI^](B)P#PLWV4LB8JH
MMRAO%W)W\@"(OFT@0?].%NNR[ XHZMK@/FG*VRX/]D;9.PI#)7,E VTE:Y?E
M0QUU^NC (&KV&FUO-<9E]B2!VIO/6? AY)B?@)A \*D<S&?YX';Z\XWU(\!2
MXHKVP5HZ_FS^80ITI *;>^O^KU),?O C8(GB+OX1P!6:J>U[C'G?[YLFILK(
MY3M'Z1VF +6@@*Q/>3N)%SF@%D9XMFC;-Y7\4$$_O,1LX/94W?TZ%_,IH^-[
M!PV396RX_QSN^JM7P<I!2#_]P^/]^[V$U]\+ZC7"8*H>-_>%>^ 3:R(T17^)
MYCS2?L&DY?UBX<+*)'GI5FW?N='?G8K3;M;=EY,N%-[4B/V/I-;F_B$U!XG\
M!+E6[_PPSK.E]J9GGL<$*C2X2U2L6_0UA2YHS;M.=.=S8O-/F@%I;BB6%R6&
M,%+R%9BBD_%TNK)?&L0(N3N[8PQ14)^44S,QE-;%G1SYAL0/!_P40@R&AU%\
M/[U^47\,X7?X4$:-^"W2$%WIF8[7O_L.5QFPO=,2;%" FH7]_U!LIVT=A8,1
MG0==746YH%B>'S\!=151(F<<8%K(Q<\ESXN&SQNA?O0Z8W"T&F;1R>\6LV5T
M]X8-C*,PYLM3204<^@P2O]ALG]'Z0NE'AZ@GN%A++/C2]N_V41ZL<0H3ER]K
M?!VRMD:Q_]<T61!DE)KF>EXAN8NG@2KYYN6^ST/>-0<&?\NU8;X2N< >N_F(
M5C%]WJ,J\>8LE@"W/(M@8.,M,Y^8>W_%CYUN$D/J[=YAJGH)(C0![L-+"[4$
M$-$="/O =7GX\C-0,.[F_/?S:OM=8M6DU3/'OQ>F5E*RAHH6W$CK-F45$B:A
MRA'#=)3FHXMAK,'&/=%SJ3Y\AUQ09HZJSCGG0F7P@K51]4A-,1UQ*(6B$&MY
M3:">Q5Y)HZ15>U%E@)H^/ES1B&4.ZPL<)UPLC&[-<O" %+T2U3LAQ%BW#6A!
MW'17U_8D'H)E/:$NDATMJZ5V"5R]#22&()PR],&Z1IV)T%0VE-7JJP9AN=J
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M^RW^77Z@4TA-%C<V'^K%RUT$ V%!R3.I#1A2T_<K! @_"2SN5X4S:\$ A3!
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M2(>*M H2(B @_P%OO;WC>=[WB?6N]7V++6?.WE?]KGWMZ^Q]]CG+<S)Y\A9
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M&!]01$I43$I(G/FWPB*'C_J5@=O92^FIJ/X&AVK)LOS6+Q\?'WX?87YWN(,
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M0/ Y[U'I_?"-&QA-'R7W5?6-D^[;XA<SD\E:2A/?!!,;]PJSI%3S4YABWZU
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MIP_*6!G?]'\B\F\?\GH:J_"2/1,L_@(X>J$_;J-Y4#0+%+$NG7B!B\[89"C
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MBHT?W;&*A-UB#>SBAK=XEE^ZJ4S+677IQ7MZ$U?7I ]X8T\;%?%N#AJK\>J
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M!3^^4WW\5.5 GB_]3/7[*RCFZ,93V9&N-R;J3]I?&*>_LLC($2_"%W0-R,O
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M9?[(^5\B#2-0)XH!]W;C+1VKB+1W'F>J247 8[#AYV>ZA=7G=Y>.CAY\;)7
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MEY5!_$!Y4,&B9 WV0<560Y50='_!/W#?*"X_8AO) [3GE30CR126$ONK""I
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MD4_B5Z91M(4MEJFYIDUSI<?[C,51"ZBM!-O81^<3H;#J:@JPI9,(+^T'O)1
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MDXG$+*AB=IY[\./</,%MSCMB> 1]=)-,?5-K]"%-DX(@BE^BK>_YW#L^-$'
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M[ WP]]SPE<Z]"FU)MHZ3K/=")8\LLB^V^+@^+^A7D#R#K?<K4=0+PE+36J[
MLXB>"DEP$3*@.4[U,:DEV.B4K3SJ 3EWT$8B_DKK3%6^R\+'.P;*MM.2G?(
M^SKWP7IQ%B8"JI#E>-+SA.QE+XA B@X=*5+#A3#),&I] 0_C1!6=N?<6,BJ3
M)W!4)WU;P@6K0*+Z]>@X69M!]>F0_!-3VKT6ER:GE#R.&I!E&2@A"YS5R32!
MDO;W#> 5&L@I3%:WIJ9ZN_R7>$3EFNY*\Q7JB<A=[]D0>Y$L$$^GK#C<J!_&
MK[G53K$23I9^:)\ARE!&7.%B8;.FGKE<>AYM(%?^0,XH/BP%@OEJ1+LZ'+&C
M!!R^9F]0J#^I?"9(0Z?%1?S2EXW)_D(_$*HH[!")#<QIL>N@;OA9SJ'DARPD
M#8CV,U3UVX-LV7 1ZI@V17_35Q$JK:LW"IINU]V*A1%E$\!< PX[^OL$#1\]
M0@&SL,&8GX]&?0>2]XO_$KXH!$:[[1";FD*O!*2&*FFN:^F#%&Y"H:QL$EGU
M\J-/#:VZ813,JH,B([LD\/*X@F1]UG,&I6Y>%Z!9JN(W@%)+[ O?C#9-FQH@
M?.;)*-JKGYYJD:*=:N6D$0U'P(X7X:LU$5DW] -SO:&S-ZWWY[5.'T[G]13>
MQA-Y!Q.D1UL^$>_W3'VE&2LHYKT01?;:2^'W]P7AC-2;,%F%?3J#_OBRCC/4
MQ_1K86'QB*[^%[%;DRTYR.>0R._BHZGXMDHAXW^VG,2+ K0Z8S<O9&V):D(X
M73[KP-4D(05*0B'\/'&$"_R6[?22G&KL/WV$+1?? !^/1'/H/!*WLNF*T'RO
MPPF('M3*YKPK'E"/[QE_OP%DVO\O[MXJJ,ZF"Q?<. 1W]PW!@[L&=W=GX^X.
MP=TMN$MPV+@&=W=W#Q#<(2??]_]SJL[4W)Q3,S=S]=;;W6NMY^GNZM6K5E?W
M8'_]4S;S,0&2A<J+U.>AV8G:KC^ ^6]J+/DH"Z -:&D0#*T.Z[$US#X]PEUU
MV!&C^V]7W0:;60VU^MY;0!)3Q6=UBLM2-'#EHF;ML@UOM0.CN $VZ:)_Q+??
M.]P/Z$(-V(M+<AU2^5T.K'67N/<^9 TQ/9Y_ ).M:D%D"$9=II.//PPB).ZJ
M(8<:DU]H]$;AHK>Q\'O@+8AJD4'[!KW$;RG/"FJ[V)[7\L8K>04;1L;N<?AE
MS]_%AC][+BLC&N=5"?/4<VNB<^!#W^&+>[]^D04+R7A:9MLM2Q#Z_TP23S7K
M*89?N/[E7N_/5_M1J^ZEZ/WDDAS^0GY-)&EE/#'Z(K[C6A?=NY2F#_4'H-G\
MQ$^8CX:Z8$G-(,]TJ49H=V!^XJT22HMG*+$5_P#9]WM8!O9T582<0>S:\9S,
M32O[-VP3F&,L^JB;O^0C^D[U#\#!QCV-:(4O%/H3LKQ'YP<NV^!'K3';ZAL)
MI401?N_0'0[T;QQ(-YW3-I_C4X+H;R]<R^MWWOW7F<ZLO^!+S8@/5@..>XUU
MA'F@)EIMQ&7$JH<.ZP4Y>1':YU@:!"7![#;=T\BKI(7?7@PM3>*6!H;W'%<$
MHYU$^JF%;-EY"H:$ ^&T#F^<.C3O;7Q$@_N_630@A@T,0%SV_4XO=YU("YA5
MI7RS1?;/^'UY<)CE8ABANZ"CHJ[<N/IILI29AK$F*=O22,V.D7_)S3D'<2RU
M3FL,.E0;&2DFA87ZFVY\G_LWY,"!?9-=;H$!."(:JFHR3/R(A:C>0"D@Y$^7
M(="^D9%Q5S%<=L$<!'5J0>9H.G:5%5W/JL#AIFWZ1N8X;4%C>W]I1UH105WY
MP!ZDDF(P^<\:JHJ8EEQ=6U>=GHHHNAO/K[E0%F0:_7R:B>_Z9;U7G7RKX:'(
M R-]#S&2W$035FT3!#;,M'\ SP9,B+%[UU";47.._=F$R.,P-;P]0!7X6(^*
MNG-OJ4LV^M_B\32]HN"B20]+F'8[10=]4UA(#J_&IY5>:2<*$9!]&AU_*/=I
ME(NX:U'/*?KYLH2[.:K3,/*T31VW9@+)+NH0D.^M-%A&S$5;H"!.9_\>BI(P
MPHA'5V.W-8Q=BIT,@AEAJSC[%9P5FW:L3:*VSI=)V&DKLX;?[V;$LDPHGI0^
M=]0Y*&7#@.*7HE;87MZ@(S.K]XL5&8'B0)-3"-?2L56/CSF:>3/L^+M<V]0$
M=("UD1P>E/6F-Q]?S-">DQ-AQ-514RP%P5(O+SR&F+4T1K.L(:-?R/_F5L$$
M^:&\IGVMJJ][T=A(9<D]:50@@"-Q:/<HS+(XX94%N38P<62H;<PH!.7N$"QV
M5-'DN8?';:'TD+7@.7)[*#;;8SW'/Z"G:^014'496_:R;(<<PM7I$>[EHPT3
MXC <BV*%=]1.3W=Z?6;-JQJBB;9*<!)@W6UY&!(N34]:JT&ETT\M:^/3@WE;
M&NC8S_RF!(W4!V\5+*_PF'D?ZQG:O+JRGO^V,>-HLQ09UYW.']E,#6H3J#KN
M5 -GD0&0Q.J. IR&C>Y%15P+^U>K+@E8/Z5).&'WN^A_B&DJ0V]/Q&6&+K]E
MGGEX')>N.5#^5E_1KVQ;R]P(RSZ>%U&R&QA65E=7&*<-)/$8I<70-F#BB4DT
MUQ:3.OT9"L5>.%2-CTR;V"Q^HNA6_0>@C.% 8',L0F5<38E^9(I&Z2C_>'\3
MF@U/U&80%_"(-%5!,32[DXKM99BZE%KC3%=8Z)C].0S<CC[]52A'4 =7T;7^
MJ>&C^//F[7L>9ZY_[M+]4<[%<.*C\B:#/\,?P)>3KUZO?P#)[]F6J1M>I*Z7
M:4(XR6=?_28Q.N+_!L3M6F_:?P JN)N';WGS99&"!NXRE_SQ[7&GH-TWA\\G
M\(JD2XOSQV/0-?LCK^7_R'K_ 5Q^?=^^G/WO)4+Q@WF'[_"*0MYO>0XGKZ2"
MJMN%FDX'?@N/LJ310F?_M/P#Z+H]%.)[^I\".??DWQ0;WGQ?5+X?Z[ZH'J;\
M_K9_X.OV//JW,OZZX<-AY^O3MYO7;U?SN\<GM3Y_M<W_ _-C^VU$D=1#B(J_
MVY[]7Y0>?VV,WI,+_O[UGNV#H/^7M,(QZ-H+\P_ &?/R/>__AF3S7\:M/SY7
MW'=97K:\Z@^(&V8-EY_?O*TE=C47^_V-[WW^VQYUW^/M="-T]]NSUWM[,=2Q
MK.J$8>8_RN;;5KQ>_D9B*ICCFV]YC')%Q@?\%V_._T'#AQK5<4;AMWU].4^S
MXH5J]Z^]G*E!_NJ\X3\ ,.:])X?@EE_W(  0J)# FZ7WK[F_&GW5MY4Q+Y]O
M_P#"6Z0(H28"S_\9*;?XFH>*GV1C5FQ08*2,%KR[ZLP*YM]VE6>2R?4)5AN-
M!3G(IA5:<_P@'V.#T)Y*HE-*W,IB=B45:8I@F1/*H0]:@[_> /2A<*_Y @.Z
M:#K>?@,8DJ!S_W4RV],_5TLULAJ)?PC$[](7D%#6#+B^E5]^?E/>SFL-G_X;
M9Y(8D.B8V?>/V,U[EWB02&ZBT4/?-'F0'$"+*?B=WOCBYDU70E+P?I)HEURC
M/_AWMJENG/,+Q1KN_@&4(QQ>?BB&$V2(6_(HJ<[RK?_MA*(VTK&*-;J*UU[,
M\=M[KX?:S.OIB4XKR.S".NI<TMMJE8[X+X<@N08[,-%WZGZP"-O<R78XFM?7
M0%@>"<O#:3,]?9$HL;"OSXG1>J8S0R.Y"U$&52<5![MN O9NV[=MBQ8,&>1@
M:$BQ) [H+$BCGD6]9Q0!/4MEXB3.BB4&/T-'AB7/=_V0U $8@O'MGJ_A&>),
MG/73IOL/SDT;;@:1A_-PF-CQ4'#HYRXC#DZ7YK9# '<5((:;]@"(J#^GVM'R
M<^>,46QP8,1\:HE1IV*QQJ*>I!RR?G63W"I,2:B^/$NZSE*F51V[2G0B9(B%
M))8X54(#<Y(^)KSVDB1?[UB>*":X0S@Y2L)YJ.EP'\.Y,4BL-7MSHUV84-GW
MX2$<>OIB%GP,8(4=+T6&H0-I5YW59^O.@]5JA[(LFBEG3-JP5@VDQG5]V:#+
M"@+>O@ZM-;.5^L"#9+H;=5912V0>OIOLQ 1YZ?$9'#@TP#6\BA(B=:!&#[S$
M(AGWV3.1.[YWS4'@B^I]>XB@-O:LY_Y ,^$H@PDM>0K3#QNY_.X1&0'L917+
MP'0#OW*  LRU6G6_A^PNIG>XT)2P>AG]*(+<.%G3NP;KJECA>([YUL1*B27T
M8<<E^JB;OA<1WG(?.7'C#8?O.>5%.)Y U1-=(<D#LU!EE?T$X:^>8E]6\+0\
MO8J)8D#2F$JRPESQ:&(,@[6?'DO_-Y,3>NURH.<'Z4 1]984C986L2WXT57M
MW(T=)MBF_I0^1>!?)U!80QXXCL&9!J(@RM@FFN,IAT,<O: Z#R1#_RS\V7KR
M:/Z3..W5"^I Q=_)/2'S^&E=IQTI2:_=QBFJ+J'<12^**'=/$DVV[)<D"&D
MZ#92JP' '*%0SK?1_>=<5N+F)A8@"( -B/KU+57O*CADA*+TP[WF9:JI8G)M
M[.S_(.%RB\, &\MM)HH/F0I=E, _*=G/S\8"2L+7ZD:-D^"92*Q1(!JF\W&%
M;@P"HIFB?^7XY:D4"4V(CJ/!Q]G@0!$(&XT\3!F*85[LM!"V8(T)#5)<=):(
MVEJ"-XY\-^"=B(PU!*K=H7!%&9&!3/I#T(CD 67YMP86CKZ"E,$Y07WB)87?
M**67IV3R-6QQ)E4'D;!]+,)"T9KFU6*Q7(T9T)82V8[): JTEFB&,S5'*?=M
MT+&GU0T\]^4$N:+Z@0VDV"&9"2? B9DX'QI/$JR)'7!Q9B-!UEMJHB7+FIY.
M%2^_=Q6!M?>3DB,]O62$<'!H18U4. $.F*;H%\_4;K5BRJ,/KMZUDQ-+KA.+
M@1.)_2,^]37PIO!W:&AXT$:Z';+MB&4^,65V<E52I?=1^_]!0JM '7/05=P:
M]-S-D8+O82AKO!4['"U<'>J+&<\\SX,-\E"*V'--&(MU'N2W/"F1J*B_%-.G
MAY@E6XGU=U%ESF[0[>M@_W\*[O^_>N%3IK4,YUSAP+29>2!9E%<0O#:5'C<'
M5YQ8%%7.0&'XJ0VSB7BN"I/K0)9PK2(S! Z>0A+,X-22I2((]RW+5-JZ/V;2
M#M3 [G@&4PI)2VZS,KI!<R._95L*FBU=&:60TE3N,N<:Y1#HZ8&&XO]P:+L?
MM?TI(&2O0A%V?^:%*FLZ9_TK]INE%BCISD&9F-_J\^BA9N5-FP*/NB&C^(^'
MMN=]MYE&]LH_ /7@RRL2]H^ACVT!'M41O\MB&T.VAW3E,P+#T-#??P!<\>?O
MN3H-\R,^ACES<$)LEV4+[#\1X<;C;ST_IH7RIJ5/N\);2I+^J<DM*%6DZTE^
M[Q?8\/DYG)>;//+MV@$L?'SD-_^/#.+V'K_-^W;#N'35O VJ:>#TQ.N/>^0O
M??^<Z6*>;E ='_&VVZGR=A%"C3H\XW7 NC<R$'KI_%;OW5EVLB_]#+5[K?*/
ME:(%]FTDA&_<U[4/9;\>7]TLRA(>I(C>IMNIL%F]-&#NT#^V44GGRX7(?!\7
M*6LS5,_H',)@[I">/QSRWAPS_R$"1/&WV!00E[_JZ:XE7?U1Y9OD?_;O[T=@
MGGG5W0W)]J/Z7\G'_X@>#M\BO?)_?&-_L!+@#P=+&OX#06T;"?4$_\'S(^<O
ML)TKJ5__</QOH?6T(OEY L]SGNL]-E<_U NL7V;R#63]C4R>LJKG-QR8O[XT
MW^+BZOJ=M\%',^&)'^L_/?&W+>3C3=%0Y<LBSSN)8;7;%PR(V)X'J5\&%ENY
MGP1$9*_JNO^+;Y38=[K]KS9?9J%\B]7B):L#RK%1K*CGC-O_E'[Y6_JW TC;
M_Q>P5D)D0+=;VG](P=TAO7)8E"Z1;+5(_>J:_EF24DW,>_NFA1O?ZCE_[[B-
M.GM\L? /J07OL*S=0#\HP>DL#;>RA--_Z9?]HQ'Q?\X 90J/6\IS-49DUN<E
MZ)^7^ _^F]JG!P+58Z/$[FV/]^W>8=]WC=X-A#K*_> 2<$\2"9^3'_]!868D
M_9P?*]0Q?'LJ1.;V?&@:U['Q^J+MWJNLP5"=[7U-GM%Y;Q8'OT[II8 ;7N0]
M$A75#=]I6>7+\5H1]_]>BOS_+Y^H3L^:?U=(S<T7KYO][:GBM\?U0:SGLT++
MR&F2;WE'5\]WST?_$7#Y$!I^TI?&)-C$5,=RSJ[PZ7S[ V@9?_-=2T*Z::>]
MO5D4)RH+G_XM+OYN8/7B^N_MZ?FL4=C*_._=I-OOVYO'A105GUO6AX\-G7V6
MQ<2=/PL*&DP[M*P>=<MTDPP<CZN()3:]*2OF5L^RBQ.;/G@^43Q1U-)TRV1_
MCO*W]_?#O,HN"X_/^RZ(^/)3(:(LY0^ =//W.X'\,T6(FN$7TKS0_?6#;MG#
M\X^[6:R3R$)_U93'OP"+MO_#-HI'<:W\H-LRN_;IG<2F[!#K#R!^,9_-]']9
M@%7$ KLZT25IITFV>!Y>GSZV+7*375HH;P>!]MEE\)U/=%?1?_?E'O'A\2W]
MT_W"(M>8.Y%C7^*%]L=?Y]6%15K$#OG?\_8??#]TZ+++?KYY^I6_W(FIB]U^
M##Y>?P@9IA6_KA1/)F)CHZL.X@[B;N6^J[7G_#7WX/DE/J@V_&<OMB_/U?4L
MM:!G^7$.&C[X']"D0J@9WRS"XT^.5<2&I_,>1DIP<Y3,1_X=/TR$,9?AEK=O
M\7FACTP1F;24CG^M3H^+J_Y?[]$[1^7>J3WZ;Z)%ML]-I1"FSD'9,5ZK<@ZM
M6Z[&:&N:':RI6^"A6"6:HGY&&OARBX'1O!?LZOBR M> D<L[8D(=40Z1Z87J
M!0UF)]1;.2;2Y'AV1N+B%Q^UUU54Q73F;'8B8RF6=LG%1X/'0$BB[N/X!1Y<
M^5YL0="P0?QSC2C9DHLSRQ$\!P6Y1M93VYR?3S93*4]TRD@?QX3PRR)HQKG8
MAMK+S:0+9XB3!S=W@T\1;9FG;F9&>I)-GD8H2M_L]XL],EG261(#^W**CE?-
M^?R<9,#>^L^$\RZ)]2.>;D518S+[+_AM Z1*<F3[;5.2[J(QO#L2X0)XK3 C
MPQI3.>](*=Q9GXIK7)CGB";V'XY<+++LO=T,OAMSLW.CG48A+LAI"#1KJ ^7
M8$++==UY?N Z^I$(OG3$]-V7+&JCI*N'NHU:Z*F.Z]N.% D1YA9:L7ZZ59&6
M0*' X!3TG^)8)\R(\R+/EY-^[W<"W&1.DQ>T4CUGTIT'SEH2;*A%B:G(GW3%
MW>48'[6F+5[X>R/F?R=N*L-9D*% F;JF?_Y\J;'2.G/0R\QMVR^, O\JO74"
MVX!^LY"X1L?&@6>!%L3:CBB-P3.X?X!][!/MY'C5,V$ ;-5R\*NE<#UQB7(]
M6L=SSX/<[*#KL!Z+^?C^I:&FAN9,2Q9G&,4TRH"+!3J;V=2 %*A TJALE@J?
MP\?9\6YGU-&]),*3J9\N)ASEP'%"3SU?"$)XJI?@9X^5FY1(5&A"-#R^J[M@
M3BN<)6Q\[5R/M&?\545761[<SOF#H 6P<AYMIRTF?%\G.N=4.41A,L,RRGB2
M*-%^ L&&+BSO[9R7^0,>Z(IRF_A[N=>PR4^H G9U<V%KHQ+5B/L2-WU^?^52
M2#\9)+YET.L4N_1W%_M+REYA>*1#"Y'JH@II2+%G&AWTV^EG=G**<;)JQ$D
MJJOE,:;3_+CZRFXO&3JRD?N\-XH$[7RO^N.7.>30BR'ZJ".%=>+^D1-P=?=
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MD=S"5V;&M&B"%V?HU\@79-DFN#[8%@JGI,'NI'7/L^RJA@VYRHJH3<SC3GU
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M5,0->'S(Q:WC'8W-^0@<\5 S6@0$LF"MI=QO"$WVZKHXI]6SF0L,WU"Z"KY
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M*^&LFAG\]//MO;!+!)6G3'I99<CF6:J_?>U;:DS_C?A)[+ULT[@U:3_-DKV
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M/N'V^BU:0_?P$4J38_Y8(M XZ9/L0L5\%7TE67G$0R"K(+Q,6JMP,)U$$]^
M<%2\XB"'IA$ '@,"F)D!G%@R!_^/ -P)(_9U4=WG-<ZI: ULBP $"(B@%SN9
M*L)G1EZ/49]5:LV8VY994>1E9?4'-Q6J0JNR<V2&8N]$G0?M(;*>48>20EKD
M>Y\$+N>8F*VCNQ%(M\*KN_\ NK]O(4\%<!.R&SYF:%[C%;:X:1GA[ F&9=-0
M@27Y#:V6&8#M+)T*DJX.48=X[^NCXG0Q=1R=1O =TYA0WD=(^U/^(>]$U@0.
M0^?G=43).C9L%F&5W&=93M!@%_F.0TRX[>Y-:8W7EW-O1J(X'U58GRPNG,"0
M-SAFP3O>QL2]1J(FLAK1F@#O_NW/C<>$*0*?^(@5-!^?%4R;HL]'WKS$5^U&
M&45B11#XM)<4%&!47"XT,X=6T+;,2!A<=7+$+$-./'(U)!D6%7(U=4  0+4I
M)_QM\UU5;W"2VA-^?6;VUZ*XK?8/9G(L;Q/$<CVWQ;(\<P6>,G$:O(JYM[#0
M$Q.ZS" )+9QA$<R>2RNF>]S.(W*L:(W5NJ"0' $@._=%)DDZ6N;0 # @45K1
M]$GHQPE=]BV'VNB*6[;DCI8\/J&*^];,20VTD1HR,E+9.87*R21KNK(3.YJ(
MLKU<TC04M^;K( %>4:V55"Z,O1[KAF!@[-;="BQ%GGQ#18O5M@B,M"AC;$F*
M+L.I%*86&(00Z-&]I*-"YW/9MXT'.;8D=/G);#G"8-W9CKWH(FO_ +C2U9B5
M7P]C]H*_+PL_ VVP\+-JYMDT'*1*0(>[&;<33$6B1V$4;".#YR)YBNL]>VDF
MD>_ESW*N6G+FRTSSFYR9,DU4<2\@NJ1;36=(U5%'Z-FP EK<7@VSFW<-QD%P
M#D-W91XK5-,M+RL/=:5ML;/W;KSG@63Y#PRGJLHQ<LI$+F2RR.=&-# 0T0#?
M6==9UKU1Q+B"23EM4B/*/#;1<H>C?L(.F5)!M#@$3<Y2V;F#&8W7)'D;+Y6K
M<LMH^QZA<=GU6H;'(U63HUJ/:J-1$I +/ID2S;RUOINLQWQB?YBF:3TJ+'Q'
M-8<9T!NBW#N+7;A"[95(<E;CQ>-#XB&,!!@G<3!SQ3'2XX@7#Y2AK,R,B!I3
M:PB212YZ^0[@K66$Y7#0FUP*@R)J*JNEQ!-QM%>L_B#"S;B_1\V/PF\J,FQ+
M:K!L=R&@J4H:6ZJL? $LZNG1DD25P1D<230"I%+)&D;'HB1O>Q/DN5%W)KS$
M&*2-J*908FL&1)-#6M[U/A2RMFQZ)/1BM[ ZUM-AMJ["RL[@B_L33,-I2"#;
MDOM^]6),DHKG2D3J20LKG*J/6:1RM57*NL@ " (%H"V7.-R3_$QY254P^CIM
M#5YEA694^(U]&=MZF138K64L ]70@6N5B"UMS>NK0QXNWN9JH5E;&5-,Z&,2
M1[4'69(YHC>[F H#0B!J 3SKO\.#4UJ:&Y_QB/*E+:JFY_T5]AMQQKAF0[;8
MY%:6]5?T[\HJ:X*NR<07*IYRKUX%Q' ^> BQ+*(*+DE9/&5-/,I,4T<\S),9
M&MG*,N:2\@WB))O/AXR%LO<[]QFLP?XCTA6U1]##H]U&$[8[>%83#DF*[0W%
MSD.(5V4R0VX[;^_G+,L;<\1P\-?.3WLZ<@.. (0.O>K& ##PQ11,VX!\9JP"
M!I0U(IS^0L-):"T4! !%#-9O%*C0UC0&M[471AZ.^,7,^18[LKMM2WI-@VUG
MMJW$ZD0^6Q85.:PQY,(S9%GC+)()C?UN8YIY9&=5TCE7326"&DM&P6LQ@MFA
M$$<OQX0KCN]D=H,E9BT>0;;X=<Q839E76(P6-&"5!CML:1(678U,$L3H0S""
MI929)XF(]T\CY>>NY5U@L:79R.]!$R;&I$3%>B@HW**-V_F_JK-9T3>C+$9#
M81[$;6L.'EM9X2VX=3(0R6\>K[=_:]UZ[E/>JNGZZN1RJJM1O.M-.4DMH3%N
M0@=*;7N:K):"(,D<R>N\^UE=<6Q.SXV5&9P'MYC0&8V)U/8V635H7JVZLBZ!
MRNJ)+&P >.0?&$JJD8Y;YAGM^1-#(Q$;J15QU<2XDDF22237<DE5S0X &H:
M!4B +"09I&J\L?1ZV-AS&RW"BVGP2+.;@R2PM,LBQRNCOCSI1E#E+*LF0H3*
M1**Y8))7/5[XUX<JZ96W@2+&!(5=WFACI+18$G_OLO;CNQ>S>)7MMD^,;8X5
M0Y#?5:TMU<U>/UX=A:5"Q0PNK3B886R$!/B'A8\>171O2)BO:Y4YT< \0ZHB
M*[3/59#0V T1!D030P1]B50?_P L?1Z2MQ^G39G;MM5B9\UIC5>W&*QHE'8$
MPPC$%UL#8$C%FF@'@AE=&U.O'#$UR*C&\:)+B":Y1 Y#9;!(;E![I,QSWFZ\
MU#T5^C?BQH=CCFR.VE&?7E&&A&5>)U(9(Q=B&)7G$Q2P#L>V8L$ $2>3GK20
M"#Q.560L1MS.B)H=* +)$MRF2V9B3?>_)>^PZ->P%J95'V.SNWAAM' @M05/
MC%8^>N%;60TK119.P1T8S:D>"N:.B]BT2&.%&(QC43+1EJVE2?$[3;PHKK,F
M=Y/S17*-L[M6%86EJ+M]B<%E=4Y&/VYT=*$A5E2%(U":LV;LE>2$1U&=M!*K
MF2=5.NB\:C@'3FKFJ9FL&?NJ22<TF1-9@UZ*R,>Z,.R>)9;AV7XG@]5C!&!
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M.&N_??Q]0R/$QR<D(KQ(1'21G(B(B/STC8C\NPK)?\? 20> Y +*^1P,-!8
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M@ 9 P\!"^\-#*M$PL'$PL4X?/(>.$O"[" !@H:-C8!$2$^#A$>%AH/B86-@
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M%-';NWW]"EEUC=R4 $W\@T N,L5]<3/J*/(:MG7ST-<UHE'#:KC&2;:\4_/
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M_).XDJ4=G9&\@SXM!+R#2M#VP9TF@9H]$C3\VCHX+69"F8/TGD_YI2#>T@N
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M\@&A$('>9579@/Z<^#W;]<0-(N<DX8J8EGMN9:TK;(>K*VN(EI%'G[=%;LP
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M;K-MNCE"S%]-4JG7R()WW2#/F>Y%1GR;Z@RGWB@I+P4E#[N\_1P6+D5I'J*
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M^\+P4\\FPKID376"\\W^J;RH[L']XIUO80?Y4@>L7V-G\Y@N5=_Q<$A]FP?
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M<TLZD= -'BY=AL=\R0!QCC*L?GSU(R= 8VV^I(QAQF'WJ?!J9*4R38*D4>C
MIFT ]S,\,:?4T<-X5Z3[MT<6\3Y\0=/?'7PL)M)0BH4@D*K<88@8:T&UDHCX
M.M[Z:47$^,JHB(3A&.Q(C.N2A1 BL]YF:V(*/.0P@5LCK#=0XZ\M==P$D?]$
M"K#?I%"+><<*^*YY[C.PRU_)>>21/L<%YZFK01D&[D7^I%P;L\[J1";# D4.
MV*:>[455RUNB-P!I^\@; &],;G[)A'[W#2 I:&Y[=H2UB-YP_$JK_5SDIZJ6
M:B)IQ65-O:K+?(__IT']P03,[I62FBY*EMG(H/:WZ)66:M903:W&VM3J HG9
M80%[2+(HT[0V/U]5IT[!C#O5R/@"*0@&J2']\;BJE&E1?V.JJ;?K C1U="S@
M9.EX495%,@)] 9W*_AYN3&!2U#DQL7]2?568K"8YIMEK+%L4$.%@AT=<9DQ?
MS6N9_;ZXDCRWM'GQ2@5?KCAO"?D^8ZQT/THUD979>>U]6):/JU$*#70M+,<B
MF<CTWL+)FOIT7E,ZRV@@JW@\K7A-NS\%W,*P,G%C(9F16=H$KC%^I"&GL((7
MG^[T(Z;DZJ>ECV2Q7E_95)1=D(-.+P;R%BGU8^Y7@NZ5W]<C=]=O (4G-X!]
MD-R 2&30M'&OM2?BRJ;P$OBO[CE4CGM8;%UW6Q'6G9Y=XNJZ)\0F1F(^_J,Y
MK I'XD' B<N3Z_N2.ZO*/)7.19$C"F9%?,\$97_UBE^7M:T8V/JP6FOJ>\>:
M?/&#5PP%K-+#^22;P1&^DU*?Y 01104IL+JYLN_FG%HG0D-5BH&=[6:LPL*-
M-.M?3=0FI,8>GNYA*1J;*B-3O&.Q^4:7]@S%J4*TE+@SI-)-3E!BT-_\JHF=
MDE?^1!*&3O9=/;0'G+/:EO.SGA*WX[*S9M4('A#8D\;'RSE5D8*/&]?:(\4B
M/J=D@_]4+ <NE5>L%)7.*BS%("GH+U<QB%76J!R=MWL"N:*HR/I7+QU:.#8/
M+]KQNS>W-G?[1[-K==7QOIF1V4V'_LPCX?[K"[3M5%_A8'>HG=$-P%">MPS"
M43@HZK[PZ*)3]Q?8II<N3K6/P-16 &ED>8G37N%.BW4+ZZQXZBP?8S>.LNUJ
MA*H^7MV(!M#&2#7(P?-^NGUF2%7.#UXK,GHM-H:6057V8F">6%P+%Z;:F_2-
M^9)UXDS!R9]37T;?2L3CF^\4A>5O/ZZZ)[EGRCW8.1I1H]G'1K>6C06R\0NB
M@VIF=+Q1U-D_%N.:BJ,FW,LB =4[NE1?M75&7QI*AC.ZJ2BF4_(NA**30:+K
MWUK/"F!Q.[\.?%A'7FP$>"=4=8Q5@QRZ$!-I<<V^ 70=AD7JMF;LR.R@K6_@
M(6ME;P KZ1)/0SOA/E*C9=F'[,8DD[$2 ?=%CJR/'+B!8OSRO;:)Y?XGT1-R
M7GUB [66>H<\Z(U+=/07VI?UA\#K#_VCV/#F"W57Q8.V(2:;01_2]^\N6>$H
M+Q>F/??[ZD$6Q\GUBX$#NM<'7:9UOC> V\YOG+WNO J6%V[;F'DVD"E,+W8)
M:W=G?0E+Y"O2U^5.@6ZG*B%!1SEFET$<";5::.K+TU@G_H;/@^.ZI7WSE.A&
M!%^Q*^<&G[2W\5=K?A=088 +;/D9YY1RAB]+*;SP5*MCZ3@6+%6@E<X5G37A
M*S;YA3?X.%E9GL\VGB8Z/4%S/+"=,/)A_JIIH>C[UG5.F)=JW)>,P!\4P?LC
MX>C):7&(F52J^%%%U[1'/M@./G6D_=<YN+W56@Y:!M 6K@^I4 6,(HPR2S.,
MTR,'KHTM!5D\40VU=<O\["SH2#\[9IR;%F^9/4  [VFH:EH)E$.>-$A*ZGO;
MVY8795@#2;4AT9H9<2,]Z[D_,F:"2F"OY2_J/[^X7J2I*KH!$%*3W$Y'IK]A
M#A%!"SHA[/X+Y[>S\&FD\B"]/XD<8J"'4ZA^3("\U>I?Y!L%#N='(9]77_7Y
M]7K1I-AB5G8?JQ6X6[;MNJ[>B_^8^3H/ZB/L<X?V:]>.&T!N>;SA+=R+M?.=
MDEU5'SYLI6O./:"J+3(E%\'?G;Z,B*BV'&6:\2N2H4B>>)!92>=B$]$VE"T^
M9J2SDO0=K@C#50;U/X "C26QB4Q Q\W^0-;G\S'Y1!\'MM],W N83#>#MAGB
MZ/[ $13FZI52#@TS?5+(_;&[$H43.M&PW"88_3Q(_%4$HUJT]=B[>UF'5,R6
MA2;)"BXKKX8ES2>TPQQG!C+$!O+I_0KI"F4K?)R'#5*HG4'MO"OO8IX15YLZ
M"(]WE)!DJY>FZ=.39D)=E%A@+(Q!:LG$=LN/:?@JX]@+!<0&BY60#-2#P^/6
M?,[2VCA9$DY=RNI)A2R+@R3T(W@HL%BJN2??JYLINN8P&CCZOM.MQ?;OV_0)
M/J%B6W\. '2N-&>AO/X5GY"/\Y2*:\\7G'*VAVIA&Y3O5'$[0_6>^*$3;5^7
ML5!"TEQM>L[$'5KZ'=RU"'$=JB3&!!%AAI>R: [F+*SQ]0PXM8/"E2N7J0(+
M1@+U4'_?F75R[0,WQ?@]3M+9T=:6^.U?1WT\RT3G%^XE%]$*=YG\23&5*G*;
MHMK*ZG\OXL_3XZ,V=\AI?()P#YK#4:$5\30E,@'<Q7%-XUE=3OALG]<Z5#<A
MN@+@K>,;N.-Q\".@!6QL13JFV]:J[R!P:3\$$:P]*S.+8/^\B?_:=%J;+X_S
MR1DR!Q&1=:]R0K6F)V-*_9%&_&7_) 7%*R+,R5)[^34@;NLP_[FQ7K-G1O-I
MISBMI'$I9DWZ9AJG%5KY!O\J4.D&P#GUR9P:WH.@#3?9MFT1UYZ+*[,)J7\U
MTW%23#9MD^L];888:39_-E(J>Q[GEE?^"OKL"&)_RI-:E#Z/IR(5#L5;Y9F9
MKX*)*= A.L]X8O+TT4G D(;]_2M5W-KYOH7JDAV-W%)03MG7#V"!D;)P>L@H
M217GY:<"HETGP_:9$2#GB)TE--PXWKA>$ETF2VXX9H;>M9 !1N.1S5R9DVZL
MFKYB:B19V4OR ,BV3N";&_0#FMB"<5FT#V\A8]"L@YY5*[88H@?\JEC];#MG
M8?EMBP.7;;>P"LE7:>O<O5D!YAZHG'_TH'7JQ3?DF_=OQ.< )#XZ.8?7_0N!
M+5N25X1IN5K<+1OK!)W<;@E)D6<.*N'RS7IR.<HQTI$A_D/ZN"?;TS[K<N86
M=>M,70BO^V^>LKP!1Z!M$1B&EX4&FR[@D&'<JE2,";'I:7*"YK_0K?@ENK Z
M#QG/R?SDC]E&S^B[^/:X/'T^G*_&HIF(N[><6:ZJ\TPC_/TR!+"?C<<AO.6Y
M>A$8U=K?$9X4V- GT%4B[?OW\KA-24ZS-N*4?$)S:]3YS?W2"JD'93Z#EC%S
M,Y\E-#>P1'G==Z6U:A41Y$1*MD[H>QB?:.NU?=E-XLO=[GBXUVTWP^U5N23X
MH@JQQ4WH4U:UT8*0SY..C&NIU8P=Z)Y(O4*] :"Y.!9>X5U0!Y&1\$*N_$="
MU)6:ZKGS0C(T!<-((",+6R;[.\#TEA"Y\#3>H ?SKC"K'MO)O)71&#,IAH34
M((/I^)Z$&P!6SEZ BSM^58NJDEW<.C'%"\\@]<TMWVNH-N>KM+5,DVH3D$FY
MK$'A&R1&,5Q(!5/965)4)8-F'CRS8XVB-M-61QK'A^P3 O5C\3]*$PK4K.5P
M#,T[S=:2'T'Q*S7^@" LY952I60ZWH7,[&Z05-][BWY&YPM5R4[7T=@IF!1F
MPV).;FQ/@+JXJ* ;Z$A]NHYF@B788 G> '1@S!H*A3)J)OT1)L:A@YQPQ3P4
MM<*YOMD..JG6C![#!82T[+%*M=7%=" V60Y.]PP-[1=:OC'-S2@!H0,BK<8A
M^0]5D' F<<)W*Z(TR0KT0=?2= ]G+**JMCX[FCYY.-6 :HZ#X;E]Y=%4'Z@L
M>RW.D*,!UJ1FJ-X(C'/'TK9(/:=<YY?A95L(K!T^%]X69"3 NP$\\:M15U9D
M6UNPC1)*V[$/V<DG$AQ_N/7I'J4 !<XH!1%.Q-O&B+S<>/D%'P=M]4Q>V]VD
M_T9"OWFMGJ[W- 9K>TI;_.1.K/9_[O@E_3/%V<,NR>T]J\_'*T+_HC21!4='
M%XW?G(7+<\=*LV&&+O_$2G_GK#M&JZ*YXT"Z_\*!L]>T1_9T_Y86N9>);@#/
MWMZ)]6]&L^CBJ/O-:+A[)N#2=)P/TFJUX'3,";*E+-7<^MCJ&#)'U]%)'J]*
M7TT4\Z3A^WA,8)>#Q;C8R$"O/UZS"TQJ'\<AH[/3T^AF_<6-KG&[-;,; #CT
M!M#727LTW+.M<R!VI/+OSL#J\HF-O^KO9[L!3 =J\Z%->+D(!?8Y5Y,>TE_)
MEXC4-5YD+6"GO;@U";4.S6OD0I[= )Y*S$A=^ILF:%Z:*6N8/\NI_IGM6KEF
MM4W,#.^'*G;+$DS-OXLD+.$L4_/"QZL:R>[J47TO0!UWVO,<WP%\#1]AM@Y0
MZJ.@)TQ3S(*#]=^7U^'G!2N*F@>(QO]R*99SV7X@'ELS^#)OM=>O!=YGYD6/
M&R9NA14]8%I$$.;!D+%";:[:!?LD]\/\ 9EF#_5VTP92Y109Y>3DEL/%/"8%
MDALQ.)S 2XG:TC*LWO%T_X:]$^O#9S=/AM7O.8A9N8%1AKPB.K<P4KY^M269
M=Z3SJRREWN_':&3Z5?OZYG&BSD8.L71ZLU@=0S;!8?+A:^/A4<3UF]#S^Q=V
M SJA!_&T6PM7*_;**9<SV!,ZWO/J@EX/=$W)3W)O %1&IFC+\U=YPEEG"^M1
M1,;O BLOV*31?)CE)1Y90J(WQQKPQUA-1$:GDXI=P:470JN@(?PN?^4K5'<T
M@[KLVE_NEX2YXF&-6B3VW>Q[X&XT\[SV67BY+J^--O29N>I0?,CIA R2O1O%
MQVAC;!R 2/RLNYX4%EOZB;A8S01<5UPX^*XQ0B\/3>UMHH5@V<E!D@7K"T7^
M5OU5@_P$>3X<>'W[>8VG>@#JB5(ZR4K\\<KQN_#XY_<0N4'^KW=,1HHK\[\9
M:F^.6,> )MXOA<&5NKD-2 -<&[J^60XH&>MSYG@Y3I=Q_VR 1.]Y]T[?-]X(
M20-2[6CJQ*H>@LDPM=^U)\RL:#@8/5.V<TR-+5<+QS7GFES)CK(T'8OHG]\^
MK6Y\RY!O 'IYL3S#E#/RLH6NF[=9L&@/B9C<UF_"HR[V;Y."SEYR#OIU ?@O
M[M^+J-7FV]A[!+!?4T&*#]I'^0 9#<)F5N2&!%M? H;.^5K8*F$/"TG[9*,
MWC-K@;W]8].NY,"R'?*!Q:LI5LH,W>;,Z_:9F?X-]QN  ?_J!V5YM:'C*^U-
M=_S6?P' O7%.K.X_5N18XGC**?O=AG9F%9<50\S(NSB/T:P[)_0UWU*PB<$)
MJ[N(5?9^LNNCI?N4!5P!"O\F<@2;@<S<TC!-$,.F[Z0 !^O>K5$&\W7D^D*>
M63@KFCA\\=9]U=9-'=AR"RS\:[N1\/K4TZMVR<<W %_*'6HWL5J8<R42KY=Y
M^V6SW[PT<VG,4)#EA+F.ETD/F49IOO5*-<<(6 QO@ YBC+ZAY^R4Q+#5)Z7:
M O9Y(;2)[F\W&T!*:O$BX]@,W1S!E1..;V?RJN#TJPRTB%YKD-[8.ML@#RTR
M<NT*S[D<WPM[$=T8RSCC)T/WX&"IRF1Q?C73 P/29U&VM8C:R !0ME2#Z=SV
M<=9D5924DL:T;!:,U2X.)]LK;,S.==>B'^1XBZQ=&<HF$B)?H9>;OIMC$9I%
MDR]U,B?)CPA-WO-MU%+5GX*TQ<"TZYM'U\$;1<A3,V:Y<S&[2"(J5XP8]Q!$
M?8>2^QN0K7S:Y:KDA6.]4WS86CV/Y[%BA1KVR[? R?:KC1M YXL7C6?J[L;.
MJ:M.&3;?="?$ AM[IB@-6.&524]8$:9-OYYV,(^^[)[.XEXB>O@9!KT>6FRZ
M,(0Y@$2>_# :$>CIV3*IM8B] ;QU;QQ+#4JQ^$((0:UKV>@19V(124TL63C:
M,8^.7O1>IQP5'&@,1@+D[*=\U'W82%#R(*H'0SY;M%6ZU5&&7/F!V9F>EX[4
M3>Y0EB.K# _M@164'F($WNHF^;6LJ-#,.+(CQJGM3&7,?NZ<SZ&9#>;_I.R7
MGX4[?[DD*0)U?BRA9%4_"^4& &01>K?8Q\ =3ON]WMYV000MM/7K"&?U.$%?
M2;DQMXQYC%#-0.5JY.2J SN90S-,E=HDXMP*R-"(;X$Z SGE@N\5R;%^\9NF
M^IQESF:S(&=Y [CFN <O>]D<+M!5S2J^^ T[M::&B.?T]%-ENW,@W=2L8I61
MS\6B]<CU*D]I'E^ AU#<J36<7VI$V>@2G_5;J7N0]Z=.U>5B:H:E[1 1%8LO
M3HW5*#IZ1Y6!R7TL&&N%M.]W"KT&VH\+Y+?TRG[D$TB!E@*&Q(E9>%[#!8=B
M8<51&L'>_7T>CO0,^Y73-<(!V?GHHNY!WUX$36HX,@,JJ3 CB1IA<<01M1_)
M&P 3+?S?C0II%DS+@-Z[!7S?=YGJ61]$7DJ9"G/6! Q); 20E!I0$4<M$>VJ
MBXQ)^*-;SL(:A -)K3ZFN5L\+&;.U)PU:[R_Y/^R:]&&Q.?4$[SIL<)MNF.U
M-1+-N9"SKA9GPT(6P".T'1C ?7%*<[&Q;LI1*O):Z*VX\07>$U3K.B)NW+-<
MEI+W]RKI'EU9/M0([#[EZ*H[6#MSSPCM/'2<']O,%=#OD8N\5=5*;P#+*,4)
M@QO9[^0@%7N":E9/ZKUUT<0AW@CM#7=\L?^!2(1R;@U58/J4]*ZD&Z7L"4/U
M)+<%AS>\_;\N9?5:6)\<]-CJOJ*X%[5YTF(-V/(-?#N1@_4Z?_ M \&FN.!:
M3LI4<D4K4:,:37/\,QNE:,%:,_U*WPL5&HI=\'OGSM?W,V.8-3I_I2ID+,!J
M^'H>G:1KVO"5-BD6:*6;H,0UT<4P&_40+YVFDH:4Y;HP/Z$4BI)WT74@D7+E
MJX\%F<[;.'KMV4*BHC7G75B6C[E# AJ64IE;7R[X2)_5ABZ4<1H*OFYAW\/W
M;4]^\^[U&(L:*KO.IE?KM  ON1,8B_7Q ,@.ZB.8P6JK3/4,#_!2Z'4D>9\,
MVS>2 [&=&95E52YU*".1VH3)EP?^N$DRUJV9$=$,$-3F/NZYDJ+-<O 8J($\
M(S .89S=%Q-1=FKILK^>G"C,XE\L?"2I.B%/"IC%PAE[)^(UH=9@X8.&3$YL
MVLQFU$63:!S&W)V[LN4X!86!&;_6D9#82VGX7)?KT]CMR3K?_B?/]W9_4I1W
M>T7Y^RJD%,6%5P2$<5YVC2Q*@SH.C<Y9^#SZG5_N1YYFSZ/^OGE[%5G!JYEJ
MC[\5*?GA[V6$GPP-WVOA?6.XFIP(1!.;B*<9T.A7WY]?F18H$S*^AZHT7,E_
M>*P7R4Z3P3[$M'*BIY.;C['? ;!?;LZOICQD],K/G,2\ 93=:D_S.Q9[3""+
M7&K=-:2PLUHUHZ;VNK'('JKK$JRCK'*6<)E+M\NVI[58[EQN/,_J^K<2I133
M[!"106"EJI]Y_X<.,T2?C.='"ZBYL\')R<E2*9K:94I5-FM+*RMF=,XQ)^MT
M1YXW?<7NY\BWM!ZS,)D]+?SARU"]#RD9FY>:8*XTV6=Y20SZ;-#7(8-[(!U5
MWV"&UM)TT&?;+O/ 3CDK\0>,'_*F$8PM?:0OJ=\(UL..U+04G[$,]Y*8;$-E
MJ]X[60Q:N_!IQ"Z]0DJWQ GR7U2&_(B4^%FW%=?J<>AA46/WR*O,VT%;P+I;
MP"UW\KFKS^0/_\NAM-HP/5O+X\DZG[4-/.2TZHRSV6M]]I%CX.<J6V$/:/&:
MABQTE)C:F&57-%+ 7/7CHR^R7_,$XNOXUQ*EY2+3F[:K9(SSAM3C=N?L@<G&
MAR!B5?F'! D=R="_C96ZX'>0KP($6C40QK%L^0A[NYK[T2.LWBU)3=@+E%R-
M&T"TPXK#@DJOA& 8A4K*6T87T$LG(>&774IA-JE^8UDJ5O2A56&2!#/Z)T%\
M# BI)Q(4Q0QGV\6;?9^/ZF+3U\_=H)Z$TH/"QS0IV95Y.;VG*GP[$S> >>K#
M],V^+T<Z;9L)DZY:64?"/JEKSEA!#Y]OSZT-2O)7<:9O39AJ;;P[B]$IK=A8
M;(DVT#PZWVM>A*'MORNX ;S38<06*$M GHV[LM/= /:PF!;W[&KN';P2[,$9
M'UT@O]4BI8Z/&Z?H+X,W1?K'+NMQW06P,X#N1H4BIY\-\JLEAGT/.*U))J<D
MV. Z5%WM09<6$XN(_,1.K.8K3/<NW=7/A_#KO4\! L4[HX?0\KHTB>CTAO$%
MTCS)"$NS/MJ SQ/9MSFS]N_> #I$XH.&&.M+U&\ S<1OG'Z1&02[UYJC(%K\
M=/N(>4UN:R* S9+MQ56,79E\N>D6[3[#I'*EXS0A*IPF$IV.U JZ6H(+.V;^
M:9;N_J7$0<'YEQN H]4-X'MB]K,58Y,+@OE<?UQJO5;8V6?S?(SL/VW"(#DH
M<!<@S] ]\2<__7!^5R[6Q]'%&X 3;N]Q>6"/_)*/WK5WR77OE07*73?)W #H
MK'IK!]]UWS;]#2H/??/UOGX\3(>WS-)^H_Z+ .9L#N-U3GT 8H%\M_!<OWS?
M'\_PU$^6DN[DU]%MMPHV.#"W6)-<L:?'.1^95WB)A)#ZZ!X("C.BK#:A'=PF
M4#OV)PPD.D)9>7\6H_$%4^Y%A01N>G20!:T%<^GMR][(ZP\IA]OIBYKMF-[
M7=CYEXC9$O62P$T67 ,PV>']?BUQ&1D)?W55/:B-^"$69B<!:_P'LF>XX?W^
M'S2,7EI;*02;LU6_X2NDC"VQ\YI8UJW.LD<SL+>0OU8<J2)OM/5_TARBFC[H
M([[.M^FU-X.XXG=]Z4IQ++_'4Q*?ZY]O1]ZDMTXN\>-SK0^A$V=>7/J^ #:&
MZ/<O1%U$IQQ78Q^]70M/D#-2H\>3E@M%\0]/+=VJB"Y9NB3%[ZXT:EBZ0LHM
M,K.(YQN;S9+C1)#V2@K$\TW\:X:[U0Q=?V?4<&H96=L_='E-J$_-]C=Z5%++
M;:KS^!L-YTS=^XMFB^'?&:1L3X2JN84!_WBJ\H_LA%U.P 6WA9[?%40W*<<Q
M-9O$HG9"A=5IICF9%YZ-2>Q1^GCG25>-606X.KJ""PL(\#@6A39"DY@P[D*N
MK]%9S6<791%_MF,"L6HQ$[>*W,_.J+)CI\H-X;N<)K-SFTI (R0BJ?K;6A4<
M6.)I^W4OG?S]I!6M)@MF3^!C!8$0PF =XWCE/#GN [7'[\ G@$%^6MRSC*D:
MFU"4W(&*=M2*:),)24*6J,_OE8D7X(\,V0I_=.J9+&(Q&:MJ0,+G=H/5Q!\]
M&(NL'*,3K_STD:5[BTU[;.<TY$3-Q6@,?58(IZ[H(RY!VV-K+JS'(_4+9*^$
MY)=AD3SJ-/@NP<./XU]0'L<8>_/@JM@55@F&@]J>ZWVG+-5,D>7?*WB@81RF
M%<_N,%T]E_$XO7%4-!H.(;P8]"R4G/II3G"TD0=Q5;E>*ESJURG1GA[-$_3@
M4[=E5T(75_SPE))IA#O1:;7UJHFU?-JP+I&((^!87;]<PS5"5[\Q?'36" 1N
M$!!%2BAX')L\@L=,#6[;N"ND[BJY/4#GX:O/4CQ]37[?P_SWO4_"#P!3*]?)
M$G,M+NCW*GNN1(,:?4_Q4&QBS[W(/7%VZ1ZN\ARABSRDG%/ [+78P'/#D&A(
M(HZ;'::[?![T]<U_F!U:>! /5<B'08(GQM0$LJG>E$=ID>"(&P 3 \9W9D!Y
M=3#VT[$OPEY:KM(EA-=NZ*MGC-$'>20BAU^]6$I')G\<RNF9N6.4&02&*B_W
M/IZ[2LNKUFZMJO$Y'!-82#A<BJV2-U#-'6JE@Y$SWDZ;N<J-53J!^>'F8(T:
MHRYZ3<A@K5X%8BY=(..!%)UM;JXOG#ZV/1 8S)!IPN=?4N3,J!.CC4UQLI9B
MF\9Y +=;YXID?$/_1/*T21+(6_)5S=K+5 K!V"S\A8'+?H%$#=RF!J$IL;^?
MOK#%I^J7C]08O<9'Q8[(N[A^JTH=?C&2;\PWU(8?F_%K<F]>T$'7Q9QGC<UC
MP8#$^ZU#XO/MCWR/'J%,8AQ@%'?83?(WH*+:W,/(';H0S2RXD.V[)DR+)YG?
M#9=GEA\8IKRLSJ%^=FK&IT3 %&Z3>I J[(4IN_:@L)Q3$M7Y'DVAS(? DN6@
MK/P?MO5QZR(6Y#L<1;78*U4B$^+U?QL[1K3@_VU4\!ESYJXI_O[&_Y_^*?Q_
M(Z;_R Y34I] -EE/31WT-4&-4+],DPA) BT!H.A^\KCJ?WX#0+]B?>5\<(&G
M4W"Q7D)#; R49?B;ORWJZQ^&JK7"NSM-'U4@?ONX@/1=\[]QNP7=N=UV97PN
MGP>Z0L?54-K_6Q3& ^<QM6OD@FU@XNDWX7W@DI;V@5\;K0-PZ=!++3&DS@7B
M#;<^9%3ID49\4&8+.QOB(M3'MRO.B4L9<-"&;CR07F6D1D\HCX:"2] #^!2E
MRP;[Z"^FUC\RY$Q4]^P\S14_#+ML2!G%:^LTL6!D!3"HPC!?^#@WQVQJ\@XS
M#/%"68F8XL27+0@>J(6,PQ)ZF.?+?F*SLK+T/9!T,4DI@0[MEO"GY4G@Q1O'
MFQ[PK+%FF), 3 [F2>&LS1]L)B():FOS]F'R6Q@W !S[5*LK8)IM,6@,UJK,
M<7B$6@\_STCT:C81,XF0&IE9I3LG*G6G+EL>?BPR N]K!^&MB_ -NLVPSACJ
M\[/VS%V%F2+1@O_#W3M_G3P<45\HMF?YPH(PDI2\><B"7Z&7V+'^;V<3MF#W
M=5++_+5GY]]EMY^\LHIVW/QF__@UW*#P@BV7!5.'HD]M6G5\)UE^PS7YZD3B
MMV,4&PG2NLA<ZPUY=I7_EUM4^R0&7ON#1 /NO&4\6<+[)U(FLZU2RV 2[%V&
MI]REXU16?D8#36_**"H7'R.?3)V0?_)!F8=;<JR+I)P];K(D'I"5SL5@:RRM
MVJM:+NIOAI[KF0&,MDO)R]@_>N/DY&",%<2)A.Y;, XR9)7J+>PCI$; $_3O
MF\.&.D'=4^A<C]7\#&*+()\&XX4:L#3LCTSGA_GV3/L,/PM/LV(S3KYB=BF#
M27+\0*P350Z9NSV\ : "2&2;@\?6FOC)SP8QHW>/'8_OHNGNWP#>VJ>E,^8<
MQHH4#4]8]L9BC]QJP6/G>:KYD:@\&I?ZY ^'#?J20]4RRF;W41,XEP-LY=,O
M=R0O''?<NQP$Z ?<+- V4W75!;_]AWNN,-R]W")_"3-WLK*,"7%_;S:9T=[[
MY^/20F?O *8AJ_T-\M1?4$*="GM-,X':E,DBL#SGF=-%53,6M9!?R#W]6:-8
MJXW'3/<O\C!V^H2_L#Q-J:GCLRE8-%4I)THW>Z'(^4Y[<CH31U#2\H=>@Q#)
M>Z?*0OR!\:[]T(1: >EZ]D^*5CI)X5*QA ?-+;%X&KW?]@K$1UP1VOHZQLKD
M[5:,!'%S;(9N$&ZPQ2<1HA=[?B-SXY"T7YE/YUBAA66.\?[!! '19OKOH(/+
M:2*E91[\U &<I4&B3,&T5&VQ+N6A*MGH_O;6<<T9:P;V [-XLBU&/_3]XZ9F
M28#9P7P$EQ I^S+5SO[ZA,%"5,>B;68-Z*_EB/$.Y9#C)=0.3)GTB;!5[N:W
MZBR:Y\JC0C:][12$).G\[WK% U<?B!'PX/X8ZI1UCFW6LT]( E,D5X\0V94]
MU&RA$SRQ6:>.':(:8I4.C\^/7JRGAT]G@P2M=_LZ\0*C:1+:G_#)D_25'_?J
M\">AAAB)S"U;&/().K1>9*I;G1;?OGFV>V 46N])RB[K&DA@G<"W'Y,>=1%[
M>/M?*)  #!\0=*@_;NO"-=3%&\L6NKNI9IT@D'M%"Y]Z'.#(L^;1>5L&(]I9
M'\F9? T>C'5)B5\_!D+"O"SHL$SD>*E"M3-W37*:/$0U-CYO2'];O2M;NO40
MXTW+<F&6Z-2ZG?=G9GU"*C#O&X MI%/@5,3C]N&MI=A+7N6XVN7HNKW,"#_#
M2XBFB:F'A,=/"#H S]^<.63WP>!^OWT$OVY;;G#"B*+FYI?:1"(HQ3XWD6"+
M.1/H#]9)%/FZ/-M3JKE43C[7QL\1U>&H%Z5E\AE(J4/Y42 'IS[A5=W^YCV2
M4IV7"4Y8&L O;EYZ=EC]/B)#<Y$X(?XCESNXEC> \JVZRI%0Q2M27'!W)E E
M)<)J;]TC:.'QQ8#[+[!-[F5&''<\)7?&#FWA*BWY?-%4+7J)D]5>"M"83W;+
M'T\QAW]$3?7Z7'0RXQ@]^$BN7M]1/ERI%ZS 4)%GZ,RP-&@+M7%N-;B?CZ"=
M0\;:S$O:9Y%6Q3X;830N'-)25,('G-14NYZ[%8<M>I$.(SY)]@4KZ577!N=R
MX#Q=U]J:00L>/.#T"56U5U5SXL\K^NCD9+)U$5_)4%&DF./GG\Z1.MW$:T)F
MA>R;L0C^6C7UH1FQR9J@C;MV-!I&.*'?IHW]X3W3$UA5?X$YB6<,S@J8M*K4
M)V=KV>N8U=@A]CIW<&+@FC'6:)$^-?E<0.1*;X0T,Z.1P636":3%N:#55(/M
M#AXD\@/WC(;[=/46/$WK: @IT(BRB06@@E^_T;E/<<]RA7Q6OP25,<6573IC
M7:_KDH;7/GS&7H.R*![%(GEMF?,BRFBJVJ#'4"94_G-X7&;@22G=B[T$)?XO
M?TE0^0CE-%QXV_96K"1G&R\?WPF.=7'87E]8?YIM)^<QKT:7XTZ78 4WYN-;
MT?GZ=_'<#W)@('#RO@)(W@DGMUT?Z8YKH:@,<B'FB#)#$E;8U*O<[J:\;?CV
M->SA%8[0ZY[;9 Y?]OIWKM=&EA-4?DOQEY@+$J9E09MESCL11CV\+8[OKCC#
M:P6R=\K-0SH:'W[+\>_JG#GLIT6/>>IDV79RW=7*=[7+N$_P,J]]:C;Y3ZTL
MKX;:!1*W$\BV^$YWIVC<5FK_2LXB'+U8M_I^553&M+'^O?SOKH@/$MSK;K^B
M!3Z0&HQ%?KH3\M_HB74LI2>[ ;@SI,5?DC?<HB+:L+:K=TQF;^KX!A"V9SJ_
M< OH8Q?CE;]7WV%9)#^;UOWA[R[]W9R7._W%Y#9NGAF2&6Z13P1<.6Y[8A;.
M_SBQ$J9X5\ZR >RLCY3D0K?*7>SQG_[YW0#]-G;'G<H!(B_.@_&[[-%.>;6F
M0MLE;@"5R;3N:+M_(Q!^X85?+_!L?W=7>;[C-JB0S'?'+;@KW5I;VUGR-VA#
M?Y=CB#TMZ,"LL7LHCY5_ _@4/M&^7!\I)2$3*E,\LVQHFN&X[<;U<GODF8B-
M3NKO0:NI+9%P4WP#ZC&)9'JON(U97I);8['JBZ$2K]]RP/-(*^9[I([8Y70E
MZ"@22V.)O\$(L^FO0,*^T93CJ\-9%I:7I*6Z38CR.O._+0-5_%X&HE\*9N2K
MA8_A* 4R[V6[^!J0SF][K)!H%D\2(7.4"8@]%:2'I)5"OC8^DJ/J,&#GPH1A
M@9$$G<2P=\Z&;&KABA+!YK)94IPI%H7LW]>A<D[ 4+MC'2I(Y.->^YF#;!O$
MHY]XW>$>92%,1A^6I#M>E; 0X_&%E6CGJY>(SU<:;Q#ZYFE8?V53HZLZP'M<
MKD/Y]H7R8MDK^1;1QWC?4EZC*H93LG.8X^!UOFF@2FDY8C"32VAFJ7F60;7\
M0X::_HT&]8Q3*C@BX.31=]!J:<5J0PW=OXDG?,_I_0V-[/ERXMF\+M8 6:^&
M_E_*Z8MKXM2K$>%%7^%@W;,Q-?<S<X0^*17MA7903?@9P9@0GWJA)O50( 2D
MG:-V\I?JDS= )SNCW_.YV7J@A[H_)8"_LBJ<RQOZ(0-1V_] :U8*&L3L@"3N
MQR>NX6&;G,X)9'0]1 \.NU6'OJR\^D&_L-:0^C-_N=L<0JNO+SCZ5G44VD-"
M_S-Y'72<A4]<I^+%X52K5,*P7()>;B/IJQK+(ZS1DFV3A!_5DP.O:9UFV,WZ
ML1>;)A%Q[7+FQ[-&4R/;'-=@)[V(<,=(QL(4Y;^X!_N)QJJ\]4#@2<E\]Y'Y
MKTT;GV>(1U="\3KU(]RV%2K\JKS&$N15A/T]63:FX*<;J.X;RV/_'$#H?^ H
MHO_BO''I/]U8KO[\=\@JGNYAQIG),,F+G.J#OA<U&X9H2S!R-=7FQ'<F KB_
ME9U@U_/>__%TV/\R6((HQ^_>'+E[DG@6'NL!#0LG3I!_5AG?76R25P52G+^]
M+AW)O I=U'7ZI\#/45IM3>D\6?TLKR;*EL4I;JW(9,V"9-D;  -/69F,SCHS
MNSX^].!U.*>%T$A4UYN\;M?,0K571S'=!P W&*O-T2ZG=_F -%1P6;$77I"V
MK1A;I89@"1"MC95!+RKQGS79$=9F3E)10#J\X-<YJ=F*ST//L?6+*OZ.#%-*
M\+=4QD#&[DF+X1"H^(XFJ<16>$^)Y]/%T\2^TH%+[*P&U,B>/XE:,">%6 8N
MGZZCN0./ %[.B4;NPZZ9Y*FVH=<$-4('W*&'QRXW@,@CH-@5-T%XXK*:"_$H
MX_N!0PZ3:VGP#8!"\CH?=*>-WJTLW@#^OK0(RR-[^Q^> _!0I*E>^B[N_M1F
MK$^V#]Z"YXXMY_"O,19WQL1&#^&( IA:N"A!<S&TFCN+/F_Q6664Z%+&^*03
M][V,D#HD9M6P=P1H-$K/!+5ZLVBN"OD&]6$":CB,@ZR$47,38<U.PJSS4X$>
M]RU_OTJ<$AD#RY-'JPQO&JEF()9>Z0>$TSU3% 0&E.$$:TQ0)^"<"5S0\SM"
MDC?5G**1"BG%#F\)A98AMNGZR^97#1Z43UA.N $?E$^^ A ^_*B*6$2,D]3G
M%OX;.T?_XN7'./+:P/R.)TU0C8N)U2C#HNJ7AW2Q&Z"4?1"/Q.)I;@^D]^7Y
M6YC6QJU@%EL?CS&7SJ-)/CYZ*NY^CEO_:G+5\'FLBKF6<EFVB(MLCM4*>6=S
MI3-^=M-AJ<$NPBYO^75J.C[HI5H-'K_,_GX6/@V)83@Q!+0ED#?X1IDJ)!P<
M2V:[<-"!KK^*3@*7L]58.8I^HY)NS[2V2JMI&%-!C%:$ES:S)R95Q>??,VU,
MU($/8D#6._LK!;+'EWC0,V0;IBN'SX-"XS;0"",!6_N(<%+;L.%R_3AHSMZ7
M.)4@QEEJ_AF^*)Y3VELKU5OOULIYT6XQ44*TZ[$Q#S<D?. <9,0X[IH5X0I,
M@]P "*Q[2\+Y-]SR>S-U-T)V!N>4EML7&0>$''APT.O?$?SJ@59?>E&XSQ$N
M+\?_MG:D2M9?P\X21D_/XD-_RQ@PN4(-F^(_/&@"S3"A1^:WU2.4?$Q7^Z[\
M= ABIUOI;'/PURZX-9>M+#)Z XI;';.ODF)K2W\R;^6$U;UAX#RLID.1R? -
M J?RS*_WX%EG M1-=!BG[>+,'UN=KH\8R/? ;UMPGKX.*8]EUZUA2617*E,U
M&".SVU6:JFUN%W$^XM,7I*QA_B0L_9E2MEQ -Z_/TX^!'<22ELV"?&V66IQ1
M(E/)E7QR%O+@?;&.B&R4\ H6+PE9?)I$O1S1,<YRC&,@Z)T<2SBQTZ1@J=>\
MTM['YFA(1>^J"3:?C&PL<>$T-WXSZ"F=YO"I#V[?]S).R6C%C5<7.'7<<LH2
M<H+WBBT-L7J- IBD+8B]4@.&'/VZ@O3+@)3!DS2\G3^_IEK8_<0A$E<,@F.;
M5]8ZTX:Q_/C2^])NGW'XZV-Y]^!Q="HYZ%;6T_3 *"B''D4ZW_<8')HLA+F!
MCN12.5]964]9E9E5!'CWQW)SN'2'4OJ+;SC0VDK%]( T*%.(RDS,WM.G[(-X
M"*>'OH!'-C0(NZHC+Z5V]I.#IM;(P>Z^"?J^4$6+V!R@:O.*Q[J!\6;$:F=4
M><_P[X,;-*(OJ/FL#9@7+\C(CO-/[S9'#BT6 'YVGUK1=[R;[-9J/Q8X5*H:
M<^A^=I<5-3Q4T3WVV,GP;N_F3O=]?HT8R._T!PZDC,4^W5@1!M'.^GSV;1P$
M$Z<U M<,0$/L*%*F[JN0N&IA^T^S/&"R-7MZ$! [ZAY1].Z"<O -@/OV[MY@
MU1EX-IV\XC:]T_EM^BH-?WOWU@9!E?Q<GSYWGMO;;IUR[RXG_!U$9K9O +5-
M^;TD-A=E'J^C,YP+Z3L$2)E:?6X [:MJE><2M5\'N[MM^G"U2[UUO%.NXMT[
MKQ+Q'PWWCI!E1EIPCZ"$NHF\?6SC(G0XWRQG,H*6+/IMKMANQ$=@5;8E1'9.
MP"F5J6H;4(&B8"^]IH7K*@U+]ZF^$GYL/=45+@&FS\B;OP%8[):.5I74G1Q:
MT-6IY);PI*=@12G?19*A;5&[B=78]5;$[G"A4V<:1$!>A>6W%^[]60?5L$&?
M*!?/CLL16'ZZ-J6>DA.QD7=D.2R80?I9:^3>A_!GLJJ3SM6"JYIL#/0_'!GH
MQS,^,3*P2EHBT'.V>#MW$,^J!#E4T 4DO%5WP;VEBY9T(;Z+)DJFX=G\7S],
MQH-L5+Z7F@^I''^5[E&[#%_.K :3C"FB;)OMCWQ( 2IZAX^6:CLP/QIN_402
MN_0*L=WR4["@V)P!F5YX_1$.+GE?7:[W2,M1RQ*DOV@4Z-+3V.UK\A3]B+1N
ML1 BC<=OIQ-.=1#' O.*&Z'O(4\MCCR[ :A$W@!</=7]9+G"->'?<H2N>,17
M"'EXIG1>589^3);\I4?J'T5P/6"05'<\7_..J=Z;!W2K^.&,#,A%]TD/"M+K
MR:>U+4!9VVQ58\ "C/U#*6M#UJ,8##J6 1_%#5QXPY9$>J(JW$_/]]1*]\L3
M6?6Q*>ZD-VSY5GK]-QVJ$^NE-N</4-*C,V"S]/#B50-FV V 97]A4:UT6MIF
M;_>/T+B.#VO-F&.S, !5&R_?/.\>FJ#O$(E]#=8]<X_\E$7*U",4,G7&07!6
ME6YO>78K.4.L,IE,!XC!;BU#PGU7A8<<''U#]!TH_NFWD)G18;C;=?SU-ZC@
MH:_-;P#[#N;A8W"WZ2GNN[2_[YI=U'^N;4"_DWP4HCMXH1G>)B:<VQ9R(;F3
MYSN0)/R19DC/?//V\D2N#K!//K#A/@?'?$OFR\W#8H*S^DJEJC/7!MMBSF,I
MZ\VS"7_'NG:3[54I9%5"*2SX=[7CRNR*"1!MY)\]V^,9<R;D-<<Z;G%[BS2?
MLV*"D]B*]3N8_<%>)1?!6?7TO:W!JOR_87[?Y!:S-9SYN9ZG?]K3 ;&**J^9
M(L&[XX6'')QS+9D4UV:M=Y$CP_E@RR#(;4\G%BE'TJ3,B!0VPTJ#_^#X3P&>
M0;W=6BL[+I!W4AMERJN[?]Y-I+G%MM/O]Q*Q'?_JC ,3YH4+TN:)WO_2E1;D
MXSLV#$#0X>&@R]TH>>+&>=XVXZP:#C3DNAV9[>7^/UQCZ=K=6EV_XW"D5(6,
MQ+C>E9?F$":1M-X63[D!\ 0PAFK3SGQUX$K7#, QGB+I<53].$7#RL?PWB$&
MQ3(@B7X 3PK"Y_^>&>M3 W%1MYWOR&ILH--9K/?DWSZ>J@AQ.[<PR3VUZ?L5
MQ[WG!C,]@DQH_6/)[L]D-2:X[[]*09I$S#[1V#JYJ?J 0DZLIO\>-4"'2->(
MT #HON=J7@#H!J I 'SU124$#7\.7]U3>Q 10>"A8:[=4_GPS;T" /<78G8X
M4ZE9DB2C31^WQ!I3B<BW>^:%Y%  YN<2:SA3^W<()_WY_S#9.BD<V-P JL@>
MOLP]*20C*35OJJ<X8?QO6G*FYL;L]*7+H1-__#\,&L'%A&/F0'^(].<15B++
MN;\4Y:*L'"A15O3LAS'!+BXGJS-]U>ZEP9YU28> LBX/E6@[R_16H\&)\*%(
M[651#ZB0"A(?2LJM&Y6D,AMA8FMJ9FC(40?8?Z%1_RAU:CFW"F$SDI02R9Z\
M##0LE0_R;F!0L[G,Z3WGWTC6B>'NQS?<3)MW1LPR!%Z_%#^I'3 V-SHL&^^I
ML*Y<\;Y"A;ML\HV=Z)&2BKX,-N_"A-AM[H_I)$[27[_:D@6JKNNUCCD0E"%"
M XC.^7W.FW-:=><MM\=AB=]\%EPQ)NM#$.X=N'<!>,K_+0 /F/R?J\ED.AH*
M?RV,.)E>_+9JL+%)@;N(R-=+AMAW-HW:G4TC5"9_D>!.E3@V?2<13O_R4:!_
MN/"7W_7T7J\949@>%I!6VZ"%"T@8DMH+K"F?WUH KIXGBBWD'[B0("W6M?B[
M<.2_N]VMY"&X<0A5XW1^J<B03C&0G%"S_JT2FB.FK-A4$>IG>ZK[F6[BW.=0
M!5RRL?#J4TG=TO&8)5Z4E/[0D^^1D3\5-=KRL%F9-KJG>6NYM^NZCU2"16!@
MF16FD!SS(B3;[$\UE:\?BL(RCU1=A\-QN((9JJ9%P[4&M^V5+M+O?8B2+$GO
MV?]!NXP>V7-/D6J!-"_7J78D4\SU+F+'=*)9=572I"L_(JIT%C/G$?)#],75
ME.SYX_58'_XZY.)DT>A]U@^\O$=(F/P6YJTABG2##IJ:;S--@S)TO2BNA!*?
MP(YX,J6]550MI#7*5(6]P;J=X/JE1S> $7C^#]O$NW5 PAV.HGC"E0*W+JXC
MSX[_S,!! :,4GR!:[EP?#KB7N+J&5R4S(A2IJPD&2\T6A'=&3J*TSPJ1T^;=
M3LIMR?P,"^N3L%IY_I:E&"?/7U\BG3) P;Z3&O8!)U, P"M*<-*KVQ^^+R_:
M<F$=)(ZRZ5C/=>Q?!J^Q1W7%<09Q=)/C2B[ 9'PJFI>DXA"+@[[3/T(\1+B$
M^=FK2RE*29LJ2!2TXY6HFM))NTC:7%+D876,LL4[/V*GHVZEJS2#8JFRZLMP
MF35V%^6O2+I4/Z7T ,58*;ZSPQ51CZ-'T;&XV>_36G]LTR:J+XS'OY0BK$SZ
MD$1SP7T)*[I4_*47RJVQ*-2W=QWT.DU;6TLI5V>R, TX,YISR(A/);Z@:7=U
M_XFO4C1_.+WRMU[O6DUI>0N^5Z44<1?PG(M-%OA/]@OIHOY>Y$X%4U'_8A7R
M.P"EZ-4]T1BA(?!1*[97YFG7O2IP747R;LD-@.@-CVSY&)XP0>(BW</ULO,%
MGZ:A2WW -/>LML*IIOO/).(,!/('^1/YO3 46X2KU;MYXVMV#_-8BWPZ%V:1
M-@7,_PMYBO?]E6=X_BRF/*.P^=LE\C02@@4LN@OF9A+O?9D"N.B<HVJ6.#P?
M0,;6)UB<W^&*3K<!2F40R5A;4&NU^-4\^T'^<B=G](J,7KGP0'OT(&WX!M""
M<Q)R9]6YR#I,4=O' J.'OJBYR0?M7LN1W@6GD5 E*['L]]">3XRTVJ03[5Y4
MK8?IJH2]+\<TM\*&Y+^5;HZ(RZQ55**)+A78CJ(2T.;;7#@I16XK;37[Z+ &
MQ@Z&XRN\"N!O,ZDV2[&>J"V@"_W!4\A9!&<\!6?ABY0"3=)#8BP@6S[<!]BL
MK!0Y"%_;<+5Y"]@/Y>DC&71=$$V 5(Z;" /@91LQ[^G#5*>F6K7Z'^OX<L;X
M4 +1Z%,+GG&N1G,:O9%)#WZ+H$=3E,$ E"Z,%IN)"-V1\%M3#WB.73($SSD,
MZQ* ,1,@-#]>D2:LPHXTW6?UPHY2 C@SE)779(:7)C'!#2R/WIW<?SN:YS'Y
MUOU":BU3\JPW]'C/[4" ?@"8LG8#T'=^<?7WT6I<^K]Q8/^?$);_]_-\DOH1
M;/6&M/3N>@3/6$+](:Z>003?LA-P4M\S(KD+B0HF\5%8XL]"3^#_NSKA0N1>
M%AN1WXKQ^T/LV@+=GTVX5]AKWDR4#TP%HS!'FRUBNG!Q0"+K$RL&--^W4UG9
MZ5D91M<6)!LI,( HH5N_5(WTO;3LO%%L0E;;>'BX%S#+X$-3$$9/)7\FX0-F
M7MF2W$W.>")&LB? >BT$;ZT<U\N A2]?S5_6+)@'*OCAA*1AF#'&#B\PDOAG
M/$]]_QT9\SE;$_1I;4(I+2C)*5BRQ4?B56/OFS3E<2ASVW@E/SY=MM[.<K?
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M/E16V.7T1"HE7U 7^B'E7X_<^W\O4GE3-^P58E(^2)X,_P]02P,$%     @
MRXM[6%"E\#$1: ( ELP" !$   !G-S4Y,S<P9S P83 W+FIP9^R\!U136_,W
MG$#H1;IT X0N2*^"=)+00P=12BB!D$ (Q8)25:1(ER[2JR!=0 1%I A*+P&4
MJG0+H(+E!;QZO>WYE^?YWO6]:S'AE#VS9WZS9V;O<Q+..M_&OKT$T,%U8#H
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MOX[U%TO5F[?2SU8/6GZ=.KO>].;KIONJ9_3D-./M6YR].FI9W1)WUCTD&I<
M#XID\X+%F&6?JP$)9^LJ^CY\ \A_ Y!FWC]5&IGNU'AEAN^"'U#L>MIBI5ZJ
M[0.M77GT-P#5IT@3?OZ<JS<F%J?"A\M\<I6=J#)>]EO-#=WI3M_]!LB]7?=\
MX_+2Y<QO@!!C+N4R]D#!+0:'2G)[4$JI@\^#C!V#!T,?OB8,?7Y<$F]1PGW*
M(WF5MO(; +;^C*:NT KFP7/G"&%)=GA]XAM NR4W\!N@):LO<VBUH*!)9;K6
MK_%)L[R]CR^S^=*0]:IK_=+]W9'PNKJ"=?]  &?BD7KY#T=>YF1=])(5!B#
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M56AVVN9OU@UTBA 9.7+DXXW.*F^ER^,5\HVO;-Y;YO@?90-.Y^K=UR5\?O'
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MC=);T*"Y1D='IYY.TTT^; #&%=51XJUU%:32*%(4=U6@_(PUX+8Q$R(7I)[
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M$NWC4HU?>)J0)3[UE'#2GCY^ ^Y0<*O>%,,4JUF>5'1B_J'&EH@_N\;U6@!
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M88=;_-N4\U$[VOC7C)4B_4^MK>[?TE]C[8R7N -;M5EY>Y0AGXS-&T@)56+
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M!]:GT8,X\3D)II1A3R/?4A68]7:G>8/$;*A:A<3J+2D0@U,/8RG41809HH7
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M"N%F?HF20;0@?4XR4LYYS37NF<Y/G#$78Q*+5@74+E#%TM%Q/^\D1P(T8T"
MCM9/U#$G8Q*SZ8(4B1+)%DD QU@WC]P\YL^>JF*@11LZ9?C0526_,RCHAAM2
MS3NV[R0M,<\V6:<L9V[B4US6W9%8 7NC,Y=VL@;>OKD9!* E#J*V)YX'!CV9
M9,>V^*A.MSQ02N$Z>3]3B%]HCA_8.B\%4*#C#+HZ0<2K^#ZN+S%X\!EA) @
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M^+K!RERYNW[V223 %@!!:&"N,TXYUSN=V3RP^M2$QOMI@A^N0WNKZ[L_TX4
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MMWX B,^WN3F(WA#<)<*F6WHR\UFW#@6.%H#I)\'W&'/>SRCZ^>--^9F\)^@
M8DHP^"$;9 *$X=0(JJ:N!#7[_-+>_1A&+94TG$:0P6S!WF$]XJ5QJ*O[%YK]
MN52>\TD 5#8R217%I-@J4]C7U+!]?IX-;+LMP^1FDIAA[TD0_AFI6R=F'DHB
M9KK-G]1^<PXZXAGG.2V'Q6\!7-T8N#\*X%MJ;J&N]2"\^>.[Z]+0)Q7-9"&8
MZ@A^'YBXF%8%0N<D5F.7>QP&%A[B0S(IXR2"4*0') $(&)=7&0K >B=R-B_6
M=TV]E."5-!26_"/B1AP>9J7%I:$& #'.'C\GH>>"F9[;AWG=8RU5WY)5D?B2
M(=]TP4ZWW_(&DE@J@(BS->SA.K,F_Y;Y%20# <8IA"50:['8T0944YC.F K;
M#P@?X@7AM ":B*$L'E4K$E@F+&(K4/OQ#TRX^V[ZVDM3,=V^*RW=:6<7LNJ(
MY@:&J^?(A@3R.(1._ISC EE!UT-@V-,; AE3?B.PF*&1H0]Y[ ]<-.^9@H"N
M5&$1<&!GS)K8V^TGL_4:WZK%0,8P/75*B'E\9P'/N_7,DJ5-"Q]I7FDB+T7O
M.,YP;36E__RG,ONU!>,B<<H*81QRZ\,^OM6D=>=BX3BE1J;-6Y=VJJC'',KB
M$ G,O[B^7Q04G7G?(_4%=K/GN?CPAU_'.EZ:_-^!D--H\96;%#H=);@Q[(N%
MT"'$Z^.QMHM,AV-7 :[A5=]QM6LWE>HPGLHPRJV;NIQLIYZ,TX\3U 7MM!XR
M$KP4*@;.-T62PW,YV5%=MABMS0+W4Y9S96]]/6_<,?1)M53G\:O(C4E1:\;A
M?]FC]8A+#(HG#744O'H3^Q= -WFM3;3RSG?5SSV93*EC][SCLGIFKDW<&_)4
M?2/#@L<]JB<R\A,WH ,!$+;L_["=P2(\F]N7RR" _[5., &$\ >A$%3 -TJ>
M.06J=$F_;YJ04J9'%<7+$^4NR4HER\KH,QI \H!^MG4ZJVH(D7[X?;B;TIU
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M;,V)W[EMTQ[_I/6^S6]$?#^1*J[T<=-+-:_6)?L3Q8'#F$D%D?*8#@0A/D0
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M9Y:)GNF2W_QY/PPH;RZ@^!&!F+B@UYXS\Z>?FR@ ) XU.-Q!6YGBX-]:Y(^
M.]$Q]U;)D"PM]JV ^W7G;YW]$C0NPFY*P>J[ZT.J>=YRZ[=11_KQ(_A5.#!5
M1]CH!A,QOO",B'%M41"G)NZ?J+;;M[>+H;$-C!$J(D6HVVY5C&96!W^S8ZY_
MBYXHQIZ"@%/0,.(^.==K1RBV7IYAN,^WN9:D&*2C6O)%IVN:OAA'[\U>E>U
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M%@XXQGD1Y[D8]ULE&8\?$7E&%Q=7CIN"WF?5)]>'F1X# 3Q>./<14&RF0Z[
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MM2G_U0>F3[8I=-?&I@K.+&N'\ *FL4\JMR-S4\->M 355%ISF/;D9D47JAN
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MTM?72]!.4&).H"_<ZX]+:J7-0-EAU;;A:18RVG[2]HJLA]A]%OXQT-PL:!>
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MT-HR2S'YL:K[/O9@9Y"O;2_L-7,M\MB*O*IVI<@(OG,HLI<V&$2#4!<D5%*
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MO/KP0*81<W.4 G25G73Z7Y]6)8J(!-?\@/-_/[XW(C.W?[:!]4#])\D/EK*
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M@8#Y\7'A+%3%$N,F%&"K[[QBTFBEADJ8&'O&2Q$!QAM.HQ1 W_YDD\3D.0"
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M54<A1[GBZE\*\-NA4B=*Q<7DBA4V4OU&>Z#0'G*W[K2SG2?-+>VWVOC>W:
MQ@WN\RLDDG:8^V(8^6_E>\,U&K.*/.4>ZJ?'#__>T("/6D?6X,4"+0*.: )P
MH^3 @EW<:1^9QH9?+*S#[*:1N_^HLY-."YX C-0Y"F Q/0S42]2=@.O:5DA'
MN7C+G;[#IO/D-^,4(.(@\.3ROT=]'1T4I';K3>"MTU%)R7NFRQ=2CQO.[Y.6
MG8+5!_;\PP-+_Z58#^DE_K!5KT]PV+R[AH1_.H05GSUJRV7YBQP%&+@#V2W(
M/-!?.6TS-@,PN<C[N.E3W/[\75C6>Q+-J0?_!4/%Y%(^$#P)^69M>[@9X*:\
MC)_$-^C_:W;<.M4R26PWYF]H6 :MOX7\)N6IXV/QT?5MY(J*[<WHH%HRP72V
M:_J'U$1QR?J*#-)R\'1-W/]:4]YI_&S#>,9/^$G>1\<?@B_61:R=7S,C93V!
MN!>$X \TSC?:ORX,:Y\[SNO;V,[_9U5E#0,GF_M3>,XI<LB]^: DIG\OZ)@"
M9%2<X+<R?#<+_JUH])I,-5VF_A?0ZI7BDJ6I;)\+*= @))?@GIH3TCZK=FX8
M-OS7!@I0N'I\;/W9);A8\>S!U_V=,_NP<;;]UB?_;RA43),M*$#?XE_MXX.Z
MAB^F T.__F7#''%^_A2"?_D5LUCXDAB-*YUK*S[Z+M5J;7M:Y]\YD;S7,+D[
M,%LS_4-B(K@SR'9 %K1S_$AG8/I.8 G9 K;>>AHOWO]X-BKH_9!<GVN@3LOK
M?S(I=<\H^=01#5V;&7+'7N7NVZQ[:1C#O_ 2#^]-YV^NXRV&V!TV'Z[_.3]@
MB_NX/%:@/CM 3=U@U!+.DE;GC#-A9=W#!WMPS03W:-:SJ_!EHF9_-?.V?NE]
MA&KBJSNZ$/]MO4JZ7@?8!3SB254MCN9;OQSV^B\I6;UYKNF;O6XB%?0XDCTB
MI5$SWG521?=/)?58%:M8KQOM$GE!-!W6!6.N>[/2YW1I:C;M3,S8^"8+QX>'
M>>PCE>@.DS/Z9E=8WRN;G37SL$D*6PI ^OC8S%0$CPY)Z^K1B/,CKJ'EIWW[
M9-@?R;M4H0MRDU9#'YS=HSI;WR2HYO1TSG2%9<+$M+;E)O%Q\($'V%@,1= U
M=7GSH?AEHX(]26Y40O@ _UBQI:;6X,7$C^V0H/YP&CVG0FWPV1R4 36H4P[_
MV&7=-=W4?&^-UM@L15-?<R;N[&?@EV['4'?JUBCFTVU?-[E-.#]!;;?2GX5\
M?H"J%3-</(2/CFWO([L_5HT*U8D?5^_S\D-&KF/)]SUE6%6/B:^E%0I.HXU9
MSB8*1#R^\AD"X^<$KD!^2WV9.XWA!&4)ON]DF+.Z1/T_^9OW2TTZT*B5Y<2K
MH6_%V)WD"\OXZ[:YPWM3F.G3"-Y]A#]WCQP2/+=G-*7P!O_IMK<;QZ96*P97
M1@'06<@*HU8+.^2=.P'F-.H7ZQ:^G428G S!+$LWV5I"14)V Z>QQ+ZU^A3B
MZB!95D4(-Q]EL'JHL3;MCX\LS@KB[7N/N[<%^?0W=@H:MD,OZK2QO*4+AN>1
M<!=PK=9VM,?W1K:^-26NC?>MYA\4[=F>4C$;*2M(^X</7PJ?T]\H+CD(,/@3
M?,I-1V/3BT&)9&39YMWU/YQKR(=_<^(T'!M^%[YL(Y=L[O1Q#VPFCQQ2@)Y5
M<@H)YWKXK]C]:3%*^DNEW]LM'[@)MEHK]*H_X!MHZS-J-;(SH@#1MYV5W(SR
M"?8C$J?D[GY(0]@YVA\?AJ3=M+8<G,#XS"%M%T9@-?O6^\=_DT/==B[ ]<&F
M^A^<M-$' [- BZ"3NWU2]'V5L)(4Q*/WRWRI?<?PR-/J"N;82B6(G_2%^@<>
MS/@.!LN2^(_&QA=Q7T^3E;AUII7,&931=T^AY=2R^L3-0-SAMFL&LC-H^A%$
MJ97:.KJ^/;B\X@CSV_3O:L]W;=_L&]UO[?^;W;WJ^*A="L#L_(<;2EYL/,&7
MA,R9'G2M8)8#,'DD]Y!ETH-3INDCG(_9".[^AQ+)UE$4P-#YM!,Y7#Q5#,8D
M%Y+Q!\$=N(?_4%)=YS]:Q(-@.1RRX0Z$ DSNS"'W;4\=_Y<UQK?Q7*IYXRI!
ML^__H<\_'S\]G2?)&7WRMX=MA,KA80UW,)NJ.,7#&:W>?]/MUF;0C-<?]Y0K
MR']'5G#?E'#P%X>P:$N!P[8#QV"Y[9.!HY("&+U:'))\L54;QTH!6#;S_V&\
MQ:V;>T$!9J?DA"12WU-#8N2)8/ZY_X>0LXZ*ZNO;_AEJ!D0:I1E@B*&DNYNA
MAU!*::0[!1PZ) 88$*2[2SJE!460[@:1+@$1T??WO/?O?O]\G[7.G_N<M;_7
M]3G7=Z]]UME+]M-)N47_^/M/O'*9;M]9!9W?_*?QW%,&9US/W%OK>^2-0S[\
M^+;^^E;GX^[AOW%:\[O+^G!?_S_,/%W4^T? /R_^IT6Z3/P%JL][+\2(!+=S
M9*F#D_:&CO]D#_]Y;M9]Q?B?:>_N[DU,E/RW_0BW+LGNRO1-G[]=^ O,7?\%
MU!@_/*DKT?F_D+6_^!\<_TE'*ZJ)?PC_ Y1M)RK.\/]7D%]!]\LJ]JX&_T9Z
MX\'ZI\@51, 8+D\4>_)5T((8(_6G//O%"IU^69NY?/*A8\)ODC/A] )^APVY
MJHY);]R@N;MC.M^XWBI2TS\TTV1CL8DC:$"_/&:)[O<]+&W ";H.C?'@E<,1
M *B)/%T"-8@D^]LP@?3W-</Y%-C:K$JX-MAX6"AF5>.:IU0!A8H)%3@ZGT@;
MPL-S#N?FK2K_]P_6U99M-\7[DRC/6 JT=\&D#2H+E[_;T+1)J3\%*DLJI]CV
MC=D"*)@F^]VX*=I:?2T96=W4Q'DUP[!/8" _]LU.'@JB%F-/\_%_2F1^UR>A
M'9IBC:-S>KG4-&?EJQW0G\3*0#]5&9.-LR?:J-JVV@\IM20KUB,B,#C3W4["
M91R@\VNA<VH2?=#>T>8CO_=H7V'-YZ6:2=R/8@XT)B%004$.D NE_$'[G&&H
MB0FB@ #4GZFEP:5&L3SEV<E[Y&(N!O (8ZS%2$D!T C*QG]<:F]<\ #*DB1B
M]%Z=4T S@XT]V]XUK0>)4IM*G0;&U5;BL]4GS*PT?\LH 3B*Z&$P]8_;X)6D
M;$^IYKH]KGW&EE#\B4@Q62$&N1^7_'=PU+TNZ3 XB2EYQ ;[A.0<1;>C*.'T
M8OSIE*R+"D9GE,3^4D5D1]68[A([GY!"6H#1#T4$GOZX&D^<B..3>/>5E?U2
MCU^2W2MC#TNZV!Y']U7$A_8T81P^,7$U7<88%'8*)$,NOYPE60]*&<=LE:F-
M-4S3UH9,&>&$]GX7 6?T7D(UC]_5R$,$#.2R8ZF&!]YF _R[<6$9_6;9Y,RV
MV)#R3'TQ"&,3(->?2=9;JEBL2\Z:=@')8=4F4IC/Z+0(,2104!K-QH(,U[1D
M+J,ORQ^XJ()'Y*G%AO&9-<F@O2L&&WS,4 8<627!B;+D,W%">^JKV\/(:I0/
M%W.(WIWC*CX3#$8=YBX@.BYX=WM%1O6/ .Y2H)"O&W+2@#_H+]#A\Q_1WI$R
MPE0L4-+&XE?'B5YX^4!17@2.8B@I(8 BGLCK4IP_GC;YX]F3?.=0(,8$!T8S
MP.C#5EDF!G<;@A=4O1O@WO.\#TEMXKU[X^_F+]-^)"TC=7-^E/+74^]G_ 6P
MXT.%2 #0!C;5-B ;O4 7"-A(W?[[/">2"+F(<*GM^;&02YGW0/DQT>DD870R
MR0]"<!D6,W9>H]B_ QV]RV"LDN0T*ALY.VI4B8K^X10D5\=GV/&H@%[K).J=
M8)DQ^X%_ARJ0MV!2)_KY=^=G_+*/]5%[F\3?03LRIQDV'H?9]E2/FG_O!K-<
MSSBH,[(*DE_(+WR3/@.%C\SXHKR6J$?L0?%!MQ/W*UZ][G,?LNN*0Y8H6%C4
M2'<$/Q=(;GA)QN:CB/,#B:4 (#@?="#K*B=X\5]I2E@ND:IB:IE7]N @>^:
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M?("AD HX_UA:,=>84H(]ADL%SK@V/!,O9G< 29VC1$-;5FZ2Y;$2%7$9!#<
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M>:4[(_\N-:!ES_"EQAB?M/SGX5*+;LLWD<_:V(A\-:)+EY^6[G=KW116SFK
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MKSOUU824=0*\?9!T'CQ#+ B6ZDC1 J.NSJB'Y11G5.FB?Z "@#,)79N<[O4
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M[?T_I2?P3Z:^M_LT5UQ%5NPP/3"92I]=8V7B?#"E@-Z0D%-)P1=;6;R9$-I
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MOB]J\CI\)T=$%U8%;#?A: 9= Q0H7;(,3UTXPBP00P#0N?_,BHE_X[>S,4"
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M7LQ^L_.E-5/Z.%!H.;A?SD;./N,[$R[>I<ND.T-!&)Y.9,RG5U<V,TS%@5;
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M%TS^\09.;^(++]B/=MI<V27$Q>KY3X&$3)VF79O#_<]?'C(CV';.%^W#9O\
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M?1/ QXCSTCM9QIY&@@Q))T04P97" 63+WIL!XK*@]6>;[?BXDVBOZEF?W:N
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MH^<C2HDV.$V9/1)*S,5B!,,P.KR4TX@=Z[:\NM RC>C0)!5!D8=I*[N(R'/
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M:)EA9F!W$#F$T:&VXJ/Q,4D<ISFV.B*H6&+1@G$V(&R:":+]+J(QW(&X<D_
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M4_A.Z1[0_?ZF[\5UP1E57&U&=J6%R\/GGB7?'J$82>_&*^$R,?XR+^WL C8
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M/];2CAJ4VVN?>:<OI1DO/'UAGZ0O:9<$!!4E\CUW2?3*=6TZ4%GED#SF*7V
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M^@_:U$KQ2VLZ7*:O)Z9XV$M7+"\?EZZ5EZ*/4W*-Y!0FY2:AQ6(3HN4KT<
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MN1@MKM96H9)^Y(OILD0UA:%5QJP^HA#*]@JDWT0P(O"'$Z]A.#,K".# D4:
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MTW/U&0)5?<W1-,DD#HL/8!?\8'GZ$"7H,FG1+5W]V*9C_<58>DDP2[- )@E
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MF<?">H;,'X[Y$WNV F+8G]LYZ I3Q5_6UXFZ#MT&W4#V*N3M#Z'@?F%Z$9F
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MO[KI%>7&V%7[:4B<Z,"D2+K;Q&\3S4WQSD4+7J:! %0/>D[<Y(UW[L"AW1]
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M7]',T]9G'.UDV&EXDFLIV>9E2ABZ4QB+>3\#QVV'H?.""&:<&W+4L=C]M2:
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MAAW,*MYJN^6,.._Y> ^(WE;D1E;)[57(GW7;S,+6N9!+':G0'"U<2.Z2?D1
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M9511\L__.^7) Y#C^Y*\^#_PB^W4+O6TO+BBF;D"SV(YP5 5D9_62G$'ED)
MI(Q2Q'D24Z]JSR7PV^7GS>+@<K<\=K,!LCG1;S*LG)./"0X"Z4;0246L=)9:
M[0U&;K&R:KB7(10&MOD@WBR2\S3])A(*!5CT4VL*:H>A_$Z'S)#=B2QTPF6L
MQV6\I *66GXZ$,)L/N'6FCU<:X$?IBC.*<_OCYZH=O,D9PI.[=GX!ES7#>81
MCQ[U;(@UEW*OXZ$;J2\'<7GY&L$S)A]^LYQ<Y3$$9<4Q>(&)^(H%OHNY=#.A
M=W'4^CZKF_I[)HN;^* !<;ZC,V)QJ^23I+JSV/=$N#<&ZEF>N#O)0:;.L \
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MK%KP.*$5,E^W5+L.43)>M6I%#\.T;-RK=7O_-'Y:%IOG+I\\)"K/7]2NW_I
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M*#L^^:+'EB0D=T;M)RDM9L2 ^#ASM(Q:#HA-A6(/8 N2X8B,I *2\O(IX;&
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M+7[V\J3<2@Q62LX1MD6@1(!^UDP*Z<%T]L21<1-'3?![GI5AD"'Q,4$J&+X
M7^6@ :Q&$0!QKRNM:?!N8_N@9E!0,00"Q12#]'G#]5@XMI!K%H"<-@>9H9ZX
MJ]!G$I%;WL!QM^QX?T71B9* GBV #-;[6:U8X @O2.'!N%8RUN'/*6!+PB=
MXN^6*(.Q0"]"HK1LQX/FJ'5%)IVMREGD&K#+)$J/1SWN1PQ0C/4O*%:;XB51
M)[*YW#J5VC#_/#=U=$W,+\VW)D*BXM(=%&2K ?:]O_45R,:@_RRH;B$Z$9L@
MX;,ILCDHE?M-8D_E.G")27+'/YDZUUD"L#OM'W"(%X\5C^UW?<M;FDCC3=\6
M2QL"?EK/:U[>G4 ;48.539(GY<I$+Q \[BJ& F5/=.9ZHQU=#LM/;P<K+W^^
M'B\,4A\G<BT!R(B.LXFLA3'*8 ^(1E 3F7Y"N<3:'2@_R6I!.RZG&6G5>,H)
M<F! DD 0(M\OTSH\8E-0S24]#' R2J8G9].<K>3!P*;AW*KR:"83J00,9%Z$
MJ&O1_VS@ZT9& %$A,>R PJ%/@#P,(H#E;X:F+EPIDN7#HR\;<V-ART:, )PB
M>YAV1HAI.E]P!<C&A1XOP>7UBOCR:Z@MCJRH**!;&YXT&O6'P=IG[A?GV?^Z
M!X,L2@NI9(K!?DV$BR?E2M\V(2UINOG!'>>)DN:S4X0,Z)K4V4X6A.IY%NO0
M\4[O"\_G4-#GYS JE<^IF/C9.WQA \_P+9$.!:-F0/Y/*L,W5ZX8M:D>G]>R
M&HR*-;,-,)>WJ^WU%^#X*=5O8& 64M?R1(P5Z$I[:K;Q_I02M@@R"-/P3R0F
M8%R&E)?DE>F7KGSS(&>HK0Q;2%#&MUX3E>TZ_'0I<P#SEDLVWH3.0WPG%?NG
M$WJ"Y!)K.1NL /E$K.'VO+ K\)"<K*B8)<"'Z%"(:K%T'Y,K85V//G"OY=;M
MX>F 6[;+*0:1[1V=UUNN.3PHJ\6$>-S7N[V_JFX_?&<N?W@0OAJ<G#1N PJX
M_ /<.<U+I7='E#W>W?KVHD4ET-[/=T*#OB*AUR#CFN.@OO,?H&GDZF8?S]1\
MD*%WTC!PTFDO[^Z]/]Y@@EC?/\#G4H)MGTL?\OBL@:G]%04^Z; Y.KQ<':T+
MG.>)#,66#0>AC,&W@3$1";</LE7?0FOQJ<X'$UIF#NA=76BW7H0NVN=&G?86
M!<Z<Y!]2O$^XTE6^'CM+>/O;[+XSB"2AT47ZUUZOVINS3>:,I&\MN:8*/[^4
MW[&V_I)XT+W JN,S&9X,C/$+6%WY?KF).ML=;W@@O@/+G _&FKO3WGMMYYG4
M2Q/4M+,]U)YH?^IY\P_ .817NB>\AB5"%.-$+S"N*)49_!"_Q&2Y(F%3#L*_
M]5_Y8?<8X,,6$'TV,;Q[>^_^F"-P>-+B\DKX>O<./1B+C[_Y0\*"_"$^F_7M
MG[DK/KQQ14-KJ?+^M^N"$Y#=(1.3&$F."QPJ*:NB3A_JUKO.H.9_@, .C3LZ
MD;<7<P])!W2!-IQYO?:1<1S_ !6< ?GF_P I10^!1:O40%0$=UC@A[]G$T&!
M>&KD]^X/W]AO6VX^^3=H/+9-_+]O<+V_8%#GRQNN9\Z^YJ?_=F'2&FAJ%QA:
M2B!].Q=VEGS;?(4Q]>Q_ZG^O?1,<<YZ".'^X;B6ANKAR%$#Y?!(9J&?X==2+
M]W"T";P>E/@V.)*Q_=^S?TI?^#=)JVMX[^@KR?\#<'0%7CGXY^U/!^(9/Y>>
MRJ,OEJ%C(N$X.TLOIRMII8UH4/^O4[O\DQ97&5UN>:)73B*_I:7?9OT5=V[(
M4VN]+!N]W16XL+$MNV-MVR(_?E?G5Z!Q@?4\Z8$R^?8VZ\_> SR/ZN+.;Y_D
M1LPY@VTJ3_HNH<6-;2[G3TY>6 N#H%0@U\G7_[ VVIBW\$>8UN:ABCZW[?Q/
MMCW?0_P=*]Z?P>;K+7B\=5[8G$1(X/[#[\7@.HW@#7TE"9>EB/6[]P''>%.[
M5=*/50'GJ09*0I?N [I,=![[,SC&<.$TD5$1:L8L#R([#4X\%\.8P-F]:HV\
MPT!/E&!-O<\[=UO'!NZUD'J^F.FZ):>9>,78*AAUQ-TCS4+G2A$8\#"<5_;^
MY]DK+E3Z4EE0O J(E6%CM<@,0$[2OP1ZG+MC_ C\G(:/B7/1O8A;#\"B&O7I
M#([KER9P]&%SC-ZNNS99U[Z7?1.)][LH#2MO2D;*BYB&6&2P)M!)+&]MKS>P
MYEO"$>W);I[QK8W=(T9JHNC[+98J_&7?W"A#/WDS1'T;?:3V7U>I@CPCZ#^
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M("AT4]NG@WKY1]Q">:9&84VS:O1_)U<:0>:?2K[WUGL9@V\#)*^WP*,6T,^
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M.1D&CR$<K;8N97.,A'"=\BI2DK[=!5<%YE_=O[0=>P6?XJ ..XR9[J,3$QH
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M6MD442T(J3_=]ES?F+M:#;YH1'\,JT7!IQ\.Z*@%^+Q$7"M7CQ%SF?X9,<+
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M4)1!6OKIZ:IA^4\5EX>YM/M=XK)-+S3GJ^I>H\I3D-$ B7.^R$@"#63!Z>_
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MVRH?\145ED) F/C])N*3=35FMFSE;X8DN#0QF3:K,K\N8((],S1HFUP XVL
M/JSWC#IP\RU=.\W(#A&MT= ]*HKHBGY>YSO&?S%@_@/_TF.FG:USN?26H*?;
MJC M7KPR(*0RULMT2?A[XBA?:R'_$H [4@'E5SB2MF1@-::6]ZD^#JN_Z9(X
M/.^W.$RUO6/4G$W*;4VC:5:&@B.=!#4!3@,,J\?B>^&&/>&[38'$^]MFK\J:
M;A[,,0RUY=5KC0T2T?+HG<BWYF7BHHK&8TT_CL6YV-E2G;6IFB<W$#&Y0L?\
M=.E=RO\X> LQ-C-@85+Y]# > ?;[SFB3GP^>]TA4[Z%6F'UCJRA8<;TLF:RW
MREFCTVLY$2!'G]]N6E<5-O?$6J\7;OA<_!3;35/26FRVH"W&S(24AAJA+U$[
M.W=RL.TD:)&ANB^3,DPM/I-O@GK^2<&S[L$/VA8"\W9>D\8>DA>0,_?Z2TDW
M;>3_4%3L>_*H*_=^JAI)#TP,-4,-/C;OL/R4@S(&58-@9/*!-ZU<_P(M@?4U
MQ##5H;7E6KD$H@"=W'C7R>B9.?J=6,A^:7G27MH6/]?Z,E+IJ:*G5JQME"0U
MP4_2O&[OKC*SL>_E/0D#H-@T$Z $C*FR/D/@[$S@O2Y;A;%ODUE+?OK5$AU%
MC-C2):,/C!C6.!X4(KT7P]H9_KEA%X8KV\'SDBL#O%0C 0?W2XZ/J\ \??>[
M3&FHO:AQI6!V$E#D)CDY.1G?-J541#_?IJX)G$>!.%9)LDV2O,_^8RK@>K_H
M/=((1C4"_&* J=W&_.F@_^<"+P(FVP'"2';483#8BZ^,)"3?&6]!C2A$ ("E
M&% &_CMW<RB5[G8C35I+28VA6J7\_.STU/$[6@_91]($KH[ @3S!^PN92B+Q
M#&1@@2C&':J^>&<9#@89WH<G<W_^?*\ U  J]J^\]Y\$8Q22 _$&N*J^YS'[
MVXO*T]O3&U.XXLC;&)++'>#Y]H-4L@>^SULC0UBJ3H0?T(31W^[G?JUVF_NU
MP/[> ^DYV(%Z?R8\7?Q.1\)F40DVFYP[\A_EVZ\Q)-O<D<];9QC O/9:.ZY.
MX^$QW-O$ZQ]FH9)D #O#P\B^VQ,/[O)=+EA='KP8<QJONO'PY9A2OBBR?=[&
M*@__[Y$ *I(%H 5(HB.= ))D@)(,X/:]*P'F&9BA>M2H]AH),.;[VOZFOK@&
MJ'_N]_E-IP8F<-DSY+\[5#<P-'G__LHT2B\2 /J<80 9() ?'_&+.ZU!=Q\O
M"@/4*.^?0HT WDA>W2&U_2(B9O_T/VW!AD:2,KPPM<@=M=^1W^[RW01&S1Y=
M_0NDB#Y#DF%$@/_M0ME4HWRA<<#[)IZ'0O0^L/V%I(]2B8$NGVJ5@YNJ0G>_
M.AF=9JY6G>;^>ZL@]G+IL:[R*8/NE_WAHMAW_P*?[XW(1<W@3H2/[J3=I?8;
MN3V^9W3W'1!!9DQ6?(TJ'M"'J<9K %.JB<8 ,SN]THA?!D#]SP1P'R87J043
M"$UVR@\S=1K_9YKX8V[SU3X%][9 )/<W_KLS_'Q7\6D-E84AOR^N3/]._OGG
M3^N)<&K_=G<W3\GO)_7;WWLW'G@7=<"^D3D<L3*JW-KWCHAX$7@"_@5][O3]
M89\;R?:PP'"J[O^B,)V[RBZ*O2_N%KE/$CD]3=+GUN?A;KKYOYV63/< ;N=B
M]DVR65*2OM#_4@4>/Q X?%*5/F>:@!1(AVJ]< 0$#H_3&A\ O]R%Z_49,LV!
MAZ0DR4Z\.;^<=O'0R%]4-ZDOWQ:]+X :K]A>![\.F28I,GQR/^HGU3B<:TAG
MN/P<6;Z90VE ONE/:G\;3&K$N*T,,#$H]\6'\L!S!T8_I&9,CWG0ZR:"T<II
M%D4U.88Q]E&%,"U 1HW!7VW_R^WVR%^490:^,BKTWW<13+(QBZSFM$I2P.TJ
M+D"-(8SDQO^^VLZ+<#>?VJE*KC\OS$A1:5B<WS:8+&U #B^C'[S3P2"-Z0L'
MG&9W4P2XG.;C[[I @HC33C!2-[X5?K+]*$;>B+#A=/IP(-X=\$]S=BSC[;C?
M(<]/\0W,SN /YF: !4RGPJ@>2)%<EAM"#X^KJTY%+J/3JAB ,,:A@*M79/=+
M*F84CA2F"Z3?=\Q;TCMQAPY7W+=&59]*PM;P(Z'<E ^3?95&?/GOAG#ZI]HI
MF\)RH]3#/B&-F9B@6OH )1,P$@E$ JG* !D[0/5)=T_%M&]=)D3=R8.$FAV
MPL@ @ +H W8 I6VR$:>^RW)Z)Z_;?*T,.8.B_H#2B/-S(.W!ZP+P.?LQ@LL@
MW(0"&"(#>-6EM_^>MR/-^);4_E';?$XED RDK9!$TG\C&4H'"8S\'?/A_I58
M*_@K^[<<7O=C\G.E7WXI6K>*=>%X53@'[\QKWYV/D3]? QQ,/[@!2MU/_S'%
M_?\EL[8T0 *BB0">^16US%IIK-!_3TQ@E!'(^GQ2Z>@Z!->@M[\/2B-5[O/;
MU"W*"IMS=D)?'&]L3&%N@U]TI9_P4K4^_ZIT>?SG?F":1'*R5PC5XO1Q];_
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MH,'(M>9/1.:J\?VGJ10:E(=NYURR(2Z&U/=2#:..^E[R(Y4TE@-[^8*,LYL
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M;*Z77%I*]G-5\F)F7JO M.<U_0V"'DK?#&M< I",Q5-3LY]>_6J<=.??+D"
M4)W"YC@(M%XHZ%V2',H/8A!ARBT:=*WF$.J2NWGZMJ$ WGA=:F"/K7+!AZ3F
M]X@Y+OZ5;*P?ZV_3S,W6JA*VD30WZ0C),-'>0&OSQR_MQ.';74F1"J2D@9.T
M>"#)8C(9X^@#,+YE#[[4\A68 ?I"^7LX891TWED#^CTKSO>N='FQAV3<;'L4
MT&'HUG%BU2C2=/7=/Z8#LKVL<T.UU!ZR4C\G[W)U)]0N2/O,:\W@#IO+;V3+
M;(4[2Q&B*> PT@1]4M*8C:'**MR(F-Z^X#Z(F,'"^_X=)^-#)B<:26A6QX4
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M?'KQ][WWS;JHAWF:K>&@9W/6=?^:6"D"QG+/)C^VQFM)*^1B6*EU^D[H,+?
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M*8OOVH9,L(3+OXP:R&R:WK+7&$REX;.P21$:<M@D*+C%L[K-U%$^"%(9)X[
MV;F8^-7+F38::FKXM'P[O1=PUR[V7UXC&EB]%'Y?++7:>/-YL..HZ4LZ%AGY
M!2A>J>/M.]Y)3DY*/HK72?^H]((27G]%$)X>TBAZ*19K8@OD><4)W:ZJJH8K
MFE1UIFHG5M:L<;"6@4J-J1F/,GI.TF_-MO>Q,9V[I%J_8I0-7?V/A>G3-R)3
M^CMM&^U'4=>/BJ4M0Q><JBBWJ\M:;K>" R)V_E#,[F^J!OF[6A'6A;FXFF<+
M_;]^F74*%=(4S?96V%O"(:79QN8IU\A-@L-]7>(.YH'IW+._=Y%DP&QZ0/;B
MW4I1LZ??*7/DD:8)/+5Y8HC6K66Z-BUO:EICX9U<;C+.@+*^.RR%1R)H>X0A
M:(,2F6O,_QE:SRXUNNG?Q02',N'Q-/KQG'>'!S>KZ3:R?DL\W@X(*\W829S6
MN;KJ9&E78.RT_20L/R<PG8:RK)/V4"6,9&$RF"[:O2SL3XG'8OD_BE#N*EZ;
M/[F6N@.*P[^Q0"!0)?I+)Z5:V.V:6N 1FOK'=6;T/WN8.\W8!. A_4(,0TP,
M]K% ]B\2$I)=2HC"?7T>];\?MY$,SH]79R.^WYB51;Y9N=FL4P[KGQ6D-&^6
M?)2^U5ZO'))-@2Q.*1@I:O4YVOSSW 2BY/W>1)V,)-4$QA;,)Z),=@[\3BJI
M'%%+L*[W8H8; XUZV$ZQL1<\P<'R07$GD'Y#1A/!90/,+"F[(I/18!()R4,*
M&"@>2OV<C>0^&%',%0R,>MK?KI=BC(K#:\887],+Y&=&OH!1#) *TB;KQE*[
M"J2'4P/\[_R+*05B5C0V5?\'B+8-F6IJ&_P3=J<R](B0KJ\Q-?">YG&GP:;
M/*"/9_>;[_MW.#I:)7<5VH&R@5J5:#..YYCT X&+LVNG"/!)CI_ H7^I9.DN
MC#+$_XIMF)SZ,/P@=N7DR>.?=W?A!N EQ>^9)GC [/=2M"?79?2927= ?=>!
MWSGH@T<SU.' 3E]\&GD6DEEWN/GV;?5NFP%/BU&UX.&!$R?79)Q0T%4[SV)C
M8U87GM-J%IB=_ZY3/Y]20#5LJCDRK;9Y,;?9.!<&BJM?Q='@'+$D$M1?;+*(
M!/6\_+XGEAL;'*Z^3X?'MS;[E-)3@']G&"8\[@_T^.!]YI[6.$'71;;.5_WR
MZT^@9&V?P8+XF?B@BP7WF^+P3]11&B$C0BQ ^D9]X#SP&'"Q(*$N)=P'ZETA
M<M<>()**-(X:8V1W>\:9!RK%[MVN<H1[W.;9ZIQT6D /\"9+'C*VHVZQU(43
M!NH7JQY>U?J@4ZV(P\QG;8H[<@2Z.T\TGDE0B.J3L%.FK>';9_&RD;F:SRD4
MI=@ 4VG;Q52_%HI=O_+RS;<A,-@ 3N3//X.G&]RZ@V:"2OQL9$**]+00<LF$
M2J&+R>2PRP6W3%4(5V9P%O)SU,?N<KB:HO+UB(2+:M\+Q6.+S(]O.,UT_Y%G
M=.Z6<X;;666NF<NR! 1(07X&"O$^J<_29]-NB_YFY[/\D.NJ6!^H^=#EB91;
M?164.(0E$+*\#E*@WFLAUZ4F$)[L3GT/Y3&Q DO-#V P"G$L.JVICJ\L!P%
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M*SM2H09\KC%L9EEC3&Z2:T#0IJ."3[+LAO,DWI C=#%3F1]>EJOS-4X^SS(
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MS/*25*=RNXG_[V=Z@A2 0E:!Q)F090Q2F:)L:S+#B=^WI:^B@DEAL%]>@!#
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ML);.9)BA#SZ<^G)\7&")UC_ 94CJDEF)XZQ#Q.&UC<R3].IKUE9G_3DZVSV
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MP#YM?WS\OH%P+ES P<7!Q\7%)\+%Q24Z><,E^BY"\)\H.&X$"# 0QF<@@^@
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M>R4M74I7&Q'#/2XZ(F5B=M'8L>N<@' \CW(;R]8'O597^[CW#C(HLI40=5.
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M5*PMO&E<[>/V,,@)/7C_&"C>[<NL9TND$KT'*[ WF2']K'4KC,RRN3 :O4X
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M+2P]D"CO%! H,H]YE=\$4AK$$HSNEJ'#A">;VK)[PZ:/.DL&0-IUD*(WNK2
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M2<S[(M_NE4<\;FVGX.#&W&I=27'\@ B#)_& B<<U%XGBR1N%E7IK.8$Y*?F
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M9YJIURB[?-9/(1Y'B\U@.E#8\?/G!-HP@R)>SUXFFA80ECEZG"9^-IIH+$(
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M"?)]EIM,FK?BFE%A']\7GV?C.K00#GU!K:\[N/:MQ<PLR'7A^KX.%5Y^G=X
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M,\'UAN+LI,_5,W-V&'M.>ZG!US&BG.1F=%*9TZ-17@?C#8[9<A.&F.5@,Z@
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M=B>S0F$:+%B+0Q3A'K\?EFJ,TGX>]A8"?,,XT',V?%,+.%E7T25D@XO2\1D
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MJ:F2AV:OOK4DLZV8G_ZX*2@ZH50I[Y./TV7W\J 5K'VT^EH8GC=(6.+6:^A
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MT"YQ5#B&Q/6;,4.X0YB7<!_G+^(A-R\/VC54/VCMW*IOJA*@P\?!PM,; H%
ML5T;DQ=LM_SM[XXPAK=]L,%[@;'UQ;'5$EJZR-ST]S)E!<&K0!;?<7Y4["!S
M!7@MYG)(Z/[ +4@Q%R=4LJQK5DT\=@N)1*2+U)M8O.8<-CN*EL7H.'EEAS8-
MQ\3G7<Z%X)4%LW;6P<ZII0S)$O6'(&=D%ID2O$0#CA#4P!R"T\']YXD8U]+C
MNDM)SR3_SX.!N_-YU:WMX4^ G-&?,G7L)P :&%^F>C#QR*3H[NK^'ZTS>-?_
M5:<6'QQ;$_R#X;W]Y(-SW :P]=GX[+ENQZOE GRKK*>N]_8+QPT7UV-$Q21L
MFZ;)>)F0D)AH1DU%3A-&H(SC314XF&Y%9G;(A4(RF B8 2G54^43>'8<;H@4
M5LI1%9)^^( V%:0Y*6RN'%6>4*-39<54D1/'>HIT?D9/'U0@+M-$3BLL+)0Z
M4KPLCQ=.GXB,:0S2\GM.M08?:YQO:1=C4IF<91.DG"98MX%2?30Y($KVQ;0$
M6<7>?3-SQ3(0P#PK)G! -:Q[/?>L2Y-EZ9)0:($@HN;YA;-4[@>J((&EY(F%
M BLOMY)*+7O.Q@4H$9G5:AGQ"ZR:BN4*)O&9'!$Y1(J%4QINISG3\P#.Q/I5
M)3T!70=9 N9")68F[5Z%YB_."^'S]/R*>.&DX)68@P$;VJ28)Q/C*61 _1+-
MYV,\Y=4WPH971H7T(Z_GG"5*9[-$?;4[J,T7Y0,Z/S?TFFC F=YK'5?'7!Q7
M0R7'3S+$)*A6;US(G1\NNLNI6R1:G^3@&D^;$R383-H6)2,.#2?&)K;.=@O?
MW+\[S?6L6V54FFBI>2%6S)D3D9 #*Q,TS]BY!-S]+,FR;9XOL1!()"()(2O$
MX-:>29M+%I63(E* 52%+D/FNCTXJ>_"1/5"9!^=BV82?E!K5^@*#4L8+"LH4
M4%J$*B:5DRI7?[\O5Y"E%(NE6B:O5BDU'S8B0#&F5JA9)\O20P%?FR(@(")D
M4)W-\[P@OC0U>J7?HTHQ4Z";R,5".2(624E:+)7(:1*7R>4(P29)$J< 99*D
M "-- 0" =R-(?7D>?QO=_QLM[H/ZF=E,^4)<W" '@;)/90,-Z:__1HS1;U+X
M&^$Z!G-BOW#_@HS?MXKU;;<6Q\<NJ8Y.NG&SA%>D'Q!U3_SLXQB<_+B9^7VY
MSJY09^R/;I!XC_V8J=]B/@$>0ATH[\UG%-XNJ@[>#@\^OIA;-V:3O(MA']AP
M@O(2E I5C9$2K%>J(YT/=.=\UD9ECY-AE@^LZ2>1$*H-+71LI^[$).O$D>J>
MP*F-#4-Y6\6",&>Q2:T;%+M$"I'BGMRQVJFJ&ECV5U5)MP/"6(=,7I%6OAH'
M VHZK6+"3FW6A;/O2E6DW&L&*IN':>H:(GTNJK(N7PZ+2 OX4Z;("E%0DG1<
MB4/:/"KL%; DK&_$M2SRJMGE2,K&JW545[GNNWB6L8D=Q]I.Y&ST.VF9!1XN
MP"X,]8[EW49^H\4.]'(%TTFUQ"ICVXGYKL@A::E=>FV/]LP"0J%:Y &9[\!&
MS"-(L+\&8D.0Z"B.#Y0.DI\?M\J#U,3&_ LU@S)6HSPT%E"+1^X6S37FDJBD
MJQY=M!+[L,)*+FSXL9,V9D-^%9=ZQ: K;NCT!ROFR%*<EM.N>_0;+I?<:Y@3
M(#O@$NT27-#2U,KB^_G-T:*X'LB)=0G'PJHUT/:,)!MENEQ^,8KM?U=O6D(6
M':?]0LD@0T%\S](F:"/7-K\R)DDG*):YB@[+*'O=G'M ]'UDMRX-=*50/+Y4
MBJ@X^.;%?;:8:+7F[.=H19],E+&WW9EA[25-E'#RF@+[['.*TTGI08'J2"9^
MJ2%,&=N%P9GH!/?WFD&=!ML*WY)26Q46-R2G[K1<SE?O9&TVB1W.DR)TA<W\
MVN2]VQFY2B$7^!@T6OT5O?#J5K=C*+'#976?T':LNGG9E<1EP9( =*!%W9EX
MYR8M6'8N[/HP0T&TPAJ;NOG$Q,6T$M1,>@@GE_E+U82$665563I+"]*,6B\3
M6W5?>I6I+C[-U493=%I1Q7E3?^R7*%>^3*NEWALFL3,+TIG\])R@P<0?RW)K
MSL<<A]RJVBUN1KC+'@5'.0[[;8P-;&5A"A7QYXY2&XPJP(*(^\\P8.[VTM#H
MC@NLPZ864Z&6RM''H))Y3<[)X5M>+2+O%W/$V#+JVMQL2S(ZR_%V2K9"T*JO
M4II);V"=%_)R;=4,*76VM<KN)RNQ,NEB'%"FH^5<RPPS)UMJUR0=*J86AG>[
MSHUNA^/ 5;4L5$N-4HN2.W:V7L]-#N>3Z;'.Z8I7"YBCJK:BR=;J)"XY69\
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MO<Y[<$7'TP"XI]0(CI0RJA>?+#? 6N[<<UX]!G1\7VLL*Z/\LEM56LR<8^/
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M/[H_ U">5==2!T @') OR!< ]M<8U/6=4!B4AQ/*#2S"+PA(*FOIX.$!V,+
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M[<%@>Y2GG2)J!OA1--#(O]&4$7_OIXRV-S9!8M0Y#!$8X)>BC+ '_XYNZ('
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MR,B.T3'2T-#1T#!2D1V6[X??%Q Y*2DY!3DE!04E+04%!>W!%P7M-Q:J?T?
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MF"20<G\F-O!@1Q%>7D4LN".3PZ_VTI^0WP!^?+XH&S8@,$JY;!X:R04;H4T
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MD:&O)N?E5"UUP89I;?6 L,QF6Y5<^JQ!.TB$DLL'E/Y!K7QLD,9RQUW1(MC
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M)%VD#S8]M@\LVA.1'9M26#@70H6XJ94Y97.[^Q)P)CMX ^0\(['=+^D^;>P
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M.X]FJ$&C?+? LMB'_SJ5!AT9<OPD^[EU,D]OI2LRLB(LA*UTV2N%5)1RI@\
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MWEP4+V2N<0'Q4BZ5<<F6CEFC__FQ>0$73ET>A$WBR$W!%($$JZ3&&2D%"U(
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M;H#(*&"0NLRF[F,$^BN@;&<$@,@FT'4#??"6$UL*FLRT$W\D8LH;,1UVGA+
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M5O$6% VVST$=T1ZZ<<,.6<3LU"PVXQ"UTPL0HEHD<Z8<'$UH(H&D4%5_0)-
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M^UADYS)F<HT,(#Z1!8TO\?4$=-=>?A#:)T(<XVI&X2IE9DJU@D5M[HEHH2(
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M10IV!R"&J_<?]I%'*1:RUNG[F9W:9I>AU2"H%T6=X-A&2"DUA*G#;X?S@\W
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MA0]:4;=?%I".:G9;<4*V)F^7@J*;4PJD8D7T&( &4" B"&)J?>%[7^K6*4?
MX+40$Q89D\;4.U4(T&K#3B<'X(FH)"BIS?G3XO@S0]H\ZS$%LP,QBB4*OOO1
M;>=#KQ<>)*:1TLUU&)EY[00TYN\>7AKJ4N]G<,.N=S$4RW<4V )VVDAJ/NKU
MVR('X!F<C^.,/WI)!?.0P^HH'PD(9A8A94U.W<ZN,]E%71B>Q(04UTT7<+ZL
MQ#45@HKP4WS&.?'HT4TV"!1/KD.TU*2*VI2&U?J+,=A/TTXKF_.C/[8!.*&A
M _*PMIG/I]]Z>C)LF$BW6X%*Q"/CQ](* ]"2 ,E] 5!0,(!M82=HW*#EU6A?
M'G_M^Q1>1^M@#$\1H4IR:?) $5@,<<T@\G7B:A_@D53<.)H>B#ED=2B.\(C[
MVCU7%^/ZL'UEE>)3549*F$H"YS8:CEB!UJYN%!_AAX+U;Y8M2J1) W,OW.>N
M\K:Z*LUDB+LBN"%VE_3VG%?0:,-FNZ!C]U0_@R;?@N+04JF7ZFA>K^+&&$RU
M-7]" -ZD9"@3?@Q>/Z8,)Y8"3CBL##M.1'Q^8'PP+4XQX!PZ&0#@!S"LJY2,
MR]MRHRVRPC<5D@, 4*, @!Z2HR.S(Q6$"D+#+I/XGEWV4=V*F885H^#CZVQA
M*ZYV9!=Y"+)AZ0Y%6_<DW28L>OI\4M[<28PG,V+Y*XB:D3JAE7",Q8FZ?+/!
MYZF"F(<^?DI;5DK :*NHPZEA%Z3AG^F")Y8]%?0IB"%HQSOK*[IA"Y<T^<A[
MAO=O"T;Y(JDPM;S"W+U@ZNTR!S43I9G*P(3^<<JGCL4^9DRQ;40N=RIZW!OD
M!_2ZQRVZ@]C^"7 0..D?JHX6\0BY3R2+\G8W0?:?D">^VFH;:'.><O]TAH:L
MNES*VC'M,X"':F )VX(_N^*584G,4[7^D!"Q08[R)$ L+7/.1&FF*0+?2X7$
M_@90"+)@UE8]@\Y@K\ ]N](3O$M<%[AXLK".5[$P:V\7-@4#Q/69_$X'0S[[
M638EQU1$1PF*":ZNS?!/1'3*(4K=+S10..8M#)!_)/^Y^GZ"S(6DBXZ8@B2B
M;\S+:UN=WE"/?ZW-'S&K*9W\NEFE1 X?"[ K36:V99!887&8/V%EFV>=:+1N
M:MO&.#\O*SVDV-I&8;(F\4XM$5LIZ3UY=:K][GYDJM"*!H8\6N>0?&414IO&
M1PQBZH.\#G]0.O3AHG(-J!/S6]J9X:>&Y,=:]3^%8 <VC [4KZ0/649+B6SN
MS;]VXGZFM*O:="E6OTCNNC2[KT3<-NPGTSJ7HTY4_(#P?CRZ*##BLS-[@(L1
MM\)EBJKSBEHOU,:\->Q4'SF69P 8"^GG".DL"(N_17 F#0UV=37@;L:$.6T+
M\50PPGIS:M8D4(-$FQTZVGED>H5'3:&@:@7!R6'Q5Y2_7;T5>?YFOP08#IM-
MU23"7UI?++/=R*SW,:3FL^+WCADRH"!-1/J>_7B/-6Z33XJ2BOP(G? P@#2>
MK5F6NG<;U8;8I."=BVV23:@4/ 9T-#74/M*MA#_[KQ8:0]-<\5%+ ?Z\F-:2
M="8.M')%?9TY[D[D^P$D\)JDQ$O.$),@XZS^/H'K-@E[Q,>Y7="LZ*%ND?QA
MJ]]5IPHL3"N90HNS0_0-<;TG;B6FJI*QE8BS[O8,M'3.NVS[/O-KY,#C@CIA
MX4J0! #!P9\DSQ *-186X!XJ14)K([W=S#F*$)ZK=E=0L=91LJZ3LKZ^9[*+
MJT_/MG8[)LC<" N&K%#2PB6DV^/R=EJKV.Q(R8A+EZ794ZK%!!+K25TBM>1J
M/@S!Y[S($9[;J577/*TI5.$W9TH3/D&VO#D<\KH6-YRU+X>"3F@1%]'P(^*2
M6@-=@ZTC &Z-/H OAI>D$IFTI])5LYO$G2BAPIR;-$.E6\+D4S6-1$5X:#.[
MSID"/.)!1_$0<[8:/9PU89A-PL=?!F]L/UYM=53W3I("?37HZ3O]M%WIS>68
M5.UX==R %QY%C39&ZFMG"0=M#*Q548'-,I_KF6PKDQ,;*FCSY5>Y5AT9516X
MDMW9^V#G]01(GI<X"38X>+[K^"^MPQ0#XG<YL:^VTM29(Z[#=#3L224;UU=M
M;//K0)-C#47,!=,LS,MQ.2.T)Q.*A1&2 B(3<,U\37>#@V(7KOLZTJ"3)-OD
MWX VD::0H"R==K-7>KG(HE0VB77:)B\1%)JPN+H_:4TR9I0UTV+V(L:9NQ,!
M1V)4%T^R>;H;-Y<5IS[2V&]=;8I5NXVN.SG8YE$C3IFS5>N6Z BIXYJ8H$:,
M.C,XU27+L)=UT&J)@FJ&VUUASE0+1."BF2T)L0"L,GA+<[SM<2EUM1BF.T4D
MVY.YP\:1G8WVRE1-0A"N*3:;YF82V/-?8B[&)>NZ2@VH'XM2XZP=>Q4$ IK)
MI$45,#%=^@;2:&_2 @WE8XD#64@NG<7<#2<;20JH;:\$%AG=[F][@]Y2Y()S
M>_6K-:MFP[\TJ(%U9"TE9LI2YH?3Z&\7)TE;V$S!YN]840PH'72EUV0+/.ZJ
M7!;CK#%^3JB!0+9#+,'2244)AY&_5$RZ"]51H-[BZI_GP(03)DTH@H<VJ&H=
MQF(2N6C\VW)3NCW92MP'?*7JF+Q7*FQF)??#K:D11]J][C*H=0,@11OK6?*P
M0<$)JCC2N)Y(>/O](D<$>0[L'T<K%>9S6Z6_P*X^8'%1 AN5*^@;?+3W'1:Y
M.D=_ ZR>JO .EMP.\!1T!1SR,>T6X'29RT=@%7!4V"-I/XX:%E'(&]NC]?(/
MA!L]V#5!(OSE752AI6'8A4EE0FIF/QUC$^)#9EML$-/3EI>NXPRZ7H[/9QRL
M,:,/FJ A>S%FBZN)$ONW[4O\/).V"/9[J*B8&KE9,KL1G"1?DB*--[?0][$0
MP80G93ME8Y:#"R\9A9:M"-@Y)[#RIF#GS/#M9E:QP&"Z 5XVX5YH HS1UP^S
MNW^H>PA>KPG,D%-!Y327F#*PL7TBO;,X@$IG&"C:8E%91. :G%0<.<O'6TM*
M4)T1=50!6M>M$9@P(KC$A:%.\S\MUW!V@K^_B;+EL":+=\ZD7Z:^OXDKZTE=
M,;Y,<.H,7*AL>&_+>ZP96G.%!C;UDJ]:O(W[3.SFNJ^"Y*QU090H6#FVD,[I
M92R4<@A,LJ,K46$[PN.S<,I6Y-F&[$0W/'X_!IZI;&H^VM1=$7<!/6#V/8+.
MK ^9K'2PPCNQD_$ZQ8^YZK"Y[X)DTNE6FF<PE2"E1&O[3FFD7,5;.1)K[C)%
MP>+F G>BN.T58$UB=FGDRGJ2]HD)76)[;-V=W%]&YO,.^PW6*"7;4%F9US#I
M@65\^..$>N:M=\BH]YTN,-Y<WS]$^T!.B -DC@<4UC'$$QV6#2F^&JJMZT!T
MN3E5GC+HS&HP:?3P1&BJB.Q1!2?H$P44F0** ![9,F1RL?1R$X!Q9LD>"@2Q
MT>6I>O.]QQ^5<$U_B@?\]QDR_Z49U!AUYC+=IM4IO5M(M]R%FQA1T[KF\%"N
MFG^@!)YY(NRC3&8$IG1@6JZ)M&B\+ZU1'E3QH-D.@A9>T_6H26'H-PO7 ?E&
M!YY?E:L5Y>*Z\A_26 U''>_#.A'"T5\HQ!RD<-1_Z>5;]8V-*8CIQ-=]N$%J
MD527Y>,JY$FDXV0OL9&*)2[*B$4.2-4<@R[A[JUP?--.!(.&AF<!"HT. *>-
MX0Z]@BV9%)/09;/?H:%,GQ"7Y5;+BK:^Q78:.Y,8!VEUI)PFCU4D!F/2C3I%
MB"-XJ))CPDJK8J%&X<HVVE3*]@7;VZZHGTO4 F:D4+C#@TVB?;P8^#4O]>@S
MS0Z ILK]IZ2F<0V-!:'8:>(#&>V<%C, A[=^7.$ +.&VMH=2$5/G&=4"!OBS
MV2G>;I,",Q9B^O6V8D/I UXMI+3AJXVADMNLM7XV/2=2R0,7$2Q>V,'.[[#2
M)3/BHGE_)$0LT>U5WRA/H6-X!!WB?H#453T+ABINU%VT>G] PE6L5\:P28B+
MDU$#Y.7/V03()L#V?O _3X9QL*N*H 9K.@D#0 'I20MZ:KBRP.N39^Q9_A)M
M.[?]N4Q1.[/].%M<01H:Q+&U,8]%JQ:]2ORSJH38G0;7C!8UG&1,>BM@^BC
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M'LPFL"^Z)$>9XLFX$+;*%"8D\;RCKN2^VFCCJ%/=RT0RKN SF2?/9H]($T"
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MQ;X.V''H9;8#GZYZG@S@R+_/\2XN/3X6H"!M]4,CO-T-W5CK&;E'_PV(C/>
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M>+@X8B<AL A18F,B\(!2X0B')%,?1_#$8.BK")OM##(T1=F0Q@XENL:.>QP
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MK78Y@L8CCP!-]C:1 RKYU8XCH#09QK']5UTKH^L;\D,BAQ/RNYI\.P6?S(X
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M4M.DB<3#HT6WIQ29;?AW6N<!0QB$(8^+_G4)B60;7=_X_$/=3\1<<X0MP:&
M&_PRM7(2!:G"@@!#,!FSP^VYC<I7(^9I\5VSMJ^'^&0)Y/42]8EOQ=\DT(I8
M+R]*8%0%\N-!L\L?V]WE];ZO2!=PW!'9$*&;4]+<4KAR":L:.@9A[+95OS-\
MM^0UPO/6 _#9N^6/I_$A>-0.=#PX%-_ !&<$SQ34)2KN7"W7'LJ[F_@M7U;2
MQ*NA_NY;XZ5W[$QEMY8355)?QD1A&5134^%!"!ZH?&#9($U-E"M:W"#+NBJ5
MW99JXA$M7B7Y HG'H%AR1Y.6!X\-'=T.4[D%(E4>D2*+\E<>&YZG/VN(ZZ2W
M3,%]1\.D2@ROHD>2/_G^C%*B/'^0E=M4@?'3RI?#L\V-_+1A*2&%HK6!+]ZT
M5;?)3S7?&AP;D<_R-,U3F$--VSZ,')]*:&?=DYK5R&2XGC@Z\Z %<SV[/\VR
MY[-_!/!!;1\>[I,FDWWM074D+20F) LNS.QW[ 6(!B5\J59BB+P%.S17XJ.B
MQBM5;ZMC(-N1?,7,S+AV1;DYR.IB05#5F(;,OK]7//2!$OV_^4#4]I@^BA@[
M;4X8&P4WZ)CQ3C_IR-8898>SYIRM#XT(4929Q%ZQA&GT2:#$OD@907,)QCRL
M4M6K;V\(6M8:W7UEGJ3HD7)1)?^#SR<?)U("D3/?;B@81R&):)^%W+P@Z5+B
MNMIV3FG&B>IEJJ-V3$:RH.[-1R[OM4LSL]ZVY+?FVQ+R)S,V(8NRPKJU4F!O
MJ5A>NHP5G+<<%FR",'"5.8D"(9/OI6?3^5YP^PVX-0.MGT<2FA0I469J0\IX
M+#M]\H7M\L]+R48_V'*MCAT8>GL< 6-5\F-Q3F'[N_[>G21^@]WY<E*==:\X
M_MYQYKP@DQW12$334JP?T: L'LO>;H 564;9BPV:IR0ZR,E+_HM3(]".PIB\
MD&&6ELVY0ME]4>RX:,9Z+J4F#5BH](6.KA9(^0=8<1?Y;,2YTJ#(B_)Q^E]Z
MW (M[T+MVS6[?<ZP+>?NE;";E7()I85*V%RX=O-\GOKNZR&O+_K/+LF6@6.6
MXFI?EW#Y9H=V%]NUZ*.H/U_"UC4LC'E!;'#3DU(C]'9'Q01^0NO\E=<[*52.
M1IL;SL^DMAEO>FR\MDQXN\PX([>>[&4V=#7?$B78FF*1(8J=LD(' ^-/!"DX
M6Q&6!7T\ HI-=\GJ@B#7O[)N[?I=2RRX62!9\OJ"U[Y/3\O\'FV&,VN40D*?
M45\.#F6)181&L6RT89R#4M1:#Q2(PI.WJBT<S$.9!;W[WGPIV<:FD;AZO<W=
MWS.@7"KTEAG9%A;KWOOAG102=9C,VN 7YDK<+KC\M!;SIXL/Z0*HJQ/W0!0'
M7Z[M!L4,Y]_<7OB>.$K&TICXE3WP@\PC4QS=1N85;/7O+;<VV&\O+,1EU$W)
M&Y'$/ OJ[SOHW'L2$T!5?02T4S"_GR_8,D<-!W'5;I!!&P^53#YS/$)O._T0
M"YV(I5%-08R6:W+J\/WW)I_QZX:T!H,6B14V-A*=,=@'#U##://69]_I?!DS
MURG;/.2-##_==#P$H@Z_BQX!#2.HX3:&P[7=HCDOJ^<? Z=WB]M4EIF_8LM_
M;ZD[R.PX F!2BU,)03X'^DRJ\/WPMHF+HW7?(H>D!_=!I,SVJ"N8->J"KI_W
M;,%[>2/9F/X= O4:@KIP#(0]#,+2LYKHQ-S *+4X\*8_< AA_Z.# =N4AU N
M,>EGN^W*WS</,^]@ELHONW=EOWWIN93X2LJ;1#@RV4Q>(E7[ <&M<&1*@Z5&
M.[KP@Z$>H$!ZB43+#1M#[9FR^/B1&U>)WY9*2!9U?7C:ZZ!KP([%]/#=E:)F
MMUM>GX93SEUN-\B&/88'Q%;J-EXVHG"+KW$J7TCF<1VB_72N6HN=)EDYW-"T
M2SA<HXQ%&X=;X='M1WR]22Z]=WBUI$KIE^M<?%!>ZHZWKB"_^&;"L[UV;%(E
M^TD!4*R]AHT!,\]]BCL7%<IXL A'SR\L4=$IV)I&X6?Y4C!/@Y,I/K/V>% P
M@?/%^C]2=6&/-E,=V+U=/\=QSUG@"4NK<$)LG%D"(QWQAT03/:TK*=%%IOC!
MJ$'0/EY[$)W40EN0WDMS3K(UFJDUW8K*VF7*3ZVBZ20?60YRG.GZXQ_;2%@&
M!@J4,0\(YLW3X4\+)=@L"<5!)K!5GD(YF'PI*)CU%\QC RIPJ=*FKMU!57YL
MI;6\),71TNR@_0XT5>NOX3I%>&=I2]OCD@LAF4$$@B[,73)RL]A:)1Q,H)P$
M$J13SN\8UW.]EWK($G !#U9]L2TJE/_R ZLJ!X5!SK-W3?6[<]3!\0]F-H?7
M#V\T:$L'^ZIZ1]$]Q$_$EKZ0UH6YP@8D0:1$;P!)(G@AN6_'Q9A]61K4FPQ\
MX4^H1>YQK=9/LNA27RW76$J&B5NXF_7^A*^?2$^$+6X_)9 G)1F<18*70,O/
M$FH^-B56*[5=;</K"'?@EZ'7:.=@#3Q;Q>BWM1>.+' SR@^EN7/W;7(JDX%^
MV:N^Z&%2;&F@*W5.LWUMN-UK<\&(-ET*#=DRB<=<)^467]$L<+I((69<!L)I
M![VX_&)[@V&UE@6.O;JN9AO/%0P4=W",GRL9 ?5DSV5H4.%(3F-/D$$,@H/7
MGBWE.FEP"[-7UBX(?>8KV>.2*I_@L U-];U<)NB@TMEPF]\2MQ8UV7JE*:"Y
MU:'%Y%I>4S;Q%07\#[N'BDS)I)*TZSCHD/"(Z5+)U*IZ@A;!Z/ J6[(=,X7]
M,Z1DF[4-W"V<A?<??<$""YY7]B@G"<1-7KQ!>O?6",G&9W.5L&=IE=+5CX6T
M89WMWIL]'$PJ*GY2V&'U-,)I0)&A<P:R2<NMNDLB%%>Q:>K<3N.PVL,:RU*J
M=TYD[HF";R[R<3[)^1S$&AK2L^MU.^8]&_MV<*FYB#Z5?P(/&3-E%/Z-FH\&
MNE[.UV\&LU;L$R^:/I'0><2^_\7I4K5>"NDNY>3CYS+Q#0E(AZQ2G:>R2>02
MYF[L'A]E7P#7O^8\7D)0OU4)A+/:&Y.O+@!?I8MOF8WJ.I(: S)Z<]-2 E/G
MB!@_Y*UV*3CI)7<H7&P-9S3\SI^,+_0V)KBQC!Q$8*&]\Q17@.D1Q0XEMVUN
M$FCN#+!)FH\M^>",[1% :3'Q.('A"+A>QYL#A>=O:S",5BK*5Z<J5A0K/,^S
MORSN]>EZIC<7G1]B6VB'D&%3(-9M(--J7I%:N.]3\QPXM *_EGV%0V-VW.1Z
MLV<AO/CBP]1W"L-<\P3O%#3.U_-)<UNL&UE6&*11WWA5NC?]>H;1)__>(%U>
MUMV[4'5FW]7GMM]9SB369'5?CJ9>K=2&!0FK!;_1F>-FB!YAB5.68!F#A.:/
MAKL< 2D7Q<-$=>R"DPBP2:,W'^6^F&7&N2,BI:'SW:M\.1UN'''A8MI9% >!
M]9G.,]$"&;L G:/FG;ZQ5MQ0I0&;_<N0;,-]>-7.5?ME1D6 B? ]BJ&S7(_T
MHU#$& 3*"+&>>S(SH!J>CKIVV3D*ES5XP,-G;UET;X?[8IKIRD<C0N%;7*\3
M%LV=R]7"*F$X(K0."8;]R>,Z=]\2ZAU&U4VNM8[$0671-%(RLC*U&J#>.+Y=
M]7IRG<&KT$$^M^&7=%<_[J6>R^V;Y(WSMO_ PV3^L?IKD2G,=_[MPHM9=Q&*
M.;"6]4KGR%-WS@L\RV<_2V%ED0U0-WVE[L1NY^2*HNZ:GO"DJEQL*%+<+]8K
M&<F<AEE\<YTI;'V/Q+J8ZWK5[^4%237/G2?O&3S<5<ZY!::P+6=4?<0G[:;X
M_ECR;C. ]7W.CS4= )&JX"4O)+3#[B8W5F1DW.%=4$*66387!&Z-GGE8G(=B
M&TSC>E-V>^)3.]V*T*0#L7]%T;='7CR9%=J:6L]K!36PR;G#%P+P0]D_P]HB
M*,C!=/+4Q=*^-"5K\E_(:CX8!EC.I66_P>?MU^IQ-=@U]$UTY>N=CLC [>H;
ML9\XET#N:1]C7Q^\[Y^9D&0$GF9(DHY,$H"""QO,237\WQ?'Y^Y?95EHO2.0
M*YZ&LW"CQ3,)1[ZD.X QR=E@FFGYSM@<=CN6GJ,(PYS.,V +VZ(@_REC1Q+3
M=3+&S9Q274U(D:Z,78WX,D\P%'U/OC;I>O[C9[U1FRU]N#CXLKL 5W9X@-3A
MG:?@'M@V!;"Y$.]@4)1C="XD/GS1'HLV9>93X>27E<D'4HKH\$D(DJS.74H]
M! !]:=]:G6JCOR&3Z!&+4YJ![>:O^0&)<RBI#J$K^63-7(TMW[\GX\6H3)$5
M:WNNQR=FG5E^*E_>K8!I,*'C^%=AZ;!\J2_K!_)SC(J\9HFFU*O1,4LVI$$F
MKBS4"PER#;,S.VT7#_VO@F2B/N].KXYK%#*44P!,,TO,Y'N!5@6/RS9F\A3X
M)Y0[]28'RJCO]X[:KE[L'NO>ZKB92O_:I.')J'/M34A2+2GS@$ZZRKOLK#//
M558NUT%5\?$4@FVQ2C_FW+K)H[?YM2+UOGC@P;51'7(P5TJ[%"MG44E<TUAU
M"PE]LUW2G:6'QAG"9=&"'R&U[\'9YSBH'DL\>YE*1JDJA.M%L#D@$C^7"VD@
M?ILZRS\1Q8!S'\J0)J.\P67X,@6_/*%K ]E3=>_AEXU^C0G\VU+#U]U$BRIH
ML& !W5^*BYJ)8_K2':H?7:>/X)?^8G]35R?6A)B5L\Q%SST\](:[;6M3M29/
MQ]<"7H]VZQR9&/0<J7HGT*Y-R ,8L^P>UL[6?OK&;D8C;"5)#;"%W"YD&Q9)
M[F?-<[50;I&4#5-HL?PL9(6R:MF8UII^K:OSL$JR8L%]Z)Y3M$*JM2)T];W)
M/.M-?H-B/)=/+^B_WC;@Z?M\^ZH6>XTV=KN6Z6,5+%EE1KMP2JT49>KJLDB2
M"_<^/WXSM&?^0K*RW_Z]SBNL93(1TYCG'G6E[+,1[U;?-9DPZ.=PM/3QQ33$
M%"]6*/EJ5G!\8@('CXI$]T-T';L+?7(VP?J4J]TV/:XF26Z/XJE'8FON-<MQ
MY[0=XC[^:A[F#)!?A2"Y^%^2<16?3S,B+6T'GN)G3E_+'!T;H_',7)L5D6;-
M)=3,3J.Z=CZ)MBZR/\(+B@];>:.@Y<$5F<%0>652!6"4ZYC2QPMB)A1U?S#P
M9C(%J=724)H,M9Y=072:RU,HT1NK4-I^4Z@)UU8=049K94NG<Q6L#7,!"4E!
M\5WCLUKT/2)Y;8EFV3,,;_0U5L[SUGP.-G_,S-,&)2#2!"VZP%2,:"^$QW!8
M/+**R_9A(L<+&?9D[DDP\U:M<N!%AM@3U\1C81NQRE"MB9A@KH"5'PO;7UWQ
M<8$I5%0J8/>.%!*TT86T?UUE/NO]2"SLJ]RYZ)=?8V\Z$/L\>X6#LE45BJD3
MNZN!'/VZ)TK4(7'>9.$8T/2%/E9YUDUKJD!I^+0*UJ/L/3FQ$+[/'W2-5ZK-
M9P5G[Y6YPZLUR>G;U=^=^5@R\RDT32-6R%]6G$EKAAW?MI2A^DHAN%Q_#H2W
MLKSE[UC2P_JP-3$;O(:RUI3W4KC;)/>Q:FC+1_V6IOA@?(?-$K3<3(Z*TZ +
MM&_?KAPOZ>_O3R</WMPD7AQ-5^XA;$ED+'9F&VV JD*O5:\B 3XK@LOM;;3!
M0SOAY\CT:<X\E]2X>2%S4,  /OW4I*>GX\D4S\*:U6*W5!Y\P'](W5FRGBWY
MS1/1Q@>@J]_\LTQ*.AS+%UW<M&ZY40D8/)G0S@)0I<PAL F?N_0-W1M"LQGL
MR2)5]-RT/%AR+_;?]VVWAS/<'D\.FZ&\QU0L*5-*:-0[TJ!R!"1D^TB0OG\F
M9R0V,^VYVA]G\=BZQS7-*^4U6U0)?;],6'&L^E-N$ZMTUCO)3.?(V"QB2VU+
MKY@ \K.E^B! \3N>S/VF377ZEE1&2%I*WYMD%JA-]ALV8CXK?(GHP-L4Q^,'
M15841T=F*-!HX<YU J 9+.3L6ENS14(-0^WZ%LS6F;*EOCBYN*K&-;'=_!$S
M%/0)PC>'K5B?-B<II>)_IW/Y3-U:*BE>. &HJ=:*WJNK:I[!ZPUCS&LV#6)K
MNK>3R-'M'4&D9OJEB_$=^G-5',B"/H'SU-A^PR!2481WG'*&.P&B)K?ZZE6N
MZP+>F4(;%$EXAHM0(7>^E<'VYU>BFL.]T(8NVY-\G<2JNC.4Z<($&2 ]Z50N
M4#B%P-K[PV<SEX7MRF<AQM4:24.>]\3'GJS413X+3A%1$@Z$\456Q)[=T\.4
M9H/_RV5M:9U78:UY;_*R/J[I/IM#9:XMBS&6SK?G: F%7'- *SIMJW*I%RQZ
M=[QZHZ!Q"_P43L7+0&9@,Y[&[(G>]HIE=.!%#[[/'[95%;P1;..8_+%J9LM)
MD[4P5Z)[IGZ3PJY%H3 GX-J9NM1RAG/ARF.\4UXYCN:/G&#["<*?Y:ZM!C\*
M@1(1]I^_7H];I_/1I%1#]>RSP/,><[$T2E%L#+57@AB%%REW)%EV<U=7OM,V
M=-OVZ*0&5KX6U<BS."]#M4&D/KOR]<N()D<B-J@^.J9A3 ,D#$H'!*,QF;^8
MF!AO*^0N$U:/1#*;#=?R^V8)S>(PERYUQCC&8<XY.3*XO[42Z$OZRBLLR'@8
MQZT\72K.\V>2E[4?.E,NZ!]XNV_!F -J14AEKIIT7^D.M6'$?OKLJVIK!Q;Y
M*V?,N)&\G'C*;AK)_; 1E,Y%AL>B?B\I$&_Y,*=5O.%Z->9TV^NT&"Q/4E40
M:VJCP%1^E'JHTCT_&%_\B+&J$L"A6Q96=5P?T6ZLLU8Q7\.^RD1>645695R]
MIG'7ORW1_#9;RA9VE$_.QGG#];WSPT0^W&3GWUHQ:$UHV58M<#YUCDX78'VM
M]"TASI^Y$6B['N ;DLKTHA[ZW1?%+*3_P<V%@,.!G,_E15L1,QUEA ^,+S\J
MO7Z=D*Q8]:/UG'0JZ;X*,^PRVD-ZP'0U\Y'J\PBV4$J<^(R+&77AYD][TUO>
M/!*DP8R>.SI2RWFS6E\>3_LA&?'Z]FNRUJK9JBMOJO*Z$G+ #5<ZDV$W[O5-
M+.]2;.\8[U /&><%?WWC"^VT9,527;(H1/1H%(.?DK6/5<'>+LQT\RP(VG5'
MI$AO44>99JEE<,ZN)$8^B_2_K7_UJ]]E_*S*"F1F83#\PB '!$_:1[DIJ-O?
MQ][VN$.-HD6,II0J+T?G,VZ3BY@4DTP78"F-[L1=FN>.J> M($C3KB>X+VP-
MD963>Q-G0>J:Z=9Z-Y']\_6.M4K-,M; ,-MJ/B^YM_RQJ0\T37=7*E#,/!]%
MQ)=TFNK)J7W)1!6"S@HR0M_N^XNB-!QE+] *MQ]^QQV;,/:2T'0W4P>$-IU9
MR:MO,;@'?VNP,(*D/>D+!O>FDD"9/5$SF8GN0J-6[J;PQL9/-4F%5)>PZA@]
ML[7[I,#JH_"N)#5=23+'E=Y/ST2PL1]I95EP[M/AZ:7CN7^0(1-YS)(H^_2B
MP$N^].":QN8!"F,+:KME W9P0[;' :FL,%(?Q-(_$A02I;]:>G$<,YTRD'T'
MW?CP:$78#!>G4''T0VWCTZ))]^XJ\1)[V_(QRGN"8(FEARY&V*%P2=-0]#-&
M"R@3/ZK ?9G%3ST;"Z=EUGFM>:%+.D'ALF$Y"*QF2GUX@_D37@1ZPD#(+^V0
M6CI5 /R4<V7/MG9CGM'>+/7!,W)\RD<6B<TZ=,L"!P(U?14Q^AM$WYHEB"<9
MT5'9T:\#2X()P&'ND6T"=!J. S"J+X+);>UW1,7,XE\;T1BW$_%49[_4"7]7
M>&F>V0Y=4CZ=E%JCCP.H"@(29 G[Q<S-UXU;P?OR>'=?3 L.B\X9>R85DK/I
M7.698;.KG ;=='")YJ82KB/9$_%7?27, 5!]+?)[IL\D&IW@O3-.T<W-G[HW
M1V4,N3KTW0Q9615,2V.FISZY<>TXOIM$X;(-G.8/>0S/"I*BHP)KCX"FD-52
MSS,3'&>N^AI-V&NM<X97J5N6:7GF!==77LA.MG.8P&L*/*\>!AGL75PR\E_W
MY+A"S*XRUCP[L\]ZY[NL+=UL/\7F%D']D]?9%NP/NRR"%"ZQA4?8"4]K3;1?
M<M-&ACIP9>UG ;V9&I$S5LN/:[3?/9#UG/,&W[!5LK!'T@3<NE^E+W$6(68B
M_Y(F>EB"364X(6-^T6'_16XH]$I)8LZ5XC-M^#!9F6O:]]UB;SKNBW>9L3'9
MT^$N*X_:U:Y'5U0EE!M+H<>KSLHV7T !@GZYY3T*TU /GLXE%A45$-[V]NJV
ME\P@G6<.2M=R:OI<2O/EA&:=BLI:H.%N=EAIG$M_TGK0JT32!ZH:G=QI^^[@
M)+"ZE)QO0ETEJS#I2BX_I_N,@<8'Z,+.,IDJO:;$]T^T863Z=GXI/'WW08[Z
M*2*VC3=-02V1;_)B7S_62R.N"&WGT"[$@D3WW]G<OUX2\C[@Z7.J%)GJ$$M-
M2;\YSWLJ/?KM%.ENIJ6R]@^>DG3"HJ>Y%#6ZYMHY "%"UNX$[T[J,K/@0+E!
M4HIW 7D>V#9E0T&^H=>^!=8^7> WIK:*>E==H,@ZGS$#!H10\^24PDIP\ #7
M66A40L)^H-R;C+/B1G6$\%N&P"S7XH/!-YH5VD2Y!ZZ"(35=%AS2 _=CZ4?Z
MXE-BLB_?*.F7J)1U4M'6;0JNUFVDEIJ)2BQ5]NCW-L$/#3^#+GWLAINMVN@;
M2]!X!<Y]/@+.;GV-U\T0VX):LKZZEP"_V_F)ZNUG) R$A4;AC]29!=NY@S<]
M CU<WHR,E+-N[C/.B\RSI<;F9.A<"W><;(]<J>H)D4GQFDMVZ(=)*/&X&U=4
MQ;V]H@ZM:*@:. OMTI9:LK794K]E!G$SH%'.K4O6P-;IC&Y25>F*'"SU5QSK
M%K%,&104GNO5F^45A ;[RS *QU]WO-88'9SDZA3;>5$)6L/H$Y@6X2"&$J[L
MXT@9:JH\:]H%T+?JH!.2GW&8^K>38TI!S,,YAT!R(N7CDK?GERTXPX9;%?50
MA %%1':HPA?HHT)9N]D+;[&)G#N$V=4J(@+;SGKD7FIBMZZX_J!5',EYCO^C
M>6M4!"Q]9R#I3.F\/J)S(_43MT*S>.]J#A(\>N%5=M)F89V1;6["%^7P?CUL
M$8(F!;O[!"%WUV88O3<#ZB^EIU*CQ#6JSQ-<<D:E\)R=%6IQ>UK'8V\(EZR2
MNBY;(N" =,3'PF-%\3+:O#*@)JDZ9]^%:Z"G2&-?7GC/:##2WS[V1@^W:6GM
ML !2M=@9^,+BDWMGQ%XT@?-Y!45EOY3=0]DB_#02),\85VQT9=ZRT])$@U1<
MEGM-2HC@MKD\%U*5^.N"1&&(BOHEVMMVKY.HG5!NT/1SQ4W\T7WZ1E4!Y69^
M##X1\D[QGD/9SZK]*(=?V!BD*?)-%0]I\'1ZOC.^P YMYG4P/BO(;3K0@C^?
MI,IJ8HON8J? XE(4I#, YD ?+WG79$D)J#9]*3&9^19M/.X3'AS;Z\RRJV9.
M>ZV5,@U'_<KJV@)?1BW-URQ%R]Z9%F/K*OWOW ;/7CFPC,!-LWA 9P57SE[H
M!9FWRF3,*RRN%_55()/5DPBS[QE3;+"S5/9Q:CEF+.'><M%R:>XL)>=KG*^0
MK^-BXYI;20N5WAUPOWV?N ;W@_/9V'M3I026F%7C.<7#] >P8?J)+/*A5\L4
MIH[<8>I7;.%@CN(8/#TZ RZ"8%[5J /VTJ_8B:ZH+_3!=N2MV^1 DS9I=ZP.
MN.66(9,4(L&79,S2.B./K91##!GAUG#&(]LX0T&:J.?UO'^!]X4';NO8CXAO
M$I92&X&SE6F4Z P%6(?1%^K/2U4Q+XHR/R1UD6-X!;]WF$8V<<GW;OG96%(2
MQ7WZI@D>W&1:[Z(/5/F"UQG,,P0[5LO+&WG#@KQ+&ZO>IB9;SQ23O8-T)CD3
MA<=#)I%G)70?I@WS1%"P1*XICS[XW']OQ &U59BA%:-QVYT 3&"@B 2(+UI>
MD9._MM7L7!O^=G\<E;UD\=;6&F0(:*5EDE(,6<_EW%.,<MJ=5,G.K#=<-DP=
MTE(<T'K2U98:;4K,TR/O\YR3-)NY'NE5Q? IZWHB._F"E<Q5+;876=F.E$HQ
MBH5L6-YRGP[H/]\QY[MT7G19I8D#W2L\KZU(%G%5@UW,P58'WWW 3OD+;D0,
MWQNM9;YT)\'O]V@(5QZ.7!46=&]*M'M?^@:[%IIR4T>-JT4H*ME8^@"?$';%
M]V$]!2F1 H'1W<CN%,K4=RLUT\NM#V":RA2L@HI^,%P_6JGNG*_[RHRLEKU%
MJK[DJ^\R[G]TZ7U]+3UFU"SUXS1KIBLS;5]^J%Z,E-.H 3M7 VE3ZL/EC00<
M+-S6_FSA)P[LJEGSA1+SW%LWI<R@HY)L.>PL=P8R^^.TSL^_;U"[>%_%LFXT
MC4^X7FQ'>NZ\,VK/2-M.JKA%U[A?\B,A-SO;05/9V?M^N#2D(U&L[5@$!.[X
M&EYG%QBYL^Z(TY!CQ>2JL\3&=^HUR5XWK2-_Y?[(X[E;PM N;[[F;=Z=@<ZJ
MQ5Z306/-5M$1;TZVRL^O627GXTKHH'#9>W%GQ=V2%?#MF-4E#5(T"8B3T,PN
M#LKI##&QJ3V3J_'RS0: _?.)8()PN<\K\1/7-[X+%64% #($805U^7C-KBHB
MYRJ1T]>OVYIZ;"861C)&Y@>R/O,[K)T=U\CX&K,VGK@>E)HX6LI2"KT) ;4C
MF?GQAIL9PUY*;@-XH/57%)8LU)3!N_OA<N >*/B-"MX'0)[_R7B],W[= O/%
MJF^[?H=U51JJDIN?88<OIAP14_$L $#6G"#%-+O$NKR\]NT;63!N4LPB?B$>
MLV.['.@-.'BWU1G?8RI??66A^=/!WA)^P&S5[#@^@8*"\D+/:UAKI,?"R^N1
M<J&P^R-/L0"6]F"/]6G) _"XAFI0T-3W;6>RQ,2$\AM)D<P%JP=[@:XLGV\D
MQ7A,J"^,K^S)F:M(='^NL7G%L+$DZS$!+ACN@1W*DT#-X]_2'!P!ZN7))&M:
MG@9<+(.?R!>:60;[-P,LPS0*(K>GJB5W.X,\=CPV#G)4)%H?^I-^J@,M]WAL
M,A<PY:AT29*-MOMYD54U]S3+6_O?"9<\@(7E3VSM3R$6&5E(@8#K!X^. ,0S
M3-0%)-"S!7&29&.#=:N[C^L42)]T)PM9LI M;+ZB4""%X6UXS>:KJ 3 5-23
M=Q*2(D'C<TPA7TEA,GY>LTD[9.5)P<'X[G)A2XSWF74[QE_Z?-E*''W*S,S,
MM%W'S#_E^*4[*08 _(\ ]P/_1*CLQH0*.LS?4SEA LDRGC"!23!H"].A>TF(
MNME9'CBIC,?R>.)4/&3$[1D H'IZ9M=6&/QV$]_)+I*_[]YV_3J[Y2YW\W!J
M;-.;$6H;JD<Q=WV+G%0!+R' 9W4P*#$0[P.]$@\ 6ER?EL&SW@:\OI$E;90J
M(U!J=:X^](L J?S@U#?_Q^TKS  )I&-V-@Y;:N? PE]JDWSW\'V0NK1B9$]S
M79RT<C+S%>40T.SR_NSRVL+2K$9! J8S'[],S0XN,5_,P(S=\N9!P:TC0#XC
M:7M[.5(#B-I7'[F.^H1!GDJ0(O6=5@FD5\("Y ?D678B7S.#7I$ODDX$DS'E
M!7MM>ZV.)ZV.:SB2PGR_;)(QFXQNHK8.W<ACT)$>VXFP0Y9G'F_4\^7=OZV6
MGI.3)UE[S.IE/JG&U2%>L72S=^"3C'NXW=O;7!6&O4K#4(>/E.$Q6??E<5*^
M:[O$54983Z)?^4 J8A(H55M(6YQ?<)9;".-K155Q:[^?R&W6J,]H9.1FH[]!
M;6W:Y*AWW0KMG*L>=3A^-=Z!Z5G;_6S:%-Z2RL/GIN ;.ENM+$M7Y7I(+R4I
MIDW8$71_IN^53?(D5>MT\<;!T3.^/4%@(ID&,C36&V(S>&AY2.R@H805#7"E
MW=)-\F:<CC]?NW,Q<7U5@*.,:3YO<Z25FSZ-9""QG^%C*QNK2P7%P'G':_>A
MUFFMW:'>8?0&%3--1ETFUE$\;VA?V]+P)M6_L7P1QU3WED8KM/X+=U=&VNK
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M8OE8D>&AY(LH1(C+",1I6$Q+-/L$@;#]Z6&PRUAL"W\YSH"2@RZ@E=38!T"
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M.O$/4#3@MZJ/?#^F&,:@4",S9GR5YZ!S 3?II@WTN&& 26NXT%FF6N&.L=*
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M<%MZUCGMY4I! 'L):'+S<>+H5>=7?[9IC4$,(@"E4E.HO2+>1POXXBC+&BH
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MFDE=PMXB?^9A"YM&#W["Q9NH0!$?].453ZC[>P":Z)0?_U'['S1'LV-6SB/
M0E?)^FI&D30E>*0R4@ PKYUI.<MVG:Q/AD'J WGG@R9Y:7\"/**)^-=!K"/0
M!TB^P9JM)D)-4\*[>F9C0Z<;RW]_[LB J4""#Q%5K"-H!FS$ 2BAIIV.$N[0
M^L@LA2'.)%V]B0URZEU4V8 HM_MOM>*=0;30WG*\A1;+GE"YH2U^U@E(Z L
MD<XX>X3XOT((9^CA_0J@%T8IQXPZSTCUCF0T&8:9C JAI/**WX.9)%1;N7T
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MA_"1;>-HJBG2%P2J!?HP SG:2#!WT1OF.=0Z>FWNQ99L"8JGJ,4X,7 DJ?S
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M3C(:K=C-^$I76-H(QN1H*''_93>=O>!=E:I5["HL>=?<#1L3>T"?12LKI"#
MF[6-7DWJNYJ[7E#8[8TQ0L[)F8]8$9QFUE$!;3VV8]Y[Q_**NZ"%:9BM^\,
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M4X&#?!2">P_,3N)8OVH,.R[[@'[2ZQP*PK_-*MB@DY^$*AS5#@5M:\)G"&;
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M\BKH)5\@ MD\"D&4R5"H<(JR'J\\ZZ2*"BXQ5"=C=/!#9?3QDF]!4+\/73;
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M"JS(W:RSR!R]@+]$PEIX9:%&9,CZ)3.4ED[[7-W&GGI[GH":,5K[4>,G\@B
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M#.I*3J[GC+"94\).PS+"1?#P(TV(*#XU^&>&0F:G8"D56^JQM:.6K?,!N$!
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M[!/./OX?(K0D_R]\K=ZWF\16- CGK&Y2!=7Y7VM%\'N^X5'T%=CJ+L/]RS!
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MKC%>=2)$!,U]D2?F'#D"1C&5[SKBA[J9_1$1:%FG:7OW<O,(D7')(S#+Q>W
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MZ+!RYB^1DP%S9FN7OXUSBRX8S=6"#Q>L@[^UHU(*(,]5,1HS0.?I0"._(TF
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MYR%%O6VZ=X2)&@I-]A*KLN$;<?-"(J(SL Z7"E_L;M-C427/92D+0N<L/F"
M\WA6J;)[OV0QJM.ND4\C5DI%V)+S-1'B>,E!6_&P@HZ#'VP\]TUU(0L[>Q<0
MU?:.O.[8_&I%%Z0W[%Y@J\P^T;'QFKMMW/]3'0-4;1.%>4V?MW9,W!@V@\K\
MLVPM7SK-7+9(7R7GXTCGKO4VD'(^4P@D37&8,OZGMP74\DK9G=8D!K2+&!03
MWJ:Y(ILB?)OPD:2,UW?OH*"47< O,/2F "^#1#^@K&H5?/PQ_6(Y\.12K^+O
MVL*L*90,_$@G-A2V(LK$N4VP-!/U@M:@4MRQ"161F*!),A"U*V&<3!N.]=7#
M[ @F'*9G9 <QP(_=<JFSR&9VD/ZB(+-5^5R:SRFKYB!K#T/^D;H>%+8*)OE%
M)^\6%NA2LT%2QDG)],94-%GBTZ1JE'O-Q?R)N\;?C/D4!9A5*X,NI!KDKXN+
M;^@\M&Z_]?HP4#3%#5R4,E==1.%+9&I*XJIUDDH,77.^W3_M9"T#8K\7\@^M
MW&2:GAIRH3G651#]#R .W5G7:+050KO9P+7J^*_:W)H:^!@$=V%'X (*3$X!
M,:=&URTW=NDQ!B/G_5RKI*@I>"-L>;IUPXM$=%H%(%TLQ1RH\.P\Y<_WO?\
MG1CY.M:/^)&7/QKGI#@'I"?6*S;7F;6=HS_+M,!ZK*>]^97E#[\Z R7W\G!,
MB-Y@F1?GQ2+T5UB(+/2V5/!AE&<I>47).;,P03?ZI[TL(Q5=))9[T>5%4/CZ
MT.B6$^-]'\+]M)F!@7JGK2A;-%4U.*_]!ZFM7\_&CP7!,4M.T%F]@*/[Z'JN
M&9#3O551!5EY;E;L';(CR\/Y4A.JX^0TA%B^KI)O)UAYH4J5]<F<'TN'XPN
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M]=51!VT@I?IZ\_U_5[02?'XT<6U[GK!:CTM42<=[B<=S0>W^B(X;'M:O8D[
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MSH^;<;2"4ZEJ(]T:0_KOWE 8-BO.](/@;BF3U<?*")JZ3BWU<U;M:@]D<PL
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MG3"W647GV&JCK9F#\OABA511U$1;UBLMR*RY3",[1WTLS?[6&UFA0SY=M1"
MCV$[6[U@V(W4!,-D/6E,LKGKI7 $,%<RBV*98Z*M(ZU I6975H79VL9;Q!>$
MG^-<R'):#[(,L<XXOX'Y\-LF4QF#DT 337%!9-2*FNW:PDVW!#&@S!@2V)OC
MS*[C^YC;4RS):AM@F>4/U4JWY2\C]EX$7K>^34X@K4YGRSQ\&]P,767#W$>=
M57&1'+KP6I:6A6CPV,,&Y<Y#6H+M/D?F@_\H<,[QRL7NK?E5%^3[!:$126I)
MVL23$8,A.K-N<>,D3VEV;5;MYYS;>^CG<"/;-[3"ENR$$=SGG(IM-COG*]7_
M]*P;D>)IL$A(W=-<!1#@(CQJ^$BXT "I^Z K2AVG6"-:L\FG\/7GQ3"3U84\
ME(MVJL^7A'*31\C_AFY+@X%Y]#Y 08=JGK7Y(;950\XM.06#[/B\E*1X2;"4
MG1EN@J;37B,_D,^-,GD]A1*ASQU'+;J5PU;\A=!4D9?Y%8649[S5VO[!M 1#
MK#.Y LG@DG/F>83G^.,IB8-W<.J$&9NM!4'D1UP#:$\UMNY!"EN!E;(DSOZB
M/8_M!2:HNO@OH$>/-6B-E\+<4FVU3-WD0GFJRYKQ3DQZ0S&:VV-]98X$;S!)
M3I,4+97F1O>E<&P$_&8H3%GZ]HF6#'LF0<*TF9.*?+-T>.U<,LG4)QDV,,J
MWY(V*$86GV$]NR-5>J&/2R4.(IDI\8[)F<\H)ZXT*D\JYLWX<CP>2RO$C2\F
MM4'"5;K=Q@L55\GV 62+0>KLI#"I2G!'5X*R=H3S:#J[T5=OELG!/7G1<17-
MT1H7&<TN//#4=7:?ZUSFG7?VF8&3_?HM[>]M=Q?==5%UU"=)[=ZUYW[B J[P
M9L6 @VR'B%<<U]PGVQ5?AVX(\;@I35LAF\KQSQJ(3<2D@''?4+2""_8+),3)
M_T#3PHVL)T;*-HV<%EJK?#]_7@4>$A]SM7I=J< TD2Z/)"PD4H;+&!TB-EM]
MKIK1J-I-SB;[W_ 2!U8[8+*PR(9<>M@6,>.>P'[);$#G/=9#N0H7ESTI<=1G
MWD685J\;$=$2$_+88ZY5ZA@3.7]*<A9=28WSX6DO746?UJO-7^&/+Z5;RQ:O
M+]PEGZ4M/M#HMLX3"$R-]<P78GN+'QIL%F8G[*)M A80\$>>-=)O!TK .H[N
M;%+A@9-6*YM&E>A]W7VUW:*#3;K-P^_3A&+SE?:Y7,3B>80#3#V._<WB'>.]
M-?0Z406B.Y4K'UIV1R6'E#J)#5M:G#TK1[.2:(4\CHL&+;K>3"]XRDM6FP.Q
M&":JBH93EITZSFK_\T(V'*!.A!W6D.I \9S.Z6H1CG]BH%I .=KWJ_%E4<ED
MY[',W@CQJ5R/UK5+#H_F>F>T#$>\+%0:?V1AS7&>XCC9^31Y<8:I6?+2_8N6
M),>=H4FHS;,_0^!FK0"TZ4N8G.T:D'3;H$UQ)+# N0@U)WL,@*?(;CMS5)VW
M$#-Q6(^#D4-L8P0N@5%,S2@RB-#6Q 0VN8$%?,D=RF%O',G[BR]9:4:)W[74
MJZH+Y7NL@XL)8I!B9W5;R++E$]-FO-@(+-%$;++$5YK+W3F.'JV79<FXXPWB
M:;"$*!/2E']751&$*]?N$_!<-9.?D-M,S>7)M3A70EQ0+2LW<(_9V2)2H8#D
M4"+V_9QR%SNT=06:)S;S-U/W2$@IP;MQ>&DSN%B?]@-9N^*EB]8L)J^GB<)-
M?/CE7"'JJFY.L.MG=8LLFKW(.TG=U+J?5@3[OWOMQN[U-P!IQ4.@M>+3F@5X
MM0(8-+!>9DFE9$@^(OW^N+2H!O<$=_36H3'Y0057ZYSU3R]Q4F"U#11C<CAJ
M>_G+"NPM6S>S'L&),:..'M04B$+*R#^RS) IMC>\/$$43"RZR_K0LL)&.FW8
M6"KHW#J5H5^JKOE62##F)F[9B3Q'M*0MPVURID:Q-"7>[>M-D,4WPE8M.;Z&
M?E<65 [AJI@,/I"\SGZ"0,2MQ*"=RS@#P>W'IF&R736J0A*Z'*U"\NA FZHU
M4W7#%(W]>L,ZZ]46+MW(;WZN=%8<)MDF1M<4/]SOPTW4B-_U.O/#W6%CJ+'H
MUP10*,LK-36E7Y6D<CDRHE%K@CM%/:73.D>;K#-@O7!2J#*U(^$@&VZ$ N.3
M>VQ)RDZJ40R1Q_I0 \>[3Q"<5 X7)2EYXQ9EOT0',ZJ,XF$EENBOE=LT,ZO5
M_&DCC:;[VLJFSBOAW+5%:-]7)F9]\K\:;\5:<*;(!K"7%\/#23#0+W7O_.^S
M5WC#*\O .&C(H+HTK;4(JW3-(6?X9Y(38W*@K!D1MXY'H702:S$"J%HX)2 1
M3/-]N]AD<5S/V3N.J0Z7$KMIN *4$YCDL3&\.D,-'AN5BG"1H-]HJE%<,P4Q
M2/#*<EA9F5'H3+WW;-&/D9]/FX'(ZQ2CB W!BY%L:[2E4+TJ_HTJL[34I$V$
M)4I.5E][B<)[K;7DY-B*_:J9T<3]18;&N9U(VB^':S72(-H)C1.HOQ! H.1]
M9+"QM2-62) 6[+(.P%&,)M-KV9KC*,L78@3F&*OVN7),CM2HCQ!Q"\"8":?P
M(L9* NR,,"(\/C9%$]&>-/:4$7N55:81%/Q,1=NH,<6%T-])?HOZP]VR[J@A
M/*V5^C&A*9UGW,_T/HW15AA8/<_21O::U2*/D,;:9:J%2%CU)FFJ(["0QV;)
MV2M&FR-&..S64$NCVA[##"M96[/V_E6_:N/1J4TF^W:ZL$Z),'PEB3N<OYD9
M:TWZ98_&['MI>MYX6N9/9_:>!QT0BWUCOY(UW,AXWE#Y*LG'VS)%ON?'P1G7
MQB=L_H;Y JZ8Z*;WG2DR5-C7]P)D[$:V6? Q%H#V>7:WOIRR9X>@N3">=6>+
M.AEW%/*D*@0N@%ZTL_/U_H+ Y"JVC0+&U,2E'HPUNNI<I3(V?RM._GNE':&=
M%.>\\W0%][;F<H*Q'^_"A<XKF[U^P[';Y50PA03<^$=/"EI\4ZO ABVS6N P
M#"Q;H!9><H6J</[$"G6!<W9&N$D;+QB<.Z5-3?^96NX<^$O4Q>IUK?P'KW4'
M+XK'#Z>8*S:($E5-E[SB/#L;U+@(>'5:,1B]U0Y*($K%7&I%5(?<XQR[RAU:
M7<2X7S4%333ZUKU!3^20>:"5$X7_"B6JS!,5G>II*U]SX#)[V"]]!%Q.')6J
M<Q[X*45K9(UM3HQF_.?[V:6*>H,4$DOG,A19LWZ^Y&DB?7B"-W:B;1Y%2DXI
MYK%E9DNC8,S1NSJ".FKZ_10.X;..5U7)*$OSOD68[]+4,4SEHW$T#\AIG%*T
M>1<JC_X";&A4_^6KW.1YC! T.% !GT-;G]B<T;IYO6[>VD@X<![-2N0U36%*
MY'098'L2$3:"!M$5\!Q,$;?E@%G^84^554BB57[]RS],)6T&[:?V\ YA7N@&
M"XZ93>-[1"&BW^'EL$V"[H/T0K H$17>EJG+_-GI#W^'TZTE8YVYH5==;/\0
M6)\'3EL&41JBB$RP(W7E%.C%O.Q+J!R&#'3L)6I*)S*,T_&(_7*4_.4?["O0
MQ_3Y=>H+ML4?ROYLN@^:"\'D1-2O7*^"^NOG?[6Z2N]^S%/__E0<_/8!W.^'
M2'O1_0N0E/Z>5Y)8AS9.]^7YX^VYY+._E(NV!'9 SA#3?WUG9P@EMAEJ/Y"(
MA*-82"CC/42,_05\N:6;,?^\UUZ>7O7I\>T?@_9"*K;::8M+.-%?0(3<<P E
M2D->"=ZSO)7;7\#.O4SN<$7!&Q5/IZQU6<KO]1OX/BC6]YW.4DWN ;K[R<M*
M@PVUQ=^IOYBX3WR<7!V^>1K/ _6[RK^;.GD\YU_BH?P7X2[3VUE""OX,4#0?
MU_A>##Y&N) ]AQZZ_[@6.OF=*--?GA_4<_Z0%?$78'Q.<1/R'VD<C]DCZ/L<
M45KD53=R!%0>W<Z#'UP97* !E(>49=(.#U^<$&3P\#A020F_&:77E A_"+*%
MXJD<4Y;TZ%$AP\#C6H7OKL^63K=Y@90GH75=C![KUW[(FEE)2F#^@G/MH)?Q
M>PF-/5]0L^9=:I(^%T$6GKI&H;B.RIK.>.J$##_Q1Y"L]VUU<:IH@7-P#_P,
MM)L4R/BB:/2_;:KYS^A7_SC[97>'U8(MC908@T2TM&%;=2*2N1?4*33Z@]$)
M!X.4RA]*."6:) TB).3'VA+B=2*U8CXU(RD*34LV?=Y/B99BLZ4/FS-Y=;G+
M204&]!$M61)B%I5W/>9>4'X<3M!#X=#9VS496CD\L8=^.__,[;3!>I&J"W/A
MH"!';!1LO1>M>*TJ#354-.9*]6_5AXVFO?EJJ"3G22"CI'+"DAJI/NY!51:1
M=9$I=$6R*"8N'SC"Q;*4(B;6R)PM$2_ZHZ RCYZ14>H7 /?59]'3CE<#*OD'
MM#VOI@V4&^AN@W?W3I;8Z6JVKF%Y[6YO=D1\ <CO?GC92P+P*@^QWC!:?-M+
MI@T2NWIPP/^S].U\YYMGKO(+XFC;4W5Z:]/"J6N5,W'GO:W<%+?M:?%!FF''
M0M49UEGQCRDL&MJ6.5FM4D*L"$)O#PC!D]K4I$.>3;<N*W@UV48M";,F1=EY
M./*-WH'*28!(@&F;Q*F3S>85G%GS;MU:/3><,,4ZB0X+IB<?<8<J#*&'P#>)
MU).<F\9N8C=VB6.\\7M*U+R#D'PV-H_=.K=+<SYS1CE2A[-W::=%,(8%F5)'
M=B0SWJM'&(ZDW:EIB;H=*6O(DO<Z; Y)G:7/INNV"O\%O&GT4VSA0#*#1MKX
MSU%G< G9+1Q@'F@-;3"XC%4PY%BXUQ9W]TS[@,;68#6OE4#DT<S5:1TCK$P&
MZQ-/I(Y\SV2+[M4EC(/W 7!@)8!"$</RT>S1N\WR_6VT@*Q2%I)<*Y[\2E6-
M% KL5V_B)G:"R4LYL <1S=EWQ<(\GT[-C\GN@>ECA\MNK)R^8O"Z=(5=$,=M
MG'=YK?;S+,\E@;=O==9LNJWWX2]#L6Z4(2Y<:@EW,4XF4>XMQ 8,)(JFU!#&
M3B)#Z;+U/@>6(S@8+PK6PC*&"=4;GZI_"IH2SCX AT6<68Q@Z-I-2]?*D$,[
MT7U]$.;D*A0N_:X_I]FM+H.Z]#0*CC*@U]I=4LU6&9ZZ JJ"I'S[V+2VI6%N
M'_0.M.1&6CQ/\=+8WS#7M"H.UY+Y[F(W3S57S_*IIEY]!D+S*HNSR1P3F#OB
MQA9,'+([AWXT'IAIV*<"Q)/ !<+B;>I6$(Z6V0(&*6A!_7LC],S].OJ>_9ZJ
M>\@8=?@[L8'=Y5A/)LZ@P$UR6A8)*@;RN%R%"1:KT)3Q-PF8F&9UK^9GT[]'
MPW]GVV?P(4EN@##EU.[AY/>IER9) Y!1;RJ(^R?N8,^&B&F('I^T&<NGJ.*^
M=-EN %)U=+G!@;'2P-7Q8DO) 8H#E;W&9Y;5W "^3]94HL]9:WFZY[6O4<_K
M['5&$?)'<ENI1N7'YY/8$:D7AEH4&ENN<O+AT85EU.NOU=FD: 9JD!=TKX1&
MFL#U$@1G:8D%2IC,2>*&$OD\/ZH2^4,;=TH^[U;PKOD2I+0)0/.6\PVY$-]Q
M>@:Z'T"VO&T&49J.4[3M'!BKNCK@30Q#%37\/,)9TV2;*015T[:"G^3BK%Y-
M3#P@,'HZE$\:OLUBT'-JB?M"QYX1)3D!E#C+:%&V(&N)SVOT#+-^]UZSW3)S
MJ&.,"9]2<X8<ZO7>"T;!-*U(_R,WCBA2**L-3UT!/JCABLD37+!O F0EP*Z[
M;N=QK* 2'&CMT&9IGLMJRTH^)+TO/N*?*?$WB,$*RYS/R'%8/-3'/8I:%+8E
M'<YQ'*;P3M!WZ-;7*W#3/OVJ*^[\8XFFR+ANQ9F4:6,U@:_8D#\U6P+$HO-
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MW#62)L.@8IW.E=J*2M;OXDS6H!*JPU)[60UK,_BR?<:NF/I&MKOVJY'./Y%
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M+-N5F>KCKZ3&.2*Y7F#;\ ,EF8P]T,4+V@F!?U.(_[Z!L'/_!U!+ P04
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MU^X[/'W4GBRY&%.H:95$A*:-KG*W6A=P0T?BI+$Z5U-EWO)*]8Q%H81C.N)
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M7(@JA0PK0OV>CSVZF$IV%.M*SURL(?3&35W,B/%R%"O_ 5W 2'=/['7)^&-
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MFG*-BMV""A!%:DDR2-*5.M__^#@).M\'LQRVKV+AYP**)B6&STKECZMX\AG
M^2$2*&\GS4K/<Q%2.;(?;C>4[_M<)K]V=YA1W)&WAOLRB6F+A1K-TYG,Q<G%
M;A_)ZGJ.WYK M6DE.9KQTD16I#+5T-Y,F?)"YZ91)\V]ZFG$AKL\^<9FTI//
MMR\YO\JHCK7Z<.WDY!Z>]W3W&]V2+Q=?C*FJ3:K=[!<NT#5J9T:.4_>;Y I1
MU2[VE@HIL(F5&\:^FTBU2G?+2L0?M<2RTV07XZ*,2%5\H:4IPO%Y\'DH8ITB
M?J/U**]U_R*L=OGVU9UCP%JC..:V:=L];,_O!9[\P_ZZ;6&VH] I*^=[BKI;
M>+X/T6,81AWK8J/DI_&LK>K"F*ES.P>PM:O>7RULTXX/ACD78BXKI!'#$RL
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M-JC8M,N9& .TBEN,H5L,!':B!0F?VC\\[2:T1I_C"B\E@4\Z71ECK"BEP4#
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M%BIVG#](?.,N^]2+,]3=->0+GA>W!9C2X_Q^#C97[&Q_6I-5L=I(@)*"LQ(
M=:EG<FK5[OJF:1QM:UG 3JO%,I)J!2S]9B&;'6V\Q[6P.[$ %3M'<* 2FO>?
M1K[:VJ=L2R<]'=M3&=-I*@'8P?24!J54UJZ.KVD&=-X)Y9"<T20X'B&\:Q#C
M,2V^M-(UY.-CNDR>!8,4 ,NH#\S@6DL 'P!R>L#*:39; I#C=2K"LK=%N\9U
M/\R:<FZ9,_3TSQ/EPF(PP?2+CY7J2UOG&/6HY5%*)M/')NEQI:(/64>];WV2
MO$ ??N>\4@#C5_") H4<_LY_P<^HC9BJ:=_"X!@G(7[*GI$ 5B=+PK$3U,WI
MU:0\2*T/XP8?7]>Y_5D)6+7!E\_.:P6IJFVS$J X5@7+ @,RN$<E@+<:%>30
MSCR8$4/'$?83+$B+NQ0E<ZESM?,%>O*:MA0/": %PLMD2%OE/%Q&LA6=>,,(
M_T42;,E#QC+@17$5["]W+!>]T+25,F34NSV*Y%9@)WI"X<'C[.&((O$OQ2XY
MK^ZD(_C68V @I.?;N$-03I.KE"VW/U>XNJ>B(#W!LAZ%'9@3J:_HY]YKL$CR
MRN\1AWS9^[)\8*2(W^U).238G^>4($P+H98KSPHQLIF<7WM1#DT_EYH12(FQ
M>Q/&N\;'%'+^Z)]?T;%1>P8.O2L5IE,NS"H.RZ3>JR;WU#OC[$<(D6//-='S
MQWPM:6_(F9=7KOXN\B5^4IS0GC-TYT8<7Z[2A2Q(D[O)&!Z.&$TYBC;GT(+1
M71M&&HPDP)7Q9"R#$XB7,ZYJCD/HLL6-=1+ GC>?V075IRTCBNQNM-3YY_#A
M6Y=K>2=<%BUT68H0D#%0*&< 4 1540AQ-,DV8S5/GQ6Q,+. ,(\]N"N3*P$\
M1%K2(#@G-22=KF-MHBOM:.V$NHQ?:'Q^3YSV:42IBH(_3#U5^@;PUZDH7(KT
MOH#8'),L#6J;)*C5,HG\1X+!(HNUM^XW64PCAA4J7?:IY69"P'8Y".C&H 0A
MD7Z<XKM$!(G>Z<N1)74QE>36L8P"R<PK X<*^R?(;9"!MJU7\01A,@*KF09#
M:_(C=B\AL_O#%]J<'$UMN&D82J6UR4GS1,[)=8BHFF#8-N8<LT7_N%K\_Y!E
M $!#POH;4$L#!!0    ( ,N+>UB6;)*2F*@  '\+ 0 1    9S<U.3,W,&<P
M,&$Q,BYJ<&?LO0=4DUGS/_[015"D*B!%JI2 ] X* H8J7?I2 @1( B'TMKIB
MHTD7$%BEB33I'5:1WJ27@ @(2.^]_1/LN_N^W^_WW??\SOF?PVB2>^?.S&?N
MS-Q[GR<\Z-' T0?@G(H26 G P<'%\<3Q!("C!=:S-^T0*(2+'<*)68CO"B N
M#U;'QP<PQ+):_5#I>Q> 7L0Q O#HV96_?>(" .;O1=R;P"DD4E!"6%A<["(N
M 7!5'6J%1+@@;%#,!@BD-3.(6<<*Z@CQP#1N(EQ0S(HV-A K%-0-PGP-!H%;
M8UXH9@T$GP"S)M("!K%FUOGL!/LQZCG/5DN$L7KH[11P.\1%J-+H>$SR>&P2
M.XYYX1SW2)R04#A*TQ7EY(K"= FPO)LN*!U+!,+Q6 (,1T$@<%?8US;V4\$1
MB>V3'>OJ0#VP$O)0%%;GNTT(4@/CF*[B+=UO8)\5;B(1"!L=",K52=/2W@K#
M)@5N D@ @?EC S #.@ $0 &N@-.QRFFG;])?S<@[HN!?/"*U=(4ZHJ#P8Y.8
M/O&QM(*ZH>KG:$AAY7%!/\V8XH<9:SJAH BX"X9[_GA>3BCXUTE@)FF)_-;1
MMG51_SZ"A"M\[\!1WSMJEHXNWSH:MBBW;QU%F./U;QU,'+^;EK=RL/T2B,\.
M MK*\@J8#[SCMC4SLS7"U?(JX@/PE921\+_PY!W_*B>/M-;5@Z.46+4=4< /
M).]HS?QW?&T71]0Q_Z:'XU53^-[5S^S3;IC"0R"O6Z LOE7%3=N;+E^K MO^
M\JEP' 2(#>KOS.MB%LO?\76L'#_S;R*MKAI^8Y_#+ <G SL()KF8?$'AME\C
M=A8[H(WQ21Z!0B%@C@BX[1<5TJ\C6!=^X)_YRM>&VMK].$#R=0#CVS<VMG+P
M%C[[@%=S*()9KCA?/X^KBN-X[.SW&<C]^D5K]7/ ,%O$,7WFXI\YYF+W X_C
M/NVW/N.QUMIQG_BK-9QC+<YS7VSA?&4?RVX<MV\ _#8VF!%'S#OA%Z7/G&>Q
M<=\X@L?O1ICWKQR1XW?0=\ZQS>WCMM-7K_],>)^PP__]L>-8G/H<YV._ -RK
MGU]?QAB_Q>ESGP[;PA/YYOWG*:QC=$R^A>ZO] ,/*X>5_Y<"W^C[=@' 71VQ
M98>+A;5$N,*M7?ZT6JU0 E_=Q);X#^4%_*D. ?EO]?K9#>UOY7@\!4(71Z@5
MQ$7?40V[H'!^PB$X'L,T*# OHN,.^/H/MHELD0A7IY]8A @DU!;Z;:]4U,$J
M:1[S,/TS%JXHA#($#D%:H"#6Q]Y[.GW=ZD]_%L9RL"-@F"WS_X/YX[DB'7\Z
M,(Z#_S-'W<7VYT.%T,(1I6MA^Q/OK!4$HP?Q0(%=;NBJJWW=MDY]9?\D3&R'
M0'I=<X3:?HT4V>?)W_C*QD;7&F)CX7J\;Q&[09"HOQ'7_\K^69S$TE8!X8A
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M'@*WEF%Q9Y&3/4(#"@#./R2LD7]J ^?H#X#\%,X3G 4\''( EQP'CQSGZ"W
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MZ*A(;Q)Z0J]20N_U=<\]]]YS[WGON67^SB_YY#O/S#PS\YWYM;H(4GS>WQL
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M<C@BIR5G!0BK_1'=DFL94+.;S_[R?["+82OG283O.</,6VFQN[0?A,6A4]3
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M*7N_/<3]_)?_/JXUML[]]6;ZH9HY=]OMWJ(C'M%_ [9C8Z69Q9KOD1AL:R,
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MV>_.&6+K>%(GBL:A:32(4KO1I%02S?WX@)]0JU1)\G_ZAO(5R>X4!Y-JD?%
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MGO?N(0"U?B1FY+OVUXCPIT2(G#/\[4[4&0[X58FS6L%5^+CQSPE]8]'YT@;
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M1W[T^\$QS;G38,OV/)=JT^J& LI$6<(USC9'T#QJ27^6 -%U["II =V2?%U
M MQUQ[\"?\!?H93NVBQ6#O5DD480@^.]5EL*&*!<GJB2#$(/WM%]*I:JV3WJ
MK(, HYV7O'0PUO1S:(24S7.6@$,&OBU.5%5]X.^W]'H.&2165Z-_.;N]1VU8
M_*08$Z.Q@Z$<-TTS\%!4P%X0&AVY\;FZ-@VB](9SU9CDFS-#/Q*]7DK/O/LS
M0&XFU#>7+X"9?/19E?)0ZO["J)%%FJ0#:;QAQ+YJM%28D.@:_3,C) L_<7P1
MDI@ E$>M>7OM+1*=^V9.@D:GZ".5L2(Q;I#C.4'.6GGUJ7XG;O5+R:TYSTOL
M8O.4O.(-Z*.W&?QY9Z^L.\^+!PRD]G,=,BQ\"1M-#\6@H<?J.S/@?VU/D^5&
M2&==JX=<VFP%#E149VW&2JJEWP6MS]&\D_I5'^5A%VO0U_.^G4?VKKP(8V\O
M2&,5GRA+R4]W485&$VXOQ,7&.%U/LC>\J)VC.\%T 7DIPT7H_OU%= PU(&F]
M/")V3[/[%A$_VFM/!,JA1+<[A$_><T])03379PWY]&@M(*SU;5997E(7-Q1T
MW!"GS\>8)^>A9Q^?K$.AZ@/?@--/'Y#[G7OHU/VQA_L[:U,*.CI>]/,<O/[U
MQ63]UE68W_[47=#W];$=W[;<(XF4EHZD[Z 7+51M$A.H!BM'#MG&2>>%GMYU
MSF.K.=+<A:/QO)56#?\"#$+VRV61&)U'&*JT>^(1F N8[3"AV]R[1"4^9]&T
M/W3>138(I%,/&>J_G*31S>JOJQX; +G7>=/KR<'2B:/EP7OV2(6C^T>0LC77
M*\BA9CO#+.CY%]QFZ\,L%.$OS>MQU'VO.7L\^<Y3JXL;LM5I4;6 ::VF99/L
M^F>R+L9Q!D-8\_/?*SNT2Y#W\9_$)NJ;AN.1&JA;HOI3=U,IWP8A6:3?%@-6
M:OIWPR(N+YV*HVIJ#D;ACXQ^>)^CWPE:6]]O-G+A1!J=N?.G>D0,M77F&-<?
MZ4>X5J-G#<]N[XJ^Z?V3Y6Y-6YW:HU#V_FSJA!X2Z82Y+IX<0M/BX/6)W_>/
M7,!L13F@,9TGZ07M?QAQO=3OQDKO6_N9 <H[RW6,IME(*OZ00?;+#_._K<1C
M=/%T$CJ]DB$WS_4/N'2.+>>ET$)R\HX4)>E('T?P7] E]8HGH!JS"$6B0'JK
MG@G;=-V"4E&1LHF;$@,+PA1>I] *[8V 9 R<$SSO$OFE+N]74?]^DW(?!6=?
MD'U!\;Y/F>?G@AL7-[0;OQ<\!3_?X?(XRX/L+;UU@VF$7J,5>2KIKX6TT/W"
MN]Y69OIL/42?I4N(&:.]@)?"L)?'?^5NG:OJ+Y@U-'W=3'WR _-E&)F;NLL*
M?.[, 'Y*-;^Y]_8;9ZK.4Z(CQA(BXVI7<.V^23(SY<I/14O.?D+#A/D8S->?
MCUP+]N1-8;&K.>^?E8DV_O3 H6R8-7C8MNRB8\4PJW+LS9^XU=7"+, .ID')
M$Z-A;/J8R6E+-4W%D\8A*X]4M7VCJ'D#HN5Q29&D8LDE@BO>;#.VZ%-&7&81
M6*#Y-%J"GRACW0O.:NB1R-PS)^Q?"!JNJ,+:]I)$)T<)<-:_!#6<ND6LHY8*
MG6'Q(UP.;2_9Y04[63JW%OG1>AI[@7R_9#:C4RWZ(<.WKF24U6*R D6RL@L_
M.2B7XXJFN,%?+#06TW*LU'S.-=F^KUVUEQ-/@R\C E<)PB%U">TTCH0^$47K
M#=.V*$M@6Q77+="=W38PX.ZQ"S[U\A]5&7\@,APR*!HE*6AJ78B"52D/EQ3\
M^MYF(Q\MJH*=RS8:4<O*+&KY )$=NGA](3E(50_Z4_])L7.HRGF/J2*-2.DI
M/L]E>R.; !FRZW33&Z?MKP%*S,-;4J^60*=%>J[,@?!FWY!W_RSO1B;8P8Y8
M5C':.D;LV8/?Y4*;6SYJ'AM;!XK.#V:6BPR/0C$V[V6@]J.GH351YJP?ST-L
MJK.X3[TV("B'NR0[B7H^C<]A;G1I%EOKZ%$JU@.XHY.QLU-+:&>CY$]_B2!.
MMOC'^9NZQ=G(<KCK%OXD<S&KF.6523#8\<>EH(\E.J&*IWCPZMI103S6L!HH
M5 0X3')WAC#T4\?3/2J3 F1.G^AKL9RX!-&9G"LMJ<(&J2U_%718/+L(-F#;
MF% M2:+,<PS!)'6S;P::G$O.<WPMWF!L>SO;R]X:78-.ZNVIVH:'. (0%0AX
M!.6X\S,IZ*W$_+^EK/S6E,C)!/'H\O@H_41:P/9+IC^=2#KQT!^WM>4M0V]<
MWG,<YC96' MX5FQNL9)W3U4_RVY!%JJ9S@TNL<4H\*F(9!4ZU;UFIY<1PJG"
M)?8&+H(^@#)D+EOK+V"_T.WJ".@4R02QH0G4V]372-;$OI^]E*>U9W8^J6MH
M1659?(6VN C?@ B!^KY;WOC+VM2K:*U7P(@N$_VC,$X-FR&^BK,Y=:<4%_<(
MC6/W%D[IXN9M5+W>M#>).MA9IR\P7^J?0(U7-HD\,YMT<TSK7&+WH9A>;FHJ
M-3?L"BQ4RX]M2IL(R<D&^YPY\ZU@).+K0UB,@5DM=_GE:8CG? ZQ_A)!:+XC
MS,B-[ZHKL,8<\F/S*I/(GU^'L:9<.J27K=U[1.."0-8&=050SLYRR(#/X)X2
MXNWU)'AJNE7W?12 %E&WE,1DQ:"PZ3Q\GTB. 4SF_$<L"DF]\Y;BTA<W3PY6
M\*PL>Q$YAT05?S)[_;[_FYWYBG<'@%?WOI^7*?23BB(.ER^E)0:!+D1FAAG#
M5O*'7,=3/^O7N+ \,7*NK*&$AL.<$*B:O2RB$:CO,W1 ["]A1DA],"T(4,9?
M*C?*"W686S_R-KA]=HK*2+7A;5%5 R5^B0DDSX3GK?JB<3+\<AJ!'2#QOC:N
M=(6+:YT5F3K>A-,<40]>STTIR'>(.JBT+3TOORAGPQOUC(U*Z/_Q3'I5T!-.
MWT*2@4<MJV;#A!RP.5M>9I*_6DI]N5W2JS8I=*2T?AM*#%JVM_JL#NR'^ 7K
M&_MU$TQ]R/,VDWNR_#9_,1 .RF*8UK:J?/&^RM-*BAR<5\\2^:UW)$KF:H6B
M>L %SD7EK"89+@<;V,>T*FNK5\9AEY+UUI;M%KXJRLB-FEU1/V1X=\CPT*!9
M)\:@0[YPM)ND>25+R_([U8B7.=CJJC5'I+6GP6" C^CN?(X1P%]?1I8G:>!.
M:Z;' ,1D5+I7,#]O@<E9AF6WA'"=9F.>N-\_>ZE4VVMJ-6/:3P02I7,V5->"
MO(1W]/*3+UJJ,3%V'8/$Z[7TLBE;J:OKIO&@3C=8J:1^*_OX7 &K789$PL/#
M/JL$&\Z5UJF<^;T*KU^Z0^K@*5"_2/QZQUL?H_U:S#0C/$S1C9;VC6UV8??6
M/]+OA-NK:W+RVCX\$+HL^B1./N.SCM[U*-=GVF\Y?$I4.Y.DF$_!<7)!"3=A
M;37_%E)&O='1,Z.@?A82&JN7:?"U_S:N$DYI5<-;+>5>=3S[;IQ]P JC6\Z"
M4JTO4ABV*IL2+J^ =[[\UP!0(/0EJ>8IPXGEE\*&A05A@LISWVZH)M_N([O]
M$L:!TH[@44Z;>T>T]=@$.X 7]0O#'"O.#MG#UG"TU8F'<:NP #B\@]S18K;K
M0SN]^@NK+@.M]D^CGQ$0,-8-RA:ZC[35UE7.0@D"8^-XMF^!HQ.O'A%G:]L)
M^S-UC [NRD5!K*=4MA<F&L([#><F%/J_=/SD6+9B;0T7 '9N*SX]^]>PV]"P
M7X]83*KH_PR\Y9+=/5/\AM/^NNUHD/^C>+)SA%SZF4HO8(\EL,D(*B=4R'69
MM'.!.M[6@@V9<.61 AY8<OKJ*/<:(Y>!]DAV#2:>DO@14YCT*Q@/^#DR@[=7
M66TP[)F\R005;N['IJ\^!+S"2*J\]M._CK.-"<:[PI<GHWT,$<X5!Q\R#AE$
M>Y:F5TX<GV?KZ)N _8T<OG,*5%V3=GMCGVZ<-7,*TV-8[7F3-4 YIX8@;+HE
M]:JC$LM41?DUUU]<,$D&:,<F@5-"H-X]FVETP_B1N59X(H23?.SVO^\F1EH/
MQI^-A.UV*T433+$&:(2E#'#*-PQAH\/ZBLB=JZS2V^M\W99-#Q6.L6=;('*'
MHFI]-)YI50AFT9+ZH>#6ABW/#L6T*WSDD9H2"-+(Q8B8;.3>(78],F6WA$]^
M"DMCE59+],8\:_#]NFO[:Y1=AR%3TZ-<5\_'VHZH;(P7I^\XH+*VN_RZP",U
M@$JU04WE)R%>,M7 G"M1SXL'2W0LE/8E\.5A>1"JT  \$/HF!3KE,0CT][?W
M.M]GZ<Z&A%D;+H6B*GZ^K)%XU[\Y1I3\2&WS5KN)7BZ@2A7_U56&6QT-6YKD
MBRWJ,ZC&B<A+UU]DC4V[V:<I:VMW%$%IH#G,X"*J'K ^:ZMA'?>"/-026K87
MJ-,AZMN)>5Q4/,><%#O\BRL 9C%5T3!_<]O!N%G*_'JRTW74CYL0R<V(7B:0
M7?K\EHO=*GW6ST08[V&TAEN42 [+R4S>B@29L6C"LI=6L >%97U9.; 'P?/=
M F]J(\S!T6_'+]Z2\./>%*[IL;$V,*!B!J2G8Z0>$VX6,"U4\)@U>,^J^2?R
M]O7@*QY5YU!(I1H> !OXZ'5"&"3BH"W<RU+JJM2JE*.,;9$17V%A7+SU@^OS
MJ$^)6@8OQ]=7W4-+/*U&4DM%=8?]IJL@]N_P5KVB=@-/08*A84P>\3O[C_4N
MZ_\,&Y"1J>R]&K]^,12PS*'67#N8G]OE9=(C!>\5(3X)<QYQ'C&5WQP@R:2>
M"30K.8A>DN,W?:\U];-':*"FL\"=G&DV&?N(F2<V=662"\OHR2&M/&5#C,.P
MI-Z "_NO(N)M/R?' 1@^%F#2XFWKKF@=@*SCXG;B8I-JO%Q#1XS,-G#&I(MU
M ? +W[*X6%B6BQ-9TFBY57Z'#!"'4+-"5T]J6UNRK503Y=3+_VP!)XK40/-E
MC>N-Z#7OE/3QM5_/&HSWT$ 76+<PQ[FJC#[U8U<O=F 7#EJ/#\5M_#-;];_1
MQ_BC5^ *G)]A,-X^I\5Y,H*#7\(%Q00K 1=4#%DC(1>NLK"X.%A;*4-?*PMF
M(DV+XHWYX%79Z:<G+BBLO%3=;^<E8[W$E-SM)L1F(OL4PG>=;!;#MV=T4HEU
M**",W"8UX:;]'G6R<Y]73#,Y]/ZU>]C]C]EEK EM2.MR%I:"+IZ'G3W1+-XG
MR/EF[<.^\PA1;''M$KJ[G5Y"32SZ]JQR2XQ=5_TY<TN88(,C,O,3?O.<DM6J
MN41E1+7]BB&ZSDGQ4SA*&#";YL(/D"X<V#;6(H 5IQ?368TU<P8B%VOSS>M(
M'I*L;Z_*7[\S!-%K[E\K>XV4#N\RO<8WD!3>B;<=[.SL\>]4*RFO-EF=\>%_
MHE$B;J&PT]8NI^QOW:)2BP-TMG6&=\ <LJ^PM9Q96);R7!GQ.8!7>;!!3"3L
MC8=,0)CV@>X=F<H@YHAEQ8>RK#!#R_EX=YR/NJGLO$[R L]0:] ^J=#@9])K
M<N@[U"/E:$&Y\Y*D!-PSF%5!06%<%2^R'A!0"TPLB78P\5=,OW]2_;\L@-_.
M!Y?5F:]+<ZX2^4[\UOOJ]_QIO<G]#D6EH;8C3Y2B8O@W]/YWB6#E)P1:E^82
MD#\*[4#KQ_UI_Z@U2%ESW>[4I,XMKT$6_L[W^^\2\Y];XOK@7#'- 6?;1T?9
M1F,O3%T];U:8?,@0 *C:J].@>5]]^G\VZU]*C.YECV\HNA0*C3^JL#:MN"7K
M%F'[H$/#NDP@OL+8B_A6\0?1T42'9Q3JA.9R#ZX^/NB0 3$/1YT=_SY_PH.
MH[WY_X3[;6>-XY A>R,+]$8UBY%@_K]G]P_2![WH">WOZC@XWUV!PO]/.-<Y
M>F,]I4XW:&V.\K)Z<>H_<O6(F/WSAPR]N]I7&C-[3RZB_\+2Z) EN4,&C6DU
M\_-1:F>/=S&/6>+H$?^*]@'D%*!Y\&Z5!HJ["9=5N"%2O:OT^?\)YWK(,)O9
MN/)?)?V_X?X-KS\  O\!T/;NG=$]<\'[.^Z^=Z$>&XAGOW'K])4_@?=O6/YO
MV.V_B]#QINM_DZL%*#JI59(TI9J,'+;X<C\%IES&NC/+W]=DBN$63XRG!=^]
M/P"1']X!*3B['0[]#U!+ P04    " #+BWM8E[HS*:[)  !P*0$ $0   &<W
M-3DS-S!G,#!A,3,N:G!G[+P'6!1+LS\\RY)SSF')2<*207*0(" 9!%3"+K"$
MW659DI$D.0<)DB0+HH!D44D2E8Q*DBR@@@03HO(!'CUZ]+SWOO<]]S[?_WDH
MF)WIZJKZ55?7]/1LS\[NT]T9@%+OF.XQ  3" ?F#_ %@=Y6)UL@%A45YN:#0
M$$E1<4!.7=< %Q?8(\8/]QP3_RP""%:0-0!FX=7^OL<!@+U_5APC@!"#D9"7
MDI*39<7! U0-$(X8E!?*"0NQ1&%@$!&(J2/"'>ZW=V"$\L)"M)R<X(Y8A \<
MHN8!1\+V-BS$$"4*A9S V'O 81#3KT[P'J!2^C]T0-D8Q 46Z/;!O22;K _J
M% [J%O?K]S;008D$C4$@L2>\L6AO[%X1;Y]GY(4U=4"AW \D=)%8.!SI[?'M
M>'^OX8[9+U,<Z)HB_/8EU!'8?9T_;<(QAGN.F6E9F7T'^ZI@A$&AG$SA6&_T
M"0=7QSTV*6 $8 #4WI\3  %, 3B !;P!]($*,?J[]#<SZNY8Y!\>D3IX(]RQ
M".2!R;TRT8&TAL')XU^C<71?'D?DIQ93_]#B$V@L H7TVN,R'+0+C45^:\1>
M(QTPWPLFSEX&?]9@D!I_%I#8/POZ#NY>WPN&SEB?[P4M#W?-[X6]./YI6MW1
MS?F/0'QU$##15M?8VX$/CF$0" SE[:"*F@&^D38&^0M/W?U7.74,S,P<B3W&
M;>*.!7X@=7<8Y'=\$R]W[ '?R,]=U4[U&YO89R_Q4!A->ZS]]ZPP<C;R^I85
M^\=_[#4.@@!WPO[.O-G>R?([OJFC^U>^$<91]>1W-N7>Z8"V=('O=>Y>?R&0
MSM\B1KY?8;+GDSH*BT5YN*.0SG^HD'ZKV7?A!S[9-[X)PMGEQPJ2;Q5[OGUG
M[V<.>/6K#^#[7Z3W3E?0M_U!5O$=U)'_V0*5@#^T-K\&;&^(.*"O7%RR ^[^
M>.!W4&;Z7F8_T-HZ*!-]LP8ZT.*G_,,6Z!O[0/;MP;$.(.;DM%?COO>)_X?2
M5\ZU](SO'(F#3^N]SV\<Z8-/D3\Y!S8_'!RCOWG]5P(O[U?_\W4'L2#\&N<#
MOP <U:_;'W7LW^/TM<R\?P26_N[]UR9T[>G8? _=K_0#;U]N7_YO!;[3G\,%
M@/1VWT\[G'U8!Y0W$N;UE[/5$0O]YN9^BO^07L!?\A!0_YZO7]TP^9Z.!TW
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M^81>*:KM>/S\G:RVI;-O6&IQ7>>3I?=4  [.GK>X!SX1X.-)'[C ":7&W?/
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MTB$=TB$=TB$=TB']']#NK-J*"Q:+5A 30WJ)VN_?_(LZHCS$_.S18E!1<3%
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M#.7H]S4X[HB_N"CVJX^*8K]ISGX3';_F[F\::0KW_+M&*G];H_U7#ORL?^#
MKV#[+CBA,![V6&6$A[TS7 R.]G(ZD/V#^T^GP=Y)8F#PKX<4#P^QWVEZ8;5\
ML/]:TVO_:VLQ$[@7RAOC"-?RV>M'[M^;,H'_S:GT>U-[XMQ_'>D,#!1TD5Y8
M>^3^FH?R'D,4@8 I:$(UCLFI24$EM;34M;2@4#5I*74MJ(2ZA)J\A)26A.3!
M,/&SZB]F-5&.WOLY^(=9V)Y9"0TY<0UY<2U)]7]M]@?57\Q^762Q=_\/S/_&
MQ"\P.GM## KC_^]E]$':H.TQ7@>K.TI<WP+/]8O"OLY!*BC8.QXDHI>]#QRF
M*/83[^^5$+]VV7_=^%]4_]Z^KPL<^9>+!%1& 2KU[2+Q@]3?&]D?J7SM,7 U
MY[T8_U=7P-^I_+UI1Y>]L1$.4Q;[IOB-\4O'_'9H^?])CVG^[_>8[&&/_=D[
MCBCD_@+CO]%K>SA[ETXL'..E[(1!>4#LT6AWA*/]OI:8#Q+VQXB+_AXB+ KR
MXP7H%R/_AXV%P3&(?R=!?_#R>YP@_Z\U^C\_)[4.S\G_MT;1_WJJ\I_UV$\W
M1_^/]]COI]1_-^'Y-H_[.I <VQ\*_GO]K'@P,_V?7O+^HOH[R[#_R=SO%]7?
M64;])[/+OS7Q:[1_".H_?X/]+=?^YC;[6_6OWWQ\KU(X>'S&  6#*TLIBOV.
M_2^=_LHUT3RF3+S7X&]?,OTNK_]Y.@0Y!#D$.00Y!#D$.00Y!#D$.00Y!#D$
M.00Y!#D$.00Y!#D$.00Y!#D$.00Y!#D$.00Y!#D$.00Y!#D$.00Y!#D$.00Y
M!#D$.00Y!#D$.00Y!#D$.00Y!#D$.03YAT&(_WQM QP)4^+RY5)1WIT - #0
M?TC[1OY3&Z"#-SJ"C$%WP2"J;V]T; ?8 1  P@6#?GBS*R$(#Y\ !TR$2[Q7
M[T0) 'A@'# ./@DQ(0$YF @ [;_-$<"G(N DI(;2J-'2<1G;)Q%)FYI[>@56
M5@^-T#-R2V 34J\]7F?@X964L_)IX5/7,@FMV1"0DM'0M,0D7JFJ'1R=97+L
MX)?5-KL<EI+7OH?#NN<!#@[XQQ?,[K\G<O^UD7NU&E3[)3 >/AX.'A@,Q@4#
M7U_:B(L'Q:=6,[8GH/$,3!CDNE;9LDXK0<>M/KLA:>) 2!_$HX%AD#(;,D],
M_OFMBY]?I8]$5AE:2^/#N&',@GTS#/*QSLI46</4R4!N.$A5E0"'6XMA=HMC
M4JSXBM<4UV>;6[=,D=HCYWBWXS36,F]GKS"\F+IPUB;A+7OW1<>!G>(C2XU:
M'^O.G+ZR<$&[ZDS:&^657OFUA(OE3YX4-G 8OTI]KD31B.D[5W"FS/OMRJ&A
M0T.'AOZ/#97P9E)RM&J]X?CPH^J+RCY:GP=T3W"H3-/MY'C',41)5BN$J8IM
M/9 T0B!6@]MX^T7QUJ"WU+LUTTV=6^F?J4XO1VCJ<1E3AR=KYO%2"?QC!2UX
MV+O*^QV*'QW>\I_A^XP36'SU7B'SJJP0NU/E&<F/[&S:D[GS Y^#[IH)_F_
M:^8)'U&IB?D"71IFN*ZP+;M,2Z8X]58H1NE.RANI2- ;.XZP?HVVW)UDYAR.
M"LO&RX*:MKBJN3B</4Q4TRROE !<K^P9LL^TFG2$; ;K[D<_,9)]FN,<D&6K
MR^.75^FC4'F]L_VI3=,VH!D9G-,_O?4I!0A&1]8(_).MH+O",=ZQ"S!NK42-
M9)V_^H88/QOY,>58]E3/15VZ+942DUM8S3RQK/XMOI8=2;O)8D @@JS+#AS
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MAOL:,PCM77!P5951_9KF>SI&!/)OR FDM,Z$?K=A877)C>638W^1F(GW)FI
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M/B,9]&FT8O*TX,WL-_%R'/7AFW6QMW/\-BCGV]I:57A$KYP%%[H/2JA@8MA
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MR8S"ZS1]GUPPPQ_ MG\3F9A[LOB/(O>"I3<> ETE9P(S('UQ*E#>1E)O';\
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M\94@:'=2L]PTC?JI#\AONI!_@=07T'FJ,QV1).\K:HG)!CFMN:O5W@*T3//
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ML9\754.PU*M1&VK>2U+FG%,. 0;;X!@*]C2_3 >4.P4 '\"D+HFJ4<E9:1Q
M-W&3"D"?.?2)FIV2;,&G $(1OYK[G\:0VY.YWX6/Z.V5*8$#>O=2#O'#;QS-
MVC%X&?=^OI]T@$U<%H)A(GT"C0BM]/JSB(\:M!YHYCZHOT,'P]@C+[![>$0
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M\,*-^+@#KH)^]D+CC:[U1F+UDV.]Z6*G\ ^O<8N<Y4&ZH^A"^PK[(F@;#[&
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MWJ#Z4&AVG,8\*$&^@\TX9A<7T^W+X^+2G6)A[R]E9&/8J/>_FH)H&_YE\O6
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M40;X8B>Y(_=JL]-_07X+ML]9DL)U#P"Y4"6Q:!1=8K+ UF.#670-3[M<PXS
M@%?=D_WE16V.('^9X8-?G!%-^<<_/JX[:O+\FXGCNO ^T$\.+"3X;Z#,&>(3
M@JEEF(+]'BUX2 C;-\4SW:LQUUZWXX_;,KXL2&X2YGQQ:#H:<U3ZN33R ]U
MR*>W6\KWJQ5-!O\ZZ_7L1NEM;Y,%-#.:@B'#D RA2*PK",\ZU(E# X_P*\B,
M\FOH PAL:]?\!W9;%^F80)$JCDC(.&"FK./^>D4CK*[[10JWGT:<T"!6&9ZF
M*RS2Y4\%GV9'DF#P.F8\F=AZ=W2Z'3OM^KML7BQO!*FB4#0N>WF-A,)XAES*
MX]Q30?N;X@T) "+I+39E'42YQ8G&L> ';4'$ Q%U(I:IK!O]F[!Z2[7V5E(.
MRN:8]^JGRQZ'8B0W:^G<R2&U?TA"UX?;HMV\H=\-_>>[LXI?:&B)<@GZ3,I8
ML<P>*:LRZ\5J^?#CZAP+3 (1RC/FJ9LI,VZ=*2^0G8E.9M^%;*TER50[@;Z
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MCV@)]>:&/F ;+Y>ATK13L46KG0JEZ+/RXLD1ID-3H7T3N)54C&F7]O-M*;A
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M^OZ3R6WS>PFKD]5!CN:7\IGU<;.SY!EBM_,#CN N..%I%O$ ,S!FYP26(=^
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M"\;;.?P5)<=86)B7W6:[R2#E?E) 4&.*N0P'PX/RXY-[=S&4RC7(S\Y26K'
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M/_76V,T+XX5V\T*RB@F) -*J.@9X> "VG1I^Z.;\6Q> ,8&L =S37%J_CC@
M@/UCPC$&B% H41EQ<6DI)AQ\0-D YH3R0GNY8%C/>:&<605939U@<*@_]L38
M"XUAU7!Q@3IA8+Y05A5/*,(9^\:P&GH)@5F-4 Z>4&=6T^]&<!VA4EX<=/0Z
M;Q ;E*\S!$6+W;<^&I,]&EL^',>^04<]4B0*AL 8^6"0/AAL%_^09HS&F#IZ
M><&/.'00&"@4X>/Y\_SPJ 9''?9/',F:POP/.51AF$.9WW1"4898P\PT+,U^
M@7T7,$9Y>;F80C$^2"-'=R<LF0PP!E" %_;E K "I@ 4P  ^ /)(A 3YB_NG
M&E4X!O'#(C)''Q@< T,<J<3VB8^XU0RL]+Y[0^Z0'T?P#S.F_MV,C9 8F!<"
MC:4R',T+B4'\G 1VDHZH7QV(*]K@MQ$40NVW#@+S6T??$8[^U3%TQ?C^ZFAX
MPM5_=;!^_$VUJI.'ZP]'?#<0@&BIJF$/N$?GSJRLSEX^CLI>SX&?30N%^ M-
M%?Y7/E64LYDY J/) 8%C@-\U5;@SZ]_1(6@XYHAN[ ]7MCSWKNT[F<07FWA>
M*'4'C,.OK#!V-4;_S(K#\Q]'M2,G0%TP?Z?>#+M8_HYNZ@3_3C=&.2E;_2)3
M8I<#\IP;%!M<;+Q@"->?'J,X'(!@;5+UPF"\/.%>"-<?(F0_1PY-^!V=_"<=
M G-U^_T Z<\!K&V_R(>9@[O^W0;<UF\2V.4*^GD\RBKNHS&*WV:@%/A#:N>[
MP[ EXJA]I^*1'U$/ZX'_4?_DKS[+D=3N49_XIS;0D=19RA^Z0#_)1[S[1^?:
M@+"+"W8$COTD^"'TG9*3EOZ+(GKT:8W]_$F1./H4_(URI//#T3GRI]5_;KBO
M#X?_\V-'OB#Z[N<CNP <Y>_O'V,LO_STO7_J\ Q7XI?UWZ= BI5Q^>6ZO[;?
MT0[Y#OG_D>%7^ZU<  @?^&':X1S".GKY()S1?UJM3ACP3S,/4_QWZ07\*0\!
MU5_Y^MT,R*]T/)H" 1H.<X*B+>#ZAPL*] <<_*,Q[ DU]DUXU-%1_YUN0E>4
MEP_R#R0"+Q3,%?:K5FJ8'@H9'=&P?7(''XR7%A0!13E@H,Y'UE]$_BSU)-^9
M#RF'(SJ>KJS_"_/']4'!_[!A'#G_CQ0#M.L?-Q4"!SC&S,'U#S0*)RA6#NJ/
MT4%KFQGH_RQ;1#_)?V F=O-"75*!PUQ_>NK$]\EK_R0?>M<9ZN+@<U2WB'VA
M*,S?L%O\)/^1G=315<T+[H7ZG7.IO@NH:OT:.#3#T MQ>"3&>"&QFQ,:^GO'
MD<"QCOP+E<SQJ #^A4Z*.BQS?R(?K2">[W*'Z:RT!?Q&ISHZ!7VO/'BT1[W#
M@.(>]0_Y 4KP#X=E8]^:V-/G '!=&4NG Q@!T,'TP3I IN+LY0BU4S, < XV
M (JC'N <>"AW, >$ &1$1$3$1&3$Q&14I"2D5'0GR,A.T#'2T-#1T#!2D1VU
M'X>_;R!R4E)R"G)*"@I*6@H*"MK##PK:[R)4_QT%!VT %1'6^&Q<$#N 0P7"
MI0(=S&,G2G+0!5+"6HD/.FH_W(@+@'#P\ D(B8A)2$%_'@0!.+@_!RD!$!X(
M%P</!Y^0@ @?ETP,.TB%B\=&#<97,7&@8?<.$B6@O953I<K!20=I=Q031P6/
MJ!%RQ9MN+6X[H27H<ZNO<ZLGF#EK=.1A)!E&S5] =VI".L=\EG8USR;FA]8F
M=8V_W"NHZYY8WK=P\0U++JQ_-+GR3DKKG*M?>$I10\_4J_=4  X.UEJ\(YL(
M"? ECDQ@ U/C82WP9J?!%PVZ17MH03MD9$N,TW$1%1RO9DKGA!;?YB(X-("0
M6Z)C%&M$'H.SAKDD!OKBEPG_;,'9WTPXF 7(<(\PJ0 EX/7)_9;R9$++_FE;
M3DV%&/P'MZ>N%$3(W+&2G;@=H\=<]^&)L""ME:F>3^FCEU[-*P^S%A[?'E P
M&JVH?$>HOO36K$L=SN3/-]-J<4GC45%Z6JR!D.2%2>"92?:9D7GGV.&-KUQW
M'A;0A'XI5PM7(K^<LJ_D<=-UBN4NM&,PP'<J; 7<];#HP3HZ@]-K'U:^WW0
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MUA)/FKS\:L[2A)<LFW>4-/[665]Q.3V9[D'EA?=U90 7J/5U+56K$ AA+^M
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M,)G-;]D3+EW?6^(G(JP3]ZAM7W+INI3A]CJ%3R?*G(PJ-RC1GZ=@.>:1^0'
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M+X.[X\P>6]=(:1FR/NI D8KMK"7W,=5$E*PU<GNMKN>Q6"3YB&Z1U<PPM9"
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M.8=*/5DXGH:(M;BP((7+E6?Q1O/%(E)4T6Z%-'\#$O.+DFRN$FHP^H6_-
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MPB@@22'Z ;0>BFB$/<BBGK M:RUK^.D,RG@2J+65'! 0S!J"=H1*@6V\L-L
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M)489B11)&">:PI!%6:$CNTVB2:)4FQ2'8# -NAATVY<Y63! "4(0L@< @#"
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MB.YO]1;_R/+LRD%YJ*Q>!S:B>[^4W4O4+DR&?'-W]-82OQS6?)P_7PFRAR+
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M>XY(3,,1_+Q/2*236!1<"MTH3O(,D0R<H\. L :D4E J_[(M;#-.UB01YRN
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MS"L2(-\QT.'3P[,KT,'!"_A0+O!V#)$!Y!<D'.=GPU9=50"!6"W)OG83IG=
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M]5?F>'GJ!4)+( W$7SW\IAZ:O$T*GQ?)%&UF51.%R&;$6->IE2F^0( GR :
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MME!O]VX=H8@/(M:! _U&'&L?N M_75A>P\.O>IS"8G+>LSF=A_Z7[_U*G%]
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MI72C"[K*1@GWNQ>[X_:.!4]Z2+Q/4*08 PYQD8(IH0J',LC,)JN$*B\2!CT
MYHOIYBX%8[JJ8C\%"M *@KQOV5Y<Q-&N[L' <4FYK"CGH?$B[V2@L0T="'7B
MCF_\4<<L^'\[LE>HQ(DH>Q2AH+7"MEM3^/SPQ\<@4&!/.<,M;;=PSMT]FJ1'
MK?2<V44]*4%U-8(F4_5?623_"/%L#M5N7; U=[OK?*6Q\V,(9A)=-6FI<[B@
MF?3N9ER2WUIQ002[8\FZFNT8N$*3!PO(HOV1)P[5Z1"HK+G<.HM/=DZ#H]+
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M>KEO+U:+)-^K3*RN&U&_U%)8T,(X,?ZXQ+V.UB*5ZX]0(WI%,U&\#G /KDE
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M^WB=@;:N*'#IH/U8>,%! D@B[+(KEZ4LZN#U-=P; (_C+N_P%=>VF&#P?F^
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M=B.X='Q@).D9!VGO;:CIBH@Q/*\25Z;^X2*^]4?,%V"UZU< W5G/P.TR3E;
M"VU1K</FLTT)QW_"87MT7_>>@NT13-PB#GC<IK!^&H9  U.G'[S47>F/PE,R
M%^.J>=(_%> HV16*2@T3T\,4YED7&64[)1<\$(P6M?N'@3.Y) ZI<7U*W<^
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MLSO8LLFE:2&JU=S(+\O*H&[9,@%[.J;^ H[*)K4- @!(<AN^0:U?<'W9H !
M@ 4D<ED0:5E.1S!L5*=&\ZPWG. U^/S19 9MD_9;BG6(XYKJ&GZ/*GDYVRX2
M0EFV.'RV1')=.<1ZD8) ^]"&R,@QQ"Z1 G*J;*E&']$9W=URAF] Q.%NJDTQ
MMNA?$_/8;,;S%/K =.ZP#1\N6P^)J<L6!_BN^*)&*;;;U45B?P&$[K]EEOU<
M>Q'# ['BT3U[%1FSDLPKG7R[&[JYH"W8;,:],"-\!<>F<6OZ'J78 J6[:AK7
MKXB\,EQI$44#B1P*$(/P=4B0T[=#Z@ILQ417O*N"71,0,\K@2U<009NDG;JH
MS?D"$ K5Q'B=M5-@U=APA_%&,K'UZ5-$&2B'I@*D]1DB]3\#94!S0U,AM:#@
M<8)6A"-$AFL&"4Q_AKL6&'FY2DO_:K B['F Y42*OF@[?!&TZ&H#  J2-;%(
M:Z&K-!?>W==N,@=!=6B^<<'CT;MP\C$R!^=MS> ^L[/(X\[M? &25]PRI&II
M7JQ,Z#"?A@15K <-_K#]W'?#Z@<H+;&*^N99;T*P+7?GY08?:S@WXT2M)SXH
M'"8L;=]%M@Z,L+3@6U82-.,Q==WW=? *E+ML=070,8E(L=\&UY95 T -?;UA
M04!:-\2>$&$M0PB=F6]/RW*AR$H@:;0-J7N\%*WG.B_7"?_0DC:;:E.':"ON
MZ6[D$C\PC,Y#"X<NL?).?2, H%WKH]!Q#X,PF'T#@"S<>#90"_5N)*RM@@R@
MF3C\/<(/+8/A&'.MYD>X69W$:*7%##O=D7&>*/IX",2;[E(DD!W;NHR"CN'7
MD"5?\/N!V/9C+T.31\GU%A/BU,Z_&E@R<%DQ][L)\H[F^(@;1+79 +9Z8NZ[
MA8GU&U1:&(#4QB3H1]#'*S#D"("T@L@8( [$=L#F8&BIII%F-_6'%*H;"]K,
M[<A;TL#YO@/U6QA&9L7-W-9;V)K'WF.0-P3 ++F27^&:&O6C_4$]S>T!K2=^
M"2YM[UR?Y4'LLSE\5R#6<U=_W4EZG+G:T^]IN,*;\$[+]5S;!_K1<<#GQJF-
MWN&D1X<])W8-M]#9AZJ^>P P6N.JF[NHI\**."C7;P&,QVH]YT\/,7^T*O^M
M"66<BS>AD?DBRZJ\YGG57_O\T-+W[FQ[<!0>OFBG?:P=G:E=_SE6.O\I\P*!
M$[1Z'W1'LI-VL2G'R.,HC?M16=MS-6W$\J\9!XAZN8;KRR[&]>HR6?_ZYIY"
MF=<0]JU:?JANWJ*M"BO^$;Y2OXKF$Y"6.A\Q;0YO+I6MWUT:\TS5@U%&?$;\
MHXK'^@_<EAT<;H<IZ);UO9+C*81/">5;5H99>BUB"TXZHNS2O_?_J- \0I].
MZ- L-92*$I>'AH$=I\[N&A!.*0) '0#8</?7%T37D_FNX'M<%UE,MI1$$814
M)$RA>=#5J"!G,D9S-CK0\QV[0U2K9!?UE#\BI(F<M2\YON=\_QV=[3<QL;#V
MQL,D1\]T^^CG5\AT:E%=!9PU8":GZLR1%U19*(  6EU4&%\&)DG-"1=O@:),
M5N-KL&]LZ"(W\LL?K-&AC*?QLL6."_G/H0 X6@&FC4O^=75=3M0R-MA+9]VT
MH7%&2?JJI64.AT46[L=08J6R>II1'.AFJR.U$(HK(F82L+<OOQE[]'0Y\3TV
M83\4R7,].FZBW<R+$P+>+RSY_XAAEYV%@Q(PA?[2L-.[9GJ$>[Y>?AE>Z7Y8
M0W_-EQ=?17!I5XQI7NID&]\+KN9W4:E8^TCD\B;JL_P$T^'Y5,/[EYR,GDN[
MPM%'C45ND:+R [NA2W*XMR]3S&,(>,TS$C]>=B3OF1/]@TBZZ^5;OF?37,BG
M2]/]N.WUQ]N@?-,7@.(+8!;+?RWDP\-[UOA7+-6S<2YFZ?'ODL=W]I?7CX Q
M@N5!"4!3->^Q+.V$\_TZ@L<%[-11PE8ZI"Q+=L%ZA!IJN>,?!0V[W$V,N,9#
MX>$.]Y1K3EO))G-"5G**B*34EF-%(FAV,WV=T\+N76BG<.RQ7<)VA=:]81Z*
M9XJ.BP0:-&K_OE&9+#;=^J)@Z&2U*,,B!A1XX5H:N^FN8_Y 6&"P<[7WC76:
M>7P8C$HC31)R8YY,+$]ZJ2^CUTF@\:>8,9 W$5%$LIS$4X&72#PE12'P9%$%
M+-\8J54'+0QJ(RS1QGKS@7T!]]RC)< 6DMTD:'/.GY0(V&Q5:RJO /[S"T""
MUKN]&^T*<=*N5_3X0=%<;G5 B69N88ZFKTE(M[:/#*)6890$:H#^SA&=#&CJ
MUJX[E=$-9,5@@YLB+AG<[6>@MFP++:697466LQ!-%+&TNK3?0D:6BS7^W>J)
MNZR&NM'*958(\0,EZ$<F0(51"M1^A-*U2*IA.CE6K4@%+&1ED_<VNJ"0&?B[
M18<Z-3<P0DE'B@8RMG(2V[R?*3)M.=&S"&2B'.N=?L\8ZNSH.J0B]<'(S"HY
MA=\W32>,]XTX [UI#> )S(%\+V?XM18M;U*9_S2>Y]%3WDK'JY=SPZ,T?_>#
MKRSBHFO]?IS_1G'^R*";?+6 XN..0DZO>A3OU^7[/R+,?&617<T=?%G 3Y:>
M!_'(ZM.HC :^Y,3\AF]EXUCU">E7"BDE!^5FHGO&W)-S].D!A; D BJE/%:;
M8Z*,E:HSLCJ;MR@"5LDQ:6E2,21/TQPCZYX-)TO:FR72Y,@#4X/G:_;#/*+6
MX'7-QM1X76[%\JIR1(18RG5RI*=0XK C0B.3PRI6Q*M5.TKEFVR.M;-*H[C,
M22I;XDW:Y2"S% %#M/R,S*>IW>LZ6S)Q[R+J/HPSH@=3_3.3<L-\V$3KC/;2
MLHITJZ24<J"0]X%W;>ASC?L9H!)IE87*(<K*U"2+KW3*ICOHVX-82;M#K#?2
MTI#QW5A%+R=-&5=A%TT;?^$B"3HJ3F,[/-84G*O3WEI+L0N#S6UF+)4[4\&8
M:B"*%7&)XXQ\5AU02J:GM,RD?V<C_Y1;ZEM>4EQV^-5>&S?F"%BRC2&_*#JT
M/$KC^^!TN>=3)?B%J]%>LM?6==C&%F8MZHB3)Q>:$?"]&5H/\= A/OYZ;7(Q
M@09GDVV\6S O*RO!R$F^VV28XQ89#RY&O,  1[Q:XG># UV9S(VT_(3,:_&W
MQP[?VZIX_O#H]J'>1XLQ?J]V].=E\"_ KX'_48ZGK8LWV_2[RJ]RO$E-T5)/
MTID6>$'5WB_ UO4_<TR\%M,W+[O.TWP!AD3=W%4/0W'.Q@A@H_^&U" C)]6P
M\OS3[VT[N\DY:6D/,L*>F[F<S9J]:R:Y"#=BE,B5Q51=+>8A+!/OK (!7@D9
MX$O!"4"R>"*//&*4\JSX,R3FU*(?('*D2("N*B_;!U2ZH?):)9V-8 S?Q8&%
MAV&NY\;?C2<H31+I865HSL@*A:6JPJJCI#GD9M/UUP@,7AJ[Q&TB.U &4,-5
MU32<")J_DJ#06Q"*H7KZ\2%X(OZY@'/R,?5KF'2^<<3]VOX?]N*C[8O[;)$L
MC;0SUM.\'O$K+\;[DGIV7>OYF&''$])CO0^KWA@O>3=?ZZZ]3ZAX#!UA_Q?
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M%! GX\P0X RMR<:;6GO)6*RQME6./CPWQ723A/15G@:"SPS:2FW6K'WM1LM
M/DMUS8ZDA6&K0>L:!#GE)E66VRJ3J89Q*;KL- -PG,YT>KQQ\0X?8KQP/(@4
M.T>J7/3._/T_OA$2R^/LL#K!/>%PB[:"%FH=9PV$SEM'V"O*=)(KJK7K$9RL
MA]'=A5/IQ2D35@WC9;1ME'V.Z77N,<1RJG"WC\%JD6;-ZO2BQ$I#4PL@)&IQ
MR+X>CUEHUCBAN'/T7)9D?B#*G3:#7X#?/[*]13[673$O=#[_@H7]8,?1;+O)
M$X_]H>KWDOH)IOK0\8M%(3%:F)=*JWI;LW*DVN$>C_NX24WNDZUB* XE0>,"
MJ7A_",@QLJG> R$2RST7G/. $C(?QR>C*';@1VA7Z8([N=WI9K+FR"H"?N;=
MI4%:WT6'A'1G:2J:$G0A$%:DPYYJ\(1+(QHC/V OPC^+#6%"J:C3$12R'[R!
M_5LF6P>:FD@+UE.)!T;^6<\U^H#JBE2Q9BNJ#[T@/DL:LPGN0@(F;WNIFCP1
M&A%RE+9B(R4.@Z9P$@-UH>B31&KL$:':%H5K:V86OW@W>C:[T2N5G9?GL@MW
MKDW'L\(6V&+,ML?J+79; 9X!6\ $50#/3V,4W86[\27Y,\Y7S(3>WUPZ4NX;
M7?SB>=IM.M J.;BD1MJ"=**:W3+!DOT%L^AQ(806=8B?5)F?;),3+VW5H.1(
MOATLOA4O*Q:M\$"X%S3NM]I6EBY@SB*;YY(6+[X9UE)V%267:);+DE3A:+H#
M7VJ%.3ER-"%*6E'1V(O39K,UW>( ,^J<U92]C)P0M TA7/4@PJW(]G/FHW6)
M+E)L^]63K?6 2L#O\PKF:([,O0J_R=,YC^Z)=)#B]5H1YZ39>Z\D047Z%!9)
M<W&)I;@$Y)LR$=EX@4EC;58@"$UGOL2GG6!^M1JB17P%V4W'#X0AI7<M5QRM
M*#O$Q^HO %B )X-MV@@/HQ5>:_!4B]F)R:U)''E+=!17'!UV4X(L%E:$B@:7
M6Z!CL=7&-[G)V7:7/[J4)M9BE[AH<LRYLL*2C-1A>R[\^<49;U'WYV[=2WKG
MD"U@AK^()I.TY[KT+VJ,R&&SKB,)BLA<5HN("DX=B*KX;H4"\M=:4D3[*V=D
M!U#5W$0V6$[VC6*9^S$F)3HC/<@TROF,5?_\<W".5R'>-]X5/>LOQW=20Z]E
MVDR0CB]!17>$#)F ]2E?50OSPHAVOS)**JBI7:3PY&LP7PDV:+RD^BKR(0IU
M:!H%14S1&4,'T!8HDM*?YS:'8YC7]D'4BF+DS(F&-N-O#[\=^(RW)8AM1DHY
M1E+&/(Y8&QPIC)B'B:W0[C^@Z?G5YV6S%S4U)87*F19T+/D%)_+!-%?]1*:Y
MY22>_,-P!.>)"O>#OF$(U&#7?:?QJS_/K7#L$19%!WY:7G0@RQ\W%'\7OIA>
M=#B%TKXM-M@M.7R<*R;>.=)*FJ#)2(<)$PULAV&Y6E"-=JF8:W'ROPBL(-GY
MD84D*;+XX]X$U#!")X*;R'&ROICVR=:_NN,-W_I/-#_8045/M(YB-*9J(ZYU
M^LT>,W[3R8D$/D3U>T/2L*HBR[Y'!$M%2>F083@]J>=>/Y74_"VY55HLI78S
M)8I-?@A#L=:>"[&BL31<.>#\\%<S>5/*]?!C@6(1=]QI]=@1.A-7W20G]&LP
M28>I8'-8R?;)JZ\E.0LX0$I*,TDB8G$UGD@F?H2Y*2.W;SY$CX$061!5#1P^
M'1:3<\^%YCS,/LJ;5X21HTF?;OP+0+UN>AP1U85MMX4.+X7-O4M2L&O\N%",
M)2D]D)P;:5RMISCD3 QF*IN&9I!@YT35'LU<$KF&M&O,]>V@G]+V/KP8TNT@
MYCALP/+P?;.+@5WG0^^Q(RM?DG[.,QH,%D-F:Y*U/@QGC6QQ_*D\<C?;+9?3
M*&5/HS"R2V LVP*&F68UM9A,\3<^M#R1,F[8:!V,47FX%(_-P+W(LJ?!?&-#
M"X^\)?UM,GL/0A\C0I1FSK<-.PY/B,5B\S&@B]'A!W<S8#%15[EC@F-M=H@Y
MH7$CX9$I3:DQP>.1LD'0+L:K)\ =@6!VS)@#Y:R%$YG3OY\>NX[]5K"[&OJJ
MV_=PE[XIY5&]E2/V>W7FN+.M20R-S-K$G:?J/-T2$]&3%4CT(Z6^3%KQQ'FH
MU(&J8B8<[D(0<0(:$NC<?68X]+=#QBPIQ//U) /!W2I==L.2W;*3O2V*["6]
MW?Q'UCPB50B$P? +\ !3W$7-5/<TT<,'XO@[+>!0?$T%QI(2)).[N5@V6XI8
M:,F/\@.A6C?3?1KH&*@RW7KB_L33W'(8C$)9)_C<M7/Y]R1>PJQR%Y 0-.O\
MOV;P@= \U'PK%(B\L 8N-HQM>855DWZE:A/ VW8\ MMN<[(&522L:*HQJ=%-
M8[0,*5 #KA)O1*2O_SZ.Q'?O]FUS1*PTL8#'9EC[.5_+_=(S7:RDJ>5Z^)D#
M818WP^XT>M^@893RX;1N72D-R[Q]>]5\[N !QZR^C5&9$3N@UGDV"RA1;D$4
M!C:BB?I#DX!+BLR1QV;D7N7^]6P6U&5KJQH>GT7>(%*MM+D@IYC9P*HX=IU0
M'0$;.4ER4Q,W$:7BE;>SRB%=>O9Z),WJ_H3J\:];"H /#"&H7!VCRF+.)Z#'
MJ?-&Y,<R&C#Y!+6!.)N#_'25QGGAXB,]/:*S(R8B,6[ PPBO8FP9UA4E27@@
M2ORI%)N;1J()%G\5T("*,THFJ(V=J ;6*S(L4\)IHX3O@JT:61051RC^NF"]
MK^\*;^*V@ Y\AWVSV68@CRMC\;$.IN7UK'>J:,_:"+)MVN?1$58J=K_+/TPH
M)!Y:=^Y;S_78K-M$$2P?-'R>E!%HB&_PH&V7NW.">N%]VVX1H3]SJ'JL ,OC
M,R S@":@1I9$B.B +Q]Q[F!)D:'+H&C0M&V[C4_8!T,@01ME^SX!0&%E-=L=
MEXFC17P:H?IA0T5K<$OX38#@6!.-%%KC=J(P-927"0B^$T\S9B.G+]X'749&
MA9I.59G]),:#9S8<H27:?567KSUSOV W(4;2;0S,9FSNMJVB[S:&Y:U^T5[H
M\"_T/9<H!;QTN^;39S%C9BYF3F1Q2UX,B*LH7^<^ _,(CSU(WQM=_0_0 A(A
M[2_^9,U!1&38-(K$4L7)](OXSJX0U<T3?K /GVL\Y_NTF)F>[VF<BIWU4"W7
MD6;ZP++!+0GXA#9C_DIS3TJ%.WW0L(X=0]K$SD!]E.6-++OMC@G]1:YQL+#N
MX6/.H5;1O>4S--'0''=C"]V:&3%"NT:@^ZK*(G,SCC +<=JL33W#N9U1_P4P
M92_#8(^U](5$W*#RH+XU/K14QUQ-L4]+D;EH@L-$(.@8KA!?:+,7'90=;#-5
MDE/J_:/&J'ZH4_9':K[>7#RL5_#4+#PTK$4%["I:PVQ)<*KXHL YI1J)M[)'
M<_)<##_?I0@O(-=F=*1U#'WU+BMX0DA12X6NI2[90!)8)%1165@4;U-Y[R1"
MLMT:[B!.542,?,B6&ZU3L2 [6S.' X-&.HP-#)O>#=N<SU"VP:X/IQM_;GU<
M:%VEW]T1YS!9:=(>.L1)6>NTP5M3^XRL++9=?37)H>/(YC1\)?+8?5/V^6S%
MX40^J#L[GB)P,+6D\U0BM'$=6S/2K<5/O\8;-WP^",X)C[2,QFYYVA-=]CGR
MK%S,2( ;@"2M+[87V"]>'.94P2W%\OMM)[.7I%(W)< 0_ P2:8\(:A,KDDL
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M/KWW]AY ^_0.92<_LGC]^7#F]:8B]MY4W4X)7QD.W?Z_-?!_:$.R]^N+(U^
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M6529BW:$*9KTF(0X$9AWF-HYO,N@//E>4!8'S>E"I]L1'!5>H#'6)T:1%V]
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MSJ+%Z'S%VPL_LO?=S-05TTO(Y]=@ Y9J875"#V;H/(B_^W@.@><[^?X;EK^
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M>>FXSEFC.+W!\]7QXU"%UN<EBEF,3#.J"HF!!55Q<XSA\FR, <[+?#@ V 5
MIT +G[NZRNHW@ UL"L;MXPT@H47XSUX^H>'&*DD]Z76!3T+S;21KLNLBUTJ3
MTS]5D=[_!4#&7[X':L<$]5S]NZ\OD][;M&=/"'7Y,06!1O^J39KR?+G8#?Z.
M36I'"Q<T=QURG9+(2YI)L,DUZS@$20@3WQN"V2X8_N_4GJ:]XY/]C]BM,&SN
M.I7UK&N$ZVL'5_P20?ODH[^*GN!ZC!W^SQ(']B]S ;SS7KVG<]_OCZ#_\Z?Z
MP=Z@-AE61]3&C9PKXURC9J5<$39;$:4C(;7#SD-C1%<P*(9LM. T!(2\P4"[
MTST&5]\5-N =IO$EB+K21BG,>CG05$Y@&+8-^)5VWK9^5.:_'&F;-H6I5:Y^
MN>_;E"E3\6;I<*B/?71&B- _WM6^3K/3%X=EE,,@(\$P?_?HULPMXTC<G+$-
M'G\!JY3GVRF17.#&677M$6]P_9"NXY.]:4N!P@=A3MG4"MCD0H9(/T?4<.]*
MDT@#Z8IQ@:^5\!76BH8-ZDW[^6*T7VD27:S[1_PID^R8,EOLWC^$;G70Q?0Q
M0; ^T/.V2LEZ^XC)>AW8KQ\,!574K76ICULWPF&_P4AAP@#N,=8<1YHW2$@%
MS+)Y'.:YE<9C#6"NJN3M;I,:"=L6_CV7Z?^W%JM$.(RVYX(V&XS<"\^N[YE<
M'-^/-L#].R,;5U[;,T)6L\"H<.C#G5/QV['%O9S<?#Y5K5,_ETPGQ+32YGB/
M:&%QUQ81FP54$%B>-4[YU+&CJUY-00'KS)O[C0(4>USJ0;;F="5"4";)J,6_
M0RN"$_;#$5.50$\C**QQ\4#CG4:*()V<);*50O.6N7P?E?O8GSLF\M4<Z;44
MMAH6&;U50VARB/SL17<!U!/%I'\GI+$ MZYKP?X("W2GGB,/JXE5;+7;/MY?
MY>#1.\!T15_W''M9JLZ=ZIG6E,JMTN@+IW*Y&F88;K4L$IK$]O]?-O^DQ;U"
MUXTVD92P(^K),*^=F3E^[HH;U#G&OA@P><ETW>XB_.-C1-J5^T??NY2KBO=.
MS$F 8&6?_-" -.O\?F7P+Y"B]E3HHCUE_OO'^X2^+4J44\"V&NH).AA,ZH_[
MW\&Q(W6M4P%>;C9IS_/V\K^2._R3$??/\Q_HP_M_76R1GOC7Q1;B!?,?&@&D
MOU_C  +>CVN):G[UIRE+9O^[!,[_U18-MGJ')XGS/U/,__OQ L)/6&VBH![<
M&=,RBA=4PDBH4+? RW]E>?M#*GJ <79VK7*_>_!/597+G;O[(H76GFMFY+_
MW"(I\4_9?_*\I?\4"I:KNGD<72]_7GNQ[O815?&YY7NEGA\WLP$_=#T6&I6Y
M$!/_GZ3"G'?N^%')18LF%;RMC;WK;A&_AR7_N-[^'Z^:;,L<Z7M$FZU_M@<(
M4OR/E=C^;S;9R<Z6J_@4'"VNR?I6#'!."3:*T%N)##$5>R ASK4.X4#&XH4C
M#9/#7%533*4>H/MH2HII_! ?BI.OH%H"NUA'';:O:TE4HEEZ2+TH!NM89EM+
M D/IZ'L[4D86A4?$>Q/OFQWO9CZ )_&?&WN1?=PK,@#1#++_H\\@#MCU?/E/
MS;_7R;O=.DO\-V"R:[AJR$"=?^3;-F6>:$DV'FUO_I6]Y"]@7703&6[ZRW[^
M_979;?;1]\W5_5'31.P^:<Z-A%K3!>C-(7&W87U:A?)'+V;"(-6UA8L!MAQ]
MS0'PRULAV^VNV^[<S[+>M'0<4.= 6(E]&,(.O%^C"8,OMS^"=ZO""G 9<?T%
MW+CR1Q/5;HZS>COB-I,-UQ5[N"0@IMO/P^?;A,;;<3M[J.FWI_5+)J+O7!-?
MO1Q@@-*,+FIB$D_\.R_. R:V&0XNL,\S@(Z+,CTE:<([>#[D8MSV'B'[A]]/
MH6<^[,";2,:$NFCT5M+^NS_Q1(XQ1IE7$\YK:XB/<+^6'V]?#-#07-AJ^C\'
MFXW \/PB@)HLB[)J7;0*D^L,9)O,;OW0<R$A>*DG<D3W;>_\OH/X&-%10U[[
M8#Y4,_W[YL(F&WJ#1L0>AT9I;T.2 CS?A&OT"(O_W!U VR')_WUCAE &ORO@
M%PY!R&&,=&F#$ O]NGT=R:R+V.P"=?2N]W.?^ "UE^?W;S]SP$&D84JZ.M9!
MOPW.,,-UXZ"N:*A\D6@QH-XQ47AT2,#/'QT4L&*BQ:((D911UC5LK,E!OW]\
M!_/V,(:%^-3CHOCY#G$]!S'N\ZT+F.MX_?B=?AYYXPGUD[R]']3E[!:\'^@4
M^!YX,-?@_.J%#71RGF]<G(PD#K &_?ZSBDYXBKN0\/)HAI!#CMY%]$!2&569
M5'ECC@'/SMA8VRNJ,?!;_]&.8/_@[>5:7@#$("$\7$SHMP[B+Y_PD(SA]OV5
MO*22;G2YSX,#OUL/;LR'W.ON>8NCG9.>BNX>S"";?MVN)MHY04ADSQI"I+TD
M&6:0DQ/LGY*:#J?1*\I"O_.2$+I_?C^-&*P2-@O[T;'1@LXG0:8$6KI Z17]
M<M!"&18"3YF;&Q T>B ;,QR'[G+R)>]@R+5)@A:'>$BZSS>J2C 8!^WXNK%W
MAT^"8N^Y&3F(5#:OT5#9U.[VG]5O]:3PU?\+.O1_25V']/AJZ"V$73=]K5$D
MI^%B#8T&19M4+@A]F(^TMY(/=TQ4U-H5S[K%8;-;5$)"27*,F9ABH#3);6GB
M?49LB@1HTN!-L(3CUA*",]41(1Z$!'%O^5>K(2]UUH995KD&M8K$)L:G1575
MLMV13LKY7_A&+8KK3WGO6\@8#,<1Y?.IZ>GUY>T68?8:2R@[UR9L;"YGXV0(
M7*TN*W'H<'NR\78EQM$Y/L[@AT0>=T.UE%@LAF16Z'8(\^""L!RR=,P:UIB]
M8FR[J.7E=/7$U!?A]-+DJ',G8*XD$!*0!6:S5>(W<'F4FB<[2\LR.3TU)=2-
M0N, .GI\LQZPO7WWP/HF5WO3+"!"HOL=V4QA3KQ_;&_](4EPW0!FPW6PHK.P
MZ]\/L?\';S.PX((0];1 9@"W=P')Z+?)S-?G_V86$><1ZI4\U![!E;#@&<2B
M[XW!$RH)C! 8US;H+\'/74'VC#.Z-7A7O\C+=Y[^8?S%YQ/HUOD>%I.8@#G
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M<BPUSFQ[P7#N])!Y34X/)(0< C>$L/(2NS0P4"C,8*"LL2G!WDWD EF^U#C
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MDRD2[\FMV\0 :P2S_]!& FL@Y^BZ7I]Q&Q\'L4A"6D4J[XG^JYK"PA_2EYB
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M9?OHE9";2:I;I*]33W!BI'H.Z$TP5/VB&)955%Q05SZF(&4:D!$>55KZ2BO
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M&U!BF:]TQU<-';[PO7<\U9'6_J,V2\!B/E' C<Q4<:?C3@MMH%KW+.%%Z0T
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MP4_K)R1^;IJ91A$.8!LDH[HAC]'0Z4K!"CRE;N($4G4P\RH7_X&?7]]KH6?
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MD&.3*%,9-B.'Y8TGD '!*[=GK0=9]U>%N!&'M#B:D#XV'7$15K0C<FF>G*"
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M?X#J&#FAL6@/)[0;5%1 ")!2T=;'PP-P!!6HOR+U1Q5 LH+, 0@+M^:/;S
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ML)4G#3 HTEX>=EY<7TC?317AA-3RPR!,_ Q,X7[.<&E[F*("B9R/C _*#87
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M*XH53[Q?K-@FC7UX:7#+U;),Z/UQ50.=2JUH:.ET^$Q"EQM,]Y2%(#>J2%O
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MV0S>VNJ(<.VHD[T^W?&D>#:9$+^M(Z%HUFZ9HWOJA/OE@2O5V.6GXC!SCKO
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MLU2)JF@TW?K-!]4UIEZ65X!T>-^&46&=(3*FR@6KQ&;8?@#<V'0:3T^Q.[Z
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MBEZQ@%@[OH<]IUGTBJ>_ >Y,XIZ-F]=-Q>-&ZCR%GF20?&@0NS/,>$^_EGW
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M;F0?7]G3+;_"5B/0EUAV=65'>;&^3M/@>F&>E9K9^,3U.F?_?(L/==@)U=Z
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MOMA^0RP<V(E3,/%,5C#&8[UET!![JR1T4[:2C[YI<(G2H%([D5NP)7  \;"
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M+L]MVC22/EV;.<W13MOBBDU9N-DELX]S8V3QUE.M6>S)I2ED+(M9%%-=W.H
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MHWDIM9Q:3A9>549%EK(0*(0%<?IKLR :&A$#R5/RIEOQ:)$C"HV]-4=D>L^
M:HNZC7G>8\!DS^!KF]Z"F5S+L,W9?1E?YJ8\P99CTDE=X:@--,QS\==RF^27
M/.Q]UO%HV]!Z<\SGUV(HP3E1&+)!O8W++%*1[IBA^H=KOX#QA#_T&DMV2ZT>
MP_N*_L]J>U'.J_%4LBG %0Q#]\'&Y!+^UZJ5N?0N2"[7V!P#]YY#T(YF-3(:
MV^GL23-!9</<[7H@Q5_GOP\_S*FB8PP.FO&>C.SCO!$5I=2:J/-#5SMU<G23
M9]6I!PUT]655U2U8Y+"9DN%[\4Y/S[+OGST,<$GOOJ58@3W8!MN\QS&HS)=D
MN--6SW52/+ZM2S"XIF^I-"MHONSMU^+Z,RBTL#TS;NQ%5W-?=;U2,4BUMN2_
MBW''0K0HYRZ2S%WU<9M2*9R SS;[S2CEQ5[X3SCO$WUKPOP59"NK89??$9XR
M+I(MG.HOQ2_8>A@P0G/Q<7PUI.JC76^R71OTLI/TR&I.L=^P?BQB,%*H,9\)
MQV.MZWLP&!%6GZ4,#/'>SB+S52DI_(7*VX/':Y%/:E^-A<K6S^S%LLE1'.(1
MN<Y[")_XNG^:OO(1L4QOOYQ*1,_O*G"*4>VQ8B#BOX*1YJ*2XIKE"A:+<*<_
M=F+.H)KHX"?5%;EW+RQN,FK!FU,D,S#?X,Q&?#_H?V^O%0AWBTE)7Z 4,3%'
M?QY[K03UK4LMIDB/%?FQ=A1+MIK76![L"B1)S3//X)S.[0DPZU<$<YL#?0PR
M-AD2R]+!2Q%C?$'!G;:G2K&%DP=0A?GEPI0,7D.Z\MQ-["LJR.,_PRILU"O)
M.2P\U6/4%NOG5_42\EYM-((!R!D\X#EHA<A0T!!_NGDO&+_)0*Y-) F6<9 ]
MQX@10\O;G9*J;;=2#DY;X$=S$+<H0:.K*IC R3I?8"2A$#$TQK,=S$O_BS(:
M.=A6J!C_0H\EZ_F"2# P@UA!_>3MX?@1#\&! ^''@'4LU\/<O"(0N'^5B)$L
M J_[17:9,L 8<+G7BOXEC6@9]^,7X:$IE7[[(^_ITN''B]NZ;SIGRNH[5U#+
MM@?$(\AG]_];8_I?/U0\?Y6:Y+]<++Z8:U*BG#\BH.AOG6FL=I!F?MB$,Q@W
M.^[H@XR?=80+ZS\"8BCR=><TW+N03P^>*^%@AG#'^?QW,DE2.XF;H9M.\5&1
M6RO#F912DS<%G/N,/IC@^?4G.P)DY?T7UB/SMEZZTZ8' ?.R5_!<?*Z!<[M^
MGP 'KBQ5J7*N2K5HBMA*2 49U-*Y>0'7X#+)>T18D]=>J9>XW! /-\!I \1I
MEV]?37#P,E#W1/6_=38ZQ):MLYXXS?_YX%\[GM_>$6>4NZW13=9BOFU_B-I?
M/9\YM;K[E2]UC['-M,O@;)('8Y6M,Y90 N]B':R_MU&\?E#$X+Q+U@Y&RQ![
MLAVME1/9=UV>,T->9W6;CLZV8*K8S-7)<Y!.JB<O[H/B8.LZ#V]YGUC)S-F2
M6&<TC0R/K>?(VS)KK$'0=VR>(O::K:E0*-$E[#&L=364CF^BD3\ G_&4?*GD
M1Q.! H'#A((P1$I',W.\]%N-'.%0F<1$H!<\(.Y<>\9H[SKT9"G;U!(^ ?.&
MKLQ-R'&!=9U"\Q>DI:/O&IK6B?"@,^6BMGS20NX'R/O9X0TW,.A,FMV2"=5.
M=M"EXZLHL?&D*E#^BD MF6LB#$@55OYS,RP#!_74&M;/Q)WW=KV&U$JD>#5"
MNKU"J9#"!*:K5$&OE[2TTA>11;KS$$TVO7RT1ZI=PD<O2]VAWJ=9(J=)'+F\
M OUG8AO;W27Y-;Z.B KVKM/<%$-L@6A$)[^S"T134_CY$OD;#[Q.X(1Y;3"R
M&P#FRZ]AI:HRJ#J4IOF6]B[JT:K_#?X.1E3!):5='^S51NW=\,E_"*,'%M O
MR]6:7JT6YYYOA* #'^P^*BGR=%9ESN].IT^$V8[\CF(/C*@D;(2)6S&]=2Q1
M8CW1KZ_^8+=LJ7:T1(VKRWC+J/TB[S,GH<C6$RHF*P\K^+D/+D" <;RL_P2$
M7I:E3C7D\")7Z^Y)S/B*]G7I?>-/B!3B[/2G[X6@2CAU298V<[\!<,,$4Q82
MT*X>U"0YH>Q\'1>2^V\5W__"U;MAV8 8-^X7PF@=21[L7#]K(-/9)<]J_B'&
M[.[D[E*3^ O1UZMQ(2KCVX7H/(J"M^TWGJKV[<13^R\I(T.96+]HJH78H<*B
MIS.L0UIV@EB<NHY[ L_YS76'&MI(UV>FR+\%1/H)=0UT'O"<6A 5'=M'.T]>
M9TMQI. PN?:37%___L;/]-#H,_*;_DN#H 4? 4/]#C4"<F/)2XX(8#[.FO6P
M=)49 :]BKBI,9+[6U5_"W5C7_,VC:0]_N]]TY8(9ELB-RTU,2T],U;;58+I6
M?S.!Y-#>N]FDC43#>C;31[ -;3>5R1'AP*(5PXVFGY5RYN^&X073?LM)$M_,
M$:V]U'BM64WAJ[5WMU.DI:+S5TH']AW$].<5^SUN,'\R9S'5Z\DPY_U6K2W0
M-!W,+&'L%ZTJ*!>R/P [3M'T%SPZ4F/?-)%G"O:I6L\FO@<#H5U2\V)6A !S
MP<C5"OD7"4*UQ"^,O$L93DT_N<R#HW H77=BSQJ),,[&+G0FDG<1,C*<5N<%
MRYGNO[YFYD043?IQ8Y1BK!J,9<KE,/.0VS(6P**%NW@OHG8\Q$DE\U6-!Q.R
M0]37_<7$#3]R&EQ\L,15[AMHY(8)?^HVF[-(1/UY,7H2EOL)T"!-:7[-S?7K
M4?2 XD$$D$G7)B*\ /_WTEXBPA1]:Z=#^SCN/U%[TQ TOK2\J#U_ ARA[KBM
M8IS[&O,]AE].R_(S7_[IRB.@FJANL]VJY-WOFW$WN_CEMN\,2N%\*KGZ1'6Y
M.Q_&O#ZK:S,:TM2]/P8C#*A;!#6^0-:%L%?V7H$4*SJRN1/AIK[S9+9>#]T3
M*YX%DW\"('X$.?KEQ(>\([Q\XULS.<M]SB5-/37^FI#!PT8 TVC]I2"4TM<_
M?5Q(][]WL/^JXGIK?"U_9)&)K%OGP=HV$AHBBJXZ[FQ+T?=R'B!BB79VD(U9
ME]K6;SAU</VZ81MIX=1&H2X?T<*,V#H2TT@-$:(YI,%[K?%S&_FK&A@ND0@.
M@]&,$[2G-<GDB*H1(GX7G1DI RW:5>PEH>">WW9L.G8=*,7(W_=SU]N#+Z#E
MNV>8,&D4KQ';P-N<#Y4A+E/'E'C\SL7HB+IK7A8*<$7K<!,C>U^_QJMO,$$_
MFLDW4\]NU1[:1.;)><^Q!FEL>V<B<A65C;<^I?T=!JDQ2",]6RZU) U()Z=1
MI$^5+ *=K)9[]@G0_+ICT!K5F#U4.L)0"I$%Z&T\=HYKT%#B^AC\!+Q_[+S8
M)2Q\K4Q3#5YFL=^D_]:;C2P!/19.P_\@LFID;46Y*2.KU[3@)L35GLY/0LDM
MS'M1H=NYD"<\9]_5'>RW/\"#24J\8_X7P9H[.T(T>M1>55"7!$.3*6*%)>W+
M@"V(?##YSX3*8]"R#KT]_]Y#. ]'W,X)XAN5+!Z*%<UC+.(>WNJILKDFRX,V
MML+1U?JQTJ]LYQG$0YE9?\$@!,P9JR#W7S5=O@RU($.R$ A(?HKNDO^?.#.(
M/D3-GO&?G1Y -;^_O/C.8O]/3J7.0/EI$P2H=*KEYAZRT@ BM+&H$TVJ#]HO
MC2PT3,6SIU/LS=/FG:NR[M_ET (J):(B'^G_K)5KO>_(/RERBUBRNJ@,)'3>
M&-MA=GGMWS3JL+*8>=?H7'8<.]<04O7FGA>RPN%.8/E3)F>(30?U8L']\]"Q
M,CF.NSD,K%"J04'R.80T2' "3XXK_I2$ST%G#-9*462Y5J<^H.D+0LI"F,92
M@+F)=#]G'!:O**69]*0/_<G_65X_H\Y_ G[PM4!V8;56#'83&_S2;3CS^<J_
M4;K/\<0==:WI]??W0^12!5_X*>F0:;E4SI%B_ZM7L%V0G,68&SL(" ;3X_C^
M@C%Z8(T-17'#6\";V_RF+8TJO?FS+G!GKO+*^87 D-*0\[RZL:?M?MB(S'EM
M-A(!C(KA^&/K9CSBNW,H,WAH)!+D$<OJ0$+T3=UI)UTZW72JHO0]G-#R1C^*
M_FH/9D-MWBC7P[=APD]C=?>1UK$8$?O0Z9+%]L#N$:"PVP8I ]+?/+W#EB.0
MDYO3!"-3H4_ &NWZOJ4%D6V'XH<R%$J86_B1["R#:I5.NW,M.VJZ*D>^0AUA
MH;:]I+%1ILGL/RAS1W2D-(A0&O8^M%Q IZBR><>7GX8NO^..<U/R$_\2#"*\
MI@)W&@<8:!$F1XFV8AX,M$M?XX"3,5+[6B.70J1C^$2V6+=XFI6Y"#2_[)P-
M75\--8WRD@U6?@*.YY:T=NGP  0%MSI^]@=+T%ELK"A9;/?Z<G*)(<DH<RDS
MH>M^^7M+Y^Q+>:'CRLFS_402$AB4MCL6573_)7*%9)YD_T"T\NB)W.")W+P!
M\^_C93VU<A1E[(&;RDO"ANA\*1\W ?67H)ZM^<-C50H:"<<B-Y"EV*YYH1[$
M$:=&TL(#L7)^1O>OW/SUK?>!FU*4X:>3SO%\9 @CJG05 +6D4B%1@1V&K,H,
M@9!?H_]B5JUL@\%#(U+R0=32C4=[A[6F<\2\;W0=1+RP2)&%Q?*=@^4__XW(
MR5OKY>2C=VL*U,(QV7C*7B,DJTX6=<4;7M9(Q^TX"-WSX$<=FO9D7301D6(Y
M#RQQ\);>!E/IT/%XQ89PWJIJI^^>9I"O."]'3,X113O*A""4-DQ\(W)^)(Z'
M?>DGM*LN4DL+*BG&(_J.8L%UEA=&Y(;+0P: OD1 11Q$792JD@AF+KT2,/Q%
M;.J-.^CGK<=&\)<9Z$)?RGU>A3SND#0NNE _9\! >8UXK+L<M0M6F\D@1L;B
M;**)WPT:HJ_-<5'W;8*TXVH[@NBJ=>[G6WI,U?T$G%6.N3BB3VP'M#M4)^6T
M)_MKHT[2%@L3)Y96LVW'Z]*YVR2K>N;;Z9JQVJ;+,CT5.C9&K+BEW:A^S#!1
M\!I1A9+>Y%?PU U^MZQ]_<KLE8>A\)%'D?V;DO7LG >$\8>2]B^IS+T"S1YW
MF\R':NLJ.)>=D)%)- MCN 1H(\?GH2<'KZ(T"C'DC UPY74AD$WPXC-L6MTA
M4SAV#A<?4/E^"B904&"-7'V$QN,=*C@ <?$PGC^-Z7L--7.&(C<U+U35^T/J
M^I/;,3GO(G-&>!Q&Q:4QHF'^F>LOPR_!&;1Q_"VZ)-A^]'O5#V(:7<7(1)W[
MFBW;P*-9<^"=3&@"$0=/1,ZJ4&0\51,QS8A=(SD5NIN(BELLQAN5N]G-)C#!
M0U>QFUVJ%%IT]9F":H4RR"[HI*;;6P06G8I(#_R!.$TR/XA=2.$A:6/MDXQ5
MSFUYAETM!804/Y5E)"L;%%QUEJ6"OM3 \AI)B"FWCLWLG!K,"JX-PA?5#K<B
M4V/I# *+""&)0O)'+1J^X8X1JP]+V;I #)LWATDU#YCWNC=RD[@C IWE6!B!
M?L58!20:N0])_=I9GEBO,D&<F]\<#]D*M 2-4:%14!*7+FCFE."G)PXM79R\
M&9*IA=/W+X+YU%-P=_!^2]I3^_V-2,\*"<^,4DK9 8*PO"&3J^^J F%.;[7+
MI7KSB;Z;L)4&6WB5&F=$%FU$8?)-<]^F@)EK/P'2Z1P[62@6F#CKWXM<9?ZZ
M4$3B)1:5J=U]JU&4<)\^:;S9K5C"+&[<]3FE#2H (X;FB009<G>>8GYH!.+K
M2 .10#N0+TJ,+LT=AI78/^E-U\"E@FX0I3,&QCQTR*]RSG)Z"^KG0'EJ><HL
MB639DS+%QNRQ/DC9^+(V8<UIM5\G'5E[;3/0.;W](WXS9@""F<Y5J<B,EU/W
M\G^-HHG]KH\AQ;R@?">N?[!7AUR[T=\3/R]HOX_2$>.BJ&;4VWM5W(F/5*3:
M)^J("?O>T99K:>B?MWF05.5UL>7BH^(HY%;.(X2Z8A[_%/!4<AJ@,->3K5/(
M[!-PCKZ5:3Y-*#?47PCF=?04OI;FQ'OR-LY+@>WSQX>^E;+T=VO6TUF>G4L4
MB$M&[=E8=H-,+9@WQ=MW6'.[KSSRBN0-+'_7;FC4_-\AP6L&NM+$2/D1WS'L
MHK9S>85_NQ,!KX\G]#(/N# +((CK\O1.K!!)SM,U].YE.XV>>U9AYS(SB_DQ
M[*\N\B/_ VP17&??>/?*$J)#3IA F_/!N.\FYW,']D)+=_ DUWWK!6KEAHN=
MI:+'MR!+Q*,O5I(IL]H0S0.=3@^^UMWC&CRMUOY##9TVA+;I&%&QHT[9DBGX
M7>O@5IFVB19]2O;=,23>LO0T&>.J(9+OW)S%?=[14+BM/2"1SDT\-- $Z4'K
M\B;*(:R0>?L+P="  \7:[7RJH5?,??^HQF&LB0/AC[J;R08[%G0@>TX",;-\
M$LG1+6-C*OD1,O=?.._M0V(TW<DI"%K<K8>D'WBK_/2P@MS$T *99R+0HO%U
M]G7=L37@(V?NAOD+V/0LUV3PLS?" HU04VK9LJ@J(3DAX6U5]MW9CS\B6:==
MDTN]Q<2 U!   73\;B;)AP7# 4$YA01*ONJ=NO5Y(*O(_8?VY(5(Q)+SB#X^
MH<=S_ Y^P\R+L0M_^GW#>SPUG;@$9F$(Y^EYG?=S>EHU56=(ZT.H^'O>?!5B
M/7<(' 6(G=9XFN6/?,6K=C0,36'1@62IGMZNDVA7?&MK8L>2,%]5>/JB$(/8
MNPOT][89'$)M >3?J5]*Z.$ 9ZX D:]+\;WCD96KJ=:=^.G!K)*]K:VD\K52
M'8@,FJ9H>H^03+9W5+9!"L#V#;/_E"=HN>ZEZ+I3<:ZN;LN$IPMYH8;<GMT_
M-]_*8Q!>DW1_J_Z(S3GX%815N@+A*)NLDERTKA-'[4+-*W*T[I%CG*G4#A(R
MHL@EI^YW0Y.] >1GY.$LM/HTY1 ,I_"D "#X6Y=)PJ8E2UZ67%.ZD4O2K_49
M4!L;I]J';=SGKHF'4\&I0TTV8DRRB(QQ4\P3:O+1&E9#\ R[CSF.:-\R;C*1
M<[;AG3Q0Z=AA>K#0&7[/;S_Y:GCVE >JXT\0RL0AUH%=F:B G&;/[*MT&5D&
M1,Z*7V<]J C]N +QU+=;^?1=Y>-3RZD21=6:U:1%RPL'\Y_28N//T2A%B9$F
M7W;,3N[@GZP ,Q*0W_=![5TZ>ENV_1D!HUL']A%C*2[H::T[9&V3V$@WK<_*
M F/$."4,HD R.$%4-NI%&^L7!4349:\-JTW>>0!['":F)RO?2D[2/O0RDEA3
M#>DJ1E/K[N-?>HT53)$DO];J1L&7O_K6TM54<$<'Y.D )NY$C-2P8"E?_A19
MFA)MV4S7EFY_OX5\:RV*+_R0-,+I&P%YO\M!2%</B6I5#"Z0F2[LL^P:?X/M
M>#4,K+]I1'J'YNQ5!?B23@K9;4)%VLFX?@(NG 6VV-#-6(2ILW9;8X.V9V<+
MT/C1NNJO!*4(:V028LTG1]T:R_(E\S:S4/%&Y2@S2) BB1F;$]>,*-Z#8,E%
MCMR):)$H@.S+3])3H,U/@#SC-.Y@UL_I[BG*L6VO['M]3*T'_&4' 46["ND!
M,0R^5(\20*ZOO)#LD=)+^<EO7ANR41/8 BC[2)%R6TT.+J)O(&?^T(INKK1S
M>5-:$2H4392U$YFE!_[GM[1R6ZG0$=#L-UDVUZS[ADXJ2!]D-Y#HQ>ER8#Y]
M)B$J6:&V"'$0Q..10R(WB2BVS7]<_$E^\7T=9!GQJ)W7^T]V!678_V97@#,C
MN?0 -WMM0EHP8&YL%(=NAR5Y6UL"!Q5>VZD!AO:+)/"U&Y60;F9!1TM<R$!0
M&0^7AV"@\J2<J@?C3XN5]QQGNSD)]T0LJ8PTI1WS3>T##E[YE[I>F,^_D6LM
MRT&(_R321&N*Q&WH%\XIK%-J:G*L6";&@/_)4SS]*CU^4G/+XHQ'(QE5/^SO
M72&WJ/E_=ET9ZB_L3UKJG +;N(D]DB,=@K=$<)([10H. "8<O-'VF,TS<U=@
M4AQX+1FZM(!O("U%HT]<'!&\F7AW[(N;3RN<7/G^:";P,EN9\#TF(TI8O!F;
MX,3YJ?NZ,3IY-\(D>O_(Z4WA)EP]_?5"[=2-"O=$&F?J<380B3^H\VQ7H;#E
MI1D.?A/HSV$_I+:)<QAB/68_4R'Y(398/.0MY[T// S\@8"]9;A_8<VT_P1E
MLKSJ !N1Z".V7S0S\QKJ3?0'TQKZU)KB4/*!_"0OS\9XWUXS9E%L-^@E9:2T
MRR=P>L[\$U 3\_N=<N1$JP^T!U*^WMI;ZO[)P$SH;Z/PE=_L5,1*WT6)X,!C
M/%AG-;=UQ;$U]9207"@5'>8XC1>]Q%,51)^N_BN3WJE)3^)F*KV5K^LV\,O
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M.1>PG-T"ZZ)S(F^#U&&7";6^"9F&L4,@)C_4;1FU(R/K+?/%E'!/;H'/AL@
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M15&N!-F+!U+GUX.V, 0U(!7\.F!RV&$YP04G5\64R0<ZZ< O_,3![A=E.N\
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MN$&DM)3FR?'.808NP< 2)+.ZX,5O^S3JSH;I,V-LE_CNPVND:Z.@4B@)C.Q
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MO/@6(ZMH9CB S6?!^R'(WQU/J1=M:)'?DK!6_VMZUUR)H*NF^#N2,) T/D6
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M*V-\I7V)JPG0$AJERJ%3C%%Z.4<I,D3734 ??/HYC*(+-U]4R6>Z4@&7^5#
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MI2O>%G787',0?1#)<-P(%2B$[V;2/:[$>IA[47169( B$SOP.RU1[*%Y%3P
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MA^#$A8G1#R\-%%:FG7:3S^_-F,#))8D#W8D[%57A&"]C 9:6 6UYE1FVP02
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M^%N1Y:O$,C+H*NP(" >VIVF"2\>5#)*7/OM>O0ZV5JM+?5=)RGPO(RLVB?J
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M?;]'69HB"W9)VDUNR02 -9QE4<4B]GC9]M,+UP5GJ,1+U?X W(V#*XV&:Z$
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MHT'-!IR.(/J@?&E%0$3=$AV1C;V@RF80X'E0)<;(]U-86,?QWD9),6+8X(D
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MRG3<OR'"%X,D!5'M#SBLWZ70;;IFV'64@A:FJ^)VEI#@.LZ36@*%.'E5_3D
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M=+.Q>;HJH6>^=4@L3E!_ZS"+[0G0B'VD!)T]U^/J1- )$[@+)3T.OP'") 0
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M8FUOM]II6)J<8C[YK4WVQ+$CV1,?#DOI$M):2V!KD_MCJ*2@+O5RI#67Q=;
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M<)6D5T5>I&Q=9TQM^5)[%JXE5@H5]32(VBJ$&!G]!A%;ZV:WI,_HQ0LC](0
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M#$;MY>B*;>GJ!D.W/-)=A4D&K+OER5?WE)+/64G)AP_2-A#HG04[IJ2;"G9
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MV$/XOD +:#6/M6@&XF!%_%H%(_<&)4$Y-]121FM5HF$:SFF1AYXUI]#GOQH
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MC-8B0IAN&\U9'##BA:,][MQII4DCCK +-Y=AB9=AD!$Y?' XC+@!#D+7B!K
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MHNUY=G@L3Q^S0_E3)H)/LO;,4Y?!VJ<2R)6>CVW2JN,H3(0TB;@X$?*DKB"
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M[$9+M#4%R[U<6NA =DJ7A=JQ8(^,[;['6!KX<;&]N7FI\ 9@=]VQ'Q9;^.L
M!B#HYFS9R"]K%SX(U@N! MF@NXR)MG"(L!YE";G&S>[N#B(9]C8$H=S9<:>
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MD!$TYFT?R:FV$B3+225#JB^01G8E0G<=(P8]OA&E6%,^B  <"\!*"LZQ *9
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MR;$TSF9)1UO##@GYI2D'_'1GM,9_#F3W9H@&PY;-$ HP=[9Z-]6.%P8Z[MP
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M<V*W3R!$=T_HYT+\KZO))6M,_O/]%TKW[:"IH\W(RJ#(-=;685_T][Q$36)
MXMW35$8X#*M?B?I(6R$"7Y<Q_- 8WL-E9;CX52$,W^@,!W,!DS#><Q3X '=R
M)^$!'63B/-B][CRPOMGP67SQKW0;7Z6W65YNLFUBRJ'J7Q7@!'J$G=+<DA5;
M$5[N)$E/VI*=&VW=2 8XT^<9S+Q1/98/8!4[%JG#V?-8F *E0ZQ/B8J;#3\V
M,M!-+@J:]%#24[Y3W!3A_H\7P@I:XZ,LUU6$\>#0YSC9TF[&(-S4C&ILR-D8
MU<   ? ]S5\2/I)=)]%CE6J6K5&3_"_1]D!ORF>:GSVSAJ=7:?O;>S8P4Q$O
M8'.5KK,=O<G/LMT^I\\T+42Z//[+B]>2__BXI1<I&\USY6#>:2UH10#)!][&
M<LZ96@'2:K B_%M$?&Q%JN_SK=#N;X5J*]+J4CT?Y1\F64YZ^C2__^6H$NGH
MA)HB%0?B0Y;CX#LH'U)T;)O!$_2K"Y#/ WL=6,F#T$L,K-E9].F),U^=R?2C
MO]EP@UY4!H7H(E0('DMT%7RG)"NB^8ZM2CGY+RG5[OI*Q<#2$TGZ#4%1'DN0
M#2N"D8W(JN2#14FXY$/J_NYG'5JPL]W2#4WJ](E7AF^C-W[F>?J::-D@%8.\
MU-O73WD)L2Y"?N&%\!)=:5I3NC6Z5%,Z7P.=U*3SP.T\VT6):J&C*X@ N59'
M<PM5Q8* 7;]5=<!;H$E]H3>^:2? [U.6EL_;MX]1D13F)(6JDE  5&HY;*:Z
M$!&E,!,3SJ@M&&'T..@Q9F$0.%%FIN:=EHV:QX=.:''++'R."GKZE%.QWK;F
MI;8) F:HMMJ@2$!<RY!&B+12R&FK@8P!(Z0SQH99K0$!YIK?&J!O0':K_D+%
M_67-LD!9"G!OJ:_=L$GKOR*N!PRM.-P(430A9 =K)^*:<O"=K)TKMMV,. ,W
MMJ:FJ_M-";/W_!SEE,T/:,RWQFE:"#=V^B7*XX<\2M?/]":EVO%\5"V0.\U>
MUDD.F$N?"/$V6/1IGO/-Q^IA8UT'894@#?SS&-JQ W47V1^+TN:Q/Q #H=D#
M^](<1.O5$Q35^A:.)INH)GBZF8WMV1(VY12X]">= I2AT.Y+-@?ICK6$1;F.
M=>,)]R4+GVX&0SMV!$ZU(19'$&T(1+!HC\?5*K]/6&9-'K33[3;[PG2CEUE>
M/>&YSHKB.DGI54FM249&UPH<*7*\]<I][F-U]07<,CMI\K&M2%LIV?![1-73
M+UXO^8773$35J(N>&0"ABN0X$0T3-CNENT4W&V7B<=V>I[L\U-:GAT4NMT_$
MG7]EZ-#YAHP_56:EXIUQ;-P+7=BZ6&L=V-:H+R)[.Z0H<'3:*$6!)<@@^3DK
M:7%5% <:?S",>OUB@,/80#_IM2;_,ZG^CG6QW:(B_XL8%IU]$>28J.K_X2"G
MZOP)HU9[,UY-(MU@916#&J/L^AO?-2@Q@' PMX09> ./(ZAZXPTDHIR&F:61
M!3*B]#7OS(ZM.QI62<!QQVZ%)41]=[F$O%$QV9::W*@G[Y[P&HYACMB"V?];
M/]/XL&632,W6R7&_J_CX=BQ3[X=5.RO\QIEI=W"^;T#N'<[8,M+.8ETW]Y3=
M7<9N_=VMQH(\OA'E=B3_"OE%? ?W"=3<.))V]N8&$0B]Q&?/V6+<<AED4 X0
MYD,-I4!G F&\0 !W0I3-.42*LBUA>]MZ,T0JB='CVMLAW3X/X(*(IEFU_8YP
M2>3CH4A26A2GZ]\.29$(AV1FO%8"$ EZK8>(:$J23M$ _(&EV8<(L;0Y&E+X
M/W-J]QH.LLCH&5KB@J,5:<2"\#;.'>2"+F7OP"Q]MU%1W&S^&O%Y47F3WR5/
MSZ7%)QED()>[!LVEQ2$ORV?1=6D>-D"4#\ Y67M 6A?:FA\/.%;79)3"!H_6
M'1G@$X G<N@))PCY>Q_=&>\V*T0<T31]JS]A?LAB$  [Q37H+,-!E"6B<(L)
M]#<>UF;OGUR"M+G;4>4B;3\I3N=1$\L[1F51N!B;*CWEP(*=I@K@<:"A=0?Q
M'Y=M6L?HCC,U\90'@H?'@OYV$$F%.MI\L+P.M$B!/0VT:2_M>K8"9-"N'_#!
MZ]87_5=T<!WA]H1NZ0Z9'^K?CX+Z]X% _?L1+?M]L%#_WA_J2W3$%*C/UR'S
M0_V'45#_(1"H_S"B97\(%NH_^$-]B8Z8 O7Y.F1^J/\X"NH_!@+U'T>T[(_!
M0OU'?Z@OT1%3H#Y?A\P/]5%(#P3H(YHU5)3[@SPPC,_4%Q, _C\.:9+EY\F^
M22!DAK:V.!2H]?H.F[ J2<ZO;H_IGQ"CT$Q2'(UX%GCT* >!#2>RS8^1*9N/
M>?(2E=1Q^U%=&&P#4J.KM#]6E;,/$ "\&JLSWGZI"1#]'=/%T>"V9SHG*J8P
MZ?"X3=:.1%*6!>.16E.IP42Q,%@T2F,\#AF@T*?0TCAP8]!\>)ARCLO36%7W
M8K4GM]TB8&>U/;VD$T*1(*WZ,P(QQBL'=U L]VO_:'BA3G4[#![5?FA77HJ2
M7R7E2=[^^IRLGQLJUE<JBHM7FJ^3PO+R86K%R!=GO-K ^6[-JKI9+#+>?>'U
M'OU<4Z0@G;J1'BK-W1ZMD?18C,3(R8?G0;[++21_V./==JN5H6P>NZ;M'UM=
M38_31]:'?4/.P6(/?C>U$5%=ITR'X>&P>HSQE6%[FI."OS3">NX_ESEMA^V;
M#BN?*;FC>Z9[-:Z_X*Z79Z&KTV5)5ZZ"A8VZ2HLR%].K;D9WD;DK/J:6-;@D
MGTJ @T(YVZ:, 7647I%&GO *ZHQR,3G6@>-N)MEX\9J4/&,-=I@J/P"JHE+Y
MH6_"PK83$T>\ "V8"ZL#@\>ZE:Y9!FKI:]%\B(W+7OR>2H)T1!#6QV,L^$MC
M05%FZU])KC< ; WM J'>HAH,/TZK[ 5Q- \OFP'5@8['H@@L[.AI@.[-1CLM
M@J7<9'4Q"#;$@HY7BP#!ETZ36G@"=T2PJ^/G'[(FU47%5AV/K&)0G++KKXI2
MUE\UEMDQP4<EAL"V"89\P2:=(XAZ!(1$D!,9ET<2R*+NFCY%6TT&5449P"59
M5[-A4XJ_D4OPK*GNNO'DGB1*8T)?>508W%B&4B</UT52#T\8(CX?^.E@/>.[
M.91%R9HA29]T8X.^/-2@8-!8"JLIBO*!510FG=((@\ RBH.- S:D] 8 $)@X
M>?[Y6QTFN%JTI<5I&E^\\AW%A^BUSLYY=LAS]=F[LR1D(#2K%=*=52XA7'$E
M0YA0DYET16HYI$0)WL;4)I3,A&V3;QTUTIH;J*3X:6Z(FG)#7DRGFME5?%K>
M1M7:Z><TIOD]W^&14OOI1JAQ=8'=IQ]GJ3*_R#%U84Q.>?[>9B4IZB*B,D5V
M0XSLF>%9#??L8 *V^Z\1L('M]D@AK*Z>SRE-=T4A.J")O1*ZIP$U#\NE3'0D
M(;L/L/Z;X"=X=JABP]<8M@,*54DHWBNU5&7SXH6Z^UX()/;6%7V35(^!'O,6
M!H 3PV8!P@2ZU-4U67FC4ILJ0U42BBY*+37W,DF3$OE<<243@"Y>NK[4NF)=
M'[5@H$>7A0'@1)=9@#!E%JH<_"QOQXTR8#--L^;2X*T9I3%?-/F:D(D-D2S
M&:,#BOIS1"@(N<T*%X32U!7B<[9ED\SBXK=#4KZ=TS)*MH4NK863%.A*T*2]
M<GI="_P#J43(5[70UYBI)#QZ0UX)P72%^^IG;)<T/5*+D(?A"Y@IS_ZR%^8I
MAPGBA\@>E@)[_#?43DX$]$()+X$YF,R@)=QS0&5_]U\$+M?9;H\"IS7G!#+\
MZR$NLO1C9 ES(A6#HH.LW[!IJA*$%<$DQ"QZ@E%"T^L]3BS9Y4ZDF-RD$VAQ
M6CX\TT]1_BLMJQ-#M\6*50R*-G;]I60WY4GY3$\J&5(=70>Q;AEARL,G9P/
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M$\(FI0$^?8!O"]QO6P./;BYDJ027%M@LNQGR121?O(];PRA*GN"EE0#,(.R
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MU7P2)5?U(G/&ZZA_EB*GXLK6QL:A$9+S>2'9,MP4,CPL:WX1_$"-_#2#IT\
M,W(0T-X;4^N@,9ZSG8VOL?D>EW]3: QQTM/*G<&V2Q.V*-]6J)K"&9QF4'@P
M8=K4^O&G$LB7@)GG#F0S)]U1C,_61\J3*]8_/M-\_Z]CV:IL*A2VJO7T9VO3
MCBQ!>$L!<M5-W0%7\T8[.6MD@NSYM/*31GEQ3MPUP-J+NP9,3]C2$(TUMSB_
MTO)^6UWE?,ARU?*U7H$[5(3:V'#1H8^WN\Y2Y'-%4BJ6*%6V#'*0-1'V(0&U
M =NN<4999\<&%F).FS9 G0,R&,LU:M?G-*K5D_DKXZ&K>Q. @Z^'7L.NXE7;
MVS;5X-M*85!FY(6R=6>R0)@&#S:R#;83U)/18W(\/6@6SI#CIB\"^^.E+_R"
MHM57^KU\_J"[=_ISEI9OIAV:\4T&2#N%WM-HN"*_L3DAN4^1(@1F5)R!Z=_.
M@9 Z[(XEJ ZX01&6H^R&06@&HIZ:"I"@+3UG(29O*VQF&C1F:/G/<V!D'YQC
MF=A'9G ,%+GX9Z)@U5:@'*PUG86$HK'P6:C3F4'F/\Z%AAV$3N%A!Y[A$?$C
MFXN&O*5022BTG(>"']D9$%"I+P/*OY\-_4ZXG$2^$RCQJ?=+6A]=T<WU]Y@5
ME8F5QA)0WUXH-#1H/(:,[>:(;&_VW%1^@0-S:D^2_>%8BK ;^4AYL%RU =F+
ML384(QQI-K(YGURV:J =4+:EMIY#-H5#.&LT2=[>[6S%G(5S4#@ B_D\<("4
M"<=^/$MS4HKQ;IUN>!I)]A6:QLP^SZ:[!O9Z4(=^#AJHDHY75<0[\9U*Y)NH
MAO?RAVN7=([(0/O#Z80,HE^6 ?Y=DM+;DNY5._$>=0,@0%L33V/SJD34#9()
M@SYR9<,R'325$?-WU 1JK%]S*D*U?X[*8\[&&4U^25-A*/#K9!V^O5"5(W5!
M9=K%9:<N(R7>UQ)OD!)%VE'18=_RD'"BVXS0F$"FJR/EJ2H?9;+?ARA7+@GT
M1:&(I)9SD%/^2 DO1JIR1!1$PZ3!N!U$+FU9)SS.96&0U>Q-DO(W69S7LIKR
M@"M9G<1] U?E EG%^DH=U"K6")+^&M:($#Q,/S'2"N]_OY6_)]'N(2L2SN3K
M[R5-BX2M.NZ2PK3'.KEE;)YX6<&542O2-,O#')N&2=TR^79JFURGS(7FPH.B
MK#AF1HD3_/TA@G8$,8PZ]SQS4#6 ?,B@U,GY5"&<:Q>C=3OIM),ZJ2Y;A':&
MH$>BRZ&!'H9HU.)"W&_%$S[F&_(NE9$I-=#%F4Z\)A\FZKKA4,FJTX!&X9)'
MC347XJB!!D,:-B"^BIG!$RW+G1@QKV5R'1-;3+4@:6*4?L"/IC0Y%><)<$4%
M)%)X:7#:3RF:TO4M U0ZV%$TX($=0A.VANKMID>:TH]H=T6+.$\.IKMVIAI0
M&T5&J?M8:';4JM*D51QA[]5+=L4&;%YIL=%K ;;W94=/9PL,"#I..V&+0 @A
MR,,^!FG*HP5XZ+WV8#Z&.N*X2BU77AI1\0(Z+,.*$14@.'[,/J-=^6D'<+\@
M('(',O8[ORJ BU1G*:MLD*@;MNIN[\-3W>>0N/SI&(D<M[1HGYG;(EU=*L/C
MUZR+#BVG6OQ1U:8>[D.JHS1:QW%^I!N25YI5F3A#X($#S#3<<,#8A(5!]9$J
M$+W*SQ.]TOOT*RV?(GU4GD-%J&6"BPXZ\-<)PT^UR'U*6#W"*R*L&\8HTQ*>
MK>5YJH="(3S8<L$94YU5 RR@G!8/,,!:@+W5@?YS=G/D[S3PNR7:"$._-K Y
MK=',HQ?J8(?GC,@VQ$VI&9,Y3J:ZIX[5?A=/S5OKV'KO>RMU_%3IB.X13#AU
M<@Z+@W22GP !*TP\0_W@P,5G<Z)\N8N*8OT],641L=2#C$6P:##<'*\*$5&*
M?./E<*,%7/I@$ O@T@&P$+H[113]3$6NYLU]^DAY:JHD?;V(BJ3X)<U>"IJ_
M\]G[;7HXENQG9B162_"PK\M5Q@]:76"XW+<QH+R@)0>!-\V3./S)G0$Y9+TP
MZ+$TOK046QI<4R:*M&#C1ORV3C=7])WNL@,?:6ZBN)&7OY"FG2(ZU@:;'+IJ
M,QAIJXKB<D.K*CG5)=]D;;RK*'Y]U9TFP7>4VP0)NL.F1-'+K[#9NYD4PW)@
M\?-#"0>AW4T1?#SK#-H-FU_2FFXQ\Y.M.@%T-UF^I_GU_K#+/BDU T]=%@I\
M&DD'\P51C-3E\%%HLG 'B8N;UPF-,YIY-EC>IU[(;!7' 6=;7IOA6-G (#JP
MM@&ERYAZ!%!G,/D$N/XDG/-+9$9IOQ04. ?2]0WTT]W]P_7CQ1K?6:H-V0'@
M@E9TPMTT:\(\5%Q?N;@X%DE*B^*)OLK3._.FF:4>Y"/ %@T&#R)6/P>P6^9D
M_,'KK2Z6A\&._+!U9ZM7#A(;/0GU6 A@<TAISD'OJVPY83BZ3MERH;2,1KU"
M4(-17[9^[U6_XP]%2B-V1J+E+.@T$+E:4A:8::9S?<AVT8;F>PNX^L7 X#60
M;V"6ND0 $%,;LPNR!2WI!C,/B\X*M8<\>SENCKD9:?U24$ ;2#>(C:D*X,-,
M;<@.RA:THA/(W*TY*\2>XF1'OS^\1?G>,EJJ2H(]-J^2<C#K$86(+(6/.;UE
MN^^P+VM6M\?7O<T[$_J^9NDEOR^_XX=R(DR^N8YC.0)PJ0F%3B<M^N9DE;[$
M3:WJ<OFI'CY^W?NF@V?@CG'"-U@'31OK-\>X;!VTG3);V89_6T7 &8%5!\6P
MQNMT3AA/=_+06>#<+?W)!&"?N,XO /H&9(.F>H+OAK(9=[03&T?K='/'OK5[
MCKY7%UHN:$JW2=E_U%VQCS.N.<#MGI'Z#C),5@\05NU4>7O$\;YH:T58:_4U
M*_*'JL$_DF]UFZC;2%,ZO;_;-*7'$1 ^D,D9S(J::+A5:6&!J!J0.+>B_)6I
MBH9#&BV.S/S0@@B2"K=IG.WI""9H*\(30:^#C@>R!A0-7)XC]59%IN6O'K\-
M@ L6(&FH8$$1)!/,PY6=$+;Z\+RP:J2C1V\"$^!PX:V:J!  3=Q0IF&+&\1
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MUO>@AN^ZR\\/@Z]:X5:*$(<08GK5H.G#7(V8R<\.W&^ODMV1C^%/-#[FNG>
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M4]M\SZ)NG:<OE9,EW/<'((PSNEW,'9U9>=3?]YF51"!NY=>(O_U66D_9>^4
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MS<5P3BS6M%H#=>4<SGF86>'%)6EC,]>=9.2U0"K#.<8T'M5:@ 3MOMB=I.E
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M;[\'*:"@[S6(X@#0"VND'@-!4D]&1RH :<U 6OT[QQ#G9^(! !>XZXGSI.;
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M=D*9>$UVFUN#/ G6MP;/03@+XVEU:S!;WA $M026^EL7J^9 0/X8[5IA))3
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M0M>"Z7F82XH#-9!"]3Q$]JUX7FZR=G/CJ!1 40N$R7S5YE8!M%!;1\+N*":
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M2X[LFU@\B%2UR=DM"]B9K0XJ3H@MB1R$WT&.MF<EV*J(RUPL5+,K46-R\/&
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M'7@H_1/P37[^MKGHT@UZ53V0*!/970Y\/6)'GL7]:\$.).UXEY:'D<#\&-*
M(CFW"CR.THWVSVEMIC(X6TE*@\"87@%T.(I)G([RB++RK!VWDM7K@/EJG21$
MRU\=@:L$H2R'J$WT+XS]=?)F,%P5M4!Z3#:P#H>M%J^K7* #4  CVXBB%LB1
M>1W6LF5(\BXF5PD^&4@NLCQ9B'0/HMYHHJX)TQ^S,X*6-8)L$URNDG@.8%2?
MO)V(>/JT"%*=/457=?*)*_U;OQ.\!+2K'*!#T(<5.ONI?J<JG%/8'U"8D&=*
MO R=J\2?/':U;)DSZUKHC>32\B"$H<WR4IIH(QH!R56JS_YY75[T JZI"%]P
M>M-22U6!M8[YN7T;=M6H7*7R9#A70]OC^0A3C#^61B6=!456'F8^IKUXES84
M&JFKS)X,XWD#![V K@' YC<UJX,^FI%E2R!IY@M0!9_$D&^"T%4N4$>JD:5Y
M32W@IXU*P ^36X1#C/BMOX.<F'9?'8QP"3)7>3Q[I(T<H3LE8%7C.DCMRYD@
MHMY35QDR^Z'B6QB'BV*A)&.K#(#D<A>027N?$$EO726^[(F2X%5/2;T,[.&8
MUB932O9[ZRHM95^4_%>2KFQAU*6[O"#,&USD=+/R4!!=)9#LA]'*3V0+"VGB
M498'G6>*$:\B8Y\V#0""O>Y--U1*9_BK6 .CYT*J+,PRC+1HA+W#CAH#P0QO
M=,-&T\J5(C"I@U9!\]^/)X0S>1#JXX%I9V.JRJY%?EJD2('B1"\M#[+EF@=<
M,2@_W2O0$I1;FW=>1/J0L/@W2R,"UNP9)V_RV&SU=)^K>&SGKR*=AIFX2<.I
M*G% =Q^%>=P[XX.1#G8M,D*1K8U1@PC+?1%,,<M)H9S#J"J33X=,5TL=JY :
M,/'HQMJLQ3:3(;S?1?CXE(O9"'H1/(K+&-119#G&!-%H@J(FR,>[8Z6Q0FAQ
M$WKARRO[O8N\&YCZ1/GT^4"A$JIJ()?WN<_1@R:4H:<83,0!:=/+\1SV9\M[
M]3OXSED(LUWX4$!+Y$'(K#:(S;L''$K.K;$3U+</F330$ ?;H4LQ?B7\!Y]%
MO 017O/U'^U W@^3N+O*BD!OOY'@B>[DIT&:OH7Q8[E;M8>S77_RZ2-S;#,3
MJ1/SL#E OT/@W J<9:881%P*66F!4%<%\7 [B#7FWPR;W^$0$=(.K#W8V[\P
MTXM6[8)@N1\*M)HT6@)W%10QR8.(<86_"@'8+,S?RG2[,%^6^]IT*$&+ZMLW
MZ%F61.&L4K-X5M^ C#&3:Q!/PR!:/^,T6>V=M \*\<G!UIRB0AGM2%EI\ND3
MLVNH0_E*MN0&X+T-;[1M@-)XC^X7!O2<ACD#9DSL;ALDW@8NV@:$%[#:)QM4
ME<FGS\SQR2AV3+C<Q>%MX*)E*I^;(,W?ZNZJ)V_UOVA&K'DC("W.6YK&(]D6
MH:/01[SZH!W;^X5!ALS[:%NF]'S7D0TKII$[Q^W/G'9MZU$IZ?RPH@ZY=<W^
MQ#5E[HN9X*'>TV%%_G'O!OR)ZSI )NQ]/B2]]3=NCYMW9UQI%-MM.11@O W0
MP_>R[--'YM.&@DXY_XT0L@7_H6YHBW3Z%&1B])@*U0BF"X.(.)^-VN]--$C8
MHO.8,D1[Z"N*@R0X=Y *>9NP4\? %EB'X&=T^_<D_>,EC"*QUV^UQ[Z^)LP9
MG,[<2AXDO)D"<A4JQZFORBA?E,$?3,F3%X==.*<EU)HQ%0I7$6RXXD.O3/NG
M49!EAO&AJ3HP5WEI%], \C=631V//BS17F'0<.Y0[FIFB*MD HB_L6DP$W$2
MEX ,@O+OE(7EA&E7HR.$H$\.P-_ ,RU3-9V\R1O0S-(=?A4&'^>.J_$\W[E(
M/(Z6(T5F=#>JJPICG3DD<>>\VZC;KF &%D;'0F>J(.O?XS#?VU'K35_ZRC"2
MN7-_&1$H)]\4GZMP/$Z/>=0,>Z5[EJVM"..%,YAU,T.8(:J!A?.Q.@7"9NLR
MRPHQ.P,MCQ]AZ@N363G[9=?B1_DG]9'0I $0\! O,79HI,Z(Y@A=!1%J^A:1
M&-6_)^D?B#IX#G/LEWP(;Y>"*8[SX5 CRD@8KB(),?J<]_#PY/,0]_9&8]0"
MH*L01$RJL'S]%3]6F>,Q_;G*I7J_-(B1,Y5;*YI).*XB$S&1BL$Y0'5OTN0E
MA'/)R=OW3,PNXS7<T10VHN46%*0%ORC@=YMG@ K^VS4,LAVBW[*1JKA SAM5
MR8$O9 Y'%3%;G6I'TVFQ*$K'P#,Q#Z>A.E".KC+(R+L-@BTZ5X&1G)[1:BE+
M9^(!Y%2DXADVIM/P.8@"*GJ(:54 SADTHOF^SQB;J]!';F,!K'IZ%8"PE21*
MB@*P(7K ZDDCL7@>UF<GK;#RUF:KY.335V^W9U(H[R(\S^;E3&4(6*NM@EAE
M/9"-MP81 V"\L7>(*79<Y%D>Q#. >P(K @ >SV_%2Q*]P&\N@FD8@4"H2=>H
M,H#W;L-LBXXWDH[+"_7*@E?IK]FU>KT&2&.(CIV&$[4"DJMX.8YMF+4^8V_1
M;$^9O93E :1WQQ8#0 1K/9FU",[*_BW=/^Z2:':1I/<B783Q\KYU/(>>@0PH
M#DWK@PB&Z'ZFY]0.(,%Q3U8N@N-;#,-WG]R)*%J^W;DN\))S/-^;92B:+9H
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M]B8SD'0X#X/U[J04 : 9Q;,K^#6ZA>%S>$S0*3#$W[1*,5O[VSA_4N[,^ND
M#&5FA=0KD5KY^I"/JW!'3OU+OC^#,.,\JNPB<T$Z?.T5!%!,)I^FI*MPN(IA
MY/;50I6O]_LS3*-/8@3B$"^EV:I,RU?&3B-?,>BK G#F_4$C HV1^1O8: DQ
MNTC2V^0MB' B41Z_]XN#^)@WYTVG9!J-JRA 3#Y;+M>:7;M&N<S</P7Q;TDR
M^Q%&JI<3O?8#F&.^&QW"UL!03*Y"%CE=A,Z67Y["SCZ<+9_P1AN(U JDJP>0
MF6W"C98?,UB\T8>ZF*JJ=]R/(-;3.O*5KLM>]K1H#:3(?#'O<-HP ^LJRE$7
M.]#[9#F]+>]/-;O.W>( T,>C@A*-JUA$;L-(3Z=I(6;5OND-^H_K$SE#RTL#
MO(&XGEJ1I0+#&Y^(XJI\CGU6"-CH7HL?9VGQ.'I^AG-I*6Z2,V4M@.OCD<X$
M5&>!A7KVU;\(PK1\BO!-!%F1+C-X#,-I?]VWLQ!X2;![)D[[JFJ3SU^_]+IU
MV3BOCM,J5N0WD3\EL 5_$5DN1,U5\N1MO_"JF-:AW^%G)I^/F6=</8/RS8Y[
M*7C[$,!--JK/Q\Q6&_>,RC5' =_;AP%\^:L^<SW6,Z!3SG\CA-[FT77\2NB8
M>9/7UR2A$8&W:70[?T%TS&Q9TQ!'L&T(;!"O&AI=ZZ3A2Y"+FRB8JKWMU15
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M5,6@G<F70^X0M%H.B M5>YC>OJ):R^CD;?W/?P]AI4FG3V]7XD5$NBC61@V
ME+CW6_:DRK7#!K"W+ZNDT_4^7'W8:IMV0&;,:[H-MQKM, ?L[2.K-:S+^+G(
MLU(^!UKW744MD ?S8;X!?1H]H% .)]6+*^H/&U%_N!8*=Q#S+JG?0NGH/=6
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MPE0H[S=! &]6P5KLX6H3=2N>5SMFBA%5'8#JQ1G?$ C!&6\^OUJW=<N.I"@
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MG-Z.N')\FS(CZ:_GD01AWYPL8+D-\G)"O\*/H-#5AWU%+=R9<=^Q]'+VU\O
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M<V%M+FAT;5!+ 0(4 Q0    ( ,N+>U@W-LDW?QP" +%T @ 1
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M83 U+FIP9U!+ 0(4 Q0    ( ,N+>UCC,)?8,:0   <  0 1
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M83$P+FIP9U!+ 0(4 Q0    ( ,N+>UCQ_V5-^(L   'I   1
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M83$U+FIP9U!+ 0(4 Q0    ( ,N+>UA<$D*XJAP  -1& 0 1
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M&@!S8VQX+3(P,C,Q,C,Q7W!R92YX;6Q02P4&     !< %P"Z!0  %<T:

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>d759370dposam_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sclx="http://www.vickersvantagecorp.com/20231231"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sclx-20231231.xsd" xlink:type="simple"/>
    <context id="PAsOn12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn09_25_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2023-09-25</instant>
        </period>
    </context>
    <context id="P04_30_2023To04_30_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2023-04-30</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="P06_02_2022To06_02_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2022-06-02</startDate>
            <endDate>2022-06-02</endDate>
        </period>
    </context>
    <context id="PAsOn06_30_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="P06_27_2023To06_27_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2023-06-27</startDate>
            <endDate>2023-06-27</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="P02_13_2023To02_13_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2023-02-13</startDate>
            <endDate>2023-02-13</endDate>
        </period>
    </context>
    <context id="PAsOn04_30_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:PatentRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AcquiredTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AssembledWorkforceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AcquiredLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_MaximumMembersrtRangeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_WarrantsMemberusgaapAwardTypeAxis_WarrantTransferAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:WarrantTransferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RomegLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AssembledWorkforceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AcquiredLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AcquiredTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">sclx:PatentRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_BRileyPurchaseAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:BRileyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_WarrantsMemberusgaapAwardTypeAxis_WarrantTransferAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:WarrantTransferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_MaximumMembersrtRangeAxis_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ResearchMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_PreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RomegLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_EquityUnitPurchaseAgreementsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_GloperbaMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:GloperbaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_MaximumMembersrtRangeAxis_NonCancelableLeaseAgreementsMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentFacilitiesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sclx:ResearchAndDevelopmentFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:NonCancelableLeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_MinimumMembersrtRangeAxis_NonCancelableLeaseAgreementsMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentFacilitiesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sclx:ResearchAndDevelopmentFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:NonCancelableLeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants2MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrants2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants4MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrants4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants3MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrants3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants1MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrants1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:ARYorkvillePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:AtmSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_NonEmployeeDirectorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:NonEmployeeDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CoveLaneMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:CoveLaneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_HudsonBayMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:HudsonBayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_SorrentoMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_StockOptionsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_PublicWarrantsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ConvertibleDebenturesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ConvertibleDebenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_SharesIssuablePursuantToEsppMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SharesIssuablePursuantToEsppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_PrivateWarrantsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RetainerSharesMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:RetainerSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_WarrantsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_StockOptionsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PublicWarrantsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ConvertibleDebenturesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ConvertibleDebenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PrivateWarrantsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_RetainerSharesMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:RetainerSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_SharesIssuablePursuantToEsppMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SharesIssuablePursuantToEsppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ThreeCustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_WarrantsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_StockOptionsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ConvertibleDebenturesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ConvertibleDebenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_PrivateWarrantsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_RetainerSharesMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:RetainerSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_SharesIssuablePursuantToEsppMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sclx:SharesIssuablePursuantToEsppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_FormerEmployeeOneMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:FormerEmployeeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_FormerEmployeeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:FormerEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_EmployeeStockPurchasePlanMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sclx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sclx:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_StockOptionMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sclx:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ConvertibleDebtSecuritiesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_MaximumMembersrtRangeAxis_StockOptionMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sclx:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_MinimumMembersrtRangeAxis_StockOptionMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sclx:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_EpoladermMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sclx:EpoladermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_EnveltaMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sclx:EnveltaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ProbudurMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sclx:ProbudurMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ThreeCustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_WarrantsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sclx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:ARYorkvillePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis_CommonStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:ARYorkvillePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_EquityUnitPurchaseAgreementsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_BRileyPurchaseAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:BRileyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_NonEmployeeDirectorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:NonEmployeeDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_MaximumMembersrtRangeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_MinimumMembersrtRangeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PennyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_SubsequentPennyWarrants3MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrants3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_SubsequentPennyWarrants2MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrants2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_SubsequentPennyWarrants1MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrants1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_SubsequentPennyWarrants4MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrants4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockPreferredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn04_30_2022_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2023_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="P11_17_2022To11_17_2022_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:ARYorkvillePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-17</startDate>
            <endDate>2022-11-17</endDate>
        </period>
    </context>
    <context id="P11_17_2022To11_17_2022_BRileyPurchaseAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:BRileyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-17</startDate>
            <endDate>2022-11-17</endDate>
        </period>
    </context>
    <context id="PAsOn11_17_2022_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:ARYorkvillePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-17</instant>
        </period>
    </context>
    <context id="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-21</startDate>
            <endDate>2023-03-21</endDate>
        </period>
    </context>
    <context id="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-21</startDate>
            <endDate>2023-03-21</endDate>
        </period>
    </context>
    <context id="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-21</startDate>
            <endDate>2023-03-21</endDate>
        </period>
    </context>
    <context id="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ShareBasedCompensationAwardTrancheThreeMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-21</startDate>
            <endDate>2023-03-21</endDate>
        </period>
    </context>
    <context id="P03_21_2023To03_21_2023_EquityUnitPurchaseAgreementsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-21</startDate>
            <endDate>2023-03-21</endDate>
        </period>
    </context>
    <context id="P06_27_2023To06_27_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-27</startDate>
            <endDate>2023-06-27</endDate>
        </period>
    </context>
    <context id="PAsOn12_22_2023_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis_CommonStockMemberusgaapStatementClassOfStockAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:AtmSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-22</instant>
        </period>
    </context>
    <context id="P05_31_2022To05_31_2022_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_SorrentoMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-31</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="P06_14_2022To06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RomegLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-14</startDate>
            <endDate>2022-06-14</endDate>
        </period>
    </context>
    <context id="PAsOn06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RomegLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-14</instant>
        </period>
    </context>
    <context id="P09_30_2023To09_30_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-30</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P04_30_2023To04_30_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:ARYorkvillePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-30</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="P11_30_2022To11_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-30</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="PAsOn03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-21</instant>
        </period>
    </context>
    <context id="PAsOn10_11_2023_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-11</instant>
        </period>
    </context>
    <context id="PAsOn10_11_2023_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-11</instant>
        </period>
    </context>
    <context id="PAsOn06_27_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-27</instant>
        </period>
    </context>
    <context id="P07_01_2023To07_01_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-01</endDate>
        </period>
    </context>
    <context id="PAsOn09_21_2023_WarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-21</instant>
        </period>
    </context>
    <context id="PAsOn09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-21</instant>
        </period>
    </context>
    <context id="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-21</instant>
        </period>
    </context>
    <context id="PAsOn09_21_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-21</instant>
        </period>
    </context>
    <context id="PAsOn09_21_2023_PublicWarrantsMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-21</instant>
        </period>
    </context>
    <context id="PAsOn09_21_2023_PrivateWarrantsMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sclx:PrivateWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-21</instant>
        </period>
    </context>
    <context id="PAsOn09_21_2023_ClosingPennyWarrantMemberusgaapClassOfWarrantOrRightAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:ClosingPennyWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-21</instant>
        </period>
    </context>
    <context id="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-21</instant>
        </period>
    </context>
    <context id="PAsOn09_21_2023_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PennyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-21</instant>
        </period>
    </context>
    <context id="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:PennyWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-21</instant>
        </period>
    </context>
    <context id="PAsOn09_21_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sclx:SubsequentPennyWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-21</instant>
        </period>
    </context>
    <context id="PAsOn09_21_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-21</instant>
        </period>
    </context>
    <context id="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-21</endDate>
        </period>
    </context>
    <context id="P09_21_2023To09_21_2023_FristInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:FristInstallmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-21</endDate>
        </period>
    </context>
    <context id="P09_21_2023To09_21_2023_SecondInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:SecondInstallmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-21</endDate>
        </period>
    </context>
    <context id="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ThirdInstallmentMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ThirdInstallmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-21</endDate>
        </period>
    </context>
    <context id="P09_21_2023To09_21_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-21</endDate>
        </period>
    </context>
    <context id="P09_21_2023To09_21_2023_MonthlyBasisMemberSCLXDebtPayableAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:DebtPayableAxis">sclx:MonthlyBasisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-21</endDate>
        </period>
    </context>
    <context id="P09_21_2023To09_21_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-21</endDate>
        </period>
    </context>
    <context id="P09_21_2023To09_21_2023_FristInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:FristInstallmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-21</endDate>
        </period>
    </context>
    <context id="P09_21_2023To09_21_2023_SecondInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:SecondInstallmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-21</endDate>
        </period>
    </context>
    <context id="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_ThirdInstallmentMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ThirdInstallmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-21</endDate>
        </period>
    </context>
    <context id="P09_21_2023To09_21_2023_FourthInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:FourthInstallmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-21</endDate>
        </period>
    </context>
    <context id="P09_21_2023To09_21_2023_FiveInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:FiveInstallmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-21</endDate>
        </period>
    </context>
    <context id="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SixInstallmentMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:SixInstallmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-21</endDate>
        </period>
    </context>
    <context id="P07_05_2023To07_05_2023_JuniorDipFacilityMemberusgaapLongtermDebtTypeAxis_SorrentoMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:JuniorDipFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-05</startDate>
            <endDate>2023-07-05</endDate>
        </period>
    </context>
    <context id="PAsOn07_05_2023_JuniorDipFacilityMemberusgaapLongtermDebtTypeAxis_SorrentoMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:JuniorDipFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-05</instant>
        </period>
    </context>
    <context id="P08_31_2023To08_31_2023_HudsonBayMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:HudsonBayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-31</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="P12_22_2023To12_22_2023_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-22</startDate>
            <endDate>2023-12-22</endDate>
        </period>
    </context>
    <context id="P12_22_2023To12_22_2023_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PurchaseAgreementAxis">sclx:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-22</startDate>
            <endDate>2023-12-22</endDate>
        </period>
    </context>
    <context id="PAsOn05_04_2023_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-04</instant>
        </period>
    </context>
    <context id="PAsOn05_04_2023_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-04</instant>
        </period>
    </context>
    <context id="PAsOn05_04_2023_MaximumMembersrtRangeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-04</instant>
        </period>
    </context>
    <context id="PAsOn05_04_2023_MinimumMembersrtRangeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-04</instant>
        </period>
    </context>
    <context id="PAsOn01_17_2023_TwoThousandTwentyThreeInducementPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyThreeInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-17</instant>
        </period>
    </context>
    <context id="P10_01_2022To10_31_2022_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="P02_01_2013To02_28_2013_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MaximumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-02-01</startDate>
            <endDate>2013-02-28</endDate>
        </period>
    </context>
    <context id="P02_01_2013To02_28_2013_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MinimumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-02-01</startDate>
            <endDate>2013-02-28</endDate>
        </period>
    </context>
    <context id="P02_01_2013To02_28_2013_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:DevelopersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-02-01</startDate>
            <endDate>2013-02-28</endDate>
        </period>
    </context>
    <context id="P02_29_2024To02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RodmanRenshawLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-29</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="P02_29_2024To02_29_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-29</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:RodmanRenshawLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="PAsOn02_29_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="PAsOn02_29_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="P02_16_2024To02_16_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-16</startDate>
            <endDate>2024-02-16</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ConvertibleDebtSecuritiesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ConvertibleDebtSecuritiesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SeniorNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockPreferredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:DocumentType contextRef="P01_01_2023To12_31_2023" id="hidden107552269">POS AM</dei:DocumentType>
    <dei:AmendmentFlag contextRef="P01_01_2023To12_31_2023" id="ixv-23974">true</dei:AmendmentFlag>
    <dei:EntityAddressStateOrProvince contextRef="P01_01_2023To12_31_2023" id="hidden107552536">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressStateOrProvince
      contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="hidden107552537">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityCentralIndexKey contextRef="P01_01_2023To12_31_2023" id="ixv-23977">0001820190</dei:EntityCentralIndexKey>
    <dei:AmendmentDescription contextRef="P01_01_2023To12_31_2023" id="ixv-25970">Post-Effective Amendment No.&#160;1</dei:AmendmentDescription>
    <dei:EntityRegistrantName contextRef="P01_01_2023To12_31_2023" id="ixv-25971">Scilex Holding Company</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="P01_01_2023To12_31_2023" id="ixv-25972">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityPrimarySicNumber contextRef="P01_01_2023To12_31_2023" id="ixv-25973">2836</dei:EntityPrimarySicNumber>
    <dei:EntityTaxIdentificationNumber contextRef="P01_01_2023To12_31_2023" id="ixv-25974">92-1062542</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2023To12_31_2023" id="ixv-25975">960 San Antonio Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2023To12_31_2023" id="ixv-25976">Palo Alto</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2023To12_31_2023" id="ixv-25977">94303</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="P01_01_2023To12_31_2023" id="ixv-25978">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P01_01_2023To12_31_2023" id="ixv-25979">516-4310</dei:LocalPhoneNumber>
    <dei:ContactPersonnelName
      contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-25980">Jaisim Shah</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1
      contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-25981">960 San Antonio Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-25982">Palo Alto</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-25983">94303</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-25984">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="P01_01_2023To12_31_2023_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-25985">516-4310</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="P01_01_2023To12_31_2023" id="ixv-25986">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P01_01_2023To12_31_2023" id="ixv-25987">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2023To12_31_2023" id="ixv-25988">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="P01_01_2023To12_31_2023" id="ixv-25989">false</dei:EntityExTransitionPeriod>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration contextRef="PAsOn12_31_2023" id="hidden107552736">http://fasb.org/us-gaap/2023#DerivativeLiabilitiesNoncurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration contextRef="PAsOn12_31_2022" id="hidden107552737">http://fasb.org/us-gaap/2023#DerivativeLiabilitiesNoncurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList contextRef="PAsOn12_31_2023" id="hidden107553186">http://fasb.org/us-gaap/2023#DerivativeLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:ServicingLiabilityAtFairValueOtherChangeInFairValueStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="P01_01_2023To12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      id="hidden107552752">http://fasb.org/us-gaap/2023#OperatingCostsAndExpenses</us-gaap:ServicingLiabilityAtFairValueOtherChangeInFairValueStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-25998"
      unitRef="Unit_USD">3921000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-25999"
      unitRef="Unit_USD">2184000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26000"
      unitRef="Unit_USD">34597000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26001"
      unitRef="Unit_USD">21236000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26002"
      unitRef="Unit_USD">4214000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26003"
      unitRef="Unit_USD">1378000</us-gaap:InventoryNet>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26004"
      unitRef="Unit_USD">4049000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26005"
      unitRef="Unit_USD">4810000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26006"
      unitRef="Unit_USD">46781000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26007"
      unitRef="Unit_USD">29608000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26008"
      unitRef="Unit_USD">722000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26009"
      unitRef="Unit_USD">772000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26010"
      unitRef="Unit_USD">2943000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26011"
      unitRef="Unit_USD">1131000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26012"
      unitRef="Unit_USD">36485000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26013"
      unitRef="Unit_USD">40591000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26014"
      unitRef="Unit_USD">13481000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26015"
      unitRef="Unit_USD">13481000</us-gaap:Goodwill>
    <us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26016"
      unitRef="Unit_USD">897000</us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment>
    <us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26017"
      unitRef="Unit_USD">944000</us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26018"
      unitRef="Unit_USD">101309000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26019"
      unitRef="Unit_USD">86527000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26020"
      unitRef="Unit_USD">40954000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26021"
      unitRef="Unit_USD">8450000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26022"
      unitRef="Unit_USD">2681000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26023"
      unitRef="Unit_USD">1354000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26024"
      unitRef="Unit_USD">89658000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26025"
      unitRef="Unit_USD">30893000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <sclx:AccruedExpenses
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26026"
      unitRef="Unit_USD">7408000</sclx:AccruedExpenses>
    <sclx:AccruedExpenses
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26027"
      unitRef="Unit_USD">3136000</sclx:AccruedExpenses>
    <sclx:CurrentPortionOfDeferredConsideration
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26028"
      unitRef="Unit_USD">491000</sclx:CurrentPortionOfDeferredConsideration>
    <sclx:CurrentPortionOfDeferredConsideration
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26029"
      unitRef="Unit_USD">264000</sclx:CurrentPortionOfDeferredConsideration>
    <us-gaap:DebtCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26030"
      unitRef="Unit_USD">108429000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26031"
      unitRef="Unit_USD">0</us-gaap:DebtCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26032"
      unitRef="Unit_USD">759000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26033"
      unitRef="Unit_USD">745000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26034"
      unitRef="Unit_USD">250380000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26035"
      unitRef="Unit_USD">44842000</us-gaap:LiabilitiesCurrent>
    <sclx:LongTermPortionOfDeferredConsideration
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26036"
      unitRef="Unit_USD">2895000</sclx:LongTermPortionOfDeferredConsideration>
    <sclx:LongTermPortionOfDeferredConsideration
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26037"
      unitRef="Unit_USD">3387000</sclx:LongTermPortionOfDeferredConsideration>
    <us-gaap:OtherLongTermDebtNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26038"
      unitRef="Unit_USD">17038000</us-gaap:OtherLongTermDebtNoncurrent>
    <us-gaap:OtherLongTermDebtNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26039"
      unitRef="Unit_USD">0</us-gaap:OtherLongTermDebtNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26040"
      unitRef="Unit_USD">1518000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26041"
      unitRef="Unit_USD">1231000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26042"
      unitRef="Unit_USD">2237000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26043"
      unitRef="Unit_USD">665000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26044"
      unitRef="Unit_USD">179000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26045"
      unitRef="Unit_USD">163000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26046"
      unitRef="Unit_USD">274247000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26047"
      unitRef="Unit_USD">50288000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2023"
      id="ixv-26048"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2022"
      id="ixv-26049"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022"
      decimals="4"
      id="ixv-26050"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023"
      decimals="4"
      id="ixv-26051"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-26052"
      unitRef="Unit_shares">45000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-26053"
      unitRef="Unit_shares">45000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-26054"
      unitRef="Unit_shares">29057097</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-26055"
      unitRef="Unit_shares">29057097</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-26056"
      unitRef="Unit_shares">29057097</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-26057"
      unitRef="Unit_shares">29057097</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26058"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26059"
      unitRef="Unit_USD">3000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022"
      decimals="4"
      id="ixv-26060"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023"
      decimals="4"
      id="ixv-26061"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-26062"
      unitRef="Unit_shares">740000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-26063"
      unitRef="Unit_shares">740000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-26064"
      unitRef="Unit_shares">160084250</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-26065"
      unitRef="Unit_shares">100015665</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-26066"
      unitRef="Unit_shares">141348856</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-26067"
      unitRef="Unit_shares">141348856</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26068"
      unitRef="Unit_USD">16000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26069"
      unitRef="Unit_USD">14000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26070"
      unitRef="Unit_USD">407813000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26071"
      unitRef="Unit_USD">412136000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26072"
      unitRef="Unit_USD">-490245000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26073"
      unitRef="Unit_USD">-375914000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockCommonShares
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-26074"
      unitRef="Unit_shares">60068585</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-26075"
      unitRef="Unit_shares">0</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26076"
      unitRef="Unit_USD">90522000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26077"
      unitRef="Unit_USD">0</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26078"
      unitRef="Unit_USD">-172938000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26079"
      unitRef="Unit_USD">36239000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26080"
      unitRef="Unit_USD">101309000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26081"
      unitRef="Unit_USD">86527000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26082"
      unitRef="Unit_USD">46743000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26083"
      unitRef="Unit_USD">38034000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26084"
      unitRef="Unit_USD">31317000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26085"
      unitRef="Unit_USD">15681000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26086"
      unitRef="Unit_USD">10797000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26087"
      unitRef="Unit_USD">3634000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26088"
      unitRef="Unit_USD">12746000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26089"
      unitRef="Unit_USD">9054000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26090"
      unitRef="Unit_USD">9201000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26091"
      unitRef="Unit_USD">119641000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26092"
      unitRef="Unit_USD">64895000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26093"
      unitRef="Unit_USD">50582000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26094"
      unitRef="Unit_USD">4106000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26095"
      unitRef="Unit_USD">3922000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26096"
      unitRef="Unit_USD">3738000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26097"
      unitRef="Unit_USD">152174000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26098"
      unitRef="Unit_USD">88668000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26099"
      unitRef="Unit_USD">67155000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26100"
      unitRef="Unit_USD">-105431000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26101"
      unitRef="Unit_USD">-50634000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26102"
      unitRef="Unit_USD">-35838000</us-gaap:OperatingIncomeLoss>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26103"
      unitRef="Unit_USD">-512000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26104"
      unitRef="Unit_USD">8310000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26105"
      unitRef="Unit_USD">-300000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <sclx:ChangeInFairValueOfDebtAndLiabilityInstruments
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26106"
      unitRef="Unit_USD">7189000</sclx:ChangeInFairValueOfDebtAndLiabilityInstruments>
    <sclx:ChangeInFairValueOfDebtAndLiabilityInstruments
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26107"
      unitRef="Unit_USD">0</sclx:ChangeInFairValueOfDebtAndLiabilityInstruments>
    <sclx:ChangeInFairValueOfDebtAndLiabilityInstruments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26108"
      unitRef="Unit_USD">0</sclx:ChangeInFairValueOfDebtAndLiabilityInstruments>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26109"
      unitRef="Unit_USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26110"
      unitRef="Unit_USD">28634000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26111"
      unitRef="Unit_USD">-12463000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <sclx:NotesPrincipalIncrease
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26112"
      unitRef="Unit_USD">0</sclx:NotesPrincipalIncrease>
    <sclx:NotesPrincipalIncrease
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26113"
      unitRef="Unit_USD">0</sclx:NotesPrincipalIncrease>
    <sclx:NotesPrincipalIncrease
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26114"
      unitRef="Unit_USD">-28000000</sclx:NotesPrincipalIncrease>
    <us-gaap:InterestExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26115"
      unitRef="Unit_USD">1068000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26116"
      unitRef="Unit_USD">9604000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26117"
      unitRef="Unit_USD">11764000</us-gaap:InterestExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26118"
      unitRef="Unit_USD">-118000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26119"
      unitRef="Unit_USD">-66000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26120"
      unitRef="Unit_USD">-54000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26121"
      unitRef="Unit_USD">-8887000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26122"
      unitRef="Unit_USD">27274000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26123"
      unitRef="Unit_USD">-52581000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26124"
      unitRef="Unit_USD">-114318000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26125"
      unitRef="Unit_USD">-23360000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26126"
      unitRef="Unit_USD">-88419000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26127"
      unitRef="Unit_USD">13000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26128"
      unitRef="Unit_USD">4000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26129"
      unitRef="Unit_USD">5000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26130"
      unitRef="Unit_USD">-114331000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26131"
      unitRef="Unit_USD">-23364000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26132"
      unitRef="Unit_USD">-88424000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-26133"
      unitRef="Unit_USD_per_Share">-1.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-26134"
      unitRef="Unit_USD_per_Share">-1.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      id="ixv-26135"
      unitRef="Unit_USD_per_Share">-0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      id="ixv-26136"
      unitRef="Unit_USD_per_Share">-0.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      id="ixv-26137"
      unitRef="Unit_USD_per_Share">-0.67</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      id="ixv-26138"
      unitRef="Unit_USD_per_Share">-0.67</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26139"
      unitRef="Unit_shares">130298000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26140"
      unitRef="Unit_shares">130298000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26141"
      unitRef="Unit_shares">134226000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26142"
      unitRef="Unit_shares">134226000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26143"
      unitRef="Unit_shares">132858000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26144"
      unitRef="Unit_shares">132858000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26145"
      unitRef="Unit_shares">132858000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26146"
      unitRef="Unit_USD">13000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26147"
      unitRef="Unit_USD">122430000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26148"
      unitRef="Unit_USD">-264126000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      id="ixv-26149"
      unitRef="Unit_USD">-141683000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26150"
      unitRef="Unit_USD">5822000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26151"
      unitRef="Unit_USD">5822000</us-gaap:AllocatedShareBasedCompensationExpense>
    <sclx:AdjustmentToSharesIssuedInSemnurAcquisitionValue
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26152"
      unitRef="Unit_USD">409000</sclx:AdjustmentToSharesIssuedInSemnurAcquisitionValue>
    <sclx:AdjustmentToSharesIssuedInSemnurAcquisitionValue
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26153"
      unitRef="Unit_USD">409000</sclx:AdjustmentToSharesIssuedInSemnurAcquisitionValue>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26154"
      unitRef="Unit_USD">-88424000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26155"
      unitRef="Unit_USD">-88424000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26156"
      unitRef="Unit_shares">132858000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26157"
      unitRef="Unit_USD">13000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26158"
      unitRef="Unit_USD">128661000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26159"
      unitRef="Unit_USD">-352550000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      id="ixv-26160"
      unitRef="Unit_USD">-223876000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26161"
      unitRef="Unit_shares">202000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26162"
      unitRef="Unit_USD">96000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26163"
      unitRef="Unit_USD">96000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <sclx:AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26164"
      unitRef="Unit_USD">-4127000</sclx:AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue>
    <sclx:AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26165"
      unitRef="Unit_USD">-4127000</sclx:AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue>
    <sclx:Adjustmenttoadditionalpaidincapitaldiscountamortization
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26166"
      unitRef="Unit_USD">-35000</sclx:Adjustmenttoadditionalpaidincapitaldiscountamortization>
    <sclx:Adjustmenttoadditionalpaidincapitaldiscountamortization
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26167"
      unitRef="Unit_USD">-35000</sclx:Adjustmenttoadditionalpaidincapitaldiscountamortization>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="P01_01_2022To12_31_2022_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26168"
      unitRef="Unit_shares">29057000</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="P01_01_2022To12_31_2022_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26169"
      unitRef="Unit_USD">3000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26170"
      unitRef="Unit_shares">2906000</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26171"
      unitRef="Unit_USD">289730000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26172"
      unitRef="Unit_USD">289733000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26173"
      unitRef="Unit_shares">5133000</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26174"
      unitRef="Unit_USD">-1000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26175"
      unitRef="Unit_USD">8707000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26176"
      unitRef="Unit_USD">8706000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <sclx:SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares
      contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26177"
      unitRef="Unit_shares">250000</sclx:SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreementInShares>
    <sclx:SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26178"
      unitRef="Unit_USD">1238000</sclx:SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement>
    <sclx:SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26179"
      unitRef="Unit_USD">1238000</sclx:SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26180"
      unitRef="Unit_USD">5280000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26181"
      unitRef="Unit_USD">5280000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26182"
      unitRef="Unit_USD">-23364000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26183"
      unitRef="Unit_USD">-23364000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2022_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26184"
      unitRef="Unit_shares">29057000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26185"
      unitRef="Unit_USD">3000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26186"
      unitRef="Unit_shares">141349000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26187"
      unitRef="Unit_USD">14000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26188"
      unitRef="Unit_USD">412136000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26189"
      unitRef="Unit_USD">-375914000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26190"
      unitRef="Unit_USD">36239000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <sclx:SharesIssuedUnderStandbyEquityPurchaseAgreements
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26191"
      unitRef="Unit_shares">13218000</sclx:SharesIssuedUnderStandbyEquityPurchaseAgreements>
    <sclx:ValueIssuedUnderStandbyEquityPurchaseAgreements
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26192"
      unitRef="Unit_USD">1000</sclx:ValueIssuedUnderStandbyEquityPurchaseAgreements>
    <sclx:ValueIssuedUnderStandbyEquityPurchaseAgreements
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26193"
      unitRef="Unit_USD">34256000</sclx:ValueIssuedUnderStandbyEquityPurchaseAgreements>
    <sclx:ValueIssuedUnderStandbyEquityPurchaseAgreements
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26194"
      unitRef="Unit_USD">34257000</sclx:ValueIssuedUnderStandbyEquityPurchaseAgreements>
    <sclx:DisbursementOfFundsToSorrentoAmount
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26195"
      unitRef="Unit_USD">-20000000</sclx:DisbursementOfFundsToSorrentoAmount>
    <sclx:DisbursementOfFundsToSorrentoAmount
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26196"
      unitRef="Unit_USD">-20000000</sclx:DisbursementOfFundsToSorrentoAmount>
    <sclx:StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue
      contextRef="P01_01_2023To12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26197"
      unitRef="Unit_USD">-3000</sclx:StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue>
    <sclx:StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26198"
      unitRef="Unit_USD">-53196000</sclx:StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue>
    <sclx:StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares
      contextRef="P01_01_2023To12_31_2023_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26199"
      unitRef="Unit_shares">-60069000</sclx:StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsShares>
    <sclx:StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue
      contextRef="P01_01_2023To12_31_2023_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26200"
      unitRef="Unit_USD">-90522000</sclx:StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue>
    <sclx:StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26201"
      unitRef="Unit_USD">-143721000</sclx:StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue>
    <sclx:IssuanceOfPennyWarrants
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26202"
      unitRef="Unit_USD">10401000</sclx:IssuanceOfPennyWarrants>
    <sclx:IssuanceOfPennyWarrants
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26203"
      unitRef="Unit_USD">10401000</sclx:IssuanceOfPennyWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26204"
      unitRef="Unit_shares">475000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26205"
      unitRef="Unit_USD">750000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26206"
      unitRef="Unit_USD">750000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <sclx:ConversionOfConvertibleDebenturesIntoCommonStockShares
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26207"
      unitRef="Unit_shares">632000</sclx:ConversionOfConvertibleDebenturesIntoCommonStockShares>
    <sclx:ConversionOfConvertibleDebenturesIntoCommonStockValue
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26208"
      unitRef="Unit_USD">7735000</sclx:ConversionOfConvertibleDebenturesIntoCommonStockValue>
    <sclx:ConversionOfConvertibleDebenturesIntoCommonStockValue
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26209"
      unitRef="Unit_USD">7735000</sclx:ConversionOfConvertibleDebenturesIntoCommonStockValue>
    <sclx:RetainerSharesIssued
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26210"
      unitRef="Unit_shares">4000000</sclx:RetainerSharesIssued>
    <sclx:RetainerSharesIssuedValue
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26211"
      unitRef="Unit_USD">1000</sclx:RetainerSharesIssuedValue>
    <sclx:RetainerSharesIssuedValue
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26212"
      unitRef="Unit_USD">0</sclx:RetainerSharesIssuedValue>
    <sclx:RetainerSharesIssuedValue
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26213"
      unitRef="Unit_USD">1000</sclx:RetainerSharesIssuedValue>
    <sclx:IssuanceOfCommonStockUponWarrantsExerciseShares
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26214"
      unitRef="Unit_shares">45000</sclx:IssuanceOfCommonStockUponWarrantsExerciseShares>
    <sclx:IssuanceOfCommonStockUponWarrantsExerciseValue
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26215"
      unitRef="Unit_USD">521000</sclx:IssuanceOfCommonStockUponWarrantsExerciseValue>
    <sclx:IssuanceOfCommonStockUponWarrantsExerciseValue
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26216"
      unitRef="Unit_USD">521000</sclx:IssuanceOfCommonStockUponWarrantsExerciseValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26217"
      unitRef="Unit_shares">365000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26218"
      unitRef="Unit_USD">614000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26219"
      unitRef="Unit_USD">614000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26220"
      unitRef="Unit_USD">14596000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26221"
      unitRef="Unit_USD">14596000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26222"
      unitRef="Unit_USD">-114331000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26223"
      unitRef="Unit_USD">-114331000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-26224"
      unitRef="Unit_shares">29057000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26225"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26226"
      unitRef="Unit_shares">160084000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26227"
      unitRef="Unit_USD">16000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26228"
      unitRef="Unit_USD">407813000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26229"
      unitRef="Unit_USD">-490245000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2023_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26230"
      unitRef="Unit_shares">-60069000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2023_TreasuryStockPreferredMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-26231"
      unitRef="Unit_USD">-90522000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26232"
      unitRef="Unit_USD">-172938000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26233"
      unitRef="Unit_USD">-114331000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26234"
      unitRef="Unit_USD">-23364000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26235"
      unitRef="Unit_USD">-88424000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26236"
      unitRef="Unit_USD">4146000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26237"
      unitRef="Unit_USD">3961000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26238"
      unitRef="Unit_USD">3779000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26239"
      unitRef="Unit_USD">65000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26240"
      unitRef="Unit_USD">3142000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26241"
      unitRef="Unit_USD">7909000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <sclx:NotesPrincipalIncrease
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26242"
      unitRef="Unit_USD">0</sclx:NotesPrincipalIncrease>
    <sclx:NotesPrincipalIncrease
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26243"
      unitRef="Unit_USD">0</sclx:NotesPrincipalIncrease>
    <sclx:NotesPrincipalIncrease
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26244"
      unitRef="Unit_USD">-28000000</sclx:NotesPrincipalIncrease>
    <sclx:PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26245"
      unitRef="Unit_USD">0</sclx:PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount>
    <sclx:PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26246"
      unitRef="Unit_USD">21190000</sclx:PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount>
    <sclx:PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26247"
      unitRef="Unit_USD">12487000</sclx:PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26248"
      unitRef="Unit_USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26249"
      unitRef="Unit_USD">28634000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26250"
      unitRef="Unit_USD">-12463000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <sclx:NonCashOperatingLeaseCost
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26251"
      unitRef="Unit_USD">507000</sclx:NonCashOperatingLeaseCost>
    <sclx:NonCashOperatingLeaseCost
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26252"
      unitRef="Unit_USD">492000</sclx:NonCashOperatingLeaseCost>
    <sclx:NonCashOperatingLeaseCost
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26253"
      unitRef="Unit_USD">372000</sclx:NonCashOperatingLeaseCost>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26254"
      unitRef="Unit_USD">14596000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26255"
      unitRef="Unit_USD">5280000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26256"
      unitRef="Unit_USD">5822000</us-gaap:ShareBasedCompensation>
    <us-gaap:ProceedsFromInsuranceSettlementOperatingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26257"
      unitRef="Unit_USD">750000</us-gaap:ProceedsFromInsuranceSettlementOperatingActivities>
    <us-gaap:ProceedsFromInsuranceSettlementOperatingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26258"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromInsuranceSettlementOperatingActivities>
    <us-gaap:ProceedsFromInsuranceSettlementOperatingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26259"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromInsuranceSettlementOperatingActivities>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26260"
      unitRef="Unit_USD">-512000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26261"
      unitRef="Unit_USD">8310000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26262"
      unitRef="Unit_USD">-300000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <sclx:ForfeituresOfPrivateWarrants
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26263"
      unitRef="Unit_USD">0</sclx:ForfeituresOfPrivateWarrants>
    <sclx:ForfeituresOfPrivateWarrants
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26264"
      unitRef="Unit_USD">1697000</sclx:ForfeituresOfPrivateWarrants>
    <sclx:ForfeituresOfPrivateWarrants
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26265"
      unitRef="Unit_USD">0</sclx:ForfeituresOfPrivateWarrants>
    <sclx:ChangeInFairValueOfDebtAndLiabilityInstruments
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26266"
      unitRef="Unit_USD">7189000</sclx:ChangeInFairValueOfDebtAndLiabilityInstruments>
    <sclx:ChangeInFairValueOfDebtAndLiabilityInstruments
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26267"
      unitRef="Unit_USD">0</sclx:ChangeInFairValueOfDebtAndLiabilityInstruments>
    <sclx:ChangeInFairValueOfDebtAndLiabilityInstruments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26268"
      unitRef="Unit_USD">0</sclx:ChangeInFairValueOfDebtAndLiabilityInstruments>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26269"
      unitRef="Unit_USD">57000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26270"
      unitRef="Unit_USD">0</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26271"
      unitRef="Unit_USD">0</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26272"
      unitRef="Unit_USD">13361000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26273"
      unitRef="Unit_USD">6968000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26274"
      unitRef="Unit_USD">1142000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26275"
      unitRef="Unit_USD">2838000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26276"
      unitRef="Unit_USD">-1184000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26277"
      unitRef="Unit_USD">1417000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26278"
      unitRef="Unit_USD">441000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26279"
      unitRef="Unit_USD">2629000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26280"
      unitRef="Unit_USD">-1479000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26281"
      unitRef="Unit_USD">-855000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26282"
      unitRef="Unit_USD">-350000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26283"
      unitRef="Unit_USD">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26284"
      unitRef="Unit_USD">19880000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26285"
      unitRef="Unit_USD">2806000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26286"
      unitRef="Unit_USD">-3836000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <sclx:IncreaseDecreaseInAccruedPayroll
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26287"
      unitRef="Unit_USD">1327000</sclx:IncreaseDecreaseInAccruedPayroll>
    <sclx:IncreaseDecreaseInAccruedPayroll
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26288"
      unitRef="Unit_USD">-2379000</sclx:IncreaseDecreaseInAccruedPayroll>
    <sclx:IncreaseDecreaseInAccruedPayroll
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26289"
      unitRef="Unit_USD">-21000</sclx:IncreaseDecreaseInAccruedPayroll>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26290"
      unitRef="Unit_USD">2310000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26291"
      unitRef="Unit_USD">-123000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26292"
      unitRef="Unit_USD">664000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <sclx:IncreaseDecreaseInAccruedRebatesAndFees
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26293"
      unitRef="Unit_USD">58765000</sclx:IncreaseDecreaseInAccruedRebatesAndFees>
    <sclx:IncreaseDecreaseInAccruedRebatesAndFees
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26294"
      unitRef="Unit_USD">23531000</sclx:IncreaseDecreaseInAccruedRebatesAndFees>
    <sclx:IncreaseDecreaseInAccruedRebatesAndFees
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26295"
      unitRef="Unit_USD">-255000</sclx:IncreaseDecreaseInAccruedRebatesAndFees>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26296"
      unitRef="Unit_USD">-711000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26297"
      unitRef="Unit_USD">-392000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26298"
      unitRef="Unit_USD">-80000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInNotesPayableRelatedPartiesCurrent
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26299"
      unitRef="Unit_USD">0</us-gaap:IncreaseDecreaseInNotesPayableRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInNotesPayableRelatedPartiesCurrent
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26300"
      unitRef="Unit_USD">30125000</us-gaap:IncreaseDecreaseInNotesPayableRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInNotesPayableRelatedPartiesCurrent
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26301"
      unitRef="Unit_USD">18210000</us-gaap:IncreaseDecreaseInNotesPayableRelatedPartiesCurrent>
    <sclx:OtherLongTermLiabilities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26302"
      unitRef="Unit_USD">16000</sclx:OtherLongTermLiabilities>
    <sclx:OtherLongTermLiabilities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26303"
      unitRef="Unit_USD">163000</sclx:OtherLongTermLiabilities>
    <sclx:OtherLongTermLiabilities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26304"
      unitRef="Unit_USD">0</sclx:OtherLongTermLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26305"
      unitRef="Unit_USD">-20707000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26306"
      unitRef="Unit_USD">-21258000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26307"
      unitRef="Unit_USD">-28664000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <sclx:AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26308"
      unitRef="Unit_USD">300000</sclx:AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition>
    <sclx:AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26309"
      unitRef="Unit_USD">2060000</sclx:AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition>
    <sclx:AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26310"
      unitRef="Unit_USD">0</sclx:AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26311"
      unitRef="Unit_USD">30000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26312"
      unitRef="Unit_USD">7000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26313"
      unitRef="Unit_USD">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26314"
      unitRef="Unit_USD">-330000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26315"
      unitRef="Unit_USD">-2067000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26316"
      unitRef="Unit_USD">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26317"
      unitRef="Unit_USD">35458000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26318"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26319"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26320"
      unitRef="Unit_USD">24000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26321"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26322"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26323"
      unitRef="Unit_USD">15625000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26324"
      unitRef="Unit_USD">0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26325"
      unitRef="Unit_USD">0</us-gaap:RepaymentsOfConvertibleDebt>
    <sclx:ProceedsFromIssuanceOfRevolvingFacility
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26326"
      unitRef="Unit_USD">86354000</sclx:ProceedsFromIssuanceOfRevolvingFacility>
    <sclx:ProceedsFromIssuanceOfRevolvingFacility
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26327"
      unitRef="Unit_USD">0</sclx:ProceedsFromIssuanceOfRevolvingFacility>
    <sclx:ProceedsFromIssuanceOfRevolvingFacility
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26328"
      unitRef="Unit_USD">0</sclx:ProceedsFromIssuanceOfRevolvingFacility>
    <sclx:RepaymentOfRevolvingFacility
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26329"
      unitRef="Unit_USD">69001000</sclx:RepaymentOfRevolvingFacility>
    <sclx:RepaymentOfRevolvingFacility
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26330"
      unitRef="Unit_USD">0</sclx:RepaymentOfRevolvingFacility>
    <sclx:RepaymentOfRevolvingFacility
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26331"
      unitRef="Unit_USD">0</sclx:RepaymentOfRevolvingFacility>
    <us-gaap:EarlyRepaymentOfSeniorDebt
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26332"
      unitRef="Unit_USD">5000000</us-gaap:EarlyRepaymentOfSeniorDebt>
    <us-gaap:EarlyRepaymentOfSeniorDebt
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26333"
      unitRef="Unit_USD">0</us-gaap:EarlyRepaymentOfSeniorDebt>
    <us-gaap:EarlyRepaymentOfSeniorDebt
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26334"
      unitRef="Unit_USD">0</us-gaap:EarlyRepaymentOfSeniorDebt>
    <sclx:TransactionCostsPaidRelatedToTheRecapitalizationTransaction
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26335"
      unitRef="Unit_USD">1372000</sclx:TransactionCostsPaidRelatedToTheRecapitalizationTransaction>
    <sclx:TransactionCostsPaidRelatedToTheRecapitalizationTransaction
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26336"
      unitRef="Unit_USD">2949000</sclx:TransactionCostsPaidRelatedToTheRecapitalizationTransaction>
    <sclx:TransactionCostsPaidRelatedToTheRecapitalizationTransaction
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26337"
      unitRef="Unit_USD">0</sclx:TransactionCostsPaidRelatedToTheRecapitalizationTransaction>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26338"
      unitRef="Unit_USD">380000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26339"
      unitRef="Unit_USD">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26340"
      unitRef="Unit_USD">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <sclx:DisbursementOfFunds
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26341"
      unitRef="Unit_USD">-20000000</sclx:DisbursementOfFunds>
    <sclx:DisbursementOfFunds
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26342"
      unitRef="Unit_USD">0</sclx:DisbursementOfFunds>
    <sclx:DisbursementOfFunds
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26343"
      unitRef="Unit_USD">0</sclx:DisbursementOfFunds>
    <us-gaap:AcceleratedShareRepurchasesAdjustmentToRecordedAmount
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26344"
      unitRef="Unit_USD">-10000000</us-gaap:AcceleratedShareRepurchasesAdjustmentToRecordedAmount>
    <us-gaap:AcceleratedShareRepurchasesAdjustmentToRecordedAmount
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26345"
      unitRef="Unit_USD">0</us-gaap:AcceleratedShareRepurchasesAdjustmentToRecordedAmount>
    <us-gaap:AcceleratedShareRepurchasesAdjustmentToRecordedAmount
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26346"
      unitRef="Unit_USD">0</us-gaap:AcceleratedShareRepurchasesAdjustmentToRecordedAmount>
    <sclx:TransactionCostsPaidInConnectionWithShareRepurchase
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26347"
      unitRef="Unit_USD">1987000</sclx:TransactionCostsPaidInConnectionWithShareRepurchase>
    <sclx:TransactionCostsPaidInConnectionWithShareRepurchase
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26348"
      unitRef="Unit_USD">0</sclx:TransactionCostsPaidInConnectionWithShareRepurchase>
    <sclx:TransactionCostsPaidInConnectionWithShareRepurchase
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26349"
      unitRef="Unit_USD">0</sclx:TransactionCostsPaidInConnectionWithShareRepurchase>
    <sclx:ProceedsFromTheBusinessCombination
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26350"
      unitRef="Unit_USD">0</sclx:ProceedsFromTheBusinessCombination>
    <sclx:ProceedsFromTheBusinessCombination
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26351"
      unitRef="Unit_USD">3375000</sclx:ProceedsFromTheBusinessCombination>
    <sclx:ProceedsFromTheBusinessCombination
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26352"
      unitRef="Unit_USD">0</sclx:ProceedsFromTheBusinessCombination>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26353"
      unitRef="Unit_USD">1135000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26354"
      unitRef="Unit_USD">96000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26355"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26356"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26357"
      unitRef="Unit_USD">51900000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26358"
      unitRef="Unit_USD">47850000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromSecuredNotesPayable
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26359"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromSecuredNotesPayable>
    <us-gaap:ProceedsFromSecuredNotesPayable
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26360"
      unitRef="Unit_USD">62500000</us-gaap:ProceedsFromSecuredNotesPayable>
    <us-gaap:ProceedsFromSecuredNotesPayable
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26361"
      unitRef="Unit_USD">14700000</us-gaap:ProceedsFromSecuredNotesPayable>
    <us-gaap:ProceedsFromOtherShortTermDebt
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26362"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromOtherShortTermDebt>
    <us-gaap:ProceedsFromOtherShortTermDebt
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26363"
      unitRef="Unit_USD">9857000</us-gaap:ProceedsFromOtherShortTermDebt>
    <us-gaap:ProceedsFromOtherShortTermDebt
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26364"
      unitRef="Unit_USD">47832000</us-gaap:ProceedsFromOtherShortTermDebt>
    <sclx:RepaymentOfPrincipalOnTheScilexPharmaNotes
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26365"
      unitRef="Unit_USD">0</sclx:RepaymentOfPrincipalOnTheScilexPharmaNotes>
    <sclx:RepaymentOfPrincipalOnTheScilexPharmaNotes
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26366"
      unitRef="Unit_USD">-84808000</sclx:RepaymentOfPrincipalOnTheScilexPharmaNotes>
    <sclx:RepaymentOfPrincipalOnTheScilexPharmaNotes
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26367"
      unitRef="Unit_USD">-33387000</sclx:RepaymentOfPrincipalOnTheScilexPharmaNotes>
    <sclx:ProceedsFromRepaymentOfLoansToPurchase
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26368"
      unitRef="Unit_USD">0</sclx:ProceedsFromRepaymentOfLoansToPurchase>
    <sclx:ProceedsFromRepaymentOfLoansToPurchase
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26369"
      unitRef="Unit_USD">-18800000</sclx:ProceedsFromRepaymentOfLoansToPurchase>
    <sclx:ProceedsFromRepaymentOfLoansToPurchase
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26370"
      unitRef="Unit_USD">-48832000</sclx:ProceedsFromRepaymentOfLoansToPurchase>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26371"
      unitRef="Unit_USD">23582000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26372"
      unitRef="Unit_USD">21171000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26373"
      unitRef="Unit_USD">28163000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26374"
      unitRef="Unit_USD">2545000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26375"
      unitRef="Unit_USD">-2154000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26376"
      unitRef="Unit_USD">-501000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26377"
      unitRef="Unit_USD">2184000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      id="ixv-26378"
      unitRef="Unit_USD">4338000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      id="ixv-26379"
      unitRef="Unit_USD">4839000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26380"
      unitRef="Unit_USD">4729000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26381"
      unitRef="Unit_USD">2184000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      id="ixv-26382"
      unitRef="Unit_USD">4338000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestIncomeOperatingPaidInCash
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26383"
      unitRef="Unit_USD">1426000</us-gaap:InterestIncomeOperatingPaidInCash>
    <us-gaap:InterestIncomeOperatingPaidInCash
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26384"
      unitRef="Unit_USD">0</us-gaap:InterestIncomeOperatingPaidInCash>
    <us-gaap:InterestIncomeOperatingPaidInCash
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26385"
      unitRef="Unit_USD">0</us-gaap:InterestIncomeOperatingPaidInCash>
    <us-gaap:StockIssued1
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26386"
      unitRef="Unit_USD">1869000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26387"
      unitRef="Unit_USD">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26388"
      unitRef="Unit_USD">0</us-gaap:StockIssued1>
    <sclx:ConversionOfConvertibleDebenturesIntoCommonStock
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26389"
      unitRef="Unit_USD">7735000</sclx:ConversionOfConvertibleDebenturesIntoCommonStock>
    <sclx:ConversionOfConvertibleDebenturesIntoCommonStock
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26390"
      unitRef="Unit_USD">0</sclx:ConversionOfConvertibleDebenturesIntoCommonStock>
    <sclx:ConversionOfConvertibleDebenturesIntoCommonStock
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26391"
      unitRef="Unit_USD">0</sclx:ConversionOfConvertibleDebenturesIntoCommonStock>
    <sclx:RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26392"
      unitRef="Unit_USD">2523000</sclx:RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification>
    <sclx:RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26393"
      unitRef="Unit_USD">0</sclx:RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification>
    <sclx:RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26394"
      unitRef="Unit_USD">0</sclx:RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification>
    <sclx:OramedNoteIssuanceAtFairValue
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26395"
      unitRef="Unit_USD">106252000</sclx:OramedNoteIssuanceAtFairValue>
    <sclx:OramedNoteIssuanceAtFairValue
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26396"
      unitRef="Unit_USD">0</sclx:OramedNoteIssuanceAtFairValue>
    <sclx:OramedNoteIssuanceAtFairValue
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26397"
      unitRef="Unit_USD">0</sclx:OramedNoteIssuanceAtFairValue>
    <sclx:OtherNonCashConsiderationInConnectionWithShareRepurchase
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26398"
      unitRef="Unit_USD">26154000</sclx:OtherNonCashConsiderationInConnectionWithShareRepurchase>
    <sclx:OtherNonCashConsiderationInConnectionWithShareRepurchase
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26399"
      unitRef="Unit_USD">0</sclx:OtherNonCashConsiderationInConnectionWithShareRepurchase>
    <sclx:OtherNonCashConsiderationInConnectionWithShareRepurchase
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26400"
      unitRef="Unit_USD">0</sclx:OtherNonCashConsiderationInConnectionWithShareRepurchase>
    <sclx:ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26401"
      unitRef="Unit_USD">1310000</sclx:ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses>
    <sclx:ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26402"
      unitRef="Unit_USD">0</sclx:ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses>
    <sclx:ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26403"
      unitRef="Unit_USD">0</sclx:ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses>
    <sclx:RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26404"
      unitRef="Unit_USD">0</sclx:RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement>
    <sclx:RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26405"
      unitRef="Unit_USD">289733000</sclx:RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement>
    <sclx:RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26406"
      unitRef="Unit_USD">0</sclx:RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement>
    <sclx:DeferredConsiderationForRomegIntangibleAssetAcquisition
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26407"
      unitRef="Unit_USD">0</sclx:DeferredConsiderationForRomegIntangibleAssetAcquisition>
    <sclx:DeferredConsiderationForRomegIntangibleAssetAcquisition
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26408"
      unitRef="Unit_USD">3650000</sclx:DeferredConsiderationForRomegIntangibleAssetAcquisition>
    <sclx:DeferredConsiderationForRomegIntangibleAssetAcquisition
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26409"
      unitRef="Unit_USD">0</sclx:DeferredConsiderationForRomegIntangibleAssetAcquisition>
    <sclx:PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26410"
      unitRef="Unit_USD">0</sclx:PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount>
    <sclx:PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26411"
      unitRef="Unit_USD">4162000</sclx:PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount>
    <sclx:PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26412"
      unitRef="Unit_USD">0</sclx:PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount>
    <sclx:FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26413"
      unitRef="Unit_USD">0</sclx:FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring>
    <sclx:FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26414"
      unitRef="Unit_USD">30400000</sclx:FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring>
    <sclx:FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26415"
      unitRef="Unit_USD">0</sclx:FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring>
    <sclx:ScilexPharmaNotesPrincipalIncrease
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26416"
      unitRef="Unit_USD">0</sclx:ScilexPharmaNotesPrincipalIncrease>
    <sclx:ScilexPharmaNotesPrincipalIncrease
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26417"
      unitRef="Unit_USD">0</sclx:ScilexPharmaNotesPrincipalIncrease>
    <sclx:ScilexPharmaNotesPrincipalIncrease
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26418"
      unitRef="Unit_USD">-28000000</sclx:ScilexPharmaNotesPrincipalIncrease>
    <sclx:TransactionCostsObligationAssumedBySorrento
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26419"
      unitRef="Unit_USD">0</sclx:TransactionCostsObligationAssumedBySorrento>
    <sclx:TransactionCostsObligationAssumedBySorrento
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26420"
      unitRef="Unit_USD">5148000</sclx:TransactionCostsObligationAssumedBySorrento>
    <sclx:TransactionCostsObligationAssumedBySorrento
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26421"
      unitRef="Unit_USD">0</sclx:TransactionCostsObligationAssumedBySorrento>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17768">&lt;div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1. Nature of Operations and Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Organization and Principal Activities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Scilex Holding Company (&#x201c;Scilex&#x201d; and together with its wholly owned subsidiaries, the &#x201c;Company&#x201d;) is the successor entity to Vickers Vantage Corp. I (&#x201c;Vickers&#x201d;), a special purpose acquisition company. The Company is an innovative revenue-generating company focused on acquiring, developing and commercializing &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-opioid&lt;/div&gt; pain management products for the treatment of acute and chronic pain. The Company was originally formed in 2019 and currently has five wholly owned subsidiaries, Scilex Inc. (&#x201c;Legacy Scilex&#x201d;), Scilex Pharmaceuticals Inc. (&#x201c;Scilex Pharma&#x201d;), Semnur Pharmaceuticals, Inc. (&#x201c;Semnur&#x201d;), SCLX DRE Holdings LLC and SCLX Stock Acquisition JV LLC. The business combination with Vickers (the &#x201c;Business Combination&#x201d;) was closed in November 2022. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company launched its first commercial product in October 2018, ZTlido (lidocaine topical system) 1.8% (&#x201c;ZTlido&#x201d;), a prescription lidocaine topical system that is designed with novel technology to address the limitations of current prescription lidocaine therapies by providing significantly improved adhesion and continuous pain relief throughout the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12-hour&lt;/div&gt; administration period. The Company &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-licensed&lt;/div&gt; the exclusive right to commercialize GLOPERBA (colchicine USP) oral solution (&#x201c;GLOPERBA&#x201d;), a U.S. Food and Drug Administration (&#x201c;FDA&#x201d;)-approved prophylactic treatment for painful gout flares in adults, in the United States (&#x201c;U.S.&#x201d;). In February 2023, the Company acquired the rights related to ELYXYB (celecoxib oral solution) (&#x201c;ELYXYB&#x201d;) and the commercialization thereof in the U.S. and Canada. ELYXYB is a first-line treatment and the only &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;FDA-approved,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ready-to-use&lt;/div&gt;&lt;/div&gt; oral solution for the acute treatment of migraine, with or without aura, in adults. In April 2023, the Company launched ELYXYB in the U.S. The Company expects to commercialize GLOPERBA in the U.S. in the first half of 2024. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company is currently developing three product candidates, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-102&lt;/div&gt; (10 mg, dexamethasone sodium phosphate viscous gel), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica for which the Company has completed a Phase 3 study &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;SP-102&#x201d;&lt;/div&gt; or &#x201c;SEMDEXA&#x201d;), &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-103&lt;/div&gt; (lidocaine topical system) 5.4% &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;SP-103&#x201d;),&lt;/div&gt; a next-generation, triple-strength formulation of ZTlido, for the treatment of chronic neck pain and for which the Company has recently completed a Phase 2 trial in low back pain, and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104&lt;/div&gt; (4.5 mg, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;low-dose&lt;/div&gt; naltrexone hydrochloride delayed-burst release low dose naltrexone hydrochloride capsules) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;SP-104&#x201d;),&lt;/div&gt; a novel &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;low-dose&lt;/div&gt; delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia, for which Phase 1 trials were completed in the second quarter of 2022 and a Phase 2 clinical trial is expected to commence in 2024. Since inception, the Company has devoted substantially all of its efforts to the development of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-102,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-103&lt;/div&gt; and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104,&lt;/div&gt; and the commercialization of ZTlido. In 2024, the Company will also devote efforts on the commercialization of GLOPERBA and ELYXYB. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sorrento Chapter 11 Filing &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On February&#160;13, 2023, Sorrento Therapeutics, Inc. (&#x201c;Sorrento&#x201d;), the Company&#x2019;s then-controlling stockholder, and Sorrento&#x2019;s wholly owned direct subsidiary, Scintilla Pharmaceuticals, Inc. (&#x201c;Scintilla&#x201d; and together with Sorrento, the &#x201c;Debtors&#x201d;), commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code (the &#x201c;Bankruptcy Code&#x201d;) in the United States Bankruptcy Court for the Southern District of Texas (the &#x201c;Bankruptcy Court&#x201d;). The Debtors&#x2019; Chapter 11 proceedings are jointly administered under the caption In re Sorrento Therapeutics, Inc., et al., Case Number &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;23-90085&lt;/div&gt; (DRJ) (the &#x201c;Chapter 11 Cases&#x201d;). While the Company was majority-owned by Sorrento, the Company was not a debtor in the Chapter 11 Cases. As of December&#160;31, 2023, Sorrento no longer holds a majority of the voting power of the Company&#x2019;s outstanding capital stock entitled to vote. As of December&#160;31, 2023, the Company had a $3.2&#160;million receivable from Sorrento, which was fully reserved. The Company evaluates the collectability of this receivable on a quarterly basis. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and include all adjustments necessary for the fair presentation of the Company&#x2019;s financial position for the periods presented. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The accompanying consolidated financial statements include the accounts of the Company as well as its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Operating segments are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assessing performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer, as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions. The Company is engaged primarily in the development of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-opioid&lt;/div&gt; products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single reportable segment. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The preparation of these consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer Concentration Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Prior to April 2022, sales to the Company&#x2019;s sole distributor represented 100% of net revenue. In April 2022, the Company announced the expansion of its direct distribution network to national and regional wholesalers and pharmacies. The Company had three and four customers during the years ended December&#160;31, 2023 and 2022, respectively, each of which individually generated 10% or more of the Company&#x2019;s total revenue. These customers accounted for 85% and 83% of the Company&#x2019;s revenue for the years ended December&#160;31, 2023 and 2022, respectively, individually ranging from 22% to 32% and 19% to 24%, respectively. As of December&#160;31, 2023 and 2022, these customers represented 91% and 90% of the Company&#x2019;s outstanding accounts receivable, respectively, individually ranging between 24% and 36% for both periods. Additionally, during the years ended December&#160;31, 2023 and 2022, the Company purchased ZTlido inventory from its sole supplier, Itochu Chemical Frontier Corporation (&#x201c;Itochu&#x201d;). This exposes the Company to concentration of customer and supplier risk. The Company monitors the financial condition of its customers, limits its credit exposure by setting credit limits, and has not experienced any credit losses during the years ended December&#160;31, 2023 and 2022. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Financial assets and liabilities are recorded at fair value on a recurring basis in the consolidated balance sheets. The carrying values of the Company&#x2019;s financial assets and liabilities, including cash and cash equivalents, restricted cash, prepaid and other current assets, accounts payable and accrued expenses approximate to their fair value due to the short-term nature of these instruments. The derivative warrant liability associated with the Private Warrants (as defined below) is valued using the Black-Scholes option pricing model, which is further discussed in Note 4. The Company elected the fair value option to account for the Convertible Debentures (as defined below) in an aggregate principal amount of up to $25.0&#160;million that were issued in March and April 2023 &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;and for the Oramed Note (as defined below) in the principal amount of $101.9&#160;million that was issued in September 2023 (see Note 7 titled &#x201c;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Debt&#x201d; &lt;/div&gt;&lt;/div&gt;below). These instruments are measured at fair value on a recurring basis using Level&#160;3 inputs. The Binomial Lattice Model valuation technique and a discounted cash flow model were employed to measure the fair value of the Convertible Debentures and the Oramed Note, respectively. The Revolving Facility (as defined below) in an aggregate principal amount of up to $30.0&#160;million was issued in June 2023 (see Note 7 titled &#x201c;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Debt&#x201d; &lt;/div&gt;&lt;/div&gt;below). The Company accounts for the Revolving Facility using the amortized cost basis and recognizes interest expense over the expected term using the effective interest rate method. The carrying value of the Revolving Facility approximates its fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. Assets and liabilities recorded at fair value are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels are directly related to the amount of subjectivity with the inputs to the valuation of these assets or liabilities as follows: &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level 1 - &lt;/div&gt;&lt;/div&gt;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level 2 - &lt;/div&gt;&lt;/div&gt;Inputs (other than quoted prices included in Level&#160;1) that are either directly or indirectly observable inputs for similar assets or liabilities. These include quoted prices for identical or similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active; and &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level 3 - &lt;/div&gt;&lt;/div&gt;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash, Cash Equivalents and Restricted Cash &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company considers all highly liquid investments that are readily convertible into cash without penalty and with original maturities of three months or less at the date of purchase to be cash equivalents. The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents are valued at cost, which approximate their fair value. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Restricted cash as of December&#160;31, 2023 consist of deposits placed in a segregated bank account as required under the terms of the Credit and Security Agreement, dated as of June&#160;27, 2023, between Scilex Pharma and eCapital Healthcare Corp., which is discussed further in Note 7. Restricted cash is recorded as other long-term assets within the Company&#x2019;s consolidated balance sheet. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that together reflect the same amounts shown in the consolidated statements of cash flows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:60%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,921&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,184&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Restricted cash&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;808&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total cash, cash equivalents, and restricted cash&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,729&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,184&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts Receivable, Net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Accounts receivable are presented net of allowances for expected credit losses and prompt payment discounts. Accounts receivable consists of trade receivables from product sales to customers, which are generally unsecured. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for expected credit losses within accounts receivable, net. The Company reviews &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for expected credit losses. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventory &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company determines inventory cost on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;first-in,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;first-out&lt;/div&gt; basis. The Company reduces the carrying value of inventories to a lower of cost or net realizable value for those items that are potentially excess, obsolete or slow- moving. The Company reserves for excess and obsolete inventory based upon historical experience, sales trends, and specific categories of inventory and expiration dates for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;on-hand&lt;/div&gt; inventory. Inventory costs resulting from these adjustments are recognized as cost of sales in the period in which they are incurred. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#x2019;s judgment, the Company capitalizes &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-launch&lt;/div&gt; inventory costs prior to regulatory approval. As of December&#160;31, 2023 and 2022, the Company&#x2019;s inventory was primarily comprised of finished goods. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and Equipment, Net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment are carried at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally five to seven years. Leasehold improvements are amortized over the lesser of their estimated useful lives or the term of the respective lease on a straight-line basis.&#160;The cost of repairs and maintenance is expensed as incurred. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquisitions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company accounts for business combinations using the acquisition method of accounting, which requires that assets acquired, including &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development (&#x201c;IPR&amp;amp;D&#x201d;) projects and liabilities assumed be recorded at their fair values as of the acquisition date on the Company`s consolidated balance sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;When the Company determines net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the transaction is accounted for as an acquisition of assets and, therefore, no goodwill is recorded and contingent consideration such as payments upon achievement of various developmental, regulatory and commercial milestones generally is not recognized at the acquisition date. In an asset acquisition, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;up-front&lt;/div&gt; payments allocated to IPR&amp;amp;D projects at the acquisition date and subsequent milestone payments are charged to expense in the Company`s consolidated statements of operations unless there is an alternative future use. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates. Intangible assets acquired in a business combination that are used for IPR&amp;amp;D activities are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Upon commercialization of the relevant research and development project, the Company amortizes the acquired IPR&amp;amp;D over its estimated useful life. Capitalized IPR&amp;amp;D is reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill and Other Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Goodwill, which has an indefinite life, represents the excess cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if events occur &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="line-height:normal;background-color:white;display: inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;indicating the potential for impairment. The Company has one reporting unit. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company performs a quantitative goodwill impairment test. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative goodwill impairment test.&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company evaluates its long-lived and intangible assets with definite lives, such as property and equipment, patent rights, and acquired technology, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-generic&lt;/div&gt; and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of useful life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets&#x2019; book value to future net undiscounted cash flows that the assets are expected to generate to determine if a write-down to the recoverable amount is appropriate. If such assets are written down, an impairment will be recognized as the amount by which the book value of the asset group exceeds the recoverable amount. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent Consideration &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The fair value of contingent consideration liabilities assumed in business combinations is recorded as part of the purchase price consideration of the acquisition, and is determined using a discounted cash flow model or Monte Carlo simulation model. The significant inputs of such models are not observable in the market, such as certain financial metric growth rates, volatility rates, projections associated with applicable milestones, discount rates and the related probabilities and payment structure in the contingent consideration arrangement. Fair value adjustments to contingent consideration liabilities are recorded through operating expenses in the consolidated statement of operations. Other than contingent consideration that is accounted for in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 480, Distinguishing Liabilities from Equity, and Topic 815, Derivatives and Hedging, contingent consideration arrangements assumed in an asset acquisition will be measured and accrued when such contingency is resolved. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Public Warrants and Private Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Upon completion of the Business Combination, the Company assumed public and private placement warrants to purchase Common Stock, each with an exercise price of $11.50 per share (&#x201c;Public Warrants&#x201d; and &#x201c;Private Warrants&#x201d;, respectively, and collectively, the &#x201c;SPAC Warrants&#x201d;) that were issued by Vickers in connection with its initial public offering (declared effective by the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on January&#160;11, 2021) whereby holders of the public and private placement warrants are entitled to acquire ordinary shares of Vickers. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Subsequent to the Business Combination, the Public Warrants were accounted for as equity per FASB ASC Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;815-40,&lt;/div&gt; Contracts on an Entity&#x2019;s Own Equity. Warrants classified as equity are recorded at their issuance cost and are not subject to remeasurement at each subsequent balance sheet date. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Subsequent to the Business Combination, the Private Warrants were accounted for as liabilities per ASC Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;815-40.&lt;/div&gt; The Private Warrants are not considered indexed to the Company&#x2019;s stock per ASC Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;815-40&lt;/div&gt; as the fair value calculation applicable upon a cashless exercise of a Private Warrant changes based upon the holder of the instrument, which is not an input to a valuation model for a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;fixed-for-fixed&lt;/div&gt;&lt;/div&gt; option contract. Therefore, Private Warrants are recognized as derivative liabilities at their estimated fair value on November&#160;10, 2022, the date of the closing of the Business Combination, and are revalued at each subsequent balance sheet &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;date, with fair value changes recognized in the statement of operations. The Company estimates the value of these warrants using a Black-Scholes option pricing formula. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Debt &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company may enter into financing arrangements, the terms of which involve significant assumptions and estimates. This involves estimating future net product sales, determining interest expense, determining the amortization period of the debt discount, as well as determining the classification between current and long-term portions. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Convertible Debentures and the Oramed Note &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has elected the fair value option to account for the Convertible Debentures (as defined in Note 2 &#x201c;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Liquidity and Going Concern&lt;/div&gt;&lt;/div&gt;&#x201d; below) that were issued in March and April 2023, as discussed further in Note 7. The Company has also elected the fair value option to account for the Oramed Note (as defined in Note 4 &#x201c;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurements&lt;/div&gt;&lt;/div&gt;&#x201d; below). The Company recorded the Convertible Debentures and the Oramed Note at fair value upon issuance with changes in fair value recorded as change in fair value of debt and liability instruments in the consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. Interest expense related to these financial instruments is included in the changes in fair value. As a result of applying the fair value option, direct costs and fees related to the Convertible Debentures and the Oramed Note were expensed as incurred. The weighted-average interest rates for the short-term loans, including the Convertible Debentures and the Oramed Note, were 13.55% and nil for the years ended December&#160;31, 2023 and 2022, respectively. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivative Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Derivative liabilities are recorded on the Company&#x2019;s consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and Development Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company expenses the cost of research and development as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and preclinical materials as well as other contracted services, license fees and other external costs.&#160;Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with FASB ASC Topic 730, Research and Development. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The provisions of the FASB ASC Topic 740, Income Taxes, address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;740-10,&lt;/div&gt; the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position.&#160;The Company has determined that it has uncertain tax positions. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;will be realized. As of December&#160;31, 2023 and 2022, the Company maintained a full valuation allowance against its deferred tax assets. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company determines if an arrangement is a lease at inception. Operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; (&#x201c;ROU&#x201d;) assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company&#x2019;s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and is reduced by lease incentives. The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term in selling, general and administrative expenses. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s revenue is generated from product sales within the United States. The Company does not incur significant direct costs to obtain contracts with its customers. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenue from product sales is comprised of sales of ZTlido and ELYXYB. The Company&#x2019;s performance obligation with respect to sales of ZTlido and ELYXYB is satisfied at a point in time, when control is transferred upon delivery of product to the customer. The Company considers control to have transferred upon delivery because the customer has legal title to the product, physical possession of the product has been transferred to the customer, the customer has significant risks and rewards of ownership of the product, and the Company has a present right to payment at that time.&#160;Invoicing typically occurs upon shipment and the length of time between invoicing and when payment is due is not significant. The aggregate dollar value of unfulfilled orders as of December&#160;31, 2023 and 2022 were not material. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenues from product sales are recorded net of reserves established for commercial and government rebates, fees and chargebacks, wholesaler and distributor fees, sales returns and prompt payment discounts. Such variable consideration is estimated in the period of the sale and is estimated using a most likely amount approach based primarily upon provisions included in the Company&#x2019;s customer contract, customary industry practices and current government regulations. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Rebates and Chargebacks &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Rebates are discounts which the Company pays under either government or private health care programs.&#160;Government rebate programs include state Medicaid drug rebate programs, the Medicare coverage gap discount programs and the Tricare programs. Commercial rebate and fee programs relate to contractual agreements with commercial healthcare providers, under which the Company pays rebates and fees for access to and position on that provider&#x2019;s patient drug formulary. Rebates and chargebacks paid under government programs are generally mandated under law, whereas private rebates and fees are generally contractually negotiated by the Company with commercial healthcare providers. Both types of rebates vary over time. The Company records a reduction to gross product sales at the time the customer takes title to the product based on estimates of expected rebate claims. The Company monitors the sales trends and adjusts for these rebates on a regular basis to reflect the most recent rebate experience and contractual obligations. Reserves for rebates and chargebacks are now separately presented as accrued rebates and fees under current liabilities within the Company&#x2019;s consolidated balance sheet. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Prompt Payment Discounts &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company provides its customers with prompt payment discounts which may result in adjustments to the price that is invoiced for the product transferred, in the case that payments are made within a defined period. The &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;prompt payment discount reserve is based on actual gross sales and contractual discount rates. Reserves for prompt payment discounts are included in accounts receivable, net on the consolidated balance sheets. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Service Fees &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company compensates its customer and others in the distribution chain for wholesaler and distribution services. The Company has determined such services received to date are not distinct from the Company&#x2019;s sale of products to the customer and, therefore, these payments have been recorded as a reduction of revenue. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product Returns &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company is obligated to accept the return of products sold that are expiring within six months, damaged or do not meet certain specifications. The Company may authorize the return of products sold in accordance with the term of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company estimates the amount of its product sales that may be returned by its customer and records this estimate as a reduction of revenue in the period the related product revenue is recognized. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Co-Payment&lt;/div&gt; Assistance &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Patients who have commercial insurance or pay cash and meet certain eligibility requirements may receive &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-&lt;/div&gt; payment assistance. The Company accrues for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-payment&lt;/div&gt; assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, Compensation &#x2013; Stock Compensation which establishes accounting for equity instruments exchanged for employee and consulting services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee&#x2019;s requisite service period (generally the vesting period of the equity grant) or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&#x2019;s&lt;/div&gt; vesting period. The Company accounts for forfeitures as incurred. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;For purposes of determining the inputs used in the calculation of stock-based compensation, the Company determines the expected life assumption for options issued using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period since the Company does not have historic exercise behavior. Then the Company determines an estimate of option volatility based on an assessment of historical volatilities of comparable companies whose share prices are publicly available. The Company uses these estimates as variables in the Black-Scholes option pricing model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in our consolidated statement of operations. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Treasury Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company uses the cost method to account for repurchases of its stock. In the computation of net (loss) income per share, treasury shares are not included as part of the outstanding shares. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net Loss per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Basic and diluted net loss per share attributable to common stockholders is presented in conformity with the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-class&lt;/div&gt; method required for participating securities. Net loss per share has been retrospectively adjusted for all periods presented prior to the Business Combination. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Under the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-class&lt;/div&gt; method, basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share attributable to common stockholders adjusts basic earnings per share for the potentially dilutive impact of stock options and warrants. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As the Company has reported losses for all periods presented, all potentially dilutive securities are antidilutive and accordingly, basic net loss per share equals diluted net loss per share. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Recently Adopted Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In October 2021, FASB issued Accounting Standards Updates (&#x201c;ASU&#x201d;) 2021-08, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Business Combinations (Topic&#160;805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;ASU&#160;2021-08&#x201d;)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;, which requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities in accordance with ASC Topic 606. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021-08&lt;/div&gt; is effective for fiscal years beginning after December&#160;15, 2022. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021-08&lt;/div&gt; should be applied prospectively to business combinations occurring on or after the adoption date. The Company adopted this guidance as of January&#160;1, 2023 and the adoption did not have a material impact on the Company&#x2019;s consolidated financial statements. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In June 2022, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022-03,&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022-03&#x201d;),&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;which clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered when measuring fair value. Recognizing such a restriction as a separate unit of account is also not permitted. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022-03&lt;/div&gt; is effective for fiscal years beginning after December&#160;15, 2023, with early adoption permitted. The Company elected to early adopt this guidance as of January&#160;1, 2023 and the adoption did not have a material impact on the Company&#x2019;s consolidated financial statements. &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:ReceivablesNetCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-5"
      id="ixv-26422"
      unitRef="Unit_USD">3200000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17814">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and include all adjustments necessary for the fair presentation of the Company&#x2019;s financial position for the periods presented. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The accompanying consolidated financial statements include the accounts of the Company as well as its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. &lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17820">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Operating segments are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assessing performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer, as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions. The Company is engaged primarily in the development of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-opioid&lt;/div&gt; products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single reportable segment. &lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="P01_01_2023To12_31_2023" id="ixv-17826">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The preparation of these consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates. &lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2023To12_31_2023" id="ixv-17831">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Customer Concentration Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Prior to April 2022, sales to the Company&#x2019;s sole distributor represented 100% of net revenue. In April 2022, the Company announced the expansion of its direct distribution network to national and regional wholesalers and pharmacies. The Company had three and four customers during the years ended December&#160;31, 2023 and 2022, respectively, each of which individually generated 10% or more of the Company&#x2019;s total revenue. These customers accounted for 85% and 83% of the Company&#x2019;s revenue for the years ended December&#160;31, 2023 and 2022, respectively, individually ranging from 22% to 32% and 19% to 24%, respectively. As of December&#160;31, 2023 and 2022, these customers represented 91% and 90% of the Company&#x2019;s outstanding accounts receivable, respectively, individually ranging between 24% and 36% for both periods. Additionally, during the years ended December&#160;31, 2023 and 2022, the Company purchased ZTlido inventory from its sole supplier, Itochu Chemical Frontier Corporation (&#x201c;Itochu&#x201d;). This exposes the Company to concentration of customer and supplier risk. The Company monitors the financial condition of its customers, limits its credit exposure by setting credit limits, and has not experienced any credit losses during the years ended December&#160;31, 2023 and 2022. &lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <sclx:PercentageOfNetRevenueSoleDistributors
      contextRef="PAsOn04_30_2022_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"
      decimals="2"
      id="ixv-26424"
      unitRef="Unit_pure">1</sclx:PercentageOfNetRevenueSoleDistributors>
    <sclx:PercentageOfNetRevenueSoleDistributors
      contextRef="PAsOn12_31_2022_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"
      decimals="INF"
      id="ixv-26425"
      unitRef="Unit_pure">0.10</sclx:PercentageOfNetRevenueSoleDistributors>
    <sclx:PercentageOfNetRevenueSoleDistributors
      contextRef="PAsOn12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"
      decimals="INF"
      id="ixv-26426"
      unitRef="Unit_pure">0.10</sclx:PercentageOfNetRevenueSoleDistributors>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2023To12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-26427"
      unitRef="Unit_pure">0.85</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2022To12_31_2022_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-26428"
      unitRef="Unit_pure">0.83</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2023To12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-26429"
      unitRef="Unit_pure">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2023To12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-26430"
      unitRef="Unit_pure">0.32</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2022To12_31_2022_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-26431"
      unitRef="Unit_pure">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2022To12_31_2022_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_ThreeCustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-26432"
      unitRef="Unit_pure">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2023To12_31_2023_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ThreeCustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-26433"
      unitRef="Unit_pure">0.91</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2022To12_31_2022_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_ThreeCustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-26434"
      unitRef="Unit_pure">0.90</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2023To12_31_2023_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-26435"
      unitRef="Unit_pure">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2022To12_31_2022_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_ThreeCustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-26436"
      unitRef="Unit_pure">0.36</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="P01_01_2023To12_31_2023" id="ixv-17836">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Financial assets and liabilities are recorded at fair value on a recurring basis in the consolidated balance sheets. The carrying values of the Company&#x2019;s financial assets and liabilities, including cash and cash equivalents, restricted cash, prepaid and other current assets, accounts payable and accrued expenses approximate to their fair value due to the short-term nature of these instruments. The derivative warrant liability associated with the Private Warrants (as defined below) is valued using the Black-Scholes option pricing model, which is further discussed in Note 4. The Company elected the fair value option to account for the Convertible Debentures (as defined below) in an aggregate principal amount of up to $25.0&#160;million that were issued in March and April 2023 &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;and for the Oramed Note (as defined below) in the principal amount of $101.9&#160;million that was issued in September 2023 (see Note 7 titled &#x201c;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Debt&#x201d; &lt;/div&gt;&lt;/div&gt;below). These instruments are measured at fair value on a recurring basis using Level&#160;3 inputs. The Binomial Lattice Model valuation technique and a discounted cash flow model were employed to measure the fair value of the Convertible Debentures and the Oramed Note, respectively. The Revolving Facility (as defined below) in an aggregate principal amount of up to $30.0&#160;million was issued in June 2023 (see Note 7 titled &#x201c;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Debt&#x201d; &lt;/div&gt;&lt;/div&gt;below). The Company accounts for the Revolving Facility using the amortized cost basis and recognizes interest expense over the expected term using the effective interest rate method. The carrying value of the Revolving Facility approximates its fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. Assets and liabilities recorded at fair value are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels are directly related to the amount of subjectivity with the inputs to the valuation of these assets or liabilities as follows: &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level 1 - &lt;/div&gt;&lt;/div&gt;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level 2 - &lt;/div&gt;&lt;/div&gt;Inputs (other than quoted prices included in Level&#160;1) that are either directly or indirectly observable inputs for similar assets or liabilities. These include quoted prices for identical or similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active; and &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level 3 - &lt;/div&gt;&lt;/div&gt;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_31_2023_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis"
      decimals="-5"
      id="ixv-26437"
      unitRef="Unit_USD">25000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn09_30_2023_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis"
      decimals="-5"
      id="ixv-26439"
      unitRef="Unit_USD">101900000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn06_30_2023_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis"
      decimals="-5"
      id="ixv-26440"
      unitRef="Unit_USD">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="P01_01_2023To12_31_2023" id="ixv-17875">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash, Cash Equivalents and Restricted Cash &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company considers all highly liquid investments that are readily convertible into cash without penalty and with original maturities of three months or less at the date of purchase to be cash equivalents. The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents are valued at cost, which approximate their fair value. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Restricted cash as of December&#160;31, 2023 consist of deposits placed in a segregated bank account as required under the terms of the Credit and Security Agreement, dated as of June&#160;27, 2023, between Scilex Pharma and eCapital Healthcare Corp., which is discussed further in Note 7. Restricted cash is recorded as other long-term assets within the Company&#x2019;s consolidated balance sheet. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that together reflect the same amounts shown in the consolidated statements of cash flows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:60%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,921&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,184&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Restricted cash&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;808&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total cash, cash equivalents, and restricted cash&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,729&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,184&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17881">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that together reflect the same amounts shown in the consolidated statements of cash flows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:60%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,921&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,184&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Restricted cash&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;808&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total cash, cash equivalents, and restricted cash&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,729&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,184&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26441"
      unitRef="Unit_USD">3921000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26442"
      unitRef="Unit_USD">2184000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26443"
      unitRef="Unit_USD">808000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26444"
      unitRef="Unit_USD">0</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26445"
      unitRef="Unit_USD">4729000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26446"
      unitRef="Unit_USD">2184000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="P01_01_2023To12_31_2023" id="ixv-17970">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts Receivable, Net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Accounts receivable are presented net of allowances for expected credit losses and prompt payment discounts. Accounts receivable consists of trade receivables from product sales to customers, which are generally unsecured. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for expected credit losses within accounts receivable, net. The Company reviews &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for expected credit losses.</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17992">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventory &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company determines inventory cost on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;first-in,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;first-out&lt;/div&gt; basis. The Company reduces the carrying value of inventories to a lower of cost or net realizable value for those items that are potentially excess, obsolete or slow- moving. The Company reserves for excess and obsolete inventory based upon historical experience, sales trends, and specific categories of inventory and expiration dates for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;on-hand&lt;/div&gt; inventory. Inventory costs resulting from these adjustments are recognized as cost of sales in the period in which they are incurred. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#x2019;s judgment, the Company capitalizes &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-launch&lt;/div&gt; inventory costs prior to regulatory approval. As of December&#160;31, 2023 and 2022, the Company&#x2019;s inventory was primarily comprised of finished goods. &lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-18001">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and Equipment, Net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment are carried at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally five to seven years. Leasehold improvements are amortized over the lesser of their estimated useful lives or the term of the respective lease on a straight-line basis.&#160;The cost of repairs and maintenance is expensed as incurred. &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy contextRef="P01_01_2023To12_31_2023" id="ixv-18006">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquisitions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company accounts for business combinations using the acquisition method of accounting, which requires that assets acquired, including &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development (&#x201c;IPR&amp;amp;D&#x201d;) projects and liabilities assumed be recorded at their fair values as of the acquisition date on the Company`s consolidated balance sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;When the Company determines net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the transaction is accounted for as an acquisition of assets and, therefore, no goodwill is recorded and contingent consideration such as payments upon achievement of various developmental, regulatory and commercial milestones generally is not recognized at the acquisition date. In an asset acquisition, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;up-front&lt;/div&gt; payments allocated to IPR&amp;amp;D projects at the acquisition date and subsequent milestone payments are charged to expense in the Company`s consolidated statements of operations unless there is an alternative future use. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates. Intangible assets acquired in a business combination that are used for IPR&amp;amp;D activities are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Upon commercialization of the relevant research and development project, the Company amortizes the acquired IPR&amp;amp;D over its estimated useful life. Capitalized IPR&amp;amp;D is reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable. &lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-18015">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill and Other Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Goodwill, which has an indefinite life, represents the excess cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if events occur &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="line-height:normal;background-color:white;display: inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;indicating the potential for impairment. The Company has one reporting unit. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company performs a quantitative goodwill impairment test. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative goodwill impairment test.&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company evaluates its long-lived and intangible assets with definite lives, such as property and equipment, patent rights, and acquired technology, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-generic&lt;/div&gt; and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of useful life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets&#x2019; book value to future net undiscounted cash flows that the assets are expected to generate to determine if a write-down to the recoverable amount is appropriate. If such assets are written down, an impairment will be recognized as the amount by which the book value of the asset group exceeds the recoverable amount. &lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:ContingentLiabilityReserveEstimatePolicy contextRef="P01_01_2023To12_31_2023" id="ixv-18046">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent Consideration &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The fair value of contingent consideration liabilities assumed in business combinations is recorded as part of the purchase price consideration of the acquisition, and is determined using a discounted cash flow model or Monte Carlo simulation model. The significant inputs of such models are not observable in the market, such as certain financial metric growth rates, volatility rates, projections associated with applicable milestones, discount rates and the related probabilities and payment structure in the contingent consideration arrangement. Fair value adjustments to contingent consideration liabilities are recorded through operating expenses in the consolidated statement of operations. Other than contingent consideration that is accounted for in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 480, Distinguishing Liabilities from Equity, and Topic 815, Derivatives and Hedging, contingent consideration arrangements assumed in an asset acquisition will be measured and accrued when such contingency is resolved. &lt;/div&gt;</us-gaap:ContingentLiabilityReserveEstimatePolicy>
    <sclx:PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-18051">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Public Warrants and Private Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Upon completion of the Business Combination, the Company assumed public and private placement warrants to purchase Common Stock, each with an exercise price of $11.50 per share (&#x201c;Public Warrants&#x201d; and &#x201c;Private Warrants&#x201d;, respectively, and collectively, the &#x201c;SPAC Warrants&#x201d;) that were issued by Vickers in connection with its initial public offering (declared effective by the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on January&#160;11, 2021) whereby holders of the public and private placement warrants are entitled to acquire ordinary shares of Vickers. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Subsequent to the Business Combination, the Public Warrants were accounted for as equity per FASB ASC Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;815-40,&lt;/div&gt; Contracts on an Entity&#x2019;s Own Equity. Warrants classified as equity are recorded at their issuance cost and are not subject to remeasurement at each subsequent balance sheet date. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Subsequent to the Business Combination, the Private Warrants were accounted for as liabilities per ASC Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;815-40.&lt;/div&gt; The Private Warrants are not considered indexed to the Company&#x2019;s stock per ASC Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;815-40&lt;/div&gt; as the fair value calculation applicable upon a cashless exercise of a Private Warrant changes based upon the holder of the instrument, which is not an input to a valuation model for a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;fixed-for-fixed&lt;/div&gt;&lt;/div&gt; option contract. Therefore, Private Warrants are recognized as derivative liabilities at their estimated fair value on November&#160;10, 2022, the date of the closing of the Business Combination, and are revalued at each subsequent balance sheet &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;date, with fair value changes recognized in the statement of operations. The Company estimates the value of these warrants using a Black-Scholes option pricing formula.</sclx:PublicWarrantAndPrivatePlacementWarrantsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn12_31_2023"
      decimals="2"
      id="ixv-26450"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:DebtPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-18080">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Debt &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company may enter into financing arrangements, the terms of which involve significant assumptions and estimates. This involves estimating future net product sales, determining interest expense, determining the amortization period of the debt discount, as well as determining the classification between current and long-term portions. &lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
    <sclx:ConvertibleDebenturesAndTheOramedNotePolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-18085">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Convertible Debentures and the Oramed Note &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has elected the fair value option to account for the Convertible Debentures (as defined in Note 2 &#x201c;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Liquidity and Going Concern&lt;/div&gt;&lt;/div&gt;&#x201d; below) that were issued in March and April 2023, as discussed further in Note 7. The Company has also elected the fair value option to account for the Oramed Note (as defined in Note 4 &#x201c;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurements&lt;/div&gt;&lt;/div&gt;&#x201d; below). The Company recorded the Convertible Debentures and the Oramed Note at fair value upon issuance with changes in fair value recorded as change in fair value of debt and liability instruments in the consolidated statements of operations, with the exception of changes in fair value due to instrument-specific credit risk, if any, which are recorded as a component of other comprehensive income. Interest expense related to these financial instruments is included in the changes in fair value. As a result of applying the fair value option, direct costs and fees related to the Convertible Debentures and the Oramed Note were expensed as incurred. The weighted-average interest rates for the short-term loans, including the Convertible Debentures and the Oramed Note, were 13.55% and nil for the years ended December&#160;31, 2023 and 2022, respectively. &lt;/div&gt;</sclx:ConvertibleDebenturesAndTheOramedNotePolicyTextBlock>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="PAsOn12_31_2022_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis"
      decimals="4"
      id="ixv-26453"
      unitRef="Unit_pure">0.1355</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="PAsOn12_31_2023_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis"
      decimals="4"
      id="ixv-26454"
      unitRef="Unit_pure">0.1355</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DerivativesPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-18094">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivative Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Derivative liabilities are recorded on the Company&#x2019;s consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense. &lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P01_01_2023To12_31_2023" id="ixv-18099">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and Development Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company expenses the cost of research and development as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and preclinical materials as well as other contracted services, license fees and other external costs.&#160;Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with FASB ASC Topic 730, Research and Development. &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-18104">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The provisions of the FASB ASC Topic 740, Income Taxes, address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;740-10,&lt;/div&gt; the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position.&#160;The Company has determined that it has uncertain tax positions. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;will be realized. As of December&#160;31, 2023 and 2022, the Company maintained a full valuation allowance against its deferred tax assets.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-18132">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company determines if an arrangement is a lease at inception. Operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; (&#x201c;ROU&#x201d;) assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company&#x2019;s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and is reduced by lease incentives. The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term in selling, general and administrative expenses. &lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-18139">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s revenue is generated from product sales within the United States. The Company does not incur significant direct costs to obtain contracts with its customers. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenue from product sales is comprised of sales of ZTlido and ELYXYB. The Company&#x2019;s performance obligation with respect to sales of ZTlido and ELYXYB is satisfied at a point in time, when control is transferred upon delivery of product to the customer. The Company considers control to have transferred upon delivery because the customer has legal title to the product, physical possession of the product has been transferred to the customer, the customer has significant risks and rewards of ownership of the product, and the Company has a present right to payment at that time.&#160;Invoicing typically occurs upon shipment and the length of time between invoicing and when payment is due is not significant. The aggregate dollar value of unfulfilled orders as of December&#160;31, 2023 and 2022 were not material. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenues from product sales are recorded net of reserves established for commercial and government rebates, fees and chargebacks, wholesaler and distributor fees, sales returns and prompt payment discounts. Such variable consideration is estimated in the period of the sale and is estimated using a most likely amount approach based primarily upon provisions included in the Company&#x2019;s customer contract, customary industry practices and current government regulations. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Rebates and Chargebacks &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Rebates are discounts which the Company pays under either government or private health care programs.&#160;Government rebate programs include state Medicaid drug rebate programs, the Medicare coverage gap discount programs and the Tricare programs. Commercial rebate and fee programs relate to contractual agreements with commercial healthcare providers, under which the Company pays rebates and fees for access to and position on that provider&#x2019;s patient drug formulary. Rebates and chargebacks paid under government programs are generally mandated under law, whereas private rebates and fees are generally contractually negotiated by the Company with commercial healthcare providers. Both types of rebates vary over time. The Company records a reduction to gross product sales at the time the customer takes title to the product based on estimates of expected rebate claims. The Company monitors the sales trends and adjusts for these rebates on a regular basis to reflect the most recent rebate experience and contractual obligations. Reserves for rebates and chargebacks are now separately presented as accrued rebates and fees under current liabilities within the Company&#x2019;s consolidated balance sheet. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Prompt Payment Discounts &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company provides its customers with prompt payment discounts which may result in adjustments to the price that is invoiced for the product transferred, in the case that payments are made within a defined period. The &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;prompt payment discount reserve is based on actual gross sales and contractual discount rates. Reserves for prompt payment discounts are included in accounts receivable, net on the consolidated balance sheets. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Service Fees &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company compensates its customer and others in the distribution chain for wholesaler and distribution services. The Company has determined such services received to date are not distinct from the Company&#x2019;s sale of products to the customer and, therefore, these payments have been recorded as a reduction of revenue. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product Returns &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company is obligated to accept the return of products sold that are expiring within six months, damaged or do not meet certain specifications. The Company may authorize the return of products sold in accordance with the term of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company estimates the amount of its product sales that may be returned by its customer and records this estimate as a reduction of revenue in the period the related product revenue is recognized. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Co-Payment&lt;/div&gt; Assistance &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Patients who have commercial insurance or pay cash and meet certain eligibility requirements may receive &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-&lt;/div&gt; payment assistance. The Company accrues for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-payment&lt;/div&gt; assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators. &lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P01_01_2023To12_31_2023" id="ixv-18187">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, Compensation &#x2013; Stock Compensation which establishes accounting for equity instruments exchanged for employee and consulting services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee&#x2019;s requisite service period (generally the vesting period of the equity grant) or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&#x2019;s&lt;/div&gt; vesting period. The Company accounts for forfeitures as incurred. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;For purposes of determining the inputs used in the calculation of stock-based compensation, the Company determines the expected life assumption for options issued using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period since the Company does not have historic exercise behavior. Then the Company determines an estimate of option volatility based on an assessment of historical volatilities of comparable companies whose share prices are publicly available. The Company uses these estimates as variables in the Black-Scholes option pricing model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in our consolidated statement of operations. &lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <sclx:TreasuryStockPolicyTextblock contextRef="P01_01_2023To12_31_2023" id="ixv-18194">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Treasury Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company uses the cost method to account for repurchases of its stock. In the computation of net (loss) income per share, treasury shares are not included as part of the outstanding shares. &lt;/div&gt;</sclx:TreasuryStockPolicyTextblock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-18199">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net Loss per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Basic and diluted net loss per share attributable to common stockholders is presented in conformity with the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-class&lt;/div&gt; method required for participating securities. Net loss per share has been retrospectively adjusted for all periods presented prior to the Business Combination. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Under the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-class&lt;/div&gt; method, basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share attributable to common stockholders adjusts basic earnings per share for the potentially dilutive impact of stock options and warrants. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As the Company has reported losses for all periods presented, all potentially dilutive securities are antidilutive and accordingly, basic net loss per share equals diluted net loss per share. &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-18228">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Recently Adopted Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In October 2021, FASB issued Accounting Standards Updates (&#x201c;ASU&#x201d;) 2021-08, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Business Combinations (Topic&#160;805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;ASU&#160;2021-08&#x201d;)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;, which requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities in accordance with ASC Topic 606. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021-08&lt;/div&gt; is effective for fiscal years beginning after December&#160;15, 2022. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021-08&lt;/div&gt; should be applied prospectively to business combinations occurring on or after the adoption date. The Company adopted this guidance as of January&#160;1, 2023 and the adoption did not have a material impact on the Company&#x2019;s consolidated financial statements. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In June 2022, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022-03,&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022-03&#x201d;),&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;which clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered when measuring fair value. Recognizing such a restriction as a separate unit of account is also not permitted. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022-03&lt;/div&gt; is effective for fiscal years beginning after December&#160;15, 2023, with early adoption permitted. The Company elected to early adopt this guidance as of January&#160;1, 2023 and the adoption did not have a material impact on the Company&#x2019;s consolidated financial statements. &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-18244">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2. Liquidity and Going Concern &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Management has assessed the Company&#x2019;s ability to continue as a going concern for at least one year after the issuance date of the accompanying consolidated financial statements. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On November&#160;17, 2022, the Company entered into a standby equity purchase agreement (the &#x201c;Original Purchase Agreement&#x201d;) with YA II PN, Ltd., a Cayman Islands exempt limited partnership (&#x201c;Yorkville&#x201d;). On February&#160;8, 2023, the Company entered into an amended and restated standby equity purchase agreement with Yorkville (the &#x201c;A&amp;amp;R Yorkville Purchase Agreement&#x201d;), amending, restating and superseding the Original Purchase Agreement. On January&#160;8, 2023, the Company entered into a standby equity purchase agreement (the &#x201c;B. Riley Purchase Agreement&#x201d; and together with A&amp;amp;R Yorkville Purchase Agreement, the &#x201c;Standby Equity Purchase Agreements&#x201d;) with B. Riley Principal Capital II, LLC (&#x201c;B. Riley&#x201d;). Pursuant to each of the Standby Equity Purchase Agreements, the Company has the right, but not the obligation, to sell to each of Yorkville and B. Riley up to $500.0&#160;million of shares of the Company&#x2019;s common stock, par value $0.0001 per share (the &#x201c;Common Stock&#x201d;) at its request any time during the 36 months following the date on which the registration statement related to each such purchase agreement was initially declared effective by the SEC, subject to certain conditions, which are discussed further in Note 9. On, and effective as of, February&#160;16, 2024, the Company and B. Riley mutually agreed to terminate the B. Riley Purchase Agreement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As consideration for Yorkville&#x2019;s and B. Riley&#x2019;s respective commitment to purchase shares of Common Stock at the Company&#x2019;s direction, the Company issued 250,000 commitment shares to each of Yorkville (the &#x201c;Yorkville Commitment Shares&#x201d;) and B. Riley (the &#x201c;B. Riley Commitment Shares&#x201d;). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On March 21, 2023, the Company entered into a securities purchase agreement with Yorkville (the &#x201c;Yorkville SPA&#x201d;), pursuant to which the Company would issue and sell to Yorkville convertible debentures in an aggregate &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;principal amount of up to $25.0&#160;million (the &#x201c;Convertible Debentures&#x201d;). As of December&#160;31, 2023, Convertible Debentures in the principal amount of $25.0&#160;million (for net cash proceeds of $24.0 million) were issued and sold pursuant to the Yorkville SPA, which is discussed further in Note 7. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;27, 2023, Scilex Pharma entered into a Credit and Security Agreement (the &#x201c;eCapital Credit Agreement&#x201d;) with eCapital Healthcare Corp. (the &#x201c;Lender&#x201d;), pursuant to which the Lender shall make available loans (the &#x201c;Revolving Facility&#x201d;) in an aggregate principal amount of up to $30.0&#160;million (the &#x201c;Facility Cap&#x201d;). The proceeds of the Revolving Facility will be used for (i)&#160;transaction fees incurred in connection with the eCapital Credit Agreement, (ii)&#160;working capital needs of Scilex Pharma and (iii)&#160;other uses not prohibited under the eCapital Credit Agreement. As of December&#160;31, 2023, the Company has an outstanding balance of $17.0&#160;million under the Revolving Facility. See Note 7 for additional discussion of the terms of the eCapital Credit Agreement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On December&#160;22, 2023, the Company entered into a Sales Agreement (the &#x201c;ATM Sales Agreement&#x201d;) with B. Riley Securities, Inc., Cantor Fitzgerald&#160;&amp;amp; Co. and H.C. Wainwright&#160;&amp;amp; Co., LLC (the &#x201c;Sales Agents&#x201d;). Pursuant to the ATM Sales Agreement, the Company may offer and sell (the &#x201c;Offering&#x201d;) shares of Common Stock up to $170,000,000 (the &#x201c;ATM Shares&#x201d;), through or to the Sales Agents as part of the Offering. The Company has no obligation to sell any shares of Common Stock under the ATM Sales Agreement and may suspend offers thereunder at any time. The Offering will terminate upon (i)&#160;the election of the Sales Agents upon the occurrence of certain adverse events, (ii)&#160;three business days&#x2019; advance notice from the Company to the Sales Agents or a Sales Agent to the Company, or (iii)&#160;the sale of all $170,000,000 of shares of Common Stock thereunder. As of December&#160;31, 2023, no sales of Common Stock had been made under the ATM Sales Agreement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2023, the Company&#x2019;s negative working capital was $203.6&#160;million, including cash and cash equivalents of approximately $3.9&#160;million. During the year ended December&#160;31, 2023, the Company had operating losses of $105.4&#160;million and cash flows used for operations of $20.7&#160;million. The Company had an accumulated deficit of $490.2&#160;million as of December&#160;31, 2023. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has plans to obtain additional resources to fund its currently planned operations and expenditures for at least twelve months from the issuance of these consolidated financial statements through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions. The Company&#x2019;s plans are also dependent upon the success of future sales of ZTlido and ELYXYB, among which ELYXYB is still in the early stages of commercialization, and the future commercialization of GLOPERBA. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Although the Company believes such plans, if executed, should provide the Company with financing to meet its needs, successful completion of such plans is dependent on factors outside the Company&#x2019;s control. As a result, management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company&#x2019;s ability to continue as a going concern for one year after the date the consolidated financial statements are issued. &lt;/div&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <sclx:RightToSellMaximumNumberOfCommonStockShares
      contextRef="P11_17_2022To11_17_2022_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-5"
      id="ixv-26459"
      unitRef="Unit_USD">500000000</sclx:RightToSellMaximumNumberOfCommonStockShares>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn11_17_2022_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="4"
      id="ixv-26460"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2023To12_31_2023"
      decimals="INF"
      id="ixv-26461"
      unitRef="Unit_shares">250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <sclx:Convertibledebentureprincipalamount
      contextRef="P03_21_2023To03_21_2023_EquityUnitPurchaseAgreementsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="-5"
      id="ixv-26463"
      unitRef="Unit_USD">25000000</sclx:Convertibledebentureprincipalamount>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="P01_01_2023To12_31_2023_EquityUnitPurchaseAgreementsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="-5"
      id="ixv-26464"
      unitRef="Unit_USD">25000000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:ConvertibleDebt
      contextRef="PAsOn12_31_2023_EquityUnitPurchaseAgreementsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="-5"
      id="ixv-26465"
      unitRef="Unit_USD">24000000</us-gaap:ConvertibleDebt>
    <sclx:PrincipalLaonAmount
      contextRef="P06_27_2023To06_27_2023"
      decimals="-5"
      id="ixv-26466"
      unitRef="Unit_USD">30000000</sclx:PrincipalLaonAmount>
    <sclx:OutstandingBalanceOfRevolvingFacility
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-26467"
      unitRef="Unit_USD">17000000</sclx:OutstandingBalanceOfRevolvingFacility>
    <sclx:CommonStockIssuableValue
      contextRef="PAsOn12_22_2023_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis_CommonStockMemberusgaapStatementClassOfStockAxis_MaximumMembersrtRangeAxis"
      decimals="0"
      id="ixv-26468"
      unitRef="Unit_USD">170000000</sclx:CommonStockIssuableValue>
    <sclx:ValueOfStockSoldForTerminationOfOffering
      contextRef="PAsOn12_22_2023_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis_CommonStockMemberusgaapStatementClassOfStockAxis_MaximumMembersrtRangeAxis"
      decimals="0"
      id="ixv-26469"
      unitRef="Unit_USD">170000000</sclx:ValueOfStockSoldForTerminationOfOffering>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2023_AtmSalesAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="INF"
      id="ixv-26470"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesIssued>
    <sclx:WorkingCapital
      contextRef="PAsOn12_31_2023"
      decimals="-5"
      id="ixv-26471"
      unitRef="Unit_USD">203600000</sclx:WorkingCapital>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2023"
      decimals="-5"
      id="ixv-26472"
      unitRef="Unit_USD">3900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-26473"
      unitRef="Unit_USD">-105400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-26474"
      unitRef="Unit_USD">20700000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2023"
      decimals="-5"
      id="ixv-26475"
      unitRef="Unit_USD">-490200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-18272">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3. Acquisitions &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104&lt;/div&gt; Acquisition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In May 2022, the Company acquired the Delayed Burst Release Low Dose Naltrexone asset and intellectual property rights for the treatment of chronic pain, fibromyalgia and chronic post-COVID syndrome (collectively, the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;SP-104&lt;/div&gt; Assets&#x201d;). Pursuant to the acquisition provisions, the Company is obligated to pay Aardvark Therapeutics, Inc. (&#x201c;Aardvark&#x201d;) (i) $3.0&#160;million upon initial approval by the FDA of a new drug application for the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104&lt;/div&gt; Assets (which amount may be paid in shares of Common Stock or cash, in the Company&#x2019;s sole discretion) (the &#x201c;Development Milestone Payment&#x201d;) and (ii) $20.0&#160;million in cash, upon achievement of certain net sales by the Company of a commercial product that uses the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104&lt;/div&gt; Assets (the &#x201c;Sales Milestone Payment&#x201d;). The Company will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by the Company of a commercial product that uses the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104&lt;/div&gt; Assets. &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Sales Milestone Payment and sale volume-based future royalties were determined to meet a scope exception for derivative accounting and will not be recognized until the contingencies are realized. The Development Milestone Payment represents a liability, which will be measured at fair value for each reporting period. As of December&#160;31, 2023 and December&#160;31, 2022, the contingent consideration associated with the Development Milestone Payment was $0.2&#160;million, recorded in the other long-term liabilities. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;GLOPERBA License Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In June 2022, the Company entered into a license agreement (the &#x201c;Romeg License Agreement&#x201d;) with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.) (&#x201c;Romeg&#x201d;). Pursuant to the Romeg License Agreement, among other things, Romeg granted the Company (a)&#160;a transferable license, with a right to sublicense, to (i)&#160;commercialize the pharmaceutical product comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans (the &#x201c;Initial Licensed Product&#x201d; or &#x201c;GLOPERBA&#x201d;) in the United States (including its territories) (the &#x201c;GLOPERBA Territory&#x201d;), (ii) develop other products comprising the Initial Licensed Product as an active pharmaceutical ingredient (the &#x201c;Licensed Products&#x201d;) and commercialize any such products and (iii)&#160;manufacture Licensed Products anywhere in the world, solely for commercialization in the GLOPERBA Territory; and (b)&#160;an exclusive, transferable license, with a right to sublicense, to use the trademark GLOPERBA and logos, designs, translations, and modifications thereof in connection with the commercialization of the Initial Licensed Product solely in the GLOPERBA Territory. The Initial Licensed Product, GLOPERBA, was approved and made available in the United States in 2020. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As consideration for the license under the Romeg License Agreement, the Company paid Romeg an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;up-front&lt;/div&gt; license fee of $2.0&#160;million, and has agreed to pay Romeg (a)&#160;upon the Company&#x2019;s achievement of certain net sales milestones, certain milestone payments in the aggregate amount of up to $13.0&#160;million, (b)&#160;certain royalties, at rates that do not exceed ten percent, based on annual net sales of the Licensed Products by the Company during the applicable royalty term under the Romeg License Agreement, and (c)&#160;minimum quarterly royalty payments totaling $7.1&#160;million commencing on the first year anniversary of the effective date of the Romeg License Agreement and ending on the later of (i)&#160;expiration of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;last-to-expire&lt;/div&gt;&lt;/div&gt; of the licensed patents covering the Licensed Products in the GLOPERBA Territory or (ii)&#160;the tenth anniversary of the effective date of the Romeg License Agreement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Romeg License Agreement, the Company recorded an intangible asset for acquired licenses of $5.7&#160;million, which is comprised of the upfront license fee of $2.0&#160;million and deferred consideration of $3.7&#160;million that is the present value of the future minimum royalty payments and immaterial transaction costs. No contingent consideration was recognized as a liability or included in the fair value of the assets as of December&#160;31, 2023 or December&#160;31, 2022. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ELYXYB Acquisition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On February&#160;12, 2023, the Company entered into an asset purchase agreement (the &#x201c;ELYXYB APA&#x201d;) with BioDelivery Sciences International, Inc. (&#x201c;BDSI&#x201d;) and Collegium Pharmaceutical, Inc. (&#x201c;Collegium&#x201d;, and together with BDSI, the &#x201c;Sellers&#x201d;) to acquire the rights to certain patents, trademarks, regulatory approvals, data, contracts, and other rights related to ELYXYB and its commercialization in the United States and Canada (the &#x201c;ELYXYB Territory&#x201d;). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As consideration for the acquisition, the Company assumed various rights and obligations under the asset purchase agreement between BDSI and Dr.&#160;Reddy&#x2019;s Laboratories Limited, a company incorporated under the laws of India (&#x201c;DRL&#x201d;), dated August&#160;3, 2021 (the &#x201c;DRL APA&#x201d;), including an irrevocable, royalty-free, exclusive license to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; and patents of DRL related to ELYXYB and necessary or used to exploit ELYXYB in the ELYXYB Territory. No cash consideration was or will be payable to the Sellers for such acquisition; however, the obligations under the DRL APA that were assumed by the Company include contingent sales and regulatory milestone payments and sales royalties. The Company is also obligated to make quarterly royalty payments to &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;DRL on net sales of ELYXYB in the ELYXYB Territory. In April 2023, the Company launched ELYXYB in the U.S. As of December&#160;31, 2023, the Company had ending balances of accrued royalty payables of $5.0&#160;thousand. As of December&#160;31, 2023, no sales or regulatory milestone payments had been accrued as there were no potential milestones yet considered probable of achievement.</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <sclx:AmountDueForNewDrugApplication
      contextRef="P05_31_2022To05_31_2022_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_SorrentoMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      id="ixv-26476"
      unitRef="Unit_USD">3000000</sclx:AmountDueForNewDrugApplication>
    <sclx:PaymentUponTheAchievementOfNetSales
      contextRef="P05_31_2022To05_31_2022_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_SorrentoMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      id="ixv-26477"
      unitRef="Unit_USD">20000000</sclx:PaymentUponTheAchievementOfNetSales>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
      contextRef="PAsOn12_31_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-26478"
      unitRef="Unit_USD">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
      contextRef="PAsOn12_31_2023_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-26479"
      unitRef="Unit_USD">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <sclx:Upfrontlicensefee
      contextRef="P06_14_2022To06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"
      decimals="-5"
      id="ixv-26480"
      unitRef="Unit_USD">2000000</sclx:Upfrontlicensefee>
    <sclx:PaymentUponTheAchievementOfNetSales
      contextRef="P06_14_2022To06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"
      decimals="-5"
      id="ixv-26481"
      unitRef="Unit_USD">13000000</sclx:PaymentUponTheAchievementOfNetSales>
    <us-gaap:PaymentsForRoyalties
      contextRef="P06_14_2022To06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"
      decimals="-5"
      id="ixv-26482"
      unitRef="Unit_USD">7100000</us-gaap:PaymentsForRoyalties>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"
      decimals="-5"
      id="ixv-26483"
      unitRef="Unit_USD">5700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <sclx:Upfrontlicensefee
      contextRef="P06_14_2022To06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"
      decimals="-5"
      id="ixv-26484"
      unitRef="Unit_USD">2000000</sclx:Upfrontlicensefee>
    <sclx:Deferredconsiderationliabilities
      contextRef="PAsOn06_14_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"
      decimals="-5"
      id="ixv-26485"
      unitRef="Unit_USD">3700000</sclx:Deferredconsiderationliabilities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2022_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"
      decimals="-6"
      id="ixv-26486"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn12_31_2023_LicenseAgreementMemberusgaapSubsidiarySaleOfStockAxis_RomegLicenseAgreementMemberdeiLegalEntityAxis"
      decimals="-6"
      id="ixv-26487"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <sclx:AccruedRoyaltyPayables
      contextRef="P01_01_2023To12_31_2023"
      decimals="-2"
      id="ixv-26490"
      unitRef="Unit_USD">5000</sclx:AccruedRoyaltyPayables>
    <sclx:PaymentToAcquireLicense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-6"
      id="ixv-26491"
      unitRef="Unit_USD">0</sclx:PaymentToAcquireLicense>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-18334">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4. Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table presents the Company&#x2019;s financial assets and liabilities that are measured at fair value on a recurring basis and the level of inputs used in such measurements (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:42%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Quoted&#160;Prices&lt;br/&gt; in Active&lt;br/&gt; Markets&lt;br/&gt; (Level 1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt; Other&lt;br/&gt; Observable&lt;br/&gt; Inputs&#160;(Level&#160;2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt; Unobservable&lt;br/&gt; Inputs&#160;(Level&#160;3)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Oramed Note&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;104,089&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;104,089&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Convertible Debentures&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-hidden:hidden107552736;display:inline;"&gt;Derivative liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,518&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,518&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other long-term liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;179&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;179&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total liabilities measured at fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;110,126&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;110,126&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:44%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Quoted&#160;Prices&lt;br/&gt; in Active&lt;br/&gt; Markets&lt;br/&gt; (Level&#160;1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt; Other&lt;br/&gt; Observable&lt;br/&gt; Inputs&#160;(Level&#160;2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt; Unobservable&lt;br/&gt; Inputs&#160;(Level&#160;3)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-hidden:hidden107552737;display:inline;"&gt;Derivative liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,231&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,231&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other long-term liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;163&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;163&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total liabilities measured at fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,394&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,394&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Oramed Note &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In September 2023, the Company issued a senior secured promissory note to Oramed Pharmaceuticals Inc. (&#x201c;Oramed&#x201d;) in the principal amount of $101.9&#160;million (the &#x201c;Oramed Note&#x201d;) (see Note 7). The Company elected the fair value option to account for the Oramed Note with any changes in the fair value of the note recorded in the consolidated statements of operations. The Company uses a discounted cash flow model to determine the fair value of the Oramed Note based on Level&#160;3 inputs. This methodology discounts the interest and principal payments using a risk-adjusted discount rate. The fair value as of December&#160;31, 2023 was determined to be $104.1&#160;million by applying a discount rate of 13.05%. For the year ended December&#160;31, 2023, the Company recorded $2.8&#160;million in change in fair value of the Oramed Note. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Convertible Debentures &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In March and April 2023, the Company issued the Convertible Debentures in the principal amount of $25.0&#160;million (see Note 7). The Convertible Debentures are measured at fair value on a recurring basis using Level&#160;3 inputs. The Company uses the Binomial Lattice Model valuation technique to measure the fair value of the Convertible Debentures with any changes in the fair value of the Convertible Debentures recorded in the consolidated statements of operations. Interest expense related to the Convertible Debentures is included in the changes in fair value. For the year ended December&#160;31, 2023, the Company recorded $4.4&#160;million in change in &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;fair value of the Convertible Debentures. A summary of inputs used in valuing the Convertible Debentures is as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:17%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk -Free Rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.31&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate Bond Yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15.60&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Coupon Interest Rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;70.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Dividend Yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Conversion Price&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivative Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company recorded a gain of $0.5&#160;million and $8.3&#160;million and a loss of $0.3&#160;million for the years ended December&#160;31, 2023, 2022 and 2021, respectively, on derivative liabilities which was attributed to the Private Warrants that the Company assumed from Vickers in November 2022 in connection with the Business Combination and compound derivative liabilities associated with the senior secured notes issued by Scilex Pharma in September 2018 (the &#x201c;Scilex Pharma Notes&#x201d;), respectively. The fair value of the derivative liability associated with the Scilex Pharma Notes decreased by $30.4&#160;million immediately after entry into Amendment No.&#160;4 to the Scilex Pharma Notes on June&#160;2, 2022 (&#x201c;Amendment No.&#160;4&#x201d;). The fair value of the derivative liability associated with the Scilex Pharma Notes was estimated using the discounted cash flow method combined with a Monte Carlo simulation model including consideration of the terms of Amendment No.&#160;4. Significant Level&#160;3 assumptions used in the measurement included a 6.1% risk adjusted net sales forecast and an effective debt yield of 21.5%. The Scilex Pharma Notes were fully extinguished in September 2022 and, as such, there were no remaining loan derivative liabilities associated with the Scilex Pharma Notes as of December&#160;31, 2022. At the closing of the Business Combination in November 2022, the Company assumed a derivative warrant liability of $2.5&#160;million related to the Private Warrants. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2023, 3,613,383 Private Warrants were outstanding, and the fair value of derivative warrant liability related to the Private Warrants was $1.5&#160;million. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table includes a summary of the derivative liabilities measured at fair value during the three years ended December&#160;31, 2023, 2022 and 2021 (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:84%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending Balance as of December&#160;31, 2020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;35,400&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-measurement&lt;/div&gt; of fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;300&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending Balance as of December&#160;31, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Private warrant liability acquired as part of the Business Combination&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,545&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Forfeiture of Private Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,696&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value measurement&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(38,710&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending Balance as of December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,231&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value measurement&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;512&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Forfeiture of Private Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(225&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending Balance as of December&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,518&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Warrant Liability Measurement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The derivative warrant liability was valued using the Black-Scholes option pricing model, which is considered to be Level&#160;3 fair value measurement. The primary unobservable input utilized in determining the fair value of the &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;warrant is the expected volatility of the Common Stock. The expected volatility assumption is based on historical volatilities of comparable companies whose share prices are publicly available as well as the implied volatility of the Public Warrants (see Note 9). A summary of the inputs used in valuing the derivative warrant liabilities is as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:65%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Equity value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.04&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.99&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercise price&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Term, in years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;76.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;35.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.94&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Call option value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.42&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.30&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent Consideration Related to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104&lt;/div&gt; Acquisition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Development Milestone Payment related to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104&lt;/div&gt; Assets represents an obligation to potentially settle a fixed value in a variable number of shares of Common Stock and requires remeasurement at fair value through settlement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Upon the achievement of FDA approval for a new drug application for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104,&lt;/div&gt; the Company will transfer $3.0&#160;million in cash or shares of Common Stock, at the discretion of the Company. The fair value of the contingent consideration liability associated with the Development Milestone Payment was estimated using a probability-weighted discounted cash flow method. Significant unobservable inputs assumptions included the likelihood of receiving FDA approval for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104,&lt;/div&gt; expected timing for receipt of FDA approval for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104,&lt;/div&gt; and a discount rate of 10.2%. As of December&#160;31, 2023 and December&#160;31, 2022, the fair value of contingent consideration related to the Development Milestone Payment was $0.2&#160;million. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;There were no transfers between fair value measurement levels during the years ended December&#160;31, 2023, 2022 and 2021. &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-18337">&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table presents the Company&#x2019;s financial assets and liabilities that are measured at fair value on a recurring basis and the level of inputs used in such measurements (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:42%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Quoted&#160;Prices&lt;br/&gt; in Active&lt;br/&gt; Markets&lt;br/&gt; (Level 1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt; Other&lt;br/&gt; Observable&lt;br/&gt; Inputs&#160;(Level&#160;2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt; Unobservable&lt;br/&gt; Inputs&#160;(Level&#160;3)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Oramed Note&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;104,089&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;104,089&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Convertible Debentures&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-hidden:hidden107552736;display:inline;"&gt;Derivative liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,518&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,518&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other long-term liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;179&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;179&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total liabilities measured at fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;110,126&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;110,126&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:44%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Quoted&#160;Prices&lt;br/&gt; in Active&lt;br/&gt; Markets&lt;br/&gt; (Level&#160;1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt; Other&lt;br/&gt; Observable&lt;br/&gt; Inputs&#160;(Level&#160;2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt; Unobservable&lt;br/&gt; Inputs&#160;(Level&#160;3)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-hidden:hidden107552737;display:inline;"&gt;Derivative liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,231&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,231&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other long-term liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;163&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;163&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total liabilities measured at fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,394&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,394&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26492"
      unitRef="Unit_USD">104089000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-26493"
      unitRef="Unit_USD">0</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-26494"
      unitRef="Unit_USD">0</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-26495"
      unitRef="Unit_USD">104089000</us-gaap:SeniorNotes>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26496"
      unitRef="Unit_USD">4340000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-26497"
      unitRef="Unit_USD">0</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-26498"
      unitRef="Unit_USD">0</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-26499"
      unitRef="Unit_USD">4340000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26500"
      unitRef="Unit_USD">1518000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-26501"
      unitRef="Unit_USD">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-26502"
      unitRef="Unit_USD">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-26503"
      unitRef="Unit_USD">1518000</us-gaap:DerivativeLiabilities>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26504"
      unitRef="Unit_USD">179000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-26505"
      unitRef="Unit_USD">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-26506"
      unitRef="Unit_USD">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-26507"
      unitRef="Unit_USD">179000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26508"
      unitRef="Unit_USD">110126000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-26509"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-26510"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-26511"
      unitRef="Unit_USD">110126000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26512"
      unitRef="Unit_USD">1231000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-26513"
      unitRef="Unit_USD">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-26514"
      unitRef="Unit_USD">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-26515"
      unitRef="Unit_USD">1231000</us-gaap:DerivativeLiabilities>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26516"
      unitRef="Unit_USD">163000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-26517"
      unitRef="Unit_USD">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-26518"
      unitRef="Unit_USD">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-26519"
      unitRef="Unit_USD">163000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26520"
      unitRef="Unit_USD">1394000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-26521"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-26522"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-26523"
      unitRef="Unit_USD">1394000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="P09_30_2023To09_30_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-26524"
      unitRef="Unit_USD">101900000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn12_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-26525"
      unitRef="Unit_USD">104100000</us-gaap:DebtInstrumentFairValue>
    <sclx:SecuredNoteDiscountRate
      contextRef="P01_01_2023To12_31_2023"
      decimals="4"
      id="ixv-26526"
      unitRef="Unit_pure">0.1305</sclx:SecuredNoteDiscountRate>
    <sclx:ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense
      contextRef="P01_01_2023To12_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-26527"
      unitRef="Unit_USD">2800000</sclx:ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="P04_30_2023To04_30_2023"
      decimals="-5"
      id="ixv-26528"
      unitRef="Unit_USD">25000000</us-gaap:DebtInstrumentIssuedPrincipal>
    <sclx:ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-26529"
      unitRef="Unit_USD">4400000</sclx:ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-26531">A summary of inputs used in valuing the Convertible Debentures is as follows: &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:17%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk -Free Rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.31&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate Bond Yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15.60&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Coupon Interest Rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;70.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Dividend Yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Conversion Price&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1
      contextRef="PAsOn12_31_2023"
      decimals="4"
      id="ixv-26532"
      unitRef="Unit_pure">0.0531</sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1>
    <sclx:CorporateBondYield
      contextRef="PAsOn12_31_2023"
      decimals="4"
      id="ixv-26533"
      unitRef="Unit_pure">0.156</sclx:CorporateBondYield>
    <sclx:CouponInterestRate
      contextRef="PAsOn12_31_2023"
      decimals="3"
      id="ixv-26534"
      unitRef="Unit_pure">0.07</sclx:CouponInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-26535"
      unitRef="Unit_pure">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1
      contextRef="PAsOn12_31_2023"
      decimals="3"
      id="ixv-26536"
      unitRef="Unit_pure">0</sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="PAsOn12_31_2023"
      decimals="2"
      id="ixv-26537"
      unitRef="Unit_USD_per_Share">8</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2023To12_31_2023_WarrantsMemberusgaapAwardTypeAxis"
      decimals="-5"
      id="ixv-26538"
      unitRef="Unit_USD">500000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2022To12_31_2022_WarrantsMemberusgaapAwardTypeAxis"
      decimals="-5"
      id="ixv-26539"
      unitRef="Unit_USD">8300000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2021To12_31_2021_WarrantsMemberusgaapAwardTypeAxis"
      decimals="-5"
      id="ixv-26540"
      unitRef="Unit_USD">-300000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="P06_02_2022To06_02_2022"
      decimals="-5"
      id="ixv-26541"
      unitRef="Unit_USD">30400000</us-gaap:LiabilitiesFairValueAdjustment>
    <sclx:RiskAdjustedNetSalesForecast
      contextRef="PAsOn06_30_2022"
      decimals="3"
      id="ixv-26542"
      unitRef="Unit_pure">0.061</sclx:RiskAdjustedNetSalesForecast>
    <us-gaap:DebtSecuritiesAvailableForSaleWeightedAverageYield
      contextRef="PAsOn06_30_2022"
      decimals="3"
      id="ixv-26543"
      unitRef="Unit_pure">0.215</us-gaap:DebtSecuritiesAvailableForSaleWeightedAverageYield>
    <sclx:DerivativeWarrantLiabilityPrivateWarrants
      contextRef="P11_30_2022To11_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-26544"
      unitRef="Unit_USD">2500000</sclx:DerivativeWarrantLiabilityPrivateWarrants>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2023_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-26545"
      unitRef="Unit_shares">3613383</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sclx:DerivativeWarrantLiabilityPrivateWarrants
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-26546"
      unitRef="Unit_USD">1500000</sclx:DerivativeWarrantLiabilityPrivateWarrants>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-18840">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table includes a summary of the derivative liabilities measured at fair value during the three years ended December&#160;31, 2023, 2022 and 2021 (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:84%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending Balance as of December&#160;31, 2020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;35,400&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-measurement&lt;/div&gt; of fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;300&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending Balance as of December&#160;31, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Private warrant liability acquired as part of the Business Combination&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,545&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Forfeiture of Private Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,696&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value measurement&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(38,710&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending Balance as of December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,231&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value measurement&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;512&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Forfeiture of Private Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(225&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending Balance as of December&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,518&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-26547"
      unitRef="Unit_USD">35400000</us-gaap:DerivativeLiabilities>
    <sclx:ReMeasurementOfFairValue
      contextRef="P01_01_2021To12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-26548"
      unitRef="Unit_USD">300000</sclx:ReMeasurementOfFairValue>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-26549"
      unitRef="Unit_USD">35700000</us-gaap:DerivativeLiabilities>
    <sclx:PrivatePlacementWarrantLiabilityAcquired
      contextRef="P01_01_2022To12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-26550"
      unitRef="Unit_USD">2545000</sclx:PrivatePlacementWarrantLiabilityAcquired>
    <sclx:ForfeitureOfPrivateWarrants
      contextRef="P01_01_2022To12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-26551"
      unitRef="Unit_USD">1696000</sclx:ForfeitureOfPrivateWarrants>
    <sclx:ChangeInValuationInputsOrOtherAssumptions
      contextRef="P01_01_2022To12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-26552"
      unitRef="Unit_USD">-38710000</sclx:ChangeInValuationInputsOrOtherAssumptions>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-26553"
      unitRef="Unit_USD">1231000</us-gaap:DerivativeLiabilities>
    <sclx:ChangeInValuationInputsOrOtherAssumptions
      contextRef="P01_01_2023To12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-26554"
      unitRef="Unit_USD">512000</sclx:ChangeInValuationInputsOrOtherAssumptions>
    <sclx:ForfeitureOfPrivateWarrants
      contextRef="P01_01_2023To12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-26555"
      unitRef="Unit_USD">-225000</sclx:ForfeitureOfPrivateWarrants>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="ixv-26556"
      unitRef="Unit_USD">1518000</us-gaap:DerivativeLiabilities>
    <us-gaap:FairValueConcentrationOfRiskTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-18981">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:65%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Equity value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.04&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.99&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercise price&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Term, in years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;76.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;35.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.94&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Call option value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.42&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.30&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueConcentrationOfRiskTextBlock>
    <sclx:EquityValue
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-26558"
      unitRef="Unit_USD_per_Share">2.04</sclx:EquityValue>
    <sclx:EquityValue
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      id="ixv-26559"
      unitRef="Unit_USD_per_Share">3.99</sclx:EquityValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn12_31_2023"
      decimals="2"
      id="ixv-26560"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn12_31_2022"
      decimals="2"
      id="ixv-26561"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2023To12_31_2023" id="ixv-26562">P3Y10M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2022To12_31_2022" id="ixv-26563">P4Y10M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2023To12_31_2023"
      decimals="INF"
      id="ixv-26564"
      unitRef="Unit_pure">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      id="ixv-26565"
      unitRef="Unit_pure">0.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2023To12_31_2023"
      decimals="4"
      id="ixv-26566"
      unitRef="Unit_pure">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="4"
      id="ixv-26567"
      unitRef="Unit_pure">0.0394</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-26568"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      id="ixv-26569"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <sclx:CallOptionValue
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-26570"
      unitRef="Unit_USD_per_Share">0.42</sclx:CallOptionValue>
    <sclx:CallOptionValue
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      id="ixv-26571"
      unitRef="Unit_USD_per_Share">0.3</sclx:CallOptionValue>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-26572"
      unitRef="Unit_USD">3000000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <us-gaap:ProductLiabilityContingencyAccrualDiscountRate
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-26573"
      unitRef="Unit_pure">0.102</us-gaap:ProductLiabilityContingencyAccrualDiscountRate>
    <sclx:FairValueOfContingentConsideration
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      id="ixv-26574"
      unitRef="Unit_USD">200000</sclx:FairValueOfContingentConsideration>
    <sclx:FairValueOfContingentConsideration
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-26575"
      unitRef="Unit_USD">200000</sclx:FairValueOfContingentConsideration>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-19095">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5. Balance Sheet Components &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and Equipment, Net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment, net, consists of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:66%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Construction in progress&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;689&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;689&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Furniture&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;118&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Computers and equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;77&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment, gross&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;780&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;939&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Accumulated depreciation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(58&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(167&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;722&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;772&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company recognized depreciation expense of $40.0&#160;thousand, $40.0&#160;thousand and $39.0&#160;thousand for the years ended December&#160;31, 2023, 2022 and 2021, respectively. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Accrued expenses consists of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:66%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued professional service fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,029&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,024&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued sales and marketing costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,601&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;574&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued research and development costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,546&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;459&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued tax payable&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,452&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued others&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;780&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;79&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,408&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,136&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-19101">&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment, net, consists of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:66%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Construction in progress&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;689&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;689&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Furniture&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;118&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Computers and equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;77&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment, gross&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;780&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;939&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Accumulated depreciation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(58&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(167&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;722&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;772&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-26576"
      unitRef="Unit_USD">689000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-26577"
      unitRef="Unit_USD">689000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-26578"
      unitRef="Unit_USD">5000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-26579"
      unitRef="Unit_USD">118000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-26580"
      unitRef="Unit_USD">36000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-26581"
      unitRef="Unit_USD">77000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-26582"
      unitRef="Unit_USD">50000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-26583"
      unitRef="Unit_USD">55000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26584"
      unitRef="Unit_USD">780000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26585"
      unitRef="Unit_USD">939000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26586"
      unitRef="Unit_USD">58000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26587"
      unitRef="Unit_USD">167000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26588"
      unitRef="Unit_USD">722000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26589"
      unitRef="Unit_USD">772000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="P01_01_2023To12_31_2023"
      decimals="-2"
      id="ixv-26590"
      unitRef="Unit_USD">40000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P01_01_2022To12_31_2022"
      decimals="-2"
      id="ixv-26591"
      unitRef="Unit_USD">40000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P01_01_2021To12_31_2021"
      decimals="-2"
      id="ixv-26592"
      unitRef="Unit_USD">39000</us-gaap:Depreciation>
    <sclx:AccruedExpensesTextblock contextRef="P01_01_2023To12_31_2023" id="ixv-19270">&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Accrued expenses consists of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:66%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued professional service fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,029&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,024&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued sales and marketing costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,601&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;574&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued research and development costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,546&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;459&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued tax payable&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,452&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued others&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;780&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;79&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,408&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,136&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</sclx:AccruedExpensesTextblock>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26594"
      unitRef="Unit_USD">2029000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26595"
      unitRef="Unit_USD">2024000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedMarketingCostsCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26596"
      unitRef="Unit_USD">1601000</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccruedMarketingCostsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26597"
      unitRef="Unit_USD">574000</us-gaap:AccruedMarketingCostsCurrent>
    <sclx:AccruedResearchAndDevelopmentCosts
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26598"
      unitRef="Unit_USD">1546000</sclx:AccruedResearchAndDevelopmentCosts>
    <sclx:AccruedResearchAndDevelopmentCosts
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26599"
      unitRef="Unit_USD">459000</sclx:AccruedResearchAndDevelopmentCosts>
    <us-gaap:TaxesPayableCurrentAndNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26600"
      unitRef="Unit_USD">1452000</us-gaap:TaxesPayableCurrentAndNoncurrent>
    <us-gaap:TaxesPayableCurrentAndNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26601"
      unitRef="Unit_USD">0</us-gaap:TaxesPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26602"
      unitRef="Unit_USD">780000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26603"
      unitRef="Unit_USD">79000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <sclx:AccruedExpenses
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26604"
      unitRef="Unit_USD">7408000</sclx:AccruedExpenses>
    <sclx:AccruedExpenses
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26605"
      unitRef="Unit_USD">3136000</sclx:AccruedExpenses>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-19392">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6. Goodwill and Intangible Assets &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2023 and 2022, the Company had recorded goodwill of $13.5&#160;million. No goodwill impairment was recognized for the years ended December&#160;31, 2023, 2022 and 2021. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Amortization of the intangible assets that have finite useful lives is generally recorded on a straight-line basis over their useful lives. A summary of the Company&#x2019;s identifiable intangible assets as of December&#160;31, 2023 and December&#160;31, 2022 is as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:55%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&#160;Carrying&lt;br/&gt; Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated&lt;br/&gt; Amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intangibles,&lt;br/&gt; net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Patent rights&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,630&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,591&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,039&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Acquired technology&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21,940&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,679&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14,261&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Acquired licenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,711&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;551&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,160&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Assembled workforce&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;475&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total intangible assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;60,781&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;24,296&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,485&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:55%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&#160;Carrying&lt;br/&gt; Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated&lt;br/&gt; Amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intangibles,&lt;br/&gt; net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Patent rights&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,630&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13,415&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,215&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Acquired technology&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21,940&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,216&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,724&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Acquired licenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,711&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;184&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,527&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Assembled workforce&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;375&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;125&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total intangible assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;60,781&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,190&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;40,591&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2023, the weighted average remaining life for identifiable intangible assets was 9.4 years. Aggregate amortization expense was $4.1&#160;million, $3.9&#160;million and $3.7&#160;million for the years ended December&#160;31, 2023, 2022 and 2021, respectively. Patent rights and acquired technology are amortized over a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;15-year&lt;/div&gt; period. Assembled workforce is amortized over a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5-year&lt;/div&gt; period. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Estimated future amortization expense related to intangible assets as of December&#160;31, 2023 is as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:85%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,031&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,006&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,006&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2027&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,006&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2028&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,006&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Thereafter&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,430&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,485&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2022"
      decimals="-5"
      id="ixv-26606"
      unitRef="Unit_USD">13500000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2023"
      decimals="-5"
      id="ixv-26607"
      unitRef="Unit_USD">13500000</us-gaap:Goodwill>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26608"
      unitRef="Unit_USD">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26609"
      unitRef="Unit_USD">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26610"
      unitRef="Unit_USD">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-26611">A summary of the Company&#x2019;s identifiable intangible assets as of December&#160;31, 2023 and December&#160;31, 2022 is as follows (in thousands): &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:55%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&#160;Carrying&lt;br/&gt; Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated&lt;br/&gt; Amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intangibles,&lt;br/&gt; net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Patent rights&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,630&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,591&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,039&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Acquired technology&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21,940&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,679&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14,261&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Acquired licenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,711&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;551&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,160&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Assembled workforce&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;475&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total intangible assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;60,781&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;24,296&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,485&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:55%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&#160;Carrying&lt;br/&gt; Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated&lt;br/&gt; Amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intangibles,&lt;br/&gt; net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Patent rights&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,630&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13,415&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,215&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Acquired technology&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21,940&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,216&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,724&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Acquired licenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,711&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;184&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,527&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Assembled workforce&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;375&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;125&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total intangible assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;60,781&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;20,190&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;40,591&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2023_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-26612"
      unitRef="Unit_USD">32630000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2023_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-26613"
      unitRef="Unit_USD">-15591000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2023_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-26614"
      unitRef="Unit_USD">17039000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2023_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-26615"
      unitRef="Unit_USD">21940000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2023_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-26616"
      unitRef="Unit_USD">-7679000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2023_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-26617"
      unitRef="Unit_USD">14261000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2023_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-26618"
      unitRef="Unit_USD">5711000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2023_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-26619"
      unitRef="Unit_USD">-551000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2023_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-26620"
      unitRef="Unit_USD">5160000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2023_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-26621"
      unitRef="Unit_USD">500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2023_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-26622"
      unitRef="Unit_USD">-475000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2023_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-26623"
      unitRef="Unit_USD">25000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26624"
      unitRef="Unit_USD">60781000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26625"
      unitRef="Unit_USD">-24296000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26626"
      unitRef="Unit_USD">36485000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2022_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-26627"
      unitRef="Unit_USD">32630000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2022_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-26628"
      unitRef="Unit_USD">-13415000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2022_PatentRightsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-26629"
      unitRef="Unit_USD">19215000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2022_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-26630"
      unitRef="Unit_USD">21940000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2022_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-26631"
      unitRef="Unit_USD">-6216000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2022_AcquiredTechnologyMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-26632"
      unitRef="Unit_USD">15724000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2022_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-26633"
      unitRef="Unit_USD">5711000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2022_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-26634"
      unitRef="Unit_USD">-184000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2022_AcquiredLicensesMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-26635"
      unitRef="Unit_USD">5527000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2022_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-26636"
      unitRef="Unit_USD">500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2022_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-26637"
      unitRef="Unit_USD">-375000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2022_AssembledWorkforceMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      id="ixv-26638"
      unitRef="Unit_USD">125000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26639"
      unitRef="Unit_USD">60781000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26640"
      unitRef="Unit_USD">-20190000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26641"
      unitRef="Unit_USD">40591000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="P01_01_2023To12_31_2023" id="ixv-26642">P9Y4M24D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-26643"
      unitRef="Unit_USD">4100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      id="ixv-26644"
      unitRef="Unit_USD">3900000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      id="ixv-26645"
      unitRef="Unit_USD">3700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-19736">&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Estimated future amortization expense related to intangible assets as of December&#160;31, 2023 is as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:85%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,031&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,006&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,006&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2027&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,006&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2028&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,006&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Thereafter&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,430&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,485&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26647"
      unitRef="Unit_USD">4031000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26648"
      unitRef="Unit_USD">4006000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26649"
      unitRef="Unit_USD">4006000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26650"
      unitRef="Unit_USD">4006000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26651"
      unitRef="Unit_USD">4006000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <sclx:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26652"
      unitRef="Unit_USD">16430000</sclx:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26653"
      unitRef="Unit_USD">36485000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DebtDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-19818">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7. Debt &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Convertible Debentures &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On March&#160;21, 2023, the Company entered into the Yorkville SPA, pursuant to which the Company would issue and sell to Yorkville Convertible Debentures in an aggregate principal amount of up to $25.0&#160;million. The Yorkville SPA provides that the Convertible Debentures would be issued and sold at a purchase price equal to 96% of the applicable principal amount in three tranches as follows: (i) $10.0&#160;million upon the signing of the Yorkville SPA, which was funded on March&#160;21, 2023; (ii) $7.5&#160;million upon the filing of a registration statement on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-1&lt;/div&gt; with the SEC to register the resale by Yorkville of any shares of Common Stock issuable upon conversion of the Convertible Debentures under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), which was funded on April&#160;11, 2023; and (iii) $7.5&#160;million at the time such registration statement was declared effective by the SEC, which was funded on April&#160;20, 2023. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Convertible Debentures bear interest at an annual rate of 7.00% and were initially set to mature on December 21, 2023. On &lt;div style="display:inline;"&gt;October&#160;11, 2023&lt;/div&gt;, the Company and Yorkville amended the Convertible Debentures. The Default Conversion Price (as defined therein) was originally set not to fall below $2.00 per share and such floor price has been amended to mean a price per share of Common Stock equal to 95% of the lowest daily VWAP (as defined therein) during the five consecutive trading days immediately preceding the conversion date, but not lower than $0.50 per share. The maturity date of the Convertible Debentures was also extended from December&#160;21, 2023 to March 15, 2024. The outstanding principal amount is to be repaid in equal installments that are due every 30 days beginning on May&#160;20, 2023, which is 60 days after the date on which the first Convertible Debenture was issued to Yorkville. The Convertible Debentures provide a conversion right, in which any portion of the outstanding and unpaid principal and any accrued but unpaid interest may be converted into shares of Common Stock, at a conversion price of $8.00 per share at the option of the holder of the Convertible Debentures. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has the option to repay either (i)&#160;in cash, with premium equal to&#160;5% in respect of the principal amount of such payment, or (ii)&#160;by submitting a notice for an advance under the A&amp;amp;R Yorkville Purchase Agreement, or a series of advances thereunder, or any combination of (i)&#160;or (ii) as determined by the Company. In the case of (ii), the proceeds from the shares sold to Yorkville are applied against the outstanding amounts. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has the right, but not the obligation, in its sole discretion, to redeem, upon five business days&#x2019; prior written notice to Yorkville (the &#x201c;Redemption Notice&#x201d;), all or any portion of the amounts outstanding under the Convertible Debentures; provided that the trading price of the Common Stock is less than the Conversion Price at the time of the Redemption Notice. The redemption amount shall be equal to the outstanding principal balance being redeemed by the Company, plus the redemption premium of 10% of the principal amount being redeemed, plus all accrued and unpaid interest in respect of such redeemed principal amount. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has elected the fair value option for the Convertible Debentures and records the changes in the fair value within the consolidated statements of operations at the end of each reporting period. Pursuant to the &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Yorkville SPA, the Company issued additional Convertible Debentures in an aggregate principal amount of $15.0&#160;million in April 2023 for $14.4&#160;million in net cash proceeds. In April 2023, Yorkville elected to convert $5.0&#160;million of the outstanding principal and accrued interest of the first Convertible Debentures issued to Yorkville, resulting in the issuance of 632,431 shares of Common Stock at a conversion price of $8.00&#160;per share and reducing the outstanding Convertible Debentures fair value balance by $4.4&#160;million. The Company repaid $15.6&#160;million of the Convertible Debentures during the year ended December&#160;31, 2023. &lt;div style="-sec-ix-hidden:hidden107552752;display:inline;"&gt;Interest expense related to the Convertible Debentures and included in the changes in fair value&lt;/div&gt; was $0.7&#160;million for the year ended December&#160;31, 2023. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table provides a summary of the changes in the balance and the estimated fair value of the Convertible Debentures (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Beginning Balance as of January&#160;1, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Issuance of Convertible Debentures&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;24,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Repayment of Convertible Debentures&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15,625&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value of Convertible Debentures&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,700&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Conversion of Convertible Debentures into Common Stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,735&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending Balance as of December&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revolving Facility &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;27, 2023, Scilex Pharma entered into the eCapital Credit Agreement, pursuant to which the Lender shall make available the Revolving Facility in an aggregate principal amount of up to $30.0&#160;million. The Facility Cap may, at the request of Scilex Pharma and with the consent of the Lender, be increased in increments of $250,000&#160;at such time as the outstanding principal balance under the eCapital Credit Agreement equals or exceeds 95% of the then-existing Facility Cap. The amount available to Scilex Pharma under the Revolving Facility at any one time is the lesser of the Facility Cap and 85% of the Net Collectible Value of Eligible Receivables (each as defined therein) minus the amount of any reserves or adjustments against receivables required by the Lender, in its discretion. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Under the terms of the eCapital Credit Agreement, interest will accrue daily on the principal amount outstanding at a rate per annum equal to the Wall Street Journal Prime Rate plus 1.5%, based on a year consisting of 360 days, and which shall be payable by Scilex Pharma monthly in arrears, commencing July&#160;1, 2023. The eCapital Credit Agreement provides for an early termination fee of 0.5% of the Facility Cap if Scilex Pharma voluntarily prepays and terminates in full the Revolving Facility prior to the first anniversary of the closing of the Revolving Facility. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In connection with the eCapital Credit Agreement, Scilex Pharma and the Lender entered into blocked account control agreements with respect to Scilex Pharma&#x2019;s collections and eCapital Credit Agreement funding accounts, which permit the Lender to sweep all funds in the collections account to an account of the Lender for application to the outstanding amounts under the Revolving Facility, and to exercise customary secured party remedies with respect to the eCapital Credit Agreement funding account. All indebtedness incurred and outstanding under the eCapital Credit Agreement will be due and payable in full on July&#160;1, 2026, unless the eCapital Credit Agreement is earlier terminated. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The eCapital Credit Agreement contains a financial covenant requiring Scilex Pharma to maintain cash on hand of at least $1.0&#160;million at all times. Scilex Pharma&#x2019;s obligations under the eCapital Credit Agreement are secured by a continuing security interest in Scilex Pharma&#x2019;s accounts receivable, arising from customers in the ordinary &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;course of business. The eCapital Credit Agreement contains customary events of default and also provides that an event of default includes a change of control of Scilex Pharma and the failure by the Company to issue at least $75.0&#160;million of debt or equity by September&#160;30, 2023, which condition was satisfied by the issuance of the Oramed Note. As of December&#160;31, 2023, Scilex Pharma has an outstanding balance of $17.0&#160;million under the Revolving Facility, which is classified as a long-term liability in the consolidated balance sheet. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On September&#160;21, 2023, Scilex Pharma signed a subordination agreement (the &#x201c;Subordination Agreement&#x201d;) with the Lender and Acquiom Agency Services LLC (the &#x201c;Agent&#x201d;). Pursuant to the Subordination Agreement, the rights and interests of the Lender under the eCapital Credit Agreement would be secured by first priority liens on the ABL Priority Collateral (as defined therein). The ABL Priority Collateral consists of all of the Company&#x2019;s properties identified in the description of collateral in the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;UCC-1&lt;/div&gt; Financing Statement filed with the Delaware Secretary of State on June&#160;27, 2023. The Agent&#x2019;s rights and interests under that certain Subsidiary Guarantee, dated as of September&#160;21, 2023, entered into by us and each of our subsidiaries with Oramed and the Agent (the &#x201c;Subsidiary Guarantee&#x201d;), would be secured by first priority liens on certain other collateral and second priority liens on the ABL Priority Collateral. The Subordination Agreement also includes other standard interlender terms and requires that the Facility Cap (as defined therein) shall not exceed $30.0&#160;million. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Oramed Note &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On September&#160;21, 2023, the Company entered into a securities purchase agreement with Oramed (the &#x201c;Scilex-Oramed SPA&#x201d;), pursuant to which the Company issued the Oramed Note. The Oramed Note, which has a principal amount of $101.9&#160;million, matures on March 21, 2025. It is payable in six principal installments, with the first installment of $5.0&#160;million payable on December 21, 2023, the second installment in the principal amount of $15.0&#160;million payable on March 21, 2024, the next three installments each in the principal amount of $20.0&#160;million payable on each of June 21, 2024, September 21, 2024 and December 21, 2024 and the last installment in the entire remaining principal balance of the Oramed Note payable on March 21, 2025. Interest under the Oramed Note accrues at a fluctuating per annum interest rate equal to the sum of (1)&#160;greater of (x) 4% and (y)&#160;Term SOFR (as defined in the Oramed Note) and (2) 8.5%, payable &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-kind&lt;/div&gt; on a monthly basis. If the outstanding principal has not been fully repaid by March&#160;21, 2024, an exit fee of approximately $3.1&#160;million becomes due upon repayment. Upon the occurrence and during the continuance of an event of default under the Oramed Note, holders of more than 50% of the aggregate unpaid principal amount of the Oramed Notes may elect to accrue interest at a default rate equal to the lesser of (i)&#160;Term SOFR plus 15% or (ii)&#160;the maximum rate permitted under applicable law. Voluntary prepayments made before the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-year&lt;/div&gt; anniversary of the closing date of the Scilex-Oramed SPA must include a make-whole amount equal to 50% of the additional interest that would accrue on the principal amount so prepaid from the date of such prepayment through and including the maturity date. If the Oramed Note is accelerated upon an event of default, repayment is required at a mandatory default rate of 125% of the principal amount (together with 100% of accrued and unpaid interest thereon and all other amounts due in respect of the Oramed Note). The Oramed Note contains mandatory prepayment provisions requiring use of 70% of net cash proceeds from any Cash Sweep Financing (as defined in the Oramed Note) or advances under the ELOCs (as defined in the Oramed Note) to prepay the outstanding principal after the earlier of April&#160;1, 2024 or full repayment of Acceptable Indebtedness (as defined in the Oramed Note). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Oramed Note contains affirmative and negative covenants binding on the Company and its subsidiaries, which restrict, among other things, the Company and its subsidiaries from incurring indebtedness or liens, amending charter and organizational documents, repaying or repurchasing stock, repaying, repurchasing, or acquiring indebtedness, paying or declaring cash dividends, assigning, selling, transferring or otherwise disposing of assets, making or holding investments, entering into transactions with affiliates, and entering into settlement agreements, in each case as more fully set forth in, and subject to certain qualifications and exceptions set forth in, the Oramed Note. The Company was in compliance with all of the covenants as of December&#160;31, 2023. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Oramed Note, the Company and each of its subsidiaries (collectively, the &#x201c;Guarantors&#x201d;) entered into a security agreement (the &#x201c;Security Agreement&#x201d;) with Oramed (together with its successors and &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;permitted assigns, the &#x201c;Holder&#x201d;) and the Agent, which acts as the collateral agent for the holders of the Oramed Note. Under this agreement, the Company and the Guarantors granted to the Agent (on behalf of and for the benefit of the holders of the Oramed Note and any Additional Notes as defined thereunder) a security interest in all or substantially all of the properties of the Company and each of the Guarantors. This was done to ensure the timely payment, performance, and full discharge of all obligations under the Oramed Note. The Security Agreement contains certain customary representations, warranties and covenants regarding the collateral thereunder, all of which are detailed in the Security Agreement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;At issuance, the Company concluded that certain features of the Oramed Note would be considered derivatives that would require bifurcation. In lieu of bifurcating such features, the Company has elected the fair value option for this financial instrument and records the changes in the fair value within the consolidated statements of operations at the end of each reporting period. As of December&#160;31, 2023, the fair value of the Oramed Note was $104.1&#160;million, which is classified as a current liability in the consolidated balance sheet. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table provides a summary of the changes in the balance and the estimated fair value of the Oramed Note (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Beginning Balance as of January&#160;1, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Issuance of Oramed Note&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;106,252&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value of Oramed Note&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,837&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Repayment of Oramed Note&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending Balance as of December&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;104,089&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-26654"
      unitRef="Unit_USD">25000000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentDescription
      contextRef="P01_01_2023To12_31_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      id="ixv-19825">The Yorkville SPA provides that the Convertible Debentures would be issued and sold at a purchase price equal to 96% of the applicable principal amount in three tranches as follows: (i) $10.0&#160;million upon the signing of the Yorkville SPA, which was funded on March&#160;21, 2023; (ii) $7.5&#160;million upon the filing of a registration statement on Form S-1 with the SEC to register the resale by Yorkville of any shares of Common Stock issuable upon conversion of the Convertible Debentures under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), which was funded on April&#160;11, 2023; and (iii) $7.5&#160;million at the time such registration statement was declared effective by the SEC, which was funded on April&#160;20, 2023.</us-gaap:DebtInstrumentDescription>
    <sclx:ConvertibleDebenturesIssuedPercent
      contextRef="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-26655"
      unitRef="Unit_pure">0.96</sclx:ConvertibleDebenturesIssuedPercent>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis"
      decimals="-5"
      id="ixv-26656"
      unitRef="Unit_USD">10000000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis"
      decimals="-5"
      id="ixv-26657"
      unitRef="Unit_USD">7500000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ShareBasedCompensationAwardTrancheThreeMemberusgaapVestingAxis"
      decimals="-5"
      id="ixv-26658"
      unitRef="Unit_USD">7500000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="4"
      id="ixv-26659"
      unitRef="Unit_pure">0.07</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      id="ixv-26660">2023-12-21</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="PAsOn10_11_2023_MaximumMembersrtRangeAxis"
      decimals="2"
      id="ixv-26661"
      unitRef="Unit_USD_per_Share">2</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="PAsOn10_11_2023_MinimumMembersrtRangeAxis"
      decimals="2"
      id="ixv-26662"
      unitRef="Unit_USD_per_Share">0.5</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P01_01_2023To12_31_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      id="ixv-26663">2024-03-15</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="PAsOn03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      id="ixv-26664"
      unitRef="Unit_USD_per_Share">8</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentPaymentTerms
      contextRef="P01_01_2023To12_31_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      id="ixv-26665">The Company has the option to repay either (i)&#160;in cash, with premium equal to&#160;5% in respect of the principal amount of such payment, or (ii)&#160;by submitting a notice for an advance under the A&amp;R Yorkville Purchase Agreement, or a series of advances thereunder, or any combination of (i)&#160;or (ii) as determined by the Company. In the case of (ii), the proceeds from the shares sold to Yorkville are applied against the outstanding amounts.</us-gaap:DebtInstrumentPaymentTerms>
    <sclx:DebtInstrumentPrincipalAmountPercentage
      contextRef="P03_21_2023To03_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-26666"
      unitRef="Unit_pure">0.05</sclx:DebtInstrumentPrincipalAmountPercentage>
    <us-gaap:DebtInstrumentRedemptionDescription contextRef="P01_01_2023To12_31_2023" id="ixv-26667">The Company has the right, but not the obligation, in its sole discretion, to redeem, upon five business days&#x2019; prior written notice to Yorkville (the &#x201c;Redemption Notice&#x201d;), all or any portion of the amounts outstanding under the Convertible Debentures; provided that the trading price of the Common Stock is less than the Conversion Price at the time of the Redemption Notice. The redemption amount shall be equal to the outstanding principal balance being redeemed by the Company, plus the redemption premium of 10% of the principal amount being redeemed, plus all accrued and unpaid interest in respect of such redeemed principal amount.</us-gaap:DebtInstrumentRedemptionDescription>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="P01_01_2023To12_31_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-26668"
      unitRef="Unit_pure">0.10</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="P04_30_2023To04_30_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-5"
      id="ixv-26670"
      unitRef="Unit_USD">15000000</us-gaap:DebtInstrumentIssuedPrincipal>
    <sclx:NetCashProceeds
      contextRef="P04_30_2023To04_30_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-5"
      id="ixv-26671"
      unitRef="Unit_USD">14400000</sclx:NetCashProceeds>
    <us-gaap:PrincipalAmountOutstandingOfLoansHeldInPortfolio
      contextRef="PAsOn12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-5"
      id="ixv-26672"
      unitRef="Unit_USD">5000000</us-gaap:PrincipalAmountOutstandingOfLoansHeldInPortfolio>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="INF"
      id="ixv-26673"
      unitRef="Unit_shares">632431</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockConvertibleConversionPriceIncrease
      contextRef="P01_01_2023To12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="2"
      id="ixv-26674"
      unitRef="Unit_USD_per_Share">8</us-gaap:CommonStockConvertibleConversionPriceIncrease>
    <sclx:DebtInstrumentOutstandingPrincipal
      contextRef="P01_01_2023To12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-5"
      id="ixv-26675"
      unitRef="Unit_USD">4400000</sclx:DebtInstrumentOutstandingPrincipal>
    <us-gaap:DebtInstrumentRepaidPrincipal
      contextRef="P01_01_2023To12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-5"
      id="ixv-26676"
      unitRef="Unit_USD">15600000</us-gaap:DebtInstrumentRepaidPrincipal>
    <us-gaap:ServicingLiabilityAtFairValueOtherChangesInFairValue
      contextRef="P01_01_2023To12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-5"
      id="ixv-26677"
      unitRef="Unit_USD">700000</us-gaap:ServicingLiabilityAtFairValueOtherChangesInFairValue>
    <us-gaap:ConvertibleDebtTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-19852">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table provides a summary of the changes in the balance and the estimated fair value of the Convertible Debentures (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Beginning Balance as of January&#160;1, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Issuance of Convertible Debentures&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;24,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Repayment of Convertible Debentures&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15,625&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value of Convertible Debentures&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,700&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Conversion of Convertible Debentures into Common Stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,735&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending Balance as of December&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:ConvertibleDebt
      contextRef="PAsOn12_31_2022_ConvertibleDebtSecuritiesMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-26678"
      unitRef="Unit_USD">0</us-gaap:ConvertibleDebt>
    <us-gaap:NotesIssued1
      contextRef="P01_01_2023To12_31_2023_ConvertibleDebtSecuritiesMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-26679"
      unitRef="Unit_USD">24000000</us-gaap:NotesIssued1>
    <sclx:RepaymentOfConvertibleDebenture
      contextRef="P01_01_2023To12_31_2023_ConvertibleDebtSecuritiesMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-26680"
      unitRef="Unit_USD">-15625000</sclx:RepaymentOfConvertibleDebenture>
    <sclx:ChangeInFairValueOfConvertibleDebentures
      contextRef="P01_01_2023To12_31_2023_ConvertibleDebtSecuritiesMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-26681"
      unitRef="Unit_USD">3700000</sclx:ChangeInFairValueOfConvertibleDebentures>
    <sclx:ConversionOfConvertibleDebenturesIntoCommonStock
      contextRef="P01_01_2023To12_31_2023_ConvertibleDebtSecuritiesMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-26682"
      unitRef="Unit_USD">7735000</sclx:ConversionOfConvertibleDebenturesIntoCommonStock>
    <us-gaap:ConvertibleDebt
      contextRef="PAsOn12_31_2023_ConvertibleDebtSecuritiesMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-26683"
      unitRef="Unit_USD">4340000</us-gaap:ConvertibleDebt>
    <us-gaap:FinancingReceivableRevolvingConvertedToTermLoan
      contextRef="PAsOn06_27_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-26684"
      unitRef="Unit_USD">30000000</us-gaap:FinancingReceivableRevolvingConvertedToTermLoan>
    <sclx:DebtInstrumentOutstandingPrincipal
      contextRef="P06_27_2023To06_27_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="0"
      id="ixv-26685"
      unitRef="Unit_USD">250000</sclx:DebtInstrumentOutstandingPrincipal>
    <sclx:ExistingFacilityCapMaximum
      contextRef="P06_27_2023To06_27_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="2"
      id="ixv-26686"
      unitRef="Unit_pure">0.95</sclx:ExistingFacilityCapMaximum>
    <sclx:ExistingFacilityCapMinimum
      contextRef="P06_27_2023To06_27_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="2"
      id="ixv-26687"
      unitRef="Unit_pure">0.85</sclx:ExistingFacilityCapMinimum>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="P07_01_2023To07_01_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="3"
      id="ixv-26688"
      unitRef="Unit_pure">0.015</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <sclx:TerminationFees
      contextRef="PAsOn12_31_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="3"
      id="ixv-26689"
      unitRef="Unit_pure">0.005</sclx:TerminationFees>
    <us-gaap:Cash
      contextRef="PAsOn12_31_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-26690"
      unitRef="Unit_USD">1000000</us-gaap:Cash>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="P01_01_2023To12_31_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-26692"
      unitRef="Unit_USD">75000000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:PrincipalAmountOutstandingOfLoansHeldInPortfolio
      contextRef="PAsOn12_31_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-26693"
      unitRef="Unit_USD">17000000</us-gaap:PrincipalAmountOutstandingOfLoansHeldInPortfolio>
    <us-gaap:FinancingReceivableRevolvingConvertedToTermLoan
      contextRef="PAsOn09_21_2023_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-26694"
      unitRef="Unit_USD">30000000</us-gaap:FinancingReceivableRevolvingConvertedToTermLoan>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-26695"
      unitRef="Unit_USD">101900000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P09_21_2023To09_21_2023_FristInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      id="ixv-26696">2025-03-21</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:RepaymentsOfDebt
      contextRef="P09_21_2023To09_21_2023_FristInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-26697"
      unitRef="Unit_USD">5000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P09_21_2023To09_21_2023_SecondInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      id="ixv-26698">2023-12-21</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:RepaymentsOfDebt
      contextRef="P09_21_2023To09_21_2023_SecondInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-26699"
      unitRef="Unit_USD">15000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_ThirdInstallmentMemberusgaapDebtInstrumentAxis"
      id="ixv-26700">2024-03-21</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:RepaymentsOfDebt
      contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_ThirdInstallmentMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-26701"
      unitRef="Unit_USD">20000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P09_21_2023To09_21_2023_FourthInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      id="ixv-26702">2024-06-21</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P09_21_2023To09_21_2023_FiveInstallmentMemberusgaapDebtInstrumentAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      id="ixv-26703">2024-09-21</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SixInstallmentMemberusgaapDebtInstrumentAxis"
      id="ixv-26704">2024-12-21</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      id="ixv-26705">2025-03-21</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentDescription
      contextRef="P01_01_2023To12_31_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      id="ixv-19957">Interest under the Oramed Note accrues at a fluctuating per annum interest rate equal to the sum of (1)&#160;greater of (x) 4% and (y)&#160;Term SOFR (as defined in the Oramed Note) and (2) 8.5%, payable in-kind on a monthly basis. If the outstanding principal has not been fully repaid by March&#160;21, 2024, an exit fee of approximately $3.1&#160;million becomes due upon repayment. Upon the occurrence and during the continuance of an event of default under the Oramed Note, holders of more than 50% of the aggregate unpaid principal amount of the Oramed Notes may elect to accrue interest at a default rate equal to the lesser of (i)&#160;Term SOFR plus 15% or (ii)&#160;the maximum rate permitted under applicable law. Voluntary prepayments made before the one-year anniversary of the closing date of the Scilex-Oramed SPA must include a make-whole amount equal to 50% of the additional interest that would accrue on the principal amount so prepaid from the date of such prepayment through and including the maturity date. If the Oramed Note is accelerated upon an event of default, repayment is required at a mandatory default rate of 125% of the principal amount (together with 100% of accrued and unpaid interest thereon and all other amounts due in respect of the Oramed Note). The Oramed Note contains mandatory prepayment provisions requiring use of 70% of net cash proceeds from any Cash Sweep Financing (as defined in the Oramed Note) or advances under the ELOCs (as defined in the Oramed Note) to prepay the outstanding principal after the earlier of April&#160;1, 2024 or full repayment of Acceptable Indebtedness (as defined in the Oramed Note).</us-gaap:DebtInstrumentDescription>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="P09_21_2023To09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="2"
      id="ixv-26706"
      unitRef="Unit_pure">0.04</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="P09_21_2023To09_21_2023_MonthlyBasisMemberSCLXDebtPayableAxis_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="3"
      id="ixv-26707"
      unitRef="Unit_pure">0.085</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <sclx:DebtRepaymentExitFee
      contextRef="PAsOn09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-26708"
      unitRef="Unit_USD">3100000</sclx:DebtRepaymentExitFee>
    <sclx:DebtInstrumentOwnedPercentage
      contextRef="PAsOn09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="2"
      id="ixv-26709"
      unitRef="Unit_pure">0.50</sclx:DebtInstrumentOwnedPercentage>
    <sclx:DebtInstrumentDefaultInterestRate
      contextRef="PAsOn09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="2"
      id="ixv-26710"
      unitRef="Unit_pure">0.15</sclx:DebtInstrumentDefaultInterestRate>
    <sclx:DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount
      contextRef="PAsOn09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="2"
      id="ixv-26711"
      unitRef="Unit_pure">0.50</sclx:DebtInstrumentPercentageOfInterestAccruedOnPrincipalAmount>
    <sclx:DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount
      contextRef="PAsOn09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="2"
      id="ixv-26712"
      unitRef="Unit_pure">1.25</sclx:DebtRepaymentPercentageOfMandatoryDefaultRateOfPrincipalAmount>
    <sclx:DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest
      contextRef="PAsOn09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="2"
      id="ixv-26713"
      unitRef="Unit_pure">1</sclx:DebtRepaymentPercentageOfMandatoryDefaultRateOfAccruedAndUnpaidInterest>
    <sclx:PercentageOfUsageOfCashProceedsFromCashSweepFinancing
      contextRef="PAsOn09_21_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="2"
      id="ixv-26714"
      unitRef="Unit_pure">0.70</sclx:PercentageOfUsageOfCashProceedsFromCashSweepFinancing>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn12_31_2023_SecuritiesPurchaseAgreementMemberusgaapTypeOfArrangementAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-26716"
      unitRef="Unit_USD">104100000</us-gaap:DebtInstrumentFairValue>
    <sclx:ScheduleOfTheOramedNoteTableTextBlock
      contextRef="P01_01_2023To12_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      id="ixv-19982">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table provides a summary of the changes in the balance and the estimated fair value of the Oramed Note (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Beginning Balance as of January&#160;1, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Issuance of Oramed Note&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;106,252&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value of Oramed Note&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,837&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Repayment of Oramed Note&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending Balance as of December&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;104,089&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</sclx:ScheduleOfTheOramedNoteTableTextBlock>
    <us-gaap:ConvertibleDebt
      contextRef="PAsOn12_31_2022_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-26717"
      unitRef="Unit_USD">0</us-gaap:ConvertibleDebt>
    <us-gaap:NotesIssued1
      contextRef="P01_01_2023To12_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-26718"
      unitRef="Unit_USD">106252000</us-gaap:NotesIssued1>
    <sclx:ChangeInFairValueOfConvertibleDebentures
      contextRef="P01_01_2023To12_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-26719"
      unitRef="Unit_USD">2837000</sclx:ChangeInFairValueOfConvertibleDebentures>
    <sclx:RepaymentOfConvertibleDebenture
      contextRef="P01_01_2023To12_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-26720"
      unitRef="Unit_USD">-5000000</sclx:RepaymentOfConvertibleDebenture>
    <us-gaap:ConvertibleDebt
      contextRef="PAsOn12_31_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-26721"
      unitRef="Unit_USD">104089000</us-gaap:ConvertibleDebt>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-20051">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8. Junior DIP Facility and Sorrento Stock Purchase Agreement &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Junior DIP Facility &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In July 2023, the Company entered into an agreement to provide Sorrento with a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-amortizing&lt;/div&gt; super-priority junior secured term loan facility (&#x201c;Junior DIP Facility&#x201d;) in an aggregate principal amount of $20.0&#160;million (the &#x201c;Junior DIP Loan Agreement&#x201d;), which was funded in the same month. The Junior DIP Facility bears interest at a per annum rate of 12.0% payable in kind on the first day of each month in arrears and on the DIP Termination Date (as defined in the Junior DIP Loan Agreement). Upon repayment or satisfaction of the DIP Loans (as defined in the Junior DIP Loan Agreement) in whole or in part, Sorrento is required to pay to the Company in cash an exit fee equal to 2.00% of the aggregate principal amount of the Junior DIP Facility. The Junior DIP Facility was to mature on the earliest of: (i)&#160;September&#160;30, 2023; (ii) the effective date of any Chapter 11 plan of reorganization with respect to Sorrento; (iii)&#160;the consummation of any sale or other disposition of all or substantially all of the assets of Sorrento; (iv)&#160;the date of the acceleration of the DIP Loans and the termination of the DIP Commitments (as defined in the Junior DIP Loan Agreement) in accordance with the DIP Documents (as defined in the Junior DIP Loan Agreement); and (v)&#160;dismissal of the Chapter 11 Cases or conversion of the Chapter 11 Cases into cases under Chapter 7 of the Bankruptcy Code. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On September&#160;21, 2023, Sorrento&#x2019;s obligations under the Junior DIP Facility were waived and deemed to be fully settled in conjunction with the Sorrento SPA as described below. Consequently, the transfer of funds associated with the Junior DIP Facility was deemed and accounted for as a capital distribution to Sorrento. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sorrento Stock Purchase Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On September&#160;21, 2023, the Company entered into a Stock Purchase Agreement with Sorrento (&#x201c;Sorrento SPA&#x201d;), pursuant to which the Company purchased from Sorrento (i) 60,068,585 shares of Common Stock, (ii)&#160;29,057,097 shares of Series A Preferred Stock, par value $0.0001 per share, of the Company (the &#x201c;Preferred &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Stock&#x201d;) and (iii) 1,386,617 Public Warrants and 3,104,000 Private Warrants (collectively, the &#x201c;Purchased Securities&#x201d;). On the same day, the Company and Oramed entered into the Scilex-Oramed SPA. The Company concluded that the Sorrento SPA and the Scilex-Oramed SPA were entered in contemplation of each other and the issuance of the Oramed Note was accounted as part of the consideration payable for the Purchased Securities acquired from Sorrento. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to the terms of the Scilex-Oramed SPA, the Company issued the Oramed Note (see Note 7), which replaced Sorrento&#x2019;s outstanding obligations to Oramed, warrants to purchase up to an aggregate of 4,500,000 shares of Common Stock (the &#x201c;Closing Penny Warrant&#x201d;) with an exercise price of $0.01 per share and restrictions on exercisability, and warrants to purchase up to an aggregate of 8,500,000 shares of Common Stock (the &#x201c;Subsequent Penny Warrants&#x201d; and together with the Closing Penny Warrant, the &#x201c;Penny Warrants&#x201d;), each with an exercise price of $0.01 per share and each with restrictions on exercisability. Additionally, the Company agreed to transfer to Oramed 4,000,000 SPAC Warrants, which were acquired by the Company under the Sorrento SPA. There was no change in the terms for the warrants transferred to Oramed as a result of the transactions described above. The remaining consideration for the Purchased Securities was comprised of a credit bid for all amounts of principal and accrued but unpaid interest outstanding under the Junior DIP Facility, a $10.0&#160;million cash payment, and the assumption and assignment of certain obligations of Sorrento for legal fees and expenses amounting to approximately $12.3&#160;million. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company allocated the total consideration between the repurchased instruments by allocating to the repurchased Private Warrants their full value, with the remaining consideration allocated to the Common Stock, Preferred Stock, and Public Warrants based on their relative fair values as of September&#160;21, 2023. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Before the closing of the Sorrento SPA transactions and in connection with the transactions contemplated by the Sorrento SPA, the Company formed two entities: (a)&#160;Scilex DRE Holdings LLC (&#x201c;Holdco&#x201d;), a single purpose entity that is the Company&#x2019;s direct wholly owned subsidiary and (b)&#160;Scilex Stock Acquisition Joint Venture LLC, a single purpose bankruptcy-remote entity that is the Company&#x2019;s indirect wholly owned subsidiary (&#x201c;SCLX JV&#x201d;), which was formed to hold the Purchased Securities. Holdco was formed to hold all of the equity interests in SCLX JV. Holdco and SCLX JV are parties to the Security Agreement and Subsidiary Guarantee (see Note 7). &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Preferred Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to the terms of the Sorrento SPA, the Company repurchased all of the outstanding Preferred Stock. The Preferred Stock is classified in equity and does not have any bifurcated features. Therefore, the repurchase of the Preferred Stock by the Company is treated as a redemption of shares and viewed as a deemed dividend. The fair value of Preferred Stock as of the repurchase date of September&#160;21, 2023 was $52.6&#160;million. The Company derecognized the carrying value of the Preferred Stock, with any excess amount allocated as the reduction in additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital. The Preferred Stock is currently held as collateral for the Oramed Note. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Treasury Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Common Stock that has been repurchased by the Company under the Sorrento SPA is not intended for constructive retirement, and is being held as collateral for the Oramed Note. In accordance with treasury stock accounting guidance, the consideration allocated to Common Stock is presented under a separate caption of Treasury Stock as a reduction of equity. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Penny Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Closing Penny Warrant will be exercisable upon the earliest of (i)&#160;March 14, 2025, (ii) the date on which the Oramed Note has been repaid in full and (iii)&#160;the Management Sale Trigger Date (as defined therein), if any, and will expire on the date that is the fifth anniversary of the issuance date. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company issued four Subsequent Penny Warrants, each for 2,125,000&#160;shares of Common Stock, one of which shall vest and become exercisable on the date that is the later of (i)&#160;each of March 19, 2024, June 17, 2024, &lt;div style="display:inline;"&gt;&lt;/div&gt;&lt;div style="display:inline;"&gt;September 15&lt;/div&gt;, 2024 or December 14, 2024 (the &#x201c;Subsequent Penny Warrant Vesting Date&#x201d;) and (ii)&#160;the earliest of (A)&#160;March 14, 2025, (B) the date on which the Oramed Note has been repaid in full and (C)&#160;the Management Sale Trigger Date (as defined therein), if any. Each Subsequent Penny Warrant will expire on the date that is the fifth anniversary of the issuance date; provided that, if the Oramed Note is repaid in full prior to the Subsequent Penny Warrant Vesting Date applicable to such Subsequent Penny Warrant, such Subsequent Penny Warrant will expire on the date the Oramed Note is repaid in full. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The exercise price of the Penny Warrants is $0.01 per share, subject to adjustments provided therein. The exercise price and number of shares of Common Stock issuable upon the exercise of the Penny Warrants will be subject to adjustment in the event of any stock dividend, stock split, recapitalization, reorganization or similar transaction, as described in the Penny Warrants; provided that there shall not be any adjustment to the exercise price of the Penny Warrants in the event the Company combines (by combination, reverse stock split or otherwise) its Common Stock into a smaller number of shares. Oramed may exercise the Penny Warrants by means of a &#x201c;cashless exercise.&#x201d; The Closing Penny Warrant and the Subsequent Penny Warrants utilize the same form of warrant. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Penny Warrants may not be exercised if Oramed, together with its affiliates, would beneficially own in excess of 9.9% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise (the &#x201c;Oramed Beneficial Ownership Limitation&#x201d;); provided, however, that upon 61 days&#x2019; prior notice to the Company, Oramed may increase or decrease the Oramed Beneficial Ownership Limitation. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company accounted for the Penny Warrants as an equity classified instrument as they are indexed to the Company&#x2019;s own stock and meet the conditions to be classified in equity under FASB ASC 815, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Derivatives and Hedging,&lt;/div&gt;&lt;/div&gt; including sufficient available shares for the Company to settle the exercise of the warrants in shares. The Penny Warrants are recognized in additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital in the Company&#x2019;s consolidated balance sheets. The fair value of Penny Warrants as of September&#160;21, 2023, the date of issuance, was $10.4&#160;million. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Excise Tax &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In December 2022, the Department of the Treasury and the Internal Revenue Service (the &#x201c;IRS&#x201d;) issued guidelines on the implementation of the new code section added by the Inflation Reduction Act of 2022, which imposes a 1% excise tax on the total fair market value of stock repurchases during the tax year, subject to adjustments. Pursuant to the terms of the Sorrento SPA, the Company repurchased the Purchased Securities from Sorrento. The total fair market value of the Purchased Securities was offset by the fair market value of the shares issued during the year ended December&#160;31, 2023. The Company has accrued $1.3&#160;million of the excise tax liability, which is recorded as accrued expenses under current liabilities on the consolidated balance sheet. The excise tax will be adjusted based on any new guidance that the IRS may release. &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn07_05_2023_JuniorDipFacilityMemberusgaapLongtermDebtTypeAxis_SorrentoMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      id="ixv-26722"
      unitRef="Unit_USD">20000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="P07_05_2023To07_05_2023_JuniorDipFacilityMemberusgaapLongtermDebtTypeAxis_SorrentoMemberusgaapBusinessAcquisitionAxis"
      decimals="3"
      id="ixv-26723"
      unitRef="Unit_pure">0.12</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn07_05_2023_JuniorDipFacilityMemberusgaapLongtermDebtTypeAxis_SorrentoMemberusgaapBusinessAcquisitionAxis"
      decimals="4"
      id="ixv-26724"
      unitRef="Unit_pure">0.02</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentDescription
      contextRef="P07_05_2023To07_05_2023_JuniorDipFacilityMemberusgaapLongtermDebtTypeAxis_SorrentoMemberusgaapBusinessAcquisitionAxis"
      id="ixv-26725">The Junior DIP Facility was to mature on the earliest of: (i)&#160;September&#160;30, 2023; (ii) the effective date of any Chapter 11 plan of reorganization with respect to Sorrento; (iii)&#160;the consummation of any sale or other disposition of all or substantially all of the assets of Sorrento; (iv)&#160;the date of the acceleration of the DIP Loans and the termination of the DIP Commitments (as defined in the Junior DIP Loan Agreement) in accordance with the DIP Documents (as defined in the Junior DIP Loan Agreement); and (v)&#160;dismissal of the Chapter 11 Cases or conversion of the Chapter 11 Cases into cases under Chapter 7 of the Bankruptcy Code.</us-gaap:DebtInstrumentDescription>
    <sclx:SharesPurchasedUnderStockPurchaseAgreement
      contextRef="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-26726"
      unitRef="Unit_shares">60068585</sclx:SharesPurchasedUnderStockPurchaseAgreement>
    <sclx:SharesPurchasedUnderStockPurchaseAgreement
      contextRef="PAsOn09_21_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-26727"
      unitRef="Unit_shares">29057097</sclx:SharesPurchasedUnderStockPurchaseAgreement>
    <sclx:SharesPurchasedAtParValueUnderStockPurchaseAgreement
      contextRef="PAsOn09_21_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="4"
      id="ixv-26728"
      unitRef="Unit_USD_per_Share">0.0001</sclx:SharesPurchasedAtParValueUnderStockPurchaseAgreement>
    <sclx:SharesPurchasedUnderStockPurchaseAgreement
      contextRef="PAsOn09_21_2023_PublicWarrantsMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-26730"
      unitRef="Unit_shares">1386617</sclx:SharesPurchasedUnderStockPurchaseAgreement>
    <sclx:SharesPurchasedUnderStockPurchaseAgreement
      contextRef="PAsOn09_21_2023_PrivateWarrantsMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-26731"
      unitRef="Unit_shares">3104000</sclx:SharesPurchasedUnderStockPurchaseAgreement>
    <sclx:IssueOfWarrantsToPurchaseShares
      contextRef="PAsOn09_21_2023_ClosingPennyWarrantMemberusgaapClassOfWarrantOrRightAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      id="ixv-26732"
      unitRef="Unit_shares">4500000</sclx:IssueOfWarrantsToPurchaseShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn09_21_2023_ClosingPennyWarrantMemberusgaapClassOfWarrantOrRightAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="2"
      id="ixv-26733"
      unitRef="Unit_USD_per_Share">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <sclx:IssueOfWarrantsToPurchaseShares
      contextRef="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      id="ixv-26734"
      unitRef="Unit_shares">8500000</sclx:IssueOfWarrantsToPurchaseShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-26735"
      unitRef="Unit_USD_per_Share">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <sclx:TransferOfWarrants
      contextRef="PAsOn09_21_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      id="ixv-26736"
      unitRef="Unit_shares">4000000</sclx:TransferOfWarrants>
    <sclx:CashPayment
      contextRef="P09_21_2023To09_21_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-26737"
      unitRef="Unit_USD">10000000</sclx:CashPayment>
    <us-gaap:LegalFees
      contextRef="P09_21_2023To09_21_2023_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-26738"
      unitRef="Unit_USD">12300000</us-gaap:LegalFees>
    <sclx:FairValueOfSharesRepurchased
      contextRef="P09_21_2023To09_21_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis_StockPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-26739"
      unitRef="Unit_USD">52600000</sclx:FairValueOfSharesRepurchased>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="P01_01_2023To12_31_2023_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-26740">2025-03-14</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <sclx:IssueOfWarrantsToPurchaseShares
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants2MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-26742"
      unitRef="Unit_shares">2125000</sclx:IssueOfWarrantsToPurchaseShares>
    <sclx:IssueOfWarrantsToPurchaseShares
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants3MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-26743"
      unitRef="Unit_shares">2125000</sclx:IssueOfWarrantsToPurchaseShares>
    <sclx:IssueOfWarrantsToPurchaseShares
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants4MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-26744"
      unitRef="Unit_shares">2125000</sclx:IssueOfWarrantsToPurchaseShares>
    <sclx:IssueOfWarrantsToPurchaseShares
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentPennyWarrants1MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-26745"
      unitRef="Unit_shares">2125000</sclx:IssueOfWarrantsToPurchaseShares>
    <sclx:WarrantVestingDate
      contextRef="P01_01_2023To12_31_2023_SubsequentPennyWarrants1MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-26746">2024-03-19</sclx:WarrantVestingDate>
    <sclx:WarrantVestingDate
      contextRef="P01_01_2023To12_31_2023_SubsequentPennyWarrants2MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-26747">2024-06-17</sclx:WarrantVestingDate>
    <sclx:WarrantVestingDate
      contextRef="P01_01_2023To12_31_2023_SubsequentPennyWarrants3MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-20116">2024-09-15</sclx:WarrantVestingDate>
    <sclx:WarrantVestingDate
      contextRef="P01_01_2023To12_31_2023_SubsequentPennyWarrants4MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-26748">2024-12-14</sclx:WarrantVestingDate>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="P01_01_2023To12_31_2023_MinimumMembersrtRangeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-26749">2024-12-14</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="P01_01_2023To12_31_2023_MaximumMembersrtRangeAxis_SubsequentPennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-26750">2025-03-14</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn09_21_2023_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-26751"
      unitRef="Unit_USD_per_Share">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <sclx:NumberOfShareOutstanding
      contextRef="PAsOn09_21_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis_SeniorNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="3"
      id="ixv-26752"
      unitRef="Unit_pure">0.099</sclx:NumberOfShareOutstanding>
    <sclx:FairValueOfWarrants
      contextRef="PAsOn09_21_2023_PennyWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="-5"
      id="ixv-26753"
      unitRef="Unit_USD">10400000</sclx:FairValueOfWarrants>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="PAsOn12_31_2023_SorrentoMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      id="ixv-26754"
      unitRef="Unit_USD">1300000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-20128">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9. Stockholders&#x2019; Equity &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SPAC Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Upon the completion of the Business Combination, the Company assumed the SPAC Warrants. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Holders of the SPAC Warrants are entitled to acquire shares of Common Stock. The SPAC Warrants will expire five years after the completion of the Business Combination or earlier upon redemption or liquidation. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;If the reported last sale price of the Common Stock equals or exceeds $18.00 per share for any 20 trading days within a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30-trading&lt;/div&gt; day period ending three business days before the Company sends the notice of redemption to the warrant holders, the Company may redeem all the Public Warrants at a price of $0.01 per warrant upon not less than 30 days&#x2019; prior written notice. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;If the Company calls the Public Warrants for redemption, the Company will have the option to require all holders that wish to exercise the Public Warrants to do so on a cashless basis. The Company will not be required to net cash settle the SPAC Warrants. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Public Warrants are equity-classified warrants and recognized in additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital in the accompanying consolidated balance sheets. The Private Warrants are liability-classified warrants and are recognized as liabilities (refer to Notes 1 and 4). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;During the year ended December&#160;31, 2023, the SPAC Warrants held by Sorrento were repurchased, and certain of such warrants transferred to Oramed, as a result of the Sorrento SPA (refer to Note 8). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2023 and 2022, there were 6,854,309&#160;and 6,899,988 Public Warrants outstanding, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2023 and 2022, there were 3,613,383&#160;and 4,104,000 Private Warrants outstanding, respectively. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Preferred Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2023 and 2022, there were 29,057,097 shares of Preferred Stock outstanding. On September&#160;21, 2023, the Preferred Stock was repurchased and derecognized for accounting purposes. The Preferred Stock is currently held as collateral for the Oramed Note. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Treasury Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2023, there were 60,068,585 shares of Treasury Stock. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A&amp;amp;R Yorkville Purchase Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to the A&amp;amp;R Yorkville Purchase Agreement, the Company has the right, but not the obligation, in its sole and absolute discretion, to sell to Yorkville up to $500.0&#160;million of shares of Common Stock at its request and subject to certain conditions by delivering written notice to Yorkville at any time until the first day of the month following the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;36-month&lt;/div&gt; anniversary of the date on which the Company&#x2019;s registration statement on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-1&lt;/div&gt; registering such shares has been declared effective by the SEC. Pursuant to the A&amp;amp;R Yorkville Purchase Agreement, the shares of Common Stock, if any, that the Company elects to sell to Yorkville pursuant to a sale of Common Stock will be purchased at a price equal to 98% of the VWAP (as defined below) during the applicable pricing period for such advance, which shall be the period commencing upon receipt by Yorkville of an advance notice from the Company (or the open of regular trading hours, if later) and ending on 4:00 p.m. on the same day. For purposes of the A&amp;amp;R Yorkville Purchase Agreement, &#x201c;VWAP&#x201d; means, for a specified period, the volume weighted average price of the Common Stock on the Nasdaq Capital Market for such period as reported by Bloomberg L.P. through its &#x201c;AQR&#x201d; function. Pursuant to the terms of the Original Purchase Agreement, the Company filed a registration statement on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-1&lt;/div&gt; (File &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;333-268607)&lt;/div&gt; (as it may be amended or supplemented from time to time, the &#x201c;Yorkville Registration Statement&#x201d;) related to the Original Purchase Agreement with the SEC on November&#160;30, 2022 (following the execution of the Original Purchase Agreement). The Yorkville Registration Statement was initially declared effective by the SEC on December&#160;9, 2022. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In connection with the execution of the Original Purchase Agreement, the Company issued to Yorkville 250,000 shares of Common Stock. During the year ended December&#160;31, 2023, the Company sold 11,552,074 shares of Common Stock pursuant to the A&amp;amp;R Yorkville Purchase Agreement for aggregate net proceeds of&#160;$32.3&#160;million. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B. Riley Purchase Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to the B. Riley Purchase Agreement, the Company has the right, but not the obligation, to sell to B.&#160;Riley up to $500.0&#160;million of shares of Common Stock, subject to certain limitations and conditions set forth &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;therein, from time to time at the Company&#x2019;s sole and absolute discretion, during the term of the B. Riley Purchase Agreement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s right to sell shares of Common Stock pursuant to the B. Riley Purchase Agreement shall end on the first day of the month following the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;36-month&lt;/div&gt; anniversary of the date on which the B. Riley Registration Statement (as defined below) was initially declared effective by the SEC. Pursuant to the terms of the B. Riley Purchase Agreement, the Company filed a registration statement on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-1&lt;/div&gt; (File &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;333-269205)&lt;/div&gt; (as it may be amended or supplemented from time to time, the &#x201c;B. Riley Registration Statement&#x201d;) related to the B. Riley Purchase Agreement with the SEC on January&#160;12, 2023 (following the execution of the B. Riley Purchase Agreement). The B. Riley Registration Statement was initially declared effective by the SEC on January&#160;20, 2023. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The shares of Common Stock, if any, that the Company elects to sell to B. Riley pursuant to an advance under the B. Riley Purchase Agreement will be purchased at a price equal to 98% of the VWAP (as defined in such agreement) during the pricing period prescribed therein. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In connection with the execution of the B. Riley Purchase Agreement, the Company issued to B. Riley 250,000 shares of Common Stock. During the year ended December&#160;31, 2023, the Company sold an aggregate of 1,414,554 shares of Common Stock for aggregate net proceeds of $3.2&#160;million. On, and effective as of, February&#160;16, 2024, the Company and B. Riley mutually agreed to terminate the B. Riley Purchase Agreement. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock Issued under Settlement Agreement with Hudson Bay Parties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In August 2023, the Company, along with Hudson Bay Capital Management LP (&#x201c;Hudson Bay&#x201d;), Cove Lane Onshore Fund, LLC (&#x201c;Cove Lane&#x201d;), and HBC Investments LLC (&#x201c;HBC&#x201d; and collectively, the &#x201c;Hudson Bay Parties&#x201d;), entered into several agreements. Under these agreements, the Company agreed to issue and sell up to $118.6&#160;million in securities and warrants to the Hudson Bay Parties. However, on September&#160;15, 2023, a settlement agreement was reached and released all claims related to the previous agreements. The Company acknowledged payments of $8.65&#160;million made to the Hudson Bay Parties as properly earned. To satisfy remaining obligations, the Company agreed to issue shares of Common Stock to Cove Lane and HBC worth $0.3&#160;million and $0.5&#160;million, respectively. This resulted in the issuance of an aggregate of 474,683&#160;shares of Common Stock on September&#160;25, 2023. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At-the-Market&lt;/div&gt;&lt;/div&gt; Sales Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On December&#160;22, 2023, the Company entered into a Sales Agreement (the &#x201c;ATM Sales Agreement&#x201d;) with B. Riley Securities, Inc., Cantor Fitzgerald&#160;&amp;amp; Co. and H.C. Wainwright&#160;&amp;amp; Co., LLC (the &#x201c;Sales Agents&#x201d;). Pursuant to the ATM Sales Agreement, the Company may offer and sell (the &#x201c;Offering&#x201d;) shares of Common Stock up to $170,000,000 (the &#x201c;ATM Shares&#x201d;), through or to the Sales Agents. The Company has no obligation to sell any shares of Common Stock under the ATM Sales Agreement and may suspend offers at any time. The Offering will terminate upon (i)&#160;the election of the Sales Agents upon the occurrence of certain adverse events, (ii)&#160;three business days&#x2019; advance notice from the Company to the Sales Agents or a Sales Agent to the Company, or (iii)&#160;the sale of all $170,000,000 of shares of Common Stock thereunder. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The ATM Shares offered and sold in the Offering will be issued pursuant to the Company&#x2019;s shelf registration statement on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Form&#160;S-3&#160;(the&lt;/div&gt; &#x201c;Shelf &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-3&lt;/div&gt; Registration Statement&#x201d;), filed with the SEC on December&#160;22, 2023, and declared effective by the SEC on January&#160;11, 2024. The ATM Shares may be offered only by means of a prospectus forming a part of the Shelf &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-3&lt;/div&gt; Registration Statement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Sales Agents are entitled to a commission equal to 3.0% of the gross proceeds from each sale of shares of Common Stock. The Company will also reimburse the Sales Agents for certain expenses and has agreed to &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;provide indemnification and contribution to the Sales Agents against certain civil liabilities, including liabilities under the&#160;Securities Act. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2023, no sales of Common Stock had been made under the ATM Sales Agreement. &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2023"
      decimals="2"
      id="ixv-26755"
      unitRef="Unit_USD_per_Share">18</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2023_WarrantsMemberusgaapAwardTypeAxis_WarrantTransferAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      id="ixv-26756"
      unitRef="Unit_USD_per_Share">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-26758"
      unitRef="Unit_shares">6854309</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-26759"
      unitRef="Unit_shares">6899988</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2023_WarrantsMemberusgaapAwardTypeAxis_WarrantTransferAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-26760"
      unitRef="Unit_shares">3613383</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2022_WarrantsMemberusgaapAwardTypeAxis_WarrantTransferAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-26761"
      unitRef="Unit_shares">4104000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2022_PreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-26762"
      unitRef="Unit_shares">29057097</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2023_PreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-26763"
      unitRef="Unit_shares">29057097</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:TreasuryStockCommonShares
      contextRef="PAsOn12_31_2023_TreasuryStockCommonMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-26764"
      unitRef="Unit_shares">60068585</us-gaap:TreasuryStockCommonShares>
    <sclx:RightToSellMaximumNumberOfCommonStockShares
      contextRef="P01_01_2023To12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-5"
      id="ixv-26765"
      unitRef="Unit_USD">500000000</sclx:RightToSellMaximumNumberOfCommonStockShares>
    <sclx:PurchaseOfStockPercentage
      contextRef="PAsOn12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="2"
      id="ixv-26766"
      unitRef="Unit_pure">0.98</sclx:PurchaseOfStockPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2023To12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis_CommonStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-26767"
      unitRef="Unit_shares">250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <sclx:CommonStockSold
      contextRef="P01_01_2023To12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="0"
      id="ixv-26768"
      unitRef="Unit_shares">11552074</sclx:CommonStockSold>
    <sclx:ProceedsFromSaleOfCommonStock
      contextRef="P01_01_2023To12_31_2023_ARYorkvillePurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-5"
      id="ixv-26769"
      unitRef="Unit_USD">32300000</sclx:ProceedsFromSaleOfCommonStock>
    <sclx:RightToSellMaximumNumberOfCommonStockShares
      contextRef="P11_17_2022To11_17_2022_BRileyPurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-5"
      id="ixv-26770"
      unitRef="Unit_USD">500000000</sclx:RightToSellMaximumNumberOfCommonStockShares>
    <sclx:PurchaseOfStockPercentage
      contextRef="PAsOn12_31_2023_BRileyPurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="2"
      id="ixv-26772"
      unitRef="Unit_pure">0.98</sclx:PurchaseOfStockPercentage>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2023_BRileyPurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="INF"
      id="ixv-26773"
      unitRef="Unit_shares">250000</us-gaap:CommonStockSharesIssued>
    <sclx:CommonStockSold
      contextRef="P01_01_2023To12_31_2023_BRileyPurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="INF"
      id="ixv-26774"
      unitRef="Unit_shares">1414554</sclx:CommonStockSold>
    <sclx:ProceedsFromSaleOfCommonStock
      contextRef="P01_01_2023To12_31_2023_BRileyPurchaseAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="-5"
      id="ixv-26775"
      unitRef="Unit_USD">3200000</sclx:ProceedsFromSaleOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="P08_31_2023To08_31_2023_HudsonBayMemberdeiLegalEntityAxis"
      decimals="-5"
      id="ixv-26776"
      unitRef="Unit_USD">118600000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:PaymentsOfDividends
      contextRef="P01_01_2023To12_31_2023"
      decimals="-4"
      id="ixv-26777"
      unitRef="Unit_USD">8650000</us-gaap:PaymentsOfDividends>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2023_CoveLaneMemberdeiLegalEntityAxis"
      decimals="-5"
      id="ixv-26778"
      unitRef="Unit_USD">300000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2023_HudsonBayMemberdeiLegalEntityAxis"
      decimals="-5"
      id="ixv-26779"
      unitRef="Unit_USD">500000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn09_25_2023"
      decimals="INF"
      id="ixv-26780"
      unitRef="Unit_shares">474683</us-gaap:CommonStockSharesIssued>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P12_22_2023To12_22_2023_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis_MaximumMembersrtRangeAxis"
      decimals="0"
      id="ixv-26781"
      unitRef="Unit_shares">170000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P12_22_2023To12_22_2023_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="0"
      id="ixv-26782"
      unitRef="Unit_shares">170000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <sclx:ProceedSOfSaleOfCommonSharesPercentage
      contextRef="P01_01_2023To12_31_2023_AtTheMarketSalesAgreementMemberSCLXPurchaseAgreementAxis"
      decimals="3"
      id="ixv-26783"
      unitRef="Unit_pure">0.03</sclx:ProceedSOfSaleOfCommonSharesPercentage>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-20237">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10. Stock Incentive and Employee Benefit Plan &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2017 Scilex Pharmaceuticals Inc. Equity Incentive Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In June 2017, the Board of Directors of the Company adopted the Scilex Pharmaceuticals Inc. Equity Incentive Plan (the &#x201c;Scilex Pharma 2017 Plan&#x201d;). In connection with the corporate reorganization in March 2019, the Scilex Pharma 2017 Plan was terminated. Accordingly, after such time, no additional awards were granted under the Scilex Pharma 2017 Plan. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Scilex Holding Company 2019 Stock Option Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In May 2019, the Board of Directors of the Company adopted the Scilex Holding Company 2019 Stock Option Plan (the &#x201c;2019 Stock Option Plan&#x201d;), which subsequently was amended in December 2020. The 2019 Stock Option Plan was terminated at the closing of the Business Combination, and no further awards have been granted under the 2019 Stock Option Plan thereafter. However, the 2019 Stock Option Plan will continue to govern outstanding awards granted thereunder. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Scilex Holding Company 2022 Equity Incentive Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In October 2022, the Board of Directors of the Company adopted the Scilex Holding Company 2022 Equity Incentive Plan (the &#x201c;Equity Incentive Plan&#x201d;). The total number of shares of Common Stock for which incentive stock options (&#x201c;ISOs&#x201d;) may be granted under the Equity Incentive Plan is not to exceed 20,276,666 shares, which was increased from 14,622,712 as a result of the automatic annual increase on January&#160;1, 2023 pursuant to the Equity Incentive Plan provisions. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On May&#160;4, 2023, the Company&#x2019;s stockholders approved the amendment to the Equity Incentive Plan to (i)&#160;increase the number of shares authorized for issuance thereunder by 10,000,000 shares from 20,276,666 shares to 30,276,666 shares, (ii)&#160;increase the number of shares authorized for issuance thereunder pursuant to the exercise of ISOs to 30,276,666 shares, and (iii)&#160;modify the commencement date of the automatic increase in the number of shares authorized for issuance thereunder pursuant to the exercise of ISOs to January&#160;1, 2024. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2023, options to purchase 33,123,798 shares of Common Stock were outstanding under all equity incentive plans. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;recently determined that the aggregate value of all compensation granted or paid to each &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; director for the fiscal year ending December&#160;31, 2023 (when aggregated with any remaining compensation payable for the remainder of such fiscal year) would inadvertently exceed the $750,000 annual compensation limit for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; directors (the &#x201c;Compensation Limit&#x201d;) under the Equity Incentive Plan, as a result of the previously disclosed equity grants made thereunder to such &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; directors in January 2023 (the &#x201c;Awards&#x201d;). As a result, the Company&#x2019;s current &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; directors, David Lemus and Dorman Followwill, and the Company&#x2019;s former &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; directors, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tien-Li&lt;/div&gt; Lee and Laura Hamill, each voluntarily agreed to forfeit (i)&#160;a number of shares of Common Stock subject to their Awards or (ii)&#160;a combination of shares of Common Stock subject to their Awards and cash compensation payable by the Company for such person&#x2019;s service as a director for the remainder of 2023, in each case in an amount that would bring each such &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; director&#x2019;s aggregate compensation for the fiscal year ending December&#160;31, 2023 below the Compensation Limit. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; directors forfeited an aggregate of 311,735 shares of Common Stock and an aggregate of approximately $107,424 in cash compensation. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Scilex Holding Company 2023 Inducement Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On January&#160;17, 2023, the compensation committee of the Board of Directors of the Company adopted the Scilex Holding Company 2023 Inducement Plan (the &#x201c;Inducement Plan&#x201d;). The Inducement Plan provides for the grant of equity-based awards in the form of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-statutory&lt;/div&gt; stock options, stock appreciation rights, restricted stock, restricted stock units, and other awards solely to prospective employees of the Company or an affiliate of the Company, provided that certain criteria are met. The initial maximum number of shares available for grant under the Inducement Plan is 1,400,000 shares of Common Stock (subject to adjustment for recapitalizations, stock splits, reorganizations and similar transactions). No awards were granted under the Inducement Plan during the year ended December&#160;31, 2023. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes stock option activity during the year ended December&#160;31, 2023 (shares in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:48%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise&#160;Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&#160;Life,&lt;br/&gt; in years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt; Intrinsic&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding as of December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,939&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.68&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;38,942&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,610&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.02&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercised&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(365&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.68&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Forfeited/Cancelled&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,060&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding as of December&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33,124&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.38&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,459&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercisable as of December&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,990&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.78&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,600&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the Common Stock for the options that had exercise prices that were lower than the per share fair value of the Common Stock as of the measurement date of the intrinsic value. The weighted-average grant date fair value per share of stock options granted during the year ended December&#160;31, 2023 was $3.24 per share. The total intrinsic values of options exercised during the years ended December&#160;31, 2023, 2022, and 2021 were $1.1&#160;million, $0.3&#160;million, and nil, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Total stock-based compensation recorded within operating expenses was $14.6&#160;million, $5.3&#160;million and $5.8&#160;million for the years ended December&#160;31, 2023, 2022 and 2021, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The total unrecognized compensation costs related to unvested employee and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; stock option grants as of December&#160;31, 2023 were $42.4&#160;million, which the Company expects to recognize over a weighted-average period of approximately 3.1 years. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Scilex Holding Company 2022 Employee Stock Purchase Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In October 2022, the Board of Directors of the Company adopted the Scilex Holding Company 2022 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;). The purchase price of the Common Stock is equal to&#160;85% of the lesser of the market value of such shares at the beginning of an offering period or the date of purchase. As of December&#160;31, 2023, the total number of shares of Common Stock that may be issued under the ESPP shall not exceed 2,875,759, which was increased from 1,462,271 shares as a result of automatic annual increase on January&#160;1, 2023. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Total stock-based compensation recorded as operating expense for the ESPP was $21.0&#160;thousand and nil for the year ended December&#160;31, 2023 and 2022, respectively. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Valuation Assumptions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company calculates the fair value of stock options and ESPP awards granted to employees and nonemployees using the Black-Scholes option-pricing method. The Black-Scholes option-pricing method requires the use of subjective assumptions. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following assumptions were used in the Black-Scholes options pricing model to estimate stock-based compensation on the date of grant for stock options and ESPP: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt; December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock options:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;0.00%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;40.00%&#160;-&#160;77.00%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3.59%&#160;-&#160;4.74%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Term of options (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;6.25&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Employee stock purchase plan:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;0.00%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;117.57%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;5.33%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected life (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;0.50&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Employee Benefit Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company maintains a defined contribution 401(k) plan available to eligible employees. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company made matching contributions to the 401(k) plan totaling $0.5&#160;million, $0.3&#160;million and $0.3&#160;million for the years ended December&#160;31, 2023, 2022 and 2021, respectively. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Retainer Shares &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On February&#160;13, 2023, the Company entered into a Stock Issuance Agreement (the &#x201c;SIA&#x201d;) with a law firm for the provision of legal services to the Company. Under the SIA, the Company issued 4,000,000 shares of Common Stock to the law firm (the &#x201c;Retainer Shares&#x201d;). The Retainer Shares are held by the law firm as collateral for the current and future outstanding legal fees due from the Company. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;At the option of the law firm, the Retainer Shares may be sold and the net proceeds may be applied against the outstanding legal fees. The Retainer Shares not applied against the outstanding legal fees due will be returned to the Company. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2023, it was not probable that any of the Retainer Shares would be applied against any outstanding legal fees. &lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2022_MaximumMembersrtRangeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-26785"
      unitRef="Unit_shares">20276666</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-26786"
      unitRef="Unit_shares">14622712</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="PAsOn05_04_2023_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-26787"
      unitRef="Unit_shares">10000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="PAsOn05_04_2023_MinimumMembersrtRangeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-26788"
      unitRef="Unit_shares">20276666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="PAsOn05_04_2023_MaximumMembersrtRangeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-26789"
      unitRef="Unit_shares">30276666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="PAsOn05_04_2023_MaximumMembersrtRangeAxis"
      decimals="0"
      id="ixv-26790"
      unitRef="Unit_shares">30276666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2023_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-26791"
      unitRef="Unit_shares">33123798</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <sclx:Sharebasedcompensationpayable
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-26792"
      unitRef="Unit_USD">750000</sclx:Sharebasedcompensationpayable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="P01_01_2023To12_31_2023_NonEmployeeDirectorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="INF"
      id="ixv-26793"
      unitRef="Unit_shares">311735</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:DeferredCompensationCashBasedArrangementsLiabilityCurrent
      contextRef="PAsOn12_31_2023_NonEmployeeDirectorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      id="ixv-26794"
      unitRef="Unit_USD">107424</us-gaap:DeferredCompensationCashBasedArrangementsLiabilityCurrent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="PAsOn01_17_2023_TwoThousandTwentyThreeInducementPlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-26796"
      unitRef="Unit_shares">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-20288">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes stock option activity during the year ended December&#160;31, 2023 (shares in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:48%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise&#160;Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&#160;Life,&lt;br/&gt; in years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt; Intrinsic&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding as of December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,939&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.68&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;38,942&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,610&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.02&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercised&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(365&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.68&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Forfeited/Cancelled&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,060&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding as of December&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33,124&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.38&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,459&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercisable as of December&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,990&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.78&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,600&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-26797"
      unitRef="Unit_shares">16939</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2022"
      decimals="2"
      id="ixv-26798"
      unitRef="Unit_USD_per_Share">1.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2022To12_31_2022" id="ixv-26799">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26800"
      unitRef="Unit_USD">38942000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2023To12_31_2023"
      decimals="INF"
      id="ixv-26801"
      unitRef="Unit_shares">17610</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-26802"
      unitRef="Unit_USD_per_Share">7.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-26803"
      unitRef="Unit_shares">365</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-26804"
      unitRef="Unit_USD_per_Share">1.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="P01_01_2023To12_31_2023"
      decimals="INF"
      id="ixv-26805"
      unitRef="Unit_shares">1060</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-26806"
      unitRef="Unit_USD_per_Share">6.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-26807"
      unitRef="Unit_shares">33124</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023"
      decimals="2"
      id="ixv-26808"
      unitRef="Unit_USD_per_Share">4.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2023To12_31_2023" id="ixv-26809">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26810"
      unitRef="Unit_USD">7459000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-26811"
      unitRef="Unit_shares">18990</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023"
      decimals="2"
      id="ixv-26812"
      unitRef="Unit_USD_per_Share">2.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2023To12_31_2023" id="ixv-26813">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26814"
      unitRef="Unit_USD">5600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-26815"
      unitRef="Unit_USD_per_Share">3.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-26816"
      unitRef="Unit_USD">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      id="ixv-26817"
      unitRef="Unit_USD">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2023To12_31_2023_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-5"
      id="ixv-26818"
      unitRef="Unit_USD">14600000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-5"
      id="ixv-26819"
      unitRef="Unit_USD">5300000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2021To12_31_2021_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-5"
      id="ixv-26820"
      unitRef="Unit_USD">5800000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="PAsOn12_31_2023"
      decimals="-5"
      id="ixv-26821"
      unitRef="Unit_USD">42400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <sclx:WeightedAveragePeriodOverGrant contextRef="P01_01_2023To12_31_2023" id="ixv-26822">P3Y1M6D</sclx:WeightedAveragePeriodOverGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="P10_01_2022To10_31_2022_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-26823"
      unitRef="Unit_pure">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2023_MaximumMembersrtRangeAxis_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-26824"
      unitRef="Unit_shares">2875759</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2023_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-26825"
      unitRef="Unit_shares">1462271</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2023To12_31_2023_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-2"
      id="ixv-26826"
      unitRef="Unit_USD">21000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyTwoEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      id="ixv-26827"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-20541">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following assumptions were used in the Black-Scholes options pricing model to estimate stock-based compensation on the date of grant for stock options and ESPP: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt; December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock options:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;0.00%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;40.00%&#160;-&#160;77.00%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3.59%&#160;-&#160;4.74%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Term of options (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;6.25&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Employee stock purchase plan:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;0.00%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;117.57%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;5.33%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected life (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;0.50&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2023To12_31_2023_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_StockOptionMemberusgaapFinancialInstrumentAxis"
      decimals="4"
      id="ixv-26829"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2023To12_31_2023_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_MinimumMembersrtRangeAxis_StockOptionMemberusgaapFinancialInstrumentAxis"
      decimals="4"
      id="ixv-26830"
      unitRef="Unit_pure">0.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2023To12_31_2023_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_MaximumMembersrtRangeAxis_StockOptionMemberusgaapFinancialInstrumentAxis"
      decimals="4"
      id="ixv-26831"
      unitRef="Unit_pure">0.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="P01_01_2023To12_31_2023_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_StockOptionMemberusgaapFinancialInstrumentAxis"
      decimals="4"
      id="ixv-26832"
      unitRef="Unit_pure">0.0359</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="P01_01_2023To12_31_2023_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_StockOptionMemberusgaapFinancialInstrumentAxis"
      decimals="4"
      id="ixv-26833"
      unitRef="Unit_pure">0.0474</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2023To12_31_2023_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_StockOptionMemberusgaapFinancialInstrumentAxis"
      id="ixv-26834">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2023To12_31_2023_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_EmployeeStockPurchasePlanMemberusgaapFinancialInstrumentAxis"
      decimals="4"
      id="ixv-26835"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2023To12_31_2023_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_EmployeeStockPurchasePlanMemberusgaapFinancialInstrumentAxis"
      decimals="4"
      id="ixv-26836"
      unitRef="Unit_pure">1.1757</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="P01_01_2023To12_31_2023_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_EmployeeStockPurchasePlanMemberusgaapFinancialInstrumentAxis"
      decimals="4"
      id="ixv-26837"
      unitRef="Unit_pure">0.0533</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2023To12_31_2023_BlackScholesOptionPricingMethodMemberusgaapValuationTechniqueAxis_EmployeeStockPurchasePlanMemberusgaapFinancialInstrumentAxis"
      id="ixv-26838">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-26839"
      unitRef="Unit_USD">500000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      id="ixv-26840"
      unitRef="Unit_USD">300000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      id="ixv-26841"
      unitRef="Unit_USD">300000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="P02_13_2023To02_13_2023"
      decimals="INF"
      id="ixv-26842"
      unitRef="Unit_shares">4000000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26843"
      unitRef="Unit_USD">0</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-20618">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11. Commitments and Contingencies &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Product Development Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In February 2013, Scilex Pharma became a party to a product development agreement (as amended, the &#x201c;Product Development Agreement&#x201d;) with Itochu and Oishi Koseido Co., Ltd. (&#x201c;Oishi,&#x201d; and together with Itochu, the &#x201c;Developers&#x201d;), pursuant to which the Developers will manufacture and supply lidocaine tape products, including ZTlido and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-103&lt;/div&gt; (the &#x201c;Products&#x201d;), for Scilex Pharma. The Developers initially developed and have intellectual property rights relating to the Products. Pursuant to the Product Development Agreement, Scilex Pharma acquired an exclusive right to develop and commercialize the Products worldwide except for Japan. The Developers are responsible for sourcing and supplying lidocaine for development and commercialization purposes. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to the Product Development Agreement, Scilex Pharma is required to make aggregate royalty payments between 25% and 35% to the Developers based on net profits. For the years ended December&#160;31, 2023 and 2022, Scilex Pharma made royalty payments in the amount of $8.3&#160;million and $2.3&#160;million. As of December&#160;31, 2023 and 2022, Scilex Pharma had ending balances of accrued royalty payables of $2.4&#160;million and $2.2&#160;million, respectively. Total royalty expense recorded within cost of revenue was $8.5&#160;million and $4.5&#160;million for the years ended December&#160;31, 2023 and 2022, respectively. Net profits are defined as net sales, less cost of goods and marketing expenses. Net sales are defined as total gross sales of any Product, less all applicable deductions, to the extent accrued, paid or allowed in the ordinary course of business with respect to the sale of such Product, and to the extent that they are in accordance with GAAP. If Scilex Pharma were to sublicense the licensed technologies, the Developers will receive the same proportion of any sublicensing fees received therefrom. The Product Development Agreement will continue in full force and effect until October 2, 2028, the date that is ten years from the date of the first commercial sale of ZTlido. The Product Development Agreement will renew automatically for subsequent successive &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-year&lt;/div&gt; renewal periods unless Scilex Pharma or the Developers terminate it upon &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6-month&lt;/div&gt; written notice. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On February&#160;16, 2017, Scilex Pharma entered into a Commercial Supply Agreement (as amended, the &#x201c;Supply Agreement&#x201d;) with the two Developers to provide commercial supply of ZTlido and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-103&lt;/div&gt; to Scilex Pharma. The Supply Agreement contains standard terms regarding term, termination, payment, product quality and supply. In addition, the agreement provides additional terms regarding the calculation and amount of marketing expenses that may be deducted from net sales for purposes of determining the amount of net profit under the Product Development Agreement. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Litigation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In the normal course of business, the Company may be named as a defendant in one or more lawsuits. Other than the following four lawsuits, the Company is not a party to any outstanding material litigation and management is not aware of any legal proceedings that, individually or in the aggregate, are deemed to be material to the Company&#x2019;s financial condition or results of operations. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;From time to time the Company may become involved in various legal proceedings, including those that may arise in the ordinary course of business. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc. Litigation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On February&#160;23, 2021, the Company filed an action (the &#x201c;Action&#x201d;) in the U.S. District Court for the Northern District of California against Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc., two manufacturers of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;over-the-counter&lt;/div&gt;&lt;/div&gt; (&#x201c;OTC&#x201d;) lidocaine patch products, alleging, among other things, false and deceptive advertising and unfair competition under the Lanham Act and California state laws by those companies regarding their respective OTC patch products. This lawsuit sought, among other relief, damages and an injunction enjoining the defendants from continuing to make false or misleading statements of fact about their respective OTC lidocaine patch products. The defendants filed motions to dismiss, which narrowed slightly the Company&#x2019;s claims, but which motions the court largely rejected. Discovery was proceeding. On January&#160;26 and February&#160;2, 2024, Scilex Pharma entered into two separate settlement agreements and mutual releases with the two manufacturers that resolve the Action. The terms of those agreements are confidential. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Former Employee Action &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On March&#160;12, 2021, Scilex Pharma and Sorrento (the &#x201c;Plaintiffs&#x201d;) filed an action (the &#x201c;Former Employee Action&#x201d;) in the Delaware Court of Chancery against the former President of Scilex Pharma, Anthony Mack, and Virpax Pharmaceuticals, Inc. (&#x201c;Virpax&#x201d;, together with Mr.&#160;Mack, the &#x201c;Defendants&#x201d;), a company founded and then headed by Mr.&#160;Mack, alleging, among other things, breach by Mr.&#160;Mack of a restrictive covenant agreement with Sorrento related to his sale of his Scilex Pharma stock to Sorrento, tortious interference with that agreement &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;by Virpax, breach of Mr.&#160;Mack&#x2019;s fiduciary duties to Scilex Pharma, aiding and abetting of that breach by Virpax, and misappropriation of Scilex Pharma&#x2019;s trade secrets by Mr.&#160;Mack and Virpax. Such lawsuit sought, among other relief, damages and various forms of injunctive relief. The case was tried from September&#160;12, 2022 to September&#160;14, 2022. On September&#160;1, 2023, the court found in favor of the Plaintiffs on all but three counts deemed to have been waived. In its &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;95-page&lt;/div&gt; opinion, the court instructed the parties to submit supplemental briefing on the appropriate remedy to implement its rulings. On October&#160;18, 2023, the Plaintiffs submitted a supplemental brief on remedies. On November&#160;29, 2023, Defendants submitted a supplemental brief on remedies. On December&#160;21, 2023, the Plaintiffs submitted a supplemental reply brief on remedies. On February&#160;26, 2024, the Company and Virpax entered into a term sheet regarding a mutual release and settlement agreement, pursuant to which the parties have agreed to resolve the ongoing disputes. On February&#160;29, 2024, the Company and Virpax entered into a definitive settlement agreement, which provides for, among other things, that Virpax will be obligated to make the following payments to the Company to settle the Former Employee Action: (i) $3.5&#160;million (the &#x201c;Initial Payment&#x201d;) by two business days after the Effective Date (as defined therein); (ii) $2.5&#160;million by July&#160;1, 2024 and (iii)&#160;to the extent any of the following drug candidates are ever sold, royalty payments of (a) 6% of annual Net Sales (as defined therein) of Epoladerm; (b) 6% of annual Net Sales of Probudur and (c) 6% of annual Net Sales of Envelta during the Royalty Term (as defined therein). The Company and Virpax provide mutual releases of all claims that exist as of the Effective Date, whether known or unknown, arising from any allegations set forth in the Former Employee Action. Plaintiffs&#x2019; release relates to claims against Virpax only, which does not affect its claims against Mr.&#160;Mack. Plaintiffs have not released Mr.&#160;Mack, and litigation against him remains ongoing. Plaintiffs&#x2019; release as to Virpax is conditioned upon Virpax&#x2019;s Initial Payment. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;ZTlido Patent Litigation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;22, 2022, the Company filed a complaint against Aveva Drug Delivery Systems, Inc. (&#x201c;Aveva&#x201d;), Apotex Corp., and Apotex, Inc. (together, &#x201c;Apotex&#x201d;) in the U.S. District Court for the Southern District of Florida (the &#x201c;ZTlido Patent Litigation&#x201d;) alleging infringement of certain Orange Book listed patents covering ZTlido (the &#x201c;ZTlido Patents&#x201d;). The ZTlido Patent Litigation was initiated following the submission by Apotex, in accordance with the procedures set out in the Hatch-Waxman Act, of an abbreviated new drug application (&#x201c;ANDA&#x201d;). Apotex&#x2019;s ANDA seeks approval to market a generic version of ZTlido prior to the expiration of the ZTlido Patents and alleges that the ZTlido Patents are invalid, unenforceable, and/or not infringed. The Company is seeking, among other relief, an order that the effective date of any FDA approval of Apotex&#x2019;s ANDA be no earlier than the expiration of the asserted patents listed in the Orange Book, the latest of which expires on May&#160;10, 2031, and such further and other relief as the court may deem appropriate. Apotex is subject to a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30-month&lt;/div&gt; stay preventing it from selling a generic version of ZTlido during that time. The stay should expire no earlier than November&#160;11, 2024. The two Apotex entities were recently dismissed from the litigation without prejudice, as they no longer have an interest in the generic product that Aveva seeks to market. Trial in the ZTlido Patent Litigation has been scheduled for July&#160;8, 2024. The Company cannot make any predictions about the final outcome of this matter or the timing thereof. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;GLOPERBA Patent Litigation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On November&#160;6, 2023, Takeda Pharmaceuticals U.S.A., Inc. (&#x201c;Takeda&#x201d;) filed a complaint against the Company in the U.S. District Court for the District of Delaware (the &#x201c;GLOPERBA Patent Litigation&#x201d;) alleging that the Company&#x2019;s filing with the FDA of an application for approval of a proposed revision to the product label for its GLOPERBA product infringed certain Orange Book listed patents covering Takeda&#x2019;s colchicine product, Colcrys&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#xae;&lt;/div&gt;&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;&#160;&lt;/div&gt;(the &#x201c;Colcrys Patents&#x201d;). Takeda is seeking an order that the effective date of any FDA approval of the Company&#x2019;s labeling revision be no earlier than the expiration date of the asserted patents listed in the Orange Book, and such further and other relief as the court may deem appropriate. The filing of the complaint subjects the Company to a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30-month&lt;/div&gt; stay, preventing it from selling GLOPERBA under a revised label (but not from selling GLOPERBA under its current label) during that time. The Company cannot make any predictions about the final outcome of this matter or the timing thereof. The stay could last as long as until May&#160;6, 2026, unless the &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;litigation is resolved before that time. As of December&#160;31, 2023, the Company accrued $0.5&#160;million with respect to the GLOPERBA Patent Litigation. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company leases administrative and research and development facilities under various &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cancelable&lt;/div&gt; lease agreements. Facility leases generally provide for periodic rent increases and may include options to extend. As of December&#160;31, 2023, the Company&#x2019;s leases have remaining lease terms of approximately 0.7 to 3.8 years. The terms of the Company&#x2019;s leases, ranging from 3 to 5 years, include extension options that were not reasonably certain to be exercised. Many of the Company&#x2019;s leases are subject to variable lease payments. Variable lease payments are recognized in the period in which the obligations for those payments are incurred, are not included in the measurement of the ROU assets or lease liabilities, and are immaterial. Additionally, the Company subleases certain properties to third parties. Sublease income is recognized on a straight-line basis and is immaterial. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company calculates the associated lease liability and corresponding ROU asset upon lease commencement using a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. As of December&#160;31, 2023, the Company has no &lt;div style="-sec-ix-hidden:hidden107553186;display:inline;"&gt;finance leases&lt;/div&gt;. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In April 2023, the Company modified the lease term for its principal executive offices located in Palo Alto, California. The modification extended the lease term for an additional three years, with the lease term expiring in September 2027. As a result of the modification, the Company recognized additional ROU assets and corresponding lease liabilities of $2.5&#160;million. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Lease expense was $1.1&#160;million, $0.5&#160;million and $0.6&#160;million for the years ended December&#160;31, 2023, 2022 and 2021, respectively, and was primarily comprised of operating lease costs. The lease expense also included variable lease costs and sublease income, which were immaterial for the periods presented. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Supplemental quantitative information related to leases includes the following: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:78%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating cash flows from operating leases (in thousands)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,021&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(746&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average remaining lease term in years &#x2014; operating leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average discount rate &#x2014; operating leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11.1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11.8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Approximate future minimum lease payments under operating leases were as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:86%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,042&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;916&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;944&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2027&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;724&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,626&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less imputed interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(630&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,996&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less current portion of lease liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;759&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lease liability, net of current portion&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,237&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <sclx:RoyaltyPaymentPercentageRelatedToFutureYears
      contextRef="P02_01_2013To02_28_2013_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MinimumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      id="ixv-26845"
      unitRef="Unit_pure">0.25</sclx:RoyaltyPaymentPercentageRelatedToFutureYears>
    <sclx:RoyaltyPaymentPercentageRelatedToFutureYears
      contextRef="P02_01_2013To02_28_2013_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MaximumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      id="ixv-26846"
      unitRef="Unit_pure">0.35</sclx:RoyaltyPaymentPercentageRelatedToFutureYears>
    <us-gaap:RoyaltyExpense
      contextRef="P01_01_2023To12_31_2023_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-5"
      id="ixv-26847"
      unitRef="Unit_USD">8300000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="P01_01_2022To12_31_2022_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis_ScilexPharmaMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-5"
      id="ixv-26848"
      unitRef="Unit_USD">2300000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyGuaranteesCommitmentsAmount
      contextRef="PAsOn12_31_2023_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-26849"
      unitRef="Unit_USD">2400000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
    <us-gaap:RoyaltyGuaranteesCommitmentsAmount
      contextRef="PAsOn12_31_2022_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-26850"
      unitRef="Unit_USD">2200000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
    <us-gaap:RoyaltyExpense
      contextRef="P01_01_2023To12_31_2023_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-26851"
      unitRef="Unit_USD">8500000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="P01_01_2022To12_31_2022_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-26852"
      unitRef="Unit_USD">4500000</us-gaap:RoyaltyExpense>
    <sclx:AgreementMaturityDate
      contextRef="P02_01_2013To02_28_2013_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"
      id="ixv-26853">2028-10-02</sclx:AgreementMaturityDate>
    <sclx:MaturityRenewalDescription
      contextRef="P02_01_2013To02_28_2013_DevelopersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"
      id="ixv-20645">The Product Development Agreement will renew automatically for subsequent successive one-year renewal periods unless Scilex Pharma or the Developers terminate it upon 6-month written notice.</sclx:MaturityRenewalDescription>
    <us-gaap:LitigationSettlementExpense
      contextRef="P01_01_2023To12_31_2023_FormerEmployeeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      id="ixv-26855"
      unitRef="Unit_USD">3500000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="P01_01_2023To12_31_2023_FormerEmployeeOneMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      id="ixv-26856"
      unitRef="Unit_USD">2500000</us-gaap:LitigationSettlementExpense>
    <sclx:RoyaltyPaymentPercentageOnNetSale
      contextRef="P01_01_2023To12_31_2023_EpoladermMemberusgaapStatementBusinessSegmentsAxis"
      decimals="2"
      id="ixv-26857"
      unitRef="Unit_pure">0.06</sclx:RoyaltyPaymentPercentageOnNetSale>
    <sclx:RoyaltyPaymentPercentageOnNetSale
      contextRef="P01_01_2023To12_31_2023_ProbudurMemberusgaapStatementBusinessSegmentsAxis"
      decimals="2"
      id="ixv-26858"
      unitRef="Unit_pure">0.06</sclx:RoyaltyPaymentPercentageOnNetSale>
    <sclx:RoyaltyPaymentPercentageOnNetSale
      contextRef="P01_01_2023To12_31_2023_EnveltaMemberusgaapStatementBusinessSegmentsAxis"
      decimals="2"
      id="ixv-26859"
      unitRef="Unit_pure">0.06</sclx:RoyaltyPaymentPercentageOnNetSale>
    <sclx:DueFromRelatedParty
      contextRef="PAsOn12_31_2023_GloperbaMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      id="ixv-26861"
      unitRef="Unit_USD">500000</sclx:DueFromRelatedParty>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="PAsOn12_31_2023_MinimumMembersrtRangeAxis_NonCancelableLeaseAgreementsMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentFacilitiesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      id="ixv-26862">P0Y8M12D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="PAsOn12_31_2023_MaximumMembersrtRangeAxis_NonCancelableLeaseAgreementsMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentFacilitiesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      id="ixv-26863">P3Y9M18D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="PAsOn12_31_2023_MinimumMembersrtRangeAxis_NonCancelableLeaseAgreementsMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentFacilitiesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      id="ixv-26864">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="PAsOn12_31_2023_MaximumMembersrtRangeAxis_NonCancelableLeaseAgreementsMemberusgaapTypeOfArrangementAxis_ResearchAndDevelopmentFacilitiesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      id="ixv-26865">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:FinanceLeaseLiability
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26866"
      unitRef="Unit_USD">0</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn04_30_2023"
      decimals="-5"
      id="ixv-26867"
      unitRef="Unit_USD">2500000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn04_30_2023"
      decimals="-5"
      id="ixv-26868"
      unitRef="Unit_USD">2500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-26869"
      unitRef="Unit_USD">1100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      id="ixv-26870"
      unitRef="Unit_USD">500000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      id="ixv-26871"
      unitRef="Unit_USD">600000</us-gaap:OperatingLeaseExpense>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-20722">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Supplemental quantitative information related to leases includes the following: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:78%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating cash flows from operating leases (in thousands)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,021&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(746&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average remaining lease term in years &#x2014; operating leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average discount rate &#x2014; operating leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11.1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11.8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26872"
      unitRef="Unit_USD">1021000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26873"
      unitRef="Unit_USD">746000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2023" id="ixv-26874">P3Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2022" id="ixv-26875">P1Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2023"
      decimals="3"
      id="ixv-26876"
      unitRef="Unit_pure">0.111</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2022"
      decimals="3"
      id="ixv-26877"
      unitRef="Unit_pure">0.118</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-20819">&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Approximate future minimum lease payments under operating leases were as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:86%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,042&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;916&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;944&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2027&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;724&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,626&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less imputed interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(630&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,996&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less current portion of lease liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;759&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lease liability, net of current portion&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,237&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26879"
      unitRef="Unit_USD">1042000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26880"
      unitRef="Unit_USD">916000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26881"
      unitRef="Unit_USD">944000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26882"
      unitRef="Unit_USD">724000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26883"
      unitRef="Unit_USD">3626000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26884"
      unitRef="Unit_USD">630000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26885"
      unitRef="Unit_USD">2996000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26886"
      unitRef="Unit_USD">759000</us-gaap:OperatingLeaseLiabilityCurrent>
    <sclx:LeaseLiabilityNetOfCurrentPortion
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26887"
      unitRef="Unit_USD">2237000</sclx:LeaseLiabilityNetOfCurrentPortion>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-20933">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12. Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Total loss before income taxes for the years ended December&#160;31, 2023, 2022 and 2021 did not include a foreign component. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The components of the provision expense (benefit) were as follows for the years ended December&#160;31, 2023, 2022 and 2021 (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:64%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current income tax expense (benefit):&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Federal&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total current&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred income tax expense (benefit):&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Federal&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(16,514&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10,396&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(12,981&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(11,247&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,851&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,472&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(27,761&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(12,247&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15,453&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Changes in tax rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,471&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,347&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Changes in valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29,232&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,900&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,422&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total income tax expense from continuing operations&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The components of the Company&#x2019;s net deferred tax liabilities and related valuation allowance are as follows as of December&#160;31, 2023 and 2022 (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax assets:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net operating loss carryforwards&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;71,434&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;48,984&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Debt related interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,898&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,272&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Capitalized research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,936&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,014&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Tax credit carryforwards&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,960&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,630&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock based compensation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;525&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,602&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued expense and reserves&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,584&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;568&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;774&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;315&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;159&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;77&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100,270&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;70,462&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(96,776&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(67,543&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,494&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,919&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax liabilities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Intangible assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,734&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,666&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(760&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(253&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred tax liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,494&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,919&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net deferred tax liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The reconciliation between U.S. federal income taxes at the statutory rate and the Company&#x2019;s provision for income taxes are as follows for the years ended December&#160;31, 2023, 2022 and 2021 (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:65%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Income tax benefit at federal statutory rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(24,007&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,905&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(19,150&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29,232&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,900&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,422&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Debt discount and interest limitation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9,293&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,954&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Compensation expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,798&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,469&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;224&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Acquisition related charges&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;260&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;992&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Prior year &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;true-up&lt;/div&gt; and carryback&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5,079&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(713&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,968&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State, net of federal tax benefit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5,127&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(174&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,545&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value of Convertible Debentures&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,752&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in tax rates&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,471&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;655&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;728&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;993&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Income tax expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has evaluated the available evidence supporting the realization of its gross deferred tax assets, including the amount and timing of future taxable income, and has determined that it is more likely than not that the deferred tax assets will not be realized. Due to such uncertainties surrounding the realization of the deferred tax assets, the Company maintains a valuation allowance of $96.8&#160;million against its deferred tax assets as of December&#160;31, 2023. Realization of the deferred tax assets will be primarily dependent upon the Company&#x2019;s ability to generate sufficient taxable income prior to the expiration of its net operating losses. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2023, the Company had $278.7&#160;million and $114.0&#160;million of federal and state net operating loss carryforwards, respectively. The net operating loss carryforwards begin to expire in 2035 and 2034 for federal and state, respectively. As of December&#160;31, 2023, the Company had a total of $265.9&#160;million of federal net operating losses &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;that have an indefinite life and will not expire, and had federal research and development income tax credits of $3.4&#160;million which will begin to expire in 2035. As of December&#160;31, 2023, the Company had California research and development income tax credits of $1.9&#160;million that have an indefinite life and will not expire. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Internal Revenue Code Section&#160;382 rules apply to limit a corporation&#x2019;s ability to utilize existing net operating loss and tax credit carryforwards once the corporation experiences an ownership change as defined in Section&#160;382. For the years ended December&#160;31, 2023 and 2022, there was no impact of such limitations on the Company&#x2019;s income tax provision. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company is subject to taxation in U.S. federal and state tax jurisdictions. All of the Company&#x2019;s tax years will remain open for three years for examination by the federal and state tax authorities from the date of utilizations of net operating loss. There are no active tax compliance audits as of December&#160;31, 2023. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;A reconciliation of the beginning and ending amount of unrecognized tax expense (benefits) is as follows for the years ended December&#160;31, 2023, 2022 and 2021 (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:74%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Beginning balance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;408&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;408&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;406&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Increase related to prior year tax positions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;536&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Increases related to current year tax positions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;127&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending balance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,071&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;408&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;408&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2023, 2022 and 2021, the Company had $1.1&#160;million, $0.4&#160;million and $0.4&#160;million in total unrecognized tax benefits, respectively. If these were to be recognized, they would affect the effective tax rate, however given the full valuation allowance in the jurisdiction in which the unrecognized tax benefits relate to, the impact on the effective tax rate would be nil. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s policy is to recognize interest and penalties related to income tax matters in income tax expense. No interest or penalties have been recognized as of and for the periods ended December&#160;31, 2023, 2022 and 2021. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company believes that no material amount of the liabilities for uncertain tax positions are expected to reverse within 12 months of December&#160;31, 2023. &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-20937">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The components of the provision expense (benefit) were as follows for the years ended December&#160;31, 2023, 2022 and 2021 (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:64%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current income tax expense (benefit):&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Federal&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total current&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred income tax expense (benefit):&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Federal&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(16,514&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10,396&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(12,981&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(11,247&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,851&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,472&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(27,761&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(12,247&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15,453&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Changes in tax rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,471&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,347&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Changes in valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29,232&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,900&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,422&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total income tax expense from continuing operations&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26888"
      unitRef="Unit_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26889"
      unitRef="Unit_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26890"
      unitRef="Unit_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26891"
      unitRef="Unit_USD">13000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26892"
      unitRef="Unit_USD">4000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26893"
      unitRef="Unit_USD">5000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26894"
      unitRef="Unit_USD">13000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26895"
      unitRef="Unit_USD">4000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26896"
      unitRef="Unit_USD">5000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26897"
      unitRef="Unit_USD">-16514000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26898"
      unitRef="Unit_USD">-10396000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26899"
      unitRef="Unit_USD">-12981000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26900"
      unitRef="Unit_USD">-11247000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26901"
      unitRef="Unit_USD">-1851000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26902"
      unitRef="Unit_USD">-2472000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26903"
      unitRef="Unit_USD">-27761000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26904"
      unitRef="Unit_USD">-12247000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26905"
      unitRef="Unit_USD">-15453000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26906"
      unitRef="Unit_USD">-1471000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26907"
      unitRef="Unit_USD">1347000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26908"
      unitRef="Unit_USD">31000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26909"
      unitRef="Unit_USD">29232000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26910"
      unitRef="Unit_USD">10900000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26911"
      unitRef="Unit_USD">15422000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26912"
      unitRef="Unit_USD">13000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26913"
      unitRef="Unit_USD">4000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26914"
      unitRef="Unit_USD">5000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-21243">&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The components of the Company&#x2019;s net deferred tax liabilities and related valuation allowance are as follows as of December&#160;31, 2023 and 2022 (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax assets:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net operating loss carryforwards&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;71,434&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;48,984&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Debt related interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,898&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,272&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Capitalized research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,936&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,014&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Tax credit carryforwards&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,960&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,630&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock based compensation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;525&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,602&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued expense and reserves&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,584&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;568&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;774&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;315&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;159&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;77&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100,270&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;70,462&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(96,776&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(67,543&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,494&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,919&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax liabilities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Intangible assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,734&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,666&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(760&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(253&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred tax liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,494&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,919&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net deferred tax liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26916"
      unitRef="Unit_USD">71434000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26917"
      unitRef="Unit_USD">48984000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <sclx:DeferredTaxAssetsDebtRelatedInterest
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26918"
      unitRef="Unit_USD">16898000</sclx:DeferredTaxAssetsDebtRelatedInterest>
    <sclx:DeferredTaxAssetsDebtRelatedInterest
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26919"
      unitRef="Unit_USD">15272000</sclx:DeferredTaxAssetsDebtRelatedInterest>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26920"
      unitRef="Unit_USD">4936000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26921"
      unitRef="Unit_USD">2014000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26922"
      unitRef="Unit_USD">3960000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26923"
      unitRef="Unit_USD">1630000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26924"
      unitRef="Unit_USD">525000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26925"
      unitRef="Unit_USD">1602000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <sclx:DeferredTaxAssetsAccruedExpenseAndReserves
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26926"
      unitRef="Unit_USD">1584000</sclx:DeferredTaxAssetsAccruedExpenseAndReserves>
    <sclx:DeferredTaxAssetsAccruedExpenseAndReserves
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26927"
      unitRef="Unit_USD">568000</sclx:DeferredTaxAssetsAccruedExpenseAndReserves>
    <sclx:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26928"
      unitRef="Unit_USD">774000</sclx:DeferredTaxAssetsOperatingLeaseLiabilities>
    <sclx:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26929"
      unitRef="Unit_USD">315000</sclx:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26930"
      unitRef="Unit_USD">159000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26931"
      unitRef="Unit_USD">77000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26932"
      unitRef="Unit_USD">100270000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26933"
      unitRef="Unit_USD">70462000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26934"
      unitRef="Unit_USD">96776000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26935"
      unitRef="Unit_USD">67543000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26936"
      unitRef="Unit_USD">3494000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26937"
      unitRef="Unit_USD">2919000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26938"
      unitRef="Unit_USD">2734000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26939"
      unitRef="Unit_USD">2666000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26940"
      unitRef="Unit_USD">760000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26941"
      unitRef="Unit_USD">253000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26942"
      unitRef="Unit_USD">3494000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26943"
      unitRef="Unit_USD">2919000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26944"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26945"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-21550">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The reconciliation between U.S. federal income taxes at the statutory rate and the Company&#x2019;s provision for income taxes are as follows for the years ended December&#160;31, 2023, 2022 and 2021 (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:65%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Income tax benefit at federal statutory rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(24,007&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,905&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(19,150&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29,232&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,900&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,422&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Debt discount and interest limitation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9,293&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,954&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Compensation expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,798&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,469&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;224&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Acquisition related charges&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;260&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;992&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Prior year &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;true-up&lt;/div&gt; and carryback&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5,079&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(713&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,968&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State, net of federal tax benefit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5,127&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(174&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,545&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value of Convertible Debentures&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,752&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in tax rates&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,471&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;655&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;728&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;993&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Income tax expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26946"
      unitRef="Unit_USD">-24007000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26947"
      unitRef="Unit_USD">-4905000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26948"
      unitRef="Unit_USD">-19150000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26949"
      unitRef="Unit_USD">29232000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26950"
      unitRef="Unit_USD">10900000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26951"
      unitRef="Unit_USD">15422000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <sclx:EffectiveIncomeTaxRateReconciliationDebtDiscountAmount
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26952"
      unitRef="Unit_USD">0</sclx:EffectiveIncomeTaxRateReconciliationDebtDiscountAmount>
    <sclx:EffectiveIncomeTaxRateReconciliationDebtDiscountAmount
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26953"
      unitRef="Unit_USD">-9293000</sclx:EffectiveIncomeTaxRateReconciliationDebtDiscountAmount>
    <sclx:EffectiveIncomeTaxRateReconciliationDebtDiscountAmount
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26954"
      unitRef="Unit_USD">8954000</sclx:EffectiveIncomeTaxRateReconciliationDebtDiscountAmount>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26955"
      unitRef="Unit_USD">3798000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26956"
      unitRef="Unit_USD">2469000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26957"
      unitRef="Unit_USD">224000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <sclx:IncomeTaxReconciliationAcquisitionRelatedCharges
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26958"
      unitRef="Unit_USD">260000</sclx:IncomeTaxReconciliationAcquisitionRelatedCharges>
    <sclx:IncomeTaxReconciliationAcquisitionRelatedCharges
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26959"
      unitRef="Unit_USD">992000</sclx:IncomeTaxReconciliationAcquisitionRelatedCharges>
    <sclx:IncomeTaxReconciliationAcquisitionRelatedCharges
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26960"
      unitRef="Unit_USD">75000</sclx:IncomeTaxReconciliationAcquisitionRelatedCharges>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26961"
      unitRef="Unit_USD">-5079000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26962"
      unitRef="Unit_USD">-713000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26963"
      unitRef="Unit_USD">-3968000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26964"
      unitRef="Unit_USD">-5127000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26965"
      unitRef="Unit_USD">-174000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26966"
      unitRef="Unit_USD">-2545000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <sclx:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26967"
      unitRef="Unit_USD">1752000</sclx:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount>
    <sclx:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26968"
      unitRef="Unit_USD">0</sclx:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount>
    <sclx:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26969"
      unitRef="Unit_USD">0</sclx:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount>
    <sclx:EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26970"
      unitRef="Unit_USD">-1471000</sclx:EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount>
    <sclx:EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26971"
      unitRef="Unit_USD">0</sclx:EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount>
    <sclx:EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26972"
      unitRef="Unit_USD">0</sclx:EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26973"
      unitRef="Unit_USD">655000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26974"
      unitRef="Unit_USD">728000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26975"
      unitRef="Unit_USD">993000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26976"
      unitRef="Unit_USD">13000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26977"
      unitRef="Unit_USD">4000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26978"
      unitRef="Unit_USD">5000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2023"
      decimals="-5"
      id="ixv-26979"
      unitRef="Unit_USD">96800000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      id="ixv-26980"
      unitRef="Unit_USD">278700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      id="ixv-26981"
      unitRef="Unit_USD">114000000</us-gaap:OperatingLossCarryforwards>
    <sclx:OperatingLossCarryforwardsExpirationYear
      contextRef="P01_01_2023To12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      id="ixv-26982">2035</sclx:OperatingLossCarryforwardsExpirationYear>
    <sclx:OperatingLossCarryforwardsExpirationYear
      contextRef="P01_01_2023To12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      id="ixv-26983">2034</sclx:OperatingLossCarryforwardsExpirationYear>
    <sclx:IndefiniteOperatingLossCarryforwards
      contextRef="PAsOn12_31_2023"
      decimals="-5"
      id="ixv-26984"
      unitRef="Unit_USD">265900000</sclx:IndefiniteOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="PAsOn12_31_2023"
      decimals="-5"
      id="ixv-26986"
      unitRef="Unit_USD">3400000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <sclx:IncomeTaxCreditsExpirationYear
      contextRef="P01_01_2023To12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      id="ixv-26987">2035</sclx:IncomeTaxCreditsExpirationYear>
    <sclx:TaxCreditCarryforwardNotSubjectToExpireAmount
      contextRef="PAsOn12_31_2023_ResearchMemberusgaapTaxCreditCarryforwardAxis"
      decimals="-5"
      id="ixv-26988"
      unitRef="Unit_USD">1900000</sclx:TaxCreditCarryforwardNotSubjectToExpireAmount>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-21818">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;A reconciliation of the beginning and ending amount of unrecognized tax expense (benefits) is as follows for the years ended December&#160;31, 2023, 2022 and 2021 (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:74%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Beginning balance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;408&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;408&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;406&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Increase related to prior year tax positions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;536&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Increases related to current year tax positions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;127&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending balance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,071&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;408&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;408&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26989"
      unitRef="Unit_USD">408000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      id="ixv-26990"
      unitRef="Unit_USD">408000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      id="ixv-26991"
      unitRef="Unit_USD">406000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26992"
      unitRef="Unit_USD">536000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26993"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26994"
      unitRef="Unit_USD">2000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-26995"
      unitRef="Unit_USD">127000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-26996"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-26997"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-26998"
      unitRef="Unit_USD">1071000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-26999"
      unitRef="Unit_USD">408000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      id="ixv-27000"
      unitRef="Unit_USD">408000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="PAsOn12_31_2023"
      decimals="-5"
      id="ixv-27001"
      unitRef="Unit_USD">1100000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="PAsOn12_31_2022"
      decimals="-5"
      id="ixv-27002"
      unitRef="Unit_USD">400000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      id="ixv-27003"
      unitRef="Unit_USD">400000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-27004"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-27005"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-27006"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-27007"
      unitRef="Unit_USD">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-21956">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13. Net Loss Per Share &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table sets forth the reconciliation of basic and diluted loss per share for the years ended December&#160;31, 2023, 2022 and 2021 (in thousands except per share data): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:60%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(114,331&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(23,364&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(88,424&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Premium on redemption of Preferred Stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(52,645&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss for basic and diluted loss per share available to common stockholders&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(166,976&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(23,364&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(88,424&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average number of shares outstanding - basic&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;130,298&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;134,226&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;132,858&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Effect of dilutive securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average number of shares and assumed conversions - diluted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;130,298&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;134,226&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;132,858&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Loss per share&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Basic and diluted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1.28&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.67&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Basic net loss per share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding during the period. Premium paid on redemption of Preferred Stock was added to the net loss to arrive at loss available for common stockholders as it represents a dividend to the preferred stockholder. Diluted earnings per share is computed using the weighted average number of Common Stock and, if dilutive, potential Common Stock outstanding during the period. Potential Common Stock consists of the incremental Common Stock issuable upon the exercise of stock options and warrants (using the treasury stock method). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In the computation of net loss per share, treasury shares are not included as part of the outstanding shares. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In accordance with FASB ASC 260, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Earnings Per Share, &lt;/div&gt;&lt;/div&gt;Penny Warrants are warrants that would be exercised for no or little consideration and therefore should be included in the calculation of weighted average shares outstanding for purposes of calculating basic and diluted net income (loss) per share. The Closing Penny Warrants become exercisable upon the passage of time and are included in basic and diluted net income (loss) per share from the closing date of September&#160;21, 2023. The Subsequent Penny Warrants to purchase up to an aggregate of 8,500,000 shares of Common Stock are not vested as of the closing date of September&#160;21, 2023 and the vesting is based on the passage of time, the Company&#x2019;s repayment of the Oramed Note or the occurrence of the Management Sale Trigger Date (as defined therein). Therefore, these Subsequent Penny Warrants are included in the computation for diluted net income per share once all other exercise contingencies are removed except for the passage of time. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:55%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock options&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33,123,798&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,939,093&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,967,724&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Public Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,854,309&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,899,988&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Private Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,613,383&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,104,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Retainer Shares&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,000,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Shares Issuable pursuant to ESPP&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29,806&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Convertible Debentures&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;546,921&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;48,168,217&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27,943,081&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,967,724&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-21959">&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table sets forth the reconciliation of basic and diluted loss per share for the years ended December&#160;31, 2023, 2022 and 2021 (in thousands except per share data): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:60%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(114,331&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(23,364&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(88,424&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Premium on redemption of Preferred Stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(52,645&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss for basic and diluted loss per share available to common stockholders&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(166,976&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(23,364&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(88,424&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average number of shares outstanding - basic&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;130,298&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;134,226&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;132,858&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Effect of dilutive securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average number of shares and assumed conversions - diluted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;130,298&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;134,226&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;132,858&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Loss per share&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Basic and diluted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1.28&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.67&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-27008"
      unitRef="Unit_USD">-114331000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-27009"
      unitRef="Unit_USD">-23364000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-27010"
      unitRef="Unit_USD">-88424000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockRedemptionPremium
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-27011"
      unitRef="Unit_USD">52645000</us-gaap:PreferredStockRedemptionPremium>
    <us-gaap:PreferredStockRedemptionPremium
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-27012"
      unitRef="Unit_USD">0</us-gaap:PreferredStockRedemptionPremium>
    <us-gaap:PreferredStockRedemptionPremium
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-27013"
      unitRef="Unit_USD">0</us-gaap:PreferredStockRedemptionPremium>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-27014"
      unitRef="Unit_USD">-166976000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-27015"
      unitRef="Unit_USD">-23364000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-27016"
      unitRef="Unit_USD">-88424000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-27017"
      unitRef="Unit_shares">130298000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-27018"
      unitRef="Unit_shares">134226000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-27019"
      unitRef="Unit_shares">132858000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <sclx:EffectOfDilutiveSecurities
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-27020"
      unitRef="Unit_shares">0</sclx:EffectOfDilutiveSecurities>
    <sclx:EffectOfDilutiveSecurities
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-27021"
      unitRef="Unit_shares">0</sclx:EffectOfDilutiveSecurities>
    <sclx:EffectOfDilutiveSecurities
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      id="ixv-27022"
      unitRef="Unit_shares">0</sclx:EffectOfDilutiveSecurities>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-27023"
      unitRef="Unit_shares">130298000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-27024"
      unitRef="Unit_shares">134226000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="ixv-27025"
      unitRef="Unit_shares">132858000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-27026"
      unitRef="Unit_USD_per_Share">-1.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-27027"
      unitRef="Unit_USD_per_Share">-1.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      id="ixv-27028"
      unitRef="Unit_USD_per_Share">-0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      id="ixv-27029"
      unitRef="Unit_USD_per_Share">-0.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      id="ixv-27030"
      unitRef="Unit_USD_per_Share">-0.67</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      id="ixv-27031"
      unitRef="Unit_USD_per_Share">-0.67</us-gaap:EarningsPerShareBasic>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn09_21_2023_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-27033"
      unitRef="Unit_shares">8500000</us-gaap:CommonStockSharesIssued>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-22204">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:55%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock options&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33,123,798&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,939,093&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,967,724&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Public Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,854,309&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,899,988&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Private Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,613,383&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,104,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Retainer Shares&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,000,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Shares Issuable pursuant to ESPP&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;29,806&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Convertible Debentures&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;546,921&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;48,168,217&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27,943,081&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,967,724&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_StockOptionsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-27034"
      unitRef="Unit_shares">33123798</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022_StockOptionsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-27035"
      unitRef="Unit_shares">16939093</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To12_31_2021_StockOptionsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-27036"
      unitRef="Unit_shares">18967724</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-27037"
      unitRef="Unit_shares">6854309</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022_PublicWarrantsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-27038"
      unitRef="Unit_shares">6899988</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To12_31_2021_PublicWarrantsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-27039"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_PrivateWarrantsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-27040"
      unitRef="Unit_shares">3613383</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022_PrivateWarrantsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-27041"
      unitRef="Unit_shares">4104000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To12_31_2021_PrivateWarrantsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-27042"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_RetainerSharesMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-27043"
      unitRef="Unit_shares">4000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022_RetainerSharesMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-27044"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To12_31_2021_RetainerSharesMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-27045"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_SharesIssuablePursuantToEsppMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-27046"
      unitRef="Unit_shares">29806</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022_SharesIssuablePursuantToEsppMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-27047"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To12_31_2021_SharesIssuablePursuantToEsppMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-27048"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_ConvertibleDebenturesMemberusgaapDebtInstrumentAxis"
      decimals="0"
      id="ixv-27049"
      unitRef="Unit_shares">546921</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022_ConvertibleDebenturesMemberusgaapDebtInstrumentAxis"
      decimals="0"
      id="ixv-27050"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To12_31_2021_ConvertibleDebenturesMemberusgaapDebtInstrumentAxis"
      decimals="0"
      id="ixv-27051"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-27052"
      unitRef="Unit_shares">48168217</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-27053"
      unitRef="Unit_shares">27943081</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      id="ixv-27054"
      unitRef="Unit_shares">18967724</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-22387">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14. Subsequent Events &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Termination of B. Riley Purchase Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On February&#160;16, 2024, the Company and B. Riley mutually agreed to terminate the B. Riley Purchase Agreement. The termination is effective as of February&#160;16, 2024. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Underwritten Offering &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On February&#160;29, 2024, the Company entered into an underwriting agreement (the &#x201c;Underwriting Agreement&#x201d;) with Rodman&#160;&amp;amp; Renshaw LLC and StockBlock Securities LLC, as the representatives (the &#x201c;Representatives&#x201d;) of the underwriters named in Schedule A (the &#x201c;Underwriters&#x201d;). Pursuant to the Underwriting Agreement, the Company agreed to sell, in an underwritten offering (the &#x201c;Bought Deal Offering&#x201d;), 5,882,353&#160;shares (the &#x201c;Firm Shares&#x201d;) of the Common Stock, and accompanying common warrants to purchase up to an aggregate of 5,882,353&#160;shares of Common Stock (the &#x201c;Firm Warrants&#x201d;). Pursuant to the Underwriting Agreement, the Company also granted the Underwriters an option for a period of 30 days from the date of the Underwriting Agreement to purchase up to 882,352 additional shares of Common Stock (the &#x201c;Optional Shares&#x201d;, and together with the Firm Shares, the &#x201c;Shares&#x201d;) and/or common warrants to purchase up to 882,352 shares of Common Stock (the &#x201c;Optional Warrants&#x201d;, and together with the Firm Warrants, the &#x201c;Common Warrants&#x201d;) that may be purchased &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;by the Underwriters, at a price per Optional Share of $1.5548&#160;and a price per Optional Warrant of $0.0092, which amounts reflect the public offering price of $1.69 per Optional Share and $0.01&#160;per Optional Warrant, less underwriting discounts and commissions, as applicable (the &#x201c;Underwriters&#x2019; Option&#x201d;).&#160;Each Firm Share was sold together with a Firm Warrant at a combined public offering price of $1.70. The combined price per Firm Share and accompanying Firm Warrant paid by the Underwriters was $1.564, which amount reflects the combined public offering price of $1.70, less underwriting discounts and commissions. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Subject to certain ownership limitations, the Common Warrants are exercisable immediately from the date of issuance, will expire on the five-year anniversary of the date of issuance and have an exercise price of $1.70&#160;per share. The exercise price of the Common Warrants is subject to certain adjustments, including (but not limited to) for stock dividends, stock splits, combinations and reclassifications of the Common Stock. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Bought Deal Offering, the Company agreed, pursuant to the Underwriting Agreement, to issue the Representatives warrants (the &#x201c;Representative Warrants&#x201d;, and together with the Common Warrants, the &#x201c;Warrants&#x201d;) to purchase up to an aggregate of 470,588 shares of Common Stock (which represents 8.0% of the aggregate number of Firm Shares sold in the Bought Deal Offering), or up to an aggregate of 541,176 shares of Common Stock if the Underwriters exercise the Underwriters&#x2019; Option in full. The Representative Warrants are immediately exercisable and have the same terms as the Common Warrants described above, except that the exercise price of the Representative Warrants is $2.125 per share, which represents 125% of the combined public offering price per Firm Share and accompanying Firm Warrant. The Company also agreed to pay certain expenses of the Representatives in connection with the Bought Deal Offering, including their legal fees and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;out-of-pocket&lt;/div&gt;&lt;/div&gt; expenses up to $200,000 and up to $15,950 for clearing expenses. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Shares, the Warrants and the shares of Common Stock issuable upon exercise of the Warrants were offered and sold by us pursuant to an effective shelf registration statement on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-3,&lt;/div&gt; which was originally filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on December&#160;22, 2023, as amended, and was declared effective on January&#160;11, 2024 (File &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;333-276245),&lt;/div&gt; a base prospectus dated January&#160;11, 2024, and a final prospectus supplement dated February&#160;29, 2024. &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SubsequentEventDescription
      contextRef="P02_16_2024To02_16_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      id="ixv-27055">On February&#160;16, 2024, the Company and B. Riley mutually agreed to terminate the B. Riley Purchase Agreement. The termination is effective as of February&#160;16, 2024.</us-gaap:SubsequentEventDescription>
    <sclx:CommonStockSold
      contextRef="P02_29_2024To02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-27056"
      unitRef="Unit_shares">5882353</sclx:CommonStockSold>
    <sclx:PurchaseOfCommonWarrants
      contextRef="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-27057"
      unitRef="Unit_shares">5882353</sclx:PurchaseOfCommonWarrants>
    <sclx:PurchaseOfCommonShares
      contextRef="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-27058"
      unitRef="Unit_shares">882352</sclx:PurchaseOfCommonShares>
    <sclx:PurchaseOfCommonWarrants
      contextRef="PAsOn02_29_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-27059"
      unitRef="Unit_shares">882352</sclx:PurchaseOfCommonWarrants>
    <sclx:PricePerOptionalShare
      contextRef="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="4"
      id="ixv-27061"
      unitRef="Unit_USD_per_Share">1.5548</sclx:PricePerOptionalShare>
    <sclx:PricePerOptionalWarrant
      contextRef="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="4"
      id="ixv-27062"
      unitRef="Unit_USD_per_Share">0.0092</sclx:PricePerOptionalWarrant>
    <sclx:PublicOfferingPerOptionalShare
      contextRef="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      id="ixv-27063"
      unitRef="Unit_USD_per_Share">1.69</sclx:PublicOfferingPerOptionalShare>
    <sclx:PublicOfferingPerOptionalWarrant
      contextRef="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      id="ixv-27064"
      unitRef="Unit_USD_per_Share">0.01</sclx:PublicOfferingPerOptionalWarrant>
    <sclx:PublicOfferingPriceSold
      contextRef="PAsOn02_29_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      id="ixv-27065"
      unitRef="Unit_shares">1.7</sclx:PublicOfferingPriceSold>
    <sclx:CombinedPricePaidOfWarrant
      contextRef="PAsOn02_29_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="3"
      id="ixv-27066"
      unitRef="Unit_USD_per_Share">1.564</sclx:CombinedPricePaidOfWarrant>
    <sclx:PublicOfferingPrice
      contextRef="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      id="ixv-27067"
      unitRef="Unit_USD_per_Share">1.7</sclx:PublicOfferingPrice>
    <sclx:ExercisePriceOfCommonWarrant
      contextRef="PAsOn02_29_2024_RodmanRenshawLlcMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      id="ixv-27068"
      unitRef="Unit_USD_per_Share">1.7</sclx:ExercisePriceOfCommonWarrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn02_29_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-27069"
      unitRef="Unit_shares">470588</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <sclx:CommonShareSold
      contextRef="PAsOn02_29_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="3"
      id="ixv-27070"
      unitRef="Unit_pure">0.08</sclx:CommonShareSold>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="PAsOn02_29_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-27071"
      unitRef="Unit_shares">541176</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn02_29_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="3"
      id="ixv-27072"
      unitRef="Unit_USD_per_Share">2.125</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <sclx:PublicOfferingPriceCombined
      contextRef="PAsOn02_29_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="2"
      id="ixv-27073"
      unitRef="Unit_pure">1.25</sclx:PublicOfferingPriceCombined>
    <us-gaap:LegalFees
      contextRef="P02_29_2024To02_29_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-3"
      id="ixv-27074"
      unitRef="Unit_USD">200000000</us-gaap:LegalFees>
    <sclx:OutOfPocketExpense
      contextRef="PAsOn02_29_2024_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-3"
      id="ixv-27075"
      unitRef="Unit_USD">15950000</sclx:OutOfPocketExpense>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
